<SEC-DOCUMENT>0001628280-21-022011.txt : 20211105
<SEC-HEADER>0001628280-21-022011.hdr.sgml : 20211105
<ACCEPTANCE-DATETIME>20211105161042
ACCESSION NUMBER:		0001628280-21-022011
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211105
DATE AS OF CHANGE:		20211105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		211384612

	BUSINESS ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801
		BUSINESS PHONE:		(626) 282-0288

	MAIL ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ameh-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:114d7d5d-3fd3-46db-8f4b-230f4f1be605,g:12a42f3e-83fc-4c9c-a1b4-628777c39609,d:77048548a0c546beaa10a42c80553a71--><html xmlns:ameh="http://www.apollomed.net/20210930" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ameh-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80L2ZyYWc6NzBhYTg5NDE1ZjY5NDUxYTg5ODNmNDcxNDNkOWEyM2IvdGFibGU6NzE4Mzc1YmZjZDAzNDRhYWExZTRkOTg5NDM3ZWQwYzYvdGFibGVyYW5nZTo3MTgzNzViZmNkMDM0NGFhYTFlNGQ5ODk0MzdlZDBjNl8zLTEtMS0xLTA_cba3e876-1ff9-4668-853c-fddcfbd887ea">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80L2ZyYWc6NzBhYTg5NDE1ZjY5NDUxYTg5ODNmNDcxNDNkOWEyM2IvdGFibGU6NzE4Mzc1YmZjZDAzNDRhYWExZTRkOTg5NDM3ZWQwYzYvdGFibGVyYW5nZTo3MTgzNzViZmNkMDM0NGFhYTFlNGQ5ODk0MzdlZDBjNl80LTEtMS0xLTA_fd91bec4-36e4-4d40-b705-ba6a0b771f90">2021</ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80L2ZyYWc6NzBhYTg5NDE1ZjY5NDUxYTg5ODNmNDcxNDNkOWEyM2IvdGFibGU6NzE4Mzc1YmZjZDAzNDRhYWExZTRkOTg5NDM3ZWQwYzYvdGFibGVyYW5nZTo3MTgzNzViZmNkMDM0NGFhYTFlNGQ5ODk0MzdlZDBjNl81LTEtMS0xLTA_12972328-74a2-499a-afd6-06363ee24248">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80L2ZyYWc6NzBhYTg5NDE1ZjY5NDUxYTg5ODNmNDcxNDNkOWEyM2IvdGFibGU6NzE4Mzc1YmZjZDAzNDRhYWExZTRkOTg5NDM3ZWQwYzYvdGFibGVyYW5nZTo3MTgzNzViZmNkMDM0NGFhYTFlNGQ5ODk0MzdlZDBjNl82LTEtMS0xLTA_a6219961-de06-40eb-b3f0-90f421932f05">0001083446</ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80L2ZyYWc6NzBhYTg5NDE1ZjY5NDUxYTg5ODNmNDcxNDNkOWEyM2IvdGFibGU6NzE4Mzc1YmZjZDAzNDRhYWExZTRkOTg5NDM3ZWQwYzYvdGFibGVyYW5nZTo3MTgzNzViZmNkMDM0NGFhYTFlNGQ5ODk0MzdlZDBjNl83LTEtMS0xLTA_47e03b64-0bc8-4fae-b049-73c7beaeb180">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i36da10b506ee401bb6c1ad5f810e813e_D20210101-20210930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTY0OA_28ab602c-7a29-4dcd-a454-db6a953fd86b">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ameh-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i081def6efc024948a044c021d9c0814c_I20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i38ab054fe9a44fa7991c114c1a431acf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2044abfbff374e8e958e907e8efcac87_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9a5866334d904a29bc8ab814fa041912_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad641d4c836c4802a609fb48a91e312e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id51f2960969c49fb9ecd63b28cbac656_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b4768d022194b07a1cceea1d21bda2d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44aab1fd19634a0abf32affdb96fc3d6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1a6d2676e4a4f7c93516c5989607a6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30833e792bfc43a2946adc49df5531cc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4041d40d8afd432cb4771fc0bd8f7304_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2de323650fd49ae83aa4d7539a0dadf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666e2bc0492b4dbaa017b3c5a14241bf_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd70461a565a47d1940d89ea394eb16f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8926c849258d4bf19ef81e0f57e4b423_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60a4d9502c44417c9ed0cc8ee95e6590_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08037cad3de049069310b5c67f35a842_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5095a52ac50d47f0b3d6a33cd48d5183_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a1d4a44517452191a99bec6fd96e36_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3329b671360b4adfa4fb2f7c426fc278_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0648ad97fbf94588a4eec1557fb996bd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70980a62a1e84c5983e0627f4bd4a74c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8071ae425d7b4d82a5d84d8061a175da_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f72d40ea546400db958d3bd6d935430_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie52aa3c0e803447b8b93a4eb0dcbf84c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1cbc34be30f4ca4ab2451c5ed3b56b8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0a10078cec44029a1922a6aaf038643_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1512a021721849a0b8da03b2afac2ca0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a1665ab3028449997d07390764c0066_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9204aec484984ed29b67419657e5334e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dff2d9ed6884aa7897b7d8188137fca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i801e5c00786942ddb700c1cd3c41fd90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49f40737fc5743baa30c5079d6bffc52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb86b280a3014e398f2f562416431dd5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d2ab35fb6c4b68be2a92f518c669d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i201c4a8fab204a44b9525c92e21b3124_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9ea714f06741669780227438e2ccc1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f6ed78d14764e42b9aa9957c770a040_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic77d1452e4514a5797346705209ea256_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b58c9abcd6c470686a0c881f23bcd84_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id66271d4dd164746b13d7571ddbea1e8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a74d81295e0434e935d5c9ca47dcd70_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4acdd08276e41428196b78831fc6298_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9752c3ca8824003913aa7ed5a37c7bd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic54bcb094c3c48c6b97472820dabeca3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6c7eefcf281457baaa129d1d005c758_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea5b7b7fc3a4a34b7ce723c83b3a942_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a656a56f752493b9f8d16bfa440f3d8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2ca7ada22a142c387919b0cad5803a3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e1f2152502448b5aa9088804a86dc7c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63d587f859094231993af50e9231e8ec_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ae117b2200d4e1db6a15e62e5be08b2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1cbb81479544b5d8a96c5343b4b4548_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89732b64c48345c09b7f05b7e01eade5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i051a053544f84be68b9f7b6bd5bcf38e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdce3fd00dfa4e8eac9f6af5191663ba_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82e3754a2db143119d3e1eb226e3b911_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dbf54ec60054ae5861c2aa09f4352a9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47b3e835a53b43b1bd2a7e6cca4fe332_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f277e33d13f4f028726cc591668dbbc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89100028143441aea045a96e3abea952_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib97aa22e2d604131bd5c10b48cbc94fc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447b59fe96f749059a743a4fff511b89_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f163c4d0b144be59dac47b4d4f3d1a3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3851c4c6f42140f384fa8e46fde560b9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9a43fc6ff7a472db16607b4efd8deb6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id74805f435254a939c0fb9c4467d967c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bcdaf3ce6a64dd8915c48e617c6050a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77c4d76239ba428fa3c790a5e8246b33_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide4f8e08db044e18a9dd68755ff37c94_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b428a4b73a64930be4adc92648bab3e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc6eb15301c64d8aa5fc12a0525855f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c8de92883004d2a9874fc11ec721f46_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i274e819937824ba3b8be663aca7657a1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2897209faef4ecbb6ff8ae555b62be5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f0ee689326400e8ca46a963ad334e3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80907684f53c41fa8f1a8a26101f7877_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc4bd3d0547c43cca915340944f52cf8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20946dbda53945ca95557bb7aea3d8ea_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50ed93d80d8c443db56d6af7ad9eff2d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88ea48c265674dc0b0969de2c5af9a5a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd58c0538df4442d935bad5da111604c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d6f1b1b2ef64607a7a28b3ddd19b9ca_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7da29179b9f74a138ee89825c3173019_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bd6ee7c5cf34d2a95a5baf1644fd7bd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife042466644a4588baa6a1080f3f9619_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b04caa1c2974f2e8324ddcb0d1943b0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib71e689bf17b4b1b82292ea2371b247f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a115db237054860af9384c8de85411b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7814f327568e456d93bd5dd8ffd4e59c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ab116f35bb4c18b276c3c5099436f8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1da11deec71d444dbcd9ae322ee3fdc3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8613962fee4ab98d908fabd87a1896_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cfa83865da94a5f8b9fe72abbf1e869_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d0a7a2fd7464ee299859406dbe50c73_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd2afccb5db4b0ab6d514f40ca4f851_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eea77176a0f48a2a0621621efb6b4ef_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2263b2eaaf6c4496af9ac4bdaec4bb63_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id861da65feb04df7a6d28f6b72fc6ae5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddc759fafb9d46048145c9584bd19060_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ed6e94c3224d0aaad33a4b064279c7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacd41deb825c48f7968229c9af0a5590_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57f34f8a827f48e3af8fda4fc45fb9e7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3fb118aa44b46768cc5aa112ee13ec3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e69dbc1f0334ee8901a65307444081e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf99efb1cb424f2faa5e9458d42ebbab_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4ff3ef133a4ee8bb68a8f96bce2d82_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03292c592c4f45da834c806bff481c24_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i917782072a6545aea32eaddcfe18e706_D19990701-19990701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-07-01</xbrli:startDate><xbrli:endDate>1999-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib52349b88809456791d3db024592e198_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd821e95a1334471acf3bc50924008ff_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i5e54e5787b2d4a9d913c148f7713fbd8_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i607219ce151b481d884ab20a69b7ab89_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9007c9ba55ce4f30a5723df00d10d0ab_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bc4a1721b30446ebfd6d52b47024998_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6af9311d664b339370a494ef320121_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00e774cfdab24f0aa1689be1a5900a03_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>ameh:plan</xbrli:measure></xbrli:unit><xbrli:context id="if573b2a18f354adf817ec91e584fd94c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf46a0ff42c494995871919d226ce7e_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia651540f0f3040a1b9acd90c7a76f53b_D20190830-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-30</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="clinic"><xbrli:measure>ameh:clinic</xbrli:measure></xbrli:unit><xbrli:context id="i833e8c7434554e839001ca8eddd9a2f1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f596495482b4bccb3b9cb702ba11e2a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b11e41e2b894c69abd5daa1e6e3fc87_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98241c5880794788af87b66dc6a371bd_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i865e78a6a983465c852275c72549d64c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MPPAMGPropertiesAndZLLAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fb003ee3c184ccf91aa13ae16058103_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fd12cfc45b244a5884bf4cd547e6583_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib05af751a8be4d57b25abcbf5cb700aa_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19c94975ba3e411ca4090953760b5a7f_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87665dc910e64455b39ac20a1dc7a442_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ameh:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie4f15f9c5a3844039181a10397fc0a58_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c1a64ec8e5142baa71cef9c34b44674_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ab35f4b7d54df89c058bf7cd127578_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70a8098987854f45b301221eae528a87_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21d7bfcc34ee4134a98f32759980bac4_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73149ba28e96471eb0008ad0f005eb5b_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:ClinigenceHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i620cf562ac9c414d9a3092d147a50325_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if96b5ec1dd6f464a864b0099f4d91c07_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie007473644f44d87917377c77aef7ccf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68a17291f515493a861cd6f4b6efc5d0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0844a4c64e4a4f52bffe29e4402a700d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c3b05a4a5ac46009c7ff5139937e1c3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i733800189cf14be7957deb86e6bdafa7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3852673d58ff474a9ec227fd30703a97_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04da3802734c4d5ca72ce1e9859ddf23_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib06f5b4a97614ebebfcdcb473ee362ba_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31af46ad891f405383d1dfc6a8f0cfca_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0ffcf9784294ca9a72978bc33ad7f9e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7446d9124cfd4d7585720c3d8e7122d3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7116e35a0d75437b94523ce43f9485b0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86ce34a69194485699b14fc7aa46d82c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9a026a7fbb4032abab16642bbb3559_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f1ae095a524c598ba9ab90870d3358_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56807d20331a448d82326373209f0ebc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1734fad16be4ffd9f4a18f4e906e85d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i669f4e3ef9c74609880bf5e9b21c3859_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie27ed45d3b0c4053b92fca660e1e6d1a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf8c009ddf949839ee8d70ae541980a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4de419972e0e4273afd8cb93852e239a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e3a8da4ddbe49af8195caf1c527e751_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa3259fa3ba0452db6f9b000329b0707_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if278b608177c4be99b9342cc7f6e2747_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9203d02b2a74181bd4ed2e0e1ba71f9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i875dae327fdd4ebc9c116e881e3cd106_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02eb4ac069e64a9683beb09cbf7a8921_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64112f96ecc6447d924934cf8a3517dc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie30670fa153f4da59d850909c48a2fd6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic985d70a02f643808edb2e7823ec4817_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6123d945359476aa42a8767483cbee8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i861c8815c7544ce78f48c3ea70ec379b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a0229c1ab0473da20301ac3f5f144a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i719e7a78283546f4bc429a548789a311_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91958f750e2540c1b7888e3065408687_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b1e99e4b094455782c477e1470f802f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3447f389c5504801b383b47a1c4d2bf5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if69a06c770b545248b58b9ead976504d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1dab6e4bc5e45dc9b15b4f78276c9d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>ameh:unit</xbrli:measure></xbrli:unit><xbrli:context id="iee549c3ab8a545c3962f33718601846b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a9f36c8077645449753769fc30f2343_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d3720cbb39433fad71b101f7b86012_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i125c51891f044f728be18a8712aa205b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0562f8e9b55a42e9a5ee44f0e186cecf_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice32049f82244ceebffb5a2a9e3d9448_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b6b078c674a40a6aa164bb3f282fc69_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9f56835a534891ad456a64d2c85f50_D20210731-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-31</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2f519bb3a21437e99c17cddc631e9cd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eb4d763aad449e6ba7233c66eeda68e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie718d9e05afa4852974391111b7c6f7e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0729f4ab87204534b3bd91b2c0c0e422_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21297fd10ec8466daced044c5770ee1d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i258ab2530cfc4417af6150ea2e0d1136_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf5628bdf9de416db3d14683e1f47a46_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i965b06b4b9744451a2780f3ce1c77fd5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20486305e94249099f57db0ff59aba4a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb13766dc4564b8b90da9a7ada8b71bd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie268449f84654877bacfa7e9d37cdcb0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c4c64100f14c0db098cf18e87b2987_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i117531eab6d74fa78cdef19fcd2f5e2a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i980c42c6c84b4875af45b55389e6bcdf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06bc5673bf1142388330261e2bb554f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8968b1047aac4f2ba3f6833da3d4ede6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41ded44352b54f19813c1b6eb4a76ed5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c9513c56b334510bf4095f6f01b6e47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ec7d6bab59945aaa45f7785f214840f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6e0d4064a11471ead457d43030a135a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf50be563d54838a275677850c705da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id75bf881994b43a087370158fad07e52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf4edcccc8394a23a7b3dcb738b03e7c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd1fbae30d564421bc5b7c93a54aea3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0d66e6f0814c7992ad674327d5d79b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f00bc9258974017a3430fe975bf7f46_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94b2c1e346e440078f5bd9c18d1ae3d8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d934d0b4eae4422b768334c3e49324a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28218e6fa6044467a6cfa3dd3680f60c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i455c75e2b784434dac67f0841a1568b6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4a0882d520246b09a88c6bc55fb835d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45b25d8b3c75481bbe6f42f9cd219cba_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9681bc92d994054a7f881aaf0a4c1b0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i000196b3d5424523869f9b8cf182627c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14b36f750c6e4bbbaa5984ab14f7acf6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4e845cd0750449ea326e81a9883e61b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bb296bd3d2a499caa7ee8b26bf24153_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ea5bb0ee621461d878a0145d57a8e9d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b2b4206481d4c5a820281a781ad27e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7f162484d134b13ad2cb62e25a6050d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3514de26861c4453a347bd8a1fc4b612_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i902f565b388f41cb9be67571ecc22f37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb6128c207404236beafdaee21d920e7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203bb1d43aac431a8bb988cd1f2ca55c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73ee31bc4e9a444e89365fdc6b10afa1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a8d0fe803e64bc1a1ed9278b52c95f9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="provider"><xbrli:measure>ameh:provider</xbrli:measure></xbrli:unit><xbrli:context id="id898dfbac217454a95c7fd9549d95325_I20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bd0e620dca545c990c5623c174f38f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45abc06c771b489384112954fbdfcd19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85f82fabbbfe4571ab387179ddd7a738_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91c58bf26bff4f73b162bbd22f236e8d_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80b8650ee33648d99a9a3444e64846f0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5ef16887c064530aa3691f19b525d0d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b208272f13f4a57957a453690effbf0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cb8b922bdee480c9f9aea0eff1256c0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77427e343910426d8907e4dcf7f52bc0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c127671e08453090839c66152b9457_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9acbaa81eaca438db99ca8e197a48492_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8396566a02bc4bda8fe4bcb4acc37087_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea5b5005ea214626b46b60892e1c296f_I20150731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc81f74f6ea84843a75b19e6188f7d59_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia021d902c6194cd1b515f6e5d2851f67_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if44758b50abb4b998c0cf1ed2f59be70_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cffd986457e4a40859857d465e80d31_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18eaba1b00ed42dfb2a3be9037829586_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id76dbd62385a4c2b89c6cc4a159139e7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad6d8a1fd79d4409ba2643b463115e12_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee6c2515c3594dd08fa54babfc3d2655_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74678b3019584b26a57edb839bf1d877_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0352070af4d49b7b10b093cf1d34b6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if581017651f14f9681014c41a5d3ced8_I20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica129d7dca744715affd24c98e9c389e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79b6369351c24a7caab010e07fef7ddc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39714cbfb75465e896a533af99abbae_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if78fa0d638d24b928edf2207da5c5965_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i649b46d7c3d54c2e8ddb0eb3f0f6cb20_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CollegeStreetInvestmentLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5f4c57435414bcf8530f7c1b7159a3a_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1280e975bb74d6793bb6decce02bb42_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3dca6af71454e249bc71f841ff3c773_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bc00772371f43338e0a4894146965ab_I20190423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6db22be029534d1ca263dccd767fc1fc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i567fe9f349ad4cd38b7073fc838b36af_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8c0ead5cd26416784c4b0aae0965159_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c9277df25244861a1723845d457f7c1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8f2830655ce425ba50defa19207191c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia48e961c12c64515bfac403310620fa8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fcc11a65d404699b74bae8c3005ddcd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7786b13c92d44768ab2d5ee5d1646497_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02fd82315c204d5b8e983153d3e96412_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie83b679468814dbca4be10a39fdb5bc6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db0b17b399c402d90d5cae3426b67ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie178a5bc23a34e3e968fdb0a7cc1b1d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if45e4368c403487ea641b147da7d6ec4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibecc6ab98d324e62ac84506d9b662237_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id997a6c5f4e24485b8c86ad8253ab602_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i604941a7c4e84e29bd7ca533697deae5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i464e0ae5827e4e33a2ade15334ea8236_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78f0406a51e34beb80ce3cd5596fcbed_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6a9eab9d354ba48b715b8872ad825d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78f6b75f6efe4952a520c49f86b2ac80_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa51c5973cf04aa690f31014de335453_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54cc9af425747bc9bf0db47bae0cdf5_I20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie20db30d9d2f4ad790ae13386a5e01ef_D20190701-20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d2eae5117d042b4ae64a03222d5c117_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i525bb8235fd64a5c8f0c02ec9cbb55e4_I20201030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f146f9b4b714488a52f519d85dc9915_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibff23baf29ec4ca5a5fac9212a3be6ef_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45bdfabdb85c43999bb05d916a50e971_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8494272cd6364c2a80530dff5382f450_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id37550a1e26f4222af82434fc245548e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0099b63992df486aa72820a547d7a3b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic51fbee815c34c8bbdc2590d6bb3ba93_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if29783d76d8e4e5c979ae194c2e9e7d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c70eca48984b6aa875a69a43dd3f0c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebc8ed74b68a4195a91620c9be1362c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ee83ed94cb43dcb3182dcb57e382f9_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f4f916cef32400dab83a02c9f3d1dff_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63ade4493fd74989b1999037fc8db598_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55616ddbc4dc41fca2e3f5474cb36d53_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i894dad9f04be4b80b0c5418db6c0ffac_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb62b8a56d704692b86255ec6cff3fd8_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied77ca7dcd3c44a3ad71dbbe16d60235_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i637ca2c6a62940f5bf8cd582df12b45d_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2da520099b4f4b1e85134d04cfed7267_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c74cb40c8b4d9882ce3f1381253d36_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5f64948f20549f29b7ad2775ac72e54_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3501cf38d6f349bfbb10a514b5e413c8_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id51378c59e4b46a1878e9755158c9508_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32a0cb9701af4dec94e8c8b4a88e8a16_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bcbe6284db54a94b3f1f04677fe3f92_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic51076d7bee7498eb636ef7814297785_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea7e71c000342b8995e416f3a7cff49_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7820cd54de244cb28e02edd916f67207_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e608242dd8442239280156056c80e78_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc5ad4c4fa8b4ec698a83764c9b1d2d4_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="financial_ratio"><xbrli:measure>ameh:financial_ratio</xbrli:measure></xbrli:unit><xbrli:context id="id383d2aa762447b5b54e8e4dfc37d7c1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id909b639f09f413ba4ac35e191a08c1d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d07d7302e04f1093a19129cb01db1a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6847b33d46c94f279cb67bd2e1ad4362_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f8776621075492eacb36b4093b785ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6ce9908aaf4419a562611bb678c2a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8147fcc7b25942ad8a37c6657211abf5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2acf51a712524f44ba644d48d0a00647_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd7cf95bb6ef4965bf29b2064ac819c1_D20200703-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-03</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07f6fe5be32e4b7292d433a12ca499c0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a5651c8948b4047b7eab25f8764f012_D20200703-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-03</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f31366737854b98ba91333a885afcb9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5f1743593b44f9a80d07f923a92908_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82b2d9d7053444d4aab270f6ad420a79_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c657488d54b424380f6b218f717a662_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfc39a3c7e114b588a1abebd9943f489_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeabd70c59714c11a93da612a94d392b_D20200727-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7530cbcce02f4598a2e22ba8f19dabdb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic56ef9908db04d4ba9b326259616f237_D20200727-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37601241e5164c76b84df50fe2dccd42_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a5e7cb27c6a475e8bc2918ac9af91a3_D20230101-20231201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i048bc9147744436cb31702bc505497d5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bb465d8e0fa47b281bc8588585bfd99_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd5c1f9d9879419881aa4f73dbd34259_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeae1845ac274f829e29f2feb496c443_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2c3441a286f4428b822c3dc66bbbdaa_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4908488c47c942d99a8fc66857f5053e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id34357efa1004d2ab40ef715b0949c59_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i949ff001ac544940b35caad34ef7b315_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icee52b68969c4138b7b2a2e8af0b227d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if82c8f50b6884a84bb5fec6d0c53d8e6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20c5c1427f6f4e6cbd81faa6df3205dc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5b45c5e6ea841c1a753923224520654_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0be646a9c14345fabdb07fa7e3f377f0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ae0dfc3bc32416cb6ec479fa6aee249_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaf0c3ac99784174b913090c36595512_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id92d571acf4e4268885451c976638558_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie56d0d0b55424badade9e1fc4b2d1fb1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1bd75ff5a784460bc879854f3dc5e14_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if75c2580a6e64c94a6c643c85453d033_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia33174543dcc47c381797d497163fb30_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e6ca8ac3e24c129b22e6f9b5d3b25c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26630cf67d1949a1bb14af99246ab11e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieed5052a2c264a58a60f18048fdd7abc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15e8004b924f4bdb999ba8d5a25493b0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id224224b17a647d7a1bbdb52d3c8ee5d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b5c1fd7f16d4fabaa391acdd0d5b331_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a3914dba35149aca5f59b14362cf84f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7a1b7919fd34831b23c0c3972b0f9f7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72e43a94fd374088a88895c32404f338_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bc83e3bcab6489aa067dd6bbdb2afc2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6993e6cdd0a34b838468c68d5890d474_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie42410e4e0cd4dccab9e87193dccb1b3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b411e1124154e218ae663e7d0cd0811_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if24be682ffa04df6b410bf2bdba494b9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d5fc98033004eb0a900852b969e1fd0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f1985914f0496ea8f8d5f1f4b62193_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36da10b506ee401bb6c1ad5f810e813e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75b1c7458b864e9b981a527bbfa8158f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72d599d61813449280a927233fdb0405_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4819d9b69dd44a989faef6c6cbbe20e0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01889397be3e428281f28320683c1430_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e30659b8d845b5bc23aafc96ddf13b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3b55bbdae154354b76e9f0bf837e3d5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf76fa460e274183b775eab34ea28a8a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbe9675fd54c4c248789b3ab515892fa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11d2613adfb84faeb941f179c4fb08a1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5e56d3070c14ba4a8f92e0c3ba9b04f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e8ffc3fb93241efb949e02abb5a85f0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64448178efd84c50aa3bacac86356338_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d9ad1e3f11440fbbd1039812179f70c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7886aad669f7475590e40c23c0dd147b_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeb37dc642874abea221866138cc2490_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13fdfd16535e4f75a502075defa10c8a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia318b9c86cb8437086dadd8cd7bcfdb8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4dcff1f010e404e963a5a4fee776b5c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342b9208e4894d718c1b127a0a3ff4fb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icece2b97c5c941d3af2e6952b3212f8d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40def8e50b1b4db5bd03f6203dc8a1a7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i471239abb6364a489ec282dd9c5f777c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i148d26d55f8f435b9874038459f936e1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if752ba09e479448bb94fbca2c7882209_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib35d85fe21db4cfb8b79e5c7ee1228c3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b9b3c7021d744e9b32b81acaaf16e56_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58aaac3be5054957bf60bbd75029f96c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f003a8cc01d41348437b13692cef86c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie68ce3d93d494b71998ca2d6f07d2c77_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a7e5a8570084a00adb32a4bdb60bbd1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b2df61df72d41dab21cfae235327e40_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10f15782af0443ab842ba194eb8c55f8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee30b0d2253f4bb492015b9d7da0adb5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dbf0fd1b79a4e77bdd4836d453ae1b0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if47df11b72db4b389d16b2265853b9c2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1993cd5de17942f99b55c5e4dae41d86_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec1fb7fa46f34dd39ecfb564894305ee_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7395056c59fb49af99bb8cde1bd98437_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25917a62f9c2433c936ab8aefbd468c7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied011d8645e3412aa2f3e2387b1cb1a9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b30d2846b14b2c897a80d786dde119_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6896fdcb8ae4b7ca99bd00de7787507_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5a867cf070d443da348b27bcc09a6f9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdfaf156fde64914862fc81410e5c63a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib523d137eddc47e29f0030b185a7b372_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b5a146f0b1e44f5b789255f0c543e0b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i173a4dea7cb24055b072519c2bdfe757_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54147940fa7a4e1fab0ebc8efdde6b95_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21dc815a2c734a16a45443053949a1ac_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd69f4d08ad148e9ab3a76b73d5a7b44_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5c8495e26684dcc9ad519449c4bc3ec_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9a649b9c8c46d6880482c83fb0ff4c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i478b087008894447ae487fe130dd89e6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icafd606f127347a5a215b6401a63da94_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f3ab4e5a41043c2ae92af6c8f11dc34_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib124a96ecc074da29278d04a4d7de485_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb0c1db1b2d84d2fa57edc7c15d4fac4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51e4bde9a34f42159e327cca1a631656_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic03d35847f734105a48e1318bda34af3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eb15316a75740d3a7e2f2bb4ec65285_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d0b297b84754d2ba32a089d68928fe4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95582f9ab23c40c88ff9c9aa11e8368c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i516478a0add344df8b418bb1e41a3d53_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01d16bcfadca4f16a85f305b306f3af5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb8612b46bf04b23bb32513fb5f4e06b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a1d28025a574e8f8c021b319564a04e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6dfbbc083a24b1fb873315d3843b5bc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia126933eaa88475f8ca99bc2e342801d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fe5c8cca1584e10a27f094882462ec4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82d32e9e52cd43b8bde097d8ad4cf68d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c0bdbc45944c189d1902dd97e0b2c5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c01da554a346699ef38852e5a9238e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6956147d1b1d44068bcecf36bebb1819_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e8aacaa10644e039ce5c4b96322fc8b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4380cb2b0e24e1994d0661bb4241a61_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fe20fe658aa4256aabbbd2c89d398ea_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae1ae82bc8db4b2d995d2be127951787_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9491c7189f4bc1a3a03bbff2758fdf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aa407ed2a23431cb3c6911df6e8bf96_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea3d25188b02481c84d1af0e34e1d2f0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7b7c8fa79242e4b1f9fd2aed295aac_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2ed3ce186f64ecd9e26858f4e56cbaf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i699b0a24650b4020ab36add96e94ba16_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df4d6d4265646919c8679d06c6f5f8d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6847bf6720074c31bb84ab647a20bce7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c8b780248c2455fb8dd5302f1cc8305_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f9ab052b3f24f16b3cdc5fc945ba7a2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb0ef53cb71e453a995be937fb48b3a6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447f7dcce84d4cebb5acb882ea34ecbb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5973967987a64974bf0b313e96b45d1b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id082ef37853342dbafac08634c15ffe0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1b43cafde674d70aa71314660d7da57_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i852e3ec3537a4c119c5f8a22d38b551a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0047fe9e823452fb45b32fabf79ea46_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef913adaabe443884d85c0a2a9ace03_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0932a147a2f4eaaaf31703eddb2b244_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic947409b267649339b37e4b534577ae3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c285663f977492290e465d3a04c4a3d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d3b34a11c90439a83c552a032829eb0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d750657b42421a8e440b3dd05fd4dd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67e38d8ef3944d2b52b5cddc0110cf3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5bb1b525984a4b94e3835c3d3c958d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36efa1094ce84f39a33d944df471c9bc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6cab8e82bce461aadf4a8285aaedf2d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i396303604fe24b649811f19aa1b86666_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6af953349f5741e6903f07fe40567fb1_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i347edc610f5f44f797de7ecdf6022137_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea7d2b87a68e4688b5afefdb57fd6387_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzAtMy0xLTEtMA_a5ff60fb-e978-4632-811f-8acc8fde5032 id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTUtMS0xLTEtMA_1158702b-f85a-49a8-b56e-bc619fb29d85 id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTUtMy0xLTEtMA_83cf3721-9957-4807-97c8-1f0e124151ee id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzAtMS0xLTEtMA_6c7a426a-55b6-48ec-8702-a4a1872ac251" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNzY5_61338a45-c8ff-473a-9da3-f33393b3aaba" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i77048548a0c546beaa10a42c80553a71_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDk2_e6d0fdee-4388-4e10-90ed-e0ea7d9b3d35">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6ZmRmOWFlMTk5Y2IwNGQzYWJlNTU0N2NmZTdiMDk3NDUvdGFibGVyYW5nZTpmZGY5YWUxOTljYjA0ZDNhYmU1NTQ3Y2ZlN2IwOTc0NV8wLTAtMS0xLTA_200890f9-10fd-41d0-af18-70dc49044eb2">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8xMjM_efe09c29-2fb3-4f17-b5bf-99442a1b9b83">September 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6Y2EyOThmMjk3NjFmNDI4MTg5ZTk5OTQ4NjE4NDE5M2EvdGFibGVyYW5nZTpjYTI5OGYyOTc2MWY0MjgxODllOTk5NDg2MTg0MTkzYV8wLTAtMS0xLTA_fb5b4baf-bd12-4de1-b1ab-50f9aed7262a">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from &#160;___&#160;to ___.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDk3_eceb12b6-8524-4ea8-8c51-5390695ea2aa">001-37392</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDky_eb9919d8-eaff-4c64-94f3-446863e00ea1">Apollo Medical Holdings, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6ZjdiNDJhYmEwMTA4NGMyZjhiZWQzN2Y1YTliMjc0ZjUvdGFibGVyYW5nZTpmN2I0MmFiYTAxMDg0YzJmOGJlZDM3ZjVhOWIyNzRmNV8wLTAtMS0xLTA_40cbc782-dc41-434e-965a-7b94d7891974">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6ZjdiNDJhYmEwMTA4NGMyZjhiZWQzN2Y1YTliMjc0ZjUvdGFibGVyYW5nZTpmN2I0MmFiYTAxMDg0YzJmOGJlZDM3ZjVhOWIyNzRmNV8wLTEtMS0xLTA_d0b54553-a609-49fe-a7bc-8700c351dc7b">95-4472349</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification Number)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDk4_159cb431-0edd-4429-bb28-93be6ec28903">1668 S. Garfield Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDg2_7d3a356f-ed57-424f-9f63-40ab2c063836" continuedAt="i340e50870ccc428b8c87b13fddc4ca7d">2</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i340e50870ccc428b8c87b13fddc4ca7d" continuedAt="iaca9cac63d684e8cae4704d69cfef6b6">nd</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="iaca9cac63d684e8cae4704d69cfef6b6"> Floor</ix:continuation>, <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDg3_a8a3ead5-80fb-4713-b849-46ee99fa217f">Alhambra</ix:nonNumeric>, <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDg4_7ada558f-d1b6-4852-9a89-81dc85e58501">California</ix:nonNumeric> <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDg5_522dc11c-dcce-4d80-9420-5a2cdc482bd5">91801</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDk5_539b174c-d5d7-4b74-9e44-0930909b32e4">626</ix:nonNumeric>) <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDkz_723097b5-03cc-477d-bc20-29ec0bf6fde8">282-0288</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)&#160;</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of Each Class</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Each Exchange on Which Registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6Mzk0MWQwZDlhNGUzNGVmYmJiODBmZGMyOWNlMzM1MzUvdGFibGVyYW5nZTozOTQxZDBkOWE0ZTM0ZWZiYmI4MGZkYzI5Y2UzMzUzNV8xLTAtMS0xLTA_0841dd30-e8e2-4800-badf-6ad8a17bb081">Common Stock, $0.001 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6Mzk0MWQwZDlhNGUzNGVmYmJiODBmZGMyOWNlMzM1MzUvdGFibGVyYW5nZTozOTQxZDBkOWE0ZTM0ZWZiYmI4MGZkYzI5Y2UzMzUzNV8xLTItMS0xLTA_2ea5c6ca-416c-428b-9bc5-f9cca63cb010">AMEH</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasdaq Capital Market</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDkw_6cee7f73-b151-4a24-9d6a-627eeb64e24a">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDkx_a31307a9-72e7-4295-95bd-1b7337abb485">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6YzgwMWIyOTcwYjI5NDJhNjk1Y2NlOWM1YmYyNGUyODQvdGFibGVyYW5nZTpjODAxYjI5NzBiMjk0MmE2OTVjY2U5YzViZjI0ZTI4NF8wLTItMS0xLTA_3756c1c6-e72b-41a1-80be-007b9607e9f5">Accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6YzgwMWIyOTcwYjI5NDJhNjk1Y2NlOWM1YmYyNGUyODQvdGFibGVyYW5nZTpjODAxYjI5NzBiMjk0MmE2OTVjY2U5YzViZjI0ZTI4NF8xLTMtMS0xLTA_ba0f4e86-1142-46e6-9429-359d265cc8de">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6YzgwMWIyOTcwYjI5NDJhNjk1Y2NlOWM1YmYyNGUyODQvdGFibGVyYW5nZTpjODAxYjI5NzBiMjk0MmE2OTVjY2U5YzViZjI0ZTI4NF8yLTMtMS0xLTA_5bab8c4b-c674-4fc7-b830-efb5935ca46d">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDk1_5d09612c-0bb4-470a-ade2-d1bb2f76fec0">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; No</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;26, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i081def6efc024948a044c021d9c0814c_I20211026" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8xOTg5_bba5f3bf-63df-4a9b-a618-22feff3eb32b">55,549,053</ix:nonFraction> shares of common stock of the registrant, $0.001 par value per share, issued and outstanding.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FORM 10-Q FILING</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PAGE</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_13">Introductory Note</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_13">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_13">Note About Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_13">4</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_16">PART I</a></span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_16">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_19">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_19">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_22">Consolidated Balance Sheets as of September 30, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_22"> and December 31, 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_25">Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_25">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_31">Consolidated Statements of Mezzanine and Stockholders</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_130">&#8217;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_31"> Equity for the Three and Nine Months Ended September 30, 2021 and 2020</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_31">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_34">Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_34">11</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_37">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_37">13</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_130">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_130">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_130">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_178">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_178">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_178">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_181">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_181">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_181">65</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_184">PART II</a></span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_184">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_187">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_187">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_187">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_190">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_190">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_190">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_193">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_193">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_193">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_196">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_196">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_196">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_199">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_199">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_199">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_202">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_202">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_202">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_205">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_205">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i77048548a0c546beaa10a42c80553a71_205">67</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Glossary</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:28.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Health Care</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Health Care IPA, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC Healthcare Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AIPBP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All-Inclusive Population-Based Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Care</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Care Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG Properties, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloMed Hospitalists, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apollo Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH 2 Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAACO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APA ACO, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allied Physicians of California, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Access Primary Care Medical Group</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA Designated Shareholder Medical Corporation</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAHA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bay Area Hospitalist Associates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDSC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Concourse Diagnostic Surgery Center, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CQMC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Quality Management Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">College Street Investment LP, a California limited partnership</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMHC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California Department of Managed Healthcare</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Medical Group of Southern California</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Source MSO Inc., a California corporation</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC International Cancer Center, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">independent practice association</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LMA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maverick Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MPP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Property Partners, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NGACO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next Generation Accountable Care Organization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NMM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PMIOC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacific Medical Imaging and Oncology Center, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southern California Heart Centers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Labs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Clinical Laboratories </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investments Group, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-8 Medical Investments Group, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCAP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Care Acquisition Partners, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Care, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable interest entity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZLL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZLL Partners, LLC</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i77048548a0c546beaa10a42c80553a71_13"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTORY NOTE</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context dictates otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to Apollo Medical Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;) and &#8220;ApolloMed&#8221; refers to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) have not reviewed any statements contained in this Quarterly Report on Form 10-Q describing the participation of APA ACO, Inc. (&#8220;APAACO&#8221;) in the Next Generation Accountable Care Organization (&#8220;NGACO&#8221;) Model.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names and trademarks of the Company and its subsidiaries referred to herein, and their respective logos, are our property. This Quarterly Report on Form 10-Q may contain additional trade names and/or trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names and/or trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of federal and state securities laws, including, but not limited to, statements about the Company&#8217;s guidance for the year ending December 31, 2021, any statements about our business (including the impact of the COVID-19 pandemic on our business), financial condition, operating results, plans, objectives, expectations and intentions, any guidance on, or projections of, earnings, revenue or other financial items, such as our projected capitation from CMS for the year ending December 31, 2021, or otherwise, and our future liquidity, including cash flows; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our Company; any statements concerning proposed services, developments, mergers or acquisitions; any statements regarding the outlook on our NGACO Model or strategic transactions; any statements regarding management&#8217;s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms such as &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;think,&#8221; &#8220;plan,&#8221; &#8220;envision,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;budgeted,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and the negative of such terms, other variations on such terms or other similar or comparable words, phrases, or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q and are subject to change.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K, for the year ended&#160;December 31, 2020, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;15, 2021, including the risk factors discussed under the heading &#8220;Risk Factors&#8221; in Part I, Item IA thereof. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change, and significant risks and uncertainties that could cause actual conditions, outcomes, and results to differ materially from those indicated by such statements.</span></div><div id="i77048548a0c546beaa10a42c80553a71_16"></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i77048548a0c546beaa10a42c80553a71_19"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_22"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNS0xLTEtMS0w_76856016-3001-4921-91c0-7679efde2531">204,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNS0zLTEtMS0w_4ffe6472-3aad-4768-83ef-e5dfb9b1980e">193,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNy0xLTEtMS0w_2a57a509-6f5d-4fc6-b37d-fb39868fcd6d">128,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNy0zLTEtMS0w_361b1af0-47a0-4dfa-a232-0e20fca35945">67,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfOC0xLTEtMS0w_38357055-03ad-4f3d-b1d3-7f0384df6894">18,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfOC0zLTEtMS0w_10850e34-670a-49e5-a752-94fe2a6ebacd">7,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfOS0xLTEtMS0w_85406e7d-59bf-476b-875f-1c6a9aee1d07">53,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfOS0zLTEtMS0w_591916be-8f6e-49e4-a984-710342329ad9">49,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTAtMS0xLTEtMA_6a0a89b4-cc45-4741-b18e-93d5d7738a5c">5,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTAtMy0xLTEtMA_b4ea6274-fabb-4449-98f1-1b528281a680">4,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTEtMS0xLTEtMA_48a1825b-2d95-44e1-bbdf-86dfba6f8184">11,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTEtMy0xLTEtMA_fb69067d-a20d-4547-827a-d1f1607c2975">16,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTItMS0xLTEtMA_db5a070d-d9b8-4a3a-99f4-8f9b8322c5b7">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTItMy0xLTEtMA_1827baad-1c5b-4a70-9f49-b903463cbc6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTQtMS0xLTEtMA_65d1c434-3d88-4e50-aa28-40b6ba2bfe70">427,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTQtMy0xLTEtMA_642df68f-93aa-4305-bdbb-da6d9d3097c3">338,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTctMS0xLTEtMA_ce872392-47e7-45c8-8d78-8588f6e0e2f6">49,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTctMy0xLTEtMA_94f08e34-7399-46d8-b8ea-50497e0f818c">29,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTgtMS0xLTEtMA_30418cc5-3ced-487a-bfea-352031b4a97b">83,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTgtMy0xLTEtMA_c0cada40-2dd7-4256-a8dd-999d312c36d9">86,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTktMS0xLTEtMA_05bef1ed-f7ce-4387-9835-3fee1e91f966">243,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTktMy0xLTEtMA_5af005d7-7054-4d18-8cd2-b6e11ae1b869">239,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjAtMS0xLTEtMA_e3ec8175-06bf-4305-bd00-5b38b75366f5">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjAtMy0xLTEtMA_09179401-8df1-44e6-adf7-449609e6b613">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjEtMS0xLTEtMA_8d247c6d-10d8-43f9-bbf4-b19a7096dc8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjEtMy0xLTEtMA_659bc095-5cf7-493f-bffd-9dc8575f36f5">4,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjItMS0xLTEtMA_17d5b91b-5757-44c3-b370-708f54b22367">45,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjItMy0xLTEtMA_52794099-52b4-4b37-afcc-b47e61c95c89">43,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjMtMS0xLTEtMA_936d152b-faaf-40f8-9572-0bbbe4a8a87e">896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjMtMy0xLTEtMA_58decf6f-8079-447f-bad3-5c5425e29293">37,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjQtMS0xLTEtMA_79f68df8-f929-4b88-9a0f-1fcba1f3a827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjQtMy0xLTEtMA_abdf75cf-b6a5-49a8-b036-367703096e7f">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjUtMS0xLTEtMA_36b0b661-5bc5-414b-bc18-1e2c68871462">16,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjUtMy0xLTEtMA_c85f2f94-6245-4fdf-80dc-f55704759525">18,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjYtMS0xLTEtMA_c44402c8-5391-4d79-9496-a141516cb892">5,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjYtMy0xLTEtMA_53e24e71-5bff-40ab-970e-b315970e762d">18,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjgtMS0xLTEtMA_6b7e6586-2be1-4b3d-b13e-813702668302">444,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjgtMy0xLTEtMA_ad98eacc-1576-4d5c-8e93-db49cffd26b1">478,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzAtMS0xLTEtMA_6c7a426a-55b6-48ec-8702-a4a1872ac251">871,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzAtMy0xLTEtMA_a5ff60fb-e978-4632-811f-8acc8fde5032">817,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities, mezzanine equity, and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzYtMS0xLTEtMA_53960da9-7af0-4b4b-bb45-f73bc233dff8">57,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzYtMy0xLTEtMA_71cfacac-eb67-4251-b78b-91b87415c534">36,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzctMS0xLTEtMA_5182e1f8-1fe1-420a-a32f-f142e89d7461">8,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzctMy0xLTEtMA_0caa1acd-2c83-4609-b15c-a898c931b6f7">9,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzgtMS0xLTEtMA_a06364d2-0e32-45f2-9a96-e11beaf49e13">42,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzgtMy0xLTEtMA_45060b06-f6de-416e-9237-3f43acabb4a1">50,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzktMS0xLTEtMA_e132cb23-1692-4a16-a16b-c7dc4f19f025">4,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzktMy0xLTEtMA_056fcd7e-95a2-4560-a4ac-ce67561bbfe1">4,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDAtMS0xLTEtMA_3d185abd-6d3b-4471-8329-b99997797a78">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDAtMy0xLTEtMA_37f3a146-e29a-445e-ad5b-92c40cd26f1e">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDEtMS0xLTEtMA_453f448a-9fd3-481b-9e67-df9031fa5781">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDEtMy0xLTEtMA_c78d66f4-a1e9-460a-80da-0b4bd06f3fe2">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDItMS0xLTEtMA_e2125848-f423-4612-80ec-c55df270a1e5">2,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDItMy0xLTEtMA_36092add-51ed-449e-9d28-cb33b12d7352">3,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDMtMS0xLTEtMA_00568d1d-f15b-4937-aa2f-be2f63b0824b">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDMtMy0xLTEtMA_08790ed6-e94e-4056-b8a6-3a2cc8d5cfc4">10,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDQtMS0xLTEtMA_359b1e99-0716-4cc1-aa4e-758bbd2419e8">116,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDQtMy0xLTEtMA_ef5ee17a-31f4-4170-95c8-8cdc28ff907b">114,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDctMS0xLTEtMA_5f2e0395-a8f8-43fb-96cd-ec4e709bc034">19,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDctMy0xLTEtMA_f2a85a90-74c5-4bce-9940-dcf98f6ce075">10,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDgtMS0xLTEtMA_46227711-56f4-4f9a-b2a7-f479af99e0c7">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDgtMy0xLTEtMA_8eb651d2-4716-4db1-9ac2-9305c471e4b0">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDktMS0xLTEtMA_e1bffdd8-c13f-4fcd-8380-41245b4bdbf8">13,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDktMy0xLTEtMA_53cd231b-cc02-4ff0-85e8-967532df58de">15,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTAtMS0xLTEtMA_4cbdff58-8ded-4301-8a53-3196a298101f">182,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTAtMy0xLTEtMA_2c3972d6-56d4-47ee-80db-d626484b8514">230,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTEtMS0xLTEtMA_4779c5f2-e6c5-40d3-bb7d-bc60f5ced80d">6,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTEtMy0xLTEtMA_ef30819f-e4e3-4070-80a9-a479ea6310b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTMtMS0xLTEtMA_d1f17bff-b5c9-4f34-82f3-7310320cbd07">222,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTMtMy0xLTEtMA_abe88e4e-3cc3-4ebc-8c8f-cc56ba81f4c9">257,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTUtMS0xLTEtMA_1158702b-f85a-49a8-b56e-bc619fb29d85">339,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTUtMy0xLTEtMA_83cf3721-9957-4807-97c8-1f0e124151ee">372,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and contingencies (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTctMS0xLTEtMA_c9c5ed64-c67e-46f5-8824-e75bc4ba5697"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTctMy0xLTEtMA_9e52ea7c-d2d0-48ec-882c-a9630f6e5734"></ix:nonFraction>Mezzanine equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjAtMS0xLTEtMA_d2b4301c-cc7e-43e1-8111-cd8e26f4ce3c">91,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjAtMy0xLTEtMA_2ffdf339-67b6-416b-885a-2ca146a390be">114,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9a5866334d904a29bc8ab814fa041912_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzMw_0788b370-337d-4761-84a5-8946fe7b0436"><ix:nonFraction unitRef="usdPerShare" contextRef="iad641d4c836c4802a609fb48a91e312e_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzMw_e9dcd68d-fbff-40c1-9510-2bcddc56e28b">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="iad641d4c836c4802a609fb48a91e312e_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzU0_23e85a81-e502-44d9-aa4a-8678909f2344"><ix:nonFraction unitRef="shares" contextRef="i9a5866334d904a29bc8ab814fa041912_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzU0_9dc13fd7-e927-475c-bf56-80c6eb1047e5">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series B Preferred stock); <ix:nonFraction unitRef="shares" contextRef="iad641d4c836c4802a609fb48a91e312e_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzE0Nw_6666c8ac-9dfb-4df8-9c8d-48bd9f010a43"><ix:nonFraction unitRef="shares" contextRef="i9a5866334d904a29bc8ab814fa041912_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzE0Nw_80d719a2-ede0-4229-82b5-7d541e85b7a8">1,111,111</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i9a5866334d904a29bc8ab814fa041912_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzE2MQ_6124d97f-dc7b-4a0c-baae-6fa6ddf56531"><ix:nonFraction unitRef="shares" contextRef="iad641d4c836c4802a609fb48a91e312e_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzE2MQ_d80f6988-e471-4a96-aa75-5ed16699a52f">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a5866334d904a29bc8ab814fa041912_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMS0xLTEtMA_f3888cb1-1706-496a-a8b1-241cebe86628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad641d4c836c4802a609fb48a91e312e_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMy0xLTEtMA_6b73bed6-6e71-4ee6-8d61-0f10a72a771d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id51f2960969c49fb9ecd63b28cbac656_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzMw_1373f81d-a101-40fa-85fd-6734c2d611b0"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b4768d022194b07a1cceea1d21bda2d_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzMw_57bfdeea-0e0a-4c15-967d-59d95cff670c">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i0b4768d022194b07a1cceea1d21bda2d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzU0_5946b655-f5f2-42ce-bbe2-85b73537f9b8"><ix:nonFraction unitRef="shares" contextRef="id51f2960969c49fb9ecd63b28cbac656_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzU0_e855977c-cba8-422b-a14f-dfe31331e959">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series A Preferred stock); <ix:nonFraction unitRef="shares" contextRef="i0b4768d022194b07a1cceea1d21bda2d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzE0Nw_1207b52e-21e1-449a-8d4b-1a9af3894ad7"><ix:nonFraction unitRef="shares" contextRef="id51f2960969c49fb9ecd63b28cbac656_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzE0Nw_78c015ff-f31c-4401-881e-5d3a11cc0d24">555,555</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i0b4768d022194b07a1cceea1d21bda2d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzE2MQ_453cd12d-cf6a-49fc-81b0-906866f01b3b"><ix:nonFraction unitRef="shares" contextRef="id51f2960969c49fb9ecd63b28cbac656_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzE2MQ_cc4ddfa1-d42d-43fb-b9a2-dfd99da14bb6">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b4768d022194b07a1cceea1d21bda2d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMS0xLTEtMA_ca2a9f1e-572a-4644-8549-afcde917397d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id51f2960969c49fb9ecd63b28cbac656_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMy0xLTEtMA_beb53c38-16ff-4fed-ba5c-989bf84cd700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzE4_07e08d2f-96d0-4967-87a6-ee23f2974515"><ix:nonFraction unitRef="usdPerShare" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzE4_c90d1de7-bd62-4a3b-89bc-59af1099b49e">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzQy_03ee1a8f-3947-48ea-b6a6-233c72575299"><ix:nonFraction unitRef="shares" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzQy_de26086d-8990-4669-8592-4b9eebed6250">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzY0_54cefad3-0d14-498a-8b83-5c6a98ddbf9e"><ix:nonFraction unitRef="shares" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzY0_8d1208e1-9794-46a8-9fda-fff1e9e330bf">44,397,050</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0Xzcx_3459c872-fa57-4b7d-a81e-b2437cfcb609"><ix:nonFraction unitRef="shares" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0Xzcx_69ba5845-b865-4c30-82bd-e0ea865cd498">42,249,137</ix:nonFraction></ix:nonFraction> shares issued and outstanding, excluding <ix:nonFraction unitRef="shares" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzEwNA_3e70d7c4-ecba-4477-a528-50af4cee5245">10,925,702</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzExMQ_101d1cdc-616d-4791-b141-7a88f1187310">12,323,164</ix:nonFraction> treasury shares, as of September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMS0xLTEtMA_4bb22158-80e7-4688-9330-db7e51a914c3">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMy0xLTEtMA_0aeb12c9-ea38-4adf-8702-82ef0700c142">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjYtMS0xLTEtMA_65f3830c-abe3-4804-8d62-e1385a2d9e24">305,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjYtMy0xLTEtMA_3ca24ff9-e7a9-483e-b150-346e7dd12de7">261,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retained earnings</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjctMS0xLTEtMA_56a4e71a-7ca3-4ef4-ba32-38573cd74b66">129,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjctMy0xLTEtMA_3c49b39f-d8e1-462d-a4a0-00808440282a">69,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjgtMS0xLTEtMA_e360269d-916d-4895-96f4-5da7363b01e4">435,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjgtMy0xLTEtMA_9e267983-c5f1-4dcb-844c-ee4f2a072475">330,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNzAtMS0xLTEtMA_b7db59cc-c53a-47a5-a509-4b1995d2ff03">4,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNzAtMy0xLTEtMA_995b44fe-1c38-4436-8c49-d90fd234c5ae">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNzItMS0xLTEtMA_0547c91e-eb80-40d0-b3d5-b33aa2ad7c3a">440,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNzItMy0xLTEtMA_44e0a07d-e418-4b76-8f52-b0ec982f0767">330,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities, mezzanine equity, and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNzQtMS0xLTEtMA_362309d5-5404-4691-a864-6f282dfe01af">871,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNzQtMy0xLTEtMA_5ccebb15-c858-41a9-b6b3-b5cf429959d1">817,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNzY5_61338a45-c8ff-473a-9da3-f33393b3aaba" footnoteRole="http://www.xbrl.org/2003/role/footnote">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $<ix:nonFraction unitRef="usd" contextRef="i44aab1fd19634a0abf32affdb96fc3d6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNDcx_d4978182-a4e4-4210-8b97-f96a3884fced">601.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if1a6d2676e4a4f7c93516c5989607a6b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNDc4_6382b97c-1d64-4896-968e-1c37f280629a">576.1</ix:nonFraction>&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $<ix:nonFraction unitRef="usd" contextRef="i44aab1fd19634a0abf32affdb96fc3d6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNjYy_f6fa359f-8447-40a8-9797-57f96e64bacd">92.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if1a6d2676e4a4f7c93516c5989607a6b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNjY5_536aa301-ed35-4dc3-bf87-add388818bca">88.6</ix:nonFraction>&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. The VIE balances do not include $<ix:nonFraction unitRef="usd" contextRef="i44aab1fd19634a0abf32affdb96fc3d6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfMjc0ODc3OTA3MDI1Mw_d8d7578f-f53c-4e87-a82b-6b83817cc5e4">994.8</ix:nonFraction>&#160;million of investment in affiliates and $<ix:nonFraction unitRef="usd" contextRef="i44aab1fd19634a0abf32affdb96fc3d6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DueFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfMjc0ODc3OTA3MDI5MQ_c939d1df-5e91-49f0-9159-c84d0851aeca">15.8</ix:nonFraction>&#160;million of amounts due from affiliates as of September&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="if1a6d2676e4a4f7c93516c5989607a6b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfMjc0ODc3OTA3MDM0Mg_6bb71093-358b-4534-8c3a-a9a09f56f7ae">225.1</ix:nonFraction>&#160;million of investment in affiliates and $<ix:nonFraction unitRef="usd" contextRef="if1a6d2676e4a4f7c93516c5989607a6b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DueToAffiliateCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfMjc0ODc3OTA3MDM3OA_06983b0f-ba41-4490-8b55-c02ca8933e4c">22.7</ix:nonFraction>&#160;million of amounts due to affiliates as of December&#160;31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; Variable Interest Entities (VIEs) for further detail.</ix:footnote></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30833e792bfc43a2946adc49df5531cc_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMy0xLTEtMS0w_f1f29577-3700-40bc-9c1f-960ce406b773">149,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041d40d8afd432cb4771fc0bd8f7304_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMy0zLTEtMS0w_3d98d413-8120-4dc0-adbb-d23e6f536716">135,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2de323650fd49ae83aa4d7539a0dadf_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMy01LTEtMS0w_5bba4353-f82b-4b77-9138-713266368297">438,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666e2bc0492b4dbaa017b3c5a14241bf_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMy03LTEtMS0w_de96c2de-7906-42f7-ad29-e0b37ac7d882">416,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd70461a565a47d1940d89ea394eb16f_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNC0xLTEtMS0w_37ffdd25-aa06-4b5e-8951-4e360aaff954">59,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8926c849258d4bf19ef81e0f57e4b423_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNC0zLTEtMS0w_837009ae-ea8a-45ff-840e-7feae1420346">30,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a4d9502c44417c9ed0cc8ee95e6590_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNC01LTEtMS0w_7676be3a-dd12-4cea-99c8-d1e38b48455b">94,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08037cad3de049069310b5c67f35a842_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNC03LTEtMS0w_7f599c00-3bef-4b55-a109-2bda323205eb">54,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5095a52ac50d47f0b3d6a33cd48d5183_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNS0xLTEtMS0w_d09528b4-f76e-4761-80f8-a662aa78edcd">9,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a1d4a44517452191a99bec6fd96e36_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNS0zLTEtMS0w_d4cb47a5-0ac6-488e-aafd-63fc4156058d">8,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3329b671360b4adfa4fb2f7c426fc278_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNS01LTEtMS0w_8aa3e419-e23a-4341-b5cd-86236c737f90">26,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0648ad97fbf94588a4eec1557fb996bd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNS03LTEtMS0w_7bd7c0d0-7baa-4501-af8b-9cce137800e8">26,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70980a62a1e84c5983e0627f4bd4a74c_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNi0xLTEtMS0w_c368fbdc-7b39-4c04-951a-0015bd821801">7,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8071ae425d7b4d82a5d84d8061a175da_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNi0zLTEtMS0w_b93a112a-8149-46c5-80c6-f3fc200ecff5">3,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f72d40ea546400db958d3bd6d935430_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNi01LTEtMS0w_e3af71a2-a3ed-4101-8156-dc44772a68fd">14,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie52aa3c0e803447b8b93a4eb0dcbf84c_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNi03LTEtMS0w_b2a3fa33-1f91-4442-8ef7-22df20a6a943">9,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1cbc34be30f4ca4ab2451c5ed3b56b8_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNy0xLTEtMS0w_4d34d874-073b-47c9-b1a6-f94023a1015a">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0a10078cec44029a1922a6aaf038643_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNy0zLTEtMS0w_cf575b8a-27de-4b62-8fc5-5cba6f96d454">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1512a021721849a0b8da03b2afac2ca0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNy01LTEtMS0w_98f3594b-6401-42cc-bdd6-ec80063b0f34">5,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a1665ab3028449997d07390764c0066_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNy03LTEtMS0w_656b0882-1f56-4c65-adb2-2860ace7fa8f">4,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfOS0xLTEtMS0w_cf459961-1a1a-4ab3-9e84-56c97a56ac9c">227,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfOS0zLTEtMS0w_0baf222e-ff4a-41f7-a103-5babfc749a40">180,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfOS01LTEtMS0w_fc1d9154-5f7a-4427-8f08-e8696ee38ed3">578,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfOS03LTEtMS0w_3fecc510-0e63-4151-aa82-3df3797d9c26">510,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTItMS0xLTEtMA_3abeebc0-9d40-48b2-b1e4-c1713c55d290">147,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTItMy0xLTEtMA_364954cc-1238-4cfe-904a-403fbecb2832">121,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTItNS0xLTEtMA_e30b465e-4b4f-44b5-a74e-77d1297989be">424,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTItNy0xLTEtMA_06b63b8b-5aab-42d3-8fc7-d89f3a4f54f6">402,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTMtMS0xLTEtMA_21db1ed9-be6e-4619-9a7b-4133dd3648c8">21,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTMtMy0xLTEtMA_3c0bd03b-3ba8-4882-a683-81c6497f7a06">16,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTMtNS0xLTEtMA_385c1eb8-a540-425d-9f4a-c9149e6ccaff">45,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTMtNy0xLTEtMA_79dce245-9890-40f4-bb2b-e183886b3c98">39,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTQtMS0xLTEtMA_066fe9ce-ff59-4e67-8f47-97672c8e2343">4,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTQtMy0xLTEtMA_c50f062e-23d5-4f25-89e1-09df5c0e799e">4,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTQtNS0xLTEtMA_dd3ebd50-fea4-4659-9fe6-151f398935ad">13,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTQtNy0xLTEtMA_0b542e77-9655-46ea-a5b9-88e80187d76c">14,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTgtMS0xLTEtMA_129d3223-fe78-4561-b7a1-d511a4494caa">173,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTgtMy0xLTEtMA_b4480085-d01a-40bf-b4a8-6a2cad9e46e3">142,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTgtNS0xLTEtMA_7fa69ed2-5b57-464f-b5db-fc73dcc6118b">482,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTgtNy0xLTEtMA_56f8aac5-858c-4c78-be04-3b70a7c9c96b">455,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjAtMS0xLTEtMA_249052fd-fd7f-43ab-9ea2-54dd5d1e972e">53,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjAtMy0xLTEtMA_acaba20b-5c04-4323-af6f-27006523b14a">37,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjAtNS0xLTEtMA_c0b08c6f-62ca-4893-a533-0cd5a4e88012">95,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjAtNy0xLTEtMA_1e09ff6f-619c-4126-aedf-c837465bd4aa">54,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (expense) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjMtMS0xLTEtMA_36d24530-3754-47c3-846c-f99d1acb941f">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjMtMy0xLTEtMA_8d6431fa-085d-4cae-adcf-0743825128b6">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjMtNS0xLTEtMA_37d9adc6-9b43-49e7-abc9-71bd1837dc2b">3,680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjMtNy0xLTEtMA_bd399a70-f4d8-410a-8820-f5b80baa7c80">3,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjQtMS0xLTEtMA_412f9002-6271-48c2-b8ff-046aee16274b">2,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjQtMy0xLTEtMA_77bee882-be83-42de-adb0-c39c2d96e0a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjQtNS0xLTEtMA_e72b50d8-5ec8-4123-9418-0221cc6e1e15">2,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjQtNy0xLTEtMA_737b0d4a-4f9f-4db0-a527-61b9aa2da1ab">99,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjUtMS0xLTEtMA_db80960e-ee9f-4c6f-b4eb-6532b52f6995">967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjUtMy0xLTEtMA_d71cbbda-2322-4e78-91dc-d368cb578b0d">2,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjUtNS0xLTEtMA_0ec9fadb-77e4-470b-aa44-48884258e06b">4,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjUtNy0xLTEtMA_4406da31-b58e-4377-afd1-95c3c8f5ad89">8,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjYtMS0xLTEtMA_9a8d0b1e-32d5-4035-a29a-234d6e13e2f1">420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjYtMy0xLTEtMA_0743cec7-2522-48fb-9dcf-1d95684c66a4">752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjYtNS0xLTEtMA_ba896c95-38ed-44fb-a850-2bed85129085">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjYtNy0xLTEtMA_738aba2e-ea19-463b-aa98-f7fbb7a01552">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctMS0xLTEtMzAwMjg_e11c76a8-fa16-42fb-a8b6-ac9f70b0e072">60,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctMy0xLTEtMzAwMjg_5b8fd053-3dcc-4490-accc-c15189b5c86d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctNS0xLTEtMzAwNjA_4e86e884-7aec-430f-b855-390380954abb">22,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctNy0xLTEtMzAwNjA_eba4b69e-a26c-4591-be4f-b9dcd271224b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctMS0xLTEtMA_1d6fcb07-744f-491e-9894-04f13a384ff3">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctMy0xLTEtMA_715e81c7-a9c7-44be-880b-05bbcf5d25cf">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctNS0xLTEtMA_dfd20471-0fc4-4b33-9b42-a06dff71e7af">14,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctNy0xLTEtMA_e5b4bc23-5988-4f19-b518-279b688dff45">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjktMS0xLTEtMA_42bf30ac-03eb-44c0-b26a-98f8e8086b68">58,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjktMy0xLTEtMA_911758be-58e2-4c6a-8bb6-6a73499007f2">1,181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjktNS0xLTEtMA_cbbbaab8-059b-46b7-a89a-d3f2665a9760">4,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjktNy0xLTEtMA_8b214791-72c5-4cfd-8165-e1901565dcbf">98,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss) income before (benefit from) provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzEtMS0xLTEtMA_26194800-b88e-4359-b74b-f6ff2f18b1f9">5,505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzEtMy0xLTEtMA_dcd2bf5f-f0cd-45fa-bf07-6710c3b1efae">36,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzEtNS0xLTEtMA_ffae8b3b-ec3f-4554-a80e-5b94f8de6dc2">100,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzEtNy0xLTEtMA_223c4af0-ee08-4246-936e-a9a66e2e64b1">153,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzMtMS0xLTEtMA_882efaed-256f-4235-a2ac-1f1c8fd34aa0">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzMtMy0xLTEtMA_d067dbd9-4e4b-466f-a049-f8ed64fd043d">10,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzMtNS0xLTEtMA_a664d1cf-ec33-4247-b2ee-636483882867">31,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzMtNy0xLTEtMA_926cd18e-21de-4692-a585-541893a7ebbe">44,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzUtMS0xLTEtMA_bb9bd40b-c5fb-4177-b36a-37e3f70e0f0b">5,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzUtMy0xLTEtMA_97777d93-44ed-404b-964a-2a16929e2a4b">25,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzUtNS0xLTEtMA_33389796-9c65-4c05-a3ec-2a39aaa1e520">68,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzUtNy0xLTEtMA_3cdc343f-3b54-41e6-9cc6-f84c24f0ec5a">109,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzctMS0xLTEtMA_90f0554a-b127-42cc-8e93-ade399d45a07">39,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzctMy0xLTEtMA_7ed3ec43-0bfe-47bd-9cfa-daf20cd15776">8,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzctNS0xLTEtMA_d5d48212-7936-4c87-92b0-fb74bb8aec3b">8,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzctNy0xLTEtMA_0a8f03d0-54a4-4226-8520-8045a400068f">81,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzktMS0xLTEtMA_3de18ac9-bcfc-4e1d-a900-2b9b9777c946">34,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzktMy0xLTEtMA_08dc4a01-5e4d-4f33-9f5b-ad21508c2edc">16,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzktNS0xLTEtMA_399c47ed-b4b2-49f7-bf9b-d0d4dcf64fba">60,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzktNy0xLTEtMA_dfa2cd31-cc9b-4048-9a2c-aa86669f71d5">27,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDEtMS0xLTEtMA_8d6d8379-3e95-474a-a4cb-0a976499a5a1">0.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDEtMy0xLTEtMA_8b322e6c-ac3f-45ba-91a7-98fd6e2f0894">0.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDEtNS0xLTEtMA_f8756b24-9c4d-4735-bc51-e9e38cbf5415">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDEtNy0xLTEtMA_b4dc161f-b359-4542-8874-1521e2ee3102">0.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDMtMS0xLTEtMA_2f01ebcb-cab5-494e-998c-49eacb34ae78">0.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDMtMy0xLTEtMA_a05b8ca1-8f88-4b09-8533-0cc84196a5d3">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDMtNS0xLTEtMA_4290cd0f-630d-4cfe-a4dd-098c0aa433f7">1.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDMtNy0xLTEtMA_5919222a-0e68-42c7-b935-7dba731719fe">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE DATA)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.559%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mezzanine<br/>Equity&#160;&#8211;<br/>Noncontrolling<br/>Interest&#160;in&#160;APC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in&#160;Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dff2d9ed6884aa7897b7d8188137fca_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy0xLTEtMS0w_3a0f0756-364f-4fb7-824c-6f6d091d28cc">114,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i801e5c00786942ddb700c1cd3c41fd90_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy0zLTEtMS0w_b2748114-db9b-4515-9a22-6810df3dea5a">42,249,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i801e5c00786942ddb700c1cd3c41fd90_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy01LTEtMS0w_d0ee26d4-5493-4684-934a-277d31e3d220">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f40737fc5743baa30c5079d6bffc52_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy03LTEtMS0w_56916790-35fa-44dc-b112-cf313ef41ce5">261,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb86b280a3014e398f2f562416431dd5_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy05LTEtMS0w_fcf9b594-472e-4dd2-b088-ae89975b6029">69,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47d2ab35fb6c4b68be2a92f518c669d4_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy0xMy0xLTEtMA_c2b2a2f4-e51c-46c5-886c-22828da140bc">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy0xNS0xLTEtMA_0738bebc-7b05-4201-b6d3-32a93ec39e82">330,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201c4a8fab204a44b9525c92e21b3124_D20210101-20210331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNC0xLTEtMS0w_a55ae4f0-b68c-4f1b-b8e5-eee21c7bb4e7">760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9ea714f06741669780227438e2ccc1_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNC05LTEtMS0w_fb982891-41a0-40d7-8a98-a51d83d32c72">13,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6ed78d14764e42b9aa9957c770a040_D20210101-20210331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNC0xMy0xLTEtMA_1fd29010-10af-46e2-a4fe-af484226b9f8">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNC0xNS0xLTEtMA_a8c6b74a-0121-4737-86ba-956c09c47836">13,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i201c4a8fab204a44b9525c92e21b3124_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNS0xLTEtMS0w_ed46b122-a388-48b7-b7f6-768fc8a98555">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f6ed78d14764e42b9aa9957c770a040_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNS0xMy0xLTEtMA_94db3633-a3ae-4ebc-829f-47780fd693a1">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNS0xNS0xLTEtMA_bb54248d-0b2b-453b-abe2-88f94ffafcf2">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1b58c9abcd6c470686a0c881f23bcd84_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNi0zLTEtMS0yNzQ2OQ_55b70699-9455-47f6-8b9c-968d28d8d3c1">5,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id66271d4dd164746b13d7571ddbea1e8_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNi03LTEtMS0yNzQ2OQ_bdc1409c-a835-4457-be37-669829d95e89">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNi0xMy0xLTEtMjc0Njk_00dfaaba-7df9-4d4d-bbe8-10fe102dbc48">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b58c9abcd6c470686a0c881f23bcd84_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNy0zLTEtMS0yNzQ3Nw_6a0e748a-9aad-4cf7-af14-f3c95b8e3660">7,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNy0xMy0xLTEtMjc0Nzc_069fd581-3c50-4d74-8bdc-41483e6fc346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b58c9abcd6c470686a0c881f23bcd84_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOC0zLTEtMS0yNzQ4MA_9daaf7ca-bdba-4c53-a61f-71645d16f0e6">421,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b58c9abcd6c470686a0c881f23bcd84_D20210101-20210331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOC01LTEtMS0yNzQ4MA_614b6661-94ab-42f8-86f4-be5dd849d819">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66271d4dd164746b13d7571ddbea1e8_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOC03LTEtMS0yNzQ4MA_7c919310-d6c8-4c8e-ac7b-eb409add2997">4,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOC0xMy0xLTEtMjc0ODA_1b3c5bc2-9e3a-4af8-bfc1-f5555f1860b4">4,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of treasury shares by noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1b58c9abcd6c470686a0c881f23bcd84_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOS0zLTEtMS0yNzQ4Mw_5eee9f79-90f4-4a5a-b1f8-fa9b3160783d">34,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id66271d4dd164746b13d7571ddbea1e8_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOS03LTEtMS0yNzQ4Mw_e059a074-e8ec-4ba1-8368-84411e322820">342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOS0xMy0xLTEtMjc0ODM_bb843667-a623-42ed-832e-97f4f8161b97">342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66271d4dd164746b13d7571ddbea1e8_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTAtNy0xLTEtMjc0ODY_06df4ff8-8993-4549-9bfe-247a047e0908">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTAtMTMtMS0xLTI3NDg2_6125c539-88d7-42b2-bba9-898a214d438c">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6ed78d14764e42b9aa9957c770a040_D20210101-20210331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTEtMTEtMS0xLTI3NDkw_89785397-dadb-470d-92fe-c1b7ad8849e8">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTEtMTMtMS0xLTI3NDkw_5894b7ae-b283-4480-8586-c8e5f8d1b9e5">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a74d81295e0434e935d5c9ca47dcd70_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItMS0xLTEtMjc0OTM_d730438e-28c5-4929-aa1a-3a5c716fc1ce">114,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4acdd08276e41428196b78831fc6298_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItMy0xLTEtMjc0OTM_3cf61c2b-076c-4a9c-affe-9873162551a7">42,638,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4acdd08276e41428196b78831fc6298_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItNS0xLTEtMjc0OTM_be8e18a3-5a0c-454e-9a8c-813db4a48cf1">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9752c3ca8824003913aa7ed5a37c7bd_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItNy0xLTEtMjc0OTM_a9ec7e1b-3c17-4f47-9e37-38428d63f90d">266,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54bcb094c3c48c6b97472820dabeca3_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItOS0xLTEtMjc0OTM_064fe3e2-630a-4aed-aa00-eddedb89c66a">82,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6c7eefcf281457baaa129d1d005c758_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItMTEtMS0xLTI3NDkz_2f66dd0b-6a66-4385-becf-9d15a737bd3f">596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea5b7b7fc3a4a34b7ce723c83b3a942_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItMTMtMS0xLTI3NDkz_e2ce0350-6c99-44be-81ac-5cfa8381673a">349,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a656a56f752493b9f8d16bfa440f3d8_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTMtMS0xLTEtMA_f104b578-03c9-4792-b73a-c738be114fc0">46,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ca7ada22a142c387919b0cad5803a3_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTMtOS0xLTEtMA_3091d1f0-5572-4c92-bcda-1548a4e9653c">12,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1f2152502448b5aa9088804a86dc7c_D20210401-20210630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTMtMTMtMS0xLTA_197bf9b7-7b47-4501-88f6-74306de12191">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTMtMTUtMS0xLTA_71139a74-4449-4eab-9c13-24ed28ec2dba">12,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i63d587f859094231993af50e9231e8ec_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTQtMy0xLTEtMjc1MDE_c446742d-9aaf-4a4c-9c1c-c2765ad58b15">5,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ae117b2200d4e1db6a15e62e5be08b2_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTQtNy0xLTEtMjc1MDE_f3e41771-bcea-4a53-8a9a-700255e296f4">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTQtMTMtMS0xLTI3NTAx_bdbaaae6-3f23-42d7-bce1-07cae90bcfd6">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63d587f859094231993af50e9231e8ec_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTUtMy0xLTEtMjc1MDQ_20ad9871-6ec6-42b6-9bd1-3d7797356048">22,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTUtMTMtMS0xLTI3NTA0_aacaa4fc-060e-48f0-ad93-ebbf99c21981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63d587f859094231993af50e9231e8ec_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTYtMy0xLTEtMjc1MDc_e6dcad78-73fc-4f7f-9986-af290e3885fd">53,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ae117b2200d4e1db6a15e62e5be08b2_D20210401-20210630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTYtNy0xLTEtMjc1MDc_fc4df13a-d1a0-4b7d-b3e9-7182bbc5f1e1">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTYtMTMtMS0xLTI3NTA3_e76fd7ca-eb83-4f89-b537-7305175ce1e7">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of treasury shares by noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i63d587f859094231993af50e9231e8ec_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTctMy0xLTEtMjc1MTA_749c6c19-8cfc-4189-8a22-34f17a296ada">100,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ae117b2200d4e1db6a15e62e5be08b2_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTctNy0xLTEtMjc1MTA_54982ee6-a41f-4e4c-bb36-4b824a4b31a0">2,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTctMTMtMS0xLTI3NTEw_222effe5-8560-4b03-aff4-37246a4f9bcb">2,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ae117b2200d4e1db6a15e62e5be08b2_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTgtNy0xLTEtMjc1MTM_3250ae61-33bf-46ce-b8da-9c28423777be">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTgtMTMtMS0xLTI3NTEz_47d05791-1319-408a-9a0f-21e14ba511f7">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a656a56f752493b9f8d16bfa440f3d8_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTQtMS0xLTEtMA_9ea2531a-51c2-41dd-b355-ad8d5de306b0">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1f2152502448b5aa9088804a86dc7c_D20210401-20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTQtMTMtMS0xLTA_f0ee148b-7f57-4f06-946c-c09f64c4f2e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTQtMTUtMS0xLTA_45e6f313-5551-4f79-b3a1-1dfc1e6e04f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of shares by noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63d587f859094231993af50e9231e8ec_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjAtMy0xLTEtMA_83a11eaa-3b99-4d01-9b65-9170ec587cab">1,638,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63d587f859094231993af50e9231e8ec_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjAtNS0xLTEtMA_fa79042b-5526-46c0-aeec-7c837f87b895">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ae117b2200d4e1db6a15e62e5be08b2_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjAtNy0xLTEtMA_3590f071-49d2-4a4a-94b1-28d8333fe057">40,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjAtMTUtMS0xLTA_a4b0fe63-1dff-4244-a2df-41555752fcc5">40,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1f2152502448b5aa9088804a86dc7c_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjEtMTMtMS0xLTA_b632b45f-7a91-4022-afe7-299bfb98279e">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjEtMTUtMS0xLTA_2c0bac75-6ff4-4e24-a094-af4562f81462">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a656a56f752493b9f8d16bfa440f3d8_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjItMS0xLTEtMA_20107b8c-7da3-4471-821a-3216602f30d3">20,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1f2152502448b5aa9088804a86dc7c_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjItMTMtMS0xLTA_a048a1e6-8dd9-41c7-9526-293fa0b39f3b">1,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjItMTUtMS0xLTA_bb8dbc07-587b-4a3c-9238-2d4588d0768f">1,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1cbb81479544b5d8a96c5343b4b4548_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtMS0xLTEtMA_b11b9331-fd13-4cac-bd73-9cd78950ab6c">141,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89732b64c48345c09b7f05b7e01eade5_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtMy0xLTEtMA_ff5797ab-713c-461c-84c4-2f40dfd8adf4">44,246,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89732b64c48345c09b7f05b7e01eade5_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtNS0xLTEtMA_6da95088-43f1-4f45-9e1d-512937080fe7">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i051a053544f84be68b9f7b6bd5bcf38e_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtNy0xLTEtMA_442f739c-58ad-41cd-b695-af30ea4cd009">305,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdce3fd00dfa4e8eac9f6af5191663ba_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtOS0xLTEtMA_96e81aee-2a01-4d14-b2d7-6021c8691f40">95,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e3754a2db143119d3e1eb226e3b911_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtMTMtMS0xLTA_e87f3b92-9171-454b-b35d-946358480aaf">3,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbf54ec60054ae5861c2aa09f4352a9_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtMTUtMS0xLTA_fb3e18cb-db46-4d71-8612-89380d9bdc11">404,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47b3e835a53b43b1bd2a7e6cca4fe332_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjQtMS0xLTEtMTIzMA_8823b69f-b5cf-4f1c-a5d0-32d2223ef7a2">40,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f277e33d13f4f028726cc591668dbbc_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjQtOS0xLTEtMTIzMA_c9921250-8882-4c44-b420-9a9e4dc60751">34,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89100028143441aea045a96e3abea952_D20210701-20210930" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjQtMTMtMS0xLTEyMzA_26f5ec76-e64d-4b85-b61f-8e88f497ca83">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjQtMTUtMS0xLTEyMzA_2248e4c5-89d5-4b08-80ea-5990a11b9876">34,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib97aa22e2d604131bd5c10b48cbc94fc_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjctMy0xLTEtMTIzMA_cec76de9-afc8-4e0a-9c7b-874203002167">190,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447b59fe96f749059a743a4fff511b89_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjctNy0xLTEtMTIzMA_292d00be-0f51-48c1-bda9-904b74086615">1,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjctMTUtMS0xLTEyMzA_18f81ff5-49f1-4fb9-aa30-9341207a603b">1,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of treasury shares by noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib97aa22e2d604131bd5c10b48cbc94fc_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjYtMy0xLTEtMjc1MzI_a9708bac-166f-466c-b28e-8f859cee2793">40,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i447b59fe96f749059a743a4fff511b89_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjYtNy0xLTEtMjc1MzI_b6cd0856-b023-415c-a63d-2cfa3ef78a44">2,947</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjYtMTMtMS0xLTI3NTMy_2b613f8e-df64-4dda-a048-bd846490573a">2,947</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447b59fe96f749059a743a4fff511b89_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjgtNy0xLTEtMTIzMA_da2824a8-3053-4f6a-9e87-e8e5dc66015d">1,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjgtMTUtMS0xLTEyMzA_2ea63ac4-bb67-4d78-99e6-781faad6a1c8">1,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89100028143441aea045a96e3abea952_D20210701-20210930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjgtMTMtMS0xLTI0MjAy_60dea1b1-df4e-4968-911e-2bbff58b5f3b">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjgtMTUtMS0xLTI0MjAy_a4ac1f9d-cfa3-489f-a481-914e0ddabcbc">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest capital charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1f2152502448b5aa9088804a86dc7c_D20210401-20210630" decimals="-3" name="ameh:NoncontrollingInterestIncreaseFromCapitalCharge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjktMTMtMS0xLTI0MjAy_643c2d37-93a1-409f-bd70-c45aefc1cbb4">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630" decimals="-3" name="ameh:NoncontrollingInterestIncreaseFromCapitalCharge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjktMTUtMS0xLTI0MjAy_60474ac2-fb13-44f7-8a2e-b3907538a0e4">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47b3e835a53b43b1bd2a7e6cca4fe332_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzAtMS0xLTEtMTIzMA_3e9375d1-511a-4883-a19f-b86d81b65382">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89100028143441aea045a96e3abea952_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzAtMTMtMS0xLTEyMzA_1e11023b-d971-4e64-805b-93f4d33f6aed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzAtMTUtMS0xLTEyMzA_4cdde1c6-db40-460c-bc65-fe3afd22ba4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f163c4d0b144be59dac47b4d4f3d1a3_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtMS0xLTEtMTIzMA_862e9516-980b-401a-b050-be86ad812dc3">91,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3851c4c6f42140f384fa8e46fde560b9_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtMy0xLTEtMTIzMA_fd457ba7-8cf2-4dd3-ab03-8cd22b491757">44,397,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3851c4c6f42140f384fa8e46fde560b9_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtNS0xLTEtMTIzMA_f03bf5e5-a6f7-4ca2-845a-bf49d49ae366">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9a43fc6ff7a472db16607b4efd8deb6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtNy0xLTEtMTIzMA_2be0513c-7d77-4260-89ad-45488c3d20f7">305,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id74805f435254a939c0fb9c4467d967c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtOS0xLTEtMTIzMA_c0c9c7c2-a5db-4576-9170-2f79de3c5364">129,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bcdaf3ce6a64dd8915c48e617c6050a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtMTMtMS0xLTEyMzA_47bd34db-db0d-4f51-b605-54d36144056f">4,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtMTUtMS0xLTEyMzA_ab64a9b0-59a0-438e-9b21-cc2f0a1a495d">440,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:35.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.574%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mezzanine<br/>Equity&#160;&#8211;<br/>Noncontrolling<br/>Interest&#160;in&#160;APC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in&#160;Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c4d76239ba428fa3c790a5e8246b33_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy0xLTEtMS0w_623fd398-71ee-4c67-9d64-df9e5176ffe4">168,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide4f8e08db044e18a9dd68755ff37c94_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy0zLTEtMS0w_25143c9a-8e32-4352-ba66-55833a88b895">35,908,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4f8e08db044e18a9dd68755ff37c94_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy01LTEtMS0w_cd95cae2-ec82-4b14-b65b-be09dd03b978">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b428a4b73a64930be4adc92648bab3e_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy03LTEtMS0w_f8f21955-f7fb-49f9-b3a0-d73c27b52268">159,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc6eb15301c64d8aa5fc12a0525855f9_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy05LTEtMS0w_1d1ffd28-1e56-45f7-8adb-1e102679bb91">31,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c8de92883004d2a9874fc11ec721f46_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy0xMy0xLTEtMA_b791f3a6-4068-4ba6-ba29-373e3550677d">786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274e819937824ba3b8be663aca7657a1_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy0xNS0xLTEtMA_8c444dd7-131b-4bda-8cba-db7a2af141c9">192,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2897209faef4ecbb6ff8ae555b62be5_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNC0xLTEtMS0w_e23163f2-5614-4437-a48a-b6c14d85ff62">1,160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f0ee689326400e8ca46a963ad334e3_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNC05LTEtMS0w_c8af8c0c-deb5-4b43-b22e-f477c3621601">4,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80907684f53c41fa8f1a8a26101f7877_D20200101-20200331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNC0xMy0xLTEtMA_22789849-1f55-43c9-a9f2-4212efdd4b46">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNC0xNS0xLTEtMA_d8d3c926-d8d0-4c84-813f-ec05f8e6f700">4,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2897209faef4ecbb6ff8ae555b62be5_D20200101-20200331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNS0xLTEtMS0w_09ecf6dd-a667-4901-aad2-ef88177c21ca">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331" decimals="-6" format="ixt:fixed-zero" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNS0xNS0xLTEtMA_cebf27d8-9991-4559-8d6f-97a2b06c7264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifc4bd3d0547c43cca915340944f52cf8_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNi0zLTEtMS0w_33851f5e-5188-4965-b2bf-29b1c7a91ad9">16,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946dbda53945ca95557bb7aea3d8ea_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNi03LTEtMS0w_190909ce-0eb2-4f38-9c3f-f98d0dbc0efa">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNi0xNS0xLTEtMA_7f61edbf-4e8e-45d0-98b7-42605b5b01ec">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc4bd3d0547c43cca915340944f52cf8_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNy0zLTEtMS0w_53cbc68d-854d-4373-b9f1-9894b9704597">151,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946dbda53945ca95557bb7aea3d8ea_D20200101-20200331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNy03LTEtMS0w_9e2a7781-2e24-4f02-962f-08701cf850db">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNy0xNS0xLTEtMA_d7b7be76-9b4b-4453-8c62-2b823dbaae5c">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946dbda53945ca95557bb7aea3d8ea_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfOC03LTEtMS0w_c4a0ab78-3d0c-434e-89e4-a7ce628f23e6">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfOC0xNS0xLTEtMA_2f8135c2-7269-453e-81db-f7830eee99c8">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2897209faef4ecbb6ff8ae555b62be5_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfOS0xLTEtMS0w_275a12f9-7d17-4117-b75f-658241e2a864">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfOS0xNS0xLTEtMA_a0b83a70-a813-4ac9-8e92-cb11b921319a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50ed93d80d8c443db56d6af7ad9eff2d_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtMS0xLTEtMA_936904bb-d203-4888-9477-a0ded17f6553">157,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88ea48c265674dc0b0969de2c5af9a5a_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtMy0xLTEtMA_e8f79ff3-5f10-4456-ac44-90fd658521aa">36,042,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ea48c265674dc0b0969de2c5af9a5a_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtNS0xLTEtMA_d9423c3f-8a82-4486-be24-e4c13a3e2f33">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd58c0538df4442d935bad5da111604c_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtNy0xLTEtMA_2d87879a-fe6c-4aa0-9fa8-3c48ed684ceb">161,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d6f1b1b2ef64607a7a28b3ddd19b9ca_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtOS0xLTEtMA_87196368-3300-4ef3-ba1b-9a6ed323f831">35,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7da29179b9f74a138ee89825c3173019_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtMTMtMS0xLTA_c718922a-87f4-49ec-9e00-91ca30bb42e3">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd6ee7c5cf34d2a95a5baf1644fd7bd_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtMTUtMS0xLTA_35dda410-b896-4b10-a375-40d437fa4ddb">197,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife042466644a4588baa6a1080f3f9619_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTEtMS0xLTEtMA_c738234b-9f83-4de2-a5ce-01e3c61979bc">73,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b04caa1c2974f2e8324ddcb0d1943b0_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTEtOS0xLTEtMA_555e8707-869d-4d3e-b9a0-2565bf85aa8f">7,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib71e689bf17b4b1b82292ea2371b247f_D20200401-20200630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTEtMTMtMS0xLTA_b6f51737-8109-4ee4-8696-c32db25a9bee">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTEtMTUtMS0xLTA_8abb3eab-201d-48e3-a5d7-a1fd14e44da1">7,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife042466644a4588baa6a1080f3f9619_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTItMS0xLTEtMA_1654e577-2bb9-46db-b2f2-15d3ef62d002">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib71e689bf17b4b1b82292ea2371b247f_D20200401-20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTItMTMtMS0xLTA_37977ea3-5233-4401-b962-8cb12f5a2d9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTItMTUtMS0xLTA_a0b62ce5-336f-46db-af60-acb8227486d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7814f327568e456d93bd5dd8ffd4e59c_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTMtMy0xLTEtMA_854f20a7-e141-466a-a189-06e585c87d3d">24,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTMtMTUtMS0xLTA_2b30d237-36da-4231-a11d-3df7aec8f720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7814f327568e456d93bd5dd8ffd4e59c_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTQtMy0xLTEtMA_377dd07c-ced6-4611-acfd-f4b3fdf241a1">242,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ab116f35bb4c18b276c3c5099436f8_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTQtNy0xLTEtMA_0e9e191b-0c41-4791-9205-b61bf1fd93e7">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTQtMTUtMS0xLTA_09750281-32be-423f-853c-d64692b55026">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ab116f35bb4c18b276c3c5099436f8_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTUtNy0xLTEtMA_c3f07e19-448c-4d34-8321-75278f3b6956">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTUtMTUtMS0xLTA_47e6e0a4-c31c-4faa-8fe1-6fd0cbd1bed3">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79ab116f35bb4c18b276c3c5099436f8_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTYtNy0xLTEtMA_ec11a171-ae4d-413f-be66-7a77bde9ae83">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTYtMTUtMS0xLTA_737d901d-b823-4dcb-9cb5-39c23fdc5efd">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife042466644a4588baa6a1080f3f9619_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTctMS0xLTEtMA_0856d98f-330b-4a00-9e81-a5344d454d5f">20,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib71e689bf17b4b1b82292ea2371b247f_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTctMTMtMS0xLTA_90b6900e-2ecc-4acc-a6b7-b4eb064ada4a">347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTctMTUtMS0xLTA_018e275e-bc18-4787-a4e8-afb28128a31d">347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1da11deec71d444dbcd9ae322ee3fdc3_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtMS0xLTEtMA_49d3aea8-b82b-47db-bffa-e7b27f76cd54">210,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e8613962fee4ab98d908fabd87a1896_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtMy0xLTEtMA_b5ac835f-9ff0-4ba0-a2e5-b8697b2586c7">36,309,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8613962fee4ab98d908fabd87a1896_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtNS0xLTEtMA_9898b1a7-0f8a-4846-aaa2-73365c7463f0">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfa83865da94a5f8b9fe72abbf1e869_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtNy0xLTEtMA_2ec232b4-f80c-4dd3-a3ca-5b90d51aa493">163,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d0a7a2fd7464ee299859406dbe50c73_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtOS0xLTEtMA_e37697b3-a540-4d3d-b0cd-fe7c2b88d08f">43,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd2afccb5db4b0ab6d514f40ca4f851_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtMTMtMS0xLTA_bac6f837-f875-4b75-b97f-6c04ea26dc1b">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eea77176a0f48a2a0621621efb6b4ef_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtMTUtMS0xLTA_ac2824d7-dab7-4940-a5f8-7eb5bc6010f2">207,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2263b2eaaf6c4496af9ac4bdaec4bb63_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTktMS0xLTEtMTE3OA_4378157e-2761-43f6-82cb-ac379c3dba9c">8,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id861da65feb04df7a6d28f6b72fc6ae5_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTktOS0xLTEtMTE3OA_4d8f5fb7-9ddc-42c3-bd9c-eb2e158c9985">16,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc759fafb9d46048145c9584bd19060_D20200701-20200930" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTktMTMtMS0xLTExNzg_301ee5d8-42e9-4ad5-8bc3-1ae3cf907e92">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTktMTUtMS0xLTExNzg_456043f3-72c0-4e4f-b608-590b35da0e6d">16,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2263b2eaaf6c4496af9ac4bdaec4bb63_D20200701-20200930" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjAtMS0xLTEtMTE3OA_97396883-517f-4afb-ae0c-c5ba9d6b833f">771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjAtMTUtMS0xLTExNzg_eb6bc5ce-02e9-46dd-a81e-cabce172eaed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for cashless exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61ed6e94c3224d0aaad33a4b064279c7_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringPeriodSharesCashlessWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjEtMy0xLTEtMTE3OA_b92b967c-eb59-4e66-b4d9-529dc9b3dc0c">66,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="ameh:StockIssuedDuringPeriodValueCashlessWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjEtMTUtMS0xLTExNzg_5709a26b-3442-4101-88f9-8815c9e7a123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61ed6e94c3224d0aaad33a4b064279c7_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjItMy0xLTEtMTE3OA_f4982705-38af-4e75-bc56-1afc2cb14b13">399,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ed6e94c3224d0aaad33a4b064279c7_D20200701-20200930" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjItNS0xLTEtMTE3OA_ad844e82-072d-4083-aace-f642f2d63bc8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacd41deb825c48f7968229c9af0a5590_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjItNy0xLTEtMTE3OA_7e4f5559-d299-4d3b-a647-c3d5513c58fc">4,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc759fafb9d46048145c9584bd19060_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjItMTMtMS0xLTExNzg_ff6da844-e37c-4ca1-8968-64c112d1d151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjItMTUtMS0xLTExNzg_45d10b35-b1d6-45ff-98d6-3f0d5118a0ed">4,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacd41deb825c48f7968229c9af0a5590_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjMtNy0xLTEtMTE3OA_4ad0435c-286a-4450-9b03-b4da8b044ebb">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc759fafb9d46048145c9584bd19060_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjMtMTMtMS0xLTExNzg_d8e59291-46f2-4662-9f57-341e213ce7d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjMtMTUtMS0xLTExNzg_e8194dba-860a-4da2-ac0b-76a2ec52fb0f">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacd41deb825c48f7968229c9af0a5590_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjQtNy0xLTEtMTE3OA_e7762db5-126e-46a6-9687-abddbf98291d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc759fafb9d46048145c9584bd19060_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjQtMTMtMS0xLTExNzg_9ad64261-ecfa-4ded-8776-705e1634ffa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjQtMTUtMS0xLTExNzg_58f2b76a-4471-4634-a4ef-634c8437d8f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2263b2eaaf6c4496af9ac4bdaec4bb63_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjUtMS0xLTEtMTE3OA_4760e054-8069-402e-8c77-060f490d3d81">20,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ed6e94c3224d0aaad33a4b064279c7_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjUtNS0xLTEtMTE3OA_8cc928bf-a557-4993-ac72-bbaf0a1f3682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc759fafb9d46048145c9584bd19060_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjUtMTMtMS0xLTExNzg_08f71ee6-b320-4617-81ea-54599d8e1e4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjUtMTUtMS0xLTExNzg_f0b7f6b2-af4d-4b3d-a8b0-a84e92ef0776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f34f8a827f48e3af8fda4fc45fb9e7_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtMS0xLTEtMTE3OA_2afe0655-4967-49cc-8db3-971ab815d56c">198,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3fb118aa44b46768cc5aa112ee13ec3_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtMy0xLTEtMTE3OA_6436b16a-2fcd-41c4-aea8-823331641173">36,775,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3fb118aa44b46768cc5aa112ee13ec3_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtNS0xLTEtMTE3OA_58c72bd5-8f1b-4758-adb8-7153fa7eec3c">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e69dbc1f0334ee8901a65307444081e_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtNy0xLTEtMTE3OA_44fa4768-8d64-4542-a0b2-1a06827dc551">168,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99efb1cb424f2faa5e9458d42ebbab_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtOS0xLTEtMTE3OA_f8c48a29-9d91-49b5-b5e1-633da1c3c425">59,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4ff3ef133a4ee8bb68a8f96bce2d82_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtMTMtMS0xLTExNzg_3688ee40-7652-4c9c-b77e-bddc828813a0">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03292c592c4f45da834c806bff481c24_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtMTUtMS0xLTExNzg_161314c1-f1c2-45fb-8035-f7d6958960b8">229,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMy0xLTEtMS0w_1ef2471b-63d4-40b5-8077-e7df4c992346">68,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMy0zLTEtMS0w_18c58c7b-88db-494b-b0ec-2eabe792a702">109,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNS0xLTEtMS0w_9fc70455-6946-473e-88d2-07641f0e0518">13,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNS0zLTEtMS0w_da87e18b-4c63-438d-9ed8-2b2ae6091b11">14,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNy0xLTEtMS0w_7b5ee171-6303-48ee-a7e4-4c6f32f986a1">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNy0zLTEtMS0w_73c175a3-0fc9-48f7-af26-2c39c9f26c56">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfOC0xLTEtMS0w_2071479c-95a3-47c7-8757-8fb745453f9a">4,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfOC0zLTEtMS0w_c9cb2d61-0c6f-40cc-af6e-a10a5fb324d2">2,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized (gain) loss from investment in equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:UnrealizedGainLossFromInvestmentInEquitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfOS0xLTEtMS0w_db270261-c829-45ab-a0c3-76921f870330">22,826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" sign="-" name="ameh:UnrealizedGainLossFromInvestmentInEquitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfOS0zLTEtMS0w_25d33974-80fa-43f6-84b8-1276a6e1f2d1">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss (income) from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTAtMS0xLTEtMA_c8955ae7-edc8-46ce-8cb0-dca15aceb818">3,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTAtMy0xLTEtMA_6b380a3d-e2c2-45c1-86d1-521708fce4a5">3,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTEtMS0xLTEtMA_cfec7795-4fa9-4c08-b7dd-af1e3d62b349">2,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTEtMy0xLTEtMA_ce6e5374-7d4f-4e59-9c92-ddf7e7e36f53">99,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of beneficial interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTItMS0xLTEtMA_b77dc70a-eccf-41a2-8812-5b6b672c2000">15,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTItMy0xLTEtMA_4a9c5220-8474-4162-b637-fd62e60fc1fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLossOnDerivative" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTMtMS0xLTEtMA_4c74358b-eeb8-4e8b-9dd1-658e09cfe424">1,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLossOnDerivative" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTMtMy0xLTEtMA_210d5003-d88e-4529-8df2-3266fd44306b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTQtMS0xLTEtMA_7127f3be-3d13-446a-878d-4c9e88f0892f">6,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTQtMy0xLTEtMA_e5880ce1-245e-4f82-a480-d0f3215fc21b">6,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromOtherOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTUtMS0xLTEtMA_4ce032c3-0de1-496f-a78e-2be2b69f7772">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromOtherOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTUtMy0xLTEtMA_faaae88e-432e-467b-9628-f89df12a1cad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of business combinations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTctMS0xLTEtMA_727b6260-94c6-445e-b503-b0ebd198d81a">10,686</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTctMy0xLTEtMA_1760ade7-f474-46be-aa40-36c513dd5c90">6,953</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTgtMS0xLTEtMA_54a9727e-ce6d-43c0-b809-fe28d9843f44">4,367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTgtMy0xLTEtMA_f78b7f3e-5674-460b-b5ff-1516a719a88c">6,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTktMS0xLTEtMA_e670bd18-9079-4373-adc3-6a6302fea637">1,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTktMy0xLTEtMA_cdee5bd2-b592-4b7c-9f7d-da5e471bb40d">12,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjAtMS0xLTEtMA_b67a3f18-f6b9-4931-b82c-9c359f41ce97">5,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjAtMy0xLTEtMA_6c4056cc-7c62-483e-adba-c836b56a6747">1,804</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjEtMS0xLTEtMA_0948fc03-ae46-46c2-9c3b-b9c4dd8613e3">2,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjEtMy0xLTEtMA_a8cd6282-5cf6-40ce-95f7-090fddb8a0a2">2,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjItMS0xLTEtMA_5425323a-1eb4-454a-8cc2-4fdffd567bba">954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjItMy0xLTEtMA_928b29bb-fc6f-44ca-8d61-59fd6dff15ab">5,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjMtMS0xLTEtMA_a471d988-0557-4560-9fcb-dc7ebe235c22">14,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjMtMy0xLTEtMA_d8cd79ea-3111-452d-91bc-7b085fc9c04e">12,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjQtMS0xLTEtMA_e0bbe82d-9d88-42ab-b60a-bb1f03f1f6c9">815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjQtMy0xLTEtMA_81570bbb-43b1-48f8-a3e4-bd3d0762b624">1,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="ameh:IncreaseDecreaseInMedicalLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjUtMS0xLTEtMA_1f4be673-f1f4-4f81-85ac-e1c75bebd9d3">7,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="ameh:IncreaseDecreaseInMedicalLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjUtMy0xLTEtMA_d0b985c3-5505-44dd-bcc4-97a9f6ff07f2">1,566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjYtMS0xLTEtMA_56c5b422-ede2-49cb-b40c-602cb9ce5b8e">300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjYtMy0xLTEtMA_74e5c29d-e0ba-49d0-973d-bb8b1cd85d43">11,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjctMS0xLTEtMA_ad43b062-efaa-478c-a95a-25bc0526a416">2,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjctMy0xLTEtMA_d1548755-12e8-413e-bc55-eca6b4102ff1">2,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjktMS0xLTEtMA_199269b3-9c36-428e-bb1b-510cbda20b61">82,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjktMy0xLTEtMA_579864f6-59ea-4c67-838c-00a4de4a8e13">48,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for business acquisition, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzItMS0xLTEtMA_f4d0d5ee-d4ac-4f4c-9e8a-e3b91f603a42">2,575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzItMy0xLTEtMA_e08f2450-b236-449c-a458-3d3ee2b78883">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from repayment of loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzMtMS0xLTEtMA_b95a1096-8da0-4753-8bc9-2de7194ce3d4">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzMtMy0xLTEtMA_e727701d-3a76-44ab-94ec-de58320e7fd5">16,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzgtMS0xLTEtMA_0216a5c7-5544-4c7d-b59a-1b23844fdcc1">1,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzgtMy0xLTEtMA_0f87a207-7624-4f22-abd3-d0a6b88704af">1,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of investment &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzktMS0xLTEtMA_4675de01-d493-4186-b073-e4e0a56925dd">13,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzktMy0xLTEtMA_7d036ef2-aaf7-48e8-8eb8-a2f26f7369f6">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDAtMS0xLTEtMA_b11ffcf5-96bb-497f-adbe-5b845b0c9660">6,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDAtMy0xLTEtMA_46574ed7-27d2-49f7-afa1-0489cdc54a52">52,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDEtMS0xLTEtMA_df32ec9b-be35-4cd9-a2de-3d4f5cf5a581">16,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDEtMy0xLTEtMA_920ae884-bc66-4d63-b9d9-aef090aae1a4">553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDItMS0xLTEtMA_c008f379-63f8-4838-86ab-b88b7a8862f4">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDItMy0xLTEtMA_41d7972a-ca4b-4e29-8c0e-2c9d88649b56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from consolidation of VIE</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDMtMS0xLTEtMA_ad0ca1b1-e968-49c1-9f0f-90a5c55ad0f0">3,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDMtMy0xLTEtMA_28b4e352-83db-4db9-bf15-ace3c6c6f692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDUtMS0xLTEtMA_7cb86302-dd20-488c-a081-3581b28185dc">22,544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDUtMy0xLTEtMA_83365072-711d-4a87-9b27-60c64e8efdfa">66,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDktMS0xLTEtMA_38235cef-807b-4001-96a1-e22c33ae8e72">31,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDktMy0xLTEtMA_e44e71ad-a8ad-42f8-902c-b48b4ac85eff">50,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTAtMS0xLTEtMA_8cc91c54-1a47-4459-8f35-797b7b453a4e">238,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTAtMy0xLTEtMA_55474d4b-846f-4649-ae7f-62efb7f3b28f">7,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTEtMS0xLTEtMA_f8839a33-ecc0-45aa-98de-60eb2febb181">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTEtMy0xLTEtMA_fea4f148-b0c6-404c-a192-a136e755e220">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTItMS0xLTEtMA_01ea116c-4072-4fb9-a9e2-43544d46f825">6,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTItMy0xLTEtMA_6636917a-a1a5-4f19-a1bd-4ca973a1a00b">6,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTMtMS0xLTEtMA_a1fffe04-5c0d-4e6f-b0d3-2823f580ca04">5,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTMtMy0xLTEtMA_6acab7c8-8c01-402d-9196-33a4e6fafc4a">1,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTQtMS0xLTEtMA_bccb0757-60fe-4c0a-99e8-38d60601b23c">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTQtMy0xLTEtMA_eb2f9522-1476-474f-b5c9-95a3755d11e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="ameh:ProceedsFromSaleOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTUtMS0xLTEtMA_b2f29361-7f68-4687-896c-474735d9eaa9">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="ameh:ProceedsFromSaleOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTUtMy0xLTEtMA_74a9617e-ed36-47e1-bde4-270d1b020644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on revolver</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTctMS0xLTEtMA_98b39a58-c47d-408c-ba6a-a3026446b034">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTctMy0xLTEtMA_7f3c5976-51fe-40bf-b2c1-cef7e4b2f3d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTgtMS0xLTEtMA_00d5381d-bfa6-49eb-a281-c999efdd80b4">40,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTgtMy0xLTEtMA_1573b385-7406-4502-8ee7-d149cc00eb95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTktMS0xLTEtMA_9a7b59d1-8d01-43fe-b065-47fa0ba02581">727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTktMy0xLTEtMA_0ef881c1-94c5-432c-bdbc-783e950e0447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjAtMS0xLTEtMA_8c59a1ca-5ffd-445d-a4a2-3adf7937b40e">49,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjAtMy0xLTEtMA_354b03de-7566-4d50-bd84-64ac3b92ccce">52,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjItMS0xLTEtMA_bd673f65-166c-4b01-946c-3a0ca54f7b72">10,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjItMy0xLTEtMA_6fe6679c-de69-41a7-8471-3d18968d8b6c">62,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjQtMS0xLTEtMA_2453389b-6eb1-4651-aa00-e6f3593a0409">193,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274e819937824ba3b8be663aca7657a1_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjQtMy0xLTEtMA_78860757-b297-47a1-8794-51a02a987af2">104,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjYtMS0xLTEtMA_3385f1c6-d136-450a-aef1-af37aa2cc015">204,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03292c592c4f45da834c806bff481c24_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjYtMy0xLTEtMA_8209827a-a5d4-4fce-b910-5fdcdb59e00c">166,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjktMS0xLTEtMA_ac3216d0-53ae-407a-8a7b-78ae36f1ccec">24,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjktMy0xLTEtMA_74f8a5ea-7eec-42c1-8f20-66f472b9792b">37,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzAtMS0xLTEtMA_51331568-cff6-44ae-b44e-7e5181634889">3,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzAtMy0xLTEtMA_3bdb7943-3d32-41de-9002-928617b12864">6,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend declared included in dividend payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzMtMS0xLTEtMA_a22e3545-1751-4743-9d03-4714f774307c">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03292c592c4f45da834c806bff481c24_I20200930" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzMtMy0xLTEtMA_71d04bfc-9946-491a-b0f4-4cfca47cf247">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred shares received from sale of equity investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzQtMS0xLTEtMA_f423aac1-5365-4de2-85d5-a79529e1380f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzQtMy0xLTEtMA_1e8279e7-01f3-4540-9d93-9176400402bf">36,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="ameh:CancellationOfRestrictedStockAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzUtMS0xLTEtMA_8af7e3d0-6bd7-426b-9f38-8ccf115c04e4">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="ameh:CancellationOfRestrictedStockAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzUtMy0xLTEtMA_ba063332-017a-4033-af18-fb5e7041115d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability adjustment to goodwill</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:DeferredTaxLiabilitiesAdjustedToGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzYtMS0xLTEtMA_1167a531-7100-478c-bd8a-cdbf2e250d54">1,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="ameh:DeferredTaxLiabilitiesAdjustedToGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzYtMy0xLTEtMA_805b26c2-5f50-4f5b-b59d-cc23db54bf89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability adjustment related to warrant exercises</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:DeferredTaxLiabilitiesWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzgtMS0xLTEtMA_5ce34f4f-65e6-41c2-ac5d-4cadb44a3906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" name="ameh:DeferredTaxLiabilitiesWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzgtMy0xLTEtMA_2121fc20-c690-4ea0-93d5-a34f1d68d3e4">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfMi0xLTEtMS0w_a6fdf42f-d6ec-43cc-bd03-c296fb271785"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfMi0xLTEtMS0w_b74fe390-b790-453a-beab-946428333539">204,768</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03292c592c4f45da834c806bff481c24_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfMi0zLTEtMS0w_866920a5-5718-4299-8b6d-ab269ee27915">166,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfNC0xLTEtMS0w_41fadea4-b256-4c80-949a-b0411e1e6ca0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03292c592c4f45da834c806bff481c24_I20200930" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfNC0zLTEtMS0w_6fcedbdc-5872-4d7f-afbc-2269946a8e89">746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfNS0xLTEtMS0w_04039f51-f96c-4056-be70-c0890b10db46">204,768</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03292c592c4f45da834c806bff481c24_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfNS0zLTEtMS0w_4ca8d128-c32b-4a35-a2b1-bb980a3591d5">166,828</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfMi0xLTEtMS0w_56cff224-a4d8-4f27-bbb8-71fb1bc38391">193,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274e819937824ba3b8be663aca7657a1_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfMi0zLTEtMS0w_cf0db6ea-0e43-4f96-a4dc-7e2027b778e3">103,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfMy0xLTEtMS0w_0b887c7e-61e4-475f-a1f0-a0f264ee1d9b">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274e819937824ba3b8be663aca7657a1_I20191231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfMy0zLTEtMS0w_60fb1f54-9063-43e0-b58b-f9f315be5885">746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfNC0xLTEtMS0w_3f2d15cf-11c1-4296-8896-3afec300aadb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274e819937824ba3b8be663aca7657a1_I20191231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfNC0zLTEtMS0w_ec4feabe-d07e-4f23-871d-6f5f053ee826">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfNS0xLTEtMS0w_2fee5a9e-7d3e-4cf2-8023-7ba92ee760e9">193,970</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274e819937824ba3b8be663aca7657a1_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfNS0zLTEtMS0w_f27e0829-e96d-409a-8af2-d1761e157cc5">104,010</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div id="i77048548a0c546beaa10a42c80553a71_40"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTQ1MTY_7a63f49d-6c12-4d2b-bfca-dd998208f840" continuedAt="i3b6add36db7e42abb4e37a61510cca92" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="i3b6add36db7e42abb4e37a61510cca92" continuedAt="if48b5dc13a72457eb2c5d063b1c72825"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#8220;NMM&#8221;) in December 2017 (the &#8220;2017 Merger&#8221;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed&#8217;s subsidiaries and VIEs include management services organizations (&#8220;MSOs&#8221;), affiliated independent practice associations (&#8220;IPAs&#8221;), and a Next Generation Accountable Care Organization (&#8220;NGACO&#8221;). NMM and Apollo Medical Management, Inc. (&#8220;AMM&#8221;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), (ii) Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). The Company&#8217;s NGACO operates under the APA ACO, Inc. (&#8220;APAACO&#8221;) brand and participates in the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#8217;s attribution-based risk-sharing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSOs and Affiliates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPAs and Affiliates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (&#8220;HMOs&#8221;) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of <ix:nonNumeric contextRef="i917782072a6545aea32eaddcfe18e706_D19990701-19990701" format="ixt-sec:duryear" name="ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNDY3Nw_024fd689-5518-4d4d-9c3b-ba7b1456220f">30</ix:nonNumeric> years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="if48b5dc13a72457eb2c5d063b1c72825" continuedAt="i83d3bae1136a4871b6b67d54b90dbfe1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) and AP-AMH 2 Medical Corporation (&#8220;AP-AMH 2&#8221;) was formed in May 2019 and July 2021, respectively, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. In accordance with relevant accounting guidance, AP-AMH and AP-AMH 2 is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed loaned AP-AMH $<ix:nonFraction unitRef="usd" contextRef="ib52349b88809456791d3db024592e198_I20190930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNTU2Mw_7b84a20c-888d-4a72-8ca5-6e5e47d736ad">545.0</ix:nonFraction> million pursuant to a <ix:nonNumeric contextRef="ibd821e95a1334471acf3bc50924008ff_D20190901-20190930" format="ixt-sec:duryear" name="ameh:FinanceReceivableTermOfReceivable" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNTU4MA_684c0014-962f-4b53-b4e3-9a26b44044d5">10</ix:nonNumeric>-year secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="ib52349b88809456791d3db024592e198_I20190930" decimals="2" name="ameh:FinanceReceivableStatedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNTY2OQ_35afe62d-ddc6-4717-a95a-d8317bcb0566">10</ix:nonFraction>% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="ib52349b88809456791d3db024592e198_I20190930" decimals="4" name="ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNjM4NA_3bd35eb3-08a6-4dcd-ae91-e6bd544a497b">10.75</ix:nonFraction>% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">AP-AMH purchased <ix:nonFraction unitRef="shares" contextRef="i5e54e5787b2d4a9d913c148f7713fbd8_D20190901-20190930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNjQzMQ_fc505281-89f2-4ab0-a9e1-71bffb95207e">1,000,000</ix:nonFraction> shares of APC Series A Preferred Stock for aggregate consideration of $<ix:nonFraction unitRef="usd" contextRef="ib52349b88809456791d3db024592e198_I20190930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNjUwNA_f1ec3979-ad71-43ec-b8f5-b2f596f2b369">545.0</ix:nonFraction> million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the &#8220;Certificate of Determination&#8221;), AP-AMH is entitled to receive preferential, cumulative dividends (&#8220;Series A Dividends&#8221;) that accrue on a daily basis and that are equal to the sum of (i) APC&#8217;s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC&#8217;s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">APC purchased <ix:nonFraction unitRef="shares" contextRef="i607219ce151b481d884ab20a69b7ab89_D20190901-20190930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNzA5Mw_4eaec33a-a258-4b23-994f-8eca2492653b">15,015,015</ix:nonFraction> shares of ApolloMed&#8217;s common stock for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i607219ce151b481d884ab20a69b7ab89_D20190901-20190930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNzE1OA_c985d646-5f44-4a5b-92a9-28ce41eb6e2f">300.0</ix:nonFraction> million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed&#8217;s common stock that APC purchased, and APC agreed that APC votes in excess of <ix:nonFraction unitRef="number" contextRef="i607219ce151b481d884ab20a69b7ab89_D20190901-20190930" decimals="4" name="ameh:StockIssuedDuringPeriodProxyVotesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNzM2Mg_9aaebb1b-2e95-4144-b1ee-b2c91407d41d">9.99</ix:nonFraction>% of ApolloMed&#8217;s then outstanding shares will be voted by proxy given to ApolloMed&#8217;s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed&#8217;s stockholders.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the series of transactions described above, APC and AP-AMH entered into a Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term &#8220;Excluded Assets.&#8221; Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price (as defined in the purchase agreement), (ii) the assets of APC that are not Healthcare Services Assets (as defined in the purchase agreement), including APC&#8217;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC&#8217;s ownership in ApolloMed was <ix:nonFraction unitRef="number" contextRef="i9007c9ba55ce4f30a5723df00d10d0ab_I20210930" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfOTA3Mg_5a8c746c-c0af-4200-8480-fd7b902f1341">19.77</ix:nonFraction>% as of September&#160;30, 2021 and <ix:nonFraction unitRef="number" contextRef="i8bc4a1721b30446ebfd6d52b47024998_I20201231" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfOTA4NQ_85b1cf61-8f90-4443-8afc-54e54840b66a">22.58</ix:nonFraction>% as of December&#160;31, 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of September&#160;30, 2021, APC owned <ix:nonFraction unitRef="number" contextRef="iae6af9311d664b339370a494ef320121_I20210930" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfOTU3Mg_a844a166-c770-49b5-8e71-934a8579bed3">45.01</ix:nonFraction>% of CDSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i83d3bae1136a4871b6b67d54b90dbfe1" continuedAt="i7cd1d9e4111a4761b2d86d30751c90d3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group of Southern California (&#8220;DMG&#8221;), and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a <ix:nonFraction unitRef="number" contextRef="i00e774cfdab24f0aa1689be1a5900a03_I20210930" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTA4NDg_a132b547-651e-40fa-8aea-2166b3b0ffca">100</ix:nonFraction>% ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through <ix:nonFraction unitRef="plan" contextRef="if573b2a18f354adf817ec91e584fd94c_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="ameh:NumberOfFederallyQualifiedHealthPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTE4NDY_ec022a95-ad83-4d49-95c3-378c0395fa34">three</ix:nonFraction> federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#8217;s capital stock that they did not already own (comprising <ix:nonFraction unitRef="number" contextRef="i8bf46a0ff42c494995871919d226ce7e_I20190830" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTIxMTY_6546d248-556a-4972-bccb-fe17657cd1e1">75</ix:nonFraction>%) for&#160;$<ix:nonFraction unitRef="usd" contextRef="ia651540f0f3040a1b9acd90c7a76f53b_D20190830-20190830" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTIxMjQ_b21bd5b3-56fc-4e67-9ea8-78da8808e0c8">7.3</ix:nonFraction> million&#160;in cash.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating out of <ix:nonFraction unitRef="clinic" contextRef="i833e8c7434554e839001ca8eddd9a2f1_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="ameh:NumberOfFamilyPracticeClinics" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTIxOTc_e62f717c-082e-404c-a169-78c96d3671f4">three</ix:nonFraction> main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased <ix:nonFraction unitRef="number" contextRef="i7f596495482b4bccb3b9cb702ba11e2a_I20190930" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTI0NDQ_aeb0ccf4-7ce0-484d-9cb5-03d2e0387b52">100</ix:nonFraction>% of the shares of capital stock of AMG for $<ix:nonFraction unitRef="usd" contextRef="i1b11e41e2b894c69abd5daa1e6e3fc87_D20190901-20190930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTI0ODk_5acbf55e-c6ed-44fd-9609-23a27e3c6598">1.2</ix:nonFraction> million in cash and $<ix:nonFraction unitRef="usd" contextRef="i98241c5880794788af87b66dc6a371bd_D20190901-20190930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTI1MDQ_19abf7d0-fa68-436b-819a-b7fcb1776523">0.4</ix:nonFraction> million of APC common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="i865e78a6a983465c852275c72549d64c_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTI2MTA_af71248d-f87a-4024-9114-136555773127">100</ix:nonFraction>% interest in each of Medical Property Partners, LLC (&#8220;MPP&#8221;), AMG Properties, LLC (&#8220;AMG Properties&#8221;), and ZLL Partners, LLC (&#8220;ZLL&#8221;) and a <ix:nonFraction unitRef="number" contextRef="i5fb003ee3c184ccf91aa13ae16058103_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTI3NDk_23d49c58-42c2-4789-815c-2aa3bc0853fa">50</ix:nonFraction>% interest in each of One MSO, LLC (&#8220;One MSO&#8221;), Tag-6 Medical Investment Group, LLC (&#8220;Tag 6&#8221;), and Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;). These entities own buildings that are currently leased to tenants as well as vacant land which they plan to develop in the future. MPP, AMG Properties, and ZLL are <ix:nonFraction unitRef="number" contextRef="i865e78a6a983465c852275c72549d64c_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTMwNTg_af71248d-f87a-4024-9114-136555773127">100</ix:nonFraction>% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#8217;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, AP-AMH 2 Medical Corporation (&#8220;AP-AMH 2&#8221;), a VIE of the Company, purchased an <ix:nonFraction unitRef="number" contextRef="i3fd12cfc45b244a5884bf4cd547e6583_I20210731" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTY0OTI2NzQ2NTI3MA_9f4d5568-1c08-45ae-9fdd-a48df7dc25dc">80</ix:nonFraction>% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#8220;APCMG&#8221;), a primary care physicians&#8217; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company (see Note 3). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2021, Apollo Medical Holdings, Inc. acquired <ix:nonFraction unitRef="number" contextRef="ib05af751a8be4d57b25abcbf5cb700aa_I20210831" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMjc0ODc3OTEwMjkxNw_c5102dd8-23a7-4e50-a011-e60c7c4afce4">49</ix:nonFraction>% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#8220;Sun Labs&#8221;) for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i19c94975ba3e411ca4090953760b5a7f_D20210801-20210831" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMjc0ODc3OTEwMzA2Mw_e4c8ab89-1f4a-49e2-8c4b-9d5028fe4ba1">4.0</ix:nonFraction> million. Sun Labs is a Clinical Laboratory Improvement Amendments certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company (see Note 3). The Company is obligated to purchase the remaining equity interest within <ix:nonNumeric contextRef="i19c94975ba3e411ca4090953760b5a7f_D20210801-20210831" format="ixt-sec:durwordsen" name="ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMjc0ODc3OTEwMzY1MA_98622117-6023-4b55-aea5-71ef343a9726">three years</ix:nonNumeric> from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of at $<ix:nonFraction unitRef="usd" contextRef="i87665dc910e64455b39ac20a1dc7a442_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMjc0ODc3OTEwMzUzOQ_4f850cbf-1f67-49ac-b451-c26b4ecb301e">4.2</ix:nonFraction> million at September&#160;30, 2021. As the financing obligation is embedded in the noncontrolling interest, the noncontrolling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7cd1d9e4111a4761b2d86d30751c90d3">APAACO, jointly owned by NMM and AMM, began participating in the NGACO Model of CMS in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNzg_bc4b77a2-855d-4168-b231-d57c61f5b1ad" continuedAt="i403533f1bc5e4fb083950e74a3a7a58c" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i403533f1bc5e4fb083950e74a3a7a58c" continuedAt="i7f2163becbdc423cb2d812f61ccbd577"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzOTg_42125e00-443f-4665-8607-8ad2febc48e4" continuedAt="i00345833d9434367a3c65d459adb2a44" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i00345833d9434367a3c65d459adb2a44">The accompanying consolidated balance sheets at December&#160;31, 2020, have been derived from the Company&#8217;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of September&#160;30, 2021, and for the three and nine months ended September&#160;30, 2021 and 2020, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;15, 2021. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.</ix:continuation> Operating results for the three and nine months ended September&#160;30, 2021, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or any future periods.</span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MTU_10ac3f87-a007-42d0-b14e-fa500811d764" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of September&#160;30, 2021 and December&#160;31, 2020, and the consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020, include the accounts of ApolloMed; its consolidated subsidiaries, NMM, AMM, and APAACO; its consolidated VIEs, AP-AMH, AP-AMH 2, and Sun Labs; AP-AMH 2&#8217;s consolidated subsidiary, APCMG; AMM&#8217;s consolidated VIE, SCHC; NMM&#8217;s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM&#8217;s consolidated VIE, APC; APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties and ZLL, APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNTQ_26ea3756-cc4f-4e78-ac6b-21c6922fad42" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0Mjc_a91a1f4e-1a32-4c0e-8433-b90dbc71c12f" continuedAt="ib55e21cd72114498acc408311da6dc41" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i7f2163becbdc423cb2d812f61ccbd577" continuedAt="if0f36078f5c646bda95b38cda1820c03"><ix:continuation id="ib55e21cd72114498acc408311da6dc41" continuedAt="i8d54d71861bf4d1abef1f370296239e3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8d54d71861bf4d1abef1f370296239e3">If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.</ix:continuation><br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzOTE_7f90921b-2f7b-4e92-9114-a9f676cb0525" continuedAt="i569d320006fa4612b9bd0e69c320427c" escape="true">Business Combinations</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i569d320006fa4612b9bd0e69c320427c">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</ix:continuation></span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MDY_39605b9e-ea00-48ac-bba3-7fd2bdcdfe47" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNzQwOA_4a864832-6d3d-436a-9041-e1d5ac1fb060"><ix:nonFraction unitRef="segment" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNzQwOA_63ad19ff-cbca-434a-a7aa-450e2c4541b1">one</ix:nonFraction></ix:nonFraction> reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in <ix:nonFraction unitRef="segment" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNzY4NQ_4a864832-6d3d-436a-9041-e1d5ac1fb060"><ix:nonFraction unitRef="segment" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNzY4NQ_63ad19ff-cbca-434a-a7aa-450e2c4541b1">one</ix:nonFraction></ix:nonFraction> reportable segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MzY_c353730c-c557-4ac4-84ea-99e8c81fd534" continuedAt="i272b4a2e4d8846cf8dbf3e6325e54bb9" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i272b4a2e4d8846cf8dbf3e6325e54bb9">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash.</ix:continuation> As of September&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $<ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashUninsuredAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfODQ0OQ_2615fc01-967e-41e3-8965-63ba123f94ca">301.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashUninsuredAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfODQ1Ng_0f50cccb-e1ad-4e8b-836d-2a6901b94fa3">294.9</ix:nonFraction> million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="if0f36078f5c646bda95b38cda1820c03" continuedAt="i0136738dc10745aca902af71f03c5eed"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0NTE_6884312d-acfb-4f7a-b4ec-45772cbcde94" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MDI_d9e677c2-a8a1-4140-8b24-98e08f426c6c" continuedAt="iafdf04c708c34d048691538f6f7ac985" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from <ix:nonNumeric contextRef="ie4f15f9c5a3844039181a10397fc0a58_D20210101-20210930" format="ixt-sec:durwordsen" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MTY_5e4532c0-f19c-4c1c-b36b-e52b53c9334b">four months</ix:nonNumeric> to <ix:nonNumeric contextRef="i5c1a64ec8e5142baa71cef9c34b44674_D20210101-20210930" format="ixt-sec:durmonth" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfOTIxNg_a81d065e-a39c-49a2-99f3-e08bbcbaea0c">24</ix:nonNumeric> months. As of September&#160;30, 2021 and December&#160;31, 2020, certificates of deposit amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="id0ab35f4b7d54df89c058bf7cd127578_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfOTI5NA_d879af6b-1933-4e66-ad71-35c87085e09e">67.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70a8098987854f45b301221eae528a87_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfOTMwMQ_8d52d086-7da4-4289-9ca4-669cfda30631">67.6</ix:nonFraction> million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><ix:continuation id="iafdf04c708c34d048691538f6f7ac985" continuedAt="i8118281c5a9c45aebd9b6e0053e7e565"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Equity securities held by the Company are comprised of common stock of a payor partner that completed its initial public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i8118281c5a9c45aebd9b6e0053e7e565">(&#8220;IPO&#8221;) in June 2021 and Clinigence Holdings, Inc. (&#8220;Clinigence&#8221;). The shares were acquired as a result of UCAP selling its</ix:continuation> <ix:nonFraction unitRef="number" contextRef="i21d7bfcc34ee4134a98f32759980bac4_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfOTg0OQ_62d62d98-11c4-47c8-8dce-3a2e94248e48">48.9</ix:nonFraction>% ownership interest in Universal Care, Inc. (&#8220;UCI&#8221;) in April 2020. As of September&#160;30, 2021, the equity securities from the payor partner amounted to $<ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfOTk1OA_4d280a62-a047-48e9-bf2c-998f88f16cc3">57.0</ix:nonFraction> million. As of December&#160;31, 2020, prior to our payor partner&#8217;s IPO, the related investment balance was included in investments in privately held entities at its cost basis of $<ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTAxMTI_1bbf36b8-1a92-4e0f-a0d0-25192b36628f">36.2</ix:nonFraction> million in the accompanying consolidated balance sheets. In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $<ix:nonFraction unitRef="usd" contextRef="i73149ba28e96471eb0008ad0f005eb5b_D20210901-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentsToAcquireCommonStockAndWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTA5OTUxMTY4Njc0MA_a9aabffe-095f-418a-a569-83344e727a25">3.0</ix:nonFraction>&#160;million. The common stock is included in investments in marketable securities. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three and nine months ended September&#160;30, 2021, the Company recognized unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTA5OTUxMTY4MzMyMg_16ed5d3c-ac1c-40bf-ade3-df9fd630ca75">62.0</ix:nonFraction>&#160;million and unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTAyNDI_be50d974-2f4f-473e-8e1f-3feea36264c6">21.8</ix:nonFraction> million on all equity securities in unrealized gain or loss on investments in the accompanying consolidated statements of operations.</span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNTU_629c1a53-1146-4783-b4e8-87b80c6a63fa" continuedAt="ic336c288dbea41a7a3500a8059eee570" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables,  Receivables &#8211; Related Parties, and Loan Receivable - Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivable &#8211; related party consist of promissory notes from payees that are expected to be collected between two to four years and accrue interest per annum. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivables relate to each health plan&#8217;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:durmonth" name="ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTE2MzA_78d412c4-72a0-4383-b381-6fd3f8e65c3e">18</ix:nonNumeric> months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i0136738dc10745aca902af71f03c5eed" continuedAt="i21c35121d9624a5e915b312529e30e49"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic336c288dbea41a7a3500a8059eee570">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MDM_3ad72830-369d-43dc-afbe-3e18ae5d84c8" continuedAt="ia1063674b83e4d5994d08c0ac59b6a9d" escape="true">Concentrations of Credit Risks</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia1063674b83e4d5994d08c0ac59b6a9d">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of operations present disaggregated revenue by service type.</ix:continuation> <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MzE_39db88b6-f7a6-4493-891c-1a5b08daaee1" continuedAt="i2098ae0db88d45deb7cd01765c44b15d" escape="true">The following table presents disaggregated revenue generated by payor type for the three and nine months ended September&#160;30, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i2098ae0db88d45deb7cd01765c44b15d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620cf562ac9c414d9a3092d147a50325_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfMy0xLTEtMS0w_b9a8be42-6ef7-4643-a1cf-84d652ea3ef2">36,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96b5ec1dd6f464a864b0099f4d91c07_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfMy0zLTEtMS0w_4210bbb7-b198-4212-abff-6b752f98efaf">25,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie007473644f44d87917377c77aef7ccf_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfMy01LTEtMS0w_ff52907a-9eab-4fc0-960c-66b2b2d51a69">102,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a17291f515493a861cd6f4b6efc5d0_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfMy03LTEtMS0w_7ce2d237-d0f6-4080-ab8a-76166adb471d">75,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0844a4c64e4a4f52bffe29e4402a700d_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNC0xLTEtMS0w_15887b3a-a032-4315-bcc7-a07eac34c2d0">103,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3b05a4a5ac46009c7ff5139937e1c3_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNC0zLTEtMS0w_2a402e3d-860a-46ca-8162-167915ba5f2e">79,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733800189cf14be7957deb86e6bdafa7_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNC01LTEtMS0w_047de25b-ba81-444f-856c-4b0818c2d367">232,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3852673d58ff474a9ec227fd30703a97_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNC03LTEtMS0w_a5ddda1b-d05c-4882-bf05-e510c4b9d175">206,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04da3802734c4d5ca72ce1e9859ddf23_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNS0xLTEtMS0w_3ca54fb1-cf56-4874-bb17-acd59adcbec3">74,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib06f5b4a97614ebebfcdcb473ee362ba_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNS0zLTEtMS0w_0b7540db-c103-4a9f-bae9-e27b97d01c60">65,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31af46ad891f405383d1dfc6a8f0cfca_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNS01LTEtMS0w_67eb9365-144a-4367-89ea-35d448b05252">212,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ffcf9784294ca9a72978bc33ad7f9e_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNS03LTEtMS0w_46f7fee5-6bab-4bda-8486-b2685ca43055">200,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7446d9124cfd4d7585720c3d8e7122d3_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNi0xLTEtMS0w_e8be7ef6-00aa-4260-ae1a-0d07a5b6aa64">11,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7116e35a0d75437b94523ce43f9485b0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNi0zLTEtMS0w_ac65a4aa-2837-4053-8029-e511196bce79">9,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ce34a69194485699b14fc7aa46d82c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNi01LTEtMS0w_9345ec37-6ca5-4e98-abdf-3bee997864d6">31,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9a026a7fbb4032abab16642bbb3559_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNi03LTEtMS0w_64a5c24d-9c45-49a9-9006-e13e2546277a">27,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNy0xLTEtMS0w_88eab1c4-c926-4762-b1fa-b0043f18b64f">227,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNy0zLTEtMS0w_62f9df4a-2bb8-40f2-a7a0-d104a08830ee">180,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNy01LTEtMS0w_8aafdbac-233d-4840-9a60-bcde8ed51dbe">578,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNy03LTEtMS0w_91237115-bf8d-4f04-8c4e-7f00328696a1">510,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNTY_3a8e3da7-b002-4551-9a06-8f229f8e38da" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51f1ae095a524c598ba9ab90870d3358_D20210701-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfMy0xLTEtMS0w_25fdb1bf-e7a4-413a-86e3-336a1ba1063b">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56807d20331a448d82326373209f0ebc_D20200701-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfMy0zLTEtMS0w_a7ba2cc4-1367-4b22-9e99-6b9aaa92d9ff">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1734fad16be4ffd9f4a18f4e906e85d_D20210101-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfMy01LTEtMS0w_1aae538a-dcb4-44bd-83bd-a92d121b0d8c">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i669f4e3ef9c74609880bf5e9b21c3859_D20200101-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfMy03LTEtMS0w_70a6be73-15e9-403d-955d-e62dd1d03577">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie27ed45d3b0c4053b92fca660e1e6d1a_D20210101-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNC01LTEtMS0w_bfb4109a-4f1b-4080-8cb4-17d9e54a8b9c">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf8c009ddf949839ee8d70ae541980a_D20200101-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNC03LTEtMS0w_7f5d3c18-e50b-460a-8618-431cce037f3d">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4de419972e0e4273afd8cb93852e239a_D20210701-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNS0xLTEtMS0w_4a7f1fa2-a02f-4e45-a60f-7d60aedd7c13">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e3a8da4ddbe49af8195caf1c527e751_D20200701-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNS0zLTEtMS0w_586e5cf6-3693-4567-90fa-5b357882643a">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa3259fa3ba0452db6f9b000329b0707_D20210101-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNS01LTEtMS0w_535f48ca-fe7e-4095-9c7f-5e60d3439a76">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if278b608177c4be99b9342cc7f6e2747_D20200101-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNS03LTEtMS0w_3e7763a8-5f70-4a39-a344-55ec1059b687">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic9203d02b2a74181bd4ed2e0e1ba71f9_D20210701-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNi0xLTEtMS0w_1fa3ec61-ba3e-41ab-ae62-5c97353f28e5">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i875dae327fdd4ebc9c116e881e3cd106_D20200701-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNi0zLTEtMS0w_c45e88df-9da4-4c91-96db-d1a9fd4fff8f">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02eb4ac069e64a9683beb09cbf7a8921_D20210101-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNi01LTEtMS0w_f2547f64-6c28-4c33-957f-34f2c308c284">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i64112f96ecc6447d924934cf8a3517dc_D20200101-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNi03LTEtMS0w_097949cb-3030-4aa4-8cd4-acf43cfad2c8">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie30670fa153f4da59d850909c48a2fd6_D20210101-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmRjOWJkN2M5MTQ3YTQ5NTY5YzliOGE5YTVjZmQ4ODY2L3RhYmxlcmFuZ2U6ZGM5YmQ3YzkxNDdhNDk1NjljOWI4YTlhNWNmZDg4NjZfMy0xLTEtMS0w_867b770a-3dab-47b2-90f0-2b3e9a7c6c35">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic985d70a02f643808edb2e7823ec4817_D20210101-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmRjOWJkN2M5MTQ3YTQ5NTY5YzliOGE5YTVjZmQ4ODY2L3RhYmxlcmFuZ2U6ZGM5YmQ3YzkxNDdhNDk1NjljOWI4YTlhNWNmZDg4NjZfNC0xLTEtMS0w_e1bf244b-dc3b-43aa-8b58-3c202c71306c">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6123d945359476aa42a8767483cbee8_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmRjOWJkN2M5MTQ3YTQ5NTY5YzliOGE5YTVjZmQ4ODY2L3RhYmxlcmFuZ2U6ZGM5YmQ3YzkxNDdhNDk1NjljOWI4YTlhNWNmZDg4NjZfNC0zLTEtMS0w_2a28c750-46ed-4a1e-9e54-38f74c2383a7">43.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i861c8815c7544ce78f48c3ea70ec379b_D20210101-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmRjOWJkN2M5MTQ3YTQ5NTY5YzliOGE5YTVjZmQ4ODY2L3RhYmxlcmFuZ2U6ZGM5YmQ3YzkxNDdhNDk1NjljOWI4YTlhNWNmZDg4NjZfNS0xLTEtMS0w_528c5cff-358d-47b8-8e71-51907c0b5bae">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i59a0229c1ab0473da20301ac3f5f144a_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmRjOWJkN2M5MTQ3YTQ5NTY5YzliOGE5YTVjZmQ4ODY2L3RhYmxlcmFuZ2U6ZGM5YmQ3YzkxNDdhNDk1NjljOWI4YTlhNWNmZDg4NjZfNS0zLTEtMS0w_e9e402ed-219a-433b-a3ea-1df9f31ab3e2">36.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNjY_cadcbe73-36d7-4b97-9a7b-15031acd780f" continuedAt="i54d425444ac149af87d1c1d1e156d3a2" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i21c35121d9624a5e915b312529e30e49" continuedAt="ibef42badcf46441fb98bf124ebcd1402"><ix:continuation id="i54d425444ac149af87d1c1d1e156d3a2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div></ix:continuation><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNjQ_5a2d051d-72e3-44f6-8a98-cc6860e4b435" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of September&#160;30, 2021, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds*</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719e7a78283546f4bc429a548789a311_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMy0xLTEtMS0w_7ee0c0f0-5556-4a32-bcb0-9b8f0cc2708f">89,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91958f750e2540c1b7888e3065408687_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMy0zLTEtMS0w_69a17f8e-5f86-4ccf-9024-d53d4e8d1a30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMy01LTEtMS0w_e249481e-07a8-40cb-968a-e20cec7535bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMy03LTEtMS0w_bf0b6abe-14c8-4b76-adaa-e2b226ab48b2">89,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; certificates of deposit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719e7a78283546f4bc429a548789a311_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNC0xLTEtMS0w_0084a33e-87c3-4cf6-a224-44dc96c2fbfb">67,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91958f750e2540c1b7888e3065408687_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNC0zLTEtMS0w_33a6e325-b5ca-4bae-9b21-0b50f8805b86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNC01LTEtMS0w_e77c933f-173f-4c17-b700-0536b0bb3647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNC03LTEtMS0w_d31d205b-95be-4345-9554-5839c694d2bf">67,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719e7a78283546f4bc429a548789a311_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNS0xLTEtMS0w_71543a00-4f12-4c37-b3df-b2c0dfdb8223">57,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91958f750e2540c1b7888e3065408687_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNS0zLTEtMS0w_cfedd670-b141-46de-b00c-fd6e847018ac">3,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNS01LTEtMS0w_e677afed-a012-47a0-a108-73b93d1304a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNS03LTEtMS0w_bf2bd9ab-7c18-4bb6-b498-a0b16053ab4c">61,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719e7a78283546f4bc429a548789a311_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNy0xLTEtMS0yMzI4Mw_17b4018c-d5fc-484d-9f2d-887697e4f493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91958f750e2540c1b7888e3065408687_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNy0zLTEtMS0yMzI4Mw_0d1ff0d4-1c32-4d12-a6a0-cede58d38563">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNy01LTEtMS0yMzI4Mw_32d2250e-1898-42da-a2e7-e925f0b97da9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNy03LTEtMS0yMzI4Mw_2fcbc473-b974-46dd-8398-a04efc6d511b">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719e7a78283546f4bc429a548789a311_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNi0xLTEtMS0w_f802ea17-9104-4893-a5ce-f9c604cfedd3">214,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91958f750e2540c1b7888e3065408687_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNi0zLTEtMS0w_777febd2-7992-41f4-a02d-49de9d0637fc">4,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNi01LTEtMS0w_cbb9b165-98e0-4bc1-83c9-6d83bb62d0a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNi03LTEtMS0w_47811ed6-5356-4566-a1f8-f0e8796724e5">219,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719e7a78283546f4bc429a548789a311_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOC0xLTEtMS0w_b5e406a7-871b-44cc-8bb9-01932fc09a42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91958f750e2540c1b7888e3065408687_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOC0zLTEtMS0w_f1e38918-beac-466d-8400-fbd11b21e4c9">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOC01LTEtMS0w_245fc4da-1789-4326-ab92-b7bec50f5a9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOC03LTEtMS0w_2aa0d250-2b53-4960-939c-3978e6a2a797">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719e7a78283546f4bc429a548789a311_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMTEtMS0xLTEtMjcwNzg_7d2b27b4-a4dc-479d-885a-9d58945ab4eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91958f750e2540c1b7888e3065408687_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMTEtMy0xLTEtMjcwNzg_e26dd285-f482-497b-99af-79d3ecf4c3ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMTEtNS0xLTEtMjcwNzg_9c337bb0-99ad-4f0d-8220-acaa8628beb0">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMTEtNy0xLTEtMjcwNzg_75d268e5-878a-4a3d-b725-12ef6c9a83b2">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719e7a78283546f4bc429a548789a311_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOS0xLTEtMS0w_547f7623-9e57-47ff-9385-80a217470a89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91958f750e2540c1b7888e3065408687_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOS0zLTEtMS0w_78f5581a-bbcc-4c96-9077-5f8fff33c9c3">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOS01LTEtMS0w_bf61ab89-d004-4c5d-a744-49aae3680105">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOS03LTEtMS0w_c85a0100-fcfe-4ce3-b20a-799bd2808490">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2020, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3447f389c5504801b383b47a1c4d2bf5_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfMy0xLTEtMS0w_8958fff9-8907-4410-aad1-044173c148f6">115,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69a06c770b545248b58b9ead976504d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfMy0zLTEtMS0w_636f727f-27e3-46d6-8f47-606910249aad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1dab6e4bc5e45dc9b15b4f78276c9d2_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfMy01LTEtMS0w_bc62f7e5-bc3d-48cd-b8a2-86c2f3dbd60f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfMy03LTEtMS0w_181acfc3-cd5f-4c80-81bc-b7ba1d06f9ce">115,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3447f389c5504801b383b47a1c4d2bf5_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNC0xLTEtMS0w_33416672-5035-4f74-8a46-2ebc80ecf3b0">67,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69a06c770b545248b58b9ead976504d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNC0zLTEtMS0w_88139c74-5f46-4305-bd33-04806179aa29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1dab6e4bc5e45dc9b15b4f78276c9d2_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNC01LTEtMS0w_59d2ed7f-9f91-4434-816c-9e3fd427c65f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNC03LTEtMS0w_31474748-2b55-4b04-b80a-b9ffd9c979be">67,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3447f389c5504801b383b47a1c4d2bf5_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNS0xLTEtMS0w_c8cbf8d3-c888-4bb5-949f-4bd100d6e087">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69a06c770b545248b58b9ead976504d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNS0zLTEtMS0w_7cd8d5ee-b50a-4216-afb2-20d235bd4bf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1dab6e4bc5e45dc9b15b4f78276c9d2_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNS01LTEtMS0w_2ed6d0c0-0810-416b-a2c4-9ecf16d65464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNS03LTEtMS0w_6a72a578-2b47-4cb3-b813-9fd912c88493">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3447f389c5504801b383b47a1c4d2bf5_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNi0xLTEtMS0w_af27f153-3f27-46c2-a2ed-c96fe3b455c2">183,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69a06c770b545248b58b9ead976504d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNi0zLTEtMS0w_4d38374f-63e4-4a79-8b01-b86a35e0efd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1dab6e4bc5e45dc9b15b4f78276c9d2_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNi01LTEtMS0w_9a63c071-20fd-424d-a1d6-d5ad18fd546d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNi03LTEtMS0w_7cbcfa11-d4df-4638-badf-e0917c8e0db0">183,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the nine months ended September&#160;30, 2021.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ibef42badcf46441fb98bf124ebcd1402" continuedAt="i5bc892678c364ab798453cbf24956109"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNjc_acbed529-c393-48ac-aecf-396789bd0e1d" continuedAt="i7bf4fe4d874d4cc98bdfb1c1e8bbce23" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7bf4fe4d874d4cc98bdfb1c1e8bbce23">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</ix:continuation> The Company determined that there was <ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTc5Mjk_1305803b-0926-4c7b-b4e9-0ae66afe2136"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTc5Mjk_2bb082d3-6cdc-4c34-81ba-26a1b92f47ea"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTc5Mjk_7906dc8c-0ffa-434a-a3da-c3c27b28dfd8"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTc5Mjk_a933742e-9f28-4bb6-bd3d-59d55300a5f7">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its finite-lived intangible or long-lived assets during the nine months ended September&#160;30, 2021 and 2020.</span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MzI_1ed10c2d-9aee-44fb-afd3-7eefb38b413a" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s <ix:nonFraction unitRef="unit" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTg2NjM_5e424982-0e0a-4525-9ab0-a5f39426c4ec">three</ix:nonFraction> reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMjAwMTI_0e078519-365a-4c39-8894-5cccd4da23e4"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMjAwMTI_2c040b6d-e568-4c88-86de-6bf7c63abb37">no</ix:nonFraction></ix:nonFraction> impairment of its goodwill or indefinite-lived intangible assets during the nine months ended September&#160;30, 2021 and 2020. </span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNjg_7547d899-d6d7-4a8a-9aba-8b5aa988e69b" continuedAt="i4896ce64111c4d788a703acec2e88d4b" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of operations under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i5bc892678c364ab798453cbf24956109" continuedAt="i85c8f890f40b48d388a3a59ae906b993"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4896ce64111c4d788a703acec2e88d4b">investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</ix:continuation></span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:HealthCareCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MzM_eeb989d3-f299-418e-87cd-3a891f58e18c" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, and APCMG (&#8220;consolidated IPAs&#8221;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="ameh:FiduciaryCashAndPayablePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0NDc_6c351547-908c-4292-a62d-45dc12a922d1" continuedAt="ieaee4ce759fd4d4090976019ee35e06a" escape="true">Fiduciary Cash and Payable</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieaee4ce759fd4d4090976019ee35e06a">The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them.</ix:continuation> The fiduciary cash balance of $<ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMjM0Nzc_f7ea4b02-e785-474f-8c50-e88e2a883eb5">8.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMjM0ODQ_569af036-15b7-4771-aa72-a2edf3deb74c">9.6</ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.</span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MzQ_e06e4f2b-b743-4d6d-9847-e84f491e0d9e" continuedAt="i94e3966c57f3449fbe0fb4444f4387df" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of operations.</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. The fair value of the derivative instrument as of September&#160;30, 2021, was $<ix:nonFraction unitRef="usd" contextRef="iee549c3ab8a545c3962f33718601846b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMjQ2MzI_1a74f02a-6723-4947-9f25-c5e3c80b4f8a">1.0</ix:nonFraction> million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants<br/></span></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i94e3966c57f3449fbe0fb4444f4387df">In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $<ix:nonFraction unitRef="usd" contextRef="i73149ba28e96471eb0008ad0f005eb5b_D20210901-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentsToAcquireCommonStockAndWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTA5OTUxMTY4NzA4MQ_a9aabffe-095f-418a-a569-83344e727a25">3.0</ix:nonFraction>&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of operations.  The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. The fair value of the derivative instrument as of September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i91958f750e2540c1b7888e3065408687_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTA5OTUxMTY4NzgzNg_c9ccf7de-2a8c-4bca-8d20-4ee3fb7aad84">1.0</ix:nonFraction>&#160;million and is presented within other assets in the accompanying consolidated balance sheets.</ix:continuation>  </span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzODE_b0b167a8-4072-4558-a390-cecb14ba6a53" continuedAt="ie7f8b4ee181a4e24bcf04fd180f1bf8a" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i85c8f890f40b48d388a3a59ae906b993" continuedAt="i377138cb3c6545109d7fc8b4fe5947ff"><ix:continuation id="ie7f8b4ee181a4e24bcf04fd180f1bf8a" continuedAt="i7cef8bb3fba349d9890921bbdabd878d"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of <ix:nonNumeric contextRef="i5a9f36c8077645449753769fc30f2343_D20210101-20210930" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNzU_fef5bc46-cbe9-4053-a9c3-bb6ccd7edca5">one year</ix:nonNumeric> or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospital&#8217;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i377138cb3c6545109d7fc8b4fe5947ff" continuedAt="i2cadc41bdc604996b9dbabfd27741b5e"><ix:continuation id="i7cef8bb3fba349d9890921bbdabd878d" continuedAt="i026315ea48044ea0a20635195523583f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, the Company must submit to CMS its selections for risk arrangement, the amount of the profit/loss cap, alternative payment mechanism, benefits enhancements, if any, and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 8), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within <ix:nonNumeric contextRef="i17d3720cbb39433fad71b101f7b86012_D20210101-20210930" format="ixt-sec:durday" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzYyNTQ_007e184f-d371-44d5-a45e-1ff35e72b5a0">30</ix:nonNumeric> days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within <ix:nonNumeric contextRef="i17d3720cbb39433fad71b101f7b86012_D20210101-20210930" format="ixt-sec:durday" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzY1MTQ_b7f944fb-b570-4362-a28e-be14bb59efcb">30</ix:nonNumeric> days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within <ix:nonNumeric contextRef="i17d3720cbb39433fad71b101f7b86012_D20210101-20210930" format="ixt-sec:durday" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzY2Mzc_b7f944fb-b570-4362-a28e-be14bb59efcb">30</ix:nonNumeric> days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i2cadc41bdc604996b9dbabfd27741b5e" continuedAt="ie2a0b47f657d42f79d6ccdb3672f6354"><ix:continuation id="i026315ea48044ea0a20635195523583f" continuedAt="i985dc6c801204c0ba6a904ba6218457d"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i17d3720cbb39433fad71b101f7b86012_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:RevenueFromRiskPoolSettlementsFromPriorPerformanceYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTA5OTUxMTY4ODQ5Mw_660a2c24-9ed2-4803-a1b0-a499af0e2cfb">21.8</ix:nonFraction>&#160;million related to savings from the 2020 performance years. The settlement was finalized in October 2021 and recorded as revenue in risk pool settlements and incentives in the accompanying consolidated statements of operations for the three and nine months ended September&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance year 2021, the Company receives monthly AIPBP payments at a rate of approximately $<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentOfRevenueMonthlyAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzgwMTA_6c0352d0-d2b3-4a2a-a9c3-3fdc1670ffc2">8.0</ix:nonFraction> million per month from CMS, and must comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzgyNTg_0eb97b23-a635-46eb-ae6c-fe2baa542978">23.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzgyNjU_cdf23685-1bd5-41dc-bd1f-c0dc57e66801">72.0</ix:nonFraction> million in total AIPBP payments for the three and nine months ended September&#160;30, 2021, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentOfRevenueRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzgzNTA_42429408-6e2b-4ead-9815-f3f45d961a21">17.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentOfRevenueRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzgzNTc_5620121d-086d-4114-aedf-4b89c262b75f">48.9</ix:nonFraction> million has been recognized as revenue for the three months and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., <ix:nonNumeric contextRef="i3329b671360b4adfa4fb2f7c426fc278_D20210101-20210930" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzOTY_1f42e997-069f-4a65-bbd4-108f6ea339ee">10 years</ix:nonNumeric>), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system, and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ie2a0b47f657d42f79d6ccdb3672f6354" continuedAt="i5696f63da37f49f5b0326ae3f9fe6e72"><ix:continuation id="i985dc6c801204c0ba6a904ba6218457d" continuedAt="i8f541b572e71425599162a026d62073e"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of operations in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8f541b572e71425599162a026d62073e">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</ix:continuation> The Company&#8217;s contract liability balance was $<ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNDY3OTQ_33abb94a-8adb-42f6-9bc8-b33facd8251e">17.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNDY4MDE_d8bf7c88-b79b-4a6c-94e6-2236fe293ce5">13.0</ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and is presented within accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the nine months ended September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i125c51891f044f728be18a8712aa205b_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNDY5Nzc_b95ff8e7-d191-496e-9934-66d8c81b6424">0.4</ix:nonFraction> million of the Company&#8217;s contract liability accrued in 2020 has been recognized as revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0NDE_f1231f6b-781f-4195-8862-4a0866f48e4a" continuedAt="i65aa0242df9c486da22c9230ce3b4411" escape="true">Income Taxes</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i5696f63da37f49f5b0326ae3f9fe6e72" continuedAt="i591b4a5b82f845a8b83f458b096813a3"><ix:continuation id="i65aa0242df9c486da22c9230ce3b4411"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div></ix:continuation><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0NDk_e465e9af-3bc9-4702-8be2-65d261cd1362" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards, such as options, is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNzY_b248b735-3897-47e0-935f-4b4b72bcb751" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 for a discussion of shares treated as treasury shares for accounting purposes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="ameh:MinorityInterestPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNzc_50ea7982-f843-431d-b57a-2a2fcdfbeaea" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="ameh:TemporaryEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNzM_4b87cf43-24a5-4a4f-a0ee-7b62ad117a34" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of September&#160;30, 2021 and December&#160;31, 2020, APC&#8217;s shares were not redeemable, nor was it probable the shares would become redeemable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MDk_8ea8179c-1f5c-4791-b92d-a1506292fc9a" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i591b4a5b82f845a8b83f458b096813a3"><div style="margin-top:10pt;text-align:justify"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="ameh:BeneficialInterestPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNTk_17c86fc7-a845-4c84-9d5b-4dac0e0af36e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Interest<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, when UCAP, a <ix:nonFraction unitRef="number" contextRef="i0562f8e9b55a42e9a5ee44f0e186cecf_I20200430" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTE5Mjg_eff2d53e-fff4-4fb5-9232-abff4ea8cdfb">100</ix:nonFraction>% owned subsidiary of APC, sold its <ix:nonFraction unitRef="number" contextRef="i21d7bfcc34ee4134a98f32759980bac4_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTE5NjU_62d62d98-11c4-47c8-8dce-3a2e94248e48">48.9</ix:nonFraction>% ownership interest in UCI, APC received a beneficial interest in the equity method investment sold, pursuant to the terms of the stock purchase agreement. The estimated fair value of such interest in April 2020, was&#160;$<ix:nonFraction unitRef="usd" contextRef="ice32049f82244ceebffb5a2a9e3d9448_D20200401-20200430" decimals="-5" format="ixt:num-dot-decimal" name="ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTIxODM_5b08e68a-bbf2-4de4-ab41-8c6aac3e292b">15.7</ix:nonFraction> million and is included in other assets in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $<ix:nonFraction unitRef="usd" contextRef="i21d7bfcc34ee4134a98f32759980bac4_I20200430" decimals="-5" format="ixt:num-dot-decimal" name="ameh:EquityMethodInvestmentSaleContingentConsiderationCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTI0OTU_2d4858c2-00b8-4721-afe2-848bcee97374">15.6</ix:nonFraction>&#160;million and preferred shares with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i21d7bfcc34ee4134a98f32759980bac4_I20200430" decimals="-5" format="ixt:num-dot-decimal" name="ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTI1NTE_78c94bb4-eaf1-450f-ac5f-d95db03e79bf">6.4</ix:nonFraction>&#160;million, total estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i21d7bfcc34ee4134a98f32759980bac4_I20200430" decimals="-5" format="ixt:num-dot-decimal" name="ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTI1ODU_ffe34273-50bf-4d8f-85b1-81162d4d02fa">22.0</ix:nonFraction>&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#8217;s gross margin for the year ended December 31, 2020, was assessed and beneficial interest was concluded to not be collectible. The $<ix:nonFraction unitRef="usd" contextRef="i9b6b078c674a40a6aa164bb3f282fc69_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:EquityMethodInvestmentWriteOffOfAdditionalProceeds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTQyMDc_31a1a2f6-afa5-4f08-afbd-b620d1030f32">15.7</ix:nonFraction> million was written off and expensed in other income in the accompanying consolidated statements of operations for the nine months ended September&#160;30, 2021.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNjA_d4d48ca2-92ac-460b-aeed-6a4ad6027371" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="i77048548a0c546beaa10a42c80553a71_55"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTY1MQ_59e84fee-6e90-4b31-b17d-968dde10187f" continuedAt="i0083c1cad16c4849acbf5746de86f9fa" escape="true">Business Combinations and Goodwill</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i0083c1cad16c4849acbf5746de86f9fa" continuedAt="i905cc209b99f4eb1a4f26bb9d532409b"><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APCMG</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2021, the Company acquired an <ix:nonFraction unitRef="number" contextRef="i3fd12cfc45b244a5884bf4cd547e6583_I20210731" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTA5OTUxMTYyOTYyNg_9f4d5568-1c08-45ae-9fdd-a48df7dc25dc">80</ix:nonFraction>% equity interest (on a fully diluted basis) in APCMG for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i8b9f56835a534891ad456a64d2c85f50_D20210731-20210731" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTA5OTUxMTYyOTcxOA_ef3e879d-434e-4c85-a0eb-0d9916393388">2.0</ix:nonFraction> million. As part of the transaction, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i8b9f56835a534891ad456a64d2c85f50_D20210731-20210731" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTA5OTUxMTYyOTc5Mw_cb1c35f3-6c1e-4c36-bd49-f94f51cb6bbc">1.0</ix:nonFraction> million in cash and the remaining amount will be paid out in cash as a contingent consideration related to APCMG&#8217;s financial performance for fiscal year 2022. The contingent consideration is met if gross revenue and EBITDA targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of September&#160;30, 2021, the contingent consideration is valued at $<ix:nonFraction unitRef="usd" contextRef="if2f519bb3a21437e99c17cddc631e9cd_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTA5OTUxMTYzMDE1MA_eb04f530-cdcc-465c-b0d4-ae4ba991531f">1.0</ix:nonFraction> million and was included within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sun Labs</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2021, the Company acquired <ix:nonFraction unitRef="number" contextRef="ib05af751a8be4d57b25abcbf5cb700aa_I20210831" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTA5OTUxMTYzMDQ0MQ_c5102dd8-23a7-4e50-a011-e60c7c4afce4">49</ix:nonFraction>% of the aggregate issued and outstanding shares of capital stock of Sun Labs for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i19c94975ba3e411ca4090953760b5a7f_D20210801-20210831" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTA5OTUxMTYzMDU1Ng_e4c8ab89-1f4a-49e2-8c4b-9d5028fe4ba1">4.0</ix:nonFraction> million. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within <ix:nonNumeric contextRef="i19c94975ba3e411ca4090953760b5a7f_D20210801-20210831" format="ixt-sec:durwordsen" name="ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMjc0ODc3OTA3NDUzNg_98622117-6023-4b55-aea5-71ef343a9726">three years</ix:nonNumeric> from the effective date. As the financing obligation is embedded in the noncontrolling interest, the noncontrolling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i905cc209b99f4eb1a4f26bb9d532409b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of APCMG and Sun Labs have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not deductible for tax purposes.</span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTY1MA_4060a40f-cf87-4b9a-91d5-21d4e3cbb421" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the nine months ended September&#160;30, 2021 was as follows (in thousands);</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RhYmxlOjA3NzY2Njk4NmMyYzQ2NmM5ZTU5ZWIzNjM1NzZjNDg4L3RhYmxlcmFuZ2U6MDc3NjY2OTg2YzJjNDY2YzllNTllYjM2MzU3NmM0ODhfMC0xLTEtMS0w_2e6ce5ba-1a73-4e0b-b41a-aca29954dfd7">239,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RhYmxlOjA3NzY2Njk4NmMyYzQ2NmM5ZTU5ZWIzNjM1NzZjNDg4L3RhYmxlcmFuZ2U6MDc3NjY2OTg2YzJjNDY2YzllNTllYjM2MzU3NmM0ODhfMS0xLTEtMS0w_dc2a8a8b-1dd8-4f4a-8b56-0834f6a3cfbe">4,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RhYmxlOjA3NzY2Njk4NmMyYzQ2NmM5ZTU5ZWIzNjM1NzZjNDg4L3RhYmxlcmFuZ2U6MDc3NjY2OTg2YzJjNDY2YzllNTllYjM2MzU3NmM0ODhfMi0xLTEtMS0w_4dd006f7-536d-45aa-a1cc-27cf68e1c678">243,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i77048548a0c546beaa10a42c80553a71_58"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfNTY3_3788ba4d-db78-4655-96d4-3fc1db913c1f" continuedAt="i6d6fe93f953a48bbbfc6e59682014c5b" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="i6d6fe93f953a48bbbfc6e59682014c5b"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfNTY5_1b5fa750-97d5-4a42-9f3c-b51707520387" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb4d763aad449e6ba7233c66eeda68e_I20210930" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfMi0zLTEtMS0w_26594d31-8ba7-46f1-901c-a908010008bf">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb4d763aad449e6ba7233c66eeda68e_I20210930" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfMi03LTEtMS0w_7566a39a-0f37-479e-8b3d-2de671f31254">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie718d9e05afa4852974391111b7c6f7e_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNC0xLTEtMS0wL3RleHRyZWdpb246OGRkMDg4YWEzMzNmNGZmMTg2Yzk4NThiMjIzNTk2YjdfNA_d04fa427-7a41-460e-b3e0-3e421ce3c029">11</ix:nonNumeric>-<ix:nonNumeric contextRef="i0729f4ab87204534b3bd91b2c0c0e422_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNC0xLTEtMS0wL3RleHRyZWdpb246OGRkMDg4YWEzMzNmNGZmMTg2Yzk4NThiMjIzNTk2YjdfNw_661f4400-dbc6-41cb-a3d4-006deeab7a83">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21297fd10ec8466daced044c5770ee1d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNC0zLTEtMS0w_28cf1f79-b92d-4282-b27d-a207744afefe">148,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21297fd10ec8466daced044c5770ee1d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNC01LTEtMS0w_6d95e00e-4541-44bf-95ee-739d0ba70888">82,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21297fd10ec8466daced044c5770ee1d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNC03LTEtMS0w_9429f1f3-2fde-4b5c-b3a2-a5d638b9bc66">66,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i258ab2530cfc4417af6150ea2e0d1136_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNS0xLTEtMS0w_bf3b28cf-4769-4c6f-85cc-7742738ffd7e">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf5628bdf9de416db3d14683e1f47a46_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNS0zLTEtMS0w_f5a07bfa-be77-45fa-ab36-24c71b0b8e24">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf5628bdf9de416db3d14683e1f47a46_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNS01LTEtMS0w_1ff8a865-a5d5-44c4-a87f-e4e83ca752ac">13,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf5628bdf9de416db3d14683e1f47a46_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNS03LTEtMS0w_a329e1cb-8148-4954-b37e-37e72d90a833">9,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i965b06b4b9744451a2780f3ce1c77fd5_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNi0xLTEtMS0w_9bc8f5eb-7cf7-462b-adec-b5d3613521a2">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20486305e94249099f57db0ff59aba4a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNi0zLTEtMS0w_4012c388-17dc-4bb9-ad31-41e828967ced">8,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20486305e94249099f57db0ff59aba4a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNi01LTEtMS0w_b5cf7e65-248f-4be5-9c9b-43db12fe8a14">4,129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20486305e94249099f57db0ff59aba4a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNi03LTEtMS0w_4cf043f5-150a-4b26-a5ef-66070b767f6c">4,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb13766dc4564b8b90da9a7ada8b71bd_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNy0xLTEtMS0w_8b744f82-9c9a-45df-9927-a5f4a09427c8">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie268449f84654877bacfa7e9d37cdcb0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNy0zLTEtMS0w_a5c3b37d-1971-47b8-b2c2-deb230b5fcb5">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie268449f84654877bacfa7e9d37cdcb0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNy01LTEtMS0w_4ceb5c65-4d33-4e64-bf0d-7846f57aecba">1,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie268449f84654877bacfa7e9d37cdcb0_I20210930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNy03LTEtMS0w_e1121c7c-1aaf-4851-a5ae-b7b20f534a37">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i65c4c64100f14c0db098cf18e87b2987_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOC0xLTEtMS0w_fd3aaaf4-6c1e-4089-afb7-c2385fa5356e">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117531eab6d74fa78cdef19fcd2f5e2a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOC0zLTEtMS0w_0f1148c3-d223-414d-a554-ab3c21875093">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i117531eab6d74fa78cdef19fcd2f5e2a_I20210930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOC01LTEtMS0w_52d21a3c-05ce-4031-a68b-82b79d2308b1">194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117531eab6d74fa78cdef19fcd2f5e2a_I20210930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOC03LTEtMS0w_0c1fe8ff-6b91-4e5d-90e7-27576ed2a62a">817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOS0zLTEtMS0w_fe7348b1-825f-4a0a-a359-a8813e0f63d5">184,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOS01LTEtMS0w_81e85d44-79bd-4bfb-bda5-c75deab03db6">101,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOS03LTEtMS0w_dc6fe2b5-e178-4eda-8f02-593cfa92ba87">83,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i980c42c6c84b4875af45b55389e6bcdf_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMi0xLTEtMS0wL3RleHRyZWdpb246MjE5MmQyNjExZWUzNDRhMzhmNjZiZDZlYTdhMmZhN2VfNA_d919fbae-0096-493d-bef3-8026ac736c20">11</ix:nonNumeric>-<ix:nonNumeric contextRef="i06bc5673bf1142388330261e2bb554f1_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMi0xLTEtMS0wL3RleHRyZWdpb246MjE5MmQyNjExZWUzNDRhMzhmNjZiZDZlYTdhMmZhN2VfNw_b9b62089-7ecd-4b22-ae24-4cf437021c3c">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8968b1047aac4f2ba3f6833da3d4ede6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMi0zLTEtMS0w_065f7274-a510-4552-a400-09b5250513d9">143,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8968b1047aac4f2ba3f6833da3d4ede6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMi01LTEtMS0w_2915545b-5d70-4a06-a43a-e157d3168db2">73,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8968b1047aac4f2ba3f6833da3d4ede6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMi03LTEtMS0w_1129691e-31ec-4ad3-8cbe-b6019f4f5751">70,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i41ded44352b54f19813c1b6eb4a76ed5_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMy0xLTEtMS0w_f7960cf6-0c34-4777-84d7-b78a6ca0bc98">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9513c56b334510bf4095f6f01b6e47_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMy0zLTEtMS0w_75c164ce-5de7-438c-bb3b-74a071290aeb">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9513c56b334510bf4095f6f01b6e47_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMy01LTEtMS0w_803cc659-69d2-4daa-b3e3-12e6f504c06a">11,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9513c56b334510bf4095f6f01b6e47_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMy03LTEtMS0w_b43723f7-533b-4cb3-9dcc-8a7cb6302d06">11,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9ec7d6bab59945aaa45f7785f214840f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNC0xLTEtMS0w_2260b0e7-d009-44f8-aad4-883558948df1">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6e0d4064a11471ead457d43030a135a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNC0zLTEtMS0w_14d84afb-4e5c-480e-8ad7-88924dbfdcd2">6,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6e0d4064a11471ead457d43030a135a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNC01LTEtMS0w_f3765687-a3ab-417a-a8af-1421c4574405">3,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6e0d4064a11471ead457d43030a135a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNC03LTEtMS0w_0ba301af-ad84-43ad-bc35-7886c3c3ef72">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iecf50be563d54838a275677850c705da_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNS0xLTEtMS0w_fcc43926-4f7f-45c4-956c-56bcaa5cad9f">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75bf881994b43a087370158fad07e52_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNS0zLTEtMS0w_9567a52c-18d9-4c65-8379-7db1c42ea0c1">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id75bf881994b43a087370158fad07e52_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNS01LTEtMS0w_9e528151-0b43-4e40-9906-7e274cc5cfce">1,270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75bf881994b43a087370158fad07e52_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNS03LTEtMS0w_d27967de-0b97-4805-ab59-85a7aed2e890">790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf4edcccc8394a23a7b3dcb738b03e7c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNi0xLTEtMS0w_cbaca48a-ecfa-458e-90bf-5994f5c69a81">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd1fbae30d564421bc5b7c93a54aea3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNi0zLTEtMS0w_4d688482-92b8-4b27-8f11-7730ee735165">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd1fbae30d564421bc5b7c93a54aea3a_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNi01LTEtMS0w_f794e59c-8377-4bd4-9c85-580729d37fc2">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd1fbae30d564421bc5b7c93a54aea3a_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNi03LTEtMS0w_1be6ba81-407c-430f-aeb2-41a348f6686b">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNy0zLTEtMS0w_3cd147a8-c2ef-4f29-b9d1-8f3fb4a739f9">176,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNy01LTEtMS0w_24a11046-8406-4542-9c9e-4e5bdb605b0a">89,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNy03LTEtMS0w_2c303298-f91f-4866-9f75-acc4deef192b">86,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in depreciation and amortization on the accompanying consolidated statements of operations is amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfMzM2_717a3175-9acb-465f-9c49-4e1d729ca222">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfMzQz_8aa59b00-b0f6-4ff7-9362-c1d5c9f13315">4.0</ix:nonFraction> million for the three months ended September&#160;30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfMzk5_03ec68fb-c6a2-4e0f-9753-43a813cdf752">11.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfNDA2_fc58337c-bc2f-4fca-8463-f7838f078214">12.3</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfNTcy_7d3a8fd9-526d-4ec8-b24e-7d1488dce80c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September 30, 2021) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfMi0xLTEtMS0w_02102ce8-fcac-4c7e-903c-e20ebc384188">4,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfMy0xLTEtMS0w_952759f9-b984-4a8b-8032-ff39ca6fb4b2">13,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfNC0xLTEtMS0w_d7809c4e-493e-4829-a6b7-97890c3c2f55">11,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfNS0xLTEtMS0w_f1326a21-3070-4259-9d31-eb0dfb79c162">10,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfNi0xLTEtMS0w_f5ea5c6f-b874-4f66-9d6f-f647bfded101">9,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfNy0xLTEtMS0w_080ceae2-67ec-48c7-b4cd-a423e875f2e9">32,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfOS0xLTEtMS0w_e5322dbc-1b27-4021-9b7f-9bd4cc12ebc6">82,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="ameh:EquityMethodAndOtherEquityInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODkwOA_be2d51f7-3b92-4fc9-b35c-28706f847a35" continuedAt="ifc96579d9ee74cd2853ca6aa07756fe1" escape="true">Investments in Other Entities &#8212; Equity Method</ix:nonNumeric></span></div><ix:continuation id="ifc96579d9ee74cd2853ca6aa07756fe1" continuedAt="i2120661060304e15b6ac7ac0b2227db1"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODkwOQ_1604da8f-4a89-433d-a8c7-b0854f1c7150" continuedAt="iec096885847945edb09c76fa94690642" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rollforward of Equity Method Investment (in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Investment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allocation of Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Entity Consolidated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sale</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA Line of Business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0d66e6f0814c7992ad674327d5d79b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS0xLTEtMS0w_bede7a90-c6c0-47f8-be0a-7d2515f3518c">13,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f00bc9258974017a3430fe975bf7f46_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentAdditionalInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS0zLTEtMS0w_35dab747-04af-4730-900f-76dad2185245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f00bc9258974017a3430fe975bf7f46_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS01LTEtMS0w_7ed677a9-28b2-4818-959a-c21a589c820d">4,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f00bc9258974017a3430fe975bf7f46_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS03LTEtMS0w_83835cb4-3fdf-4cda-861c-5710580287e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f00bc9258974017a3430fe975bf7f46_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsConsolidated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS05LTEtMS0w_c90c8404-288e-48f6-80ff-3b26f6214f10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f00bc9258974017a3430fe975bf7f46_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS0xMC0xLTEtMA_394231aa-cc8c-421f-93cd-0924abc2f10e">4,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94b2c1e346e440078f5bd9c18d1ae3d8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS0xMi0xLTEtMA_8dde0424-a7b1-44ea-8cbc-78fbc86c0616">4,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d934d0b4eae4422b768334c3e49324a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi0xLTEtMS0w_7e0dc5f4-2812-4bab-989b-a0f4a68fa869">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28218e6fa6044467a6cfa3dd3680f60c_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentAdditionalInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi0zLTEtMS0w_9913b7f5-4417-4257-b2e1-ce0bd2eaabe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28218e6fa6044467a6cfa3dd3680f60c_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi01LTEtMS0w_2b31b247-5ed7-403e-8987-b7157f80ddae">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28218e6fa6044467a6cfa3dd3680f60c_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi03LTEtMS0w_29ac1512-7365-4984-b640-6748d23ec12d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28218e6fa6044467a6cfa3dd3680f60c_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi05LTEtMS0w_0a072b42-7012-4c49-b805-4c375568e0e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28218e6fa6044467a6cfa3dd3680f60c_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi0xMC0xLTEtMA_b1b11456-236c-4995-8ace-1324634c9780">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i455c75e2b784434dac67f0841a1568b6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi0xMi0xLTEtMA_0e65e9ab-b30c-4108-8187-31db0bfefec2">1,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diagnostic Medical Group</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a0882d520246b09a88c6bc55fb835d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy0xLTEtMS0w_ed33f4f6-3230-462d-a1fa-a924f0e14954">2,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b25d8b3c75481bbe6f42f9cd219cba_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentAdditionalInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy0zLTEtMS0w_82295276-0c7c-416b-917c-2d4e18a30b5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b25d8b3c75481bbe6f42f9cd219cba_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy01LTEtMS0w_5d83c491-e788-48f4-aeb6-9530355dbec5">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b25d8b3c75481bbe6f42f9cd219cba_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy03LTEtMS0w_2a70b621-155f-4428-ac17-a030895bfc56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b25d8b3c75481bbe6f42f9cd219cba_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy05LTEtMS0w_51cee8ca-28ce-49f2-969c-d604d92472a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b25d8b3c75481bbe6f42f9cd219cba_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy0xMC0xLTEtMA_cd54dd1c-0091-424d-923e-130ac6423595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9681bc92d994054a7f881aaf0a4c1b0_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy0xMi0xLTEtMA_21ba091c-fed1-4ca9-b67a-35b30a2ce190">2,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">531 W. College, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000196b3d5424523869f9b8cf182627c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC0xLTEtMS0w_2d3f5549-2ead-44bd-930c-98a347ccedc4">17,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b36f750c6e4bbbaa5984ab14f7acf6_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentAdditionalInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC0zLTEtMS0w_4fbbd4c5-3f20-48f2-b5d4-312ceb464431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14b36f750c6e4bbbaa5984ab14f7acf6_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC01LTEtMS0w_5d7cba0e-e0d5-474b-aa64-ed0da6429b3c">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b36f750c6e4bbbaa5984ab14f7acf6_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC03LTEtMS0w_367ff26b-b262-441f-9d85-e6b16540414c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b36f750c6e4bbbaa5984ab14f7acf6_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC05LTEtMS0w_b9ea9266-d542-4ad8-a1ad-e594e15aea7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b36f750c6e4bbbaa5984ab14f7acf6_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC0xMC0xLTEtMA_49a8df53-9344-4f05-b654-3ea40c10da15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4e845cd0750449ea326e81a9883e61b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC0xMi0xLTEtMA_322a5b30-d7ea-46b5-847f-c85ba54c46cf">17,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">One MSO, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb296bd3d2a499caa7ee8b26bf24153_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS0xLTEtMS0w_b13713e4-3f1e-409a-aab1-d317d9cb87c6">2,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentAdditionalInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS0zLTEtMS0w_c4b89532-a4e8-43be-b036-bbddb6e7df59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS01LTEtMS0w_6ced9a6c-ac63-41c2-a4e8-ae25194a34a6">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS03LTEtMS0w_a25554d5-6367-4f50-8fe1-bada3b98141c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS05LTEtMS0w_8fb84206-dea8-466f-a0eb-143cbccfaac2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS0xMC0xLTEtMA_ac24b0ef-8be6-4d56-9d57-eee0cdb9a2da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ea5bb0ee621461d878a0145d57a8e9d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS0xMi0xLTEtMA_a79802eb-c390-4872-8c41-068f0837a4cf">2,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2b4206481d4c5a820281a781ad27e3_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi0xLTEtMS0w_04466f8d-3dd9-4e6f-80b7-809ee6e409aa">4,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f162484d134b13ad2cb62e25a6050d_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentAdditionalInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi0zLTEtMS0w_bbdec88b-7c1f-4c4d-bd42-6d035423d15b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f162484d134b13ad2cb62e25a6050d_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi01LTEtMS0w_0c176838-7158-493f-80d0-b22467aa2b1c">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f162484d134b13ad2cb62e25a6050d_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi03LTEtMS0w_7eaccacc-9c72-4292-8ce6-bec25269ed76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f162484d134b13ad2cb62e25a6050d_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi05LTEtMS0w_d8f2c5fa-437a-4c20-b927-66abd72e1042">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f162484d134b13ad2cb62e25a6050d_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi0xMC0xLTEtMA_564d09c6-e8f0-4098-b19c-68e341954732">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3514de26861c4453a347bd8a1fc4b612_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi0xMi0xLTEtMA_95124066-80ca-49e2-8e28-6b5d0028315f">4,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tag-8 Medical Investment Group, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i902f565b388f41cb9be67571ecc22f37_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy0xLTEtMS0w_60b1f74c-22b7-4249-996a-b8d47f047f32">2,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb6128c207404236beafdaee21d920e7_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentAdditionalInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy0zLTEtMS0w_d786ca59-c38b-4f11-9df0-7d1f9091cf4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb6128c207404236beafdaee21d920e7_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy01LTEtMS0w_3651e8d4-d0e0-4c9a-a95e-f6b79679372b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb6128c207404236beafdaee21d920e7_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy03LTEtMS0w_ab5697c6-c0ed-4982-bb1b-34a88e337dde">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb6128c207404236beafdaee21d920e7_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy05LTEtMS0w_791bccd1-e21d-414a-899c-0bf1fe20945d">3,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb6128c207404236beafdaee21d920e7_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy0xMC0xLTEtMA_7b6e033d-c668-48fa-a76b-c878b4c7738c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i203bb1d43aac431a8bb988cd1f2ca55c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy0xMi0xLTEtMA_f7e21288-cdfe-47ad-8089-93e82bc17593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73ee31bc4e9a444e89365fdc6b10afa1_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOS0xLTEtMS00Njc1_281619d2-5a3e-42f5-9c26-e027a13747ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:EquityMethodInvestmentAdditionalInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC0zLTEtMS02NTI1_3541ed98-88eb-4196-88e1-b2d7e657f0de">11,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOS01LTEtMS00Njc1_180f3391-bbb5-4cdd-ba31-788a40f8b3c0">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOS03LTEtMS00Njc1_baf02a97-df79-4d0f-bc2b-a2c7630380ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOS05LTEtMS00Njc1_9837275c-21be-48dd-97a6-7730cf33d48f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC0xMS0xLTEtMjQzMjc_b9401ef8-14e4-421b-be85-3381a569db41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8d0fe803e64bc1a1ed9278b52c95f9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOS0xMi0xLTEtNDY3NQ_8a76aa09-20de-4eb1-9dc8-bdc8e52e1447">11,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC0xLTEtMS0w_26715326-064a-4e80-a148-be35d34e1fb6">43,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:EquityMethodInvestmentAdditionalInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC0zLTEtMS0w_0abb3f40-9244-4ab8-8984-23253dae6d8a">11,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC01LTEtMS0w_976c8350-abc7-45ff-8c52-e59310ba028c">3,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC03LTEtMS0w_f043bfd2-5e2d-4487-ac45-3aca121a5c58">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC05LTEtMS0w_c255cd0e-5150-49f4-8192-e368210378b5">3,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC0xMC0xLTEtMA_5d858b28-21d1-4f2e-be2d-0e5025f20f05">4,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC0xMi0xLTEtMA_4fc440c3-b932-4fd8-bbed-2511150abe05">45,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LaSalle Medical Associates &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPA Line of Business</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care to patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino, and Tulare Counties through its network of approximately <ix:nonFraction unitRef="provider" contextRef="i94b2c1e346e440078f5bd9c18d1ae3d8_I20210930" decimals="-2" format="ixt:num-dot-decimal" name="ameh:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzk0_a8d3f6e3-f0dd-4010-8ff7-a45378e81896">2,400</ix:nonFraction> independently contracted primary care physicians and specialist providers. LMA&#8217;s patients are primarily served by Medi-Cal, but are also served by Blue Cross, Blue Shield, Molina, Health Net, and Inland Empire Health Plan. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $<ix:nonFraction unitRef="usd" contextRef="id898dfbac217454a95c7fd9549d95325_I20121231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzE1_2fc2287e-9041-4f1f-987d-12710de01116">5.0</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="id898dfbac217454a95c7fd9549d95325_I20121231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzI0_4cc248e6-a44f-4e33-91e9-9e6f2b48d292">25</ix:nonFraction>% interest in LMA&#8217;s IPA line of business. In December 2020, the Company exercised its option to convert the promissory note totaling $<ix:nonFraction unitRef="usd" contextRef="i3bd0e620dca545c990c5623c174f38f3_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODYy_00b5282c-d753-46c0-b838-e7e28080290e">6.4</ix:nonFraction>&#160;million due from Dr. Arteaga into an additional <ix:nonFraction unitRef="number" contextRef="i3bd0e620dca545c990c5623c174f38f3_I20201231" decimals="4" name="ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfOTA1_fbc62da3-adaa-4484-89e5-c9a0f0cf27e1">21.25</ix:nonFraction>% interest in LMA&#8217;s IPA line of business. As a result, APC-LSMA&#8217;s interest in LMA&#8217;s IPA line of business increased to <ix:nonFraction unitRef="number" contextRef="i45abc06c771b489384112954fbdfcd19_I20201231" decimals="4" name="ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTAyNA_516b3be0-c245-40e3-94d3-940fff659e22">46.25</ix:nonFraction>%. In September 2021, APC-LSMA sold <ix:nonFraction unitRef="number" contextRef="i85f82fabbbfe4571ab387179ddd7a738_I20210930" decimals="4" name="ameh:EquityMethodInvestmentOwnershipPercentageSold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ2MDUxNg_f82aaac5-f5ac-44d0-a8c8-bf0e8818e8e4">21.25</ix:nonFraction>% of its interest in LMA back to Dr. Arteaga for $<ix:nonFraction unitRef="usd" contextRef="i91c58bf26bff4f73b162bbd22f236e8d_D20210901-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ2MDUyMA_fb004fad-3665-4d4c-9623-9c6128340a60">6.4</ix:nonFraction> million, which resulted in  APC-LSMA owning a <ix:nonFraction unitRef="number" contextRef="i80b8650ee33648d99a9a3444e64846f0_I20210930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ2MDUyOQ_61fd2ae2-9643-46ee-afd8-176a0b3d542c">25</ix:nonFraction>% interest in LMA as of September&#160;30, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended September&#160;30, 2021 and 2020, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="id5ef16887c064530aa3691f19b525d0d_D20210701-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTI2OQ_89fbb4c0-8c6b-463c-992d-2df562715bc6">0.3</ix:nonFraction> million and income of $<ix:nonFraction unitRef="usd" contextRef="i1b208272f13f4a57957a453690effbf0_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTI4Ng_cee8eddf-e009-4713-9642-21d73f5a25da">0.5</ix:nonFraction> million, respectively, in the accompanying consolidated statements of operations. For the nine months ended September&#160;30, 2021 and September&#160;30, 2020, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="i9cb8b922bdee480c9f9aea0eff1256c0_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTQ0MA_b110a159-14c0-48b3-ba89-ca025ca6314d">4.7</ix:nonFraction> million and income of $<ix:nonFraction unitRef="usd" contextRef="i77427e343910426d8907e4dcf7f52bc0_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTQ0OQ_f625eb64-ce4d-4c39-9ad2-7c975a1e1232">28,000</ix:nonFraction>, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i94b2c1e346e440078f5bd9c18d1ae3d8_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTYxMA_c68b1a01-55aa-4836-8c1e-7d3be61ab7ee">4.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaa0d66e6f0814c7992ad674327d5d79b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTYxNw_1079b7e7-d0d8-4ad3-9c9d-7abe672524a6">13.0</ix:nonFraction> million at September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i2120661060304e15b6ac7ac0b2227db1" continuedAt="i277c343c470642e48e4bfdfe45e9c65c"><ix:continuation id="iec096885847945edb09c76fa94690642" continuedAt="ie9b094fccc9c4e3f98a4731e493a3ad5"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at September&#160;30, 2021 and December&#160;31, 2020, and summarized statements of operations for the nine months ended September&#160;30, 2021 and 2020, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c127671e08453090839c66152b9457_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMy0xLTEtMS0w_4ca2e212-e536-410f-ae35-e023a9822e05">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMy0zLTEtMS0w_4ab1116c-9840-4490-b624-c6ef09581471">9,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c127671e08453090839c66152b9457_I20210930" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNC0xLTEtMS0w_b15243f5-2d49-4496-806e-6a1eed4308a5">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNC0zLTEtMS0w_03cdfdfc-5752-4005-8607-d0b2304edd30">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c127671e08453090839c66152b9457_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNS0xLTEtMS0w_5c965c9e-b782-4996-917a-c91c042407af">6,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNS0zLTEtMS0w_3980ccdf-3dc9-42f9-87b2-c30d6b70c9d5">3,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c127671e08453090839c66152b9457_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNi0xLTEtMS0w_9d65c1d7-45ff-4805-bb5c-d581b016faa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNi0zLTEtMS0w_949f5fd5-7898-4cce-873c-4c7908e8561f">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c127671e08453090839c66152b9457_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNy0xLTEtMS0w_13abf2d0-1699-48b5-8ca8-2ee1c1445d9b">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNy0zLTEtMS0w_d1c4d7cd-d79d-481f-8e32-4b867af237aa">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c127671e08453090839c66152b9457_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfOS0xLTEtMS0w_57b112ad-c775-462e-ac0a-0d78ea281c7f">11,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfOS0zLTEtMS0w_d6da356b-aed2-4469-976b-6f3b611ab05f">17,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c127671e08453090839c66152b9457_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMTItMS0xLTEtMA_7b4b2e79-8e9b-4d72-a2fa-a673dff5bc0a">27,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMTItMy0xLTEtMA_57563283-82c7-43f8-a3ee-4cbc025e7823">21,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5c127671e08453090839c66152b9457_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMTMtMS0xLTEtMA_1e080075-1c61-4888-9e26-4c0ff3ae25db">15,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMTMtMy0xLTEtMA_1757cc4c-a562-410d-8891-3b668c50d21c">4,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c127671e08453090839c66152b9457_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMTUtMS0xLTEtMA_4698fdcd-1608-477e-93e5-848d9e1d3731">11,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMTUtMy0xLTEtMA_544a8824-6aac-4573-ae0a-019b3c264b50">17,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9acbaa81eaca438db99ca8e197a48492_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOmIxZDliNjc3MTZmZDQxYWY5YzdlNTIyOTg5ZDk4NDZkL3RhYmxlcmFuZ2U6YjFkOWI2NzcxNmZkNDFhZjljN2U1MjI5ODlkOTg0NmRfMy0xLTEtMS0w_cee24fc5-eb3b-4c6e-a9f8-f0517ddba4d2">144,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8396566a02bc4bda8fe4bcb4acc37087_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOmIxZDliNjc3MTZmZDQxYWY5YzdlNTIyOTg5ZDk4NDZkL3RhYmxlcmFuZ2U6YjFkOWI2NzcxNmZkNDFhZjljN2U1MjI5ODlkOTg0NmRfMy0zLTEtMS0w_1fe6bf43-3b1c-4021-a7ec-cc8e36e10e20">138,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9acbaa81eaca438db99ca8e197a48492_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOmIxZDliNjc3MTZmZDQxYWY5YzdlNTIyOTg5ZDk4NDZkL3RhYmxlcmFuZ2U6YjFkOWI2NzcxNmZkNDFhZjljN2U1MjI5ODlkOTg0NmRfNC0xLTEtMS0w_dc3652fb-8359-449b-bc8b-99294a02cf64">155,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8396566a02bc4bda8fe4bcb4acc37087_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOmIxZDliNjc3MTZmZDQxYWY5YzdlNTIyOTg5ZDk4NDZkL3RhYmxlcmFuZ2U6YjFkOWI2NzcxNmZkNDFhZjljN2U1MjI5ODlkOTg0NmRfNC0zLTEtMS0w_ecbff1dd-e26b-492d-9d68-3e0752492ea0">138,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9acbaa81eaca438db99ca8e197a48492_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOmIxZDliNjc3MTZmZDQxYWY5YzdlNTIyOTg5ZDk4NDZkL3RhYmxlcmFuZ2U6YjFkOWI2NzcxNmZkNDFhZjljN2U1MjI5ODlkOTg0NmRfNi0xLTEtMS0w_d7a4ffb0-9c81-426a-8472-665fd2db054e">11,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8396566a02bc4bda8fe4bcb4acc37087_D20200101-20200930" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOmIxZDliNjc3MTZmZDQxYWY5YzdlNTIyOTg5ZDk4NDZkL3RhYmxlcmFuZ2U6YjFkOWI2NzcxNmZkNDFhZjljN2U1MjI5ODlkOTg0NmRfNi0zLTEtMS0w_775f31f2-6c53-4c72-8154-87d25aabc2f3">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography at its facilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $<ix:nonFraction unitRef="usd" contextRef="iea5b5005ea214626b46b60892e1c296f_I20150731" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMjM0Nw_98627dcf-0e5c-465f-954f-f3f2b4ed0b6f">1.2</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="iea5b5005ea214626b46b60892e1c296f_I20150731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMjM1Ng_f9789901-89eb-4715-b376-2e9b6ed724fc">40</ix:nonFraction>% ownership interest in PMIOC.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $<ix:nonFraction unitRef="usd" contextRef="icc81f74f6ea84843a75b19e6188f7d59_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMjYxMw_e75c41f7-a2bb-4392-9abc-37901d2f6d23">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia021d902c6194cd1b515f6e5d2851f67_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMjYyMA_61989ee6-b6b9-40a7-aeba-7b46859b6790">0.5</ix:nonFraction> million, for the three months ended September&#160;30, 2021 and 2020, respectively, and fees of approximately $<ix:nonFraction unitRef="usd" contextRef="if44758b50abb4b998c0cf1ed2f59be70_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMjY5OQ_7500cd2d-f4be-47ad-b687-23d6716d1706">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0cffd986457e4a40859857d465e80d31_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMjcwNg_e238b771-96cb-4633-883e-b68a5ec53197">1.5</ix:nonFraction> million for the nine months ended September&#160;30, 2021 and 2020, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. For the three months ended September&#160;30, 2021 and 2020, APC recognized a gain from this investment of approximately $<ix:nonFraction unitRef="usd" contextRef="i18eaba1b00ed42dfb2a3be9037829586_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzAzMQ_e39b2e91-535c-482a-8f42-2f508acec15c">0.2</ix:nonFraction> million and a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="id76dbd62385a4c2b89c6cc4a159139e7_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzAzOA_d8d44a49-4f04-4210-a4a9-66de19813919">52,000</ix:nonFraction>, respectively, in the accompanying consolidated statements of operations. For the nine months ended September&#160;30, 2021 and 2020, APC recognized income of $<ix:nonFraction unitRef="usd" contextRef="iad6d8a1fd79d4409ba2643b463115e12_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzE3MQ_ede35590-61b8-4d5d-8f5f-47516f834fd9">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iee6c2515c3594dd08fa54babfc3d2655_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzE4OA_0a115b96-f004-4ec4-9abb-1ea8fda992ab">25,000</ix:nonFraction>, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets had investment balances of $<ix:nonFraction unitRef="usd" contextRef="i74678b3019584b26a57edb839bf1d877_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzMzMw_2cbb2175-8d94-4739-bcb4-5197a9336df7">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib0352070af4d49b7b10b093cf1d34b6b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzM0MA_2115d6dc-4db8-4394-836e-39280ef97e85">1.4</ix:nonFraction> million at September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i277c343c470642e48e4bfdfe45e9c65c" continuedAt="i17daf80a728a4f8ab6785c15929fdf9a"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Medical Group</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, David C.P. Chen M.D., individually, and APC-LSMA entered into a share purchase agreement whereby APC-LSMA acquired a <ix:nonFraction unitRef="number" contextRef="if581017651f14f9681014c41a5d3ced8_I20160531" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzUyNg_2835a3cb-0af6-4299-a8cd-59a21a832fb9">40</ix:nonFraction>% ownership interest in DMG. APC accounted for its investment in DMG under the equity method of accounting as APC had the ability to exercise significant influence, but not control over DMG&#8217;s operations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2021 and 2020, APC recognized income from this investment of $<ix:nonFraction unitRef="usd" contextRef="ica129d7dca744715affd24c98e9c389e_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ1ODgzMw_35061b90-633c-4d31-9ba6-05389c6a37b5">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i79b6369351c24a7caab010e07fef7ddc_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ1ODg0MQ_eda5cad5-c020-454e-8fb8-58475bcdf6d9">0.1</ix:nonFraction> million, respectively, in the consolidated statements of operations. For the nine months ended September&#160;30, 2021 and 2020, APC recognized income from this investment of $<ix:nonFraction unitRef="usd" contextRef="ic39714cbfb75465e896a533af99abbae_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ1ODk4MQ_9b4ac041-0731-4e62-b0ac-55470194f131">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if78fa0d638d24b928edf2207da5c5965_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ1ODk4OQ_d8e04215-f13e-4759-b32d-e26a8676c610">19,000</ix:nonFraction>, respectively, in the consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="if9681bc92d994054a7f881aaf0a4c1b0_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ1OTEzOA_1e73d1d0-b5a8-42e7-945e-26ccba1f5477">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic4a0882d520246b09a88c6bc55fb835d_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ1OTE0Ng_f5685c78-8a3d-4bbf-a4b6-0b4c5f7ee887">2.6</ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">531 W. College LLC &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, College Street Investment LP, a California limited partnership (&#8220;CSI&#8221;), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC, and the conduct of its business, and to specify their relative rights and obligations. CSI, APC, and NMM, each owned <ix:nonFraction unitRef="number" contextRef="i649b46d7c3d54c2e8ddb0eb3f0f6cb20_I20180930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDUxOA_d6d2453d-3300-4837-9965-f0549ddf70f2">50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ic5f4c57435414bcf8530f7c1b7159a3a_I20180930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDUyMg_cb9985a4-79ff-488d-86c4-64d331806594">25</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="id1280e975bb74d6793bb6decce02bb42_I20180930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDUzMA_b5504cc0-1b35-4fbf-836a-9866e145ad91">25</ix:nonFraction>%, respectively, of member units based on initial capital contributions of $<ix:nonFraction unitRef="usd" contextRef="i649b46d7c3d54c2e8ddb0eb3f0f6cb20_I20180930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MembersCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDYwNg_a8cc992a-6136-4b96-bd45-20b5ccb6db11">16.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic5f4c57435414bcf8530f7c1b7159a3a_I20180930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MembersCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDYxMA_a23b2ea8-230b-43b2-9a8c-cf4da9674688">8.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="id1280e975bb74d6793bb6decce02bb42_I20180930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MembersCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDYxOA_09e2fc85-482f-454b-a1c4-ba291bc960f2">8.3</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $<ix:nonFraction unitRef="usd" contextRef="id3dca6af71454e249bc71f841ff3c773_D20180601-20180630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDg3Mw_21d53092-2bd6-42c2-841d-3421060a1ba7">33.3</ix:nonFraction> million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#8217;s <ix:nonFraction unitRef="number" contextRef="i9bc00772371f43338e0a4894146965ab_I20190423" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDk3Nw_a8ffc15f-fa14-42b8-afe1-51f21ff2c129">25</ix:nonFraction>% membership interest in 531 W. College, LLC for approximately $<ix:nonFraction unitRef="usd" contextRef="i9bc00772371f43338e0a4894146965ab_I20190423" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTA0MQ_d542d3e7-fa15-42a6-82a8-3cf3859346cf">8.3</ix:nonFraction> million. Subsequently, APC has a <ix:nonFraction unitRef="number" contextRef="i6db22be029534d1ca263dccd767fc1fc_I20210930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTA2OQ_3c2bb8ff-3cdc-49cf-ab32-d36afcb2d6b9">50</ix:nonFraction>% ownership in 531 W. College LLC with a total investment balance of approximately $<ix:nonFraction unitRef="usd" contextRef="i567fe9f349ad4cd38b7073fc838b36af_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTE1Mw_ff0b7a46-c165-41b6-b8e3-57191ba42ddc">16.1</ix:nonFraction>&#160;million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended September&#160;30, 2021 and 2020, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="ib8c0ead5cd26416784c4b0aae0965159_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTQ0OQ_64403987-e318-4728-92bc-ec7edf09b273">34,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4c9277df25244861a1723845d457f7c1_D20200701-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTQ1Ng_0fe7e3d2-415f-44cc-895b-19109c763fb4">0.1</ix:nonFraction> million, respectively, in the accompanying consolidated statements of operations. For the nine months ended September&#160;30, 2021 and 2020, APC recorded a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="id8f2830655ce425ba50defa19207191c_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTYwOA_87415aff-7c02-485a-b3e7-39adb84b0650">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia48e961c12c64515bfac403310620fa8_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTYxNQ_3be21da4-0135-435a-9203-65f1284ec6c1">0.4</ix:nonFraction> million in the accompanying consolidated statements of operations, respectively. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="id4e845cd0750449ea326e81a9883e61b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTc3NQ_2985217c-4449-469d-b659-d5afefa0e6e8">17.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i000196b3d5424523869f9b8cf182627c_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTc4Mg_3d954085-66d4-49eb-a1c5-b17b9f35fd70">17.2</ix:nonFraction> million at September&#160;30, 2021 and December&#160;31, 2020, respectively. </span></div><ix:continuation id="ie9b094fccc9c4e3f98a4731e493a3ad5" continuedAt="ie54723a77d9a45a9a4d6c5fcceb7cfec"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College LLC&#8217;s balance sheets at September&#160;30, 2021 and December&#160;31, 2020, and statements of operations for the nine months ended September&#160;30, 2021 and 2020, are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMy0xLTEtMS0w_970dae51-4483-42d0-9e2c-40b611a67234">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMy0zLTEtMS0w_a2c0734d-5444-411a-a30a-10102519b321">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfNC0xLTEtMS0w_81bab23e-2139-41ee-ae0c-32282499f247">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfNC0zLTEtMS0w_949c5d96-a3e7-485e-8110-7cf3bfc04856">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfNS0xLTEtMS0w_62d2ec70-82e4-4652-b7ce-5bb03f32c40b">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfNS0zLTEtMS0w_220374fa-c52c-4197-b0cc-86d08a43879d">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfNi0xLTEtMS0w_d57ad476-8494-4190-94cf-6c026e5f3c6c">33,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfNi0zLTEtMS0w_2b1fabcd-311b-4487-b094-2728595d6fa4">33,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfOC0xLTEtMS0w_9dfef9b8-05a5-419b-8fe6-786ea0a8ed05">34,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfOC0zLTEtMS0w_43b36e27-311d-402d-a531-09832a232854">34,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Members&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMTItMS0xLTEtMA_75ad5d1d-9287-4fc8-9960-e39e2c6df29c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMTItMy0xLTEtMA_2ee62ba2-fdcd-463b-898c-4804b6122e77">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMTMtMS0xLTEtMA_4ddabbbd-606b-4356-9fac-b183add97853">34,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMTMtMy0xLTEtMA_0f3e0d00-1ede-4359-9780-777c12937718">34,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and members&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMTUtMS0xLTEtMA_ba9659ce-13f1-43f7-b027-c1921105ccfc">34,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMTUtMy0xLTEtMA_f46e7090-426c-4db3-aebb-76c22b46105e">34,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i17daf80a728a4f8ab6785c15929fdf9a" continuedAt="ic91a24aef5034b699d4443753f812f67"><ix:continuation id="ie54723a77d9a45a9a4d6c5fcceb7cfec"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operation</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfMi0xLTEtMS0w_26ef8823-86bb-49c5-b447-22f18887ee33">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfMi0zLTEtMS0w_5eeff0a8-1b5f-4806-aed5-de80cc35fcbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930" decimals="-3" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfMy0xLTEtMS0w_bb50273e-c0bf-47a1-87ec-6e6456fbfaec">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930" decimals="-3" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfMy0zLTEtMS0w_288aaf31-4880-4c0a-a40c-d7eb562af014">828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfNC0xLTEtMS0w_cebae6a8-840e-4ec1-87e0-aa857208f893">295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfNC0zLTEtMS0w_5a7d81ca-219c-4e59-8d0b-4f27facecb85">828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfNi0xLTEtMS0w_5fac98b9-a160-4dff-a342-02e2d3f6de94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfNi0zLTEtMS0w_b36d7e56-274f-4970-b953-a2d1e4d7e43f">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfOC0xLTEtMS0w_9fcd4926-9f34-477b-90ec-eea6cacc3a74">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfOC0zLTEtMS0w_b8879817-78cc-496b-9dcd-c2c57c2279c5">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfMTAtMS0xLTEtMA_aaba70b1-1ee6-42af-9c46-0315b150555e">297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfMTAtMy0xLTEtMA_1ac6a0bf-8fd4-466f-a70d-a4b7936faae5">799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>One MSO, LLC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="i7786b13c92d44768ab2d5ee5d1646497_I20201231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjExNw_b0a23db4-8dc8-4aa5-bc21-190827207dff">50</ix:nonFraction>% membership interest in One MSO LLC (&#8220;One MSO&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="i8bb296bd3d2a499caa7ee8b26bf24153_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjE3MQ_6764265a-45d2-4892-b663-01b66460ae42">2.4</ix:nonFraction> million. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. For the three months ended September&#160;30, 2021, One MSO recognized income of $<ix:nonFraction unitRef="usd" contextRef="i02fd82315c204d5b8e983153d3e96412_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjM1MQ_4041ab8c-4075-40d3-a730-e08cebffa72a">0.1</ix:nonFraction> million in the accompanying consolidated statements of operations. For the nine months ended September&#160;30, 2021, One MSO recognized income of $<ix:nonFraction unitRef="usd" contextRef="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjQ2Ng_266bd468-ea1a-4b97-ad1a-f0e4cca55287">0.4</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i5ea5bb0ee621461d878a0145d57a8e9d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjYxMg_d245c7a0-3c00-4926-88ba-cc09b0cb1101">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8bb296bd3d2a499caa7ee8b26bf24153_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjYxOQ_6764265a-45d2-4892-b663-01b66460ae42">2.4</ix:nonFraction> million at September&#160;30, 2021 and December&#160;31, 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tag-6 Medical Investment Group, LLC and Tag-8 Medical Investment Group, LLC &#8212; Related Party</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="ie83b679468814dbca4be10a39fdb5bc6_I20201231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjgzMQ_90c66460-036d-47d3-89d3-02aba8455630">50</ix:nonFraction>% membership interest in Tag 6 for $<ix:nonFraction unitRef="usd" contextRef="i5db0b17b399c402d90d5cae3426b67ab_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjg2Nw_0767afff-7930-45c2-bd14-f1f4d42251f5">4.5</ix:nonFraction> million and a <ix:nonFraction unitRef="number" contextRef="ie178a5bc23a34e3e968fdb0a7cc1b1d7_I20201231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjg3Ng_10d93faf-c6d6-4f04-8085-a48985a24a14">50</ix:nonFraction>% membership interest in Tag 8 for $<ix:nonFraction unitRef="usd" contextRef="if45e4368c403487ea641b147da7d6ec4_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjkxMg_4772b2f2-1ec4-4b26-b291-85e37312fff9">2.1</ix:nonFraction> million. The Company reevaluated Tag 8 as a VIE since APC is a guarantor on the loan agreement between Tag 8 and MUFG Union Bank N.A. Based on the reevaluation, Tag 8 is a VIE and is consolidated by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tag 6 shares common ownership with certain board members of APC and as such is considered a related party. For the three and nine months ended September&#160;30, 2021, Tag 6 recognized income of $<ix:nonFraction unitRef="usd" contextRef="ibecc6ab98d324e62ac84506d9b662237_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTA5OTUxMTYzNzE2NA_69d9caa5-08cb-40d6-addd-3a975976fd9d">45,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id997a6c5f4e24485b8c86ad8253ab602_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzI5MA_093e421e-0add-4c50-86bf-a3f0d89dd547">0.2</ix:nonFraction> million, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the Tag 6 investment of $<ix:nonFraction unitRef="usd" contextRef="i604941a7c4e84e29bd7ca533697deae5_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzQyNQ_b8b2987d-30a7-4a2b-ac71-a6eddc4fe080">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5db0b17b399c402d90d5cae3426b67ab_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzY5NjU4MTQxMjk4OQ_0767afff-7930-45c2-bd14-f1f4d42251f5">4.5</ix:nonFraction>&#160;million at September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAIPA MSO, LLC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, ApolloMed purchased <ix:nonFraction unitRef="number" contextRef="i464e0ae5827e4e33a2ade15334ea8236_I20210831" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzg0ODI5MDcxNTMzMg_50709669-2867-4870-93f9-9b07e910317d">30</ix:nonFraction>% interests in CAIPA MSO, LLC for $<ix:nonFraction unitRef="usd" contextRef="i78f0406a51e34beb80ce3cd5596fcbed_I20210831" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTA5OTUxMTYzODE3Nw_2e9dea72-0b7f-489a-ac9f-0d371f560e3a">11.7</ix:nonFraction> million. CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d/b/a Coalition of Asian-American IPA (&#8220;CAIPA&#8221;), a leading independent practice association serving the greater New York City area. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO&#8217;s operations. For the three and nine months ended September&#160;30, 2021, ApolloMed recognized income from investment of $<ix:nonFraction unitRef="usd" contextRef="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTA5OTUxMTYzOTIzNg_0388435e-5874-4472-98dd-f680dae2eff4"><ix:nonFraction unitRef="usd" contextRef="iae6a9eab9d354ba48b715b8872ad825d_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTA5OTUxMTYzOTIzNg_7df774b2-4ff8-4033-98b5-d8b8f63e186a">45,000</ix:nonFraction></ix:nonFraction>, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i9a8d0fe803e64bc1a1ed9278b52c95f9_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTA5OTUxMTYzOTI0Ng_5d7dc82e-12b6-4ec0-abae-8d90071e4b13">11.8</ix:nonFraction> million as of September&#160;30, 2021.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ic91a24aef5034b699d4443753f812f67"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in privately held entities that do not report net asset value</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MediPortal, LLC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, APC purchased <ix:nonFraction unitRef="shares" contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531" decimals="INF" format="ixt:num-dot-decimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzU4MA_d59c14db-8a71-42b1-9aa1-3b3224cde684">270,000</ix:nonFraction> membership interests of MediPortal LLC, a New York limited liability company, for $<ix:nonFraction unitRef="usd" contextRef="ifa51c5973cf04aa690f31014de335453_D20180501-20180531" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzY2NQ_fdf7fcf9-8ea9-4dc1-b73c-af514467d927">0.4</ix:nonFraction> million or $<ix:nonFraction unitRef="usdPerShare" contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzY3MQ_6bfcc3b3-6c7b-46a4-868e-07871d32c718">1.50</ix:nonFraction> per membership interest, which represented an approximately <ix:nonFraction unitRef="number" contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531" decimals="3" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzczNA_cf37976a-4d44-4549-82f8-508ee215ac4d">2.8</ix:nonFraction>% ownership interest. In connection with the initial purchase, APC received a <ix:nonNumeric contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODkxNw_9739e6fb-aa10-4246-9c5a-9456f43ad88d">five-year</ix:nonNumeric> warrant to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzg1NQ_5bc61d7c-9c4c-4e5c-847e-fe112ecdefa6">270,000</ix:nonFraction> membership interests. A <ix:nonNumeric contextRef="ifa51c5973cf04aa690f31014de335453_D20180501-20180531" format="ixt-sec:durwordsen" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODkxMg_d846ef69-6beb-49fa-af0f-1195c54b6d43">five-year</ix:nonNumeric> option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="ifa51c5973cf04aa690f31014de335453_D20180501-20180531" decimals="INF" format="ixt:num-dot-decimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzkyMw_01a35f81-3bb8-4927-a0c6-77e8898601bf">380,000</ix:nonFraction> membership interests and a <ix:nonNumeric contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODkwNg_4b2e8f90-8ae1-4d1a-bc0d-9dcc1bb3cd05">five-year</ix:nonNumeric> warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531" decimals="INF" format="ixt:num-dot-decimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzk4MQ_fef8a2f1-0ef7-4202-9e35-9bafb9b97f02">480,000</ix:nonFraction> membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AchievaMed</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase <ix:nonFraction unitRef="number" contextRef="ib54cc9af425747bc9bf0db47bae0cdf5_I20190701" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODU5MQ_03930749-bd19-4c5b-a660-e954eb350654">50</ix:nonFraction>% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed <ix:nonNumeric contextRef="ie20db30d9d2f4ad790ae13386a5e01ef_D20190701-20190701" format="ixt-sec:durwordsen" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODY4NQ_5c052c21-91f6-4314-8fb9-cd765c177de4">five years</ix:nonNumeric>. As a result of this transaction NMM invested $<ix:nonFraction unitRef="usd" contextRef="ib54cc9af425747bc9bf0db47bae0cdf5_I20190701" decimals="-5" format="ixt:num-dot-decimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODczNA_0af867f1-668f-4b33-95c0-85989a03f3c8">0.5</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="ib54cc9af425747bc9bf0db47bae0cdf5_I20190701" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODc0Mw_0324dbb0-b7b7-46da-9000-4d6ffc26f349">10</ix:nonFraction>% interest. The related investment balance of $<ix:nonFraction unitRef="usd" contextRef="i2d2eae5117d042b4ae64a03222d5c117_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODc5MA_88a49090-7feb-431d-9b01-1dc8ce40091f">0.5</ix:nonFraction> million is included in investments in privately held entities in the accompanying consolidated balance sheets as of September&#160;30, 2021.</span></div></ix:continuation><div id="i77048548a0c546beaa10a42c80553a71_70"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="ameh:LoanReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83MC9mcmFnOmVlOTk5ZTFmOTY0NDRmNTM5OTVmOWUzZDE5ZWE3MTM2L3RleHRyZWdpb246ZWU5OTllMWY5NjQ0NGY1Mzk5NWY5ZTNkMTllYTcxMzZfMTI1MA_326e94d4-71b3-48c7-9dc0-74d067ff12dd" continuedAt="i459b70661d2e41929dbdbe288a98a32a" escape="true">Loan Receivable and Loan Receivable &#8211; Related Parties</ix:nonNumeric></span></div><ix:continuation id="i459b70661d2e41929dbdbe288a98a32a"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific6</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NMM received a promissory note from Pacific6 totaling $<ix:nonFraction unitRef="usd" contextRef="i525bb8235fd64a5c8f0c02ec9cbb55e4_I20201030" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83MC9mcmFnOmVlOTk5ZTFmOTY0NDRmNTM5OTVmOWUzZDE5ZWE3MTM2L3RleHRyZWdpb246ZWU5OTllMWY5NjQ0NGY1Mzk5NWY5ZTNkMTllYTcxMzZfMTU5_4c181351-3f20-4ef1-814b-b6eec722c6af">0.5</ix:nonFraction>&#160;million as a result of the sale of the Company&#8217;s interest in MWN. Interest accrues at a rate of <ix:nonFraction unitRef="number" contextRef="i525bb8235fd64a5c8f0c02ec9cbb55e4_I20201030" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83MC9mcmFnOmVlOTk5ZTFmOTY0NDRmNTM5OTVmOWUzZDE5ZWE3MTM2L3RleHRyZWdpb246ZWU5OTllMWY5NjQ0NGY1Mzk5NWY5ZTNkMTllYTcxMzZfMjUw_c1d6b7b8-a282-4ab9-8173-e84f3a176d3f">5</ix:nonFraction>% per annum and is payable monthly through the maturity date of December 1, 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> related parties</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AHMC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, APC entered into a promissory note with AHMC (the &#8220;AHMC Note&#8221;) for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i8f146f9b4b714488a52f519d85dc9915_I20201031" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83MC9mcmFnOmVlOTk5ZTFmOTY0NDRmNTM5OTVmOWUzZDE5ZWE3MTM2L3RleHRyZWdpb246ZWU5OTllMWY5NjQ0NGY1Mzk5NWY5ZTNkMTllYTcxMzZfNDc4_e569cb12-016a-4672-9fd0-5d1701a44c1f">4.0</ix:nonFraction>&#160;million with a maturity date of April 2022. The contractual interest rate on the AHMC Note is <ix:nonFraction unitRef="number" contextRef="i8f146f9b4b714488a52f519d85dc9915_I20201031" decimals="INF" name="ameh:FinanceReceivableInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83MC9mcmFnOmVlOTk5ZTFmOTY0NDRmNTM5OTVmOWUzZDE5ZWE3MTM2L3RleHRyZWdpb246ZWU5OTllMWY5NjQ0NGY1Mzk5NWY5ZTNkMTllYTcxMzZfNTY3_94ef2498-37ce-416b-94f3-98643bbd9288">3.75</ix:nonFraction>% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of September&#160;30, 2021, the total principal of $<ix:nonFraction unitRef="usd" contextRef="ibff23baf29ec4ca5a5fac9212a3be6ef_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83MC9mcmFnOmVlOTk5ZTFmOTY0NDRmNTM5OTVmOWUzZDE5ZWE3MTM2L3RleHRyZWdpb246ZWU5OTllMWY5NjQ0NGY1Mzk5NWY5ZTNkMTllYTcxMzZfNzYx_0b4cc0bd-3016-4dae-af32-6d26a5204145">4.0</ix:nonFraction>&#160;million remains outstanding. One of the Company&#8217;s board members is an officer of AHMC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loan receivable under the CECL model by assessing the party&#8217;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RleHRyZWdpb246M2IyMGZlOWQyNWU2NDU1ZWI4YzUxMGU1NWQ4ODc1ZDdfMTQ0_98a0317e-2065-4e79-98de-aadae6f97c82" continuedAt="i182ea3266b3441609150e0d7341eca3c" escape="true">Accounts Payable and Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i182ea3266b3441609150e0d7341eca3c"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RleHRyZWdpb246M2IyMGZlOWQyNWU2NDU1ZWI4YzUxMGU1NWQ4ODc1ZDdfMTQ3_56627607-c53f-40a2-9bd0-1a954362e8d0" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfMS0xLTEtMS0w_ca4b3e98-d272-4cd2-8923-76950faf0a99">23,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfMS0zLTEtMS0w_1e1784ff-61c5-4a08-9a6e-f1e96e4aef7f">9,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:SpecialtyCapitationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfMi0xLTEtMS0w_62d3f096-18c1-480f-b17a-58215f99c85b">2,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="ameh:SpecialtyCapitationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfMi0zLTEtMS0w_d286293b-1bcf-4005-8079-641918e10517">3,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:SubcontractorIPAPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfMy0xLTEtMS0w_c744e461-03ba-48e8-9a2e-6bef7fb6039f">2,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="ameh:SubcontractorIPAPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfMy0zLTEtMS0w_ba1d8379-41be-44be-898e-89f29955fa1b">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNC0xLTEtMS0w_bbc95f6f-2b88-473d-987b-fa5f426af0ff">697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNC0zLTEtMS0w_74287d29-e77f-42e9-97d3-23940b952bb8">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNS0xLTEtMS0w_8f80fb4c-a450-4f72-be10-d0bdcbfb5da9">2,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNS0zLTEtMS0w_bc912245-52e9-4cbe-8f88-24528bf0a2ce">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNi0xLTEtMS0w_8db86c38-b39e-4542-b6c2-017aa0bb219a">17,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNi0zLTEtMS0w_adda621f-b0a6-4fb6-aa58-f6c6be5fdd72">12,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNy0xLTEtMS0w_5c7b7d68-ad6b-4a16-8acc-1bb376f0542e">8,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNy0zLTEtMS0w_ccf07569-cf9a-4d5c-abd4-dc20bde53eb3">6,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfOC0xLTEtMS0w_def4f9da-2127-4c1b-b7cf-6adea64b313f">57,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfOC0zLTEtMS0w_feb62d47-985b-43d1-9cf1-206a778bef61">36,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i77048548a0c546beaa10a42c80553a71_79"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RleHRyZWdpb246ZGJlNTJhNDJiOGU1NDVhYmFhNDIzMmYyOTZmNDRlZWVfMTA3_25ba0b31-cb0e-4a81-9e1b-f2e28fa86ca8" continuedAt="i953d90829bf84db2b509650bde7c154b" escape="true">Medical Liabilities</ix:nonNumeric></span></div><ix:continuation id="i953d90829bf84db2b509650bde7c154b"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RleHRyZWdpb246ZGJlNTJhNDJiOGU1NDVhYmFhNDIzMmYyOTZmNDRlZWVfMTA5_dfc7942c-24fa-4b87-a3a8-0e266c6b97e7" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMS0xLTEtMS0w_4879cf50-2b59-4d39-bb40-3b51bede6087">50,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274e819937824ba3b8be663aca7657a1_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMS0zLTEtMS0w_b2fb1e9d-3603-4ef8-bc07-496cf03dafa3">58,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMi0xLTEtMS0yNDk3Ng_ab706cd1-7329-436e-b296-5daa01111746">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMi0zLTEtMS0yNDk3Ng_826beede-d4f5-46b5-969a-024ec526141c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMy0xLTEtMS0w_2f5eb0e1-879d-4c29-a1e3-9469a1f9c712">242,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMy0zLTEtMS0w_70f5dda7-067f-4c6c-aecc-224333b0380d">229,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfNC0xLTEtMS0w_c3d1df90-8062-4885-9d63-160354f46c9a">498</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfNC0zLTEtMS0w_0b0e2575-c878-43de-95bc-974215c9a690">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfNS0xLTEtMS0w_29cc1da1-8432-492c-b5af-652799bde6ba">242,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfNS0zLTEtMS0w_8f73ee71-ee4d-44a4-9f49-bf10553e1462">230,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfNy0xLTEtMS0w_9739adec-6f4b-4fa1-a9c6-45ba72ba6f61">200,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfNy0zLTEtMS0w_1eaee081-8915-477e-a50d-82e84fe0384e">178,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfOC0xLTEtMS0w_b64a16ad-cf48-498d-8bc8-24962615907d">48,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfOC0zLTEtMS0w_bb31c430-85dd-47c0-a043-e4d880476d74">53,231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfOS0xLTEtMS0w_e46edd75-dbbf-4ec4-ab62-1d1a7ff6bb44">249,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfOS0zLTEtMS0w_b6f139eb-b173-4560-be79-1b55f45cd95f">232,027</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMTAtMS0xLTEtMA_939b3475-daaf-43c9-8177-30ed442b9fb6">224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMTAtMy0xLTEtMA_c28e7f26-359c-43d9-a81a-f13d6138b301">168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMTItMS0xLTEtMA_aa5e5a08-5f42-4a84-8521-c3fca1c1d0f1">42,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03292c592c4f45da834c806bff481c24_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMTItMy0xLTEtMA_25f3b27d-3b40-4519-83c3-55f5cab156a4">57,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyNDQ_411bf453-77e4-4d96-9cbb-3887ec01640a" continuedAt="i1a42f2cb1612413e80eda7ce033b82f5" escape="true">Credit Facility, Bank Loans, and Lines of Credit</ix:nonNumeric></span></div><ix:continuation id="i1a42f2cb1612413e80eda7ce033b82f5" continuedAt="i0543bc22513c486aa32115da5e915bd3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyNDE_067b0c2b-e571-4cf9-a814-5b63d70cdf78" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bdfabdb85c43999bb05d916a50e971_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfMi0xLTEtMS0w_10acbc78-856c-454a-a19f-32c3d9c83587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8494272cd6364c2a80530dff5382f450_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfMi0zLTEtMS0w_fe51807b-94b1-4cb9-b626-5db9801639ac">178,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37550a1e26f4222af82434fc245548e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfMy0xLTEtMS0w_3e36f23a-89a2-412c-b7ed-427ca56d08ce">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0099b63992df486aa72820a547d7a3b5_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfMy0zLTEtMS0w_773b1b13-3b2a-4664-979d-122537458d25">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic51fbee815c34c8bbdc2590d6bb3ba93_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfNC0xLTEtMS0w_dd728f64-8f0f-4109-9676-25ed8a395a55">7,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if29783d76d8e4e5c979ae194c2e9e7d8_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfNC0zLTEtMS0w_9e5d317b-edc6-4ae0-8da8-cd3fd7e9dd7f">7,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c70eca48984b6aa875a69a43dd3f0c_I20210930" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfNS0xLTEtMS0w_eada6565-1340-4b13-80cc-5f6146d3e361">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc8ed74b68a4195a91620c9be1362c7_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfNS0zLTEtMS0w_9a4f4125-89c7-4419-8b48-d085bc331ffd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfNi0xLTEtMS0w_acfc8a08-7a76-4d7b-a000-11390b476f84">187,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfNi0zLTEtMS0w_169a5b34-7a68-46d3-a542-db5126340d0a">245,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfOC0xLTEtMS0w_6291328e-45d9-4bd1-a976-1ca4a7e32a9d">207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfOC0zLTEtMS0w_fa74530c-4cbb-404c-9266-03eed8d94b57">10,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfOS0xLTEtMS0w_2f928de9-701f-4d29-b912-ff20f1e2b61c">4,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfOS0zLTEtMS0w_32ef02d4-9b17-4b33-a372-29c0e3fca656">4,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfMTEtMS0xLTEtMA_e834ae69-6826-4cc2-8d62-0d6eb5541121">182,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfMTEtMy0xLTEtMA_7aab2a27-ed3f-4931-a914-84d1657c980a">230,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of September&#160;30, 2021 and December&#160;31, 2020, the carrying value was not materially different from fair value, as the interest rates on the Company&#8217;s debt approximated rates currently available to the Company.</span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyMzE_d528b94f-c3fe-45e6-b79a-463fd1cdd9bc" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September 30, 2021) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOmI2OTE3ODEzN2NmMzQ4NjhiZmM2NzI3NzRkNDFmZWJmL3RhYmxlcmFuZ2U6YjY5MTc4MTM3Y2YzNDg2OGJmYzY3Mjc3NGQ0MWZlYmZfMS0xLTEtMS0w_d4ef773c-1927-4f36-bc14-f5ced6004cb0">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOmI2OTE3ODEzN2NmMzQ4NjhiZmM2NzI3NzRkNDFmZWJmL3RhYmxlcmFuZ2U6YjY5MTc4MTM3Y2YzNDg2OGJmYzY3Mjc3NGQ0MWZlYmZfMi0xLTEtMS0w_499dc73d-7690-4057-a40d-b75b7ac81fad">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOmI2OTE3ODEzN2NmMzQ4NjhiZmM2NzI3NzRkNDFmZWJmL3RhYmxlcmFuZ2U6YjY5MTc4MTM3Y2YzNDg2OGJmYzY3Mjc3NGQ0MWZlYmZfMy0xLTEtMS0w_047bb6be-f553-465b-b32b-09f2a5e677b9">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOmI2OTE3ODEzN2NmMzQ4NjhiZmM2NzI3NzRkNDFmZWJmL3RhYmxlcmFuZ2U6YjY5MTc4MTM3Y2YzNDg2OGJmYzY3Mjc3NGQ0MWZlYmZfNC0xLTEtMS0w_6c945653-bf57-4206-895d-711e8404cdc2">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:LongTermDebtMaturityAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOmI2OTE3ODEzN2NmMzQ4NjhiZmM2NzI3NzRkNDFmZWJmL3RhYmxlcmFuZ2U6YjY5MTc4MTM3Y2YzNDg2OGJmYzY3Mjc3NGQ0MWZlYmZfNS0xLTEtMS0w_41addef3-8b7d-4ac4-93d8-e9c6509324a8">186,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOmI2OTE3ODEzN2NmMzQ4NjhiZmM2NzI3NzRkNDFmZWJmL3RhYmxlcmFuZ2U6YjY5MTc4MTM3Y2YzNDg2OGJmYzY3Mjc3NGQ0MWZlYmZfNy0xLTEtMS0w_534e025c-5e8b-4259-8402-b53619c55b7c">187,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i0543bc22513c486aa32115da5e915bd3" continuedAt="id04ed0b45b5c4e8389f28f8b279f5156"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a secured credit agreement (the &#8220;Credit Agreement,&#8221; and the credit facility thereunder, the &#8220;Credit Facility&#8221;) with Truist Bank (f.k.a. SunTrust Bank), in its capacity as administrative agent for the lenders, as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders. The Credit Agreement provided a <ix:nonNumeric contextRef="ic2ee83ed94cb43dcb3182dcb57e382f9_D20190901-20190930" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyMzU_2ea3387d-6a4e-4cd3-a7c2-0789a7dd36e9">five-year</ix:nonNumeric> revolving credit facility to the Company of $<ix:nonFraction unitRef="usd" contextRef="i3f4f916cef32400dab83a02c9f3d1dff_I20190930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfOTQ2_7feac512-2532-45b8-ad76-2a993bac2b51">100.0</ix:nonFraction> million, which includes a letter of credit subfacility of up to $<ix:nonFraction unitRef="usd" contextRef="i63ade4493fd74989b1999037fc8db598_I20190930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTAwNQ_e00b38fe-b761-426b-929f-8834f20d0c43">25.0</ix:nonFraction> million. The Credit Agreement also provided a term loan of $<ix:nonFraction unitRef="usd" contextRef="i55616ddbc4dc41fca2e3f5474cb36d53_I20190930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTA1OQ_ffefe082-149b-422f-913b-5c6d3b6a933a">190.0</ix:nonFraction> million. Amounts borrowed under the Credit Agreement bore interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#8220;LIBOR&#8221;), adjusted for any reserve requirement in effect, plus a spread of between <ix:nonFraction unitRef="number" contextRef="i894dad9f04be4b80b0c5418db6c0ffac_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTM5Mg_f30b95cd-f402-438e-bd0c-63d6dec28086">2.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ieb62b8a56d704692b86255ec6cff3fd8_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTM5OQ_b2af06b9-a37c-4b27-8321-692fc3a1ca4b">3.00</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread between <ix:nonFraction unitRef="number" contextRef="ied77ca7dcd3c44a3ad71dbbe16d60235_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTUxOQ_5089c47e-4bac-42ec-8ddb-93277c9e53b7">1.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i637ca2c6a62940f5bf8cd582df12b45d_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTUyNg_dd21f02e-98ae-4462-a3e7-2b6bcb33b326">2.00</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the agent entered into a Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement and, together with the Company, granted the lenders a security interest in all of its assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the &#8220;Lenders&#8221;), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Wells Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent, in its entirety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement provides for a <ix:nonNumeric contextRef="i2da520099b4f4b1e85134d04cfed7267_D20210616-20210616" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyMzM_f41d7555-bed3-4a2e-9998-1a952bdb93eb">five-year</ix:nonNumeric> revolving credit facility (&#8220;Revolver Loan&#8221;) to the Company of $<ix:nonFraction unitRef="usd" contextRef="ib4c74cb40c8b4d9882ce3f1381253d36_I20210616" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMzE2OA_02046ece-e48d-4fbb-ac4d-f381c10233bc">400.0</ix:nonFraction> million, which includes a letter of credit sub-facility of up to $<ix:nonFraction unitRef="usd" contextRef="if5f64948f20549f29b7ad2775ac72e54_I20210616" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMzIyOA_05a1a7b1-b0c7-4774-adfc-35014852106b">25.0</ix:nonFraction> million and a swingline loan sub-facility of $<ix:nonFraction unitRef="usd" contextRef="i3501cf38d6f349bfbb10a514b5e413c8_I20210616" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMzI2OA_7c0b143a-4c8e-4001-8ae5-edafeaac44fb">25.0</ix:nonFraction> million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts borrowed under the Amended Credit Agreement will bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on  LIBOR, adjusted for any reserve requirement in effect, plus a spread of from <ix:nonFraction unitRef="number" contextRef="id51378c59e4b46a1878e9755158c9508_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMzk5Nw_32ca4494-68c0-4cf1-adef-0cec62f866a2">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i32a0cb9701af4dec94e8c8b4a88e8a16_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDAwMw_5cb5a38d-5b8c-42c0-aa1d-36e4c12ba26a">2.5</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of <ix:nonFraction unitRef="number" contextRef="i6bcbe6284db54a94b3f1f04677fe3f92_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDExOA_780933a0-34bf-4865-b228-d2509dafcb92">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic51076d7bee7498eb636ef7814297785_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDEyNA_58430736-37ed-45bc-b662-75b74d82cd9f">1.5</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. As of September&#160;30, 2021, the interest rate on Amended Credit Facility was <ix:nonFraction unitRef="number" contextRef="idea7e71c000342b8995e416f3a7cff49_I20210930" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDI2MQ_d9b0296d-2f3a-4f6d-82bb-4512b8a62f57">1.65</ix:nonFraction>%.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual agent fee of $<ix:nonFraction unitRef="usd" contextRef="i7820cd54de244cb28e02edd916f67207_D20210616-20210616" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDMxOQ_3d51cfe2-b153-44a6-9fc2-6103887a2daf">50,000</ix:nonFraction> and an annual facility fee of <ix:nonFraction unitRef="number" contextRef="i6bcbe6284db54a94b3f1f04677fe3f92_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDM1Mg_9996f114-946b-4724-9aa6-eddaf5eccc17">0.175</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic51076d7bee7498eb636ef7814297785_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDM1OA_69be2b14-815d-4721-bfc7-d45b56c2c6bc">0.35</ix:nonFraction>% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to <ix:nonFraction unitRef="number" contextRef="i0e608242dd8442239280156056c80e78_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDYyNQ_c585999f-da5d-4018-b86b-662cc1f590a2">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="icc5ad4c4fa8b4ec698a83764c9b1d2d4_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDYzMQ_96bcbf53-add3-4d9e-950f-92646e74b534">2.5</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with <ix:nonFraction unitRef="financial_ratio" contextRef="id383d2aa762447b5b54e8e4dfc37d7c1_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="ameh:DebtInstrumentNumberOfKeyFinancialRatios" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNTAwNg_d34c91d7-97a1-4ed8-9a79-4957f0fcf549">two</ix:nonFraction> key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="id383d2aa762447b5b54e8e4dfc37d7c1_I20210930" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNTE1Ng_ef6dcf21-38a7-44f1-897c-252eb7e3638e">3.75</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter.  The Company must maintain a minimum consolidated interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="id909b639f09f413ba4ac35e191a08c1d_D20210101-20210930" decimals="INF" name="ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNTMwMQ_fea268e3-17e0-41df-b805-5955b31f66fe">3.25</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="ia7d07d7302e04f1093a19129cb01db1a_I20190930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNTQ1MA_515b619c-6f9d-4321-9bc3-3028ad9c3f25">6.5</ix:nonFraction> million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i6847b33d46c94f279cb67bd2e1ad4362_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNTU3NA_26a94b4d-1f13-46c1-b2cb-4839b659698e">0.7</ix:nonFraction>&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="id04ed0b45b5c4e8389f28f8b279f5156" continuedAt="ife3dd3a8731f41b6bb0d535ebdeb400c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. At September&#160;30, 2021 and December&#160;31, 2020, the unamortized deferred financing cost was $<ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjAzNg_2c7fcd6d-40c7-442d-abb0-2a3e86e9b2dd">4.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjA0Mw_024012bb-0d24-4068-a022-f7bd0f32a0b6">4.6</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="i6f8776621075492eacb36b4093b785ae_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjE2Ng_c2a21c9e-1782-46d9-95a1-438fb9321038"><ix:nonFraction unitRef="number" contextRef="i2c6ce9908aaf4419a562611bb678c2a2_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjE2Ng_c4667cc6-bd60-484a-9ab9-d9558b8b0b0d"><ix:nonFraction unitRef="number" contextRef="i8147fcc7b25942ad8a37c6657211abf5_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjE2Ng_f51a4bf0-0b44-44c3-9ea5-1c592a9c371c">100</ix:nonFraction></ix:nonFraction></ix:nonFraction>% interest in MPP, AMG Properties, and ZLL. As a result of this purchase, APC assumed the existing loans held by MPP, AMG Properties, and ZLL. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MPP</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $<ix:nonFraction unitRef="usd" contextRef="i2acf51a712524f44ba644d48d0a00647_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjQ2OQ_4cbe57f4-9611-4a82-9a4f-47f88569f668">6.4</ix:nonFraction>&#160;million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="idd7cf95bb6ef4965bf29b2064ac819c1_D20200703-20200703" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjUwNQ_e2123dcf-77a6-4170-b200-26d40f2056c5">0.50</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of September&#160;30, 2021, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="i07f6fe5be32e4b7292d433a12ca499c0_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjgzNA_3fc08870-3761-4917-8dcf-a9741a9e4dd2">6.1</ix:nonFraction> million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i4a5651c8948b4047b7eab25f8764f012_D20200703-20200703" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjk5Nw_bda6b3f2-4fb8-414f-b759-5b4171324961">1.25</ix:nonFraction> to 1. <br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG Properties</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $<ix:nonFraction unitRef="usd" contextRef="i5f31366737854b98ba91333a885afcb9_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNzE4OQ_8612d249-72e5-49a5-b788-c695fa820a80">0.7</ix:nonFraction>&#160;million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="ice5f1743593b44f9a80d07f923a92908_D20200805-20200805" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNzIyNQ_15653616-a913-4064-b481-802cfe0987d7">0.30</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of September&#160;30, 2021, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="i82b2d9d7053444d4aab270f6ad420a79_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNzU2NQ_512120a2-fc1a-4644-98c1-c97564862d2c">0.7</ix:nonFraction> million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i2c657488d54b424380f6b218f717a662_D20200805-20200805" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNzczOQ_c1d80373-443e-4967-92f0-4724deebec0c">1.25</ix:nonFraction> to 1.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZLL</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $<ix:nonFraction unitRef="usd" contextRef="icfc39a3c7e114b588a1abebd9943f489_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNzkwNw_3b505393-859e-436d-9707-09942f01e545">0.7</ix:nonFraction>&#160;million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="iaeabd70c59714c11a93da612a94d392b_D20200727-20201231" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNzk0Mw_b29869e6-117a-4a44-8755-5c8f5d3d607a">0.50</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of September&#160;30, 2021, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="i7530cbcce02f4598a2e22ba8f19dabdb_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfODI3Mg_404c562a-ae41-4866-afa2-0be8fb837353">0.6</ix:nonFraction> million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="ic56ef9908db04d4ba9b326259616f237_D20200727-20201231" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfODQzNQ_0b816a44-d263-4f11-a61f-2c1a806810d6">1.25</ix:nonFraction> to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;). Tag 8 is a VIE consolidated by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Construction Loan allows Tag 8 to borrow up to $<ix:nonFraction unitRef="usd" contextRef="i37601241e5164c76b84df50fe2dccd42_I20210430" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfODY3NA_5adb8a7e-f59d-46d9-957c-6a0caaf24c0d">10.7</ix:nonFraction> million with a maturity date of December 1, 2022 (&#8220;Construction Loan Term&#8221;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#8220;Permanent Loan Term&#8221;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be <ix:nonFraction unitRef="number" contextRef="i4a5e7cb27c6a475e8bc2918ac9af91a3_D20230101-20231201" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfOTQ1Mw_f0b279c1-a091-468c-9008-6692da7a68b2">2.0</ix:nonFraction>% per annum in excess of the LIBOR rate. As of September&#160;30, 2021, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="i048bc9147744436cb31702bc505497d5_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfOTUzMw_24df62e0-ec5f-4719-afac-4b25a233ccf0">0.1</ix:nonFraction>&#160;million. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#8217;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated earnings before interest, taxes, depreciation, and amortization (&#8220;EBITDA&#8221;) minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i048bc9147744436cb31702bc505497d5_I20210930" decimals="INF" name="ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfOTg0Ng_5d34fbc8-b407-4da5-81d4-f84ade2ce49d">1.25</ix:nonFraction> to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the nine months ended September&#160;30, 2021 and 2020, was <ix:nonFraction unitRef="number" contextRef="id909b639f09f413ba4ac35e191a08c1d_D20210101-20210930" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfOTk4OA_b63971a5-dca1-464d-a2f3-3aba8a09ce80">2.15</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0bb465d8e0fa47b281bc8588585bfd99_D20200101-20200930" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfOTk5NQ_7960e33a-0149-48cd-9b92-66adf11ff63c">3.79</ix:nonFraction>%, respectively. Interest expense in the consolidated statements of operations included amortization of deferred </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ife3dd3a8731f41b6bb0d535ebdeb400c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">debt issuance costs for the three and nine months ended September&#160;30, 2021 and 2020, of $<ix:nonFraction unitRef="usd" contextRef="ifd5c1f9d9879419881aa4f73dbd34259_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTAxNzA_db8fc938-8305-4ef8-841a-e8792c687d58">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id909b639f09f413ba4ac35e191a08c1d_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTAxNzc_3baed4ba-0064-4474-ba5b-b91c6d24723c">0.3</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ieeae1845ac274f829e29f2feb496c443_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTAxOTk_2131bea0-dfb6-4336-a0d4-16825bee8188">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0bb465d8e0fa47b281bc8588585bfd99_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTAyMDY_df75e313-d4da-4e74-893f-c0ffe9a020d0">1.0</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit &#8211; Related Party</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#8220;APC Business Loan Agreement&#8221;) was amended to decrease loan availability to $<ix:nonFraction unitRef="usd" contextRef="ia2c3441a286f4428b822c3dc66bbbdaa_I20190910" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTA0MTY_879e9655-9df0-4d4f-8c13-8b7522d63f48">4.1</ix:nonFraction> million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. One of the Company&#8217;s board members is the chairman and CEO of Preferred Bank. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO established an irrevocable standby letter of credit with Preferred Bank, which is affiliated with one of the Company&#8217;s board members, totaling $<ix:nonFraction unitRef="usd" contextRef="i4908488c47c942d99a8fc66857f5053e_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTExMzI_401d57af-e088-46dc-b78d-a47e39aad9d2">14.8</ix:nonFraction>&#160;million for the benefit of CMS. In August 2020, the irrevocable standby letter of credit was  released by CMS. As of September&#160;30, 2021, there were <ix:nonFraction unitRef="usd" contextRef="id34357efa1004d2ab40ef715b0949c59_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LettersOfCreditOutstandingAmount" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyMzY_9c0017b8-3652-43ef-a856-8be11e977edb">no</ix:nonFraction> outstanding letters of credit and the Company had $<ix:nonFraction unitRef="usd" contextRef="i949ff001ac544940b35caad34ef7b315_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTEzMTI_db0cd7da-474e-4d4c-8cad-7fa01cb17062">25.0</ix:nonFraction>&#160;million available under the Amended Credit Facility.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="icee52b68969c4138b7b2a2e8af0b227d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTE0ODc_bdacb059-1391-415b-b012-58329cf80703">0.3</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="if82c8f50b6884a84bb5fec6d0c53d8e6_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyMzc_88522d89-5a5e-4ee5-9532-b52528dbffc6">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="i20c5c1427f6f4e6cbd81faa6df3205dc_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTE5MjQ_43ff29e4-ca0b-41cf-b38f-d4d705ec670c">3.8</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="ib5b45c5e6ea841c1a753923224520654_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyNDI_f0b9a137-e3b7-4444-8783-311af7750e2b">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div></ix:continuation><div id="i77048548a0c546beaa10a42c80553a71_88"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMjA2MQ_33218e5d-bb58-4976-944c-6f8a541ba70b" continuedAt="iaa5b25b267d7404394594bcbd86c610f" escape="true">Mezzanine and Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="iaa5b25b267d7404394594bcbd86c610f" continuedAt="i3fc252b76c7e42ca9b40eb21fc9938a7"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature of the APC shares (see Note 2) is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC&#8217;s shares were not redeemable, and it was not probable that the shares would become redeemable, as of September&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringPeriodSharesMerger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfNDQy_14e6eb9f-8b22-4bb6-9019-88bc7e3eb19f">141,638</ix:nonFraction> holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Treasury Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC owned <ix:nonFraction unitRef="shares" contextRef="i0be646a9c14345fabdb07fa7e3f377f0_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTI5OA_f0dd5a54-e307-44fe-93fb-bf09026c10ed">10,925,702</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4ae0dfc3bc32416cb6ec479fa6aee249_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTMwNQ_7b2957ee-8cab-4cfb-964c-a49accc59be8">12,323,164</ix:nonFraction> shares of ApolloMed&#8217;s common stock as of September&#160;30, 2021 and December&#160;31, 2020, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. In March 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="ieaf0c3ac99784174b913090c36595512_D20210301-20210331" decimals="INF" format="ixt:num-dot-decimal" name="ameh:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTU5NDI5MTg2MDU0MTY_217270ad-7e62-4ec0-abe8-e6bd126f711c">34,158</ix:nonFraction> shares of common stock to APC as a result of APC exercising their warrants.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i3fc252b76c7e42ca9b40eb21fc9938a7"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, APC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="id92d571acf4e4268885451c976638558_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTc3OQ_ca559502-e17c-4cbd-8adb-6a05d38c8cab">10.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie56d0d0b55424badade9e1fc4b2d1fb1_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTc4Ng_cea57427-a214-48ec-8ff4-b9a0a7b9d6d8">19.9</ix:nonFraction>&#160;million, respectively. During the nine months ended September&#160;30, 2021 and 2020, APC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="ia1bd75ff5a784460bc879854f3dc5e14_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTg2NA_ba4b35a7-11c9-449a-945f-761445384ff8">29.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if75c2580a6e64c94a6c643c85453d033_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTg3MQ_bf77d22d-eccd-440d-b6cc-386dea9dfa18">49.5</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, CDSC did not pay any dividends. During the nine months ended September&#160;30, 2021 and 2020, CDSC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="ia33174543dcc47c381797d497163fb30_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMjAzNg_1bbbff7b-30e6-493f-8275-348e89f654b4">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib9e6ca8ac3e24c129b22e6f9b5d3b25c_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMjA0Mw_500c71a4-49d8-4c9a-abf8-f3b084797661">0.6</ix:nonFraction> million, respectively.</span></div></ix:continuation><div><span><br/></span></div><div id="i77048548a0c546beaa10a42c80553a71_94"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMjA4Mg_a1ffa369-beae-43b2-8340-aadf3844a414" continuedAt="i89fba1c0a49d471f9c8efc4ad3bb7a6d" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i89fba1c0a49d471f9c8efc4ad3bb7a6d" continuedAt="i4c2672144c2e4225a6d8963f053949a0"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMjA3Nw_6cdfba6e-1531-48af-b606-a5d2641c078e" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three and nine months ended September&#160;30, 2021 and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of operations (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26630cf67d1949a1bb14af99246ab11e_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMi0xLTEtMS0w_e4cc5edd-e604-4d24-b097-1bf1227d60a2">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieed5052a2c264a58a60f18048fdd7abc_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMi0zLTEtMS0w_817c3ddb-b127-4b8f-97b2-4b5080a9765f">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e8004b924f4bdb999ba8d5a25493b0_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMi01LTEtMS0w_e6671af9-6cf7-40b0-9e80-7991e9c142e3">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224224b17a647d7a1bbdb52d3c8ee5d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMi03LTEtMS0w_cb7cf3bf-c13b-4150-b1c2-d287bbe5c053">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b5c1fd7f16d4fabaa391acdd0d5b331_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMy0xLTEtMS0w_dd81b0f3-6e3c-41bd-a5f4-7e63ff3d6b75">818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3914dba35149aca5f59b14362cf84f_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMy0zLTEtMS0w_42d38507-afbc-4f0e-929d-a803e11a0860">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a1b7919fd34831b23c0c3972b0f9f7_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMy01LTEtMS0w_9c177654-4f0c-44fe-9216-c42d95164bb3">2,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e43a94fd374088a88895c32404f338_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMy03LTEtMS0w_80eafdc3-f1fb-4521-bf7a-c8d9604f5509">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfNS0xLTEtMS0w_25a63df5-f3d7-4cf0-83a7-ff37e0b0ff41">1,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfNS0zLTEtMS0w_f33530aa-1df2-4891-933d-a770c2e5c1b2">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfNS01LTEtMS0w_83de1c1f-582b-4933-b0d9-c13b18338bb0">4,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfNS03LTEtMS0w_ce0476b6-59ca-427f-8fe6-2c686a486cba">2,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to total share-based payments outstanding as of September&#160;30, 2021, was $<ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfNTI0_7e4990f8-3b5d-48fb-94f2-b3d192082380">7.4</ix:nonFraction> million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMjA3OA_2b6e869f-e626-480d-bab0-3e063da439bb" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMS0xLTEtMS0w_fe34072a-5a3e-45f1-ba4b-316d7c2ac6f5">725,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMS0zLTEtMS0w_9de4a9ea-7f7c-40de-b441-4766d2cb2de0">13.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1bc83e3bcab6489aa067dd6bbdb2afc2_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMS01LTEtMS0w_37cbac13-36ec-4d6d-92ea-93b2222123e1">3.75</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMS03LTEtMS0w_d7a5dcfa-75cb-4055-98a1-9caf0e42872c">3,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMi0xLTEtMS0w_e4b832d3-6c67-4852-b415-b36935205553">24,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMi0zLTEtMS0w_08fa6787-56f9-4b3d-89e1-60ad69e8957f">23.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMy0xLTEtMS0w_3854abc4-dd1a-4079-9a8b-7136c18cde92">40,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMy0zLTEtMS0w_a2a45961-ee9d-42a2-89f4-1f3a8bc5031e">5.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMy03LTEtMS0w_6e3992ff-e870-4279-8229-f7e482371312">2,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfNC0xLTEtMS0w_b71a0e04-3403-4c25-9b71-00d62202a9cb">9,826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfNC0zLTEtMS0w_4cfe6eed-f218-431e-a2c7-cea4d018c3e6">3.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfNi0xLTEtMS0w_38c444c6-f3b2-400e-ad75-d8e4d15d4378">700,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfNi0zLTEtMS0w_183fadfd-ca4e-446b-9cb4-8e3c5d4a3773">14.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfNi01LTEtMS0w_fb7006f1-fa6f-4583-b3f1-b75a8f86924d">3.18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfNi03LTEtMS0w_fe88ad07-a057-4c04-850a-31532fe2334d">53,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfOC0xLTEtMS0w_2cd44599-2186-48fc-8e23-756d7c4e94c3">534,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfOC0zLTEtMS0w_51bd662c-1424-4111-9742-4dc30ffc2192">9.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfOC01LTEtMS0w_b288901c-200d-409d-9604-d3d65e6ccda9">2.24</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfOC03LTEtMS0w_93251c8f-9831-4f10-bbf9-c0eaa5e443ea">41,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, options were exercised for <ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfNjM3_3854abc4-dd1a-4079-9a8b-7136c18cde92">40,000</ix:nonFraction> shares of the Company&#8217;s common stock, resulting in proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6993e6cdd0a34b838468c68d5890d474_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTA5OTUxMTYyOTkzMA_49b599bd-76d3-4b76-a472-b413ecb86763">0.2</ix:nonFraction>&#160;million. During the nine months ended September&#160;30, 2020, options were exercised for <ix:nonFraction unitRef="shares" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfNzI4_24f40f0c-03e0-4103-a080-cff72ecf94ec">120,000</ix:nonFraction> shares of the Company&#8217;s common stock, resulting in proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ie42410e4e0cd4dccab9e87193dccb1b3_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfODA4_a1c05704-9e99-4443-9038-89e8ebe84ee3">0.3</ix:nonFraction> million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMjA3NA_09df9a65-f5b3-429f-838a-5c332fb55d6e" continuedAt="ifcbc32e940064ebc813d3e87f88e2e34" escape="true">During the nine months ended September&#160;30, 2021, the Company granted <ix:nonFraction unitRef="shares" contextRef="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfODYz_6340eb55-3100-4435-8174-38ec98879de1">24,437</ix:nonFraction> stock options with a vesting period of <ix:nonNumeric contextRef="i2b411e1124154e218ae663e7d0cd0811_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfOTA1_a578b614-1c8d-4d78-9fae-082f03d3314c">two years</ix:nonNumeric> to certain ApolloMed executives with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if24be682ffa04df6b410bf2bdba494b9_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfOTY2_f6adea3b-e45e-42cf-92ce-ccfdfaed9791">23.24</ix:nonFraction>, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i4c2672144c2e4225a6d8963f053949a0" continuedAt="id81e263fd6234a14b7607b6772bb4576"><div style="margin-top:5pt"><ix:continuation id="ifcbc32e940064ebc813d3e87f88e2e34"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjg5NzhjNzIxZDhkYzQ0ODdiODkxNjViMmMxNzI5ZjkzL3RhYmxlcmFuZ2U6ODk3OGM3MjFkOGRjNDQ4N2I4OTE2NWIyYzE3MjlmOTNfMS0xLTEtMS0w_f8ca19ab-e799-4939-a87f-9e70aacc9891">3.5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjg5NzhjNzIxZDhkYzQ0ODdiODkxNjViMmMxNzI5ZjkzL3RhYmxlcmFuZ2U6ODk3OGM3MjFkOGRjNDQ4N2I4OTE2NWIyYzE3MjlmOTNfMi0xLTEtMS0w_fb61ef9f-e0f1-4975-8b0f-cf7a6656557f">81.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjg5NzhjNzIxZDhkYzQ0ODdiODkxNjViMmMxNzI5ZjkzL3RhYmxlcmFuZ2U6ODk3OGM3MjFkOGRjNDQ4N2I4OTE2NWIyYzE3MjlmOTNfMy0xLTEtMS0w_04f53bfc-1ea2-4a61-8ad9-e88b53294cc8">0.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if24be682ffa04df6b410bf2bdba494b9_I20210930" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjg5NzhjNzIxZDhkYzQ0ODdiODkxNjViMmMxNzI5ZjkzL3RhYmxlcmFuZ2U6ODk3OGM3MjFkOGRjNDQ4N2I4OTE2NWIyYzE3MjlmOTNfNC0xLTEtMS0w_27717c4d-ea94-4789-b62e-129013bec753">12.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjg5NzhjNzIxZDhkYzQ0ODdiODkxNjViMmMxNzI5ZjkzL3RhYmxlcmFuZ2U6ODk3OGM3MjFkOGRjNDQ4N2I4OTE2NWIyYzE3MjlmOTNfNS0xLTEtMS0w_00d5a8d3-bca2-4b98-ac6a-5ee026a1fee1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjg5NzhjNzIxZDhkYzQ0ODdiODkxNjViMmMxNzI5ZjkzL3RhYmxlcmFuZ2U6ODk3OGM3MjFkOGRjNDQ4N2I4OTE2NWIyYzE3MjlmOTNfNi0xLTEtMS0w_18fbe611-54d5-4b3a-8913-600cb024df9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock awards to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day&#8217;s closing market price of the Company&#8217;s common stock. During the nine months ended September&#160;30, 2021, the Company granted restricted stock awards totaling <ix:nonFraction unitRef="shares" contextRef="i8d5fc98033004eb0a900852b969e1fd0_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTQ0NQ_c6aa5c8f-3e42-4cd6-8c7e-dbe5301dcd29">159,267</ix:nonFraction> shares with a weighted average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8d5fc98033004eb0a900852b969e1fd0_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTUwNA_eb4d6680-72ea-4118-88c0-69e287416352">28.24</ix:nonFraction>. The grant date fair value of the restricted stock was $<ix:nonFraction unitRef="usd" contextRef="i83f1985914f0496ea8f8d5f1f4b62193_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTU2Mg_5db9be23-4fc1-4a9b-8512-98544e0ee176">4.5</ix:nonFraction>&#160;million and will be recognized on a straight-line basis over the awards&#8217; vesting period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTY0OA_28ab602c-7a29-4dcd-a454-db6a953fd86b">one</span> to <ix:nonNumeric contextRef="i75b1c7458b864e9b981a527bbfa8158f_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMjA3NQ_0fc9d1d1-3940-40d3-9db8-c4b47b934b96">three years</ix:nonNumeric>. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMjA3Ng_2f9dd22e-0794-457f-964d-0ceffc1f3af2" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMS0xLTEtMS0w_b3b22daf-82e3-4012-94d8-1b120417993a">1,878,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMS0zLTEtMS0w_f8d803a2-2ba4-4c4b-87aa-b92022b3a545">10.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1bc83e3bcab6489aa067dd6bbdb2afc2_D20200101-20201231" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMS01LTEtMS0w_83f15321-7389-4f42-ad21-6683c1966d8d">1.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMS03LTEtMS0w_65db6f68-e3ff-4bd4-bb47-6d0ad0a1e572">14,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="ameh:NumberOfWarrantsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMi0xLTEtMS0w_17ae7b38-71fa-43cb-87e6-cc1e087d49b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="2" format="ixt:fixed-zero" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMi0zLTEtMS0w_63348dc3-3d29-4672-8ccd-c0503c6eed17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMi03LTEtMS0w_003b9141-ffa2-41c4-86a7-91d449acd57b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:NumberOfWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMy0xLTEtMS0w_785bf67d-e7ef-489e-9f41-4a281214389c">624,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMy0zLTEtMS0w_da6e352d-9cc8-4cf3-a68e-b78b2ab8be34">10.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMy03LTEtMS0w_b4a6b54d-2486-4a3f-a9f6-1edea6dfd037">20,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants expired/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:ClassOfWarrantOrRightCancelledInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNC0xLTEtMS0w_74ae1d6b-34a6-408f-b97a-bbd33f7cfde0">17,803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNC0zLTEtMS0w_ceaef9c7-23b2-41c0-8836-edee57286ec6">9.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNC03LTEtMS0w_28fc9a50-50a7-40c9-8f95-d7c16a5a269f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNi0xLTEtMS0w_ab575686-739c-4ca1-bb4b-6686852f01e6">1,235,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNi0zLTEtMS0w_8ff709e3-60e8-4680-b0ff-b8056e8d29a9">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNi01LTEtMS0w_98024c6b-896e-44c5-900a-26a306728e23">1.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNi03LTEtMS0w_29b8e4c8-d0cb-401a-b6ac-be2d9160d589">99,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72d599d61813449280a927233fdb0405_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMS0wLTEtMS0w_646cb41b-dab5-45d2-946c-ea4cc7a96123">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4819d9b69dd44a989faef6c6cbbe20e0_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMS0yLTEtMS0w_1c5e5313-bc8f-4220-b406-742074fe70db">635,428</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4819d9b69dd44a989faef6c6cbbe20e0_D20210101-20210930" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMS00LTEtMS0w_6d4c90d5-bbfc-4d4b-a162-080d6eace000">1.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72d599d61813449280a927233fdb0405_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMS02LTEtMS0w_be27dc41-ea34-4b28-b01d-1bed4aa2e040">635,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72d599d61813449280a927233fdb0405_I20210930" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMS04LTEtMS0w_96879898-8d0e-4bd9-acad-032ccf3b3961">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01889397be3e428281f28320683c1430_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMi0wLTEtMS0w_53df2c6a-f093-4f19-8af1-57b12a5bf706">11.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22e30659b8d845b5bc23aafc96ddf13b_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMi0yLTEtMS0w_0a1f0d65-6313-4911-9790-5bbdcb441102">600,135</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22e30659b8d845b5bc23aafc96ddf13b_D20210101-20210930" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMi00LTEtMS0w_f72b05e9-e72d-49c6-b930-ce1028484d48">1.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01889397be3e428281f28320683c1430_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMi02LTEtMS0w_73d698fa-a900-4af3-b3e6-d423c8990566">600,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01889397be3e428281f28320683c1430_I20210930" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMi04LTEtMS0w_10a123d1-cb00-4eb8-b4c8-233b0fbf6a71">11.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                  <ix:nonFraction unitRef="usdPerShare" contextRef="ic3b55bbdae154354b76e9f0bf837e3d5_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfNC0wLTEtMS0wL3RleHRyZWdpb246MjQ2ZWFlYWZkMWQxNDcwZDgwYmExYWJkMGJjNjZmMmFfMjM_6c09370d-ba99-4c75-97d7-053826d758d5">10.00</ix:nonFraction> &#8211; <ix:nonFraction unitRef="usdPerShare" contextRef="ibf76fa460e274183b775eab34ea28a8a_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfNC0wLTEtMS0wL3RleHRyZWdpb246MjQ2ZWFlYWZkMWQxNDcwZDgwYmExYWJkMGJjNjZmMmFfMjg_647684e3-15f4-4464-900d-7e6320343fed">11.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbe9675fd54c4c248789b3ab515892fa_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfNC0yLTEtMS0w_3946f526-9d6b-4177-ba6a-c3be89dd21b7">1,235,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icbe9675fd54c4c248789b3ab515892fa_D20210101-20210930" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfNC00LTEtMS0w_6d904b12-faa9-4184-a866-8785ca6fe17e">1.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11d2613adfb84faeb941f179c4fb08a1_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfNC02LTEtMS0w_295d3111-0548-4317-af89-a465cc9137a1">1,235,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11d2613adfb84faeb941f179c4fb08a1_I20210930" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfNC04LTEtMS0w_b30a5c6a-334e-4ced-8e22-21bd9fde0f54">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id81e263fd6234a14b7607b6772bb4576">During the nine months ended September&#160;30, 2021 and 2020, common stock warrants were exercised for <ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTgyNA_71aa21c1-27ea-4cef-bbb8-960b9d7dfd44">624,760</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTgzMQ_a161f1e0-881e-4f1b-b16b-626bc5d31bea">800,709</ix:nonFraction> shares of the Company&#8217;s common stock, respectively, which resulted in proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTkzMA_3ef6c7fd-c5e0-46b9-98c2-8b950b69c836">6.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTkzNw_cd006e06-695c-44c2-a356-1d27ee460415">6.2</ix:nonFraction> million, respectively. The exercise price ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="id5e56d3070c14ba4a8f92e0c3ba9b04f_D20210101-20210930" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTk4Ng_6e48ebab-01fe-4391-a0bd-4ee9558e03cf"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e8ffc3fb93241efb949e02abb5a85f0_D20200101-20200930" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTk4Ng_a090a45b-d84d-4a3a-a558-05142fcc7ac1">9.00</ix:nonFraction></ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i64448178efd84c50aa3bacac86356338_D20200101-20200930" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTk5Mg_41be1f6a-0348-4eba-b48c-e756c0de51a0"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d9ad1e3f11440fbbd1039812179f70c_D20210101-20210930" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTk5Mg_6cfc5fea-cd9f-4327-82aa-ed7882911baf">11.00</ix:nonFraction></ix:nonFraction> per share for the exercises during the nine months ended September&#160;30, 2021 and 2020, respectively.</ix:continuation> </span></div><div id="i77048548a0c546beaa10a42c80553a71_100"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDAvZnJhZzo3MDQ2ODI1NDgzMzI0NDE0YjJmNDk0NjI3ZjY2OTk2YS90ZXh0cmVnaW9uOjcwNDY4MjU0ODMzMjQ0MTRiMmY0OTQ2MjdmNjY5OTZhXzM5MTQ_8fdf2e30-5ce5-42cb-88c2-68ac69d72f68" continuedAt="iae25de1ad9234a68b34e5739deebbf24" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="iae25de1ad9234a68b34e5739deebbf24"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California Department of Managed Healthcare (&#8220;DMHC&#8221;) regulations, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the payor and provider contracts with the Company&#8217;s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS. The guarantee generally must be in an amount equal to <ix:nonFraction unitRef="number" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="2" name="ameh:PercentageOfFinancialGuaranteeBenchmarkAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDAvZnJhZzo3MDQ2ODI1NDgzMzI0NDE0YjJmNDk0NjI3ZjY2OTk2YS90ZXh0cmVnaW9uOjcwNDY4MjU0ODMzMjQ0MTRiMmY0OTQ2MjdmNjY5OTZhXzE4NDY_89bd4ae6-d71b-40d6-9b56-20633187f57c">2</ix:nonFraction>% of the Company&#8217;s benchmark Medicare Part A and Part B expenditures. In August 2020, $<ix:nonFraction unitRef="usd" contextRef="i7886aad669f7475590e40c23c0dd147b_I20200831" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDAvZnJhZzo3MDQ2ODI1NDgzMzI0NDE0YjJmNDk0NjI3ZjY2OTk2YS90ZXh0cmVnaW9uOjcwNDY4MjU0ODMzMjQ0MTRiMmY0OTQ2MjdmNjY5OTZhXzE5MzM_fe0b0b79-6eb5-40bf-bb03-387847bc7354">14.8</ix:nonFraction>&#160;million of the irrevocable standby letters of credit were released by CMS and <ix:nonFraction unitRef="usd" contextRef="ibeb37dc642874abea221866138cc2490_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDAvZnJhZzo3MDQ2ODI1NDgzMzI0NDE0YjJmNDk0NjI3ZjY2OTk2YS90ZXh0cmVnaW9uOjcwNDY4MjU0ODMzMjQ0MTRiMmY0OTQ2MjdmNjY5OTZhXzIwMDY_45223160-5012-4868-adfe-cd78f5d01928">no</ix:nonFraction> amounts remained outstanding as of September&#160;30, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $<ix:nonFraction unitRef="usd" contextRef="i13fdfd16535e4f75a502075defa10c8a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDAvZnJhZzo3MDQ2ODI1NDgzMzI0NDE0YjJmNDk0NjI3ZjY2OTk2YS90ZXh0cmVnaW9uOjcwNDY4MjU0ODMzMjQ0MTRiMmY0OTQ2MjdmNjY5OTZhXzIxNDY_0c45482a-f915-4cb8-aa71-6149ee2a1edc">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia318b9c86cb8437086dadd8cd7bcfdb8_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDAvZnJhZzo3MDQ2ODI1NDgzMzI0NDE0YjJmNDk0NjI3ZjY2OTk2YS90ZXh0cmVnaW9uOjcwNDY4MjU0ODMzMjQ0MTRiMmY0OTQ2MjdmNjY5OTZhXzE2NDkyNjc0NDU2MTQ_617b91dd-483a-4644-a4da-57e6a019e778">3.8</ix:nonFraction>&#160;million, respectively, for the benefit of certain health plans (see Note 9). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div></ix:continuation><div id="i77048548a0c546beaa10a42c80553a71_103"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzQ1NDI_e371d572-0e11-46a7-8282-701f3fcec821" continuedAt="id11cb2790eb54a7480673de75c365c41" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id11cb2790eb54a7480673de75c365c41" continuedAt="i63ae021d9689436a8996593a904194f1">During the three and nine months ended September&#160;30, 2021 and 2020, NMM earned approximately $<ix:nonFraction unitRef="usd" contextRef="ic4dcff1f010e404e963a5a4fee776b5c_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzEwNw_71810d5f-f764-4a4f-93d1-e39a448a6ed0">4.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i342b9208e4894d718c1b127a0a3ff4fb_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzExNA_ce4b86bb-311e-4d58-85d8-33e4188a64ba">4.2</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="icece2b97c5c941d3af2e6952b3212f8d_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzEzNg_60105e5f-9248-4772-98f5-d9bda164c0de">13.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i40def8e50b1b4db5bd03f6203dc8a1a7_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE0Mw_2d061019-f708-4c6c-9941-3c9996374f51">12.6</ix:nonFraction> million, respectively, in management fees from LMA, which is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="i471239abb6364a489ec282dd9c5f777c_I20210930" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI0Ng_48812cbc-ef0c-44fe-8166-0ded907d876b"><ix:nonFraction unitRef="number" contextRef="i148d26d55f8f435b9874038459f936e1_I20200930" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI0Ng_bc95016f-7e59-4109-b629-32c725437c8f">25</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5).</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i63ae021d9689436a8996593a904194f1" continuedAt="ie5117ba76ba344d589a28c9900b988c3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="if752ba09e479448bb94fbca2c7882209_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM5OQ_ba88a58a-4de7-4ab5-a8c6-494afddb055c">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib35d85fe21db4cfb8b79e5c7ee1228c3_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzQwNg_0fb3a89c-0017-4473-bc2b-dc6800d95233">0.5</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i1b9b3c7021d744e9b32b81acaaf16e56_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzQyOA_7a408a8c-4ba4-47d9-9172-993aed48ea42">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i58aaac3be5054957bf60bbd75029f96c_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzQzNQ_edd43cf3-5007-4591-b17f-17b10fa399fd">1.5</ix:nonFraction> million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="i3f003a8cc01d41348437b13692cef86c_I20200930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzU0MQ_c413147d-f5b0-40e4-9380-80ec4cfc98e9"><ix:nonFraction unitRef="number" contextRef="ie68ce3d93d494b71998ca2d6f07d2c77_I20210930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzU0MQ_d93f26ad-8338-46f5-8250-111534fb8fc9">40</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC (see Note 5).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i3a7e5a8570084a00adb32a4bdb60bbd1_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzY2NA_a537f79c-1d66-423d-95b5-4005fa8fb614">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8b2df61df72d41dab21cfae235327e40_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzY3MQ_320969cb-3f3f-488c-9ccc-7df0353086f3">1.2</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i10f15782af0443ab842ba194eb8c55f8_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzY5Mw_7d002d4f-b7c7-4df3-a039-ccf52d2d520f">5.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iee30b0d2253f4bb492015b9d7da0adb5_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzcwMA_ac7a8b60-6150-4773-bb27-1f678e3a22de">3.8</ix:nonFraction> million, respectively, to DMG for provider services, which is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="i4dbf0fd1b79a4e77bdd4836d453ae1b0_I20210930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzgwNA_7777d488-b0d3-4d66-ac64-5eefbc036aa2">40</ix:nonFraction>% equity ownership interest held by APC (see Note 5).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="if47df11b72db4b389d16b2265853b9c2_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzkyNw_946bc8d2-bf9d-45e8-8e48-d3cffbdd634b">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1993cd5de17942f99b55c5e4dae41d86_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzkzNA_0baacd78-ac49-4d73-9142-8d63a1de8b8c">0.1</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="iec1fb7fa46f34dd39ecfb564894305ee_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzk1Ng_038cb298-79c9-471a-9d3a-41c026745deb">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7395056c59fb49af99bb8cde1bd98437_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzk2Mw_a28d147b-ce4c-44d2-a9f5-57276a6303ef">0.2</ix:nonFraction> million to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i25917a62f9c2433c936ab8aefbd468c7_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzExOTQ_c8f6df1b-cc32-4bf9-9783-587819fbee18">24,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ied011d8645e3412aa2f3e2387b1cb1a9_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzEyMDE_6f754deb-bb9f-4f04-a8b2-cf420e9e94e4">23,000</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i23b30d2846b14b2c897a80d786dde119_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzEyMjM_ebffbf90-68b5-496e-b5b6-deb79c6f9a46">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia6896fdcb8ae4b7ca99bd00de7787507_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzEyMzA_f7e01749-78fc-4625-8486-384a58139a3b">0.1</ix:nonFraction> million, respectively, to Fresenius Medical Care (&#8220;Fresenius&#8221;) and its subsidiaries for services as a provider. During the three and nine months ended September&#160;30, 2021 and 2020, APAACO paid approximately $<ix:nonFraction unitRef="usd" contextRef="ib5a867cf070d443da348b27bcc09a6f9_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE0MTA_8796d96c-aa53-4dc5-9a35-16548dfc1e73">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibdfaf156fde64914862fc81410e5c63a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE0MTc_aec2a98d-c6bf-416d-b497-04a85c502454">0.2</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ib523d137eddc47e29f0030b185a7b372_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE0Mzk_3559e760-8274-4aef-a12a-c6cc813b5818">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1b5a146f0b1e44f5b789255f0c543e0b_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE0NDY_beafa884-9523-4c25-8703-ebab5c6e094c">0.5</ix:nonFraction> million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company&#8217;s board members is an officer of Fresenius.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i173a4dea7cb24055b072519c2bdfe757_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE2NTg_6399b1f6-d594-4756-bc64-07735e6392cd">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i54147940fa7a4e1fab0ebc8efdde6b95_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE2NjU_104639e6-ccc7-475c-8d97-3424ea67b599">0.1</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i21dc815a2c734a16a45443053949a1ac_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE2ODc_28038777-82f7-4699-8599-5fcd6ed890cc">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifd69f4d08ad148e9ab3a76b73d5a7b44_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE2OTQ_82e58db3-0e34-4942-bf26-10d29144ee3a">0.1</ix:nonFraction> million, respectively, to Fulgent Genetics, Inc. for services as a provider. One of the Company&#8217;s board members is a board member of Fulgent Genetics, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, APC paid an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="ie5c8495e26684dcc9ad519449c4bc3ec_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE5MTM_c5308740-f380-43d0-8999-143ca56aa62d">10.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3b9a649b9c8c46d6880482c83fb0ff4c_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE5MjA_f3cddece-831a-4cb8-9493-796fdbafd590">7.1</ix:nonFraction> million to shareholders, respectively, which included approximately $<ix:nonFraction unitRef="usd" contextRef="i478b087008894447ae487fe130dd89e6_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE5ODM_77c4c879-b026-46f5-98fa-744dbccc5d99">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icafd606f127347a5a215b6401a63da94_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE5OTA_3d8b8789-17f0-454a-8f09-c5147bd6c43c">1.7</ix:nonFraction> million, respectively, to shareholders who are also officers of APC. During the nine months ended September&#160;30, 2021 and 2020, APC paid an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i5f3ab4e5a41043c2ae92af6c8f11dc34_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIxMzE_08278ff4-0196-4c50-8029-a901f2e461eb">25.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib124a96ecc074da29278d04a4d7de485_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIxMzg_2f1c1228-b702-4786-bcfb-bfc18745066c">23.4</ix:nonFraction> million to shareholders, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ifb0c1db1b2d84d2fa57edc7c15d4fac4_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIxNzY_c41f697f-a8c8-4b5c-8ed2-513023caab75">5.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i51e4bde9a34f42159e327cca1a631656_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIxODM_d8c25a4e-3c88-4cb5-b131-0db73850756f">6.5</ix:nonFraction> million, respectively, to shareholders who are also officers of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, the Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="ic03d35847f734105a48e1318bda34af3_D20210701-20210930" decimals="-3" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIzMjQ_d7402942-8d80-4ba0-87f9-d1eb0645eb9c">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7eb15316a75740d3a7e2f2bb4ec65285_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIzMzE_c2eba0f7-b7da-45c0-b87d-33f6bc3b79a2">39,000</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i2d0b297b84754d2ba32a089d68928fe4_D20200701-20200930" decimals="-5" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIzNTM_0bc50cd3-2c07-4f51-890d-7003d8eb1311">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i95582f9ab23c40c88ff9c9aa11e8368c_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIzNjA_f1aec528-8c85-4fbd-9990-b899b676c056">0.3</ix:nonFraction> million, respectively, to Critical Quality Management Corporation (&#8220;CQMC&#8221;) for an office lease. CQMC shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2021 and 2020, SCHC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i516478a0add344df8b418bb1e41a3d53_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI1ODE_3e16e54d-814e-4f7b-9df7-a07a170e77e2">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i01d16bcfadca4f16a85f305b306f3af5_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI1ODg_9e34e200-528c-4056-abb5-1c60b008b66d">0.1</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="icb8612b46bf04b23bb32513fb5f4e06b_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI2MTA_f2c3868f-b56c-49c9-a344-4ba39dc0b978">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0a1d28025a574e8f8c021b319564a04e_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI2MTc_d90163a1-1476-4ed3-ad4d-289a4d75b009">0.3</ix:nonFraction> million, respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine ended September&#160;30, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="if6dfbbc083a24b1fb873315d3843b5bc_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI3ODI_52cf86b3-763a-46a6-b9af-c2dc9c577710">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia126933eaa88475f8ca99bc2e342801d_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI3ODk_3c25f2ad-fd35-4b4d-ad31-1e0b4a0de6b0">0.4</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i5fe5c8cca1584e10a27f094882462ec4_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI4MTE_bec7e36d-3517-41d5-a47f-ad4ebef12743">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82d32e9e52cd43b8bde097d8ad4cf68d_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI4MTg_92eebc3b-ba94-4e3f-8296-bbd63e9a4d81">1.1</ix:nonFraction> million, respectively, to One MSO for an office lease, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="i11c0bdbc45944c189d1902dd97e0b2c5_I20200930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI5NDI_342ce120-e035-40e8-86fd-132c209c99ff"><ix:nonFraction unitRef="number" contextRef="i33c01da554a346699ef38852e5a9238e_I20210930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI5NDI_e615ace2-0bf7-44fb-807c-6c75165bbd76">50</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC (see Note 5).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;), Aurion Corporation (&#8220;Aurion&#8221;), and AHMC Healthcare Inc. (&#8220;AHMC&#8221;) for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzQ1NDY_004dc216-32f3-4acd-a55e-52425abe723d" continuedAt="i9a2c3dcd95ce43ec8ca22bbdd4bde450" escape="true">The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i9a2c3dcd95ce43ec8ca22bbdd4bde450"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6956147d1b1d44068bcecf36bebb1819_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzItMS0xLTEtMA_1e5cb734-ed4d-42f0-95ac-cb58c53ed93e">10,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8aacaa10644e039ce5c4b96322fc8b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzItMy0xLTEtMA_98d6fa45-9ca7-488c-9ae8-2a2cc88d4c2f">5,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4380cb2b0e24e1994d0661bb4241a61_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzItNS0xLTEtMA_f40a59e9-1379-45fd-878e-b6d03b91af63">36,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fe20fe658aa4256aabbbd2c89d398ea_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzItNy0xLTEtMA_b7ae4512-223f-46a9-ae9c-b0f6561d7679">23,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae1ae82bc8db4b2d995d2be127951787_D20210701-20210930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzMtMS0xLTEtMA_5941ac5a-5ad2-428a-a2a6-8b259c9ad3fe">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9491c7189f4bc1a3a03bbff2758fdf_D20200701-20200930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzMtMy0xLTEtMA_62921fd0-8a16-4ed4-a7dd-bd5e81ec54cb">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aa407ed2a23431cb3c6911df6e8bf96_D20210101-20210930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzMtNS0xLTEtMA_e3dac50a-3b7f-4519-95e6-eab90e10dbc5">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea3d25188b02481c84d1af0e34e1d2f0_D20200101-20200930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzMtNy0xLTEtMA_1dcabc52-bb17-4048-b740-709586b7f7e4">430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b7b7c8fa79242e4b1f9fd2aed295aac_D20210701-20210930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzQtMS0xLTEtMA_813fc5d4-a7ff-40d5-83f9-564e285b4701">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2ed3ce186f64ecd9e26858f4e56cbaf_D20200701-20200930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzQtMy0xLTEtMA_278f6f2c-e42d-4759-bf0c-bed35245cd71">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i699b0a24650b4020ab36add96e94ba16_D20210101-20210930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzQtNS0xLTEtMA_050a4260-0a3f-4fff-98d1-8c5adb427403">252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df4d6d4265646919c8679d06c6f5f8d_D20200101-20200930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzQtNy0xLTEtMA_6c7f5ccd-f299-45ac-8b6b-67fc8d8830ad">228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzYtMS0xLTEtMA_d16f2ecc-f6da-45de-8bb8-4dd33bbe093a">10,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzYtMy0xLTEtMA_351f560d-1234-4a08-b7f9-725d59d61f4c">5,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzYtNS0xLTEtMA_4e06a118-d44b-4864-8ced-05292fa88071">36,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzYtNy0xLTEtMA_25ce00a1-59c0-4d94-8792-cc2bf9b495e3">23,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and nine months ended September&#160;30, 2021 and 2020, the Company has recognized risk pool revenue under this agreement of $<ix:nonFraction unitRef="usd" contextRef="i6956147d1b1d44068bcecf36bebb1819_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM3MTQ_ad1bc8a3-a780-4010-b5b9-869c1cb10448">21.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia4380cb2b0e24e1994d0661bb4241a61_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM3MjE_c694884e-48ab-4d4f-9632-3981d9a80575">10.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i3e8aacaa10644e039ce5c4b96322fc8b_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM3NDM_d1d558c6-e660-4108-9f59-eb2ab50a99db">47.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9fe20fe658aa4256aabbbd2c89d398ea_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM3NTA_97145e65-287e-4345-964b-16a8132b4e97">31.5</ix:nonFraction>&#160;million, respectfully, of which $<ix:nonFraction unitRef="usd" contextRef="i6847bf6720074c31bb84ab647a20bce7_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredCreditsAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM3NTQ_b42572d7-a9e5-42de-8aa1-70841d040f09">47.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7c8b780248c2455fb8dd5302f1cc8305_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredCreditsAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM3NjE_7a949cd3-3f3c-4e79-a2f9-e4c00ebeec53">45.3</ix:nonFraction> million remained outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ie5117ba76ba344d589a28c9900b988c3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021 and 2020, NMM paid approximately $<ix:nonFraction unitRef="usd" contextRef="i4f9ab052b3f24f16b3cdc5fc945ba7a2_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM5MTQ_8ed1299e-4316-48a2-8416-35520c9ad51b">44,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idb0ef53cb71e453a995be937fb48b3a6_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM5MjE_85b66301-bcac-4e01-86c1-91497d41670f">27,000</ix:nonFraction>, respectively, to an ApolloMed board member for consulting services. During the three months ended September&#160;30, 2021 and 2020, there were <ix:nonFraction unitRef="usd" contextRef="i447f7dcce84d4cebb5acb882ea34ecbb_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM4NDgyOTA3MDQxODA_21b30c3c-711d-4b96-8c55-06f354cd47da"><ix:nonFraction unitRef="usd" contextRef="i5973967987a64974bf0b313e96b45d1b_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM4NDgyOTA3MDQxODA_e145f581-0fd4-411c-bf16-1ad535991d75">no</ix:nonFraction></ix:nonFraction> payments to such ApolloMed board member for consulting services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s officers, including the Company&#8217;s Co-CEOs, Dr. Kenneth Sim and Dr. Thomas Lam, are reported in the accompanying consolidated statements of operations on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments, loans receivable, and line of credits from related parties, see Notes 5, 6, and 9, respectively.</span></div></ix:continuation><div id="i77048548a0c546beaa10a42c80553a71_109"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDkvZnJhZzo4MGY4YWQwZTRhZGM0OWVkODIxODI3YjY1ODk2OGFkNi90ZXh0cmVnaW9uOjgwZjhhZDBlNGFkYzQ5ZWQ4MjE4MjdiNjU4OTY4YWQ2XzI0Nzk_2faab9d5-14e9-442a-bfef-947d234d3ccc" continuedAt="id004d10dfe794e77a2127ed8a0ed6e4d" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="id004d10dfe794e77a2127ed8a0ed6e4d"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for the nine months ended September&#160;30, 2021 and September&#160;30, 2020, was <ix:nonFraction unitRef="number" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDkvZnJhZzo4MGY4YWQwZTRhZGM0OWVkODIxODI3YjY1ODk2OGFkNi90ZXh0cmVnaW9uOjgwZjhhZDBlNGFkYzQ5ZWQ4MjE4MjdiNjU4OTY4YWQ2XzE1NTQ_003dca79-0b71-44c7-b00f-18636dfe393a">31.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDkvZnJhZzo4MGY4YWQwZTRhZGM0OWVkODIxODI3YjY1ODk2OGFkNi90ZXh0cmVnaW9uOjgwZjhhZDBlNGFkYzQ5ZWQ4MjE4MjdiNjU4OTY4YWQ2XzE1NjE_32e025f6-998b-4546-ac51-b966973e6f63">28.8</ix:nonFraction>%, respectively. The tax rate for the nine months ended September&#160;30, 2021, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2016 through December&#160;31, 2020, and for the years ended December 31, 2017 through December&#160;31, 2020, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.</span></div></ix:continuation><div id="i77048548a0c546beaa10a42c80553a71_112"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90ZXh0cmVnaW9uOjI2OWFjMDM0ODVlOTQ3YjNiN2JlMzA2NjdkZDk0NTBjXzExMTU_2a6c9316-d372-4e86-9cf9-aa20b9eeb7d7" continuedAt="i3bf71d59097b457bae8f1b1e09e85ba3" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="i3bf71d59097b457bae8f1b1e09e85ba3" continuedAt="i7917910f8f334b469bd7cb8c019e9dc6"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, APC held <ix:nonFraction unitRef="shares" contextRef="ia1bd75ff5a784460bc879854f3dc5e14_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90ZXh0cmVnaW9uOjI2OWFjMDM0ODVlOTQ3YjNiN2JlMzA2NjdkZDk0NTBjXzcyNw_447bacae-22c7-45a4-9d76-9563d1fb4782">10,925,702</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id082ef37853342dbafac08634c15ffe0_D20200101-20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90ZXh0cmVnaW9uOjI2OWFjMDM0ODVlOTQ3YjNiN2JlMzA2NjdkZDk0NTBjXzczNA_f93a0675-96c2-4a24-b802-e5df957bd727">12,323,164</ix:nonFraction> shares of ApolloMed&#8217;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i7917910f8f334b469bd7cb8c019e9dc6"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90ZXh0cmVnaW9uOjI2OWFjMDM0ODVlOTQ3YjNiN2JlMzA2NjdkZDk0NTBjXzExMTc_38b24c5a-499b-4919-8bea-db5bc4a50986" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzEtMi0xLTEtMA_49c4cde8-8abd-44bd-afa2-c1bca752f205">0.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzEtNC0xLTEtMA_23c64d35-252e-42c0-a49e-25967a31c831">0.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzItMi0xLTEtMA_9b107943-0056-4f8c-824a-729615acfc5e">0.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzItNC0xLTEtMA_dc24899e-2c56-4f0d-aa98-1e05f2fd3ad9">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzMtMi0xLTEtMA_d45ced46-c086-418a-ac3a-c21fca022cb2">44,301,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzMtNC0xLTEtMA_5ad832c8-c967-4d09-b7b8-69740104f487">36,364,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzQtMi0xLTEtMA_ae1368c1-edaf-4b51-ad45-8930c3daf66b">46,273,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzQtNC0xLTEtMA_1d2a509e-2ec2-4a99-91b4-844ab2850dba">37,551,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:71.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzEtMi0xLTEtMA_2c15b048-7548-4310-9e74-93d2834b3fc1">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzEtNC0xLTEtMA_7f9623c8-4383-4d31-84cb-63929048593b">0.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzItMi0xLTEtMA_56c70f49-b3d9-4904-a359-2a4856c78fc4">1.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzItNC0xLTEtMA_1548ef3d-f376-4341-9d93-1217fa324ef9">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzMtMi0xLTEtMA_2b86f5a9-114b-40e9-850d-a35785114aa9">43,608,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzMtNC0xLTEtMA_1082fb12-4dff-489c-aa90-3d304fea273e">36,149,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzQtMi0xLTEtMA_fea4bcd5-ee04-4b6b-9942-9cdba35a48e0">45,339,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzQtNC0xLTEtMA_9cf8a4c1-3342-420c-aa77-1eb76fa63a37">37,249,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90ZXh0cmVnaW9uOjI2OWFjMDM0ODVlOTQ3YjNiN2JlMzA2NjdkZDk0NTBjXzExMTI_a2ec5795-9963-4337-959c-faa44af6d2b4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzEtMi0xLTEtMA_a8a502b9-aaa2-48e3-8b8b-6ca52e682d90">44,301,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzEtNC0xLTEtMA_b134d3fc-df5b-4a7f-abb5-287646090a22">36,364,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1b43cafde674d70aa71314660d7da57_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzMtMi0xLTEtMA_0759806a-7818-47fd-aa5f-384a8d6201de">583,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i852e3ec3537a4c119c5f8a22d38b551a_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzMtNC0xLTEtMA_afe0c555-eba6-4605-ae4e-b85f036e8185">187,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0047fe9e823452fb45b32fabf79ea46_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzQtMi0xLTEtMA_3bba995c-2ae7-4135-bfef-d816e7a373bd">1,083,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ef913adaabe443884d85c0a2a9ace03_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzQtNC0xLTEtMA_182f02df-ec56-4764-ab87-73a0cc928af0">960,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0932a147a2f4eaaaf31703eddb2b244_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzUtMi0xLTEtMA_5ba6ddae-ed65-42ea-b202-3be023cec8d7">305,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic947409b267649339b37e4b534577ae3_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzUtNC0xLTEtMA_08ea9669-eee4-45ea-a130-923891f7834d">38,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzYtMi0xLTEtMA_7fedcc25-2750-40ca-b8e9-03a545f7fefd">46,273,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzYtNC0xLTEtMA_253d045a-8838-4dde-a9c6-b81519d8e23a">37,551,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzEtMi0xLTEtMA_52feb3d1-b9b4-46a5-aecc-86a87f18f1a2">43,608,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzEtNC0xLTEtMA_228158eb-9103-403b-a85a-0ddedbde61de">36,149,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c285663f977492290e465d3a04c4a3d_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzMtMi0xLTEtMA_82f3286e-b457-4441-941c-69dc265a1bac">498,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d3b34a11c90439a83c552a032829eb0_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzMtNC0xLTEtMA_c0c8b0e3-9d54-4ce4-adce-64bc6fbd8e9c">178,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56d750657b42421a8e440b3dd05fd4dd_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzQtMi0xLTEtMA_965a8b13-a0eb-4310-9ea2-403c7bf98c97">971,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib67e38d8ef3944d2b52b5cddc0110cf3_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzQtNC0xLTEtMA_213d82ad-8b0d-478b-a275-781cb312bc14">890,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a5bb1b525984a4b94e3835c3d3c958d_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzUtMi0xLTEtMA_7c8688e3-c2e5-4ce7-82bd-2a0f6af2f58b">261,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36efa1094ce84f39a33d944df471c9bc_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzUtNC0xLTEtMA_dd51e457-0717-4105-bd82-8f604e78aa2d">31,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzYtMi0xLTEtMA_1e97afb8-bccb-4ebb-82de-7f8377fd943f">45,339,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzYtNC0xLTEtMA_8d3c3b0d-4bb0-4df0-a89a-0684a5afe0d1">37,249,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i77048548a0c546beaa10a42c80553a71_115"></div><div style="margin-top:10pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90ZXh0cmVnaW9uOmM0N2E3ZjJmMDgwNDQzMTI5Y2M5NzE2YWJmNWI3YWM2XzE5MTY_d20e369c-0bfa-4f8b-9bd6-f74212ce9b81" continuedAt="ibc142b749a524c43b76dda93550c9d86" escape="true">Variable Interest Entities (VIEs)</ix:nonNumeric></span></div><ix:continuation id="ibc142b749a524c43b76dda93550c9d86" continuedAt="ic2d50ba28bcc4f98be37ba82a21497fd"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Variable Interest Entities&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and their treatment.</span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90ZXh0cmVnaW9uOmM0N2E3ZjJmMDgwNDQzMTI5Y2M5NzE2YWJmNWI3YWM2XzE5MTM_65cce0f9-9270-461d-adf4-1b45b20d9a8e" continuedAt="i0faa6cc86be94f259b2a8f10a1c343ea" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#8217;s other consolidated VIEs were not considered significant. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQtMS0xLTEtMA_1128f282-c56f-4570-b3cd-919c98695676">121,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQtMy0xLTEtMA_b9a93b96-c990-4b5c-8ed6-0580f4e0d301">126,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzYtMS0xLTEtMA_1189dc89-3ae0-470e-b5eb-3fd844862a9d">124,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzYtMy0xLTEtMA_f5c224c3-0c4c-4449-8156-4f7318df5ea5">67,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzctMS0xLTEtMA_11d65af9-ffdb-48bc-b05b-ff068ede8721">15,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzctMy0xLTEtMA_201ba4ff-676c-41d1-a52f-f9dfeba2e68d">5,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzgtMS0xLTEtMA_a1a31332-7bf8-4a82-8488-da92d1a0cffa">50,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzgtMy0xLTEtMA_dde676fe-d92e-4814-86e3-3174b620b94c">46,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzktMS0xLTEtMjkxMzQ_f3b5ff23-b4f4-435e-aab3-bfefc45eb62e">4,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzktMy0xLTEtMjkxMzQ_7926a09f-347f-4233-b044-9ea8f00955e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzktMS0xLTEtMA_ada1a9c0-c869-4f08-b216-0dd11a991ae5">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzktMy0xLTEtMA_32f4bfba-465b-4cb5-b3e2-ec1ec1a5426b">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzEwLTEtMS0xLTA_a38dc82e-8ca3-4bb9-bc51-01cdba280121">9,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzEwLTMtMS0xLTA_6d5ed2da-1db0-4916-bfac-ed6fffaf26da">14,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzEzLTEtMS0xLTA_bc9669ad-9778-437d-8bf5-c50302050803">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NotesReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzEzLTMtMS0xLTA_336821d6-fb44-4718-b66e-299a01c3dde8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due from affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DueFromAffiliateCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE0LTEtMS0xLTA_acc71875-8909-4b3e-8d3f-7da414bb49b6">15,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DueFromAffiliateCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE0LTMtMS0xLTA_7a5ab83a-252f-49ee-bc8b-fca775648939">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE1LTEtMS0xLTA_83c6e474-6177-4c95-8917-b46fc0db95c0">346,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE1LTMtMS0xLTA_d427cbea-fb0b-4615-9713-65788fe7cd88">261,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE4LTEtMS0xLTA_5a7f620f-c751-496e-ba06-cfb68129bff9">47,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE4LTMtMS0xLTA_eaff5de0-3fa7-40ae-b51a-48912f1f8ee3">27,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE5LTEtMS0xLTA_677b985b-4896-461a-b05f-7bbb999d9189">61,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE5LTMtMS0xLTA_3e338e23-4059-4fd8-9f54-40ca9c9df6b1">69,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIwLTEtMS0xLTA_59c566a4-9ac7-4184-9c91-9c0f945ab7e0">109,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIwLTMtMS0xLTA_7a7ec3b6-1f23-4199-88c9-1da455aa99e9">109,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIxLTEtMS0xLTA_824dcd79-d0f9-436f-8acb-8c4f5b075521">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIxLTMtMS0xLTA_d2990072-910c-4a5d-9664-3bcce6cc01e0">4,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIyLTEtMS0xLTA_a3790c39-ebeb-44fc-950f-79dda6a6f451">994,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIyLTMtMS0xLTA_6777943d-e6d1-4309-aa6d-773e7004f1a2">225,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIzLTEtMS0xLTA_42d6419a-61af-4256-a98c-d82c931df827">45,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIzLTMtMS0xLTA_41bbb638-d424-4926-96f0-b267aac0302a">43,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI0LTEtMS0xLTA_8bf8d93b-d4bd-4052-8a8c-4b726592638e">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI0LTMtMS0xLTA_036f8695-e672-4d12-b81e-0a863a5571c4">36,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI1LTEtMS0xLTA_4c540d57-90ac-4baf-8bfb-aa2a43ee42ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI1LTMtMS0xLTA_c4fe6333-674b-4df9-a34e-4338ae049070">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI2LTEtMS0xLTA_56d891bc-3ad9-4925-b706-d27592c601fc">5,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI2LTMtMS0xLTA_22e50072-dd26-44ef-96fb-44e1d1c75e6c">6,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI3LTEtMS0xLTA_f4a843e9-9df8-4753-8b68-1f74f5404f9b">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI3LTMtMS0xLTA_f87475d6-7901-40d9-993c-640143f3b500">17,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI5LTEtMS0xLTA_864e753c-f4d7-4601-b92b-a91a19ebf35b">1,265,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI5LTMtMS0xLTA_32ea4950-024c-48ad-9d29-8476c690db07">539,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzMxLTEtMS0xLTA_65447f52-9292-44a2-b11d-10abe2b89810">1,612,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzMxLTMtMS0xLTA_ff1be1fe-36c4-4241-8263-3c6326b82b95">801,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><ix:continuation id="ic2d50ba28bcc4f98be37ba82a21497fd"><ix:continuation id="i0faa6cc86be94f259b2a8f10a1c343ea"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM0LTEtMS0xLTA_e11b244c-e8fe-49f7-868e-344e63012828">15,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM0LTMtMS0xLTA_675f1604-9fa5-4347-8e9e-f99a4de1e3bb">12,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM1LTEtMS0xLTA_dbe5cf7c-b75c-4422-8908-ea111a43397a">8,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM1LTMtMS0xLTA_22628707-a4a9-4851-a1dc-83e37878fd86">9,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM2LTEtMS0xLTA_1dc29460-a5dd-4165-9012-ebb4a2af71c4">34,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM2LTMtMS0xLTA_dc797418-90e5-417e-8ad1-f0dbb6822628">37,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM3LTEtMS0xLTA_4f29bd7a-e993-4335-997b-e7e9e1411344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM3LTMtMS0xLTA_1e454a82-1e5a-403f-bd4e-92723a25fd7c">4,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM4LTEtMS0xLTA_91968cbd-1731-48d3-946c-366e54ae9a7d">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM4LTMtMS0xLTA_2193de96-4ae8-4831-8033-34234e412670">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DueToAffiliateCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM5LTEtMS0xLTA_b45d142a-7287-4b40-b8c1-e1d2b5d66730">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DueToAffiliateCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM5LTMtMS0xLTA_1f06bdfe-55d6-46d7-b724-19f955db0a97">22,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQwLTEtMS0xLTA_501dd3dd-228d-466c-a8ef-e1880346f559">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQwLTMtMS0xLTA_416e6aa8-6e2f-4ea9-8d90-01d887bc7d9d">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQxLTEtMS0xLTA_7cb467b3-8505-4857-a144-53e3982f2b6f">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQxLTMtMS0xLTA_893f9880-950b-4c4f-9b61-664b463b1985">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQyLTEtMS0xLTA_c76ad574-e57e-4988-be99-3afe54914132">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQyLTMtMS0xLTA_c8f9eb40-5bde-40d4-a113-9a7d740a9030">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ0LTEtMS0xLTA_56df6159-0c7b-4b17-a693-c0e8db183532">61,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ0LTMtMS0xLTA_d3b94ce0-8fff-4029-8d25-d48227d9e9c7">89,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ3LTEtMS0xLTA_1246024a-a32c-4ad1-be7c-8d645b04f50c">7,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ3LTMtMS0xLTA_ce170a0b-fb4d-4b31-ab56-6a6fb97833cb">7,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ4LTEtMS0xLTA_6e9a26c8-8dea-4f31-b7a8-4c5ef8b8fe7d">18,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ4LTMtMS0xLTA_63f81412-fa02-412c-baf0-46de6bebb73b">9,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ5LTEtMS0xLTA_e172b868-5b98-42d8-92fa-ff1b5eb4cc73">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ5LTMtMS0xLTA_c69a86a5-3c40-441e-ad58-e8c344f167a6">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzUwLTEtMS0xLTA_2d0ae06e-ef9a-415b-aa0c-a42c516f02d5">4,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzUwLTMtMS0xLTA_7be27547-14de-4ff5-885a-19c8d854ba75">5,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzUxLTEtMS0xLTA_63ab0148-7300-4ad9-a74c-d0b0b1c79da4">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzUxLTMtMS0xLTA_f73a16e6-e853-491f-80d1-0e712b9a7c48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzUzLTEtMS0xLTA_b756c984-d0ec-45cf-b85b-da18b7b2d674">31,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzUzLTMtMS0xLTA_7ca2277a-ad8e-4fc0-be52-db735faa7fe1">22,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzU1LTEtMS0xLTA_29cbd84f-438e-4a0a-9288-8fb2a0924ace">92,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzU1LTMtMS0xLTA_860e6811-ad29-472e-b03c-a66d24f316b7">111,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i77048548a0c546beaa10a42c80553a71_118"></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzEwNjE_20c74ba0-ee8a-4d1c-832e-a454f455074b" continuedAt="i35486e0c3979451f92d96d3783e12b5c" escape="true"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzEwNjg_bb605654-caa7-483e-aaff-85b617e84ab3" continuedAt="idb796eaf70a84ef78c7b43ac58e63ff0" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i35486e0c3979451f92d96d3783e12b5c" continuedAt="ic61af6b1c00c429da9b37cd6f2801ca3"><ix:continuation id="idb796eaf70a84ef78c7b43ac58e63ff0" continuedAt="ib8fb4be763ec435bba11e6ec7a068890"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of <ix:nonNumeric contextRef="ib6cab8e82bce461aadf4a8285aaedf2d_I20210930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzE3Mw_67f3f515-b662-43b5-8f9d-054bd9b94733"><ix:nonNumeric contextRef="ib6cab8e82bce461aadf4a8285aaedf2d_I20210930" format="ixt-sec:durwordsen" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzE3Mw_9c215b35-3190-4102-b0a8-1d0bdb1d92f0">one month</ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="i396303604fe24b649811f19aa1b86666_I20210930" format="ixt-sec:durwordsen" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzE3OQ_1ab50a1d-bc4e-4ca1-a575-e55e3867f654"><ix:nonNumeric contextRef="i396303604fe24b649811f19aa1b86666_I20210930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzE3OQ_229c689d-ead4-4bb8-9aff-46d1e7fb0fbc">five years</ix:nonNumeric></ix:nonNumeric>, some of which may include options to extend the leases for up to <ix:nonNumeric contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzI0OA_e997c0d6-11c2-4924-a578-68ebad08d82f"><ix:nonNumeric contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzI0OA_ed643b88-b0ad-46bc-ab63-38ec79b67ae0">10</ix:nonNumeric></ix:nonNumeric> years, and some of which may include options to terminate the leases within <ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:durwordsen" name="ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzMyNw_767b6ba6-334c-4275-ba01-28c2123c1788"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" format="ixt-sec:durwordsen" name="ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzMyNw_a036cfa7-d834-4042-8f52-386637034f2c">one year</ix:nonNumeric></ix:nonNumeric>. As of September&#160;30, 2021 and December&#160;31, 2020, assets recorded under finance leases were $<ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzM5MA_73a7a900-d681-4337-9933-c3ce34ffd0d0">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzM5Nw_0347fbea-36ef-46de-9020-6c3bdc0f6495">0.4</ix:nonFraction> million, respectively, and accumulated depreciation associated with finance leases were $<ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzQ4MA_9690e4f3-0416-4d39-bcab-610c3b3020c6">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzQ4Nw_b831f37b-b0fe-43e5-a6ea-54bca0625ca2">0.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzEwNjQ_5f46b5ec-d98a-47e8-b16c-0363412542d8" continuedAt="i88b1b11d00a64013a7392e30b4404324" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzMtMS0xLTEtMA_300e26a4-6791-4ac4-9e45-e5bcdb3e1558">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzMtMy0xLTEtMA_a9bf0c53-6f5a-45ce-b8ea-94422251990c">1,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzYtMS0xLTEtMA_e661d3b2-367d-46cc-b438-e3af724602c1">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzYtMy0xLTEtMA_40a23e0d-7889-4c4e-82d5-3ac621faca7d">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzctMS0xLTEtMA_f5869e3b-b8e5-41b5-b7ac-48ec5d5ac4ee">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzctMy0xLTEtMA_8a167c3f-d681-46b2-b440-9e95fb0c208f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzktMS0xLTEtMA_6ca9001b-15b1-4591-b550-0791d900297b">235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzktMy0xLTEtMA_6b5dccd1-48a7-48e4-a960-31faedef182b">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzExLTEtMS0xLTA_0435b662-8899-4d48-aa8f-4afef5e65341">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzExLTMtMS0xLTA_5c99dd61-718e-45fc-8d65-8a766cc2d333">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzQtMS0xLTEtMA_448c54e0-c1d1-409a-8f83-55bcc059e993">3,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzQtMy0xLTEtMA_cfdc3002-6942-416b-b14a-76d687c1aa98">5,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzctMS0xLTEtMA_42e22d09-f520-4da6-b96d-ac064bdf9640">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzctMy0xLTEtMA_096952d4-0dc9-4ea1-baa3-b6cefb034495">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzgtMS0xLTEtMA_3fbc6017-1a3a-45ee-a404-b257a8d6569d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzgtMy0xLTEtMA_33994c82-4699-48f5-a03b-f8ae09aea159">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzEwLTEtMS0xLTA_5edf57bf-0bb0-4369-b6b7-e482ebfe1f2c">709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzEwLTMtMS0xLTA_452fa786-db8a-4f5f-862c-62b659d21770">567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzEyLTEtMS0xLTA_8731d281-e509-475f-8a92-feff28192ff6">3,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzEyLTMtMS0xLTA_562b0767-aae5-4e0f-9078-9855d5cff2d8">4,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ic61af6b1c00c429da9b37cd6f2801ca3" continuedAt="if869db486cdc4dfaa31574d65307a49a"><ix:continuation id="ib8fb4be763ec435bba11e6ec7a068890" continuedAt="i8522009d2da84c14aa43f784ee3e9e2f"><ix:continuation id="i88b1b11d00a64013a7392e30b4404324"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzYtMS0xLTEtMA_008a46f1-8a3e-47a1-8252-b7ee1c69ab2a">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzYtMy0xLTEtMA_e05b6a69-4ad4-46bf-bc62-c9eccf8120c5">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzctMS0xLTEtMA_f5869e3b-b8e5-41b5-b7ac-48ec5d5ac4ee">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzctMy0xLTEtMA_8a167c3f-d681-46b2-b440-9e95fb0c208f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzgtMS0xLTEtMA_e661d3b2-367d-46cc-b438-e3af724602c1">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzgtMy0xLTEtMA_40a23e0d-7889-4c4e-82d5-3ac621faca7d">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzExLTEtMS0xLTA_241d2d2e-b124-48e9-8aa3-5a93f2a1bf35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzExLTMtMS0xLTA_2fb0d348-d4a9-447d-a210-91e569131f06">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzE5LTEtMS0xLTA_b1ff6526-07e7-4d67-abc9-d1a1ad364fd5">3,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzE5LTMtMS0xLTA_0622c3cc-25b1-4248-b21b-2f4e1990f165">4,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzIwLTEtMS0xLTA_3fbc6017-1a3a-45ee-a404-b257a8d6569d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzIwLTMtMS0xLTA_33994c82-4699-48f5-a03b-f8ae09aea159">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzIxLTEtMS0xLTA_42e22d09-f520-4da6-b96d-ac064bdf9640">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzIxLTMtMS0xLTA_096952d4-0dc9-4ea1-baa3-b6cefb034495">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzI0LTEtMS0xLTA_e1679224-eb7e-40df-bda4-b88f6177e4f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzI0LTMtMS0xLTA_85f3d07a-c6ff-4cb0-970d-ae8add55c2d9">7,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzMxLTEtMS0xLTA_f8660ea0-f3ac-403e-8127-d74b8417bdfd">6.44</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03292c592c4f45da834c806bff481c24_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzMxLTMtMS0xLTA_a9f14d73-09f3-42c1-92ad-062fa61f29f8">6.93</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzMyLTEtMS0xLTA_49ddd540-bd6a-4d5f-9732-e1e170ac9584">2.92</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03292c592c4f45da834c806bff481c24_I20200930" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzMyLTMtMS0xLTA_8b02633c-190f-455b-90ff-4a55c0717201">3.92</ix:nonNumeric> years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzM2LTEtMS0xLTA_29689737-9e7f-4a54-82f2-b7486ef2eac5">6.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03292c592c4f45da834c806bff481c24_I20200930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzM2LTMtMS0xLTA_07596c8f-7991-44a5-ae47-68aff7b5cd87">6.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzM3LTEtMS0xLTA_828d69f4-e6f4-49a2-8d35-59e38325807d">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03292c592c4f45da834c806bff481c24_I20200930" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzM3LTMtMS0xLTA_a1e86399-6dc2-437f-85e1-82b3b5a89064">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="if869db486cdc4dfaa31574d65307a49a"><ix:continuation id="i8522009d2da84c14aa43f784ee3e9e2f"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzEwNTg_d2580e02-235a-457e-be31-c001a670fe79" escape="true"><ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzEwNjc_6a0d4a14-91c1-404f-a438-875007256de0" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of September&#160;30, 2021, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September&#160;30, 2021)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzEtMS0xLTEtMA_7cd16092-67ae-47ff-bd67-edf01b277645">950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzEtMy0xLTEtMA_e0605b71-41c9-4e3d-a446-e5b33ab68125">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzItMS0xLTEtMA_52824e27-b80e-4f7e-a9ab-fe19bf471adf">3,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzItMy0xLTEtMA_bf982d29-27a5-456b-a2f4-dcb77af638b1">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzMtMS0xLTEtMA_490f62bf-0a42-4161-923e-481b4c81c0c1">3,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzMtMy0xLTEtMA_142905d2-e9bd-44a7-9861-a3aed3986ccc">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzQtMS0xLTEtMA_7182943c-be2e-4d54-a606-b4e34d1b0b13">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzQtMy0xLTEtMA_05d5fadb-e846-40a8-baf5-c4f97ec11267">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzUtMS0xLTEtMA_27b5b774-0632-4aa2-a5bc-d8d12001b307">2,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzUtMy0xLTEtMA_4b37ab60-9275-433f-ad1a-46026e5776fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzYtMS0xLTEtMA_ab0e5c86-c277-4609-9d96-8bc69a3cf708">6,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:fixed-zero" name="ameh:FinanceLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzYtMy0xLTEtMA_f5b14df1-e729-4ca9-b57c-c3f7276b2219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzgtMS0xLTEtMA_614d1f01-7983-475a-91e8-d68961c951be">20,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzgtMy0xLTEtMA_ed5414ea-fbc3-47b0-89a3-8dd48597e95f">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzktMS0xLTEtMA_f941247c-4f60-44e7-a805-6177cff8cd45">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzktMy0xLTEtMA_89781763-a834-45e2-9f18-e9ae1e61ee92">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzEwLTEtMS0xLTA_bbdf957a-e49c-494e-a76e-bf5d82df9a11">16,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzEwLTMtMS0xLTA_7171917e-180a-4c20-882e-a5a28e28dac3">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzExLTEtMS0xLTA_42aede68-018a-46d6-b4d2-78f5dbc2e448">2,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzExLTMtMS0xLTA_b3d6262d-513f-44b7-9fd7-a81cdafdd711">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzEyLTEtMS0xLTA_162c5635-5323-45aa-8fb5-fd7e04c6e3f6">13,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzEyLTMtMS0xLTA_750d4ac8-d3ab-450b-9304-504eb776d658">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company does not have additional operating and finance leases that have not yet commenced.</span></div></ix:continuation></ix:continuation><div id="i77048548a0c546beaa10a42c80553a71_124"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMjQvZnJhZzozN2FhNzk5MjMxZWI0N2FjOTk3NWY4YjY1ODJjNDNkMy90ZXh0cmVnaW9uOjM3YWE3OTkyMzFlYjQ3YWM5OTc1ZjhiNjU4MmM0M2QzXzEwMzc_8b230aa7-e23c-4f3a-bb73-4c8fd0c738bf" continuedAt="i225c41f866064aab9689675c987db5ef" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:continuation id="i225c41f866064aab9689675c987db5ef" continuedAt="i31192aae97db484caddf0b3fd55b6104">DMG</ix:continuation><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i31192aae97db484caddf0b3fd55b6104">In October 2021, the Company entered into an agreement to purchase within <ix:nonNumeric contextRef="i6af953349f5741e6903f07fe40567fb1_D20211001-20211031" format="ixt-sec:durwordsen" name="ameh:EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMjQvZnJhZzozN2FhNzk5MjMxZWI0N2FjOTk3NWY4YjY1ODJjNDNkMy90ZXh0cmVnaW9uOjM3YWE3OTkyMzFlYjQ3YWM5OTc1ZjhiNjU4MmM0M2QzXzM4NDgyOTA3MDkyNTI_b57eaee3-7938-4eb4-92f5-c6d2fedaac4c">three years</ix:nonNumeric> all of the remaining equity interests in DMG. The Company currently owns <ix:nonFraction unitRef="number" contextRef="i347edc610f5f44f797de7ecdf6022137_I20210930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMjQvZnJhZzozN2FhNzk5MjMxZWI0N2FjOTk3NWY4YjY1ODJjNDNkMy90ZXh0cmVnaW9uOjM3YWE3OTkyMzFlYjQ3YWM5OTc1ZjhiNjU4MmM0M2QzXzM4NDgyOTA3MDkyODI_b45c5c8a-75d5-4cc4-84fd-093b6444113a">40</ix:nonFraction>% of DMG and has committed to purchasing the remaining <ix:nonFraction unitRef="number" contextRef="iea7d2b87a68e4688b5afefdb57fd6387_I20211031" decimals="2" name="ameh:EquityMethodInvestmentAdditionalPercentageCommittedToPurchase" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMjQvZnJhZzozN2FhNzk5MjMxZWI0N2FjOTk3NWY4YjY1ODJjNDNkMy90ZXh0cmVnaW9uOjM3YWE3OTkyMzFlYjQ3YWM5OTc1ZjhiNjU4MmM0M2QzXzM4NDgyOTA3MDg0NTY_5ce67379-7f73-40a8-896c-4db9fe1c3c4d">60</ix:nonFraction>% within <ix:nonNumeric contextRef="i6af953349f5741e6903f07fe40567fb1_D20211001-20211031" format="ixt-sec:durwordsen" name="ameh:EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMjQvZnJhZzozN2FhNzk5MjMxZWI0N2FjOTk3NWY4YjY1ODJjNDNkMy90ZXh0cmVnaW9uOjM3YWE3OTkyMzFlYjQ3YWM5OTc1ZjhiNjU4MmM0M2QzXzM4NDgyOTA3MDkyNzI_a0d7e59e-1a83-4339-9ee9-3f08857f80ab">three years</ix:nonNumeric>. In accordance with relevant accounting guidance, the Company has determined that DMG is a variable interest entity of the Company; therefore, DMG's financial statements will be consolidated with those of the Company.</ix:continuation> </span></div><div id="i77048548a0c546beaa10a42c80553a71_130"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited consolidated financial statements and the notes thereto included in Part I, Item 1, &#8220;Financial Statements&#8221; of this Quarterly Report on Form 10-Q. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the SEC on March&#160;15, 2021.</span></div><div id="i77048548a0c546beaa10a42c80553a71_133"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, together with our affiliated physician-owned medical groups and consolidated entities, are a leading physician-centric, technology-enabled healthcare management company. Leveraging our proprietary population health management and healthcare delivery platform, we operate an integrated, value-based healthcare model. We aim to empower the healthcare providers in our network to deliver the highest quality of care to our patients in a cost-effective manner.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, our subsidiaries and VIEs include management services organizations (&#8220;MSOs&#8221;), affiliated independent practice associations (&#8220;IPAs&#8221;), and a Next Generation Accountable Care Organization (&#8220;NGACO&#8221;). Network Medical Management, Inc. (&#8220;NMM&#8221;) and Apollo Medical Management, Inc. (&#8220;AMM&#8221;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under brands including (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), (ii) Alpha Care Medical Group, Inc., and (iii) Accountable Health Care IPA. These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;), and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). Our NGACO operates under the APA ACO, Inc. (&#8220;APAACO&#8221;) brand and participates in the Centers for Medicare &amp; Medicaid Services program, which allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward under an attribution-based risk-sharing model.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, together with our affiliated physician-owned medical groups and consolidated entities, provide coordinated outcomes-based medical care primarily serving patients in California. The majority of our patients are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (&#8220;HMOs&#8221;). However, a small portion of our revenue comes from non-insured patients. We provide care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Our physician network consists of primary care physicians, specialist physicians, and hospitalists. We operate primarily through Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) and the following subsidiaries: NMM, AMM, and APAACO and their consolidated entities, including consolidated VIEs.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Led by a management team with several decades of experience, we are focused on physicians providing high-quality medical care, population health management, and care coordination for patients. As a result, we are well positioned to take advantage of the shift in the U.S. healthcare industry toward providing value-based and results-oriented healthcare with a focus on patient satisfaction, high-quality care, and cost efficiency.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our NGACO model and a network of IPAs with more than 2,000 primary care physicians, 7,000 specialist physicians, 10 dual physicians, and 350 physician and specialist extenders, we are currently responsible for coordinating care for approximately 1.1&#160;million patients in California.</span></div><div id="i77048548a0c546beaa10a42c80553a71_136"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent and Other Developments</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">DMG<br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an agreement to purchase within three years all of the remaining equity interests in DMG. The Company currently owns 40% of DMG and has committed to purchasing the remaining 60% within three years. In accordance with relevant accounting guidance, the Company has determined that DMG is a variable interest entity of the Company; therefore, DMG's financial statements will be consolidated with those of the Company. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Appointment and Departure of Certain Officers<br/><br/>&#160;&#160;&#160;&#160;In November 2021, the Company appointed Brandon Sim as its Co-Chief Executive Officer. With this appointment, Kenneth Sim, M.D. will no longer serve as Co-CEO of ApolloMed but will continue in his role as Executive Chairman. Over the past several months, Mr. Sim has taken leadership of the Company&#8217;s corporate strategy, operations and engineering teams, and he will continue to lead all these aspects of ApolloMed&#8217;s business as Co-CEO.</span></div><div id="i77048548a0c546beaa10a42c80553a71_139"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Financial Measures and Indicators</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Revenues</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO AIPBP revenue, management fee income, and FFS revenue. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Expenses</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest expenses are the patient care cost paid to contracted physicians and the cost of providing management and administrative support services to our affiliated physician groups. These management services include utilization and case management, physician practice billing, revenue cycle services, physician practice management, administrative oversight, coding services, and other consulting services.</span></div><div id="i77048548a0c546beaa10a42c80553a71_142"></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.893%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-services, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (expense) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,665)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,181)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,484)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Loss) income before (benefit from) provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Benefit from) provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,385)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,424&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,809)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,664)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,566&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Percentage change of over 500%</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-services, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(899)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Loss) income from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,007)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,080)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,742)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,629)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,603&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,412&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,809)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,088)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,088&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,809&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Percentage change of over 500%</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Attributable to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income attributable to Apollo Medical Holdings, Inc. for the three months ended September&#160;30, 2021, was $34.3 million, as compared to $16.7 million for the same period in 2020, an increase of $17.6 million. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income attributable to Apollo Medical Holdings, Inc. for the nine months ended September&#160;30, 2021, was $60.1 million, as compared to $27.8 million for the same period in 2020, an increase of $32.3 million. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Groups and Patients</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and 2020, we managed a total of 12 and 14 groups of affiliated physicians, respectively, and the total number of patients for whom we managed the delivery of healthcare services was approximately 1.1&#160;million and 1.1 million, respectively. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue for the three months ended September&#160;30, 2021, was $227.1 million, as compared to $180.1 million for the three months ended September&#160;30, 2020, an increase of $47.0 million, or 26%. The increase in revenue was primarily attributable to the following:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Capitation revenue increased by approximately $14.0 million driven primarily by membership growth at APC and Alpha Care.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Risk pool settlement and incentive revenue increased by $29.0 million driven by an incentive payment received from one of our payor partners totaling approximately $14.6 million, increased risk pool revenue of $12.4 million driven by reduced utilization at ApolloMed&#8217;s partner hospitals resulting from the suspension of non-emergency medical procedures in early 2020 when the COVID-19 pandemic first began, as these revenues from ApolloMed&#8217;s partner hospitals reflect a 15-18 month lag, and a $2.0 million increase in the shared savings settlement earned from ApolloMed&#8217;s participation in an ACO for performance year 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (iii) Fee for service increased by approximately $3.5 million driven by the consolidation of Sun Labs beginning August 2021 which contributed $2.0 million and increased visits to our surgery and heart centers, which were partially closed in the prior year due COVID-19 of $1.5 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue for the nine months ended September&#160;30, 2021, was $578.8 million, as compared to $510.4 million for the nine months ended September&#160;30, 2020, an increase of $68.4 million, or 13%. The increase in revenue was primarily attributable to the following:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Capitation revenue increased by approximately $21.9 million driven by membership growth at APC and Alpha Care and higher average capitation rate at APC. APC and Alpha Care contributed additional capitation revenue of approximately $29.9 million and $5.7 million, respectively. This was offset with a decrease in capitation revenue at APAACO and Accountable Health Care of $4.5 million and $9.1 million, respectively. The decrease in revenue at APAACO was due to timing of claims expenditures incurred and the decrease at Accountable Health Care was a result of membership reductions. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Risk pool settlement and incentive revenue increased by $40.0 million driven by reduced utilization at ApolloMed&#8217;s partner hospitals resulting from the suspension of non-emergency medical procedures in early 2020 when the COVID-19 pandemic first began, as these revenues from ApolloMed&#8217;s partner hospitals reflect a 15-18 month lag, the reduced utilization resulted in increased risk pool revenue of $23.4 million. The remaining increase was driven by an incentive payment received from one of our payor partners totaling approximately $14.6 million and a $2.0 million increase in the shared savings settlement earned from ApolloMed&#8217;s participation in an ACO for performance year 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) Fee for service increased by approximately $5.5 million due to increased visits to our surgery and heart centers, which were partially closed in the prior year due COVID-19 of $3.5 million and $2.0 million as a result of the consolidation of Sun Labs beginning August 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Services, excluding depreciation and amortization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to cost of services for the three months ended September&#160;30, 2021, were $147.5 million, as compared to $121.8 million for the same period in 2020, an increase of $25.7 million. The overall increase was primarily due to an increase in medical claims, capitation, and other health services expenses.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to cost of services for the nine months ended September&#160;30, 2021, were $424.3 million, as compared to $402.1 million for the same period in 2020, an increase of $22.2 million. The overall increase was primarily due to an increase in medical claims, capitation, and other health services expenses.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the three months ended September&#160;30, 2021, were $21.8 million, as compared to $16.3 million for the same period in 2020, an increase of $5.5 million, or 34%. The increase was primarily due to an increase in bonus paid certain physicians driven by the increase in shared savings earned related to the settlement of the 2020 ACO performance year.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the nine months ended September&#160;30, 2021, were $45.5 million, as compared to $39.7 million for the same period in 2020, an increase of $5.8 million, or 15%. The increase is primarily due to costs incurred as a result of the execution of the Amended Credit Facility agreement and an increase in bonus paid to certain physicians driven </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the increase in shared savings earned related to the settlement of the 2020 ACO performance year. This is partially offset by a reduction in consulting and professional costs as a result of efficiencies gained from our continued development of our in-house technology platform of approximately $1.0 million and the elimination of rent expense for properties leased by MPP, ZLL, and AMG Properties as a result of the Company's acquisition of these entities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses for the three months ended September&#160;30, 2021, were $4.7 million, as compared to $4.7 million for the same period in 2020. This amount includes depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses for the nine months ended September&#160;30, 2021, were $13.1 million, as compared to $14.0 million for the same period in 2020. This amount includes depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Loss) Income from Equity Method Investments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity method investments for the three months ended September&#160;30, 2021, was $0.1 million, as compared to income from equity method investments of $0.4 million for the same period in 2020, a decrease of $0.3 million. The decrease was primarily due to our investment in LMA. The Company incurred a loss of $0.3 million from LMA as a result of increased claims expense for the three months ended September&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from equity method investments for the nine months ended September&#160;30, 2021, was $3.7 million, as compared to income from equity method investments of $3.3 million for the same period in 2020, a decrease of $7.0 million. The decrease was partially due to the sale of UCI in April 2020. For the nine months ended September&#160;30, 2020, UCI contributed equity earnings of $3.6 million. The additional decrease is from our investment in LMA. For the nine months ended September&#160;30, 2021, the Company incurred a loss of $4.7&#160;million from LMA as a result of increased claims expense as compared to equity earnings of $1.8 million for the nine months ended September 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended September&#160;30, 2021, was $1.0 million, as compared to $2.5 million for the same period in 2020, a decrease of $1.5 million.  The decrease in interest expense for the three months ended September&#160;30, 2021 was due to lower interest rates and lower outstanding debt balance at September&#160;30, 2021 as compared to September&#160;30, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the nine months ended September&#160;30, 2021, was $4.3 million, as compared to $8.0 million for the same period in 2020, a decrease of $3.7 million. The decrease in interest expense for the nine months ended September&#160;30, 2021, was primarily due to the Company refinancing their Credit Facility to the Amended Credit Facility in June 2021 which resulted in lower interest rates for the nine months ended September&#160;30, 2021, as compared to the same periods in 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three and nine months ended September&#160;30, 2021, was $0.4 million and $1.3 million, respectively, as compared to $0.8 million and $2.5 million, respectively, for the three and nine months ended September&#160;30, 2020. Interest income reflects interest earned on cash held in money market and certificate of deposit accounts and the interest from notes receivable.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrealized (Loss) Gain on Investments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three and nine months ended September&#160;30, 2021 we recognized an unrealized loss of $60.9&#160;million and unrealized gain of $22.8 million, respectively. The unrealized loss and gain is driven by fluctuations in the stock price of a payor partner in which we hold shares in. These shares are recorded as marketable securities and deemed an Excluded Assets that are solely for the benefit of APC and its shareholders. Any resulting gain or loss does not impact net income attributable to Apollo Medical Holdings, Inc. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income for the three months ended September&#160;30, 2021, was $0.5 million, as compared to $0.1 million for the same period in 2020, an increase of $0.4 million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense for the nine months ended September&#160;30, 2021, was $14.1 million, as compared to income of $1.5 million for the same period in 2020, a decrease of $15.6 million. The decrease was primarily due to the write-off of certain beneficial interest related to the UCI disposition totaling $15.7 million. The beneficial interest was an Excluded Assets that was deemed solely for the benefit of APC and its shareholders. As such, the write-off did not result in any impact to net income attributable to Apollo Medical Holdings, Inc.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Benefit from) Provision for Income Taxes</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from provision for income taxes was $0.1 million for the three months ended September&#160;30, 2021, as compared to provision for income taxes of $10.8 million for the same period in 2020. This was due to a decrease in pre-tax income for the three months ended September&#160;30, 2021, period as compared to the same period in 2020, as described above.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $31.6 million for the nine months ended September&#160;30, 2021, as compared to $44.2 million for the same period in 2020. The decrease in provision for income taxes was due to a decrease in pre-tax income for the nine months ended September&#160;30, 2021, period as compared to the same period in 2020, as described above.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net (Loss) Income Attributable to Noncontrolling Interests</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to noncontrolling interests for the three months ended September&#160;30, 2021, was $39.7 million, as compared to net income attributable to noncontrolling interests for the three months ended September&#160;30, 2020 of $8.7 million, respectively, a decrease of $48.4 million. The decrease was primarily driven by an unrealized loss resulting from a decreased fair value in our marketable securities related to shares held of a payor partner.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests for the nine months ended September&#160;30, 2021 and September&#160;30, 2020, was $8.5 million and $81.6 million, respectively, a decrease of $73.1 million. The decrease was primarily driven by the sale of UCI which was completed in April 2020.</span></div><div id="i77048548a0c546beaa10a42c80553a71_148"></div><div style="margin-bottom:5pt;margin-top:5pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Guidance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;ApolloMed is raising its full-year 2021 guidance, previously disclosed on August 5, 2021, as a result of its continued organic growth and increased risk pool settlements and incentives revenue as a result of reduced utilization at ApolloMed&#8217;s partner hospitals in 2020 during the COVID-19 pandemic and a shared savings settlement of $21.8 million from ApolloMed's participation in an Accountable Care Organization ("ACO") for the 2020 performance year. Net income and EBITDA include the impact of APC investment in a payor partner, which completed an initial public offering to become a publicly traded company in June 2021. As APC&#8217;s investment is an excluded asset solely for the benefit of APC and its shareholders, any gains or losses as a result of this investment do not affect the net income attributable to ApolloMed and adjusted EBITDA attributable to ApolloMed. The November 4, 2021 revised net income and EBITDA guidance ranges assume a stock price of the payor partner of $8.49. These assumptions are based on the Company&#8217;s existing business, current view of existing market conditions, and assumptions for the year ending December&#160;31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Guidance Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Guidance Range</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(as of August 5, 2021)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(as of November 4, 2021)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to ApolloMed</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EBITDA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Range was not previously provided as of August 5, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See &#8220;Guidance Reconciliation of Net Income to EBITDA and adjusted EBITDA&#8221; and &#8220;Use of Non-GAAP Financial Measures&#8221; for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See &#8220;Forward-Looking Statements&#8221; within this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Guidance Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Guidance Range</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(as of August 5, 2021)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(as of November 4, 2021)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,500&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in payor partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider bonus payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss adjustment for recently acquired IPAs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,500&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,500&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,500&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,500&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Non-GAAP Financial Measures</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains the non-GAAP financial measures EBITDA and adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) is net (loss) income. These measures are not in accordance with, or an alternative to, GAAP, and may be different from other non-GAAP financial measures used by other companies. The Company uses adjusted EBITDA as a supplemental performance measure of our operations,&#160;for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income from equity method investments, provider bonuses, impairment of intangibles, provision of doubtful accounts, and other income earned that is not related to the Company&#8217;s normal operations. Adjusted EBITDA also excludes the effect on EBITDA of certain IPAs we recently acquired. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company&#8217;s ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation from, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.</span></div><div id="i77048548a0c546beaa10a42c80553a71_151"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and investment in marketable securities at September&#160;30, 2021, totaled $333.3 million as compared to $261.2 million at December&#160;31, 2020. Working capital totaled $310.5 million at September&#160;30, 2021, as compared to $223.6 million at December&#160;31, 2020, an increase of $86.9 million, or 39%.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operations primarily through internally generated funds. We generate cash primarily from capitation contracts, risk pool settlements and incentives, fees for medical management services provided to our affiliated physician groups, and fee-for-service reimbursements. We generally invest cash in money market accounts, which are classified as cash and cash equivalents. We believe we have sufficient liquidity to fund our operations through at least the next 12 months.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents and restricted cash increased by $10.8 million from $194.0 million at December&#160;31, 2020, to $204.8 million at September&#160;30, 2021. Cash provided by operating activities for the nine months ended September&#160;30, 2021, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $82.5 million, as compared to cash provided by operating activities of $48.8 million for the nine months ended September&#160;30, 2020. The increase in cash provided by operating activities was primarily driven by increase in earnings adjusted for non-cash items of approximately $89.4 million for the nine months ended September&#160;30, 2021 compared to $17.9 million for the nine months ended September&#160;30, 2020 and timing of working capital accounts. For the nine months ended September&#160;30, 2021, prepaid expenses and other current assets and accounts payable and accrued expenses resulted in cash inflow of $19.4 million, while receivable, net, receivable, net - related parties, other receivable, medical liabilities, and income taxes payable resulted in cash outflow of $24.5 million. For the nine months ended September&#160;30, 2020, receivable, net - related parties, other receivables, accounts payable and accrued expenses, fiduciary accounts payable, and income taxes payable resulted in cash inflow of $45.8 million, while receivable, net, prepaid expenses and other current assets, other assets, and medical liabilities resulted in a cash outflow of $15.4 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cash used in investing activities during the nine months ended September&#160;30, 2021, was $22.5 million, primarily due to purchases of property and equipment of $16.4 million, payments for business acquisition of $2.6 million, funding for an equity method investment of $13.4 million, and purchase of marketable securities of $1.0 million. The cash used in investing activities was partially offset by cash received from consolidation of Tag 8 of $3.3 million, proceeds from sale of equity method investment of $6.4 million, and proceeds from sale of marketable securities of $1.1 million. This is compared to cash provided by investing activities during the nine months ended September 30, 2020, of $66.4 million, which was primarily due to proceeds received related to the sale of UCI totaling $52.7 million and loan receivables of $16.5 million offset with cash outflow related to the purchase of marketable securities of $1.8 million, funding for an equity method investment of $0.5 million, and capital expenditures (mainly purchases of property and equipment) of $0.5 million. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during the nine months ended September&#160;30, 2021, was $49.2 million as compared to cash used in financing activities of $52.3 million for the nine months ended September&#160;30, 2020. Cash used for the nine months ended September&#160;30, 2021 was primarily due to repayment of long-term debt of $238.3 million, dividend payment of $31.1 million, and repurchase of shares of $5.7 million. The cash used in financing activities was partially offset by a drawdown of $180.0 million on the Amended Credit Facility, proceeds from sale of shares of $40.1 million, and proceeds from the exercise of options and warrants of $6.6 million. This is compared to cash used in financing activities for the nine months ended September 30, 2020 of $52.3 million which was due to the payments of dividends totaling $50.1 million, repayment on our term loan totaling $7.1 million and repurchase of shares of $1.6 million, offset with proceeds from exercise of stock options and warrants of $6.6 million.</span></div><div id="i77048548a0c546beaa10a42c80553a71_157"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Excluded Assets</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2019, APC and AP-AMH entered into Second Amendment to Series A Preferred Stock Purchase Agreement, which clarified the term &#8220;Excluded Assets&#8221;. &#8220;Excluded Assets&#8221; means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price (as defined in the purchase agreement), (ii) the assets of APC that are not Healthcare Services Assets (as defined in the purchase agreement), including APC&#8217;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Excluded Assets as of September&#160;30, 2021, are primarily comprised of assets and liabilities from operating real estate and proceeds from the sale of UCI. Any dividends issued to APC shareholders are paid using cash from Excluded Assets. As of September&#160;30, 2021 and December&#160;31, 2020, the Excluded Assets balance consisted of the following (in thousands):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,452)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Excluded Assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,087&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase in investment in marketable securities is due to a 1-to-3 conversion of a payor partner&#8217;s preferred shares to common stock as a result of the payor partner becoming a public company in June 2021. Prior to the payor partner becoming a public company, the preferred shares were recognized as investments in privately held entities. </span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i77048548a0c546beaa10a42c80553a71_160"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,504)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September 30, 2021) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,524&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the &#8220;Lenders&#8221;), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Well Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent, in its entirety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement provides for a five-year revolving credit facility (&#8220;Revolver Loan&#8221;) to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covenant Ratios </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Requirement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated leverage ratio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 3.75 to 1.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated interest coverage ratio</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 3.25 to 1.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.55</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) All covenant ratio titles utilize terms as defined in the respective debt agreements. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this Quarterly Report on Form 10-Q for additional information. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Interest Rate</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the nine months ended September&#160;30, 2021 and 2020, were 2.15% and 3.79%, respectively.  Interest expense in the consolidated statements of operations included amortization of deferred debt issuance costs for the three and nine months ended September&#160;30, 2021 and 2020, of $0.2 million and $0.3 million, respectively, and $0.9 million and $1.0 million, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of the purchase, APC assumed $6.4&#160;million, $0.7&#160;million, and $0.7&#160;million of existing loans held by MPP, AMG Properties, and ZLL, respectively. Refer to Note 9 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;) that allows Tag 8 to borrow up to $10.7 million. Tag 8 is a VIE consolidated by the Company. Refer to Note 9 &#8211; &#8220;Credit </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany Loans</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of AMH, MMG, AKM Medical Group, Inc. (&#8220;AKM&#8221;), SCHC, and Bay Area Hospitalist Associates (&#8220;BAHA&#8221;) has entered into an Intercompany Loan Agreement with AMM under which AMM has agreed to provide a revolving loan commitment to each such affiliated entity in an amount set forth in each Intercompany Loan Agreement. Each Intercompany Loan Agreement provides that AMM&#8217;s obligation to make any advances automatically terminates upon the termination of the management agreement with the applicable affiliated entity. In addition, each Intercompany Loan Agreement provides that (i) any material breach by the shareholder of record of the applicable Physician Shareholder Agreement or (ii) the termination of the management agreement with the applicable affiliated entity constitutes an event of default under the Intercompany Loan Agreement. All the intercompany loans have been eliminated in consolidation (in thousands).  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Entity</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intercompany Credit Facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest<br/>Rate<br/>per Annum</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maximum</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During&#160;Period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMG</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAHA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div id="i77048548a0c546beaa10a42c80553a71_166"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires our management to make judgments, assumptions, and estimates that affect the amounts of revenue, expenses, income, assets, and liabilities, reported in our consolidated financial statements and accompanying notes. Actual results and the timing of recognition of such amounts could differ from those judgments, assumptions, and estimates. In addition, judgments, assumptions, and estimates routinely require adjustment based on changing circumstances and the receipt of new or better information. Understanding our accounting policies and the extent to which our management uses judgment, assumptions, and estimates in applying these policies, therefore, is integral to understanding our financial statements. Critical accounting policies and estimates are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions.&#160;We summarize our most significant accounting policies in relation to the accompanying consolidated financial statements in Note 2 thereto. Please also refer to the Critical Accounting Policies section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><div id="i77048548a0c546beaa10a42c80553a71_169"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to the accompanying consolidated financial statements for recently issued accounting pronouncements, including information on new accounting standards and the future adoption of such standards.</span></div><div id="i77048548a0c546beaa10a42c80553a71_172"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had no off-balance sheet arrangements that are or have been reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.</span></div><div id="i77048548a0c546beaa10a42c80553a71_175"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation and changing prices have had de minimis effect on our continuing operations over our two most recent fiscal years.</span></div><div id="i77048548a0c546beaa10a42c80553a71_178"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under our Amended Credit Agreement exposed us to interest rate risk. As of September&#160;30, 2021, we had $180.0&#160;million in outstanding borrowings under our Amended Credit Agreement. The amount borrowed under the Credit Agreement bears interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of 1.25% to 2.5%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.5%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. The base rate is defined in a manner such that it will not be less than LIBOR. In addition, as of September&#160;30, 2021, Tag 8, a VIE consolidated by the Company, had $0.1&#160;million in outstanding borrowings for the Construction Loan.  Interest rate on the &#8220;Construction Loan&#8221; is equal to an index rate determined by the bank. Furthermore, as of September&#160;30, 2021, APC had $7.4 million in outstanding borrowings for real estate loans related to ZLL, MPP, and AMG Properties (&#8220;Real Estate Loans&#8221;). Each agreement bears interest that is subject to change from time to time based on changes in an independent index, which is the daily Wall Street Journal Prime Rate, as quoted in the &#8220;Money Rates&#8221; column of The Wall Street Journal (Western edition) as determined by the Lender (the &#8220;Index&#8221;). On the dates of the agreement, the Index is 3.25% per annum. Under no circumstances will the interest rate on this loan be less than 3.500% per annum or more than the maximum rate allowed by applicable law. The Company has entered into interest rate swap agreements for certain of these agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. A hypothetical 1% change in our interest rates for our outstanding borrowings under our Credit Agreement, Construction Loan, and Real Estate Loans would have increased or decreased our interest expense for the three months ended September&#160;30, 2021, by $1.9 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our Co-Chief Executive Officers and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our management, including Co-Chief Executive Officers and Chief Financial Officer, concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15(d)-15(e) under the Exchange Act, were effective as of September&#160;30, 2021, to ensure that information required to be disclosed by us in this Quarterly Report on Form 10-Q or submitted under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officers and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rule&#160;13a-15(f)&#160;under Exchange Act) during our third fiscal quarter of 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i77048548a0c546beaa10a42c80553a71_184"></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i77048548a0c546beaa10a42c80553a71_187"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we from time to time become involved in pending and threatened legal actions and proceedings. Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services, which may not come to light until a substantial period of time has passed following contract implementation. We may also become subject to other lawsuits which could involve significant claims and/or significant defense costs, but as of the date of this Quarterly Report on Form 10-Q, except as disclosed, we are not a party to any lawsuit or proceeding which management expects to, individually or in the aggregate, have a material adverse effect on us or our business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div id="i77048548a0c546beaa10a42c80553a71_190"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition, and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry, as well as&#160;risks that affect businesses in general. In addition to the information and risk factors set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the SEC on March&#160;15, 2021. The risks disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows, or results of operations and thus our stock price. We believe there have been no material changes in our risk factors from those disclosed in the Annual Report. However, additional risks and uncertainties not currently known or which we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the consolidated financial statements and related notes in Part I, Item 1, &#8220;Financial Statements&#8221; and Part I, Item 2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of this Quarterly Report on Form 10-Q. Because of such risk factors, as well as other factors affecting the Company&#8217;s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.</span></div><div id="i77048548a0c546beaa10a42c80553a71_193"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None for the three months ended September&#160;30, 2021.</span></div><div id="i77048548a0c546beaa10a42c80553a71_196"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None </span></div><div id="i77048548a0c546beaa10a42c80553a71_199"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i77048548a0c546beaa10a42c80553a71_202"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_205"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;EXHIBITS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are either incorporated by reference into or filed or furnished with this Quarterly Report on Form 10-Q, as indicated below.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Agreement and Plan of Merger, dated December 21, 2016, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp., and Kenneth Sim, M.D. (the &#8220;Merger Agreement&#8221;) (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017, that is a part of a Registration Statement on Form S-4)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment to the Merger Agreement, dated March 30, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp., and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment No. 2 to the Merger Agreement, dated October 17, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025049/tv520199_ex2-4.htm">Stock purchase agreement dated March 15, 2019 (incorporated herein by reference to Exhibit 2.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2019)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415002897/v398912_ex3-1.htm">Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on January 21, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415025170/v408340_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 27, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 21, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415066090/v423843_ex3-2.htm">Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 16, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on June 21, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex3-1.htm">Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on October 19, 2015).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex3-1.htm">Amended and Restated Certificate of Designation of Apollo Medical Holdings, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 4, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-1.htm">Form of Certificate for Common Stock of Apollo Medical Holdings, Inc., par value $0.001 per share (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-3.htm">Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $11.00 per share (incorporated herein by reference to Exhibit 4.3 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-4.htm">Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $10.00 per share (incorporated herein by reference to Exhibit 4.4 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex4-1.htm">Common Stock Purchase Warrant (&#8220;Series A Warrant&#8221;) dated October 14, 2015, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 1,111,111 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on October 19, 2015).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-6.htm">Form of Assignment of Series A Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.6 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex4-1.htm">Common Stock Purchase Warrant (&#8220;Series B Warrant&#8221;) dated March 30, 2016, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 555,555 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on April 4, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-8.htm">Form of Assignment of Series B Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.8 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828020003626/ameh-20191231xexx410.htm">Description of Registered Securities</a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3112021093010-q.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex3122021093010-q.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3132021093010-q.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322021093010-q.htm">Certification of Principal Executive Officers and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furnished herewith</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The schedules and exhibits thereof have been omitted pursuant to Item&#160;601(b)(2) of Regulation&#160;S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i77048548a0c546beaa10a42c80553a71_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 5, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas Lam</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas Lam, M.D., M.P.H.<br/>Co-Chief Executive Officer &amp; President<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 5, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brandon Sim</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brandon Sim<br/>Co-Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 5, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Eric Chin</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Chin<br/>Chief Financial Officer<br/>(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex3112021093010-q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8cb90ed7dabf4fdf81ab344373fdf0a0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas Lam, M.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Lam</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thomas Lam</font></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex3122021093010-q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i15ecc0cdf08147af86d2e582bad6a57a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 31.2</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brandon Sim, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brandon Sim</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brandon Sim</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>4
<FILENAME>ex3132021093010-q.htm
<DESCRIPTION>EX-31.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if5ab5b92bdb94c6cbeba07263c2c2500_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 31.3</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Eric Chin, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Chin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eric Chin</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>ex322021093010-q.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i51a3af6b05de4b9a91010b36830aa61d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERS AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas Lam, M.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended September&#160;30, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Lam</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thomas Lam</font></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brandon Sim, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended September&#160;30, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brandon Sim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brandon Sim</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Eric Chin, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended September&#160;30, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Chin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eric Chin</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ameh-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:114d7d5d-3fd3-46db-8f4b-230f4f1be605,g:12a42f3e-83fc-4c9c-a1b4-628777c39609-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ameh="http://www.apollomed.net/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.apollomed.net/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.apollomed.net/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.apollomed.net/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
        <link:definition>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails">
        <link:definition>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwill" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill">
        <link:definition>2110103 - Disclosure - Business Combinations and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillTables" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables">
        <link:definition>2311302 - Disclosure - Business Combinations and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails">
        <link:definition>2412406 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillSummaryofGoodwillDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails">
        <link:definition>2413407 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.apollomed.net/role/IntangibleAssetsNet">
        <link:definition>2114104 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables">
        <link:definition>2315303 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
        <link:definition>2416408 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1">
        <link:definition>2416408 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>2417409 - Disclosure - Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetFutureAmortizationExpenseDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails">
        <link:definition>2418410 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethod" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod">
        <link:definition>2119105 - Disclosure - Investments in Other Entities &#8212; Equity Method</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodTables" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables">
        <link:definition>2320304 - Disclosure - Investments in Other Entities &#8212; Equity Method (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails">
        <link:definition>2421411 - Disclosure - Investments in Other Entities &#8212; Equity Method - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails">
        <link:definition>2422412 - Disclosure - Investments in Other Entities &#8212; Equity Method - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails">
        <link:definition>2423413 - Disclosure - Investments in Other Entities &#8212; Equity Method - Summarized Balance Sheets and Statements of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanReceivableandLoanReceivableRelatedParties" roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties">
        <link:definition>2124106 - Disclosure - Loan Receivable and Loan Receivable &#8211; Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails">
        <link:definition>2425414 - Disclosure - Loan Receivable and Loan Receivable &#8211; Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpenses" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses">
        <link:definition>2126107 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesTables" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables">
        <link:definition>2327305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails">
        <link:definition>2428415 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilities" roleURI="http://www.apollomed.net/role/MedicalLiabilities">
        <link:definition>2129108 - Disclosure - Medical Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesTables" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables">
        <link:definition>2330306 - Disclosure - Medical Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails">
        <link:definition>2431416 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCredit" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit">
        <link:definition>2132109 - Disclosure - Credit Facility, Bank Loans and Lines of Credit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditTables" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables">
        <link:definition>2333307 - Disclosure - Credit Facility, Bank Loans and Lines of Credit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails">
        <link:definition>2434417 - Disclosure - Credit Facility, Bank Loans and Lines of Credit - Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails">
        <link:definition>2435418 - Disclosure - Credit Facility, Bank Loans and Lines of Credit - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails">
        <link:definition>2436419 - Disclosure - Credit Facility, Bank Loans and Lines of Credit - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquity" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity">
        <link:definition>2137110 - Disclosure - Mezzanine and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails">
        <link:definition>2438420 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.apollomed.net/role/StockBasedCompensation">
        <link:definition>2139111 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.apollomed.net/role/StockBasedCompensationTables">
        <link:definition>2340308 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>2441421 - Disclosure - Stock Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2442422 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>2443423 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails">
        <link:definition>2444424 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofWarrantDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails">
        <link:definition>2445425 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWarrantsDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails">
        <link:definition>2446426 - Disclosure - Stock-Based Compensation - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.apollomed.net/role/CommitmentsandContingencies">
        <link:definition>2147112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2448427 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.apollomed.net/role/RelatedPartyTransactions">
        <link:definition>2149113 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables">
        <link:definition>2350309 - Disclosure - Related-Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>2451428 - Disclosure - Related-Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails">
        <link:definition>2452429 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.apollomed.net/role/IncomeTaxes">
        <link:definition>2153114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2454430 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.apollomed.net/role/EarningsPerShare">
        <link:definition>2155115 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.apollomed.net/role/EarningsPerShareTables">
        <link:definition>2356310 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails">
        <link:definition>2457431 - Disclosure - Earnings Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails">
        <link:definition>2458432 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails">
        <link:definition>2459433 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEs" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs">
        <link:definition>2160116 - Disclosure - Variable Interest Entities (VIEs)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsTables" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables">
        <link:definition>2361311 - Disclosure - Variable Interest Entities (VIEs) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsDetails" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails">
        <link:definition>2462434 - Disclosure - Variable Interest Entities (VIEs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.apollomed.net/role/Leases">
        <link:definition>2163117 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.apollomed.net/role/LeasesTables">
        <link:definition>2364312 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalinformationDetails" roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails">
        <link:definition>2465435 - Disclosure - Leases - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2466436 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOtherInformationRelatedtoLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails">
        <link:definition>2467437 - Disclosure - Leases - Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails">
        <link:definition>2468438 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1">
        <link:definition>2468438 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.apollomed.net/role/SubsequentEvents">
        <link:definition>2169118 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails">
        <link:definition>2470439 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ameh_NumberOfFamilyPracticeClinics" abstract="false" name="NumberOfFamilyPracticeClinics" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_DiagnosticMedicalGroupMember" abstract="true" name="DiagnosticMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" abstract="true" name="MPPAMGPropertiesAndZLLAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_CDSCMember" abstract="true" name="CDSCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" abstract="false" name="EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_AccountableHealthCareIPAMember" abstract="true" name="AccountableHealthCareIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FulgentGeneticsIncMember" abstract="true" name="FulgentGeneticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" abstract="false" name="FinanceReceivableModificationsSubsequentDefaultInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" abstract="false" name="BusinessCombinationEquityInterestPurchaseObligationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PaymentMadeToRelatedParty" abstract="false" name="PaymentMadeToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" abstract="true" name="ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeFinanceLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" abstract="false" name="InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightExercisable" abstract="false" name="ClassOfWarrantOrRightExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_FinanceReceivableInterestRateStatedPercentage" abstract="false" name="FinanceReceivableInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_SpecialtyCapitationPayableCurrent" abstract="false" name="SpecialtyCapitationPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_FinanceReceivableStatedInterestRate" abstract="false" name="FinanceReceivableStatedInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_DeferredTaxLiabilitiesWarrantsExercised" abstract="false" name="DeferredTaxLiabilitiesWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightCancelledInPeriod" abstract="false" name="ClassOfWarrantOrRightCancelledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" abstract="false" name="PercentageOfFinancialGuaranteeBenchmarkAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageDiscountRateAbstract" abstract="true" name="LeaseWeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AlphaCareMedicalGroupInc.Member" abstract="true" name="AlphaCareMedicalGroupInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_HSMSOMember" abstract="true" name="HSMSOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NumberOfEmployees" abstract="false" name="NumberOfEmployees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_APAMHMedicalCorporationMember" abstract="true" name="APAMHMedicalCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantCashFlowCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_Tag6MedicalInvestmentGroupLLCMember" abstract="true" name="Tag6MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_UniversalCareAcquisitionPartnersLlcMember" abstract="true" name="UniversalCareAcquisitionPartnersLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NumenLLCMember" abstract="true" name="NumenLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApolloSunLabsManagementLLCMember" abstract="true" name="ApolloSunLabsManagementLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_AccountsReceivableAndNetRevenueTable" abstract="true" name="AccountsReceivableAndNetRevenueTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" abstract="false" name="InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_MarketableSecuritiesCurrentMaturityPeriod" abstract="false" name="MarketableSecuritiesCurrentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NoncontrollingInterestIncreaseFromCapitalCharge" abstract="false" name="NoncontrollingInterestIncreaseFromCapitalCharge" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" abstract="true" name="Tag8MedicalInvestmentGroupLLCRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeOperatingLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_MediPortalLLCMember" abstract="true" name="MediPortalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LmaMember" abstract="true" name="LmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AurionMember" abstract="true" name="AurionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" abstract="false" name="NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_SharesWarrantsRollForward" abstract="true" name="SharesWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" abstract="false" name="WarrantIssuedDuringPeriodValueStockOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AmgIncMember" abstract="true" name="AmgIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" abstract="true" name="LeaseWeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ZLLPartnersLLCMember" abstract="true" name="ZLLPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" abstract="true" name="CashPaidForLeaseLiabilitiesAbstractAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PerMemberPerMonthManagedCareContractMember" abstract="true" name="PerMemberPerMonthManagedCareContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FiduciaryAccountsPayableCurrent" abstract="false" name="FiduciaryAccountsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NumberOfWarrantsGranted" abstract="false" name="NumberOfWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentOwnershipPercentageDisposed" abstract="false" name="EquityMethodInvestmentOwnershipPercentageDisposed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInOperatingLeaseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesCashlessWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" abstract="false" name="RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears" abstract="false" name="RevenueFromRiskPoolSettlementsFromPriorPerformanceYears" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ContractTypeAxis" abstract="true" name="ContractTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ApaAcoIncMember" abstract="true" name="ApaAcoIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" abstract="false" name="BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_APCAndAPCLSMAMember" abstract="true" name="APCAndAPCLSMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_Tag8MedicalInvestmentGroupLLCMember" abstract="true" name="Tag8MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MezzanineMember" abstract="true" name="MezzanineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PreferredBankMember" abstract="true" name="PreferredBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentOfRevenueMonthlyAmount" abstract="false" name="PaymentOfRevenueMonthlyAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsContribution" abstract="false" name="EquityMethodInvestmentsContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ConstructionLoanMember" abstract="true" name="ConstructionLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessTable" abstract="true" name="DescriptionOfBusinessTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" abstract="false" name="DeferredTaxLiabilitiesAdjustedToGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AMGPropertiesLLCMember" abstract="true" name="AMGPropertiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_OtherThirdPartiesMember" abstract="true" name="OtherThirdPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockAwardsAndUnitsMember" abstract="true" name="StockAwardsAndUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_PayorCMember" abstract="true" name="PayorCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AccountsPayableAndAccruedExpensesMember" abstract="true" name="AccountsPayableAndAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeOneMember" abstract="true" name="WarrantExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PmiocMember" abstract="true" name="PmiocMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AdvanceDiagnosticSurgeryCenterMember" abstract="true" name="AdvanceDiagnosticSurgeryCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorGMember" abstract="true" name="PayorGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorAMember" abstract="true" name="PayorAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_PaymentsForMedicalCareCostsAbstract" abstract="true" name="PaymentsForMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" abstract="false" name="ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" abstract="true" name="LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ApcShareholdersMember" abstract="true" name="ApcShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MedicalPropertyPartnersLLCMember" abstract="true" name="MedicalPropertyPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_ManagementContractsMember" abstract="true" name="ManagementContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MemberRelationshipsMember" abstract="true" name="MemberRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApcLsmaMember" abstract="true" name="ApcLsmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightIssuedInPeriod" abstract="false" name="ClassOfWarrantOrRightIssuedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_CollegeStreetInvestmentLpMember" abstract="true" name="CollegeStreetInvestmentLpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ConcourseDiagnosticSurgeryCenterLlcMember" abstract="true" name="ConcourseDiagnosticSurgeryCenterLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_HealthCareCapitationRevenueMember" abstract="true" name="HealthCareCapitationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EarningsPerShareLineItems" abstract="true" name="EarningsPerShareLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_LasalleMedicalAssociatesIpaMember" abstract="true" name="LasalleMedicalAssociatesIpaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" abstract="false" name="EquityMethodInvestmentWriteOffOfAdditionalProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_WeightedaverageremainingcontractualtermyearsAbstract" abstract="true" name="WeightedaverageremainingcontractualtermyearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeTwoMember" abstract="true" name="WarrantExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInMedicalLiabilities" abstract="false" name="IncreaseDecreaseInMedicalLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AccessPrimaryCareMedicalGroupMember" abstract="true" name="AccessPrimaryCareMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CAIPAMSOLLCMember" abstract="true" name="CAIPAMSOLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_ProceedsFromSaleOfNoncontrollingInterest" abstract="false" name="ProceedsFromSaleOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MaverickMedicalGroupIncMember" abstract="true" name="MaverickMedicalGroupIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_FreseniusMember" abstract="true" name="FreseniusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApolloMedicalHoldingsIncMember" abstract="true" name="ApolloMedicalHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_TemporaryEquityPolicyTextBlock" abstract="false" name="TemporaryEquityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_NumberOfWarrantsExercised" abstract="false" name="NumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsConsolidated" abstract="false" name="EquityMethodInvestmentsConsolidated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MedicalCareCostsAbstract" abstract="true" name="MedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_CancellationOfRestrictedStockAwards" abstract="false" name="CancellationOfRestrictedStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_AlliedPacificOfCaliforniaIPAMember" abstract="true" name="AlliedPacificOfCaliforniaIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Dr.JayMember" abstract="true" name="Dr.JayMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SubcontractorIPAPayable" abstract="false" name="SubcontractorIPAPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AHMCMember" abstract="true" name="AHMCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationCash" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationCash" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentOfRevenue" abstract="false" name="PaymentOfRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AncillaryServiceContractMember" abstract="true" name="AncillaryServiceContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DmgMember" abstract="true" name="DmgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentConsultingFees" abstract="false" name="PaymentConsultingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" abstract="false" name="EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueCashlessWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" abstract="false" name="AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EarningsPerShareTable" abstract="true" name="EarningsPerShareTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_UniversalCareIncMember" abstract="true" name="UniversalCareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OneMSOLLCMember" abstract="true" name="OneMSOLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NetworkRelationshipsMember" abstract="true" name="NetworkRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareholdersAndOfficersMember" abstract="true" name="ShareholdersAndOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PacificMedicalImagingAndOncologyCenterIncMember" abstract="true" name="PacificMedicalImagingAndOncologyCenterIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AchievaMedInc.Member" abstract="true" name="AchievaMedInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" abstract="false" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_CMSMember" abstract="true" name="CMSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LoanReceivableTextBlock" abstract="false" name="LoanReceivableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_PayorBMember" abstract="true" name="PayorBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" abstract="true" name="OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_WeightedAverageExercisePriceWarrantsRollForward" abstract="true" name="WeightedAverageExercisePriceWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AggregateintrinsicvalueAbstract" abstract="true" name="AggregateintrinsicvalueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementIncMember" abstract="true" name="NetworkMedicalManagementIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CriticalQualityManagementCorpMember" abstract="true" name="CriticalQualityManagementCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApcBusinessLoanAgreementMember" abstract="true" name="ApcBusinessLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MinorityInterestPolicyPolicyTextBlock" abstract="false" name="MinorityInterestPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_PaymentOfRevenueRevenueRecognized" abstract="false" name="PaymentOfRevenueRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_PatientManagementPlatformMember" abstract="true" name="PatientManagementPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_BeneficialInterestPolicyTextBlock" abstract="false" name="BeneficialInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_ApcStockOptionMember" abstract="true" name="ApcStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentAdditionalInvestment" abstract="false" name="EquityMethodInvestmentAdditionalInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_FiduciaryCashAndPayablePolicyTextBlock" abstract="false" name="FiduciaryCashAndPayablePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase" abstract="false" name="EquityMethodInvestmentAdditionalPercentageCommittedToPurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeThreeMember" abstract="true" name="WarrantExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NumberOfFederallyQualifiedHealthPlans" abstract="false" name="NumberOfFederallyQualifiedHealthPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationPreferredShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_OneMSOInc.Member" abstract="true" name="OneMSOInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_FinanceReceivableTermOfReceivable" abstract="false" name="FinanceReceivableTermOfReceivable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ContractTypeDomain" abstract="true" name="ContractTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_DebtInstrumentNumberOfKeyFinancialRatios" abstract="false" name="DebtInstrumentNumberOfKeyFinancialRatios" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" abstract="false" name="EquityMethodAndOtherEquityInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsRollForward" abstract="true" name="EquityMethodInvestmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantDebtCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentOwnershipPercentageSold" abstract="false" name="EquityMethodInvestmentOwnershipPercentageSold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_FiveThreeOneW.CollegeLLCMember" abstract="true" name="FiveThreeOneW.CollegeLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" abstract="false" name="UnrealizedGainLossFromInvestmentInEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" abstract="false" name="ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_Dr.ArteagaMember" abstract="true" name="Dr.ArteagaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Pacific6EnterprisesMember" abstract="true" name="Pacific6EnterprisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SCHCMember" abstract="true" name="SCHCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorFMember" abstract="true" name="PayorFMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementMember" abstract="true" name="NetworkMedicalManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesMerger" abstract="false" name="StockIssuedDuringPeriodSharesMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_AccountsReceivableAndNetRevenueLineItems" abstract="true" name="AccountsReceivableAndNetRevenueLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ApaacoMember" abstract="true" name="ApaacoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorDMember" abstract="true" name="PayorDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MezzanineEquityAbstract" abstract="true" name="MezzanineEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ClinigenceHoldingsIncMember" abstract="true" name="ClinigenceHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" abstract="false" name="InsuranceServicesRevenueCapitationAndClaimsPaymentNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentsToAcquireCommonStockAndWarrants" abstract="false" name="PaymentsToAcquireCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" abstract="true" name="Tag6MedicalInvestmentGroupLLCRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodProxyVotesPercentage" abstract="false" name="StockIssuedDuringPeriodProxyVotesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod" abstract="false" name="EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_TermLoanAMember" abstract="true" name="TermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessLineItems" abstract="true" name="DescriptionOfBusinessLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AssetAcquisitionPercentageOfSharesAcquired" abstract="false" name="AssetAcquisitionPercentageOfSharesAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ameh-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:114d7d5d-3fd3-46db-8f4b-230f4f1be605,g:12a42f3e-83fc-4c9c-a1b4-628777c39609-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20210930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1cbefe5-1684-427d-aab2-e09b51e165cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7f971adc-5324-4ba6-858e-4f9d33782637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1cbefe5-1684-427d-aab2-e09b51e165cf" xlink:to="loc_us-gaap_Liabilities_7f971adc-5324-4ba6-858e-4f9d33782637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4da6344b-e808-4e8e-a894-6a916d04d967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1cbefe5-1684-427d-aab2-e09b51e165cf" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_4da6344b-e808-4e8e-a894-6a916d04d967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5edcdd8-ce9c-4526-9f28-7c9c9e3af8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1cbefe5-1684-427d-aab2-e09b51e165cf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5edcdd8-ce9c-4526-9f28-7c9c9e3af8ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d4a0365b-e9bb-4096-860c-d1a6a1a25b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1cbefe5-1684-427d-aab2-e09b51e165cf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d4a0365b-e9bb-4096-860c-d1a6a1a25b6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cfc3d74a-e217-4df2-b3c4-940b0b0911f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_babbaabd-d0c7-45a7-92ad-1dd1defdc93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cfc3d74a-e217-4df2-b3c4-940b0b0911f1" xlink:to="loc_us-gaap_AssetsCurrent_babbaabd-d0c7-45a7-92ad-1dd1defdc93e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_ee7e0a2b-7f30-4f6a-b796-f6128ba466a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cfc3d74a-e217-4df2-b3c4-940b0b0911f1" xlink:to="loc_us-gaap_AssetsNoncurrent_ee7e0a2b-7f30-4f6a-b796-f6128ba466a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b28a5f08-5190-4415-ad0f-85fc46d0f6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_085669a9-b9eb-4c15-97e6-92f32988781e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b28a5f08-5190-4415-ad0f-85fc46d0f6b0" xlink:to="loc_us-gaap_CommonStockValue_085669a9-b9eb-4c15-97e6-92f32988781e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_212e01f6-1322-4976-b882-e1a659136a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b28a5f08-5190-4415-ad0f-85fc46d0f6b0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_212e01f6-1322-4976-b882-e1a659136a5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f61734d0-d82b-4599-9848-fe8fa8312657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b28a5f08-5190-4415-ad0f-85fc46d0f6b0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f61734d0-d82b-4599-9848-fe8fa8312657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ac323c1c-4475-4781-b230-c8da9c5739d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b28a5f08-5190-4415-ad0f-85fc46d0f6b0" xlink:to="loc_us-gaap_PreferredStockValue_ac323c1c-4475-4781-b230-c8da9c5739d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7c98c715-ff80-4aba-b50e-c84be228d3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4fbf1034-f9a4-4464-852a-41f99db6bbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c98c715-ff80-4aba-b50e-c84be228d3ad" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4fbf1034-f9a4-4464-852a-41f99db6bbbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_4998cc91-b2b7-4cc6-99b0-188f39062d4a" xlink:href="ameh-20210930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c98c715-ff80-4aba-b50e-c84be228d3ad" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_4998cc91-b2b7-4cc6-99b0-188f39062d4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8975d2ec-558b-436a-9dff-a59c0b58660a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c98c715-ff80-4aba-b50e-c84be228d3ad" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8975d2ec-558b-436a-9dff-a59c0b58660a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_3a6f30a4-9329-4a60-8588-d851e616d38e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c98c715-ff80-4aba-b50e-c84be228d3ad" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_3a6f30a4-9329-4a60-8588-d851e616d38e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_6e8fc66c-2e0d-4517-ac2a-5caed8ee9316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c98c715-ff80-4aba-b50e-c84be228d3ad" xlink:to="loc_us-gaap_DividendsPayableCurrent_6e8fc66c-2e0d-4517-ac2a-5caed8ee9316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_09ea3666-93dc-40d1-a543-079e06a23ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c98c715-ff80-4aba-b50e-c84be228d3ad" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_09ea3666-93dc-40d1-a543-079e06a23ce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_63f31a47-f641-4dde-849f-37cb986aad27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c98c715-ff80-4aba-b50e-c84be228d3ad" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_63f31a47-f641-4dde-849f-37cb986aad27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_256b6e9b-feda-4506-9fe9-19631fc28d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c98c715-ff80-4aba-b50e-c84be228d3ad" xlink:to="loc_us-gaap_LongTermDebtCurrent_256b6e9b-feda-4506-9fe9-19631fc28d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_83d09a07-0685-4330-ad18-1428044f236b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5f697218-59c3-4128-aa53-59e19d6cf095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_83d09a07-0685-4330-ad18-1428044f236b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5f697218-59c3-4128-aa53-59e19d6cf095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_acdea966-b8d1-4a0f-9117-9cca7c67ee68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_83d09a07-0685-4330-ad18-1428044f236b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_acdea966-b8d1-4a0f-9117-9cca7c67ee68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_41ed2452-973e-42e7-b933-03cb79f80370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_83d09a07-0685-4330-ad18-1428044f236b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_41ed2452-973e-42e7-b933-03cb79f80370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a0f58464-0870-4334-b256-659e77cc26ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_83d09a07-0685-4330-ad18-1428044f236b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a0f58464-0870-4334-b256-659e77cc26ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_13e6d747-f7bb-4876-a32f-31bbc8553d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_83d09a07-0685-4330-ad18-1428044f236b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_13e6d747-f7bb-4876-a32f-31bbc8553d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4260c0f2-7ca8-4eaa-9a11-8a10812a13ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_beed1f02-f74d-43c3-8530-5833bde00a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4260c0f2-7ca8-4eaa-9a11-8a10812a13ce" xlink:to="loc_us-gaap_StockholdersEquity_beed1f02-f74d-43c3-8530-5833bde00a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d4aeb0b9-887c-49d9-92d1-e6c00435636a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4260c0f2-7ca8-4eaa-9a11-8a10812a13ce" xlink:to="loc_us-gaap_MinorityInterest_d4aeb0b9-887c-49d9-92d1-e6c00435636a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c2a3bae1-85f7-4b91-8a07-e6e7979d78be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_3241187d-0ff8-4dea-87de-f83afd5fd66e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c2a3bae1-85f7-4b91-8a07-e6e7979d78be" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_3241187d-0ff8-4dea-87de-f83afd5fd66e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_920367cc-0ddc-4af3-83cd-86ebb0ab9553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c2a3bae1-85f7-4b91-8a07-e6e7979d78be" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_920367cc-0ddc-4af3-83cd-86ebb0ab9553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_479a1f4b-4996-4fb0-983f-f01677b9a01a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c2a3bae1-85f7-4b91-8a07-e6e7979d78be" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_479a1f4b-4996-4fb0-983f-f01677b9a01a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ede1a6a1-bc88-4077-8fc9-30736b56d618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c2a3bae1-85f7-4b91-8a07-e6e7979d78be" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ede1a6a1-bc88-4077-8fc9-30736b56d618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_1faefc3f-915f-4fd1-9ef4-5231110fd405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c2a3bae1-85f7-4b91-8a07-e6e7979d78be" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_1faefc3f-915f-4fd1-9ef4-5231110fd405" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d4eef2df-17b9-4fcc-a288-ccfa3d66ac4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c2a3bae1-85f7-4b91-8a07-e6e7979d78be" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d4eef2df-17b9-4fcc-a288-ccfa3d66ac4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_732c9ceb-2982-4221-a9f0-4441af92c598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c2a3bae1-85f7-4b91-8a07-e6e7979d78be" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_732c9ceb-2982-4221-a9f0-4441af92c598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_68928025-87df-442f-a5a5-fae33c58ed75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_87ef7b8c-b52a-4435-a2a3-e431a2635e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_68928025-87df-442f-a5a5-fae33c58ed75" xlink:to="loc_us-gaap_LiabilitiesCurrent_87ef7b8c-b52a-4435-a2a3-e431a2635e7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_5a000670-7293-4a5e-b426-8bbd7388a7da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_68928025-87df-442f-a5a5-fae33c58ed75" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_5a000670-7293-4a5e-b426-8bbd7388a7da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_fdce7285-5914-413d-aad7-81ef95f48f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9328a8b2-89a5-4f13-9fb1-bff61ed5c8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fdce7285-5914-413d-aad7-81ef95f48f8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9328a8b2-89a5-4f13-9fb1-bff61ed5c8f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0d2cc080-4d0b-4bf4-9be9-9b6b98981bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fdce7285-5914-413d-aad7-81ef95f48f8f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0d2cc080-4d0b-4bf4-9be9-9b6b98981bf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_81ef90d1-f8e4-4e96-9b42-aebca213438a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fdce7285-5914-413d-aad7-81ef95f48f8f" xlink:to="loc_us-gaap_Goodwill_81ef90d1-f8e4-4e96-9b42-aebca213438a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_22821c9a-173a-4241-9d09-bda2871c3476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fdce7285-5914-413d-aad7-81ef95f48f8f" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_22821c9a-173a-4241-9d09-bda2871c3476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_64fdb3d2-672a-4f14-9972-05c2e4bd8dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fdce7285-5914-413d-aad7-81ef95f48f8f" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_64fdb3d2-672a-4f14-9972-05c2e4bd8dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b5be203c-0aba-4412-ac70-2e0d3d18d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fdce7285-5914-413d-aad7-81ef95f48f8f" xlink:to="loc_us-gaap_EquityMethodInvestments_b5be203c-0aba-4412-ac70-2e0d3d18d7ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_ac092089-f4b9-47c5-a2ff-e46499c3b6f1" xlink:href="ameh-20210930.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fdce7285-5914-413d-aad7-81ef95f48f8f" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_ac092089-f4b9-47c5-a2ff-e46499c3b6f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e9d52410-3475-439f-a921-c9970636d79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fdce7285-5914-413d-aad7-81ef95f48f8f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e9d52410-3475-439f-a921-c9970636d79f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_31bd4dd6-bb7c-4a26-98dd-f8b17cef25da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fdce7285-5914-413d-aad7-81ef95f48f8f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_31bd4dd6-bb7c-4a26-98dd-f8b17cef25da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b0c0a3eb-f210-4df0-bc04-1cbf158b249a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_fdce7285-5914-413d-aad7-81ef95f48f8f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b0c0a3eb-f210-4df0-bc04-1cbf158b249a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="ameh-20210930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6affcdf3-2fe4-424f-97e5-166cb5cd0ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a13ce813-14b1-4e5e-b982-b7b4e3f75323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6affcdf3-2fe4-424f-97e5-166cb5cd0ff9" xlink:to="loc_us-gaap_ProfitLoss_a13ce813-14b1-4e5e-b982-b7b4e3f75323" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_05b0a827-f6cc-48b9-b163-7da575b0dd52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6affcdf3-2fe4-424f-97e5-166cb5cd0ff9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_05b0a827-f6cc-48b9-b163-7da575b0dd52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc0d7ccf-d4e6-4ced-842c-19276db847b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_063e5ec1-8789-475b-adbe-0b97b78f320a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc0d7ccf-d4e6-4ced-842c-19276db847b9" xlink:to="loc_us-gaap_OperatingIncomeLoss_063e5ec1-8789-475b-adbe-0b97b78f320a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5f029867-73d4-4985-b449-03b5d8f5b767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc0d7ccf-d4e6-4ced-842c-19276db847b9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5f029867-73d4-4985-b449-03b5d8f5b767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2d40809b-2401-4605-9956-782ad58987f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_95a8603b-b87b-4c60-b348-d5c68d0e8a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2d40809b-2401-4605-9956-782ad58987f3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_95a8603b-b87b-4c60-b348-d5c68d0e8a29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cf335911-fd59-42ff-8c1e-d45e6abfa4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2d40809b-2401-4605-9956-782ad58987f3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cf335911-fd59-42ff-8c1e-d45e6abfa4a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f62327ff-0719-41d6-bec7-9950b46076f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2d40809b-2401-4605-9956-782ad58987f3" xlink:to="loc_us-gaap_InterestExpense_f62327ff-0719-41d6-bec7-9950b46076f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_c6af0311-0032-4e89-b039-94e441e35649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2d40809b-2401-4605-9956-782ad58987f3" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_c6af0311-0032-4e89-b039-94e441e35649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_f96cb07f-e58b-450e-b5bd-4c6e06f4ad40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2d40809b-2401-4605-9956-782ad58987f3" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_f96cb07f-e58b-450e-b5bd-4c6e06f4ad40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1ef3ef2a-8df2-497b-8e57-5f5797a36a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2d40809b-2401-4605-9956-782ad58987f3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1ef3ef2a-8df2-497b-8e57-5f5797a36a0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_543b53b9-3f47-4292-aaca-ee2fb5980d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_c4122ee2-be45-4d36-bda7-b1325edbb4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_543b53b9-3f47-4292-aaca-ee2fb5980d49" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_c4122ee2-be45-4d36-bda7-b1325edbb4e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f2fe1a1d-3768-43c6-b0ac-3a1957982caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_543b53b9-3f47-4292-aaca-ee2fb5980d49" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f2fe1a1d-3768-43c6-b0ac-3a1957982caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_444acd84-6e79-45ce-8a08-53e4631cb926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_543b53b9-3f47-4292-aaca-ee2fb5980d49" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_444acd84-6e79-45ce-8a08-53e4631cb926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5b626e37-f0ee-4d02-b002-57de88a7a471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d49295db-c203-49a0-8c27-fc3b0100c1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5b626e37-f0ee-4d02-b002-57de88a7a471" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d49295db-c203-49a0-8c27-fc3b0100c1ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9bf57976-0bdb-4701-b981-6d29e17cdf39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5b626e37-f0ee-4d02-b002-57de88a7a471" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9bf57976-0bdb-4701-b981-6d29e17cdf39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ce790c49-a4d7-42fa-b425-e3e2e06bbaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ccfff089-d566-4229-8e25-cd44b234ba92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ce790c49-a4d7-42fa-b425-e3e2e06bbaa9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ccfff089-d566-4229-8e25-cd44b234ba92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5228e10c-3b40-4176-b8a9-18dc68258f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ce790c49-a4d7-42fa-b425-e3e2e06bbaa9" xlink:to="loc_us-gaap_CostsAndExpenses_5228e10c-3b40-4176-b8a9-18dc68258f85" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ameh-20210930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81711db4-2511-487c-9879-c07577b1e315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_af86af8e-49e0-4b6b-a094-4d368e7340a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81711db4-2511-487c-9879-c07577b1e315" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_af86af8e-49e0-4b6b-a094-4d368e7340a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_d67ded1b-0bcb-45e8-abb8-9cec7d528025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81711db4-2511-487c-9879-c07577b1e315" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_d67ded1b-0bcb-45e8-abb8-9cec7d528025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_51d5a50c-c824-48ff-8995-9af81a0fa4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81711db4-2511-487c-9879-c07577b1e315" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_51d5a50c-c824-48ff-8995-9af81a0fa4d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fb8734e6-3882-4433-8a27-fcb88d5d35fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81711db4-2511-487c-9879-c07577b1e315" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fb8734e6-3882-4433-8a27-fcb88d5d35fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_e9882179-94ed-4e1b-a4e7-9fcefd30a404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81711db4-2511-487c-9879-c07577b1e315" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_e9882179-94ed-4e1b-a4e7-9fcefd30a404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e93e7070-91b5-410a-ba6b-591cf2dcddb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81711db4-2511-487c-9879-c07577b1e315" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e93e7070-91b5-410a-ba6b-591cf2dcddb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_612f3c73-91dc-41f9-ac16-6413ad24343f" xlink:href="ameh-20210930.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81711db4-2511-487c-9879-c07577b1e315" xlink:to="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_612f3c73-91dc-41f9-ac16-6413ad24343f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_5cbc7a8b-5363-4905-8056-8f0bebea42ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_81711db4-2511-487c-9879-c07577b1e315" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_5cbc7a8b-5363-4905-8056-8f0bebea42ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_de302349-f535-4841-a02a-04fd8d5a4294" xlink:href="ameh-20210930.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_de302349-f535-4841-a02a-04fd8d5a4294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_cc8c5e64-4e9a-437f-8b32-396d5c8331ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_cc8c5e64-4e9a-437f-8b32-396d5c8331ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_e7bf5308-4c5a-4681-a408-0cd14ab931c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_e7bf5308-4c5a-4681-a408-0cd14ab931c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3ae76ca7-ff62-4b56-9beb-78773d953065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3ae76ca7-ff62-4b56-9beb-78773d953065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_3e3c645e-f600-4e12-bfd0-21c91339feba" xlink:href="ameh-20210930.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_3e3c645e-f600-4e12-bfd0-21c91339feba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_edfbe8b9-424d-4e1e-b9be-af99fbe0d8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_edfbe8b9-424d-4e1e-b9be-af99fbe0d8ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_54488b49-b29b-407e-a3b7-6f331179fe29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_54488b49-b29b-407e-a3b7-6f331179fe29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fdea9f08-657a-4c5d-808e-ded369cf2666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fdea9f08-657a-4c5d-808e-ded369cf2666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a79f2f28-d22f-43e0-a708-ea2161a447cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a79f2f28-d22f-43e0-a708-ea2161a447cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_294b0be4-7938-4755-8301-de282417cea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLossOnDerivative"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_294b0be4-7938-4755-8301-de282417cea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c838f829-0395-4000-939f-59c21b4c3b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_AssetImpairmentCharges_c838f829-0395-4000-939f-59c21b4c3b33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_d1e47549-d0de-4eeb-89bb-870b6d633d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_d1e47549-d0de-4eeb-89bb-870b6d633d8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_33105568-8fb1-4e40-9925-38e61a2d4ee0" xlink:href="ameh-20210930.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_33105568-8fb1-4e40-9925-38e61a2d4ee0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_553f5d3a-f7ff-40b8-b091-3187f3bdb8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_553f5d3a-f7ff-40b8-b091-3187f3bdb8cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d2507d40-ade1-4d0a-9c99-a1d7d6c3fd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_ProfitLoss_d2507d40-ade1-4d0a-9c99-a1d7d6c3fd3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1042f128-edfa-41d1-8864-892a73f84e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1042f128-edfa-41d1-8864-892a73f84e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities_8287d509-7ce9-489c-8364-8496104fb248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_ProceedsFromOtherOperatingActivities_8287d509-7ce9-489c-8364-8496104fb248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_8576a441-ddc0-4d7a-8bd6-c40bb8740407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_8576a441-ddc0-4d7a-8bd6-c40bb8740407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_12d4d348-3b16-4451-be0c-32ed0434c005" xlink:href="ameh-20210930.xsd#ameh_UnrealizedGainLossFromInvestmentInEquitySecurities"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_12d4d348-3b16-4451-be0c-32ed0434c005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_32cf5dd8-2eff-461a-a298-f297826b5249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_32cf5dd8-2eff-461a-a298-f297826b5249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_3cab6d7e-c782-4cae-a457-c65d6dd3cd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_3cab6d7e-c782-4cae-a457-c65d6dd3cd6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c98c8b53-a034-4d85-97d6-83756ef85e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8beafa-7908-4601-b79e-1624dff75aca" xlink:to="loc_us-gaap_ShareBasedCompensation_c98c8b53-a034-4d85-97d6-83756ef85e2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a5e6ee2-8cc9-49c5-947a-34a69a371210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dfe868a8-1d01-47a7-bc85-7a6f02bd4fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a5e6ee2-8cc9-49c5-947a-34a69a371210" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dfe868a8-1d01-47a7-bc85-7a6f02bd4fcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ac429cf-b21e-46c3-a3dd-8f20f384f05a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a5e6ee2-8cc9-49c5-947a-34a69a371210" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ac429cf-b21e-46c3-a3dd-8f20f384f05a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ede503ee-61c6-4fda-9eba-717045885fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a5e6ee2-8cc9-49c5-947a-34a69a371210" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ede503ee-61c6-4fda-9eba-717045885fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ab4083a-e105-4a72-a241-749dc623a5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_6e46c793-985c-4c32-b3df-b7810b3d1a23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ab4083a-e105-4a72-a241-749dc623a5d3" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_6e46c793-985c-4c32-b3df-b7810b3d1a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43bc607c-aa51-48f7-9872-418517b3f69b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ab4083a-e105-4a72-a241-749dc623a5d3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43bc607c-aa51-48f7-9872-418517b3f69b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_d2819d8e-f8c0-4faa-bf42-3a4d17294072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ab4083a-e105-4a72-a241-749dc623a5d3" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_d2819d8e-f8c0-4faa-bf42-3a4d17294072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e66e22ba-1b35-4296-8bd4-767a07589dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b5b51b8c-0e16-4110-8e21-bb0183b19eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e66e22ba-1b35-4296-8bd4-767a07589dfd" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b5b51b8c-0e16-4110-8e21-bb0183b19eba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_cd546117-f6f8-4bcd-99b4-064e64d2cba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e66e22ba-1b35-4296-8bd4-767a07589dfd" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_cd546117-f6f8-4bcd-99b4-064e64d2cba4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_709c5e0a-2f2c-49e2-97e2-537de1971504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e66e22ba-1b35-4296-8bd4-767a07589dfd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_709c5e0a-2f2c-49e2-97e2-537de1971504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_1fb9f351-9fba-405a-b6a4-1c2bab8c98ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e66e22ba-1b35-4296-8bd4-767a07589dfd" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_1fb9f351-9fba-405a-b6a4-1c2bab8c98ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b0198e43-9caf-493b-9536-40ca25f33f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e66e22ba-1b35-4296-8bd4-767a07589dfd" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b0198e43-9caf-493b-9536-40ca25f33f94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_40025e0e-2467-4f00-9588-140120678815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e66e22ba-1b35-4296-8bd4-767a07589dfd" xlink:to="loc_us-gaap_PaymentsOfDividends_40025e0e-2467-4f00-9588-140120678815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_b8ee7734-89f1-4d1e-8e6c-12d9fb3a74dc" xlink:href="ameh-20210930.xsd#ameh_ProceedsFromSaleOfNoncontrollingInterest"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e66e22ba-1b35-4296-8bd4-767a07589dfd" xlink:to="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_b8ee7734-89f1-4d1e-8e6c-12d9fb3a74dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_05a8c8bb-de32-4056-bf02-6fbb45aecc11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e66e22ba-1b35-4296-8bd4-767a07589dfd" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_05a8c8bb-de32-4056-bf02-6fbb45aecc11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_ecbd0c67-348a-4344-b39d-ebc00c375709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e66e22ba-1b35-4296-8bd4-767a07589dfd" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_ecbd0c67-348a-4344-b39d-ebc00c375709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_17f76482-19eb-450e-872a-9ba9d647cd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e66e22ba-1b35-4296-8bd4-767a07589dfd" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_17f76482-19eb-450e-872a-9ba9d647cd86" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_fef63ddd-95b1-4815-b191-62dbc211e97f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d9ef6dd1-7b15-4759-8c51-4aeed779b7af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_fef63ddd-95b1-4815-b191-62dbc211e97f" xlink:to="loc_us-gaap_DerivativeLiabilities_d9ef6dd1-7b15-4759-8c51-4aeed779b7af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_cf033571-835e-4bb8-9979-402bf7cebba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_fef63ddd-95b1-4815-b191-62dbc211e97f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_cf033571-835e-4bb8-9979-402bf7cebba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3e2b03b2-b8ab-4c67-a73a-903a8da8ef40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6609a1c6-d5f1-43e4-be52-f9cf1aafb42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3e2b03b2-b8ab-4c67-a73a-903a8da8ef40" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6609a1c6-d5f1-43e4-be52-f9cf1aafb42d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f0aac3ea-9bf6-4a69-b07c-8fe315610641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3e2b03b2-b8ab-4c67-a73a-903a8da8ef40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f0aac3ea-9bf6-4a69-b07c-8fe315610641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2d6cf76e-fe3d-47a4-8843-10c152c9c9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3e2b03b2-b8ab-4c67-a73a-903a8da8ef40" xlink:to="loc_us-gaap_DerivativeAssets_2d6cf76e-fe3d-47a4-8843-10c152c9c9b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_fc877ae7-5d67-480f-99b1-243e6af71a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3e2b03b2-b8ab-4c67-a73a-903a8da8ef40" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_fc877ae7-5d67-480f-99b1-243e6af71a6b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_330ce827-510c-421f-a5a5-f8031b9e73e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1b1fa184-c166-4d9a-8851-ff5799642581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_330ce827-510c-421f-a5a5-f8031b9e73e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1b1fa184-c166-4d9a-8851-ff5799642581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d477a253-6c9c-4992-80e9-d120223a595b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_330ce827-510c-421f-a5a5-f8031b9e73e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d477a253-6c9c-4992-80e9-d120223a595b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_421935b9-94c7-4581-9933-99b7bef76fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8524846f-9b6b-43f3-b921-70693c29a660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_421935b9-94c7-4581-9933-99b7bef76fec" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8524846f-9b6b-43f3-b921-70693c29a660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_27236dd9-a4b7-4fad-a4f6-07306c253d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_421935b9-94c7-4581-9933-99b7bef76fec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_27236dd9-a4b7-4fad-a4f6-07306c253d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_61ff5c2c-cdab-4773-851c-6083a378c120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e0599172-354a-430d-ab24-1fcb519df065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_61ff5c2c-cdab-4773-851c-6083a378c120" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e0599172-354a-430d-ab24-1fcb519df065" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20210930.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_02267c59-4f9f-4110-b3e5-5daae499910f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_85077f94-0633-4d7d-bfca-dd72ea9d3cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_02267c59-4f9f-4110-b3e5-5daae499910f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_85077f94-0633-4d7d-bfca-dd72ea9d3cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_289cc3cb-2688-40a8-890b-adc18cd5efe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_02267c59-4f9f-4110-b3e5-5daae499910f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_289cc3cb-2688-40a8-890b-adc18cd5efe4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7cea3c60-814a-4af3-958b-0140ed1e42e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0e1a80de-b1a3-4330-980f-b74e8cef6873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7cea3c60-814a-4af3-958b-0140ed1e42e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0e1a80de-b1a3-4330-980f-b74e8cef6873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_68c62194-796f-41c0-92d0-6ffc30b62521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7cea3c60-814a-4af3-958b-0140ed1e42e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_68c62194-796f-41c0-92d0-6ffc30b62521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5e4884b0-cd6f-4e06-b924-fb5afee846d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7cea3c60-814a-4af3-958b-0140ed1e42e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5e4884b0-cd6f-4e06-b924-fb5afee846d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_634165da-3bd6-432b-99f9-f56a873236bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7cea3c60-814a-4af3-958b-0140ed1e42e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_634165da-3bd6-432b-99f9-f56a873236bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a25d4c1d-d461-4b87-9d40-652b8cad2853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7cea3c60-814a-4af3-958b-0140ed1e42e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a25d4c1d-d461-4b87-9d40-652b8cad2853" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_0fd79bff-d3d0-4db9-840d-0b7d1668cf81" xlink:href="ameh-20210930.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7cea3c60-814a-4af3-958b-0140ed1e42e7" xlink:to="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_0fd79bff-d3d0-4db9-840d-0b7d1668cf81" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1f2f312e-ae7d-4d1c-a651-02b9f9a29267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fd9fd119-77cf-4458-a553-8b0509d6cc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1f2f312e-ae7d-4d1c-a651-02b9f9a29267" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fd9fd119-77cf-4458-a553-8b0509d6cc6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ff88b52a-93e2-4bb8-8fcc-f8d98cb16e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1f2f312e-ae7d-4d1c-a651-02b9f9a29267" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ff88b52a-93e2-4bb8-8fcc-f8d98cb16e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ef231962-686c-4537-965b-c52711bce421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1f2f312e-ae7d-4d1c-a651-02b9f9a29267" xlink:to="loc_us-gaap_RestrictedCashCurrent_ef231962-686c-4537-965b-c52711bce421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_ba3575bc-3d52-46bf-928d-9e985f283911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1f2f312e-ae7d-4d1c-a651-02b9f9a29267" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_ba3575bc-3d52-46bf-928d-9e985f283911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_26c5a887-712f-44ea-8fec-293d6606313f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1f2f312e-ae7d-4d1c-a651-02b9f9a29267" xlink:to="loc_us-gaap_OtherAssetsCurrent_26c5a887-712f-44ea-8fec-293d6606313f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_3927b1c5-db5f-477d-8708-cd8ad54a3ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1f2f312e-ae7d-4d1c-a651-02b9f9a29267" xlink:to="loc_us-gaap_OtherAssets_3927b1c5-db5f-477d-8708-cd8ad54a3ce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_87f97f31-6eb5-43fa-98d6-99d4bf769559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1f2f312e-ae7d-4d1c-a651-02b9f9a29267" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_87f97f31-6eb5-43fa-98d6-99d4bf769559" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4cf178e0-7e90-468d-903a-8513dbb3da94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3aeda178-dccf-4844-a1a6-ccc4e61f0e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4cf178e0-7e90-468d-903a-8513dbb3da94" xlink:to="loc_us-gaap_AccountsPayableCurrent_3aeda178-dccf-4844-a1a6-ccc4e61f0e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_7995723b-7fd5-4c8f-a8e9-c119b9605383" xlink:href="ameh-20210930.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4cf178e0-7e90-468d-903a-8513dbb3da94" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_7995723b-7fd5-4c8f-a8e9-c119b9605383" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable_bfa624ad-bfc2-4726-8ab3-cf949559a29a" xlink:href="ameh-20210930.xsd#ameh_SubcontractorIPAPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4cf178e0-7e90-468d-903a-8513dbb3da94" xlink:to="loc_ameh_SubcontractorIPAPayable_bfa624ad-bfc2-4726-8ab3-cf949559a29a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f84f8542-fe48-41f4-8e61-657bca9253a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4cf178e0-7e90-468d-903a-8513dbb3da94" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f84f8542-fe48-41f4-8e61-657bca9253a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_09525480-3d33-471f-8d2a-0dcb38b5ea00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4cf178e0-7e90-468d-903a-8513dbb3da94" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_09525480-3d33-471f-8d2a-0dcb38b5ea00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c54f8613-b8f0-499e-8607-5a051825097f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4cf178e0-7e90-468d-903a-8513dbb3da94" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c54f8613-b8f0-499e-8607-5a051825097f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1a28f6e7-8372-45ab-b549-92e4f8e1d672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4cf178e0-7e90-468d-903a-8513dbb3da94" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1a28f6e7-8372-45ab-b549-92e4f8e1d672" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_83ac2101-d24c-4d6e-beff-eebebb40453b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_a258b879-b796-4c29-af4d-4dc35c47a115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_83ac2101-d24c-4d6e-beff-eebebb40453b" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_a258b879-b796-4c29-af4d-4dc35c47a115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_c77250f8-242c-4c06-a5cf-4cab63a37b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_83ac2101-d24c-4d6e-beff-eebebb40453b" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_c77250f8-242c-4c06-a5cf-4cab63a37b2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_4061ce4d-9259-49c7-9b82-8802dab53bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_e7646f61-f368-450f-81d9-fe6ab89b8cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_4061ce4d-9259-49c7-9b82-8802dab53bec" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_e7646f61-f368-450f-81d9-fe6ab89b8cdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_1a29f0ef-0b32-449c-9e8e-9a398f65952f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_4061ce4d-9259-49c7-9b82-8802dab53bec" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_1a29f0ef-0b32-449c-9e8e-9a398f65952f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_5c9ebaa0-40a7-42b8-b3de-ec824b2e52dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_e39df624-74b7-40a7-917c-1b8b584feaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_5c9ebaa0-40a7-42b8-b3de-ec824b2e52dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_e39df624-74b7-40a7-917c-1b8b584feaf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8834b1c8-5f11-4329-8600-a3e4372a011d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_5c9ebaa0-40a7-42b8-b3de-ec824b2e52dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8834b1c8-5f11-4329-8600-a3e4372a011d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_05b171e3-03cb-4892-9886-38e9e7f21985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_5c9ebaa0-40a7-42b8-b3de-ec824b2e52dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_05b171e3-03cb-4892-9886-38e9e7f21985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0b0dbd52-fd03-4d0d-9cf4-8751f7606beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_5c9ebaa0-40a7-42b8-b3de-ec824b2e52dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0b0dbd52-fd03-4d0d-9cf4-8751f7606beb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LongTermDebtMaturityAfterYearFour_1216ba8a-9022-4900-acba-42f2f952ca5d" xlink:href="ameh-20210930.xsd#ameh_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_5c9ebaa0-40a7-42b8-b3de-ec824b2e52dd" xlink:to="loc_ameh_LongTermDebtMaturityAfterYearFour_1216ba8a-9022-4900-acba-42f2f952ca5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_175e6c1e-d9de-4e76-a77d-82e3ae8d4096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_c85f8174-dbe1-49d4-97f0-e210402e5c15" xlink:href="ameh-20210930.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_175e6c1e-d9de-4e76-a77d-82e3ae8d4096" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_c85f8174-dbe1-49d4-97f0-e210402e5c15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_088d2f8e-c952-4a4f-8cdb-9e428b724006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_175e6c1e-d9de-4e76-a77d-82e3ae8d4096" xlink:to="loc_us-gaap_ManagementFeeExpense_088d2f8e-c952-4a4f-8cdb-9e428b724006" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d589ec01-cb89-4c73-bde5-ad0f59f229ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f3b2587b-3acc-4636-92a9-0743ebf69534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d589ec01-cb89-4c73-bde5-ad0f59f229ad" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f3b2587b-3acc-4636-92a9-0743ebf69534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_db0251e6-c11c-4d52-9105-ab739abf5498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d589ec01-cb89-4c73-bde5-ad0f59f229ad" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_db0251e6-c11c-4d52-9105-ab739abf5498" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_aada95df-3746-418c-ae18-c2bc5b290f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_01e5c246-ea38-4cf0-b928-44c2144ef574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aada95df-3746-418c-ae18-c2bc5b290f91" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_01e5c246-ea38-4cf0-b928-44c2144ef574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_1989f29b-1020-4fff-9085-d118069d4fba" xlink:href="ameh-20210930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aada95df-3746-418c-ae18-c2bc5b290f91" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_1989f29b-1020-4fff-9085-d118069d4fba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b41a4761-5b02-439b-9824-9f6321533e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aada95df-3746-418c-ae18-c2bc5b290f91" xlink:to="loc_us-gaap_LongTermDebtCurrent_b41a4761-5b02-439b-9824-9f6321533e32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_66f80b47-c5c6-43c7-b5df-c982eb09d350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aada95df-3746-418c-ae18-c2bc5b290f91" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_66f80b47-c5c6-43c7-b5df-c982eb09d350" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_32fd161d-517b-48ad-b402-d7715e7bc6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aada95df-3746-418c-ae18-c2bc5b290f91" xlink:to="loc_us-gaap_TaxesPayableCurrent_32fd161d-517b-48ad-b402-d7715e7bc6ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_7d208f90-a5b6-461a-9b99-f5d6d7744fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aada95df-3746-418c-ae18-c2bc5b290f91" xlink:to="loc_us-gaap_DueToAffiliateCurrent_7d208f90-a5b6-461a-9b99-f5d6d7744fe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_ce6c5aa5-2257-47e6-a012-ace6f02859b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aada95df-3746-418c-ae18-c2bc5b290f91" xlink:to="loc_us-gaap_DividendsPayableCurrent_ce6c5aa5-2257-47e6-a012-ace6f02859b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_0f103438-d292-4bff-96ce-e2948c177df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aada95df-3746-418c-ae18-c2bc5b290f91" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_0f103438-d292-4bff-96ce-e2948c177df0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_eaa89afc-1681-48b7-94cc-683f4480422f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aada95df-3746-418c-ae18-c2bc5b290f91" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_eaa89afc-1681-48b7-94cc-683f4480422f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_6a822361-908a-4e45-9833-c2e2935487fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_20d8cfa3-c094-40d4-81a1-8856af6498b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6a822361-908a-4e45-9833-c2e2935487fd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_20d8cfa3-c094-40d4-81a1-8856af6498b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8a4a5fbc-6715-41aa-99c0-e5afedf8402f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6a822361-908a-4e45-9833-c2e2935487fd" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8a4a5fbc-6715-41aa-99c0-e5afedf8402f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a35e3ec8-6525-409b-8f8c-6ce174ffe698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6a822361-908a-4e45-9833-c2e2935487fd" xlink:to="loc_us-gaap_Goodwill_a35e3ec8-6525-409b-8f8c-6ce174ffe698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_9d434863-7367-4135-a46f-3b8f29dff485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6a822361-908a-4e45-9833-c2e2935487fd" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_9d434863-7367-4135-a46f-3b8f29dff485" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_569e506a-bf75-40f2-aff8-8f912f955c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6a822361-908a-4e45-9833-c2e2935487fd" xlink:to="loc_us-gaap_OtherLongTermInvestments_569e506a-bf75-40f2-aff8-8f912f955c5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_cd9e3f1d-396c-4695-8c44-467a088f4bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6a822361-908a-4e45-9833-c2e2935487fd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_cd9e3f1d-396c-4695-8c44-467a088f4bf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9e7248ef-6b6f-430d-9386-b4f6591983a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6a822361-908a-4e45-9833-c2e2935487fd" xlink:to="loc_us-gaap_EquityMethodInvestments_9e7248ef-6b6f-430d-9386-b4f6591983a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d0a69697-4d2a-48c0-afd0-0a744a52b0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6a822361-908a-4e45-9833-c2e2935487fd" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d0a69697-4d2a-48c0-afd0-0a744a52b0c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_de70c3e8-ba4e-4092-a8cc-9e443868c2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6a822361-908a-4e45-9833-c2e2935487fd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_de70c3e8-ba4e-4092-a8cc-9e443868c2b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d5aa73ec-f596-451f-8f61-675450277153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6a822361-908a-4e45-9833-c2e2935487fd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d5aa73ec-f596-451f-8f61-675450277153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a690422c-906e-46f1-9bb8-d8ebeac3ac2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_73602539-df7d-4476-b5dc-68985eb76d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a690422c-906e-46f1-9bb8-d8ebeac3ac2a" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_73602539-df7d-4476-b5dc-68985eb76d79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_214279d0-0769-42bc-8364-516d6843be56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a690422c-906e-46f1-9bb8-d8ebeac3ac2a" xlink:to="loc_us-gaap_IncomeTaxesReceivable_214279d0-0769-42bc-8364-516d6843be56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8314bff8-6542-4d56-9052-f0145e3b8139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a690422c-906e-46f1-9bb8-d8ebeac3ac2a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8314bff8-6542-4d56-9052-f0145e3b8139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_37b2c165-49f1-4cab-82ad-3156dcd4df96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a690422c-906e-46f1-9bb8-d8ebeac3ac2a" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_37b2c165-49f1-4cab-82ad-3156dcd4df96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_b329b3ef-263e-4ee8-806f-97d9c46e67e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a690422c-906e-46f1-9bb8-d8ebeac3ac2a" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_b329b3ef-263e-4ee8-806f-97d9c46e67e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_29aa3823-2417-4882-9211-1e931faa41d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a690422c-906e-46f1-9bb8-d8ebeac3ac2a" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_29aa3823-2417-4882-9211-1e931faa41d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_98b621b8-0cb1-459c-be39-6265b2835cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a690422c-906e-46f1-9bb8-d8ebeac3ac2a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_98b621b8-0cb1-459c-be39-6265b2835cf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_b4a7ddd1-7f71-42a1-9413-d104054943cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a690422c-906e-46f1-9bb8-d8ebeac3ac2a" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_b4a7ddd1-7f71-42a1-9413-d104054943cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9c2f4065-c6db-4f40-90ef-b91c4e6343fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a690422c-906e-46f1-9bb8-d8ebeac3ac2a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9c2f4065-c6db-4f40-90ef-b91c4e6343fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_bbe6f09d-2d87-4155-b8cf-095fa89d2873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_adf6a44e-9dd2-4a2d-99d9-9a51c569e739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bbe6f09d-2d87-4155-b8cf-095fa89d2873" xlink:to="loc_us-gaap_OperatingLeaseCost_adf6a44e-9dd2-4a2d-99d9-9a51c569e739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fc17862d-9765-4359-ad36-13d413ebd5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bbe6f09d-2d87-4155-b8cf-095fa89d2873" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fc17862d-9765-4359-ad36-13d413ebd5ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_817b49b0-b541-4f31-b6a0-40bf84cab239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bbe6f09d-2d87-4155-b8cf-095fa89d2873" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_817b49b0-b541-4f31-b6a0-40bf84cab239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_4a92c779-f54a-4483-ab5a-4329bfc1877c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bbe6f09d-2d87-4155-b8cf-095fa89d2873" xlink:to="loc_us-gaap_SubleaseIncome_4a92c779-f54a-4483-ab5a-4329bfc1877c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0501f4e6-1aa6-431e-b88b-6bff01e8f76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e122b9e9-a080-4ba4-a586-08eff542b266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0501f4e6-1aa6-431e-b88b-6bff01e8f76b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e122b9e9-a080-4ba4-a586-08eff542b266" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_71882f26-f68c-4774-84bc-e0005d34c934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0501f4e6-1aa6-431e-b88b-6bff01e8f76b" xlink:to="loc_us-gaap_OperatingLeaseLiability_71882f26-f68c-4774-84bc-e0005d34c934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_248152bf-2be5-4cc8-ae42-de72c90d203f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f819b567-a551-4036-9624-b5a394561019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_248152bf-2be5-4cc8-ae42-de72c90d203f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f819b567-a551-4036-9624-b5a394561019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9cce2c96-736f-4748-b1f9-0cdc7167cf24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_248152bf-2be5-4cc8-ae42-de72c90d203f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9cce2c96-736f-4748-b1f9-0cdc7167cf24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_40cc16c9-f616-4819-8f26-3ea82d60d958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_27d0b92e-b54d-4dee-8ecb-9e8cd60f9d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_40cc16c9-f616-4819-8f26-3ea82d60d958" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_27d0b92e-b54d-4dee-8ecb-9e8cd60f9d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_4f7dcbcd-a183-491d-a698-3b536bc2b90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_40cc16c9-f616-4819-8f26-3ea82d60d958" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_4f7dcbcd-a183-491d-a698-3b536bc2b90b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8eff6111-aad8-45f7-aad9-50887837f6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_40cc16c9-f616-4819-8f26-3ea82d60d958" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8eff6111-aad8-45f7-aad9-50887837f6b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_8970856a-d1aa-4aa5-a31e-8be3abfeee08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_40cc16c9-f616-4819-8f26-3ea82d60d958" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_8970856a-d1aa-4aa5-a31e-8be3abfeee08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_5945d53c-ee28-4bef-bec5-e93a8d744b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_40cc16c9-f616-4819-8f26-3ea82d60d958" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_5945d53c-ee28-4bef-bec5-e93a8d744b41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_cf480a04-6034-4475-b510-93dd99573600" xlink:href="ameh-20210930.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_40cc16c9-f616-4819-8f26-3ea82d60d958" xlink:to="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_cf480a04-6034-4475-b510-93dd99573600" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cb079ce0-85ac-448f-8c1b-09503c79ff2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5d68447d-258c-4bc4-a0d9-789f49facd91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_cb079ce0-85ac-448f-8c1b-09503c79ff2a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5d68447d-258c-4bc4-a0d9-789f49facd91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dd3576e3-d94f-477b-ba41-99ecfeb620de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_cb079ce0-85ac-448f-8c1b-09503c79ff2a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dd3576e3-d94f-477b-ba41-99ecfeb620de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="ameh-20210930.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f638f275-6298-4d8f-8fd1-e8564eac397b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_75b10890-1678-4e88-aada-620aeb6932af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f638f275-6298-4d8f-8fd1-e8564eac397b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_75b10890-1678-4e88-aada-620aeb6932af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0340bf20-ae87-40c1-9783-b3a1e832ced2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f638f275-6298-4d8f-8fd1-e8564eac397b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0340bf20-ae87-40c1-9783-b3a1e832ced2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2a34d2f5-b0dd-4719-a5be-8486e9f51183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f638f275-6298-4d8f-8fd1-e8564eac397b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2a34d2f5-b0dd-4719-a5be-8486e9f51183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7673ea77-2568-4ed7-91e3-5b6f6fb3d505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f638f275-6298-4d8f-8fd1-e8564eac397b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7673ea77-2568-4ed7-91e3-5b6f6fb3d505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e6ad2814-3e59-4b92-b1b1-ed382ea20754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f638f275-6298-4d8f-8fd1-e8564eac397b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e6ad2814-3e59-4b92-b1b1-ed382ea20754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_18eae5b7-375b-4f89-befa-7dceb4e99be8" xlink:href="ameh-20210930.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f638f275-6298-4d8f-8fd1-e8564eac397b" xlink:to="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_18eae5b7-375b-4f89-befa-7dceb4e99be8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f5c4c9de-e5ed-4612-ad04-9208eadd8f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3942cd09-8653-4cd6-8d3c-65f3a26a0556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f5c4c9de-e5ed-4612-ad04-9208eadd8f45" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3942cd09-8653-4cd6-8d3c-65f3a26a0556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_88fafdf4-d4ab-4853-86a1-cd0c4b68b520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f5c4c9de-e5ed-4612-ad04-9208eadd8f45" xlink:to="loc_us-gaap_FinanceLeaseLiability_88fafdf4-d4ab-4853-86a1-cd0c4b68b520" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ameh-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:114d7d5d-3fd3-46db-8f4b-230f4f1be605,g:12a42f3e-83fc-4c9c-a1b4-628777c39609-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20210930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="ie2461cf966b445a7853a58aa1ccca1a1_CONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a29973ae-47c3-4c0c-add6-e8770c702b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ff6a9984-b42d-4cce-9ba8-48efeba331c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a29973ae-47c3-4c0c-add6-e8770c702b95" xlink:to="loc_us-gaap_AssetsAbstract_ff6a9984-b42d-4cce-9ba8-48efeba331c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ff6a9984-b42d-4cce-9ba8-48efeba331c2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44f418a7-7afc-4436-a506-4a64128ceb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44f418a7-7afc-4436-a506-4a64128ceb20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ca66b465-7577-4078-accd-7fab237f6e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ca66b465-7577-4078-accd-7fab237f6e55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_95216b6a-71be-4002-bf7b-ceac770d6cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_95216b6a-71be-4002-bf7b-ceac770d6cd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_eb662d37-2f07-4bc4-848d-3c2574e2d13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_eb662d37-2f07-4bc4-848d-3c2574e2d13b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_700281b2-ba08-4550-a324-8407dac579a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_700281b2-ba08-4550-a324-8407dac579a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2a857886-3642-4f5d-bff3-72221fe82890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2a857886-3642-4f5d-bff3-72221fe82890" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_d8e1da48-316b-4193-ade2-933b66be7a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_d8e1da48-316b-4193-ade2-933b66be7a49" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9c3a6a11-319a-4976-b17d-8e0e87329bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_AssetsCurrent_9c3a6a11-319a-4976-b17d-8e0e87329bb8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ff6a9984-b42d-4cce-9ba8-48efeba331c2" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e363a446-73f5-4259-b454-4dd235ea0049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e363a446-73f5-4259-b454-4dd235ea0049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ec1659ad-5beb-4320-969c-61e082ab1178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ec1659ad-5beb-4320-969c-61e082ab1178" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3f0c7a7f-b3d8-4e25-a834-96a59f5f0165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_Goodwill_3f0c7a7f-b3d8-4e25-a834-96a59f5f0165" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_57d336af-e8d5-4fa7-9228-5653b3550272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_57d336af-e8d5-4fa7-9228-5653b3550272" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_f3b141c3-fc27-4c14-99f8-ae0028bfc4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_f3b141c3-fc27-4c14-99f8-ae0028bfc4d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b0f70bee-a455-449b-8fa0-06fa03d57c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_EquityMethodInvestments_b0f70bee-a455-449b-8fa0-06fa03d57c3b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_face301b-bfed-48ed-a001-0c434dbdd5d7" xlink:href="ameh-20210930.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_face301b-bfed-48ed-a001-0c434dbdd5d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_acdc99d5-0c45-402b-91de-fb0963c1155e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_acdc99d5-0c45-402b-91de-fb0963c1155e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f814707e-b523-4e50-a8cb-9428c24f42e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f814707e-b523-4e50-a8cb-9428c24f42e5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d1146197-792d-4dfb-8597-0eda34efeb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d1146197-792d-4dfb-8597-0eda34efeb8d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_50971a69-1ad3-43c1-8a4f-47e3291203d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_AssetsNoncurrent_50971a69-1ad3-43c1-8a4f-47e3291203d4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_40531255-4be1-4374-afa2-dcdeedb9c8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ff6a9984-b42d-4cce-9ba8-48efeba331c2" xlink:to="loc_us-gaap_Assets_40531255-4be1-4374-afa2-dcdeedb9c8e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a29973ae-47c3-4c0c-add6-e8770c702b95" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4aef7b19-9e73-4eb0-a093-3a46447007ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4aef7b19-9e73-4eb0-a093-3a46447007ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_244bcb7f-e31c-4894-9a62-b0de975a2720" xlink:href="ameh-20210930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_244bcb7f-e31c-4894-9a62-b0de975a2720" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5331a592-f035-4d6c-9221-29a76a4e2b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5331a592-f035-4d6c-9221-29a76a4e2b23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_7fc0bb58-6732-49b7-84bd-d235159330ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_7fc0bb58-6732-49b7-84bd-d235159330ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_316b1fa3-89fc-40ea-9992-a1f5feb49410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_DividendsPayableCurrent_316b1fa3-89fc-40ea-9992-a1f5feb49410" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a8d08fa1-95b5-44b7-b89e-103d8b2e47e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a8d08fa1-95b5-44b7-b89e-103d8b2e47e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9f007128-4c77-4495-b1cb-e2b150248227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9f007128-4c77-4495-b1cb-e2b150248227" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_08cbb18c-1817-475b-ba6b-a88d05fe49d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_LongTermDebtCurrent_08cbb18c-1817-475b-ba6b-a88d05fe49d3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f9e871ec-32e3-428b-977d-9edacc6ddbad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_LiabilitiesCurrent_f9e871ec-32e3-428b-977d-9edacc6ddbad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0e65fe4d-3d8c-4354-b274-7e5205e3822a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0e65fe4d-3d8c-4354-b274-7e5205e3822a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9c374afe-ad59-4e93-96ab-cce2e0ee8f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9c374afe-ad59-4e93-96ab-cce2e0ee8f0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_07c97222-5127-4bbf-9aaa-5374fa8b35e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_07c97222-5127-4bbf-9aaa-5374fa8b35e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3e259c4e-02f3-490d-9c32-2f8f3e308ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3e259c4e-02f3-490d-9c32-2f8f3e308ff5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_658645f1-5c1c-4836-a868-3aefca762656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_658645f1-5c1c-4836-a868-3aefca762656" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_2351d667-f09f-4f97-a02b-6a504d725ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_2351d667-f09f-4f97-a02b-6a504d725ad8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a1233c3b-678f-46a4-a479-d84509c76531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_us-gaap_Liabilities_a1233c3b-678f-46a4-a479-d84509c76531" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6194d38d-5849-4d4e-bf30-bb04b9265016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6194d38d-5849-4d4e-bf30-bb04b9265016" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_e54232ff-3be7-458b-9dc0-3c2539d2228d" xlink:href="ameh-20210930.xsd#ameh_MezzanineEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_ameh_MezzanineEquityAbstract_e54232ff-3be7-458b-9dc0-3c2539d2228d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_16be0344-0b26-4862-a50f-caede8e63fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_MezzanineEquityAbstract_e54232ff-3be7-458b-9dc0-3c2539d2228d" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_16be0344-0b26-4862-a50f-caede8e63fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_14ca80d4-96e3-46a8-902b-2860ee2832d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_PreferredStockValue_14ca80d4-96e3-46a8-902b-2860ee2832d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_03feea6c-38ae-4d44-a8ac-b738b6aa54bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_CommonStockValue_03feea6c-38ae-4d44-a8ac-b738b6aa54bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0f3af9dd-ec4d-4da8-9493-984ef89e4d38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0f3af9dd-ec4d-4da8-9493-984ef89e4d38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1461488a-1a2a-4ec9-8088-ce46a2bcadf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1461488a-1a2a-4ec9-8088-ce46a2bcadf8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_009e1827-0e07-4937-a2fb-7f8d336a76f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_StockholdersEquity_009e1827-0e07-4937-a2fb-7f8d336a76f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_5efd47eb-8f74-44b0-92c9-5cdabd536f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_MinorityInterest_5efd47eb-8f74-44b0-92c9-5cdabd536f52" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf20b3bc-143f-4686-b9b2-cc2f5377e2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf20b3bc-143f-4686-b9b2-cc2f5377e2c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6beac60a-753a-4aa3-91dd-a3c3d1af2390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6beac60a-753a-4aa3-91dd-a3c3d1af2390" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_459d2f25-1fc3-4c3d-9b8f-c4372bf4ca91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a29973ae-47c3-4c0c-add6-e8770c702b95" xlink:to="loc_us-gaap_StatementTable_459d2f25-1fc3-4c3d-9b8f-c4372bf4ca91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9bb085dc-e3c9-4340-839b-d0362641a157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_459d2f25-1fc3-4c3d-9b8f-c4372bf4ca91" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9bb085dc-e3c9-4340-839b-d0362641a157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9bb085dc-e3c9-4340-839b-d0362641a157_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9bb085dc-e3c9-4340-839b-d0362641a157" xlink:to="loc_us-gaap_ClassOfStockDomain_9bb085dc-e3c9-4340-839b-d0362641a157_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_31e76f3f-66fa-461b-87bf-521c42b105eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9bb085dc-e3c9-4340-839b-d0362641a157" xlink:to="loc_us-gaap_ClassOfStockDomain_31e76f3f-66fa-461b-87bf-521c42b105eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2963929d-ff00-47cf-a1b0-2d59f62f4ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31e76f3f-66fa-461b-87bf-521c42b105eb" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2963929d-ff00-47cf-a1b0-2d59f62f4ccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_aa893995-28e9-47ba-9d89-20d4d5944477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31e76f3f-66fa-461b-87bf-521c42b105eb" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_aa893995-28e9-47ba-9d89-20d4d5944477" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ameh-20210930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="ibf9c6880511e44d09e698ca6bc671177_CONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6291b2c4-4786-4f32-be92-9fa237d7fb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6291b2c4-4786-4f32-be92-9fa237d7fb2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_cfa59f28-9ab0-4aa9-bf77-71d612ddfad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_cfa59f28-9ab0-4aa9-bf77-71d612ddfad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2bf88945-4012-4316-8d51-58b136c5ff3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2bf88945-4012-4316-8d51-58b136c5ff3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_deddb461-6674-4a06-9de3-92e7c6243e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_deddb461-6674-4a06-9de3-92e7c6243e52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c6edb7cb-068f-4ee0-8f3c-8d8055d687f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c6edb7cb-068f-4ee0-8f3c-8d8055d687f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_de1cffcf-3128-4bd8-a63c-159f0b10f296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_CommonStockSharesIssued_de1cffcf-3128-4bd8-a63c-159f0b10f296" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a91a0651-7b21-4111-b831-6ba1a54dbff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a91a0651-7b21-4111-b831-6ba1a54dbff3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e630b3b1-8e21-43cd-8cc9-7557f5e9c190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e630b3b1-8e21-43cd-8cc9-7557f5e9c190" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_6cb7baa8-7f14-4c19-b5d5-c5e05111a2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_TreasuryStockCommonShares_6cb7baa8-7f14-4c19-b5d5-c5e05111a2a3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b7e117c7-a7f7-4dac-aab9-1367fe0d46f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_Assets_b7e117c7-a7f7-4dac-aab9-1367fe0d46f1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ff4f3cde-bb37-4c9b-9831-7e1ccda69ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_Liabilities_ff4f3cde-bb37-4c9b-9831-7e1ccda69ce5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_2660297d-9479-4173-aceb-76ddb20ac114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_2660297d-9479-4173-aceb-76ddb20ac114" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates_f70b30d7-e927-4504-b57d-f8cbc6c4ad64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_DueFromAffiliates_f70b30d7-e927-4504-b57d-f8cbc6c4ad64" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_aedd8fab-329e-4bff-98c7-eebf105d8624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_aedd8fab-329e-4bff-98c7-eebf105d8624" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bad4e41c-1e38-46be-8c79-20d985d62c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_StatementTable_bad4e41c-1e38-46be-8c79-20d985d62c08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f805ec67-268e-4928-b5b7-48f4a40a48aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bad4e41c-1e38-46be-8c79-20d985d62c08" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f805ec67-268e-4928-b5b7-48f4a40a48aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f805ec67-268e-4928-b5b7-48f4a40a48aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f805ec67-268e-4928-b5b7-48f4a40a48aa" xlink:to="loc_us-gaap_ClassOfStockDomain_f805ec67-268e-4928-b5b7-48f4a40a48aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aa47db55-e1d3-496a-a1cb-4489eaffd0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f805ec67-268e-4928-b5b7-48f4a40a48aa" xlink:to="loc_us-gaap_ClassOfStockDomain_aa47db55-e1d3-496a-a1cb-4489eaffd0bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_af37cae3-7f80-4138-b3d1-e1934595bcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_aa47db55-e1d3-496a-a1cb-4489eaffd0bd" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_af37cae3-7f80-4138-b3d1-e1934595bcf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_9dca8bc2-aa94-4426-be21-15e4cce1cc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_aa47db55-e1d3-496a-a1cb-4489eaffd0bd" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_9dca8bc2-aa94-4426-be21-15e4cce1cc4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_fa539ae0-f3bd-4ace-acd5-1774b3680db1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bad4e41c-1e38-46be-8c79-20d985d62c08" xlink:to="loc_srt_ConsolidatedEntitiesAxis_fa539ae0-f3bd-4ace-acd5-1774b3680db1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_fa539ae0-f3bd-4ace-acd5-1774b3680db1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_fa539ae0-f3bd-4ace-acd5-1774b3680db1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_fa539ae0-f3bd-4ace-acd5-1774b3680db1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_42058fb5-56c9-4e28-82b3-09a110254585" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_fa539ae0-f3bd-4ace-acd5-1774b3680db1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_42058fb5-56c9-4e28-82b3-09a110254585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_bdf38dbb-04b2-4581-ad5e-ae3c32aa6858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_42058fb5-56c9-4e28-82b3-09a110254585" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_bdf38dbb-04b2-4581-ad5e-ae3c32aa6858" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="ameh-20210930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i65881675c2794ea5bd328ebf74bbb36c_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_cfa458e1-8ee3-4ffb-856a-eb0d73abe040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_RevenuesAbstract_cfa458e1-8ee3-4ffb-856a-eb0d73abe040" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9d2d93e5-ad5d-41dc-942a-d48c64195cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_cfa458e1-8ee3-4ffb-856a-eb0d73abe040" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9d2d93e5-ad5d-41dc-942a-d48c64195cce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_825a4d76-99e9-4eff-8723-708b6f2e72ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_825a4d76-99e9-4eff-8723-708b6f2e72ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_5399f492-a659-47f5-b013-e6a57e901f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_825a4d76-99e9-4eff-8723-708b6f2e72ba" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_5399f492-a659-47f5-b013-e6a57e901f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_95d49a78-5810-4904-b1b8-c00f2b77ec0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_825a4d76-99e9-4eff-8723-708b6f2e72ba" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_95d49a78-5810-4904-b1b8-c00f2b77ec0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b25456f4-e3e1-43b8-ad67-82d80cdaf1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_825a4d76-99e9-4eff-8723-708b6f2e72ba" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b25456f4-e3e1-43b8-ad67-82d80cdaf1fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7efb748a-14fe-46a6-88cf-8545eb6f2c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_825a4d76-99e9-4eff-8723-708b6f2e72ba" xlink:to="loc_us-gaap_CostsAndExpenses_7efb748a-14fe-46a6-88cf-8545eb6f2c21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0407252b-3a12-4519-b99f-f4920ba4274d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_OperatingIncomeLoss_0407252b-3a12-4519-b99f-f4920ba4274d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_af262e04-9025-45ed-9832-f1360986050f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_af262e04-9025-45ed-9832-f1360986050f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_e4b15d66-d5a9-475f-9277-14f9fb586fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_e4b15d66-d5a9-475f-9277-14f9fb586fd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0a40bfea-417e-43f8-aa8a-4b9a55f14388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_InterestExpense_0a40bfea-417e-43f8-aa8a-4b9a55f14388" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a6637ff8-2ab8-4cf7-a3ad-6c37b42fee9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a6637ff8-2ab8-4cf7-a3ad-6c37b42fee9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_baffb3f9-19b8-4183-bab0-7ac6e9396164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_baffb3f9-19b8-4183-bab0-7ac6e9396164" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_845157b5-f682-41bd-88b1-9dec9b90b7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_845157b5-f682-41bd-88b1-9dec9b90b7a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cb926ba2-6c60-4fda-9d63-345f06761cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cb926ba2-6c60-4fda-9d63-345f06761cab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_110ad2f5-78bc-4807-bf9f-beb339a1f08d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_110ad2f5-78bc-4807-bf9f-beb339a1f08d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_862bbcee-9101-462b-aff0-046a10dd7849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_862bbcee-9101-462b-aff0-046a10dd7849" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_49a211bb-a691-41ac-99b2-076f96400839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_ProfitLoss_49a211bb-a691-41ac-99b2-076f96400839" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c6bf0784-e4d9-40c5-bdba-aa53ccf289d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c6bf0784-e4d9-40c5-bdba-aa53ccf289d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e5611269-365e-4e68-8383-ac4f6935b27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_NetIncomeLoss_e5611269-365e-4e68-8383-ac4f6935b27f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f79a8f6b-67df-4cab-85ba-8c1e349e1a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_EarningsPerShareBasic_f79a8f6b-67df-4cab-85ba-8c1e349e1a82" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_58b31cef-1775-4237-83c3-76d8903e0f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_58b31cef-1775-4237-83c3-76d8903e0f6c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ad8d561c-827e-4046-bfb2-0699a82221ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_StatementTable_ad8d561c-827e-4046-bfb2-0699a82221ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b1a5852e-e821-41bc-92e0-7bd292e46b5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ad8d561c-827e-4046-bfb2-0699a82221ef" xlink:to="loc_srt_ProductOrServiceAxis_b1a5852e-e821-41bc-92e0-7bd292e46b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1a5852e-e821-41bc-92e0-7bd292e46b5f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b1a5852e-e821-41bc-92e0-7bd292e46b5f" xlink:to="loc_srt_ProductsAndServicesDomain_b1a5852e-e821-41bc-92e0-7bd292e46b5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b1a5852e-e821-41bc-92e0-7bd292e46b5f" xlink:to="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_df09ea78-ba2b-48a1-8941-ccac850ca1ce" xlink:href="ameh-20210930.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_df09ea78-ba2b-48a1-8941-ccac850ca1ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_05cf14f6-8279-4804-b77b-f41d2c577db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:to="loc_us-gaap_HealthCareOtherMember_05cf14f6-8279-4804-b77b-f41d2c577db1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_2150dd91-ca8b-41a3-9eba-5ebd9072db56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:to="loc_us-gaap_ManagementServiceMember_2150dd91-ca8b-41a3-9eba-5ebd9072db56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_34ff188a-53fb-47a7-9620-7aa57e377613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_34ff188a-53fb-47a7-9620-7aa57e377613" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_70cd41a1-ca71-46d3-a787-5afca60aff71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_70cd41a1-ca71-46d3-a787-5afca60aff71" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ameh-20210930.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended" id="i0a1cbede31fd4a7ba261762d208ba605_CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dcbf0ece-b598-4999-a1f7-d5f42385bf84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dcbf0ece-b598-4999-a1f7-d5f42385bf84" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cbb3a70e-13d0-4502-9f15-d939a49b17e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cbb3a70e-13d0-4502-9f15-d939a49b17e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_33390738-8ca5-4036-934d-303c7db21136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_SharesOutstanding_33390738-8ca5-4036-934d-303c7db21136" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_d3bfff83-d649-4fc3-a5cb-1e4825330db9" xlink:href="ameh-20210930.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_d3bfff83-d649-4fc3-a5cb-1e4825330db9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_e97761a5-535a-463a-bfe2-f7ab8c31a6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_e97761a5-535a-463a-bfe2-f7ab8c31a6bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_860f576b-c9b8-4895-ab7d-c3182cf4fab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_860f576b-c9b8-4895-ab7d-c3182cf4fab0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_01617690-251b-4356-b282-ff044d292a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_01617690-251b-4356-b282-ff044d292a69" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ead1116b-4674-424e-8147-e2ed65f6d4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ead1116b-4674-424e-8147-e2ed65f6d4e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_bef4769c-db7c-4ace-99cf-0ae098dd9bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_bef4769c-db7c-4ace-99cf-0ae098dd9bd7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_22a46f70-534e-49d0-a74c-511213df1fd4" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_22a46f70-534e-49d0-a74c-511213df1fd4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_327ba507-7b34-4f0f-8a0e-d254d3e8647c" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_327ba507-7b34-4f0f-8a0e-d254d3e8647c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_f00c2e23-0224-4d75-a746-be141ab70044" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_f00c2e23-0224-4d75-a746-be141ab70044" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_e3bf89f6-d019-47de-94c8-96d2555a771b" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_e3bf89f6-d019-47de-94c8-96d2555a771b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_68e19101-fae5-4897-95ea-9b80b2248007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_68e19101-fae5-4897-95ea-9b80b2248007" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_d2116cea-7b03-4868-a448-17179166c36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_d2116cea-7b03-4868-a448-17179166c36a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_79b9be45-a82e-4ac9-8f65-611080ab7df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_79b9be45-a82e-4ac9-8f65-611080ab7df7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d197fc1f-0315-456c-9e34-c6a78f61b053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d197fc1f-0315-456c-9e34-c6a78f61b053" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ccae894c-f3f1-42e2-986a-67407f6615fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ccae894c-f3f1-42e2-986a-67407f6615fd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_26a799da-d75a-4139-93ff-3440b7d2c8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_26a799da-d75a-4139-93ff-3440b7d2c8a8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_327a7633-7d23-457b-a7eb-da4db33f1180" xlink:href="ameh-20210930.xsd#ameh_NoncontrollingInterestIncreaseFromCapitalCharge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_327a7633-7d23-457b-a7eb-da4db33f1180" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_5eed7963-ba07-4500-9750-c5c4e9597e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_5eed7963-ba07-4500-9750-c5c4e9597e00" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_7778e747-7bbc-4d9c-a741-d50225db05d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_7778e747-7bbc-4d9c-a741-d50225db05d1" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f77568eb-5b9d-4bf8-afb3-dd81f451181a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f6b76fed-c18b-4515-9480-8e8265a4ac93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7cc2684a-69f4-4cf1-b8f5-bd7ac131396a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dcbf0ece-b598-4999-a1f7-d5f42385bf84" xlink:to="loc_us-gaap_StatementTable_7cc2684a-69f4-4cf1-b8f5-bd7ac131396a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e8bb99e0-f41f-488b-8714-433de5b1473d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7cc2684a-69f4-4cf1-b8f5-bd7ac131396a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e8bb99e0-f41f-488b-8714-433de5b1473d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e8bb99e0-f41f-488b-8714-433de5b1473d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e8bb99e0-f41f-488b-8714-433de5b1473d" xlink:to="loc_us-gaap_EquityComponentDomain_e8bb99e0-f41f-488b-8714-433de5b1473d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_419c288f-c9cb-49fc-b6d9-e4eb8610c49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e8bb99e0-f41f-488b-8714-433de5b1473d" xlink:to="loc_us-gaap_EquityComponentDomain_419c288f-c9cb-49fc-b6d9-e4eb8610c49b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1d204f6d-1f1d-4443-89c8-8bc6d6883a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_419c288f-c9cb-49fc-b6d9-e4eb8610c49b" xlink:to="loc_us-gaap_CommonStockMember_1d204f6d-1f1d-4443-89c8-8bc6d6883a85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6c2df64a-7f58-4cdb-8fa9-296896b608f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_419c288f-c9cb-49fc-b6d9-e4eb8610c49b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6c2df64a-7f58-4cdb-8fa9-296896b608f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_afb2e035-64d4-4163-8550-01d6881f0b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_419c288f-c9cb-49fc-b6d9-e4eb8610c49b" xlink:to="loc_us-gaap_RetainedEarningsMember_afb2e035-64d4-4163-8550-01d6881f0b9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f220cd99-2416-4827-ac25-8a0668e194b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_419c288f-c9cb-49fc-b6d9-e4eb8610c49b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f220cd99-2416-4827-ac25-8a0668e194b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3763cb8f-dd3f-4273-8ee4-98be3b1b4b2c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7cc2684a-69f4-4cf1-b8f5-bd7ac131396a" xlink:to="loc_dei_LegalEntityAxis_3763cb8f-dd3f-4273-8ee4-98be3b1b4b2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3763cb8f-dd3f-4273-8ee4-98be3b1b4b2c_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3763cb8f-dd3f-4273-8ee4-98be3b1b4b2c" xlink:to="loc_dei_EntityDomain_3763cb8f-dd3f-4273-8ee4-98be3b1b4b2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a3e2844d-25fa-459d-9488-dd84a578c7e6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3763cb8f-dd3f-4273-8ee4-98be3b1b4b2c" xlink:to="loc_dei_EntityDomain_a3e2844d-25fa-459d-9488-dd84a578c7e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_6feca7c4-501c-4797-8405-1065628399b9" xlink:href="ameh-20210930.xsd#ameh_MezzanineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a3e2844d-25fa-459d-9488-dd84a578c7e6" xlink:to="loc_ameh_MezzanineMember_6feca7c4-501c-4797-8405-1065628399b9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended" id="id773169704934fe581ff60c36bdac141_DescriptionofBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:href="ameh-20210930.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_cce40645-bfcb-40ad-ae1a-8db315388d9c" xlink:href="ameh-20210930.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_cce40645-bfcb-40ad-ae1a-8db315388d9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_8c179a68-eb89-41f5-b5dd-39a2591f661c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_NotesReceivableNet_8c179a68-eb89-41f5-b5dd-39a2591f661c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_8f01abf6-16bf-4a76-9f2d-3f57972de875" xlink:href="ameh-20210930.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_8f01abf6-16bf-4a76-9f2d-3f57972de875" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_f5403f6a-dfb3-4374-bcae-29dd5a4ca4c0" xlink:href="ameh-20210930.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_f5403f6a-dfb3-4374-bcae-29dd5a4ca4c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_129e582a-1c93-45c0-b018-4d992431225b" xlink:href="ameh-20210930.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_129e582a-1c93-45c0-b018-4d992431225b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ef38ee66-ecc5-465c-93ee-0ed61d3f16ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ef38ee66-ecc5-465c-93ee-0ed61d3f16ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1bd8696b-26f4-4344-bd66-ac88d4c1b591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1bd8696b-26f4-4344-bd66-ac88d4c1b591" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_dd57da48-d93a-4f40-a83f-a1d9330f7b75" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodProxyVotesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_dd57da48-d93a-4f40-a83f-a1d9330f7b75" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_794e695e-ea97-4122-a795-1072e8bd04b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_794e695e-ea97-4122-a795-1072e8bd04b1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_19ea9aba-5ae3-4cec-8c7d-aa71b1f45362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_19ea9aba-5ae3-4cec-8c7d-aa71b1f45362" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_141ffa21-b455-4fae-a05b-486d2188d303" xlink:href="ameh-20210930.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_141ffa21-b455-4fae-a05b-486d2188d303" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_97d93c3a-7c8c-450a-bdcc-5eb849c8124a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_97d93c3a-7c8c-450a-bdcc-5eb849c8124a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_deb67086-96bb-49b9-b4e1-dbff106e9b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_deb67086-96bb-49b9-b4e1-dbff106e9b9c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_9afcb1ea-b0b4-42da-ba01-0e3a6acd5bd3" xlink:href="ameh-20210930.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_9afcb1ea-b0b4-42da-ba01-0e3a6acd5bd3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f0a5cc1b-021b-40d4-a77d-5c114cd5ef83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f0a5cc1b-021b-40d4-a77d-5c114cd5ef83" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_259b4ab0-f3ee-41fb-99d7-857704f5e038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_259b4ab0-f3ee-41fb-99d7-857704f5e038" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_923c2a62-cc6d-428f-ba80-fd98e1ee1602" xlink:href="ameh-20210930.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_923c2a62-cc6d-428f-ba80-fd98e1ee1602" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_2c13d2f2-2f2c-4978-8cc3-7c0b53e9aebe" xlink:href="ameh-20210930.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_2c13d2f2-2f2c-4978-8cc3-7c0b53e9aebe" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_17a83723-96e7-4604-b256-7fafc2464c48" xlink:href="ameh-20210930.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_17a83723-96e7-4604-b256-7fafc2464c48" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:href="ameh-20210930.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6dd2ec9e-c9e9-42b6-b0ef-ff09f61d74cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_dei_LegalEntityAxis_6dd2ec9e-c9e9-42b6-b0ef-ff09f61d74cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6dd2ec9e-c9e9-42b6-b0ef-ff09f61d74cc_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6dd2ec9e-c9e9-42b6-b0ef-ff09f61d74cc" xlink:to="loc_dei_EntityDomain_6dd2ec9e-c9e9-42b6-b0ef-ff09f61d74cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6dd2ec9e-c9e9-42b6-b0ef-ff09f61d74cc" xlink:to="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f782237d-60d0-4247-8120-c26ccdf0563d" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f782237d-60d0-4247-8120-c26ccdf0563d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_abac02a3-0f6e-4eb3-a86b-560b5c06b1c0" xlink:href="ameh-20210930.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:to="loc_ameh_ApcLsmaMember_abac02a3-0f6e-4eb3-a86b-560b5c06b1c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_4ef15496-c575-4acc-8b40-67e4ff777114" xlink:href="ameh-20210930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:to="loc_ameh_AccountableHealthCareIPAMember_4ef15496-c575-4acc-8b40-67e4ff777114" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_07acbbc2-fb68-4f57-9b03-1dd655e08a44" xlink:href="ameh-20210930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:to="loc_ameh_APCAndAPCLSMAMember_07acbbc2-fb68-4f57-9b03-1dd655e08a44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_79f73d8b-1bf1-4009-8a93-fd5a36388351" xlink:href="ameh-20210930.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:to="loc_ameh_AmgIncMember_79f73d8b-1bf1-4009-8a93-fd5a36388351" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5ef59247-892e-4f14-8370-a6736739e954" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_srt_CounterpartyNameAxis_5ef59247-892e-4f14-8370-a6736739e954" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ef59247-892e-4f14-8370-a6736739e954_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5ef59247-892e-4f14-8370-a6736739e954" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ef59247-892e-4f14-8370-a6736739e954_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4f7fb0c-faae-4173-a487-1375eba5086e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5ef59247-892e-4f14-8370-a6736739e954" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4f7fb0c-faae-4173-a487-1375eba5086e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e6c9f4d3-463c-4cb2-8bcb-8c4821ec7f09" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4f7fb0c-faae-4173-a487-1375eba5086e" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e6c9f4d3-463c-4cb2-8bcb-8c4821ec7f09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_6c187a09-1c45-4adb-b4d1-90c2a53686ae" xlink:href="ameh-20210930.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4f7fb0c-faae-4173-a487-1375eba5086e" xlink:to="loc_ameh_APAMHMedicalCorporationMember_6c187a09-1c45-4adb-b4d1-90c2a53686ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_8c5a7148-05eb-4471-a7fa-a38027c7e636" xlink:href="ameh-20210930.xsd#ameh_Dr.JayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4f7fb0c-faae-4173-a487-1375eba5086e" xlink:to="loc_ameh_Dr.JayMember_8c5a7148-05eb-4471-a7fa-a38027c7e636" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d655e457-0155-4a4f-a4f4-4c2cf975c9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d655e457-0155-4a4f-a4f4-4c2cf975c9c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d655e457-0155-4a4f-a4f4-4c2cf975c9c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d655e457-0155-4a4f-a4f4-4c2cf975c9c8" xlink:to="loc_us-gaap_RelatedPartyDomain_d655e457-0155-4a4f-a4f4-4c2cf975c9c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3488e04f-6830-445c-94bc-62b19708fa22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d655e457-0155-4a4f-a4f4-4c2cf975c9c8" xlink:to="loc_us-gaap_RelatedPartyDomain_3488e04f-6830-445c-94bc-62b19708fa22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_5e7623c1-a9be-44a4-87ac-11251fb59270" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3488e04f-6830-445c-94bc-62b19708fa22" xlink:to="loc_srt_AffiliatedEntityMember_5e7623c1-a9be-44a4-87ac-11251fb59270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ae687a3f-6277-4369-8ec8-265d8c6c9d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ae687a3f-6277-4369-8ec8-265d8c6c9d07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ae687a3f-6277-4369-8ec8-265d8c6c9d07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ae687a3f-6277-4369-8ec8-265d8c6c9d07" xlink:to="loc_us-gaap_ClassOfStockDomain_ae687a3f-6277-4369-8ec8-265d8c6c9d07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d029e592-e8de-4ad6-b5b5-3a9db89d81c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ae687a3f-6277-4369-8ec8-265d8c6c9d07" xlink:to="loc_us-gaap_ClassOfStockDomain_d029e592-e8de-4ad6-b5b5-3a9db89d81c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_88f3deaa-69d0-44cd-b5e6-76d7e8f30ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d029e592-e8de-4ad6-b5b5-3a9db89d81c5" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_88f3deaa-69d0-44cd-b5e6-76d7e8f30ca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fb8edfe-ff16-4da7-ba28-660bef16a1e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fb8edfe-ff16-4da7-ba28-660bef16a1e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7fb8edfe-ff16-4da7-ba28-660bef16a1e8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fb8edfe-ff16-4da7-ba28-660bef16a1e8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7fb8edfe-ff16-4da7-ba28-660bef16a1e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e941b586-3578-4277-b59d-ae228c5fec77" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fb8edfe-ff16-4da7-ba28-660bef16a1e8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e941b586-3578-4277-b59d-ae228c5fec77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_27dd01c2-8d9b-440e-87f7-8008fbcf9b18" xlink:href="ameh-20210930.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e941b586-3578-4277-b59d-ae228c5fec77" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_27dd01c2-8d9b-440e-87f7-8008fbcf9b18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_5afbc5fc-64af-420c-bc2b-1a4d43ebc402" xlink:href="ameh-20210930.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e941b586-3578-4277-b59d-ae228c5fec77" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_5afbc5fc-64af-420c-bc2b-1a4d43ebc402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c2e91f71-946d-4cf5-8923-17dd5d8f6270" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_srt_OwnershipAxis_c2e91f71-946d-4cf5-8923-17dd5d8f6270" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c2e91f71-946d-4cf5-8923-17dd5d8f6270_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_c2e91f71-946d-4cf5-8923-17dd5d8f6270" xlink:to="loc_srt_OwnershipDomain_c2e91f71-946d-4cf5-8923-17dd5d8f6270_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_30893f79-496b-4636-8643-a7cd960a0c95" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_c2e91f71-946d-4cf5-8923-17dd5d8f6270" xlink:to="loc_srt_OwnershipDomain_30893f79-496b-4636-8643-a7cd960a0c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_ee5fd6f8-8d67-4c20-94ff-01ac1516043b" xlink:href="ameh-20210930.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_30893f79-496b-4636-8643-a7cd960a0c95" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_ee5fd6f8-8d67-4c20-94ff-01ac1516043b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_035cefda-d710-4f92-bda3-49fdf863327b" xlink:href="ameh-20210930.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_30893f79-496b-4636-8643-a7cd960a0c95" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_035cefda-d710-4f92-bda3-49fdf863327b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_534051ee-9c4a-4c5f-ae28-652e4e74b1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_534051ee-9c4a-4c5f-ae28-652e4e74b1ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_534051ee-9c4a-4c5f-ae28-652e4e74b1ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_534051ee-9c4a-4c5f-ae28-652e4e74b1ae" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_534051ee-9c4a-4c5f-ae28-652e4e74b1ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_534051ee-9c4a-4c5f-ae28-652e4e74b1ae" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_518c6af6-d639-45c6-b9b7-2eb1072594ea" xlink:href="ameh-20210930.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_518c6af6-d639-45c6-b9b7-2eb1072594ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_5657907d-c6a5-4f5d-8c76-5e91d069937f" xlink:href="ameh-20210930.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_5657907d-c6a5-4f5d-8c76-5e91d069937f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_13a86d99-db63-4b4a-8636-d1e79efab9e6" xlink:href="ameh-20210930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:to="loc_ameh_AccountableHealthCareIPAMember_13a86d99-db63-4b4a-8636-d1e79efab9e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_75572545-088d-4149-b1eb-0d1c6a136a6d" xlink:href="ameh-20210930.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:to="loc_ameh_AmgIncMember_75572545-088d-4149-b1eb-0d1c6a136a6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_b8027a1a-a7f1-4506-bd4b-2331690d2a7e" xlink:href="ameh-20210930.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_b8027a1a-a7f1-4506-bd4b-2331690d2a7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_6f946da9-1ed7-4eca-8f66-72c38c157f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_us-gaap_AssetAcquisitionAxis_6f946da9-1ed7-4eca-8f66-72c38c157f10" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_6f946da9-1ed7-4eca-8f66-72c38c157f10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6f946da9-1ed7-4eca-8f66-72c38c157f10" xlink:to="loc_us-gaap_AssetAcquisitionDomain_6f946da9-1ed7-4eca-8f66-72c38c157f10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_d8f480c0-932a-41e3-b5a4-b45bb462878d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6f946da9-1ed7-4eca-8f66-72c38c157f10" xlink:to="loc_us-gaap_AssetAcquisitionDomain_d8f480c0-932a-41e3-b5a4-b45bb462878d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_27ada3a5-fd86-4425-abb2-3a0e3172b59c" xlink:href="ameh-20210930.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d8f480c0-932a-41e3-b5a4-b45bb462878d" xlink:to="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_27ada3a5-fd86-4425-abb2-3a0e3172b59c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_1c5d59bf-d8bf-429a-a69b-96ad67df9471" xlink:href="ameh-20210930.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d8f480c0-932a-41e3-b5a4-b45bb462878d" xlink:to="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_1c5d59bf-d8bf-429a-a69b-96ad67df9471" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i5839474d5fd140ae877f2e23fec941c9_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:href="ameh-20210930.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b02e3ff5-7ace-4d06-8d32-2c5718766ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b02e3ff5-7ace-4d06-8d32-2c5718766ee6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_dfef5328-d2c0-4288-96ca-6b58ce0058a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_NumberOfReportableSegments_dfef5328-d2c0-4288-96ca-6b58ce0058a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_1a9a8d14-fd50-48c4-a512-be4dae962eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_CashUninsuredAmount_1a9a8d14-fd50-48c4-a512-be4dae962eb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_113dfdc5-913b-4bbd-a642-6c4455ff2f30" xlink:href="ameh-20210930.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_113dfdc5-913b-4bbd-a642-6c4455ff2f30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_32037e18-3720-40eb-9ccb-717c562d076e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_32037e18-3720-40eb-9ccb-717c562d076e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_633ba24b-b346-4de1-b0a8-7d5b7f39b685" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_633ba24b-b346-4de1-b0a8-7d5b7f39b685" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_05658e97-64b8-4ebb-baa8-4343a18d1e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_05658e97-64b8-4ebb-baa8-4343a18d1e98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_5cee10d0-7bbd-4f07-9c4e-48cec5dfd3ec" xlink:href="ameh-20210930.xsd#ameh_PaymentsToAcquireCommonStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_5cee10d0-7bbd-4f07-9c4e-48cec5dfd3ec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_37a1719e-5a85-4c43-803f-1beae3154c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_37a1719e-5a85-4c43-803f-1beae3154c0c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_78285b16-ddfa-4c4f-b56c-470719dd5699" xlink:href="ameh-20210930.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_78285b16-ddfa-4c4f-b56c-470719dd5699" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f85c22dc-df88-4b41-9ddf-4a718f524828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f85c22dc-df88-4b41-9ddf-4a718f524828" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_245077ee-0a3f-4828-b340-e203572f3991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_245077ee-0a3f-4828-b340-e203572f3991" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_d926b2ba-32d0-41fe-8d4b-d0616574a741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_NumberOfReportingUnits_d926b2ba-32d0-41fe-8d4b-d0616574a741" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6d0369ac-c19d-41d6-bc55-014268cdd6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6d0369ac-c19d-41d6-bc55-014268cdd6a0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_75862b95-57d7-4417-b94a-c543fff82d77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_Goodwill_75862b95-57d7-4417-b94a-c543fff82d77" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_89d68638-069e-4380-ba0b-84f3e1b7db98" xlink:href="ameh-20210930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_89d68638-069e-4380-ba0b-84f3e1b7db98" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_9be4ac47-d5c8-441a-b98c-3d6c66962b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_9be4ac47-d5c8-441a-b98c-3d6c66962b99" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_63b6354e-12b3-4f14-9f5b-eeeb9ec8ee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_DerivativeAssets_63b6354e-12b3-4f14-9f5b-eeeb9ec8ee6b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_18c5f793-3d2c-4d70-908e-832178ffb89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_18c5f793-3d2c-4d70-908e-832178ffb89c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_c3d4b414-761d-497c-b9d1-cf7d90934fb2" xlink:href="ameh-20210930.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_c3d4b414-761d-497c-b9d1-cf7d90934fb2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears_a6d5d052-42bc-4cfb-93c9-60cb5580cc3f" xlink:href="ameh-20210930.xsd#ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears_a6d5d052-42bc-4cfb-93c9-60cb5580cc3f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount_10c18ad3-1811-4cc6-86d0-fe5a53ce5747" xlink:href="ameh-20210930.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_PaymentOfRevenueMonthlyAmount_10c18ad3-1811-4cc6-86d0-fe5a53ce5747" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue_c58cd750-dd5b-4c88-a40f-251e02e1b493" xlink:href="ameh-20210930.xsd#ameh_PaymentOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_PaymentOfRevenue_c58cd750-dd5b-4c88-a40f-251e02e1b493" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueRevenueRecognized_d0ad8f35-9db5-4a12-b257-f7c570a8c57b" xlink:href="ameh-20210930.xsd#ameh_PaymentOfRevenueRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_PaymentOfRevenueRevenueRecognized_d0ad8f35-9db5-4a12-b257-f7c570a8c57b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7bcd682c-665c-48a1-a2b1-5193da7c7aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7bcd682c-665c-48a1-a2b1-5193da7c7aa1" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f6d8536c-0326-43b8-b6e1-7f2e19760a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f6d8536c-0326-43b8-b6e1-7f2e19760a05" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ea3473c3-efc1-40ea-b186-72771c451646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ea3473c3-efc1-40ea-b186-72771c451646" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_ef7d4c94-f5b1-455f-a6e4-a24a7d203a27" xlink:href="ameh-20210930.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_ef7d4c94-f5b1-455f-a6e4-a24a7d203a27" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_1f4440fc-d98d-47f7-a942-9f6cb1951001" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_1f4440fc-d98d-47f7-a942-9f6cb1951001" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_e3e96e39-fcea-4349-8ec6-b0071922f956" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_e3e96e39-fcea-4349-8ec6-b0071922f956" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_629d30f8-c265-48ba-8f11-558d7143bb3d" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_629d30f8-c265-48ba-8f11-558d7143bb3d" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_855d1a44-17fe-4d73-8d93-a91ee08fb1e1" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_855d1a44-17fe-4d73-8d93-a91ee08fb1e1" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:href="ameh-20210930.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f6995773-388a-4078-b0bf-69ec9aaacec6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_srt_RangeAxis_f6995773-388a-4078-b0bf-69ec9aaacec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6995773-388a-4078-b0bf-69ec9aaacec6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f6995773-388a-4078-b0bf-69ec9aaacec6" xlink:to="loc_srt_RangeMember_f6995773-388a-4078-b0bf-69ec9aaacec6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c92ecb9f-51d5-41c7-99e9-97f987c0530d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f6995773-388a-4078-b0bf-69ec9aaacec6" xlink:to="loc_srt_RangeMember_c92ecb9f-51d5-41c7-99e9-97f987c0530d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4d7fc85c-32ba-4e75-9efb-a58e58899848" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c92ecb9f-51d5-41c7-99e9-97f987c0530d" xlink:to="loc_srt_MinimumMember_4d7fc85c-32ba-4e75-9efb-a58e58899848" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c3016289-5cb2-4338-aff5-735322426d90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c92ecb9f-51d5-41c7-99e9-97f987c0530d" xlink:to="loc_srt_MaximumMember_c3016289-5cb2-4338-aff5-735322426d90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f62ec4ee-104f-4c6d-a822-9cff8961ca65" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_srt_CounterpartyNameAxis_f62ec4ee-104f-4c6d-a822-9cff8961ca65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f62ec4ee-104f-4c6d-a822-9cff8961ca65_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f62ec4ee-104f-4c6d-a822-9cff8961ca65" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f62ec4ee-104f-4c6d-a822-9cff8961ca65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc004ab2-531c-405b-a8d2-f1ed113ecf1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f62ec4ee-104f-4c6d-a822-9cff8961ca65" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc004ab2-531c-405b-a8d2-f1ed113ecf1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClinigenceHoldingsIncMember_9a70e35c-05c3-4e5f-8b19-1d6416c3a108" xlink:href="ameh-20210930.xsd#ameh_ClinigenceHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc004ab2-531c-405b-a8d2-f1ed113ecf1f" xlink:to="loc_ameh_ClinigenceHoldingsIncMember_9a70e35c-05c3-4e5f-8b19-1d6416c3a108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_9f6892e6-9007-4c69-8ce1-274e96f748f5" xlink:href="ameh-20210930.xsd#ameh_CMSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc004ab2-531c-405b-a8d2-f1ed113ecf1f" xlink:to="loc_ameh_CMSMember_9f6892e6-9007-4c69-8ce1-274e96f748f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_02e7d155-11ca-4922-8ee7-33eee485f7a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_srt_ProductOrServiceAxis_02e7d155-11ca-4922-8ee7-33eee485f7a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_02e7d155-11ca-4922-8ee7-33eee485f7a7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_02e7d155-11ca-4922-8ee7-33eee485f7a7" xlink:to="loc_srt_ProductsAndServicesDomain_02e7d155-11ca-4922-8ee7-33eee485f7a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3fe1da84-7776-44b6-acfb-20f4e74ccd8a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_02e7d155-11ca-4922-8ee7-33eee485f7a7" xlink:to="loc_srt_ProductsAndServicesDomain_3fe1da84-7776-44b6-acfb-20f4e74ccd8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_20d35f5d-0f6e-4608-8d95-7799b2f3dc96" xlink:href="ameh-20210930.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3fe1da84-7776-44b6-acfb-20f4e74ccd8a" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_20d35f5d-0f6e-4608-8d95-7799b2f3dc96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_770e6ed4-8eea-46e3-a127-a6335942deed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3fe1da84-7776-44b6-acfb-20f4e74ccd8a" xlink:to="loc_us-gaap_ManagementServiceMember_770e6ed4-8eea-46e3-a127-a6335942deed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1a21a42e-0e9d-4cd9-b603-f4ab5e02a4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1a21a42e-0e9d-4cd9-b603-f4ab5e02a4bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1a21a42e-0e9d-4cd9-b603-f4ab5e02a4bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1a21a42e-0e9d-4cd9-b603-f4ab5e02a4bc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1a21a42e-0e9d-4cd9-b603-f4ab5e02a4bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_66b56cc6-c6ab-4c7b-b5bd-44c05ab6e2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1a21a42e-0e9d-4cd9-b603-f4ab5e02a4bc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_66b56cc6-c6ab-4c7b-b5bd-44c05ab6e2c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_b420e6f4-df50-45b4-9997-468cb4af7acf" xlink:href="ameh-20210930.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66b56cc6-c6ab-4c7b-b5bd-44c05ab6e2c3" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_b420e6f4-df50-45b4-9997-468cb4af7acf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e4b37c74-486e-4801-8b07-3de3c1fa126c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66b56cc6-c6ab-4c7b-b5bd-44c05ab6e2c3" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e4b37c74-486e-4801-8b07-3de3c1fa126c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_d43697cc-2ee8-4ac7-a2d8-7e962ecad212" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_srt_OwnershipAxis_d43697cc-2ee8-4ac7-a2d8-7e962ecad212" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d43697cc-2ee8-4ac7-a2d8-7e962ecad212_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_d43697cc-2ee8-4ac7-a2d8-7e962ecad212" xlink:to="loc_srt_OwnershipDomain_d43697cc-2ee8-4ac7-a2d8-7e962ecad212_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6456ec83-c03f-49d0-ba7c-d10a57e2fa06" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_d43697cc-2ee8-4ac7-a2d8-7e962ecad212" xlink:to="loc_srt_OwnershipDomain_6456ec83-c03f-49d0-ba7c-d10a57e2fa06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_01527681-3a3f-410b-969f-97426389004f" xlink:href="ameh-20210930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_6456ec83-c03f-49d0-ba7c-d10a57e2fa06" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_01527681-3a3f-410b-969f-97426389004f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_baa4c26b-c98e-48f1-a4ec-9b0c95e1413d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_dei_LegalEntityAxis_baa4c26b-c98e-48f1-a4ec-9b0c95e1413d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_baa4c26b-c98e-48f1-a4ec-9b0c95e1413d_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_baa4c26b-c98e-48f1-a4ec-9b0c95e1413d" xlink:to="loc_dei_EntityDomain_baa4c26b-c98e-48f1-a4ec-9b0c95e1413d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1f0202d5-3500-4d52-8fb4-fa7d0acbf26b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_baa4c26b-c98e-48f1-a4ec-9b0c95e1413d" xlink:to="loc_dei_EntityDomain_1f0202d5-3500-4d52-8fb4-fa7d0acbf26b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_57b1e8d8-7c64-40f9-90e9-979a317918a1" xlink:href="ameh-20210930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1f0202d5-3500-4d52-8fb4-fa7d0acbf26b" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_57b1e8d8-7c64-40f9-90e9-979a317918a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_c68f0921-0d1c-4859-8152-f9c47f578804" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1f0202d5-3500-4d52-8fb4-fa7d0acbf26b" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_c68f0921-0d1c-4859-8152-f9c47f578804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_29a9c2e3-64de-4443-94c5-7bf3d37f0327" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_29a9c2e3-64de-4443-94c5-7bf3d37f0327" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_29a9c2e3-64de-4443-94c5-7bf3d37f0327_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_29a9c2e3-64de-4443-94c5-7bf3d37f0327" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_29a9c2e3-64de-4443-94c5-7bf3d37f0327_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_796e76ea-b3e5-4e60-bab9-2a38f3e80ded" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_29a9c2e3-64de-4443-94c5-7bf3d37f0327" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_796e76ea-b3e5-4e60-bab9-2a38f3e80ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_9acce27c-001d-4c60-a4c3-ebada3a68434" xlink:href="ameh-20210930.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_796e76ea-b3e5-4e60-bab9-2a38f3e80ded" xlink:to="loc_ameh_UniversalCareIncMember_9acce27c-001d-4c60-a4c3-ebada3a68434" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c966c4d8-3c6c-48e1-b3a6-129f5b3e8303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c966c4d8-3c6c-48e1-b3a6-129f5b3e8303" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c966c4d8-3c6c-48e1-b3a6-129f5b3e8303_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c966c4d8-3c6c-48e1-b3a6-129f5b3e8303" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c966c4d8-3c6c-48e1-b3a6-129f5b3e8303_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f348323-f02d-4c8a-9ccf-13adfd14f269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c966c4d8-3c6c-48e1-b3a6-129f5b3e8303" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f348323-f02d-4c8a-9ccf-13adfd14f269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_633264cf-5c2e-42ae-a5dc-087a911fb36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f348323-f02d-4c8a-9ccf-13adfd14f269" xlink:to="loc_us-gaap_CertificatesOfDepositMember_633264cf-5c2e-42ae-a5dc-087a911fb36c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ed79f0-91b6-41cf-8262-ae49de1dc863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ed79f0-91b6-41cf-8262-ae49de1dc863" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f2ed79f0-91b6-41cf-8262-ae49de1dc863_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ed79f0-91b6-41cf-8262-ae49de1dc863" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f2ed79f0-91b6-41cf-8262-ae49de1dc863_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_44899b0c-ab20-496f-af4f-154c081101b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ed79f0-91b6-41cf-8262-ae49de1dc863" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_44899b0c-ab20-496f-af4f-154c081101b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_fcc12321-23e0-4443-bc0d-15a8f6f21ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_44899b0c-ab20-496f-af4f-154c081101b6" xlink:to="loc_us-gaap_InterestRateSwapMember_fcc12321-23e0-4443-bc0d-15a8f6f21ac4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_475b9c00-7b9a-4325-984f-ff113e439282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_475b9c00-7b9a-4325-984f-ff113e439282" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_475b9c00-7b9a-4325-984f-ff113e439282_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_475b9c00-7b9a-4325-984f-ff113e439282" xlink:to="loc_us-gaap_HedgingRelationshipDomain_475b9c00-7b9a-4325-984f-ff113e439282_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_fc1a182b-aceb-4373-888b-55897a469454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_475b9c00-7b9a-4325-984f-ff113e439282" xlink:to="loc_us-gaap_HedgingRelationshipDomain_fc1a182b-aceb-4373-888b-55897a469454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2a5f9fb4-8e67-47a7-82af-7c1198c543f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_fc1a182b-aceb-4373-888b-55897a469454" xlink:to="loc_us-gaap_CashFlowHedgingMember_2a5f9fb4-8e67-47a7-82af-7c1198c543f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7f4d3dfe-79f4-4ff1-bc2d-0bf76a14e7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_us-gaap_HedgingDesignationAxis_7f4d3dfe-79f4-4ff1-bc2d-0bf76a14e7f3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7f4d3dfe-79f4-4ff1-bc2d-0bf76a14e7f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7f4d3dfe-79f4-4ff1-bc2d-0bf76a14e7f3" xlink:to="loc_us-gaap_HedgingDesignationDomain_7f4d3dfe-79f4-4ff1-bc2d-0bf76a14e7f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4b364c60-33e6-4595-9183-da539518cd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7f4d3dfe-79f4-4ff1-bc2d-0bf76a14e7f3" xlink:to="loc_us-gaap_HedgingDesignationDomain_4b364c60-33e6-4595-9183-da539518cd5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5939e026-a2f8-4563-9e8a-13cba44f0518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_4b364c60-33e6-4595-9183-da539518cd5d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5939e026-a2f8-4563-9e8a-13cba44f0518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_061fdf2b-a76e-41d2-8e2e-2aa3278fca68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_061fdf2b-a76e-41d2-8e2e-2aa3278fca68" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_061fdf2b-a76e-41d2-8e2e-2aa3278fca68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_061fdf2b-a76e-41d2-8e2e-2aa3278fca68" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_061fdf2b-a76e-41d2-8e2e-2aa3278fca68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_688d8701-daf4-4bad-9e88-6c978879f783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_061fdf2b-a76e-41d2-8e2e-2aa3278fca68" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_688d8701-daf4-4bad-9e88-6c978879f783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6e981bbc-d66c-4c5a-86c3-0fd0642f809e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_688d8701-daf4-4bad-9e88-6c978879f783" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6e981bbc-d66c-4c5a-86c3-0fd0642f809e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended" id="id1cee7fd8ecb46f8b3d2839a62253261_BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b47ef0e0-4113-4ad2-964e-ea0e2bbfde6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e65c5ab8-1a8b-415a-a065-212f98967908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b47ef0e0-4113-4ad2-964e-ea0e2bbfde6a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e65c5ab8-1a8b-415a-a065-212f98967908" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7dd99098-8c5c-4c08-a4dd-36a630c7b42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b47ef0e0-4113-4ad2-964e-ea0e2bbfde6a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7dd99098-8c5c-4c08-a4dd-36a630c7b42d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9588b8b9-449f-4339-9cd1-1d740ad75f64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7dd99098-8c5c-4c08-a4dd-36a630c7b42d" xlink:to="loc_srt_MajorCustomersAxis_9588b8b9-449f-4339-9cd1-1d740ad75f64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9588b8b9-449f-4339-9cd1-1d740ad75f64_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9588b8b9-449f-4339-9cd1-1d740ad75f64" xlink:to="loc_srt_NameOfMajorCustomerDomain_9588b8b9-449f-4339-9cd1-1d740ad75f64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f86c3d71-18b8-417c-a9f1-e7e4bd82a750" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9588b8b9-449f-4339-9cd1-1d740ad75f64" xlink:to="loc_srt_NameOfMajorCustomerDomain_f86c3d71-18b8-417c-a9f1-e7e4bd82a750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_2a8b7f27-86c9-443f-8fee-541165d9ec71" xlink:href="ameh-20210930.xsd#ameh_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f86c3d71-18b8-417c-a9f1-e7e4bd82a750" xlink:to="loc_ameh_CommercialMember_2a8b7f27-86c9-443f-8fee-541165d9ec71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_b4c9938e-c777-4d0a-b9b7-bcd67a1d3606" xlink:href="ameh-20210930.xsd#ameh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f86c3d71-18b8-417c-a9f1-e7e4bd82a750" xlink:to="loc_ameh_MedicareMember_b4c9938e-c777-4d0a-b9b7-bcd67a1d3606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_c9bfbfb6-d405-4044-8186-bdeda44ba9bd" xlink:href="ameh-20210930.xsd#ameh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f86c3d71-18b8-417c-a9f1-e7e4bd82a750" xlink:to="loc_ameh_MedicaidMember_c9bfbfb6-d405-4044-8186-bdeda44ba9bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_342948d3-1bde-42ea-a02c-92ded9fdf208" xlink:href="ameh-20210930.xsd#ameh_OtherThirdPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f86c3d71-18b8-417c-a9f1-e7e4bd82a750" xlink:to="loc_ameh_OtherThirdPartiesMember_342948d3-1bde-42ea-a02c-92ded9fdf208" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended" id="i8f95c0ac453845e5909aa23004bb2ac1_BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_803e08ef-118f-4e4e-adcb-9c6d4c5b4fb4" xlink:href="ameh-20210930.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a46e6ef7-a6ad-47b8-a9c7-da80d4cf3232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_803e08ef-118f-4e4e-adcb-9c6d4c5b4fb4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a46e6ef7-a6ad-47b8-a9c7-da80d4cf3232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_c2e0ce8d-6957-470f-9fad-3aa65be2c74f" xlink:href="ameh-20210930.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_803e08ef-118f-4e4e-adcb-9c6d4c5b4fb4" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_c2e0ce8d-6957-470f-9fad-3aa65be2c74f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d320d9b-af33-4031-b791-cdb3b83b1c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_c2e0ce8d-6957-470f-9fad-3aa65be2c74f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d320d9b-af33-4031-b791-cdb3b83b1c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0d320d9b-af33-4031-b791-cdb3b83b1c66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d320d9b-af33-4031-b791-cdb3b83b1c66" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0d320d9b-af33-4031-b791-cdb3b83b1c66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3ebc991-1137-41c1-abb3-170999c6642b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d320d9b-af33-4031-b791-cdb3b83b1c66" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3ebc991-1137-41c1-abb3-170999c6642b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_f5446bf0-aba7-473c-9bdf-f548fdb70893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3ebc991-1137-41c1-abb3-170999c6642b" xlink:to="loc_us-gaap_SalesRevenueNetMember_f5446bf0-aba7-473c-9bdf-f548fdb70893" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_970f08bf-3546-439d-9006-9314b619feba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3ebc991-1137-41c1-abb3-170999c6642b" xlink:to="loc_us-gaap_AccountsReceivableMember_970f08bf-3546-439d-9006-9314b619feba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_56fdde31-b070-40ff-9c6b-71416da17dc0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_c2e0ce8d-6957-470f-9fad-3aa65be2c74f" xlink:to="loc_srt_MajorCustomersAxis_56fdde31-b070-40ff-9c6b-71416da17dc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_56fdde31-b070-40ff-9c6b-71416da17dc0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_56fdde31-b070-40ff-9c6b-71416da17dc0" xlink:to="loc_srt_NameOfMajorCustomerDomain_56fdde31-b070-40ff-9c6b-71416da17dc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_56fdde31-b070-40ff-9c6b-71416da17dc0" xlink:to="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_37ad9ece-3c83-4713-98b9-12f1e2d0fde6" xlink:href="ameh-20210930.xsd#ameh_PayorAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:to="loc_ameh_PayorAMember_37ad9ece-3c83-4713-98b9-12f1e2d0fde6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_6e8f39d1-9ffb-4ed3-9c75-0b8332a4279e" xlink:href="ameh-20210930.xsd#ameh_PayorBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:to="loc_ameh_PayorBMember_6e8f39d1-9ffb-4ed3-9c75-0b8332a4279e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_faa45f3d-afac-45c5-aacd-cd7c0f091af2" xlink:href="ameh-20210930.xsd#ameh_PayorCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:to="loc_ameh_PayorCMember_faa45f3d-afac-45c5-aacd-cd7c0f091af2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_a70cd244-95a0-4648-9db0-07de023d9e40" xlink:href="ameh-20210930.xsd#ameh_PayorDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:to="loc_ameh_PayorDMember_a70cd244-95a0-4648-9db0-07de023d9e40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_632af24e-d083-49f4-a790-82d604354fae" xlink:href="ameh-20210930.xsd#ameh_PayorFMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:to="loc_ameh_PayorFMember_632af24e-d083-49f4-a790-82d604354fae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorGMember_91a9fb0f-b868-48db-83e1-85a5c623101a" xlink:href="ameh-20210930.xsd#ameh_PayorGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:to="loc_ameh_PayorGMember_91a9fb0f-b868-48db-83e1-85a5c623101a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ca71739d-89e5-4d49-9f7e-aa5d82f776d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_c2e0ce8d-6957-470f-9fad-3aa65be2c74f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ca71739d-89e5-4d49-9f7e-aa5d82f776d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ca71739d-89e5-4d49-9f7e-aa5d82f776d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ca71739d-89e5-4d49-9f7e-aa5d82f776d6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ca71739d-89e5-4d49-9f7e-aa5d82f776d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0cc9358d-f347-4380-a619-5ebe62b31549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ca71739d-89e5-4d49-9f7e-aa5d82f776d6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0cc9358d-f347-4380-a619-5ebe62b31549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c3e050f1-c4da-4c8e-b7fc-cece14396e71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0cc9358d-f347-4380-a619-5ebe62b31549" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c3e050f1-c4da-4c8e-b7fc-cece14396e71" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended" id="i90d75e39b96540b297e57598e1c2e51c_BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ca44e3-231b-4123-a294-bfe0b34527f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ca44e3-231b-4123-a294-bfe0b34527f2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ff95318e-7abb-4e57-8875-07885e8d4065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ff95318e-7abb-4e57-8875-07885e8d4065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_922e6aaa-8bb8-4fbf-be52-278162df1f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_922e6aaa-8bb8-4fbf-be52-278162df1f99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_28d63838-3d90-4dcd-bebb-0708344f4ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_28d63838-3d90-4dcd-bebb-0708344f4ba6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_25de5087-1888-42b5-946b-7f8d6df01a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:to="loc_us-gaap_DerivativeAssets_25de5087-1888-42b5-946b-7f8d6df01a62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4e5416c3-a88c-4fcb-a4c9-718f1ccdacd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4e5416c3-a88c-4fcb-a4c9-718f1ccdacd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_257ffdae-9aaa-4710-b9ff-8beae4727748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ca44e3-231b-4123-a294-bfe0b34527f2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_257ffdae-9aaa-4710-b9ff-8beae4727748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6322ede4-74c9-4949-a1b7-f3f7b2c8266b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_257ffdae-9aaa-4710-b9ff-8beae4727748" xlink:to="loc_us-gaap_DerivativeLiabilities_6322ede4-74c9-4949-a1b7-f3f7b2c8266b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_33fc244d-cb49-4d6d-80a0-e382e06b0b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_257ffdae-9aaa-4710-b9ff-8beae4727748" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_33fc244d-cb49-4d6d-80a0-e382e06b0b95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_074d7d2a-0f25-4ec7-a5c8-32b16e55718b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_257ffdae-9aaa-4710-b9ff-8beae4727748" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_074d7d2a-0f25-4ec7-a5c8-32b16e55718b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60692111-4616-4f27-bc11-1a2ad0e85ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ca44e3-231b-4123-a294-bfe0b34527f2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60692111-4616-4f27-bc11-1a2ad0e85ea1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a78319e-9892-457d-b7d6-1428ffd32c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60692111-4616-4f27-bc11-1a2ad0e85ea1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a78319e-9892-457d-b7d6-1428ffd32c15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a78319e-9892-457d-b7d6-1428ffd32c15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a78319e-9892-457d-b7d6-1428ffd32c15" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a78319e-9892-457d-b7d6-1428ffd32c15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcb56c68-a6af-41cd-858b-264cd62bfaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a78319e-9892-457d-b7d6-1428ffd32c15" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcb56c68-a6af-41cd-858b-264cd62bfaf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b04283b7-a87b-4f01-9b11-bba569274412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcb56c68-a6af-41cd-858b-264cd62bfaf3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b04283b7-a87b-4f01-9b11-bba569274412" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_51b60ed0-33a2-4bff-8766-895eaf376926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcb56c68-a6af-41cd-858b-264cd62bfaf3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_51b60ed0-33a2-4bff-8766-895eaf376926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a5f7ce1f-2238-4c6e-8736-669fa91350dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcb56c68-a6af-41cd-858b-264cd62bfaf3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a5f7ce1f-2238-4c6e-8736-669fa91350dc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended" id="idcecffce3c894d74a80813427b385828_BusinessCombinationsandGoodwillAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a0ff7545-4999-4966-8263-395480d5137c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f3c6e6ef-d5e1-4889-83f5-4347491c93b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0ff7545-4999-4966-8263-395480d5137c" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f3c6e6ef-d5e1-4889-83f5-4347491c93b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ae5b084b-29f3-46ad-8a23-52bd353d31fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0ff7545-4999-4966-8263-395480d5137c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ae5b084b-29f3-46ad-8a23-52bd353d31fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_75ecca91-20f3-488e-a3a0-709515213d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0ff7545-4999-4966-8263-395480d5137c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_75ecca91-20f3-488e-a3a0-709515213d92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_92443996-e3d2-4a77-b098-0dda71a1478f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0ff7545-4999-4966-8263-395480d5137c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_92443996-e3d2-4a77-b098-0dda71a1478f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7eeb06fe-0de9-4b4f-96d0-09d3e8a22dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0ff7545-4999-4966-8263-395480d5137c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7eeb06fe-0de9-4b4f-96d0-09d3e8a22dc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_72e29583-3dff-40ac-99de-f07508d98331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7eeb06fe-0de9-4b4f-96d0-09d3e8a22dc4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_72e29583-3dff-40ac-99de-f07508d98331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_72e29583-3dff-40ac-99de-f07508d98331_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_72e29583-3dff-40ac-99de-f07508d98331" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_72e29583-3dff-40ac-99de-f07508d98331_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6f8dddc-578d-4038-98f0-5f25eef511ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_72e29583-3dff-40ac-99de-f07508d98331" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6f8dddc-578d-4038-98f0-5f25eef511ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_afbaafc8-f677-41b5-a261-0630992876cd" xlink:href="ameh-20210930.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6f8dddc-578d-4038-98f0-5f25eef511ec" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_afbaafc8-f677-41b5-a261-0630992876cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_c1e689c5-b41e-4246-af18-be2d75aee93c" xlink:href="ameh-20210930.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6f8dddc-578d-4038-98f0-5f25eef511ec" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_c1e689c5-b41e-4246-af18-be2d75aee93c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i687eb06a90cd470dbe809ffa3bc84802_IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e2f07253-fdd3-4d8f-9cc7-143710316f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e2f07253-fdd3-4d8f-9cc7-143710316f27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_51ab574e-bbed-4120-abf4-bb341c3af985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_51ab574e-bbed-4120-abf4-bb341c3af985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_88140823-ec7f-4471-9eac-dd2ffadcbf20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_88140823-ec7f-4471-9eac-dd2ffadcbf20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_caefc6d0-219d-46a2-87d6-8d0e29edcb51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_caefc6d0-219d-46a2-87d6-8d0e29edcb51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2aa4ecc8-6d43-478f-8989-e294bb186d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2aa4ecc8-6d43-478f-8989-e294bb186d1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7fa6d0c-446e-4152-a056-44eb25778d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7fa6d0c-446e-4152-a056-44eb25778d73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b4afae9d-48f6-4a61-9615-6c2de23384a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b4afae9d-48f6-4a61-9615-6c2de23384a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a37387ac-411e-4638-aa4f-0a168997f68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b4afae9d-48f6-4a61-9615-6c2de23384a1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a37387ac-411e-4638-aa4f-0a168997f68a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a37387ac-411e-4638-aa4f-0a168997f68a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a37387ac-411e-4638-aa4f-0a168997f68a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a37387ac-411e-4638-aa4f-0a168997f68a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a37387ac-411e-4638-aa4f-0a168997f68a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_6748832a-ffd4-4f70-8e0e-322d127b5de5" xlink:href="ameh-20210930.xsd#ameh_NetworkRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:to="loc_ameh_NetworkRelationshipsMember_6748832a-ffd4-4f70-8e0e-322d127b5de5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_8d146dbc-2f24-406b-99be-48252b69593c" xlink:href="ameh-20210930.xsd#ameh_ManagementContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:to="loc_ameh_ManagementContractsMember_8d146dbc-2f24-406b-99be-48252b69593c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_824227c1-c0cc-4ed5-bc3c-af6b13607f93" xlink:href="ameh-20210930.xsd#ameh_MemberRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:to="loc_ameh_MemberRelationshipsMember_824227c1-c0cc-4ed5-bc3c-af6b13607f93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_c0307b10-6598-4a46-a552-b79aa755843e" xlink:href="ameh-20210930.xsd#ameh_PatientManagementPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:to="loc_ameh_PatientManagementPlatformMember_c0307b10-6598-4a46-a552-b79aa755843e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_4cdeada2-1049-4027-9d13-997881cd0bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_4cdeada2-1049-4027-9d13-997881cd0bbf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76823a7c-857e-455e-9809-11cd144e7255" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b4afae9d-48f6-4a61-9615-6c2de23384a1" xlink:to="loc_srt_RangeAxis_76823a7c-857e-455e-9809-11cd144e7255" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76823a7c-857e-455e-9809-11cd144e7255_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_76823a7c-857e-455e-9809-11cd144e7255" xlink:to="loc_srt_RangeMember_76823a7c-857e-455e-9809-11cd144e7255_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2012347a-752f-4eb9-acc8-7f060ab628b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_76823a7c-857e-455e-9809-11cd144e7255" xlink:to="loc_srt_RangeMember_2012347a-752f-4eb9-acc8-7f060ab628b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7be875c-2382-47e2-aa04-d423b2b9444f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2012347a-752f-4eb9-acc8-7f060ab628b1" xlink:to="loc_srt_MinimumMember_f7be875c-2382-47e2-aa04-d423b2b9444f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac43b141-21f1-4ea3-be54-cbcae27929e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2012347a-752f-4eb9-acc8-7f060ab628b1" xlink:to="loc_srt_MaximumMember_ac43b141-21f1-4ea3-be54-cbcae27929e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_bc5feac3-0879-4f5b-b4b5-d2dfc7048a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_13657a66-3669-4d97-b34c-e90c9c7e3a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_bc5feac3-0879-4f5b-b4b5-d2dfc7048a80" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_13657a66-3669-4d97-b34c-e90c9c7e3a5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f2171f0e-d901-418e-8077-e961c6c09d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_bc5feac3-0879-4f5b-b4b5-d2dfc7048a80" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f2171f0e-d901-418e-8077-e961c6c09d21" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3b1a4d59-6601-4d2e-9847-c3d1811724de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f2171f0e-d901-418e-8077-e961c6c09d21" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3b1a4d59-6601-4d2e-9847-c3d1811724de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3b1a4d59-6601-4d2e-9847-c3d1811724de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3b1a4d59-6601-4d2e-9847-c3d1811724de" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3b1a4d59-6601-4d2e-9847-c3d1811724de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_57b6128f-62cf-475d-b4c1-619eb21441cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3b1a4d59-6601-4d2e-9847-c3d1811724de" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_57b6128f-62cf-475d-b4c1-619eb21441cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_a363fe20-2582-4185-a8d7-bd08eab6b41b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_57b6128f-62cf-475d-b4c1-619eb21441cf" xlink:to="loc_us-gaap_TrademarksMember_a363fe20-2582-4185-a8d7-bd08eab6b41b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="extended" id="if331867bb7aa488b93c58833a7f593c4_InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b6e04dc6-6433-4a9d-9909-957570df544f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b6e04dc6-6433-4a9d-9909-957570df544f" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d4608f3a-a1b9-47b5-b14d-8679ee22e1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_us-gaap_EquityMethodInvestments_d4608f3a-a1b9-47b5-b14d-8679ee22e1fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentAdditionalInvestment_c51d5878-369e-44b0-9835-ff2cd8b5dc72" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentAdditionalInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_ameh_EquityMethodInvestmentAdditionalInvestment_c51d5878-369e-44b0-9835-ff2cd8b5dc72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9ae69d48-245c-4251-b01e-02e9050adb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9ae69d48-245c-4251-b01e-02e9050adb46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_6b269273-0a3a-45c6-9a16-e389b94e74ab" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_6b269273-0a3a-45c6-9a16-e389b94e74ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsConsolidated_78b78467-7b63-4592-8472-86b24cd1122b" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentsConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_ameh_EquityMethodInvestmentsConsolidated_78b78467-7b63-4592-8472-86b24cd1122b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_ca1defab-69f4-4df6-86bc-637bdb17f5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_ca1defab-69f4-4df6-86bc-637bdb17f5d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ad8586eb-a774-48e1-b10b-3b90ef1389fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_861b0130-a29c-416a-81cf-4bcd91b20932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b6e04dc6-6433-4a9d-9909-957570df544f" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_861b0130-a29c-416a-81cf-4bcd91b20932" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c1dc84f-69c2-414e-bc54-cda8486fe8e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_861b0130-a29c-416a-81cf-4bcd91b20932" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c1dc84f-69c2-414e-bc54-cda8486fe8e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8c1dc84f-69c2-414e-bc54-cda8486fe8e5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c1dc84f-69c2-414e-bc54-cda8486fe8e5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8c1dc84f-69c2-414e-bc54-cda8486fe8e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c1dc84f-69c2-414e-bc54-cda8486fe8e5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_4f7fcdca-20f3-4083-b0a9-b10fd9088ed7" xlink:href="ameh-20210930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_4f7fcdca-20f3-4083-b0a9-b10fd9088ed7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_872d6179-075b-48a2-877c-39be5614e776" xlink:href="ameh-20210930.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_872d6179-075b-48a2-877c-39be5614e776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_6c5fef48-e792-48aa-9196-b104a96244d8" xlink:href="ameh-20210930.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_6c5fef48-e792-48aa-9196-b104a96244d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_306338aa-7cd5-43c3-8ffb-d6babbb3c9d0" xlink:href="ameh-20210930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_306338aa-7cd5-43c3-8ffb-d6babbb3c9d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_679f3a16-308b-451a-9e1c-11e63153fe4c" xlink:href="ameh-20210930.xsd#ameh_OneMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_OneMSOLLCMember_679f3a16-308b-451a-9e1c-11e63153fe4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_c5c05caa-0403-4bd0-83a3-ff4cdc8ee4fd" xlink:href="ameh-20210930.xsd#ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_c5c05caa-0403-4bd0-83a3-ff4cdc8ee4fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_11b6b5b1-059b-41ff-8ffc-7d352c261561" xlink:href="ameh-20210930.xsd#ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_11b6b5b1-059b-41ff-8ffc-7d352c261561" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_a1521698-e90d-4f12-a3b0-391c152ac71e" xlink:href="ameh-20210930.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_CAIPAMSOLLCMember_a1521698-e90d-4f12-a3b0-391c152ac71e" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="extended" id="ide6a8d97e1094cd580ef9f21305baddf_InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_6f7572cb-88d2-4ce9-832a-bdbba3c4323b" xlink:href="ameh-20210930.xsd#ameh_NumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_NumberOfEmployees_6f7572cb-88d2-4ce9-832a-bdbba3c4323b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_e23fc8ef-0017-4033-a3c1-3449952cfbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_e23fc8ef-0017-4033-a3c1-3449952cfbea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ac420527-6d11-4916-8e15-49c145e6d778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ac420527-6d11-4916-8e15-49c145e6d778" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_58505352-1df5-4245-afc6-4384aa5788b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_NotesReceivableNet_58505352-1df5-4245-afc6-4384aa5788b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_ce182ad7-1d13-4055-8ca7-71926b6c13e5" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_ce182ad7-1d13-4055-8ca7-71926b6c13e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_c806b143-6496-49d2-b24d-63d1c03b8392" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_c806b143-6496-49d2-b24d-63d1c03b8392" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold_2a5a6eab-3d77-4a9b-b73f-b39f6a26327b" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentOwnershipPercentageSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold_2a5a6eab-3d77-4a9b-b73f-b39f6a26327b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_af7486de-16f6-4b8d-a0c4-e333a1bd9457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_af7486de-16f6-4b8d-a0c4-e333a1bd9457" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b1cd427e-d0d4-4368-a71d-d883e9f40a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b1cd427e-d0d4-4368-a71d-d883e9f40a3a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_35e85afd-5748-43df-93fd-f0f4bfb5ffea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_EquityMethodInvestments_35e85afd-5748-43df-93fd-f0f4bfb5ffea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_d0df268a-48b4-41dc-8c55-c37d29124018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_PaymentsForFees_d0df268a-48b4-41dc-8c55-c37d29124018" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital_d65253c3-d8ce-407a-9106-cf83bfbd7f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_MembersCapital_d65253c3-d8ce-407a-9106-cf83bfbd7f36" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate_ccd4449d-5874-4ac9-8a21-371ad820b18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_PaymentsToAcquireRealEstate_ccd4449d-5874-4ac9-8a21-371ad820b18e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_fcf153be-d34e-4806-92b1-09eccca1d323" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_fcf153be-d34e-4806-92b1-09eccca1d323" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_56e87ac8-f8e1-41a1-8c72-79b9a08bac54" xlink:href="ameh-20210930.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_56e87ac8-f8e1-41a1-8c72-79b9a08bac54" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_e62d6c94-9a38-40b7-8931-27332a891a43" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_e62d6c94-9a38-40b7-8931-27332a891a43" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_0532da99-08b3-4d03-a3a8-7e6bb1cc3c65" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_0532da99-08b3-4d03-a3a8-7e6bb1cc3c65" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_148ce622-53f0-45c2-b163-ad6269351996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_148ce622-53f0-45c2-b163-ad6269351996" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8a370eab-6752-419e-9840-9221afcb3103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8a370eab-6752-419e-9840-9221afcb3103" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_0b316bfc-de64-404b-9902-3069ca4f9d68" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_0b316bfc-de64-404b-9902-3069ca4f9d68" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_fdf5ce16-5e43-4f2d-a52a-437e1bc0baa1" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_fdf5ce16-5e43-4f2d-a52a-437e1bc0baa1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_b0fbb1b5-1432-43c8-b1c0-8b05e61ebd65" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_b0fbb1b5-1432-43c8-b1c0-8b05e61ebd65" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_b9333af2-613b-475f-8041-aa8c9656c99a" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_b9333af2-613b-475f-8041-aa8c9656c99a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_3b95f303-4845-4f66-95e4-487f73540017" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_3b95f303-4845-4f66-95e4-487f73540017" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_01507f87-2109-4bb5-8c9d-4dc34d7891e6" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_01507f87-2109-4bb5-8c9d-4dc34d7891e6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_879a9b19-9565-4be5-bf3b-62b24ed6bc7e" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_879a9b19-9565-4be5-bf3b-62b24ed6bc7e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b79019e-a8c4-4af6-a046-e752b2c7d970" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b79019e-a8c4-4af6-a046-e752b2c7d970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9b79019e-a8c4-4af6-a046-e752b2c7d970_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b79019e-a8c4-4af6-a046-e752b2c7d970" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9b79019e-a8c4-4af6-a046-e752b2c7d970_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b79019e-a8c4-4af6-a046-e752b2c7d970" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_f564cb78-fd7a-4ae6-ade4-251aa291ce8d" xlink:href="ameh-20210930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_f564cb78-fd7a-4ae6-ade4-251aa291ce8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_a8700011-751e-48e6-bfbb-c7fad31ca4b7" xlink:href="ameh-20210930.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_a8700011-751e-48e6-bfbb-c7fad31ca4b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_54f66e3b-408f-4515-b8c6-42ebe1485e88" xlink:href="ameh-20210930.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_54f66e3b-408f-4515-b8c6-42ebe1485e88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_470d6a10-12f3-487e-b546-a2977fa8e36e" xlink:href="ameh-20210930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_470d6a10-12f3-487e-b546-a2977fa8e36e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_aae82279-b1db-4248-b0fe-463eea114027" xlink:href="ameh-20210930.xsd#ameh_OneMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_OneMSOLLCMember_aae82279-b1db-4248-b0fe-463eea114027" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_743696a4-6ba0-4042-b077-1bd777dc0396" xlink:href="ameh-20210930.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_743696a4-6ba0-4042-b077-1bd777dc0396" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_7b0e5df2-893f-49f5-8d92-87402d25764f" xlink:href="ameh-20210930.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_7b0e5df2-893f-49f5-8d92-87402d25764f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_8e5b42ea-c921-4ae8-829d-0078656d54ee" xlink:href="ameh-20210930.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_CAIPAMSOLLCMember_8e5b42ea-c921-4ae8-829d-0078656d54ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_81aded2c-081a-456e-b9da-a05aafb35d0c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_dei_LegalEntityAxis_81aded2c-081a-456e-b9da-a05aafb35d0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_81aded2c-081a-456e-b9da-a05aafb35d0c_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_81aded2c-081a-456e-b9da-a05aafb35d0c" xlink:to="loc_dei_EntityDomain_81aded2c-081a-456e-b9da-a05aafb35d0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_aee7524d-e54a-4a68-ac56-a4b53c989770" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_81aded2c-081a-456e-b9da-a05aafb35d0c" xlink:to="loc_dei_EntityDomain_aee7524d-e54a-4a68-ac56-a4b53c989770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_fa849121-09ce-4bef-8705-1d25348dfee9" xlink:href="ameh-20210930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_aee7524d-e54a-4a68-ac56-a4b53c989770" xlink:to="loc_ameh_APCAndAPCLSMAMember_fa849121-09ce-4bef-8705-1d25348dfee9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_ed56506f-a4ff-4303-81f2-465a958bb722" xlink:href="ameh-20210930.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_APCAndAPCLSMAMember_fa849121-09ce-4bef-8705-1d25348dfee9" xlink:to="loc_ameh_ApcLsmaMember_ed56506f-a4ff-4303-81f2-465a958bb722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_714ca51a-5fb6-4ffd-acec-7fc120453b0a" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_APCAndAPCLSMAMember_fa849121-09ce-4bef-8705-1d25348dfee9" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_714ca51a-5fb6-4ffd-acec-7fc120453b0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember_06680d34-f86e-43e5-9523-15a98e9dfb53" xlink:href="ameh-20210930.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_aee7524d-e54a-4a68-ac56-a4b53c989770" xlink:to="loc_ameh_CollegeStreetInvestmentLpMember_06680d34-f86e-43e5-9523-15a98e9dfb53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_81b0a2a7-2885-46af-844a-3030ecb21df1" xlink:href="ameh-20210930.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_aee7524d-e54a-4a68-ac56-a4b53c989770" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_81b0a2a7-2885-46af-844a-3030ecb21df1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_65ccb7a2-3df6-49cf-85af-651eb5b9eb68" xlink:href="ameh-20210930.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_aee7524d-e54a-4a68-ac56-a4b53c989770" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_65ccb7a2-3df6-49cf-85af-651eb5b9eb68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis_e687c022-cad0-4c55-b5d6-ee5204fc8508" xlink:href="ameh-20210930.xsd#ameh_ContractTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_ameh_ContractTypeAxis_e687c022-cad0-4c55-b5d6-ee5204fc8508" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_e687c022-cad0-4c55-b5d6-ee5204fc8508_default" xlink:href="ameh-20210930.xsd#ameh_ContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ameh_ContractTypeAxis_e687c022-cad0-4c55-b5d6-ee5204fc8508" xlink:to="loc_ameh_ContractTypeDomain_e687c022-cad0-4c55-b5d6-ee5204fc8508_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_ca53e4de-307e-47fb-b3fd-33f1b08b45fc" xlink:href="ameh-20210930.xsd#ameh_ContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ameh_ContractTypeAxis_e687c022-cad0-4c55-b5d6-ee5204fc8508" xlink:to="loc_ameh_ContractTypeDomain_ca53e4de-307e-47fb-b3fd-33f1b08b45fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember_ec6174bd-cc66-4288-8078-112ea4eba2fd" xlink:href="ameh-20210930.xsd#ameh_AncillaryServiceContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ContractTypeDomain_ca53e4de-307e-47fb-b3fd-33f1b08b45fc" xlink:to="loc_ameh_AncillaryServiceContractMember_ec6174bd-cc66-4288-8078-112ea4eba2fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f9e84678-085d-4eb4-936c-8f5db5de6b17" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_srt_CounterpartyNameAxis_f9e84678-085d-4eb4-936c-8f5db5de6b17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9e84678-085d-4eb4-936c-8f5db5de6b17_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f9e84678-085d-4eb4-936c-8f5db5de6b17" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9e84678-085d-4eb4-936c-8f5db5de6b17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bd33a9e-0ebe-425e-bc66-b20ef452304d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f9e84678-085d-4eb4-936c-8f5db5de6b17" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bd33a9e-0ebe-425e-bc66-b20ef452304d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_52cf731f-f10c-4eab-9042-808d1dcfb7f5" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bd33a9e-0ebe-425e-bc66-b20ef452304d" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_52cf731f-f10c-4eab-9042-808d1dcfb7f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_943ce8dc-45e4-4202-917a-3e93f12bd42f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_srt_OwnershipAxis_943ce8dc-45e4-4202-917a-3e93f12bd42f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_943ce8dc-45e4-4202-917a-3e93f12bd42f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_943ce8dc-45e4-4202-917a-3e93f12bd42f" xlink:to="loc_srt_OwnershipDomain_943ce8dc-45e4-4202-917a-3e93f12bd42f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_aa65d711-b5d1-4b13-b345-9832a8bdb668" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_943ce8dc-45e4-4202-917a-3e93f12bd42f" xlink:to="loc_srt_OwnershipDomain_aa65d711-b5d1-4b13-b345-9832a8bdb668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_820cf703-5d5a-4065-9004-b2fd65e526d4" xlink:href="ameh-20210930.xsd#ameh_MediPortalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_aa65d711-b5d1-4b13-b345-9832a8bdb668" xlink:to="loc_ameh_MediPortalLLCMember_820cf703-5d5a-4065-9004-b2fd65e526d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_42d2a539-5f8e-4e00-9c7a-c4e41f7cf907" xlink:href="ameh-20210930.xsd#ameh_AchievaMedInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_aa65d711-b5d1-4b13-b345-9832a8bdb668" xlink:to="loc_ameh_AchievaMedInc.Member_42d2a539-5f8e-4e00-9c7a-c4e41f7cf907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5e18b622-86cd-446e-ad61-e542a66b5b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5e18b622-86cd-446e-ad61-e542a66b5b9d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_5e18b622-86cd-446e-ad61-e542a66b5b9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5e18b622-86cd-446e-ad61-e542a66b5b9d" xlink:to="loc_us-gaap_ReceivableTypeDomain_5e18b622-86cd-446e-ad61-e542a66b5b9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_6bda22b6-b03d-4efc-a995-954b650e5e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5e18b622-86cd-446e-ad61-e542a66b5b9d" xlink:to="loc_us-gaap_ReceivableTypeDomain_6bda22b6-b03d-4efc-a995-954b650e5e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_2ad62749-d664-4eaf-97aa-e5e9d92d282b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_6bda22b6-b03d-4efc-a995-954b650e5e01" xlink:to="loc_us-gaap_NotesReceivableMember_2ad62749-d664-4eaf-97aa-e5e9d92d282b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1d0f30a-03da-418c-932e-9fe4e03cdfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1d0f30a-03da-418c-932e-9fe4e03cdfa4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d1d0f30a-03da-418c-932e-9fe4e03cdfa4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1d0f30a-03da-418c-932e-9fe4e03cdfa4" xlink:to="loc_us-gaap_RelatedPartyDomain_d1d0f30a-03da-418c-932e-9fe4e03cdfa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3e271e71-49ac-4221-9b0f-469be3c792e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1d0f30a-03da-418c-932e-9fe4e03cdfa4" xlink:to="loc_us-gaap_RelatedPartyDomain_3e271e71-49ac-4221-9b0f-469be3c792e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_06743caf-8fa8-418e-a019-2aeb5ffbb9c5" xlink:href="ameh-20210930.xsd#ameh_Dr.ArteagaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3e271e71-49ac-4221-9b0f-469be3c792e6" xlink:to="loc_ameh_Dr.ArteagaMember_06743caf-8fa8-418e-a019-2aeb5ffbb9c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended" id="ide26c2af86d64234b1f2f3ffab71d08c_InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2984990b-1b86-463f-ab42-b307b400b20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2984990b-1b86-463f-ab42-b307b400b20d" xlink:to="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3eaf7c9-7dd8-4e16-ae17-9dc1521ee705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3eaf7c9-7dd8-4e16-ae17-9dc1521ee705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_956935a1-400a-403d-89b8-6f96acb1f797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_RestrictedCashCurrent_956935a1-400a-403d-89b8-6f96acb1f797" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7755ccd6-b678-49a3-8df3-51ece8744cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7755ccd6-b678-49a3-8df3-51ece8744cf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e08fbe4d-7014-4bb5-bbaa-47d69b278043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_OtherAssetsCurrent_e08fbe4d-7014-4bb5-bbaa-47d69b278043" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_2e490aea-95e5-4823-9489-cf3be7e30f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_OtherAssets_2e490aea-95e5-4823-9489-cf3be7e30f39" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0438e3dc-2b7c-46ef-8c13-ee98365f8d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0438e3dc-2b7c-46ef-8c13-ee98365f8d71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_a057e617-6e40-4d17-9f08-04ba0252fa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_a057e617-6e40-4d17-9f08-04ba0252fa9c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b8ea73a2-1284-4e83-8eb2-4fe5ef2ccb65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_Assets_b8ea73a2-1284-4e83-8eb2-4fe5ef2ccb65" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4e668d00-92f8-4e2c-95e5-6c880e91f8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2984990b-1b86-463f-ab42-b307b400b20d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4e668d00-92f8-4e2c-95e5-6c880e91f8ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d509725f-7b2b-4381-8eb6-2255f896be25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4e668d00-92f8-4e2c-95e5-6c880e91f8ab" xlink:to="loc_us-gaap_LiabilitiesCurrent_d509725f-7b2b-4381-8eb6-2255f896be25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b42c92f8-ad0c-4422-91d5-61147596ed0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4e668d00-92f8-4e2c-95e5-6c880e91f8ab" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b42c92f8-ad0c-4422-91d5-61147596ed0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a2e948b2-7384-4082-8f09-41b0970a14de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4e668d00-92f8-4e2c-95e5-6c880e91f8ab" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a2e948b2-7384-4082-8f09-41b0970a14de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2984990b-1b86-463f-ab42-b307b400b20d" xlink:to="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_87bcb54b-b553-4ce9-afc3-46a115ecfa10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_87bcb54b-b553-4ce9-afc3-46a115ecfa10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ce4d98be-c922-4857-a3b2-f46f05ebc7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:to="loc_us-gaap_CostsAndExpenses_ce4d98be-c922-4857-a3b2-f46f05ebc7a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_430ffb7d-353c-473b-9b1a-434fd7715a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:to="loc_us-gaap_OperatingIncomeLoss_430ffb7d-353c-473b-9b1a-434fd7715a9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_68941a99-a5d5-4ef4-b75d-064bf48e5115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_68941a99-a5d5-4ef4-b75d-064bf48e5115" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_93d0bba5-bf2a-4f63-9982-757b1ee52d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_93d0bba5-bf2a-4f63-9982-757b1ee52d72" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_87eb7ead-68db-4bfa-9f7d-2695427d62fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:to="loc_us-gaap_ProfitLoss_87eb7ead-68db-4bfa-9f7d-2695427d62fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_12fb9f6d-3d9c-40da-a341-1914cf157f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2984990b-1b86-463f-ab42-b307b400b20d" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_12fb9f6d-3d9c-40da-a341-1914cf157f5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2711bfad-ac25-495a-9c49-68ec9132abf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_12fb9f6d-3d9c-40da-a341-1914cf157f5a" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2711bfad-ac25-495a-9c49-68ec9132abf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_2711bfad-ac25-495a-9c49-68ec9132abf2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2711bfad-ac25-495a-9c49-68ec9132abf2" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_2711bfad-ac25-495a-9c49-68ec9132abf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b179d8b3-deda-4a36-bfa5-d227f88e4809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2711bfad-ac25-495a-9c49-68ec9132abf2" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b179d8b3-deda-4a36-bfa5-d227f88e4809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_77f74164-4e7f-4ba5-b085-9dc1acbc3c7d" xlink:href="ameh-20210930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b179d8b3-deda-4a36-bfa5-d227f88e4809" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_77f74164-4e7f-4ba5-b085-9dc1acbc3c7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_8696319d-037a-426e-919f-934fafba87fb" xlink:href="ameh-20210930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b179d8b3-deda-4a36-bfa5-d227f88e4809" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_8696319d-037a-426e-919f-934fafba87fb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended" id="idfc63022bd4b421a97149109d99bcc87_LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79dd31c5-6e8d-4514-9e7f-55658feb3c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_c639281f-5568-488e-8e5a-7aa7edaddfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79dd31c5-6e8d-4514-9e7f-55658feb3c35" xlink:to="loc_us-gaap_NotesReceivableNet_c639281f-5568-488e-8e5a-7aa7edaddfb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_17c62291-4514-46d6-a57b-fce744ca589c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79dd31c5-6e8d-4514-9e7f-55658feb3c35" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_17c62291-4514-46d6-a57b-fce744ca589c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_a467dcc7-cf2c-4c75-9fb4-fe2ff3cc25ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79dd31c5-6e8d-4514-9e7f-55658feb3c35" xlink:to="loc_us-gaap_NotesReceivableGross_a467dcc7-cf2c-4c75-9fb4-fe2ff3cc25ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage_06289df9-bca3-459b-bdec-8210a82a845d" xlink:href="ameh-20210930.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79dd31c5-6e8d-4514-9e7f-55658feb3c35" xlink:to="loc_ameh_FinanceReceivableInterestRateStatedPercentage_06289df9-bca3-459b-bdec-8210a82a845d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5ceba20e-3ecf-4f2d-8514-c9baa62bca18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79dd31c5-6e8d-4514-9e7f-55658feb3c35" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5ceba20e-3ecf-4f2d-8514-c9baa62bca18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_39a4d7d8-6369-4d5f-8da1-ec7e7de18363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5ceba20e-3ecf-4f2d-8514-c9baa62bca18" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_39a4d7d8-6369-4d5f-8da1-ec7e7de18363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_39a4d7d8-6369-4d5f-8da1-ec7e7de18363_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_39a4d7d8-6369-4d5f-8da1-ec7e7de18363" xlink:to="loc_us-gaap_ReceivableTypeDomain_39a4d7d8-6369-4d5f-8da1-ec7e7de18363_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_c648d7b5-d678-4907-ad65-cad30280c5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_39a4d7d8-6369-4d5f-8da1-ec7e7de18363" xlink:to="loc_us-gaap_ReceivableTypeDomain_c648d7b5-d678-4907-ad65-cad30280c5ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_0fd2d122-76a2-4094-a346-76e3eb8a737a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_c648d7b5-d678-4907-ad65-cad30280c5ff" xlink:to="loc_us-gaap_NotesReceivableMember_0fd2d122-76a2-4094-a346-76e3eb8a737a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b7d6d579-c7fc-4fdc-9887-7da5f318b75e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5ceba20e-3ecf-4f2d-8514-c9baa62bca18" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b7d6d579-c7fc-4fdc-9887-7da5f318b75e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b7d6d579-c7fc-4fdc-9887-7da5f318b75e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b7d6d579-c7fc-4fdc-9887-7da5f318b75e" xlink:to="loc_us-gaap_RelatedPartyDomain_b7d6d579-c7fc-4fdc-9887-7da5f318b75e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_63175917-b880-41d3-9fba-5751c844e320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b7d6d579-c7fc-4fdc-9887-7da5f318b75e" xlink:to="loc_us-gaap_RelatedPartyDomain_63175917-b880-41d3-9fba-5751c844e320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_da42c66f-d56b-4bd0-bde3-7b13e16c3dc0" xlink:href="ameh-20210930.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_63175917-b880-41d3-9fba-5751c844e320" xlink:to="loc_ameh_Pacific6EnterprisesMember_da42c66f-d56b-4bd0-bde3-7b13e16c3dc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_6b0c027c-361b-4c8d-84c4-7b295ddd1675" xlink:href="ameh-20210930.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_63175917-b880-41d3-9fba-5751c844e320" xlink:to="loc_ameh_AHMCMember_6b0c027c-361b-4c8d-84c4-7b295ddd1675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b960aa85-d09d-4767-8886-510004313f25" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5ceba20e-3ecf-4f2d-8514-c9baa62bca18" xlink:to="loc_dei_LegalEntityAxis_b960aa85-d09d-4767-8886-510004313f25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b960aa85-d09d-4767-8886-510004313f25_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_b960aa85-d09d-4767-8886-510004313f25" xlink:to="loc_dei_EntityDomain_b960aa85-d09d-4767-8886-510004313f25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d40e0dcb-cd8f-407b-84d6-def5a4c0bbbc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_b960aa85-d09d-4767-8886-510004313f25" xlink:to="loc_dei_EntityDomain_d40e0dcb-cd8f-407b-84d6-def5a4c0bbbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_c2b81222-d757-475b-996f-999f936f5878" xlink:href="ameh-20210930.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d40e0dcb-cd8f-407b-84d6-def5a4c0bbbc" xlink:to="loc_ameh_NetworkMedicalManagementMember_c2b81222-d757-475b-996f-999f936f5878" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_1cacf867-5fad-4e9d-84cd-e2e195a1234d" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d40e0dcb-cd8f-407b-84d6-def5a4c0bbbc" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_1cacf867-5fad-4e9d-84cd-e2e195a1234d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" xlink:type="extended" id="i8822269c86794912abb2e75c0fb9a78c_CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_5fcfbc2f-0574-4276-bfe3-4f960c6a1e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c490de1b-93a3-4029-9b43-d3ad039378d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5fcfbc2f-0574-4276-bfe3-4f960c6a1e2b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c490de1b-93a3-4029-9b43-d3ad039378d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_da2997ae-8cbe-4c7a-a36f-8d358176715f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5fcfbc2f-0574-4276-bfe3-4f960c6a1e2b" xlink:to="loc_us-gaap_LongTermDebtCurrent_da2997ae-8cbe-4c7a-a36f-8d358176715f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9c693913-dd5d-423d-98cb-309452f254ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5fcfbc2f-0574-4276-bfe3-4f960c6a1e2b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9c693913-dd5d-423d-98cb-309452f254ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3d82f6dc-a228-4f89-b639-828a9f717752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5fcfbc2f-0574-4276-bfe3-4f960c6a1e2b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3d82f6dc-a228-4f89-b639-828a9f717752" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_5920859f-c2a8-4445-9fd7-883e90b57ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5fcfbc2f-0574-4276-bfe3-4f960c6a1e2b" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_5920859f-c2a8-4445-9fd7-883e90b57ddf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_25daa970-5dcc-4ef5-8a4a-6cfe04b7cfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5920859f-c2a8-4445-9fd7-883e90b57ddf" xlink:to="loc_us-gaap_CreditFacilityAxis_25daa970-5dcc-4ef5-8a4a-6cfe04b7cfa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_25daa970-5dcc-4ef5-8a4a-6cfe04b7cfa2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_25daa970-5dcc-4ef5-8a4a-6cfe04b7cfa2" xlink:to="loc_us-gaap_CreditFacilityDomain_25daa970-5dcc-4ef5-8a4a-6cfe04b7cfa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9a9b8621-3bf4-4174-a37b-db8164882257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_25daa970-5dcc-4ef5-8a4a-6cfe04b7cfa2" xlink:to="loc_us-gaap_CreditFacilityDomain_9a9b8621-3bf4-4174-a37b-db8164882257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_dfdb934a-a48c-41d5-922f-ce736e6ba840" xlink:href="ameh-20210930.xsd#ameh_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_9a9b8621-3bf4-4174-a37b-db8164882257" xlink:to="loc_ameh_TermLoanAMember_dfdb934a-a48c-41d5-922f-ce736e6ba840" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_42f60d2d-2677-4801-8021-3d70b7b9243d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_9a9b8621-3bf4-4174-a37b-db8164882257" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_42f60d2d-2677-4801-8021-3d70b7b9243d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0f469df0-2b2c-4afb-8f21-7434715a8840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5920859f-c2a8-4445-9fd7-883e90b57ddf" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0f469df0-2b2c-4afb-8f21-7434715a8840" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0f469df0-2b2c-4afb-8f21-7434715a8840_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0f469df0-2b2c-4afb-8f21-7434715a8840" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0f469df0-2b2c-4afb-8f21-7434715a8840_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3995e74b-8f04-473a-9614-86c8dfda4775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0f469df0-2b2c-4afb-8f21-7434715a8840" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3995e74b-8f04-473a-9614-86c8dfda4775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_be7b48cf-1083-4cec-b5ed-ea60118092a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3995e74b-8f04-473a-9614-86c8dfda4775" xlink:to="loc_us-gaap_RealEstateLoanMember_be7b48cf-1083-4cec-b5ed-ea60118092a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_4712ec7a-a45b-4ede-b6ad-f54f2b2bb3fc" xlink:href="ameh-20210930.xsd#ameh_ConstructionLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3995e74b-8f04-473a-9614-86c8dfda4775" xlink:to="loc_ameh_ConstructionLoanMember_4712ec7a-a45b-4ede-b6ad-f54f2b2bb3fc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="extended" id="i0d6109c3c6954c4f8afc46a29cde970b_CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_1f4ccaa6-32f8-41eb-b2b5-fccf215cc1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtInstrumentTerm_1f4ccaa6-32f8-41eb-b2b5-fccf215cc1cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_114a928f-6653-433c-9a4b-fa650d532c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_114a928f-6653-433c-9a4b-fa650d532c8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_49e6882c-6959-4e93-8780-c5b2edb80cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_49e6882c-6959-4e93-8780-c5b2edb80cd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0e8d02d8-3623-4eaa-b6c7-bda4c5a21319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0e8d02d8-3623-4eaa-b6c7-bda4c5a21319" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_1b46d4fd-5c7f-433c-b106-c833c1c0f289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_1b46d4fd-5c7f-433c-b106-c833c1c0f289" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1f596486-ebcb-4979-982b-ab0e115b770b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1f596486-ebcb-4979-982b-ab0e115b770b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_7ce869f2-d03e-4daa-85d6-e5a761698fcc" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_7ce869f2-d03e-4daa-85d6-e5a761698fcc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_d6583a08-c5ef-4ba4-9258-b80484793b86" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_d6583a08-c5ef-4ba4-9258-b80484793b86" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_b47b29c7-cd42-412d-b77a-cc544cee1e39" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_b47b29c7-cd42-412d-b77a-cc544cee1e39" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_d4e9853c-30a4-408f-b0f1-eef2e518477a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_d4e9853c-30a4-408f-b0f1-eef2e518477a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f8c7e347-c6a6-4c5d-8ae1-cbdc2fd7f723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f8c7e347-c6a6-4c5d-8ae1-cbdc2fd7f723" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_1424828b-8b19-47e9-a370-b5732c914904" xlink:href="ameh-20210930.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_1424828b-8b19-47e9-a370-b5732c914904" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0320978d-c6f9-492b-8528-be1517b9a672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0320978d-c6f9-492b-8528-be1517b9a672" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c3179cb5-12ed-447d-bbea-d31c4cc8daf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LongTermDebt_c3179cb5-12ed-447d-bbea-d31c4cc8daf4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_cdbf1c07-c57b-4b07-b85e-042f9728d76b" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_cdbf1c07-c57b-4b07-b85e-042f9728d76b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_1f9c14e5-fc23-4774-a3cc-bfd8adbf13d0" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_1f9c14e5-fc23-4774-a3cc-bfd8adbf13d0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_0bf38b8e-42ce-4745-81f0-8789a0552a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_0bf38b8e-42ce-4745-81f0-8789a0552a8d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6549bb0a-f77b-487a-8376-5878e83547fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_InterestExpense_6549bb0a-f77b-487a-8376-5878e83547fc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_e2e60978-36d5-4ee5-9065-f6f8487b9a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_e2e60978-36d5-4ee5-9065-f6f8487b9a7d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_24737822-9df1-453b-82dc-c0f21aab131b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_24737822-9df1-453b-82dc-c0f21aab131b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_714ae442-9997-40e8-819b-5fbe6f22fd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_714ae442-9997-40e8-819b-5fbe6f22fd8e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_aa38ce97-ad41-47d3-8f66-22fb920d640b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_CreditFacilityAxis_aa38ce97-ad41-47d3-8f66-22fb920d640b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_aa38ce97-ad41-47d3-8f66-22fb920d640b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_aa38ce97-ad41-47d3-8f66-22fb920d640b" xlink:to="loc_us-gaap_CreditFacilityDomain_aa38ce97-ad41-47d3-8f66-22fb920d640b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_aa38ce97-ad41-47d3-8f66-22fb920d640b" xlink:to="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_373d8f82-8555-4ffb-a83e-5cd6ac324ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_373d8f82-8555-4ffb-a83e-5cd6ac324ecb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5b14d614-6d45-4507-9480-377a57c72625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:to="loc_us-gaap_LineOfCreditMember_5b14d614-6d45-4507-9480-377a57c72625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_3892aaa1-0e55-4e72-8ae3-ec6769ece32e" xlink:href="ameh-20210930.xsd#ameh_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:to="loc_ameh_TermLoanAMember_3892aaa1-0e55-4e72-8ae3-ec6769ece32e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_e66f6a5f-d4c3-40e9-a591-f0f1eca9253a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:to="loc_us-gaap_LetterOfCreditMember_e66f6a5f-d4c3-40e9-a591-f0f1eca9253a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_9961e618-c6fd-4779-a4a2-b86e36dd4b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:to="loc_us-gaap_BridgeLoanMember_9961e618-c6fd-4779-a4a2-b86e36dd4b01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_e6422cda-e81d-4544-b775-ad3a7e8b6b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_e6422cda-e81d-4544-b775-ad3a7e8b6b1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a146d338-9cdb-4b6b-b140-bdc76682c299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_DebtInstrumentAxis_a146d338-9cdb-4b6b-b140-bdc76682c299" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a146d338-9cdb-4b6b-b140-bdc76682c299_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a146d338-9cdb-4b6b-b140-bdc76682c299" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a146d338-9cdb-4b6b-b140-bdc76682c299_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a99ab95d-a070-408b-942f-f7efb086133e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a146d338-9cdb-4b6b-b140-bdc76682c299" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a99ab95d-a070-408b-942f-f7efb086133e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_e726216f-80e6-4548-8289-c499c35430db" xlink:href="ameh-20210930.xsd#ameh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a99ab95d-a070-408b-942f-f7efb086133e" xlink:to="loc_ameh_CreditAgreementMember_e726216f-80e6-4548-8289-c499c35430db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember_f6523025-c911-4090-a562-ab6f430abb2b" xlink:href="ameh-20210930.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a99ab95d-a070-408b-942f-f7efb086133e" xlink:to="loc_ameh_AmendedCreditAgreementMember_f6523025-c911-4090-a562-ab6f430abb2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_a05cf202-3da0-44fd-aecf-8cba1f4fd6f2" xlink:href="ameh-20210930.xsd#ameh_ConstructionLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a99ab95d-a070-408b-942f-f7efb086133e" xlink:to="loc_ameh_ConstructionLoanMember_a05cf202-3da0-44fd-aecf-8cba1f4fd6f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_caf6e762-a212-4e3e-9ce8-7afdd134efca" xlink:href="ameh-20210930.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a99ab95d-a070-408b-942f-f7efb086133e" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_caf6e762-a212-4e3e-9ce8-7afdd134efca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a3461940-22f0-4b14-98d6-8f7d61306940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a3461940-22f0-4b14-98d6-8f7d61306940" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a3461940-22f0-4b14-98d6-8f7d61306940_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a3461940-22f0-4b14-98d6-8f7d61306940" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a3461940-22f0-4b14-98d6-8f7d61306940_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b743df5e-208a-4611-ace8-85f58169922c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a3461940-22f0-4b14-98d6-8f7d61306940" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b743df5e-208a-4611-ace8-85f58169922c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c7fcf869-60d1-493b-8850-ff923b5850f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b743df5e-208a-4611-ace8-85f58169922c" xlink:to="loc_us-gaap_LineOfCreditMember_c7fcf869-60d1-493b-8850-ff923b5850f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_de4036dd-4d67-4e78-b1d8-0a808b4c3d36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_srt_RangeAxis_de4036dd-4d67-4e78-b1d8-0a808b4c3d36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_de4036dd-4d67-4e78-b1d8-0a808b4c3d36_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_de4036dd-4d67-4e78-b1d8-0a808b4c3d36" xlink:to="loc_srt_RangeMember_de4036dd-4d67-4e78-b1d8-0a808b4c3d36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2b6e5d3f-095c-4f44-8e2f-cf0f72b1d3e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_de4036dd-4d67-4e78-b1d8-0a808b4c3d36" xlink:to="loc_srt_RangeMember_2b6e5d3f-095c-4f44-8e2f-cf0f72b1d3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37031fe7-4f97-4ae0-b30f-bfeccaa739c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2b6e5d3f-095c-4f44-8e2f-cf0f72b1d3e4" xlink:to="loc_srt_MinimumMember_37031fe7-4f97-4ae0-b30f-bfeccaa739c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1f1b23f-2db5-4e74-bde4-7cd7310a014c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2b6e5d3f-095c-4f44-8e2f-cf0f72b1d3e4" xlink:to="loc_srt_MaximumMember_b1f1b23f-2db5-4e74-bde4-7cd7310a014c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e5b07ff9-7efc-4ea9-ac98-801e8e885652" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_dei_LegalEntityAxis_e5b07ff9-7efc-4ea9-ac98-801e8e885652" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e5b07ff9-7efc-4ea9-ac98-801e8e885652_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e5b07ff9-7efc-4ea9-ac98-801e8e885652" xlink:to="loc_dei_EntityDomain_e5b07ff9-7efc-4ea9-ac98-801e8e885652_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e5b07ff9-7efc-4ea9-ac98-801e8e885652" xlink:to="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2fd1061f-f1bd-4c9a-81ef-6916ad4bb9c1" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2fd1061f-f1bd-4c9a-81ef-6916ad4bb9c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_27411f14-8800-42c2-8c97-1b385a74c624" xlink:href="ameh-20210930.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_27411f14-8800-42c2-8c97-1b385a74c624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_60a0f931-752f-4cca-b79a-37250aa0dd60" xlink:href="ameh-20210930.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_AMGPropertiesLLCMember_60a0f931-752f-4cca-b79a-37250aa0dd60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_2feeb1f5-8655-4ec6-8394-41f1cb382a25" xlink:href="ameh-20210930.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_ZLLPartnersLLCMember_2feeb1f5-8655-4ec6-8394-41f1cb382a25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_c8a428ff-652f-46d8-8126-179ce9bf994e" xlink:href="ameh-20210930.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_c8a428ff-652f-46d8-8126-179ce9bf994e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_5481a353-b428-445a-8696-e8fa0781ae3e" xlink:href="ameh-20210930.xsd#ameh_ApaacoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_ApaacoMember_5481a353-b428-445a-8696-e8fa0781ae3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_b6ce7e94-c9ce-480e-8dba-2fbc6996ca69" xlink:href="ameh-20210930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_b6ce7e94-c9ce-480e-8dba-2fbc6996ca69" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_9090a800-c405-42f4-bf88-652cb04f1942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_VariableRateAxis_9090a800-c405-42f4-bf88-652cb04f1942" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9090a800-c405-42f4-bf88-652cb04f1942_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_9090a800-c405-42f4-bf88-652cb04f1942" xlink:to="loc_us-gaap_VariableRateDomain_9090a800-c405-42f4-bf88-652cb04f1942_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2d8a6941-28ae-4b8f-be95-e71f85f10762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_9090a800-c405-42f4-bf88-652cb04f1942" xlink:to="loc_us-gaap_VariableRateDomain_2d8a6941-28ae-4b8f-be95-e71f85f10762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_209a1966-cf25-4f22-bd81-b2987395e946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_2d8a6941-28ae-4b8f-be95-e71f85f10762" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_209a1966-cf25-4f22-bd81-b2987395e946" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_d426871e-70ad-4493-b949-9e5a4b1e0f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_2d8a6941-28ae-4b8f-be95-e71f85f10762" xlink:to="loc_us-gaap_PrimeRateMember_d426871e-70ad-4493-b949-9e5a4b1e0f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_a0e800a5-4cc9-423f-ac52-f7e4b288f8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_a0e800a5-4cc9-423f-ac52-f7e4b288f8b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_a0e800a5-4cc9-423f-ac52-f7e4b288f8b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_a0e800a5-4cc9-423f-ac52-f7e4b288f8b0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_a0e800a5-4cc9-423f-ac52-f7e4b288f8b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b05128e6-58c9-42b7-9d18-9f215cb4dfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_a0e800a5-4cc9-423f-ac52-f7e4b288f8b0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b05128e6-58c9-42b7-9d18-9f215cb4dfc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_a9da4447-32b4-4a7f-8808-4c55f2954693" xlink:href="ameh-20210930.xsd#ameh_PreferredBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b05128e6-58c9-42b7-9d18-9f215cb4dfc3" xlink:to="loc_ameh_PreferredBankMember_a9da4447-32b4-4a7f-8808-4c55f2954693" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_11941075-7e74-4b19-82f3-d50af093457c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_AssetAcquisitionAxis_11941075-7e74-4b19-82f3-d50af093457c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_11941075-7e74-4b19-82f3-d50af093457c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_11941075-7e74-4b19-82f3-d50af093457c" xlink:to="loc_us-gaap_AssetAcquisitionDomain_11941075-7e74-4b19-82f3-d50af093457c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_250d0ddb-ccb0-4802-9460-fed96457dfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_11941075-7e74-4b19-82f3-d50af093457c" xlink:to="loc_us-gaap_AssetAcquisitionDomain_250d0ddb-ccb0-4802-9460-fed96457dfb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_6145ed19-4be1-465e-b657-24b46fa98052" xlink:href="ameh-20210930.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_250d0ddb-ccb0-4802-9460-fed96457dfb4" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_6145ed19-4be1-465e-b657-24b46fa98052" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_77739653-3fd7-43f0-8d6b-c99f8ebca5f5" xlink:href="ameh-20210930.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_250d0ddb-ccb0-4802-9460-fed96457dfb4" xlink:to="loc_ameh_AMGPropertiesLLCMember_77739653-3fd7-43f0-8d6b-c99f8ebca5f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_358ab9d7-6cdd-47e0-ad70-ab5ab6a23f19" xlink:href="ameh-20210930.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_250d0ddb-ccb0-4802-9460-fed96457dfb4" xlink:to="loc_ameh_ZLLPartnersLLCMember_358ab9d7-6cdd-47e0-ad70-ab5ab6a23f19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a8506bbb-2cc1-4722-a1ee-4a73a471dae3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_srt_StatementScenarioAxis_a8506bbb-2cc1-4722-a1ee-4a73a471dae3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a8506bbb-2cc1-4722-a1ee-4a73a471dae3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_a8506bbb-2cc1-4722-a1ee-4a73a471dae3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a8506bbb-2cc1-4722-a1ee-4a73a471dae3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3214da5e-dfd7-4b39-878a-cccf6d9d1a67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_a8506bbb-2cc1-4722-a1ee-4a73a471dae3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3214da5e-dfd7-4b39-878a-cccf6d9d1a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_88278554-5d72-487d-b7cb-77a80f9f4136" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3214da5e-dfd7-4b39-878a-cccf6d9d1a67" xlink:to="loc_srt_ScenarioForecastMember_88278554-5d72-487d-b7cb-77a80f9f4136" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ff97b7f2-820d-4c57-968f-47949bace5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ff97b7f2-820d-4c57-968f-47949bace5fb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ff97b7f2-820d-4c57-968f-47949bace5fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ff97b7f2-820d-4c57-968f-47949bace5fb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ff97b7f2-820d-4c57-968f-47949bace5fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea0e53b3-5659-4001-b652-c3aa7409dba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ff97b7f2-820d-4c57-968f-47949bace5fb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea0e53b3-5659-4001-b652-c3aa7409dba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b925cd37-dc7b-4473-b9b5-f1ce34082951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea0e53b3-5659-4001-b652-c3aa7409dba1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b925cd37-dc7b-4473-b9b5-f1ce34082951" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i3ab4ac0bdf6848b7b9faba6d046fc346_MezzanineandStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7f5f183f-6c5e-42d5-9c08-dd2c33044294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_0ebb7140-fb5a-474d-9326-cc2d38bdabca" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7f5f183f-6c5e-42d5-9c08-dd2c33044294" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_0ebb7140-fb5a-474d-9326-cc2d38bdabca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_700d8b22-eff8-4218-a525-793a0594ef5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7f5f183f-6c5e-42d5-9c08-dd2c33044294" xlink:to="loc_us-gaap_TreasuryStockCommonShares_700d8b22-eff8-4218-a525-793a0594ef5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_e07063ee-bd8a-4664-a1c0-0e5ccbac047e" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7f5f183f-6c5e-42d5-9c08-dd2c33044294" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_e07063ee-bd8a-4664-a1c0-0e5ccbac047e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_ae0880ba-56aa-41c4-a734-7ade25ec270b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7f5f183f-6c5e-42d5-9c08-dd2c33044294" xlink:to="loc_us-gaap_Dividends_ae0880ba-56aa-41c4-a734-7ade25ec270b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_528c3f14-669f-40fb-b986-e3585b5d465d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7f5f183f-6c5e-42d5-9c08-dd2c33044294" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_528c3f14-669f-40fb-b986-e3585b5d465d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d1d360ef-7ed8-40d6-8201-b640b43ec920" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_528c3f14-669f-40fb-b986-e3585b5d465d" xlink:to="loc_dei_LegalEntityAxis_d1d360ef-7ed8-40d6-8201-b640b43ec920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d1d360ef-7ed8-40d6-8201-b640b43ec920_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d1d360ef-7ed8-40d6-8201-b640b43ec920" xlink:to="loc_dei_EntityDomain_d1d360ef-7ed8-40d6-8201-b640b43ec920_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d5f03c00-cf4d-41ff-8937-dafb6eb110af" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d1d360ef-7ed8-40d6-8201-b640b43ec920" xlink:to="loc_dei_EntityDomain_d5f03c00-cf4d-41ff-8937-dafb6eb110af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_04fb9654-40d8-49df-b9b1-c71c7baa253a" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d5f03c00-cf4d-41ff-8937-dafb6eb110af" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_04fb9654-40d8-49df-b9b1-c71c7baa253a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_833cfcb0-ef40-4c4e-a2ed-82d67bcbdc55" xlink:href="ameh-20210930.xsd#ameh_CDSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d5f03c00-cf4d-41ff-8937-dafb6eb110af" xlink:to="loc_ameh_CDSCMember_833cfcb0-ef40-4c4e-a2ed-82d67bcbdc55" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#StockBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="i85ce84636b094248ad470d372dcd6d2a_StockBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f77c800d-ab62-476b-b81b-858537bf7197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ecea69aa-0f91-4962-aa40-763f17586a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f77c800d-ab62-476b-b81b-858537bf7197" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ecea69aa-0f91-4962-aa40-763f17586a9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c82e913-834a-484d-9910-720c95edf753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f77c800d-ab62-476b-b81b-858537bf7197" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c82e913-834a-484d-9910-720c95edf753" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9e802a8b-765d-4a2d-bf1f-17d1767e3268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c82e913-834a-484d-9910-720c95edf753" xlink:to="loc_us-gaap_AwardTypeAxis_9e802a8b-765d-4a2d-bf1f-17d1767e3268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e802a8b-765d-4a2d-bf1f-17d1767e3268_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9e802a8b-765d-4a2d-bf1f-17d1767e3268" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e802a8b-765d-4a2d-bf1f-17d1767e3268_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7aecbe4c-0977-46a3-9d8d-5d766fe9d2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9e802a8b-765d-4a2d-bf1f-17d1767e3268" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7aecbe4c-0977-46a3-9d8d-5d766fe9d2b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_970e77d7-78c5-4c2e-ba37-9cfa62a5c12c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7aecbe4c-0977-46a3-9d8d-5d766fe9d2b7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_970e77d7-78c5-4c2e-ba37-9cfa62a5c12c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember_2715e26c-2975-44cf-b2f2-208ddc7cbb22" xlink:href="ameh-20210930.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7aecbe4c-0977-46a3-9d8d-5d766fe9d2b7" xlink:to="loc_ameh_StockAwardsAndUnitsMember_2715e26c-2975-44cf-b2f2-208ddc7cbb22" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i5e07fbe4e7614da69c220c955f316a99_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_794e3d14-7043-4972-b0e2-5e49b5a900b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_794e3d14-7043-4972-b0e2-5e49b5a900b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d985fa3f-cef5-42e2-875f-f86f81a7fcbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d985fa3f-cef5-42e2-875f-f86f81a7fcbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_569cf884-8c77-4103-b050-7989b5cef705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_569cf884-8c77-4103-b050-7989b5cef705" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2a94a31c-ea48-4d4e-b1f3-0dd4f5f0e89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2a94a31c-ea48-4d4e-b1f3-0dd4f5f0e89b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7912e26f-cbda-474a-bfe3-52940b2f712b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7912e26f-cbda-474a-bfe3-52940b2f712b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5d46fc62-ea6e-41ce-9873-84fea87d28b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5d46fc62-ea6e-41ce-9873-84fea87d28b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e51c3780-4d32-4a3d-8d8b-8fb0f091c335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e51c3780-4d32-4a3d-8d8b-8fb0f091c335" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ffa56f5e-2aa2-4bc4-80b4-56f52367f003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ffa56f5e-2aa2-4bc4-80b4-56f52367f003" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9af4f9fa-aede-4579-9822-0d29ad8279ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9af4f9fa-aede-4579-9822-0d29ad8279ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_65e555aa-b8af-4759-a36f-6cc6b5e596cb" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_65e555aa-b8af-4759-a36f-6cc6b5e596cb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_42384b28-44da-4c2d-bb70-2f82c2be2354" xlink:href="ameh-20210930.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_42384b28-44da-4c2d-bb70-2f82c2be2354" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_6f13532c-57f5-428c-a79c-f5dcd23d1d7c" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_6f13532c-57f5-428c-a79c-f5dcd23d1d7c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e1bcfb-2e50-46f3-8b79-ab0eadf44517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e1bcfb-2e50-46f3-8b79-ab0eadf44517" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75cd7504-31ff-4ce6-88fd-93b11ca33040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e1bcfb-2e50-46f3-8b79-ab0eadf44517" xlink:to="loc_us-gaap_AwardTypeAxis_75cd7504-31ff-4ce6-88fd-93b11ca33040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75cd7504-31ff-4ce6-88fd-93b11ca33040_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_75cd7504-31ff-4ce6-88fd-93b11ca33040" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75cd7504-31ff-4ce6-88fd-93b11ca33040_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d8f2b80-005b-42fe-b33c-6c9eefbfa43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_75cd7504-31ff-4ce6-88fd-93b11ca33040" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d8f2b80-005b-42fe-b33c-6c9eefbfa43a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3010a2d3-5d26-4e95-bf49-feb6f3621753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d8f2b80-005b-42fe-b33c-6c9eefbfa43a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3010a2d3-5d26-4e95-bf49-feb6f3621753" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_9ba926bf-8641-4035-9986-e6627822fdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d8f2b80-005b-42fe-b33c-6c9eefbfa43a" xlink:to="loc_us-gaap_RestrictedStockMember_9ba926bf-8641-4035-9986-e6627822fdd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5257e390-a8a9-4090-bef4-8abdc55fd589" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e1bcfb-2e50-46f3-8b79-ab0eadf44517" xlink:to="loc_srt_TitleOfIndividualAxis_5257e390-a8a9-4090-bef4-8abdc55fd589" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5257e390-a8a9-4090-bef4-8abdc55fd589_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5257e390-a8a9-4090-bef4-8abdc55fd589" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5257e390-a8a9-4090-bef4-8abdc55fd589_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1b4bea47-0158-4ae1-886a-6e98c2b173ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5257e390-a8a9-4090-bef4-8abdc55fd589" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1b4bea47-0158-4ae1-886a-6e98c2b173ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember_826ff87d-c186-4091-8ce9-dce8884f7d77" xlink:href="ameh-20210930.xsd#ameh_ApcStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1b4bea47-0158-4ae1-886a-6e98c2b173ee" xlink:to="loc_ameh_ApcStockOptionMember_826ff87d-c186-4091-8ce9-dce8884f7d77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_658644d9-4de5-4e66-8937-071a12c905b9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1b4bea47-0158-4ae1-886a-6e98c2b173ee" xlink:to="loc_srt_DirectorMember_658644d9-4de5-4e66-8937-071a12c905b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_11b28002-0bc0-4381-b325-c3af548221db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e1bcfb-2e50-46f3-8b79-ab0eadf44517" xlink:to="loc_srt_RangeAxis_11b28002-0bc0-4381-b325-c3af548221db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11b28002-0bc0-4381-b325-c3af548221db_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_11b28002-0bc0-4381-b325-c3af548221db" xlink:to="loc_srt_RangeMember_11b28002-0bc0-4381-b325-c3af548221db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75c59076-7184-4a2d-b647-ba8792856e0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_11b28002-0bc0-4381-b325-c3af548221db" xlink:to="loc_srt_RangeMember_75c59076-7184-4a2d-b647-ba8792856e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3a67fd95-7f90-4228-8878-73151582c8f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75c59076-7184-4a2d-b647-ba8792856e0c" xlink:to="loc_srt_MinimumMember_3a67fd95-7f90-4228-8878-73151582c8f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_738ab4e5-6077-4f78-8c32-eff0b5df9d9e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75c59076-7184-4a2d-b647-ba8792856e0c" xlink:to="loc_srt_MaximumMember_738ab4e5-6077-4f78-8c32-eff0b5df9d9e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="extended" id="ie569ee32d5754dfab4be4bc42a390870_StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24ff2661-3c27-411a-8fbc-9a12418319f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24ff2661-3c27-411a-8fbc-9a12418319f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_655615a6-c188-412c-9cb2-7d816410adc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_655615a6-c188-412c-9cb2-7d816410adc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d0a5b9d4-bbcc-4a42-8395-edb2964e7f47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d0a5b9d4-bbcc-4a42-8395-edb2964e7f47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7999ff0f-d013-4ac4-8915-112f20316855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_us-gaap_SharePrice_7999ff0f-d013-4ac4-8915-112f20316855" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6f974621-63b2-415b-a8ed-db95454946c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6f974621-63b2-415b-a8ed-db95454946c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_2227c16e-e771-4749-88d1-759805cddd53" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_2227c16e-e771-4749-88d1-759805cddd53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c55c6406-f05d-4f09-a0fc-284e30d57103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c55c6406-f05d-4f09-a0fc-284e30d57103" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8f571c2e-dc92-4392-afd3-1485d0be0b71" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c55c6406-f05d-4f09-a0fc-284e30d57103" xlink:to="loc_srt_TitleOfIndividualAxis_8f571c2e-dc92-4392-afd3-1485d0be0b71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8f571c2e-dc92-4392-afd3-1485d0be0b71_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_8f571c2e-dc92-4392-afd3-1485d0be0b71" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8f571c2e-dc92-4392-afd3-1485d0be0b71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8f133225-c366-46e4-b77f-c5cf9a68ed8d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_8f571c2e-dc92-4392-afd3-1485d0be0b71" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8f133225-c366-46e4-b77f-c5cf9a68ed8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_63e2eb78-d769-4647-9878-fbcedb6fcc43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8f133225-c366-46e4-b77f-c5cf9a68ed8d" xlink:to="loc_srt_DirectorMember_63e2eb78-d769-4647-9878-fbcedb6fcc43" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#StockBasedCompensationWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="extended" id="i510854766c744e3a894ce0a26dfc5d0b_StockBasedCompensationWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_090d210d-a810-424c-b9cd-f7e1d3cb11b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_090d210d-a810-424c-b9cd-f7e1d3cb11b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_e1764f66-9947-4b40-8c48-97a6e6cd96ad" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_e1764f66-9947-4b40-8c48-97a6e6cd96ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_30c6e44a-2df8-4a9e-b7e0-432dd19c49a7" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_30c6e44a-2df8-4a9e-b7e0-432dd19c49a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_b5551357-447b-4538-9833-5eb615e695bb" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_b5551357-447b-4538-9833-5eb615e695bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_ffc456b7-ed2a-4f96-879d-a2366aa20773" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_ffc456b7-ed2a-4f96-879d-a2366aa20773" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4701102c-b08f-432f-a1e6-cec94e15aa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_4701102c-b08f-432f-a1e6-cec94e15aa2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_48021cf4-f2da-4937-a2e9-5c61e7793224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4701102c-b08f-432f-a1e6-cec94e15aa2c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_48021cf4-f2da-4937-a2e9-5c61e7793224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_48021cf4-f2da-4937-a2e9-5c61e7793224_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_48021cf4-f2da-4937-a2e9-5c61e7793224" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_48021cf4-f2da-4937-a2e9-5c61e7793224_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_cb003951-d80c-4abf-bf4d-3a76e9eedb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_48021cf4-f2da-4937-a2e9-5c61e7793224" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_cb003951-d80c-4abf-bf4d-3a76e9eedb9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_7dd6afc8-1f1c-490a-97fb-ba27f21e794a" xlink:href="ameh-20210930.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_cb003951-d80c-4abf-bf4d-3a76e9eedb9b" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_7dd6afc8-1f1c-490a-97fb-ba27f21e794a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_18c211d1-3f65-4101-a414-741019520953" xlink:href="ameh-20210930.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_cb003951-d80c-4abf-bf4d-3a76e9eedb9b" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_18c211d1-3f65-4101-a414-741019520953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_db20c2ff-9005-4d3a-b8c4-f07d64b77631" xlink:href="ameh-20210930.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_cb003951-d80c-4abf-bf4d-3a76e9eedb9b" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_db20c2ff-9005-4d3a-b8c4-f07d64b77631" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d195059d-4ce8-4607-a6d5-9f9fb503e9ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4701102c-b08f-432f-a1e6-cec94e15aa2c" xlink:to="loc_srt_RangeAxis_d195059d-4ce8-4607-a6d5-9f9fb503e9ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d195059d-4ce8-4607-a6d5-9f9fb503e9ab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d195059d-4ce8-4607-a6d5-9f9fb503e9ab" xlink:to="loc_srt_RangeMember_d195059d-4ce8-4607-a6d5-9f9fb503e9ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c44353d-b8b6-4f61-b199-9e7cc7d9e0e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d195059d-4ce8-4607-a6d5-9f9fb503e9ab" xlink:to="loc_srt_RangeMember_3c44353d-b8b6-4f61-b199-9e7cc7d9e0e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_90e9ef29-7a61-438e-9b14-2672356c4c07" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3c44353d-b8b6-4f61-b199-9e7cc7d9e0e2" xlink:to="loc_srt_MinimumMember_90e9ef29-7a61-438e-9b14-2672356c4c07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e5bc394-35ac-49e2-a7b3-2ef96433c911" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3c44353d-b8b6-4f61-b199-9e7cc7d9e0e2" xlink:to="loc_srt_MaximumMember_1e5bc394-35ac-49e2-a7b3-2ef96433c911" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i517ba21594c44fe9a6db6dd00728e7e5_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_1c124032-1a1f-4505-9880-f60104dde951" xlink:href="ameh-20210930.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_a38b6cc8-cc16-49fd-bbb5-9c70eac7ef9d" xlink:href="ameh-20210930.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1c124032-1a1f-4505-9880-f60104dde951" xlink:to="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_a38b6cc8-cc16-49fd-bbb5-9c70eac7ef9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_364b8071-14e3-4cb5-bb51-dd29690e80a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1c124032-1a1f-4505-9880-f60104dde951" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_364b8071-14e3-4cb5-bb51-dd29690e80a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_f4392069-773c-43e8-aae3-df433dbef225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1c124032-1a1f-4505-9880-f60104dde951" xlink:to="loc_us-gaap_LineOfCredit_f4392069-773c-43e8-aae3-df433dbef225" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:href="ameh-20210930.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1c124032-1a1f-4505-9880-f60104dde951" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_226a5b50-453b-4f0c-9ae8-caf2ebccd518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:to="loc_us-gaap_CreditFacilityAxis_226a5b50-453b-4f0c-9ae8-caf2ebccd518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_226a5b50-453b-4f0c-9ae8-caf2ebccd518_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_226a5b50-453b-4f0c-9ae8-caf2ebccd518" xlink:to="loc_us-gaap_CreditFacilityDomain_226a5b50-453b-4f0c-9ae8-caf2ebccd518_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_02aeda89-9551-4bca-bebb-ac38e2b46e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_226a5b50-453b-4f0c-9ae8-caf2ebccd518" xlink:to="loc_us-gaap_CreditFacilityDomain_02aeda89-9551-4bca-bebb-ac38e2b46e46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_7cc68ac2-d0f1-4b9e-bf4b-9583e61bda5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_02aeda89-9551-4bca-bebb-ac38e2b46e46" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_7cc68ac2-d0f1-4b9e-bf4b-9583e61bda5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_3e37938e-34a8-4f2d-ad71-7ef86f2f3d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_3e37938e-34a8-4f2d-ad71-7ef86f2f3d86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_3e37938e-34a8-4f2d-ad71-7ef86f2f3d86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_3e37938e-34a8-4f2d-ad71-7ef86f2f3d86" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_3e37938e-34a8-4f2d-ad71-7ef86f2f3d86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_6c0f54dc-822b-43c7-ab93-5b899cd72378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_3e37938e-34a8-4f2d-ad71-7ef86f2f3d86" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_6c0f54dc-822b-43c7-ab93-5b899cd72378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_a18a29b1-5a36-4ed6-9e82-4b16c584a879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_6c0f54dc-822b-43c7-ab93-5b899cd72378" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_a18a29b1-5a36-4ed6-9e82-4b16c584a879" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_25cca14c-f73e-429e-a8e9-82bd30ec34fd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:to="loc_dei_LegalEntityAxis_25cca14c-f73e-429e-a8e9-82bd30ec34fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_25cca14c-f73e-429e-a8e9-82bd30ec34fd_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_25cca14c-f73e-429e-a8e9-82bd30ec34fd" xlink:to="loc_dei_EntityDomain_25cca14c-f73e-429e-a8e9-82bd30ec34fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4d7dd231-ba8e-4bc2-9e62-b702f67297a8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_25cca14c-f73e-429e-a8e9-82bd30ec34fd" xlink:to="loc_dei_EntityDomain_4d7dd231-ba8e-4bc2-9e62-b702f67297a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_4bbda8b3-2855-44b7-8f85-6dce3616eabb" xlink:href="ameh-20210930.xsd#ameh_ApaacoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4d7dd231-ba8e-4bc2-9e62-b702f67297a8" xlink:to="loc_ameh_ApaacoMember_4bbda8b3-2855-44b7-8f85-6dce3616eabb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_bf407993-c66d-4260-83fd-2ed008a44614" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4d7dd231-ba8e-4bc2-9e62-b702f67297a8" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_bf407993-c66d-4260-83fd-2ed008a44614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_52ed710b-de26-41ed-bb10-d8ec4c4eec27" xlink:href="ameh-20210930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4d7dd231-ba8e-4bc2-9e62-b702f67297a8" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_52ed710b-de26-41ed-bb10-d8ec4c4eec27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_09bd7877-ce32-4722-8235-3672e4ed71d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_09bd7877-ce32-4722-8235-3672e4ed71d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_09bd7877-ce32-4722-8235-3672e4ed71d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_09bd7877-ce32-4722-8235-3672e4ed71d8" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_09bd7877-ce32-4722-8235-3672e4ed71d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_19222fed-aedd-40be-8fc6-8940ca5b71e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_09bd7877-ce32-4722-8235-3672e4ed71d8" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_19222fed-aedd-40be-8fc6-8940ca5b71e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_762c7fae-94f8-438d-8f87-ea345e5600ed" xlink:href="ameh-20210930.xsd#ameh_PreferredBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_19222fed-aedd-40be-8fc6-8940ca5b71e1" xlink:to="loc_ameh_PreferredBankMember_762c7fae-94f8-438d-8f87-ea345e5600ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="ic685f040f5d14af99fda3656b0537869_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_5282af69-8471-4c1b-8806-075806d9e9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_us-gaap_RevenueFromRelatedParties_5282af69-8471-4c1b-8806-075806d9e9d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_622df82b-ae7f-4fdf-82a3-c8eb0f9757df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_622df82b-ae7f-4fdf-82a3-c8eb0f9757df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_e113b180-72fa-4edc-bacb-e31550cdc972" xlink:href="ameh-20210930.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_ameh_PaymentMadeToRelatedParty_e113b180-72fa-4edc-bacb-e31550cdc972" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_764572a0-36c1-4003-bb1d-8f5ca7784638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_764572a0-36c1-4003-bb1d-8f5ca7784638" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_78f7fe82-fca8-419b-bf18-e4194ed4c93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_78f7fe82-fca8-419b-bf18-e4194ed4c93a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees_dcce2e3d-60f5-4376-9c74-24a14fbb9e0a" xlink:href="ameh-20210930.xsd#ameh_PaymentConsultingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_ameh_PaymentConsultingFees_dcce2e3d-60f5-4376-9c74-24a14fbb9e0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19469e2b-7f85-4c5b-8731-089d2e1616e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19469e2b-7f85-4c5b-8731-089d2e1616e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_19469e2b-7f85-4c5b-8731-089d2e1616e6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19469e2b-7f85-4c5b-8731-089d2e1616e6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_19469e2b-7f85-4c5b-8731-089d2e1616e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0568ed3b-bad5-4ede-9a40-24748b7dff40" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19469e2b-7f85-4c5b-8731-089d2e1616e6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0568ed3b-bad5-4ede-9a40-24748b7dff40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_417c1746-ebd4-4eac-97c6-1ee1ddf74a7f" xlink:href="ameh-20210930.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0568ed3b-bad5-4ede-9a40-24748b7dff40" xlink:to="loc_ameh_LmaMember_417c1746-ebd4-4eac-97c6-1ee1ddf74a7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_e03fe282-ee43-463d-a28d-16abf4340a8f" xlink:href="ameh-20210930.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0568ed3b-bad5-4ede-9a40-24748b7dff40" xlink:to="loc_ameh_PmiocMember_e03fe282-ee43-463d-a28d-16abf4340a8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_49b438a1-a584-46de-b3f7-503180310e38" xlink:href="ameh-20210930.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0568ed3b-bad5-4ede-9a40-24748b7dff40" xlink:to="loc_ameh_DmgMember_49b438a1-a584-46de-b3f7-503180310e38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_eb06b79b-903e-4860-8acd-5ed21d6e3e8a" xlink:href="ameh-20210930.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0568ed3b-bad5-4ede-9a40-24748b7dff40" xlink:to="loc_ameh_OneMSOInc.Member_eb06b79b-903e-4860-8acd-5ed21d6e3e8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff76752d-32c3-4ec3-a546-d24d1deea730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff76752d-32c3-4ec3-a546-d24d1deea730" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ff76752d-32c3-4ec3-a546-d24d1deea730_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff76752d-32c3-4ec3-a546-d24d1deea730" xlink:to="loc_us-gaap_RelatedPartyDomain_ff76752d-32c3-4ec3-a546-d24d1deea730_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff76752d-32c3-4ec3-a546-d24d1deea730" xlink:to="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_ae6d9201-8a13-4236-86e5-97e87da38f0e" xlink:href="ameh-20210930.xsd#ameh_ApcShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_ApcShareholdersMember_ae6d9201-8a13-4236-86e5-97e87da38f0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_35e5e221-7f62-4b1c-add6-8dd4fe987606" xlink:href="ameh-20210930.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_35e5e221-7f62-4b1c-add6-8dd4fe987606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FreseniusMember_1966a22c-a528-4fb1-bce6-f0c84fe99e93" xlink:href="ameh-20210930.xsd#ameh_FreseniusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_FreseniusMember_1966a22c-a528-4fb1-bce6-f0c84fe99e93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember_adf36a90-6201-449a-9eb3-5c61ff65dfdb" xlink:href="ameh-20210930.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_FulgentGeneticsIncMember_adf36a90-6201-449a-9eb3-5c61ff65dfdb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember_d55b44f9-bd71-4dc4-8246-fccef8d557fb" xlink:href="ameh-20210930.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_ShareholdersAndOfficersMember_d55b44f9-bd71-4dc4-8246-fccef8d557fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember_471cb8f8-bc70-4d9a-9a97-b1e045bedb4c" xlink:href="ameh-20210930.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_CriticalQualityManagementCorpMember_471cb8f8-bc70-4d9a-9a97-b1e045bedb4c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_7e8a6169-a22a-4931-b79d-dcc3b318bac8" xlink:href="ameh-20210930.xsd#ameh_NumenLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_NumenLLCMember_7e8a6169-a22a-4931-b79d-dcc3b318bac8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_309c9fcd-4b2d-427a-83ae-1cd9d153aee7" xlink:href="ameh-20210930.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_OneMSOInc.Member_309c9fcd-4b2d-427a-83ae-1cd9d153aee7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_1d623606-4e9a-4e59-9c9e-ddc6f8e10dbc" xlink:href="ameh-20210930.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_AHMCMember_1d623606-4e9a-4e59-9c9e-ddc6f8e10dbc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_455ae713-1a78-434a-832c-de5e13304c3f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_dei_LegalEntityAxis_455ae713-1a78-434a-832c-de5e13304c3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_455ae713-1a78-434a-832c-de5e13304c3f_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_455ae713-1a78-434a-832c-de5e13304c3f" xlink:to="loc_dei_EntityDomain_455ae713-1a78-434a-832c-de5e13304c3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6b94ee56-d877-4932-81bb-61946f4b8f47" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_455ae713-1a78-434a-832c-de5e13304c3f" xlink:to="loc_dei_EntityDomain_6b94ee56-d877-4932-81bb-61946f4b8f47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_a83472ea-70c0-427c-aa2c-d19a341f5739" xlink:href="ameh-20210930.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6b94ee56-d877-4932-81bb-61946f4b8f47" xlink:to="loc_ameh_NetworkMedicalManagementMember_a83472ea-70c0-427c-aa2c-d19a341f5739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f8a6d2e7-d390-43bd-aa58-61b16eaa202b" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6b94ee56-d877-4932-81bb-61946f4b8f47" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f8a6d2e7-d390-43bd-aa58-61b16eaa202b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaAcoIncMember_c0138f90-eabf-40dd-bdf6-06da09a63d8d" xlink:href="ameh-20210930.xsd#ameh_ApaAcoIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6b94ee56-d877-4932-81bb-61946f4b8f47" xlink:to="loc_ameh_ApaAcoIncMember_c0138f90-eabf-40dd-bdf6-06da09a63d8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_26c8f16a-50bf-4d0b-a0ca-0531502e625b" xlink:href="ameh-20210930.xsd#ameh_SCHCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6b94ee56-d877-4932-81bb-61946f4b8f47" xlink:to="loc_ameh_SCHCMember_26c8f16a-50bf-4d0b-a0ca-0531502e625b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_41b7b793-240e-4411-9d48-7be172bc56c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_srt_ConsolidatedEntitiesAxis_41b7b793-240e-4411-9d48-7be172bc56c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_41b7b793-240e-4411-9d48-7be172bc56c0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_41b7b793-240e-4411-9d48-7be172bc56c0" xlink:to="loc_srt_ConsolidatedEntitiesDomain_41b7b793-240e-4411-9d48-7be172bc56c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d1eef7ad-c5df-4f3f-9b61-bbaa776434e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_41b7b793-240e-4411-9d48-7be172bc56c0" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d1eef7ad-c5df-4f3f-9b61-bbaa776434e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_a4c66eaa-9be5-4913-be65-ef7986d4db63" xlink:href="ameh-20210930.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d1eef7ad-c5df-4f3f-9b61-bbaa776434e9" xlink:to="loc_ameh_LmaMember_a4c66eaa-9be5-4913-be65-ef7986d4db63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_e66b1f3a-41e1-4a93-b026-2a2d965f6393" xlink:href="ameh-20210930.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d1eef7ad-c5df-4f3f-9b61-bbaa776434e9" xlink:to="loc_ameh_PmiocMember_e66b1f3a-41e1-4a93-b026-2a2d965f6393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_51214877-2312-4421-8588-22e944b50bcd" xlink:href="ameh-20210930.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d1eef7ad-c5df-4f3f-9b61-bbaa776434e9" xlink:to="loc_ameh_DmgMember_51214877-2312-4421-8588-22e944b50bcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_a73c5e25-33a0-40a3-8527-3f5e6579c089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_a73c5e25-33a0-40a3-8527-3f5e6579c089" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a73c5e25-33a0-40a3-8527-3f5e6579c089_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a73c5e25-33a0-40a3-8527-3f5e6579c089" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a73c5e25-33a0-40a3-8527-3f5e6579c089_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c1bc7081-9605-4d5e-b8d8-edb416e46433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a73c5e25-33a0-40a3-8527-3f5e6579c089" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c1bc7081-9605-4d5e-b8d8-edb416e46433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_28a1f890-d017-49ed-aa3b-2339ef8652d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c1bc7081-9605-4d5e-b8d8-edb416e46433" xlink:to="loc_us-gaap_ServiceMember_28a1f890-d017-49ed-aa3b-2339ef8652d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_76568a00-c483-4d60-be50-f336ed9f1538" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_srt_TitleOfIndividualAxis_76568a00-c483-4d60-be50-f336ed9f1538" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76568a00-c483-4d60-be50-f336ed9f1538_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_76568a00-c483-4d60-be50-f336ed9f1538" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_76568a00-c483-4d60-be50-f336ed9f1538_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d043009-5a7e-48b1-accb-556f6c939fd2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_76568a00-c483-4d60-be50-f336ed9f1538" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d043009-5a7e-48b1-accb-556f6c939fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_cfe87eaf-8671-4623-b8b7-2045d6f0bad8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d043009-5a7e-48b1-accb-556f6c939fd2" xlink:to="loc_srt_DirectorMember_cfe87eaf-8671-4623-b8b7-2045d6f0bad8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended" id="i11e3409d1bda4c01bfce1ef84b65d5dd_RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d3054512-4473-4f0e-895b-ff7bfe01a980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_f74471c2-7554-4ee8-8571-2367a53b2643" xlink:href="ameh-20210930.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d3054512-4473-4f0e-895b-ff7bfe01a980" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_f74471c2-7554-4ee8-8571-2367a53b2643" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_d3c79314-5dae-417d-94e4-3f72812a0fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d3054512-4473-4f0e-895b-ff7bfe01a980" xlink:to="loc_us-gaap_ManagementFeeExpense_d3c79314-5dae-417d-94e4-3f72812a0fcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_3f74cf45-764f-4b6b-952c-6ca9a79b5e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d3054512-4473-4f0e-895b-ff7bfe01a980" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_3f74cf45-764f-4b6b-952c-6ca9a79b5e5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_def40b75-855d-496a-ab1e-49398892fb84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d3054512-4473-4f0e-895b-ff7bfe01a980" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_def40b75-855d-496a-ab1e-49398892fb84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f186f9f-5c52-439c-9059-c67b04829ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_def40b75-855d-496a-ab1e-49398892fb84" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f186f9f-5c52-439c-9059-c67b04829ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7f186f9f-5c52-439c-9059-c67b04829ee1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f186f9f-5c52-439c-9059-c67b04829ee1" xlink:to="loc_us-gaap_RelatedPartyDomain_7f186f9f-5c52-439c-9059-c67b04829ee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7b78964c-46de-4f4d-9f7d-48d295ad9655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f186f9f-5c52-439c-9059-c67b04829ee1" xlink:to="loc_us-gaap_RelatedPartyDomain_7b78964c-46de-4f4d-9f7d-48d295ad9655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_e8968d11-4b7d-47b4-9232-861645e5eaad" xlink:href="ameh-20210930.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7b78964c-46de-4f4d-9f7d-48d295ad9655" xlink:to="loc_ameh_AHMCMember_e8968d11-4b7d-47b4-9232-861645e5eaad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_4d0c0b57-b521-4e34-a7e7-187a1252eec9" xlink:href="ameh-20210930.xsd#ameh_HSMSOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7b78964c-46de-4f4d-9f7d-48d295ad9655" xlink:to="loc_ameh_HSMSOMember_4d0c0b57-b521-4e34-a7e7-187a1252eec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_43342448-62bf-4973-ae8b-31f928286e56" xlink:href="ameh-20210930.xsd#ameh_AurionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7b78964c-46de-4f4d-9f7d-48d295ad9655" xlink:to="loc_ameh_AurionMember_43342448-62bf-4973-ae8b-31f928286e56" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended" id="i26abf814756e4f748b88f6580dd97cee_EarningsPerShareAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_ae95e274-ac77-4557-9763-7d6d1ae7705e" xlink:href="ameh-20210930.xsd#ameh_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b725137a-37f6-4114-9338-0f9c887a0017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_ae95e274-ac77-4557-9763-7d6d1ae7705e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b725137a-37f6-4114-9338-0f9c887a0017" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_f93b22ea-bf3a-48e1-abd3-6db5b6038ab0" xlink:href="ameh-20210930.xsd#ameh_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_EarningsPerShareLineItems_ae95e274-ac77-4557-9763-7d6d1ae7705e" xlink:to="loc_ameh_EarningsPerShareTable_f93b22ea-bf3a-48e1-abd3-6db5b6038ab0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3fc519b0-9b8b-4fbb-80c8-c1aba38bdcca" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_f93b22ea-bf3a-48e1-abd3-6db5b6038ab0" xlink:to="loc_dei_LegalEntityAxis_3fc519b0-9b8b-4fbb-80c8-c1aba38bdcca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3fc519b0-9b8b-4fbb-80c8-c1aba38bdcca_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3fc519b0-9b8b-4fbb-80c8-c1aba38bdcca" xlink:to="loc_dei_EntityDomain_3fc519b0-9b8b-4fbb-80c8-c1aba38bdcca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_956186b2-be16-43e2-a894-83e1ab1738cb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3fc519b0-9b8b-4fbb-80c8-c1aba38bdcca" xlink:to="loc_dei_EntityDomain_956186b2-be16-43e2-a894-83e1ab1738cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_476583e9-6fe2-4621-8527-e37b763d8967" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_956186b2-be16-43e2-a894-83e1ab1738cb" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_476583e9-6fe2-4621-8527-e37b763d8967" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended" id="i82e794edf37b41e685929f78008952ce_EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_fd853edd-b310-44b9-abdc-e01a365e82b3" xlink:href="ameh-20210930.xsd#ameh_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9e4eb66-d8c0-491c-9255-f92a0f98223e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_fd853edd-b310-44b9-abdc-e01a365e82b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9e4eb66-d8c0-491c-9255-f92a0f98223e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a2c4cb4a-7f7e-4b71-ae63-a2982d432bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_fd853edd-b310-44b9-abdc-e01a365e82b3" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a2c4cb4a-7f7e-4b71-ae63-a2982d432bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_713590c6-3292-470e-a7e8-4afe94072740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_fd853edd-b310-44b9-abdc-e01a365e82b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_713590c6-3292-470e-a7e8-4afe94072740" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_c045063f-f6fd-460e-883f-6aab659046d9" xlink:href="ameh-20210930.xsd#ameh_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_EarningsPerShareLineItems_fd853edd-b310-44b9-abdc-e01a365e82b3" xlink:to="loc_ameh_EarningsPerShareTable_c045063f-f6fd-460e-883f-6aab659046d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6529e7e5-6ffe-4160-9152-d1c418a4b483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_c045063f-f6fd-460e-883f-6aab659046d9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6529e7e5-6ffe-4160-9152-d1c418a4b483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6529e7e5-6ffe-4160-9152-d1c418a4b483_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6529e7e5-6ffe-4160-9152-d1c418a4b483" xlink:to="loc_us-gaap_EquityComponentDomain_6529e7e5-6ffe-4160-9152-d1c418a4b483_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4d4e9009-7b10-47e8-aa7d-f0095d307add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6529e7e5-6ffe-4160-9152-d1c418a4b483" xlink:to="loc_us-gaap_EquityComponentDomain_4d4e9009-7b10-47e8-aa7d-f0095d307add" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_23984e1b-1ad9-4b19-be6e-165e40e298a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4d4e9009-7b10-47e8-aa7d-f0095d307add" xlink:to="loc_us-gaap_WarrantMember_23984e1b-1ad9-4b19-be6e-165e40e298a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5eba6e83-9de8-4b73-9ea5-3751ece1daff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_c045063f-f6fd-460e-883f-6aab659046d9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5eba6e83-9de8-4b73-9ea5-3751ece1daff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5eba6e83-9de8-4b73-9ea5-3751ece1daff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5eba6e83-9de8-4b73-9ea5-3751ece1daff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5eba6e83-9de8-4b73-9ea5-3751ece1daff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3e623f7b-7ca9-400d-92e3-18f4ee691608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5eba6e83-9de8-4b73-9ea5-3751ece1daff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3e623f7b-7ca9-400d-92e3-18f4ee691608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_acb05e9a-8e2b-424a-9b9e-418420a52f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3e623f7b-7ca9-400d-92e3-18f4ee691608" xlink:to="loc_us-gaap_EmployeeStockOptionMember_acb05e9a-8e2b-424a-9b9e-418420a52f91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2d833542-d6ac-4331-81ac-54a6cbddd222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3e623f7b-7ca9-400d-92e3-18f4ee691608" xlink:to="loc_us-gaap_RestrictedStockMember_2d833542-d6ac-4331-81ac-54a6cbddd222" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended" id="i409cc555dbaa452d9ed4c929d2bbd8e0_VariableInterestEntitiesVIEsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_1d3bdf41-29e4-42dc-93ea-f695614a5e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b5140772-353f-43ed-a13d-4537f7ecc186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_1d3bdf41-29e4-42dc-93ea-f695614a5e91" xlink:to="loc_us-gaap_AssetsAbstract_b5140772-353f-43ed-a13d-4537f7ecc186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b5140772-353f-43ed-a13d-4537f7ecc186" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3274541-08de-4c71-974d-56901c39cefc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3274541-08de-4c71-974d-56901c39cefc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_cfe592ac-4891-418a-b4f3-e166b4df07ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_cfe592ac-4891-418a-b4f3-e166b4df07ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_222b602c-2758-451b-8afb-e8bde8ec0be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_222b602c-2758-451b-8afb-e8bde8ec0be0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_eec2babc-8b9b-4430-bee0-e497b5c58f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_eec2babc-8b9b-4430-bee0-e497b5c58f5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_5f02c83d-0396-4572-bba4-af43f5bce1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_IncomeTaxesReceivable_5f02c83d-0396-4572-bba4-af43f5bce1ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_5eee55ce-121b-48d9-b7d2-4ffc40334acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_5eee55ce-121b-48d9-b7d2-4ffc40334acc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_74008abe-e3f8-4dd4-b521-cd8ccae21e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_74008abe-e3f8-4dd4-b521-cd8ccae21e40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_8d443273-5b4a-486e-9c2e-b97b98e70eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_8d443273-5b4a-486e-9c2e-b97b98e70eb9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_784b2353-b13a-4af1-a494-14f39943f7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_784b2353-b13a-4af1-a494-14f39943f7a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a960c61e-54bb-4d4a-93ab-b251f35b2453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_AssetsCurrent_a960c61e-54bb-4d4a-93ab-b251f35b2453" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b5140772-353f-43ed-a13d-4537f7ecc186" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_26ffe1e0-d3d7-4fbe-9bc2-8a3e2fd90aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_26ffe1e0-d3d7-4fbe-9bc2-8a3e2fd90aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a44b9c12-a98a-47d7-be23-c1fd386bc037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a44b9c12-a98a-47d7-be23-c1fd386bc037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9f31484e-ef36-453a-975f-5d96132799e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_Goodwill_9f31484e-ef36-453a-975f-5d96132799e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_ac7d3b7e-2a12-442b-92d7-af617af64925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_ac7d3b7e-2a12-442b-92d7-af617af64925" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_5eb5e1ba-bc79-444a-9856-d7ce7358abf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_OtherLongTermInvestments_5eb5e1ba-bc79-444a-9856-d7ce7358abf3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_75175207-e8e7-4de4-b76e-2fb96bdbe056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_EquityMethodInvestments_75175207-e8e7-4de4-b76e-2fb96bdbe056" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_941066c8-98f8-4c8c-907f-0eabccc03f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_941066c8-98f8-4c8c-907f-0eabccc03f80" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_be9af98d-cc39-4b79-9b76-6fc2c797d012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_be9af98d-cc39-4b79-9b76-6fc2c797d012" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_33c9ef41-8b74-4510-bd67-c0a1caa9773f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_33c9ef41-8b74-4510-bd67-c0a1caa9773f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5f40d4d7-f68a-4de0-b06f-ad63bfad19e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5f40d4d7-f68a-4de0-b06f-ad63bfad19e3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_37eeebd7-799e-499d-bc32-bf753a9f655c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_AssetsNoncurrent_37eeebd7-799e-499d-bc32-bf753a9f655c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_47d8c10a-8492-4015-8e32-464b5c350cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b5140772-353f-43ed-a13d-4537f7ecc186" xlink:to="loc_us-gaap_Assets_47d8c10a-8492-4015-8e32-464b5c350cc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_1d3bdf41-29e4-42dc-93ea-f695614a5e91" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c1eb54e4-93ec-4f9a-926f-7afb03c77a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c1eb54e4-93ec-4f9a-926f-7afb03c77a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_6ec3ea6f-cf28-4944-8f0e-98fbafa3ad4f" xlink:href="ameh-20210930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_6ec3ea6f-cf28-4944-8f0e-98fbafa3ad4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d53a756d-f85f-4150-8465-da01a6d3e50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d53a756d-f85f-4150-8465-da01a6d3e50d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_f0935672-4f64-479f-af08-53ac7c7a23be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_TaxesPayableCurrent_f0935672-4f64-479f-af08-53ac7c7a23be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_e31ac1f0-ba83-4a13-bb0f-959e0527ec56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_DividendsPayableCurrent_e31ac1f0-ba83-4a13-bb0f-959e0527ec56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_36b29b48-187c-4746-a29d-42fbf4fec145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_DueToAffiliateCurrent_36b29b48-187c-4746-a29d-42fbf4fec145" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7b5565fc-0ba2-4fba-b596-01fd7c30366c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_LongTermDebtCurrent_7b5565fc-0ba2-4fba-b596-01fd7c30366c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_8d691517-731f-4a5c-af35-b572313fb957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_8d691517-731f-4a5c-af35-b572313fb957" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3356b648-0b55-44ab-b991-522717bb041e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3356b648-0b55-44ab-b991-522717bb041e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3880e570-23fd-436a-95dc-3985417dd528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_LiabilitiesCurrent_3880e570-23fd-436a-95dc-3985417dd528" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_1d3bdf41-29e4-42dc-93ea-f695614a5e91" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_55ca606b-b244-45d3-9c6b-10045a9bf8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_55ca606b-b244-45d3-9c6b-10045a9bf8f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bceb9dec-e0b9-4501-836b-29e974d18d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bceb9dec-e0b9-4501-836b-29e974d18d18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0d15694b-7b5f-4914-a95f-a8c3d9ab60d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0d15694b-7b5f-4914-a95f-a8c3d9ab60d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5b41ac91-cf89-4e20-8378-3be52965e551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5b41ac91-cf89-4e20-8378-3be52965e551" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_08becdce-2416-4393-b58f-6322c5c407c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_08becdce-2416-4393-b58f-6322c5c407c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3f22ca2b-21ba-426b-bc55-e141756b7a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_3f22ca2b-21ba-426b-bc55-e141756b7a17" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dca9300d-6312-48f6-b5fa-6d77538a0fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_1d3bdf41-29e4-42dc-93ea-f695614a5e91" xlink:to="loc_us-gaap_Liabilities_dca9300d-6312-48f6-b5fa-6d77538a0fcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_63f2cab9-546a-4245-a1c4-71d53a2cb269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_1d3bdf41-29e4-42dc-93ea-f695614a5e91" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_63f2cab9-546a-4245-a1c4-71d53a2cb269" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8aea3a72-edfa-4ff4-a1ef-fbf209ef0ac0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_63f2cab9-546a-4245-a1c4-71d53a2cb269" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8aea3a72-edfa-4ff4-a1ef-fbf209ef0ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8aea3a72-edfa-4ff4-a1ef-fbf209ef0ac0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8aea3a72-edfa-4ff4-a1ef-fbf209ef0ac0" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8aea3a72-edfa-4ff4-a1ef-fbf209ef0ac0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_73cf6cce-1c61-4d14-9fb0-61d47fef4c79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8aea3a72-edfa-4ff4-a1ef-fbf209ef0ac0" xlink:to="loc_srt_ConsolidatedEntitiesDomain_73cf6cce-1c61-4d14-9fb0-61d47fef4c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_b0a80a58-86b1-41fe-a283-a1eb8c728c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_73cf6cce-1c61-4d14-9fb0-61d47fef4c79" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_b0a80a58-86b1-41fe-a283-a1eb8c728c06" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#LeasesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended" id="i50ded134ae2a4b38b46e2f969d7bca1b_LeasesAdditionalinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_9dd11b8b-8b41-4439-8185-2a3bce9d430d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_9dd11b8b-8b41-4439-8185-2a3bce9d430d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_e1b10f4a-5a03-4084-847c-0e777affe8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_e1b10f4a-5a03-4084-847c-0e777affe8fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3914665-606c-48e1-8edd-f8e140ac8706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3914665-606c-48e1-8edd-f8e140ac8706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_46f0b35a-657b-42fb-876f-57ffef236413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_46f0b35a-657b-42fb-876f-57ffef236413" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_7b800240-b246-490d-8cb5-bafa9724a7a6" xlink:href="ameh-20210930.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_7b800240-b246-490d-8cb5-bafa9724a7a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_572c041d-4da8-4939-b1ef-eaef1d797860" xlink:href="ameh-20210930.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_572c041d-4da8-4939-b1ef-eaef1d797860" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_8fd496c6-e5f9-444a-9a98-83c86d3743b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_8fd496c6-e5f9-444a-9a98-83c86d3743b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_ad35462c-174b-408e-a03a-d3097edd88fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_ad35462c-174b-408e-a03a-d3097edd88fc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ae7db7e7-0dac-4099-99cc-8361f68eb5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ae7db7e7-0dac-4099-99cc-8361f68eb5c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6933d860-4749-43dd-823c-37a1876b6c76" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ae7db7e7-0dac-4099-99cc-8361f68eb5c4" xlink:to="loc_srt_RangeAxis_6933d860-4749-43dd-823c-37a1876b6c76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6933d860-4749-43dd-823c-37a1876b6c76_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6933d860-4749-43dd-823c-37a1876b6c76" xlink:to="loc_srt_RangeMember_6933d860-4749-43dd-823c-37a1876b6c76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_863e500b-5421-43d2-9c81-d71304eb521d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6933d860-4749-43dd-823c-37a1876b6c76" xlink:to="loc_srt_RangeMember_863e500b-5421-43d2-9c81-d71304eb521d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e789351c-af23-4f0f-8e22-f61fbd877a7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_863e500b-5421-43d2-9c81-d71304eb521d" xlink:to="loc_srt_MinimumMember_e789351c-af23-4f0f-8e22-f61fbd877a7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1b9b2c84-b5cf-46d0-8ee0-8fe151d515ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_863e500b-5421-43d2-9c81-d71304eb521d" xlink:to="loc_srt_MaximumMember_1b9b2c84-b5cf-46d0-8ee0-8fe151d515ea" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended" id="iff5bda47480847de85f708e397029373_SubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c7e85f65-deaf-4b75-ac54-8ef7cf552336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod_286edb33-9a50-4563-8d37-61774d12eeee" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c7e85f65-deaf-4b75-ac54-8ef7cf552336" xlink:to="loc_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod_286edb33-9a50-4563-8d37-61774d12eeee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6c175b19-5a56-4d74-8142-134d649ce26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c7e85f65-deaf-4b75-ac54-8ef7cf552336" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6c175b19-5a56-4d74-8142-134d649ce26e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase_639243c1-eb97-42c8-9599-abfe6a38fa9b" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c7e85f65-deaf-4b75-ac54-8ef7cf552336" xlink:to="loc_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase_639243c1-eb97-42c8-9599-abfe6a38fa9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9798ceff-7d60-4c74-a155-cabf5224456c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_c7e85f65-deaf-4b75-ac54-8ef7cf552336" xlink:to="loc_us-gaap_SubsequentEventTable_9798ceff-7d60-4c74-a155-cabf5224456c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b7c80aed-5abc-4495-b71b-4d3a08069dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9798ceff-7d60-4c74-a155-cabf5224456c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b7c80aed-5abc-4495-b71b-4d3a08069dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b7c80aed-5abc-4495-b71b-4d3a08069dae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b7c80aed-5abc-4495-b71b-4d3a08069dae" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b7c80aed-5abc-4495-b71b-4d3a08069dae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_acbcb984-4f46-485b-9da1-4fd64c91e0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b7c80aed-5abc-4495-b71b-4d3a08069dae" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_acbcb984-4f46-485b-9da1-4fd64c91e0b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8d5efcd8-4b4c-4853-b555-b74bf62d99ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_acbcb984-4f46-485b-9da1-4fd64c91e0b4" xlink:to="loc_us-gaap_SubsequentEventMember_8d5efcd8-4b4c-4853-b555-b74bf62d99ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7bd8012-40cf-4788-b23b-47092b64a564" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_9798ceff-7d60-4c74-a155-cabf5224456c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7bd8012-40cf-4788-b23b-47092b64a564" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a7bd8012-40cf-4788-b23b-47092b64a564_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7bd8012-40cf-4788-b23b-47092b64a564" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a7bd8012-40cf-4788-b23b-47092b64a564_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9ea011c3-5ca2-4773-bbad-c00828c639cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7bd8012-40cf-4788-b23b-47092b64a564" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9ea011c3-5ca2-4773-bbad-c00828c639cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_d3a8d460-0891-407c-8a04-edf82d77b8f9" xlink:href="ameh-20210930.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9ea011c3-5ca2-4773-bbad-c00828c639cb" xlink:to="loc_ameh_DmgMember_d3a8d460-0891-407c-8a04-edf82d77b8f9" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ameh-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:114d7d5d-3fd3-46db-8f4b-230f4f1be605,g:12a42f3e-83fc-4c9c-a1b4-628777c39609-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ebe26d6c-e867-4bd1-a854-3405965d07fd_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_54094556-a000-4429-ab85-86c260cfd905_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_0b1e5f63-250d-4887-ab74-1e60e91a6b13_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_0dd40eff-ab78-4571-8725-93a3ad75a2de_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_15641c3a-8e0e-4a64-acb3-13b3320a8417_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_99f64cf9-d486-4d64-9f15-eb2a688648e2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3db659d8-ff90-4a6a-93df-e986b9e952ea_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicaidMember_a9c009b7-5d2e-44d5-bc33-18e3733a2dfa_terseLabel_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_ameh_MedicaidMember_label_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_ameh_MedicaidMember_documentation_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicaidMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember" xlink:href="ameh-20210930.xsd#ameh_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicaidMember" xlink:to="lab_ameh_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_df8f02f5-fb99-4c0e-8d34-43c522aaa8b7_terseLabel_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_label_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC - Related Party [Member]</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_documentation_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC - Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:href="ameh-20210930.xsd#ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:to="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_ef3438e7-72a9-4f73-a83e-d703b05c2d4e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_f96cdfa7-f6d0-46de-838e-0a6de18236f4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_875ba6ad-81b2-4369-b1f4-34b587382400_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_02662bd4-b463-4e9c-898b-753aadd9e639_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_2644c808-7c74-4cdc-874d-c8eb7fc57fbb_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_092fc1ac-c452-4517-a014-d5f251f18759_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc.</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember" xlink:href="ameh-20210930.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementIncMember" xlink:to="lab_ameh_NetworkMedicalManagementIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_2da04f2c-1100-4d24-a713-af3b5e47f9ea_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable &#8211; related party</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_de5e40c6-58f7-49c0-b6f3-3c6d14736b0c_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee9b7f4c-e4d7-418c-b3d7-025fca9d77d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9f735c7a-32af-4b76-a547-3a20724f3df3_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_c3502174-afc1-42ec-ac25-0275fd7aacfc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_51338b90-c5ed-41f6-ba1d-ef0934f0967e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_aeddff11-0d2e-4ad1-9f09-a3641ffe8d3e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4d373802-c4df-4a9f-a744-7d8286cf8f5a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommercialMember_a23a840d-6b10-4e85-8793-6df269c8e4e2_terseLabel_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_ameh_CommercialMember_label_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_ameh_CommercialMember_documentation_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:CommercialMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember" xlink:href="ameh-20210930.xsd#ameh_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommercialMember" xlink:to="lab_ameh_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_d90f8664-e8d6-4848-be32-4eba9524afde_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6e8688b1-5fe7-476c-b62d-6a7f4ca1503f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_5acc59df-6018-41fc-963e-2f1f1ab5ce79_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f03d9053-1462-4d53-8c9a-246db757e0f8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_409d1340-df5b-45bb-a783-e050e666046a_terseLabel_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_label_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract" xlink:href="ameh-20210930.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract" xlink:to="lab_ameh_AggregateintrinsicvalueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_1368c1cf-75ae-41e0-83a3-684e3bfc1007_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_78629015-7dae-4274-8077-4f923b341a92_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_7c16bdcb-2485-4099-a2c0-c7492465f7f0_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount deposit accounts exceeded FDIC insured limit</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CDSCMember_32a3c676-57c4-4e19-83c8-061618a96633_terseLabel_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:label id="lab_ameh_CDSCMember_label_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC [Member]</link:label>
    <link:label id="lab_ameh_CDSCMember_documentation_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember" xlink:href="ameh-20210930.xsd#ameh_CDSCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CDSCMember" xlink:to="lab_ameh_CDSCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_9b4f9e71-2a61-4b66-b708-a6849c7c1f11_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_2280acb0-de9f-47d3-8967-e1fd39c02abc_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medical Liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:href="ameh-20210930.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:to="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_6dd5420d-2e22-4107-9c7a-715e4480db45_terseLabel_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy [Policy Text Block]</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:href="ameh-20210930.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:to="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7a675098-1560-49ea-a071-2d6d003e34e4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3578aec0-1106-4136-8da8-0f42b461e6b3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares not included in the calculation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_94a17d71-727e-45c4-917c-4fb9cae22d29_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract liability recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_88a3553d-f96a-487d-9f18-38f3ca30fb62_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AncillaryServiceContractMember_bbd1539a-8529-4a53-931d-7bf028105298_terseLabel_en-US" xlink:label="lab_ameh_AncillaryServiceContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Service Contract</link:label>
    <link:label id="lab_ameh_AncillaryServiceContractMember_label_en-US" xlink:label="lab_ameh_AncillaryServiceContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Service Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember" xlink:href="ameh-20210930.xsd#ameh_AncillaryServiceContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AncillaryServiceContractMember" xlink:to="lab_ameh_AncillaryServiceContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f1674a26-039a-4e78-9da1-56345f3d3fda_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_251a173f-03bf-4cc4-8e00-5e69d7e68c10_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_556a9dd3-26f3-41be-853c-3f9e8190454e_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_9fea6c2b-50e4-442d-97b2-e50e5158b009_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate in the event of default</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:href="ameh-20210930.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:to="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_4c02cbb6-3c28-41cf-a2ce-657d242d85f5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of restricted stock to be recognized straight-line</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_deed9d85-1148-4ac7-b2b0-89ccb2861a47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8611b85c-b08e-4b0c-8ff7-26b3cc80ba2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_46e54948-d5d4-4e77-992c-ecf2bdccce70_terseLabel_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related parties</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_label_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made To Related Party</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_documentation_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit/Duration (Amount paid to related party in relation to providing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty" xlink:href="ameh-20210930.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentMadeToRelatedParty" xlink:to="lab_ameh_PaymentMadeToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_90cb6999-c65b-497b-8bd5-8198d64b1d73_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_5b4c6159-8425-43c6-8df5-daf18e1994d5_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_e7daf3e7-823a-48fe-969b-56f41d16ece6_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9b2b6fed-7ffc-49e3-93f2-4abc3744a27e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_103d2b0f-1c39-4772-ab6e-0594aa42c73c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_14378d88-20b3-442c-9d16-429adb168c73_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_a776aea1-512d-4a52-b8c8-c6f99ea4beb8_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SubcontractorIPAPayable_4cb1c88a-85ba-4972-92a5-3b95bbab5f68_verboseLabel_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA payable</link:label>
    <link:label id="lab_ameh_SubcontractorIPAPayable_label_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:label id="lab_ameh_SubcontractorIPAPayable_documentation_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable" xlink:href="ameh-20210930.xsd#ameh_SubcontractorIPAPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SubcontractorIPAPayable" xlink:to="lab_ameh_SubcontractorIPAPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a34e132b-36ca-4517-b7ae-7165fd00af04_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CancellationOfRestrictedStockAwards_ca9629f0-c769-49df-92e0-11e83808ac59_terseLabel_en-US" xlink:label="lab_ameh_CancellationOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards</link:label>
    <link:label id="lab_ameh_CancellationOfRestrictedStockAwards_label_en-US" xlink:label="lab_ameh_CancellationOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Restricted Stock Awards</link:label>
    <link:label id="lab_ameh_CancellationOfRestrictedStockAwards_documentation_en-US" xlink:label="lab_ameh_CancellationOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Restricted Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CancellationOfRestrictedStockAwards" xlink:href="ameh-20210930.xsd#ameh_CancellationOfRestrictedStockAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CancellationOfRestrictedStockAwards" xlink:to="lab_ameh_CancellationOfRestrictedStockAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_09626c9a-b1da-48b4-846a-f98c7a193146_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_f7bcc232-c923-4741-ab56-48031c2f564e_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_449e5b95-1729-4578-87a6-536f5c0ce6e8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_cf62bfed-35f2-4405-bb0e-e489777ed7c1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_11551737-bc2a-45b8-9648-087f22acaca9_terseLabel_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional cash consideration entitled to be received</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_label_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_documentation_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:href="ameh-20210930.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:to="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_dc3ba9ad-8034-43cc-9aa2-29e1262cffde_negatedLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromAffiliates_81c47b2c-2032-49f2-93c8-65e8dec6be1d_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from affiliates</link:label>
    <link:label id="lab_us-gaap_DueFromAffiliates_label_en-US" xlink:label="lab_us-gaap_DueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromAffiliates" xlink:to="lab_us-gaap_DueFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_aee26542-82ca-467f-99af-0873f908a0c3_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9f79e075-df8d-4f1a-8232-8f40972cb484_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_288196c0-01ae-4061-9379-73dcec7c0730_terseLabel_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities, maturity period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_label_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_documentation_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:href="ameh-20210930.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:to="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears_d262867e-957c-4383-b0ab-697ebd62d75d_terseLabel_en-US" xlink:label="lab_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from risk pool settlements from prior performance years</link:label>
    <link:label id="lab_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears_label_en-US" xlink:label="lab_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Risk Pool Settlements From Prior Performance Years</link:label>
    <link:label id="lab_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears_documentation_en-US" xlink:label="lab_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Risk Pool Settlements From Prior Performance Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears" xlink:href="ameh-20210930.xsd#ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears" xlink:to="lab_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PmiocMember_d393029d-a9b2-40ed-8038-43529de0bf86_terseLabel_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC</link:label>
    <link:label id="lab_ameh_PmiocMember_label_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember" xlink:href="ameh-20210930.xsd#ameh_PmiocMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PmiocMember" xlink:to="lab_ameh_PmiocMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8797ebb7-800b-4e22-98b5-7361ecf263dd_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_055d603b-209b-4cbb-a94b-2789d73e4cb1_terseLabel_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool surplus or deficits, settlement period after risk pool performance year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_label_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_documentation_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:href="ameh-20210930.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:to="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase_e0ec3f51-ef67-4114-aded-52cb101c3a70_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional ownership percentage committed to purchase</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Additional Percentage Committed to Purchase</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Additional Percentage Committed to Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase" xlink:to="lab_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_059ef7a2-c3e2-428b-a7d6-f0a16fdf3ca0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_bc5656d4-bd5d-49ef-a793-39f8f3acef87_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_c2794317-45f6-49de-8f80-df8639c25d90_terseLabel_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember" xlink:href="ameh-20210930.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmendedCreditAgreementMember" xlink:to="lab_ameh_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_20f28a07-261b-4c28-9a59-6c1ea3fb9cbb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cc10a2a2-4b0e-4774-ab4f-51435162ca5c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_159fea09-aaa8-4a31-ac49-83043a60bf66_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_69e7aa88-35f5-4866-9b16-e1f1e9b3840e_verboseLabel_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_8a3b8167-d852-40d2-bf34-3610a9a9d05d_terseLabel_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_label_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA [Member]</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_documentation_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:to="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6af9dfb7-ddce-4f47-b058-a493c4310f19_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_4e654d50-4e1e-457e-8c71-14e78663c605_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash - noncurrent</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_371d2d65-c061-4db4-b431-3a831b5b1ffd_terseLabel_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC</link:label>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_label_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC [Member]</link:label>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_documentation_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember" xlink:href="ameh-20210930.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AMGPropertiesLLCMember" xlink:to="lab_ameh_AMGPropertiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_add76e5e-4bf0-4ec8-bb13-ed19d18093ba_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_c46ed993-52a2-442d-a34b-bbfdd17d341d_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities - Equity Method and Investments in Privately Held Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_6f65cc4d-5a1c-4796-ac01-3c9d63f82e1a_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_267c37e7-6c59-450e-aacc-ddec7b49c999_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_24bf8772-3f22-4473-a08c-9ab82b81ddeb_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_731375ff-20dd-4c44-b7a8-be7adce1943b_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, mezzanine equity, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_964982d3-a1a7-43ec-b60f-41e9a15c5bec_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcShareholdersMember_7d8d5dd6-fad6-4997-96eb-22c00a2050db_terseLabel_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders</link:label>
    <link:label id="lab_ameh_ApcShareholdersMember_label_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember" xlink:href="ameh-20210930.xsd#ameh_ApcShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcShareholdersMember" xlink:to="lab_ameh_ApcShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_e651ec08-b12b-47ee-b503-3a460a273fd8_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_662d9d6f-c6c2-42be-bce6-0e0ca75eed5a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_bbd7a57c-cd90-4748-b8c0-2f49e53ad5f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7c4637a9-81d3-4b5f-9ee8-777834f4f0fe_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b3b4fedc-27a7-4534-909c-5808136c723a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3354dd26-47db-4879-9194-2dc05e93b8df_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price adjustment from Merger</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_d248a4d4-a9b5-4ebd-8596-7891bb7d9b30_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_a78b9dbf-18c9-42a5-a02d-bcd48dbbf0a4_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorAMember_c7eccdf3-c834-41a5-bd4b-a8d0500c6bf1_terseLabel_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A</link:label>
    <link:label id="lab_ameh_PayorAMember_label_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:label id="lab_ameh_PayorAMember_documentation_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember" xlink:href="ameh-20210930.xsd#ameh_PayorAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorAMember" xlink:to="lab_ameh_PayorAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_84a7f41e-03cd-40aa-82f2-aeef0e594353_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_c14dd93d-cef6-439a-afdd-7d9d6c618dc2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_0e12c49b-c7eb-40e9-83e8-095d4ff6acab_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenue_8905299e-d073-438b-b295-b4f3b48f4ca7_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_ameh_PaymentOfRevenue_label_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue</link:label>
    <link:label id="lab_ameh_PaymentOfRevenue_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue" xlink:href="ameh-20210930.xsd#ameh_PaymentOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenue" xlink:to="lab_ameh_PaymentOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_782fbc2b-ef01-4988-81b6-d58aec17cb21_terseLabel_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Quality Management Corp</link:label>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_label_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Quality Management Corp [Member]</link:label>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_documentation_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_Critical Quality Management Corp Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember" xlink:href="ameh-20210930.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CriticalQualityManagementCorpMember" xlink:to="lab_ameh_CriticalQualityManagementCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_a4959f3e-2309-4271-acef-a5fb9ff46194_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of key financial ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_label_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:to="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfEmployees_5b21335b-3b27-4003-b71f-ce564f726983_terseLabel_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_ameh_NumberOfEmployees_label_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees</link:label>
    <link:label id="lab_ameh_NumberOfEmployees_documentation_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees" xlink:href="ameh-20210930.xsd#ameh_NumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfEmployees" xlink:to="lab_ameh_NumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_cea9f550-89ed-421c-aa30-c6f41d64684c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Sale of Parent Equity Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_1d5b9b69-3204-40ae-8406-462e927b68b4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_56e0fc37-cde1-4435-b0d1-bd7cba3cbf0d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_18c46497-e271-430c-9b93-c949450279be_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from repayment of loans receivable &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Long-term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_e137e300-af7b-45a1-bd5c-3c32259b7f48_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of shares by noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2591c6a0-81a4-4bc7-8d11-7bd216bc1075_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_2521e54e-9b81-478d-8686-9fdc36faefde_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementFeeExpense_5141398a-0400-4f58-aa6c-77ded6abf3a7_negatedLabel_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fees</link:label>
    <link:label id="lab_us-gaap_ManagementFeeExpense_label_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeeExpense" xlink:to="lab_us-gaap_ManagementFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_82c680f9-6642-47f1-bc7b-a58cfd28211d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8adb0727-79f6-47a8-aefb-ca8b458dc49d_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_9c10e0ce-f2a0-40ca-922f-20077944b986_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_a0725387-760c-45b1-8892-b1bee6b24cf5_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_40b28c06-d09c-45c9-a680-c8b6a8552396_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_58484750-b4a9-47f7-92b5-ec3c958c5298_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_6ce07f11-ef77-4aa7-839e-81bb74a73b47_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_69289d94-aca1-44f5-86ba-b2cdf73f5eb3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_81f65a46-7370-465a-82f4-7692735204b4_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares received from sale of equity investment</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:to="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_83b50654-5e8d-4b09-8391-4bcb8d2f61c2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_d1d7d516-26a3-420f-9ab5-d12c68ed16a6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_658df498-ce73-452b-a902-c05571d344cc_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdback shares not issued to former shareholders (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Merger</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of stock issued during the period pursuant to merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SharesWarrantsRollForward_95b5d613-c8c5-4885-8131-d58ac75cf422_terseLabel_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_label_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward" xlink:href="ameh-20210930.xsd#ameh_SharesWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SharesWarrantsRollForward" xlink:to="lab_ameh_SharesWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5a34d9f3-e5ca-4aa1-a9f1-e0874464b4f1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_a14a2f49-c7b8-41ea-8072-bb0ff8da12f6_terseLabel_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_label_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable And Accrued Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:href="ameh-20210930.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:to="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7b948ed4-bb84-4041-b6f0-5a3b37019d55_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,397,050 and 42,249,137 shares issued and outstanding, excluding 10,925,702 and 12,323,164 treasury shares, as of September&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_9586a00c-1655-4b16-91c6-fc7c1f2a5831_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractTypeDomain_99a84fa7-ec09-4d81-8b7b-cc50e6946941_terseLabel_en-US" xlink:label="lab_ameh_ContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Domain]</link:label>
    <link:label id="lab_ameh_ContractTypeDomain_label_en-US" xlink:label="lab_ameh_ContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain" xlink:href="ameh-20210930.xsd#ameh_ContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeDomain" xlink:to="lab_ameh_ContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_ead68c1c-e044-4b0e-9a4d-bbac31c8f5cd_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApaacoMember_328639e6-2c3f-42a0-96ba-33ea881742d9_terseLabel_en-US" xlink:label="lab_ameh_ApaacoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAACO</link:label>
    <link:label id="lab_ameh_ApaacoMember_label_en-US" xlink:label="lab_ameh_ApaacoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAACO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember" xlink:href="ameh-20210930.xsd#ameh_ApaacoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApaacoMember" xlink:to="lab_ameh_ApaacoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f2f53315-c2a3-431b-bd62-b61171db9f5f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fa7a8c6f-3d5a-4902-a87c-328665601bee_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementServiceMember_54aea90e-badc-40f3-80bb-393bbbbe2c2a_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fee income</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_8071b9a2-43f9-4db6-95a3-cfaefb16a666_verboseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Income Contract</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_label_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementServiceMember" xlink:to="lab_us-gaap_ManagementServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_41be505a-1a37-4562-b889-b4f6718ec3dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (excluding the nine months ended September&#160;30, 2021)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_ed9235ec-4127-4bad-9545-008248fd7f87_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations and Goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_32bbf00a-8e55-4588-85c3-efdcd2810b9f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DiagnosticMedicalGroupMember_9bdb98e5-7142-424f-a3e1-84f9c51b5438_terseLabel_en-US" xlink:label="lab_ameh_DiagnosticMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Medical Group</link:label>
    <link:label id="lab_ameh_DiagnosticMedicalGroupMember_label_en-US" xlink:label="lab_ameh_DiagnosticMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Medical Group [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember" xlink:href="ameh-20210930.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DiagnosticMedicalGroupMember" xlink:to="lab_ameh_DiagnosticMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_f559bae6-c989-43ce-8682-e1c927cee9d5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_8f605b84-3333-4925-84fa-04a61c3216ad_terseLabel_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrants exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_documentation_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:href="ameh-20210930.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_75915086-a4a6-423b-b5a6-ba804ade042c_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_103058eb-5452-4c0d-8173-fd282141259a_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7afb47ed-dd30-41bd-83a8-9f55223e930e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_e6ca2dbd-6413-4636-a657-cbdadf41c584_terseLabel_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc.</link:label>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_label_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc. [Member]</link:label>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_documentation_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember" xlink:href="ameh-20210930.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FulgentGeneticsIncMember" xlink:to="lab_ameh_FulgentGeneticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_0306cb6b-91f4-4826-b780-a7197dc7171c_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OtherThirdPartiesMember_64f13abf-be37-4bf5-99b4-e1dd95a844ea_terseLabel_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other third parties</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_label_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third Parties [Member]</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_documentation_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:OtherThirdPartiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember" xlink:href="ameh-20210930.xsd#ameh_OtherThirdPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OtherThirdPartiesMember" xlink:to="lab_ameh_OtherThirdPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_aedd1c1a-4a3a-46d4-a79e-ba3c5a855354_terseLabel_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_label_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_documentation_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember" xlink:href="ameh-20210930.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APAMHMedicalCorporationMember" xlink:to="lab_ameh_APAMHMedicalCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_be70f275-9cea-4795-8932-550733715fe8_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service, net</link:label>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_label_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_81ad9097-34ce-4145-a549-1e6c9b376750_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_41ea31cc-c32b-4a94-b729-9fa28e32ae52_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_dbb4047a-0bec-4c56-ae19-bda1ed787055_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac319daf-9af4-4d63-b2c6-1cb76bef1779_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dd382433-cad1-4a06-9375-306aa6666ec4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8f328de0-3176-4a4f-a0ba-bfe630a9a1ad_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApaAcoIncMember_d5e004a2-2a17-458b-982c-289e409c27df_terseLabel_en-US" xlink:label="lab_ameh_ApaAcoIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APA ACO Inc</link:label>
    <link:label id="lab_ameh_ApaAcoIncMember_label_en-US" xlink:label="lab_ameh_ApaAcoIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APA ACO Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaAcoIncMember" xlink:href="ameh-20210930.xsd#ameh_ApaAcoIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApaAcoIncMember" xlink:to="lab_ameh_ApaAcoIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c18a549e-4f72-4fae-b4ef-efd14f6d2f83_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b79fa954-9c6b-4380-83ee-462361521315_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_cedbe298-6cd6-4dd1-a1d7-f0db452a9628_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_cf5eb0b8-7d0a-4942-a765-4ef4e3b05ce3_terseLabel_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC</link:label>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_label_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:href="ameh-20210930.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:to="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_45d71e18-6030-475e-b9d4-30e2a1599654_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_56b5c6b7-2576-4234-bcf4-0e49610d5a6c_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_7b1d1211-d42f-4132-b107-9d99c19a8806_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForFees_30102635-c969-4b68-9c23-755f802ee2ec_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForFees_label_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Other Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4bcf5de0-5948-4e2b-a0e1-88db990ad579_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f3c2c5aa-e6fa-48f8-98a2-a5d932507243_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_5a37f13b-e23c-4637-91ab-bdc8382370e9_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in&#160;Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_1254e216-6e7d-4938-a7a1-9fde5e7de8b2_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable" xlink:href="ameh-20210930.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesTable" xlink:to="lab_ameh_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_32655f55-989a-4597-8d4c-c62033745c61_terseLabel_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMPM Managed Care Contract</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_label_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_documentation_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:href="ameh-20210930.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:to="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3e447f9e-ce3a-4863-b10a-69de38656981_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_76f940bc-9baa-44a0-b551-57eda3e015c1_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_b7b39e33-e64f-4e76-98ba-bd8dbfbb3587_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_ced6a441-3d3b-4d8c-9074-3c5c33ef72f4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_82849ca9-81c9-44cc-80bf-a4bc9b17a1a6_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants received (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_0eb4669c-7f8f-4b2b-8e83-18a67d3a248e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on revolver</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableNet_5e83c808-2332-4286-bfb3-b8587618022d_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of loan</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9fc68b97-ac50-46c1-a1a5-1494f2aa7445_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_84dfdc71-3081-4d6d-9708-884e1ba0c6e6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_9dacef05-86bc-4e4d-ae81-8f74caae1d98_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting common stock, within five years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_38bbbab5-ea7e-4f80-a218-fec743d18084_terseLabel_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed term of amended and restated management and administrative services agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_label_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_documentation_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The initial fixed term of amended and restated management and administrative services agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:href="ameh-20210930.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:to="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkRelationshipsMember_04c8e9d1-4f36-436f-85df-a0075ef7eac8_terseLabel_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network relationships</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_label_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships [Member]</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember" xlink:href="ameh-20210930.xsd#ameh_NetworkRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkRelationshipsMember" xlink:to="lab_ameh_NetworkRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7f55732c-40db-4039-b708-c3497505c6b9_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_8423551a-1005-4e36-8960-470393eadcf2_terseLabel_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC</link:label>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_label_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC [Member]</link:label>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_documentation_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember" xlink:href="ameh-20210930.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ZLLPartnersLLCMember" xlink:to="lab_ameh_ZLLPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_31d74ef0-5a6d-4f8b-807d-492c73ca3061_terseLabel_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC</link:label>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_label_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC [Member]</link:label>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_documentation_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember" xlink:href="ameh-20210930.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalPropertyPartnersLLCMember" xlink:to="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_a6f9698c-32db-41cd-b0fe-017206d55aee_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, preferred shares</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_989a988f-15ab-4800-a212-23af6f381278_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_43190a8a-dab4-46da-9b90-fc50a8e1492b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fdab6bb1-2a1f-4828-b990-929310261262_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_d01415e2-ab42-41f6-8189-4c703eae60d3_negatedLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Cancelled In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, cancelled in period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ccd92cbe-92b6-404a-873e-14b89e55d1d8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_bb0ba0e4-42df-41f7-b819-0d85a84cac47_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contributions to Revenue and Receivables by Payor</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a90f7d4f-5f66-4931-81f3-dc921fe533c5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity, parent</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a1d5d959-5d42-4afb-a3c0-b586e3a88e4f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_116eddd6-339e-400c-b11c-6ca88879e52a_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_9448ff0f-0dee-43be-a289-00fe429fb699_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership upon conversion of finance receivable</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:to="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_ed0397b3-bc29-47fb-852a-970c139957f4_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments:</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_13f71178-2d74-4a7f-8377-e267f552bb03_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_1ba564f5-a23c-4f88-a49c-6f10c43a84ba_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApolloSunLabsManagementLLCMember_3501506e-f0e0-4bca-b0aa-d77b97ea2def_terseLabel_en-US" xlink:label="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo-Sun Labs Management, LLC</link:label>
    <link:label id="lab_ameh_ApolloSunLabsManagementLLCMember_label_en-US" xlink:label="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo-Sun Labs Management, LLC [Member]</link:label>
    <link:label id="lab_ameh_ApolloSunLabsManagementLLCMember_documentation_en-US" xlink:label="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo-Sun Labs Management, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember" xlink:href="ameh-20210930.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApolloSunLabsManagementLLCMember" xlink:to="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_14fc200e-67b4-4966-a745-ab252b16317b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_953855e1-7a1c-40e6-ac3d-bc7f1f506bf5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under agreement</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_639bf19b-59f0-4ffe-a387-4dca71840cff_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_633092e7-f6da-4d15-bca7-cc78e554826b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b6bfa709-d447-4126-8c69-89e3a8ef7c41_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_35c20bb2-2ce2-466f-8c83-dcafb6e08c82_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_2f0d7919-cc44-4d20-a747-76081b6f910a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, principal sum</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_567607fd-27cc-4dbf-a0c9-43285a9f0c50_terseLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to purchase membership interests</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20210930.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_be470029-ad82-4ffe-a37e-7c55954bbf29_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_78abbcdc-4240-428b-a8d1-a1c5fa013d28_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_a2cc1d20-2118-425e-b483-4dcd4b54efa1_terseLabel_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center</link:label>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_label_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:href="ameh-20210930.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:to="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOInc.Member_f93d98e3-0c8d-4077-81ce-904813ba9ae0_terseLabel_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc.</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_label_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_documentation_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member" xlink:href="ameh-20210930.xsd#ameh_OneMSOInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOInc.Member" xlink:to="lab_ameh_OneMSOInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_0352bd2c-8d33-47ad-ae6a-a178b7b387b3_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_05a76886-9f77-4d01-b902-83d7a1e921a2_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_94133327-9327-4952-b339-6d6f63cb167e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term, operating</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_b8cb3b8a-f3fa-422c-872c-ddfd48d44d8f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ccc90507-0bbd-4cd8-b759-adb18eee5020_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_aaf48e6e-481b-420b-9e6c-8e727c6089e3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_a380d403-3033-4fef-8e9d-e531da5bd6bb_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_69f0c9ba-d913-4f44-9b8f-ddb923945dbf_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_6afd36aa-7d8a-4876-b81d-0739fbd97a08_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_bcae8afb-bb6b-44dd-904b-4235eabb1e63_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_ce36739c-d4ef-4115-84d0-5b7b2863a8aa_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable" xlink:href="ameh-20210930.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessTable" xlink:to="lab_ameh_DescriptionOfBusinessTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_b0d51bca-ed34-4c86-8b99-25ad9018b274_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:to="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_7140e0fb-e23f-4fc0-916b-757a189dbdd2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_55d34e66-794e-4266-aa55-b7d9f3f96b89_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_e951cb98-058e-4f3b-9415-b7d0e42e806f_terseLabel_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC &#8211; Risk pool, capitation, claims payment</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_label_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_documentation_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:href="ameh-20210930.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:to="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_ca8afacc-ab0e-4cc5-af2b-3f7faefd1597_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_410e17f7-3c65-4376-9abb-91358a7a8b1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e7b5a4cb-490c-4ac4-9211-f21e13f75cef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Benefit from) provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d2e5ced0-1b87-4a0d-aeb5-87e462e5e33f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2ce7ec0f-b55d-4404-bd72-530428bec0e3_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_c8949450-5c7f-46b0-bf9a-128927fe4703_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, debt coverage ratio, minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOtherMember_b39ddb67-4cdc-4773-b1ef-fe53ac829cdd_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool settlements and incentives</link:label>
    <link:label id="lab_us-gaap_HealthCareOtherMember_label_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOtherMember" xlink:to="lab_us-gaap_HealthCareOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentConsultingFees_a117429c-1ac3-475d-b738-aec2d6e8ce61_terseLabel_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting services paid</link:label>
    <link:label id="lab_ameh_PaymentConsultingFees_label_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Consulting Fees</link:label>
    <link:label id="lab_ameh_PaymentConsultingFees_documentation_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Consulting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees" xlink:href="ameh-20210930.xsd#ameh_PaymentConsultingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentConsultingFees" xlink:to="lab_ameh_PaymentConsultingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f23112e9-592b-435b-a047-7f2164174816_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f6d163ba-63fd-46a8-ba84-fee9d1d0f301_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_327b931a-7b1f-4520-b9ae-bebc4249096e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables and Receivables-Related Parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_0e15edbe-3ad9-4e36-8e84-22cda18d0558_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5c626598-fec8-4d84-a302-8712f348ab4b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_2d4be914-b0c6-42f2-a3c7-b9ca9be96900_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_08094292-d840-4960-864b-1ff6cb4575ba_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_613043ef-1dba-4f7d-b97c-5220bb0569d9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount invested for interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_b7dff46b-6cfb-4772-9ded-bcacd1419a1d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_975ed78c-671b-437a-a451-dc0d50cb20cb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_00bc24af-4b31-4fa7-afe9-7ddc9b3743a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_56df9104-67ef-40ba-ad1f-9b12d30f7299_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights exercised in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9fe36911-4769-49a2-8553-ac1b763922de_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_f46eae74-ed02-4f54-b915-4895c38abfcd_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Included in the Diluted Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c5071422-dfcc-4e7f-a71f-e857c3e9c386_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ebc70a15-50c9-4ebd-9760-8828b31ebe52_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_6c75edf4-1562-4c27-b4bd-acae1a141195_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_96043e1b-9fa5-463b-945c-3b7c65a6c809_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f1bc9338-c908-430d-b2f6-2ed0b83afaf3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_dbeff8f8-798a-4ed3-9251-74e17ce2bdfc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_ce47f875-b7f8-4b60-885b-6d012abbb170_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_696a931c-21c8-41a1-85da-667dcd68dd8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_f822768b-2b0b-405b-a36f-b2bae27738af_terseLabel_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="ameh-20210930.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_70e1cbf8-afcb-4046-9de2-bd1d18219498_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares transferred in acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9e1e54d9-6964-4242-a57a-34e61f744374_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_5d1d0969-beab-4d7d-951f-7462eb6a0045_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of shares by noncontrolling interest (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ce72cac5-b316-4eb0-a0de-eae12246b9a0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_a18a7280-4ba6-40ad-a71c-d63ad230e9d2_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_aaf7e1df-54ba-4b00-94e7-c3a7da050644_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_6017b0b9-5288-4bac-9cac-c6f32d34c9e0_verboseLabel_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in privately held entities</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_label_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In Privately Held Entity That Does Not Report Net Asset Value</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_documentation_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of Investment in privately held entity that does not report net asset value per share .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:href="ameh-20210930.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:to="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_722ea4d9-e9ea-4ad3-92ee-f8b602326ac6_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_66186fbf-91b5-4de1-a292-626a4fcdcfce_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1c9cc896-c2f9-4d40-8ada-c6a46364a031_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2d68e9f8-d933-4b51-b2d9-19837b13b33e_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_29abf885-4a22-410f-ac20-f18ce78259d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_c6610008-f794-4347-aeaa-c7949b5c0d51_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_ce663e59-4967-401f-8eea-a2bfbcea91ea_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_dc1be7ec-0116-4723-901a-7da1b1ba5da2_netLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e2dc456-60b9-4149-81d0-3f4a16ff857d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before (benefit from) provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_821914e2-2504-42cd-9f94-57a94ee97d86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_76b1fbae-4fcb-4b5b-bcf3-b5fce8e610db_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20210930.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_f079868a-6867-4b06-98ac-bbca431dba5f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired (see Note 3)</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d814beb4-8ed3-4dff-8004-10efaa86bb16_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_d0af88d6-c87d-46ea-9ece-c3d4be2c3195_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="ameh-20210930.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_4e3763fc-68f1-4568-86da-6ffbc75e9e7b_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_d1917b7f-3ee2-4f01-941f-fb0c3a62518c_terseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine Equity</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_label_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:href="ameh-20210930.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:to="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_63fe3c08-5175-454a-ba75-aeed925029fc_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b048f45f-6371-4daa-be84-21ec51364705_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_714e38b9-5a22-4349-82e1-62eabbeb06c9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_378cff9b-c2d9-4f3c-8bcb-9d515a9d3e79_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_02e2f3c1-1a1f-44af-a27b-a9e10cb3fe77_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_cbaebcec-3fe0-4704-a114-7cf5b4b277bd_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_d3a0fa4b-064e-421c-85f3-db528828867b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ca6f188e-a5f7-47e5-8114-750427d5e6bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a3505314-c2bb-46e5-ad47-ff7c73ddc0b4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_160a5e34-f50c-403a-8b2f-0fadab5bafde_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliates</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_920b55cf-4b2a-4dfb-b9d8-8114e4c3bfbd_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_caea7342-a6a0-4f9c-b391-47e0ce7bd5c2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_667d22b4-ea9f-48de-88d1-564c493e192f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_b20181f4-dcca-44f5-a7f1-c3ed3eb95fb4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on loan receivable</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.ArteagaMember_e33be450-08dc-4413-9381-2f80dacaf5cb_verboseLabel_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_label_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_documentation_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember" xlink:href="ameh-20210930.xsd#ameh_Dr.ArteagaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.ArteagaMember" xlink:to="lab_ameh_Dr.ArteagaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_56eb0225-575a-4577-9c7c-372385a19193_verboseLabel_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities &#8212; Equity Method</link:label>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_label_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_documentation_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:href="ameh-20210930.xsd#ameh_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:to="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_82daa5b0-d8e6-4641-a3b0-1b13e8ba15e2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_df58385a-b68f-4aba-bbaa-fd15c77166cd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_cb6c9c55-65f2-4f74-8947-f1940da8e807_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APCMG contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_aa40fb7a-0dc8-4716-be67-568d7bec2473_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_27723cc5-fc47-4e81-a79d-6e8951fd8f20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_e212895d-ada6-44c5-9a6b-1eacf0f479f7_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_2e22a409-8c95-4356-8e88-b1dcfa26c9df_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_57ac9421-3c7f-484d-8220-13bf13ef8486_verboseLabel_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation, net</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_label_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Capitation Revenue [Member]</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_documentation_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_HealthCareCapitationRevenueMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember" xlink:href="ameh-20210930.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HealthCareCapitationRevenueMember" xlink:to="lab_ameh_HealthCareCapitationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_920dfcb8-fd05-4bb6-b380-a4b07bff4c73_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Related to Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareIncMember_fa6cc838-001c-4ccd-8f70-52b0fa1df129_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Inc</link:label>
    <link:label id="lab_ameh_UniversalCareIncMember_label_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember" xlink:href="ameh-20210930.xsd#ameh_UniversalCareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareIncMember" xlink:to="lab_ameh_UniversalCareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_c815003b-5908-4367-be39-3947085e966a_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_54d62acd-a9cb-41ef-90a5-1846ae864f83_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_0b8cc2a3-72c2-4c87-93d2-e4ea53670ed9_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated rate of note of loan receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate" xlink:href="ameh-20210930.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableStatedInterestRate" xlink:to="lab_ameh_FinanceReceivableStatedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_e0d1f4f0-6138-45be-aa46-881cf9b1ee3b_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_db1ad573-39cf-40c2-9339-b1fe1d684685_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_e50cb36d-0b96-4b4d-a932-9f8a7862747c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_51763f45-b0b7-41bd-9424-6437c8a6578c_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_7b8c806c-18ae-4108-af27-bf960fdc32ed_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9731a0a5-f062-4d4c-bf11-20a315257c74_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_9bb6ca1f-874d-4cb6-8e80-fd93d1882796_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7e988edd-7200-457c-a3c0-c35452637f84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_e0d21386-983f-415c-861d-8e65a5a73746_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_88e3f931-007b-46c8-ac07-b673d6e9b7ce_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (income) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_ddb9af40-48fd-41d6-8416-9ef7a2c83444_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Income (Loss)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_08c04ca1-b918-4226-94bb-8ae62113f5ce_netLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PreferredBankMember_82061fae-fcc2-422a-a5b4-42db28dc45c7_terseLabel_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank</link:label>
    <link:label id="lab_ameh_PreferredBankMember_label_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember" xlink:href="ameh-20210930.xsd#ameh_PreferredBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PreferredBankMember" xlink:to="lab_ameh_PreferredBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.JayMember_64aeca5a-29dd-4c21-980f-5c8c387d65df_terseLabel_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay</link:label>
    <link:label id="lab_ameh_Dr.JayMember_label_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay [Member]</link:label>
    <link:label id="lab_ameh_Dr.JayMember_documentation_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember" xlink:href="ameh-20210930.xsd#ameh_Dr.JayMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.JayMember" xlink:to="lab_ameh_Dr.JayMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_48c5add4-5867-4874-9402-c900235a33b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_443c3d6c-b27a-4022-b917-ce18a05e2c7c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Finance Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueTable_66bb7e8f-c199-4143-b7a3-858c5e23f676_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueTable_label_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:href="ameh-20210930.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_bae9224f-5ef5-40f1-b9cb-e79857c03bbc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AmgIncMember_e426b806-5bfd-43be-81a7-0b151e1006e6_terseLabel_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc</link:label>
    <link:label id="lab_ameh_AmgIncMember_label_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember" xlink:href="ameh-20210930.xsd#ameh_AmgIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmgIncMember" xlink:to="lab_ameh_AmgIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4abb6cc5-d338-4c07-9e20-354cb58b634f_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_3adfec64-55a5-469d-b31b-63ccecc9cdce_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_e899f54a-b8dc-4e3f-95d2-dd6a43fd094c_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend declared included in dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_97e7d3c0-2c8f-45d1-a9eb-49b4f4d20613_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized risk pool revenue</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_b7603294-ddf4-4aa8-882d-21ead404e60a_totalLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipts, net</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Other Revenues from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_4ec9f664-dc55-4a91-8e7e-df31f65e7a20_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_44b9a807-a87e-4f72-9297-87a67bfba906_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_e074120f-025c-477f-a85f-8b564e2983d0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of main reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_9dc2af1f-d048-4b61-b159-e11f9ee1d86b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8a54796-ab80-4768-b995-27204ed27e08_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CAIPAMSOLLCMember_09ce657a-bad9-4439-8bf9-84e8422c09ec_terseLabel_en-US" xlink:label="lab_ameh_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC</link:label>
    <link:label id="lab_ameh_CAIPAMSOLLCMember_label_en-US" xlink:label="lab_ameh_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC [Member]</link:label>
    <link:label id="lab_ameh_CAIPAMSOLLCMember_documentation_en-US" xlink:label="lab_ameh_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember" xlink:href="ameh-20210930.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CAIPAMSOLLCMember" xlink:to="lab_ameh_CAIPAMSOLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_babe4bb6-0dd0-47ea-8614-8188a9b25c57_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MemberRelationshipsMember_55e2293d-e10d-4fa3-9472-ad73e6f43602_terseLabel_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member relationships</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_label_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships [Member]</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember" xlink:href="ameh-20210930.xsd#ameh_MemberRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MemberRelationshipsMember" xlink:to="lab_ameh_MemberRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_36d2a867-79b1-4a83-84b6-69382ce49397_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_fc9a82c6-02cd-45ee-b3d9-64a8fb879502_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e9f2c894-e837-4b47-819c-6e7a70c84abd_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_3ec67cfd-2950-49f2-87ea-ac5a0d116e77_verboseLabel_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Receivables &#8211; Related Parties, and Loan Receivable - Related Party</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_label_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables And Related parties Receivables Policy Text Block [Policy Text Block]</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Receivables and receivables from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:href="ameh-20210930.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:to="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2d17e9a7-f031-4066-b780-e4476d795e07_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_38d95a6f-0ac5-4734-9fe8-494f3fd665c6_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, cash flow coverage ratio, minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_9292e11d-65b8-4f08-b1dd-e4d8b67890b2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_9107bb9c-3331-4ada-8170-fd8e8ad7b57f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ce65fc35-815f-4b67-a5c6-b8ee60e31112_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareholdersAndOfficersMember_7bfefe5e-4e07-4993-a097-b8a458715210_terseLabel_en-US" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders and Officers</link:label>
    <link:label id="lab_ameh_ShareholdersAndOfficersMember_label_en-US" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders And Officers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember" xlink:href="ameh-20210930.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareholdersAndOfficersMember" xlink:to="lab_ameh_ShareholdersAndOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_bb98364f-35ee-4b34-902d-3fa56a863d9a_verboseLabel_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care</link:label>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_label_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember" xlink:href="ameh-20210930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountableHealthCareIPAMember" xlink:to="lab_ameh_AccountableHealthCareIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_12f053f9-5c82-47cc-a355-6f09d9dfaa6c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, FV-NI, unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_0bfd31bd-3fd8-4678-a4e5-97bb689ef35d_terseLabel_en-US" xlink:label="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from consolidation of VIE</link:label>
    <link:label id="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_label_en-US" xlink:label="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Cash Received from Consolidation of Variable Interest Entity</link:label>
    <link:label id="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_documentation_en-US" xlink:label="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Cash Received from Consolidation of Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:href="ameh-20210930.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:to="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_63186a39-b573-40f5-9813-b05ca26841e7_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenueRevenueRecognized_37ead667-34ce-4d9f-a1cb-a12c63e1133a_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received, revenue</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueRevenueRecognized_label_en-US" xlink:label="lab_ameh_PaymentOfRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Revenue Recognized</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueRevenueRecognized_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueRevenueRecognized" xlink:href="ameh-20210930.xsd#ameh_PaymentOfRevenueRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenueRevenueRecognized" xlink:to="lab_ameh_PaymentOfRevenueRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5d84e7f9-3380-44f7-ae81-0954c710a262_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_de2064ef-2ad3-45b5-8ed1-c4bbee3ed2f4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d2d501a9-23bb-45a7-9fa4-3b2d3dcfaaef_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_81cfb9c8-25f9-44aa-9fc2-f83eea7e26ba_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_6d879d52-7dba-447c-9638-d6fc3841ac92_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of warrant</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_18fc98c3-8e95-4df5-80e8-dd0ef0280882_verboseLabel_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_label_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:href="ameh-20210930.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:to="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_8310e107-c3db-4c0f-ace7-c27be04dd3e4_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember" xlink:href="ameh-20210930.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementMember" xlink:to="lab_ameh_NetworkMedicalManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_9114c6ef-15bd-44ac-bcd7-dc73c255e982_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a1117d50-c8ad-41df-a587-3b9c4fc78680_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_4a35f0d8-0c64-4b6e-9e5a-e6016c29ad1d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation associated with finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_75f91667-34e0-4102-9433-60d872cc32c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6e8186ec-507f-42bc-86f5-71e3212e6a9c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f7ddec47-a533-46b1-8966-fa7282bf17d0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_eabc5129-b622-4d2c-85e8-47268145a5c7_negatedLabel_en-US" xlink:label="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gain) loss from investment in equity securities</link:label>
    <link:label id="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_label_en-US" xlink:label="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (Gain) Loss from Investment in Equity Securities</link:label>
    <link:label id="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_documentation_en-US" xlink:label="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (Gain) Loss from Investment in Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:href="ameh-20210930.xsd#ameh_UnrealizedGainLossFromInvestmentInEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:to="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_a8b06234-b23c-4609-9255-6aeea8f987ea_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_9b55ad99-61a0-40ae-b2c7-19c3619a07f5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_3c3da159-f299-499f-8af0-718a62a5e43c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f6168f9a-17fa-4dde-880b-ca932d18ce8e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_01a46de4-4daf-4d44-9f17-a4be13f04fc3_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:href="ameh-20210930.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:to="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_6172b17e-782c-41c7-b20f-bfb166197a40_verboseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_f7898b39-80f4-4c89-ac6e-f26ba991d4f0_terseLabel_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:href="ameh-20210930.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:to="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_7a92015f-9375-4f2d-99a5-fcd2475c5bf7_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities (VIEs)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_517150ee-006b-401d-a096-6a7a83592b98_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_9b4e810f-f2c9-44a2-ade0-542d6faf3001_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EarningsPerShareTable_b862e21c-a19b-4549-a283-07e122b3c94f_terseLabel_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_ameh_EarningsPerShareTable_label_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_ameh_EarningsPerShareTable_documentation_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable" xlink:href="ameh-20210930.xsd#ameh_EarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EarningsPerShareTable" xlink:to="lab_ameh_EarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1f3721fb-35a5-49a8-80df-531e6c573d1b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_3a54a862-30ab-4c31-b571-63f4e2e910ee_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_236e776b-7003-41e6-90d3-903fecf260ea_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_66247d2a-d95d-4a76-9a07-15ee92fe3230_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, beginning of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_978586b0-2b2f-41e4-b6f1-78c913b40fe8_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, end of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_e03e8fbd-36bf-4336-9d67-9a8ec4767788_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_72ff0796-6bd3-4f0f-b15c-501d1d07fe73_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_134e3145-9876-43b7-a7ec-9d0086f9946d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a74b8d77-0125-4aba-9b13-9acaee6082a6_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_bad6d647-c45c-44d7-8942-3acb2014c0ff_terseLabel_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General amount of guarantee (as a percent)</link:label>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_label_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Financial Guarantee Benchmark Amount</link:label>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_documentation_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of financial guarantee on benchmark Medicare expenditure amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:href="ameh-20210930.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:to="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_11cbc196-13d7-4fe4-927c-3797c10cdc76_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_278061f7-2016-43ef-b393-b846fde13c3a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_55d0b26f-d23b-422a-8de5-79ee35d39b28_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8f09def3-e30c-473f-99ef-437f50388127_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Transactions Under Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a868023c-a8f7-4a02-9b0b-3d785daf68dd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_11f14179-8bf3-47e4-9255-4539ef8c18ef_terseLabel_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20210930.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_39c9809e-e040-4706-bd94-fd0966846c31_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total medical care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_b59f6bdc-644a-4bcd-a717-b9a8c4045335_terseLabel_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_label_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_documentation_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember" xlink:href="ameh-20210930.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Pacific6EnterprisesMember" xlink:to="lab_ameh_Pacific6EnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_b235b432-cc51-493e-b929-b74e04318a2e_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest purchase obligation, noncurrent</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_label_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Noncurrent</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:href="ameh-20210930.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:to="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_13bdd4ca-a346-405c-8a4d-dd104e02b047_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9052ac7a-a2f2-47bc-8269-de1693330dd4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_1418a630-39cf-4f74-b7df-86bb6c6c464d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ef7dc90-f277-4628-b164-5c252785a534_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fd9b7714-484a-44cb-a468-83bafcb0cd64_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_aa8386dd-c27b-4f03-b8e9-56bf0aef355b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_56c81834-458b-4578-befd-0eb4183649bf_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_9ec230fe-ebd9-4150-befc-5a3b1b07d25d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_04338842-6e08-4f7b-ac07-99ab1552ca07_verboseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1c4390fb-82ac-469b-8b50-26f6f916d673_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1766caeb-f05c-4500-8d88-2a2e685121ee_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cebbcd61-6846-42b8-9fcd-b626a8ece2ee_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent_67d7788c-8f6c-4aa7-9300-11595f84b56b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable &#8211; related party</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fab2c2bd-f161-4f58-8931-7d375ad06d21_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_30fff8b4-5049-4695-a613-1c8f923fd630_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized financing costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f8c84d4a-ae72-438c-9ae4-81fc53187393_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized financing costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableGross_228a944e-a5c7-4d7a-be51-66d836f04489_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, amount</link:label>
    <link:label id="lab_us-gaap_NotesReceivableGross_label_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableGross" xlink:to="lab_us-gaap_NotesReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_0577c1af-b230-41ea-9a09-b4fd792774dc_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period shares of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents number of share issued exercise of option and warrants during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_069dc5a0-16cd-42e5-b815-55331579328c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (excluding the nine months ended September&#160;30, 2021)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3f758ccc-900a-4afa-afbd-d71cdd33d370_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8d670a52-6c18-4127-a2de-9a7aec9e801d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod_d3094f12-fb2a-451c-8cdc-ae4fa89ea714_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, additional purchase commitment period</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Additional Purchase Commitment Period</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Additional Purchase Commitment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod" xlink:to="lab_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_b0335d94-df6f-4683-9974-e075d62dfe40_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f3085f08-6723-4c8e-b629-d7e9a7d90071_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_cd681af1-2114-4bab-a95f-56a2de9b2444_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_7ced0439-372b-4967-a8df-bb2fc712389f_verboseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_235dff17-0e4e-4027-831a-ed10b63cf238_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_ff7a2d8e-97d6-4055-9b1c-7a4766de8c2c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_ec5ab291-2589-4309-b91f-ea52bc2ae52f_terseLabel_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract" xlink:href="ameh-20210930.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalCareCostsAbstract" xlink:to="lab_ameh_MedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_529e17a8-48ca-4019-8a97-6a5fa7d2d124_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_c0ef8e89-7948-4bce-a997-c969ce32d41e_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_0d288eb0-2287-4d74-ba62-de10f26c0387_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_46ce7ad1-37ff-4992-b4fd-9778758e7860_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_cecb2889-de55-4f88-b7f0-e079cc393f43_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_e5642e30-b96c-493c-9f54-24a7becd6aeb_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, January 1, 2021</link:label>
    <link:label id="lab_us-gaap_Goodwill_60a53223-d12b-4c9a-afb4-b52210a49734_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, September 30, 2021</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_a02af5e7-cff1-45d1-9a4e-0d2b9f817a1d_terseLabel_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group</link:label>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_label_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group [Member]</link:label>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_documentation_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember" xlink:href="ameh-20210930.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccessPrimaryCareMedicalGroupMember" xlink:to="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_2b8342d8-d2ad-4baf-b017-7ad9a4d6ade4_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_0672352e-12e6-44ba-aa32-7dfbde3626f2_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_101d6080-46e8-4440-a1f0-68a70bbce319_verboseLabel_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_label_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_documentation_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="ameh-20210930.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_5ff1d4ac-3cf7-4516-9d6b-806fc82a9625_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_5fb773a8-9a7a-4645-bf00-01aa23c7c62a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Carrying Value of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cc85e1d7-3957-4b10-9c32-95bd30515fa9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_acadeed3-f902-4301-87e5-9d7efe09523b_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward" xlink:to="lab_ameh_EquityMethodInvestmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_4c577f99-6606-44fc-9bb4-548c88ccc077_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_69a74aef-1498-49db-abca-17889b1ce42e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7505ebcd-68a6-4663-91cb-ed29f61343c1_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentAdditionalInvestment_bf0b32dd-74b5-46bb-80e7-017efe86dc67_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Investment</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentAdditionalInvestment_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Additional Investment</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentAdditionalInvestment_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Additional Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentAdditionalInvestment" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentAdditionalInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentAdditionalInvestment" xlink:to="lab_ameh_EquityMethodInvestmentAdditionalInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_a6e84d1c-873b-4317-8abb-658fc93e3690_terseLabel_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_label_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_documentation_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:href="ameh-20210930.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:to="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_d5224664-a692-4715-91ca-5315797c13f9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CreditAgreementMember_c02cd641-7ac5-4b76-b3de-0921861f15a5_terseLabel_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_label_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember" xlink:href="ameh-20210930.xsd#ameh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CreditAgreementMember" xlink:to="lab_ameh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_7fe2dba0-c246-4bb1-9823-a62b7e80af19_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_71f5f3bd-2b71-403d-a284-b95dcc3d9acb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_9992e4b1-0d30-4818-9bd4-b8f66b9bc18e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_413e6a39-ff5e-461e-9567-c529899af7c3_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names/trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cbc32101-510a-415b-802b-65919e632eff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d1ec847e-3409-448c-b403-4301b37f7a8c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Apollo Medical Holdings, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a78ab636-a72a-4313-8dfc-9c2f80d203b5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0fc8a259-63a1-4caf-8dd9-379dba4ac2e5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_fb68452a-45c2-4be1-ad13-a269b5d4e8ea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_07e35dc8-e1e7-4a98-9f31-51e2f44f6c3e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_f341ac0e-a7bb-460c-91c7-2f2cdf33b599_negatedLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_909e76b3-22af-4b33-9447-925eda1614d1_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_83ac5915-4eed-4b51-ba21-14c4f58c4c96_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d0363ee7-efe3-4ef9-8c07-a71b52ea0ba3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d7858678-0a9e-4314-b1f0-7392ab57787c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_75020d49-1763-46b9-9299-e35a3035c5db_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_71a2a0b4-08a5-424f-b3f3-a6746b2d205a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_152ede43-0057-4727-9c3b-d630ef631a8a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Commitments of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8acf4eb2-d59e-402a-9c25-357da853aee3_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_409a89cc-0875-4350-b445-2eb260c24981_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercisable (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Exercisable</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:to="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_36bf4fe0-6137-475c-a46d-c5b6818dd593_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f69ceaaa-2dff-43e2-b08f-cc8b469dbb72_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b6492171-3c64-47da-9468-2c72ea5516cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_7daf311f-3bcf-4b3b-91ea-7038191f86a8_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in privately held entities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7009ddbe-7d44-4325-9b04-26de8ff89bac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_47a3d737-37ff-40c1-bb3c-a4c06ef9295e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_727fdbff-8fad-4f36-bf3e-8d0c17aac2a4_terseLabel_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_label_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards And Units [Member]</link:label>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_documentation_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards And Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember" xlink:href="ameh-20210930.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockAwardsAndUnitsMember" xlink:to="lab_ameh_StockAwardsAndUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_f2d33a8a-038b-4c28-93a2-2cd77a49b103_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (excluding the nine months ended September 30, 2021)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_ea4d64ae-984f-4785-a597-ffafe4e92756_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsContribution" xlink:to="lab_ameh_EquityMethodInvestmentsContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dfb403b-416c-4ef9-b300-87726c2c59c7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_715ccc7b-5e56-47b8-8a4f-d79009aeafda_terseLabel_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc</link:label>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_label_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:href="ameh-20210930.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:to="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DmgMember_5d07e5d3-ccfd-4271-b07b-f2d252aa1084_terseLabel_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG</link:label>
    <link:label id="lab_ameh_DmgMember_label_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember" xlink:href="ameh-20210930.xsd#ameh_DmgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DmgMember" xlink:to="lab_ameh_DmgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_3ecdce00-0498-454d-b269-91cfa875eaa5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual agent fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_70bf936b-453a-4e44-99cb-5c7e68d8de7f_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_4df6d1bc-8847-48fc-9198-89460ce3f11c_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_03cf7741-87e9-460a-a6ab-271e40ed1733_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_2e47f280-c1c0-4934-8974-bdaab856f44b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required annual facility fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_2694b9e4-ecef-4a66-a96c-87cdc0938822_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_efb3ae54-688b-48ca-8f67-008b319e07e4_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests acquired (in dollars per share)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireCommonStockAndWarrants_d7f0e29e-846b-488f-91b2-23da460ea231_terseLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire common stock and warrants</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireCommonStockAndWarrants_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Common Stock And Warrants</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireCommonStockAndWarrants_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Common Stock And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:href="ameh-20210930.xsd#ameh_PaymentsToAcquireCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:to="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_32ebb74f-437d-4575-9f07-e7d15f7bb579_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_60f14aa5-6d4c-4a29-a72c-dd31ba277d21_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4535cfe4-9d3c-4f6f-9bb5-c234a793f4ba_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_0a97ea92-8d36-42aa-b756-3ac4044ce64a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_cb783ebb-c28f-4e93-bacf-9667813e4b87_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_918dcb1b-d65f-4a10-98a9-6cfaa4add61a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_bafc629b-0414-4a70-9c34-99ffdb97ccff_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e3065ad7-49da-4744-a19c-e82eabc50d76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_2039a126-eb78-4347-9446-087bdb095a48_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_74453486-05aa-4e2b-960c-3153f73d1d9b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9b9219ee-2ad7-4c93-abe5-c975b874824d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f7b59c1c-40e1-4dee-b45e-3dc12fbdcf1a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2b08a90b-1940-4b2e-81f7-6dd089922079_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_c519700d-3fb0-4a3a-9a3f-ccef7bfb39c4_terseLabel_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:to="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MediPortalLLCMember_a12c071a-ce7b-4933-a73f-a3c613a31c9c_terseLabel_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC</link:label>
    <link:label id="lab_ameh_MediPortalLLCMember_label_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember" xlink:href="ameh-20210930.xsd#ameh_MediPortalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MediPortalLLCMember" xlink:to="lab_ameh_MediPortalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_075b07cb-6120-4d5f-9ff6-a4cbac5af78d_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest purchase obligation, period to purchase</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_label_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Period to Purchase</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Period to Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:href="ameh-20210930.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:to="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_5c868539-33cb-43da-8080-1f225086b140_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_6ee25156-f193-4019-bc43-a0653c210d11_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_61b5d21c-b4b8-422a-bfa7-c3b7b1c2c997_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_845d43ee-7e72-424d-aaac-ba976a314b0c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_50ee41f1-ca06-4fde-8146-4c6cf619aea4_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights forfeited during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d180f0e0-6ee3-49dc-840f-db117b715182_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_85665b83-0107-4b3d-9a1a-a29a2898cfe3_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_d836c4b1-d938-44c8-a3ca-49b65202012e_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights forfeited in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_3a1875bc-2626-4aba-b9e3-165a64089b2c_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, conversion of finance receivable, ownership percentage increase</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:to="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ManagementContractsMember_a867c856-dbd0-43a7-ab62-e25d2191163b_verboseLabel_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management contracts</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_label_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts [Member]</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_documentation_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember" xlink:href="ameh-20210930.xsd#ameh_ManagementContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ManagementContractsMember" xlink:to="lab_ameh_ManagementContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce49c43f-a476-4aca-bdde-6cd95ba37641_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_dc88d5ca-d4f2-44df-a736-471792b6d273_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_e35da8a9-adaa-490b-bfbb-8819f7f8b412_terseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates &#8211; IPA Line of Business</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_abe47f1e-181b-473f-becf-7a455677c37c_verboseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_label_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:href="ameh-20210930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:to="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_264ff0d5-ac7c-4995-ae3c-0c1dde179b43_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_bb0381a5-8941-42fa-b3e0-61c730842cb9_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_99e3f5b9-1176-4002-a5a4-14d13aee41a3_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities &#8211; equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_03589283-006e-4e4b-868a-d04c5f07e996_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsConsolidated_ee2999ec-b06a-4c0f-96fb-c7c35d374f3b_negatedTerseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsConsolidated" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Consolidated</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsConsolidated_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Consolidated</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsConsolidated_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsConsolidated" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentsConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsConsolidated" xlink:to="lab_ameh_EquityMethodInvestmentsConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e4e7fd4f-a42f-497f-b0ac-651c795ac7a7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d4381d4c-2402-4dcd-b981-85a89303695b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_80afde66-a881-452f-94b1-1a9c6b903acb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLossOnDerivative_c8f5f2a3-3443-4aaa-8bf6-895617431c92_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeLossOnDerivative_label_en-US" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Loss on Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLossOnDerivative" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLossOnDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLossOnDerivative" xlink:to="lab_us-gaap_DerivativeLossOnDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HSMSOMember_6a4324cf-8b89-4d40-a29a-5b01043dd701_verboseLabel_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO</link:label>
    <link:label id="lab_ameh_HSMSOMember_label_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO [Member]</link:label>
    <link:label id="lab_ameh_HSMSOMember_documentation_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_HSMSO Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember" xlink:href="ameh-20210930.xsd#ameh_HSMSOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HSMSOMember" xlink:to="lab_ameh_HSMSOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_393121c1-05ad-407a-8dab-5cc3ae2b6243_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregated Revenue by Each Payor Type</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_3c8be9ce-3fdb-44f1-a343-e0251765dd9e_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:href="ameh-20210930.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AurionMember_cae72c37-7671-4c6d-b629-42353e1b6edd_verboseLabel_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion</link:label>
    <link:label id="lab_ameh_AurionMember_label_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion [Member]</link:label>
    <link:label id="lab_ameh_AurionMember_documentation_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_Aurion Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember" xlink:href="ameh-20210930.xsd#ameh_AurionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AurionMember" xlink:to="lab_ameh_AurionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_e65a153d-e36d-4d20-b044-f0e285fe4208_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_fe6d223b-a9b6-4cb9-b41f-415df923e618_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of family practice clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_label_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Family Practice Clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_documentation_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Family Practice Clinics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics" xlink:href="ameh-20210930.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFamilyPracticeClinics" xlink:to="lab_ameh_NumberOfFamilyPracticeClinics" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_b9ff9e2c-145d-4f69-9a1c-360b1cbdc6c0_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_e123d1bc-2398-4ab4-926e-be2a90a3420c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_0a9fe7a5-d480-4e3e-8b4b-02a9f21b5ef4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_c0e98921-c889-46ea-ad67-5f360f7c3e43_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_bdd9830d-1343-4c46-9823-bd26cf246125_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets recorded under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_c1d68fd9-0bd0-4009-b0c3-6f493874a2ba_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_fa80bd23-aaed-42a6-896a-205cddc8d618_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineEquityAbstract_e4267f2e-a8f6-44bd-80a4-688d4cfd944b_verboseLabel_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine equity</link:label>
    <link:label id="lab_ameh_MezzanineEquityAbstract_label_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEZZANINE EQUITY [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract" xlink:href="ameh-20210930.xsd#ameh_MezzanineEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineEquityAbstract" xlink:to="lab_ameh_MezzanineEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_bd921cce-67b3-4864-9e63-02f55e8eb838_terseLabel_en-US" xlink:label="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest capital charge</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_label_en-US" xlink:label="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest. Increase from Capital Charge</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_documentation_en-US" xlink:label="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest. Increase from Capital Charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestIncreaseFromCapitalCharge" xlink:href="ameh-20210930.xsd#ameh_NoncontrollingInterestIncreaseFromCapitalCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NoncontrollingInterestIncreaseFromCapitalCharge" xlink:to="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_5cf7f95c-6358-4f5c-9357-254ba2265ab4_terseLabel_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_label_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Accounts Payable Current</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_documentation_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:href="ameh-20210930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:to="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateLoanMember_e94a3f9d-43e4-4a32-ae6f-6ce7f88fe79b_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Loan</link:label>
    <link:label id="lab_us-gaap_RealEstateLoanMember_label_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateLoanMember" xlink:to="lab_us-gaap_RealEstateLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_95e0a0e5-dee0-48c4-a4fd-c843e6f40fe0_terseLabel_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc</link:label>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_label_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember" xlink:href="ameh-20210930.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MaverickMedicalGroupIncMember" xlink:to="lab_ameh_MaverickMedicalGroupIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_59a5769b-bfd1-4cf4-85bc-eebf1f055d76_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, mezzanine equity, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_01f9750e-5553-43d4-94c0-7aa246233c42_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, mezzanine equity, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_51684a0c-ab77-435c-b33b-80f6c479e7b2_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum consolidated interest coverage ratio (not less than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_e2ddfc44-6d4e-4457-b8b5-ae15bd2f1c2b_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorCMember_8ac88783-e276-4fb2-a210-10854cc0832d_terseLabel_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C</link:label>
    <link:label id="lab_ameh_PayorCMember_label_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:label id="lab_ameh_PayorCMember_documentation_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember" xlink:href="ameh-20210930.xsd#ameh_PayorCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorCMember" xlink:to="lab_ameh_PayorCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_49d41311-7601-48fd-9503-11608def560f_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ce17b01d-eff9-4e89-92bb-8ac74654062e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueLineItems_051711c9-18cd-4167-8075-a61cffdea1a8_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueLineItems_label_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:href="ameh-20210930.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_eeb1d013-7fa0-4d05-9575-8627f3f89e5e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_dbf752d6-93e8-4563-9232-c25c4769161c_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcStockOptionMember_7f920059-61b8-4b1f-a057-e5572f776455_terseLabel_en-US" xlink:label="lab_ameh_ApcStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Stock Option</link:label>
    <link:label id="lab_ameh_ApcStockOptionMember_label_en-US" xlink:label="lab_ameh_ApcStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember" xlink:href="ameh-20210930.xsd#ameh_ApcStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcStockOptionMember" xlink:to="lab_ameh_ApcStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_fa51c5cd-915d-4868-b57f-e0ca50ed865c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_1c13ab27-f26d-4fc1-b523-1ef66c7da02c_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_ae176dfb-93e0-4d8a-bc9c-9c75781b6195_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b21f05c7-9b47-460b-a008-d8b8389eca74_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_38421072-d0f2-4b85-ac8d-ede027054d40_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest_3ab2c1fa-5740-46ff-8e79-759aaa59c1e0_terseLabel_en-US" xlink:label="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of noncontrolling interest</link:label>
    <link:label id="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest_label_en-US" xlink:label="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Noncontrolling Interest</link:label>
    <link:label id="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:href="ameh-20210930.xsd#ameh_ProceedsFromSaleOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:to="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_7d1dce38-8a78-4da4-a94c-a4b3676653ee_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f33f3ef1-5513-4755-9a5e-2c851eef9897_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_c0d3e6a3-607a-4efe-899b-94c3c4382a3d_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AHMCMember_e58fbfd5-a68e-4a8f-b0cb-89bb395ef2fb_terseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_459134ad-afd5-4c0c-8f8c-582fb417aeaf_verboseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_label_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember" xlink:href="ameh-20210930.xsd#ameh_AHMCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AHMCMember" xlink:to="lab_ameh_AHMCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0d3580b1-6c1e-461a-877d-e5d470b1673a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_c654be0c-adb9-4ff9-b0c9-d2fe1f1a1124_totalLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_41aa825e-2593-4298-9b1b-4a84e0e68bbf_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_9d1e57f8-954c-4179-9732-106f4aab6cf0_verboseLabel_en-US" xlink:label="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities:</link:label>
    <link:label id="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_label_en-US" xlink:label="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="ameh-20210930.xsd#ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2de08da3-fb4e-47c8-9c9a-0125b937895e_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b482de79-07db-4efa-a80a-15437d78e786_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_23ebf0f0-8662-4085-bde7-9d1644e3f0a2_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_label_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable" xlink:href="ameh-20210930.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableTermOfReceivable" xlink:to="lab_ameh_FinanceReceivableTermOfReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_49bab145-945c-4843-8040-5c6b2a705ae2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FreseniusMember_1c563695-f04d-4f53-a496-4c51669f1f27_terseLabel_en-US" xlink:label="lab_ameh_FreseniusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius</link:label>
    <link:label id="lab_ameh_FreseniusMember_label_en-US" xlink:label="lab_ameh_FreseniusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius [Member]</link:label>
    <link:label id="lab_ameh_FreseniusMember_documentation_en-US" xlink:label="lab_ameh_FreseniusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FreseniusMember" xlink:href="ameh-20210930.xsd#ameh_FreseniusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FreseniusMember" xlink:to="lab_ameh_FreseniusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_668b84da-e59e-4cfd-9615-c271db2591ca_terseLabel_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_label_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC - Related Party [Member]</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_documentation_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC - Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" xlink:href="ameh-20210930.xsd#ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" xlink:to="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_5493f6a1-fdfc-4107-bc44-ba02337bc04b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_c42e4b33-6e97-4718-b94d-bd15f2b2a9a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscriptions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7f321f77-dc93-43c2-899c-e568d7d186e6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for business acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_54b329ec-7448-47cb-be93-a9f54e518512_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Bank Loans and Lines of Credit</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_afdca3fd-09c3-4f22-acea-719c8159eac4_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for cashless exercise of warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Cashless Warrants Exercised</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Cashless Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:to="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_c0f4faec-f3b6-493f-8109-5852287aec50_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a11cdf6a-64f1-4ee3-a3f3-66e893ae9309_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_94f08ffa-35fd-4ca5-925e-e9751ece259c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_433ae9e9-df82-490e-8842-05383db73a30_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_9412f910-a280-4b63-a92a-c2cbd64c972c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_47352362-f7aa-4a2f-8288-df1af1abd7e1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares purchased by related party</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_b5492242-1197-4172-86a4-1d5c8487bf89_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_d4ab9198-48e0-43fa-b301-fd08cb659da5_terseLabel_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc.</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_label_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_documentation_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:href="ameh-20210930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:to="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_37ee7484-43be-4076-9768-a4e7b76a1a10_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_3fdb8770-28e6-4269-b3ad-2df380826aed_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_fdd363ec-17d9-4f21-bd8a-d1e0e0647ab0_terseLabel_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP</link:label>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_label_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP [Member]</link:label>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_documentation_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember" xlink:href="ameh-20210930.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CollegeStreetInvestmentLpMember" xlink:to="lab_ameh_CollegeStreetInvestmentLpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4de3576d-2768-468a-ae24-ca1db9e3eeb8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_53dc8faa-32c9-4a1a-8f6a-61ccd1ff8d2a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_8e55cd41-9c3a-40ce-9cf8-1413a217b954_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fbecad8b-3d5b-47cd-84ea-1b5a9c533d11_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d0282586-16d2-4db6-b710-f585f2e1c92e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_bd67946b-3447-439f-948b-8ef4feb3e7c7_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Par Value Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_cf9f0bdc-e596-4e25-8622-7c5e622a12a7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_f527860a-07a8-498b-8765-2d836b7f6a08_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_ab619272-03a4-4cd5-a3d7-92f7575481e2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash - current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_34c0ff74-4f2b-4219-9771-70bc58df03ef_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related investment balance</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOLLCMember_8dcf28c4-98ff-47b1-a257-07ca7ad41c48_terseLabel_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_OneMSOLLCMember_label_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC [Member]</link:label>
    <link:label id="lab_ameh_OneMSOLLCMember_documentation_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember" xlink:href="ameh-20210930.xsd#ameh_OneMSOLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOLLCMember" xlink:to="lab_ameh_OneMSOLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_5225e861-6363-40ea-99c3-42217a79c383_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_cc5e8815-3abd-43dc-ab67-4c6ba65dd22b_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests purchased (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_6cac4337-3bef-48ee-aa3c-28ac2b6bbc31_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_938b6443-5dc0-48bc-bac7-248f4ed41f0c_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents increase in operating lease assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:href="ameh-20210930.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:to="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_bd26059e-942a-434e-b44c-baeccfaee91c_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b6e23674-63b7-4d1a-9233-4e4817c10593_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_b0e8799c-c339-4b50-99ea-ef9c3ac3caac_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_b88040bd-5098-4976-97b3-30d1a67bb9f7_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c6558be1-d734-4207-a7c4-c82c7cdf675e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_b0e303a7-2df2-4bdf-8c85-f2dc98fc0e37_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, fair value</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Fair Value</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_dd425bfd-9255-487c-8486-c74375283e27_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_a34a3d3f-97fd-4a09-8b90-3fdd6b875fbf_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_35727f07-78f9-4c16-bfe1-9a7172f17d91_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ea70b250-5383-49aa-aa35-e9038efd212e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LoanReceivableTextBlock_c8fc8156-8e73-4173-94fd-f55a3435347b_verboseLabel_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable and Loan Receivable &#8211; Related Parties</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_label_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable [Text Block]</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_documentation_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock" xlink:href="ameh-20210930.xsd#ameh_LoanReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LoanReceivableTextBlock" xlink:to="lab_ameh_LoanReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9db0d004-2ac4-45e4-b10a-3d79b977b90d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_6f72b1be-044d-4c3a-90fa-fdfd4bd50867_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_58a1635a-39bd-4bfb-9bf7-a7bf0215dd49_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related party</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumenLLCMember_f67d5e90-3342-41ca-9870-6e5c6ec39fc0_terseLabel_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC</link:label>
    <link:label id="lab_ameh_NumenLLCMember_label_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember" xlink:href="ameh-20210930.xsd#ameh_NumenLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumenLLCMember" xlink:to="lab_ameh_NumenLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LongTermDebtMaturityAfterYearFour_8812e30e-84a9-463a-b0c2-3fb467c24a0c_terseLabel_en-US" xlink:label="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ameh_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:label id="lab_ameh_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LongTermDebtMaturityAfterYearFour" xlink:href="ameh-20210930.xsd#ameh_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LongTermDebtMaturityAfterYearFour" xlink:to="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ac48df79-fa3d-4b13-8d13-7d379319bff0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_420339bb-0e32-4a01-b9bd-c8c6614f2ccc_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:href="ameh-20210930.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:to="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_dfba2f5c-d295-4dee-919b-f817652f4280_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SCHCMember_6ba6c54a-e2fe-4081-b696-4456783d9a6e_terseLabel_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC</link:label>
    <link:label id="lab_ameh_SCHCMember_label_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:label id="lab_ameh_SCHCMember_documentation_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember" xlink:href="ameh-20210930.xsd#ameh_SCHCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SCHCMember" xlink:to="lab_ameh_SCHCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_dd6b5967-5239-42e8-b8a5-df7afcc0333c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LmaMember_b1d4a0fd-9747-4e4a-9f66-cb898faea8c8_terseLabel_en-US" xlink:label="lab_ameh_LmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LMA</link:label>
    <link:label id="lab_ameh_LmaMember_label_en-US" xlink:label="lab_ameh_LmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember" xlink:href="ameh-20210930.xsd#ameh_LmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LmaMember" xlink:to="lab_ameh_LmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent_52fec741-233d-475d-934c-aed10a63cff0_terseLabel_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to affiliate</link:label>
    <link:label id="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6eb50733-f2a8-45a0-9754-7ef9b078e1d6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock&#160;Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_5f954c0a-b0d1-4b4f-92ac-31d5c97798de_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c0de5535-3534-4961-a1c0-a415f165e3c9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_5c5ef9ef-9dbc-4f79-8150-79efbda4214a_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable &#8211; related party</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_1d3aed4d-830d-4272-a9d4-fa065f16c799_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ccee54fd-1411-49f5-a0d3-2246fa20c648_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f8ab3be1-8464-4f95-80d1-bd01377c97e9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_ac93febe-28cd-415d-809a-6a1298b93b9b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_a840c7bf-2fec-4902-a8b8-6dffd47b4485_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_658474d7-0c27-4baa-80ba-04368da78242_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_abc20b1d-2db4-4aec-a386-859e9fb42e85_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_48ca9d3a-25d1-4bef-8b2b-f5c6932241b4_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicareMember_09f3169a-f23e-437a-85d2-c3c755fe0dbe_terseLabel_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ameh_MedicareMember_label_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_ameh_MedicareMember_documentation_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicareMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember" xlink:href="ameh-20210930.xsd#ameh_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicareMember" xlink:to="lab_ameh_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_fc10aaa2-84a0-43a4-a246-dec39a207ba4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_6b8fdd78-d63c-4ea1-b504-ff620137b49e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of beneficial interest</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CMSMember_de4fe236-b235-4609-bf0e-b947e525171a_terseLabel_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS</link:label>
    <link:label id="lab_ameh_CMSMember_label_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:label id="lab_ameh_CMSMember_documentation_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember" xlink:href="ameh-20210930.xsd#ameh_CMSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CMSMember" xlink:to="lab_ameh_CMSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a8e2fee5-35f7-4302-963a-b8e378397e4f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_f6581020-0962-450b-b53f-7885787d3144_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_66330ba7-6d74-4d62-8e76-3541946cc6f4_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_7ad7f892-50db-453c-8f55-2495f92bbe8a_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_f34596e7-a5ab-4763-9ca5-e931ce4517c4_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received, monthly</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_label_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Monthly Amount</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Monthly Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount" xlink:href="ameh-20210930.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenueMonthlyAmount" xlink:to="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f15b8f50-09a8-492b-b5b0-76daf681850f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5996fa6e-ea76-4b9b-840f-ea94a2b81198_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_83b22215-6f8f-4c99-b95e-80dee9f0c594_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_e7b28c3c-d8d2-4758-9430-1c4ff72df0e8_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_78bec414-eee2-4769-a951-8b89bda8b65c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AchievaMedInc.Member_25da299e-6439-461e-a578-4f7635b20b0a_terseLabel_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc.</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_label_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_documentation_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member" xlink:href="ameh-20210930.xsd#ameh_AchievaMedInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AchievaMedInc.Member" xlink:to="lab_ameh_AchievaMedInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5f3a8b14-d096-4e2e-9036-74d10dc5adbf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_61838f4c-f8d3-487c-9878-a2800ecef611_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_c2fd1742-b3c9-4ea2-b32c-42d49e57bce8_terseLabel_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term Years [Abstract]</link:label>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_label_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term Years [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:href="ameh-20210930.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:to="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_c8e8b3f2-f679-4e42-9d30-5a863aeb934d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_ce3bd731-4a6f-4394-911c-caf00570714a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_dc5340a8-4bd5-4b97-a0e2-11cdf4d7737c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_274ad813-4785-41f6-9d02-ea1a6faa38d1_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, interest rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_label_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:href="ameh-20210930.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:to="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_93cd9428-3e1b-4364-97a1-e71024ac7299_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_05618a68-d6cd-4c15-b47b-858a55b6c787_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_77635162-da0b-4012-a29f-e41ec18518d1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableMember_49308313-18ad-43f9-b5af-9ed3bf90be78_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Secured Promissory Note</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_label_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_34f8d418-dc65-4443-bb04-dcbe87a7302d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a14b1303-b752-41d9-acde-a9479617272c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorDMember_20d671d3-989b-454a-8444-888eda949ff1_terseLabel_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D</link:label>
    <link:label id="lab_ameh_PayorDMember_label_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember" xlink:href="ameh-20210930.xsd#ameh_PayorDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorDMember" xlink:to="lab_ameh_PayorDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_090bfa06-f55d-4007-b17a-dcb368b9527c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_f41a9c30-7a2d-4311-bb50-84ae3719b7b3_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_d83709b7-0ea5-463c-8b43-620f49672a33_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC</link:label>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_label_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:href="ameh-20210930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:to="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4ac98c99-c67f-4942-aa65-2f03c5d953f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_6e27fbb6-62e4-483e-a9c8-b1a06d801df5_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number federally qualified health plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_label_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_documentation_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:href="ameh-20210930.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:to="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d467d4d3-9e01-4454-8a14-84861ee968f3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_69271704-d958-4f4b-8695-00e6f61a0789_verboseLabel_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_5a5a0c7d-c5e0-4257-87e3-bfa24f238e32_terseLabel_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:href="ameh-20210930.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fb813ef8-5867-4e6c-9b77-ce9f2d8acaef_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived assets:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_32ee7f05-7c79-4f7e-a68b-16950d1c33d1_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:href="ameh-20210930.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:to="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_cc5c8716-1db3-4ecc-9c39-981bf9b61f15_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_aa600e1e-9f2e-4a9a-ad6e-b5f8fc7ea9d4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_458a8eee-bd1c-4a17-ae1a-f144821fae8f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7ecbdd93-6f3a-4eb8-938d-252cc6690ef2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ddc349d6-2c1e-400b-a84a-a006aac00f96_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94902cfa-2778-4d73-970f-10aca30d5e0f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_47225aa9-2323-4df5-acb5-6e5cfddec652_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a9d267ec-2d4f-4dae-b2a1-f0b0cb9cb62a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_1ecd88c2-b3bc-49e9-844a-435676aeb9f3_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issues as a result of warrants exercised</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2c6fd79f-4910-4a0c-b4d1-dfbaefb7f3b9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86fa3b12-3391-4239-b4ef-bc19325d284c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_309b0f8c-3102-44d8-a56f-6c82edb2c08a_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for cashless exercise of warrants (shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Cashless Warrants Exercised</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Cashless Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_dbd72b0b-b989-4c5f-884c-1ab5bc342f73_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_2e7d292b-61c1-4a3a-9574-b1128ce18248_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2fe71290-377b-4430-a733-bb4ba1fdd7fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_62b518a2-5fc1-4797-a7e6-ecd5019a2904_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_76b8ebc6-8a39-46cc-b3a3-1d8a18c10987_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_25abc371-6e27-4df8-b34a-6033987a9b16_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_65b23e1d-044f-4fd1-9f0d-dc40a6732434_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_427e32f4-953a-451c-8a59-85f896f4c7a6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fees Incurred and Revenue Earned from Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_38fbdbb4-86aa-4dae-b97b-6ef0ab7c55f7_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_d6177780-251e-4749-9efd-19be859706ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_b4db1019-bbc1-4dd9-b1ab-ef16a16c0c7a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_e2711c07-1616-46fe-8c23-87e2406d2c39_verboseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:href="ameh-20210930.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:to="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_644e1218-285f-490f-9d2b-abde7acb5ed6_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromOtherOperatingActivities_ed930062-d262-4ab6-b239-2c4e269d9f01_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromOtherOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Other Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_4db0a6d1-015e-4823-96d8-ff2fb8acefb5_terseLabel_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:href="ameh-20210930.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EarningsPerShareLineItems_66866fb4-6088-477c-a74b-4c06b45cb001_terseLabel_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_ameh_EarningsPerShareLineItems_label_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_ameh_EarningsPerShareLineItems_documentation_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems" xlink:href="ameh-20210930.xsd#ameh_EarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EarningsPerShareLineItems" xlink:to="lab_ameh_EarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_3c7fbf6c-4c2f-48b3-8653-f8ca026029b1_terseLabel_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, percentage of shares acquired</link:label>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_label_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Percentage Of Shares Acquired</link:label>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_documentation_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Percentage Of Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:href="ameh-20210930.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:to="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_acbbbd1c-2d95-4b25-81cd-50af7f88f276_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_e2e919a8-368d-4ff4-8416-9682a9fd8e25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b2d09ff6-cca2-49d0-9a39-2662c19a2a6f_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ameh-20210930.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6f058e59-26f4-4038-8e53-0d351e3f6af1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_a83b7efc-9979-48c8-a378-082598e6e553_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_152c7aab-d7e4-4c78-9f48-fde3b88ec59a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities &#8211; certificates of deposit</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_2c635d4b-677c-4f3b-b09b-58be3ebd0666_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_c5c72fe0-d891-416d-8c71-908595385595_terseLabel_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due to affiliate</link:label>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_label_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_98ca9a23-2518-4ecf-86a0-a3c5b710864a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromAffiliateCurrent_97bcb316-6aa0-41c4-8a74-3d185e6dfa80_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due from affiliate</link:label>
    <link:label id="lab_us-gaap_DueFromAffiliateCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromAffiliateCurrent" xlink:to="lab_us-gaap_DueFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_44f04327-c946-423a-a882-5047241f4bcc_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_4990a448-7047-4284-af0f-62f12024b243_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, cash held in escrow</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Cash</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_09f1c927-f573-4b6c-accb-f31a9524913e_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill_99343f29-1943-4433-8e08-ebea0a712a07_terseLabel_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability adjustment to goodwill</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill_label_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Adjusted To Goodwill</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill_documentation_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Adjusted To Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" xlink:href="ameh-20210930.xsd#ameh_DeferredTaxLiabilitiesAdjustedToGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" xlink:to="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c4370e69-39e4-4a6e-bde0-561d76aaa2cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ce082c2c-7282-4ec2-9612-4b0c41003aff_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b0ccbd4-8bbf-4e10-826f-170a0b5ce1d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_75bce41e-14c7-4c2d-a0aa-875d407e6e15_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1cb48a06-a444-45b4-a7e5-e8ff457d53e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_80eed94f-3d19-4169-beda-5b31bbfb7051_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_f78f85f7-63d3-4130-a425-e88f9c52db0d_verboseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:href="ameh-20210930.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_fef07f0c-c2df-406e-a23e-296247ef934e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c2f31f2c-b3fe-4d04-89cf-092d06c97e80_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_20aee76a-b2e5-4bde-bf8c-62c134ae790b_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_216c7084-e82d-4358-b728-aaf3c93c4616_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board members</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_99e82325-b705-4a82-9dd0-f9ffb0f98964_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_edfce480-b23c-48fd-a277-3d6ef521ef7d_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorBMember_83ae9e3a-dd03-4a27-af6a-9cfb38d003d0_terseLabel_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B</link:label>
    <link:label id="lab_ameh_PayorBMember_label_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:label id="lab_ameh_PayorBMember_documentation_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember" xlink:href="ameh-20210930.xsd#ameh_PayorBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorBMember" xlink:to="lab_ameh_PayorBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_6723c764-659f-47da-8b3a-1b872d818c10_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_60bcefec-0e66-4215-8178-d7cdb443ba4f_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period value of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents value of stock issued during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_6244a27c-b383-4a29-b33c-e2b4b9d06e48_negatedLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Exercised</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised" xlink:href="ameh-20210930.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsExercised" xlink:to="lab_ameh_NumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_6c9e58ac-10d2-443e-a257-3993325cd58d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_972f9eda-ef4f-4d68-930a-b155df8026d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6939ff16-4c43-4c97-9ca9-4436aaea79e8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_d6535f1f-2e53-4ce7-8ed2-1cf67d68f798_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b9b4e18-446f-4bfd-9a87-b4f7c6e1d099_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_17b07f48-2a0d-4878-b23c-bf575dfbef5c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f82959f6-bb4f-49be-b9f8-590407c1be52_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_3dbd85ee-aa22-444f-a1b6-4290e0d62501_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_4b92ea6c-c43a-49bd-b052-3cc24020adb4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_ae14bdb2-f664-43b1-9bfd-22d14ca4aed7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_931b7f4b-b2a5-4955-81bf-4ce863906bed_verboseLabel_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_label_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Capitation Payable Current</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_documentation_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of specialty capitation payable current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:href="ameh-20210930.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:to="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5cdda673-0a1a-433b-ad71-06904a13a7a7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cd497719-1d5b-4562-ad1b-398f9a675c5b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2d1321e1-8365-4be6-9417-cb4190339def_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to weighted average shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_b50827fe-2874-4268-a1cc-75dbdc8c2078_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_86e1dab1-5032-4251-bdab-265c47b53d26_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_1f09eda9-b7bb-4a41-80f2-33769bfe9ca5_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_2eba2c6d-ecd0-4db7-bdc0-121023e99acf_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_84671a1f-33f9-476e-8546-aed78610460d_terseLabel_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition</link:label>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_label_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition [Member]</link:label>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_documentation_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:href="ameh-20210930.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:to="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_951830e3-3065-400e-b360-d18bf5c7b581_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a90feae7-aee8-45df-8518-e7e5c04fea59_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_dfc7e116-6864-444a-a66b-284268004d31_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_a61253f4-6fa2-450c-a920-91729ecefd5e_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights granted in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_7f077c0d-5f7c-40a1-8424-5b4ebd4fb267_verboseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">531 W. College, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_09a59c10-ed77-4f82-9376-beabbebe53d9_terseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">531 W. College LLC</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_label_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Three One W. College LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:href="ameh-20210930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:to="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_f4329e04-6069-418c-8d3f-d694e0417639_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_84a1cbcf-5aa0-4073-8c12-0caa4e2a8efb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_d663ea4c-4f8c-47d1-ba1b-c56c7b18dcd9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7cb90d97-f9d9-4bc0-a3b0-3308c30982f6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_67c999fb-f553-4e89-a837-7b7c548cef33_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_59f78c68-069d-49d0-93d7-0927ff51fd0e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_5bfcc24c-4e41-4440-8322-24edc8766030_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b55fc5fa-0c33-4208-8bec-79ef71515a9d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold_9e6508c2-7dbc-4f80-9014-e5edee0586eb_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage sold</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage, Sold</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage, Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentOwnershipPercentageSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:to="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_5d8a5e50-5797-41a4-889c-479b9e086e7d_terseLabel_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC and APC-LSMA</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_label_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_documentation_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember" xlink:href="ameh-20210930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APCAndAPCLSMAMember" xlink:to="lab_ameh_APCAndAPCLSMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_50ec62ab-90f9-429e-9ef5-14bea9dc9408_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities, Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_51381c61-ac56-4aab-8e20-fcae479f2f42_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (excluding the nine months ended September 30, 2021)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_d27158e7-eced-43c7-8e68-0a998dab5aa0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6e279eb5-d11e-45e6-acfe-f92098b4a0bb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40114216-ee16-43d0-b004-3037b5520626_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_82c41288-13c7-4f0d-aff2-51a612616820_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_e32ac855-021e-4b32-b9f5-8c0aa3b94c6c_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_ffcbf24e-2682-4862-b383-228ae4db1f92_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of additional proceeds</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Write-off of Additional Proceeds</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Write-off of Additional Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" xlink:to="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_e61dce27-7997-40b4-a3d3-464aaf176bc1_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost, net</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRealEstate_bde8b9f2-b558-41b4-bbf8-21722f149168_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of real estate</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRealEstate_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRealEstate" xlink:to="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5722c1c4-2afc-4541-a687-5827f6ba1279_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_40914c3f-b65e-483c-bd5c-3e3a24b2d832_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_ace6a2c6-f0c1-4762-971a-67bef83b1e8e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_4b480309-f058-49d4-938e-3cde57cf2716_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_c64960e8-ca16-497e-b333-c39584ebd15d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_e0b85828-9501-49b4-9bff-663f6dd22313_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7b7706fb-a1a2-4423-bc03-fbb335969c75_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_9894bcdb-56f4-400c-8498-9654e38efebd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_9b5ac20e-af49-49df-9957-217de828b56a_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_54d2fbe7-4372-4ac1-9f34-e85763110c14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_441e5d39-0c4e-4004-b547-2a795515be39_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise&#160;Price&#160;Per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PatientManagementPlatformMember_79f5a057-5c2e-45d4-a6f5-90004a75fdff_terseLabel_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient management platform</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_label_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform [Member]</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_documentation_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember" xlink:href="ameh-20210930.xsd#ameh_PatientManagementPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PatientManagementPlatformMember" xlink:to="lab_ameh_PatientManagementPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_5ad4c37d-ff1e-4ee3-b30d-fb949fe61501_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorFMember_9aab79a0-b6bf-4001-8c08-04ac1919881d_terseLabel_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F</link:label>
    <link:label id="lab_ameh_PayorFMember_label_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:label id="lab_ameh_PayorFMember_documentation_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember" xlink:href="ameh-20210930.xsd#ameh_PayorFMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorFMember" xlink:to="lab_ameh_PayorFMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_5c38326f-ef0e-4fd5-a9c0-f8d06a2503c7_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BeneficialInterestPolicyTextBlock_8810a64e-d023-47ac-bbfa-f5fb298e0d72_terseLabel_en-US" xlink:label="lab_ameh_BeneficialInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Interest</link:label>
    <link:label id="lab_ameh_BeneficialInterestPolicyTextBlock_label_en-US" xlink:label="lab_ameh_BeneficialInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Interest [Policy Text Block]</link:label>
    <link:label id="lab_ameh_BeneficialInterestPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_BeneficialInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BeneficialInterestPolicyTextBlock" xlink:href="ameh-20210930.xsd#ameh_BeneficialInterestPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BeneficialInterestPolicyTextBlock" xlink:to="lab_ameh_BeneficialInterestPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_26b30924-498a-4a97-a603-428848cfc837_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_08eaca99-5d74-4542-bbc7-e1b914912b48_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_58e275ca-0cf2-4195-aaba-d9c9bde61e4d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_37b7a28c-5ba1-4314-ae06-68f26a56880c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_64531484-b55c-4dbf-a956-0760cc45e06a_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:to="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_0a7dc6f1-e48e-4373-acb2-109d247c4f6f_terseLabel_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period of payment upon termination of agreement</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_label_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_documentation_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:href="ameh-20210930.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:to="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineMember_50d47c87-cf67-4964-9e9d-98afe788e353_terseLabel_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine</link:label>
    <link:label id="lab_ameh_MezzanineMember_label_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember" xlink:href="ameh-20210930.xsd#ameh_MezzanineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineMember" xlink:to="lab_ameh_MezzanineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_b1ef22b3-ddb7-47a7-b458-6530eb096b15_terseLabel_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement</link:label>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_label_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember" xlink:href="ameh-20210930.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcBusinessLoanAgreementMember" xlink:to="lab_ameh_ApcBusinessLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_f3dfc953-c398-4771-993a-ef136ba5a0db_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_fad8d446-9fe3-4568-980a-99f4ed03da08_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_9a7587a9-5ee1-4256-868c-729124a5751b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorGMember_5c6e206e-fe0f-4c84-bc21-4a719194a5cf_terseLabel_en-US" xlink:label="lab_ameh_PayorGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G</link:label>
    <link:label id="lab_ameh_PayorGMember_label_en-US" xlink:label="lab_ameh_PayorGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G [Member]</link:label>
    <link:label id="lab_ameh_PayorGMember_documentation_en-US" xlink:label="lab_ameh_PayorGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorGMember" xlink:href="ameh-20210930.xsd#ameh_PayorGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorGMember" xlink:to="lab_ameh_PayorGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_f0a7cf39-5477-4c56-9646-fdcb0dec0253_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClinigenceHoldingsIncMember_d9bbd5f4-8c31-41ac-b408-0f486c9da40d_terseLabel_en-US" xlink:label="lab_ameh_ClinigenceHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigence Holdings, Inc.</link:label>
    <link:label id="lab_ameh_ClinigenceHoldingsIncMember_label_en-US" xlink:label="lab_ameh_ClinigenceHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigence Holdings, Inc. [Member]</link:label>
    <link:label id="lab_ameh_ClinigenceHoldingsIncMember_documentation_en-US" xlink:label="lab_ameh_ClinigenceHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigence Holdings, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClinigenceHoldingsIncMember" xlink:href="ameh-20210930.xsd#ameh_ClinigenceHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClinigenceHoldingsIncMember" xlink:to="lab_ameh_ClinigenceHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_354b387b-43bc-4e4c-aa41-2c5e3e6e1840_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0626b42a-9ded-498e-954c-b4713c8311c1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5782c45e-39e0-4381-bfb9-d180435a5621_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_bf83252d-662e-40f8-b565-39a9fbff7187_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_efb9876e-9205-46aa-8c2b-c18c4eceec7b_negatedLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:href="ameh-20210930.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4d74fac8-813d-45fe-89ef-37f0f76885e0_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TermLoanAMember_f02bf469-f353-4f1b-a4b6-d3b0c9d08796_terseLabel_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_ameh_TermLoanAMember_label_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:label id="lab_ameh_TermLoanAMember_documentation_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember" xlink:href="ameh-20210930.xsd#ameh_TermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TermLoanAMember" xlink:to="lab_ameh_TermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_f38c958d-7492-41c9-b6b6-6142652ef3e9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized intangible assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_ef9a9efd-6c15-4d74-87ed-10cd3da00fca_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_aad6eb5e-99c4-49ce-b395-562e01ec1486_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_853c82fe-9fd1-4453-a355-0f3a198c9358_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_6d28243d-6ab5-4ece-81c2-1b687bd94ee9_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e0a2c87e-4268-4b65-a3da-ad0c61a03821_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_e05b860c-357a-4513-8d9c-ffbfcca94913_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:href="ameh-20210930.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:to="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_780a4be1-1ec6-4141-b777-c16fd1970322_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a973784d-129e-4230-b8f0-ef57b10e8b90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage_96acd8c2-cc21-441f-8586-dad54bc2b583_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proxy votes</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Proxy Votes, Percentage</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Proxy Votes, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodProxyVotesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:to="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcLsmaMember_9c411979-a343-4ea6-9c6c-1545c4b7dd19_terseLabel_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA</link:label>
    <link:label id="lab_ameh_ApcLsmaMember_label_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember" xlink:href="ameh-20210930.xsd#ameh_ApcLsmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcLsmaMember" xlink:to="lab_ameh_ApcLsmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_b25ee6e0-1267-48d2-9eff-f4df1e10cfd8_terseLabel_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:href="ameh-20210930.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_bd416136-c011-437b-8bd0-4f7688d6e1ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_71e1d995-18ba-4975-b759-bac883b674e2_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants available to purchase, contingent upon the portal completion date (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6c1b7c66-f3e5-4864-802d-e8106cf772d4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_60ca3435-e971-476b-b29d-b100e674e0ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_4c6168eb-8c59-4d7d-8f43-d97d381a9f5e_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase additional membership interests (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_14390482-b825-40b7-ab29-b123b57e1155_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_a3eec539-85b4-4f75-99a8-27c5810c107a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_839c9162-9392-4344-b7ef-d641301117c3_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_b4850e59-1bc7-4de7-89d3-ecb1f4074aa9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investment &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_6f17ef4b-68e5-4aa5-bb45-53766f08a9d5_terseLabel_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable</link:label>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_label_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable [Policy Text Block]</link:label>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:href="ameh-20210930.xsd#ameh_FiduciaryCashAndPayablePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:to="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4486752-a16d-44f4-8ef5-7cef7e53227b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_934edb51-f2a5-42f3-acfc-e68b8d9038a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of business combinations:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_d400e673-99a1-4259-8bf3-d8b3025ba54e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_25f7f352-d60f-4a7f-8af5-e104aa14f393_verboseLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted" xlink:href="ameh-20210930.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsGranted" xlink:to="lab_ameh_NumberOfWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConstructionLoanMember_5b7b819a-8bc3-4cbe-87dc-975c00ad7dd5_terseLabel_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan</link:label>
    <link:label id="lab_ameh_ConstructionLoanMember_label_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan [Member]</link:label>
    <link:label id="lab_ameh_ConstructionLoanMember_documentation_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember" xlink:href="ameh-20210930.xsd#ameh_ConstructionLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConstructionLoanMember" xlink:to="lab_ameh_ConstructionLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_7bf008cc-a50b-4f77-af82-9ee195aeb12f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_55b7fa31-87fc-4f99-8b53-e541955d320f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_04c219df-f308-4b80-892e-b34c5df0f0fd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum loan availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_19c7d7ba-e9ba-4312-9674-02b40dfccd4d_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_ff54f9eb-6d17-49a3-9d8b-107214052b7f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f8a84959-0f76-4107-901d-4473f0ee16ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_8158a58d-d0d6-42bd-b69d-b39221eff222_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Fair Values of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_1edef9ce-d19d-456b-9280-32b96d75843d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_75e00e33-6cdc-463e-8569-c64f7c0d6fbd_terseLabel_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ameh-20210930.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_17e2e12c-cf7a-4572-9e09-97e4f63ba139_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term, finance</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_603764dd-d4aa-4f7e-8c44-30086411ae47_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment amount</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_803376ef-712c-4ed5-976f-b652e1130ccd_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MembersCapital_c11e1955-3668-449f-be81-b78d8aa438d3_terseLabel_en-US" xlink:label="lab_us-gaap_MembersCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial capital contributions</link:label>
    <link:label id="lab_us-gaap_MembersCapital_label_en-US" xlink:label="lab_us-gaap_MembersCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Members' Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MembersCapital" xlink:to="lab_us-gaap_MembersCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_f2cff95e-7431-4c23-a0d9-0fab891d4d8c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_ffc2c06a-b47f-4bdb-82c3-bf406462eeea_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_81034d64-8deb-40d3-9586-9e57b519d23c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised_0654267f-4ff1-49cf-a746-578280a2b5e3_terseLabel_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability adjustment related to warrant exercises</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised_label_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Warrants Exercised</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilitiesWarrantsExercised" xlink:href="ameh-20210930.xsd#ameh_DeferredTaxLiabilitiesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DeferredTaxLiabilitiesWarrantsExercised" xlink:to="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_c3952d70-1fb1-4147-ad7e-1a859b407082_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio (not greater than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_91cd277b-7285-47f6-9a86-f3027e737ca0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_cac044a8-a6d7-44d0-9d9c-b733ba6ecb0b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_debae6b6-674a-4e0c-868c-2d6fdd857544_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_98f7219a-d700-494b-a091-6741c7b659c1_terseLabel_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging &amp; Oncology Center, Inc.</link:label>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_label_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging and Oncology Center, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:href="ameh-20210930.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:to="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0944f065-0e5d-447a-b280-799466a11bdf_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_bff7f74a-ac66-409e-8126-5400e69acaca_terseLabel_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_label_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:href="ameh-20210930.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:to="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractTypeAxis_7d5d1210-703f-4146-92c7-26d07b1ea95f_terseLabel_en-US" xlink:label="lab_ameh_ContractTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Axis]</link:label>
    <link:label id="lab_ameh_ContractTypeAxis_label_en-US" xlink:label="lab_ameh_ContractTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis" xlink:href="ameh-20210930.xsd#ameh_ContractTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeAxis" xlink:to="lab_ameh_ContractTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e283e589-dc84-4560-9998-6d4d281b2a27_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_2159784e-3047-4ab7-9db3-9c04dbfd2083_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_ba8b1d16-a78c-4c84-9875-94cfc43cf195_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems" xlink:href="ameh-20210930.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessLineItems" xlink:to="lab_ameh_DescriptionOfBusinessLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ameh-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:114d7d5d-3fd3-46db-8f4b-230f4f1be605,g:12a42f3e-83fc-4c9c-a1b4-628777c39609-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="ameh-20210930.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_787f328c-ad90-4460-a0c3-79951e1238bc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_DocumentType_787f328c-ad90-4460-a0c3-79951e1238bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_4f8081bb-cdd2-435a-a39d-1c2ae62b2faf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_DocumentQuarterlyReport_4f8081bb-cdd2-435a-a39d-1c2ae62b2faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cfe6b5e5-5bfe-4c03-a59d-7207e1a65c92" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_DocumentPeriodEndDate_cfe6b5e5-5bfe-4c03-a59d-7207e1a65c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_18844415-4d2f-44bb-90e7-20012f5b554d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_DocumentTransitionReport_18844415-4d2f-44bb-90e7-20012f5b554d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4cfabdb3-10e3-4fd8-96e6-332edb9825bd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityFileNumber_4cfabdb3-10e3-4fd8-96e6-332edb9825bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_31820904-ba50-4dda-a1c7-71594c2fdf1a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityRegistrantName_31820904-ba50-4dda-a1c7-71594c2fdf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21fd1c2d-599c-4573-afe0-bb05dc71349d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityIncorporationStateCountryCode_21fd1c2d-599c-4573-afe0-bb05dc71349d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_55ded25b-8663-428a-9081-fa5a9bd84dc3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityTaxIdentificationNumber_55ded25b-8663-428a-9081-fa5a9bd84dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1d090360-00dd-473a-a9a0-fe54c8780241" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityAddressAddressLine1_1d090360-00dd-473a-a9a0-fe54c8780241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_4fada18e-69a9-45ff-85dd-3fcdc9c07713" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityAddressAddressLine2_4fada18e-69a9-45ff-85dd-3fcdc9c07713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6114932e-bc93-47f1-936c-adb3d83b897d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityAddressCityOrTown_6114932e-bc93-47f1-936c-adb3d83b897d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2194d869-1cfe-4174-b11f-eddb63715328" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityAddressStateOrProvince_2194d869-1cfe-4174-b11f-eddb63715328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ece4b40d-639e-4492-a0c6-844f58bd88d0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityAddressPostalZipCode_ece4b40d-639e-4492-a0c6-844f58bd88d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6b10cc5f-7781-4f9b-9814-095ff3235da5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_CityAreaCode_6b10cc5f-7781-4f9b-9814-095ff3235da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f18b4bd8-cb0c-4f74-aa4b-cc0640a526ce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_LocalPhoneNumber_f18b4bd8-cb0c-4f74-aa4b-cc0640a526ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9ef1ec20-93de-40d5-8866-06fec69e991d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_Security12bTitle_9ef1ec20-93de-40d5-8866-06fec69e991d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a0bcf7c2-ca34-400c-ac5b-4909a7a116b1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_TradingSymbol_a0bcf7c2-ca34-400c-ac5b-4909a7a116b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_219b6234-c137-40f7-a9e3-26d94fa63345" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityCurrentReportingStatus_219b6234-c137-40f7-a9e3-26d94fa63345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e80c11f3-a301-46e5-ac0d-ba19c9369cee" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityInteractiveDataCurrent_e80c11f3-a301-46e5-ac0d-ba19c9369cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_614b632e-14d5-4abf-8e8b-d8440e718b04" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityFilerCategory_614b632e-14d5-4abf-8e8b-d8440e718b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_26ac6c4f-57ee-424a-bdf5-1287db0c0a04" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntitySmallBusiness_26ac6c4f-57ee-424a-bdf5-1287db0c0a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1ad5df50-4217-4a59-bdab-99eac721bf78" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityEmergingGrowthCompany_1ad5df50-4217-4a59-bdab-99eac721bf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4776be2f-df01-41fc-aed1-7ef4c5504d0a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityShellCompany_4776be2f-df01-41fc-aed1-7ef4c5504d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b01e130a-7f3c-4118-9a5b-3ea649da6b8c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b01e130a-7f3c-4118-9a5b-3ea649da6b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_62e961d8-ef31-432e-94c5-1c2278e87664" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_AmendmentFlag_62e961d8-ef31-432e-94c5-1c2278e87664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4924dc8a-b89f-44e8-8109-be2e67155c69" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_DocumentFiscalYearFocus_4924dc8a-b89f-44e8-8109-be2e67155c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_eb1c4eef-1240-4602-ae53-8d3d68da06c4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_DocumentFiscalPeriodFocus_eb1c4eef-1240-4602-ae53-8d3d68da06c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3ab240ca-f400-404b-aa42-74ea4eb4611c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_EntityCentralIndexKey_3ab240ca-f400-404b-aa42-74ea4eb4611c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4ff8b18d-1991-4263-a333-d3fdd946356e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_850e9415-c993-4ba5-bdb8-88dd569b5642" xlink:to="loc_dei_CurrentFiscalYearEndDate_4ff8b18d-1991-4263-a333-d3fdd946356e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20210930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_34e73015-ced6-426e-a426-57be3223caab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_459d2f25-1fc3-4c3d-9b8f-c4372bf4ca91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34e73015-ced6-426e-a426-57be3223caab" xlink:to="loc_us-gaap_StatementTable_459d2f25-1fc3-4c3d-9b8f-c4372bf4ca91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9bb085dc-e3c9-4340-839b-d0362641a157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_459d2f25-1fc3-4c3d-9b8f-c4372bf4ca91" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9bb085dc-e3c9-4340-839b-d0362641a157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_31e76f3f-66fa-461b-87bf-521c42b105eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9bb085dc-e3c9-4340-839b-d0362641a157" xlink:to="loc_us-gaap_ClassOfStockDomain_31e76f3f-66fa-461b-87bf-521c42b105eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2963929d-ff00-47cf-a1b0-2d59f62f4ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31e76f3f-66fa-461b-87bf-521c42b105eb" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2963929d-ff00-47cf-a1b0-2d59f62f4ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_aa893995-28e9-47ba-9d89-20d4d5944477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31e76f3f-66fa-461b-87bf-521c42b105eb" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_aa893995-28e9-47ba-9d89-20d4d5944477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a29973ae-47c3-4c0c-add6-e8770c702b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_459d2f25-1fc3-4c3d-9b8f-c4372bf4ca91" xlink:to="loc_us-gaap_StatementLineItems_a29973ae-47c3-4c0c-add6-e8770c702b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ff6a9984-b42d-4cce-9ba8-48efeba331c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a29973ae-47c3-4c0c-add6-e8770c702b95" xlink:to="loc_us-gaap_AssetsAbstract_ff6a9984-b42d-4cce-9ba8-48efeba331c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff6a9984-b42d-4cce-9ba8-48efeba331c2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44f418a7-7afc-4436-a506-4a64128ceb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44f418a7-7afc-4436-a506-4a64128ceb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ca66b465-7577-4078-accd-7fab237f6e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ca66b465-7577-4078-accd-7fab237f6e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_95216b6a-71be-4002-bf7b-ceac770d6cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_95216b6a-71be-4002-bf7b-ceac770d6cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_eb662d37-2f07-4bc4-848d-3c2574e2d13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_eb662d37-2f07-4bc4-848d-3c2574e2d13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_700281b2-ba08-4550-a324-8407dac579a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_700281b2-ba08-4550-a324-8407dac579a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2a857886-3642-4f5d-bff3-72221fe82890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2a857886-3642-4f5d-bff3-72221fe82890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_d8e1da48-316b-4193-ade2-933b66be7a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_d8e1da48-316b-4193-ade2-933b66be7a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9c3a6a11-319a-4976-b17d-8e0e87329bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4901a06c-e546-4fb9-8380-ee822701e1dc" xlink:to="loc_us-gaap_AssetsCurrent_9c3a6a11-319a-4976-b17d-8e0e87329bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff6a9984-b42d-4cce-9ba8-48efeba331c2" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e363a446-73f5-4259-b454-4dd235ea0049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e363a446-73f5-4259-b454-4dd235ea0049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ec1659ad-5beb-4320-969c-61e082ab1178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ec1659ad-5beb-4320-969c-61e082ab1178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3f0c7a7f-b3d8-4e25-a834-96a59f5f0165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_Goodwill_3f0c7a7f-b3d8-4e25-a834-96a59f5f0165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_57d336af-e8d5-4fa7-9228-5653b3550272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_57d336af-e8d5-4fa7-9228-5653b3550272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_f3b141c3-fc27-4c14-99f8-ae0028bfc4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_f3b141c3-fc27-4c14-99f8-ae0028bfc4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b0f70bee-a455-449b-8fa0-06fa03d57c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_EquityMethodInvestments_b0f70bee-a455-449b-8fa0-06fa03d57c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_face301b-bfed-48ed-a001-0c434dbdd5d7" xlink:href="ameh-20210930.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_face301b-bfed-48ed-a001-0c434dbdd5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_acdc99d5-0c45-402b-91de-fb0963c1155e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_acdc99d5-0c45-402b-91de-fb0963c1155e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f814707e-b523-4e50-a8cb-9428c24f42e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f814707e-b523-4e50-a8cb-9428c24f42e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d1146197-792d-4dfb-8597-0eda34efeb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d1146197-792d-4dfb-8597-0eda34efeb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_50971a69-1ad3-43c1-8a4f-47e3291203d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e283429b-1951-4309-bdbf-d9af557e9f51" xlink:to="loc_us-gaap_AssetsNoncurrent_50971a69-1ad3-43c1-8a4f-47e3291203d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_40531255-4be1-4374-afa2-dcdeedb9c8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff6a9984-b42d-4cce-9ba8-48efeba331c2" xlink:to="loc_us-gaap_Assets_40531255-4be1-4374-afa2-dcdeedb9c8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a29973ae-47c3-4c0c-add6-e8770c702b95" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4aef7b19-9e73-4eb0-a093-3a46447007ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4aef7b19-9e73-4eb0-a093-3a46447007ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_244bcb7f-e31c-4894-9a62-b0de975a2720" xlink:href="ameh-20210930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_244bcb7f-e31c-4894-9a62-b0de975a2720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5331a592-f035-4d6c-9221-29a76a4e2b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5331a592-f035-4d6c-9221-29a76a4e2b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_7fc0bb58-6732-49b7-84bd-d235159330ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_7fc0bb58-6732-49b7-84bd-d235159330ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_316b1fa3-89fc-40ea-9992-a1f5feb49410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_DividendsPayableCurrent_316b1fa3-89fc-40ea-9992-a1f5feb49410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a8d08fa1-95b5-44b7-b89e-103d8b2e47e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a8d08fa1-95b5-44b7-b89e-103d8b2e47e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9f007128-4c77-4495-b1cb-e2b150248227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9f007128-4c77-4495-b1cb-e2b150248227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_08cbb18c-1817-475b-ba6b-a88d05fe49d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_LongTermDebtCurrent_08cbb18c-1817-475b-ba6b-a88d05fe49d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f9e871ec-32e3-428b-977d-9edacc6ddbad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_467a9a42-a17c-4181-84fb-8b98f66124e5" xlink:to="loc_us-gaap_LiabilitiesCurrent_f9e871ec-32e3-428b-977d-9edacc6ddbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0e65fe4d-3d8c-4354-b274-7e5205e3822a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0e65fe4d-3d8c-4354-b274-7e5205e3822a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9c374afe-ad59-4e93-96ab-cce2e0ee8f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9c374afe-ad59-4e93-96ab-cce2e0ee8f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_07c97222-5127-4bbf-9aaa-5374fa8b35e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_07c97222-5127-4bbf-9aaa-5374fa8b35e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3e259c4e-02f3-490d-9c32-2f8f3e308ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3e259c4e-02f3-490d-9c32-2f8f3e308ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_658645f1-5c1c-4836-a868-3aefca762656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_658645f1-5c1c-4836-a868-3aefca762656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_2351d667-f09f-4f97-a02b-6a504d725ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2a0e24d3-4283-4045-8d60-fc181002eb9b" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_2351d667-f09f-4f97-a02b-6a504d725ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a1233c3b-678f-46a4-a479-d84509c76531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_us-gaap_Liabilities_a1233c3b-678f-46a4-a479-d84509c76531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6194d38d-5849-4d4e-bf30-bb04b9265016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6194d38d-5849-4d4e-bf30-bb04b9265016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_e54232ff-3be7-458b-9dc0-3c2539d2228d" xlink:href="ameh-20210930.xsd#ameh_MezzanineEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_ameh_MezzanineEquityAbstract_e54232ff-3be7-458b-9dc0-3c2539d2228d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_16be0344-0b26-4862-a50f-caede8e63fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MezzanineEquityAbstract_e54232ff-3be7-458b-9dc0-3c2539d2228d" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_16be0344-0b26-4862-a50f-caede8e63fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_14ca80d4-96e3-46a8-902b-2860ee2832d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_PreferredStockValue_14ca80d4-96e3-46a8-902b-2860ee2832d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_03feea6c-38ae-4d44-a8ac-b738b6aa54bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_CommonStockValue_03feea6c-38ae-4d44-a8ac-b738b6aa54bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0f3af9dd-ec4d-4da8-9493-984ef89e4d38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0f3af9dd-ec4d-4da8-9493-984ef89e4d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1461488a-1a2a-4ec9-8088-ce46a2bcadf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1461488a-1a2a-4ec9-8088-ce46a2bcadf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_009e1827-0e07-4937-a2fb-7f8d336a76f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_StockholdersEquity_009e1827-0e07-4937-a2fb-7f8d336a76f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_5efd47eb-8f74-44b0-92c9-5cdabd536f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_MinorityInterest_5efd47eb-8f74-44b0-92c9-5cdabd536f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf20b3bc-143f-4686-b9b2-cc2f5377e2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_57d2ba09-e7db-487e-95b6-a9cce596c877" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf20b3bc-143f-4686-b9b2-cc2f5377e2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6beac60a-753a-4aa3-91dd-a3c3d1af2390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caaf3fad-7205-4746-ab76-5d6a0d7c66b3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6beac60a-753a-4aa3-91dd-a3c3d1af2390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ameh-20210930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d102a28b-a933-4fe1-a10d-674aed7c26f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bad4e41c-1e38-46be-8c79-20d985d62c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d102a28b-a933-4fe1-a10d-674aed7c26f9" xlink:to="loc_us-gaap_StatementTable_bad4e41c-1e38-46be-8c79-20d985d62c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f805ec67-268e-4928-b5b7-48f4a40a48aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bad4e41c-1e38-46be-8c79-20d985d62c08" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f805ec67-268e-4928-b5b7-48f4a40a48aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aa47db55-e1d3-496a-a1cb-4489eaffd0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f805ec67-268e-4928-b5b7-48f4a40a48aa" xlink:to="loc_us-gaap_ClassOfStockDomain_aa47db55-e1d3-496a-a1cb-4489eaffd0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_af37cae3-7f80-4138-b3d1-e1934595bcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_aa47db55-e1d3-496a-a1cb-4489eaffd0bd" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_af37cae3-7f80-4138-b3d1-e1934595bcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_9dca8bc2-aa94-4426-be21-15e4cce1cc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_aa47db55-e1d3-496a-a1cb-4489eaffd0bd" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_9dca8bc2-aa94-4426-be21-15e4cce1cc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_fa539ae0-f3bd-4ace-acd5-1774b3680db1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bad4e41c-1e38-46be-8c79-20d985d62c08" xlink:to="loc_srt_ConsolidatedEntitiesAxis_fa539ae0-f3bd-4ace-acd5-1774b3680db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_42058fb5-56c9-4e28-82b3-09a110254585" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_fa539ae0-f3bd-4ace-acd5-1774b3680db1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_42058fb5-56c9-4e28-82b3-09a110254585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_bdf38dbb-04b2-4581-ad5e-ae3c32aa6858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_42058fb5-56c9-4e28-82b3-09a110254585" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_bdf38dbb-04b2-4581-ad5e-ae3c32aa6858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bad4e41c-1e38-46be-8c79-20d985d62c08" xlink:to="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6291b2c4-4786-4f32-be92-9fa237d7fb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6291b2c4-4786-4f32-be92-9fa237d7fb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_cfa59f28-9ab0-4aa9-bf77-71d612ddfad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_cfa59f28-9ab0-4aa9-bf77-71d612ddfad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2bf88945-4012-4316-8d51-58b136c5ff3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2bf88945-4012-4316-8d51-58b136c5ff3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_deddb461-6674-4a06-9de3-92e7c6243e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_deddb461-6674-4a06-9de3-92e7c6243e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c6edb7cb-068f-4ee0-8f3c-8d8055d687f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c6edb7cb-068f-4ee0-8f3c-8d8055d687f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_de1cffcf-3128-4bd8-a63c-159f0b10f296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_CommonStockSharesIssued_de1cffcf-3128-4bd8-a63c-159f0b10f296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a91a0651-7b21-4111-b831-6ba1a54dbff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a91a0651-7b21-4111-b831-6ba1a54dbff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e630b3b1-8e21-43cd-8cc9-7557f5e9c190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e630b3b1-8e21-43cd-8cc9-7557f5e9c190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_6cb7baa8-7f14-4c19-b5d5-c5e05111a2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_TreasuryStockCommonShares_6cb7baa8-7f14-4c19-b5d5-c5e05111a2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b7e117c7-a7f7-4dac-aab9-1367fe0d46f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_Assets_b7e117c7-a7f7-4dac-aab9-1367fe0d46f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ff4f3cde-bb37-4c9b-9831-7e1ccda69ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_Liabilities_ff4f3cde-bb37-4c9b-9831-7e1ccda69ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_2660297d-9479-4173-aceb-76ddb20ac114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_2660297d-9479-4173-aceb-76ddb20ac114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates_f70b30d7-e927-4504-b57d-f8cbc6c4ad64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliates"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_DueFromAffiliates_f70b30d7-e927-4504-b57d-f8cbc6c4ad64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_aedd8fab-329e-4bff-98c7-eebf105d8624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5afef6b5-26be-4521-b8ea-e9fa335ef37f" xlink:to="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_aedd8fab-329e-4bff-98c7-eebf105d8624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="ameh-20210930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_23bb10ea-f0ea-4689-903e-c5c15c74e8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ad8d561c-827e-4046-bfb2-0699a82221ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23bb10ea-f0ea-4689-903e-c5c15c74e8f7" xlink:to="loc_us-gaap_StatementTable_ad8d561c-827e-4046-bfb2-0699a82221ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b1a5852e-e821-41bc-92e0-7bd292e46b5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ad8d561c-827e-4046-bfb2-0699a82221ef" xlink:to="loc_srt_ProductOrServiceAxis_b1a5852e-e821-41bc-92e0-7bd292e46b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b1a5852e-e821-41bc-92e0-7bd292e46b5f" xlink:to="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_df09ea78-ba2b-48a1-8941-ccac850ca1ce" xlink:href="ameh-20210930.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_df09ea78-ba2b-48a1-8941-ccac850ca1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_05cf14f6-8279-4804-b77b-f41d2c577db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:to="loc_us-gaap_HealthCareOtherMember_05cf14f6-8279-4804-b77b-f41d2c577db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_2150dd91-ca8b-41a3-9eba-5ebd9072db56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:to="loc_us-gaap_ManagementServiceMember_2150dd91-ca8b-41a3-9eba-5ebd9072db56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_34ff188a-53fb-47a7-9620-7aa57e377613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_34ff188a-53fb-47a7-9620-7aa57e377613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_70cd41a1-ca71-46d3-a787-5afca60aff71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a973c18-df81-468a-b123-7f50b4ba6a96" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_70cd41a1-ca71-46d3-a787-5afca60aff71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ad8d561c-827e-4046-bfb2-0699a82221ef" xlink:to="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_cfa458e1-8ee3-4ffb-856a-eb0d73abe040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_RevenuesAbstract_cfa458e1-8ee3-4ffb-856a-eb0d73abe040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9d2d93e5-ad5d-41dc-942a-d48c64195cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_cfa458e1-8ee3-4ffb-856a-eb0d73abe040" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9d2d93e5-ad5d-41dc-942a-d48c64195cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_825a4d76-99e9-4eff-8723-708b6f2e72ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_825a4d76-99e9-4eff-8723-708b6f2e72ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_5399f492-a659-47f5-b013-e6a57e901f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_825a4d76-99e9-4eff-8723-708b6f2e72ba" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_5399f492-a659-47f5-b013-e6a57e901f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_95d49a78-5810-4904-b1b8-c00f2b77ec0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_825a4d76-99e9-4eff-8723-708b6f2e72ba" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_95d49a78-5810-4904-b1b8-c00f2b77ec0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b25456f4-e3e1-43b8-ad67-82d80cdaf1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_825a4d76-99e9-4eff-8723-708b6f2e72ba" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b25456f4-e3e1-43b8-ad67-82d80cdaf1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7efb748a-14fe-46a6-88cf-8545eb6f2c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_825a4d76-99e9-4eff-8723-708b6f2e72ba" xlink:to="loc_us-gaap_CostsAndExpenses_7efb748a-14fe-46a6-88cf-8545eb6f2c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0407252b-3a12-4519-b99f-f4920ba4274d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_OperatingIncomeLoss_0407252b-3a12-4519-b99f-f4920ba4274d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_af262e04-9025-45ed-9832-f1360986050f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_af262e04-9025-45ed-9832-f1360986050f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_e4b15d66-d5a9-475f-9277-14f9fb586fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_e4b15d66-d5a9-475f-9277-14f9fb586fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0a40bfea-417e-43f8-aa8a-4b9a55f14388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_InterestExpense_0a40bfea-417e-43f8-aa8a-4b9a55f14388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a6637ff8-2ab8-4cf7-a3ad-6c37b42fee9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a6637ff8-2ab8-4cf7-a3ad-6c37b42fee9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_baffb3f9-19b8-4183-bab0-7ac6e9396164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_baffb3f9-19b8-4183-bab0-7ac6e9396164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_845157b5-f682-41bd-88b1-9dec9b90b7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_845157b5-f682-41bd-88b1-9dec9b90b7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cb926ba2-6c60-4fda-9d63-345f06761cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d29cb15e-f8a3-47cd-8521-400f22c00116" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cb926ba2-6c60-4fda-9d63-345f06761cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_110ad2f5-78bc-4807-bf9f-beb339a1f08d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_110ad2f5-78bc-4807-bf9f-beb339a1f08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_862bbcee-9101-462b-aff0-046a10dd7849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_862bbcee-9101-462b-aff0-046a10dd7849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_49a211bb-a691-41ac-99b2-076f96400839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_ProfitLoss_49a211bb-a691-41ac-99b2-076f96400839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c6bf0784-e4d9-40c5-bdba-aa53ccf289d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c6bf0784-e4d9-40c5-bdba-aa53ccf289d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e5611269-365e-4e68-8383-ac4f6935b27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_NetIncomeLoss_e5611269-365e-4e68-8383-ac4f6935b27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f79a8f6b-67df-4cab-85ba-8c1e349e1a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_EarningsPerShareBasic_f79a8f6b-67df-4cab-85ba-8c1e349e1a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_58b31cef-1775-4237-83c3-76d8903e0f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ed36088-f187-40bd-934f-c3a43cc9e92e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_58b31cef-1775-4237-83c3-76d8903e0f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ameh-20210930.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5e1a6823-0f67-47bc-8ead-ef97d7a96106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7cc2684a-69f4-4cf1-b8f5-bd7ac131396a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5e1a6823-0f67-47bc-8ead-ef97d7a96106" xlink:to="loc_us-gaap_StatementTable_7cc2684a-69f4-4cf1-b8f5-bd7ac131396a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e8bb99e0-f41f-488b-8714-433de5b1473d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7cc2684a-69f4-4cf1-b8f5-bd7ac131396a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e8bb99e0-f41f-488b-8714-433de5b1473d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_419c288f-c9cb-49fc-b6d9-e4eb8610c49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e8bb99e0-f41f-488b-8714-433de5b1473d" xlink:to="loc_us-gaap_EquityComponentDomain_419c288f-c9cb-49fc-b6d9-e4eb8610c49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1d204f6d-1f1d-4443-89c8-8bc6d6883a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_419c288f-c9cb-49fc-b6d9-e4eb8610c49b" xlink:to="loc_us-gaap_CommonStockMember_1d204f6d-1f1d-4443-89c8-8bc6d6883a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6c2df64a-7f58-4cdb-8fa9-296896b608f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_419c288f-c9cb-49fc-b6d9-e4eb8610c49b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6c2df64a-7f58-4cdb-8fa9-296896b608f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_afb2e035-64d4-4163-8550-01d6881f0b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_419c288f-c9cb-49fc-b6d9-e4eb8610c49b" xlink:to="loc_us-gaap_RetainedEarningsMember_afb2e035-64d4-4163-8550-01d6881f0b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f220cd99-2416-4827-ac25-8a0668e194b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_419c288f-c9cb-49fc-b6d9-e4eb8610c49b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f220cd99-2416-4827-ac25-8a0668e194b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3763cb8f-dd3f-4273-8ee4-98be3b1b4b2c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7cc2684a-69f4-4cf1-b8f5-bd7ac131396a" xlink:to="loc_dei_LegalEntityAxis_3763cb8f-dd3f-4273-8ee4-98be3b1b4b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a3e2844d-25fa-459d-9488-dd84a578c7e6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3763cb8f-dd3f-4273-8ee4-98be3b1b4b2c" xlink:to="loc_dei_EntityDomain_a3e2844d-25fa-459d-9488-dd84a578c7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_6feca7c4-501c-4797-8405-1065628399b9" xlink:href="ameh-20210930.xsd#ameh_MezzanineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a3e2844d-25fa-459d-9488-dd84a578c7e6" xlink:to="loc_ameh_MezzanineMember_6feca7c4-501c-4797-8405-1065628399b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dcbf0ece-b598-4999-a1f7-d5f42385bf84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7cc2684a-69f4-4cf1-b8f5-bd7ac131396a" xlink:to="loc_us-gaap_StatementLineItems_dcbf0ece-b598-4999-a1f7-d5f42385bf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dcbf0ece-b598-4999-a1f7-d5f42385bf84" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cbb3a70e-13d0-4502-9f15-d939a49b17e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cbb3a70e-13d0-4502-9f15-d939a49b17e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_33390738-8ca5-4036-934d-303c7db21136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_SharesOutstanding_33390738-8ca5-4036-934d-303c7db21136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_d3bfff83-d649-4fc3-a5cb-1e4825330db9" xlink:href="ameh-20210930.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_d3bfff83-d649-4fc3-a5cb-1e4825330db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_e97761a5-535a-463a-bfe2-f7ab8c31a6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_e97761a5-535a-463a-bfe2-f7ab8c31a6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_860f576b-c9b8-4895-ab7d-c3182cf4fab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_860f576b-c9b8-4895-ab7d-c3182cf4fab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_01617690-251b-4356-b282-ff044d292a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_01617690-251b-4356-b282-ff044d292a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ead1116b-4674-424e-8147-e2ed65f6d4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ead1116b-4674-424e-8147-e2ed65f6d4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_bef4769c-db7c-4ace-99cf-0ae098dd9bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_bef4769c-db7c-4ace-99cf-0ae098dd9bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_22a46f70-534e-49d0-a74c-511213df1fd4" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_22a46f70-534e-49d0-a74c-511213df1fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_327ba507-7b34-4f0f-8a0e-d254d3e8647c" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_327ba507-7b34-4f0f-8a0e-d254d3e8647c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_f00c2e23-0224-4d75-a746-be141ab70044" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_f00c2e23-0224-4d75-a746-be141ab70044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_e3bf89f6-d019-47de-94c8-96d2555a771b" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_e3bf89f6-d019-47de-94c8-96d2555a771b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_68e19101-fae5-4897-95ea-9b80b2248007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_68e19101-fae5-4897-95ea-9b80b2248007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_d2116cea-7b03-4868-a448-17179166c36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_d2116cea-7b03-4868-a448-17179166c36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_79b9be45-a82e-4ac9-8f65-611080ab7df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_79b9be45-a82e-4ac9-8f65-611080ab7df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d197fc1f-0315-456c-9e34-c6a78f61b053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d197fc1f-0315-456c-9e34-c6a78f61b053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ccae894c-f3f1-42e2-986a-67407f6615fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ccae894c-f3f1-42e2-986a-67407f6615fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_26a799da-d75a-4139-93ff-3440b7d2c8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_26a799da-d75a-4139-93ff-3440b7d2c8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_327a7633-7d23-457b-a7eb-da4db33f1180" xlink:href="ameh-20210930.xsd#ameh_NoncontrollingInterestIncreaseFromCapitalCharge"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_327a7633-7d23-457b-a7eb-da4db33f1180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_5eed7963-ba07-4500-9750-c5c4e9597e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_5eed7963-ba07-4500-9750-c5c4e9597e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_7778e747-7bbc-4d9c-a741-d50225db05d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_7778e747-7bbc-4d9c-a741-d50225db05d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f77568eb-5b9d-4bf8-afb3-dd81f451181a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f77568eb-5b9d-4bf8-afb3-dd81f451181a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f6b76fed-c18b-4515-9480-8e8265a4ac93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97aa871-d34a-415e-ab82-865b76736363" xlink:to="loc_us-gaap_SharesOutstanding_f6b76fed-c18b-4515-9480-8e8265a4ac93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ameh-20210930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9e29ea06-e1ab-4a50-a344-2da689ede023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a29804c1-6348-4641-b81e-91b7ef5fd11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9e29ea06-e1ab-4a50-a344-2da689ede023" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a29804c1-6348-4641-b81e-91b7ef5fd11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6c305b30-30a7-4837-aa2a-31a992b22ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a29804c1-6348-4641-b81e-91b7ef5fd11e" xlink:to="loc_us-gaap_ProfitLoss_6c305b30-30a7-4837-aa2a-31a992b22ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a29804c1-6348-4641-b81e-91b7ef5fd11e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4457bcf5-7d61-4202-9b00-b2eb37b31afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4457bcf5-7d61-4202-9b00-b2eb37b31afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f4bcf4b1-0eef-4d91-9a83-61d36090e2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f4bcf4b1-0eef-4d91-9a83-61d36090e2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3759e8ba-7a37-473d-a595-6c83cf304fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:to="loc_us-gaap_ShareBasedCompensation_3759e8ba-7a37-473d-a595-6c83cf304fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_25f104dd-50b2-4c7b-b58d-8be906f74454" xlink:href="ameh-20210930.xsd#ameh_UnrealizedGainLossFromInvestmentInEquitySecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:to="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_25f104dd-50b2-4c7b-b58d-8be906f74454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ca59a2e5-e09a-44b5-b2bf-ee64d36a95e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ca59a2e5-e09a-44b5-b2bf-ee64d36a95e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_22cbbffd-70ce-483c-b7fb-cefe8ad6ad17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_22cbbffd-70ce-483c-b7fb-cefe8ad6ad17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_4f9298f3-188e-4754-9b23-3bf3956edb09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:to="loc_us-gaap_AssetImpairmentCharges_4f9298f3-188e-4754-9b23-3bf3956edb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_921d7fe8-d4a2-4801-a21c-20e68eb22672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLossOnDerivative"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_921d7fe8-d4a2-4801-a21c-20e68eb22672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_843071cb-7b4d-4fab-836c-778b62621483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_843071cb-7b4d-4fab-836c-778b62621483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities_a60efc45-3b08-4449-9b21-a578eb13e38f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:to="loc_us-gaap_ProceedsFromOtherOperatingActivities_a60efc45-3b08-4449-9b21-a578eb13e38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fcde1359-9116-4d35-aab8-ed8be8224ed2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9dbe4c85-fe9c-48a9-9099-6fd78bf654ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9dbe4c85-fe9c-48a9-9099-6fd78bf654ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_86866701-8697-4d89-ba35-63a3b2ea05b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_86866701-8697-4d89-ba35-63a3b2ea05b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_486359d9-a6b9-4c99-af9a-82e37d1d265a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_486359d9-a6b9-4c99-af9a-82e37d1d265a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_849387cf-d0dd-4e9c-8db7-f38e01587b12" xlink:href="ameh-20210930.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_849387cf-d0dd-4e9c-8db7-f38e01587b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_ebe0cf0f-ae48-4c84-8845-0d1c22959b11" xlink:href="ameh-20210930.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_ebe0cf0f-ae48-4c84-8845-0d1c22959b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7bdb9462-76f5-4b74-9d18-55211d59eaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7bdb9462-76f5-4b74-9d18-55211d59eaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e252aa62-da19-4ba4-8b06-3ba8e9bfe75b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e252aa62-da19-4ba4-8b06-3ba8e9bfe75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_52756015-4c89-464d-84e7-4bd359a52a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_52756015-4c89-464d-84e7-4bd359a52a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_b3247e09-1306-4562-aa5e-66a48b4445d8" xlink:href="ameh-20210930.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_b3247e09-1306-4562-aa5e-66a48b4445d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_fcedcaf9-6702-4a5d-899a-b6f6f36faec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_fcedcaf9-6702-4a5d-899a-b6f6f36faec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fcac8ad9-e924-4c45-bc53-57644109e827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f7f2e0-fd2f-4202-b92e-e1f8240b3a51" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fcac8ad9-e924-4c45-bc53-57644109e827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_27048e7f-706e-4589-8953-1cb9ea573240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a29804c1-6348-4641-b81e-91b7ef5fd11e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_27048e7f-706e-4589-8953-1cb9ea573240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57d32df6-f71c-4f72-bfc2-405f97506bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9e29ea06-e1ab-4a50-a344-2da689ede023" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57d32df6-f71c-4f72-bfc2-405f97506bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_841c46bd-6a6c-4ad3-a82e-f9a66ad64ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57d32df6-f71c-4f72-bfc2-405f97506bda" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_841c46bd-6a6c-4ad3-a82e-f9a66ad64ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_e5346dbf-104c-4d3e-a152-830d803f9e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57d32df6-f71c-4f72-bfc2-405f97506bda" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_e5346dbf-104c-4d3e-a152-830d803f9e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c506ad34-1c15-4950-93de-f28e5c5744f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57d32df6-f71c-4f72-bfc2-405f97506bda" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c506ad34-1c15-4950-93de-f28e5c5744f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_11dac887-38d4-469c-8beb-dd4e1ac3b1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57d32df6-f71c-4f72-bfc2-405f97506bda" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_11dac887-38d4-469c-8beb-dd4e1ac3b1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0daf833b-14f0-4323-b070-3d68af7b38a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57d32df6-f71c-4f72-bfc2-405f97506bda" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0daf833b-14f0-4323-b070-3d68af7b38a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b7b540ac-0b6b-4c62-905e-bc1e7eba9c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57d32df6-f71c-4f72-bfc2-405f97506bda" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b7b540ac-0b6b-4c62-905e-bc1e7eba9c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_75bb76b8-353d-44a8-b10f-114721493644" xlink:href="ameh-20210930.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57d32df6-f71c-4f72-bfc2-405f97506bda" xlink:to="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_75bb76b8-353d-44a8-b10f-114721493644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c32b7abd-c7a7-46ed-a7a0-59bcd17f3f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57d32df6-f71c-4f72-bfc2-405f97506bda" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c32b7abd-c7a7-46ed-a7a0-59bcd17f3f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8ab371b-09a3-407f-900b-01929ceb5072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57d32df6-f71c-4f72-bfc2-405f97506bda" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8ab371b-09a3-407f-900b-01929ceb5072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9e29ea06-e1ab-4a50-a344-2da689ede023" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_b8addcaa-af40-4280-bc39-e58a4edbe779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:to="loc_us-gaap_PaymentsOfDividends_b8addcaa-af40-4280-bc39-e58a4edbe779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3015b661-98c8-4bee-888b-210232edd5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3015b661-98c8-4bee-888b-210232edd5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_e6536350-a056-4c17-9d8e-2cb81cb793af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_e6536350-a056-4c17-9d8e-2cb81cb793af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_e3d72544-5907-46e0-a568-6a8d3d82273f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_e3d72544-5907-46e0-a568-6a8d3d82273f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_828116e5-1702-4f86-8093-e36a81855880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_828116e5-1702-4f86-8093-e36a81855880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_d197ab73-25d9-474c-9c00-933583add4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_d197ab73-25d9-474c-9c00-933583add4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_510511b4-6070-45f0-ac8f-26cc364dbf01" xlink:href="ameh-20210930.xsd#ameh_ProceedsFromSaleOfNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:to="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_510511b4-6070-45f0-ac8f-26cc364dbf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_988aeb0a-082a-4812-86ad-536e834d4a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_988aeb0a-082a-4812-86ad-536e834d4a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_eec38f12-7ae9-4f48-9acc-5aa9143cc375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_eec38f12-7ae9-4f48-9acc-5aa9143cc375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_bc288227-b4af-4879-a5c1-09a72506feb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_bc288227-b4af-4879-a5c1-09a72506feb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_baa51e09-53cb-40a3-b3a1-752b319017b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19cd4b58-ce08-4463-b1c5-32df2728c0f6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_baa51e09-53cb-40a3-b3a1-752b319017b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e50f198-b58d-42e8-a170-3cd4ffa88edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9e29ea06-e1ab-4a50-a344-2da689ede023" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e50f198-b58d-42e8-a170-3cd4ffa88edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8753afc-7870-4617-905f-60978a904fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9e29ea06-e1ab-4a50-a344-2da689ede023" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8753afc-7870-4617-905f-60978a904fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f1f81e4-81ca-41ab-a963-2c872141b178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9e29ea06-e1ab-4a50-a344-2da689ede023" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f1f81e4-81ca-41ab-a963-2c872141b178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_d0411504-12c2-4390-9f0c-ef0f1214e203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9e29ea06-e1ab-4a50-a344-2da689ede023" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_d0411504-12c2-4390-9f0c-ef0f1214e203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_35e6abfd-e85a-4dc7-8af8-60756290e6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d0411504-12c2-4390-9f0c-ef0f1214e203" xlink:to="loc_us-gaap_IncomeTaxesPaid_35e6abfd-e85a-4dc7-8af8-60756290e6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_da320a1d-037b-486b-ac15-447820837088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d0411504-12c2-4390-9f0c-ef0f1214e203" xlink:to="loc_us-gaap_InterestPaidNet_da320a1d-037b-486b-ac15-447820837088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b68d56f-a3e1-4d71-82cf-d72638f0c15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9e29ea06-e1ab-4a50-a344-2da689ede023" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b68d56f-a3e1-4d71-82cf-d72638f0c15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_49d025b6-7bfd-4cef-8fff-d3c945ab188e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b68d56f-a3e1-4d71-82cf-d72638f0c15c" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_49d025b6-7bfd-4cef-8fff-d3c945ab188e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_a32c31b3-31f5-48e9-88c4-3e64d25dc841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b68d56f-a3e1-4d71-82cf-d72638f0c15c" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_a32c31b3-31f5-48e9-88c4-3e64d25dc841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CancellationOfRestrictedStockAwards_eff32a6e-66b5-4cd7-9e1f-de76a383d8ef" xlink:href="ameh-20210930.xsd#ameh_CancellationOfRestrictedStockAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b68d56f-a3e1-4d71-82cf-d72638f0c15c" xlink:to="loc_ameh_CancellationOfRestrictedStockAwards_eff32a6e-66b5-4cd7-9e1f-de76a383d8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill_a41b6fd9-4b49-498f-96c0-99c2bab31f6f" xlink:href="ameh-20210930.xsd#ameh_DeferredTaxLiabilitiesAdjustedToGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b68d56f-a3e1-4d71-82cf-d72638f0c15c" xlink:to="loc_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill_a41b6fd9-4b49-498f-96c0-99c2bab31f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilitiesWarrantsExercised_b7518965-c81d-4503-b9c5-db9f141e596d" xlink:href="ameh-20210930.xsd#ameh_DeferredTaxLiabilitiesWarrantsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b68d56f-a3e1-4d71-82cf-d72638f0c15c" xlink:to="loc_ameh_DeferredTaxLiabilitiesWarrantsExercised_b7518965-c81d-4503-b9c5-db9f141e596d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_0f5ab53c-d218-428a-885e-0c116d4d0eef" xlink:href="ameh-20210930.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9e29ea06-e1ab-4a50-a344-2da689ede023" xlink:to="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_0f5ab53c-d218-428a-885e-0c116d4d0eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e5624c72-8817-498b-b59d-f4b12a911dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_0f5ab53c-d218-428a-885e-0c116d4d0eef" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e5624c72-8817-498b-b59d-f4b12a911dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_3673910f-5ff2-4d88-9896-79bb62a84072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_0f5ab53c-d218-428a-885e-0c116d4d0eef" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_3673910f-5ff2-4d88-9896-79bb62a84072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_109df560-a0fd-413d-846b-150ec238a01a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_0f5ab53c-d218-428a-885e-0c116d4d0eef" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_109df560-a0fd-413d-846b-150ec238a01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_754c286b-1a29-4dba-8fbd-f360cadc9de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_0f5ab53c-d218-428a-885e-0c116d4d0eef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_754c286b-1a29-4dba-8fbd-f360cadc9de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ameh-20210930.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e621d7c4-38b3-4731-8b98-1f431fa563c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_71e20126-406a-4d11-bd40-82ca234ff681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e621d7c4-38b3-4731-8b98-1f431fa563c5" xlink:to="loc_us-gaap_NatureOfOperations_71e20126-406a-4d11-bd40-82ca234ff681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ae9cc07a-ff02-40df-abb5-60e9fbf2057f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:href="ameh-20210930.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ae9cc07a-ff02-40df-abb5-60e9fbf2057f" xlink:to="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6dd2ec9e-c9e9-42b6-b0ef-ff09f61d74cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_dei_LegalEntityAxis_6dd2ec9e-c9e9-42b6-b0ef-ff09f61d74cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6dd2ec9e-c9e9-42b6-b0ef-ff09f61d74cc" xlink:to="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f782237d-60d0-4247-8120-c26ccdf0563d" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f782237d-60d0-4247-8120-c26ccdf0563d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_abac02a3-0f6e-4eb3-a86b-560b5c06b1c0" xlink:href="ameh-20210930.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:to="loc_ameh_ApcLsmaMember_abac02a3-0f6e-4eb3-a86b-560b5c06b1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_4ef15496-c575-4acc-8b40-67e4ff777114" xlink:href="ameh-20210930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:to="loc_ameh_AccountableHealthCareIPAMember_4ef15496-c575-4acc-8b40-67e4ff777114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_07acbbc2-fb68-4f57-9b03-1dd655e08a44" xlink:href="ameh-20210930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:to="loc_ameh_APCAndAPCLSMAMember_07acbbc2-fb68-4f57-9b03-1dd655e08a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_79f73d8b-1bf1-4009-8a93-fd5a36388351" xlink:href="ameh-20210930.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_161c15f8-14b9-4e54-9971-f6c63397155e" xlink:to="loc_ameh_AmgIncMember_79f73d8b-1bf1-4009-8a93-fd5a36388351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5ef59247-892e-4f14-8370-a6736739e954" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_srt_CounterpartyNameAxis_5ef59247-892e-4f14-8370-a6736739e954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4f7fb0c-faae-4173-a487-1375eba5086e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5ef59247-892e-4f14-8370-a6736739e954" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4f7fb0c-faae-4173-a487-1375eba5086e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e6c9f4d3-463c-4cb2-8bcb-8c4821ec7f09" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4f7fb0c-faae-4173-a487-1375eba5086e" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e6c9f4d3-463c-4cb2-8bcb-8c4821ec7f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_6c187a09-1c45-4adb-b4d1-90c2a53686ae" xlink:href="ameh-20210930.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4f7fb0c-faae-4173-a487-1375eba5086e" xlink:to="loc_ameh_APAMHMedicalCorporationMember_6c187a09-1c45-4adb-b4d1-90c2a53686ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_8c5a7148-05eb-4471-a7fa-a38027c7e636" xlink:href="ameh-20210930.xsd#ameh_Dr.JayMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c4f7fb0c-faae-4173-a487-1375eba5086e" xlink:to="loc_ameh_Dr.JayMember_8c5a7148-05eb-4471-a7fa-a38027c7e636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d655e457-0155-4a4f-a4f4-4c2cf975c9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d655e457-0155-4a4f-a4f4-4c2cf975c9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3488e04f-6830-445c-94bc-62b19708fa22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d655e457-0155-4a4f-a4f4-4c2cf975c9c8" xlink:to="loc_us-gaap_RelatedPartyDomain_3488e04f-6830-445c-94bc-62b19708fa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_5e7623c1-a9be-44a4-87ac-11251fb59270" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3488e04f-6830-445c-94bc-62b19708fa22" xlink:to="loc_srt_AffiliatedEntityMember_5e7623c1-a9be-44a4-87ac-11251fb59270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ae687a3f-6277-4369-8ec8-265d8c6c9d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ae687a3f-6277-4369-8ec8-265d8c6c9d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d029e592-e8de-4ad6-b5b5-3a9db89d81c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ae687a3f-6277-4369-8ec8-265d8c6c9d07" xlink:to="loc_us-gaap_ClassOfStockDomain_d029e592-e8de-4ad6-b5b5-3a9db89d81c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_88f3deaa-69d0-44cd-b5e6-76d7e8f30ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d029e592-e8de-4ad6-b5b5-3a9db89d81c5" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_88f3deaa-69d0-44cd-b5e6-76d7e8f30ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fb8edfe-ff16-4da7-ba28-660bef16a1e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fb8edfe-ff16-4da7-ba28-660bef16a1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e941b586-3578-4277-b59d-ae228c5fec77" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fb8edfe-ff16-4da7-ba28-660bef16a1e8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e941b586-3578-4277-b59d-ae228c5fec77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_27dd01c2-8d9b-440e-87f7-8008fbcf9b18" xlink:href="ameh-20210930.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e941b586-3578-4277-b59d-ae228c5fec77" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_27dd01c2-8d9b-440e-87f7-8008fbcf9b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_5afbc5fc-64af-420c-bc2b-1a4d43ebc402" xlink:href="ameh-20210930.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e941b586-3578-4277-b59d-ae228c5fec77" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_5afbc5fc-64af-420c-bc2b-1a4d43ebc402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c2e91f71-946d-4cf5-8923-17dd5d8f6270" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_srt_OwnershipAxis_c2e91f71-946d-4cf5-8923-17dd5d8f6270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_30893f79-496b-4636-8643-a7cd960a0c95" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_c2e91f71-946d-4cf5-8923-17dd5d8f6270" xlink:to="loc_srt_OwnershipDomain_30893f79-496b-4636-8643-a7cd960a0c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_ee5fd6f8-8d67-4c20-94ff-01ac1516043b" xlink:href="ameh-20210930.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_30893f79-496b-4636-8643-a7cd960a0c95" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_ee5fd6f8-8d67-4c20-94ff-01ac1516043b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_035cefda-d710-4f92-bda3-49fdf863327b" xlink:href="ameh-20210930.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_30893f79-496b-4636-8643-a7cd960a0c95" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_035cefda-d710-4f92-bda3-49fdf863327b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_534051ee-9c4a-4c5f-ae28-652e4e74b1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_534051ee-9c4a-4c5f-ae28-652e4e74b1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_534051ee-9c4a-4c5f-ae28-652e4e74b1ae" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_518c6af6-d639-45c6-b9b7-2eb1072594ea" xlink:href="ameh-20210930.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_518c6af6-d639-45c6-b9b7-2eb1072594ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_5657907d-c6a5-4f5d-8c76-5e91d069937f" xlink:href="ameh-20210930.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_5657907d-c6a5-4f5d-8c76-5e91d069937f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_13a86d99-db63-4b4a-8636-d1e79efab9e6" xlink:href="ameh-20210930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:to="loc_ameh_AccountableHealthCareIPAMember_13a86d99-db63-4b4a-8636-d1e79efab9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_75572545-088d-4149-b1eb-0d1c6a136a6d" xlink:href="ameh-20210930.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:to="loc_ameh_AmgIncMember_75572545-088d-4149-b1eb-0d1c6a136a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_b8027a1a-a7f1-4506-bd4b-2331690d2a7e" xlink:href="ameh-20210930.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b183210-b4ed-4821-ad2e-aebde63f28e8" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_b8027a1a-a7f1-4506-bd4b-2331690d2a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_6f946da9-1ed7-4eca-8f66-72c38c157f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_us-gaap_AssetAcquisitionAxis_6f946da9-1ed7-4eca-8f66-72c38c157f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_d8f480c0-932a-41e3-b5a4-b45bb462878d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6f946da9-1ed7-4eca-8f66-72c38c157f10" xlink:to="loc_us-gaap_AssetAcquisitionDomain_d8f480c0-932a-41e3-b5a4-b45bb462878d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_27ada3a5-fd86-4425-abb2-3a0e3172b59c" xlink:href="ameh-20210930.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d8f480c0-932a-41e3-b5a4-b45bb462878d" xlink:to="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_27ada3a5-fd86-4425-abb2-3a0e3172b59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_1c5d59bf-d8bf-429a-a69b-96ad67df9471" xlink:href="ameh-20210930.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d8f480c0-932a-41e3-b5a4-b45bb462878d" xlink:to="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_1c5d59bf-d8bf-429a-a69b-96ad67df9471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:href="ameh-20210930.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_d20514c2-0741-4ce9-bfdc-aea3bfd96a2a" xlink:to="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_cce40645-bfcb-40ad-ae1a-8db315388d9c" xlink:href="ameh-20210930.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_cce40645-bfcb-40ad-ae1a-8db315388d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_8c179a68-eb89-41f5-b5dd-39a2591f661c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_NotesReceivableNet_8c179a68-eb89-41f5-b5dd-39a2591f661c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_8f01abf6-16bf-4a76-9f2d-3f57972de875" xlink:href="ameh-20210930.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_8f01abf6-16bf-4a76-9f2d-3f57972de875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_f5403f6a-dfb3-4374-bcae-29dd5a4ca4c0" xlink:href="ameh-20210930.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_f5403f6a-dfb3-4374-bcae-29dd5a4ca4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_129e582a-1c93-45c0-b018-4d992431225b" xlink:href="ameh-20210930.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_129e582a-1c93-45c0-b018-4d992431225b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ef38ee66-ecc5-465c-93ee-0ed61d3f16ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ef38ee66-ecc5-465c-93ee-0ed61d3f16ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1bd8696b-26f4-4344-bd66-ac88d4c1b591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1bd8696b-26f4-4344-bd66-ac88d4c1b591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_dd57da48-d93a-4f40-a83f-a1d9330f7b75" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodProxyVotesPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_dd57da48-d93a-4f40-a83f-a1d9330f7b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_794e695e-ea97-4122-a795-1072e8bd04b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_794e695e-ea97-4122-a795-1072e8bd04b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_19ea9aba-5ae3-4cec-8c7d-aa71b1f45362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_19ea9aba-5ae3-4cec-8c7d-aa71b1f45362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_141ffa21-b455-4fae-a05b-486d2188d303" xlink:href="ameh-20210930.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_141ffa21-b455-4fae-a05b-486d2188d303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_97d93c3a-7c8c-450a-bdcc-5eb849c8124a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_97d93c3a-7c8c-450a-bdcc-5eb849c8124a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_deb67086-96bb-49b9-b4e1-dbff106e9b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_deb67086-96bb-49b9-b4e1-dbff106e9b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_9afcb1ea-b0b4-42da-ba01-0e3a6acd5bd3" xlink:href="ameh-20210930.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_9afcb1ea-b0b4-42da-ba01-0e3a6acd5bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f0a5cc1b-021b-40d4-a77d-5c114cd5ef83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f0a5cc1b-021b-40d4-a77d-5c114cd5ef83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_259b4ab0-f3ee-41fb-99d7-857704f5e038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_259b4ab0-f3ee-41fb-99d7-857704f5e038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_923c2a62-cc6d-428f-ba80-fd98e1ee1602" xlink:href="ameh-20210930.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_923c2a62-cc6d-428f-ba80-fd98e1ee1602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_2c13d2f2-2f2c-4978-8cc3-7c0b53e9aebe" xlink:href="ameh-20210930.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_2c13d2f2-2f2c-4978-8cc3-7c0b53e9aebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_17a83723-96e7-4604-b256-7fafc2464c48" xlink:href="ameh-20210930.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_52b7c323-33dc-48b5-a499-48590f19ce92" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_17a83723-96e7-4604-b256-7fafc2464c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ameh-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_81477df8-74bf-4547-8242-573081759762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_f434e40c-4a34-4006-8ef4-a5bc70d847e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_81477df8-74bf-4547-8242-573081759762" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_f434e40c-4a34-4006-8ef4-a5bc70d847e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ameh-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_029adbc7-f448-4d37-ac47-5a1ce5b3133e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_029adbc7-f448-4d37-ac47-5a1ce5b3133e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4b066db6-16c1-4937-b216-f5357647eacd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_4b066db6-16c1-4937-b216-f5357647eacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_173348c9-ff20-434d-b5aa-c13af2600e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_UseOfEstimates_173348c9-ff20-434d-b5aa-c13af2600e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_3606a269-6ae8-4ddf-bf6d-224bd7ccf084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_3606a269-6ae8-4ddf-bf6d-224bd7ccf084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_473059c5-2ebb-4c76-b230-d784516f560d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_473059c5-2ebb-4c76-b230-d784516f560d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_96db67d7-345a-4376-a198-6cbae6e183b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_96db67d7-345a-4376-a198-6cbae6e183b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ab9fa4a4-9ac0-4026-a890-b2de14967ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ab9fa4a4-9ac0-4026-a890-b2de14967ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2dc57697-72f9-48bd-b2f7-af8d64301f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2dc57697-72f9-48bd-b2f7-af8d64301f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_b2c1560a-efc1-4fef-b204-751087f70445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_b2c1560a-efc1-4fef-b204-751087f70445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_47f4098a-2d4a-4474-99c2-d77cc16a3b10" xlink:href="ameh-20210930.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_47f4098a-2d4a-4474-99c2-d77cc16a3b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_d9503982-caa6-4c88-8cde-e2f7c27444df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_d9503982-caa6-4c88-8cde-e2f7c27444df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3930fac6-568d-4833-8107-7b4fe2e1092a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3930fac6-568d-4833-8107-7b4fe2e1092a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3431d208-e079-49dd-bcf4-4306e3ae5e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3431d208-e079-49dd-bcf4-4306e3ae5e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_26ffde74-788c-47b2-8fd3-2bf7c0254171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_26ffde74-788c-47b2-8fd3-2bf7c0254171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_4cd2efc5-70dd-454c-ab8f-2cd4dcf9647a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_4cd2efc5-70dd-454c-ab8f-2cd4dcf9647a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_90783998-ca19-41b3-8b08-0ec45c552a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_90783998-ca19-41b3-8b08-0ec45c552a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock_68a68b59-86c4-4795-b036-44c575ba737c" xlink:href="ameh-20210930.xsd#ameh_FiduciaryCashAndPayablePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock_68a68b59-86c4-4795-b036-44c575ba737c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_cdf50407-1677-41b0-b458-93e3b4e1e349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_cdf50407-1677-41b0-b458-93e3b4e1e349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_55e41cab-737d-461d-b6a9-84b15d5a1034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_55e41cab-737d-461d-b6a9-84b15d5a1034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6bf6b6e3-50f1-46dd-b23f-2ea99733ae30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6bf6b6e3-50f1-46dd-b23f-2ea99733ae30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9c175b4c-5ac2-4eb2-ac0f-caea01cba7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9c175b4c-5ac2-4eb2-ac0f-caea01cba7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a8429dfb-7a2d-4a47-bf11-1a9150a552dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a8429dfb-7a2d-4a47-bf11-1a9150a552dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock_0e21f061-4a97-40f9-b212-3cdf38091ad9" xlink:href="ameh-20210930.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_ameh_MinorityInterestPolicyPolicyTextBlock_0e21f061-4a97-40f9-b212-3cdf38091ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock_f54da15e-a499-485e-8701-820392d70293" xlink:href="ameh-20210930.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_ameh_TemporaryEquityPolicyTextBlock_f54da15e-a499-485e-8701-820392d70293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_2e8a6ea6-e974-4559-b086-79ddb652608e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_2e8a6ea6-e974-4559-b086-79ddb652608e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BeneficialInterestPolicyTextBlock_c174169d-6e59-4bc6-939f-3fb5bbd01661" xlink:href="ameh-20210930.xsd#ameh_BeneficialInterestPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_ameh_BeneficialInterestPolicyTextBlock_c174169d-6e59-4bc6-939f-3fb5bbd01661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ae6b3f50-bf7c-48c8-a3ae-a33556232965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eb35f86d-e425-4f71-b23c-490763b7b526" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ae6b3f50-bf7c-48c8-a3ae-a33556232965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ameh-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d3d3b454-c90c-4f03-be9a-0b29599236bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_45a230cd-f267-46f3-af87-b77724bafab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3d3b454-c90c-4f03-be9a-0b29599236bb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_45a230cd-f267-46f3-af87-b77724bafab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_740cd21e-1773-4517-ab01-b56dad10c84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3d3b454-c90c-4f03-be9a-0b29599236bb" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_740cd21e-1773-4517-ab01-b56dad10c84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c06890fa-eb76-40fa-bb92-75bb4e407917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3d3b454-c90c-4f03-be9a-0b29599236bb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c06890fa-eb76-40fa-bb92-75bb4e407917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2eca8930-1362-4a52-a335-8dad9b15e4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:href="ameh-20210930.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2eca8930-1362-4a52-a335-8dad9b15e4bb" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f6995773-388a-4078-b0bf-69ec9aaacec6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_srt_RangeAxis_f6995773-388a-4078-b0bf-69ec9aaacec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c92ecb9f-51d5-41c7-99e9-97f987c0530d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f6995773-388a-4078-b0bf-69ec9aaacec6" xlink:to="loc_srt_RangeMember_c92ecb9f-51d5-41c7-99e9-97f987c0530d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4d7fc85c-32ba-4e75-9efb-a58e58899848" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c92ecb9f-51d5-41c7-99e9-97f987c0530d" xlink:to="loc_srt_MinimumMember_4d7fc85c-32ba-4e75-9efb-a58e58899848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c3016289-5cb2-4338-aff5-735322426d90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c92ecb9f-51d5-41c7-99e9-97f987c0530d" xlink:to="loc_srt_MaximumMember_c3016289-5cb2-4338-aff5-735322426d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f62ec4ee-104f-4c6d-a822-9cff8961ca65" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_srt_CounterpartyNameAxis_f62ec4ee-104f-4c6d-a822-9cff8961ca65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc004ab2-531c-405b-a8d2-f1ed113ecf1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f62ec4ee-104f-4c6d-a822-9cff8961ca65" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc004ab2-531c-405b-a8d2-f1ed113ecf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClinigenceHoldingsIncMember_9a70e35c-05c3-4e5f-8b19-1d6416c3a108" xlink:href="ameh-20210930.xsd#ameh_ClinigenceHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc004ab2-531c-405b-a8d2-f1ed113ecf1f" xlink:to="loc_ameh_ClinigenceHoldingsIncMember_9a70e35c-05c3-4e5f-8b19-1d6416c3a108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_9f6892e6-9007-4c69-8ce1-274e96f748f5" xlink:href="ameh-20210930.xsd#ameh_CMSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc004ab2-531c-405b-a8d2-f1ed113ecf1f" xlink:to="loc_ameh_CMSMember_9f6892e6-9007-4c69-8ce1-274e96f748f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_02e7d155-11ca-4922-8ee7-33eee485f7a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_srt_ProductOrServiceAxis_02e7d155-11ca-4922-8ee7-33eee485f7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3fe1da84-7776-44b6-acfb-20f4e74ccd8a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_02e7d155-11ca-4922-8ee7-33eee485f7a7" xlink:to="loc_srt_ProductsAndServicesDomain_3fe1da84-7776-44b6-acfb-20f4e74ccd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_20d35f5d-0f6e-4608-8d95-7799b2f3dc96" xlink:href="ameh-20210930.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3fe1da84-7776-44b6-acfb-20f4e74ccd8a" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_20d35f5d-0f6e-4608-8d95-7799b2f3dc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_770e6ed4-8eea-46e3-a127-a6335942deed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3fe1da84-7776-44b6-acfb-20f4e74ccd8a" xlink:to="loc_us-gaap_ManagementServiceMember_770e6ed4-8eea-46e3-a127-a6335942deed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1a21a42e-0e9d-4cd9-b603-f4ab5e02a4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1a21a42e-0e9d-4cd9-b603-f4ab5e02a4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_66b56cc6-c6ab-4c7b-b5bd-44c05ab6e2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1a21a42e-0e9d-4cd9-b603-f4ab5e02a4bc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_66b56cc6-c6ab-4c7b-b5bd-44c05ab6e2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_b420e6f4-df50-45b4-9997-468cb4af7acf" xlink:href="ameh-20210930.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66b56cc6-c6ab-4c7b-b5bd-44c05ab6e2c3" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_b420e6f4-df50-45b4-9997-468cb4af7acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e4b37c74-486e-4801-8b07-3de3c1fa126c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66b56cc6-c6ab-4c7b-b5bd-44c05ab6e2c3" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e4b37c74-486e-4801-8b07-3de3c1fa126c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_d43697cc-2ee8-4ac7-a2d8-7e962ecad212" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_srt_OwnershipAxis_d43697cc-2ee8-4ac7-a2d8-7e962ecad212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6456ec83-c03f-49d0-ba7c-d10a57e2fa06" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_d43697cc-2ee8-4ac7-a2d8-7e962ecad212" xlink:to="loc_srt_OwnershipDomain_6456ec83-c03f-49d0-ba7c-d10a57e2fa06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_01527681-3a3f-410b-969f-97426389004f" xlink:href="ameh-20210930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_6456ec83-c03f-49d0-ba7c-d10a57e2fa06" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_01527681-3a3f-410b-969f-97426389004f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_baa4c26b-c98e-48f1-a4ec-9b0c95e1413d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_dei_LegalEntityAxis_baa4c26b-c98e-48f1-a4ec-9b0c95e1413d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1f0202d5-3500-4d52-8fb4-fa7d0acbf26b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_baa4c26b-c98e-48f1-a4ec-9b0c95e1413d" xlink:to="loc_dei_EntityDomain_1f0202d5-3500-4d52-8fb4-fa7d0acbf26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_57b1e8d8-7c64-40f9-90e9-979a317918a1" xlink:href="ameh-20210930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1f0202d5-3500-4d52-8fb4-fa7d0acbf26b" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_57b1e8d8-7c64-40f9-90e9-979a317918a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_c68f0921-0d1c-4859-8152-f9c47f578804" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1f0202d5-3500-4d52-8fb4-fa7d0acbf26b" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_c68f0921-0d1c-4859-8152-f9c47f578804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_29a9c2e3-64de-4443-94c5-7bf3d37f0327" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_29a9c2e3-64de-4443-94c5-7bf3d37f0327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_796e76ea-b3e5-4e60-bab9-2a38f3e80ded" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_29a9c2e3-64de-4443-94c5-7bf3d37f0327" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_796e76ea-b3e5-4e60-bab9-2a38f3e80ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_9acce27c-001d-4c60-a4c3-ebada3a68434" xlink:href="ameh-20210930.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_796e76ea-b3e5-4e60-bab9-2a38f3e80ded" xlink:to="loc_ameh_UniversalCareIncMember_9acce27c-001d-4c60-a4c3-ebada3a68434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c966c4d8-3c6c-48e1-b3a6-129f5b3e8303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c966c4d8-3c6c-48e1-b3a6-129f5b3e8303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f348323-f02d-4c8a-9ccf-13adfd14f269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c966c4d8-3c6c-48e1-b3a6-129f5b3e8303" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f348323-f02d-4c8a-9ccf-13adfd14f269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_633264cf-5c2e-42ae-a5dc-087a911fb36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f348323-f02d-4c8a-9ccf-13adfd14f269" xlink:to="loc_us-gaap_CertificatesOfDepositMember_633264cf-5c2e-42ae-a5dc-087a911fb36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ed79f0-91b6-41cf-8262-ae49de1dc863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ed79f0-91b6-41cf-8262-ae49de1dc863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_44899b0c-ab20-496f-af4f-154c081101b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ed79f0-91b6-41cf-8262-ae49de1dc863" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_44899b0c-ab20-496f-af4f-154c081101b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_fcc12321-23e0-4443-bc0d-15a8f6f21ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_44899b0c-ab20-496f-af4f-154c081101b6" xlink:to="loc_us-gaap_InterestRateSwapMember_fcc12321-23e0-4443-bc0d-15a8f6f21ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_475b9c00-7b9a-4325-984f-ff113e439282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_475b9c00-7b9a-4325-984f-ff113e439282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_fc1a182b-aceb-4373-888b-55897a469454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_475b9c00-7b9a-4325-984f-ff113e439282" xlink:to="loc_us-gaap_HedgingRelationshipDomain_fc1a182b-aceb-4373-888b-55897a469454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_2a5f9fb4-8e67-47a7-82af-7c1198c543f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_fc1a182b-aceb-4373-888b-55897a469454" xlink:to="loc_us-gaap_CashFlowHedgingMember_2a5f9fb4-8e67-47a7-82af-7c1198c543f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7f4d3dfe-79f4-4ff1-bc2d-0bf76a14e7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_us-gaap_HedgingDesignationAxis_7f4d3dfe-79f4-4ff1-bc2d-0bf76a14e7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4b364c60-33e6-4595-9183-da539518cd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7f4d3dfe-79f4-4ff1-bc2d-0bf76a14e7f3" xlink:to="loc_us-gaap_HedgingDesignationDomain_4b364c60-33e6-4595-9183-da539518cd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5939e026-a2f8-4563-9e8a-13cba44f0518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_4b364c60-33e6-4595-9183-da539518cd5d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5939e026-a2f8-4563-9e8a-13cba44f0518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_061fdf2b-a76e-41d2-8e2e-2aa3278fca68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_061fdf2b-a76e-41d2-8e2e-2aa3278fca68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_688d8701-daf4-4bad-9e88-6c978879f783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_061fdf2b-a76e-41d2-8e2e-2aa3278fca68" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_688d8701-daf4-4bad-9e88-6c978879f783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6e981bbc-d66c-4c5a-86c3-0fd0642f809e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_688d8701-daf4-4bad-9e88-6c978879f783" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6e981bbc-d66c-4c5a-86c3-0fd0642f809e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:href="ameh-20210930.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_8fa15286-cbf1-48b1-a7bd-284bf36d462e" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b02e3ff5-7ace-4d06-8d32-2c5718766ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b02e3ff5-7ace-4d06-8d32-2c5718766ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_dfef5328-d2c0-4288-96ca-6b58ce0058a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_NumberOfReportableSegments_dfef5328-d2c0-4288-96ca-6b58ce0058a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_1a9a8d14-fd50-48c4-a512-be4dae962eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_CashUninsuredAmount_1a9a8d14-fd50-48c4-a512-be4dae962eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_113dfdc5-913b-4bbd-a642-6c4455ff2f30" xlink:href="ameh-20210930.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_113dfdc5-913b-4bbd-a642-6c4455ff2f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_32037e18-3720-40eb-9ccb-717c562d076e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_32037e18-3720-40eb-9ccb-717c562d076e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_633ba24b-b346-4de1-b0a8-7d5b7f39b685" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_633ba24b-b346-4de1-b0a8-7d5b7f39b685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_05658e97-64b8-4ebb-baa8-4343a18d1e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_05658e97-64b8-4ebb-baa8-4343a18d1e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_5cee10d0-7bbd-4f07-9c4e-48cec5dfd3ec" xlink:href="ameh-20210930.xsd#ameh_PaymentsToAcquireCommonStockAndWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_5cee10d0-7bbd-4f07-9c4e-48cec5dfd3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_37a1719e-5a85-4c43-803f-1beae3154c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_37a1719e-5a85-4c43-803f-1beae3154c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_78285b16-ddfa-4c4f-b56c-470719dd5699" xlink:href="ameh-20210930.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_78285b16-ddfa-4c4f-b56c-470719dd5699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f85c22dc-df88-4b41-9ddf-4a718f524828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_f85c22dc-df88-4b41-9ddf-4a718f524828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_245077ee-0a3f-4828-b340-e203572f3991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_245077ee-0a3f-4828-b340-e203572f3991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_d926b2ba-32d0-41fe-8d4b-d0616574a741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_NumberOfReportingUnits_d926b2ba-32d0-41fe-8d4b-d0616574a741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6d0369ac-c19d-41d6-bc55-014268cdd6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6d0369ac-c19d-41d6-bc55-014268cdd6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_75862b95-57d7-4417-b94a-c543fff82d77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_Goodwill_75862b95-57d7-4417-b94a-c543fff82d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_89d68638-069e-4380-ba0b-84f3e1b7db98" xlink:href="ameh-20210930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_89d68638-069e-4380-ba0b-84f3e1b7db98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_9be4ac47-d5c8-441a-b98c-3d6c66962b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_9be4ac47-d5c8-441a-b98c-3d6c66962b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_63b6354e-12b3-4f14-9f5b-eeeb9ec8ee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_DerivativeAssets_63b6354e-12b3-4f14-9f5b-eeeb9ec8ee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_18c5f793-3d2c-4d70-908e-832178ffb89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_18c5f793-3d2c-4d70-908e-832178ffb89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_c3d4b414-761d-497c-b9d1-cf7d90934fb2" xlink:href="ameh-20210930.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_c3d4b414-761d-497c-b9d1-cf7d90934fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears_a6d5d052-42bc-4cfb-93c9-60cb5580cc3f" xlink:href="ameh-20210930.xsd#ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears_a6d5d052-42bc-4cfb-93c9-60cb5580cc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount_10c18ad3-1811-4cc6-86d0-fe5a53ce5747" xlink:href="ameh-20210930.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_PaymentOfRevenueMonthlyAmount_10c18ad3-1811-4cc6-86d0-fe5a53ce5747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue_c58cd750-dd5b-4c88-a40f-251e02e1b493" xlink:href="ameh-20210930.xsd#ameh_PaymentOfRevenue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_PaymentOfRevenue_c58cd750-dd5b-4c88-a40f-251e02e1b493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueRevenueRecognized_d0ad8f35-9db5-4a12-b257-f7c570a8c57b" xlink:href="ameh-20210930.xsd#ameh_PaymentOfRevenueRevenueRecognized"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_PaymentOfRevenueRevenueRecognized_d0ad8f35-9db5-4a12-b257-f7c570a8c57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7bcd682c-665c-48a1-a2b1-5193da7c7aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7bcd682c-665c-48a1-a2b1-5193da7c7aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f6d8536c-0326-43b8-b6e1-7f2e19760a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f6d8536c-0326-43b8-b6e1-7f2e19760a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ea3473c3-efc1-40ea-b186-72771c451646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ea3473c3-efc1-40ea-b186-72771c451646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_ef7d4c94-f5b1-455f-a6e4-a24a7d203a27" xlink:href="ameh-20210930.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_ef7d4c94-f5b1-455f-a6e4-a24a7d203a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_1f4440fc-d98d-47f7-a942-9f6cb1951001" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_1f4440fc-d98d-47f7-a942-9f6cb1951001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_e3e96e39-fcea-4349-8ec6-b0071922f956" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_e3e96e39-fcea-4349-8ec6-b0071922f956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_629d30f8-c265-48ba-8f11-558d7143bb3d" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_629d30f8-c265-48ba-8f11-558d7143bb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_855d1a44-17fe-4d73-8d93-a91ee08fb1e1" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_abc010b7-cb2e-450a-8e82-4671006a2088" xlink:to="loc_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_855d1a44-17fe-4d73-8d93-a91ee08fb1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_53f926f9-8752-42f1-b64e-9ecc04f4bc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7dd99098-8c5c-4c08-a4dd-36a630c7b42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_53f926f9-8752-42f1-b64e-9ecc04f4bc9e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7dd99098-8c5c-4c08-a4dd-36a630c7b42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9588b8b9-449f-4339-9cd1-1d740ad75f64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7dd99098-8c5c-4c08-a4dd-36a630c7b42d" xlink:to="loc_srt_MajorCustomersAxis_9588b8b9-449f-4339-9cd1-1d740ad75f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f86c3d71-18b8-417c-a9f1-e7e4bd82a750" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9588b8b9-449f-4339-9cd1-1d740ad75f64" xlink:to="loc_srt_NameOfMajorCustomerDomain_f86c3d71-18b8-417c-a9f1-e7e4bd82a750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_2a8b7f27-86c9-443f-8fee-541165d9ec71" xlink:href="ameh-20210930.xsd#ameh_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f86c3d71-18b8-417c-a9f1-e7e4bd82a750" xlink:to="loc_ameh_CommercialMember_2a8b7f27-86c9-443f-8fee-541165d9ec71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_b4c9938e-c777-4d0a-b9b7-bcd67a1d3606" xlink:href="ameh-20210930.xsd#ameh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f86c3d71-18b8-417c-a9f1-e7e4bd82a750" xlink:to="loc_ameh_MedicareMember_b4c9938e-c777-4d0a-b9b7-bcd67a1d3606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_c9bfbfb6-d405-4044-8186-bdeda44ba9bd" xlink:href="ameh-20210930.xsd#ameh_MedicaidMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f86c3d71-18b8-417c-a9f1-e7e4bd82a750" xlink:to="loc_ameh_MedicaidMember_c9bfbfb6-d405-4044-8186-bdeda44ba9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_342948d3-1bde-42ea-a02c-92ded9fdf208" xlink:href="ameh-20210930.xsd#ameh_OtherThirdPartiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f86c3d71-18b8-417c-a9f1-e7e4bd82a750" xlink:to="loc_ameh_OtherThirdPartiesMember_342948d3-1bde-42ea-a02c-92ded9fdf208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b47ef0e0-4113-4ad2-964e-ea0e2bbfde6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7dd99098-8c5c-4c08-a4dd-36a630c7b42d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b47ef0e0-4113-4ad2-964e-ea0e2bbfde6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e65c5ab8-1a8b-415a-a065-212f98967908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b47ef0e0-4113-4ad2-964e-ea0e2bbfde6a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e65c5ab8-1a8b-415a-a065-212f98967908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_550c2edd-c949-4bfc-83b4-f09b54349aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_c2e0ce8d-6957-470f-9fad-3aa65be2c74f" xlink:href="ameh-20210930.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_550c2edd-c949-4bfc-83b4-f09b54349aff" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_c2e0ce8d-6957-470f-9fad-3aa65be2c74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d320d9b-af33-4031-b791-cdb3b83b1c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_c2e0ce8d-6957-470f-9fad-3aa65be2c74f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d320d9b-af33-4031-b791-cdb3b83b1c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3ebc991-1137-41c1-abb3-170999c6642b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d320d9b-af33-4031-b791-cdb3b83b1c66" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3ebc991-1137-41c1-abb3-170999c6642b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_f5446bf0-aba7-473c-9bdf-f548fdb70893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3ebc991-1137-41c1-abb3-170999c6642b" xlink:to="loc_us-gaap_SalesRevenueNetMember_f5446bf0-aba7-473c-9bdf-f548fdb70893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_970f08bf-3546-439d-9006-9314b619feba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3ebc991-1137-41c1-abb3-170999c6642b" xlink:to="loc_us-gaap_AccountsReceivableMember_970f08bf-3546-439d-9006-9314b619feba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_56fdde31-b070-40ff-9c6b-71416da17dc0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_c2e0ce8d-6957-470f-9fad-3aa65be2c74f" xlink:to="loc_srt_MajorCustomersAxis_56fdde31-b070-40ff-9c6b-71416da17dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_56fdde31-b070-40ff-9c6b-71416da17dc0" xlink:to="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_37ad9ece-3c83-4713-98b9-12f1e2d0fde6" xlink:href="ameh-20210930.xsd#ameh_PayorAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:to="loc_ameh_PayorAMember_37ad9ece-3c83-4713-98b9-12f1e2d0fde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_6e8f39d1-9ffb-4ed3-9c75-0b8332a4279e" xlink:href="ameh-20210930.xsd#ameh_PayorBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:to="loc_ameh_PayorBMember_6e8f39d1-9ffb-4ed3-9c75-0b8332a4279e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_faa45f3d-afac-45c5-aacd-cd7c0f091af2" xlink:href="ameh-20210930.xsd#ameh_PayorCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:to="loc_ameh_PayorCMember_faa45f3d-afac-45c5-aacd-cd7c0f091af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_a70cd244-95a0-4648-9db0-07de023d9e40" xlink:href="ameh-20210930.xsd#ameh_PayorDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:to="loc_ameh_PayorDMember_a70cd244-95a0-4648-9db0-07de023d9e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_632af24e-d083-49f4-a790-82d604354fae" xlink:href="ameh-20210930.xsd#ameh_PayorFMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:to="loc_ameh_PayorFMember_632af24e-d083-49f4-a790-82d604354fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorGMember_91a9fb0f-b868-48db-83e1-85a5c623101a" xlink:href="ameh-20210930.xsd#ameh_PayorGMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7a3d7703-6c17-4d01-a97d-5b778f423f66" xlink:to="loc_ameh_PayorGMember_91a9fb0f-b868-48db-83e1-85a5c623101a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ca71739d-89e5-4d49-9f7e-aa5d82f776d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_c2e0ce8d-6957-470f-9fad-3aa65be2c74f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ca71739d-89e5-4d49-9f7e-aa5d82f776d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0cc9358d-f347-4380-a619-5ebe62b31549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ca71739d-89e5-4d49-9f7e-aa5d82f776d6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0cc9358d-f347-4380-a619-5ebe62b31549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c3e050f1-c4da-4c8e-b7fc-cece14396e71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0cc9358d-f347-4380-a619-5ebe62b31549" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c3e050f1-c4da-4c8e-b7fc-cece14396e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_803e08ef-118f-4e4e-adcb-9c6d4c5b4fb4" xlink:href="ameh-20210930.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_c2e0ce8d-6957-470f-9fad-3aa65be2c74f" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueLineItems_803e08ef-118f-4e4e-adcb-9c6d4c5b4fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a46e6ef7-a6ad-47b8-a9c7-da80d4cf3232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_803e08ef-118f-4e4e-adcb-9c6d4c5b4fb4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a46e6ef7-a6ad-47b8-a9c7-da80d4cf3232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aa337d5c-7af1-4c4c-970e-9e16d6b3aed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60692111-4616-4f27-bc11-1a2ad0e85ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa337d5c-7af1-4c4c-970e-9e16d6b3aed9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60692111-4616-4f27-bc11-1a2ad0e85ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a78319e-9892-457d-b7d6-1428ffd32c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60692111-4616-4f27-bc11-1a2ad0e85ea1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a78319e-9892-457d-b7d6-1428ffd32c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcb56c68-a6af-41cd-858b-264cd62bfaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a78319e-9892-457d-b7d6-1428ffd32c15" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcb56c68-a6af-41cd-858b-264cd62bfaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b04283b7-a87b-4f01-9b11-bba569274412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcb56c68-a6af-41cd-858b-264cd62bfaf3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b04283b7-a87b-4f01-9b11-bba569274412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_51b60ed0-33a2-4bff-8766-895eaf376926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcb56c68-a6af-41cd-858b-264cd62bfaf3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_51b60ed0-33a2-4bff-8766-895eaf376926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a5f7ce1f-2238-4c6e-8736-669fa91350dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcb56c68-a6af-41cd-858b-264cd62bfaf3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a5f7ce1f-2238-4c6e-8736-669fa91350dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ca44e3-231b-4123-a294-bfe0b34527f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_60692111-4616-4f27-bc11-1a2ad0e85ea1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ca44e3-231b-4123-a294-bfe0b34527f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ca44e3-231b-4123-a294-bfe0b34527f2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ff95318e-7abb-4e57-8875-07885e8d4065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ff95318e-7abb-4e57-8875-07885e8d4065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_922e6aaa-8bb8-4fbf-be52-278162df1f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_922e6aaa-8bb8-4fbf-be52-278162df1f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_28d63838-3d90-4dcd-bebb-0708344f4ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_28d63838-3d90-4dcd-bebb-0708344f4ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_25de5087-1888-42b5-946b-7f8d6df01a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:to="loc_us-gaap_DerivativeAssets_25de5087-1888-42b5-946b-7f8d6df01a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4e5416c3-a88c-4fcb-a4c9-718f1ccdacd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_14f15f46-bfaa-4733-aa85-2c1fdcc7cd17" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4e5416c3-a88c-4fcb-a4c9-718f1ccdacd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_257ffdae-9aaa-4710-b9ff-8beae4727748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ca44e3-231b-4123-a294-bfe0b34527f2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_257ffdae-9aaa-4710-b9ff-8beae4727748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6322ede4-74c9-4949-a1b7-f3f7b2c8266b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_257ffdae-9aaa-4710-b9ff-8beae4727748" xlink:to="loc_us-gaap_DerivativeLiabilities_6322ede4-74c9-4949-a1b7-f3f7b2c8266b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_33fc244d-cb49-4d6d-80a0-e382e06b0b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_257ffdae-9aaa-4710-b9ff-8beae4727748" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_33fc244d-cb49-4d6d-80a0-e382e06b0b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_074d7d2a-0f25-4ec7-a5c8-32b16e55718b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_257ffdae-9aaa-4710-b9ff-8beae4727748" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_074d7d2a-0f25-4ec7-a5c8-32b16e55718b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="simple" xlink:href="ameh-20210930.xsd#BusinessCombinationsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9682b563-ee63-42ef-bbf3-72e6535a4f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c38bd0a1-4a33-49c8-a731-d4657933b893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9682b563-ee63-42ef-bbf3-72e6535a4f43" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c38bd0a1-4a33-49c8-a731-d4657933b893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="simple" xlink:href="ameh-20210930.xsd#BusinessCombinationsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c7dedc95-058f-4dfa-8602-925904526e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_811096de-af34-416d-b9c0-9ceb2e58a666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c7dedc95-058f-4dfa-8602-925904526e30" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_811096de-af34-416d-b9c0-9ceb2e58a666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2fabace6-704e-4f3c-b1c8-f06dd82db32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7eeb06fe-0de9-4b4f-96d0-09d3e8a22dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2fabace6-704e-4f3c-b1c8-f06dd82db32d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7eeb06fe-0de9-4b4f-96d0-09d3e8a22dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_72e29583-3dff-40ac-99de-f07508d98331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7eeb06fe-0de9-4b4f-96d0-09d3e8a22dc4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_72e29583-3dff-40ac-99de-f07508d98331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6f8dddc-578d-4038-98f0-5f25eef511ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_72e29583-3dff-40ac-99de-f07508d98331" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6f8dddc-578d-4038-98f0-5f25eef511ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_afbaafc8-f677-41b5-a261-0630992876cd" xlink:href="ameh-20210930.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6f8dddc-578d-4038-98f0-5f25eef511ec" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_afbaafc8-f677-41b5-a261-0630992876cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_c1e689c5-b41e-4246-af18-be2d75aee93c" xlink:href="ameh-20210930.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6f8dddc-578d-4038-98f0-5f25eef511ec" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_c1e689c5-b41e-4246-af18-be2d75aee93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a0ff7545-4999-4966-8263-395480d5137c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7eeb06fe-0de9-4b4f-96d0-09d3e8a22dc4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a0ff7545-4999-4966-8263-395480d5137c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f3c6e6ef-d5e1-4889-83f5-4347491c93b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0ff7545-4999-4966-8263-395480d5137c" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f3c6e6ef-d5e1-4889-83f5-4347491c93b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ae5b084b-29f3-46ad-8a23-52bd353d31fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0ff7545-4999-4966-8263-395480d5137c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ae5b084b-29f3-46ad-8a23-52bd353d31fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_75ecca91-20f3-488e-a3a0-709515213d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0ff7545-4999-4966-8263-395480d5137c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_75ecca91-20f3-488e-a3a0-709515213d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_92443996-e3d2-4a77-b098-0dda71a1478f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0ff7545-4999-4966-8263-395480d5137c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_92443996-e3d2-4a77-b098-0dda71a1478f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#BusinessCombinationsandGoodwillSummaryofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3d96d909-b8b8-4d71-9e85-085944c97966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_d90a45cf-47be-4170-bdd5-c1ad30872821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3d96d909-b8b8-4d71-9e85-085944c97966" xlink:to="loc_us-gaap_GoodwillRollForward_d90a45cf-47be-4170-bdd5-c1ad30872821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bc49b520-e533-458a-8458-cb4dff5cacef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d90a45cf-47be-4170-bdd5-c1ad30872821" xlink:to="loc_us-gaap_Goodwill_bc49b520-e533-458a-8458-cb4dff5cacef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_33eace21-2e92-487f-b293-f8ea0b806907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d90a45cf-47be-4170-bdd5-c1ad30872821" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_33eace21-2e92-487f-b293-f8ea0b806907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3a9dbb18-78d0-47e2-ac44-ebb2c508ed4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d90a45cf-47be-4170-bdd5-c1ad30872821" xlink:to="loc_us-gaap_Goodwill_3a9dbb18-78d0-47e2-ac44-ebb2c508ed4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="ameh-20210930.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3deef83-208c-4290-b4df-7caa8351fa86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_82e3050d-00df-44c8-8174-0d1ed26bb0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3deef83-208c-4290-b4df-7caa8351fa86" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_82e3050d-00df-44c8-8174-0d1ed26bb0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="ameh-20210930.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c36c0dd-f289-4cc1-97d0-b93fbedcbcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_9560c8a4-435f-4f27-bf02-9dec580b6c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c36c0dd-f289-4cc1-97d0-b93fbedcbcc6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_9560c8a4-435f-4f27-bf02-9dec580b6c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_983b8a0e-bcc0-44e0-9716-8d84608a07a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c36c0dd-f289-4cc1-97d0-b93fbedcbcc6" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_983b8a0e-bcc0-44e0-9716-8d84608a07a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c9fb3f78-ad38-4a97-81b2-ac2ccc9c8bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b4afae9d-48f6-4a61-9615-6c2de23384a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c9fb3f78-ad38-4a97-81b2-ac2ccc9c8bb0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b4afae9d-48f6-4a61-9615-6c2de23384a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a37387ac-411e-4638-aa4f-0a168997f68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b4afae9d-48f6-4a61-9615-6c2de23384a1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a37387ac-411e-4638-aa4f-0a168997f68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a37387ac-411e-4638-aa4f-0a168997f68a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_6748832a-ffd4-4f70-8e0e-322d127b5de5" xlink:href="ameh-20210930.xsd#ameh_NetworkRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:to="loc_ameh_NetworkRelationshipsMember_6748832a-ffd4-4f70-8e0e-322d127b5de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_8d146dbc-2f24-406b-99be-48252b69593c" xlink:href="ameh-20210930.xsd#ameh_ManagementContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:to="loc_ameh_ManagementContractsMember_8d146dbc-2f24-406b-99be-48252b69593c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_824227c1-c0cc-4ed5-bc3c-af6b13607f93" xlink:href="ameh-20210930.xsd#ameh_MemberRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:to="loc_ameh_MemberRelationshipsMember_824227c1-c0cc-4ed5-bc3c-af6b13607f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_c0307b10-6598-4a46-a552-b79aa755843e" xlink:href="ameh-20210930.xsd#ameh_PatientManagementPlatformMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:to="loc_ameh_PatientManagementPlatformMember_c0307b10-6598-4a46-a552-b79aa755843e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_4cdeada2-1049-4027-9d13-997881cd0bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3edb22f4-2a8f-488c-abf7-9d78b53ff06e" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_4cdeada2-1049-4027-9d13-997881cd0bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76823a7c-857e-455e-9809-11cd144e7255" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b4afae9d-48f6-4a61-9615-6c2de23384a1" xlink:to="loc_srt_RangeAxis_76823a7c-857e-455e-9809-11cd144e7255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2012347a-752f-4eb9-acc8-7f060ab628b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_76823a7c-857e-455e-9809-11cd144e7255" xlink:to="loc_srt_RangeMember_2012347a-752f-4eb9-acc8-7f060ab628b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7be875c-2382-47e2-aa04-d423b2b9444f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2012347a-752f-4eb9-acc8-7f060ab628b1" xlink:to="loc_srt_MinimumMember_f7be875c-2382-47e2-aa04-d423b2b9444f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac43b141-21f1-4ea3-be54-cbcae27929e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2012347a-752f-4eb9-acc8-7f060ab628b1" xlink:to="loc_srt_MaximumMember_ac43b141-21f1-4ea3-be54-cbcae27929e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b4afae9d-48f6-4a61-9615-6c2de23384a1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e2f07253-fdd3-4d8f-9cc7-143710316f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e2f07253-fdd3-4d8f-9cc7-143710316f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_51ab574e-bbed-4120-abf4-bb341c3af985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_51ab574e-bbed-4120-abf4-bb341c3af985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_88140823-ec7f-4471-9eac-dd2ffadcbf20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_88140823-ec7f-4471-9eac-dd2ffadcbf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_caefc6d0-219d-46a2-87d6-8d0e29edcb51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_caefc6d0-219d-46a2-87d6-8d0e29edcb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2aa4ecc8-6d43-478f-8989-e294bb186d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2aa4ecc8-6d43-478f-8989-e294bb186d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7fa6d0c-446e-4152-a056-44eb25778d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c49593d8-2b33-4782-9ca6-c4db7c5e3c0f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7fa6d0c-446e-4152-a056-44eb25778d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f2171f0e-d901-418e-8077-e961c6c09d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c9fb3f78-ad38-4a97-81b2-ac2ccc9c8bb0" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f2171f0e-d901-418e-8077-e961c6c09d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3b1a4d59-6601-4d2e-9847-c3d1811724de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f2171f0e-d901-418e-8077-e961c6c09d21" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3b1a4d59-6601-4d2e-9847-c3d1811724de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_57b6128f-62cf-475d-b4c1-619eb21441cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3b1a4d59-6601-4d2e-9847-c3d1811724de" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_57b6128f-62cf-475d-b4c1-619eb21441cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_a363fe20-2582-4185-a8d7-bd08eab6b41b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_57b6128f-62cf-475d-b4c1-619eb21441cf" xlink:to="loc_us-gaap_TrademarksMember_a363fe20-2582-4185-a8d7-bd08eab6b41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_bc5feac3-0879-4f5b-b4b5-d2dfc7048a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f2171f0e-d901-418e-8077-e961c6c09d21" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_bc5feac3-0879-4f5b-b4b5-d2dfc7048a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_13657a66-3669-4d97-b34c-e90c9c7e3a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_bc5feac3-0879-4f5b-b4b5-d2dfc7048a80" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_13657a66-3669-4d97-b34c-e90c9c7e3a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20210930.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a6658a36-6b24-47e7-9921-d629c2932095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d2126481-26bb-4e3d-bed5-e3f5799a2f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a6658a36-6b24-47e7-9921-d629c2932095" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d2126481-26bb-4e3d-bed5-e3f5799a2f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_daf9401d-18a1-4c57-babb-1c616c11da80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_998f736c-ac04-4420-b37d-32cd8a23a839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_daf9401d-18a1-4c57-babb-1c616c11da80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_998f736c-ac04-4420-b37d-32cd8a23a839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_52797080-1bc9-42fa-b30f-c1d4fae1e0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_daf9401d-18a1-4c57-babb-1c616c11da80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_52797080-1bc9-42fa-b30f-c1d4fae1e0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e2ac65dc-31c2-4b25-91ef-d0d7c132c373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_daf9401d-18a1-4c57-babb-1c616c11da80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e2ac65dc-31c2-4b25-91ef-d0d7c132c373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7701a189-7a07-4b46-8fe6-6ee624f95ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_daf9401d-18a1-4c57-babb-1c616c11da80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7701a189-7a07-4b46-8fe6-6ee624f95ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7d9d0c18-3617-4246-b1db-c9fc29fd35af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_daf9401d-18a1-4c57-babb-1c616c11da80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7d9d0c18-3617-4246-b1db-c9fc29fd35af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_3427aa0f-fc2a-4da2-b3a8-63aa81f757fb" xlink:href="ameh-20210930.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_daf9401d-18a1-4c57-babb-1c616c11da80" xlink:to="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_3427aa0f-fc2a-4da2-b3a8-63aa81f757fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36cf3740-a52f-4093-8a50-63b2f93a5975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_daf9401d-18a1-4c57-babb-1c616c11da80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_36cf3740-a52f-4093-8a50-63b2f93a5975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="simple" xlink:href="ameh-20210930.xsd#InvestmentsinOtherEntitiesEquityMethod"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_1507eb7d-dfd1-4426-a53a-93590b669c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_47bb2f3b-ef6c-411d-9216-4481f8f6af62" xlink:href="ameh-20210930.xsd#ameh_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_1507eb7d-dfd1-4426-a53a-93590b669c7c" xlink:to="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_47bb2f3b-ef6c-411d-9216-4481f8f6af62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="simple" xlink:href="ameh-20210930.xsd#InvestmentsinOtherEntitiesEquityMethodTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_6206654c-fc41-4267-b123-8337fa7e7878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_ecb22c4f-ea28-4631-9bda-5f30464e032d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_6206654c-fc41-4267-b123-8337fa7e7878" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_ecb22c4f-ea28-4631-9bda-5f30464e032d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_6b0c3f87-0948-4d86-83e6-1a2466cf6f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_861b0130-a29c-416a-81cf-4bcd91b20932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_6b0c3f87-0948-4d86-83e6-1a2466cf6f9f" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_861b0130-a29c-416a-81cf-4bcd91b20932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c1dc84f-69c2-414e-bc54-cda8486fe8e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_861b0130-a29c-416a-81cf-4bcd91b20932" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c1dc84f-69c2-414e-bc54-cda8486fe8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8c1dc84f-69c2-414e-bc54-cda8486fe8e5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_4f7fcdca-20f3-4083-b0a9-b10fd9088ed7" xlink:href="ameh-20210930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_4f7fcdca-20f3-4083-b0a9-b10fd9088ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_872d6179-075b-48a2-877c-39be5614e776" xlink:href="ameh-20210930.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_872d6179-075b-48a2-877c-39be5614e776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_6c5fef48-e792-48aa-9196-b104a96244d8" xlink:href="ameh-20210930.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_6c5fef48-e792-48aa-9196-b104a96244d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_306338aa-7cd5-43c3-8ffb-d6babbb3c9d0" xlink:href="ameh-20210930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_306338aa-7cd5-43c3-8ffb-d6babbb3c9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_679f3a16-308b-451a-9e1c-11e63153fe4c" xlink:href="ameh-20210930.xsd#ameh_OneMSOLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_OneMSOLLCMember_679f3a16-308b-451a-9e1c-11e63153fe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_c5c05caa-0403-4bd0-83a3-ff4cdc8ee4fd" xlink:href="ameh-20210930.xsd#ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_c5c05caa-0403-4bd0-83a3-ff4cdc8ee4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_11b6b5b1-059b-41ff-8ffc-7d352c261561" xlink:href="ameh-20210930.xsd#ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_11b6b5b1-059b-41ff-8ffc-7d352c261561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_a1521698-e90d-4f12-a3b0-391c152ac71e" xlink:href="ameh-20210930.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_adea58d5-31b3-4706-bd46-c78b4c5adf7c" xlink:to="loc_ameh_CAIPAMSOLLCMember_a1521698-e90d-4f12-a3b0-391c152ac71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b6e04dc6-6433-4a9d-9909-957570df544f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_861b0130-a29c-416a-81cf-4bcd91b20932" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b6e04dc6-6433-4a9d-9909-957570df544f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_b6e04dc6-6433-4a9d-9909-957570df544f" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d4608f3a-a1b9-47b5-b14d-8679ee22e1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_us-gaap_EquityMethodInvestments_d4608f3a-a1b9-47b5-b14d-8679ee22e1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentAdditionalInvestment_c51d5878-369e-44b0-9835-ff2cd8b5dc72" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentAdditionalInvestment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_ameh_EquityMethodInvestmentAdditionalInvestment_c51d5878-369e-44b0-9835-ff2cd8b5dc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9ae69d48-245c-4251-b01e-02e9050adb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9ae69d48-245c-4251-b01e-02e9050adb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_6b269273-0a3a-45c6-9a16-e389b94e74ab" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_6b269273-0a3a-45c6-9a16-e389b94e74ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsConsolidated_78b78467-7b63-4592-8472-86b24cd1122b" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentsConsolidated"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_ameh_EquityMethodInvestmentsConsolidated_78b78467-7b63-4592-8472-86b24cd1122b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_ca1defab-69f4-4df6-86bc-637bdb17f5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_ca1defab-69f4-4df6-86bc-637bdb17f5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ad8586eb-a774-48e1-b10b-3b90ef1389fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_34dfd158-0f3a-4eca-bf24-b9f0098c105c" xlink:to="loc_us-gaap_EquityMethodInvestments_ad8586eb-a774-48e1-b10b-3b90ef1389fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d942d1f7-f98d-468c-b53d-1dd12a50e711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d942d1f7-f98d-468c-b53d-1dd12a50e711" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b79019e-a8c4-4af6-a046-e752b2c7d970" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b79019e-a8c4-4af6-a046-e752b2c7d970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b79019e-a8c4-4af6-a046-e752b2c7d970" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_f564cb78-fd7a-4ae6-ade4-251aa291ce8d" xlink:href="ameh-20210930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_f564cb78-fd7a-4ae6-ade4-251aa291ce8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_a8700011-751e-48e6-bfbb-c7fad31ca4b7" xlink:href="ameh-20210930.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_a8700011-751e-48e6-bfbb-c7fad31ca4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_54f66e3b-408f-4515-b8c6-42ebe1485e88" xlink:href="ameh-20210930.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_54f66e3b-408f-4515-b8c6-42ebe1485e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_470d6a10-12f3-487e-b546-a2977fa8e36e" xlink:href="ameh-20210930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_470d6a10-12f3-487e-b546-a2977fa8e36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_aae82279-b1db-4248-b0fe-463eea114027" xlink:href="ameh-20210930.xsd#ameh_OneMSOLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_OneMSOLLCMember_aae82279-b1db-4248-b0fe-463eea114027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_743696a4-6ba0-4042-b077-1bd777dc0396" xlink:href="ameh-20210930.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_743696a4-6ba0-4042-b077-1bd777dc0396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_7b0e5df2-893f-49f5-8d92-87402d25764f" xlink:href="ameh-20210930.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_7b0e5df2-893f-49f5-8d92-87402d25764f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_8e5b42ea-c921-4ae8-829d-0078656d54ee" xlink:href="ameh-20210930.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b9d8fe87-966f-4433-8b56-6d8814803dfd" xlink:to="loc_ameh_CAIPAMSOLLCMember_8e5b42ea-c921-4ae8-829d-0078656d54ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_81aded2c-081a-456e-b9da-a05aafb35d0c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_dei_LegalEntityAxis_81aded2c-081a-456e-b9da-a05aafb35d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_aee7524d-e54a-4a68-ac56-a4b53c989770" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_81aded2c-081a-456e-b9da-a05aafb35d0c" xlink:to="loc_dei_EntityDomain_aee7524d-e54a-4a68-ac56-a4b53c989770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_fa849121-09ce-4bef-8705-1d25348dfee9" xlink:href="ameh-20210930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_aee7524d-e54a-4a68-ac56-a4b53c989770" xlink:to="loc_ameh_APCAndAPCLSMAMember_fa849121-09ce-4bef-8705-1d25348dfee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_ed56506f-a4ff-4303-81f2-465a958bb722" xlink:href="ameh-20210930.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_APCAndAPCLSMAMember_fa849121-09ce-4bef-8705-1d25348dfee9" xlink:to="loc_ameh_ApcLsmaMember_ed56506f-a4ff-4303-81f2-465a958bb722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_714ca51a-5fb6-4ffd-acec-7fc120453b0a" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_APCAndAPCLSMAMember_fa849121-09ce-4bef-8705-1d25348dfee9" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_714ca51a-5fb6-4ffd-acec-7fc120453b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember_06680d34-f86e-43e5-9523-15a98e9dfb53" xlink:href="ameh-20210930.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_aee7524d-e54a-4a68-ac56-a4b53c989770" xlink:to="loc_ameh_CollegeStreetInvestmentLpMember_06680d34-f86e-43e5-9523-15a98e9dfb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_81b0a2a7-2885-46af-844a-3030ecb21df1" xlink:href="ameh-20210930.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_aee7524d-e54a-4a68-ac56-a4b53c989770" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_81b0a2a7-2885-46af-844a-3030ecb21df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_65ccb7a2-3df6-49cf-85af-651eb5b9eb68" xlink:href="ameh-20210930.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_aee7524d-e54a-4a68-ac56-a4b53c989770" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_65ccb7a2-3df6-49cf-85af-651eb5b9eb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis_e687c022-cad0-4c55-b5d6-ee5204fc8508" xlink:href="ameh-20210930.xsd#ameh_ContractTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_ameh_ContractTypeAxis_e687c022-cad0-4c55-b5d6-ee5204fc8508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_ca53e4de-307e-47fb-b3fd-33f1b08b45fc" xlink:href="ameh-20210930.xsd#ameh_ContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeAxis_e687c022-cad0-4c55-b5d6-ee5204fc8508" xlink:to="loc_ameh_ContractTypeDomain_ca53e4de-307e-47fb-b3fd-33f1b08b45fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember_ec6174bd-cc66-4288-8078-112ea4eba2fd" xlink:href="ameh-20210930.xsd#ameh_AncillaryServiceContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeDomain_ca53e4de-307e-47fb-b3fd-33f1b08b45fc" xlink:to="loc_ameh_AncillaryServiceContractMember_ec6174bd-cc66-4288-8078-112ea4eba2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f9e84678-085d-4eb4-936c-8f5db5de6b17" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_srt_CounterpartyNameAxis_f9e84678-085d-4eb4-936c-8f5db5de6b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bd33a9e-0ebe-425e-bc66-b20ef452304d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f9e84678-085d-4eb4-936c-8f5db5de6b17" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bd33a9e-0ebe-425e-bc66-b20ef452304d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_52cf731f-f10c-4eab-9042-808d1dcfb7f5" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bd33a9e-0ebe-425e-bc66-b20ef452304d" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_52cf731f-f10c-4eab-9042-808d1dcfb7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_943ce8dc-45e4-4202-917a-3e93f12bd42f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_srt_OwnershipAxis_943ce8dc-45e4-4202-917a-3e93f12bd42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_aa65d711-b5d1-4b13-b345-9832a8bdb668" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_943ce8dc-45e4-4202-917a-3e93f12bd42f" xlink:to="loc_srt_OwnershipDomain_aa65d711-b5d1-4b13-b345-9832a8bdb668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_820cf703-5d5a-4065-9004-b2fd65e526d4" xlink:href="ameh-20210930.xsd#ameh_MediPortalLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_aa65d711-b5d1-4b13-b345-9832a8bdb668" xlink:to="loc_ameh_MediPortalLLCMember_820cf703-5d5a-4065-9004-b2fd65e526d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_42d2a539-5f8e-4e00-9c7a-c4e41f7cf907" xlink:href="ameh-20210930.xsd#ameh_AchievaMedInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_aa65d711-b5d1-4b13-b345-9832a8bdb668" xlink:to="loc_ameh_AchievaMedInc.Member_42d2a539-5f8e-4e00-9c7a-c4e41f7cf907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5e18b622-86cd-446e-ad61-e542a66b5b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5e18b622-86cd-446e-ad61-e542a66b5b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_6bda22b6-b03d-4efc-a995-954b650e5e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5e18b622-86cd-446e-ad61-e542a66b5b9d" xlink:to="loc_us-gaap_ReceivableTypeDomain_6bda22b6-b03d-4efc-a995-954b650e5e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_2ad62749-d664-4eaf-97aa-e5e9d92d282b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_6bda22b6-b03d-4efc-a995-954b650e5e01" xlink:to="loc_us-gaap_NotesReceivableMember_2ad62749-d664-4eaf-97aa-e5e9d92d282b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1d0f30a-03da-418c-932e-9fe4e03cdfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1d0f30a-03da-418c-932e-9fe4e03cdfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3e271e71-49ac-4221-9b0f-469be3c792e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d1d0f30a-03da-418c-932e-9fe4e03cdfa4" xlink:to="loc_us-gaap_RelatedPartyDomain_3e271e71-49ac-4221-9b0f-469be3c792e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_06743caf-8fa8-418e-a019-2aeb5ffbb9c5" xlink:href="ameh-20210930.xsd#ameh_Dr.ArteagaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3e271e71-49ac-4221-9b0f-469be3c792e6" xlink:to="loc_ameh_Dr.ArteagaMember_06743caf-8fa8-418e-a019-2aeb5ffbb9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_61e234d5-446a-4e90-a930-78fc43de4670" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_6f7572cb-88d2-4ce9-832a-bdbba3c4323b" xlink:href="ameh-20210930.xsd#ameh_NumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_NumberOfEmployees_6f7572cb-88d2-4ce9-832a-bdbba3c4323b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_e23fc8ef-0017-4033-a3c1-3449952cfbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_e23fc8ef-0017-4033-a3c1-3449952cfbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ac420527-6d11-4916-8e15-49c145e6d778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ac420527-6d11-4916-8e15-49c145e6d778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_58505352-1df5-4245-afc6-4384aa5788b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_NotesReceivableNet_58505352-1df5-4245-afc6-4384aa5788b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_ce182ad7-1d13-4055-8ca7-71926b6c13e5" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_ce182ad7-1d13-4055-8ca7-71926b6c13e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_c806b143-6496-49d2-b24d-63d1c03b8392" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_c806b143-6496-49d2-b24d-63d1c03b8392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold_2a5a6eab-3d77-4a9b-b73f-b39f6a26327b" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentOwnershipPercentageSold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold_2a5a6eab-3d77-4a9b-b73f-b39f6a26327b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_af7486de-16f6-4b8d-a0c4-e333a1bd9457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_af7486de-16f6-4b8d-a0c4-e333a1bd9457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b1cd427e-d0d4-4368-a71d-d883e9f40a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b1cd427e-d0d4-4368-a71d-d883e9f40a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_35e85afd-5748-43df-93fd-f0f4bfb5ffea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_EquityMethodInvestments_35e85afd-5748-43df-93fd-f0f4bfb5ffea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_d0df268a-48b4-41dc-8c55-c37d29124018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_PaymentsForFees_d0df268a-48b4-41dc-8c55-c37d29124018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital_d65253c3-d8ce-407a-9106-cf83bfbd7f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_MembersCapital_d65253c3-d8ce-407a-9106-cf83bfbd7f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate_ccd4449d-5874-4ac9-8a21-371ad820b18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_PaymentsToAcquireRealEstate_ccd4449d-5874-4ac9-8a21-371ad820b18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_fcf153be-d34e-4806-92b1-09eccca1d323" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_fcf153be-d34e-4806-92b1-09eccca1d323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_56e87ac8-f8e1-41a1-8c72-79b9a08bac54" xlink:href="ameh-20210930.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_56e87ac8-f8e1-41a1-8c72-79b9a08bac54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_e62d6c94-9a38-40b7-8931-27332a891a43" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_e62d6c94-9a38-40b7-8931-27332a891a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_0532da99-08b3-4d03-a3a8-7e6bb1cc3c65" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_0532da99-08b3-4d03-a3a8-7e6bb1cc3c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_148ce622-53f0-45c2-b163-ad6269351996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_148ce622-53f0-45c2-b163-ad6269351996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8a370eab-6752-419e-9840-9221afcb3103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8a370eab-6752-419e-9840-9221afcb3103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_0b316bfc-de64-404b-9902-3069ca4f9d68" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_0b316bfc-de64-404b-9902-3069ca4f9d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_fdf5ce16-5e43-4f2d-a52a-437e1bc0baa1" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_fdf5ce16-5e43-4f2d-a52a-437e1bc0baa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_b0fbb1b5-1432-43c8-b1c0-8b05e61ebd65" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_b0fbb1b5-1432-43c8-b1c0-8b05e61ebd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_b9333af2-613b-475f-8041-aa8c9656c99a" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_b9333af2-613b-475f-8041-aa8c9656c99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_3b95f303-4845-4f66-95e4-487f73540017" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_3b95f303-4845-4f66-95e4-487f73540017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_01507f87-2109-4bb5-8c9d-4dc34d7891e6" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_01507f87-2109-4bb5-8c9d-4dc34d7891e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_879a9b19-9565-4be5-bf3b-62b24ed6bc7e" xlink:href="ameh-20210930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730c5577-2adb-4d2b-8269-e18458f3e00f" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_879a9b19-9565-4be5-bf3b-62b24ed6bc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_71780a61-0e2d-4d1e-93c3-900ada0299bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_12fb9f6d-3d9c-40da-a341-1914cf157f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_71780a61-0e2d-4d1e-93c3-900ada0299bd" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_12fb9f6d-3d9c-40da-a341-1914cf157f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2711bfad-ac25-495a-9c49-68ec9132abf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_12fb9f6d-3d9c-40da-a341-1914cf157f5a" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2711bfad-ac25-495a-9c49-68ec9132abf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b179d8b3-deda-4a36-bfa5-d227f88e4809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2711bfad-ac25-495a-9c49-68ec9132abf2" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b179d8b3-deda-4a36-bfa5-d227f88e4809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_77f74164-4e7f-4ba5-b085-9dc1acbc3c7d" xlink:href="ameh-20210930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b179d8b3-deda-4a36-bfa5-d227f88e4809" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_77f74164-4e7f-4ba5-b085-9dc1acbc3c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_8696319d-037a-426e-919f-934fafba87fb" xlink:href="ameh-20210930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b179d8b3-deda-4a36-bfa5-d227f88e4809" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_8696319d-037a-426e-919f-934fafba87fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2984990b-1b86-463f-ab42-b307b400b20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_12fb9f6d-3d9c-40da-a341-1914cf157f5a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2984990b-1b86-463f-ab42-b307b400b20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2984990b-1b86-463f-ab42-b307b400b20d" xlink:to="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3eaf7c9-7dd8-4e16-ae17-9dc1521ee705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3eaf7c9-7dd8-4e16-ae17-9dc1521ee705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_956935a1-400a-403d-89b8-6f96acb1f797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_RestrictedCashCurrent_956935a1-400a-403d-89b8-6f96acb1f797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7755ccd6-b678-49a3-8df3-51ece8744cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7755ccd6-b678-49a3-8df3-51ece8744cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e08fbe4d-7014-4bb5-bbaa-47d69b278043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_OtherAssetsCurrent_e08fbe4d-7014-4bb5-bbaa-47d69b278043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_2e490aea-95e5-4823-9489-cf3be7e30f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_OtherAssets_2e490aea-95e5-4823-9489-cf3be7e30f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0438e3dc-2b7c-46ef-8c13-ee98365f8d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0438e3dc-2b7c-46ef-8c13-ee98365f8d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_a057e617-6e40-4d17-9f08-04ba0252fa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_a057e617-6e40-4d17-9f08-04ba0252fa9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b8ea73a2-1284-4e83-8eb2-4fe5ef2ccb65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7df99fdf-5c63-4aa9-97ce-89f90f189747" xlink:to="loc_us-gaap_Assets_b8ea73a2-1284-4e83-8eb2-4fe5ef2ccb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4e668d00-92f8-4e2c-95e5-6c880e91f8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2984990b-1b86-463f-ab42-b307b400b20d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4e668d00-92f8-4e2c-95e5-6c880e91f8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d509725f-7b2b-4381-8eb6-2255f896be25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4e668d00-92f8-4e2c-95e5-6c880e91f8ab" xlink:to="loc_us-gaap_LiabilitiesCurrent_d509725f-7b2b-4381-8eb6-2255f896be25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b42c92f8-ad0c-4422-91d5-61147596ed0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4e668d00-92f8-4e2c-95e5-6c880e91f8ab" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b42c92f8-ad0c-4422-91d5-61147596ed0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a2e948b2-7384-4082-8f09-41b0970a14de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4e668d00-92f8-4e2c-95e5-6c880e91f8ab" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a2e948b2-7384-4082-8f09-41b0970a14de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2984990b-1b86-463f-ab42-b307b400b20d" xlink:to="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_87bcb54b-b553-4ce9-afc3-46a115ecfa10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_87bcb54b-b553-4ce9-afc3-46a115ecfa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ce4d98be-c922-4857-a3b2-f46f05ebc7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:to="loc_us-gaap_CostsAndExpenses_ce4d98be-c922-4857-a3b2-f46f05ebc7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_430ffb7d-353c-473b-9b1a-434fd7715a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:to="loc_us-gaap_OperatingIncomeLoss_430ffb7d-353c-473b-9b1a-434fd7715a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_68941a99-a5d5-4ef4-b75d-064bf48e5115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_68941a99-a5d5-4ef4-b75d-064bf48e5115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_93d0bba5-bf2a-4f63-9982-757b1ee52d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_93d0bba5-bf2a-4f63-9982-757b1ee52d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_87eb7ead-68db-4bfa-9f7d-2695427d62fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f1255571-8584-4f53-aac2-f86a10ff5fc4" xlink:to="loc_us-gaap_ProfitLoss_87eb7ead-68db-4bfa-9f7d-2695427d62fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="simple" xlink:href="ameh-20210930.xsd#LoanReceivableandLoanReceivableRelatedParties"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_fc0f3a56-2aa3-4773-9a09-5c7ab61f649f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock_2b63a172-b95c-4d2e-b551-47d814d50834" xlink:href="ameh-20210930.xsd#ameh_LoanReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_fc0f3a56-2aa3-4773-9a09-5c7ab61f649f" xlink:to="loc_ameh_LoanReceivableTextBlock_2b63a172-b95c-4d2e-b551-47d814d50834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_ec59a389-d60c-4e56-a3ab-30a047ff192a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5ceba20e-3ecf-4f2d-8514-c9baa62bca18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_ec59a389-d60c-4e56-a3ab-30a047ff192a" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5ceba20e-3ecf-4f2d-8514-c9baa62bca18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_39a4d7d8-6369-4d5f-8da1-ec7e7de18363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5ceba20e-3ecf-4f2d-8514-c9baa62bca18" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_39a4d7d8-6369-4d5f-8da1-ec7e7de18363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_c648d7b5-d678-4907-ad65-cad30280c5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_39a4d7d8-6369-4d5f-8da1-ec7e7de18363" xlink:to="loc_us-gaap_ReceivableTypeDomain_c648d7b5-d678-4907-ad65-cad30280c5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_0fd2d122-76a2-4094-a346-76e3eb8a737a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_c648d7b5-d678-4907-ad65-cad30280c5ff" xlink:to="loc_us-gaap_NotesReceivableMember_0fd2d122-76a2-4094-a346-76e3eb8a737a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b7d6d579-c7fc-4fdc-9887-7da5f318b75e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5ceba20e-3ecf-4f2d-8514-c9baa62bca18" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b7d6d579-c7fc-4fdc-9887-7da5f318b75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_63175917-b880-41d3-9fba-5751c844e320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b7d6d579-c7fc-4fdc-9887-7da5f318b75e" xlink:to="loc_us-gaap_RelatedPartyDomain_63175917-b880-41d3-9fba-5751c844e320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_da42c66f-d56b-4bd0-bde3-7b13e16c3dc0" xlink:href="ameh-20210930.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_63175917-b880-41d3-9fba-5751c844e320" xlink:to="loc_ameh_Pacific6EnterprisesMember_da42c66f-d56b-4bd0-bde3-7b13e16c3dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_6b0c027c-361b-4c8d-84c4-7b295ddd1675" xlink:href="ameh-20210930.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_63175917-b880-41d3-9fba-5751c844e320" xlink:to="loc_ameh_AHMCMember_6b0c027c-361b-4c8d-84c4-7b295ddd1675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b960aa85-d09d-4767-8886-510004313f25" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5ceba20e-3ecf-4f2d-8514-c9baa62bca18" xlink:to="loc_dei_LegalEntityAxis_b960aa85-d09d-4767-8886-510004313f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d40e0dcb-cd8f-407b-84d6-def5a4c0bbbc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_b960aa85-d09d-4767-8886-510004313f25" xlink:to="loc_dei_EntityDomain_d40e0dcb-cd8f-407b-84d6-def5a4c0bbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_c2b81222-d757-475b-996f-999f936f5878" xlink:href="ameh-20210930.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d40e0dcb-cd8f-407b-84d6-def5a4c0bbbc" xlink:to="loc_ameh_NetworkMedicalManagementMember_c2b81222-d757-475b-996f-999f936f5878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_1cacf867-5fad-4e9d-84cd-e2e195a1234d" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d40e0dcb-cd8f-407b-84d6-def5a4c0bbbc" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_1cacf867-5fad-4e9d-84cd-e2e195a1234d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79dd31c5-6e8d-4514-9e7f-55658feb3c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5ceba20e-3ecf-4f2d-8514-c9baa62bca18" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79dd31c5-6e8d-4514-9e7f-55658feb3c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_c639281f-5568-488e-8e5a-7aa7edaddfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79dd31c5-6e8d-4514-9e7f-55658feb3c35" xlink:to="loc_us-gaap_NotesReceivableNet_c639281f-5568-488e-8e5a-7aa7edaddfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_17c62291-4514-46d6-a57b-fce744ca589c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79dd31c5-6e8d-4514-9e7f-55658feb3c35" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_17c62291-4514-46d6-a57b-fce744ca589c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_a467dcc7-cf2c-4c75-9fb4-fe2ff3cc25ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79dd31c5-6e8d-4514-9e7f-55658feb3c35" xlink:to="loc_us-gaap_NotesReceivableGross_a467dcc7-cf2c-4c75-9fb4-fe2ff3cc25ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage_06289df9-bca3-459b-bdec-8210a82a845d" xlink:href="ameh-20210930.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_79dd31c5-6e8d-4514-9e7f-55658feb3c35" xlink:to="loc_ameh_FinanceReceivableInterestRateStatedPercentage_06289df9-bca3-459b-bdec-8210a82a845d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ameh-20210930.xsd#AccountsPayableandAccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3096c52c-8012-485c-b57b-5de0a1f8df6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_8b8de550-7924-4594-9153-e36c261d3277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3096c52c-8012-485c-b57b-5de0a1f8df6f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_8b8de550-7924-4594-9153-e36c261d3277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ameh-20210930.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3a5dd4e7-3d4b-4b8e-9bfc-a5a22d78f105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_64175b3f-123e-4c52-80c3-62ae3ac1a780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3a5dd4e7-3d4b-4b8e-9bfc-a5a22d78f105" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_64175b3f-123e-4c52-80c3-62ae3ac1a780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6443fa89-3621-4353-925e-967533542aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9b835169-942d-43a4-81a6-dad7486b2303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6443fa89-3621-4353-925e-967533542aaf" xlink:to="loc_us-gaap_AccountsPayableCurrent_9b835169-942d-43a4-81a6-dad7486b2303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_fcda449d-df07-42b1-a349-eb72f4b448e3" xlink:href="ameh-20210930.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6443fa89-3621-4353-925e-967533542aaf" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_fcda449d-df07-42b1-a349-eb72f4b448e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable_7670a5e1-6075-401a-8eff-34a92a347d2e" xlink:href="ameh-20210930.xsd#ameh_SubcontractorIPAPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6443fa89-3621-4353-925e-967533542aaf" xlink:to="loc_ameh_SubcontractorIPAPayable_7670a5e1-6075-401a-8eff-34a92a347d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_8cfc6cb1-60d0-4462-9b8a-295d204b7380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6443fa89-3621-4353-925e-967533542aaf" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_8cfc6cb1-60d0-4462-9b8a-295d204b7380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_0ae10578-5bb9-4a63-8ffc-d971a739dc99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6443fa89-3621-4353-925e-967533542aaf" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_0ae10578-5bb9-4a63-8ffc-d971a739dc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9f356bba-e5a8-4484-8ac2-df0a4fa0a317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6443fa89-3621-4353-925e-967533542aaf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9f356bba-e5a8-4484-8ac2-df0a4fa0a317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_91179641-f9ce-4a93-a7e6-25084bd6f6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6443fa89-3621-4353-925e-967533542aaf" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_91179641-f9ce-4a93-a7e6-25084bd6f6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c2743e8e-c757-43cc-869f-0341fcfac083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6443fa89-3621-4353-925e-967533542aaf" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c2743e8e-c757-43cc-869f-0341fcfac083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="simple" xlink:href="ameh-20210930.xsd#MedicalLiabilities"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_bf313d16-aced-40b6-a268-fbf8bf9bc3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_ddd5d2c3-2092-4676-98e3-7b657a24b1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_bf313d16-aced-40b6-a268-fbf8bf9bc3aa" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_ddd5d2c3-2092-4676-98e3-7b657a24b1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="simple" xlink:href="ameh-20210930.xsd#MedicalLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_4bde363c-2323-488a-ab12-849227599fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_6ef77f27-c285-4d5e-b822-44d2a68da88b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_4bde363c-2323-488a-ab12-849227599fcb" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_6ef77f27-c285-4d5e-b822-44d2a68da88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_5adc2d35-7550-47c3-8884-fbe76ee0395c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_2176e7ef-7a51-4092-835c-b8784099fc69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_5adc2d35-7550-47c3-8884-fbe76ee0395c" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_2176e7ef-7a51-4092-835c-b8784099fc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_dc21316a-fe97-4946-9368-1842792fc912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_2176e7ef-7a51-4092-835c-b8784099fc69" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_dc21316a-fe97-4946-9368-1842792fc912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_106fc9e6-a4b5-4b03-93d3-b364bc0db32c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_2176e7ef-7a51-4092-835c-b8784099fc69" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_106fc9e6-a4b5-4b03-93d3-b364bc0db32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract_0d4011f2-d7e7-4c0b-9cdc-9cff18999241" xlink:href="ameh-20210930.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_2176e7ef-7a51-4092-835c-b8784099fc69" xlink:to="loc_ameh_MedicalCareCostsAbstract_0d4011f2-d7e7-4c0b-9cdc-9cff18999241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_23c067f1-ac7e-4b7e-9b5e-1f17bef76ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_0d4011f2-d7e7-4c0b-9cdc-9cff18999241" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_23c067f1-ac7e-4b7e-9b5e-1f17bef76ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_cea0e7f0-1bdb-4ed8-b686-232f3a718f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_0d4011f2-d7e7-4c0b-9cdc-9cff18999241" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_cea0e7f0-1bdb-4ed8-b686-232f3a718f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_afea3c6a-2659-4734-bf4e-89c9774e2af3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_0d4011f2-d7e7-4c0b-9cdc-9cff18999241" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_afea3c6a-2659-4734-bf4e-89c9774e2af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract_0e499dfc-3e18-430c-b664-165bd562aaf6" xlink:href="ameh-20210930.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_2176e7ef-7a51-4092-835c-b8784099fc69" xlink:to="loc_ameh_PaymentsForMedicalCareCostsAbstract_0e499dfc-3e18-430c-b664-165bd562aaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_6d87e776-725d-4e64-95a3-d89bfb67bb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_0e499dfc-3e18-430c-b664-165bd562aaf6" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_6d87e776-725d-4e64-95a3-d89bfb67bb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_4722bceb-1b99-47db-a9ac-39e371675c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_0e499dfc-3e18-430c-b664-165bd562aaf6" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_4722bceb-1b99-47db-a9ac-39e371675c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_adc03ca5-6704-467e-99ab-2488cca9e05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_0e499dfc-3e18-430c-b664-165bd562aaf6" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_adc03ca5-6704-467e-99ab-2488cca9e05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_d23be0aa-e7af-4367-a4c7-0cfe5b62fe8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_2176e7ef-7a51-4092-835c-b8784099fc69" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_d23be0aa-e7af-4367-a4c7-0cfe5b62fe8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8f7d2355-6e0f-433b-9a0a-adfde2e3e597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_2176e7ef-7a51-4092-835c-b8784099fc69" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8f7d2355-6e0f-433b-9a0a-adfde2e3e597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit" xlink:type="simple" xlink:href="ameh-20210930.xsd#CreditFacilityBankLoansandLinesofCredit"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cbca10a5-2fd8-42b1-9b9a-fdff1cb4dacf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_f1b13667-7f41-406a-896c-fbffbf150cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cbca10a5-2fd8-42b1-9b9a-fdff1cb4dacf" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_f1b13667-7f41-406a-896c-fbffbf150cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables" xlink:type="simple" xlink:href="ameh-20210930.xsd#CreditFacilityBankLoansandLinesofCreditTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_92ad888e-297a-4f92-bf81-4c1addce94b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_d68c0203-3c78-4396-9c1f-8f7720168085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_92ad888e-297a-4f92-bf81-4c1addce94b1" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_d68c0203-3c78-4396-9c1f-8f7720168085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_aa5da544-c47d-4e49-9e04-ae1fe70c8a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_92ad888e-297a-4f92-bf81-4c1addce94b1" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_aa5da544-c47d-4e49-9e04-ae1fe70c8a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d4cd7525-5334-4558-b209-73c592317710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_5920859f-c2a8-4445-9fd7-883e90b57ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d4cd7525-5334-4558-b209-73c592317710" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_5920859f-c2a8-4445-9fd7-883e90b57ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_25daa970-5dcc-4ef5-8a4a-6cfe04b7cfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5920859f-c2a8-4445-9fd7-883e90b57ddf" xlink:to="loc_us-gaap_CreditFacilityAxis_25daa970-5dcc-4ef5-8a4a-6cfe04b7cfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9a9b8621-3bf4-4174-a37b-db8164882257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_25daa970-5dcc-4ef5-8a4a-6cfe04b7cfa2" xlink:to="loc_us-gaap_CreditFacilityDomain_9a9b8621-3bf4-4174-a37b-db8164882257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_dfdb934a-a48c-41d5-922f-ce736e6ba840" xlink:href="ameh-20210930.xsd#ameh_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_9a9b8621-3bf4-4174-a37b-db8164882257" xlink:to="loc_ameh_TermLoanAMember_dfdb934a-a48c-41d5-922f-ce736e6ba840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_42f60d2d-2677-4801-8021-3d70b7b9243d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_9a9b8621-3bf4-4174-a37b-db8164882257" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_42f60d2d-2677-4801-8021-3d70b7b9243d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0f469df0-2b2c-4afb-8f21-7434715a8840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5920859f-c2a8-4445-9fd7-883e90b57ddf" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0f469df0-2b2c-4afb-8f21-7434715a8840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3995e74b-8f04-473a-9614-86c8dfda4775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0f469df0-2b2c-4afb-8f21-7434715a8840" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3995e74b-8f04-473a-9614-86c8dfda4775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_be7b48cf-1083-4cec-b5ed-ea60118092a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3995e74b-8f04-473a-9614-86c8dfda4775" xlink:to="loc_us-gaap_RealEstateLoanMember_be7b48cf-1083-4cec-b5ed-ea60118092a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_4712ec7a-a45b-4ede-b6ad-f54f2b2bb3fc" xlink:href="ameh-20210930.xsd#ameh_ConstructionLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3995e74b-8f04-473a-9614-86c8dfda4775" xlink:to="loc_ameh_ConstructionLoanMember_4712ec7a-a45b-4ede-b6ad-f54f2b2bb3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_5fcfbc2f-0574-4276-bfe3-4f960c6a1e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5920859f-c2a8-4445-9fd7-883e90b57ddf" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_5fcfbc2f-0574-4276-bfe3-4f960c6a1e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c490de1b-93a3-4029-9b43-d3ad039378d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5fcfbc2f-0574-4276-bfe3-4f960c6a1e2b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c490de1b-93a3-4029-9b43-d3ad039378d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_da2997ae-8cbe-4c7a-a36f-8d358176715f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5fcfbc2f-0574-4276-bfe3-4f960c6a1e2b" xlink:to="loc_us-gaap_LongTermDebtCurrent_da2997ae-8cbe-4c7a-a36f-8d358176715f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9c693913-dd5d-423d-98cb-309452f254ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5fcfbc2f-0574-4276-bfe3-4f960c6a1e2b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9c693913-dd5d-423d-98cb-309452f254ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3d82f6dc-a228-4f89-b639-828a9f717752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_5fcfbc2f-0574-4276-bfe3-4f960c6a1e2b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3d82f6dc-a228-4f89-b639-828a9f717752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f6742abc-273e-4247-ada2-3b62b4ac7273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f6742abc-273e-4247-ada2-3b62b4ac7273" xlink:to="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_aa38ce97-ad41-47d3-8f66-22fb920d640b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_CreditFacilityAxis_aa38ce97-ad41-47d3-8f66-22fb920d640b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_aa38ce97-ad41-47d3-8f66-22fb920d640b" xlink:to="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_373d8f82-8555-4ffb-a83e-5cd6ac324ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_373d8f82-8555-4ffb-a83e-5cd6ac324ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5b14d614-6d45-4507-9480-377a57c72625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:to="loc_us-gaap_LineOfCreditMember_5b14d614-6d45-4507-9480-377a57c72625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_3892aaa1-0e55-4e72-8ae3-ec6769ece32e" xlink:href="ameh-20210930.xsd#ameh_TermLoanAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:to="loc_ameh_TermLoanAMember_3892aaa1-0e55-4e72-8ae3-ec6769ece32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_e66f6a5f-d4c3-40e9-a591-f0f1eca9253a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:to="loc_us-gaap_LetterOfCreditMember_e66f6a5f-d4c3-40e9-a591-f0f1eca9253a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_9961e618-c6fd-4779-a4a2-b86e36dd4b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:to="loc_us-gaap_BridgeLoanMember_9961e618-c6fd-4779-a4a2-b86e36dd4b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_e6422cda-e81d-4544-b775-ad3a7e8b6b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4d2f3214-d2c1-476b-8418-f8ecafd23bc2" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_e6422cda-e81d-4544-b775-ad3a7e8b6b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a146d338-9cdb-4b6b-b140-bdc76682c299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_DebtInstrumentAxis_a146d338-9cdb-4b6b-b140-bdc76682c299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a99ab95d-a070-408b-942f-f7efb086133e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a146d338-9cdb-4b6b-b140-bdc76682c299" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a99ab95d-a070-408b-942f-f7efb086133e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_e726216f-80e6-4548-8289-c499c35430db" xlink:href="ameh-20210930.xsd#ameh_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a99ab95d-a070-408b-942f-f7efb086133e" xlink:to="loc_ameh_CreditAgreementMember_e726216f-80e6-4548-8289-c499c35430db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember_f6523025-c911-4090-a562-ab6f430abb2b" xlink:href="ameh-20210930.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a99ab95d-a070-408b-942f-f7efb086133e" xlink:to="loc_ameh_AmendedCreditAgreementMember_f6523025-c911-4090-a562-ab6f430abb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_a05cf202-3da0-44fd-aecf-8cba1f4fd6f2" xlink:href="ameh-20210930.xsd#ameh_ConstructionLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a99ab95d-a070-408b-942f-f7efb086133e" xlink:to="loc_ameh_ConstructionLoanMember_a05cf202-3da0-44fd-aecf-8cba1f4fd6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_caf6e762-a212-4e3e-9ce8-7afdd134efca" xlink:href="ameh-20210930.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a99ab95d-a070-408b-942f-f7efb086133e" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_caf6e762-a212-4e3e-9ce8-7afdd134efca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a3461940-22f0-4b14-98d6-8f7d61306940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a3461940-22f0-4b14-98d6-8f7d61306940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b743df5e-208a-4611-ace8-85f58169922c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a3461940-22f0-4b14-98d6-8f7d61306940" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b743df5e-208a-4611-ace8-85f58169922c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c7fcf869-60d1-493b-8850-ff923b5850f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b743df5e-208a-4611-ace8-85f58169922c" xlink:to="loc_us-gaap_LineOfCreditMember_c7fcf869-60d1-493b-8850-ff923b5850f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_de4036dd-4d67-4e78-b1d8-0a808b4c3d36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_srt_RangeAxis_de4036dd-4d67-4e78-b1d8-0a808b4c3d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2b6e5d3f-095c-4f44-8e2f-cf0f72b1d3e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_de4036dd-4d67-4e78-b1d8-0a808b4c3d36" xlink:to="loc_srt_RangeMember_2b6e5d3f-095c-4f44-8e2f-cf0f72b1d3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37031fe7-4f97-4ae0-b30f-bfeccaa739c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2b6e5d3f-095c-4f44-8e2f-cf0f72b1d3e4" xlink:to="loc_srt_MinimumMember_37031fe7-4f97-4ae0-b30f-bfeccaa739c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1f1b23f-2db5-4e74-bde4-7cd7310a014c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2b6e5d3f-095c-4f44-8e2f-cf0f72b1d3e4" xlink:to="loc_srt_MaximumMember_b1f1b23f-2db5-4e74-bde4-7cd7310a014c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e5b07ff9-7efc-4ea9-ac98-801e8e885652" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_dei_LegalEntityAxis_e5b07ff9-7efc-4ea9-ac98-801e8e885652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e5b07ff9-7efc-4ea9-ac98-801e8e885652" xlink:to="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2fd1061f-f1bd-4c9a-81ef-6916ad4bb9c1" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2fd1061f-f1bd-4c9a-81ef-6916ad4bb9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_27411f14-8800-42c2-8c97-1b385a74c624" xlink:href="ameh-20210930.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_27411f14-8800-42c2-8c97-1b385a74c624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_60a0f931-752f-4cca-b79a-37250aa0dd60" xlink:href="ameh-20210930.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_AMGPropertiesLLCMember_60a0f931-752f-4cca-b79a-37250aa0dd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_2feeb1f5-8655-4ec6-8394-41f1cb382a25" xlink:href="ameh-20210930.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_ZLLPartnersLLCMember_2feeb1f5-8655-4ec6-8394-41f1cb382a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_c8a428ff-652f-46d8-8126-179ce9bf994e" xlink:href="ameh-20210930.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_c8a428ff-652f-46d8-8126-179ce9bf994e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_5481a353-b428-445a-8696-e8fa0781ae3e" xlink:href="ameh-20210930.xsd#ameh_ApaacoMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_ApaacoMember_5481a353-b428-445a-8696-e8fa0781ae3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_b6ce7e94-c9ce-480e-8dba-2fbc6996ca69" xlink:href="ameh-20210930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_890205ef-f61f-484a-a484-13ed90f2f1a3" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_b6ce7e94-c9ce-480e-8dba-2fbc6996ca69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_9090a800-c405-42f4-bf88-652cb04f1942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_VariableRateAxis_9090a800-c405-42f4-bf88-652cb04f1942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2d8a6941-28ae-4b8f-be95-e71f85f10762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_9090a800-c405-42f4-bf88-652cb04f1942" xlink:to="loc_us-gaap_VariableRateDomain_2d8a6941-28ae-4b8f-be95-e71f85f10762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_209a1966-cf25-4f22-bd81-b2987395e946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_2d8a6941-28ae-4b8f-be95-e71f85f10762" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_209a1966-cf25-4f22-bd81-b2987395e946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_d426871e-70ad-4493-b949-9e5a4b1e0f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_2d8a6941-28ae-4b8f-be95-e71f85f10762" xlink:to="loc_us-gaap_PrimeRateMember_d426871e-70ad-4493-b949-9e5a4b1e0f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_a0e800a5-4cc9-423f-ac52-f7e4b288f8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_a0e800a5-4cc9-423f-ac52-f7e4b288f8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b05128e6-58c9-42b7-9d18-9f215cb4dfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_a0e800a5-4cc9-423f-ac52-f7e4b288f8b0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b05128e6-58c9-42b7-9d18-9f215cb4dfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_a9da4447-32b4-4a7f-8808-4c55f2954693" xlink:href="ameh-20210930.xsd#ameh_PreferredBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b05128e6-58c9-42b7-9d18-9f215cb4dfc3" xlink:to="loc_ameh_PreferredBankMember_a9da4447-32b4-4a7f-8808-4c55f2954693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_11941075-7e74-4b19-82f3-d50af093457c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_AssetAcquisitionAxis_11941075-7e74-4b19-82f3-d50af093457c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_250d0ddb-ccb0-4802-9460-fed96457dfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_11941075-7e74-4b19-82f3-d50af093457c" xlink:to="loc_us-gaap_AssetAcquisitionDomain_250d0ddb-ccb0-4802-9460-fed96457dfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_6145ed19-4be1-465e-b657-24b46fa98052" xlink:href="ameh-20210930.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_250d0ddb-ccb0-4802-9460-fed96457dfb4" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_6145ed19-4be1-465e-b657-24b46fa98052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_77739653-3fd7-43f0-8d6b-c99f8ebca5f5" xlink:href="ameh-20210930.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_250d0ddb-ccb0-4802-9460-fed96457dfb4" xlink:to="loc_ameh_AMGPropertiesLLCMember_77739653-3fd7-43f0-8d6b-c99f8ebca5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_358ab9d7-6cdd-47e0-ad70-ab5ab6a23f19" xlink:href="ameh-20210930.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_250d0ddb-ccb0-4802-9460-fed96457dfb4" xlink:to="loc_ameh_ZLLPartnersLLCMember_358ab9d7-6cdd-47e0-ad70-ab5ab6a23f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a8506bbb-2cc1-4722-a1ee-4a73a471dae3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_srt_StatementScenarioAxis_a8506bbb-2cc1-4722-a1ee-4a73a471dae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3214da5e-dfd7-4b39-878a-cccf6d9d1a67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_a8506bbb-2cc1-4722-a1ee-4a73a471dae3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3214da5e-dfd7-4b39-878a-cccf6d9d1a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_88278554-5d72-487d-b7cb-77a80f9f4136" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3214da5e-dfd7-4b39-878a-cccf6d9d1a67" xlink:to="loc_srt_ScenarioForecastMember_88278554-5d72-487d-b7cb-77a80f9f4136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ff97b7f2-820d-4c57-968f-47949bace5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ff97b7f2-820d-4c57-968f-47949bace5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea0e53b3-5659-4001-b652-c3aa7409dba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ff97b7f2-820d-4c57-968f-47949bace5fb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea0e53b3-5659-4001-b652-c3aa7409dba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b925cd37-dc7b-4473-b9b5-f1ce34082951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea0e53b3-5659-4001-b652-c3aa7409dba1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b925cd37-dc7b-4473-b9b5-f1ce34082951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_35957883-b7ff-42c4-8293-9ca06470c79f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_1f4ccaa6-32f8-41eb-b2b5-fccf215cc1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtInstrumentTerm_1f4ccaa6-32f8-41eb-b2b5-fccf215cc1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_114a928f-6653-433c-9a4b-fa650d532c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_114a928f-6653-433c-9a4b-fa650d532c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_49e6882c-6959-4e93-8780-c5b2edb80cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_49e6882c-6959-4e93-8780-c5b2edb80cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0e8d02d8-3623-4eaa-b6c7-bda4c5a21319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0e8d02d8-3623-4eaa-b6c7-bda4c5a21319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_1b46d4fd-5c7f-433c-b106-c833c1c0f289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_1b46d4fd-5c7f-433c-b106-c833c1c0f289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1f596486-ebcb-4979-982b-ab0e115b770b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_1f596486-ebcb-4979-982b-ab0e115b770b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_7ce869f2-d03e-4daa-85d6-e5a761698fcc" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_7ce869f2-d03e-4daa-85d6-e5a761698fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_d6583a08-c5ef-4ba4-9258-b80484793b86" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_d6583a08-c5ef-4ba4-9258-b80484793b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_b47b29c7-cd42-412d-b77a-cc544cee1e39" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_b47b29c7-cd42-412d-b77a-cc544cee1e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_d4e9853c-30a4-408f-b0f1-eef2e518477a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_d4e9853c-30a4-408f-b0f1-eef2e518477a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f8c7e347-c6a6-4c5d-8ae1-cbdc2fd7f723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f8c7e347-c6a6-4c5d-8ae1-cbdc2fd7f723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_1424828b-8b19-47e9-a370-b5732c914904" xlink:href="ameh-20210930.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_1424828b-8b19-47e9-a370-b5732c914904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0320978d-c6f9-492b-8528-be1517b9a672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0320978d-c6f9-492b-8528-be1517b9a672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c3179cb5-12ed-447d-bbea-d31c4cc8daf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LongTermDebt_c3179cb5-12ed-447d-bbea-d31c4cc8daf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_cdbf1c07-c57b-4b07-b85e-042f9728d76b" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_cdbf1c07-c57b-4b07-b85e-042f9728d76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_1f9c14e5-fc23-4774-a3cc-bfd8adbf13d0" xlink:href="ameh-20210930.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_1f9c14e5-fc23-4774-a3cc-bfd8adbf13d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_0bf38b8e-42ce-4745-81f0-8789a0552a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_0bf38b8e-42ce-4745-81f0-8789a0552a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6549bb0a-f77b-487a-8376-5878e83547fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_InterestExpense_6549bb0a-f77b-487a-8376-5878e83547fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_e2e60978-36d5-4ee5-9065-f6f8487b9a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_e2e60978-36d5-4ee5-9065-f6f8487b9a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_24737822-9df1-453b-82dc-c0f21aab131b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_24737822-9df1-453b-82dc-c0f21aab131b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_714ae442-9997-40e8-819b-5fbe6f22fd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e38f2bc0-1425-44c0-8dea-35560a180b36" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_714ae442-9997-40e8-819b-5fbe6f22fd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a40a6a7f-d816-4760-bdaf-41290b8380ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a81b9611-d6b7-4957-bd94-aeea4a7a8405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a40a6a7f-d816-4760-bdaf-41290b8380ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a81b9611-d6b7-4957-bd94-aeea4a7a8405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ee270df4-c8c4-469a-9e11-28c10e225bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a40a6a7f-d816-4760-bdaf-41290b8380ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ee270df4-c8c4-469a-9e11-28c10e225bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_acec62bd-7837-4bf8-a6a1-c569cc2c9987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a40a6a7f-d816-4760-bdaf-41290b8380ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_acec62bd-7837-4bf8-a6a1-c569cc2c9987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8453bfc4-71d2-4239-b788-94cc8ebf58bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a40a6a7f-d816-4760-bdaf-41290b8380ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8453bfc4-71d2-4239-b788-94cc8ebf58bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LongTermDebtMaturityAfterYearFour_039dbccc-bbc8-468b-a0d1-dcf1cdcfeefe" xlink:href="ameh-20210930.xsd#ameh_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a40a6a7f-d816-4760-bdaf-41290b8380ec" xlink:to="loc_ameh_LongTermDebtMaturityAfterYearFour_039dbccc-bbc8-468b-a0d1-dcf1cdcfeefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_eea74dfa-33e3-4f67-9342-27f2005a4c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a40a6a7f-d816-4760-bdaf-41290b8380ec" xlink:to="loc_us-gaap_LineOfCredit_eea74dfa-33e3-4f67-9342-27f2005a4c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="simple" xlink:href="ameh-20210930.xsd#MezzanineandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_79aaf129-af71-4861-84f4-befa54a13910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6b7a6b9f-29ca-464f-a7de-2d148671af4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_79aaf129-af71-4861-84f4-befa54a13910" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6b7a6b9f-29ca-464f-a7de-2d148671af4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_ef3f28d2-6aee-4b06-9789-cda91ee713af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_528c3f14-669f-40fb-b986-e3585b5d465d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ef3f28d2-6aee-4b06-9789-cda91ee713af" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_528c3f14-669f-40fb-b986-e3585b5d465d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d1d360ef-7ed8-40d6-8201-b640b43ec920" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_528c3f14-669f-40fb-b986-e3585b5d465d" xlink:to="loc_dei_LegalEntityAxis_d1d360ef-7ed8-40d6-8201-b640b43ec920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d5f03c00-cf4d-41ff-8937-dafb6eb110af" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d1d360ef-7ed8-40d6-8201-b640b43ec920" xlink:to="loc_dei_EntityDomain_d5f03c00-cf4d-41ff-8937-dafb6eb110af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_04fb9654-40d8-49df-b9b1-c71c7baa253a" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d5f03c00-cf4d-41ff-8937-dafb6eb110af" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_04fb9654-40d8-49df-b9b1-c71c7baa253a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_833cfcb0-ef40-4c4e-a2ed-82d67bcbdc55" xlink:href="ameh-20210930.xsd#ameh_CDSCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d5f03c00-cf4d-41ff-8937-dafb6eb110af" xlink:to="loc_ameh_CDSCMember_833cfcb0-ef40-4c4e-a2ed-82d67bcbdc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7f5f183f-6c5e-42d5-9c08-dd2c33044294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_528c3f14-669f-40fb-b986-e3585b5d465d" xlink:to="loc_us-gaap_ClassOfStockLineItems_7f5f183f-6c5e-42d5-9c08-dd2c33044294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_0ebb7140-fb5a-474d-9326-cc2d38bdabca" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7f5f183f-6c5e-42d5-9c08-dd2c33044294" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_0ebb7140-fb5a-474d-9326-cc2d38bdabca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_700d8b22-eff8-4218-a525-793a0594ef5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7f5f183f-6c5e-42d5-9c08-dd2c33044294" xlink:to="loc_us-gaap_TreasuryStockCommonShares_700d8b22-eff8-4218-a525-793a0594ef5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_e07063ee-bd8a-4664-a1c0-0e5ccbac047e" xlink:href="ameh-20210930.xsd#ameh_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7f5f183f-6c5e-42d5-9c08-dd2c33044294" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_e07063ee-bd8a-4664-a1c0-0e5ccbac047e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_ae0880ba-56aa-41c4-a734-7ade25ec270b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7f5f183f-6c5e-42d5-9c08-dd2c33044294" xlink:to="loc_us-gaap_Dividends_ae0880ba-56aa-41c4-a734-7ade25ec270b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensation" xlink:type="simple" xlink:href="ameh-20210930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9cf9b32a-21e6-4901-94e2-e37ebb382e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6b876036-9ccd-4499-871b-e65b06a3af40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9cf9b32a-21e6-4901-94e2-e37ebb382e5a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6b876036-9ccd-4499-871b-e65b06a3af40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ameh-20210930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c027dcf8-e132-42d7-a844-b0e1af76e2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2030fde9-4288-4b01-bc5c-0d70c181a01a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c027dcf8-e132-42d7-a844-b0e1af76e2a1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2030fde9-4288-4b01-bc5c-0d70c181a01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0b208e5f-b3bc-4081-815a-b6961638528b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c027dcf8-e132-42d7-a844-b0e1af76e2a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0b208e5f-b3bc-4081-815a-b6961638528b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_36591f04-2797-46e3-b9bf-c6a1ab9386ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c027dcf8-e132-42d7-a844-b0e1af76e2a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_36591f04-2797-46e3-b9bf-c6a1ab9386ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1fdee8ae-09a0-45ad-8141-5baaaa2956da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c027dcf8-e132-42d7-a844-b0e1af76e2a1" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1fdee8ae-09a0-45ad-8141-5baaaa2956da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#StockBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f93f0338-2246-4936-a507-9feefa105215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c82e913-834a-484d-9910-720c95edf753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f93f0338-2246-4936-a507-9feefa105215" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c82e913-834a-484d-9910-720c95edf753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9e802a8b-765d-4a2d-bf1f-17d1767e3268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c82e913-834a-484d-9910-720c95edf753" xlink:to="loc_us-gaap_AwardTypeAxis_9e802a8b-765d-4a2d-bf1f-17d1767e3268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7aecbe4c-0977-46a3-9d8d-5d766fe9d2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9e802a8b-765d-4a2d-bf1f-17d1767e3268" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7aecbe4c-0977-46a3-9d8d-5d766fe9d2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_970e77d7-78c5-4c2e-ba37-9cfa62a5c12c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7aecbe4c-0977-46a3-9d8d-5d766fe9d2b7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_970e77d7-78c5-4c2e-ba37-9cfa62a5c12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember_2715e26c-2975-44cf-b2f2-208ddc7cbb22" xlink:href="ameh-20210930.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7aecbe4c-0977-46a3-9d8d-5d766fe9d2b7" xlink:to="loc_ameh_StockAwardsAndUnitsMember_2715e26c-2975-44cf-b2f2-208ddc7cbb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f77c800d-ab62-476b-b81b-858537bf7197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c82e913-834a-484d-9910-720c95edf753" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f77c800d-ab62-476b-b81b-858537bf7197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ecea69aa-0f91-4962-aa40-763f17586a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f77c800d-ab62-476b-b81b-858537bf7197" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ecea69aa-0f91-4962-aa40-763f17586a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a648619e-3d07-4ee0-a0ca-69989caac9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e1bcfb-2e50-46f3-8b79-ab0eadf44517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a648619e-3d07-4ee0-a0ca-69989caac9d4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e1bcfb-2e50-46f3-8b79-ab0eadf44517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75cd7504-31ff-4ce6-88fd-93b11ca33040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e1bcfb-2e50-46f3-8b79-ab0eadf44517" xlink:to="loc_us-gaap_AwardTypeAxis_75cd7504-31ff-4ce6-88fd-93b11ca33040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d8f2b80-005b-42fe-b33c-6c9eefbfa43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_75cd7504-31ff-4ce6-88fd-93b11ca33040" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d8f2b80-005b-42fe-b33c-6c9eefbfa43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3010a2d3-5d26-4e95-bf49-feb6f3621753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d8f2b80-005b-42fe-b33c-6c9eefbfa43a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3010a2d3-5d26-4e95-bf49-feb6f3621753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_9ba926bf-8641-4035-9986-e6627822fdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d8f2b80-005b-42fe-b33c-6c9eefbfa43a" xlink:to="loc_us-gaap_RestrictedStockMember_9ba926bf-8641-4035-9986-e6627822fdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5257e390-a8a9-4090-bef4-8abdc55fd589" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e1bcfb-2e50-46f3-8b79-ab0eadf44517" xlink:to="loc_srt_TitleOfIndividualAxis_5257e390-a8a9-4090-bef4-8abdc55fd589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1b4bea47-0158-4ae1-886a-6e98c2b173ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_5257e390-a8a9-4090-bef4-8abdc55fd589" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1b4bea47-0158-4ae1-886a-6e98c2b173ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember_826ff87d-c186-4091-8ce9-dce8884f7d77" xlink:href="ameh-20210930.xsd#ameh_ApcStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1b4bea47-0158-4ae1-886a-6e98c2b173ee" xlink:to="loc_ameh_ApcStockOptionMember_826ff87d-c186-4091-8ce9-dce8884f7d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_658644d9-4de5-4e66-8937-071a12c905b9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1b4bea47-0158-4ae1-886a-6e98c2b173ee" xlink:to="loc_srt_DirectorMember_658644d9-4de5-4e66-8937-071a12c905b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_11b28002-0bc0-4381-b325-c3af548221db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e1bcfb-2e50-46f3-8b79-ab0eadf44517" xlink:to="loc_srt_RangeAxis_11b28002-0bc0-4381-b325-c3af548221db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75c59076-7184-4a2d-b647-ba8792856e0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_11b28002-0bc0-4381-b325-c3af548221db" xlink:to="loc_srt_RangeMember_75c59076-7184-4a2d-b647-ba8792856e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3a67fd95-7f90-4228-8878-73151582c8f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75c59076-7184-4a2d-b647-ba8792856e0c" xlink:to="loc_srt_MinimumMember_3a67fd95-7f90-4228-8878-73151582c8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_738ab4e5-6077-4f78-8c32-eff0b5df9d9e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75c59076-7184-4a2d-b647-ba8792856e0c" xlink:to="loc_srt_MaximumMember_738ab4e5-6077-4f78-8c32-eff0b5df9d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c9e1bcfb-2e50-46f3-8b79-ab0eadf44517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_794e3d14-7043-4972-b0e2-5e49b5a900b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_794e3d14-7043-4972-b0e2-5e49b5a900b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d985fa3f-cef5-42e2-875f-f86f81a7fcbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d985fa3f-cef5-42e2-875f-f86f81a7fcbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_569cf884-8c77-4103-b050-7989b5cef705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_569cf884-8c77-4103-b050-7989b5cef705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2a94a31c-ea48-4d4e-b1f3-0dd4f5f0e89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2a94a31c-ea48-4d4e-b1f3-0dd4f5f0e89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7912e26f-cbda-474a-bfe3-52940b2f712b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7912e26f-cbda-474a-bfe3-52940b2f712b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5d46fc62-ea6e-41ce-9873-84fea87d28b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5d46fc62-ea6e-41ce-9873-84fea87d28b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e51c3780-4d32-4a3d-8d8b-8fb0f091c335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e51c3780-4d32-4a3d-8d8b-8fb0f091c335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ffa56f5e-2aa2-4bc4-80b4-56f52367f003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ffa56f5e-2aa2-4bc4-80b4-56f52367f003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9af4f9fa-aede-4579-9822-0d29ad8279ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9af4f9fa-aede-4579-9822-0d29ad8279ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_65e555aa-b8af-4759-a36f-6cc6b5e596cb" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_65e555aa-b8af-4759-a36f-6cc6b5e596cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_42384b28-44da-4c2d-bb70-2f82c2be2354" xlink:href="ameh-20210930.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_42384b28-44da-4c2d-bb70-2f82c2be2354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_6f13532c-57f5-428c-a79c-f5dcd23d1d7c" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a1a6ca9-0189-42f2-8526-6bae6e178975" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_6f13532c-57f5-428c-a79c-f5dcd23d1d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_179bb823-a210-4d3a-8d35-7951e31acfb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ab44e7f6-1be6-44c0-9f0d-0a39ac659802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_179bb823-a210-4d3a-8d35-7951e31acfb1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ab44e7f6-1be6-44c0-9f0d-0a39ac659802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7faaa844-0bb7-48e8-a69e-152da9fdd794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ab44e7f6-1be6-44c0-9f0d-0a39ac659802" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7faaa844-0bb7-48e8-a69e-152da9fdd794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_fae9c986-cfb8-4978-9d5a-444faf567d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ab44e7f6-1be6-44c0-9f0d-0a39ac659802" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_fae9c986-cfb8-4978-9d5a-444faf567d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1808eaf8-8038-4b67-815e-2488e9e5cda5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ab44e7f6-1be6-44c0-9f0d-0a39ac659802" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1808eaf8-8038-4b67-815e-2488e9e5cda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4e1f8b77-d1d2-4ba1-a4e4-239dfaea9da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ab44e7f6-1be6-44c0-9f0d-0a39ac659802" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4e1f8b77-d1d2-4ba1-a4e4-239dfaea9da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b2e85e5e-cc24-4948-8a82-490cf0b37b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ab44e7f6-1be6-44c0-9f0d-0a39ac659802" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b2e85e5e-cc24-4948-8a82-490cf0b37b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b112dfb7-a078-439f-ba61-4496087ad3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_179bb823-a210-4d3a-8d35-7951e31acfb1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b112dfb7-a078-439f-ba61-4496087ad3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_aa60b048-4322-4b33-a4a9-448c6f547a49" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_179bb823-a210-4d3a-8d35-7951e31acfb1" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_aa60b048-4322-4b33-a4a9-448c6f547a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_24ff428c-f79a-4155-a069-28779af32518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_aa60b048-4322-4b33-a4a9-448c6f547a49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_24ff428c-f79a-4155-a069-28779af32518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb202f11-eb07-4c42-a328-df304bb7fbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_aa60b048-4322-4b33-a4a9-448c6f547a49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb202f11-eb07-4c42-a328-df304bb7fbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_94f3a976-d480-4981-bcbd-7d4673fd190a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_aa60b048-4322-4b33-a4a9-448c6f547a49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_94f3a976-d480-4981-bcbd-7d4673fd190a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_655a8998-2dc0-453b-af66-31fa572e7f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_aa60b048-4322-4b33-a4a9-448c6f547a49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_655a8998-2dc0-453b-af66-31fa572e7f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3bd3c30c-d768-4688-8aa2-f4652f4a3ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_aa60b048-4322-4b33-a4a9-448c6f547a49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3bd3c30c-d768-4688-8aa2-f4652f4a3ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1edcc962-392c-41fe-9711-0229ac1fa9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_179bb823-a210-4d3a-8d35-7951e31acfb1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1edcc962-392c-41fe-9711-0229ac1fa9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_af8d55f0-5c6e-4e73-8165-69afa641756c" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_179bb823-a210-4d3a-8d35-7951e31acfb1" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_af8d55f0-5c6e-4e73-8165-69afa641756c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1c5626bb-c5e9-429c-aaab-c66d91d1fea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_af8d55f0-5c6e-4e73-8165-69afa641756c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1c5626bb-c5e9-429c-aaab-c66d91d1fea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_14e26e21-cc83-4a5b-877f-220fd6b2a562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_af8d55f0-5c6e-4e73-8165-69afa641756c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_14e26e21-cc83-4a5b-877f-220fd6b2a562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_96f63fe3-1618-48eb-bddc-bdf58161e1e6" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_179bb823-a210-4d3a-8d35-7951e31acfb1" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_96f63fe3-1618-48eb-bddc-bdf58161e1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_285351ff-3909-4662-95e5-1db6a77e875b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_96f63fe3-1618-48eb-bddc-bdf58161e1e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_285351ff-3909-4662-95e5-1db6a77e875b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_09df9816-dfde-45f6-8089-de0fd89550a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_96f63fe3-1618-48eb-bddc-bdf58161e1e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_09df9816-dfde-45f6-8089-de0fd89550a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a3d3c482-5f64-467f-8024-09927262292f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_96f63fe3-1618-48eb-bddc-bdf58161e1e6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a3d3c482-5f64-467f-8024-09927262292f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ceb4aa4a-9d4c-4ef7-99d9-1e0bd7d70570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c55c6406-f05d-4f09-a0fc-284e30d57103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ceb4aa4a-9d4c-4ef7-99d9-1e0bd7d70570" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c55c6406-f05d-4f09-a0fc-284e30d57103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8f571c2e-dc92-4392-afd3-1485d0be0b71" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c55c6406-f05d-4f09-a0fc-284e30d57103" xlink:to="loc_srt_TitleOfIndividualAxis_8f571c2e-dc92-4392-afd3-1485d0be0b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8f133225-c366-46e4-b77f-c5cf9a68ed8d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_8f571c2e-dc92-4392-afd3-1485d0be0b71" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8f133225-c366-46e4-b77f-c5cf9a68ed8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_63e2eb78-d769-4647-9878-fbcedb6fcc43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8f133225-c366-46e4-b77f-c5cf9a68ed8d" xlink:to="loc_srt_DirectorMember_63e2eb78-d769-4647-9878-fbcedb6fcc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c55c6406-f05d-4f09-a0fc-284e30d57103" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24ff2661-3c27-411a-8fbc-9a12418319f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24ff2661-3c27-411a-8fbc-9a12418319f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_655615a6-c188-412c-9cb2-7d816410adc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_655615a6-c188-412c-9cb2-7d816410adc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d0a5b9d4-bbcc-4a42-8395-edb2964e7f47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d0a5b9d4-bbcc-4a42-8395-edb2964e7f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7999ff0f-d013-4ac4-8915-112f20316855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_us-gaap_SharePrice_7999ff0f-d013-4ac4-8915-112f20316855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6f974621-63b2-415b-a8ed-db95454946c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6f974621-63b2-415b-a8ed-db95454946c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_2227c16e-e771-4749-88d1-759805cddd53" xlink:href="ameh-20210930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8e908ec-93f4-4efa-94a3-7792da7b199f" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_2227c16e-e771-4749-88d1-759805cddd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#StockBasedCompensationSummaryofWarrantDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f53fece-01bf-437a-8082-81ce33e8ad79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward_0ebdad58-4fc2-48c6-bf8d-36228480012c" xlink:href="ameh-20210930.xsd#ameh_SharesWarrantsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f53fece-01bf-437a-8082-81ce33e8ad79" xlink:to="loc_ameh_SharesWarrantsRollForward_0ebdad58-4fc2-48c6-bf8d-36228480012c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7241c5dc-8dbf-4251-93f9-814091b94d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_0ebdad58-4fc2-48c6-bf8d-36228480012c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7241c5dc-8dbf-4251-93f9-814091b94d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted_185842f1-79cb-4b07-aebf-0a8f0e100b6f" xlink:href="ameh-20210930.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_0ebdad58-4fc2-48c6-bf8d-36228480012c" xlink:to="loc_ameh_NumberOfWarrantsGranted_185842f1-79cb-4b07-aebf-0a8f0e100b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised_6321fa97-0c87-4f40-acc6-37cda06bced0" xlink:href="ameh-20210930.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_0ebdad58-4fc2-48c6-bf8d-36228480012c" xlink:to="loc_ameh_NumberOfWarrantsExercised_6321fa97-0c87-4f40-acc6-37cda06bced0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_fa7d147e-bdf5-4cc0-8c18-b2b150eeeb69" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_0ebdad58-4fc2-48c6-bf8d-36228480012c" xlink:to="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_fa7d147e-bdf5-4cc0-8c18-b2b150eeeb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_38bb9319-ac65-49b8-a06d-213865630542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_0ebdad58-4fc2-48c6-bf8d-36228480012c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_38bb9319-ac65-49b8-a06d-213865630542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_cb8ac960-8cdd-468c-86d8-71effaa93f9e" xlink:href="ameh-20210930.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f53fece-01bf-437a-8082-81ce33e8ad79" xlink:to="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_cb8ac960-8cdd-468c-86d8-71effaa93f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_fbebd816-4253-4f82-8d24-90460b53fe32" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_cb8ac960-8cdd-468c-86d8-71effaa93f9e" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_fbebd816-4253-4f82-8d24-90460b53fe32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_191e6f2a-fcd8-4e6f-9ae0-236b86c601a3" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_cb8ac960-8cdd-468c-86d8-71effaa93f9e" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_191e6f2a-fcd8-4e6f-9ae0-236b86c601a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_5c18f9a7-f0d3-4ad7-b9fe-688190af97bf" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_cb8ac960-8cdd-468c-86d8-71effaa93f9e" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_5c18f9a7-f0d3-4ad7-b9fe-688190af97bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_6787e4f7-3258-4021-87f9-588fa14b74bc" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_cb8ac960-8cdd-468c-86d8-71effaa93f9e" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_6787e4f7-3258-4021-87f9-588fa14b74bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_79d455be-5bb1-4bf1-b051-2d1606507873" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_cb8ac960-8cdd-468c-86d8-71effaa93f9e" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_79d455be-5bb1-4bf1-b051-2d1606507873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_2442b731-bfb5-40b2-afac-c17a47f50247" xlink:href="ameh-20210930.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f53fece-01bf-437a-8082-81ce33e8ad79" xlink:to="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_2442b731-bfb5-40b2-afac-c17a47f50247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_1cc710af-6b12-485f-80ff-d29fe1d2ba69" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_2442b731-bfb5-40b2-afac-c17a47f50247" xlink:to="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_1cc710af-6b12-485f-80ff-d29fe1d2ba69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract_e49508f0-b691-43af-9cd4-ad64b3cff135" xlink:href="ameh-20210930.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f53fece-01bf-437a-8082-81ce33e8ad79" xlink:to="loc_ameh_AggregateintrinsicvalueAbstract_e49508f0-b691-43af-9cd4-ad64b3cff135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_a96d3f23-a7e2-42ce-b883-5648cefebfb2" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_e49508f0-b691-43af-9cd4-ad64b3cff135" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_a96d3f23-a7e2-42ce-b883-5648cefebfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_ac10166a-a69f-4913-8cee-d54fa3a852f0" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_e49508f0-b691-43af-9cd4-ad64b3cff135" xlink:to="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_ac10166a-a69f-4913-8cee-d54fa3a852f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_e8498f88-afc7-4cb9-bc17-6293355906c1" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_e49508f0-b691-43af-9cd4-ad64b3cff135" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_e8498f88-afc7-4cb9-bc17-6293355906c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_737b018f-5123-4e0a-9678-8052d8afc647" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_e49508f0-b691-43af-9cd4-ad64b3cff135" xlink:to="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_737b018f-5123-4e0a-9678-8052d8afc647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_e935cccd-c6c2-44f2-a876-da3a271e6a8e" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_e49508f0-b691-43af-9cd4-ad64b3cff135" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_e935cccd-c6c2-44f2-a876-da3a271e6a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#StockBasedCompensationWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc9b3a4d-2d0e-4c0e-86ad-336e18cc6b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4701102c-b08f-432f-a1e6-cec94e15aa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc9b3a4d-2d0e-4c0e-86ad-336e18cc6b3d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_4701102c-b08f-432f-a1e6-cec94e15aa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_48021cf4-f2da-4937-a2e9-5c61e7793224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4701102c-b08f-432f-a1e6-cec94e15aa2c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_48021cf4-f2da-4937-a2e9-5c61e7793224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_cb003951-d80c-4abf-bf4d-3a76e9eedb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_48021cf4-f2da-4937-a2e9-5c61e7793224" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_cb003951-d80c-4abf-bf4d-3a76e9eedb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_7dd6afc8-1f1c-490a-97fb-ba27f21e794a" xlink:href="ameh-20210930.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_cb003951-d80c-4abf-bf4d-3a76e9eedb9b" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_7dd6afc8-1f1c-490a-97fb-ba27f21e794a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_18c211d1-3f65-4101-a414-741019520953" xlink:href="ameh-20210930.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_cb003951-d80c-4abf-bf4d-3a76e9eedb9b" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_18c211d1-3f65-4101-a414-741019520953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_db20c2ff-9005-4d3a-b8c4-f07d64b77631" xlink:href="ameh-20210930.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_cb003951-d80c-4abf-bf4d-3a76e9eedb9b" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_db20c2ff-9005-4d3a-b8c4-f07d64b77631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d195059d-4ce8-4607-a6d5-9f9fb503e9ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4701102c-b08f-432f-a1e6-cec94e15aa2c" xlink:to="loc_srt_RangeAxis_d195059d-4ce8-4607-a6d5-9f9fb503e9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c44353d-b8b6-4f61-b199-9e7cc7d9e0e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d195059d-4ce8-4607-a6d5-9f9fb503e9ab" xlink:to="loc_srt_RangeMember_3c44353d-b8b6-4f61-b199-9e7cc7d9e0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_90e9ef29-7a61-438e-9b14-2672356c4c07" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3c44353d-b8b6-4f61-b199-9e7cc7d9e0e2" xlink:to="loc_srt_MinimumMember_90e9ef29-7a61-438e-9b14-2672356c4c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e5bc394-35ac-49e2-a7b3-2ef96433c911" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3c44353d-b8b6-4f61-b199-9e7cc7d9e0e2" xlink:to="loc_srt_MaximumMember_1e5bc394-35ac-49e2-a7b3-2ef96433c911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4701102c-b08f-432f-a1e6-cec94e15aa2c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_090d210d-a810-424c-b9cd-f7e1d3cb11b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_090d210d-a810-424c-b9cd-f7e1d3cb11b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_e1764f66-9947-4b40-8c48-97a6e6cd96ad" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_e1764f66-9947-4b40-8c48-97a6e6cd96ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_30c6e44a-2df8-4a9e-b7e0-432dd19c49a7" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_30c6e44a-2df8-4a9e-b7e0-432dd19c49a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_b5551357-447b-4538-9833-5eb615e695bb" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_b5551357-447b-4538-9833-5eb615e695bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_ffc456b7-ed2a-4f96-879d-a2366aa20773" xlink:href="ameh-20210930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d5635e5a-a642-48f5-b243-9471a5dd777f" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_ffc456b7-ed2a-4f96-879d-a2366aa20773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ameh-20210930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8f72d4f8-74ae-48e2-91b6-cd1c096afc02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b1630809-de32-41b9-8284-53ff550a991a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8f72d4f8-74ae-48e2-91b6-cd1c096afc02" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b1630809-de32-41b9-8284-53ff550a991a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8449e0dc-9e00-47b5-8694-49faa2deb739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:href="ameh-20210930.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8449e0dc-9e00-47b5-8694-49faa2deb739" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_226a5b50-453b-4f0c-9ae8-caf2ebccd518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:to="loc_us-gaap_CreditFacilityAxis_226a5b50-453b-4f0c-9ae8-caf2ebccd518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_02aeda89-9551-4bca-bebb-ac38e2b46e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_226a5b50-453b-4f0c-9ae8-caf2ebccd518" xlink:to="loc_us-gaap_CreditFacilityDomain_02aeda89-9551-4bca-bebb-ac38e2b46e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_7cc68ac2-d0f1-4b9e-bf4b-9583e61bda5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_02aeda89-9551-4bca-bebb-ac38e2b46e46" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_7cc68ac2-d0f1-4b9e-bf4b-9583e61bda5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_3e37938e-34a8-4f2d-ad71-7ef86f2f3d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_3e37938e-34a8-4f2d-ad71-7ef86f2f3d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_6c0f54dc-822b-43c7-ab93-5b899cd72378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_3e37938e-34a8-4f2d-ad71-7ef86f2f3d86" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_6c0f54dc-822b-43c7-ab93-5b899cd72378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_a18a29b1-5a36-4ed6-9e82-4b16c584a879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_6c0f54dc-822b-43c7-ab93-5b899cd72378" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_a18a29b1-5a36-4ed6-9e82-4b16c584a879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_25cca14c-f73e-429e-a8e9-82bd30ec34fd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:to="loc_dei_LegalEntityAxis_25cca14c-f73e-429e-a8e9-82bd30ec34fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4d7dd231-ba8e-4bc2-9e62-b702f67297a8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_25cca14c-f73e-429e-a8e9-82bd30ec34fd" xlink:to="loc_dei_EntityDomain_4d7dd231-ba8e-4bc2-9e62-b702f67297a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_4bbda8b3-2855-44b7-8f85-6dce3616eabb" xlink:href="ameh-20210930.xsd#ameh_ApaacoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4d7dd231-ba8e-4bc2-9e62-b702f67297a8" xlink:to="loc_ameh_ApaacoMember_4bbda8b3-2855-44b7-8f85-6dce3616eabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_bf407993-c66d-4260-83fd-2ed008a44614" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4d7dd231-ba8e-4bc2-9e62-b702f67297a8" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_bf407993-c66d-4260-83fd-2ed008a44614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_52ed710b-de26-41ed-bb10-d8ec4c4eec27" xlink:href="ameh-20210930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4d7dd231-ba8e-4bc2-9e62-b702f67297a8" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_52ed710b-de26-41ed-bb10-d8ec4c4eec27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_09bd7877-ce32-4722-8235-3672e4ed71d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_09bd7877-ce32-4722-8235-3672e4ed71d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_19222fed-aedd-40be-8fc6-8940ca5b71e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_09bd7877-ce32-4722-8235-3672e4ed71d8" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_19222fed-aedd-40be-8fc6-8940ca5b71e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_762c7fae-94f8-438d-8f87-ea345e5600ed" xlink:href="ameh-20210930.xsd#ameh_PreferredBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_19222fed-aedd-40be-8fc6-8940ca5b71e1" xlink:to="loc_ameh_PreferredBankMember_762c7fae-94f8-438d-8f87-ea345e5600ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_1c124032-1a1f-4505-9880-f60104dde951" xlink:href="ameh-20210930.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_a5803c71-9305-42b3-9a1f-b41488955831" xlink:to="loc_ameh_CommitmentsAndContingenciesLineItems_1c124032-1a1f-4505-9880-f60104dde951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_a38b6cc8-cc16-49fd-bbb5-9c70eac7ef9d" xlink:href="ameh-20210930.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1c124032-1a1f-4505-9880-f60104dde951" xlink:to="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_a38b6cc8-cc16-49fd-bbb5-9c70eac7ef9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_364b8071-14e3-4cb5-bb51-dd29690e80a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1c124032-1a1f-4505-9880-f60104dde951" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_364b8071-14e3-4cb5-bb51-dd29690e80a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_f4392069-773c-43e8-aae3-df433dbef225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_1c124032-1a1f-4505-9880-f60104dde951" xlink:to="loc_us-gaap_LineOfCredit_f4392069-773c-43e8-aae3-df433dbef225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ameh-20210930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_7d1b7df1-fa10-4947-ae3c-f602c36d594b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b1527ec3-6729-43d3-9fb4-941cbeaacfda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_7d1b7df1-fa10-4947-ae3c-f602c36d594b" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b1527ec3-6729-43d3-9fb4-941cbeaacfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="ameh-20210930.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0b6023fe-d9c8-4755-8f01-1cbea50bb749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2785a309-9c09-40c0-88d6-ccfafec451c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0b6023fe-d9c8-4755-8f01-1cbea50bb749" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2785a309-9c09-40c0-88d6-ccfafec451c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_23b02fb5-ddea-4268-9dd3-841ac3f60135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_23b02fb5-ddea-4268-9dd3-841ac3f60135" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19469e2b-7f85-4c5b-8731-089d2e1616e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19469e2b-7f85-4c5b-8731-089d2e1616e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0568ed3b-bad5-4ede-9a40-24748b7dff40" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19469e2b-7f85-4c5b-8731-089d2e1616e6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0568ed3b-bad5-4ede-9a40-24748b7dff40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_417c1746-ebd4-4eac-97c6-1ee1ddf74a7f" xlink:href="ameh-20210930.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0568ed3b-bad5-4ede-9a40-24748b7dff40" xlink:to="loc_ameh_LmaMember_417c1746-ebd4-4eac-97c6-1ee1ddf74a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_e03fe282-ee43-463d-a28d-16abf4340a8f" xlink:href="ameh-20210930.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0568ed3b-bad5-4ede-9a40-24748b7dff40" xlink:to="loc_ameh_PmiocMember_e03fe282-ee43-463d-a28d-16abf4340a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_49b438a1-a584-46de-b3f7-503180310e38" xlink:href="ameh-20210930.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0568ed3b-bad5-4ede-9a40-24748b7dff40" xlink:to="loc_ameh_DmgMember_49b438a1-a584-46de-b3f7-503180310e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_eb06b79b-903e-4860-8acd-5ed21d6e3e8a" xlink:href="ameh-20210930.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0568ed3b-bad5-4ede-9a40-24748b7dff40" xlink:to="loc_ameh_OneMSOInc.Member_eb06b79b-903e-4860-8acd-5ed21d6e3e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff76752d-32c3-4ec3-a546-d24d1deea730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff76752d-32c3-4ec3-a546-d24d1deea730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff76752d-32c3-4ec3-a546-d24d1deea730" xlink:to="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_ae6d9201-8a13-4236-86e5-97e87da38f0e" xlink:href="ameh-20210930.xsd#ameh_ApcShareholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_ApcShareholdersMember_ae6d9201-8a13-4236-86e5-97e87da38f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_35e5e221-7f62-4b1c-add6-8dd4fe987606" xlink:href="ameh-20210930.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_35e5e221-7f62-4b1c-add6-8dd4fe987606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FreseniusMember_1966a22c-a528-4fb1-bce6-f0c84fe99e93" xlink:href="ameh-20210930.xsd#ameh_FreseniusMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_FreseniusMember_1966a22c-a528-4fb1-bce6-f0c84fe99e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember_adf36a90-6201-449a-9eb3-5c61ff65dfdb" xlink:href="ameh-20210930.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_FulgentGeneticsIncMember_adf36a90-6201-449a-9eb3-5c61ff65dfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember_d55b44f9-bd71-4dc4-8246-fccef8d557fb" xlink:href="ameh-20210930.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_ShareholdersAndOfficersMember_d55b44f9-bd71-4dc4-8246-fccef8d557fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember_471cb8f8-bc70-4d9a-9a97-b1e045bedb4c" xlink:href="ameh-20210930.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_CriticalQualityManagementCorpMember_471cb8f8-bc70-4d9a-9a97-b1e045bedb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_7e8a6169-a22a-4931-b79d-dcc3b318bac8" xlink:href="ameh-20210930.xsd#ameh_NumenLLCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_NumenLLCMember_7e8a6169-a22a-4931-b79d-dcc3b318bac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_309c9fcd-4b2d-427a-83ae-1cd9d153aee7" xlink:href="ameh-20210930.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_OneMSOInc.Member_309c9fcd-4b2d-427a-83ae-1cd9d153aee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_1d623606-4e9a-4e59-9c9e-ddc6f8e10dbc" xlink:href="ameh-20210930.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e65af30d-b9dc-45ce-92d3-02689cc1e035" xlink:to="loc_ameh_AHMCMember_1d623606-4e9a-4e59-9c9e-ddc6f8e10dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_455ae713-1a78-434a-832c-de5e13304c3f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_dei_LegalEntityAxis_455ae713-1a78-434a-832c-de5e13304c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6b94ee56-d877-4932-81bb-61946f4b8f47" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_455ae713-1a78-434a-832c-de5e13304c3f" xlink:to="loc_dei_EntityDomain_6b94ee56-d877-4932-81bb-61946f4b8f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_a83472ea-70c0-427c-aa2c-d19a341f5739" xlink:href="ameh-20210930.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6b94ee56-d877-4932-81bb-61946f4b8f47" xlink:to="loc_ameh_NetworkMedicalManagementMember_a83472ea-70c0-427c-aa2c-d19a341f5739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f8a6d2e7-d390-43bd-aa58-61b16eaa202b" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6b94ee56-d877-4932-81bb-61946f4b8f47" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f8a6d2e7-d390-43bd-aa58-61b16eaa202b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaAcoIncMember_c0138f90-eabf-40dd-bdf6-06da09a63d8d" xlink:href="ameh-20210930.xsd#ameh_ApaAcoIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6b94ee56-d877-4932-81bb-61946f4b8f47" xlink:to="loc_ameh_ApaAcoIncMember_c0138f90-eabf-40dd-bdf6-06da09a63d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_26c8f16a-50bf-4d0b-a0ca-0531502e625b" xlink:href="ameh-20210930.xsd#ameh_SCHCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6b94ee56-d877-4932-81bb-61946f4b8f47" xlink:to="loc_ameh_SCHCMember_26c8f16a-50bf-4d0b-a0ca-0531502e625b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_41b7b793-240e-4411-9d48-7be172bc56c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_srt_ConsolidatedEntitiesAxis_41b7b793-240e-4411-9d48-7be172bc56c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d1eef7ad-c5df-4f3f-9b61-bbaa776434e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_41b7b793-240e-4411-9d48-7be172bc56c0" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d1eef7ad-c5df-4f3f-9b61-bbaa776434e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_a4c66eaa-9be5-4913-be65-ef7986d4db63" xlink:href="ameh-20210930.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d1eef7ad-c5df-4f3f-9b61-bbaa776434e9" xlink:to="loc_ameh_LmaMember_a4c66eaa-9be5-4913-be65-ef7986d4db63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_e66b1f3a-41e1-4a93-b026-2a2d965f6393" xlink:href="ameh-20210930.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d1eef7ad-c5df-4f3f-9b61-bbaa776434e9" xlink:to="loc_ameh_PmiocMember_e66b1f3a-41e1-4a93-b026-2a2d965f6393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_51214877-2312-4421-8588-22e944b50bcd" xlink:href="ameh-20210930.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d1eef7ad-c5df-4f3f-9b61-bbaa776434e9" xlink:to="loc_ameh_DmgMember_51214877-2312-4421-8588-22e944b50bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_a73c5e25-33a0-40a3-8527-3f5e6579c089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_a73c5e25-33a0-40a3-8527-3f5e6579c089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c1bc7081-9605-4d5e-b8d8-edb416e46433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a73c5e25-33a0-40a3-8527-3f5e6579c089" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c1bc7081-9605-4d5e-b8d8-edb416e46433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_28a1f890-d017-49ed-aa3b-2339ef8652d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c1bc7081-9605-4d5e-b8d8-edb416e46433" xlink:to="loc_us-gaap_ServiceMember_28a1f890-d017-49ed-aa3b-2339ef8652d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_76568a00-c483-4d60-be50-f336ed9f1538" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_srt_TitleOfIndividualAxis_76568a00-c483-4d60-be50-f336ed9f1538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d043009-5a7e-48b1-accb-556f6c939fd2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_76568a00-c483-4d60-be50-f336ed9f1538" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d043009-5a7e-48b1-accb-556f6c939fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_cfe87eaf-8671-4623-b8b7-2045d6f0bad8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d043009-5a7e-48b1-accb-556f6c939fd2" xlink:to="loc_srt_DirectorMember_cfe87eaf-8671-4623-b8b7-2045d6f0bad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b5a719e8-47cc-47ee-9bea-2fb00660b112" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_5282af69-8471-4c1b-8806-075806d9e9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_us-gaap_RevenueFromRelatedParties_5282af69-8471-4c1b-8806-075806d9e9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_622df82b-ae7f-4fdf-82a3-c8eb0f9757df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_622df82b-ae7f-4fdf-82a3-c8eb0f9757df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_e113b180-72fa-4edc-bacb-e31550cdc972" xlink:href="ameh-20210930.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_ameh_PaymentMadeToRelatedParty_e113b180-72fa-4edc-bacb-e31550cdc972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_764572a0-36c1-4003-bb1d-8f5ca7784638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_764572a0-36c1-4003-bb1d-8f5ca7784638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_78f7fe82-fca8-419b-bf18-e4194ed4c93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_78f7fe82-fca8-419b-bf18-e4194ed4c93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees_dcce2e3d-60f5-4376-9c74-24a14fbb9e0a" xlink:href="ameh-20210930.xsd#ameh_PaymentConsultingFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e10c831d-93f7-4c48-a28b-ec382a10410f" xlink:to="loc_ameh_PaymentConsultingFees_dcce2e3d-60f5-4376-9c74-24a14fbb9e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_821d44cd-9df9-4ef4-ba44-bc03dc9ef25e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_def40b75-855d-496a-ab1e-49398892fb84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_821d44cd-9df9-4ef4-ba44-bc03dc9ef25e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_def40b75-855d-496a-ab1e-49398892fb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f186f9f-5c52-439c-9059-c67b04829ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_def40b75-855d-496a-ab1e-49398892fb84" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f186f9f-5c52-439c-9059-c67b04829ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7b78964c-46de-4f4d-9f7d-48d295ad9655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f186f9f-5c52-439c-9059-c67b04829ee1" xlink:to="loc_us-gaap_RelatedPartyDomain_7b78964c-46de-4f4d-9f7d-48d295ad9655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_e8968d11-4b7d-47b4-9232-861645e5eaad" xlink:href="ameh-20210930.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7b78964c-46de-4f4d-9f7d-48d295ad9655" xlink:to="loc_ameh_AHMCMember_e8968d11-4b7d-47b4-9232-861645e5eaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_4d0c0b57-b521-4e34-a7e7-187a1252eec9" xlink:href="ameh-20210930.xsd#ameh_HSMSOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7b78964c-46de-4f4d-9f7d-48d295ad9655" xlink:to="loc_ameh_HSMSOMember_4d0c0b57-b521-4e34-a7e7-187a1252eec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_43342448-62bf-4973-ae8b-31f928286e56" xlink:href="ameh-20210930.xsd#ameh_AurionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7b78964c-46de-4f4d-9f7d-48d295ad9655" xlink:to="loc_ameh_AurionMember_43342448-62bf-4973-ae8b-31f928286e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d3054512-4473-4f0e-895b-ff7bfe01a980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_def40b75-855d-496a-ab1e-49398892fb84" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_d3054512-4473-4f0e-895b-ff7bfe01a980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_f74471c2-7554-4ee8-8571-2367a53b2643" xlink:href="ameh-20210930.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d3054512-4473-4f0e-895b-ff7bfe01a980" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_f74471c2-7554-4ee8-8571-2367a53b2643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_d3c79314-5dae-417d-94e4-3f72812a0fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d3054512-4473-4f0e-895b-ff7bfe01a980" xlink:to="loc_us-gaap_ManagementFeeExpense_d3c79314-5dae-417d-94e4-3f72812a0fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_3f74cf45-764f-4b6b-952c-6ca9a79b5e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d3054512-4473-4f0e-895b-ff7bfe01a980" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_3f74cf45-764f-4b6b-952c-6ca9a79b5e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxes" xlink:type="simple" xlink:href="ameh-20210930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_794b2c0d-f9f4-41df-9fc9-560964774051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0858879d-2ecd-492a-b386-69f166e553e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_794b2c0d-f9f4-41df-9fc9-560964774051" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0858879d-2ecd-492a-b386-69f166e553e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ef741fcb-7c16-455e-b687-78d05ae47412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_44b4e724-245d-4037-a6ad-fb634ce56667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef741fcb-7c16-455e-b687-78d05ae47412" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_44b4e724-245d-4037-a6ad-fb634ce56667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShare" xlink:type="simple" xlink:href="ameh-20210930.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1deb0607-cf4c-4bf3-a04f-534821e2b525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_6395b935-15de-4257-9e27-0be6609f3740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1deb0607-cf4c-4bf3-a04f-534821e2b525" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_6395b935-15de-4257-9e27-0be6609f3740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ameh-20210930.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_97239c71-271c-4b04-8637-c9015eb1ca52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6c7f0db3-3856-40a0-9321-e61b01d92ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_97239c71-271c-4b04-8637-c9015eb1ca52" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6c7f0db3-3856-40a0-9321-e61b01d92ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_d5a5c093-dbcf-49d5-81d2-cc971a0891f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_97239c71-271c-4b04-8637-c9015eb1ca52" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_d5a5c093-dbcf-49d5-81d2-cc971a0891f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_42c9d1ef-3564-4c5e-a581-e69891b6c2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_f93b22ea-bf3a-48e1-abd3-6db5b6038ab0" xlink:href="ameh-20210930.xsd#ameh_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_42c9d1ef-3564-4c5e-a581-e69891b6c2cd" xlink:to="loc_ameh_EarningsPerShareTable_f93b22ea-bf3a-48e1-abd3-6db5b6038ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3fc519b0-9b8b-4fbb-80c8-c1aba38bdcca" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_f93b22ea-bf3a-48e1-abd3-6db5b6038ab0" xlink:to="loc_dei_LegalEntityAxis_3fc519b0-9b8b-4fbb-80c8-c1aba38bdcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_956186b2-be16-43e2-a894-83e1ab1738cb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3fc519b0-9b8b-4fbb-80c8-c1aba38bdcca" xlink:to="loc_dei_EntityDomain_956186b2-be16-43e2-a894-83e1ab1738cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_476583e9-6fe2-4621-8527-e37b763d8967" xlink:href="ameh-20210930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_956186b2-be16-43e2-a894-83e1ab1738cb" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_476583e9-6fe2-4621-8527-e37b763d8967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_ae95e274-ac77-4557-9763-7d6d1ae7705e" xlink:href="ameh-20210930.xsd#ameh_EarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_f93b22ea-bf3a-48e1-abd3-6db5b6038ab0" xlink:to="loc_ameh_EarningsPerShareLineItems_ae95e274-ac77-4557-9763-7d6d1ae7705e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b725137a-37f6-4114-9338-0f9c887a0017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_ae95e274-ac77-4557-9763-7d6d1ae7705e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b725137a-37f6-4114-9338-0f9c887a0017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#EarningsPerShareEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_60a59914-7425-4f57-87d5-a8345f9d78dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3ae71917-6cda-409d-aaac-3d4729ca5519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_60a59914-7425-4f57-87d5-a8345f9d78dd" xlink:to="loc_us-gaap_EarningsPerShareBasic_3ae71917-6cda-409d-aaac-3d4729ca5519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b83cc62c-1282-4c34-ba08-0806975b003b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_60a59914-7425-4f57-87d5-a8345f9d78dd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b83cc62c-1282-4c34-ba08-0806975b003b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1cbcec92-be8f-4bbc-8b29-c898b1ed4c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_60a59914-7425-4f57-87d5-a8345f9d78dd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1cbcec92-be8f-4bbc-8b29-c898b1ed4c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32a959d5-5b72-4bc4-beb5-d9ce19883260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_60a59914-7425-4f57-87d5-a8345f9d78dd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32a959d5-5b72-4bc4-beb5-d9ce19883260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_45a16115-8d0c-42ec-83e3-b26eb270ea82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_c045063f-f6fd-460e-883f-6aab659046d9" xlink:href="ameh-20210930.xsd#ameh_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45a16115-8d0c-42ec-83e3-b26eb270ea82" xlink:to="loc_ameh_EarningsPerShareTable_c045063f-f6fd-460e-883f-6aab659046d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6529e7e5-6ffe-4160-9152-d1c418a4b483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_c045063f-f6fd-460e-883f-6aab659046d9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6529e7e5-6ffe-4160-9152-d1c418a4b483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4d4e9009-7b10-47e8-aa7d-f0095d307add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6529e7e5-6ffe-4160-9152-d1c418a4b483" xlink:to="loc_us-gaap_EquityComponentDomain_4d4e9009-7b10-47e8-aa7d-f0095d307add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_23984e1b-1ad9-4b19-be6e-165e40e298a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4d4e9009-7b10-47e8-aa7d-f0095d307add" xlink:to="loc_us-gaap_WarrantMember_23984e1b-1ad9-4b19-be6e-165e40e298a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5eba6e83-9de8-4b73-9ea5-3751ece1daff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_c045063f-f6fd-460e-883f-6aab659046d9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5eba6e83-9de8-4b73-9ea5-3751ece1daff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3e623f7b-7ca9-400d-92e3-18f4ee691608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5eba6e83-9de8-4b73-9ea5-3751ece1daff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3e623f7b-7ca9-400d-92e3-18f4ee691608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_acb05e9a-8e2b-424a-9b9e-418420a52f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3e623f7b-7ca9-400d-92e3-18f4ee691608" xlink:to="loc_us-gaap_EmployeeStockOptionMember_acb05e9a-8e2b-424a-9b9e-418420a52f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2d833542-d6ac-4331-81ac-54a6cbddd222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3e623f7b-7ca9-400d-92e3-18f4ee691608" xlink:to="loc_us-gaap_RestrictedStockMember_2d833542-d6ac-4331-81ac-54a6cbddd222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_fd853edd-b310-44b9-abdc-e01a365e82b3" xlink:href="ameh-20210930.xsd#ameh_EarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_c045063f-f6fd-460e-883f-6aab659046d9" xlink:to="loc_ameh_EarningsPerShareLineItems_fd853edd-b310-44b9-abdc-e01a365e82b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9e4eb66-d8c0-491c-9255-f92a0f98223e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_fd853edd-b310-44b9-abdc-e01a365e82b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9e4eb66-d8c0-491c-9255-f92a0f98223e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a2c4cb4a-7f7e-4b71-ae63-a2982d432bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_fd853edd-b310-44b9-abdc-e01a365e82b3" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a2c4cb4a-7f7e-4b71-ae63-a2982d432bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_713590c6-3292-470e-a7e8-4afe94072740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_fd853edd-b310-44b9-abdc-e01a365e82b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_713590c6-3292-470e-a7e8-4afe94072740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="simple" xlink:href="ameh-20210930.xsd#VariableInterestEntitiesVIEs"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33eff221-3b27-413b-823a-42c7e8995cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_04c8dc3f-f07b-4837-afab-1b6ba26da03c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33eff221-3b27-413b-823a-42c7e8995cb8" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_04c8dc3f-f07b-4837-afab-1b6ba26da03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="simple" xlink:href="ameh-20210930.xsd#VariableInterestEntitiesVIEsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_efaa5b7f-d63a-4a57-9978-2e7e876a1fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_56c395d1-df26-4b4e-b103-55dfa5b646c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_efaa5b7f-d63a-4a57-9978-2e7e876a1fcb" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_56c395d1-df26-4b4e-b103-55dfa5b646c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a91ffd2f-5f3b-413b-a371-7a4c5867f27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_63f2cab9-546a-4245-a1c4-71d53a2cb269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a91ffd2f-5f3b-413b-a371-7a4c5867f27e" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_63f2cab9-546a-4245-a1c4-71d53a2cb269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8aea3a72-edfa-4ff4-a1ef-fbf209ef0ac0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_63f2cab9-546a-4245-a1c4-71d53a2cb269" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8aea3a72-edfa-4ff4-a1ef-fbf209ef0ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_73cf6cce-1c61-4d14-9fb0-61d47fef4c79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8aea3a72-edfa-4ff4-a1ef-fbf209ef0ac0" xlink:to="loc_srt_ConsolidatedEntitiesDomain_73cf6cce-1c61-4d14-9fb0-61d47fef4c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_b0a80a58-86b1-41fe-a283-a1eb8c728c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_73cf6cce-1c61-4d14-9fb0-61d47fef4c79" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_b0a80a58-86b1-41fe-a283-a1eb8c728c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_1d3bdf41-29e4-42dc-93ea-f695614a5e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_63f2cab9-546a-4245-a1c4-71d53a2cb269" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_1d3bdf41-29e4-42dc-93ea-f695614a5e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b5140772-353f-43ed-a13d-4537f7ecc186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_1d3bdf41-29e4-42dc-93ea-f695614a5e91" xlink:to="loc_us-gaap_AssetsAbstract_b5140772-353f-43ed-a13d-4537f7ecc186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b5140772-353f-43ed-a13d-4537f7ecc186" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3274541-08de-4c71-974d-56901c39cefc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3274541-08de-4c71-974d-56901c39cefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_cfe592ac-4891-418a-b4f3-e166b4df07ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_cfe592ac-4891-418a-b4f3-e166b4df07ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_222b602c-2758-451b-8afb-e8bde8ec0be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_222b602c-2758-451b-8afb-e8bde8ec0be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_eec2babc-8b9b-4430-bee0-e497b5c58f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_eec2babc-8b9b-4430-bee0-e497b5c58f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_5f02c83d-0396-4572-bba4-af43f5bce1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_IncomeTaxesReceivable_5f02c83d-0396-4572-bba4-af43f5bce1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_5eee55ce-121b-48d9-b7d2-4ffc40334acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_5eee55ce-121b-48d9-b7d2-4ffc40334acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_74008abe-e3f8-4dd4-b521-cd8ccae21e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_74008abe-e3f8-4dd4-b521-cd8ccae21e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_8d443273-5b4a-486e-9c2e-b97b98e70eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_8d443273-5b4a-486e-9c2e-b97b98e70eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_784b2353-b13a-4af1-a494-14f39943f7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_784b2353-b13a-4af1-a494-14f39943f7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a960c61e-54bb-4d4a-93ab-b251f35b2453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a87eaa11-6e19-4df4-8bff-800bb003e627" xlink:to="loc_us-gaap_AssetsCurrent_a960c61e-54bb-4d4a-93ab-b251f35b2453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b5140772-353f-43ed-a13d-4537f7ecc186" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_26ffe1e0-d3d7-4fbe-9bc2-8a3e2fd90aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_26ffe1e0-d3d7-4fbe-9bc2-8a3e2fd90aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a44b9c12-a98a-47d7-be23-c1fd386bc037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a44b9c12-a98a-47d7-be23-c1fd386bc037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9f31484e-ef36-453a-975f-5d96132799e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_Goodwill_9f31484e-ef36-453a-975f-5d96132799e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_ac7d3b7e-2a12-442b-92d7-af617af64925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_ac7d3b7e-2a12-442b-92d7-af617af64925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_5eb5e1ba-bc79-444a-9856-d7ce7358abf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_OtherLongTermInvestments_5eb5e1ba-bc79-444a-9856-d7ce7358abf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_75175207-e8e7-4de4-b76e-2fb96bdbe056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_EquityMethodInvestments_75175207-e8e7-4de4-b76e-2fb96bdbe056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_941066c8-98f8-4c8c-907f-0eabccc03f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_941066c8-98f8-4c8c-907f-0eabccc03f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_be9af98d-cc39-4b79-9b76-6fc2c797d012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_be9af98d-cc39-4b79-9b76-6fc2c797d012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_33c9ef41-8b74-4510-bd67-c0a1caa9773f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_33c9ef41-8b74-4510-bd67-c0a1caa9773f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5f40d4d7-f68a-4de0-b06f-ad63bfad19e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5f40d4d7-f68a-4de0-b06f-ad63bfad19e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_37eeebd7-799e-499d-bc32-bf753a9f655c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bfe51526-fe71-486d-9cf8-7958296f24ac" xlink:to="loc_us-gaap_AssetsNoncurrent_37eeebd7-799e-499d-bc32-bf753a9f655c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_47d8c10a-8492-4015-8e32-464b5c350cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b5140772-353f-43ed-a13d-4537f7ecc186" xlink:to="loc_us-gaap_Assets_47d8c10a-8492-4015-8e32-464b5c350cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_1d3bdf41-29e4-42dc-93ea-f695614a5e91" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c1eb54e4-93ec-4f9a-926f-7afb03c77a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c1eb54e4-93ec-4f9a-926f-7afb03c77a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_6ec3ea6f-cf28-4944-8f0e-98fbafa3ad4f" xlink:href="ameh-20210930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_6ec3ea6f-cf28-4944-8f0e-98fbafa3ad4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d53a756d-f85f-4150-8465-da01a6d3e50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d53a756d-f85f-4150-8465-da01a6d3e50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_f0935672-4f64-479f-af08-53ac7c7a23be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_TaxesPayableCurrent_f0935672-4f64-479f-af08-53ac7c7a23be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_e31ac1f0-ba83-4a13-bb0f-959e0527ec56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_DividendsPayableCurrent_e31ac1f0-ba83-4a13-bb0f-959e0527ec56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_36b29b48-187c-4746-a29d-42fbf4fec145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_DueToAffiliateCurrent_36b29b48-187c-4746-a29d-42fbf4fec145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7b5565fc-0ba2-4fba-b596-01fd7c30366c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_LongTermDebtCurrent_7b5565fc-0ba2-4fba-b596-01fd7c30366c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_8d691517-731f-4a5c-af35-b572313fb957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_8d691517-731f-4a5c-af35-b572313fb957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3356b648-0b55-44ab-b991-522717bb041e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3356b648-0b55-44ab-b991-522717bb041e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3880e570-23fd-436a-95dc-3985417dd528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_425df57d-971b-45f2-af69-f4165835843d" xlink:to="loc_us-gaap_LiabilitiesCurrent_3880e570-23fd-436a-95dc-3985417dd528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_1d3bdf41-29e4-42dc-93ea-f695614a5e91" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_55ca606b-b244-45d3-9c6b-10045a9bf8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_55ca606b-b244-45d3-9c6b-10045a9bf8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bceb9dec-e0b9-4501-836b-29e974d18d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bceb9dec-e0b9-4501-836b-29e974d18d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0d15694b-7b5f-4914-a95f-a8c3d9ab60d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0d15694b-7b5f-4914-a95f-a8c3d9ab60d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5b41ac91-cf89-4e20-8378-3be52965e551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5b41ac91-cf89-4e20-8378-3be52965e551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_08becdce-2416-4393-b58f-6322c5c407c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_08becdce-2416-4393-b58f-6322c5c407c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3f22ca2b-21ba-426b-bc55-e141756b7a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_2eb6bb06-c8d2-4a9c-af7b-d1a4131ebfff" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_3f22ca2b-21ba-426b-bc55-e141756b7a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dca9300d-6312-48f6-b5fa-6d77538a0fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_1d3bdf41-29e4-42dc-93ea-f695614a5e91" xlink:to="loc_us-gaap_Liabilities_dca9300d-6312-48f6-b5fa-6d77538a0fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Leases" xlink:type="simple" xlink:href="ameh-20210930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_99f9a62f-f56d-444d-8dc8-9f01360bc18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_e97291f7-b132-4336-a0cc-cd0b3f12902c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_99f9a62f-f56d-444d-8dc8-9f01360bc18c" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_e97291f7-b132-4336-a0cc-cd0b3f12902c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_8606152c-4d72-48f1-888e-d086b5bd563b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_99f9a62f-f56d-444d-8dc8-9f01360bc18c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_8606152c-4d72-48f1-888e-d086b5bd563b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesTables" xlink:type="simple" xlink:href="ameh-20210930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3e308311-c2e2-4621-b379-b01fd358ed04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_5bce70ae-4987-4162-9224-20b29f08c7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e308311-c2e2-4621-b379-b01fd358ed04" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_5bce70ae-4987-4162-9224-20b29f08c7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f9fa5ff8-2703-4b6c-873c-601eb7443869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e308311-c2e2-4621-b379-b01fd358ed04" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f9fa5ff8-2703-4b6c-873c-601eb7443869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_08fc8b39-eca8-463b-a796-d79a8d2be816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e308311-c2e2-4621-b379-b01fd358ed04" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_08fc8b39-eca8-463b-a796-d79a8d2be816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#LeasesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_69bf41f9-3fd5-4558-8648-47ebe64ea344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ae7db7e7-0dac-4099-99cc-8361f68eb5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_69bf41f9-3fd5-4558-8648-47ebe64ea344" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ae7db7e7-0dac-4099-99cc-8361f68eb5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6933d860-4749-43dd-823c-37a1876b6c76" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ae7db7e7-0dac-4099-99cc-8361f68eb5c4" xlink:to="loc_srt_RangeAxis_6933d860-4749-43dd-823c-37a1876b6c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_863e500b-5421-43d2-9c81-d71304eb521d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6933d860-4749-43dd-823c-37a1876b6c76" xlink:to="loc_srt_RangeMember_863e500b-5421-43d2-9c81-d71304eb521d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e789351c-af23-4f0f-8e22-f61fbd877a7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_863e500b-5421-43d2-9c81-d71304eb521d" xlink:to="loc_srt_MinimumMember_e789351c-af23-4f0f-8e22-f61fbd877a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1b9b2c84-b5cf-46d0-8ee0-8fe151d515ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_863e500b-5421-43d2-9c81-d71304eb521d" xlink:to="loc_srt_MaximumMember_1b9b2c84-b5cf-46d0-8ee0-8fe151d515ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ae7db7e7-0dac-4099-99cc-8361f68eb5c4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_9dd11b8b-8b41-4439-8185-2a3bce9d430d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_9dd11b8b-8b41-4439-8185-2a3bce9d430d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_e1b10f4a-5a03-4084-847c-0e777affe8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_e1b10f4a-5a03-4084-847c-0e777affe8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3914665-606c-48e1-8edd-f8e140ac8706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3914665-606c-48e1-8edd-f8e140ac8706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_46f0b35a-657b-42fb-876f-57ffef236413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_46f0b35a-657b-42fb-876f-57ffef236413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_7b800240-b246-490d-8cb5-bafa9724a7a6" xlink:href="ameh-20210930.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_7b800240-b246-490d-8cb5-bafa9724a7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_572c041d-4da8-4939-b1ef-eaef1d797860" xlink:href="ameh-20210930.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_572c041d-4da8-4939-b1ef-eaef1d797860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_8fd496c6-e5f9-444a-9a98-83c86d3743b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_8fd496c6-e5f9-444a-9a98-83c86d3743b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_ad35462c-174b-408e-a03a-d3097edd88fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55004e2c-4c97-4708-b5a1-9fd4d74830b3" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_ad35462c-174b-408e-a03a-d3097edd88fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8bb4ada5-d526-460f-9ddb-90e5f069f38e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b4e7d016-50f0-41cf-8e4f-601018b4d1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8bb4ada5-d526-460f-9ddb-90e5f069f38e" xlink:to="loc_us-gaap_OperatingLeaseCost_b4e7d016-50f0-41cf-8e4f-601018b4d1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_13fe61a5-57fe-4e26-80b1-27b5f6de8c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8bb4ada5-d526-460f-9ddb-90e5f069f38e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_13fe61a5-57fe-4e26-80b1-27b5f6de8c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_4298a8b7-57ce-4fe2-a64f-03a742351b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8bb4ada5-d526-460f-9ddb-90e5f069f38e" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_4298a8b7-57ce-4fe2-a64f-03a742351b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_74ffb00b-7649-4d25-8f37-b5a35d9ac711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8bb4ada5-d526-460f-9ddb-90e5f069f38e" xlink:to="loc_us-gaap_SubleaseIncome_74ffb00b-7649-4d25-8f37-b5a35d9ac711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_95b948f7-0d90-44e7-9378-f1ade830d05a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8bb4ada5-d526-460f-9ddb-90e5f069f38e" xlink:to="loc_us-gaap_LeaseCost_95b948f7-0d90-44e7-9378-f1ade830d05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0f0c0ba4-09b3-4321-8af6-08bbbdec5448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_a8fbfa21-4514-4fdb-b8a0-321dae957367" xlink:href="ameh-20210930.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f0c0ba4-09b3-4321-8af6-08bbbdec5448" xlink:to="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_a8fbfa21-4514-4fdb-b8a0-321dae957367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_b07db056-7b59-40a8-ac98-4f4286997bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_a8fbfa21-4514-4fdb-b8a0-321dae957367" xlink:to="loc_us-gaap_OperatingLeasePayments_b07db056-7b59-40a8-ac98-4f4286997bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_0d771d59-4b5a-413f-ae9f-0effbc5245ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_a8fbfa21-4514-4fdb-b8a0-321dae957367" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_0d771d59-4b5a-413f-ae9f-0effbc5245ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_4de8f0a5-50e9-442d-8697-f28f17d51920" xlink:href="ameh-20210930.xsd#ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f0c0ba4-09b3-4321-8af6-08bbbdec5448" xlink:to="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_4de8f0a5-50e9-442d-8697-f28f17d51920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_57dce0c0-89bc-419c-a119-982b8aabaa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_4de8f0a5-50e9-442d-8697-f28f17d51920" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_57dce0c0-89bc-419c-a119-982b8aabaa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_ec43e9dd-d7cf-4344-9da1-0767fead92a0" xlink:href="ameh-20210930.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f0c0ba4-09b3-4321-8af6-08bbbdec5448" xlink:to="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_ec43e9dd-d7cf-4344-9da1-0767fead92a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1eeaae0f-79be-41f8-87cd-370938cd67e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_ec43e9dd-d7cf-4344-9da1-0767fead92a0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1eeaae0f-79be-41f8-87cd-370938cd67e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1e79d5d1-51e1-4b66-8789-e1742edfd0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_ec43e9dd-d7cf-4344-9da1-0767fead92a0" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1e79d5d1-51e1-4b66-8789-e1742edfd0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_a2724525-cf53-4391-a325-021468210d45" xlink:href="ameh-20210930.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f0c0ba4-09b3-4321-8af6-08bbbdec5448" xlink:to="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_a2724525-cf53-4391-a325-021468210d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3940751c-67bd-48fa-8e03-7439d324cf58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_a2724525-cf53-4391-a325-021468210d45" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3940751c-67bd-48fa-8e03-7439d324cf58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_b56a95fe-cd65-4c60-bc1e-a58703c05574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_a2724525-cf53-4391-a325-021468210d45" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_b56a95fe-cd65-4c60-bc1e-a58703c05574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8b381325-175c-4f32-a736-de572943265e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b381325-175c-4f32-a736-de572943265e" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f99b853f-a309-44b6-91c4-1c7dcc5ce77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f99b853f-a309-44b6-91c4-1c7dcc5ce77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9099b1e5-7e96-4802-8ff4-ea49a28c99a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9099b1e5-7e96-4802-8ff4-ea49a28c99a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7e574387-595c-4f2f-bf2b-faf7f57baf87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7e574387-595c-4f2f-bf2b-faf7f57baf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2525b485-622f-4f8e-9682-8a849039d358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2525b485-622f-4f8e-9682-8a849039d358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_547a0c35-9cb3-4735-ac21-9673707e0eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_547a0c35-9cb3-4735-ac21-9673707e0eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b70a33b7-b10e-48b0-8d5a-dc6c6ecfcab4" xlink:href="ameh-20210930.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:to="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b70a33b7-b10e-48b0-8d5a-dc6c6ecfcab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a9ea79cd-bb1c-462d-a631-b018252cf6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a9ea79cd-bb1c-462d-a631-b018252cf6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e05b84d4-70dc-4542-a100-45a09166fea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e05b84d4-70dc-4542-a100-45a09166fea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e5ae599c-3c98-4b7f-8516-ecbecd316e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:to="loc_us-gaap_OperatingLeaseLiability_e5ae599c-3c98-4b7f-8516-ecbecd316e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cbd31250-646d-4dbe-9447-e72b5bde0d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cbd31250-646d-4dbe-9447-e72b5bde0d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_10b4e564-deb8-45f3-bb9c-cbf179a2fcac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d4d42e3-cb4e-4c2d-ae0d-409617937faa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_10b4e564-deb8-45f3-bb9c-cbf179a2fcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b381325-175c-4f32-a736-de572943265e" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_7e5bb6d2-bfd9-4f66-ba58-c5b9664ce0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_7e5bb6d2-bfd9-4f66-ba58-c5b9664ce0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_62b2e1d2-e9eb-47e7-94eb-e832e3964a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_62b2e1d2-e9eb-47e7-94eb-e832e3964a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_a41b09b8-6d1d-4e3a-bd7f-e08622176b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_a41b09b8-6d1d-4e3a-bd7f-e08622176b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_7a761270-b9ed-47cb-84a6-00b3f4d44c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_7a761270-b9ed-47cb-84a6-00b3f4d44c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_71852743-31f8-4b26-afa8-f116bf8c5539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_71852743-31f8-4b26-afa8-f116bf8c5539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_8d3e9c01-8902-4288-828c-4a545061129d" xlink:href="ameh-20210930.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:to="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_8d3e9c01-8902-4288-828c-4a545061129d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_445f11ca-8dfd-49a6-86b6-935cb3443423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_445f11ca-8dfd-49a6-86b6-935cb3443423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_9bc46703-29f1-469f-9dd2-482acd0300c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_9bc46703-29f1-469f-9dd2-482acd0300c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_a377ce1e-0ff8-4a52-b984-ea894dd21bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:to="loc_us-gaap_FinanceLeaseLiability_a377ce1e-0ff8-4a52-b984-ea894dd21bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a2f72944-2cc7-44c3-a99b-c8255b03131f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a2f72944-2cc7-44c3-a99b-c8255b03131f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e2e8c71b-06ea-4f0b-84e1-8cb3070bb276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_49f58d1c-abb7-4dd8-ae73-8b9a4b5e168a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e2e8c71b-06ea-4f0b-84e1-8cb3070bb276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="ameh-20210930.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEvents" xlink:type="simple" xlink:href="ameh-20210930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_4269e03e-e533-4eb0-83f0-56ee82b833b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c50c0244-03b3-44df-8850-29c9eea5ff09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_4269e03e-e533-4eb0-83f0-56ee82b833b4" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c50c0244-03b3-44df-8850-29c9eea5ff09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210930.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1bedea33-39b4-4067-859f-1b6450250ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_9798ceff-7d60-4c74-a155-cabf5224456c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1bedea33-39b4-4067-859f-1b6450250ff9" xlink:to="loc_us-gaap_SubsequentEventTable_9798ceff-7d60-4c74-a155-cabf5224456c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b7c80aed-5abc-4495-b71b-4d3a08069dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9798ceff-7d60-4c74-a155-cabf5224456c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b7c80aed-5abc-4495-b71b-4d3a08069dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_acbcb984-4f46-485b-9da1-4fd64c91e0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b7c80aed-5abc-4495-b71b-4d3a08069dae" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_acbcb984-4f46-485b-9da1-4fd64c91e0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8d5efcd8-4b4c-4853-b555-b74bf62d99ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_acbcb984-4f46-485b-9da1-4fd64c91e0b4" xlink:to="loc_us-gaap_SubsequentEventMember_8d5efcd8-4b4c-4853-b555-b74bf62d99ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7bd8012-40cf-4788-b23b-47092b64a564" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9798ceff-7d60-4c74-a155-cabf5224456c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7bd8012-40cf-4788-b23b-47092b64a564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9ea011c3-5ca2-4773-bbad-c00828c639cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7bd8012-40cf-4788-b23b-47092b64a564" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9ea011c3-5ca2-4773-bbad-c00828c639cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_d3a8d460-0891-407c-8a04-edf82d77b8f9" xlink:href="ameh-20210930.xsd#ameh_DmgMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9ea011c3-5ca2-4773-bbad-c00828c639cb" xlink:to="loc_ameh_DmgMember_d3a8d460-0891-407c-8a04-edf82d77b8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c7e85f65-deaf-4b75-ac54-8ef7cf552336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_9798ceff-7d60-4c74-a155-cabf5224456c" xlink:to="loc_us-gaap_SubsequentEventLineItems_c7e85f65-deaf-4b75-ac54-8ef7cf552336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod_286edb33-9a50-4563-8d37-61774d12eeee" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c7e85f65-deaf-4b75-ac54-8ef7cf552336" xlink:to="loc_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod_286edb33-9a50-4563-8d37-61774d12eeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6c175b19-5a56-4d74-8142-134d649ce26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c7e85f65-deaf-4b75-ac54-8ef7cf552336" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6c175b19-5a56-4d74-8142-134d649ce26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase_639243c1-eb97-42c8-9599-abfe6a38fa9b" xlink:href="ameh-20210930.xsd#ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c7e85f65-deaf-4b75-ac54-8ef7cf552336" xlink:to="loc_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase_639243c1-eb97-42c8-9599-abfe6a38fa9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>ameh-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ameh="http://www.apollomed.net/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ameh-20210930.xsd" xlink:type="simple"/>
    <context id="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i081def6efc024948a044c021d9c0814c_I20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-10-26</instant>
        </period>
    </context>
    <context id="i38ab054fe9a44fa7991c114c1a431acf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2044abfbff374e8e958e907e8efcac87_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a5866334d904a29bc8ab814fa041912_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iad641d4c836c4802a609fb48a91e312e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id51f2960969c49fb9ecd63b28cbac656_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b4768d022194b07a1cceea1d21bda2d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i44aab1fd19634a0abf32affdb96fc3d6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if1a6d2676e4a4f7c93516c5989607a6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30833e792bfc43a2946adc49df5531cc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4041d40d8afd432cb4771fc0bd8f7304_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2de323650fd49ae83aa4d7539a0dadf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i666e2bc0492b4dbaa017b3c5a14241bf_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibd70461a565a47d1940d89ea394eb16f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8926c849258d4bf19ef81e0f57e4b423_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i60a4d9502c44417c9ed0cc8ee95e6590_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i08037cad3de049069310b5c67f35a842_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5095a52ac50d47f0b3d6a33cd48d5183_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if8a1d4a44517452191a99bec6fd96e36_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3329b671360b4adfa4fb2f7c426fc278_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0648ad97fbf94588a4eec1557fb996bd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i70980a62a1e84c5983e0627f4bd4a74c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8071ae425d7b4d82a5d84d8061a175da_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0f72d40ea546400db958d3bd6d935430_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie52aa3c0e803447b8b93a4eb0dcbf84c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1cbc34be30f4ca4ab2451c5ed3b56b8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic0a10078cec44029a1922a6aaf038643_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1512a021721849a0b8da03b2afac2ca0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a1665ab3028449997d07390764c0066_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9204aec484984ed29b67419657e5334e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4dff2d9ed6884aa7897b7d8188137fca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i801e5c00786942ddb700c1cd3c41fd90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49f40737fc5743baa30c5079d6bffc52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb86b280a3014e398f2f562416431dd5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47d2ab35fb6c4b68be2a92f518c669d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i201c4a8fab204a44b9525c92e21b3124_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibf9ea714f06741669780227438e2ccc1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9f6ed78d14764e42b9aa9957c770a040_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic77d1452e4514a5797346705209ea256_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1b58c9abcd6c470686a0c881f23bcd84_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id66271d4dd164746b13d7571ddbea1e8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4a74d81295e0434e935d5c9ca47dcd70_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if4acdd08276e41428196b78831fc6298_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib9752c3ca8824003913aa7ed5a37c7bd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic54bcb094c3c48c6b97472820dabeca3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib6c7eefcf281457baaa129d1d005c758_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9ea5b7b7fc3a4a34b7ce723c83b3a942_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7a656a56f752493b9f8d16bfa440f3d8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2ca7ada22a142c387919b0cad5803a3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6e1f2152502448b5aa9088804a86dc7c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i63d587f859094231993af50e9231e8ec_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3ae117b2200d4e1db6a15e62e5be08b2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia1cbb81479544b5d8a96c5343b4b4548_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i89732b64c48345c09b7f05b7e01eade5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i051a053544f84be68b9f7b6bd5bcf38e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifdce3fd00dfa4e8eac9f6af5191663ba_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i82e3754a2db143119d3e1eb226e3b911_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2dbf54ec60054ae5861c2aa09f4352a9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i47b3e835a53b43b1bd2a7e6cca4fe332_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f277e33d13f4f028726cc591668dbbc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i89100028143441aea045a96e3abea952_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib97aa22e2d604131bd5c10b48cbc94fc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i447b59fe96f749059a743a4fff511b89_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8f163c4d0b144be59dac47b4d4f3d1a3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3851c4c6f42140f384fa8e46fde560b9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic9a43fc6ff7a472db16607b4efd8deb6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id74805f435254a939c0fb9c4467d967c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4bcdaf3ce6a64dd8915c48e617c6050a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i77c4d76239ba428fa3c790a5e8246b33_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide4f8e08db044e18a9dd68755ff37c94_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1b428a4b73a64930be4adc92648bab3e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc6eb15301c64d8aa5fc12a0525855f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c8de92883004d2a9874fc11ec721f46_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i274e819937824ba3b8be663aca7657a1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if2897209faef4ecbb6ff8ae555b62be5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id6f0ee689326400e8ca46a963ad334e3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i80907684f53c41fa8f1a8a26101f7877_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifc4bd3d0547c43cca915340944f52cf8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i20946dbda53945ca95557bb7aea3d8ea_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i50ed93d80d8c443db56d6af7ad9eff2d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i88ea48c265674dc0b0969de2c5af9a5a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icd58c0538df4442d935bad5da111604c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6d6f1b1b2ef64607a7a28b3ddd19b9ca_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7da29179b9f74a138ee89825c3173019_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5bd6ee7c5cf34d2a95a5baf1644fd7bd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ife042466644a4588baa6a1080f3f9619_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7b04caa1c2974f2e8324ddcb0d1943b0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib71e689bf17b4b1b82292ea2371b247f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7a115db237054860af9384c8de85411b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7814f327568e456d93bd5dd8ffd4e59c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i79ab116f35bb4c18b276c3c5099436f8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1da11deec71d444dbcd9ae322ee3fdc3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9e8613962fee4ab98d908fabd87a1896_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7cfa83865da94a5f8b9fe72abbf1e869_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4d0a7a2fd7464ee299859406dbe50c73_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4dd2afccb5db4b0ab6d514f40ca4f851_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2eea77176a0f48a2a0621621efb6b4ef_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2263b2eaaf6c4496af9ac4bdaec4bb63_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id861da65feb04df7a6d28f6b72fc6ae5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iddc759fafb9d46048145c9584bd19060_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i61ed6e94c3224d0aaad33a4b064279c7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iacd41deb825c48f7968229c9af0a5590_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i57f34f8a827f48e3af8fda4fc45fb9e7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id3fb118aa44b46768cc5aa112ee13ec3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0e69dbc1f0334ee8901a65307444081e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibf99efb1cb424f2faa5e9458d42ebbab_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iad4ff3ef133a4ee8bb68a8f96bce2d82_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i03292c592c4f45da834c806bff481c24_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i917782072a6545aea32eaddcfe18e706_D19990701-19990701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-07-01</startDate>
            <endDate>1999-07-01</endDate>
        </period>
    </context>
    <context id="ib52349b88809456791d3db024592e198_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ibd821e95a1334471acf3bc50924008ff_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5e54e5787b2d4a9d913c148f7713fbd8_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i607219ce151b481d884ab20a69b7ab89_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9007c9ba55ce4f30a5723df00d10d0ab_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8bc4a1721b30446ebfd6d52b47024998_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae6af9311d664b339370a494ef320121_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i00e774cfdab24f0aa1689be1a5900a03_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if573b2a18f354adf817ec91e584fd94c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8bf46a0ff42c494995871919d226ce7e_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="ia651540f0f3040a1b9acd90c7a76f53b_D20190830-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-30</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="i833e8c7434554e839001ca8eddd9a2f1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7f596495482b4bccb3b9cb702ba11e2a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1b11e41e2b894c69abd5daa1e6e3fc87_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i98241c5880794788af87b66dc6a371bd_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i865e78a6a983465c852275c72549d64c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MPPAMGPropertiesAndZLLAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5fb003ee3c184ccf91aa13ae16058103_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3fd12cfc45b244a5884bf4cd547e6583_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="ib05af751a8be4d57b25abcbf5cb700aa_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i19c94975ba3e411ca4090953760b5a7f_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i87665dc910e64455b39ac20a1dc7a442_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie4f15f9c5a3844039181a10397fc0a58_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5c1a64ec8e5142baa71cef9c34b44674_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id0ab35f4b7d54df89c058bf7cd127578_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i70a8098987854f45b301221eae528a87_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i21d7bfcc34ee4134a98f32759980bac4_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i73149ba28e96471eb0008ad0f005eb5b_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:ClinigenceHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i620cf562ac9c414d9a3092d147a50325_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if96b5ec1dd6f464a864b0099f4d91c07_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie007473644f44d87917377c77aef7ccf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i68a17291f515493a861cd6f4b6efc5d0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0844a4c64e4a4f52bffe29e4402a700d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1c3b05a4a5ac46009c7ff5139937e1c3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i733800189cf14be7957deb86e6bdafa7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3852673d58ff474a9ec227fd30703a97_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i04da3802734c4d5ca72ce1e9859ddf23_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib06f5b4a97614ebebfcdcb473ee362ba_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i31af46ad891f405383d1dfc6a8f0cfca_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie0ffcf9784294ca9a72978bc33ad7f9e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7446d9124cfd4d7585720c3d8e7122d3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7116e35a0d75437b94523ce43f9485b0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i86ce34a69194485699b14fc7aa46d82c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf9a026a7fbb4032abab16642bbb3559_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i51f1ae095a524c598ba9ab90870d3358_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i56807d20331a448d82326373209f0ebc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if1734fad16be4ffd9f4a18f4e906e85d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i669f4e3ef9c74609880bf5e9b21c3859_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie27ed45d3b0c4053b92fca660e1e6d1a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6cf8c009ddf949839ee8d70ae541980a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4de419972e0e4273afd8cb93852e239a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2e3a8da4ddbe49af8195caf1c527e751_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaa3259fa3ba0452db6f9b000329b0707_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if278b608177c4be99b9342cc7f6e2747_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic9203d02b2a74181bd4ed2e0e1ba71f9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i875dae327fdd4ebc9c116e881e3cd106_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i02eb4ac069e64a9683beb09cbf7a8921_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i64112f96ecc6447d924934cf8a3517dc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie30670fa153f4da59d850909c48a2fd6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic985d70a02f643808edb2e7823ec4817_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6123d945359476aa42a8767483cbee8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i861c8815c7544ce78f48c3ea70ec379b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i59a0229c1ab0473da20301ac3f5f144a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i719e7a78283546f4bc429a548789a311_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i91958f750e2540c1b7888e3065408687_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8b1e99e4b094455782c477e1470f802f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3447f389c5504801b383b47a1c4d2bf5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if69a06c770b545248b58b9ead976504d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1dab6e4bc5e45dc9b15b4f78276c9d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee549c3ab8a545c3962f33718601846b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5a9f36c8077645449753769fc30f2343_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i17d3720cbb39433fad71b101f7b86012_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i125c51891f044f728be18a8712aa205b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0562f8e9b55a42e9a5ee44f0e186cecf_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ice32049f82244ceebffb5a2a9e3d9448_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i9b6b078c674a40a6aa164bb3f282fc69_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8b9f56835a534891ad456a64d2c85f50_D20210731-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-31</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="if2f519bb3a21437e99c17cddc631e9cd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0eb4d763aad449e6ba7233c66eeda68e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie718d9e05afa4852974391111b7c6f7e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0729f4ab87204534b3bd91b2c0c0e422_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i21297fd10ec8466daced044c5770ee1d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i258ab2530cfc4417af6150ea2e0d1136_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaf5628bdf9de416db3d14683e1f47a46_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i965b06b4b9744451a2780f3ce1c77fd5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i20486305e94249099f57db0ff59aba4a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idb13766dc4564b8b90da9a7ada8b71bd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie268449f84654877bacfa7e9d37cdcb0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i65c4c64100f14c0db098cf18e87b2987_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i117531eab6d74fa78cdef19fcd2f5e2a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i980c42c6c84b4875af45b55389e6bcdf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i06bc5673bf1142388330261e2bb554f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8968b1047aac4f2ba3f6833da3d4ede6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41ded44352b54f19813c1b6eb4a76ed5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c9513c56b334510bf4095f6f01b6e47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ec7d6bab59945aaa45f7785f214840f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic6e0d4064a11471ead457d43030a135a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iecf50be563d54838a275677850c705da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id75bf881994b43a087370158fad07e52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf4edcccc8394a23a7b3dcb738b03e7c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd1fbae30d564421bc5b7c93a54aea3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa0d66e6f0814c7992ad674327d5d79b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f00bc9258974017a3430fe975bf7f46_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i94b2c1e346e440078f5bd9c18d1ae3d8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0d934d0b4eae4422b768334c3e49324a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28218e6fa6044467a6cfa3dd3680f60c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i455c75e2b784434dac67f0841a1568b6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic4a0882d520246b09a88c6bc55fb835d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45b25d8b3c75481bbe6f42f9cd219cba_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if9681bc92d994054a7f881aaf0a4c1b0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i000196b3d5424523869f9b8cf182627c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14b36f750c6e4bbbaa5984ab14f7acf6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id4e845cd0750449ea326e81a9883e61b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8bb296bd3d2a499caa7ee8b26bf24153_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5ea5bb0ee621461d878a0145d57a8e9d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2b2b4206481d4c5a820281a781ad27e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7f162484d134b13ad2cb62e25a6050d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3514de26861c4453a347bd8a1fc4b612_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i902f565b388f41cb9be67571ecc22f37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb6128c207404236beafdaee21d920e7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i203bb1d43aac431a8bb988cd1f2ca55c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i73ee31bc4e9a444e89365fdc6b10afa1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a8d0fe803e64bc1a1ed9278b52c95f9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id898dfbac217454a95c7fd9549d95325_I20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="i3bd0e620dca545c990c5623c174f38f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45abc06c771b489384112954fbdfcd19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85f82fabbbfe4571ab387179ddd7a738_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i91c58bf26bff4f73b162bbd22f236e8d_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i80b8650ee33648d99a9a3444e64846f0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id5ef16887c064530aa3691f19b525d0d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1b208272f13f4a57957a453690effbf0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9cb8b922bdee480c9f9aea0eff1256c0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i77427e343910426d8907e4dcf7f52bc0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic5c127671e08453090839c66152b9457_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9acbaa81eaca438db99ca8e197a48492_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8396566a02bc4bda8fe4bcb4acc37087_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea5b5005ea214626b46b60892e1c296f_I20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="icc81f74f6ea84843a75b19e6188f7d59_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia021d902c6194cd1b515f6e5d2851f67_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if44758b50abb4b998c0cf1ed2f59be70_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0cffd986457e4a40859857d465e80d31_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i18eaba1b00ed42dfb2a3be9037829586_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id76dbd62385a4c2b89c6cc4a159139e7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iad6d8a1fd79d4409ba2643b463115e12_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee6c2515c3594dd08fa54babfc3d2655_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i74678b3019584b26a57edb839bf1d877_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib0352070af4d49b7b10b093cf1d34b6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if581017651f14f9681014c41a5d3ced8_I20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="ica129d7dca744715affd24c98e9c389e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i79b6369351c24a7caab010e07fef7ddc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic39714cbfb75465e896a533af99abbae_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if78fa0d638d24b928edf2207da5c5965_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i649b46d7c3d54c2e8ddb0eb3f0f6cb20_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CollegeStreetInvestmentLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ic5f4c57435414bcf8530f7c1b7159a3a_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="id1280e975bb74d6793bb6decce02bb42_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="id3dca6af71454e249bc71f841ff3c773_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i9bc00772371f43338e0a4894146965ab_I20190423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-23</instant>
        </period>
    </context>
    <context id="i6db22be029534d1ca263dccd767fc1fc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i567fe9f349ad4cd38b7073fc838b36af_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib8c0ead5cd26416784c4b0aae0965159_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c9277df25244861a1723845d457f7c1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id8f2830655ce425ba50defa19207191c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia48e961c12c64515bfac403310620fa8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6fcc11a65d404699b74bae8c3005ddcd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7786b13c92d44768ab2d5ee5d1646497_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02fd82315c204d5b8e983153d3e96412_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie83b679468814dbca4be10a39fdb5bc6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5db0b17b399c402d90d5cae3426b67ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie178a5bc23a34e3e968fdb0a7cc1b1d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if45e4368c403487ea641b147da7d6ec4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibecc6ab98d324e62ac84506d9b662237_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id997a6c5f4e24485b8c86ad8253ab602_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i604941a7c4e84e29bd7ca533697deae5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i464e0ae5827e4e33a2ade15334ea8236_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i78f0406a51e34beb80ce3cd5596fcbed_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="iae6a9eab9d354ba48b715b8872ad825d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i78f6b75f6efe4952a520c49f86b2ac80_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ifa51c5973cf04aa690f31014de335453_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ib54cc9af425747bc9bf0db47bae0cdf5_I20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-01</instant>
        </period>
    </context>
    <context id="ie20db30d9d2f4ad790ae13386a5e01ef_D20190701-20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-01</endDate>
        </period>
    </context>
    <context id="i2d2eae5117d042b4ae64a03222d5c117_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i525bb8235fd64a5c8f0c02ec9cbb55e4_I20201030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-30</instant>
        </period>
    </context>
    <context id="i8f146f9b4b714488a52f519d85dc9915_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="ibff23baf29ec4ca5a5fac9212a3be6ef_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i45bdfabdb85c43999bb05d916a50e971_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8494272cd6364c2a80530dff5382f450_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id37550a1e26f4222af82434fc245548e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0099b63992df486aa72820a547d7a3b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic51fbee815c34c8bbdc2590d6bb3ba93_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if29783d76d8e4e5c979ae194c2e9e7d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3c70eca48984b6aa875a69a43dd3f0c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iebc8ed74b68a4195a91620c9be1362c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic2ee83ed94cb43dcb3182dcb57e382f9_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3f4f916cef32400dab83a02c9f3d1dff_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i63ade4493fd74989b1999037fc8db598_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i55616ddbc4dc41fca2e3f5474cb36d53_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i894dad9f04be4b80b0c5418db6c0ffac_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ieb62b8a56d704692b86255ec6cff3fd8_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ied77ca7dcd3c44a3ad71dbbe16d60235_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i637ca2c6a62940f5bf8cd582df12b45d_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2da520099b4f4b1e85134d04cfed7267_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="ib4c74cb40c8b4d9882ce3f1381253d36_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="if5f64948f20549f29b7ad2775ac72e54_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="i3501cf38d6f349bfbb10a514b5e413c8_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="id51378c59e4b46a1878e9755158c9508_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i32a0cb9701af4dec94e8c8b4a88e8a16_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i6bcbe6284db54a94b3f1f04677fe3f92_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="ic51076d7bee7498eb636ef7814297785_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="idea7e71c000342b8995e416f3a7cff49_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7820cd54de244cb28e02edd916f67207_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i0e608242dd8442239280156056c80e78_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="icc5ad4c4fa8b4ec698a83764c9b1d2d4_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="id383d2aa762447b5b54e8e4dfc37d7c1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id909b639f09f413ba4ac35e191a08c1d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7d07d7302e04f1093a19129cb01db1a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6847b33d46c94f279cb67bd2e1ad4362_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6f8776621075492eacb36b4093b785ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c6ce9908aaf4419a562611bb678c2a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8147fcc7b25942ad8a37c6657211abf5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2acf51a712524f44ba644d48d0a00647_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd7cf95bb6ef4965bf29b2064ac819c1_D20200703-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-03</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i07f6fe5be32e4b7292d433a12ca499c0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4a5651c8948b4047b7eab25f8764f012_D20200703-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-03</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i5f31366737854b98ba91333a885afcb9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice5f1743593b44f9a80d07f923a92908_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="i82b2d9d7053444d4aab270f6ad420a79_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2c657488d54b424380f6b218f717a662_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="icfc39a3c7e114b588a1abebd9943f489_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaeabd70c59714c11a93da612a94d392b_D20200727-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7530cbcce02f4598a2e22ba8f19dabdb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic56ef9908db04d4ba9b326259616f237_D20200727-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i37601241e5164c76b84df50fe2dccd42_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i4a5e7cb27c6a475e8bc2918ac9af91a3_D20230101-20231201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-01</endDate>
        </period>
    </context>
    <context id="i048bc9147744436cb31702bc505497d5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0bb465d8e0fa47b281bc8588585bfd99_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifd5c1f9d9879419881aa4f73dbd34259_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieeae1845ac274f829e29f2feb496c443_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia2c3441a286f4428b822c3dc66bbbdaa_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="i4908488c47c942d99a8fc66857f5053e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id34357efa1004d2ab40ef715b0949c59_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i949ff001ac544940b35caad34ef7b315_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icee52b68969c4138b7b2a2e8af0b227d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if82c8f50b6884a84bb5fec6d0c53d8e6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i20c5c1427f6f4e6cbd81faa6df3205dc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib5b45c5e6ea841c1a753923224520654_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0be646a9c14345fabdb07fa7e3f377f0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4ae0dfc3bc32416cb6ec479fa6aee249_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieaf0c3ac99784174b913090c36595512_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id92d571acf4e4268885451c976638558_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie56d0d0b55424badade9e1fc4b2d1fb1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia1bd75ff5a784460bc879854f3dc5e14_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if75c2580a6e64c94a6c643c85453d033_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia33174543dcc47c381797d497163fb30_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib9e6ca8ac3e24c129b22e6f9b5d3b25c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i26630cf67d1949a1bb14af99246ab11e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieed5052a2c264a58a60f18048fdd7abc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i15e8004b924f4bdb999ba8d5a25493b0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id224224b17a647d7a1bbdb52d3c8ee5d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b5c1fd7f16d4fabaa391acdd0d5b331_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a3914dba35149aca5f59b14362cf84f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib7a1b7919fd34831b23c0c3972b0f9f7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i72e43a94fd374088a88895c32404f338_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1bc83e3bcab6489aa067dd6bbdb2afc2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6993e6cdd0a34b838468c68d5890d474_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie42410e4e0cd4dccab9e87193dccb1b3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2b411e1124154e218ae663e7d0cd0811_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if24be682ffa04df6b410bf2bdba494b9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8d5fc98033004eb0a900852b969e1fd0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i83f1985914f0496ea8f8d5f1f4b62193_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i36da10b506ee401bb6c1ad5f810e813e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i75b1c7458b864e9b981a527bbfa8158f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i72d599d61813449280a927233fdb0405_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4819d9b69dd44a989faef6c6cbbe20e0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01889397be3e428281f28320683c1430_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i22e30659b8d845b5bc23aafc96ddf13b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic3b55bbdae154354b76e9f0bf837e3d5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibf76fa460e274183b775eab34ea28a8a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icbe9675fd54c4c248789b3ab515892fa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i11d2613adfb84faeb941f179c4fb08a1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id5e56d3070c14ba4a8f92e0c3ba9b04f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0e8ffc3fb93241efb949e02abb5a85f0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i64448178efd84c50aa3bacac86356338_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5d9ad1e3f11440fbbd1039812179f70c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7886aad669f7475590e40c23c0dd147b_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ibeb37dc642874abea221866138cc2490_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i13fdfd16535e4f75a502075defa10c8a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia318b9c86cb8437086dadd8cd7bcfdb8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic4dcff1f010e404e963a5a4fee776b5c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i342b9208e4894d718c1b127a0a3ff4fb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icece2b97c5c941d3af2e6952b3212f8d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i40def8e50b1b4db5bd03f6203dc8a1a7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i471239abb6364a489ec282dd9c5f777c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i148d26d55f8f435b9874038459f936e1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if752ba09e479448bb94fbca2c7882209_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib35d85fe21db4cfb8b79e5c7ee1228c3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1b9b3c7021d744e9b32b81acaaf16e56_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58aaac3be5054957bf60bbd75029f96c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f003a8cc01d41348437b13692cef86c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie68ce3d93d494b71998ca2d6f07d2c77_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3a7e5a8570084a00adb32a4bdb60bbd1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8b2df61df72d41dab21cfae235327e40_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i10f15782af0443ab842ba194eb8c55f8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iee30b0d2253f4bb492015b9d7da0adb5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4dbf0fd1b79a4e77bdd4836d453ae1b0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if47df11b72db4b389d16b2265853b9c2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1993cd5de17942f99b55c5e4dae41d86_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iec1fb7fa46f34dd39ecfb564894305ee_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7395056c59fb49af99bb8cde1bd98437_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i25917a62f9c2433c936ab8aefbd468c7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ied011d8645e3412aa2f3e2387b1cb1a9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23b30d2846b14b2c897a80d786dde119_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia6896fdcb8ae4b7ca99bd00de7787507_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib5a867cf070d443da348b27bcc09a6f9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibdfaf156fde64914862fc81410e5c63a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib523d137eddc47e29f0030b185a7b372_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b5a146f0b1e44f5b789255f0c543e0b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i173a4dea7cb24055b072519c2bdfe757_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i54147940fa7a4e1fab0ebc8efdde6b95_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i21dc815a2c734a16a45443053949a1ac_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifd69f4d08ad148e9ab3a76b73d5a7b44_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie5c8495e26684dcc9ad519449c4bc3ec_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3b9a649b9c8c46d6880482c83fb0ff4c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i478b087008894447ae487fe130dd89e6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icafd606f127347a5a215b6401a63da94_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f3ab4e5a41043c2ae92af6c8f11dc34_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib124a96ecc074da29278d04a4d7de485_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifb0c1db1b2d84d2fa57edc7c15d4fac4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i51e4bde9a34f42159e327cca1a631656_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic03d35847f734105a48e1318bda34af3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7eb15316a75740d3a7e2f2bb4ec65285_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2d0b297b84754d2ba32a089d68928fe4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i95582f9ab23c40c88ff9c9aa11e8368c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i516478a0add344df8b418bb1e41a3d53_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01d16bcfadca4f16a85f305b306f3af5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icb8612b46bf04b23bb32513fb5f4e06b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0a1d28025a574e8f8c021b319564a04e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if6dfbbc083a24b1fb873315d3843b5bc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia126933eaa88475f8ca99bc2e342801d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5fe5c8cca1584e10a27f094882462ec4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i82d32e9e52cd43b8bde097d8ad4cf68d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i11c0bdbc45944c189d1902dd97e0b2c5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i33c01da554a346699ef38852e5a9238e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6956147d1b1d44068bcecf36bebb1819_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e8aacaa10644e039ce5c4b96322fc8b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia4380cb2b0e24e1994d0661bb4241a61_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9fe20fe658aa4256aabbbd2c89d398ea_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iae1ae82bc8db4b2d995d2be127951787_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5e9491c7189f4bc1a3a03bbff2758fdf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5aa407ed2a23431cb3c6911df6e8bf96_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iea3d25188b02481c84d1af0e34e1d2f0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5b7b7c8fa79242e4b1f9fd2aed295aac_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if2ed3ce186f64ecd9e26858f4e56cbaf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i699b0a24650b4020ab36add96e94ba16_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1df4d6d4265646919c8679d06c6f5f8d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6847bf6720074c31bb84ab647a20bce7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7c8b780248c2455fb8dd5302f1cc8305_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f9ab052b3f24f16b3cdc5fc945ba7a2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idb0ef53cb71e453a995be937fb48b3a6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i447f7dcce84d4cebb5acb882ea34ecbb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5973967987a64974bf0b313e96b45d1b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id082ef37853342dbafac08634c15ffe0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1b43cafde674d70aa71314660d7da57_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i852e3ec3537a4c119c5f8a22d38b551a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie0047fe9e823452fb45b32fabf79ea46_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6ef913adaabe443884d85c0a2a9ace03_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie0932a147a2f4eaaaf31703eddb2b244_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic947409b267649339b37e4b534577ae3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1c285663f977492290e465d3a04c4a3d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4d3b34a11c90439a83c552a032829eb0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i56d750657b42421a8e440b3dd05fd4dd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib67e38d8ef3944d2b52b5cddc0110cf3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2a5bb1b525984a4b94e3835c3d3c958d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i36efa1094ce84f39a33d944df471c9bc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6cab8e82bce461aadf4a8285aaedf2d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i396303604fe24b649811f19aa1b86666_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6af953349f5741e6903f07fe40567fb1_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i347edc610f5f44f797de7ecdf6022137_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iea7d2b87a68e4688b5afefdb57fd6387_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>ameh:plan</measure>
    </unit>
    <unit id="clinic">
        <measure>ameh:clinic</measure>
    </unit>
    <unit id="segment">
        <measure>ameh:segment</measure>
    </unit>
    <unit id="unit">
        <measure>ameh:unit</measure>
    </unit>
    <unit id="provider">
        <measure>ameh:provider</measure>
    </unit>
    <unit id="financial_ratio">
        <measure>ameh:financial_ratio</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80L2ZyYWc6NzBhYTg5NDE1ZjY5NDUxYTg5ODNmNDcxNDNkOWEyM2IvdGFibGU6NzE4Mzc1YmZjZDAzNDRhYWExZTRkOTg5NDM3ZWQwYzYvdGFibGVyYW5nZTo3MTgzNzViZmNkMDM0NGFhYTFlNGQ5ODk0MzdlZDBjNl8zLTEtMS0xLTA_cba3e876-1ff9-4668-853c-fddcfbd887ea">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80L2ZyYWc6NzBhYTg5NDE1ZjY5NDUxYTg5ODNmNDcxNDNkOWEyM2IvdGFibGU6NzE4Mzc1YmZjZDAzNDRhYWExZTRkOTg5NDM3ZWQwYzYvdGFibGVyYW5nZTo3MTgzNzViZmNkMDM0NGFhYTFlNGQ5ODk0MzdlZDBjNl80LTEtMS0xLTA_fd91bec4-36e4-4d40-b705-ba6a0b771f90">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80L2ZyYWc6NzBhYTg5NDE1ZjY5NDUxYTg5ODNmNDcxNDNkOWEyM2IvdGFibGU6NzE4Mzc1YmZjZDAzNDRhYWExZTRkOTg5NDM3ZWQwYzYvdGFibGVyYW5nZTo3MTgzNzViZmNkMDM0NGFhYTFlNGQ5ODk0MzdlZDBjNl81LTEtMS0xLTA_12972328-74a2-499a-afd6-06363ee24248">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80L2ZyYWc6NzBhYTg5NDE1ZjY5NDUxYTg5ODNmNDcxNDNkOWEyM2IvdGFibGU6NzE4Mzc1YmZjZDAzNDRhYWExZTRkOTg5NDM3ZWQwYzYvdGFibGVyYW5nZTo3MTgzNzViZmNkMDM0NGFhYTFlNGQ5ODk0MzdlZDBjNl82LTEtMS0xLTA_a6219961-de06-40eb-b3f0-90f421932f05">0001083446</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80L2ZyYWc6NzBhYTg5NDE1ZjY5NDUxYTg5ODNmNDcxNDNkOWEyM2IvdGFibGU6NzE4Mzc1YmZjZDAzNDRhYWExZTRkOTg5NDM3ZWQwYzYvdGFibGVyYW5nZTo3MTgzNzViZmNkMDM0NGFhYTFlNGQ5ODk0MzdlZDBjNl83LTEtMS0xLTA_47e03b64-0bc8-4fae-b049-73c7beaeb180">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i36da10b506ee401bb6c1ad5f810e813e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTY0OA_28ab602c-7a29-4dcd-a454-db6a953fd86b">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDk2_e6d0fdee-4388-4e10-90ed-e0ea7d9b3d35">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6ZmRmOWFlMTk5Y2IwNGQzYWJlNTU0N2NmZTdiMDk3NDUvdGFibGVyYW5nZTpmZGY5YWUxOTljYjA0ZDNhYmU1NTQ3Y2ZlN2IwOTc0NV8wLTAtMS0xLTA_200890f9-10fd-41d0-af18-70dc49044eb2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8xMjM_efe09c29-2fb3-4f17-b5bf-99442a1b9b83">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6Y2EyOThmMjk3NjFmNDI4MTg5ZTk5OTQ4NjE4NDE5M2EvdGFibGVyYW5nZTpjYTI5OGYyOTc2MWY0MjgxODllOTk5NDg2MTg0MTkzYV8wLTAtMS0xLTA_fb5b4baf-bd12-4de1-b1ab-50f9aed7262a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDk3_eceb12b6-8524-4ea8-8c51-5390695ea2aa">001-37392</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDky_eb9919d8-eaff-4c64-94f3-446863e00ea1">Apollo Medical Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6ZjdiNDJhYmEwMTA4NGMyZjhiZWQzN2Y1YTliMjc0ZjUvdGFibGVyYW5nZTpmN2I0MmFiYTAxMDg0YzJmOGJlZDM3ZjVhOWIyNzRmNV8wLTAtMS0xLTA_40cbc782-dc41-434e-965a-7b94d7891974">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6ZjdiNDJhYmEwMTA4NGMyZjhiZWQzN2Y1YTliMjc0ZjUvdGFibGVyYW5nZTpmN2I0MmFiYTAxMDg0YzJmOGJlZDM3ZjVhOWIyNzRmNV8wLTEtMS0xLTA_d0b54553-a609-49fe-a7bc-8700c351dc7b">95-4472349</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDk4_159cb431-0edd-4429-bb28-93be6ec28903">1668 S. Garfield Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDg2_7d3a356f-ed57-424f-9f63-40ab2c063836">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDg3_a8a3ead5-80fb-4713-b849-46ee99fa217f">Alhambra</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDg4_7ada558f-d1b6-4852-9a89-81dc85e58501">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDg5_522dc11c-dcce-4d80-9420-5a2cdc482bd5">91801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDk5_539b174c-d5d7-4b74-9e44-0930909b32e4">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDkz_723097b5-03cc-477d-bc20-29ec0bf6fde8">282-0288</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6Mzk0MWQwZDlhNGUzNGVmYmJiODBmZGMyOWNlMzM1MzUvdGFibGVyYW5nZTozOTQxZDBkOWE0ZTM0ZWZiYmI4MGZkYzI5Y2UzMzUzNV8xLTAtMS0xLTA_0841dd30-e8e2-4800-badf-6ad8a17bb081">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6Mzk0MWQwZDlhNGUzNGVmYmJiODBmZGMyOWNlMzM1MzUvdGFibGVyYW5nZTozOTQxZDBkOWE0ZTM0ZWZiYmI4MGZkYzI5Y2UzMzUzNV8xLTItMS0xLTA_2ea5c6ca-416c-428b-9bc5-f9cca63cb010">AMEH</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDkw_6cee7f73-b151-4a24-9d6a-627eeb64e24a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDkx_a31307a9-72e7-4295-95bd-1b7337abb485">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6YzgwMWIyOTcwYjI5NDJhNjk1Y2NlOWM1YmYyNGUyODQvdGFibGVyYW5nZTpjODAxYjI5NzBiMjk0MmE2OTVjY2U5YzViZjI0ZTI4NF8wLTItMS0xLTA_3756c1c6-e72b-41a1-80be-007b9607e9f5">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6YzgwMWIyOTcwYjI5NDJhNjk1Y2NlOWM1YmYyNGUyODQvdGFibGVyYW5nZTpjODAxYjI5NzBiMjk0MmE2OTVjY2U5YzViZjI0ZTI4NF8xLTMtMS0xLTA_ba0f4e86-1142-46e6-9429-359d265cc8de">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGFibGU6YzgwMWIyOTcwYjI5NDJhNjk1Y2NlOWM1YmYyNGUyODQvdGFibGVyYW5nZTpjODAxYjI5NzBiMjk0MmE2OTVjY2U5YzViZjI0ZTI4NF8yLTMtMS0xLTA_5bab8c4b-c674-4fc7-b830-efb5935ca46d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8yMDk1_5d09612c-0bb4-470a-ade2-d1bb2f76fec0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i081def6efc024948a044c021d9c0814c_I20211026"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xL2ZyYWc6YzUxNDNjNmRlYjM0NGI2ODk0M2FiYjA3M2U4OThhY2YvdGV4dHJlZ2lvbjpjNTE0M2M2ZGViMzQ0YjY4OTQzYWJiMDczZTg5OGFjZl8xOTg5_bba5f3bf-63df-4a9b-a618-22feff3eb32b"
      unitRef="shares">55549053</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNS0xLTEtMS0w_76856016-3001-4921-91c0-7679efde2531"
      unitRef="usd">204768000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNS0zLTEtMS0w_4ffe6472-3aad-4768-83ef-e5dfb9b1980e"
      unitRef="usd">193470000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNy0xLTEtMS0w_2a57a509-6f5d-4fc6-b37d-fb39868fcd6d"
      unitRef="usd">128558000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNy0zLTEtMS0w_361b1af0-47a0-4dfa-a232-0e20fca35945"
      unitRef="usd">67695000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfOC0xLTEtMS0w_38357055-03ad-4f3d-b1d3-7f0384df6894"
      unitRef="usd">18753000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfOC0zLTEtMS0w_10850e34-670a-49e5-a752-94fe2a6ebacd"
      unitRef="usd">7058000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfOS0xLTEtMS0w_85406e7d-59bf-476b-875f-1c6a9aee1d07"
      unitRef="usd">53626000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfOS0zLTEtMS0w_591916be-8f6e-49e4-a984-710342329ad9"
      unitRef="usd">49260000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTAtMS0xLTEtMA_6a0a89b4-cc45-4741-b18e-93d5d7738a5c"
      unitRef="usd">5773000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTAtMy0xLTEtMA_b4ea6274-fabb-4449-98f1-1b528281a680"
      unitRef="usd">4297000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTEtMS0xLTEtMA_48a1825b-2d95-44e1-bbdf-86dfba6f8184"
      unitRef="usd">11734000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTEtMy0xLTEtMA_fb69067d-a20d-4547-827a-d1f1607c2975"
      unitRef="usd">16797000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTItMS0xLTEtMA_db5a070d-d9b8-4a3a-99f4-8f9b8322c5b7"
      unitRef="usd">4000000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTItMy0xLTEtMA_1827baad-1c5b-4a70-9f49-b903463cbc6e"
      unitRef="usd">0</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTQtMS0xLTEtMA_65d1c434-3d88-4e50-aa28-40b6ba2bfe70"
      unitRef="usd">427212000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTQtMy0xLTEtMA_642df68f-93aa-4305-bdbb-da6d9d3097c3"
      unitRef="usd">338577000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTctMS0xLTEtMA_ce872392-47e7-45c8-8d78-8588f6e0e2f6"
      unitRef="usd">49280000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTctMy0xLTEtMA_94f08e34-7399-46d8-b8ea-50497e0f818c"
      unitRef="usd">29890000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTgtMS0xLTEtMA_30418cc5-3ced-487a-bfea-352031b4a97b"
      unitRef="usd">83594000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTgtMy0xLTEtMA_c0cada40-2dd7-4256-a8dd-999d312c36d9"
      unitRef="usd">86985000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTktMS0xLTEtMA_05bef1ed-f7ce-4387-9835-3fee1e91f966"
      unitRef="usd">243353000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMTktMy0xLTEtMA_5af005d7-7054-4d18-8cd2-b6e11ae1b869"
      unitRef="usd">239053000</us-gaap:Goodwill>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjAtMS0xLTEtMA_e3ec8175-06bf-4305-bd00-5b38b75366f5"
      unitRef="usd">584000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjAtMy0xLTEtMA_09179401-8df1-44e6-adf7-449609e6b613"
      unitRef="usd">480000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjEtMS0xLTEtMA_8d247c6d-10d8-43f9-bbf4-b19a7096dc8a"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjEtMy0xLTEtMA_659bc095-5cf7-493f-bffd-9dc8575f36f5"
      unitRef="usd">4145000</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjItMS0xLTEtMA_17d5b91b-5757-44c3-b370-708f54b22367"
      unitRef="usd">45046000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjItMy0xLTEtMA_52794099-52b4-4b37-afcc-b47e61c95c89"
      unitRef="usd">43292000</us-gaap:EquityMethodInvestments>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjMtMS0xLTEtMA_936d152b-faaf-40f8-9572-0bbbe4a8a87e"
      unitRef="usd">896000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjMtMy0xLTEtMA_58decf6f-8079-447f-bad3-5c5425e29293"
      unitRef="usd">37075000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjQtMS0xLTEtMA_79f68df8-f929-4b88-9a0f-1fcba1f3a827"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjQtMy0xLTEtMA_abdf75cf-b6a5-49a8-b036-367703096e7f"
      unitRef="usd">500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjUtMS0xLTEtMA_36b0b661-5bc5-414b-bc18-1e2c68871462"
      unitRef="usd">16134000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjUtMy0xLTEtMA_c85f2f94-6245-4fdf-80dc-f55704759525"
      unitRef="usd">18574000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjYtMS0xLTEtMA_c44402c8-5391-4d79-9496-a141516cb892"
      unitRef="usd">5195000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjYtMy0xLTEtMA_53e24e71-5bff-40ab-970e-b315970e762d"
      unitRef="usd">18915000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjgtMS0xLTEtMA_6b7e6586-2be1-4b3d-b13e-813702668302"
      unitRef="usd">444082000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMjgtMy0xLTEtMA_ad98eacc-1576-4d5c-8e93-db49cffd26b1"
      unitRef="usd">478909000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzAtMS0xLTEtMA_6c7a426a-55b6-48ec-8702-a4a1872ac251"
      unitRef="usd">871294000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzAtMy0xLTEtMA_a5ff60fb-e978-4632-811f-8acc8fde5032"
      unitRef="usd">817486000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzYtMS0xLTEtMA_53960da9-7af0-4b4b-bb45-f73bc233dff8"
      unitRef="usd">57505000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzYtMy0xLTEtMA_71cfacac-eb67-4251-b78b-91b87415c534"
      unitRef="usd">36143000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzctMS0xLTEtMA_5182e1f8-1fe1-420a-a32f-f142e89d7461"
      unitRef="usd">8827000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzctMy0xLTEtMA_0caa1acd-2c83-4609-b15c-a898c931b6f7"
      unitRef="usd">9642000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzgtMS0xLTEtMA_a06364d2-0e32-45f2-9a96-e11beaf49e13"
      unitRef="usd">42872000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzgtMy0xLTEtMA_45060b06-f6de-416e-9237-3f43acabb4a1"
      unitRef="usd">50330000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzktMS0xLTEtMA_e132cb23-1692-4a16-a16b-c7dc4f19f025"
      unitRef="usd">4024000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzktMy0xLTEtMA_056fcd7e-95a2-4560-a4ac-ce67561bbfe1"
      unitRef="usd">4224000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDAtMS0xLTEtMA_3d185abd-6d3b-4471-8329-b99997797a78"
      unitRef="usd">556000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDAtMy0xLTEtMA_37f3a146-e29a-445e-ad5b-92c40cd26f1e"
      unitRef="usd">485000</us-gaap:DividendsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDEtMS0xLTEtMA_453f448a-9fd3-481b-9e67-df9031fa5781"
      unitRef="usd">110000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDEtMy0xLTEtMA_c78d66f4-a1e9-460a-80da-0b4bd06f3fe2"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDItMS0xLTEtMA_e2125848-f423-4612-80ec-c55df270a1e5"
      unitRef="usd">2658000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDItMy0xLTEtMA_36092add-51ed-449e-9d28-cb33b12d7352"
      unitRef="usd">3177000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDMtMS0xLTEtMA_00568d1d-f15b-4937-aa2f-be2f63b0824b"
      unitRef="usd">207000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDMtMy0xLTEtMA_08790ed6-e94e-4056-b8a6-3a2cc8d5cfc4"
      unitRef="usd">10889000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDQtMS0xLTEtMA_359b1e99-0716-4cc1-aa4e-758bbd2419e8"
      unitRef="usd">116759000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDQtMy0xLTEtMA_ef5ee17a-31f4-4170-95c8-8cdc28ff907b"
      unitRef="usd">114992000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDctMS0xLTEtMA_5f2e0395-a8f8-43fb-96cd-ec4e709bc034"
      unitRef="usd">19592000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDctMy0xLTEtMA_f2a85a90-74c5-4bce-9940-dcf98f6ce075"
      unitRef="usd">10959000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDgtMS0xLTEtMA_46227711-56f4-4f9a-b2a7-f479af99e0c7"
      unitRef="usd">221000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDgtMy0xLTEtMA_8eb651d2-4716-4db1-9ac2-9305c471e4b0"
      unitRef="usd">311000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDktMS0xLTEtMA_e1bffdd8-c13f-4fcd-8380-41245b4bdbf8"
      unitRef="usd">13856000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNDktMy0xLTEtMA_53cd231b-cc02-4ff0-85e8-967532df58de"
      unitRef="usd">15865000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTAtMS0xLTEtMA_4cbdff58-8ded-4301-8a53-3196a298101f"
      unitRef="usd">182813000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTAtMy0xLTEtMA_2c3972d6-56d4-47ee-80db-d626484b8514"
      unitRef="usd">230211000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTEtMS0xLTEtMA_4779c5f2-e6c5-40d3-bb7d-bc60f5ced80d"
      unitRef="usd">6232000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTEtMy0xLTEtMA_ef30819f-e4e3-4070-80a9-a479ea6310b3"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTMtMS0xLTEtMA_d1f17bff-b5c9-4f34-82f3-7310320cbd07"
      unitRef="usd">222714000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTMtMy0xLTEtMA_abe88e4e-3cc3-4ebc-8c8f-cc56ba81f4c9"
      unitRef="usd">257346000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTUtMS0xLTEtMA_1158702b-f85a-49a8-b56e-bc619fb29d85"
      unitRef="usd">339473000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTUtMy0xLTEtMA_83cf3721-9957-4807-97c8-1f0e124151ee"
      unitRef="usd">372338000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTctMS0xLTEtMA_c9c5ed64-c67e-46f5-8824-e75bc4ba5697"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTctMy0xLTEtMA_9e52ea7c-d2d0-48ec-882c-a9630f6e5734"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjAtMS0xLTEtMA_d2b4301c-cc7e-43e1-8111-cd8e26f4ce3c"
      unitRef="usd">91500000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjAtMy0xLTEtMA_2ffdf339-67b6-416b-885a-2ca146a390be"
      unitRef="usd">114237000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9a5866334d904a29bc8ab814fa041912_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzMw_0788b370-337d-4761-84a5-8946fe7b0436"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iad641d4c836c4802a609fb48a91e312e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzMw_e9dcd68d-fbff-40c1-9510-2bcddc56e28b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iad641d4c836c4802a609fb48a91e312e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzU0_23e85a81-e502-44d9-aa4a-8678909f2344"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9a5866334d904a29bc8ab814fa041912_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzU0_9dc13fd7-e927-475c-bf56-80c6eb1047e5"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iad641d4c836c4802a609fb48a91e312e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzE0Nw_6666c8ac-9dfb-4df8-9c8d-48bd9f010a43"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9a5866334d904a29bc8ab814fa041912_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzE0Nw_80d719a2-ede0-4229-82b5-7d541e85b7a8"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9a5866334d904a29bc8ab814fa041912_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzE2MQ_6124d97f-dc7b-4a0c-baae-6fa6ddf56531"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iad641d4c836c4802a609fb48a91e312e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjRjMTNmYzhhMDkyOTQ2YTc5ZTRjZDEwMTg4MTExNTFjXzE2MQ_d80f6988-e471-4a96-aa75-5ed16699a52f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i9a5866334d904a29bc8ab814fa041912_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMS0xLTEtMA_f3888cb1-1706-496a-a8b1-241cebe86628"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iad641d4c836c4802a609fb48a91e312e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjMtMy0xLTEtMA_6b73bed6-6e71-4ee6-8d61-0f10a72a771d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id51f2960969c49fb9ecd63b28cbac656_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzMw_1373f81d-a101-40fa-85fd-6734c2d611b0"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0b4768d022194b07a1cceea1d21bda2d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzMw_57bfdeea-0e0a-4c15-967d-59d95cff670c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0b4768d022194b07a1cceea1d21bda2d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzU0_5946b655-f5f2-42ce-bbe2-85b73537f9b8"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id51f2960969c49fb9ecd63b28cbac656_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzU0_e855977c-cba8-422b-a14f-dfe31331e959"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0b4768d022194b07a1cceea1d21bda2d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzE0Nw_1207b52e-21e1-449a-8d4b-1a9af3894ad7"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id51f2960969c49fb9ecd63b28cbac656_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzE0Nw_78c015ff-f31c-4401-881e-5d3a11cc0d24"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0b4768d022194b07a1cceea1d21bda2d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzE2MQ_453cd12d-cf6a-49fc-81b0-906866f01b3b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id51f2960969c49fb9ecd63b28cbac656_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOjY4MDBhMzlmMGQ3YTQxZTI4YmI3NWU3MzVlYzA0N2FkXzE2MQ_cc4ddfa1-d42d-43fb-b9a2-dfd99da14bb6"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i0b4768d022194b07a1cceea1d21bda2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMS0xLTEtMA_ca2a9f1e-572a-4644-8549-afcde917397d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id51f2960969c49fb9ecd63b28cbac656_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjQtMy0xLTEtMA_beb53c38-16ff-4fed-ba5c-989bf84cd700"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzE4_07e08d2f-96d0-4967-87a6-ee23f2974515"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzE4_c90d1de7-bd62-4a3b-89bc-59af1099b49e"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzQy_03ee1a8f-3947-48ea-b6a6-233c72575299"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzQy_de26086d-8990-4669-8592-4b9eebed6250"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzY0_54cefad3-0d14-498a-8b83-5c6a98ddbf9e"
      unitRef="shares">44397050</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzY0_8d1208e1-9794-46a8-9fda-fff1e9e330bf"
      unitRef="shares">44397050</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0Xzcx_3459c872-fa57-4b7d-a81e-b2437cfcb609"
      unitRef="shares">42249137</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0Xzcx_69ba5845-b865-4c30-82bd-e0ea865cd498"
      unitRef="shares">42249137</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzEwNA_3e70d7c4-ecba-4477-a528-50af4cee5245"
      unitRef="shares">10925702</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzY3NDhiZWJjYTRlMjViMjkzZjQyNGI5Yjg5MDE0XzExMQ_101d1cdc-616d-4791-b141-7a88f1187310"
      unitRef="shares">12323164</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockValue
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMS0xLTEtMA_4bb22158-80e7-4688-9330-db7e51a914c3"
      unitRef="usd">44000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjUtMy0xLTEtMA_0aeb12c9-ea38-4adf-8702-82ef0700c142"
      unitRef="usd">42000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjYtMS0xLTEtMA_65f3830c-abe3-4804-8d62-e1385a2d9e24"
      unitRef="usd">305994000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjYtMy0xLTEtMA_3ca24ff9-e7a9-483e-b150-346e7dd12de7"
      unitRef="usd">261011000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjctMS0xLTEtMA_56a4e71a-7ca3-4ef4-ba32-38573cd74b66"
      unitRef="usd">129859000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjctMy0xLTEtMA_3c49b39f-d8e1-462d-a4a0-00808440282a"
      unitRef="usd">69771000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjgtMS0xLTEtMA_e360269d-916d-4895-96f4-5da7363b01e4"
      unitRef="usd">435897000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNjgtMy0xLTEtMA_9e267983-c5f1-4dcb-844c-ee4f2a072475"
      unitRef="usd">330824000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNzAtMS0xLTEtMA_b7db59cc-c53a-47a5-a509-4b1995d2ff03"
      unitRef="usd">4424000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNzAtMy0xLTEtMA_995b44fe-1c38-4436-8c49-d90fd234c5ae"
      unitRef="usd">87000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNzItMS0xLTEtMA_0547c91e-eb80-40d0-b3d5-b33aa2ad7c3a"
      unitRef="usd">440321000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNzItMy0xLTEtMA_44e0a07d-e418-4b76-8f52-b0ec982f0767"
      unitRef="usd">330911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNzQtMS0xLTEtMA_362309d5-5404-4691-a864-6f282dfe01af"
      unitRef="usd">871294000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNzQtMy0xLTEtMA_5ccebb15-c858-41a9-b6b3-b5cf429959d1"
      unitRef="usd">817486000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets
      contextRef="i44aab1fd19634a0abf32affdb96fc3d6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNDcx_d4978182-a4e4-4210-8b97-f96a3884fced"
      unitRef="usd">601800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if1a6d2676e4a4f7c93516c5989607a6b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNDc4_6382b97c-1d64-4896-968e-1c37f280629a"
      unitRef="usd">576100000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i44aab1fd19634a0abf32affdb96fc3d6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNjYy_f6fa359f-8447-40a8-9797-57f96e64bacd"
      unitRef="usd">92800000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if1a6d2676e4a4f7c93516c5989607a6b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNjY5_536aa301-ed35-4dc3-bf87-add388818bca"
      unitRef="usd">88600000</us-gaap:Liabilities>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i44aab1fd19634a0abf32affdb96fc3d6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfMjc0ODc3OTA3MDI1Mw_d8d7578f-f53c-4e87-a82b-6b83817cc5e4"
      unitRef="usd">994800000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DueFromAffiliates
      contextRef="i44aab1fd19634a0abf32affdb96fc3d6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfMjc0ODc3OTA3MDI5MQ_c939d1df-5e91-49f0-9159-c84d0851aeca"
      unitRef="usd">15800000</us-gaap:DueFromAffiliates>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="if1a6d2676e4a4f7c93516c5989607a6b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfMjc0ODc3OTA3MDM0Mg_6bb71093-358b-4534-8c3a-a9a09f56f7ae"
      unitRef="usd">225100000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DueToAffiliateCurrentAndNoncurrent
      contextRef="if1a6d2676e4a4f7c93516c5989607a6b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfMjc0ODc3OTA3MDM3OA_06983b0f-ba41-4490-8b55-c02ca8933e4c"
      unitRef="usd">22700000</us-gaap:DueToAffiliateCurrentAndNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30833e792bfc43a2946adc49df5531cc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMy0xLTEtMS0w_f1f29577-3700-40bc-9c1f-960ce406b773"
      unitRef="usd">149059000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4041d40d8afd432cb4771fc0bd8f7304_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMy0zLTEtMS0w_3d98d413-8120-4dc0-adbb-d23e6f536716"
      unitRef="usd">135032000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2de323650fd49ae83aa4d7539a0dadf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMy01LTEtMS0w_5bba4353-f82b-4b77-9138-713266368297"
      unitRef="usd">438350000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i666e2bc0492b4dbaa017b3c5a14241bf_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMy03LTEtMS0w_de96c2de-7906-42f7-ad29-e0b37ac7d882"
      unitRef="usd">416402000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd70461a565a47d1940d89ea394eb16f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNC0xLTEtMS0w_37ffdd25-aa06-4b5e-8951-4e360aaff954"
      unitRef="usd">59923000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8926c849258d4bf19ef81e0f57e4b423_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNC0zLTEtMS0w_837009ae-ea8a-45ff-840e-7feae1420346"
      unitRef="usd">30916000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60a4d9502c44417c9ed0cc8ee95e6590_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNC01LTEtMS0w_7676be3a-dd12-4cea-99c8-d1e38b48455b"
      unitRef="usd">94146000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08037cad3de049069310b5c67f35a842_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNC03LTEtMS0w_7f599c00-3bef-4b55-a109-2bda323205eb"
      unitRef="usd">54155000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5095a52ac50d47f0b3d6a33cd48d5183_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNS0xLTEtMS0w_d09528b4-f76e-4761-80f8-a662aa78edcd"
      unitRef="usd">9652000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8a1d4a44517452191a99bec6fd96e36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNS0zLTEtMS0w_d4cb47a5-0ac6-488e-aafd-63fc4156058d"
      unitRef="usd">8707000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3329b671360b4adfa4fb2f7c426fc278_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNS01LTEtMS0w_8aa3e419-e23a-4341-b5cd-86236c737f90"
      unitRef="usd">26345000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0648ad97fbf94588a4eec1557fb996bd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNS03LTEtMS0w_7bd7c0d0-7baa-4501-af8b-9cce137800e8"
      unitRef="usd">26212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70980a62a1e84c5983e0627f4bd4a74c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNi0xLTEtMS0w_c368fbdc-7b39-4c04-951a-0015bd821801"
      unitRef="usd">7260000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8071ae425d7b4d82a5d84d8061a175da_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNi0zLTEtMS0w_b93a112a-8149-46c5-80c6-f3fc200ecff5"
      unitRef="usd">3737000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f72d40ea546400db958d3bd6d935430_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNi01LTEtMS0w_e3af71a2-a3ed-4101-8156-dc44772a68fd"
      unitRef="usd">14968000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie52aa3c0e803447b8b93a4eb0dcbf84c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNi03LTEtMS0w_b2a3fa33-1f91-4442-8ef7-22df20a6a943"
      unitRef="usd">9434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1cbc34be30f4ca4ab2451c5ed3b56b8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNy0xLTEtMS0w_4d34d874-073b-47c9-b1a6-f94023a1015a"
      unitRef="usd">1223000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0a10078cec44029a1922a6aaf038643_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNy0zLTEtMS0w_cf575b8a-27de-4b62-8fc5-5cba6f96d454"
      unitRef="usd">1731000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1512a021721849a0b8da03b2afac2ca0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNy01LTEtMS0w_98f3594b-6401-42cc-bdd6-ec80063b0f34"
      unitRef="usd">5006000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a1665ab3028449997d07390764c0066_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNy03LTEtMS0w_656b0882-1f56-4c65-adb2-2860ace7fa8f"
      unitRef="usd">4194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfOS0xLTEtMS0w_cf459961-1a1a-4ab3-9e84-56c97a56ac9c"
      unitRef="usd">227117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfOS0zLTEtMS0w_0baf222e-ff4a-41f7-a103-5babfc749a40"
      unitRef="usd">180123000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfOS01LTEtMS0w_fc1d9154-5f7a-4427-8f08-e8696ee38ed3"
      unitRef="usd">578815000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfOS03LTEtMS0w_3fecc510-0e63-4151-aa82-3df3797d9c26"
      unitRef="usd">510397000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTItMS0xLTEtMA_3abeebc0-9d40-48b2-b1e4-c1713c55d290"
      unitRef="usd">147473000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTItMy0xLTEtMA_364954cc-1238-4cfe-904a-403fbecb2832"
      unitRef="usd">121823000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTItNS0xLTEtMA_e30b465e-4b4f-44b5-a74e-77d1297989be"
      unitRef="usd">424303000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTItNy0xLTEtMA_06b63b8b-5aab-42d3-8fc7-d89f3a4f54f6"
      unitRef="usd">402106000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTMtMS0xLTEtMA_21db1ed9-be6e-4619-9a7b-4133dd3648c8"
      unitRef="usd">21813000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTMtMy0xLTEtMA_3c0bd03b-3ba8-4882-a683-81c6497f7a06"
      unitRef="usd">16270000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTMtNS0xLTEtMA_385c1eb8-a540-425d-9f4a-c9149e6ccaff"
      unitRef="usd">45476000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTMtNy0xLTEtMA_79dce245-9890-40f4-bb2b-e183886b3c98"
      unitRef="usd">39660000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTQtMS0xLTEtMA_066fe9ce-ff59-4e67-8f47-97672c8e2343"
      unitRef="usd">4671000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTQtMy0xLTEtMA_c50f062e-23d5-4f25-89e1-09df5c0e799e"
      unitRef="usd">4674000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTQtNS0xLTEtMA_dd3ebd50-fea4-4659-9fe6-151f398935ad"
      unitRef="usd">13105000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTQtNy0xLTEtMA_0b542e77-9655-46ea-a5b9-88e80187d76c"
      unitRef="usd">14004000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTgtMS0xLTEtMA_129d3223-fe78-4561-b7a1-d511a4494caa"
      unitRef="usd">173957000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTgtMy0xLTEtMA_b4480085-d01a-40bf-b4a8-6a2cad9e46e3"
      unitRef="usd">142767000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTgtNS0xLTEtMA_7fa69ed2-5b57-464f-b5db-fc73dcc6118b"
      unitRef="usd">482884000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMTgtNy0xLTEtMA_56f8aac5-858c-4c78-be04-3b70a7c9c96b"
      unitRef="usd">455770000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjAtMS0xLTEtMA_249052fd-fd7f-43ab-9ea2-54dd5d1e972e"
      unitRef="usd">53160000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjAtMy0xLTEtMA_acaba20b-5c04-4323-af6f-27006523b14a"
      unitRef="usd">37356000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjAtNS0xLTEtMA_c0b08c6f-62ca-4893-a533-0cd5a4e88012"
      unitRef="usd">95931000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjAtNy0xLTEtMA_1e09ff6f-619c-4126-aedf-c837465bd4aa"
      unitRef="usd">54627000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjMtMS0xLTEtMA_36d24530-3754-47c3-846c-f99d1acb941f"
      unitRef="usd">132000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjMtMy0xLTEtMA_8d6431fa-085d-4cae-adcf-0743825128b6"
      unitRef="usd">403000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjMtNS0xLTEtMA_37d9adc6-9b43-49e7-abc9-71bd1837dc2b"
      unitRef="usd">-3680000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjMtNy0xLTEtMA_bd399a70-f4d8-410a-8820-f5b80baa7c80"
      unitRef="usd">3291000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjQtMS0xLTEtMA_412f9002-6271-48c2-b8ff-046aee16274b"
      unitRef="usd">2193000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjQtMy0xLTEtMA_77bee882-be83-42de-adb0-c39c2d96e0a9"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjQtNS0xLTEtMA_e72b50d8-5ec8-4123-9418-0221cc6e1e15"
      unitRef="usd">2193000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjQtNy0xLTEtMA_737b0d4a-4f9f-4db0-a527-61b9aa2da1ab"
      unitRef="usd">99647000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:InterestExpense
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjUtMS0xLTEtMA_db80960e-ee9f-4c6f-b4eb-6532b52f6995"
      unitRef="usd">967000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjUtMy0xLTEtMA_d71cbbda-2322-4e78-91dc-d368cb578b0d"
      unitRef="usd">2466000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjUtNS0xLTEtMA_0ec9fadb-77e4-470b-aa44-48884258e06b"
      unitRef="usd">4343000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjUtNy0xLTEtMA_4406da31-b58e-4377-afd1-95c3c8f5ad89"
      unitRef="usd">8007000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjYtMS0xLTEtMA_9a8d0b1e-32d5-4035-a29a-234d6e13e2f1"
      unitRef="usd">420000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjYtMy0xLTEtMA_0743cec7-2522-48fb-9dcf-1d95684c66a4"
      unitRef="usd">752000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjYtNS0xLTEtMA_ba896c95-38ed-44fb-a850-2bed85129085"
      unitRef="usd">1331000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjYtNy0xLTEtMA_738aba2e-ea19-463b-aa98-f7fbb7a01552"
      unitRef="usd">2544000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctMS0xLTEtMzAwMjg_e11c76a8-fa16-42fb-a8b6-ac9f70b0e072"
      unitRef="usd">-60943000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctMy0xLTEtMzAwMjg_5b8fd053-3dcc-4490-accc-c15189b5c86d"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctNS0xLTEtMzAwNjA_4e86e884-7aec-430f-b855-390380954abb"
      unitRef="usd">22826000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctNy0xLTEtMzAwNjA_eba4b69e-a26c-4591-be4f-b9dcd271224b"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctMS0xLTEtMA_1d6fcb07-744f-491e-9894-04f13a384ff3"
      unitRef="usd">500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctMy0xLTEtMA_715e81c7-a9c7-44be-880b-05bbcf5d25cf"
      unitRef="usd">130000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctNS0xLTEtMA_dfd20471-0fc4-4b33-9b42-a06dff71e7af"
      unitRef="usd">-14080000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjctNy0xLTEtMA_e5b4bc23-5988-4f19-b518-279b688dff45"
      unitRef="usd">1514000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjktMS0xLTEtMA_42bf30ac-03eb-44c0-b26a-98f8e8086b68"
      unitRef="usd">-58665000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjktMy0xLTEtMA_911758be-58e2-4c6a-8bb6-6a73499007f2"
      unitRef="usd">-1181000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjktNS0xLTEtMA_cbbbaab8-059b-46b7-a89a-d3f2665a9760"
      unitRef="usd">4247000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMjktNy0xLTEtMA_8b214791-72c5-4cfd-8165-e1901565dcbf"
      unitRef="usd">98989000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzEtMS0xLTEtMA_26194800-b88e-4359-b74b-f6ff2f18b1f9"
      unitRef="usd">-5505000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzEtMy0xLTEtMA_dcd2bf5f-f0cd-45fa-bf07-6710c3b1efae"
      unitRef="usd">36175000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzEtNS0xLTEtMA_ffae8b3b-ec3f-4554-a80e-5b94f8de6dc2"
      unitRef="usd">100178000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzEtNy0xLTEtMA_223c4af0-ee08-4246-936e-a9a66e2e64b1"
      unitRef="usd">153616000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzMtMS0xLTEtMA_882efaed-256f-4235-a2ac-1f1c8fd34aa0"
      unitRef="usd">-120000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzMtMy0xLTEtMA_d067dbd9-4e4b-466f-a049-f8ed64fd043d"
      unitRef="usd">10751000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzMtNS0xLTEtMA_a664d1cf-ec33-4247-b2ee-636483882867"
      unitRef="usd">31575000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzMtNy0xLTEtMA_926cd18e-21de-4692-a585-541893a7ebbe"
      unitRef="usd">44204000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzUtMS0xLTEtMA_bb9bd40b-c5fb-4177-b36a-37e3f70e0f0b"
      unitRef="usd">-5385000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzUtMy0xLTEtMA_97777d93-44ed-404b-964a-2a16929e2a4b"
      unitRef="usd">25424000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzUtNS0xLTEtMA_33389796-9c65-4c05-a3ec-2a39aaa1e520"
      unitRef="usd">68603000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzUtNy0xLTEtMA_3cdc343f-3b54-41e6-9cc6-f84c24f0ec5a"
      unitRef="usd">109412000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzctMS0xLTEtMA_90f0554a-b127-42cc-8e93-ade399d45a07"
      unitRef="usd">-39664000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzctMy0xLTEtMA_7ed3ec43-0bfe-47bd-9cfa-daf20cd15776"
      unitRef="usd">8711000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzctNS0xLTEtMA_d5d48212-7936-4c87-92b0-fb74bb8aec3b"
      unitRef="usd">8515000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzctNy0xLTEtMA_0a8f03d0-54a4-4226-8520-8045a400068f"
      unitRef="usd">81603000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzktMS0xLTEtMA_3de18ac9-bcfc-4e1d-a900-2b9b9777c946"
      unitRef="usd">34279000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzktMy0xLTEtMA_08dc4a01-5e4d-4f33-9f5b-ad21508c2edc"
      unitRef="usd">16713000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzktNS0xLTEtMA_399c47ed-b4b2-49f7-bf9b-d0d4dcf64fba"
      unitRef="usd">60088000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfMzktNy0xLTEtMA_dfa2cd31-cc9b-4048-9a2c-aa86669f71d5"
      unitRef="usd">27809000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDEtMS0xLTEtMA_8d6d8379-3e95-474a-a4cb-0a976499a5a1"
      unitRef="usdPerShare">0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDEtMy0xLTEtMA_8b322e6c-ac3f-45ba-91a7-98fd6e2f0894"
      unitRef="usdPerShare">0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDEtNS0xLTEtMA_f8756b24-9c4d-4735-bc51-e9e38cbf5415"
      unitRef="usdPerShare">1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDEtNy0xLTEtMA_b4dc161f-b359-4542-8874-1521e2ee3102"
      unitRef="usdPerShare">0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDMtMS0xLTEtMA_2f01ebcb-cab5-494e-998c-49eacb34ae78"
      unitRef="usdPerShare">0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDMtMy0xLTEtMA_a05b8ca1-8f88-4b09-8533-0cc84196a5d3"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDMtNS0xLTEtMA_4290cd0f-630d-4cfe-a4dd-098c0aa433f7"
      unitRef="usdPerShare">1.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yNS9mcmFnOmFiYWM2ZDBkZGJjYTRhZDJhZDBkZWI3ZDZjYmU4MjBiL3RhYmxlOjhjNWEzZjVlN2I4ODQ4OTlhYzMzZDljODRjYzdjZjBmL3RhYmxlcmFuZ2U6OGM1YTNmNWU3Yjg4NDg5OWFjMzNkOWM4NGNjN2NmMGZfNDMtNy0xLTEtMA_5919222a-0e68-42c7-b935-7dba731719fe"
      unitRef="usdPerShare">0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4dff2d9ed6884aa7897b7d8188137fca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy0xLTEtMS0w_3a0f0756-364f-4fb7-824c-6f6d091d28cc"
      unitRef="usd">114237000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i801e5c00786942ddb700c1cd3c41fd90_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy0zLTEtMS0w_b2748114-db9b-4515-9a22-6810df3dea5a"
      unitRef="shares">42249137</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i801e5c00786942ddb700c1cd3c41fd90_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy01LTEtMS0w_d0ee26d4-5493-4684-934a-277d31e3d220"
      unitRef="usd">42000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49f40737fc5743baa30c5079d6bffc52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy03LTEtMS0w_56916790-35fa-44dc-b112-cf313ef41ce5"
      unitRef="usd">261011000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibb86b280a3014e398f2f562416431dd5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy05LTEtMS0w_fcf9b594-472e-4dd2-b088-ae89975b6029"
      unitRef="usd">69771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47d2ab35fb6c4b68be2a92f518c669d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy0xMy0xLTEtMA_c2b2a2f4-e51c-46c5-886c-22828da140bc"
      unitRef="usd">87000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMy0xNS0xLTEtMA_0738bebc-7b05-4201-b6d3-32a93ec39e82"
      unitRef="usd">330911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i201c4a8fab204a44b9525c92e21b3124_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNC0xLTEtMS0w_a55ae4f0-b68c-4f1b-b8e5-eee21c7bb4e7"
      unitRef="usd">760000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ibf9ea714f06741669780227438e2ccc1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNC05LTEtMS0w_fb982891-41a0-40d7-8a98-a51d83d32c72"
      unitRef="usd">13151000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i9f6ed78d14764e42b9aa9957c770a040_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNC0xMy0xLTEtMA_1fd29010-10af-46e2-a4fe-af484226b9f8"
      unitRef="usd">547000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNC0xNS0xLTEtMA_a8c6b74a-0121-4737-86ba-956c09c47836"
      unitRef="usd">13698000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i201c4a8fab204a44b9525c92e21b3124_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNS0xLTEtMS0w_ed46b122-a388-48b7-b7f6-768fc8a98555"
      unitRef="usd">150000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i9f6ed78d14764e42b9aa9957c770a040_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNS0xMy0xLTEtMA_94db3633-a3ae-4ebc-829f-47780fd693a1"
      unitRef="usd">75000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNS0xNS0xLTEtMA_bb54248d-0b2b-453b-abe2-88f94ffafcf2"
      unitRef="usd">75000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i1b58c9abcd6c470686a0c881f23bcd84_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNi0zLTEtMS0yNzQ2OQ_55b70699-9455-47f6-8b9c-968d28d8d3c1"
      unitRef="shares">5281</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="id66271d4dd164746b13d7571ddbea1e8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNi03LTEtMS0yNzQ2OQ_bdc1409c-a835-4457-be37-669829d95e89"
      unitRef="usd">144000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNi0xMy0xLTEtMjc0Njk_00dfaaba-7df9-4d4d-bbe8-10fe102dbc48"
      unitRef="usd">144000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i1b58c9abcd6c470686a0c881f23bcd84_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNy0zLTEtMS0yNzQ3Nw_6a0e748a-9aad-4cf7-af14-f3c95b8e3660"
      unitRef="shares">7689</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfNy0xMy0xLTEtMjc0Nzc_069fd581-3c50-4d74-8bdc-41483e6fc346"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i1b58c9abcd6c470686a0c881f23bcd84_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOC0zLTEtMS0yNzQ4MA_9daaf7ca-bdba-4c53-a61f-71645d16f0e6"
      unitRef="shares">421002</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i1b58c9abcd6c470686a0c881f23bcd84_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOC01LTEtMS0yNzQ4MA_614b6661-94ab-42f8-86f4-be5dd849d819"
      unitRef="usd">1000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="id66271d4dd164746b13d7571ddbea1e8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOC03LTEtMS0yNzQ4MA_7c919310-d6c8-4c8e-ac7b-eb409add2997"
      unitRef="usd">4255000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOC0xMy0xLTEtMjc0ODA_1b3c5bc2-9e3a-4af8-bfc1-f5555f1860b4"
      unitRef="usd">4256000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i1b58c9abcd6c470686a0c881f23bcd84_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOS0zLTEtMS0yNzQ4Mw_5eee9f79-90f4-4a5a-b1f8-fa9b3160783d"
      unitRef="shares">34158</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="id66271d4dd164746b13d7571ddbea1e8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOS03LTEtMS0yNzQ4Mw_e059a074-e8ec-4ba1-8368-84411e322820"
      unitRef="usd">342000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfOS0xMy0xLTEtMjc0ODM_bb843667-a623-42ed-832e-97f4f8161b97"
      unitRef="usd">342000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id66271d4dd164746b13d7571ddbea1e8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTAtNy0xLTEtMjc0ODY_06df4ff8-8993-4549-9bfe-247a047e0908"
      unitRef="usd">1346000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTAtMTMtMS0xLTI3NDg2_6125c539-88d7-42b2-bba9-898a214d438c"
      unitRef="usd">1346000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i9f6ed78d14764e42b9aa9957c770a040_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTEtMTEtMS0xLTI3NDkw_89785397-dadb-470d-92fe-c1b7ad8849e8"
      unitRef="usd">37000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="ic77d1452e4514a5797346705209ea256_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTEtMTMtMS0xLTI3NDkw_5894b7ae-b283-4480-8586-c8e5f8d1b9e5"
      unitRef="usd">37000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a74d81295e0434e935d5c9ca47dcd70_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItMS0xLTEtMjc0OTM_d730438e-28c5-4929-aa1a-3a5c716fc1ce"
      unitRef="usd">114847000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="if4acdd08276e41428196b78831fc6298_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItMy0xLTEtMjc0OTM_3cf61c2b-076c-4a9c-affe-9873162551a7"
      unitRef="shares">42638389</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4acdd08276e41428196b78831fc6298_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItNS0xLTEtMjc0OTM_be8e18a3-5a0c-454e-9a8c-813db4a48cf1"
      unitRef="usd">43000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9752c3ca8824003913aa7ed5a37c7bd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItNy0xLTEtMjc0OTM_a9ec7e1b-3c17-4f47-9e37-38428d63f90d"
      unitRef="usd">266126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic54bcb094c3c48c6b97472820dabeca3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItOS0xLTEtMjc0OTM_064fe3e2-630a-4aed-aa00-eddedb89c66a"
      unitRef="usd">82922000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6c7eefcf281457baaa129d1d005c758_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItMTEtMS0xLTI3NDkz_2f66dd0b-6a66-4385-becf-9d15a737bd3f"
      unitRef="usd">596000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ea5b7b7fc3a4a34b7ce723c83b3a942_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTItMTMtMS0xLTI3NDkz_e2ce0350-6c99-44be-81ac-5cfa8381673a"
      unitRef="usd">349687000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i7a656a56f752493b9f8d16bfa440f3d8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTMtMS0xLTEtMA_f104b578-03c9-4792-b73a-c738be114fc0"
      unitRef="usd">46859000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="id2ca7ada22a142c387919b0cad5803a3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTMtOS0xLTEtMA_3091d1f0-5572-4c92-bcda-1548a4e9653c"
      unitRef="usd">12658000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i6e1f2152502448b5aa9088804a86dc7c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTMtMTMtMS0xLTA_197bf9b7-7b47-4501-88f6-74306de12191"
      unitRef="usd">13000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTMtMTUtMS0xLTA_71139a74-4449-4eab-9c13-24ed28ec2dba"
      unitRef="usd">12671000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i63d587f859094231993af50e9231e8ec_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTQtMy0xLTEtMjc1MDE_c446742d-9aaf-4a4c-9c1c-c2765ad58b15"
      unitRef="shares">5426</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i3ae117b2200d4e1db6a15e62e5be08b2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTQtNy0xLTEtMjc1MDE_f3e41771-bcea-4a53-8a9a-700255e296f4"
      unitRef="usd">189000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTQtMTMtMS0xLTI3NTAx_bdbaaae6-3f23-42d7-bce1-07cae90bcfd6"
      unitRef="usd">189000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i63d587f859094231993af50e9231e8ec_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTUtMy0xLTEtMjc1MDQ_20ad9871-6ec6-42b6-9bd1-3d7797356048"
      unitRef="shares">22284</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTUtMTMtMS0xLTI3NTA0_aacaa4fc-060e-48f0-ad93-ebbf99c21981"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i63d587f859094231993af50e9231e8ec_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTYtMy0xLTEtMjc1MDc_e6dcad78-73fc-4f7f-9986-af290e3885fd"
      unitRef="shares">53504</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i3ae117b2200d4e1db6a15e62e5be08b2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTYtNy0xLTEtMjc1MDc_fc4df13a-d1a0-4b7d-b3e9-7182bbc5f1e1"
      unitRef="usd">561000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTYtMTMtMS0xLTI3NTA3_e76fd7ca-eb83-4f89-b537-7305175ce1e7"
      unitRef="usd">561000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i63d587f859094231993af50e9231e8ec_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTctMy0xLTEtMjc1MTA_749c6c19-8cfc-4189-8a22-34f17a296ada"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i3ae117b2200d4e1db6a15e62e5be08b2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTctNy0xLTEtMjc1MTA_54982ee6-a41f-4e4c-bb36-4b824a4b31a0"
      unitRef="usd">2450000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTctMTMtMS0xLTI3NTEw_222effe5-8560-4b03-aff4-37246a4f9bcb"
      unitRef="usd">2450000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3ae117b2200d4e1db6a15e62e5be08b2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTgtNy0xLTEtMjc1MTM_3250ae61-33bf-46ce-b8da-9c28423777be"
      unitRef="usd">1556000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTgtMTMtMS0xLTI3NTEz_47d05791-1319-408a-9a0f-21e14ba511f7"
      unitRef="usd">1556000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i7a656a56f752493b9f8d16bfa440f3d8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTQtMS0xLTEtMA_9ea2531a-51c2-41dd-b355-ad8d5de306b0"
      unitRef="usd">-150000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i6e1f2152502448b5aa9088804a86dc7c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTQtMTMtMS0xLTA_f0ee148b-7f57-4f06-946c-c09f64c4f2e8"
      unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMTQtMTUtMS0xLTA_45e6f313-5551-4f79-b3a1-1dfc1e6e04f1"
      unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i63d587f859094231993af50e9231e8ec_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjAtMy0xLTEtMA_83a11eaa-3b99-4d01-9b65-9170ec587cab"
      unitRef="shares">1638045</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i63d587f859094231993af50e9231e8ec_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjAtNS0xLTEtMA_fa79042b-5526-46c0-aeec-7c837f87b895"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i3ae117b2200d4e1db6a15e62e5be08b2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjAtNy0xLTEtMA_3590f071-49d2-4a4a-94b1-28d8333fe057"
      unitRef="usd">40132000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjAtMTUtMS0xLTA_a4b0fe63-1dff-4244-a2df-41555752fcc5"
      unitRef="usd">40133000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i6e1f2152502448b5aa9088804a86dc7c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjEtMTMtMS0xLTA_b632b45f-7a91-4022-afe7-299bfb98279e"
      unitRef="usd">3769000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjEtMTUtMS0xLTA_2c0bac75-6ff4-4e24-a094-af4562f81462"
      unitRef="usd">3769000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i7a656a56f752493b9f8d16bfa440f3d8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjItMS0xLTEtMA_20107b8c-7da3-4471-821a-3216602f30d3"
      unitRef="usd">20000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i6e1f2152502448b5aa9088804a86dc7c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjItMTMtMS0xLTA_a048a1e6-8dd9-41c7-9526-293fa0b39f3b"
      unitRef="usd">1156000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjItMTUtMS0xLTA_bb8dbc07-587b-4a3c-9238-2d4588d0768f"
      unitRef="usd">1156000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1cbb81479544b5d8a96c5343b4b4548_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtMS0xLTEtMA_b11b9331-fd13-4cac-bd73-9cd78950ab6c"
      unitRef="usd">141856000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i89732b64c48345c09b7f05b7e01eade5_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtMy0xLTEtMA_ff5797ab-713c-461c-84c4-2f40dfd8adf4"
      unitRef="shares">44246796</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89732b64c48345c09b7f05b7e01eade5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtNS0xLTEtMA_6da95088-43f1-4f45-9e1d-512937080fe7"
      unitRef="usd">44000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i051a053544f84be68b9f7b6bd5bcf38e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtNy0xLTEtMA_442f739c-58ad-41cd-b695-af30ea4cd009"
      unitRef="usd">305736000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifdce3fd00dfa4e8eac9f6af5191663ba_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtOS0xLTEtMA_96e81aee-2a01-4d14-b2d7-6021c8691f40"
      unitRef="usd">95580000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i82e3754a2db143119d3e1eb226e3b911_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtMTMtMS0xLTA_e87f3b92-9171-454b-b35d-946358480aaf"
      unitRef="usd">3222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2dbf54ec60054ae5861c2aa09f4352a9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjMtMTUtMS0xLTA_fb3e18cb-db46-4d71-8612-89380d9bdc11"
      unitRef="usd">404582000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i47b3e835a53b43b1bd2a7e6cca4fe332_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjQtMS0xLTEtMTIzMA_8823b69f-b5cf-4f1c-a5d0-32d2223ef7a2"
      unitRef="usd">-40356000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i5f277e33d13f4f028726cc591668dbbc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjQtOS0xLTEtMTIzMA_c9921250-8882-4c44-b420-9a9e4dc60751"
      unitRef="usd">34279000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i89100028143441aea045a96e3abea952_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjQtMTMtMS0xLTEyMzA_26f5ec76-e64d-4b85-b61f-8e88f497ca83"
      unitRef="usd">692000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjQtMTUtMS0xLTEyMzA_2248e4c5-89d5-4b08-80ea-5990a11b9876"
      unitRef="usd">34971000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="ib97aa22e2d604131bd5c10b48cbc94fc_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjctMy0xLTEtMTIzMA_cec76de9-afc8-4e0a-9c7b-874203002167"
      unitRef="shares">190254</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i447b59fe96f749059a743a4fff511b89_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjctNy0xLTEtMTIzMA_292d00be-0f51-48c1-bda9-904b74086615"
      unitRef="usd">1785000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjctMTUtMS0xLTEyMzA_18f81ff5-49f1-4fb9-aa30-9341207a603b"
      unitRef="usd">1785000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib97aa22e2d604131bd5c10b48cbc94fc_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjYtMy0xLTEtMjc1MzI_a9708bac-166f-466c-b28e-8f859cee2793"
      unitRef="shares">40000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i447b59fe96f749059a743a4fff511b89_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjYtNy0xLTEtMjc1MzI_b6cd0856-b023-415c-a63d-2cfa3ef78a44"
      unitRef="usd">2947000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjYtMTMtMS0xLTI3NTMy_2b613f8e-df64-4dda-a048-bd846490573a"
      unitRef="usd">2947000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i447b59fe96f749059a743a4fff511b89_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjgtNy0xLTEtMTIzMA_da2824a8-3053-4f6a-9e87-e8e5dc66015d"
      unitRef="usd">1420000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjgtMTUtMS0xLTEyMzA_2ea63ac4-bb67-4d78-99e6-781faad6a1c8"
      unitRef="usd">1420000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i89100028143441aea045a96e3abea952_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjgtMTMtMS0xLTI0MjAy_60dea1b1-df4e-4968-911e-2bbff58b5f3b"
      unitRef="usd">500000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjgtMTUtMS0xLTI0MjAy_a4ac1f9d-cfa3-489f-a481-914e0ddabcbc"
      unitRef="usd">500000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <ameh:NoncontrollingInterestIncreaseFromCapitalCharge
      contextRef="i6e1f2152502448b5aa9088804a86dc7c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjktMTMtMS0xLTI0MjAy_643c2d37-93a1-409f-bd70-c45aefc1cbb4"
      unitRef="usd">10000</ameh:NoncontrollingInterestIncreaseFromCapitalCharge>
    <ameh:NoncontrollingInterestIncreaseFromCapitalCharge
      contextRef="i8fc5566d836f42f5861bd38382f33e31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMjktMTUtMS0xLTI0MjAy_60474ac2-fb13-44f7-8a2e-b3907538a0e4"
      unitRef="usd">10000</ameh:NoncontrollingInterestIncreaseFromCapitalCharge>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i47b3e835a53b43b1bd2a7e6cca4fe332_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzAtMS0xLTEtMTIzMA_3e9375d1-511a-4883-a19f-b86d81b65382"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i89100028143441aea045a96e3abea952_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzAtMTMtMS0xLTEyMzA_1e11023b-d971-4e64-805b-93f4d33f6aed"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzAtMTUtMS0xLTEyMzA_4cdde1c6-db40-460c-bc65-fe3afd22ba4b"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f163c4d0b144be59dac47b4d4f3d1a3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtMS0xLTEtMTIzMA_862e9516-980b-401a-b050-be86ad812dc3"
      unitRef="usd">91500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i3851c4c6f42140f384fa8e46fde560b9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtMy0xLTEtMTIzMA_fd457ba7-8cf2-4dd3-ab03-8cd22b491757"
      unitRef="shares">44397050</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3851c4c6f42140f384fa8e46fde560b9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtNS0xLTEtMTIzMA_f03bf5e5-a6f7-4ca2-845a-bf49d49ae366"
      unitRef="usd">44000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9a43fc6ff7a472db16607b4efd8deb6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtNy0xLTEtMTIzMA_2be0513c-7d77-4260-89ad-45488c3d20f7"
      unitRef="usd">305994000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id74805f435254a939c0fb9c4467d967c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtOS0xLTEtMTIzMA_c0c9c7c2-a5db-4576-9170-2f79de3c5364"
      unitRef="usd">129859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bcdaf3ce6a64dd8915c48e617c6050a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtMTMtMS0xLTEyMzA_47bd34db-db0d-4f51-b605-54d36144056f"
      unitRef="usd">4424000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOmRjOTdjOGI5NzM4NDQ0NDViODhjMTQwNDQ0ZTZmMGVjL3RhYmxlcmFuZ2U6ZGM5N2M4Yjk3Mzg0NDQ0NWI4OGMxNDA0NDRlNmYwZWNfMzEtMTUtMS0xLTEyMzA_ab64a9b0-59a0-438e-9b21-cc2f0a1a495d"
      unitRef="usd">440321000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i77c4d76239ba428fa3c790a5e8246b33_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy0xLTEtMS0w_623fd398-71ee-4c67-9d64-df9e5176ffe4"
      unitRef="usd">168725000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ide4f8e08db044e18a9dd68755ff37c94_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy0zLTEtMS0w_25143c9a-8e32-4352-ba66-55833a88b895"
      unitRef="shares">35908057</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide4f8e08db044e18a9dd68755ff37c94_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy01LTEtMS0w_cd95cae2-ec82-4b14-b65b-be09dd03b978"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b428a4b73a64930be4adc92648bab3e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy03LTEtMS0w_f8f21955-f7fb-49f9-b3a0-d73c27b52268"
      unitRef="usd">159608000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc6eb15301c64d8aa5fc12a0525855f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy05LTEtMS0w_1d1ffd28-1e56-45f7-8adb-1e102679bb91"
      unitRef="usd">31905000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c8de92883004d2a9874fc11ec721f46_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy0xMy0xLTEtMA_b791f3a6-4068-4ba6-ba29-373e3550677d"
      unitRef="usd">786000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i274e819937824ba3b8be663aca7657a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMy0xNS0xLTEtMA_8c444dd7-131b-4bda-8cba-db7a2af141c9"
      unitRef="usd">192335000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="if2897209faef4ecbb6ff8ae555b62be5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNC0xLTEtMS0w_e23163f2-5614-4437-a48a-b6c14d85ff62"
      unitRef="usd">-1160000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="id6f0ee689326400e8ca46a963ad334e3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNC05LTEtMS0w_c8af8c0c-deb5-4b43-b22e-f477c3621601"
      unitRef="usd">4052000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i80907684f53c41fa8f1a8a26101f7877_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNC0xMy0xLTEtMA_22789849-1f55-43c9-a9f2-4212efdd4b46"
      unitRef="usd">95000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNC0xNS0xLTEtMA_d8d3c926-d8d0-4c84-813f-ec05f8e6f700"
      unitRef="usd">4147000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="if2897209faef4ecbb6ff8ae555b62be5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNS0xLTEtMS0w_09ecf6dd-a667-4901-aad2-ef88177c21ca"
      unitRef="usd">126000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNS0xNS0xLTEtMA_cebf27d8-9991-4559-8d6f-97a2b06c7264"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ifc4bd3d0547c43cca915340944f52cf8_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNi0zLTEtMS0w_33851f5e-5188-4965-b2bf-29b1c7a91ad9"
      unitRef="shares">16897</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i20946dbda53945ca95557bb7aea3d8ea_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNi03LTEtMS0w_190909ce-0eb2-4f38-9c3f-f98d0dbc0efa"
      unitRef="usd">301000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNi0xNS0xLTEtMA_7f61edbf-4e8e-45d0-98b7-42605b5b01ec"
      unitRef="usd">301000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="ifc4bd3d0547c43cca915340944f52cf8_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNy0zLTEtMS0w_53cbc68d-854d-4373-b9f1-9894b9704597"
      unitRef="shares">151601</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i20946dbda53945ca95557bb7aea3d8ea_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNy03LTEtMS0w_9e2a7781-2e24-4f02-962f-08701cf850db"
      unitRef="usd">722000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfNy0xNS0xLTEtMA_d7b7be76-9b4b-4453-8c62-2b823dbaae5c"
      unitRef="usd">722000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i20946dbda53945ca95557bb7aea3d8ea_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfOC03LTEtMS0w_c4a0ab78-3d0c-434e-89e4-a7ce628f23e6"
      unitRef="usd">1058000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfOC0xNS0xLTEtMA_2f8135c2-7269-453e-81db-f7830eee99c8"
      unitRef="usd">1058000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if2897209faef4ecbb6ff8ae555b62be5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfOS0xLTEtMS0w_275a12f9-7d17-4117-b75f-658241e2a864"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ia69f62f9fbc84c45b30c0016b8d93de0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfOS0xNS0xLTEtMA_a0b83a70-a813-4ac9-8e92-cb11b921319a"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50ed93d80d8c443db56d6af7ad9eff2d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtMS0xLTEtMA_936904bb-d203-4888-9477-a0ded17f6553"
      unitRef="usd">157439000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i88ea48c265674dc0b0969de2c5af9a5a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtMy0xLTEtMA_e8f79ff3-5f10-4456-ac44-90fd658521aa"
      unitRef="shares">36042761</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88ea48c265674dc0b0969de2c5af9a5a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtNS0xLTEtMA_d9423c3f-8a82-4486-be24-e4c13a3e2f33"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd58c0538df4442d935bad5da111604c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtNy0xLTEtMA_2d87879a-fe6c-4aa0-9fa8-3c48ed684ceb"
      unitRef="usd">161087000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d6f1b1b2ef64607a7a28b3ddd19b9ca_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtOS0xLTEtMA_87196368-3300-4ef3-ba1b-9a6ed323f831"
      unitRef="usd">35957000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7da29179b9f74a138ee89825c3173019_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtMTMtMS0xLTA_c718922a-87f4-49ec-9e00-91ca30bb42e3"
      unitRef="usd">881000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bd6ee7c5cf34d2a95a5baf1644fd7bd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTAtMTUtMS0xLTA_35dda410-b896-4b10-a375-40d437fa4ddb"
      unitRef="usd">197961000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ife042466644a4588baa6a1080f3f9619_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTEtMS0xLTEtMA_c738234b-9f83-4de2-a5ce-01e3c61979bc"
      unitRef="usd">73666000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i7b04caa1c2974f2e8324ddcb0d1943b0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTEtOS0xLTEtMA_555e8707-869d-4d3e-b9a0-2565bf85aa8f"
      unitRef="usd">7044000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ib71e689bf17b4b1b82292ea2371b247f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTEtMTMtMS0xLTA_b6f51737-8109-4ee4-8696-c32db25a9bee"
      unitRef="usd">291000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTEtMTUtMS0xLTA_8abb3eab-201d-48e3-a5d7-a1fd14e44da1"
      unitRef="usd">7335000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ife042466644a4588baa6a1080f3f9619_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTItMS0xLTEtMA_1654e577-2bb9-46db-b2f2-15d3ef62d002"
      unitRef="usd">125000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ib71e689bf17b4b1b82292ea2371b247f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTItMTMtMS0xLTA_37977ea3-5233-4401-b962-8cb12f5a2d9d"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTItMTUtMS0xLTA_a0b62ce5-336f-46db-af60-acb8227486d1"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i7814f327568e456d93bd5dd8ffd4e59c_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTMtMy0xLTEtMA_854f20a7-e141-466a-a189-06e585c87d3d"
      unitRef="shares">24453</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTMtMTUtMS0xLTA_2b30d237-36da-4231-a11d-3df7aec8f720"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i7814f327568e456d93bd5dd8ffd4e59c_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTQtMy0xLTEtMA_377dd07c-ced6-4611-acfd-f4b3fdf241a1"
      unitRef="shares">242299</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i79ab116f35bb4c18b276c3c5099436f8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTQtNy0xLTEtMA_0e9e191b-0c41-4791-9205-b61bf1fd93e7"
      unitRef="usd">2283000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTQtMTUtMS0xLTA_09750281-32be-423f-853c-d64692b55026"
      unitRef="usd">2283000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i79ab116f35bb4c18b276c3c5099436f8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTUtNy0xLTEtMA_c3f07e19-448c-4d34-8321-75278f3b6956"
      unitRef="usd">852000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTUtMTUtMS0xLTA_47e6e0a4-c31c-4faa-8fe1-6fd0cbd1bed3"
      unitRef="usd">852000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i79ab116f35bb4c18b276c3c5099436f8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTYtNy0xLTEtMA_ec11a171-ae4d-413f-be66-7a77bde9ae83"
      unitRef="usd">236000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTYtMTUtMS0xLTA_737d901d-b823-4dcb-9cb5-39c23fdc5efd"
      unitRef="usd">236000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ife042466644a4588baa6a1080f3f9619_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTctMS0xLTEtMA_0856d98f-330b-4a00-9e81-a5344d454d5f"
      unitRef="usd">20000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib71e689bf17b4b1b82292ea2371b247f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTctMTMtMS0xLTA_90b6900e-2ecc-4acc-a6b7-b4eb064ada4a"
      unitRef="usd">347000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i7a115db237054860af9384c8de85411b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTctMTUtMS0xLTA_018e275e-bc18-4787-a4e8-afb28128a31d"
      unitRef="usd">347000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1da11deec71d444dbcd9ae322ee3fdc3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtMS0xLTEtMA_49d3aea8-b82b-47db-bffa-e7b27f76cd54"
      unitRef="usd">210980000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i9e8613962fee4ab98d908fabd87a1896_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtMy0xLTEtMA_b5ac835f-9ff0-4ba0-a2e5-b8697b2586c7"
      unitRef="shares">36309513</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9e8613962fee4ab98d908fabd87a1896_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtNS0xLTEtMA_9898b1a7-0f8a-4846-aaa2-73365c7463f0"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7cfa83865da94a5f8b9fe72abbf1e869_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtNy0xLTEtMA_2ec232b4-f80c-4dd3-a3ca-5b90d51aa493"
      unitRef="usd">163986000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d0a7a2fd7464ee299859406dbe50c73_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtOS0xLTEtMA_e37697b3-a540-4d3d-b0cd-fe7c2b88d08f"
      unitRef="usd">43001000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4dd2afccb5db4b0ab6d514f40ca4f851_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtMTMtMS0xLTA_bac6f837-f875-4b75-b97f-6c04ea26dc1b"
      unitRef="usd">825000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2eea77176a0f48a2a0621621efb6b4ef_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTgtMTUtMS0xLTA_ac2824d7-dab7-4940-a5f8-7eb5bc6010f2"
      unitRef="usd">207848000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i2263b2eaaf6c4496af9ac4bdaec4bb63_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTktMS0xLTEtMTE3OA_4378157e-2761-43f6-82cb-ac379c3dba9c"
      unitRef="usd">8522000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="id861da65feb04df7a6d28f6b72fc6ae5_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTktOS0xLTEtMTE3OA_4d8f5fb7-9ddc-42c3-bd9c-eb2e158c9985"
      unitRef="usd">16713000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="iddc759fafb9d46048145c9584bd19060_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTktMTMtMS0xLTExNzg_301ee5d8-42e9-4ad5-8bc3-1ae3cf907e92"
      unitRef="usd">189000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMTktMTUtMS0xLTExNzg_456043f3-72c0-4e4f-b608-590b35da0e6d"
      unitRef="usd">16902000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i2263b2eaaf6c4496af9ac4bdaec4bb63_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjAtMS0xLTEtMTE3OA_97396883-517f-4afb-ae0c-c5ba9d6b833f"
      unitRef="usd">771000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjAtMTUtMS0xLTExNzg_eb6bc5ce-02e9-46dd-a81e-cabce172eaed"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <ameh:StockIssuedDuringPeriodSharesCashlessWarrantsExercised
      contextRef="i61ed6e94c3224d0aaad33a4b064279c7_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjEtMy0xLTEtMTE3OA_b92b967c-eb59-4e66-b4d9-529dc9b3dc0c"
      unitRef="shares">66517</ameh:StockIssuedDuringPeriodSharesCashlessWarrantsExercised>
    <ameh:StockIssuedDuringPeriodValueCashlessWarrantsExercised
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjEtMTUtMS0xLTExNzg_5709a26b-3442-4101-88f9-8815c9e7a123"
      unitRef="usd">0</ameh:StockIssuedDuringPeriodValueCashlessWarrantsExercised>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i61ed6e94c3224d0aaad33a4b064279c7_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjItMy0xLTEtMTE3OA_f4982705-38af-4e75-bc56-1afc2cb14b13"
      unitRef="shares">399787</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i61ed6e94c3224d0aaad33a4b064279c7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjItNS0xLTEtMTE3OA_ad844e82-072d-4083-aace-f642f2d63bc8"
      unitRef="usd">1000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="iacd41deb825c48f7968229c9af0a5590_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjItNy0xLTEtMTE3OA_7e4f5559-d299-4d3b-a647-c3d5513c58fc"
      unitRef="usd">4019000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="iddc759fafb9d46048145c9584bd19060_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjItMTMtMS0xLTExNzg_ff6da844-e37c-4ca1-8968-64c112d1d151"
      unitRef="usd">0</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjItMTUtMS0xLTExNzg_45d10b35-b1d6-45ff-98d6-3f0d5118a0ed"
      unitRef="usd">4020000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iacd41deb825c48f7968229c9af0a5590_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjMtNy0xLTEtMTE3OA_4ad0435c-286a-4450-9b03-b4da8b044ebb"
      unitRef="usd">648000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iddc759fafb9d46048145c9584bd19060_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjMtMTMtMS0xLTExNzg_d8e59291-46f2-4662-9f57-341e213ce7d3"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjMtMTUtMS0xLTExNzg_e8194dba-860a-4da2-ac0b-76a2ec52fb0f"
      unitRef="usd">648000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="iacd41deb825c48f7968229c9af0a5590_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjQtNy0xLTEtMTE3OA_e7762db5-126e-46a6-9687-abddbf98291d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="iddc759fafb9d46048145c9584bd19060_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjQtMTMtMS0xLTExNzg_9ad64261-ecfa-4ded-8776-705e1634ffa0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjQtMTUtMS0xLTExNzg_58f2b76a-4471-4634-a4ef-634c8437d8f8"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2263b2eaaf6c4496af9ac4bdaec4bb63_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjUtMS0xLTEtMTE3OA_4760e054-8069-402e-8c77-060f490d3d81"
      unitRef="usd">20000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i61ed6e94c3224d0aaad33a4b064279c7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjUtNS0xLTEtMTE3OA_8cc928bf-a557-4993-ac72-bbaf0a1f3682"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="iddc759fafb9d46048145c9584bd19060_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjUtMTMtMS0xLTExNzg_08f71ee6-b320-4617-81ea-54599d8e1e4b"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjUtMTUtMS0xLTExNzg_f0b7f6b2-af4d-4b3d-a8b0-a84e92ef0776"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57f34f8a827f48e3af8fda4fc45fb9e7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtMS0xLTEtMTE3OA_2afe0655-4967-49cc-8db3-971ab815d56c"
      unitRef="usd">198731000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="id3fb118aa44b46768cc5aa112ee13ec3_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtMy0xLTEtMTE3OA_6436b16a-2fcd-41c4-aea8-823331641173"
      unitRef="shares">36775817</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3fb118aa44b46768cc5aa112ee13ec3_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtNS0xLTEtMTE3OA_58c72bd5-8f1b-4758-adb8-7153fa7eec3c"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e69dbc1f0334ee8901a65307444081e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtNy0xLTEtMTE3OA_44fa4768-8d64-4542-a0b2-1a06827dc551"
      unitRef="usd">168653000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf99efb1cb424f2faa5e9458d42ebbab_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtOS0xLTEtMTE3OA_f8c48a29-9d91-49b5-b5e1-633da1c3c425"
      unitRef="usd">59714000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad4ff3ef133a4ee8bb68a8f96bce2d82_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtMTMtMS0xLTExNzg_3688ee40-7652-4c9c-b77e-bddc828813a0"
      unitRef="usd">1014000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03292c592c4f45da834c806bff481c24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zMS9mcmFnOjRlNDMxMzQxNDY4MDRkOTFhZjJjYmM2YjhhZmU2OTQ1L3RhYmxlOjFlYTM5ZTE2MDE1YjQzOTNiMzMzZDljYTkzNDlkMTI4L3RhYmxlcmFuZ2U6MWVhMzllMTYwMTViNDM5M2IzMzNkOWNhOTM0OWQxMjhfMjYtMTUtMS0xLTExNzg_161314c1-f1c2-45fb-8035-f7d6958960b8"
      unitRef="usd">229418000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMy0xLTEtMS0w_1ef2471b-63d4-40b5-8077-e7df4c992346"
      unitRef="usd">68603000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMy0zLTEtMS0w_18c58c7b-88db-494b-b0ec-2eabe792a702"
      unitRef="usd">109412000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNS0xLTEtMS0w_9fc70455-6946-473e-88d2-07641f0e0518"
      unitRef="usd">13105000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNS0zLTEtMS0w_da87e18b-4c63-438d-9ed8-2b2ae6091b11"
      unitRef="usd">14004000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNy0xLTEtMS0w_7b5ee171-6303-48ee-a7e4-4c6f32f986a1"
      unitRef="usd">900000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNy0zLTEtMS0w_73c175a3-0fc9-48f7-af26-2c39c9f26c56"
      unitRef="usd">1004000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfOC0xLTEtMS0w_2071479c-95a3-47c7-8757-8fb745453f9a"
      unitRef="usd">4322000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfOC0zLTEtMS0w_c9cb2d61-0c6f-40cc-af6e-a10a5fb324d2"
      unitRef="usd">2558000</us-gaap:ShareBasedCompensation>
    <ameh:UnrealizedGainLossFromInvestmentInEquitySecurities
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfOS0xLTEtMS0w_db270261-c829-45ab-a0c3-76921f870330"
      unitRef="usd">22826000</ameh:UnrealizedGainLossFromInvestmentInEquitySecurities>
    <ameh:UnrealizedGainLossFromInvestmentInEquitySecurities
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfOS0zLTEtMS0w_25d33974-80fa-43f6-84b8-1276a6e1f2d1"
      unitRef="usd">-23000</ameh:UnrealizedGainLossFromInvestmentInEquitySecurities>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTAtMS0xLTEtMA_c8955ae7-edc8-46ce-8cb0-dca15aceb818"
      unitRef="usd">-3680000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTAtMy0xLTEtMA_6b380a3d-e2c2-45c1-86d1-521708fce4a5"
      unitRef="usd">3291000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTEtMS0xLTEtMA_cfec7795-4fa9-4c08-b7dd-af1e3d62b349"
      unitRef="usd">2193000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTEtMy0xLTEtMA_ce6e5374-7d4f-4e59-9c92-ddf7e7e36f53"
      unitRef="usd">99647000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:AssetImpairmentCharges
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTItMS0xLTEtMA_b77dc70a-eccf-41a2-8812-5b6b672c2000"
      unitRef="usd">15723000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTItMy0xLTEtMA_4a9c5220-8474-4162-b637-fd62e60fc1fc"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTMtMS0xLTEtMA_4c74358b-eeb8-4e8b-9dd1-658e09cfe424"
      unitRef="usd">1069000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTMtMy0xLTEtMA_210d5003-d88e-4529-8df2-3266fd44306b"
      unitRef="usd">0</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTQtMS0xLTEtMA_7127f3be-3d13-446a-878d-4c9e88f0892f"
      unitRef="usd">6847000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTQtMy0xLTEtMA_e5880ce1-245e-4f82-a480-d0f3215fc21b"
      unitRef="usd">-6137000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:ProceedsFromOtherOperatingActivities
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTUtMS0xLTEtMA_4ce032c3-0de1-496f-a78e-2be2b69f7772"
      unitRef="usd">189000</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:ProceedsFromOtherOperatingActivities
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTUtMy0xLTEtMA_faaae88e-432e-467b-9628-f89df12a1cad"
      unitRef="usd">0</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTctMS0xLTEtMA_727b6260-94c6-445e-b503-b0ebd198d81a"
      unitRef="usd">10686000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTctMy0xLTEtMA_1760ade7-f474-46be-aa40-36c513dd5c90"
      unitRef="usd">6953000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTgtMS0xLTEtMA_54a9727e-ce6d-43c0-b809-fe28d9843f44"
      unitRef="usd">4367000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTgtMy0xLTEtMA_f78b7f3e-5674-460b-b5ff-1516a719a88c"
      unitRef="usd">-6618000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTktMS0xLTEtMA_e670bd18-9079-4373-adc3-6a6302fea637"
      unitRef="usd">1477000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMTktMy0xLTEtMA_cdee5bd2-b592-4b7c-9f7d-da5e471bb40d"
      unitRef="usd">-12898000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjAtMS0xLTEtMA_b67a3f18-f6b9-4931-b82c-9c359f41ce97"
      unitRef="usd">-5064000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjAtMy0xLTEtMA_6c4056cc-7c62-483e-adba-c836b56a6747"
      unitRef="usd">1804000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjEtMS0xLTEtMA_0948fc03-ae46-46c2-9c3b-b9c4dd8613e3"
      unitRef="usd">2440000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjEtMy0xLTEtMA_a8cd6282-5cf6-40ce-95f7-090fddb8a0a2"
      unitRef="usd">2601000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjItMS0xLTEtMA_5425323a-1eb4-454a-8cc2-4fdffd567bba"
      unitRef="usd">954000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjItMy0xLTEtMA_928b29bb-fc6f-44ca-8d61-59fd6dff15ab"
      unitRef="usd">5090000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjMtMS0xLTEtMA_a471d988-0557-4560-9fcb-dc7ebe235c22"
      unitRef="usd">14362000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjMtMy0xLTEtMA_d8cd79ea-3111-452d-91bc-7b085fc9c04e"
      unitRef="usd">12644000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjQtMS0xLTEtMA_e0bbe82d-9d88-42ab-b60a-bb1f03f1f6c9"
      unitRef="usd">-815000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjQtMy0xLTEtMA_81570bbb-43b1-48f8-a3e4-bd3d0762b624"
      unitRef="usd">1958000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjUtMS0xLTEtMA_1f4be673-f1f4-4f81-85ac-e1c75bebd9d3"
      unitRef="usd">-7633000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjUtMy0xLTEtMA_d0b985c3-5505-44dd-bcc4-97a9f6ff07f2"
      unitRef="usd">-1566000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjYtMS0xLTEtMA_56c5b422-ede2-49cb-b40c-602cb9ce5b8e"
      unitRef="usd">-300000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjYtMy0xLTEtMA_74e5c29d-e0ba-49d0-973d-bb8b1cd85d43"
      unitRef="usd">11642000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjctMS0xLTEtMA_ad43b062-efaa-478c-a95a-25bc0526a416"
      unitRef="usd">-2528000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjctMy0xLTEtMA_d1548755-12e8-413e-bc55-eca6b4102ff1"
      unitRef="usd">-2110000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjktMS0xLTEtMA_199269b3-9c36-428e-bb1b-510cbda20b61"
      unitRef="usd">82525000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMjktMy0xLTEtMA_579864f6-59ea-4c67-838c-00a4de4a8e13"
      unitRef="usd">48764000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzItMS0xLTEtMA_f4d0d5ee-d4ac-4f4c-9e8a-e3b91f603a42"
      unitRef="usd">2575000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzItMy0xLTEtMA_e08f2450-b236-449c-a458-3d3ee2b78883"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzMtMS0xLTEtMA_b95a1096-8da0-4753-8bc9-2de7194ce3d4"
      unitRef="usd">41000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzMtMy0xLTEtMA_e727701d-3a76-44ab-94ec-de58320e7fd5"
      unitRef="usd">16500000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzgtMS0xLTEtMA_0216a5c7-5544-4c7d-b59a-1b23844fdcc1"
      unitRef="usd">1009000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzgtMy0xLTEtMA_0f87a207-7624-4f22-abd3-d0a6b88704af"
      unitRef="usd">1793000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzktMS0xLTEtMA_4675de01-d493-4186-b073-e4e0a56925dd"
      unitRef="usd">13384000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfMzktMy0xLTEtMA_7d036ef2-aaf7-48e8-8eb8-a2f26f7369f6"
      unitRef="usd">500000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDAtMS0xLTEtMA_b11ffcf5-96bb-497f-adbe-5b845b0c9660"
      unitRef="usd">6375000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDAtMy0xLTEtMA_46574ed7-27d2-49f7-afa1-0489cdc54a52"
      unitRef="usd">52743000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDEtMS0xLTEtMA_df32ec9b-be35-4cd9-a2de-3d4f5cf5a581"
      unitRef="usd">16420000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDEtMy0xLTEtMA_920ae884-bc66-4d63-b9d9-aef090aae1a4"
      unitRef="usd">553000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDItMS0xLTEtMA_c008f379-63f8-4838-86ab-b88b7a8862f4"
      unitRef="usd">1106000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDItMy0xLTEtMA_41d7972a-ca4b-4e29-8c0e-2c9d88649b56"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDMtMS0xLTEtMA_ad0ca1b1-e968-49c1-9f0f-90a5c55ad0f0"
      unitRef="usd">3322000</ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity>
    <ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDMtMy0xLTEtMA_28b4e352-83db-4db9-bf15-ace3c6c6f692"
      unitRef="usd">0</ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDUtMS0xLTEtMA_7cb86302-dd20-488c-a081-3581b28185dc"
      unitRef="usd">-22544000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDUtMy0xLTEtMA_83365072-711d-4a87-9b27-60c64e8efdfa"
      unitRef="usd">66397000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividends
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDktMS0xLTEtMA_38235cef-807b-4001-96a1-e22c33ae8e72"
      unitRef="usd">31089000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNDktMy0xLTEtMA_e44e71ad-a8ad-42f8-902c-b48b4ac85eff"
      unitRef="usd">50133000</us-gaap:PaymentsOfDividends>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTAtMS0xLTEtMA_8cc91c54-1a47-4459-8f35-797b7b453a4e"
      unitRef="usd">238254000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTAtMy0xLTEtMA_55474d4b-846f-4649-ae7f-62efb7f3b28f"
      unitRef="usd">7125000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTEtMS0xLTEtMA_f8839a33-ecc0-45aa-98de-60eb2febb181"
      unitRef="usd">81000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTEtMy0xLTEtMA_fea4f148-b0c6-404c-a192-a136e755e220"
      unitRef="usd">78000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTItMS0xLTEtMA_01ea116c-4072-4fb9-a9e2-43544d46f825"
      unitRef="usd">6601000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTItMy0xLTEtMA_6636917a-a1a5-4f19-a1bd-4ca973a1a00b"
      unitRef="usd">6552000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTMtMS0xLTEtMA_a1fffe04-5c0d-4e6f-b0d3-2823f580ca04"
      unitRef="usd">5739000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTMtMy0xLTEtMA_6acab7c8-8c01-402d-9196-33a4e6fafc4a"
      unitRef="usd">1559000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTQtMS0xLTEtMA_bccb0757-60fe-4c0a-99e8-38d60601b23c"
      unitRef="usd">75000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTQtMy0xLTEtMA_eb2f9522-1476-474f-b5c9-95a3755d11e7"
      unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
    <ameh:ProceedsFromSaleOfNoncontrollingInterest
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTUtMS0xLTEtMA_b2f29361-7f68-4687-896c-474735d9eaa9"
      unitRef="usd">48000</ameh:ProceedsFromSaleOfNoncontrollingInterest>
    <ameh:ProceedsFromSaleOfNoncontrollingInterest
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTUtMy0xLTEtMA_74a9617e-ed36-47e1-bde4-270d1b020644"
      unitRef="usd">0</ameh:ProceedsFromSaleOfNoncontrollingInterest>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTctMS0xLTEtMA_98b39a58-c47d-408c-ba6a-a3026446b034"
      unitRef="usd">180000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTctMy0xLTEtMA_7f3c5976-51fe-40bf-b2c1-cef7e4b2f3d9"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTgtMS0xLTEtMA_00d5381d-bfa6-49eb-a281-c999efdd80b4"
      unitRef="usd">40133000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTgtMy0xLTEtMA_1573b385-7406-4502-8ee7-d149cc00eb95"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTktMS0xLTEtMA_9a7b59d1-8d01-43fe-b065-47fa0ba02581"
      unitRef="usd">727000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNTktMy0xLTEtMA_0ef881c1-94c5-432c-bdbc-783e950e0447"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjAtMS0xLTEtMA_8c59a1ca-5ffd-445d-a4a2-3adf7937b40e"
      unitRef="usd">-49183000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjAtMy0xLTEtMA_354b03de-7566-4d50-bd84-64ac3b92ccce"
      unitRef="usd">-52343000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjItMS0xLTEtMA_bd673f65-166c-4b01-946c-3a0ca54f7b72"
      unitRef="usd">10798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjItMy0xLTEtMA_6fe6679c-de69-41a7-8471-3d18968d8b6c"
      unitRef="usd">62818000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjQtMS0xLTEtMA_2453389b-6eb1-4651-aa00-e6f3593a0409"
      unitRef="usd">193970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i274e819937824ba3b8be663aca7657a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjQtMy0xLTEtMA_78860757-b297-47a1-8794-51a02a987af2"
      unitRef="usd">104010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjYtMS0xLTEtMA_3385f1c6-d136-450a-aef1-af37aa2cc015"
      unitRef="usd">204768000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i03292c592c4f45da834c806bff481c24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjYtMy0xLTEtMA_8209827a-a5d4-4fce-b910-5fdcdb59e00c"
      unitRef="usd">166828000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjktMS0xLTEtMA_ac3216d0-53ae-407a-8a7b-78ae36f1ccec"
      unitRef="usd">24800000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNjktMy0xLTEtMA_74f8a5ea-7eec-42c1-8f20-66f472b9792b"
      unitRef="usd">37900000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzAtMS0xLTEtMA_51331568-cff6-44ae-b44e-7e5181634889"
      unitRef="usd">3330000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzAtMy0xLTEtMA_3bdb7943-3d32-41de-9002-928617b12864"
      unitRef="usd">6961000</us-gaap:InterestPaidNet>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzMtMS0xLTEtMA_a22e3545-1751-4743-9d03-4714f774307c"
      unitRef="usd">71000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i03292c592c4f45da834c806bff481c24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzMtMy0xLTEtMA_71d04bfc-9946-491a-b0f4-4cfca47cf247"
      unitRef="usd">485000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzQtMS0xLTEtMA_f423aac1-5365-4de2-85d5-a79529e1380f"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzQtMy0xLTEtMA_1e8279e7-01f3-4540-9d93-9176400402bf"
      unitRef="usd">36179000</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <ameh:CancellationOfRestrictedStockAwards
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzUtMS0xLTEtMA_8af7e3d0-6bd7-426b-9f38-8ccf115c04e4"
      unitRef="usd">334000</ameh:CancellationOfRestrictedStockAwards>
    <ameh:CancellationOfRestrictedStockAwards
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzUtMy0xLTEtMA_ba063332-017a-4033-af18-fb5e7041115d"
      unitRef="usd">0</ameh:CancellationOfRestrictedStockAwards>
    <ameh:DeferredTaxLiabilitiesAdjustedToGoodwill
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzYtMS0xLTEtMA_1167a531-7100-478c-bd8a-cdbf2e250d54"
      unitRef="usd">1786000</ameh:DeferredTaxLiabilitiesAdjustedToGoodwill>
    <ameh:DeferredTaxLiabilitiesAdjustedToGoodwill
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzYtMy0xLTEtMA_805b26c2-5f50-4f5b-b59d-cc23db54bf89"
      unitRef="usd">0</ameh:DeferredTaxLiabilitiesAdjustedToGoodwill>
    <ameh:DeferredTaxLiabilitiesWarrantsExercised
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzgtMS0xLTEtMA_5ce34f4f-65e6-41c2-ac5d-4cadb44a3906"
      unitRef="usd">0</ameh:DeferredTaxLiabilitiesWarrantsExercised>
    <ameh:DeferredTaxLiabilitiesWarrantsExercised
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmYyOWQ5NjNhNzkyYzRjYTViZjllNGU2YThlMWUxYmRjL3RhYmxlcmFuZ2U6ZjI5ZDk2M2E3OTJjNGNhNWJmOWU0ZTZhOGUxZTFiZGNfNzgtMy0xLTEtMA_2121fc20-c690-4ea0-93d5-a34f1d68d3e4"
      unitRef="usd">473000</ameh:DeferredTaxLiabilitiesWarrantsExercised>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfMi0xLTEtMS0w_a6fdf42f-d6ec-43cc-bd03-c296fb271785"
      unitRef="usd">204768000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfMi0xLTEtMS0w_b74fe390-b790-453a-beab-946428333539"
      unitRef="usd">204768000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i03292c592c4f45da834c806bff481c24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfMi0zLTEtMS0w_866920a5-5718-4299-8b6d-ab269ee27915"
      unitRef="usd">166082000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfNC0xLTEtMS0w_41fadea4-b256-4c80-949a-b0411e1e6ca0"
      unitRef="usd">0</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i03292c592c4f45da834c806bff481c24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfNC0zLTEtMS0w_6fcedbdc-5872-4d7f-afbc-2269946a8e89"
      unitRef="usd">746000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfNS0xLTEtMS0w_04039f51-f96c-4056-be70-c0890b10db46"
      unitRef="usd">204768000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i03292c592c4f45da834c806bff481c24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOmZiZmY0NzUzY2ZkYTQ4MDk4YmZiMzE3OWY4NDk4M2JkL3RhYmxlcmFuZ2U6ZmJmZjQ3NTNjZmRhNDgwOThiZmIzMTc5Zjg0OTgzYmRfNS0zLTEtMS0w_4ca8d128-c32b-4a35-a2b1-bb980a3591d5"
      unitRef="usd">166828000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfMi0xLTEtMS0w_56cff224-a4d8-4f27-bbb8-71fb1bc38391"
      unitRef="usd">193470000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i274e819937824ba3b8be663aca7657a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfMi0zLTEtMS0w_cf0db6ea-0e43-4f96-a4dc-7e2027b778e3"
      unitRef="usd">103189000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfMy0xLTEtMS0w_0b887c7e-61e4-475f-a1f0-a0f264ee1d9b"
      unitRef="usd">500000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i274e819937824ba3b8be663aca7657a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfMy0zLTEtMS0w_60fb1f54-9063-43e0-b58b-f9f315be5885"
      unitRef="usd">746000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfNC0xLTEtMS0w_3f2d15cf-11c1-4296-8896-3afec300aadb"
      unitRef="usd">0</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i274e819937824ba3b8be663aca7657a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfNC0zLTEtMS0w_ec4feabe-d07e-4f23-871d-6f5f053ee826"
      unitRef="usd">75000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfNS0xLTEtMS0w_2fee5a9e-7d3e-4cf2-8023-7ba92ee760e9"
      unitRef="usd">193970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i274e819937824ba3b8be663aca7657a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8zNC9mcmFnOjg2OWIwZmUzODMzYjQ5NTRhYTQ4OGMzYWUzNTVmMWRkL3RhYmxlOjE2YTlkNDI0NmM3NzQ4NDY5NWUxNjY0ODA0ZTk2ZjAyL3RhYmxlcmFuZ2U6MTZhOWQ0MjQ2Yzc3NDg0Njk1ZTE2NjQ4MDRlOTZmMDJfNS0zLTEtMS0w_f27e0829-e96d-409a-8af2-d1761e157cc5"
      unitRef="usd">104010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTQ1MTY_7a63f49d-6c12-4d2b-bfca-dd998208f840">Description of Business&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Apollo Medical Holdings, Inc. (&#x201c;ApolloMed&#x201d;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#x201c;NMM&#x201d;) in December 2017 (the &#x201c;2017 Merger&#x201d;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#x201c;VIEs&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Headquartered in Alhambra, California, ApolloMed&#x2019;s subsidiaries and VIEs include management services organizations (&#x201c;MSOs&#x201d;), affiliated independent practice associations (&#x201c;IPAs&#x201d;), and a Next Generation Accountable Care Organization (&#x201c;NGACO&#x201d;). NMM and Apollo Medical Management, Inc. (&#x201c;AMM&#x201d;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#x201c;APC&#x201d;), (ii) Alpha Care Medical Group, Inc. (&#x201c;Alpha Care&#x201d;), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (&#x201c;Accountable Health Care&#x201d;). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#x201c;AMH&#x201d;) and Southern California Heart Centers, a Medical Corporation (&#x201c;SCHC&#x201d;). The Company&#x2019;s NGACO operates under the APA ACO, Inc. (&#x201c;APAACO&#x201d;) brand and participates in the Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#x2019;s attribution-based risk-sharing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#x2019;s physician network consists of primary care physicians, specialist physicians, and hospitalists. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSOs and Affiliates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#x201c;AMH&#x201d;) and Southern California Heart Centers, a Medical Corporation (&#x201c;SCHC&#x201d;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPAs and Affiliates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (&#x201c;HMOs&#x201d;) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#x201c;PMPM&#x201d;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AP-AMH Medical Corporation (&#x201c;AP-AMH&#x201d;) and AP-AMH 2 Medical Corporation (&#x201c;AP-AMH 2&#x201d;) was formed in May 2019 and July 2021, respectively, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. In accordance with relevant accounting guidance, AP-AMH and AP-AMH 2 is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;ApolloMed loaned AP-AMH $545.0 million pursuant to a 10-year secured loan agreement (the &#x201c;AP-AMH Loan&#x201d;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the &#x201c;Certificate of Determination&#x201d;), AP-AMH is entitled to receive preferential, cumulative dividends (&#x201c;Series A Dividends&#x201d;) that accrue on a daily basis and that are equal to the sum of (i) APC&#x2019;s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC&#x2019;s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;APC purchased 15,015,015 shares of ApolloMed&#x2019;s common stock for total consideration of $300.0 million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed&#x2019;s common stock that APC purchased, and APC agreed that APC votes in excess of 9.99% of ApolloMed&#x2019;s then outstanding shares will be voted by proxy given to ApolloMed&#x2019;s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed&#x2019;s stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of the series of transactions described above, APC and AP-AMH entered into a Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term &#x201c;Excluded Assets.&#x201d; Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price (as defined in the purchase agreement), (ii) the assets of APC that are not Healthcare Services Assets (as defined in the purchase agreement), including APC&#x2019;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC&#x2019;s ownership in ApolloMed was 19.77% as of September&#160;30, 2021 and 22.58% as of December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concourse Diagnostic Surgery Center, LLC (&#x201c;CDSC&#x201d;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of September&#160;30, 2021, APC owned 45.01% of CDSC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC-LSMA Designated Shareholder Medical Corporation (&#x201c;APC-LSMA&#x201d;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#x2019;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#x201c;LMA&#x201d;), Pacific Medical Imaging and Oncology Center, Inc. (&#x201c;PMIOC&#x201d;), Diagnostic Medical Group of Southern California (&#x201c;DMG&#x201d;), and AHMC International Cancer Center, a Medical Corporation (&#x201c;ICC&#x201d;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (&#x201c;MMG&#x201d;), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (&#x201c;AMG&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#x2019;s capital stock that they did not already own (comprising 75%) for&#160;$7.3 million&#160;in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (&#x201c;MPP&#x201d;), AMG Properties, LLC (&#x201c;AMG Properties&#x201d;), and ZLL Partners, LLC (&#x201c;ZLL&#x201d;) and a 50% interest in each of One MSO, LLC (&#x201c;One MSO&#x201d;), Tag-6 Medical Investment Group, LLC (&#x201c;Tag 6&#x201d;), and Tag-8 Medical Investment Group, LLC (&#x201c;Tag 8&#x201d;). These entities own buildings that are currently leased to tenants as well as vacant land which they plan to develop in the future. MPP, AMG Properties, and ZLL are 100% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#x2019;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, AP-AMH 2 Medical Corporation (&#x201c;AP-AMH 2&#x201d;), a VIE of the Company, purchased an 80% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#x201c;APCMG&#x201d;), a primary care physicians&#x2019; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company (see Note 3). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#x201c;Sun Labs&#x201d;) for an aggregate purchase price of $4.0 million. Sun Labs is a Clinical Laboratory Improvement Amendments certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company (see Note 3). The Company is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of at $4.2 million at September&#160;30, 2021. As the financing obligation is embedded in the noncontrolling interest, the noncontrolling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO&lt;/span&gt;&lt;/div&gt;APAACO, jointly owned by NMM and AMM, began participating in the NGACO Model of CMS in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model.</us-gaap:NatureOfOperations>
    <ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement
      contextRef="i917782072a6545aea32eaddcfe18e706_D19990701-19990701"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNDY3Nw_024fd689-5518-4d4d-9c3b-ba7b1456220f">P30Y</ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement>
    <us-gaap:NotesReceivableNet
      contextRef="ib52349b88809456791d3db024592e198_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNTU2Mw_7b84a20c-888d-4a72-8ca5-6e5e47d736ad"
      unitRef="usd">545000000</us-gaap:NotesReceivableNet>
    <ameh:FinanceReceivableTermOfReceivable
      contextRef="ibd821e95a1334471acf3bc50924008ff_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNTU4MA_684c0014-962f-4b53-b4e3-9a26b44044d5">P10Y</ameh:FinanceReceivableTermOfReceivable>
    <ameh:FinanceReceivableStatedInterestRate
      contextRef="ib52349b88809456791d3db024592e198_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNTY2OQ_35afe62d-ddc6-4717-a95a-d8317bcb0566"
      unitRef="number">0.10</ameh:FinanceReceivableStatedInterestRate>
    <ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate
      contextRef="ib52349b88809456791d3db024592e198_I20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNjM4NA_3bd35eb3-08a6-4dcd-ae91-e6bd544a497b"
      unitRef="number">0.1075</ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5e54e5787b2d4a9d913c148f7713fbd8_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNjQzMQ_fc505281-89f2-4ab0-a9e1-71bffb95207e"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:NotesReceivableNet
      contextRef="ib52349b88809456791d3db024592e198_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNjUwNA_f1ec3979-ad71-43ec-b8f5-b2f596f2b369"
      unitRef="usd">545000000</us-gaap:NotesReceivableNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i607219ce151b481d884ab20a69b7ab89_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNzA5Mw_4eaec33a-a258-4b23-994f-8eca2492653b"
      unitRef="shares">15015015</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i607219ce151b481d884ab20a69b7ab89_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNzE1OA_c985d646-5f44-4a5b-92a9-28ce41eb6e2f"
      unitRef="usd">300000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ameh:StockIssuedDuringPeriodProxyVotesPercentage
      contextRef="i607219ce151b481d884ab20a69b7ab89_D20190901-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfNzM2Mg_9aaebb1b-2e95-4144-b1ee-b2c91407d41d"
      unitRef="number">0.0999</ameh:StockIssuedDuringPeriodProxyVotesPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9007c9ba55ce4f30a5723df00d10d0ab_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfOTA3Mg_5a8c746c-c0af-4200-8480-fd7b902f1341"
      unitRef="number">0.1977</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i8bc4a1721b30446ebfd6d52b47024998_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfOTA4NQ_85b1cf61-8f90-4443-8afc-54e54840b66a"
      unitRef="number">0.2258</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iae6af9311d664b339370a494ef320121_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfOTU3Mg_a844a166-c770-49b5-8e71-934a8579bed3"
      unitRef="number">0.4501</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i00e774cfdab24f0aa1689be1a5900a03_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTA4NDg_a132b547-651e-40fa-8aea-2166b3b0ffca"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ameh:NumberOfFederallyQualifiedHealthPlans
      contextRef="if573b2a18f354adf817ec91e584fd94c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTE4NDY_ec022a95-ad83-4d49-95c3-378c0395fa34"
      unitRef="plan">3</ameh:NumberOfFederallyQualifiedHealthPlans>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i8bf46a0ff42c494995871919d226ce7e_I20190830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTIxMTY_6546d248-556a-4972-bccb-fe17657cd1e1"
      unitRef="number">0.75</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia651540f0f3040a1b9acd90c7a76f53b_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTIxMjQ_b21bd5b3-56fc-4e67-9ea8-78da8808e0c8"
      unitRef="usd">7300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:NumberOfFamilyPracticeClinics
      contextRef="i833e8c7434554e839001ca8eddd9a2f1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTIxOTc_e62f717c-082e-404c-a169-78c96d3671f4"
      unitRef="clinic">3</ameh:NumberOfFamilyPracticeClinics>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i7f596495482b4bccb3b9cb702ba11e2a_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTI0NDQ_aeb0ccf4-7ce0-484d-9cb5-03d2e0387b52"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i1b11e41e2b894c69abd5daa1e6e3fc87_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTI0ODk_5acbf55e-c6ed-44fd-9609-23a27e3c6598"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i98241c5880794788af87b66dc6a371bd_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTI1MDQ_19abf7d0-fa68-436b-819a-b7fcb1776523"
      unitRef="usd">400000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i865e78a6a983465c852275c72549d64c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTI2MTA_af71248d-f87a-4024-9114-136555773127"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i5fb003ee3c184ccf91aa13ae16058103_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTI3NDk_23d49c58-42c2-4789-815c-2aa3bc0853fa"
      unitRef="number">0.50</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i865e78a6a983465c852275c72549d64c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTMwNTg_af71248d-f87a-4024-9114-136555773127"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i3fd12cfc45b244a5884bf4cd547e6583_I20210731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMTY0OTI2NzQ2NTI3MA_9f4d5568-1c08-45ae-9fdd-a48df7dc25dc"
      unitRef="number">0.80</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ib05af751a8be4d57b25abcbf5cb700aa_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMjc0ODc3OTEwMjkxNw_c5102dd8-23a7-4e50-a011-e60c7c4afce4"
      unitRef="number">0.49</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i19c94975ba3e411ca4090953760b5a7f_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMjc0ODc3OTEwMzA2Mw_e4c8ab89-1f4a-49e2-8c4b-9d5028fe4ba1"
      unitRef="usd">4000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase
      contextRef="i19c94975ba3e411ca4090953760b5a7f_D20210801-20210831"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMjc0ODc3OTEwMzY1MA_98622117-6023-4b55-aea5-71ef343a9726">P3Y</ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent
      contextRef="i87665dc910e64455b39ac20a1dc7a442_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80MC9mcmFnOmExYTM4MzlmNTg3YzQ4MTdhYTY0YjI4N2QwZTg0Y2EwL3RleHRyZWdpb246YTFhMzgzOWY1ODdjNDgxN2FhNjRiMjg3ZDBlODRjYTBfMjc0ODc3OTEwMzUzOQ_4f850cbf-1f67-49ac-b451-c26b4ecb301e"
      unitRef="usd">4200000</ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNzg_bc4b77a2-855d-4168-b231-d57c61f5b1ad">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated balance sheets at December&#160;31, 2020, have been derived from the Company&#x2019;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited consolidated financial statements as of September&#160;30, 2021, and for the three and nine months ended September&#160;30, 2021 and 2020, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;15, 2021. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. Operating results for the three and nine months ended September&#160;30, 2021, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or any future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated balance sheets as of September&#160;30, 2021 and December&#160;31, 2020, and the consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020, include the accounts of ApolloMed; its consolidated subsidiaries, NMM, AMM, and APAACO; its consolidated VIEs, AP-AMH, AP-AMH 2, and Sun Labs; AP-AMH 2&#x2019;s consolidated subsidiary, APCMG; AMM&#x2019;s consolidated VIE, SCHC; NMM&#x2019;s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM&#x2019;s consolidated VIE, APC; APC&#x2019;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#x201c;UCAP&#x201d;), MPP, AMG Properties and ZLL, APC&#x2019;s consolidated VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and APC-LSMA&#x2019;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#x201c;IBNR&#x201d;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#x2019;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company has a variable interest in the legal entity &#x2013; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#x2019;s net assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A legal entity is determined to be a VIE if it has any of the following three characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity does not have sufficient equity to finance its activities without additional subordinated financial support;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#x2019;s economic performance, as evidenced by:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;Substantive participating rights in day-to-day management of the entity&#x2019;s activities; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;Substantive kick-out rights over the party responsible for significant decisions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;The obligation to absorb the entity&#x2019;s expected losses; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;The right to receive the entity&#x2019;s expected residual returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable interest model&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#x2013; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#x2019;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#x2013; &#x201c;Variable Interest Entities (VIEs)&#x201d; to the consolidated financial statements for information on the Company&#x2019;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash. As of September&#160;30, 2021 and December&#160;31, 2020, the Company&#x2019;s deposit accounts with banks exceeded the FDIC&#x2019;s insured limit by approximately $301.7 million and $294.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#x2019;s concentration of risk exposure.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of September&#160;30, 2021 and December&#160;31, 2020, certificates of deposit amounted to approximately $67.5 million and $67.6 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Equity securities held by the Company are comprised of common stock of a payor partner that completed its initial public offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(&#x201c;IPO&#x201d;) in June 2021 and Clinigence Holdings, Inc. (&#x201c;Clinigence&#x201d;). The shares were acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (&#x201c;UCI&#x201d;) in April 2020. As of September&#160;30, 2021, the equity securities from the payor partner amounted to $57.0 million. As of December&#160;31, 2020, prior to our payor partner&#x2019;s IPO, the related investment balance was included in investments in privately held entities at its cost basis of $36.2 million in the accompanying consolidated balance sheets. In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The common stock is included in investments in marketable securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the three and nine months ended September&#160;30, 2021, the Company recognized unrealized losses of $62.0&#160;million and unrealized gains of $21.8 million on all equity securities in unrealized gain or loss on investments in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables,  Receivables &#x2013; Related Parties, and Loan Receivable - Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loan receivable &#x2013; related party consist of promissory notes from payees that are expected to be collected between two to four years and accrue interest per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation and claims receivables relate to each health plan&#x2019;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#x201c;CECL&#x201d;) model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of operations present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three and nine months ended September&#160;30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#x2014; related parties, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of September&#160;30, 2021, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APCMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2020, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the nine months ended September&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no impairment of its goodwill or indefinite-lived intangible assets during the nine months ended September&#160;30, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2014; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of operations under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Privately Held Entities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC, Alpha Care, Accountable Health Care, and APCMG (&#x201c;consolidated IPAs&#x201d;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fiduciary Cash and Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of $8.8 million and $9.6 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#x2019;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. The fair value of the derivative instrument as of September&#160;30, 2021, was $1.0 million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of operations.  The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. The fair value of the derivative instrument as of September&#160;30, 2021 was $1.0&#160;million and is presented within other assets in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#x201c;AIPBP&#x201d;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospital&#x2019;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk share revenue is deemed to be fully constrained until APC is notified of the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, the Company must submit to CMS its selections for risk arrangement, the amount of the profit/loss cap, alternative payment mechanism, benefits enhancements, if any, and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#x2019;s in-network contracted providers are paid by APAACO. The Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 8), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#x201c;Participation Agreement&#x201d;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company recognized $21.8&#160;million related to savings from the 2020 performance years. The settlement was finalized in October 2021 and recorded as revenue in risk pool settlements and incentives in the accompanying consolidated statements of operations for the three and nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance year 2021, the Company receives monthly AIPBP payments at a rate of approximately $8.0 million per month from CMS, and must comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $23.9 million and $72.0 million in total AIPBP payments for the three and nine months ended September&#160;30, 2021, respectively, of which $17.6 million and $48.9 million has been recognized as revenue for the three months and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#x2019;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system, and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based on the information known at the time of entering of such information into the Company&#x2019;s billing systems, as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of operations in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#x2019;s contract assets are comprised of receivables and receivables &#x2013; related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities (Deferred Revenue)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company&#x2019;s contract liability balance was $17.3 million and $13.0 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and is presented within accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the nine months ended September&#160;30, 2021, $0.4 million of the Company&#x2019;s contract liability accrued in 2020 has been recognized as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards, such as options, is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net income attributable to holders of the Company&#x2019;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of September&#160;30, 2021 and December&#160;31, 2020, APC&#x2019;s shares were not redeemable, nor was it probable the shares would become redeemable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Beneficial Interest&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI, APC received a beneficial interest in the equity method investment sold, pursuant to the terms of the stock purchase agreement. The estimated fair value of such interest in April 2020, was&#160;$15.7 million and is included in other assets in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#x2019;s gross margin for the year ended December 31, 2020, was assessed and beneficial interest was concluded to not be collectible. The $15.7 million was written off and expensed in other income in the accompanying consolidated statements of operations for the nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2019, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASU 2019-12&#x201d;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzOTg_42125e00-443f-4665-8607-8ad2febc48e4">Basis of PresentationThe accompanying consolidated balance sheets at December&#160;31, 2020, have been derived from the Company&#x2019;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited consolidated financial statements as of September&#160;30, 2021, and for the three and nine months ended September&#160;30, 2021 and 2020, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;15, 2021. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MTU_10ac3f87-a007-42d0-b14e-fa500811d764">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated balance sheets as of September&#160;30, 2021 and December&#160;31, 2020, and the consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020, include the accounts of ApolloMed; its consolidated subsidiaries, NMM, AMM, and APAACO; its consolidated VIEs, AP-AMH, AP-AMH 2, and Sun Labs; AP-AMH 2&#x2019;s consolidated subsidiary, APCMG; AMM&#x2019;s consolidated VIE, SCHC; NMM&#x2019;s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM&#x2019;s consolidated VIE, APC; APC&#x2019;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#x201c;UCAP&#x201d;), MPP, AMG Properties and ZLL, APC&#x2019;s consolidated VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and APC-LSMA&#x2019;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNTQ_26ea3756-cc4f-4e78-ac6b-21c6922fad42">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#x201c;IBNR&#x201d;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0Mjc_a91a1f4e-1a32-4c0e-8433-b90dbc71c12f">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#x2019;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company has a variable interest in the legal entity &#x2013; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#x2019;s net assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A legal entity is determined to be a VIE if it has any of the following three characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity does not have sufficient equity to finance its activities without additional subordinated financial support;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#x2019;s economic performance, as evidenced by:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;Substantive participating rights in day-to-day management of the entity&#x2019;s activities; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;Substantive kick-out rights over the party responsible for significant decisions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;The obligation to absorb the entity&#x2019;s expected losses; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;The right to receive the entity&#x2019;s expected residual returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable interest model&lt;/span&gt;&lt;/div&gt;If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#x2013; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#x2019;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#x2013; &#x201c;Variable Interest Entities (VIEs)&#x201d; to the consolidated financial statements for information on the Company&#x2019;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzOTE_7f90921b-2f7b-4e92-9114-a9f676cb0525">Business CombinationsThe Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MDY_39605b9e-ea00-48ac-bba3-7fd2bdcdfe47">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNzQwOA_4a864832-6d3d-436a-9041-e1d5ac1fb060"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNzQwOA_63ad19ff-cbca-434a-a7aa-450e2c4541b1"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNzY4NQ_4a864832-6d3d-436a-9041-e1d5ac1fb060"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNzY4NQ_63ad19ff-cbca-434a-a7aa-450e2c4541b1"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MzY_c353730c-c557-4ac4-84ea-99e8c81fd534">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfODQ0OQ_2615fc01-967e-41e3-8965-63ba123f94ca"
      unitRef="usd">301700000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfODQ1Ng_0f50cccb-e1ad-4e8b-836d-2a6901b94fa3"
      unitRef="usd">294900000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0NTE_6884312d-acfb-4f7a-b4ec-45772cbcde94">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MDI_d9e677c2-a8a1-4140-8b24-98e08f426c6c">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of September&#160;30, 2021 and December&#160;31, 2020, certificates of deposit amounted to approximately $67.5 million and $67.6 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Equity securities held by the Company are comprised of common stock of a payor partner that completed its initial public offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;(&#x201c;IPO&#x201d;) in June 2021 and Clinigence Holdings, Inc. (&#x201c;Clinigence&#x201d;). The shares were acquired as a result of UCAP selling its</us-gaap:MarketableSecuritiesPolicy>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="ie4f15f9c5a3844039181a10397fc0a58_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MTY_5e4532c0-f19c-4c1c-b36b-e52b53c9334b">P4M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="i5c1a64ec8e5142baa71cef9c34b44674_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfOTIxNg_a81d065e-a39c-49a2-99f3-e08bbcbaea0c">P24M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0ab35f4b7d54df89c058bf7cd127578_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfOTI5NA_d879af6b-1933-4e66-ad71-35c87085e09e"
      unitRef="usd">67500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i70a8098987854f45b301221eae528a87_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfOTMwMQ_8d52d086-7da4-4289-9ca4-669cfda30631"
      unitRef="usd">67600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="i21d7bfcc34ee4134a98f32759980bac4_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfOTg0OQ_62d62d98-11c4-47c8-8dce-3a2e94248e48"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfOTk1OA_4d280a62-a047-48e9-bf2c-998f88f16cc3"
      unitRef="usd">57000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTAxMTI_1bbf36b8-1a92-4e0f-a0d0-25192b36628f"
      unitRef="usd">36200000</us-gaap:EquitySecuritiesFvNi>
    <ameh:PaymentsToAcquireCommonStockAndWarrants
      contextRef="i73149ba28e96471eb0008ad0f005eb5b_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTA5OTUxMTY4Njc0MA_a9aabffe-095f-418a-a569-83344e727a25"
      unitRef="usd">3000000</ameh:PaymentsToAcquireCommonStockAndWarrants>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTA5OTUxMTY4MzMyMg_16ed5d3c-ac1c-40bf-ade3-df9fd630ca75"
      unitRef="usd">-62000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTAyNDI_be50d974-2f4f-473e-8e1f-3feea36264c6"
      unitRef="usd">21800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNTU_629c1a53-1146-4783-b4e8-87b80c6a63fa">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables,  Receivables &#x2013; Related Parties, and Loan Receivable - Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loan receivable &#x2013; related party consist of promissory notes from payees that are expected to be collected between two to four years and accrue interest per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation and claims receivables relate to each health plan&#x2019;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/span&gt;&lt;/div&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#x201c;CECL&#x201d;) model.</ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock>
    <ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTE2MzA_78d412c4-72a0-4383-b381-6fd3f8e65c3e">P18M</ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MDM_3ad72830-369d-43dc-afbe-3e18ae5d84c8">Concentrations of Credit RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of operations present disaggregated revenue by service type.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MzE_39db88b6-f7a6-4493-891c-1a5b08daaee1">The following table presents disaggregated revenue generated by payor type for the three and nine months ended September&#160;30, 2021 and 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i620cf562ac9c414d9a3092d147a50325_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfMy0xLTEtMS0w_b9a8be42-6ef7-4643-a1cf-84d652ea3ef2"
      unitRef="usd">36960000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if96b5ec1dd6f464a864b0099f4d91c07_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfMy0zLTEtMS0w_4210bbb7-b198-4212-abff-6b752f98efaf"
      unitRef="usd">25041000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie007473644f44d87917377c77aef7ccf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfMy01LTEtMS0w_ff52907a-9eab-4fc0-960c-66b2b2d51a69"
      unitRef="usd">102522000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68a17291f515493a861cd6f4b6efc5d0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfMy03LTEtMS0w_7ce2d237-d0f6-4080-ab8a-76166adb471d"
      unitRef="usd">75233000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0844a4c64e4a4f52bffe29e4402a700d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNC0xLTEtMS0w_15887b3a-a032-4315-bcc7-a07eac34c2d0"
      unitRef="usd">103919000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c3b05a4a5ac46009c7ff5139937e1c3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNC0zLTEtMS0w_2a402e3d-860a-46ca-8162-167915ba5f2e"
      unitRef="usd">79649000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i733800189cf14be7957deb86e6bdafa7_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNC01LTEtMS0w_047de25b-ba81-444f-856c-4b0818c2d367"
      unitRef="usd">232869000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3852673d58ff474a9ec227fd30703a97_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNC03LTEtMS0w_a5ddda1b-d05c-4882-bf05-e510c4b9d175"
      unitRef="usd">206567000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04da3802734c4d5ca72ce1e9859ddf23_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNS0xLTEtMS0w_3ca54fb1-cf56-4874-bb17-acd59adcbec3"
      unitRef="usd">74262000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib06f5b4a97614ebebfcdcb473ee362ba_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNS0zLTEtMS0w_0b7540db-c103-4a9f-bae9-e27b97d01c60"
      unitRef="usd">65849000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31af46ad891f405383d1dfc6a8f0cfca_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNS01LTEtMS0w_67eb9365-144a-4367-89ea-35d448b05252"
      unitRef="usd">212408000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0ffcf9784294ca9a72978bc33ad7f9e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNS03LTEtMS0w_46f7fee5-6bab-4bda-8486-b2685ca43055"
      unitRef="usd">200746000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7446d9124cfd4d7585720c3d8e7122d3_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNi0xLTEtMS0w_e8be7ef6-00aa-4260-ae1a-0d07a5b6aa64"
      unitRef="usd">11976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7116e35a0d75437b94523ce43f9485b0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNi0zLTEtMS0w_ac65a4aa-2837-4053-8029-e511196bce79"
      unitRef="usd">9584000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86ce34a69194485699b14fc7aa46d82c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNi01LTEtMS0w_9345ec37-6ca5-4e98-abdf-3bee997864d6"
      unitRef="usd">31016000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf9a026a7fbb4032abab16642bbb3559_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNi03LTEtMS0w_64a5c24d-9c45-49a9-9006-e13e2546277a"
      unitRef="usd">27851000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNy0xLTEtMS0w_88eab1c4-c926-4762-b1fa-b0043f18b64f"
      unitRef="usd">227117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNy0zLTEtMS0w_62f9df4a-2bb8-40f2-a7a0-d104a08830ee"
      unitRef="usd">180123000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNy01LTEtMS0w_8aafdbac-233d-4840-9a60-bcde8ed51dbe"
      unitRef="usd">578815000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjI0ZDMwYjdhZjBiNzRjNjdiZjg3NTUyODdjODg1ZjY5L3RhYmxlcmFuZ2U6MjRkMzBiN2FmMGI3NGM2N2JmODc1NTI4N2M4ODVmNjlfNy03LTEtMS0w_91237115-bf8d-4f04-8c4e-7f00328696a1"
      unitRef="usd">510397000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNTY_3a8e3da7-b002-4551-9a06-8f229f8e38da">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#x2014; related parties, net&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i51f1ae095a524c598ba9ab90870d3358_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfMy0xLTEtMS0w_25fdb1bf-e7a4-413a-86e3-336a1ba1063b"
      unitRef="number">0.138</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i56807d20331a448d82326373209f0ebc_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfMy0zLTEtMS0w_a7ba2cc4-1367-4b22-9e99-6b9aaa92d9ff"
      unitRef="number">0.127</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if1734fad16be4ffd9f4a18f4e906e85d_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfMy01LTEtMS0w_1aae538a-dcb4-44bd-83bd-a92d121b0d8c"
      unitRef="number">0.131</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i669f4e3ef9c74609880bf5e9b21c3859_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfMy03LTEtMS0w_70a6be73-15e9-403d-955d-e62dd1d03577"
      unitRef="number">0.121</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie27ed45d3b0c4053b92fca660e1e6d1a_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNC01LTEtMS0w_bfb4109a-4f1b-4080-8cb4-17d9e54a8b9c"
      unitRef="number">0.101</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6cf8c009ddf949839ee8d70ae541980a_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNC03LTEtMS0w_7f5d3c18-e50b-460a-8618-431cce037f3d"
      unitRef="number">0.101</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4de419972e0e4273afd8cb93852e239a_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNS0xLTEtMS0w_4a7f1fa2-a02f-4e45-a60f-7d60aedd7c13"
      unitRef="number">0.133</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2e3a8da4ddbe49af8195caf1c527e751_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNS0zLTEtMS0w_586e5cf6-3693-4567-90fa-5b357882643a"
      unitRef="number">0.162</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaa3259fa3ba0452db6f9b000329b0707_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNS01LTEtMS0w_535f48ca-fe7e-4095-9c7f-5e60d3439a76"
      unitRef="number">0.154</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if278b608177c4be99b9342cc7f6e2747_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNS03LTEtMS0w_3e7763a8-5f70-4a39-a344-55ec1059b687"
      unitRef="number">0.170</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic9203d02b2a74181bd4ed2e0e1ba71f9_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNi0xLTEtMS0w_1fa3ec61-ba3e-41ab-ae62-5c97353f28e5"
      unitRef="number">0.171</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i875dae327fdd4ebc9c116e881e3cd106_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNi0zLTEtMS0w_c45e88df-9da4-4c91-96db-d1a9fd4fff8f"
      unitRef="number">0.167</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i02eb4ac069e64a9683beb09cbf7a8921_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNi01LTEtMS0w_f2547f64-6c28-4c33-957f-34f2c308c284"
      unitRef="number">0.121</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i64112f96ecc6447d924934cf8a3517dc_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc0NWQ0NWM1YzhhZjRkMTk4NjA4ZTdiM2NmNWY1MDU4L3RhYmxlcmFuZ2U6NzQ1ZDQ1YzVjOGFmNGQxOTg2MDhlN2IzY2Y1ZjUwNThfNi03LTEtMS0w_097949cb-3030-4aa4-8cd4-acf43cfad2c8"
      unitRef="number">0.142</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie30670fa153f4da59d850909c48a2fd6_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmRjOWJkN2M5MTQ3YTQ5NTY5YzliOGE5YTVjZmQ4ODY2L3RhYmxlcmFuZ2U6ZGM5YmQ3YzkxNDdhNDk1NjljOWI4YTlhNWNmZDg4NjZfMy0xLTEtMS0w_867b770a-3dab-47b2-90f0-2b3e9a7c6c35"
      unitRef="number">0.137</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic985d70a02f643808edb2e7823ec4817_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmRjOWJkN2M5MTQ3YTQ5NTY5YzliOGE5YTVjZmQ4ODY2L3RhYmxlcmFuZ2U6ZGM5YmQ3YzkxNDdhNDk1NjljOWI4YTlhNWNmZDg4NjZfNC0xLTEtMS0w_e1bf244b-dc3b-43aa-8b58-3c202c71306c"
      unitRef="number">0.420</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib6123d945359476aa42a8767483cbee8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmRjOWJkN2M5MTQ3YTQ5NTY5YzliOGE5YTVjZmQ4ODY2L3RhYmxlcmFuZ2U6ZGM5YmQ3YzkxNDdhNDk1NjljOWI4YTlhNWNmZDg4NjZfNC0zLTEtMS0w_2a28c750-46ed-4a1e-9e54-38f74c2383a7"
      unitRef="number">0.439</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i861c8815c7544ce78f48c3ea70ec379b_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmRjOWJkN2M5MTQ3YTQ5NTY5YzliOGE5YTVjZmQ4ODY2L3RhYmxlcmFuZ2U6ZGM5YmQ3YzkxNDdhNDk1NjljOWI4YTlhNWNmZDg4NjZfNS0xLTEtMS0w_528c5cff-358d-47b8-8e71-51907c0b5bae"
      unitRef="number">0.258</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i59a0229c1ab0473da20301ac3f5f144a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmRjOWJkN2M5MTQ3YTQ5NTY5YzliOGE5YTVjZmQ4ODY2L3RhYmxlcmFuZ2U6ZGM5YmQ3YzkxNDdhNDk1NjljOWI4YTlhNWNmZDg4NjZfNS0zLTEtMS0w_e9e402ed-219a-433b-a3ea-1df9f31ab3e2"
      unitRef="number">0.365</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNjY_cadcbe73-36d7-4b97-9a7b-15031acd780f">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNjQ_5a2d051d-72e3-44f6-8a98-cc6860e4b435">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of September&#160;30, 2021, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APCMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2020, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i719e7a78283546f4bc429a548789a311_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMy0xLTEtMS0w_7ee0c0f0-5556-4a32-bcb0-9b8f0cc2708f"
      unitRef="usd">89678000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i91958f750e2540c1b7888e3065408687_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMy0zLTEtMS0w_69a17f8e-5f86-4ccf-9024-d53d4e8d1a30"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMy01LTEtMS0w_e249481e-07a8-40cb-968a-e20cec7535bb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMy03LTEtMS0w_bf0b6abe-14c8-4b76-adaa-e2b226ab48b2"
      unitRef="usd">89678000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i719e7a78283546f4bc429a548789a311_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNC0xLTEtMS0w_0084a33e-87c3-4cf6-a224-44dc96c2fbfb"
      unitRef="usd">67540000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91958f750e2540c1b7888e3065408687_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNC0zLTEtMS0w_33a6e325-b5ca-4bae-9b21-0b50f8805b86"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNC01LTEtMS0w_e77c933f-173f-4c17-b700-0536b0bb3647"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNC03LTEtMS0w_d31d205b-95be-4345-9554-5839c694d2bf"
      unitRef="usd">67540000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i719e7a78283546f4bc429a548789a311_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNS0xLTEtMS0w_71543a00-4f12-4c37-b3df-b2c0dfdb8223"
      unitRef="usd">57108000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i91958f750e2540c1b7888e3065408687_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNS0zLTEtMS0w_cfedd670-b141-46de-b00c-fd6e847018ac"
      unitRef="usd">3910000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNS01LTEtMS0w_e677afed-a012-47a0-a108-73b93d1304a8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNS03LTEtMS0w_bf2bd9ab-7c18-4bb6-b498-a0b16053ab4c"
      unitRef="usd">61018000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:DerivativeAssets
      contextRef="i719e7a78283546f4bc429a548789a311_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNy0xLTEtMS0yMzI4Mw_17b4018c-d5fc-484d-9f2d-887697e4f493"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i91958f750e2540c1b7888e3065408687_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNy0zLTEtMS0yMzI4Mw_0d1ff0d4-1c32-4d12-a6a0-cede58d38563"
      unitRef="usd">1045000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNy01LTEtMS0yMzI4Mw_32d2250e-1898-42da-a2e7-e925f0b97da9"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNy03LTEtMS0yMzI4Mw_2fcbc473-b974-46dd-8398-a04efc6d511b"
      unitRef="usd">1045000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i719e7a78283546f4bc429a548789a311_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNi0xLTEtMS0w_f802ea17-9104-4893-a5ce-f9c604cfedd3"
      unitRef="usd">214326000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i91958f750e2540c1b7888e3065408687_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNi0zLTEtMS0w_777febd2-7992-41f4-a02d-49de9d0637fc"
      unitRef="usd">4955000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNi01LTEtMS0w_cbb9b165-98e0-4bc1-83c9-6d83bb62d0a0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfNi03LTEtMS0w_47811ed6-5356-4566-a1f8-f0e8796724e5"
      unitRef="usd">219281000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i719e7a78283546f4bc429a548789a311_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOC0xLTEtMS0w_b5e406a7-871b-44cc-8bb9-01932fc09a42"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i91958f750e2540c1b7888e3065408687_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOC0zLTEtMS0w_f1e38918-beac-466d-8400-fbd11b21e4c9"
      unitRef="usd">1010000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOC01LTEtMS0w_245fc4da-1789-4326-ab92-b7bec50f5a9e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOC03LTEtMS0w_2aa0d250-2b53-4960-939c-3978e6a2a797"
      unitRef="usd">1010000</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i719e7a78283546f4bc429a548789a311_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMTEtMS0xLTEtMjcwNzg_7d2b27b4-a4dc-479d-885a-9d58945ab4eb"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i91958f750e2540c1b7888e3065408687_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMTEtMy0xLTEtMjcwNzg_e26dd285-f482-497b-99af-79d3ecf4c3ea"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMTEtNS0xLTEtMjcwNzg_9c337bb0-99ad-4f0d-8220-acaa8628beb0"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfMTEtNy0xLTEtMjcwNzg_75d268e5-878a-4a3d-b725-12ef6c9a83b2"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i719e7a78283546f4bc429a548789a311_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOS0xLTEtMS0w_547f7623-9e57-47ff-9385-80a217470a89"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i91958f750e2540c1b7888e3065408687_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOS0zLTEtMS0w_78f5581a-bbcc-4c96-9077-5f8fff33c9c3"
      unitRef="usd">1010000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i8b1e99e4b094455782c477e1470f802f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOS01LTEtMS0w_bf61ab89-d004-4c5d-a744-49aae3680105"
      unitRef="usd">1000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOjc2NTJlZDNhNjJiYjRmYzBiYjVlMzBlYTk3ZDJkMGM3L3RhYmxlcmFuZ2U6NzY1MmVkM2E2MmJiNGZjMGJiNWUzMGVhOTdkMmQwYzdfOS03LTEtMS0w_c85a0100-fcfe-4ce3-b20a-799bd2808490"
      unitRef="usd">2010000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3447f389c5504801b383b47a1c4d2bf5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfMy0xLTEtMS0w_8958fff9-8907-4410-aad1-044173c148f6"
      unitRef="usd">115769000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if69a06c770b545248b58b9ead976504d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfMy0zLTEtMS0w_636f727f-27e3-46d6-8f47-606910249aad"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib1dab6e4bc5e45dc9b15b4f78276c9d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfMy01LTEtMS0w_bc62f7e5-bc3d-48cd-b8a2-86c2f3dbd60f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfMy03LTEtMS0w_181acfc3-cd5f-4c80-81bc-b7ba1d06f9ce"
      unitRef="usd">115769000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3447f389c5504801b383b47a1c4d2bf5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNC0xLTEtMS0w_33416672-5035-4f74-8a46-2ebc80ecf3b0"
      unitRef="usd">67637000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if69a06c770b545248b58b9ead976504d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNC0zLTEtMS0w_88139c74-5f46-4305-bd33-04806179aa29"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1dab6e4bc5e45dc9b15b4f78276c9d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNC01LTEtMS0w_59d2ed7f-9f91-4434-816c-9e3fd427c65f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNC03LTEtMS0w_31474748-2b55-4b04-b80a-b9ffd9c979be"
      unitRef="usd">67637000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i3447f389c5504801b383b47a1c4d2bf5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNS0xLTEtMS0w_c8cbf8d3-c888-4bb5-949f-4bd100d6e087"
      unitRef="usd">58000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="if69a06c770b545248b58b9ead976504d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNS0zLTEtMS0w_7cd8d5ee-b50a-4216-afb2-20d235bd4bf0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ib1dab6e4bc5e45dc9b15b4f78276c9d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNS01LTEtMS0w_2ed6d0c0-0810-416b-a2c4-9ecf16d65464"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNS03LTEtMS0w_6a72a578-2b47-4cb3-b813-9fd912c88493"
      unitRef="usd">58000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3447f389c5504801b383b47a1c4d2bf5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNi0xLTEtMS0w_af27f153-3f27-46c2-a2ed-c96fe3b455c2"
      unitRef="usd">183464000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if69a06c770b545248b58b9ead976504d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNi0zLTEtMS0w_4d38374f-63e4-4a79-8b01-b86a35e0efd7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib1dab6e4bc5e45dc9b15b4f78276c9d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNi01LTEtMS0w_9a63c071-20fd-424d-a1d6-d5ad18fd546d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RhYmxlOmIxNjJlNGNmODY1OTRkZDViMDlmZTMzY2MwYTI0MzFiL3RhYmxlcmFuZ2U6YjE2MmU0Y2Y4NjU5NGRkNWIwOWZlMzNjYzBhMjQzMWJfNi03LTEtMS0w_7cbcfa11-d4df-4638-badf-e0917c8e0db0"
      unitRef="usd">183464000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNjc_acbed529-c393-48ac-aecf-396789bd0e1d">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTc5Mjk_1305803b-0926-4c7b-b4e9-0ae66afe2136"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTc5Mjk_2bb082d3-6cdc-4c34-81ba-26a1b92f47ea"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTc5Mjk_7906dc8c-0ffa-434a-a3da-c3c27b28dfd8"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTc5Mjk_a933742e-9f28-4bb6-bd3d-59d55300a5f7"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MzI_1ed10c2d-9aee-44fb-afd3-7eefb38b413a">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTg2NjM_5e424982-0e0a-4525-9ab0-a5f39426c4ec"
      unitRef="unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMjAwMTI_0e078519-365a-4c39-8894-5cccd4da23e4"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMjAwMTI_2c040b6d-e568-4c88-86de-6bf7c63abb37"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNjg_7547d899-d6d7-4a8a-9aba-8b5aa988e69b">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2014; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of operations under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Privately Held Entities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The &lt;/span&gt;&lt;/div&gt;investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:HealthCareCostsPolicyPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MzM_eeb989d3-f299-418e-87cd-3a891f58e18c">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC, Alpha Care, Accountable Health Care, and APCMG (&#x201c;consolidated IPAs&#x201d;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.&lt;/span&gt;&lt;/div&gt;</us-gaap:HealthCareCostsPolicyPolicyTextBlock>
    <ameh:FiduciaryCashAndPayablePolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0NDc_6c351547-908c-4292-a62d-45dc12a922d1">Fiduciary Cash and PayableThe consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them.</ameh:FiduciaryCashAndPayablePolicyTextBlock>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMjM0Nzc_f7ea4b02-e785-474f-8c50-e88e2a883eb5"
      unitRef="usd">8800000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMjM0ODQ_569af036-15b7-4771-aa72-a2edf3deb74c"
      unitRef="usd">9600000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MzQ_e06e4f2b-b743-4d6d-9847-e84f491e0d9e">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#x2019;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. The fair value of the derivative instrument as of September&#160;30, 2021, was $1.0 million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of operations.  The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. The fair value of the derivative instrument as of September&#160;30, 2021 was $1.0&#160;million and is presented within other assets in the accompanying consolidated balance sheets.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iee549c3ab8a545c3962f33718601846b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMjQ2MzI_1a74f02a-6723-4947-9f25-c5e3c80b4f8a"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <ameh:PaymentsToAcquireCommonStockAndWarrants
      contextRef="i73149ba28e96471eb0008ad0f005eb5b_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTA5OTUxMTY4NzA4MQ_a9aabffe-095f-418a-a569-83344e727a25"
      unitRef="usd">3000000</ameh:PaymentsToAcquireCommonStockAndWarrants>
    <us-gaap:DerivativeAssets
      contextRef="i91958f750e2540c1b7888e3065408687_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTA5OTUxMTY4NzgzNg_c9ccf7de-2a8c-4bca-8d20-4ee3fb7aad84"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzODE_b0b167a8-4072-4558-a390-cecb14ba6a53">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#x201c;AIPBP&#x201d;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospital&#x2019;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk share revenue is deemed to be fully constrained until APC is notified of the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, the Company must submit to CMS its selections for risk arrangement, the amount of the profit/loss cap, alternative payment mechanism, benefits enhancements, if any, and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#x2019;s in-network contracted providers are paid by APAACO. The Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 8), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#x201c;Participation Agreement&#x201d;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company recognized $21.8&#160;million related to savings from the 2020 performance years. The settlement was finalized in October 2021 and recorded as revenue in risk pool settlements and incentives in the accompanying consolidated statements of operations for the three and nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance year 2021, the Company receives monthly AIPBP payments at a rate of approximately $8.0 million per month from CMS, and must comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $23.9 million and $72.0 million in total AIPBP payments for the three and nine months ended September&#160;30, 2021, respectively, of which $17.6 million and $48.9 million has been recognized as revenue for the three months and nine months ended September&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#x2019;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system, and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based on the information known at the time of entering of such information into the Company&#x2019;s billing systems, as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of operations in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#x2019;s contract assets are comprised of receivables and receivables &#x2013; related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities (Deferred Revenue)&lt;/span&gt;&lt;/div&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i5a9f36c8077645449753769fc30f2343_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNzU_fef5bc46-cbe9-4053-a9c3-bb6ccd7edca5">one year</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i17d3720cbb39433fad71b101f7b86012_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzYyNTQ_007e184f-d371-44d5-a45e-1ff35e72b5a0">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i17d3720cbb39433fad71b101f7b86012_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzY1MTQ_b7f944fb-b570-4362-a28e-be14bb59efcb">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i17d3720cbb39433fad71b101f7b86012_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzY2Mzc_b7f944fb-b570-4362-a28e-be14bb59efcb">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueFromRiskPoolSettlementsFromPriorPerformanceYears
      contextRef="i17d3720cbb39433fad71b101f7b86012_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMTA5OTUxMTY4ODQ5Mw_660a2c24-9ed2-4803-a1b0-a499af0e2cfb"
      unitRef="usd">21800000</ameh:RevenueFromRiskPoolSettlementsFromPriorPerformanceYears>
    <ameh:PaymentOfRevenueMonthlyAmount
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzgwMTA_6c0352d0-d2b3-4a2a-a9c3-3fdc1670ffc2"
      unitRef="usd">8000000</ameh:PaymentOfRevenueMonthlyAmount>
    <ameh:PaymentOfRevenue
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzgyNTg_0eb97b23-a635-46eb-ae6c-fe2baa542978"
      unitRef="usd">23900000</ameh:PaymentOfRevenue>
    <ameh:PaymentOfRevenue
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzgyNjU_cdf23685-1bd5-41dc-bd1f-c0dc57e66801"
      unitRef="usd">72000000</ameh:PaymentOfRevenue>
    <ameh:PaymentOfRevenueRevenueRecognized
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzgzNTA_42429408-6e2b-4ead-9815-f3f45d961a21"
      unitRef="usd">17600000</ameh:PaymentOfRevenueRevenueRecognized>
    <ameh:PaymentOfRevenueRevenueRecognized
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfMzgzNTc_5620121d-086d-4114-aedf-4b89c262b75f"
      unitRef="usd">48900000</ameh:PaymentOfRevenueRevenueRecognized>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i3329b671360b4adfa4fb2f7c426fc278_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzOTY_1f42e997-069f-4a65-bbd4-108f6ea339ee">10 years</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNDY3OTQ_33abb94a-8adb-42f6-9bc8-b33facd8251e"
      unitRef="usd">17300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNDY4MDE_d8bf7c88-b79b-4a6c-94e6-2236fe293ce5"
      unitRef="usd">13000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i125c51891f044f728be18a8712aa205b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNDY5Nzc_b95ff8e7-d191-496e-9934-66d8c81b6424"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0NDE_f1231f6b-781f-4195-8862-4a0866f48e4a">Income Taxes&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0NDk_e465e9af-3bc9-4702-8be2-65d261cd1362">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards, such as options, is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNzY_b248b735-3897-47e0-935f-4b4b72bcb751">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net income attributable to holders of the Company&#x2019;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <ameh:MinorityInterestPolicyPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNzc_50ea7982-f843-431d-b57a-2a2fcdfbeaea">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</ameh:MinorityInterestPolicyPolicyTextBlock>
    <ameh:TemporaryEquityPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNzM_4b87cf43-24a5-4a4f-a0ee-7b62ad117a34">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of September&#160;30, 2021 and December&#160;31, 2020, APC&#x2019;s shares were not redeemable, nor was it probable the shares would become redeemable.&lt;/span&gt;&lt;/div&gt;</ameh:TemporaryEquityPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTU0MDk_8ea8179c-1f5c-4791-b92d-a1506292fc9a">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <ameh:BeneficialInterestPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNTk_17c86fc7-a845-4c84-9d5b-4dac0e0af36e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Beneficial Interest&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI, APC received a beneficial interest in the equity method investment sold, pursuant to the terms of the stock purchase agreement. The estimated fair value of such interest in April 2020, was&#160;$15.7 million and is included in other assets in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#x2019;s gross margin for the year ended December 31, 2020, was assessed and beneficial interest was concluded to not be collectible. The $15.7 million was written off and expensed in other income in the accompanying consolidated statements of operations for the nine months ended September&#160;30, 2021.&lt;/span&gt;</ameh:BeneficialInterestPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i0562f8e9b55a42e9a5ee44f0e186cecf_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTE5Mjg_eff2d53e-fff4-4fb5-9232-abff4ea8cdfb"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="i21d7bfcc34ee4134a98f32759980bac4_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTE5NjU_62d62d98-11c4-47c8-8dce-3a2e94248e48"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet
      contextRef="ice32049f82244ceebffb5a2a9e3d9448_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTIxODM_5b08e68a-bbf2-4de4-ab41-8c6aac3e292b"
      unitRef="usd">15700000</ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationCash
      contextRef="i21d7bfcc34ee4134a98f32759980bac4_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTI0OTU_2d4858c2-00b8-4721-afe2-848bcee97374"
      unitRef="usd">15600000</ameh:EquityMethodInvestmentSaleContingentConsiderationCash>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares
      contextRef="i21d7bfcc34ee4134a98f32759980bac4_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTI1NTE_78c94bb4-eaf1-450f-ac5f-d95db03e79bf"
      unitRef="usd">6400000</ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue
      contextRef="i21d7bfcc34ee4134a98f32759980bac4_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTI1ODU_ffe34273-50bf-4d8f-85b1-81162d4d02fa"
      unitRef="usd">22000000</ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue>
    <ameh:EquityMethodInvestmentWriteOffOfAdditionalProceeds
      contextRef="i9b6b078c674a40a6aa164bb3f282fc69_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTQyMDc_31a1a2f6-afa5-4f08-afbd-b620d1030f32"
      unitRef="usd">15700000</ameh:EquityMethodInvestmentWriteOffOfAdditionalProceeds>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV80OS9mcmFnOmMwOTVjMGE0N2E0MTQzNDliMzgzMjgxOGJjMGFmNjFmL3RleHRyZWdpb246YzA5NWMwYTQ3YTQxNDM0OWIzODMyODE4YmMwYWY2MWZfNTUzNjA_d4d48ca2-92ac-460b-aeed-6a4ad6027371">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2019, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASU 2019-12&#x201d;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTY1MQ_59e84fee-6e90-4b31-b17d-968dde10187f">Business Combinations and Goodwill&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;APCMG&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2021, the Company acquired an 80% equity interest (on a fully diluted basis) in APCMG for an aggregate purchase price of $2.0 million. As part of the transaction, the Company paid $1.0 million in cash and the remaining amount will be paid out in cash as a contingent consideration related to APCMG&#x2019;s financial performance for fiscal year 2022. The contingent consideration is met if gross revenue and EBITDA targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of September&#160;30, 2021, the contingent consideration is valued at $1.0 million and was included within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sun Labs&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2021, the Company acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Labs for an aggregate purchase price of $4.0 million. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the noncontrolling interest, the noncontrolling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of APCMG and Sun Labs have been included in the Company&#x2019;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying value of goodwill for the nine months ended September&#160;30, 2021 was as follows (in thousands);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i3fd12cfc45b244a5884bf4cd547e6583_I20210731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTA5OTUxMTYyOTYyNg_9f4d5568-1c08-45ae-9fdd-a48df7dc25dc"
      unitRef="number">0.80</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i8b9f56835a534891ad456a64d2c85f50_D20210731-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTA5OTUxMTYyOTcxOA_ef3e879d-434e-4c85-a0eb-0d9916393388"
      unitRef="usd">2000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i8b9f56835a534891ad456a64d2c85f50_D20210731-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTA5OTUxMTYyOTc5Mw_cb1c35f3-6c1e-4c36-bd49-f94f51cb6bbc"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if2f519bb3a21437e99c17cddc631e9cd_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTA5OTUxMTYzMDE1MA_eb04f530-cdcc-465c-b0d4-ae4ba991531f"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ib05af751a8be4d57b25abcbf5cb700aa_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTA5OTUxMTYzMDQ0MQ_c5102dd8-23a7-4e50-a011-e60c7c4afce4"
      unitRef="number">0.49</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i19c94975ba3e411ca4090953760b5a7f_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTA5OTUxMTYzMDU1Ng_e4c8ab89-1f4a-49e2-8c4b-9d5028fe4ba1"
      unitRef="usd">4000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase
      contextRef="i19c94975ba3e411ca4090953760b5a7f_D20210801-20210831"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMjc0ODc3OTA3NDUzNg_98622117-6023-4b55-aea5-71ef343a9726">P3Y</ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RleHRyZWdpb246ODY1MjA5ZTJiNDk4NGZhNGJmNzliN2RmOTc4MTA4ODBfMTY1MA_4060a40f-cf87-4b9a-91d5-21d4e3cbb421">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying value of goodwill for the nine months ended September&#160;30, 2021 was as follows (in thousands);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RhYmxlOjA3NzY2Njk4NmMyYzQ2NmM5ZTU5ZWIzNjM1NzZjNDg4L3RhYmxlcmFuZ2U6MDc3NjY2OTg2YzJjNDY2YzllNTllYjM2MzU3NmM0ODhfMC0xLTEtMS0w_2e6ce5ba-1a73-4e0b-b41a-aca29954dfd7"
      unitRef="usd">239053000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RhYmxlOjA3NzY2Njk4NmMyYzQ2NmM5ZTU5ZWIzNjM1NzZjNDg4L3RhYmxlcmFuZ2U6MDc3NjY2OTg2YzJjNDY2YzllNTllYjM2MzU3NmM0ODhfMS0xLTEtMS0w_dc2a8a8b-1dd8-4f4a-8b56-0834f6a3cfbe"
      unitRef="usd">4300000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81NS9mcmFnOjg2NTIwOWUyYjQ5ODRmYTRiZjc5YjdkZjk3ODEwODgwL3RhYmxlOjA3NzY2Njk4NmMyYzQ2NmM5ZTU5ZWIzNjM1NzZjNDg4L3RhYmxlcmFuZ2U6MDc3NjY2OTg2YzJjNDY2YzllNTllYjM2MzU3NmM0ODhfMi0xLTEtMS0w_4dd006f7-536d-45aa-a1cc-27cf68e1c678"
      unitRef="usd">243353000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfNTY3_3788ba4d-db78-4655-96d4-3fc1db913c1f">Intangible Assets, Net&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2021, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in depreciation and amortization on the accompanying consolidated statements of operations is amortization expense of $4.1 million and $4.0 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $11.6 million and $12.3&#160;million for the nine months ended September&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the nine months ended September 30, 2021) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfNTY5_1b5fa750-97d5-4a42-9f3c-b51707520387">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2021, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0eb4d763aad449e6ba7233c66eeda68e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfMi0zLTEtMS0w_26594d31-8ba7-46f1-901c-a908010008bf"
      unitRef="usd">996000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0eb4d763aad449e6ba7233c66eeda68e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfMi03LTEtMS0w_7566a39a-0f37-479e-8b3d-2de671f31254"
      unitRef="usd">996000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie718d9e05afa4852974391111b7c6f7e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNC0xLTEtMS0wL3RleHRyZWdpb246OGRkMDg4YWEzMzNmNGZmMTg2Yzk4NThiMjIzNTk2YjdfNA_d04fa427-7a41-460e-b3e0-3e421ce3c029">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0729f4ab87204534b3bd91b2c0c0e422_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNC0xLTEtMS0wL3RleHRyZWdpb246OGRkMDg4YWEzMzNmNGZmMTg2Yzk4NThiMjIzNTk2YjdfNw_661f4400-dbc6-41cb-a3d4-006deeab7a83">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i21297fd10ec8466daced044c5770ee1d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNC0zLTEtMS0w_28cf1f79-b92d-4282-b27d-a207744afefe"
      unitRef="usd">148845000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i21297fd10ec8466daced044c5770ee1d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNC01LTEtMS0w_6d95e00e-4541-44bf-95ee-739d0ba70888"
      unitRef="usd">82117000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i21297fd10ec8466daced044c5770ee1d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNC03LTEtMS0w_9429f1f3-2fde-4b5c-b3a2-a5d638b9bc66"
      unitRef="usd">66728000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i258ab2530cfc4417af6150ea2e0d1136_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNS0xLTEtMS0w_bf3b28cf-4769-4c6f-85cc-7742738ffd7e">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaf5628bdf9de416db3d14683e1f47a46_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNS0zLTEtMS0w_f5a07bfa-be77-45fa-ab36-24c71b0b8e24"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaf5628bdf9de416db3d14683e1f47a46_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNS01LTEtMS0w_1ff8a865-a5d5-44c4-a87f-e4e83ca752ac"
      unitRef="usd">13128000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaf5628bdf9de416db3d14683e1f47a46_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNS03LTEtMS0w_a329e1cb-8148-4954-b37e-37e72d90a833"
      unitRef="usd">9704000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i965b06b4b9744451a2780f3ce1c77fd5_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNi0xLTEtMS0w_9bc8f5eb-7cf7-462b-adec-b5d3613521a2">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i20486305e94249099f57db0ff59aba4a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNi0zLTEtMS0w_4012c388-17dc-4bb9-ad31-41e828967ced"
      unitRef="usd">8997000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i20486305e94249099f57db0ff59aba4a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNi01LTEtMS0w_b5cf7e65-248f-4be5-9c9b-43db12fe8a14"
      unitRef="usd">4129000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i20486305e94249099f57db0ff59aba4a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNi03LTEtMS0w_4cf043f5-150a-4b26-a5ef-66070b767f6c"
      unitRef="usd">4868000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idb13766dc4564b8b90da9a7ada8b71bd_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNy0xLTEtMS0w_8b744f82-9c9a-45df-9927-a5f4a09427c8">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie268449f84654877bacfa7e9d37cdcb0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNy0zLTEtMS0w_a5c3b37d-1971-47b8-b2c2-deb230b5fcb5"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie268449f84654877bacfa7e9d37cdcb0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNy01LTEtMS0w_4ceb5c65-4d33-4e64-bf0d-7846f57aecba"
      unitRef="usd">1579000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie268449f84654877bacfa7e9d37cdcb0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfNy03LTEtMS0w_e1121c7c-1aaf-4851-a5ae-b7b20f534a37"
      unitRef="usd">481000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i65c4c64100f14c0db098cf18e87b2987_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOC0xLTEtMS0w_fd3aaaf4-6c1e-4089-afb7-c2385fa5356e">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i117531eab6d74fa78cdef19fcd2f5e2a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOC0zLTEtMS0w_0f1148c3-d223-414d-a554-ab3c21875093"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i117531eab6d74fa78cdef19fcd2f5e2a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOC01LTEtMS0w_52d21a3c-05ce-4031-a68b-82b79d2308b1"
      unitRef="usd">194000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i117531eab6d74fa78cdef19fcd2f5e2a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOC03LTEtMS0w_0c1fe8ff-6b91-4e5d-90e7-27576ed2a62a"
      unitRef="usd">817000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOS0zLTEtMS0w_fe7348b1-825f-4a0a-a359-a8813e0f63d5"
      unitRef="usd">184741000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOS01LTEtMS0w_81e85d44-79bd-4bfb-bda5-c75deab03db6"
      unitRef="usd">101147000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjk4Y2RiZTVhZjAyNDRkMWJiNDUyYzcyNTJkNzYwN2NhL3RhYmxlcmFuZ2U6OThjZGJlNWFmMDI0NGQxYmI0NTJjNzI1MmQ3NjA3Y2FfOS03LTEtMS0w_dc6fe2b5-e178-4eda-8f02-593cfa92ba87"
      unitRef="usd">83594000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i980c42c6c84b4875af45b55389e6bcdf_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMi0xLTEtMS0wL3RleHRyZWdpb246MjE5MmQyNjExZWUzNDRhMzhmNjZiZDZlYTdhMmZhN2VfNA_d919fbae-0096-493d-bef3-8026ac736c20">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i06bc5673bf1142388330261e2bb554f1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMi0xLTEtMS0wL3RleHRyZWdpb246MjE5MmQyNjExZWUzNDRhMzhmNjZiZDZlYTdhMmZhN2VfNw_b9b62089-7ecd-4b22-ae24-4cf437021c3c">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8968b1047aac4f2ba3f6833da3d4ede6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMi0zLTEtMS0w_065f7274-a510-4552-a400-09b5250513d9"
      unitRef="usd">143930000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8968b1047aac4f2ba3f6833da3d4ede6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMi01LTEtMS0w_2915545b-5d70-4a06-a43a-e157d3168db2"
      unitRef="usd">73169000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8968b1047aac4f2ba3f6833da3d4ede6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMi03LTEtMS0w_1129691e-31ec-4ad3-8cbe-b6019f4f5751"
      unitRef="usd">70761000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i41ded44352b54f19813c1b6eb4a76ed5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMy0xLTEtMS0w_f7960cf6-0c34-4777-84d7-b78a6ca0bc98">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7c9513c56b334510bf4095f6f01b6e47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMy0zLTEtMS0w_75c164ce-5de7-438c-bb3b-74a071290aeb"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7c9513c56b334510bf4095f6f01b6e47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMy01LTEtMS0w_803cc659-69d2-4daa-b3e3-12e6f504c06a"
      unitRef="usd">11715000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7c9513c56b334510bf4095f6f01b6e47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfMy03LTEtMS0w_b43723f7-533b-4cb3-9dcc-8a7cb6302d06"
      unitRef="usd">11117000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9ec7d6bab59945aaa45f7785f214840f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNC0xLTEtMS0w_2260b0e7-d009-44f8-aad4-883558948df1">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic6e0d4064a11471ead457d43030a135a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNC0zLTEtMS0w_14d84afb-4e5c-480e-8ad7-88924dbfdcd2"
      unitRef="usd">6696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic6e0d4064a11471ead457d43030a135a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNC01LTEtMS0w_f3765687-a3ab-417a-a8af-1421c4574405"
      unitRef="usd">3234000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic6e0d4064a11471ead457d43030a135a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNC03LTEtMS0w_0ba301af-ad84-43ad-bc35-7886c3c3ef72"
      unitRef="usd">3462000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iecf50be563d54838a275677850c705da_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNS0xLTEtMS0w_fcc43926-4f7f-45c4-956c-56bcaa5cad9f">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id75bf881994b43a087370158fad07e52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNS0zLTEtMS0w_9567a52c-18d9-4c65-8379-7db1c42ea0c1"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id75bf881994b43a087370158fad07e52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNS01LTEtMS0w_9e528151-0b43-4e40-9906-7e274cc5cfce"
      unitRef="usd">1270000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id75bf881994b43a087370158fad07e52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNS03LTEtMS0w_d27967de-0b97-4805-ab59-85a7aed2e890"
      unitRef="usd">790000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icf4edcccc8394a23a7b3dcb738b03e7c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNi0xLTEtMS0w_cbaca48a-ecfa-458e-90bf-5994f5c69a81">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icd1fbae30d564421bc5b7c93a54aea3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNi0zLTEtMS0w_4d688482-92b8-4b27-8f11-7730ee735165"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icd1fbae30d564421bc5b7c93a54aea3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNi01LTEtMS0w_f794e59c-8377-4bd4-9c85-580729d37fc2"
      unitRef="usd">156000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icd1fbae30d564421bc5b7c93a54aea3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNi03LTEtMS0w_1be6ba81-407c-430f-aeb2-41a348f6686b"
      unitRef="usd">855000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNy0zLTEtMS0w_3cd147a8-c2ef-4f29-b9d1-8f3fb4a739f9"
      unitRef="usd">176529000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNy01LTEtMS0w_24a11046-8406-4542-9c9e-4e5bdb605b0a"
      unitRef="usd">89544000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjdkZDM1MjM1OTg4NjQ5MDA5NmE3NTE4ZmQ3NTJmMzg1L3RhYmxlcmFuZ2U6N2RkMzUyMzU5ODg2NDkwMDk2YTc1MThmZDc1MmYzODVfNy03LTEtMS0w_2c303298-f91f-4866-9f75-acc4deef192b"
      unitRef="usd">86985000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfMzM2_717a3175-9acb-465f-9c49-4e1d729ca222"
      unitRef="usd">4100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfMzQz_8aa59b00-b0f6-4ff7-9362-c1d5c9f13315"
      unitRef="usd">4000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfMzk5_03ec68fb-c6a2-4e0f-9753-43a813cdf752"
      unitRef="usd">11600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfNDA2_fc58337c-bc2f-4fca-8463-f7838f078214"
      unitRef="usd">12300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RleHRyZWdpb246MWFkNWE4OTZlNTAwNGJiOGFkMGE1YjNlZGUwM2RlNjZfNTcy_7d3a8fd9-526d-4ec8-b24e-7d1488dce80c">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the nine months ended September 30, 2021) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfMi0xLTEtMS0w_02102ce8-fcac-4c7e-903c-e20ebc384188"
      unitRef="usd">4007000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfMy0xLTEtMS0w_952759f9-b984-4a8b-8032-ff39ca6fb4b2"
      unitRef="usd">13962000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfNC0xLTEtMS0w_d7809c4e-493e-4829-a6b7-97890c3c2f55"
      unitRef="usd">11767000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfNS0xLTEtMS0w_f1326a21-3070-4259-9d31-eb0dfb79c162"
      unitRef="usd">10584000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfNi0xLTEtMS0w_f5ea5c6f-b874-4f66-9d6f-f647bfded101"
      unitRef="usd">9370000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfNy0xLTEtMS0w_080ceae2-67ec-48c7-b4cd-a423e875f2e9"
      unitRef="usd">32908000</ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV81OC9mcmFnOjFhZDVhODk2ZTUwMDRiYjhhZDBhNWIzZWRlMDNkZTY2L3RhYmxlOjRmOTY0MDQ3MTkzYjRmZDQ5ZTcwNTg5MGJhYWVhNzY1L3RhYmxlcmFuZ2U6NGY5NjQwNDcxOTNiNGZkNDllNzA1ODkwYmFhZWE3NjVfOS0xLTEtMS0w_e5322dbc-1b27-4021-9b7f-9bd4cc12ebc6"
      unitRef="usd">82598000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ameh:EquityMethodAndOtherEquityInvestmentsTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODkwOA_be2d51f7-3b92-4fc9-b35c-28706f847a35">Investments in Other Entities &#x2014; Equity Method&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Rollforward of Equity Method Investment (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.044%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Initial Investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Entity Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;One MSO, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tag-6 Medical Investment Group, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tag-8 Medical Investment Group, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;LaSalle Medical Associates &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care to patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino, and Tulare Counties through its network of approximately 2,400 independently contracted primary care physicians and specialist providers. LMA&#x2019;s patients are primarily served by Medi-Cal, but are also served by Blue Cross, Blue Shield, Molina, Health Net, and Inland Empire Health Plan. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA&#x2019;s IPA line of business. In December 2020, the Company exercised its option to convert the promissory note totaling $6.4&#160;million due from Dr. Arteaga into an additional 21.25% interest in LMA&#x2019;s IPA line of business. As a result, APC-LSMA&#x2019;s interest in LMA&#x2019;s IPA line of business increased to 46.25%. In September 2021, APC-LSMA sold 21.25% of its interest in LMA back to Dr. Arteaga for $6.4 million, which resulted in  APC-LSMA owning a 25% interest in LMA as of September&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#x2019;s operations. For the three months ended September&#160;30, 2021 and 2020, APC recognized a loss from this investment of $0.3 million and income of $0.5 million, respectively, in the accompanying consolidated statements of operations. For the nine months ended September&#160;30, 2021 and September&#160;30, 2020, APC recognized a loss from this investment of $4.7 million and income of $28,000, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $4.2 million and $13.0 million at September&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA&#x2019;s summarized balance sheets at September&#160;30, 2021 and December&#160;31, 2020, and summarized statements of operations for the nine months ended September&#160;30, 2021 and 2020, with respect to its IPA line of business are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net (loss) income &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Pacific Medical Imaging and Oncology Center, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography at its facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership interest in PMIOC.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $0.7 million and $0.5 million, for the three months ended September&#160;30, 2021 and 2020, respectively, and fees of approximately $1.7 million and $1.5 million for the nine months ended September&#160;30, 2021 and 2020, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#x2019;s operations. For the three months ended September&#160;30, 2021 and 2020, APC recognized a gain from this investment of approximately $0.2 million and a loss from this investment of $52,000, respectively, in the accompanying consolidated statements of operations. For the nine months ended September&#160;30, 2021 and 2020, APC recognized income of $0.1 million and $25,000, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets had investment balances of $1.5 million and $1.4 million at September&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2016, David C.P. Chen M.D., individually, and APC-LSMA entered into a share purchase agreement whereby APC-LSMA acquired a 40% ownership interest in DMG. APC accounted for its investment in DMG under the equity method of accounting as APC had the ability to exercise significant influence, but not control over DMG&#x2019;s operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September&#160;30, 2021 and 2020, APC recognized income from this investment of $0.1&#160;million and $0.1 million, respectively, in the consolidated statements of operations. For the nine months ended September&#160;30, 2021 and 2020, APC recognized income from this investment of $0.3 million and $19,000, respectively, in the consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $2.9 million and $2.6 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;531 W. College LLC &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, College Street Investment LP, a California limited partnership (&#x201c;CSI&#x201d;), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC, and the conduct of its business, and to specify their relative rights and obligations. CSI, APC, and NMM, each owned 50%, 25%, and 25%, respectively, of member units based on initial capital contributions of $16.7 million, $8.3 million, and $8.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $33.3 million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#x2019;s 25% membership interest in 531 W. College, LLC for approximately $8.3 million. Subsequently, APC has a 50% ownership in 531 W. College LLC with a total investment balance of approximately $16.1&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended September&#160;30, 2021 and 2020, APC recognized a loss from this investment of $34,000 and $0.1 million, respectively, in the accompanying consolidated statements of operations. For the nine months ended September&#160;30, 2021 and 2020, APC recorded a loss from this investment of $0.1 million and $0.4 million in the accompanying consolidated statements of operations, respectively. The accompanying consolidated balance sheets include the related investment balances of $17.1 million and $17.2 million at September&#160;30, 2021 and December&#160;31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;531 W. College LLC&#x2019;s balance sheets at September&#160;30, 2021 and December&#160;31, 2020, and statements of operations for the nine months ended September&#160;30, 2021 and 2020, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Members&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and members&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;br/&gt;One MSO, LLC &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 50% membership interest in One MSO LLC (&#x201c;One MSO&#x201d;) for $2.4 million. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. For the three months ended September&#160;30, 2021, One MSO recognized income of $0.1 million in the accompanying consolidated statements of operations. For the nine months ended September&#160;30, 2021, One MSO recognized income of $0.4&#160;million in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $2.8 million and $2.4 million at September&#160;30, 2021 and December&#160;31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tag-6 Medical Investment Group, LLC and Tag-8 Medical Investment Group, LLC &#x2014; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 50% membership interest in Tag 6 for $4.5 million and a 50% membership interest in Tag 8 for $2.1 million. The Company reevaluated Tag 8 as a VIE since APC is a guarantor on the loan agreement between Tag 8 and MUFG Union Bank N.A. Based on the reevaluation, Tag 8 is a VIE and is consolidated by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tag 6 shares common ownership with certain board members of APC and as such is considered a related party. For the three and nine months ended September&#160;30, 2021, Tag 6 recognized income of $45,000 and $0.2 million, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the Tag 6 investment of $4.8 million and $4.5&#160;million at September&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, ApolloMed purchased 30% interests in CAIPA MSO, LLC for $11.7 million. CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d/b/a Coalition of Asian-American IPA (&#x201c;CAIPA&#x201d;), a leading independent practice association serving the greater New York City area. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO&#x2019;s operations. For the three and nine months ended September&#160;30, 2021, ApolloMed recognized income from investment of $45,000, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $11.8 million as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in privately held entities that do not report net asset value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MediPortal, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. A five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AchievaMed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, NMM and AchievaMed, Inc., a California corporation (&#x201c;AchievaMed&#x201d;), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in investments in privately held entities in the accompanying consolidated balance sheets as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;</ameh:EquityMethodAndOtherEquityInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODkwOQ_1604da8f-4a89-433d-a8c7-b0854f1c7150">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Rollforward of Equity Method Investment (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.044%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Initial Investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Entity Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;One MSO, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tag-6 Medical Investment Group, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tag-8 Medical Investment Group, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA&#x2019;s summarized balance sheets at September&#160;30, 2021 and December&#160;31, 2020, and summarized statements of operations for the nine months ended September&#160;30, 2021 and 2020, with respect to its IPA line of business are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net (loss) income &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;531 W. College LLC&#x2019;s balance sheets at September&#160;30, 2021 and December&#160;31, 2020, and statements of operations for the nine months ended September&#160;30, 2021 and 2020, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Members&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and members&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="iaa0d66e6f0814c7992ad674327d5d79b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS0xLTEtMS0w_bede7a90-c6c0-47f8-be0a-7d2515f3518c"
      unitRef="usd">13047000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentAdditionalInvestment
      contextRef="i7f00bc9258974017a3430fe975bf7f46_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS0zLTEtMS0w_35dab747-04af-4730-900f-76dad2185245"
      unitRef="usd">0</ameh:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7f00bc9258974017a3430fe975bf7f46_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS01LTEtMS0w_7ed677a9-28b2-4818-959a-c21a589c820d"
      unitRef="usd">-4654000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i7f00bc9258974017a3430fe975bf7f46_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS03LTEtMS0w_83835cb4-3fdf-4cda-861c-5710580287e7"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i7f00bc9258974017a3430fe975bf7f46_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS05LTEtMS0w_c90c8404-288e-48f6-80ff-3b26f6214f10"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i7f00bc9258974017a3430fe975bf7f46_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS0xMC0xLTEtMA_394231aa-cc8c-421f-93cd-0924abc2f10e"
      unitRef="usd">4182000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i94b2c1e346e440078f5bd9c18d1ae3d8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMS0xMi0xLTEtMA_8dde0424-a7b1-44ea-8cbc-78fbc86c0616"
      unitRef="usd">4211000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i0d934d0b4eae4422b768334c3e49324a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi0xLTEtMS0w_7e0dc5f4-2812-4bab-989b-a0f4a68fa869"
      unitRef="usd">1413000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentAdditionalInvestment
      contextRef="i28218e6fa6044467a6cfa3dd3680f60c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi0zLTEtMS0w_9913b7f5-4417-4257-b2e1-ce0bd2eaabe6"
      unitRef="usd">0</ameh:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i28218e6fa6044467a6cfa3dd3680f60c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi01LTEtMS0w_2b31b247-5ed7-403e-8987-b7157f80ddae"
      unitRef="usd">129000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i28218e6fa6044467a6cfa3dd3680f60c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi03LTEtMS0w_29ac1512-7365-4984-b640-6748d23ec12d"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i28218e6fa6044467a6cfa3dd3680f60c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi05LTEtMS0w_0a072b42-7012-4c49-b805-4c375568e0e6"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i28218e6fa6044467a6cfa3dd3680f60c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi0xMC0xLTEtMA_b1b11456-236c-4995-8ace-1324634c9780"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i455c75e2b784434dac67f0841a1568b6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMi0xMi0xLTEtMA_0e65e9ab-b30c-4108-8187-31db0bfefec2"
      unitRef="usd">1542000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ic4a0882d520246b09a88c6bc55fb835d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy0xLTEtMS0w_ed33f4f6-3230-462d-a1fa-a924f0e14954"
      unitRef="usd">2613000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentAdditionalInvestment
      contextRef="i45b25d8b3c75481bbe6f42f9cd219cba_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy0zLTEtMS0w_82295276-0c7c-416b-917c-2d4e18a30b5d"
      unitRef="usd">0</ameh:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i45b25d8b3c75481bbe6f42f9cd219cba_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy01LTEtMS0w_5d83c491-e788-48f4-aeb6-9530355dbec5"
      unitRef="usd">330000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i45b25d8b3c75481bbe6f42f9cd219cba_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy03LTEtMS0w_2a70b621-155f-4428-ac17-a030895bfc56"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i45b25d8b3c75481bbe6f42f9cd219cba_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy05LTEtMS0w_51cee8ca-28ce-49f2-969c-d604d92472a7"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i45b25d8b3c75481bbe6f42f9cd219cba_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy0xMC0xLTEtMA_cd54dd1c-0091-424d-923e-130ac6423595"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="if9681bc92d994054a7f881aaf0a4c1b0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfMy0xMi0xLTEtMA_21ba091c-fed1-4ca9-b67a-35b30a2ce190"
      unitRef="usd">2943000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i000196b3d5424523869f9b8cf182627c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC0xLTEtMS0w_2d3f5549-2ead-44bd-930c-98a347ccedc4"
      unitRef="usd">17200000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentAdditionalInvestment
      contextRef="i14b36f750c6e4bbbaa5984ab14f7acf6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC0zLTEtMS0w_4fbbd4c5-3f20-48f2-b5d4-312ceb464431"
      unitRef="usd">0</ameh:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i14b36f750c6e4bbbaa5984ab14f7acf6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC01LTEtMS0w_5d7cba0e-e0d5-474b-aa64-ed0da6429b3c"
      unitRef="usd">-149000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i14b36f750c6e4bbbaa5984ab14f7acf6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC03LTEtMS0w_367ff26b-b262-441f-9d85-e6b16540414c"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i14b36f750c6e4bbbaa5984ab14f7acf6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC05LTEtMS0w_b9ea9266-d542-4ad8-a1ad-e594e15aea7a"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i14b36f750c6e4bbbaa5984ab14f7acf6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC0xMC0xLTEtMA_49a8df53-9344-4f05-b654-3ea40c10da15"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="id4e845cd0750449ea326e81a9883e61b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNC0xMi0xLTEtMA_322a5b30-d7ea-46b5-847f-c85ba54c46cf"
      unitRef="usd">17051000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i8bb296bd3d2a499caa7ee8b26bf24153_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS0xLTEtMS0w_b13713e4-3f1e-409a-aab1-d317d9cb87c6"
      unitRef="usd">2395000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentAdditionalInvestment
      contextRef="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS0zLTEtMS0w_c4b89532-a4e8-43be-b036-bbddb6e7df59"
      unitRef="usd">0</ameh:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS01LTEtMS0w_6ced9a6c-ac63-41c2-a4e8-ae25194a34a6"
      unitRef="usd">379000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS03LTEtMS0w_a25554d5-6367-4f50-8fe1-bada3b98141c"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS05LTEtMS0w_8fb84206-dea8-466f-a0eb-143cbccfaac2"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS0xMC0xLTEtMA_ac24b0ef-8be6-4d56-9d57-eee0cdb9a2da"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i5ea5bb0ee621461d878a0145d57a8e9d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNS0xMi0xLTEtMA_a79802eb-c390-4872-8c41-068f0837a4cf"
      unitRef="usd">2774000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2b2b4206481d4c5a820281a781ad27e3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi0xLTEtMS0w_04466f8d-3dd9-4e6f-80b7-809ee6e409aa"
      unitRef="usd">4516000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentAdditionalInvestment
      contextRef="id7f162484d134b13ad2cb62e25a6050d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi0zLTEtMS0w_bbdec88b-7c1f-4c4d-bd42-6d035423d15b"
      unitRef="usd">0</ameh:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id7f162484d134b13ad2cb62e25a6050d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi01LTEtMS0w_0c176838-7158-493f-80d0-b22467aa2b1c"
      unitRef="usd">240000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="id7f162484d134b13ad2cb62e25a6050d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi03LTEtMS0w_7eaccacc-9c72-4292-8ce6-bec25269ed76"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="id7f162484d134b13ad2cb62e25a6050d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi05LTEtMS0w_d8f2c5fa-437a-4c20-b927-66abd72e1042"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="id7f162484d134b13ad2cb62e25a6050d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi0xMC0xLTEtMA_564d09c6-e8f0-4098-b19c-68e341954732"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i3514de26861c4453a347bd8a1fc4b612_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNi0xMi0xLTEtMA_95124066-80ca-49e2-8e28-6b5d0028315f"
      unitRef="usd">4756000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i902f565b388f41cb9be67571ecc22f37_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy0xLTEtMS0w_60b1f74c-22b7-4249-996a-b8d47f047f32"
      unitRef="usd">2108000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentAdditionalInvestment
      contextRef="ifb6128c207404236beafdaee21d920e7_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy0zLTEtMS0w_d786ca59-c38b-4f11-9df0-7d1f9091cf4f"
      unitRef="usd">0</ameh:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ifb6128c207404236beafdaee21d920e7_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy01LTEtMS0w_3651e8d4-d0e0-4c9a-a95e-f6b79679372b"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ifb6128c207404236beafdaee21d920e7_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy03LTEtMS0w_ab5697c6-c0ed-4982-bb1b-34a88e337dde"
      unitRef="usd">1660000</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="ifb6128c207404236beafdaee21d920e7_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy05LTEtMS0w_791bccd1-e21d-414a-899c-0bf1fe20945d"
      unitRef="usd">3768000</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="ifb6128c207404236beafdaee21d920e7_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy0xMC0xLTEtMA_7b6e033d-c668-48fa-a76b-c878b4c7738c"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i203bb1d43aac431a8bb988cd1f2ca55c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfNy0xMi0xLTEtMA_f7e21288-cdfe-47ad-8089-93e82bc17593"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i73ee31bc4e9a444e89365fdc6b10afa1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOS0xLTEtMS00Njc1_281619d2-5a3e-42f5-9c26-e027a13747ee"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentAdditionalInvestment
      contextRef="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC0zLTEtMS02NTI1_3541ed98-88eb-4196-88e1-b2d7e657f0de"
      unitRef="usd">11724000</ameh:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOS01LTEtMS00Njc1_180f3391-bbb5-4cdd-ba31-788a40f8b3c0"
      unitRef="usd">45000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOS03LTEtMS00Njc1_baf02a97-df79-4d0f-bc2b-a2c7630380ff"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOS05LTEtMS00Njc1_9837275c-21be-48dd-97a6-7730cf33d48f"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC0xMS0xLTEtMjQzMjc_b9401ef8-14e4-421b-be85-3381a569db41"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i9a8d0fe803e64bc1a1ed9278b52c95f9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOS0xMi0xLTEtNDY3NQ_8a76aa09-20de-4eb1-9dc8-bdc8e52e1447"
      unitRef="usd">11769000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC0xLTEtMS0w_26715326-064a-4e80-a148-be35d34e1fb6"
      unitRef="usd">43292000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentAdditionalInvestment
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC0zLTEtMS0w_0abb3f40-9244-4ab8-8984-23253dae6d8a"
      unitRef="usd">11724000</ameh:EquityMethodInvestmentAdditionalInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC01LTEtMS0w_976c8350-abc7-45ff-8c52-e59310ba028c"
      unitRef="usd">-3680000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC03LTEtMS0w_f043bfd2-5e2d-4487-ac45-3aca121a5c58"
      unitRef="usd">1660000</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC05LTEtMS0w_c255cd0e-5150-49f4-8192-e368210378b5"
      unitRef="usd">3768000</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC0xMC0xLTEtMA_5d858b28-21d1-4f2e-be2d-0e5025f20f05"
      unitRef="usd">4182000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjYwMzM3ZGFlOTg0NTQxODU4ZmMxNDM2MmYwMTZhMjYwL3RhYmxlcmFuZ2U6NjAzMzdkYWU5ODQ1NDE4NThmYzE0MzYyZjAxNmEyNjBfOC0xMi0xLTEtMA_4fc440c3-b932-4fd8-bbed-2511150abe05"
      unitRef="usd">45046000</us-gaap:EquityMethodInvestments>
    <ameh:NumberOfEmployees
      contextRef="i94b2c1e346e440078f5bd9c18d1ae3d8_I20210930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzk0_a8d3f6e3-f0dd-4010-8ff7-a45378e81896"
      unitRef="provider">2400</ameh:NumberOfEmployees>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="id898dfbac217454a95c7fd9549d95325_I20121231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzE1_2fc2287e-9041-4f1f-987d-12710de01116"
      unitRef="usd">5000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="id898dfbac217454a95c7fd9549d95325_I20121231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzI0_4cc248e6-a44f-4e33-91e9-9e6f2b48d292"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NotesReceivableNet
      contextRef="i3bd0e620dca545c990c5623c174f38f3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODYy_00b5282c-d753-46c0-b838-e7e28080290e"
      unitRef="usd">6400000</us-gaap:NotesReceivableNet>
    <ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease
      contextRef="i3bd0e620dca545c990c5623c174f38f3_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfOTA1_fbc62da3-adaa-4484-89e5-c9a0f0cf27e1"
      unitRef="number">0.2125</ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease>
    <ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion
      contextRef="i45abc06c771b489384112954fbdfcd19_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTAyNA_516b3be0-c245-40e3-94d3-940fff659e22"
      unitRef="number">0.4625</ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion>
    <ameh:EquityMethodInvestmentOwnershipPercentageSold
      contextRef="i85f82fabbbfe4571ab387179ddd7a738_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ2MDUxNg_f82aaac5-f5ac-44d0-a8c8-bf0e8818e8e4"
      unitRef="number">0.2125</ameh:EquityMethodInvestmentOwnershipPercentageSold>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i91c58bf26bff4f73b162bbd22f236e8d_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ2MDUyMA_fb004fad-3665-4d4c-9623-9c6128340a60"
      unitRef="usd">6400000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i80b8650ee33648d99a9a3444e64846f0_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ2MDUyOQ_61fd2ae2-9643-46ee-afd8-176a0b3d542c"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id5ef16887c064530aa3691f19b525d0d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTI2OQ_89fbb4c0-8c6b-463c-992d-2df562715bc6"
      unitRef="usd">-300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1b208272f13f4a57957a453690effbf0_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTI4Ng_cee8eddf-e009-4713-9642-21d73f5a25da"
      unitRef="usd">500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9cb8b922bdee480c9f9aea0eff1256c0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTQ0MA_b110a159-14c0-48b3-ba89-ca025ca6314d"
      unitRef="usd">-4700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i77427e343910426d8907e4dcf7f52bc0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTQ0OQ_f625eb64-ce4d-4c39-9ad2-7c975a1e1232"
      unitRef="usd">28000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i94b2c1e346e440078f5bd9c18d1ae3d8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTYxMA_c68b1a01-55aa-4836-8c1e-7d3be61ab7ee"
      unitRef="usd">4200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="iaa0d66e6f0814c7992ad674327d5d79b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTYxNw_1079b7e7-d0d8-4ad3-9c9d-7abe672524a6"
      unitRef="usd">13000000</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic5c127671e08453090839c66152b9457_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMy0xLTEtMS0w_4ca2e212-e536-410f-ae35-e023a9822e05"
      unitRef="usd">2150000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMy0zLTEtMS0w_4ab1116c-9840-4490-b624-c6ef09581471"
      unitRef="usd">9350000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="ic5c127671e08453090839c66152b9457_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNC0xLTEtMS0w_b15243f5-2d49-4496-806e-6a1eed4308a5"
      unitRef="usd">695000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNC0zLTEtMS0w_03cdfdfc-5752-4005-8607-d0b2304edd30"
      unitRef="usd">691000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic5c127671e08453090839c66152b9457_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNS0xLTEtMS0w_5c965c9e-b782-4996-917a-c91c042407af"
      unitRef="usd">6178000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNS0zLTEtMS0w_3980ccdf-3dc9-42f9-87b2-c30d6b70c9d5"
      unitRef="usd">3918000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ic5c127671e08453090839c66152b9457_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNi0xLTEtMS0w_9d65c1d7-45ff-4805-bb5c-d581b016faa9"
      unitRef="usd">0</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNi0zLTEtMS0w_949f5fd5-7898-4cce-873c-4c7908e8561f"
      unitRef="usd">881000</us-gaap:OtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="ic5c127671e08453090839c66152b9457_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNy0xLTEtMS0w_13abf2d0-1699-48b5-8ca8-2ee1c1445d9b"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfNy0zLTEtMS0w_d1c4d7cd-d79d-481f-8e32-4b867af237aa"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:Assets
      contextRef="ic5c127671e08453090839c66152b9457_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfOS0xLTEtMS0w_57b112ad-c775-462e-ac0a-0d78ea281c7f"
      unitRef="usd">11273000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfOS0zLTEtMS0w_d6da356b-aed2-4469-976b-6f3b611ab05f"
      unitRef="usd">17090000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic5c127671e08453090839c66152b9457_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMTItMS0xLTEtMA_7b4b2e79-8e9b-4d72-a2fa-a673dff5bc0a"
      unitRef="usd">27141000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMTItMy0xLTEtMA_57563283-82c7-43f8-a3ee-4cbc025e7823"
      unitRef="usd">21589000</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic5c127671e08453090839c66152b9457_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMTMtMS0xLTEtMA_1e080075-1c61-4888-9e26-4c0ff3ae25db"
      unitRef="usd">-15868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMTMtMy0xLTEtMA_1757cc4c-a562-410d-8891-3b668c50d21c"
      unitRef="usd">-4499000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic5c127671e08453090839c66152b9457_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMTUtMS0xLTEtMA_4698fdcd-1608-477e-93e5-848d9e1d3731"
      unitRef="usd">11273000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJiZDAzZjQwMDZhNjQ1NTNiZTlhYTQyOGMwMDVkMjNlL3RhYmxlcmFuZ2U6MmJkMDNmNDAwNmE2NDU1M2JlOWFhNDI4YzAwNWQyM2VfMTUtMy0xLTEtMA_544a8824-6aac-4573-ae0a-019b3c264b50"
      unitRef="usd">17090000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9acbaa81eaca438db99ca8e197a48492_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOmIxZDliNjc3MTZmZDQxYWY5YzdlNTIyOTg5ZDk4NDZkL3RhYmxlcmFuZ2U6YjFkOWI2NzcxNmZkNDFhZjljN2U1MjI5ODlkOTg0NmRfMy0xLTEtMS0w_cee24fc5-eb3b-4c6e-a9f8-f0517ddba4d2"
      unitRef="usd">144417000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8396566a02bc4bda8fe4bcb4acc37087_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOmIxZDliNjc3MTZmZDQxYWY5YzdlNTIyOTg5ZDk4NDZkL3RhYmxlcmFuZ2U6YjFkOWI2NzcxNmZkNDFhZjljN2U1MjI5ODlkOTg0NmRfMy0zLTEtMS0w_1fe6bf43-3b1c-4021-a7ec-cc8e36e10e20"
      unitRef="usd">138490000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i9acbaa81eaca438db99ca8e197a48492_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOmIxZDliNjc3MTZmZDQxYWY5YzdlNTIyOTg5ZDk4NDZkL3RhYmxlcmFuZ2U6YjFkOWI2NzcxNmZkNDFhZjljN2U1MjI5ODlkOTg0NmRfNC0xLTEtMS0w_dc3652fb-8359-449b-bc8b-99294a02cf64"
      unitRef="usd">155786000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8396566a02bc4bda8fe4bcb4acc37087_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOmIxZDliNjc3MTZmZDQxYWY5YzdlNTIyOTg5ZDk4NDZkL3RhYmxlcmFuZ2U6YjFkOWI2NzcxNmZkNDFhZjljN2U1MjI5ODlkOTg0NmRfNC0zLTEtMS0w_ecbff1dd-e26b-492d-9d68-3e0752492ea0"
      unitRef="usd">138233000</us-gaap:CostsAndExpenses>
    <us-gaap:ProfitLoss
      contextRef="i9acbaa81eaca438db99ca8e197a48492_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOmIxZDliNjc3MTZmZDQxYWY5YzdlNTIyOTg5ZDk4NDZkL3RhYmxlcmFuZ2U6YjFkOWI2NzcxNmZkNDFhZjljN2U1MjI5ODlkOTg0NmRfNi0xLTEtMS0w_d7a4ffb0-9c81-426a-8472-665fd2db054e"
      unitRef="usd">-11369000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8396566a02bc4bda8fe4bcb4acc37087_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOmIxZDliNjc3MTZmZDQxYWY5YzdlNTIyOTg5ZDk4NDZkL3RhYmxlcmFuZ2U6YjFkOWI2NzcxNmZkNDFhZjljN2U1MjI5ODlkOTg0NmRfNi0zLTEtMS0w_775f31f2-6c53-4c72-8154-87d25aabc2f3"
      unitRef="usd">257000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="iea5b5005ea214626b46b60892e1c296f_I20150731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMjM0Nw_98627dcf-0e5c-465f-954f-f3f2b4ed0b6f"
      unitRef="usd">1200000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iea5b5005ea214626b46b60892e1c296f_I20150731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMjM1Ng_f9789901-89eb-4715-b376-2e9b6ed724fc"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsForFees
      contextRef="icc81f74f6ea84843a75b19e6188f7d59_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMjYxMw_e75c41f7-a2bb-4392-9abc-37901d2f6d23"
      unitRef="usd">700000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="ia021d902c6194cd1b515f6e5d2851f67_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMjYyMA_61989ee6-b6b9-40a7-aeba-7b46859b6790"
      unitRef="usd">500000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="if44758b50abb4b998c0cf1ed2f59be70_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMjY5OQ_7500cd2d-f4be-47ad-b687-23d6716d1706"
      unitRef="usd">1700000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="i0cffd986457e4a40859857d465e80d31_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMjcwNg_e238b771-96cb-4633-883e-b68a5ec53197"
      unitRef="usd">1500000</us-gaap:PaymentsForFees>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i18eaba1b00ed42dfb2a3be9037829586_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzAzMQ_e39b2e91-535c-482a-8f42-2f508acec15c"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id76dbd62385a4c2b89c6cc4a159139e7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzAzOA_d8d44a49-4f04-4210-a4a9-66de19813919"
      unitRef="usd">-52000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iad6d8a1fd79d4409ba2643b463115e12_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzE3MQ_ede35590-61b8-4d5d-8f5f-47516f834fd9"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iee6c2515c3594dd08fa54babfc3d2655_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzE4OA_0a115b96-f004-4ec4-9abb-1ea8fda992ab"
      unitRef="usd">25000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i74678b3019584b26a57edb839bf1d877_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzMzMw_2cbb2175-8d94-4739-bcb4-5197a9336df7"
      unitRef="usd">1500000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ib0352070af4d49b7b10b093cf1d34b6b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzM0MA_2115d6dc-4db8-4394-836e-39280ef97e85"
      unitRef="usd">1400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="if581017651f14f9681014c41a5d3ced8_I20160531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzUyNg_2835a3cb-0af6-4299-a8cd-59a21a832fb9"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ica129d7dca744715affd24c98e9c389e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ1ODgzMw_35061b90-633c-4d31-9ba6-05389c6a37b5"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i79b6369351c24a7caab010e07fef7ddc_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ1ODg0MQ_eda5cad5-c020-454e-8fb8-58475bcdf6d9"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic39714cbfb75465e896a533af99abbae_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ1ODk4MQ_9b4ac041-0731-4e62-b0ac-55470194f131"
      unitRef="usd">300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if78fa0d638d24b928edf2207da5c5965_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ1ODk4OQ_d8e04215-f13e-4759-b32d-e26a8676c610"
      unitRef="usd">19000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if9681bc92d994054a7f881aaf0a4c1b0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ1OTEzOA_1e73d1d0-b5a8-42e7-945e-26ccba1f5477"
      unitRef="usd">2900000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ic4a0882d520246b09a88c6bc55fb835d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTY0OTI2NzQ1OTE0Ng_f5685c78-8a3d-4bbf-a4b6-0b4c5f7ee887"
      unitRef="usd">2600000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i649b46d7c3d54c2e8ddb0eb3f0f6cb20_I20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDUxOA_d6d2453d-3300-4837-9965-f0549ddf70f2"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic5f4c57435414bcf8530f7c1b7159a3a_I20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDUyMg_cb9985a4-79ff-488d-86c4-64d331806594"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="id1280e975bb74d6793bb6decce02bb42_I20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDUzMA_b5504cc0-1b35-4fbf-836a-9866e145ad91"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MembersCapital
      contextRef="i649b46d7c3d54c2e8ddb0eb3f0f6cb20_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDYwNg_a8cc992a-6136-4b96-bd45-20b5ccb6db11"
      unitRef="usd">16700000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="ic5f4c57435414bcf8530f7c1b7159a3a_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDYxMA_a23b2ea8-230b-43b2-9a8c-cf4da9674688"
      unitRef="usd">8300000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="id1280e975bb74d6793bb6decce02bb42_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDYxOA_09e2fc85-482f-454b-a1c4-ba291bc960f2"
      unitRef="usd">8300000</us-gaap:MembersCapital>
    <us-gaap:PaymentsToAcquireRealEstate
      contextRef="id3dca6af71454e249bc71f841ff3c773_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDg3Mw_21d53092-2bd6-42c2-841d-3421060a1ba7"
      unitRef="usd">33300000</us-gaap:PaymentsToAcquireRealEstate>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9bc00772371f43338e0a4894146965ab_I20190423"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNDk3Nw_a8ffc15f-fa14-42b8-afe1-51f21ff2c129"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i9bc00772371f43338e0a4894146965ab_I20190423"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTA0MQ_d542d3e7-fa15-42a6-82a8-3cf3859346cf"
      unitRef="usd">8300000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i6db22be029534d1ca263dccd767fc1fc_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTA2OQ_3c2bb8ff-3cdc-49cf-ab32-d36afcb2d6b9"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i567fe9f349ad4cd38b7073fc838b36af_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTE1Mw_ff0b7a46-c165-41b6-b8e3-57191ba42ddc"
      unitRef="usd">16100000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib8c0ead5cd26416784c4b0aae0965159_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTQ0OQ_64403987-e318-4728-92bc-ec7edf09b273"
      unitRef="usd">-34000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4c9277df25244861a1723845d457f7c1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTQ1Ng_0fe7e3d2-415f-44cc-895b-19109c763fb4"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id8f2830655ce425ba50defa19207191c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTYwOA_87415aff-7c02-485a-b3e7-39adb84b0650"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia48e961c12c64515bfac403310620fa8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTYxNQ_3be21da4-0135-435a-9203-65f1284ec6c1"
      unitRef="usd">-400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="id4e845cd0750449ea326e81a9883e61b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTc3NQ_2985217c-4449-469d-b659-d5afefa0e6e8"
      unitRef="usd">17100000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i000196b3d5424523869f9b8cf182627c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNTc4Mg_3d954085-66d4-49eb-a1c5-b17b9f35fd70"
      unitRef="usd">17200000</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMy0xLTEtMS0w_970dae51-4483-42d0-9e2c-40b611a67234"
      unitRef="usd">266000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMy0zLTEtMS0w_a2c0734d-5444-411a-a30a-10102519b321"
      unitRef="usd">648000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfNC0xLTEtMS0w_81bab23e-2139-41ee-ae0c-32282499f247"
      unitRef="usd">25000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfNC0zLTEtMS0w_949c5d96-a3e7-485e-8110-7cf3bfc04856"
      unitRef="usd">17000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssets
      contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfNS0xLTEtMS0w_62d2ec70-82e4-4652-b7ce-5bb03f32c40b"
      unitRef="usd">122000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfNS0zLTEtMS0w_220374fa-c52c-4197-b0cc-86d08a43879d"
      unitRef="usd">70000</us-gaap:OtherAssets>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfNi0xLTEtMS0w_d57ad476-8494-4190-94cf-6c026e5f3c6c"
      unitRef="usd">33689000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfNi0zLTEtMS0w_2b1fabcd-311b-4487-b094-2728595d6fa4"
      unitRef="usd">33697000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Assets
      contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfOC0xLTEtMS0w_9dfef9b8-05a5-419b-8fe6-786ea0a8ed05"
      unitRef="usd">34102000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfOC0zLTEtMS0w_43b36e27-311d-402d-a531-09832a232854"
      unitRef="usd">34432000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMTItMS0xLTEtMA_75ad5d1d-9287-4fc8-9960-e39e2c6df29c"
      unitRef="usd">0</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMTItMy0xLTEtMA_2ee62ba2-fdcd-463b-898c-4804b6122e77"
      unitRef="usd">32000</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMTMtMS0xLTEtMA_4ddabbbd-606b-4356-9fac-b183add97853"
      unitRef="usd">34102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMTMtMy0xLTEtMA_0f3e0d00-1ede-4359-9780-777c12937718"
      unitRef="usd">34400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0de5dd7b82084e18b4cc8f3d297362b8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMTUtMS0xLTEtMA_ba9659ce-13f1-43f7-b027-c1921105ccfc"
      unitRef="usd">34102000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6fcc11a65d404699b74bae8c3005ddcd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjJjNjE1YzM5YjhjMjRiNDA4MzRlOGMzNDBjYWQxODkzL3RhYmxlcmFuZ2U6MmM2MTVjMzliOGMyNGI0MDgzNGU4YzM0MGNhZDE4OTNfMTUtMy0xLTEtMA_f46e7090-426c-4db3-aebb-76c22b46105e"
      unitRef="usd">34432000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfMi0xLTEtMS0w_26ef8823-86bb-49c5-b447-22f18887ee33"
      unitRef="usd">181000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfMi0zLTEtMS0w_5eeff0a8-1b5f-4806-aed5-de80cc35fcbe"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfMy0xLTEtMS0w_bb50273e-c0bf-47a1-87ec-6e6456fbfaec"
      unitRef="usd">476000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfMy0zLTEtMS0w_288aaf31-4880-4c0a-a40c-d7eb562af014"
      unitRef="usd">828000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfNC0xLTEtMS0w_cebae6a8-840e-4ec1-87e0-aa857208f893"
      unitRef="usd">-295000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfNC0zLTEtMS0w_5a7d81ca-219c-4e59-8d0b-4f27facecb85"
      unitRef="usd">-828000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfNi0xLTEtMS0w_5fac98b9-a160-4dff-a342-02e2d3f6de94"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfNi0zLTEtMS0w_b36d7e56-274f-4970-b953-a2d1e4d7e43f"
      unitRef="usd">32000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfOC0xLTEtMS0w_9fcd4926-9f34-477b-90ec-eea6cacc3a74"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfOC0zLTEtMS0w_b8879817-78cc-496b-9dcd-c2c57c2279c5"
      unitRef="usd">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="idaed54b80b8e4e6a972891fe32b77b1c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfMTAtMS0xLTEtMA_aaba70b1-1ee6-42af-9c46-0315b150555e"
      unitRef="usd">-297000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iea62dd55b05948fcb2124ead2542e772_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RhYmxlOjQ1M2I5ZThhNjk4ODRhNzA4ZmI4NTVkNzZjYTM0ZWMyL3RhYmxlcmFuZ2U6NDUzYjllOGE2OTg4NGE3MDhmYjg1NWQ3NmNhMzRlYzJfMTAtMy0xLTEtMA_1ac6a0bf-8fd4-466f-a70d-a4b7936faae5"
      unitRef="usd">-799000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i7786b13c92d44768ab2d5ee5d1646497_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjExNw_b0a23db4-8dc8-4aa5-bc21-190827207dff"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i8bb296bd3d2a499caa7ee8b26bf24153_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjE3MQ_6764265a-45d2-4892-b663-01b66460ae42"
      unitRef="usd">2400000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i02fd82315c204d5b8e983153d3e96412_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjM1MQ_4041ab8c-4075-40d3-a730-e08cebffa72a"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i347786e35f6b48348893e6ea1d53de7f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjQ2Ng_266bd468-ea1a-4b97-ad1a-f0e4cca55287"
      unitRef="usd">400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5ea5bb0ee621461d878a0145d57a8e9d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjYxMg_d245c7a0-3c00-4926-88ba-cc09b0cb1101"
      unitRef="usd">2800000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i8bb296bd3d2a499caa7ee8b26bf24153_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjYxOQ_6764265a-45d2-4892-b663-01b66460ae42"
      unitRef="usd">2400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie83b679468814dbca4be10a39fdb5bc6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjgzMQ_90c66460-036d-47d3-89d3-02aba8455630"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i5db0b17b399c402d90d5cae3426b67ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjg2Nw_0767afff-7930-45c2-bd14-f1f4d42251f5"
      unitRef="usd">4500000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie178a5bc23a34e3e968fdb0a7cc1b1d7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjg3Ng_10d93faf-c6d6-4f04-8085-a48985a24a14"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="if45e4368c403487ea641b147da7d6ec4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNjkxMg_4772b2f2-1ec4-4b26-b291-85e37312fff9"
      unitRef="usd">2100000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ibecc6ab98d324e62ac84506d9b662237_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTA5OTUxMTYzNzE2NA_69d9caa5-08cb-40d6-addd-3a975976fd9d"
      unitRef="usd">45000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id997a6c5f4e24485b8c86ad8253ab602_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzI5MA_093e421e-0add-4c50-86bf-a3f0d89dd547"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i604941a7c4e84e29bd7ca533697deae5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzQyNQ_b8b2987d-30a7-4a2b-ac71-a6eddc4fe080"
      unitRef="usd">4800000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5db0b17b399c402d90d5cae3426b67ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzY5NjU4MTQxMjk4OQ_0767afff-7930-45c2-bd14-f1f4d42251f5"
      unitRef="usd">4500000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i464e0ae5827e4e33a2ade15334ea8236_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMzg0ODI5MDcxNTMzMg_50709669-2867-4870-93f9-9b07e910317d"
      unitRef="number">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i78f0406a51e34beb80ce3cd5596fcbed_I20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTA5OTUxMTYzODE3Nw_2e9dea72-0b7f-489a-ac9f-0d371f560e3a"
      unitRef="usd">11700000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ice09f13be5b34aafb926ba8f8c134a6b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTA5OTUxMTYzOTIzNg_0388435e-5874-4472-98dd-f680dae2eff4"
      unitRef="usd">45000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iae6a9eab9d354ba48b715b8872ad825d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTA5OTUxMTYzOTIzNg_7df774b2-4ff8-4033-98b5-d8b8f63e186a"
      unitRef="usd">45000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9a8d0fe803e64bc1a1ed9278b52c95f9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfMTA5OTUxMTYzOTI0Ng_5d7dc82e-12b6-4ec0-abae-8d90071e4b13"
      unitRef="usd">11800000</us-gaap:EquityMethodInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares
      contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzU4MA_d59c14db-8a71-42b1-9aa1-3b3224cde684"
      unitRef="shares">270000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares>
    <ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="ifa51c5973cf04aa690f31014de335453_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzY2NQ_fdf7fcf9-8ea9-4dc1-b73c-af514467d927"
      unitRef="usd">400000</ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest
      contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzY3MQ_6bfcc3b3-6c7b-46a4-868e-07871d32c718"
      unitRef="usdPerShare">1.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzczNA_cf37976a-4d44-4549-82f8-508ee215ac4d"
      unitRef="number">0.028</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODkxNw_9739e6fb-aa10-4246-9c5a-9456f43ad88d">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzg1NQ_5bc61d7c-9c4c-4e5c-847e-fe112ecdefa6"
      unitRef="shares">270000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption
      contextRef="ifa51c5973cf04aa690f31014de335453_D20180501-20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODkxMg_d846ef69-6beb-49fa-af0f-1195c54b6d43">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests
      contextRef="ifa51c5973cf04aa690f31014de335453_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzkyMw_01a35f81-3bb8-4927-a0c6-77e8898601bf"
      unitRef="shares">380000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODkwNg_4b2e8f90-8ae1-4d1a-bc0d-9dcc1bb3cd05">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet
      contextRef="i78f6b75f6efe4952a520c49f86b2ac80_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfNzk4MQ_fef8a2f1-0ef7-4202-9e35-9bafb9b97f02"
      unitRef="shares">480000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears
      contextRef="ib54cc9af425747bc9bf0db47bae0cdf5_I20190701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODU5MQ_03930749-bd19-4c5b-a660-e954eb350654"
      unitRef="number">0.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment
      contextRef="ie20db30d9d2f4ad790ae13386a5e01ef_D20190701-20190701"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODY4NQ_5c052c21-91f6-4314-8fb9-cd765c177de4">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost
      contextRef="ib54cc9af425747bc9bf0db47bae0cdf5_I20190701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODczNA_0af867f1-668f-4b33-95c0-85989a03f3c8"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="ib54cc9af425747bc9bf0db47bae0cdf5_I20190701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODc0Mw_0324dbb0-b7b7-46da-9000-4d6ffc26f349"
      unitRef="number">0.10</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="i2d2eae5117d042b4ae64a03222d5c117_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV82NC9mcmFnOmZjMTVjMTI5ZjU2MTRlNjZiNjRiMDhlMTEzYjAwZmJmL3RleHRyZWdpb246ZmMxNWMxMjlmNTYxNGU2NmI2NGIwOGUxMTNiMDBmYmZfODc5MA_88a49090-7feb-431d-9b01-1dc8ce40091f"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:LoanReceivableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83MC9mcmFnOmVlOTk5ZTFmOTY0NDRmNTM5OTVmOWUzZDE5ZWE3MTM2L3RleHRyZWdpb246ZWU5OTllMWY5NjQ0NGY1Mzk5NWY5ZTNkMTllYTcxMzZfMTI1MA_326e94d4-71b3-48c7-9dc0-74d067ff12dd">Loan Receivable and Loan Receivable &#x2013; Related Parties&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pacific6&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, NMM received a promissory note from Pacific6 totaling $0.5&#160;million as a result of the sale of the Company&#x2019;s interest in MWN. Interest accrues at a rate of 5% per annum and is payable monthly through the maturity date of December 1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; related parties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AHMC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, APC entered into a promissory note with AHMC (the &#x201c;AHMC Note&#x201d;) for a principal amount of $4.0&#160;million with a maturity date of April 2022. The contractual interest rate on the AHMC Note is 3.75% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of September&#160;30, 2021, the total principal of $4.0&#160;million remains outstanding. One of the Company&#x2019;s board members is an officer of AHMC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the outstanding loan receivable under the CECL model by assessing the party&#x2019;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.&lt;/span&gt;&lt;/div&gt;</ameh:LoanReceivableTextBlock>
    <us-gaap:NotesReceivableNet
      contextRef="i525bb8235fd64a5c8f0c02ec9cbb55e4_I20201030"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83MC9mcmFnOmVlOTk5ZTFmOTY0NDRmNTM5OTVmOWUzZDE5ZWE3MTM2L3RleHRyZWdpb246ZWU5OTllMWY5NjQ0NGY1Mzk5NWY5ZTNkMTllYTcxMzZfMTU5_4c181351-3f20-4ef1-814b-b6eec722c6af"
      unitRef="usd">500000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i525bb8235fd64a5c8f0c02ec9cbb55e4_I20201030"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83MC9mcmFnOmVlOTk5ZTFmOTY0NDRmNTM5OTVmOWUzZDE5ZWE3MTM2L3RleHRyZWdpb246ZWU5OTllMWY5NjQ0NGY1Mzk5NWY5ZTNkMTllYTcxMzZfMjUw_c1d6b7b8-a282-4ab9-8173-e84f3a176d3f"
      unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesReceivableGross
      contextRef="i8f146f9b4b714488a52f519d85dc9915_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83MC9mcmFnOmVlOTk5ZTFmOTY0NDRmNTM5OTVmOWUzZDE5ZWE3MTM2L3RleHRyZWdpb246ZWU5OTllMWY5NjQ0NGY1Mzk5NWY5ZTNkMTllYTcxMzZfNDc4_e569cb12-016a-4672-9fd0-5d1701a44c1f"
      unitRef="usd">4000000</us-gaap:NotesReceivableGross>
    <ameh:FinanceReceivableInterestRateStatedPercentage
      contextRef="i8f146f9b4b714488a52f519d85dc9915_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83MC9mcmFnOmVlOTk5ZTFmOTY0NDRmNTM5OTVmOWUzZDE5ZWE3MTM2L3RleHRyZWdpb246ZWU5OTllMWY5NjQ0NGY1Mzk5NWY5ZTNkMTllYTcxMzZfNTY3_94ef2498-37ce-416b-94f3-98643bbd9288"
      unitRef="number">0.0375</ameh:FinanceReceivableInterestRateStatedPercentage>
    <us-gaap:NotesReceivableGross
      contextRef="ibff23baf29ec4ca5a5fac9212a3be6ef_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83MC9mcmFnOmVlOTk5ZTFmOTY0NDRmNTM5OTVmOWUzZDE5ZWE3MTM2L3RleHRyZWdpb246ZWU5OTllMWY5NjQ0NGY1Mzk5NWY5ZTNkMTllYTcxMzZfNzYx_0b4cc0bd-3016-4dae-af32-6d26a5204145"
      unitRef="usd">4000000</us-gaap:NotesReceivableGross>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RleHRyZWdpb246M2IyMGZlOWQyNWU2NDU1ZWI4YzUxMGU1NWQ4ODc1ZDdfMTQ0_98a0317e-2065-4e79-98de-aadae6f97c82">Accounts Payable and Accrued Expenses&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to related parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RleHRyZWdpb246M2IyMGZlOWQyNWU2NDU1ZWI4YzUxMGU1NWQ4ODc1ZDdfMTQ3_56627607-c53f-40a2-9bd0-1a954362e8d0">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to related parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfMS0xLTEtMS0w_ca4b3e98-d272-4cd2-8923-76950faf0a99"
      unitRef="usd">23051000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfMS0zLTEtMS0w_1e1784ff-61c5-4a08-9a6e-f1e96e4aef7f"
      unitRef="usd">9554000</us-gaap:AccountsPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfMi0xLTEtMS0w_62d3f096-18c1-480f-b17a-58215f99c85b"
      unitRef="usd">2967000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfMi0zLTEtMS0w_d286293b-1bcf-4005-8079-641918e10517"
      unitRef="usd">3541000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SubcontractorIPAPayable
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfMy0xLTEtMS0w_c744e461-03ba-48e8-9a2e-6bef7fb6039f"
      unitRef="usd">2686000</ameh:SubcontractorIPAPayable>
    <ameh:SubcontractorIPAPayable
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfMy0zLTEtMS0w_ba1d8379-41be-44be-898e-89f29955fa1b"
      unitRef="usd">1662000</ameh:SubcontractorIPAPayable>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNC0xLTEtMS0w_bbc95f6f-2b88-473d-987b-fa5f426af0ff"
      unitRef="usd">697000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNC0zLTEtMS0w_74287d29-e77f-42e9-97d3-23940b952bb8"
      unitRef="usd">1378000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNS0xLTEtMS0w_8f80fb4c-a450-4f72-be10-d0bdcbfb5da9"
      unitRef="usd">2298000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNS0zLTEtMS0w_bc912245-52e9-4cbe-8f88-24528bf0a2ce"
      unitRef="usd">50000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNi0xLTEtMS0w_8db86c38-b39e-4542-b6c2-017aa0bb219a"
      unitRef="usd">17259000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNi0zLTEtMS0w_adda621f-b0a6-4fb6-aa58-f6c6be5fdd72"
      unitRef="usd">12988000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNy0xLTEtMS0w_5c7b7d68-ad6b-4a16-8acc-1bb376f0542e"
      unitRef="usd">8547000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfNy0zLTEtMS0w_ccf07569-cf9a-4d5c-abd4-dc20bde53eb3"
      unitRef="usd">6970000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfOC0xLTEtMS0w_def4f9da-2127-4c1b-b7cf-6adea64b313f"
      unitRef="usd">57505000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83Ni9mcmFnOjNiMjBmZTlkMjVlNjQ1NWViOGM1MTBlNTVkODg3NWQ3L3RhYmxlOjQzNzMzNjE5ZjEzZDRmMGY4YzJjNmM5YzE0NWNhODE1L3RhYmxlcmFuZ2U6NDM3MzM2MTlmMTNkNGYwZjhjMmM2YzljMTQ1Y2E4MTVfOC0zLTEtMS0w_feb62d47-985b-43d1-9cf1-206a778bef61"
      unitRef="usd">36143000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RleHRyZWdpb246ZGJlNTJhNDJiOGU1NDVhYmFhNDIzMmYyOTZmNDRlZWVfMTA3_25ba0b31-cb0e-4a81-9e1b-f2e28fa86ca8">Medical Liabilities&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RleHRyZWdpb246ZGJlNTJhNDJiOGU1NDVhYmFhNDIzMmYyOTZmNDRlZWVfMTA5_dfc7942c-24fa-4b87-a3a8-0e266c6b97e7">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMS0xLTEtMS0w_4879cf50-2b59-4d39-bb40-3b51bede6087"
      unitRef="usd">50330000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i274e819937824ba3b8be663aca7657a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMS0zLTEtMS0w_b2fb1e9d-3603-4ef8-bc07-496cf03dafa3"
      unitRef="usd">58725000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMi0xLTEtMS0yNDk3Ng_ab706cd1-7329-436e-b296-5daa01111746"
      unitRef="usd">175000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMi0zLTEtMS0yNDk3Ng_826beede-d4f5-46b5-969a-024ec526141c"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMy0xLTEtMS0w_2f5eb0e1-879d-4c29-a1e3-9469a1f9c712"
      unitRef="usd">242619000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMy0zLTEtMS0w_70f5dda7-067f-4c6c-aecc-224333b0380d"
      unitRef="usd">229194000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfNC0xLTEtMS0w_c3d1df90-8062-4885-9d63-160354f46c9a"
      unitRef="usd">-498000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfNC0zLTEtMS0w_0b0e2575-c878-43de-95bc-974215c9a690"
      unitRef="usd">1731000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfNS0xLTEtMS0w_29cc1da1-8432-492c-b5af-652799bde6ba"
      unitRef="usd">242121000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfNS0zLTEtMS0w_8f73ee71-ee4d-44a4-9f49-bf10553e1462"
      unitRef="usd">230925000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfNy0xLTEtMS0w_9739adec-6f4b-4fa1-a9c6-45ba72ba6f61"
      unitRef="usd">200582000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfNy0zLTEtMS0w_1eaee081-8915-477e-a50d-82e84fe0384e"
      unitRef="usd">178796000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfOC0xLTEtMS0w_b64a16ad-cf48-498d-8bc8-24962615907d"
      unitRef="usd">48948000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfOC0zLTEtMS0w_bb31c430-85dd-47c0-a043-e4d880476d74"
      unitRef="usd">53231000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfOS0xLTEtMS0w_e46edd75-dbbf-4ec4-ab62-1d1a7ff6bb44"
      unitRef="usd">249530000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfOS0zLTEtMS0w_b6f139eb-b173-4560-be79-1b55f45cd95f"
      unitRef="usd">232027000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMTAtMS0xLTEtMA_939b3475-daaf-43c9-8177-30ed442b9fb6"
      unitRef="usd">-224000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMTAtMy0xLTEtMA_c28e7f26-359c-43d9-a81a-f13d6138b301"
      unitRef="usd">-168000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMTItMS0xLTEtMA_aa5e5a08-5f42-4a84-8521-c3fca1c1d0f1"
      unitRef="usd">42872000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i03292c592c4f45da834c806bff481c24_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV83OS9mcmFnOmRiZTUyYTQyYjhlNTQ1YWJhYTQyMzJmMjk2ZjQ0ZWVlL3RhYmxlOmE1ODM1NWIyMmIwYTQ1MjhiZWI2OGVhYmI1YWM5MjI0L3RhYmxlcmFuZ2U6YTU4MzU1YjIyYjBhNDUyOGJlYjY4ZWFiYjVhYzkyMjRfMTItMy0xLTEtMA_25f3b27d-3b40-4519-83c3-55f5cab156a4"
      unitRef="usd">57455000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyNDQ_411bf453-77e4-4d96-9cbb-3887ec01640a">Credit Facility, Bank Loans, and Lines of Credit&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s debt balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real Estate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of September&#160;30, 2021 and December&#160;31, 2020, the carrying value was not materially different from fair value, as the interest rates on the Company&#x2019;s debt approximated rates currently available to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s debt for the years ending &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the nine months ended September 30, 2021) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company entered into a secured credit agreement (the &#x201c;Credit Agreement,&#x201d; and the credit facility thereunder, the &#x201c;Credit Facility&#x201d;) with Truist Bank (f.k.a. SunTrust Bank), in its capacity as administrative agent for the lenders, as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders. The Credit Agreement provided a five-year revolving credit facility to the Company of $100.0 million, which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also provided a term loan of $190.0 million. Amounts borrowed under the Credit Agreement bore interest at an annual rate equal to either, at the Company&#x2019;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#x201c;LIBOR&#x201d;), adjusted for any reserve requirement in effect, plus a spread of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, or (b) a base rate, plus a spread between 1.00% and 2.00%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio. In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the agent entered into a Guaranty and Security Agreement (the &#x201c;Guaranty and Security Agreement&#x201d;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement and, together with the Company, granted the lenders a security interest in all of its assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#x201c;Amended Credit Agreement&#x201d; and the credit facility thereunder, the &#x201c;Amended Credit Facility&#x201d;) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the &#x201c;Agent&#x201d;), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the &#x201c;Lenders&#x201d;), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Wells Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent, in its entirety.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement provides for a five-year revolving credit facility (&#x201c;Revolver Loan&#x201d;) to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts borrowed under the Amended Credit Agreement will bear interest at an annual rate equal to either, at the Company&#x2019;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on  LIBOR, adjusted for any reserve requirement in effect, plus a spread of from 1.25% to 2.5%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.5%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio. As of September&#160;30, 2021, the interest rate on Amended Credit Facility was 1.65%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to pay an annual agent fee of $50,000 and an annual facility fee of 0.175% to 0.35% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#x2019;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to 1.25% to 2.5%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter.  The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. At September&#160;30, 2021 and December&#160;31, 2020, the unamortized deferred financing cost was $4.5&#160;million and $4.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Real Estate Loans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of this purchase, APC assumed the existing loans held by MPP, AMG Properties, and ZLL. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MPP&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $6.4&#160;million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of September&#160;30, 2021, the balance outstanding was $6.1 million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1. &lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AMG Properties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $0.7&#160;million with a variable interest rate of 0.30% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of September&#160;30, 2021, the balance outstanding was $0.7 million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ZLL&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $0.7&#160;million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of September&#160;30, 2021, the balance outstanding was $0.6 million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Construction Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#x201c;Construction Loan&#x201d;). Tag 8 is a VIE consolidated by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Construction Loan allows Tag 8 to borrow up to $10.7 million with a maturity date of December 1, 2022 (&#x201c;Construction Loan Term&#x201d;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#x201c;Permanent Loan Term&#x201d;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be 2.0% per annum in excess of the LIBOR rate. As of September&#160;30, 2021, the balance outstanding was $0.1&#160;million. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#x2019;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated earnings before interest, taxes, depreciation, and amortization (&#x201c;EBITDA&#x201d;) minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s average effective interest rate on its total debt during the nine months ended September&#160;30, 2021 and 2020, was 2.15% and 3.79%, respectively. Interest expense in the consolidated statements of operations included amortization of deferred &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;debt issuance costs for the three and nine months ended September&#160;30, 2021 and 2020, of $0.2 million and $0.3 million, respectively, and $0.9 million and $1.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lines of Credit &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;APC Business Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#x201c;APC Business Loan Agreement&#x201d;) was amended to decrease loan availability to $4.1 million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#x2019;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. One of the Company&#x2019;s board members is the chairman and CEO of Preferred Bank. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APAACO established an irrevocable standby letter of credit with Preferred Bank, which is affiliated with one of the Company&#x2019;s board members, totaling $14.8&#160;million for the benefit of CMS. In August 2020, the irrevocable standby letter of credit was  released by CMS. As of September&#160;30, 2021, there were no outstanding letters of credit and the Company had $25.0&#160;million available under the Amended Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyNDE_067b0c2b-e571-4cf9-a814-5b63d70cdf78">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s debt balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real Estate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i45bdfabdb85c43999bb05d916a50e971_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfMi0xLTEtMS0w_10acbc78-856c-454a-a19f-32c3d9c83587"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8494272cd6364c2a80530dff5382f450_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfMi0zLTEtMS0w_fe51807b-94b1-4cb9-b626-5db9801639ac"
      unitRef="usd">178125000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id37550a1e26f4222af82434fc245548e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfMy0xLTEtMS0w_3e36f23a-89a2-412c-b7ed-427ca56d08ce"
      unitRef="usd">180000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0099b63992df486aa72820a547d7a3b5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfMy0zLTEtMS0w_773b1b13-3b2a-4664-979d-122537458d25"
      unitRef="usd">60000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic51fbee815c34c8bbdc2590d6bb3ba93_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfNC0xLTEtMS0w_dd728f64-8f0f-4109-9676-25ed8a395a55"
      unitRef="usd">7447000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if29783d76d8e4e5c979ae194c2e9e7d8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfNC0zLTEtMS0w_9e5d317b-edc6-4ae0-8da8-cd3fd7e9dd7f"
      unitRef="usd">7580000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic3c70eca48984b6aa875a69a43dd3f0c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfNS0xLTEtMS0w_eada6565-1340-4b13-80cc-5f6146d3e361"
      unitRef="usd">77000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iebc8ed74b68a4195a91620c9be1362c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfNS0zLTEtMS0w_9a4f4125-89c7-4419-8b48-d085bc331ffd"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfNi0xLTEtMS0w_acfc8a08-7a76-4d7b-a000-11390b476f84"
      unitRef="usd">187524000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfNi0zLTEtMS0w_169a5b34-7a68-46d3-a542-db5126340d0a"
      unitRef="usd">245705000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfOC0xLTEtMS0w_6291328e-45d9-4bd1-a976-1ca4a7e32a9d"
      unitRef="usd">207000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfOC0zLTEtMS0w_fa74530c-4cbb-404c-9266-03eed8d94b57"
      unitRef="usd">10889000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfOS0xLTEtMS0w_2f928de9-701f-4d29-b912-ff20f1e2b61c"
      unitRef="usd">4504000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfOS0zLTEtMS0w_32ef02d4-9b17-4b33-a372-29c0e3fca656"
      unitRef="usd">4605000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfMTEtMS0xLTEtMA_e834ae69-6826-4cc2-8d62-0d6eb5541121"
      unitRef="usd">182813000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOjFlMmY5MmZhMmI1MDQwZTY4YTliYzkyNjQwYzdlZTRjL3RhYmxlcmFuZ2U6MWUyZjkyZmEyYjUwNDBlNjhhOWJjOTI2NDBjN2VlNGNfMTEtMy0xLTEtMA_7aab2a27-ed3f-4931-a914-84d1657c980a"
      unitRef="usd">230211000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyMzE_d528b94f-c3fe-45e6-b79a-463fd1cdd9bc">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s debt for the years ending &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the nine months ended September 30, 2021) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOmI2OTE3ODEzN2NmMzQ4NjhiZmM2NzI3NzRkNDFmZWJmL3RhYmxlcmFuZ2U6YjY5MTc4MTM3Y2YzNDg2OGJmYzY3Mjc3NGQ0MWZlYmZfMS0xLTEtMS0w_d4ef773c-1927-4f36-bc14-f5ced6004cb0"
      unitRef="usd">55000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOmI2OTE3ODEzN2NmMzQ4NjhiZmM2NzI3NzRkNDFmZWJmL3RhYmxlcmFuZ2U6YjY5MTc4MTM3Y2YzNDg2OGJmYzY3Mjc3NGQ0MWZlYmZfMi0xLTEtMS0w_499dc73d-7690-4057-a40d-b75b7ac81fad"
      unitRef="usd">285000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOmI2OTE3ODEzN2NmMzQ4NjhiZmM2NzI3NzRkNDFmZWJmL3RhYmxlcmFuZ2U6YjY5MTc4MTM3Y2YzNDg2OGJmYzY3Mjc3NGQ0MWZlYmZfMy0xLTEtMS0w_047bb6be-f553-465b-b32b-09f2a5e677b9"
      unitRef="usd">215000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOmI2OTE3ODEzN2NmMzQ4NjhiZmM2NzI3NzRkNDFmZWJmL3RhYmxlcmFuZ2U6YjY5MTc4MTM3Y2YzNDg2OGJmYzY3Mjc3NGQ0MWZlYmZfNC0xLTEtMS0w_6c945653-bf57-4206-895d-711e8404cdc2"
      unitRef="usd">222000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <ameh:LongTermDebtMaturityAfterYearFour
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOmI2OTE3ODEzN2NmMzQ4NjhiZmM2NzI3NzRkNDFmZWJmL3RhYmxlcmFuZ2U6YjY5MTc4MTM3Y2YzNDg2OGJmYzY3Mjc3NGQ0MWZlYmZfNS0xLTEtMS0w_41addef3-8b7d-4ac4-93d8-e9c6509324a8"
      unitRef="usd">186747000</ameh:LongTermDebtMaturityAfterYearFour>
    <us-gaap:LineOfCredit
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RhYmxlOmI2OTE3ODEzN2NmMzQ4NjhiZmM2NzI3NzRkNDFmZWJmL3RhYmxlcmFuZ2U6YjY5MTc4MTM3Y2YzNDg2OGJmYzY3Mjc3NGQ0MWZlYmZfNy0xLTEtMS0w_534e025c-5e8b-4259-8402-b53619c55b7c"
      unitRef="usd">187524000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentTerm
      contextRef="ic2ee83ed94cb43dcb3182dcb57e382f9_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyMzU_2ea3387d-6a4e-4cd3-a7c2-0789a7dd36e9">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3f4f916cef32400dab83a02c9f3d1dff_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfOTQ2_7feac512-2532-45b8-ad76-2a993bac2b51"
      unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i63ade4493fd74989b1999037fc8db598_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTAwNQ_e00b38fe-b761-426b-929f-8834f20d0c43"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i55616ddbc4dc41fca2e3f5474cb36d53_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTA1OQ_ffefe082-149b-422f-913b-5c6d3b6a933a"
      unitRef="usd">190000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i894dad9f04be4b80b0c5418db6c0ffac_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTM5Mg_f30b95cd-f402-438e-bd0c-63d6dec28086"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ieb62b8a56d704692b86255ec6cff3fd8_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTM5OQ_b2af06b9-a37c-4b27-8321-692fc3a1ca4b"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ied77ca7dcd3c44a3ad71dbbe16d60235_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTUxOQ_5089c47e-4bac-42ec-8ddb-93277c9e53b7"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i637ca2c6a62940f5bf8cd582df12b45d_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTUyNg_dd21f02e-98ae-4462-a3e7-2b6bcb33b326"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentTerm
      contextRef="i2da520099b4f4b1e85134d04cfed7267_D20210616-20210616"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyMzM_f41d7555-bed3-4a2e-9998-1a952bdb93eb">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib4c74cb40c8b4d9882ce3f1381253d36_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMzE2OA_02046ece-e48d-4fbb-ac4d-f381c10233bc"
      unitRef="usd">400000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if5f64948f20549f29b7ad2775ac72e54_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMzIyOA_05a1a7b1-b0c7-4774-adfc-35014852106b"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3501cf38d6f349bfbb10a514b5e413c8_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMzI2OA_7c0b143a-4c8e-4001-8ae5-edafeaac44fb"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id51378c59e4b46a1878e9755158c9508_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMzk5Nw_32ca4494-68c0-4cf1-adef-0cec62f866a2"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i32a0cb9701af4dec94e8c8b4a88e8a16_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDAwMw_5cb5a38d-5b8c-42c0-aa1d-36e4c12ba26a"
      unitRef="number">0.025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6bcbe6284db54a94b3f1f04677fe3f92_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDExOA_780933a0-34bf-4865-b228-d2509dafcb92"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic51076d7bee7498eb636ef7814297785_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDEyNA_58430736-37ed-45bc-b662-75b74d82cd9f"
      unitRef="number">0.015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="idea7e71c000342b8995e416f3a7cff49_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDI2MQ_d9b0296d-2f3a-4f6d-82bb-4512b8a62f57"
      unitRef="number">0.0165</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="i7820cd54de244cb28e02edd916f67207_D20210616-20210616"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDMxOQ_3d51cfe2-b153-44a6-9fc2-6103887a2daf"
      unitRef="usd">50000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i6bcbe6284db54a94b3f1f04677fe3f92_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDM1Mg_9996f114-946b-4724-9aa6-eddaf5eccc17"
      unitRef="number">0.00175</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ic51076d7bee7498eb636ef7814297785_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDM1OA_69be2b14-815d-4721-bfc7-d45b56c2c6bc"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i0e608242dd8442239280156056c80e78_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDYyNQ_c585999f-da5d-4018-b86b-662cc1f590a2"
      unitRef="number">0.0125</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="icc5ad4c4fa8b4ec698a83764c9b1d2d4_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNDYzMQ_96bcbf53-add3-4d9e-950f-92646e74b534"
      unitRef="number">0.025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <ameh:DebtInstrumentNumberOfKeyFinancialRatios
      contextRef="id383d2aa762447b5b54e8e4dfc37d7c1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNTAwNg_d34c91d7-97a1-4ed8-9a79-4957f0fcf549"
      unitRef="financial_ratio">2</ameh:DebtInstrumentNumberOfKeyFinancialRatios>
    <ameh:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="id383d2aa762447b5b54e8e4dfc37d7c1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNTE1Ng_ef6dcf21-38a7-44f1-897c-252eb7e3638e"
      unitRef="number">0.0375</ameh:DebtInstrumentCovenantLeverageRatioMaximum>
    <ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="id909b639f09f413ba4ac35e191a08c1d_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNTMwMQ_fea268e3-17e0-41df-b805-5955b31f66fe"
      unitRef="number">0.0325</ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="ia7d07d7302e04f1093a19129cb01db1a_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNTQ1MA_515b619c-6f9d-4321-9bc3-3028ad9c3f25"
      unitRef="usd">6500000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i6847b33d46c94f279cb67bd2e1ad4362_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNTU3NA_26a94b4d-1f13-46c1-b2cb-4839b659698e"
      unitRef="usd">700000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjAzNg_2c7fcd6d-40c7-442d-abb0-2a3e86e9b2dd"
      unitRef="usd">4500000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjA0Mw_024012bb-0d24-4068-a022-f7bd0f32a0b6"
      unitRef="usd">4600000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i6f8776621075492eacb36b4093b785ae_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjE2Ng_c2a21c9e-1782-46d9-95a1-438fb9321038"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i2c6ce9908aaf4419a562611bb678c2a2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjE2Ng_c4667cc6-bd60-484a-9ab9-d9558b8b0b0d"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i8147fcc7b25942ad8a37c6657211abf5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjE2Ng_f51a4bf0-0b44-44c3-9ea5-1c592a9c371c"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2acf51a712524f44ba644d48d0a00647_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjQ2OQ_4cbe57f4-9611-4a82-9a4f-47f88569f668"
      unitRef="usd">6400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="idd7cf95bb6ef4965bf29b2064ac819c1_D20200703-20200703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjUwNQ_e2123dcf-77a6-4170-b200-26d40f2056c5"
      unitRef="number">-0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i07f6fe5be32e4b7292d433a12ca499c0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjgzNA_3fc08870-3761-4917-8dcf-a9741a9e4dd2"
      unitRef="usd">6100000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="i4a5651c8948b4047b7eab25f8764f012_D20200703-20200703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNjk5Nw_bda6b3f2-4fb8-414f-b759-5b4171324961"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5f31366737854b98ba91333a885afcb9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNzE4OQ_8612d249-72e5-49a5-b788-c695fa820a80"
      unitRef="usd">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ice5f1743593b44f9a80d07f923a92908_D20200805-20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNzIyNQ_15653616-a913-4064-b481-802cfe0987d7"
      unitRef="number">-0.0030</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i82b2d9d7053444d4aab270f6ad420a79_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNzU2NQ_512120a2-fc1a-4644-98c1-c97564862d2c"
      unitRef="usd">700000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="i2c657488d54b424380f6b218f717a662_D20200805-20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNzczOQ_c1d80373-443e-4967-92f0-4724deebec0c"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icfc39a3c7e114b588a1abebd9943f489_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNzkwNw_3b505393-859e-436d-9707-09942f01e545"
      unitRef="usd">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iaeabd70c59714c11a93da612a94d392b_D20200727-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfNzk0Mw_b29869e6-117a-4a44-8755-5c8f5d3d607a"
      unitRef="number">-0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i7530cbcce02f4598a2e22ba8f19dabdb_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfODI3Mg_404c562a-ae41-4866-afa2-0be8fb837353"
      unitRef="usd">600000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="ic56ef9908db04d4ba9b326259616f237_D20200727-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfODQzNQ_0b816a44-d263-4f11-a61f-2c1a806810d6"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i37601241e5164c76b84df50fe2dccd42_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfODY3NA_5adb8a7e-f59d-46d9-957c-6a0caaf24c0d"
      unitRef="usd">10700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4a5e7cb27c6a475e8bc2918ac9af91a3_D20230101-20231201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfOTQ1Mw_f0b279c1-a091-468c-9008-6692da7a68b2"
      unitRef="number">0.020</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i048bc9147744436cb31702bc505497d5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfOTUzMw_24df62e0-ec5f-4719-afac-4b25a233ccf0"
      unitRef="usd">100000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum
      contextRef="i048bc9147744436cb31702bc505497d5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfOTg0Ng_5d34fbc8-b407-4da5-81d4-f84ade2ce49d"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="id909b639f09f413ba4ac35e191a08c1d_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfOTk4OA_b63971a5-dca1-464d-a2f3-3aba8a09ce80"
      unitRef="number">0.0215</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i0bb465d8e0fa47b281bc8588585bfd99_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfOTk5NQ_7960e33a-0149-48cd-9b92-66adf11ff63c"
      unitRef="number">0.0379</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestExpense
      contextRef="ifd5c1f9d9879419881aa4f73dbd34259_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTAxNzA_db8fc938-8305-4ef8-841a-e8792c687d58"
      unitRef="usd">200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id909b639f09f413ba4ac35e191a08c1d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTAxNzc_3baed4ba-0064-4474-ba5b-b91c6d24723c"
      unitRef="usd">300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ieeae1845ac274f829e29f2feb496c443_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTAxOTk_2131bea0-dfb6-4336-a0d4-16825bee8188"
      unitRef="usd">900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0bb465d8e0fa47b281bc8588585bfd99_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTAyMDY_df75e313-d4da-4e74-893f-c0ffe9a020d0"
      unitRef="usd">1000000</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia2c3441a286f4428b822c3dc66bbbdaa_I20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTA0MTY_879e9655-9df0-4d4f-8c13-8b7522d63f48"
      unitRef="usd">4100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i4908488c47c942d99a8fc66857f5053e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTExMzI_401d57af-e088-46dc-b78d-a47e39aad9d2"
      unitRef="usd">14800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="id34357efa1004d2ab40ef715b0949c59_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyMzY_9c0017b8-3652-43ef-a856-8be11e977edb"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i949ff001ac544940b35caad34ef7b315_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTEzMTI_db0cd7da-474e-4d4c-8cad-7fa01cb17062"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icee52b68969c4138b7b2a2e8af0b227d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTE0ODc_bdacb059-1391-415b-b012-58329cf80703"
      unitRef="usd">300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="if82c8f50b6884a84bb5fec6d0c53d8e6_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyMzc_88522d89-5a5e-4ee5-9532-b52528dbffc6">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i20c5c1427f6f4e6cbd81faa6df3205dc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTE5MjQ_43ff29e4-ca0b-41cf-b38f-d4d705ec670c"
      unitRef="usd">3800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="ib5b45c5e6ea841c1a753923224520654_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84Mi9mcmFnOjAwMTk1ZDA1Y2MzZjRiMTQ5NmY2MDllM2I3MWZjODQyL3RleHRyZWdpb246MDAxOTVkMDVjYzNmNGIxNDk2ZjYwOWUzYjcxZmM4NDJfMTIyNDI_f0b9a137-e3b7-4444-8783-311af7750e2b">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMjA2MQ_33218e5d-bb58-4976-944c-6f8a541ba70b">Mezzanine and Stockholders&#x2019; Equity&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the redemption feature of the APC shares (see Note 2) is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC&#x2019;s shares were not redeemable, and it was not probable that the shares would become redeemable, as of September&#160;30, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, 141,638 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC owned 10,925,702 and 12,323,164 shares of ApolloMed&#x2019;s common stock as of September&#160;30, 2021 and December&#160;31, 2020, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. In March 2021, the Company issued 34,158 shares of common stock to APC as a result of APC exercising their warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2021 and 2020, APC paid dividends of $10.0&#160;million and $19.9&#160;million, respectively. During the nine months ended September&#160;30, 2021 and 2020, APC paid dividends of $29.9 million and $49.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2021 and 2020, CDSC did not pay any dividends. During the nine months ended September&#160;30, 2021 and 2020, CDSC paid dividends of $1.5 million and $0.6 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ameh:StockIssuedDuringPeriodSharesMerger
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfNDQy_14e6eb9f-8b22-4bb6-9019-88bc7e3eb19f"
      unitRef="shares">141638</ameh:StockIssuedDuringPeriodSharesMerger>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i0be646a9c14345fabdb07fa7e3f377f0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTI5OA_f0dd5a54-e307-44fe-93fb-bf09026c10ed"
      unitRef="shares">10925702</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i4ae0dfc3bc32416cb6ec479fa6aee249_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTMwNQ_7b2957ee-8cab-4cfb-964c-a49accc59be8"
      unitRef="shares">12323164</us-gaap:TreasuryStockCommonShares>
    <ameh:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ieaf0c3ac99784174b913090c36595512_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTU5NDI5MTg2MDU0MTY_217270ad-7e62-4ec0-abe8-e6bd126f711c"
      unitRef="shares">34158</ameh:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:Dividends
      contextRef="id92d571acf4e4268885451c976638558_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTc3OQ_ca559502-e17c-4cbd-8adb-6a05d38c8cab"
      unitRef="usd">10000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ie56d0d0b55424badade9e1fc4b2d1fb1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTc4Ng_cea57427-a214-48ec-8ff4-b9a0a7b9d6d8"
      unitRef="usd">19900000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ia1bd75ff5a784460bc879854f3dc5e14_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTg2NA_ba4b35a7-11c9-449a-945f-761445384ff8"
      unitRef="usd">29900000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="if75c2580a6e64c94a6c643c85453d033_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMTg3MQ_bf77d22d-eccd-440d-b6cc-386dea9dfa18"
      unitRef="usd">49500000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ia33174543dcc47c381797d497163fb30_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMjAzNg_1bbbff7b-30e6-493f-8275-348e89f654b4"
      unitRef="usd">1500000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ib9e6ca8ac3e24c129b22e6f9b5d3b25c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV84OC9mcmFnOjVhMzIxZTY4NTdlZjQ5MTRhZWJlNzNiY2E0YWIyZDExL3RleHRyZWdpb246NWEzMjFlNjg1N2VmNDkxNGFlYmU3M2JjYTRhYjJkMTFfMjA0Mw_500c71a4-49d8-4c9a-abf8-f3b084797661"
      unitRef="usd">600000</us-gaap:Dividends>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMjA4Mg_a1ffa369-beae-43b2-8340-aadf3844a414">Stock-Based Compensation&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock-based compensation expense recognized under all of the Company&#x2019;s stock plans for the three and nine months ended September&#160;30, 2021 and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to total share-based payments outstanding as of September&#160;30, 2021, was $7.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2021, options were exercised for 40,000 shares of the Company&#x2019;s common stock, resulting in proceeds of $0.2&#160;million. During the nine months ended September&#160;30, 2020, options were exercised for 120,000 shares of the Company&#x2019;s common stock, resulting in proceeds of approximately $0.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2021, the Company granted 24,437 stock options with a vesting period of two years to certain ApolloMed executives with an exercise price of $23.24, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Executives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Annual dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeiture rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants restricted stock awards to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day&#x2019;s closing market price of the Company&#x2019;s common stock. During the nine months ended September&#160;30, 2021, the Company granted restricted stock awards totaling 159,267 shares with a weighted average grant date fair value of $28.24. The grant date fair value of the restricted stock was $4.5&#160;million and will be recognized on a straight-line basis over the awards&#x2019; vesting period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTY0OA_28ab602c-7a29-4dcd-a454-db6a953fd86b"&gt;one&lt;/span&gt; to three years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(624,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants expired/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&#160;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635,428&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,135&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$                  10.00 &#x2013; 11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the nine months ended September&#160;30, 2021 and 2020, common stock warrants were exercised for 624,760 and 800,709 shares of the Company&#x2019;s common stock, respectively, which resulted in proceeds of approximately $6.4&#160;million and $6.2 million, respectively. The exercise price ranged from $9.00 to $11.00 per share for the exercises during the nine months ended September&#160;30, 2021 and 2020, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMjA3Nw_6cdfba6e-1531-48af-b606-a5d2641c078e">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock-based compensation expense recognized under all of the Company&#x2019;s stock plans for the three and nine months ended September&#160;30, 2021 and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26630cf67d1949a1bb14af99246ab11e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMi0xLTEtMS0w_e4cc5edd-e604-4d24-b097-1bf1227d60a2"
      unitRef="usd">602000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieed5052a2c264a58a60f18048fdd7abc_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMi0zLTEtMS0w_817c3ddb-b127-4b8f-97b2-4b5080a9765f"
      unitRef="usd">298000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i15e8004b924f4bdb999ba8d5a25493b0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMi01LTEtMS0w_e6671af9-6cf7-40b0-9e80-7991e9c142e3"
      unitRef="usd">1794000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id224224b17a647d7a1bbdb52d3c8ee5d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMi03LTEtMS0w_cb7cf3bf-c13b-4150-b1c2-d287bbe5c053"
      unitRef="usd">1270000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b5c1fd7f16d4fabaa391acdd0d5b331_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMy0xLTEtMS0w_dd81b0f3-6e3c-41bd-a5f4-7e63ff3d6b75"
      unitRef="usd">818000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9a3914dba35149aca5f59b14362cf84f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMy0zLTEtMS0w_42d38507-afbc-4f0e-929d-a803e11a0860"
      unitRef="usd">350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib7a1b7919fd34831b23c0c3972b0f9f7_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMy01LTEtMS0w_9c177654-4f0c-44fe-9216-c42d95164bb3"
      unitRef="usd">2528000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i72e43a94fd374088a88895c32404f338_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfMy03LTEtMS0w_80eafdc3-f1fb-4521-bf7a-c8d9604f5509"
      unitRef="usd">1288000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfNS0xLTEtMS0w_25a63df5-f3d7-4cf0-83a7-ff37e0b0ff41"
      unitRef="usd">1420000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfNS0zLTEtMS0w_f33530aa-1df2-4891-933d-a770c2e5c1b2"
      unitRef="usd">648000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfNS01LTEtMS0w_83de1c1f-582b-4933-b0d9-c13b18338bb0"
      unitRef="usd">4322000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhhMDMzNTVkZDVjYjRkYmM4MTVlODIyY2IwZjkyM2JiL3RhYmxlcmFuZ2U6OGEwMzM1NWRkNWNiNGRiYzgxNWU4MjJjYjBmOTIzYmJfNS03LTEtMS0w_ce0476b6-59ca-427f-8fe6-2c686a486cba"
      unitRef="usd">2558000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfNTI0_7e4990f8-3b5d-48fb-94f2-b3d192082380"
      unitRef="usd">7400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMjA3OA_2b6e869f-e626-480d-bab0-3e063da439bb">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMS0xLTEtMS0w_fe34072a-5a3e-45f1-ba4b-316d7c2ac6f5"
      unitRef="shares">725864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMS0zLTEtMS0w_9de4a9ea-7f7c-40de-b441-4766d2cb2de0"
      unitRef="usdPerShare">13.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i1bc83e3bcab6489aa067dd6bbdb2afc2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMS01LTEtMS0w_37cbac13-36ec-4d6d-92ea-93b2222123e1">P3Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMS03LTEtMS0w_d7a5dcfa-75cb-4055-98a1-9caf0e42872c"
      unitRef="usd">3400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMi0xLTEtMS0w_e4b832d3-6c67-4852-b415-b36935205553"
      unitRef="shares">24437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMi0zLTEtMS0w_08fa6787-56f9-4b3d-89e1-60ad69e8957f"
      unitRef="usdPerShare">23.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMy0xLTEtMS0w_3854abc4-dd1a-4079-9a8b-7136c18cde92"
      unitRef="shares">40000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMy0zLTEtMS0w_a2a45961-ee9d-42a2-89f4-1f3a8bc5031e"
      unitRef="usdPerShare">5.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfMy03LTEtMS0w_6e3992ff-e870-4279-8229-f7e482371312"
      unitRef="usd">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfNC0xLTEtMS0w_b71a0e04-3403-4c25-9b71-00d62202a9cb"
      unitRef="shares">9826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfNC0zLTEtMS0w_4cfe6eed-f218-431e-a2c7-cea4d018c3e6"
      unitRef="usdPerShare">3.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfNi0xLTEtMS0w_38c444c6-f3b2-400e-ad75-d8e4d15d4378"
      unitRef="shares">700475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfNi0zLTEtMS0w_183fadfd-ca4e-446b-9cb4-8e3c5d4a3773"
      unitRef="usdPerShare">14.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfNi01LTEtMS0w_fb7006f1-fa6f-4583-b3f1-b75a8f86924d">P3Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfNi03LTEtMS0w_fe88ad07-a057-4c04-850a-31532fe2334d"
      unitRef="usd">53800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfOC0xLTEtMS0w_2cd44599-2186-48fc-8e23-756d7c4e94c3"
      unitRef="shares">534638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfOC0zLTEtMS0w_51bd662c-1424-4111-9742-4dc30ffc2192"
      unitRef="usdPerShare">9.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfOC01LTEtMS0w_b288901c-200d-409d-9604-d3d65e6ccda9">P2Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjhjYTU0NDNhNjc4ODRiOGJiMzcxMjMyMjExNjM1NDg3L3RhYmxlcmFuZ2U6OGNhNTQ0M2E2Nzg4NGI4YmIzNzEyMzIyMTE2MzU0ODdfOC03LTEtMS0w_93251c8f-9831-4f10-bbf9-c0eaa5e443ea"
      unitRef="usd">41900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfNjM3_3854abc4-dd1a-4079-9a8b-7136c18cde92"
      unitRef="shares">40000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6993e6cdd0a34b838468c68d5890d474_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTA5OTUxMTYyOTkzMA_49b599bd-76d3-4b76-a472-b413ecb86763"
      unitRef="usd">200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfNzI4_24f40f0c-03e0-4103-a080-cff72ecf94ec"
      unitRef="shares">120000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie42410e4e0cd4dccab9e87193dccb1b3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfODA4_a1c05704-9e99-4443-9038-89e8ebe84ee3"
      unitRef="usd">300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMjA3NA_09df9a65-f5b3-429f-838a-5c332fb55d6e">During the nine months ended September&#160;30, 2021, the Company granted 24,437 stock options with a vesting period of two years to certain ApolloMed executives with an exercise price of $23.24, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Executives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Annual dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeiture rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfODYz_6340eb55-3100-4435-8174-38ec98879de1"
      unitRef="shares">24437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2b411e1124154e218ae663e7d0cd0811_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfOTA1_a578b614-1c8d-4d78-9fae-082f03d3314c">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if24be682ffa04df6b410bf2bdba494b9_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfOTY2_f6adea3b-e45e-42cf-92ce-ccfdfaed9791"
      unitRef="usdPerShare">23.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjg5NzhjNzIxZDhkYzQ0ODdiODkxNjViMmMxNzI5ZjkzL3RhYmxlcmFuZ2U6ODk3OGM3MjFkOGRjNDQ4N2I4OTE2NWIyYzE3MjlmOTNfMS0xLTEtMS0w_f8ca19ab-e799-4939-a87f-9e70aacc9891">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjg5NzhjNzIxZDhkYzQ0ODdiODkxNjViMmMxNzI5ZjkzL3RhYmxlcmFuZ2U6ODk3OGM3MjFkOGRjNDQ4N2I4OTE2NWIyYzE3MjlmOTNfMi0xLTEtMS0w_fb61ef9f-e0f1-4975-8b0f-cf7a6656557f"
      unitRef="number">0.8110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjg5NzhjNzIxZDhkYzQ0ODdiODkxNjViMmMxNzI5ZjkzL3RhYmxlcmFuZ2U6ODk3OGM3MjFkOGRjNDQ4N2I4OTE2NWIyYzE3MjlmOTNfMy0xLTEtMS0w_04f53bfc-1ea2-4a61-8ad9-e88b53294cc8"
      unitRef="number">0.0019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="if24be682ffa04df6b410bf2bdba494b9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjg5NzhjNzIxZDhkYzQ0ODdiODkxNjViMmMxNzI5ZjkzL3RhYmxlcmFuZ2U6ODk3OGM3MjFkOGRjNDQ4N2I4OTE2NWIyYzE3MjlmOTNfNC0xLTEtMS0w_27717c4d-ea94-4789-b62e-129013bec753"
      unitRef="usdPerShare">12.86</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjg5NzhjNzIxZDhkYzQ0ODdiODkxNjViMmMxNzI5ZjkzL3RhYmxlcmFuZ2U6ODk3OGM3MjFkOGRjNDQ4N2I4OTE2NWIyYzE3MjlmOTNfNS0xLTEtMS0w_00d5a8d3-bca2-4b98-ac6a-5ee026a1fee1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjg5NzhjNzIxZDhkYzQ0ODdiODkxNjViMmMxNzI5ZjkzL3RhYmxlcmFuZ2U6ODk3OGM3MjFkOGRjNDQ4N2I4OTE2NWIyYzE3MjlmOTNfNi0xLTEtMS0w_18fbe611-54d5-4b3a-8913-600cb024df9f"
      unitRef="number">0</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8d5fc98033004eb0a900852b969e1fd0_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTQ0NQ_c6aa5c8f-3e42-4cd6-8c7e-dbe5301dcd29"
      unitRef="shares">159267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8d5fc98033004eb0a900852b969e1fd0_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTUwNA_eb4d6680-72ea-4118-88c0-69e287416352"
      unitRef="usdPerShare">28.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i83f1985914f0496ea8f8d5f1f4b62193_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTU2Mg_5db9be23-4fc1-4a9b-8512-98544e0ee176"
      unitRef="usd">4500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i75b1c7458b864e9b981a527bbfa8158f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMjA3NQ_0fc9d1d1-3940-40d3-9db8-c4b47b934b96">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMjA3Ng_2f9dd22e-0794-457f-964d-0ceffc1f3af2">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(624,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants expired/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&#160;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635,428&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,135&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$                  10.00 &#x2013; 11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMS0xLTEtMS0w_b3b22daf-82e3-4012-94d8-1b120417993a"
      unitRef="shares">1878126</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMS0zLTEtMS0w_f8d803a2-2ba4-4c4b-87aa-b92022b3a545"
      unitRef="usdPerShare">10.39</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i1bc83e3bcab6489aa067dd6bbdb2afc2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMS01LTEtMS0w_83f15321-7389-4f42-ad21-6683c1966d8d">P1Y7M17D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMS03LTEtMS0w_65db6f68-e3ff-4bd4-bb47-6d0ad0a1e572"
      unitRef="usd">14800000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsGranted
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMi0xLTEtMS0w_17ae7b38-71fa-43cb-87e6-cc1e087d49b5"
      unitRef="shares">0</ameh:NumberOfWarrantsGranted>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMi0zLTEtMS0w_63348dc3-3d29-4672-8ccd-c0503c6eed17"
      unitRef="usdPerShare">0</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod>
    <ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMi03LTEtMS0w_003b9141-ffa2-41c4-86a7-91d449acd57b"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsExercised
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMy0xLTEtMS0w_785bf67d-e7ef-489e-9f41-4a281214389c"
      unitRef="shares">624760</ameh:NumberOfWarrantsExercised>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMy0zLTEtMS0w_da6e352d-9cc8-4cf3-a68e-b78b2ab8be34"
      unitRef="usdPerShare">10.23</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod>
    <ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfMy03LTEtMS0w_b4a6b54d-2486-4a3f-a9f6-1edea6dfd037"
      unitRef="usd">20618000</ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue>
    <ameh:ClassOfWarrantOrRightCancelledInPeriod
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNC0xLTEtMS0w_74ae1d6b-34a6-408f-b97a-bbd33f7cfde0"
      unitRef="shares">17803</ameh:ClassOfWarrantOrRightCancelledInPeriod>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNC0zLTEtMS0w_ceaef9c7-23b2-41c0-8836-edee57286ec6"
      unitRef="usdPerShare">9.72</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod>
    <ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNC03LTEtMS0w_28fc9a50-50a7-40c9-8f95-d7c16a5a269f"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNi0xLTEtMS0w_ab575686-739c-4ca1-bb4b-6686852f01e6"
      unitRef="shares">1235563</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNi0zLTEtMS0w_8ff709e3-60e8-4680-b0ff-b8056e8d29a9"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNi01LTEtMS0w_98024c6b-896e-44c5-900a-26a306728e23">P1Y2M8D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOmJmYmUyYmUxNGZhYTQ4YWNiMTFmY2JjYmJkNTFlNGU4L3RhYmxlcmFuZ2U6YmZiZTJiZTE0ZmFhNDhhY2IxMWZjYmNiYmQ1MWU0ZThfNi03LTEtMS0w_29b8e4c8-d0cb-401a-b6ac-be2d9160d589"
      unitRef="usd">99500000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i72d599d61813449280a927233fdb0405_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMS0wLTEtMS0w_646cb41b-dab5-45d2-946c-ea4cc7a96123"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i4819d9b69dd44a989faef6c6cbbe20e0_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMS0yLTEtMS0w_1c5e5313-bc8f-4220-b406-742074fe70db"
      unitRef="shares">635428</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i4819d9b69dd44a989faef6c6cbbe20e0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMS00LTEtMS0w_6d4c90d5-bbfc-4d4b-a162-080d6eace000">P1Y2M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i72d599d61813449280a927233fdb0405_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMS02LTEtMS0w_be27dc41-ea34-4b28-b01d-1bed4aa2e040"
      unitRef="shares">635428</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i72d599d61813449280a927233fdb0405_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMS04LTEtMS0w_96879898-8d0e-4bd9-acad-032ccf3b3961"
      unitRef="usdPerShare">10.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i01889397be3e428281f28320683c1430_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMi0wLTEtMS0w_53df2c6a-f093-4f19-8af1-57b12a5bf706"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i22e30659b8d845b5bc23aafc96ddf13b_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMi0yLTEtMS0w_0a1f0d65-6313-4911-9790-5bbdcb441102"
      unitRef="shares">600135</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i22e30659b8d845b5bc23aafc96ddf13b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMi00LTEtMS0w_f72b05e9-e72d-49c6-b930-ce1028484d48">P1Y2M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i01889397be3e428281f28320683c1430_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMi02LTEtMS0w_73d698fa-a900-4af3-b3e6-d423c8990566"
      unitRef="shares">600135</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i01889397be3e428281f28320683c1430_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfMi04LTEtMS0w_10a123d1-cb00-4eb8-b4c8-233b0fbf6a71"
      unitRef="usdPerShare">11.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic3b55bbdae154354b76e9f0bf837e3d5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfNC0wLTEtMS0wL3RleHRyZWdpb246MjQ2ZWFlYWZkMWQxNDcwZDgwYmExYWJkMGJjNjZmMmFfMjM_6c09370d-ba99-4c75-97d7-053826d758d5"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibf76fa460e274183b775eab34ea28a8a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfNC0wLTEtMS0wL3RleHRyZWdpb246MjQ2ZWFlYWZkMWQxNDcwZDgwYmExYWJkMGJjNjZmMmFfMjg_647684e3-15f4-4464-900d-7e6320343fed"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="icbe9675fd54c4c248789b3ab515892fa_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfNC0yLTEtMS0w_3946f526-9d6b-4177-ba6a-c3be89dd21b7"
      unitRef="shares">1235563</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="icbe9675fd54c4c248789b3ab515892fa_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfNC00LTEtMS0w_6d904b12-faa9-4184-a866-8785ca6fe17e">P1Y2M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i11d2613adfb84faeb941f179c4fb08a1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfNC02LTEtMS0w_295d3111-0548-4317-af89-a465cc9137a1"
      unitRef="shares">1235563</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i11d2613adfb84faeb941f179c4fb08a1_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RhYmxlOjRjZDEwNTM1YTg3YjQwZjM5NmIxNGY0ZDQ0MjQ0YmQ4L3RhYmxlcmFuZ2U6NGNkMTA1MzVhODdiNDBmMzk2YjE0ZjRkNDQyNDRiZDhfNC04LTEtMS0w_b30a5c6a-334e-4ced-8e22-21bd9fde0f54"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTgyNA_71aa21c1-27ea-4cef-bbb8-960b9d7dfd44"
      unitRef="shares">624760</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTgzMQ_a161f1e0-881e-4f1b-b16b-626bc5d31bea"
      unitRef="shares">800709</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTkzMA_3ef6c7fd-c5e0-46b9-98c2-8b950b69c836"
      unitRef="usd">6400000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTkzNw_cd006e06-695c-44c2-a356-1d27ee460415"
      unitRef="usd">6200000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="id5e56d3070c14ba4a8f92e0c3ba9b04f_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTk4Ng_6e48ebab-01fe-4391-a0bd-4ee9558e03cf"
      unitRef="usdPerShare">9.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i0e8ffc3fb93241efb949e02abb5a85f0_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTk4Ng_a090a45b-d84d-4a3a-a558-05142fcc7ac1"
      unitRef="usdPerShare">9.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i64448178efd84c50aa3bacac86356338_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTk5Mg_41be1f6a-0348-4eba-b48c-e756c0de51a0"
      unitRef="usdPerShare">11.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i5d9ad1e3f11440fbbd1039812179f70c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTk5Mg_6cfc5fea-cd9f-4327-82aa-ed7882911baf"
      unitRef="usdPerShare">11.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDAvZnJhZzo3MDQ2ODI1NDgzMzI0NDE0YjJmNDk0NjI3ZjY2OTk2YS90ZXh0cmVnaW9uOjcwNDY4MjU0ODMzMjQ0MTRiMmY0OTQ2MjdmNjY5OTZhXzM5MTQ_8fdf2e30-5ce5-42cb-88c2-68ac69d72f68">Commitments and Contingencies&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California Department of Managed Healthcare (&#x201c;DMHC&#x201d;) regulations, including maintenance of minimum working capital, tangible net equity (&#x201c;TNE&#x201d;), cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of the payor and provider contracts with the Company&#x2019;s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS. The guarantee generally must be in an amount equal to 2% of the Company&#x2019;s benchmark Medicare Part A and Part B expenditures. In August 2020, $14.8&#160;million of the irrevocable standby letters of credit were released by CMS and no amounts remained outstanding as of September&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $0.3 million and $3.8&#160;million, respectively, for the benefit of certain health plans (see Note 9). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#x2019;s financial condition, cash flows, or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its insurance coverage is appropriate based upon the Company&#x2019;s claims experience and the nature and risks of the Company&#x2019;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#x2019;s affiliated professional organizations or the Company&#x2019;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#x2019;s insurance coverage, will not have a material adverse effect on the Company&#x2019;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#x2019;s business. Contracted physicians are required to obtain their own insurance coverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ameh:PercentageOfFinancialGuaranteeBenchmarkAmount
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDAvZnJhZzo3MDQ2ODI1NDgzMzI0NDE0YjJmNDk0NjI3ZjY2OTk2YS90ZXh0cmVnaW9uOjcwNDY4MjU0ODMzMjQ0MTRiMmY0OTQ2MjdmNjY5OTZhXzE4NDY_89bd4ae6-d71b-40d6-9b56-20633187f57c"
      unitRef="number">0.02</ameh:PercentageOfFinancialGuaranteeBenchmarkAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7886aad669f7475590e40c23c0dd147b_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDAvZnJhZzo3MDQ2ODI1NDgzMzI0NDE0YjJmNDk0NjI3ZjY2OTk2YS90ZXh0cmVnaW9uOjcwNDY4MjU0ODMzMjQ0MTRiMmY0OTQ2MjdmNjY5OTZhXzE5MzM_fe0b0b79-6eb5-40bf-bb03-387847bc7354"
      unitRef="usd">14800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="ibeb37dc642874abea221866138cc2490_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDAvZnJhZzo3MDQ2ODI1NDgzMzI0NDE0YjJmNDk0NjI3ZjY2OTk2YS90ZXh0cmVnaW9uOjcwNDY4MjU0ODMzMjQ0MTRiMmY0OTQ2MjdmNjY5OTZhXzIwMDY_45223160-5012-4868-adfe-cd78f5d01928"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i13fdfd16535e4f75a502075defa10c8a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDAvZnJhZzo3MDQ2ODI1NDgzMzI0NDE0YjJmNDk0NjI3ZjY2OTk2YS90ZXh0cmVnaW9uOjcwNDY4MjU0ODMzMjQ0MTRiMmY0OTQ2MjdmNjY5OTZhXzIxNDY_0c45482a-f915-4cb8-aa71-6149ee2a1edc"
      unitRef="usd">300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ia318b9c86cb8437086dadd8cd7bcfdb8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDAvZnJhZzo3MDQ2ODI1NDgzMzI0NDE0YjJmNDk0NjI3ZjY2OTk2YS90ZXh0cmVnaW9uOjcwNDY4MjU0ODMzMjQ0MTRiMmY0OTQ2MjdmNjY5OTZhXzE2NDkyNjc0NDU2MTQ_617b91dd-483a-4644-a4da-57e6a019e778"
      unitRef="usd">3800000</us-gaap:LineOfCredit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzQ1NDI_e371d572-0e11-46a7-8282-701f3fcec821">Related-Party TransactionsDuring the three and nine months ended September&#160;30, 2021 and 2020, NMM earned approximately $4.5 million and $4.2 million, respectively, and $13.2 million and $12.6 million, respectively, in management fees from LMA, which is accounted for under the equity method based on the 25% equity ownership interest held by APC in LMA&#x2019;s IPA line of business (see Note 5).&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $0.7 million and $0.5 million, respectively, and $1.7 million and $1.5 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $2.2 million and $1.2 million, respectively, and $5.4 million and $3.8 million, respectively, to DMG for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $0.3&#160;million and $0.1 million, respectively, and $0.4 million and $0.2 million to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $24,000 and $23,000, respectively, and $0.1 million and $0.1 million, respectively, to Fresenius Medical Care (&#x201c;Fresenius&#x201d;) and its subsidiaries for services as a provider. During the three and nine months ended September&#160;30, 2021 and 2020, APAACO paid approximately $0.2 million and $0.2 million, respectively, and $0.5 million and $0.5 million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company&#x2019;s board members is an officer of Fresenius.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $0.7 million and $0.1 million, respectively, and $1.1 million and $0.1 million, respectively, to Fulgent Genetics, Inc. for services as a provider. One of the Company&#x2019;s board members is a board member of Fulgent Genetics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2021 and 2020, APC paid an aggregate of approximately $10.1 million and $7.1 million to shareholders, respectively, which included approximately $1.8 million and $1.7 million, respectively, to shareholders who are also officers of APC. During the nine months ended September&#160;30, 2021 and 2020, APC paid an aggregate of approximately $25.3 million and $23.4 million to shareholders, respectively, and $5.6 million and $6.5 million, respectively, to shareholders who are also officers of APC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021 and 2020, the Company paid approximately $0 and $39,000, respectively, and $0 and $0.3 million, respectively, to Critical Quality Management Corporation (&#x201c;CQMC&#x201d;) for an office lease. CQMC shares common ownership with certain board members of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2021 and 2020, SCHC paid approximately $0.1 million and $0.1 million, respectively, and $0.3 million and $0.3 million, respectively, to Numen, LLC (&#x201c;Numen&#x201d;) for an office lease. Numen is owned by a shareholder of APC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine ended September&#160;30, 2021 and 2020, APC paid approximately $0.4 million and $0.4 million, respectively, and $1.1 million and $1.1 million, respectively, to One MSO for an office lease, which is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with Health Source MSO Inc., a California corporation (&#x201c;HSMSO&#x201d;), Aurion Corporation (&#x201c;Aurion&#x201d;), and AHMC Healthcare Inc. (&#x201c;AHMC&#x201d;) for services provided to the Company. One of the Company&#x2019;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#x2019;s board members. The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AHMC &#x2013; Risk pool, capitation, claims payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and nine months ended September&#160;30, 2021 and 2020, the Company has recognized risk pool revenue under this agreement of $21.5 million and $10.5 million, and $47.1&#160;million and $31.5&#160;million, respectfully, of which $47.9 million and $45.3 million remained outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2021 and 2020, NMM paid approximately $44,000 and $27,000, respectively, to an ApolloMed board member for consulting services. During the three months ended September&#160;30, 2021 and 2020, there were no payments to such ApolloMed board member for consulting services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, affiliates wholly owned by the Company&#x2019;s officers, including the Company&#x2019;s Co-CEOs, Dr. Kenneth Sim and Dr. Thomas Lam, are reported in the accompanying consolidated statements of operations on a consolidated basis, together with the Company&#x2019;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#x2019;s subsidiaries as related-party transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity method investments, loans receivable, and line of credits from related parties, see Notes 5, 6, and 9, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ic4dcff1f010e404e963a5a4fee776b5c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzEwNw_71810d5f-f764-4a4f-93d1-e39a448a6ed0"
      unitRef="usd">4500000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i342b9208e4894d718c1b127a0a3ff4fb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzExNA_ce4b86bb-311e-4d58-85d8-33e4188a64ba"
      unitRef="usd">4200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="icece2b97c5c941d3af2e6952b3212f8d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzEzNg_60105e5f-9248-4772-98f5-d9bda164c0de"
      unitRef="usd">13200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i40def8e50b1b4db5bd03f6203dc8a1a7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE0Mw_2d061019-f708-4c6c-9941-3c9996374f51"
      unitRef="usd">12600000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i471239abb6364a489ec282dd9c5f777c_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI0Ng_48812cbc-ef0c-44fe-8166-0ded907d876b"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i148d26d55f8f435b9874038459f936e1_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI0Ng_bc95016f-7e59-4109-b629-32c725437c8f"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="if752ba09e479448bb94fbca2c7882209_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM5OQ_ba88a58a-4de7-4ab5-a8c6-494afddb055c"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ib35d85fe21db4cfb8b79e5c7ee1228c3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzQwNg_0fb3a89c-0017-4473-bc2b-dc6800d95233"
      unitRef="usd">500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i1b9b3c7021d744e9b32b81acaaf16e56_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzQyOA_7a408a8c-4ba4-47d9-9172-993aed48ea42"
      unitRef="usd">1700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i58aaac3be5054957bf60bbd75029f96c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzQzNQ_edd43cf3-5007-4591-b17f-17b10fa399fd"
      unitRef="usd">1500000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3f003a8cc01d41348437b13692cef86c_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzU0MQ_c413147d-f5b0-40e4-9380-80ec4cfc98e9"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie68ce3d93d494b71998ca2d6f07d2c77_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzU0MQ_d93f26ad-8338-46f5-8250-111534fb8fc9"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3a7e5a8570084a00adb32a4bdb60bbd1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzY2NA_a537f79c-1d66-423d-95b5-4005fa8fb614"
      unitRef="usd">2200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i8b2df61df72d41dab21cfae235327e40_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzY3MQ_320969cb-3f3f-488c-9ccc-7df0353086f3"
      unitRef="usd">1200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i10f15782af0443ab842ba194eb8c55f8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzY5Mw_7d002d4f-b7c7-4df3-a039-ccf52d2d520f"
      unitRef="usd">5400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="iee30b0d2253f4bb492015b9d7da0adb5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzcwMA_ac7a8b60-6150-4773-bb27-1f678e3a22de"
      unitRef="usd">3800000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4dbf0fd1b79a4e77bdd4836d453ae1b0_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzgwNA_7777d488-b0d3-4d66-ac64-5eefbc036aa2"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="if47df11b72db4b389d16b2265853b9c2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzkyNw_946bc8d2-bf9d-45e8-8e48-d3cffbdd634b"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i1993cd5de17942f99b55c5e4dae41d86_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzkzNA_0baacd78-ac49-4d73-9142-8d63a1de8b8c"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="iec1fb7fa46f34dd39ecfb564894305ee_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzk1Ng_038cb298-79c9-471a-9d3a-41c026745deb"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i7395056c59fb49af99bb8cde1bd98437_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzk2Mw_a28d147b-ce4c-44d2-a9f5-57276a6303ef"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i25917a62f9c2433c936ab8aefbd468c7_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzExOTQ_c8f6df1b-cc32-4bf9-9783-587819fbee18"
      unitRef="usd">24000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ied011d8645e3412aa2f3e2387b1cb1a9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzEyMDE_6f754deb-bb9f-4f04-a8b2-cf420e9e94e4"
      unitRef="usd">23000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i23b30d2846b14b2c897a80d786dde119_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzEyMjM_ebffbf90-68b5-496e-b5b6-deb79c6f9a46"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ia6896fdcb8ae4b7ca99bd00de7787507_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzEyMzA_f7e01749-78fc-4625-8486-384a58139a3b"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ib5a867cf070d443da348b27bcc09a6f9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE0MTA_8796d96c-aa53-4dc5-9a35-16548dfc1e73"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ibdfaf156fde64914862fc81410e5c63a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE0MTc_aec2a98d-c6bf-416d-b497-04a85c502454"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ib523d137eddc47e29f0030b185a7b372_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE0Mzk_3559e760-8274-4aef-a12a-c6cc813b5818"
      unitRef="usd">500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i1b5a146f0b1e44f5b789255f0c543e0b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE0NDY_beafa884-9523-4c25-8703-ebab5c6e094c"
      unitRef="usd">500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i173a4dea7cb24055b072519c2bdfe757_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE2NTg_6399b1f6-d594-4756-bc64-07735e6392cd"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i54147940fa7a4e1fab0ebc8efdde6b95_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE2NjU_104639e6-ccc7-475c-8d97-3424ea67b599"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i21dc815a2c734a16a45443053949a1ac_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE2ODc_28038777-82f7-4699-8599-5fcd6ed890cc"
      unitRef="usd">1100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ifd69f4d08ad148e9ab3a76b73d5a7b44_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE2OTQ_82e58db3-0e34-4942-bf26-10d29144ee3a"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ie5c8495e26684dcc9ad519449c4bc3ec_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE5MTM_c5308740-f380-43d0-8999-143ca56aa62d"
      unitRef="usd">10100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3b9a649b9c8c46d6880482c83fb0ff4c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE5MjA_f3cddece-831a-4cb8-9493-796fdbafd590"
      unitRef="usd">7100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i478b087008894447ae487fe130dd89e6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE5ODM_77c4c879-b026-46f5-98fa-744dbccc5d99"
      unitRef="usd">1800000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="icafd606f127347a5a215b6401a63da94_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzE5OTA_3d8b8789-17f0-454a-8f09-c5147bd6c43c"
      unitRef="usd">1700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i5f3ab4e5a41043c2ae92af6c8f11dc34_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIxMzE_08278ff4-0196-4c50-8029-a901f2e461eb"
      unitRef="usd">25300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ib124a96ecc074da29278d04a4d7de485_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIxMzg_2f1c1228-b702-4786-bcfb-bfc18745066c"
      unitRef="usd">23400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ifb0c1db1b2d84d2fa57edc7c15d4fac4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIxNzY_c41f697f-a8c8-4b5c-8ed2-513023caab75"
      unitRef="usd">5600000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i51e4bde9a34f42159e327cca1a631656_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIxODM_d8c25a4e-3c88-4cb5-b131-0db73850756f"
      unitRef="usd">6500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ic03d35847f734105a48e1318bda34af3_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIzMjQ_d7402942-8d80-4ba0-87f9-d1eb0645eb9c"
      unitRef="usd">0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i7eb15316a75740d3a7e2f2bb4ec65285_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIzMzE_c2eba0f7-b7da-45c0-b87d-33f6bc3b79a2"
      unitRef="usd">39000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i2d0b297b84754d2ba32a089d68928fe4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIzNTM_0bc50cd3-2c07-4f51-890d-7003d8eb1311"
      unitRef="usd">0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i95582f9ab23c40c88ff9c9aa11e8368c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzIzNjA_f1aec528-8c85-4fbd-9990-b899b676c056"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i516478a0add344df8b418bb1e41a3d53_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI1ODE_3e16e54d-814e-4f7b-9df7-a07a170e77e2"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i01d16bcfadca4f16a85f305b306f3af5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI1ODg_9e34e200-528c-4056-abb5-1c60b008b66d"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="icb8612b46bf04b23bb32513fb5f4e06b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI2MTA_f2c3868f-b56c-49c9-a344-4ba39dc0b978"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i0a1d28025a574e8f8c021b319564a04e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI2MTc_d90163a1-1476-4ed3-ad4d-289a4d75b009"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="if6dfbbc083a24b1fb873315d3843b5bc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI3ODI_52cf86b3-763a-46a6-b9af-c2dc9c577710"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ia126933eaa88475f8ca99bc2e342801d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI3ODk_3c25f2ad-fd35-4b4d-ad31-1e0b4a0de6b0"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i5fe5c8cca1584e10a27f094882462ec4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI4MTE_bec7e36d-3517-41d5-a47f-ad4ebef12743"
      unitRef="usd">1100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i82d32e9e52cd43b8bde097d8ad4cf68d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI4MTg_92eebc3b-ba94-4e3f-8296-bbd63e9a4d81"
      unitRef="usd">1100000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i11c0bdbc45944c189d1902dd97e0b2c5_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI5NDI_342ce120-e035-40e8-86fd-132c209c99ff"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i33c01da554a346699ef38852e5a9238e_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzI5NDI_e615ace2-0bf7-44fb-807c-6c75165bbd76"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzQ1NDY_004dc216-32f3-4acd-a55e-52425abe723d">The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AHMC &#x2013; Risk pool, capitation, claims payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i6956147d1b1d44068bcecf36bebb1819_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzItMS0xLTEtMA_1e5cb734-ed4d-42f0-95ac-cb58c53ed93e"
      unitRef="usd">10712000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i3e8aacaa10644e039ce5c4b96322fc8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzItMy0xLTEtMA_98d6fa45-9ca7-488c-9ae8-2a2cc88d4c2f"
      unitRef="usd">5683000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="ia4380cb2b0e24e1994d0661bb4241a61_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzItNS0xLTEtMA_f40a59e9-1379-45fd-878e-b6d03b91af63"
      unitRef="usd">36505000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i9fe20fe658aa4256aabbbd2c89d398ea_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzItNy0xLTEtMA_b7ae4512-223f-46a9-ae9c-b0f6561d7679"
      unitRef="usd">23739000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <us-gaap:ManagementFeeExpense
      contextRef="iae1ae82bc8db4b2d995d2be127951787_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzMtMS0xLTEtMA_5941ac5a-5ad2-428a-a2a6-8b259c9ad3fe"
      unitRef="usd">33000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i5e9491c7189f4bc1a3a03bbff2758fdf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzMtMy0xLTEtMA_62921fd0-8a16-4ed4-a7dd-bd5e81ec54cb"
      unitRef="usd">109000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i5aa407ed2a23431cb3c6911df6e8bf96_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzMtNS0xLTEtMA_e3dac50a-3b7f-4519-95e6-eab90e10dbc5"
      unitRef="usd">141000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="iea3d25188b02481c84d1af0e34e1d2f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzMtNy0xLTEtMA_1dcabc52-bb17-4048-b740-709586b7f7e4"
      unitRef="usd">430000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i5b7b7c8fa79242e4b1f9fd2aed295aac_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzQtMS0xLTEtMA_813fc5d4-a7ff-40d5-83f9-564e285b4701"
      unitRef="usd">100000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="if2ed3ce186f64ecd9e26858f4e56cbaf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzQtMy0xLTEtMA_278f6f2c-e42d-4759-bf0c-bed35245cd71"
      unitRef="usd">100000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i699b0a24650b4020ab36add96e94ba16_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzQtNS0xLTEtMA_050a4260-0a3f-4fff-98d1-8c5adb427403"
      unitRef="usd">252000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i1df4d6d4265646919c8679d06c6f5f8d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzQtNy0xLTEtMA_6c7f5ccd-f299-45ac-8b6b-67fc8d8830ad"
      unitRef="usd">228000</us-gaap:ManagementFeeExpense>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzYtMS0xLTEtMA_d16f2ecc-f6da-45de-8bb8-4dd33bbe093a"
      unitRef="usd">10579000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzYtMy0xLTEtMA_351f560d-1234-4a08-b7f9-725d59d61f4c"
      unitRef="usd">5474000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzYtNS0xLTEtMA_4e06a118-d44b-4864-8ced-05292fa88071"
      unitRef="usd">36112000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90YWJsZTo4NWRjMzE2ZmRiNWY0YmU2OTEwM2MzYzNkYWNiNWE3ZC90YWJsZXJhbmdlOjg1ZGMzMTZmZGI1ZjRiZTY5MTAzYzNjM2RhY2I1YTdkXzYtNy0xLTEtMA_25ce00a1-59c0-4d94-8792-cc2bf9b495e3"
      unitRef="usd">23081000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i6956147d1b1d44068bcecf36bebb1819_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM3MTQ_ad1bc8a3-a780-4010-b5b9-869c1cb10448"
      unitRef="usd">21500000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="ia4380cb2b0e24e1994d0661bb4241a61_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM3MjE_c694884e-48ab-4d4f-9632-3981d9a80575"
      unitRef="usd">10500000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i3e8aacaa10644e039ce5c4b96322fc8b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM3NDM_d1d558c6-e660-4108-9f59-eb2ab50a99db"
      unitRef="usd">47100000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i9fe20fe658aa4256aabbbd2c89d398ea_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM3NTA_97145e65-287e-4345-964b-16a8132b4e97"
      unitRef="usd">31500000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i6847bf6720074c31bb84ab647a20bce7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM3NTQ_b42572d7-a9e5-42de-8aa1-70841d040f09"
      unitRef="usd">47900000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i7c8b780248c2455fb8dd5302f1cc8305_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM3NjE_7a949cd3-3f3c-4e79-a2f9-e4c00ebeec53"
      unitRef="usd">45300000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <ameh:PaymentConsultingFees
      contextRef="i4f9ab052b3f24f16b3cdc5fc945ba7a2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM5MTQ_8ed1299e-4316-48a2-8416-35520c9ad51b"
      unitRef="usd">44000</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="idb0ef53cb71e453a995be937fb48b3a6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM5MjE_85b66301-bcac-4e01-86c1-91497d41670f"
      unitRef="usd">27000</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="i447f7dcce84d4cebb5acb882ea34ecbb_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM4NDgyOTA3MDQxODA_21b30c3c-711d-4b96-8c55-06f354cd47da"
      unitRef="usd">0</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="i5973967987a64974bf0b313e96b45d1b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDMvZnJhZzowZTMwNTUwODE4MTI0ZTY4YjAyZjNmMGM0ZTk1ZDRlYy90ZXh0cmVnaW9uOjBlMzA1NTA4MTgxMjRlNjhiMDJmM2YwYzRlOTVkNGVjXzM4NDgyOTA3MDQxODA_e145f581-0fd4-411c-bf16-1ad535991d75"
      unitRef="usd">0</ameh:PaymentConsultingFees>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDkvZnJhZzo4MGY4YWQwZTRhZGM0OWVkODIxODI3YjY1ODk2OGFkNi90ZXh0cmVnaW9uOjgwZjhhZDBlNGFkYzQ5ZWQ4MjE4MjdiNjU4OTY4YWQ2XzI0Nzk_2faab9d5-14e9-442a-bfef-947d234d3ccc">Income Taxes&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the liability method of accounting for income taxes as set forth in ASC 740&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#x2019;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#x2019;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for the nine months ended September&#160;30, 2021 and September&#160;30, 2020, was 31.5% and 28.8%, respectively. The tax rate for the nine months ended September&#160;30, 2021, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#x2019; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2016 through December&#160;31, 2020, and for the years ended December 31, 2017 through December&#160;31, 2020, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDkvZnJhZzo4MGY4YWQwZTRhZGM0OWVkODIxODI3YjY1ODk2OGFkNi90ZXh0cmVnaW9uOjgwZjhhZDBlNGFkYzQ5ZWQ4MjE4MjdiNjU4OTY4YWQ2XzE1NTQ_003dca79-0b71-44c7-b00f-18636dfe393a"
      unitRef="number">0.315</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMDkvZnJhZzo4MGY4YWQwZTRhZGM0OWVkODIxODI3YjY1ODk2OGFkNi90ZXh0cmVnaW9uOjgwZjhhZDBlNGFkYzQ5ZWQ4MjE4MjdiNjU4OTY4YWQ2XzE1NjE_32e025f6-998b-4546-ac51-b966973e6f63"
      unitRef="number">0.288</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90ZXh0cmVnaW9uOjI2OWFjMDM0ODVlOTQ3YjNiN2JlMzA2NjdkZDk0NTBjXzExMTU_2a6c9316-d372-4e86-9cf9-aa20b9eeb7d7">Earnings Per Share&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated using the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, APC held 10,925,702 and 12,323,164 shares of ApolloMed&#x2019;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,301,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,364,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,273,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,551,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,608,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,149,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,339,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,249,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,301,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,364,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,273,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,551,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,608,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,149,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,339,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,249,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia1bd75ff5a784460bc879854f3dc5e14_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90ZXh0cmVnaW9uOjI2OWFjMDM0ODVlOTQ3YjNiN2JlMzA2NjdkZDk0NTBjXzcyNw_447bacae-22c7-45a4-9d76-9563d1fb4782"
      unitRef="shares">10925702</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id082ef37853342dbafac08634c15ffe0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90ZXh0cmVnaW9uOjI2OWFjMDM0ODVlOTQ3YjNiN2JlMzA2NjdkZDk0NTBjXzczNA_f93a0675-96c2-4a24-b802-e5df957bd727"
      unitRef="shares">12323164</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90ZXh0cmVnaW9uOjI2OWFjMDM0ODVlOTQ3YjNiN2JlMzA2NjdkZDk0NTBjXzExMTc_38b24c5a-499b-4919-8bea-db5bc4a50986">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,301,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,364,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,273,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,551,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,608,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,149,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,339,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,249,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzEtMi0xLTEtMA_49c4cde8-8abd-44bd-afa2-c1bca752f205"
      unitRef="usdPerShare">0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzEtNC0xLTEtMA_23c64d35-252e-42c0-a49e-25967a31c831"
      unitRef="usdPerShare">0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzItMi0xLTEtMA_9b107943-0056-4f8c-824a-729615acfc5e"
      unitRef="usdPerShare">0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzItNC0xLTEtMA_dc24899e-2c56-4f0d-aa98-1e05f2fd3ad9"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzMtMi0xLTEtMA_d45ced46-c086-418a-ac3a-c21fca022cb2"
      unitRef="shares">44301060</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzMtNC0xLTEtMA_5ad832c8-c967-4d09-b7b8-69740104f487"
      unitRef="shares">36364839</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzQtMi0xLTEtMA_ae1368c1-edaf-4b51-ad45-8930c3daf66b"
      unitRef="shares">46273640</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTpkMjFkZjM5N2U4ODg0MzMwODc2NjZmYmU5ZjMzNWI2Zi90YWJsZXJhbmdlOmQyMWRmMzk3ZTg4ODQzMzA4NzY2NmZiZTlmMzM1YjZmXzQtNC0xLTEtMA_1d2a509e-2ec2-4a99-91b4-844ab2850dba"
      unitRef="shares">37551740</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzEtMi0xLTEtMA_2c15b048-7548-4310-9e74-93d2834b3fc1"
      unitRef="usdPerShare">1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzEtNC0xLTEtMA_7f9623c8-4383-4d31-84cb-63929048593b"
      unitRef="usdPerShare">0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzItMi0xLTEtMA_56c70f49-b3d9-4904-a359-2a4856c78fc4"
      unitRef="usdPerShare">1.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzItNC0xLTEtMA_1548ef3d-f376-4341-9d93-1217fa324ef9"
      unitRef="usdPerShare">0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzMtMi0xLTEtMA_2b86f5a9-114b-40e9-850d-a35785114aa9"
      unitRef="shares">43608116</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzMtNC0xLTEtMA_1082fb12-4dff-489c-aa90-3d304fea273e"
      unitRef="shares">36149692</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzQtMi0xLTEtMA_fea4bcd5-ee04-4b6b-9942-9cdba35a48e0"
      unitRef="shares">45339372</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo4MzZlZjlkOTQxZTY0YTE0YWNlYjI2ZGFmYzk0MDBiOS90YWJsZXJhbmdlOjgzNmVmOWQ5NDFlNjRhMTRhY2ViMjZkYWZjOTQwMGI5XzQtNC0xLTEtMA_9cf8a4c1-3342-420c-aa77-1eb76fa63a37"
      unitRef="shares">37249967</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90ZXh0cmVnaW9uOjI2OWFjMDM0ODVlOTQ3YjNiN2JlMzA2NjdkZDk0NTBjXzExMTI_a2ec5795-9963-4337-959c-faa44af6d2b4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,301,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,364,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,273,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,551,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,608,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,149,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,339,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,249,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzEtMi0xLTEtMA_a8a502b9-aaa2-48e3-8b8b-6ca52e682d90"
      unitRef="shares">44301060</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzEtNC0xLTEtMA_b134d3fc-df5b-4a7f-abb5-287646090a22"
      unitRef="shares">36364839</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie1b43cafde674d70aa71314660d7da57_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzMtMi0xLTEtMA_0759806a-7818-47fd-aa5f-384a8d6201de"
      unitRef="shares">583639</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i852e3ec3537a4c119c5f8a22d38b551a_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzMtNC0xLTEtMA_afe0c555-eba6-4605-ae4e-b85f036e8185"
      unitRef="shares">187843</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie0047fe9e823452fb45b32fabf79ea46_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzQtMi0xLTEtMA_3bba995c-2ae7-4135-bfef-d816e7a373bd"
      unitRef="shares">1083216</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6ef913adaabe443884d85c0a2a9ace03_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzQtNC0xLTEtMA_182f02df-ec56-4764-ab87-73a0cc928af0"
      unitRef="shares">960806</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie0932a147a2f4eaaaf31703eddb2b244_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzUtMi0xLTEtMA_5ba6ddae-ed65-42ea-b202-3be023cec8d7"
      unitRef="shares">305725</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ic947409b267649339b37e4b534577ae3_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzUtNC0xLTEtMA_08ea9669-eee4-45ea-a130-923891f7834d"
      unitRef="shares">38252</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzYtMi0xLTEtMA_7fedcc25-2750-40ca-b8e9-03a545f7fefd"
      unitRef="shares">46273640</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZToxOWQxYTIxOWU0MzA0MmQ1YTlhNGE5ZWRmMDIxZWM4OS90YWJsZXJhbmdlOjE5ZDFhMjE5ZTQzMDQyZDVhOWE0YTllZGYwMjFlYzg5XzYtNC0xLTEtMA_253d045a-8838-4dde-a9c6-b81519d8e23a"
      unitRef="shares">37551740</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzEtMi0xLTEtMA_52feb3d1-b9b4-46a5-aecc-86a87f18f1a2"
      unitRef="shares">43608116</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzEtNC0xLTEtMA_228158eb-9103-403b-a85a-0ddedbde61de"
      unitRef="shares">36149692</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i1c285663f977492290e465d3a04c4a3d_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzMtMi0xLTEtMA_82f3286e-b457-4441-941c-69dc265a1bac"
      unitRef="shares">498296</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i4d3b34a11c90439a83c552a032829eb0_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzMtNC0xLTEtMA_c0c8b0e3-9d54-4ce4-adce-64bc6fbd8e9c"
      unitRef="shares">178445</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i56d750657b42421a8e440b3dd05fd4dd_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzQtMi0xLTEtMA_965a8b13-a0eb-4310-9ea2-403c7bf98c97"
      unitRef="shares">971935</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib67e38d8ef3944d2b52b5cddc0110cf3_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzQtNC0xLTEtMA_213d82ad-8b0d-478b-a275-781cb312bc14"
      unitRef="shares">890489</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i2a5bb1b525984a4b94e3835c3d3c958d_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzUtMi0xLTEtMA_7c8688e3-c2e5-4ce7-82bd-2a0f6af2f58b"
      unitRef="shares">261025</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i36efa1094ce84f39a33d944df471c9bc_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzUtNC0xLTEtMA_dd51e457-0717-4105-bd82-8f604e78aa2d"
      unitRef="shares">31341</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzYtMi0xLTEtMA_1e97afb8-bccb-4ebb-82de-7f8377fd943f"
      unitRef="shares">45339372</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTIvZnJhZzoyNjlhYzAzNDg1ZTk0N2IzYjdiZTMwNjY3ZGQ5NDUwYy90YWJsZTo2ZDM4M2YwNWNmZDc0MGM2YWYyMzg0OTZmYjc0M2FmMC90YWJsZXJhbmdlOjZkMzgzZjA1Y2ZkNzQwYzZhZjIzODQ5NmZiNzQzYWYwXzYtNC0xLTEtMA_8d3c3b0d-4bb0-4df0-a89a-0684a5afe0d1"
      unitRef="shares">37249967</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90ZXh0cmVnaW9uOmM0N2E3ZjJmMDgwNDQzMTI5Y2M5NzE2YWJmNWI3YWM2XzE5MTY_d20e369c-0bfa-4f8b-9bd6-f74212ce9b81">Variable Interest Entities (VIEs)&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#x2019;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#x2013; &#x201c;Basis of Presentation and Summary of Significant Accounting Policies - Variable Interest Entities&#x201d; to the accompanying consolidated financial statements for information on how the Company determines VIEs and their treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#x2019;s other consolidated VIEs were not considered significant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due from affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loans receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in privately held entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due to affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90ZXh0cmVnaW9uOmM0N2E3ZjJmMDgwNDQzMTI5Y2M5NzE2YWJmNWI3YWM2XzE5MTM_65cce0f9-9270-461d-adf4-1b45b20d9a8e">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#x2019;s other consolidated VIEs were not considered significant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due from affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loans receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in privately held entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due to affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQtMS0xLTEtMA_1128f282-c56f-4570-b3cd-919c98695676"
      unitRef="usd">121258000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQtMy0xLTEtMA_b9a93b96-c990-4b5c-8ed6-0580f4e0d301"
      unitRef="usd">126158000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzYtMS0xLTEtMA_1189dc89-3ae0-470e-b5eb-3fd844862a9d"
      unitRef="usd">124569000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzYtMy0xLTEtMA_f5c224c3-0c4c-4449-8156-4f7318df5ea5"
      unitRef="usd">67637000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzctMS0xLTEtMA_11d65af9-ffdb-48bc-b05b-ff068ede8721"
      unitRef="usd">15927000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzctMy0xLTEtMA_201ba4ff-676c-41d1-a52f-f9dfeba2e68d"
      unitRef="usd">5155000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzgtMS0xLTEtMA_a1a31332-7bf8-4a82-8488-da92d1a0cffa"
      unitRef="usd">50454000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzgtMy0xLTEtMA_dde676fe-d92e-4814-86e3-3174b620b94c"
      unitRef="usd">46718000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzktMS0xLTEtMjkxMzQ_f3b5ff23-b4f4-435e-aab3-bfefc45eb62e"
      unitRef="usd">4267000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzktMy0xLTEtMjkxMzQ_7926a09f-347f-4233-b044-9ea8f00955e2"
      unitRef="usd">0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzktMS0xLTEtMA_ada1a9c0-c869-4f08-b216-0dd11a991ae5"
      unitRef="usd">293000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzktMy0xLTEtMA_32f4bfba-465b-4cb5-b3e2-ec1ec1a5426b"
      unitRef="usd">1084000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzEwLTEtMS0xLTA_a38dc82e-8ca3-4bb9-bc51-01cdba280121"
      unitRef="usd">9808000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzEwLTMtMS0xLTA_6d5ed2da-1db0-4916-bfac-ed6fffaf26da"
      unitRef="usd">14863000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzEzLTEtMS0xLTA_bc9669ad-9778-437d-8bf5-c50302050803"
      unitRef="usd">4000000</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzEzLTMtMS0xLTA_336821d6-fb44-4718-b66e-299a01c3dde8"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE0LTEtMS0xLTA_acc71875-8909-4b3e-8d3f-7da414bb49b6"
      unitRef="usd">15764000</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE0LTMtMS0xLTA_7a5ab83a-252f-49ee-bc8b-fca775648939"
      unitRef="usd">0</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE1LTEtMS0xLTA_83c6e474-6177-4c95-8917-b46fc0db95c0"
      unitRef="usd">346340000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE1LTMtMS0xLTA_d427cbea-fb0b-4615-9713-65788fe7cd88"
      unitRef="usd">261615000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE4LTEtMS0xLTA_5a7f620f-c751-496e-ba06-cfb68129bff9"
      unitRef="usd">47253000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE4LTMtMS0xLTA_eaff5de0-3fa7-40ae-b51a-48912f1f8ee3"
      unitRef="usd">27599000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE5LTEtMS0xLTA_677b985b-4896-461a-b05f-7bbb999d9189"
      unitRef="usd">61140000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzE5LTMtMS0xLTA_3e338e23-4059-4fd8-9f54-40ca9c9df6b1"
      unitRef="usd">69250000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIwLTEtMS0xLTA_59c566a4-9ac7-4184-9c91-9c0f945ab7e0"
      unitRef="usd">109460000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIwLTMtMS0xLTA_7a7ec3b6-1f23-4199-88c9-1da455aa99e9"
      unitRef="usd">109460000</us-gaap:Goodwill>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIxLTEtMS0xLTA_824dcd79-d0f9-436f-8acb-8c4f5b075521"
      unitRef="usd">104000</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIxLTMtMS0xLTA_d2990072-910c-4a5d-9664-3bcce6cc01e0"
      unitRef="usd">4145000</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:OtherLongTermInvestments
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIyLTEtMS0xLTA_a3790c39-ebeb-44fc-950f-79dda6a6f451"
      unitRef="usd">994785000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIyLTMtMS0xLTA_6777943d-e6d1-4309-aa6d-773e7004f1a2"
      unitRef="usd">225144000</us-gaap:OtherLongTermInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIzLTEtMS0xLTA_42d6419a-61af-4256-a98c-d82c931df827"
      unitRef="usd">45046000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzIzLTMtMS0xLTA_41bbb638-d424-4926-96f0-b267aac0302a"
      unitRef="usd">43516000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI0LTEtMS0xLTA_8bf8d93b-d4bd-4052-8a8c-4b726592638e"
      unitRef="usd">405000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI0LTMtMS0xLTA_036f8695-e672-4d12-b81e-0a863a5571c4"
      unitRef="usd">36584000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI1LTEtMS0xLTA_4c540d57-90ac-4baf-8bfb-aa2a43ee42ad"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI1LTMtMS0xLTA_c4fe6333-674b-4df9-a34e-4338ae049070"
      unitRef="usd">500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI2LTEtMS0xLTA_56d891bc-3ad9-4925-b706-d27592c601fc"
      unitRef="usd">5258000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI2LTMtMS0xLTA_22e50072-dd26-44ef-96fb-44e1d1c75e6c"
      unitRef="usd">6298000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI3LTEtMS0xLTA_f4a843e9-9df8-4753-8b68-1f74f5404f9b"
      unitRef="usd">2533000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI3LTMtMS0xLTA_f87475d6-7901-40d9-993c-640143f3b500"
      unitRef="usd">17177000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI5LTEtMS0xLTA_864e753c-f4d7-4601-b92b-a91a19ebf35b"
      unitRef="usd">1265984000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzI5LTMtMS0xLTA_32ea4950-024c-48ad-9d29-8476c690db07"
      unitRef="usd">539673000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzMxLTEtMS0xLTA_65447f52-9292-44a2-b11d-10abe2b89810"
      unitRef="usd">1612324000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzMxLTMtMS0xLTA_ff1be1fe-36c4-4241-8263-3c6326b82b95"
      unitRef="usd">801288000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM0LTEtMS0xLTA_e11b244c-e8fe-49f7-868e-344e63012828"
      unitRef="usd">15202000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM0LTMtMS0xLTA_675f1604-9fa5-4347-8e9e-f99a4de1e3bb"
      unitRef="usd">12963000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM1LTEtMS0xLTA_dbe5cf7c-b75c-4422-8908-ea111a43397a"
      unitRef="usd">8827000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM1LTMtMS0xLTA_22628707-a4a9-4851-a1dc-83e37878fd86"
      unitRef="usd">9642000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM2LTEtMS0xLTA_1dc29460-a5dd-4165-9012-ebb4a2af71c4"
      unitRef="usd">34998000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM2LTMtMS0xLTA_dc797418-90e5-417e-8ad1-f0dbb6822628"
      unitRef="usd">37684000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:TaxesPayableCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM3LTEtMS0xLTA_4f29bd7a-e993-4335-997b-e7e9e1411344"
      unitRef="usd">0</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM3LTMtMS0xLTA_1e454a82-1e5a-403f-bd4e-92723a25fd7c"
      unitRef="usd">4225000</us-gaap:TaxesPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM4LTEtMS0xLTA_91968cbd-1731-48d3-946c-366e54ae9a7d"
      unitRef="usd">556000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM4LTMtMS0xLTA_2193de96-4ae8-4831-8033-34234e412670"
      unitRef="usd">485000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM5LTEtMS0xLTA_b45d142a-7287-4b40-b8c1-e1d2b5d66730"
      unitRef="usd">0</us-gaap:DueToAffiliateCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzM5LTMtMS0xLTA_1f06bdfe-55d6-46d7-b724-19f955db0a97"
      unitRef="usd">22698000</us-gaap:DueToAffiliateCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQwLTEtMS0xLTA_501dd3dd-228d-466c-a8ef-e1880346f559"
      unitRef="usd">207000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQwLTMtMS0xLTA_416e6aa8-6e2f-4ea9-8d90-01d887bc7d9d"
      unitRef="usd">201000</us-gaap:LongTermDebtCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQxLTEtMS0xLTA_7cb467b3-8505-4857-a144-53e3982f2b6f"
      unitRef="usd">110000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQxLTMtMS0xLTA_893f9880-950b-4c4f-9b61-664b463b1985"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQyLTEtMS0xLTA_c76ad574-e57e-4988-be99-3afe54914132"
      unitRef="usd">1231000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQyLTMtMS0xLTA_c8f9eb40-5bde-40d4-a113-9a7d740a9030"
      unitRef="usd">1242000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ0LTEtMS0xLTA_56df6159-0c7b-4b17-a693-c0e8db183532"
      unitRef="usd">61131000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ0LTMtMS0xLTA_d3b94ce0-8fff-4029-8d25-d48227d9e9c7"
      unitRef="usd">89242000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ3LTEtMS0xLTA_1246024a-a32c-4ad1-be7c-8d645b04f50c"
      unitRef="usd">7245000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ3LTMtMS0xLTA_ce170a0b-fb4d-4b31-ab56-6a6fb97833cb"
      unitRef="usd">7379000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ4LTEtMS0xLTA_6e9a26c8-8dea-4f31-b7a8-4c5ef8b8fe7d"
      unitRef="usd">18941000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ4LTMtMS0xLTA_63f81412-fa02-412c-baf0-46de6bebb73b"
      unitRef="usd">9144000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ5LTEtMS0xLTA_e172b868-5b98-42d8-92fa-ff1b5eb4cc73"
      unitRef="usd">221000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzQ5LTMtMS0xLTA_c69a86a5-3c40-441e-ad58-e8c344f167a6"
      unitRef="usd">311000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzUwLTEtMS0xLTA_2d0ae06e-ef9a-415b-aa0c-a42c516f02d5"
      unitRef="usd">4262000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzUwLTMtMS0xLTA_7be27547-14de-4ff5-885a-19c8d854ba75"
      unitRef="usd">5242000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzUxLTEtMS0xLTA_63ab0148-7300-4ad9-a74c-d0b0b1c79da4"
      unitRef="usd">1010000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzUxLTMtMS0xLTA_f73a16e6-e853-491f-80d1-0e712b9a7c48"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzUzLTEtMS0xLTA_b756c984-d0ec-45cf-b85b-da18b7b2d674"
      unitRef="usd">31679000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzUzLTMtMS0xLTA_7ca2277a-ad8e-4fc0-be52-db735faa7fe1"
      unitRef="usd">22076000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ic1e0dd2e99004d919fd565b247e9d0e1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzU1LTEtMS0xLTA_29cbd84f-438e-4a0a-9288-8fb2a0924ace"
      unitRef="usd">92810000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic97fcf3f2d8145e88d3f7b8726a2df40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTUvZnJhZzpjNDdhN2YyZjA4MDQ0MzEyOWNjOTcxNmFiZjViN2FjNi90YWJsZTplZGFlNGY4ZWEyNTY0ZDQ2ODMzOTViNGYxZTg2ZWNmOC90YWJsZXJhbmdlOmVkYWU0ZjhlYTI1NjRkNDY4MzM5NWI0ZjFlODZlY2Y4XzU1LTMtMS0xLTA_860e6811-ad29-472e-b03c-a66d24f316b7"
      unitRef="usd">111318000</us-gaap:Liabilities>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzEwNjE_20c74ba0-ee8a-4d1c-832e-a454f455074b">Leases&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, physicians&#x2019; offices, and certain equipment. These leases have remaining lease terms of one month to five years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of September&#160;30, 2021 and December&#160;31, 2020, assets recorded under finance leases were $0.3 million and $0.4 million, respectively, and accumulated depreciation associated with finance leases were $0.5 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.44 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.93 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.92 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of September&#160;30, 2021, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the nine months ended September&#160;30, 2021)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company does not have additional operating and finance leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzEwNjg_bb605654-caa7-483e-aaff-85b617e84ab3">Leases&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, physicians&#x2019; offices, and certain equipment. These leases have remaining lease terms of one month to five years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of September&#160;30, 2021 and December&#160;31, 2020, assets recorded under finance leases were $0.3 million and $0.4 million, respectively, and accumulated depreciation associated with finance leases were $0.5 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.44 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.93 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.92 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of September&#160;30, 2021, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the nine months ended September&#160;30, 2021)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company does not have additional operating and finance leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ib6cab8e82bce461aadf4a8285aaedf2d_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzE3Mw_67f3f515-b662-43b5-8f9d-054bd9b94733">P1M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="ib6cab8e82bce461aadf4a8285aaedf2d_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzE3Mw_9c215b35-3190-4102-b0a8-1d0bdb1d92f0">P1M</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="i396303604fe24b649811f19aa1b86666_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzE3OQ_1ab50a1d-bc4e-4ca1-a575-e55e3867f654">P5Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i396303604fe24b649811f19aa1b86666_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzE3OQ_229c689d-ead4-4bb8-9aff-46d1e7fb0fbc">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzI0OA_e997c0d6-11c2-4924-a578-68ebad08d82f">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzI0OA_ed643b88-b0ad-46bc-ab63-38ec79b67ae0">P10Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzMyNw_767b6ba6-334c-4275-ba01-28c2123c1788">P1Y</ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable>
    <ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzMyNw_a036cfa7-d834-4042-8f52-386637034f2c">P1Y</ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzM5MA_73a7a900-d681-4337-9933-c3ce34ffd0d0"
      unitRef="usd">300000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzM5Nw_0347fbea-36ef-46de-9020-6c3bdc0f6495"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzQ4MA_9690e4f3-0416-4d39-bcab-610c3b3020c6"
      unitRef="usd">500000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i2044abfbff374e8e958e907e8efcac87_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzQ4Nw_b831f37b-b0fe-43e5-a6ea-54bca0625ca2"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzEwNjQ_5f46b5ec-d98a-47e8-b16c-0363412542d8">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.44 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.93 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.92 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzMtMS0xLTEtMA_300e26a4-6791-4ac4-9e45-e5bcdb3e1558"
      unitRef="usd">1379000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzMtMy0xLTEtMA_a9bf0c53-6f5a-45ce-b8ea-94422251990c"
      unitRef="usd">1784000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzYtMS0xLTEtMA_e661d3b2-367d-46cc-b438-e3af724602c1"
      unitRef="usd">27000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzYtMy0xLTEtMA_40a23e0d-7889-4c4e-82d5-3ac621faca7d"
      unitRef="usd">26000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzctMS0xLTEtMA_f5869e3b-b8e5-41b5-b7ac-48ec5d5ac4ee"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzctMy0xLTEtMA_8a167c3f-d681-46b2-b440-9e95fb0c208f"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzktMS0xLTEtMA_6ca9001b-15b1-4591-b550-0791d900297b"
      unitRef="usd">235000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzktMy0xLTEtMA_6b5dccd1-48a7-48e4-a960-31faedef182b"
      unitRef="usd">206000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzExLTEtMS0xLTA_0435b662-8899-4d48-aa8f-4afef5e65341"
      unitRef="usd">1174000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YjEwYzk0ZTM4Y2I0NjIxOTQ3NjhjZDQ3ZTZjNTJlYy90YWJsZXJhbmdlOjRiMTBjOTRlMzhjYjQ2MjE5NDc2OGNkNDdlNmM1MmVjXzExLTMtMS0xLTA_5c99dd61-718e-45fc-8d65-8a766cc2d333"
      unitRef="usd">1607000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzQtMS0xLTEtMA_448c54e0-c1d1-409a-8f83-55bcc059e993"
      unitRef="usd">3893000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzQtMy0xLTEtMA_cfdc3002-6942-416b-b14a-76d687c1aa98"
      unitRef="usd">5172000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzctMS0xLTEtMA_42e22d09-f520-4da6-b96d-ac064bdf9640"
      unitRef="usd">81000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzctMy0xLTEtMA_096952d4-0dc9-4ea1-baa3-b6cefb034495"
      unitRef="usd">78000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzgtMS0xLTEtMA_3fbc6017-1a3a-45ee-a404-b257a8d6569d"
      unitRef="usd">8000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzgtMy0xLTEtMA_33994c82-4699-48f5-a03b-f8ae09aea159"
      unitRef="usd">11000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzEwLTEtMS0xLTA_5edf57bf-0bb0-4369-b6b7-e482ebfe1f2c"
      unitRef="usd">709000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzEwLTMtMS0xLTA_452fa786-db8a-4f5f-862c-62b659d21770"
      unitRef="usd">567000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzEyLTEtMS0xLTA_8731d281-e509-475f-8a92-feff28192ff6"
      unitRef="usd">3273000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTowMzUyZmI2NmM2NDI0ZjM0OWRkNWE4MDIwYjRkZDk1NS90YWJsZXJhbmdlOjAzNTJmYjY2YzY0MjRmMzQ5ZGQ1YTgwMjBiNGRkOTU1XzEyLTMtMS0xLTA_562b0767-aae5-4e0f-9078-9855d5cff2d8"
      unitRef="usd">4694000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzYtMS0xLTEtMA_008a46f1-8a3e-47a1-8252-b7ee1c69ab2a"
      unitRef="usd">1414000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzYtMy0xLTEtMA_e05b6a69-4ad4-46bf-bc62-c9eccf8120c5"
      unitRef="usd">1489000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzctMS0xLTEtMA_f5869e3b-b8e5-41b5-b7ac-48ec5d5ac4ee"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzctMy0xLTEtMA_8a167c3f-d681-46b2-b440-9e95fb0c208f"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzgtMS0xLTEtMA_e661d3b2-367d-46cc-b438-e3af724602c1"
      unitRef="usd">27000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzgtMy0xLTEtMA_40a23e0d-7889-4c4e-82d5-3ac621faca7d"
      unitRef="usd">26000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9204aec484984ed29b67419657e5334e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzExLTEtMS0xLTA_241d2d2e-b124-48e9-8aa3-5a93f2a1bf35"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i41ee4dfec7714e52bcb3dbced4af6282_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzExLTMtMS0xLTA_2fb0d348-d4a9-447d-a210-91e569131f06"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzE5LTEtMS0xLTA_b1ff6526-07e7-4d67-abc9-d1a1ad364fd5"
      unitRef="usd">3903000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzE5LTMtMS0xLTA_0622c3cc-25b1-4248-b21b-2f4e1990f165"
      unitRef="usd">4369000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzIwLTEtMS0xLTA_3fbc6017-1a3a-45ee-a404-b257a8d6569d"
      unitRef="usd">8000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzIwLTMtMS0xLTA_33994c82-4699-48f5-a03b-f8ae09aea159"
      unitRef="usd">11000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzIxLTEtMS0xLTA_42e22d09-f520-4da6-b96d-ac064bdf9640"
      unitRef="usd">81000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzIxLTMtMS0xLTA_096952d4-0dc9-4ea1-baa3-b6cefb034495"
      unitRef="usd">78000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzI0LTEtMS0xLTA_e1679224-eb7e-40df-bda4-b88f6177e4f7"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id7a562bf4e9e40948b74d5b1d526073d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzI0LTMtMS0xLTA_85f3d07a-c6ff-4cb0-970d-ae8add55c2d9"
      unitRef="usd">7652000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzMxLTEtMS0xLTA_f8660ea0-f3ac-403e-8127-d74b8417bdfd">P6Y5M8D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i03292c592c4f45da834c806bff481c24_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzMxLTMtMS0xLTA_a9f14d73-09f3-42c1-92ad-062fa61f29f8">P6Y11M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzMyLTEtMS0xLTA_49ddd540-bd6a-4d5f-9732-e1e170ac9584">P2Y11M1D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i03292c592c4f45da834c806bff481c24_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzMyLTMtMS0xLTA_8b02633c-190f-455b-90ff-4a55c0717201">P3Y11M1D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzM2LTEtMS0xLTA_29689737-9e7f-4a54-82f2-b7486ef2eac5"
      unitRef="number">0.0610</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i03292c592c4f45da834c806bff481c24_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzM2LTMtMS0xLTA_07596c8f-7991-44a5-ae47-68aff7b5cd87"
      unitRef="number">0.0610</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzM3LTEtMS0xLTA_828d69f4-e6f4-49a2-8d35-59e38325807d"
      unitRef="number">0.0300</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i03292c592c4f45da834c806bff481c24_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo3NDkzMjQ0ZTMxMTE0NmU4OTlkMTE4YzUyYzQxNzg5NC90YWJsZXJhbmdlOjc0OTMyNDRlMzExMTQ2ZTg5OWQxMThjNTJjNDE3ODk0XzM3LTMtMS0xLTA_a1e86399-6dc2-437f-85e1-82b3b5a89064"
      unitRef="number">0.0300</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzEwNTg_d2580e02-235a-457e-be31-c001a670fe79">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of September&#160;30, 2021, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the nine months ended September&#160;30, 2021)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90ZXh0cmVnaW9uOjMwNTlkNmFiYzFlMTRhYjlhODExODI5MWZmM2VhNTM2XzEwNjc_6a0d4a14-91c1-404f-a438-875007256de0">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of September&#160;30, 2021, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the nine months ended September&#160;30, 2021)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzEtMS0xLTEtMA_7cd16092-67ae-47ff-bd67-edf01b277645"
      unitRef="usd">950000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzEtMy0xLTEtMA_e0605b71-41c9-4e3d-a446-e5b33ab68125"
      unitRef="usd">29000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzItMS0xLTEtMA_52824e27-b80e-4f7e-a9ab-fe19bf471adf"
      unitRef="usd">3529000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzItMy0xLTEtMA_bf982d29-27a5-456b-a2f4-dcb77af638b1"
      unitRef="usd">119000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzMtMS0xLTEtMA_490f62bf-0a42-4161-923e-481b4c81c0c1"
      unitRef="usd">3303000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzMtMy0xLTEtMA_142905d2-e9bd-44a7-9861-a3aed3986ccc"
      unitRef="usd">119000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzQtMS0xLTEtMA_7182943c-be2e-4d54-a606-b4e34d1b0b13"
      unitRef="usd">2940000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzQtMy0xLTEtMA_05d5fadb-e846-40a8-baf5-c4f97ec11267"
      unitRef="usd">79000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzUtMS0xLTEtMA_27b5b774-0632-4aa2-a5bc-d8d12001b307"
      unitRef="usd">2648000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzUtMy0xLTEtMA_4b37ab60-9275-433f-ad1a-46026e5776fc"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzYtMS0xLTEtMA_ab0e5c86-c277-4609-9d96-8bc69a3cf708"
      unitRef="usd">6811000</ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <ameh:FinanceLeaseLiabilityToBePaidAfterYearFour
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzYtMy0xLTEtMA_f5b14df1-e729-4ca9-b57c-c3f7276b2219"
      unitRef="usd">0</ameh:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzgtMS0xLTEtMA_614d1f01-7983-475a-91e8-d68961c951be"
      unitRef="usd">20181000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzgtMy0xLTEtMA_ed5414ea-fbc3-47b0-89a3-8dd48597e95f"
      unitRef="usd">346000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzktMS0xLTEtMA_f941247c-4f60-44e7-a805-6177cff8cd45"
      unitRef="usd">3667000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzktMy0xLTEtMA_89781763-a834-45e2-9f18-e9ae1e61ee92"
      unitRef="usd">15000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzEwLTEtMS0xLTA_bbdf957a-e49c-494e-a76e-bf5d82df9a11"
      unitRef="usd">16514000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzEwLTMtMS0xLTA_7171917e-180a-4c20-882e-a5a28e28dac3"
      unitRef="usd">331000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzExLTEtMS0xLTA_42aede68-018a-46d6-b4d2-78f5dbc2e448"
      unitRef="usd">2658000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzExLTMtMS0xLTA_b3d6262d-513f-44b7-9fd7-a81cdafdd711"
      unitRef="usd">110000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzEyLTEtMS0xLTA_162c5635-5323-45aa-8fb5-fd7e04c6e3f6"
      unitRef="usd">13856000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i38ab054fe9a44fa7991c114c1a431acf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMTgvZnJhZzozMDU5ZDZhYmMxZTE0YWI5YTgxMTgyOTFmZjNlYTUzNi90YWJsZTo0YmI2Nzk4OTVkMmU0OWUxYjFmYjNhNzlmOGMzMjQ0OS90YWJsZXJhbmdlOjRiYjY3OTg5NWQyZTQ5ZTFiMWZiM2E3OWY4YzMyNDQ5XzEyLTMtMS0xLTA_750d4ac8-d3ab-450b-9304-504eb776d658"
      unitRef="usd">221000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i98abf3b35b1e47579577f59184a244a3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMjQvZnJhZzozN2FhNzk5MjMxZWI0N2FjOTk3NWY4YjY1ODJjNDNkMy90ZXh0cmVnaW9uOjM3YWE3OTkyMzFlYjQ3YWM5OTc1ZjhiNjU4MmM0M2QzXzEwMzc_8b230aa7-e23c-4f3a-bb73-4c8fd0c738bf">Subsequent EventsDMGIn October 2021, the Company entered into an agreement to purchase within three years all of the remaining equity interests in DMG. The Company currently owns 40% of DMG and has committed to purchasing the remaining 60% within three years. In accordance with relevant accounting guidance, the Company has determined that DMG is a variable interest entity of the Company; therefore, DMG's financial statements will be consolidated with those of the Company.</us-gaap:SubsequentEventsTextBlock>
    <ameh:EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod
      contextRef="i6af953349f5741e6903f07fe40567fb1_D20211001-20211031"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMjQvZnJhZzozN2FhNzk5MjMxZWI0N2FjOTk3NWY4YjY1ODJjNDNkMy90ZXh0cmVnaW9uOjM3YWE3OTkyMzFlYjQ3YWM5OTc1ZjhiNjU4MmM0M2QzXzM4NDgyOTA3MDkyNTI_b57eaee3-7938-4eb4-92f5-c6d2fedaac4c">P3Y</ameh:EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i347edc610f5f44f797de7ecdf6022137_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMjQvZnJhZzozN2FhNzk5MjMxZWI0N2FjOTk3NWY4YjY1ODJjNDNkMy90ZXh0cmVnaW9uOjM3YWE3OTkyMzFlYjQ3YWM5OTc1ZjhiNjU4MmM0M2QzXzM4NDgyOTA3MDkyODI_b45c5c8a-75d5-4cc4-84fd-093b6444113a"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:EquityMethodInvestmentAdditionalPercentageCommittedToPurchase
      contextRef="iea7d2b87a68e4688b5afefdb57fd6387_I20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMjQvZnJhZzozN2FhNzk5MjMxZWI0N2FjOTk3NWY4YjY1ODJjNDNkMy90ZXh0cmVnaW9uOjM3YWE3OTkyMzFlYjQ3YWM5OTc1ZjhiNjU4MmM0M2QzXzM4NDgyOTA3MDg0NTY_5ce67379-7f73-40a8-896c-4db9fe1c3c4d"
      unitRef="number">0.60</ameh:EquityMethodInvestmentAdditionalPercentageCommittedToPurchase>
    <ameh:EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod
      contextRef="i6af953349f5741e6903f07fe40567fb1_D20211001-20211031"
      id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8xMjQvZnJhZzozN2FhNzk5MjMxZWI0N2FjOTk3NWY4YjY1ODJjNDNkMy90ZXh0cmVnaW9uOjM3YWE3OTkyMzFlYjQ3YWM5OTc1ZjhiNjU4MmM0M2QzXzM4NDgyOTA3MDkyNzI_a0d7e59e-1a83-4339-9ee9-3f08857f80ab">P3Y</ameh:EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzAtMy0xLTEtMA_a5ff60fb-e978-4632-811f-8acc8fde5032"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzAtMy0xLTEtMA_a5ff60fb-e978-4632-811f-8acc8fde5032"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzAtMS0xLTEtMA_6c7a426a-55b6-48ec-8702-a4a1872ac251"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzAtMS0xLTEtMA_6c7a426a-55b6-48ec-8702-a4a1872ac251"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTUtMS0xLTEtMA_1158702b-f85a-49a8-b56e-bc619fb29d85"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTUtMS0xLTEtMA_1158702b-f85a-49a8-b56e-bc619fb29d85"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTUtMy0xLTEtMA_83cf3721-9957-4807-97c8-1f0e124151ee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTUtMy0xLTEtMA_83cf3721-9957-4807-97c8-1f0e124151ee"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNzY5_61338a45-c8ff-473a-9da3-f33393b3aaba" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNzY5_61338a45-c8ff-473a-9da3-f33393b3aaba" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company&#x2019;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#x2019;s consolidated VIEs totaling $601.8&#160;million and $576.1&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#x2019;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $92.8&#160;million and $88.6&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. The VIE balances do not include $994.8&#160;million of investment in affiliates and $15.8&#160;million of amounts due from affiliates as of September&#160;30, 2021 and $225.1&#160;million of investment in affiliates and $22.7&#160;million of amounts due to affiliates as of December&#160;31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#x2013; Variable Interest Entities (VIEs) for further detail.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzAtMy0xLTEtMA_a5ff60fb-e978-4632-811f-8acc8fde5032"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNzY5_61338a45-c8ff-473a-9da3-f33393b3aaba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfMzAtMS0xLTEtMA_6c7a426a-55b6-48ec-8702-a4a1872ac251"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNzY5_61338a45-c8ff-473a-9da3-f33393b3aaba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTUtMS0xLTEtMA_1158702b-f85a-49a8-b56e-bc619fb29d85"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNzY5_61338a45-c8ff-473a-9da3-f33393b3aaba"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RhYmxlOjE4ZTUzNGU3Y2M3NzQ3Y2E4YjVmMjA4ZjIxZDg0NDQ2L3RhYmxlcmFuZ2U6MThlNTM0ZTdjYzc3NDdjYThiNWYyMDhmMjFkODQ0NDZfNTUtMy0xLTEtMA_83cf3721-9957-4807-97c8-1f0e124151ee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV8yMi9mcmFnOmQwOWYxNTRhZDIwOTQ0MDg4M2Q1M2ZmY2M0Zjk0ODliL3RleHRyZWdpb246ZDA5ZjE1NGFkMjA5NDQwODgzZDUzZmZjYzRmOTQ4OWJfNzY5_61338a45-c8ff-473a-9da3-f33393b3aaba"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741866319400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 26, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Apollo Medical Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4472349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1668 S. Garfield Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alhambra<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">282-0288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMEH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,549,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001083446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741864814584">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 204,768<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128,558<span></span>
</td>
<td class="nump">67,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,753<span></span>
</td>
<td class="nump">7,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,626<span></span>
</td>
<td class="nump">49,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,773<span></span>
</td>
<td class="nump">4,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,734<span></span>
</td>
<td class="nump">16,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">427,212<span></span>
</td>
<td class="nump">338,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property, and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,280<span></span>
</td>
<td class="nump">29,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,594<span></span>
</td>
<td class="nump">86,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243,353<span></span>
</td>
<td class="nump">239,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Loans receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">584<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent', window );">Loans receivable &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,046<span></span>
</td>
<td class="nump">43,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">896<span></span>
</td>
<td class="nump">37,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,134<span></span>
</td>
<td class="nump">18,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,195<span></span>
</td>
<td class="nump">18,915<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">444,082<span></span>
</td>
<td class="nump">478,909<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">871,294<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57,505<span></span>
</td>
<td class="nump">36,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,827<span></span>
</td>
<td class="nump">9,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,872<span></span>
</td>
<td class="nump">50,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,024<span></span>
</td>
<td class="nump">4,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,658<span></span>
</td>
<td class="nump">3,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">207<span></span>
</td>
<td class="nump">10,889<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">116,759<span></span>
</td>
<td class="nump">114,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,592<span></span>
</td>
<td class="nump">10,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">221<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,856<span></span>
</td>
<td class="nump">15,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">182,813<span></span>
</td>
<td class="nump">230,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,232<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222,714<span></span>
</td>
<td class="nump">257,346<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">339,473<span></span>
</td>
<td class="nump">372,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">91,500<span></span>
</td>
<td class="nump">114,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,397,050 and 42,249,137 shares issued and outstanding, excluding 10,925,702 and 12,323,164 treasury shares, as of September&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">305,994<span></span>
</td>
<td class="nump">261,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">129,859<span></span>
</td>
<td class="nump">69,771<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity, parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">435,897<span></span>
</td>
<td class="nump">330,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,424<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">440,321<span></span>
</td>
<td class="nump">330,911<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">871,294<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $601.8&#160;million and $576.1&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $92.8&#160;million and $88.6&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. The VIE balances do not include $994.8&#160;million of investment in affiliates and $15.8&#160;million of amounts due from affiliates as of September&#160;30, 2021 and $225.1&#160;million of investment in affiliates and $22.7&#160;million of amounts due to affiliates as of December&#160;31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of Investment in privately held entity that does not report net asset value per share .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MezzanineEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MezzanineEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741957177016">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,397,050<span></span>
</td>
<td class="nump">42,249,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,397,050<span></span>
</td>
<td class="nump">42,249,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,925,702<span></span>
</td>
<td class="nump">12,323,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 871,294<span></span>
</td>
<td class="nump">$ 817,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">339,473<span></span>
</td>
<td class="nump">372,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">601,800<span></span>
</td>
<td class="nump">576,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92,800<span></span>
</td>
<td class="nump">88,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">994,800<span></span>
</td>
<td class="nump">225,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliates', window );">Due from affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrentAndNoncurrent', window );">Due to affiliate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,111,111<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">555,555<span></span>
</td>
<td class="nump">555,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $601.8&#160;million and $576.1&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $92.8&#160;million and $88.6&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. The VIE balances do not include $994.8&#160;million of investment in affiliates and $15.8&#160;million of amounts due from affiliates as of September&#160;30, 2021 and $225.1&#160;million of investment in affiliates and $22.7&#160;million of amounts due to affiliates as of December&#160;31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.12(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=d3e56071-112765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741858716360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 227,117<span></span>
</td>
<td class="nump">$ 180,123<span></span>
</td>
<td class="nump">$ 578,815<span></span>
</td>
<td class="nump">$ 510,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of services, excluding depreciation and amortization</a></td>
<td class="nump">147,473<span></span>
</td>
<td class="nump">121,823<span></span>
</td>
<td class="nump">424,303<span></span>
</td>
<td class="nump">402,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">21,813<span></span>
</td>
<td class="nump">16,270<span></span>
</td>
<td class="nump">45,476<span></span>
</td>
<td class="nump">39,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,671<span></span>
</td>
<td class="nump">4,674<span></span>
</td>
<td class="nump">13,105<span></span>
</td>
<td class="nump">14,004<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">173,957<span></span>
</td>
<td class="nump">142,767<span></span>
</td>
<td class="nump">482,884<span></span>
</td>
<td class="nump">455,770<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">53,160<span></span>
</td>
<td class="nump">37,356<span></span>
</td>
<td class="nump">95,931<span></span>
</td>
<td class="nump">54,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="num">(3,680)<span></span>
</td>
<td class="nump">3,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity method investment</a></td>
<td class="nump">2,193<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,193<span></span>
</td>
<td class="nump">99,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(967)<span></span>
</td>
<td class="num">(2,466)<span></span>
</td>
<td class="num">(4,343)<span></span>
</td>
<td class="num">(8,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">752<span></span>
</td>
<td class="nump">1,331<span></span>
</td>
<td class="nump">2,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized (loss) gain on investments</a></td>
<td class="num">(60,943)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,826<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="num">(14,080)<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(58,665)<span></span>
</td>
<td class="num">(1,181)<span></span>
</td>
<td class="nump">4,247<span></span>
</td>
<td class="nump">98,989<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before (benefit from) provision for income taxes</a></td>
<td class="num">(5,505)<span></span>
</td>
<td class="nump">36,175<span></span>
</td>
<td class="nump">100,178<span></span>
</td>
<td class="nump">153,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit from) provision for income taxes</a></td>
<td class="num">(120)<span></span>
</td>
<td class="nump">10,751<span></span>
</td>
<td class="nump">31,575<span></span>
</td>
<td class="nump">44,204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(5,385)<span></span>
</td>
<td class="nump">25,424<span></span>
</td>
<td class="nump">68,603<span></span>
</td>
<td class="nump">109,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to noncontrolling interest</a></td>
<td class="num">(39,664)<span></span>
</td>
<td class="nump">8,711<span></span>
</td>
<td class="nump">8,515<span></span>
</td>
<td class="nump">81,603<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Apollo Medical Holdings, Inc.</a></td>
<td class="nump">$ 34,279<span></span>
</td>
<td class="nump">$ 16,713<span></span>
</td>
<td class="nump">$ 60,088<span></span>
</td>
<td class="nump">$ 27,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember', window );">Capitation, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 149,059<span></span>
</td>
<td class="nump">$ 135,032<span></span>
</td>
<td class="nump">$ 438,350<span></span>
</td>
<td class="nump">$ 416,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember', window );">Risk pool settlements and incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">59,923<span></span>
</td>
<td class="nump">30,916<span></span>
</td>
<td class="nump">94,146<span></span>
</td>
<td class="nump">54,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management fee income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">9,652<span></span>
</td>
<td class="nump">8,707<span></span>
</td>
<td class="nump">26,345<span></span>
</td>
<td class="nump">26,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Fee-for-service, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">7,260<span></span>
</td>
<td class="nump">3,737<span></span>
</td>
<td class="nump">14,968<span></span>
</td>
<td class="nump">9,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,223<span></span>
</td>
<td class="nump">$ 1,731<span></span>
</td>
<td class="nump">$ 5,006<span></span>
</td>
<td class="nump">$ 4,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741867692920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock&#160;Outstanding</div></th>
<th class="th"><div>Additional Paid-in&#160;Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>Mezzanine</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 192,335<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 159,608<span></span>
</td>
<td class="nump">$ 31,905<span></span>
</td>
<td class="nump">$ 786<span></span>
</td>
<td class="nump">$ 168,725<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,908,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">4,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,052<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(1,160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2020</a></td>
<td class="nump">197,961<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">161,087<span></span>
</td>
<td class="nump">35,957<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="nump">157,439<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,042,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">7,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,044<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">73,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="num">(347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(347)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Jun. 30, 2020</a></td>
<td class="nump">207,848<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">163,986<span></span>
</td>
<td class="nump">43,001<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="nump">210,980<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,309,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">16,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,713<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">8,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">4,020<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised', window );">Shares issued for cashless exercise of warrants (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised', window );">Shares issued for cashless exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Sep. 30, 2020</a></td>
<td class="nump">229,418<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">168,653<span></span>
</td>
<td class="nump">59,714<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
<td class="nump">198,731<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,775,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2020</a></td>
<td class="nump">330,911<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">261,011<span></span>
</td>
<td class="nump">69,771<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">114,237<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,249,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">13,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">4,256<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sales of noncontrolling interest</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2021</a></td>
<td class="nump">349,687<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">266,126<span></span>
</td>
<td class="nump">82,922<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">114,847<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,638,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">12,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,658<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">46,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(2,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Sale of shares by noncontrolling interest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,638,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Sale of shares by noncontrolling interest</a></td>
<td class="nump">40,133<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">40,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Investment in noncontrolling interest</a></td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NoncontrollingInterestIncreaseFromCapitalCharge', window );">Noncontrolling interest capital charge</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="num">(1,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,156)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sales of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Jun. 30, 2021</a></td>
<td class="nump">404,582<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">305,736<span></span>
</td>
<td class="nump">95,580<span></span>
</td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">141,856<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,246,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">34,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,279<span></span>
</td>
<td class="nump">692<span></span>
</td>
<td class="num">(40,356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">1,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(2,947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Investment in noncontrolling interest</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 440,321<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 305,994<span></span>
</td>
<td class="nump">$ 129,859<span></span>
</td>
<td class="nump">$ 4,424<span></span>
</td>
<td class="nump">$ 91,500<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,397,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NoncontrollingInterestIncreaseFromCapitalCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest. Increase from Capital Charge</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NoncontrollingInterestIncreaseFromCapitalCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Cashless Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Cashless Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of share issued exercise of option and warrants during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents value of stock issued during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredParValueMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredParValueMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741863844824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 68,603<span></span>
</td>
<td class="nump">$ 109,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">13,105<span></span>
</td>
<td class="nump">14,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">4,322<span></span>
</td>
<td class="nump">2,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities', window );">Unrealized (gain) loss from investment in equity securities</a></td>
<td class="num">(22,826)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss (income) from equity method investments</a></td>
<td class="nump">3,680<span></span>
</td>
<td class="num">(3,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity method investment</a></td>
<td class="num">(2,193)<span></span>
</td>
<td class="num">(99,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of beneficial interest</a></td>
<td class="nump">15,723<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Loss on interest rate swaps</a></td>
<td class="nump">1,069<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax</a></td>
<td class="nump">6,847<span></span>
</td>
<td class="num">(6,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherOperatingActivities', window );">Other</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of business combinations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivables, net</a></td>
<td class="num">(10,686)<span></span>
</td>
<td class="num">(6,953)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Receivables, net &#8211; related parties</a></td>
<td class="num">(4,367)<span></span>
</td>
<td class="nump">6,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(1,477)<span></span>
</td>
<td class="nump">12,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,064<span></span>
</td>
<td class="num">(1,804)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInOperatingLeaseAssets', window );">Right-of-use assets</a></td>
<td class="nump">2,440<span></span>
</td>
<td class="nump">2,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(954)<span></span>
</td>
<td class="num">(5,090)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">14,362<span></span>
</td>
<td class="nump">12,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Fiduciary accounts payable</a></td>
<td class="num">(815)<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="num">(7,633)<span></span>
</td>
<td class="num">(1,566)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(300)<span></span>
</td>
<td class="nump">11,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,528)<span></span>
</td>
<td class="num">(2,110)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">82,525<span></span>
</td>
<td class="nump">48,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for business acquisition, net of cash acquired</a></td>
<td class="num">(2,575)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties', window );">Proceeds from repayment of loans receivable &#8211; related parties</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(1,009)<span></span>
</td>
<td class="num">(1,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of investment &#8211; equity method</a></td>
<td class="num">(13,384)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">6,375<span></span>
</td>
<td class="nump">52,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(16,420)<span></span>
</td>
<td class="num">(553)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity', window );">Cash received from consolidation of VIE</a></td>
<td class="nump">3,322<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(22,544)<span></span>
</td>
<td class="nump">66,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(31,089)<span></span>
</td>
<td class="num">(50,133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(238,254)<span></span>
</td>
<td class="num">(7,125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligations</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of stock options and warrants</a></td>
<td class="nump">6,601<span></span>
</td>
<td class="nump">6,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of shares</a></td>
<td class="num">(5,739)<span></span>
</td>
<td class="num">(1,559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(75)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ProceedsFromSaleOfNoncontrollingInterest', window );">Proceeds from sale of noncontrolling interest</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on revolver</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of shares</a></td>
<td class="nump">40,133<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(727)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(49,183)<span></span>
</td>
<td class="num">(52,343)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">10,798<span></span>
</td>
<td class="nump">62,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">193,970<span></span>
</td>
<td class="nump">104,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">204,768<span></span>
</td>
<td class="nump">166,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">24,800<span></span>
</td>
<td class="nump">37,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">3,330<span></span>
</td>
<td class="nump">6,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividend declared included in dividend payable</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Preferred shares received from sale of equity investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CancellationOfRestrictedStockAwards', window );">Cancellation of restricted stock awards</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill', window );">Deferred tax liability adjustment to goodwill</a></td>
<td class="nump">1,786<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DeferredTaxLiabilitiesWarrantsExercised', window );">Deferred tax liability adjustment related to warrant exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">204,768<span></span>
</td>
<td class="nump">166,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash - noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash total</a></td>
<td class="nump">$ 204,768<span></span>
</td>
<td class="nump">$ 166,828<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CancellationOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cancellation of Restricted Stock Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CancellationOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Adjusted To Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DeferredTaxLiabilitiesAdjustedToGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DeferredTaxLiabilitiesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DeferredTaxLiabilitiesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase in operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Cash Received from Consolidation of Variable Interest Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ProceedsFromSaleOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ProceedsFromSaleOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized (Gain) Loss from Investment in Equity Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_UnrealizedGainLossFromInvestmentInEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from operating activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741860198600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#8220;NMM&#8221;) in December 2017 (the &#8220;2017 Merger&#8221;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed&#8217;s subsidiaries and VIEs include management services organizations (&#8220;MSOs&#8221;), affiliated independent practice associations (&#8220;IPAs&#8221;), and a Next Generation Accountable Care Organization (&#8220;NGACO&#8221;). NMM and Apollo Medical Management, Inc. (&#8220;AMM&#8221;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), (ii) Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). The Company&#8217;s NGACO operates under the APA ACO, Inc. (&#8220;APAACO&#8221;) brand and participates in the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#8217;s attribution-based risk-sharing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSOs and Affiliates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPAs and Affiliates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (&#8220;HMOs&#8221;) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) and AP-AMH 2 Medical Corporation (&#8220;AP-AMH 2&#8221;) was formed in May 2019 and July 2021, respectively, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. In accordance with relevant accounting guidance, AP-AMH and AP-AMH 2 is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed loaned AP-AMH $545.0 million pursuant to a 10-year secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the &#8220;Certificate of Determination&#8221;), AP-AMH is entitled to receive preferential, cumulative dividends (&#8220;Series A Dividends&#8221;) that accrue on a daily basis and that are equal to the sum of (i) APC&#8217;s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC&#8217;s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">APC purchased 15,015,015 shares of ApolloMed&#8217;s common stock for total consideration of $300.0 million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed&#8217;s common stock that APC purchased, and APC agreed that APC votes in excess of 9.99% of ApolloMed&#8217;s then outstanding shares will be voted by proxy given to ApolloMed&#8217;s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed&#8217;s stockholders.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the series of transactions described above, APC and AP-AMH entered into a Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term &#8220;Excluded Assets.&#8221; Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price (as defined in the purchase agreement), (ii) the assets of APC that are not Healthcare Services Assets (as defined in the purchase agreement), including APC&#8217;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC&#8217;s ownership in ApolloMed was 19.77% as of September&#160;30, 2021 and 22.58% as of December&#160;31, 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of September&#160;30, 2021, APC owned 45.01% of CDSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group of Southern California (&#8220;DMG&#8221;), and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#8217;s capital stock that they did not already own (comprising 75%) for&#160;$7.3 million&#160;in cash.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (&#8220;MPP&#8221;), AMG Properties, LLC (&#8220;AMG Properties&#8221;), and ZLL Partners, LLC (&#8220;ZLL&#8221;) and a 50% interest in each of One MSO, LLC (&#8220;One MSO&#8221;), Tag-6 Medical Investment Group, LLC (&#8220;Tag 6&#8221;), and Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;). These entities own buildings that are currently leased to tenants as well as vacant land which they plan to develop in the future. MPP, AMG Properties, and ZLL are 100% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#8217;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, AP-AMH 2 Medical Corporation (&#8220;AP-AMH 2&#8221;), a VIE of the Company, purchased an 80% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#8220;APCMG&#8221;), a primary care physicians&#8217; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company (see Note 3). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#8220;Sun Labs&#8221;) for an aggregate purchase price of $4.0 million. Sun Labs is a Clinical Laboratory Improvement Amendments certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company (see Note 3). The Company is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of at $4.2 million at September&#160;30, 2021. As the financing obligation is embedded in the noncontrolling interest, the noncontrolling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO</span></div>APAACO, jointly owned by NMM and AMM, began participating in the NGACO Model of CMS in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741859975208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated balance sheets at December&#160;31, 2020, have been derived from the Company&#8217;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of September&#160;30, 2021, and for the three and nine months ended September&#160;30, 2021 and 2020, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;15, 2021. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. Operating results for the three and nine months ended September&#160;30, 2021, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or any future periods.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of September&#160;30, 2021 and December&#160;31, 2020, and the consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020, include the accounts of ApolloMed; its consolidated subsidiaries, NMM, AMM, and APAACO; its consolidated VIEs, AP-AMH, AP-AMH 2, and Sun Labs; AP-AMH 2&#8217;s consolidated subsidiary, APCMG; AMM&#8217;s consolidated VIE, SCHC; NMM&#8217;s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM&#8217;s consolidated VIE, APC; APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties and ZLL, APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash. As of September&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $301.7 million and $294.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of September&#160;30, 2021 and December&#160;31, 2020, certificates of deposit amounted to approximately $67.5 million and $67.6 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Equity securities held by the Company are comprised of common stock of a payor partner that completed its initial public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(&#8220;IPO&#8221;) in June 2021 and Clinigence Holdings, Inc. (&#8220;Clinigence&#8221;). The shares were acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (&#8220;UCI&#8221;) in April 2020. As of September&#160;30, 2021, the equity securities from the payor partner amounted to $57.0 million. As of December&#160;31, 2020, prior to our payor partner&#8217;s IPO, the related investment balance was included in investments in privately held entities at its cost basis of $36.2 million in the accompanying consolidated balance sheets. In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The common stock is included in investments in marketable securities. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three and nine months ended September&#160;30, 2021, the Company recognized unrealized losses of $62.0&#160;million and unrealized gains of $21.8 million on all equity securities in unrealized gain or loss on investments in the accompanying consolidated statements of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables,  Receivables &#8211; Related Parties, and Loan Receivable - Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivable &#8211; related party consist of promissory notes from payees that are expected to be collected between two to four years and accrue interest per annum. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivables relate to each health plan&#8217;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risks</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of operations present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three and nine months ended September&#160;30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.643%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of September&#160;30, 2021, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds*</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; certificates of deposit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,955&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2020, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the nine months ended September&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the nine months ended September&#160;30, 2021 and 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no impairment of its goodwill or indefinite-lived intangible assets during the nine months ended September&#160;30, 2021 and 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of operations under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, and APCMG (&#8220;consolidated IPAs&#8221;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiduciary Cash and Payable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of $8.8 million and $9.6 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of operations.</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. The fair value of the derivative instrument as of September&#160;30, 2021, was $1.0 million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of operations.  The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. The fair value of the derivative instrument as of September&#160;30, 2021 was $1.0&#160;million and is presented within other assets in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospital&#8217;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, the Company must submit to CMS its selections for risk arrangement, the amount of the profit/loss cap, alternative payment mechanism, benefits enhancements, if any, and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 8), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company recognized $21.8&#160;million related to savings from the 2020 performance years. The settlement was finalized in October 2021 and recorded as revenue in risk pool settlements and incentives in the accompanying consolidated statements of operations for the three and nine months ended September&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance year 2021, the Company receives monthly AIPBP payments at a rate of approximately $8.0 million per month from CMS, and must comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $23.9 million and $72.0 million in total AIPBP payments for the three and nine months ended September&#160;30, 2021, respectively, of which $17.6 million and $48.9 million has been recognized as revenue for the three months and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system, and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of operations in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company&#8217;s contract liability balance was $17.3 million and $13.0 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and is presented within accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the nine months ended September&#160;30, 2021, $0.4 million of the Company&#8217;s contract liability accrued in 2020 has been recognized as revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards, such as options, is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 for a discussion of shares treated as treasury shares for accounting purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of September&#160;30, 2021 and December&#160;31, 2020, APC&#8217;s shares were not redeemable, nor was it probable the shares would become redeemable.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Interest<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI, APC received a beneficial interest in the equity method investment sold, pursuant to the terms of the stock purchase agreement. The estimated fair value of such interest in April 2020, was&#160;$15.7 million and is included in other assets in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#8217;s gross margin for the year ended December 31, 2020, was assessed and beneficial interest was concluded to not be collectible. The $15.7 million was written off and expensed in other income in the accompanying consolidated statements of operations for the nine months ended September&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741859918296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations and Goodwill</a></td>
<td class="text">Business Combinations and Goodwill<div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APCMG</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2021, the Company acquired an 80% equity interest (on a fully diluted basis) in APCMG for an aggregate purchase price of $2.0 million. As part of the transaction, the Company paid $1.0 million in cash and the remaining amount will be paid out in cash as a contingent consideration related to APCMG&#8217;s financial performance for fiscal year 2022. The contingent consideration is met if gross revenue and EBITDA targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of September&#160;30, 2021, the contingent consideration is valued at $1.0 million and was included within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sun Labs</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2021, the Company acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Labs for an aggregate purchase price of $4.0 million. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the noncontrolling interest, the noncontrolling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of APCMG and Sun Labs have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not deductible for tax purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the nine months ended September&#160;30, 2021 was as follows (in thousands);</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861376264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,147)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,544)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in depreciation and amortization on the accompanying consolidated statements of operations is amortization expense of $4.1 million and $4.0 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $11.6 million and $12.3&#160;million for the nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September 30, 2021) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861533880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock', window );">Investments in Other Entities &#8212; Equity Method</a></td>
<td class="text">Investments in Other Entities &#8212; Equity Method<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rollforward of Equity Method Investment (in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Investment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allocation of Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contribution</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Entity Consolidated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sale</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA Line of Business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,654)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,182)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diagnostic Medical Group</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">531 W. College, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">One MSO, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tag-8 Medical Investment Group, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,680)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,768)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,182)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LaSalle Medical Associates &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPA Line of Business</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care to patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino, and Tulare Counties through its network of approximately 2,400 independently contracted primary care physicians and specialist providers. LMA&#8217;s patients are primarily served by Medi-Cal, but are also served by Blue Cross, Blue Shield, Molina, Health Net, and Inland Empire Health Plan. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA&#8217;s IPA line of business. In December 2020, the Company exercised its option to convert the promissory note totaling $6.4&#160;million due from Dr. Arteaga into an additional 21.25% interest in LMA&#8217;s IPA line of business. As a result, APC-LSMA&#8217;s interest in LMA&#8217;s IPA line of business increased to 46.25%. In September 2021, APC-LSMA sold 21.25% of its interest in LMA back to Dr. Arteaga for $6.4 million, which resulted in  APC-LSMA owning a 25% interest in LMA as of September&#160;30, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended September&#160;30, 2021 and 2020, APC recognized a loss from this investment of $0.3 million and income of $0.5 million, respectively, in the accompanying consolidated statements of operations. For the nine months ended September&#160;30, 2021 and September&#160;30, 2020, APC recognized a loss from this investment of $4.7 million and income of $28,000, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $4.2 million and $13.0 million at September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at September&#160;30, 2021 and December&#160;31, 2020, and summarized statements of operations for the nine months ended September&#160;30, 2021 and 2020, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,369)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography at its facilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership interest in PMIOC.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $0.7 million and $0.5 million, for the three months ended September&#160;30, 2021 and 2020, respectively, and fees of approximately $1.7 million and $1.5 million for the nine months ended September&#160;30, 2021 and 2020, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. For the three months ended September&#160;30, 2021 and 2020, APC recognized a gain from this investment of approximately $0.2 million and a loss from this investment of $52,000, respectively, in the accompanying consolidated statements of operations. For the nine months ended September&#160;30, 2021 and 2020, APC recognized income of $0.1 million and $25,000, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets had investment balances of $1.5 million and $1.4 million at September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Medical Group</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, David C.P. Chen M.D., individually, and APC-LSMA entered into a share purchase agreement whereby APC-LSMA acquired a 40% ownership interest in DMG. APC accounted for its investment in DMG under the equity method of accounting as APC had the ability to exercise significant influence, but not control over DMG&#8217;s operations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2021 and 2020, APC recognized income from this investment of $0.1&#160;million and $0.1 million, respectively, in the consolidated statements of operations. For the nine months ended September&#160;30, 2021 and 2020, APC recognized income from this investment of $0.3 million and $19,000, respectively, in the consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $2.9 million and $2.6 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">531 W. College LLC &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, College Street Investment LP, a California limited partnership (&#8220;CSI&#8221;), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC, and the conduct of its business, and to specify their relative rights and obligations. CSI, APC, and NMM, each owned 50%, 25%, and 25%, respectively, of member units based on initial capital contributions of $16.7 million, $8.3 million, and $8.3 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $33.3 million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#8217;s 25% membership interest in 531 W. College, LLC for approximately $8.3 million. Subsequently, APC has a 50% ownership in 531 W. College LLC with a total investment balance of approximately $16.1&#160;million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended September&#160;30, 2021 and 2020, APC recognized a loss from this investment of $34,000 and $0.1 million, respectively, in the accompanying consolidated statements of operations. For the nine months ended September&#160;30, 2021 and 2020, APC recorded a loss from this investment of $0.1 million and $0.4 million in the accompanying consolidated statements of operations, respectively. The accompanying consolidated balance sheets include the related investment balances of $17.1 million and $17.2 million at September&#160;30, 2021 and December&#160;31, 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College LLC&#8217;s balance sheets at September&#160;30, 2021 and December&#160;31, 2020, and statements of operations for the nine months ended September&#160;30, 2021 and 2020, are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Members&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and members&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,432&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operation</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(799)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>One MSO, LLC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 50% membership interest in One MSO LLC (&#8220;One MSO&#8221;) for $2.4 million. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. For the three months ended September&#160;30, 2021, One MSO recognized income of $0.1 million in the accompanying consolidated statements of operations. For the nine months ended September&#160;30, 2021, One MSO recognized income of $0.4&#160;million in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $2.8 million and $2.4 million at September&#160;30, 2021 and December&#160;31, 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tag-6 Medical Investment Group, LLC and Tag-8 Medical Investment Group, LLC &#8212; Related Party</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 50% membership interest in Tag 6 for $4.5 million and a 50% membership interest in Tag 8 for $2.1 million. The Company reevaluated Tag 8 as a VIE since APC is a guarantor on the loan agreement between Tag 8 and MUFG Union Bank N.A. Based on the reevaluation, Tag 8 is a VIE and is consolidated by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tag 6 shares common ownership with certain board members of APC and as such is considered a related party. For the three and nine months ended September&#160;30, 2021, Tag 6 recognized income of $45,000 and $0.2 million, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the Tag 6 investment of $4.8 million and $4.5&#160;million at September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAIPA MSO, LLC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, ApolloMed purchased 30% interests in CAIPA MSO, LLC for $11.7 million. CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d/b/a Coalition of Asian-American IPA (&#8220;CAIPA&#8221;), a leading independent practice association serving the greater New York City area. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO&#8217;s operations. For the three and nine months ended September&#160;30, 2021, ApolloMed recognized income from investment of $45,000, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $11.8 million as of September&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in privately held entities that do not report net asset value</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MediPortal, LLC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. A five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AchievaMed</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in investments in privately held entities in the accompanying consolidated balance sheets as of September&#160;30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method And Other Equity Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodAndOtherEquityInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741860211608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Receivable and Loan Receivable &#8211; Related Parties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LoanReceivableTextBlock', window );">Loan Receivable and Loan Receivable &#8211; Related Parties</a></td>
<td class="text">Loan Receivable and Loan Receivable &#8211; Related Parties<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific6</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NMM received a promissory note from Pacific6 totaling $0.5&#160;million as a result of the sale of the Company&#8217;s interest in MWN. Interest accrues at a rate of 5% per annum and is payable monthly through the maturity date of December 1, 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> related parties</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AHMC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, APC entered into a promissory note with AHMC (the &#8220;AHMC Note&#8221;) for a principal amount of $4.0&#160;million with a maturity date of April 2022. The contractual interest rate on the AHMC Note is 3.75% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of September&#160;30, 2021, the total principal of $4.0&#160;million remains outstanding. One of the Company&#8217;s board members is an officer of AHMC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loan receivable under the CECL model by assessing the party&#8217;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LoanReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LoanReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741868510728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts Payable and Accrued Expenses<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741860231576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">Medical Liabilities</a></td>
<td class="text">Medical Liabilities<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249,530)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,027)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741973375880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans and Lines of Credit<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Facility, Bank Loans and Lines of Credit</a></td>
<td class="text">Credit Facility, Bank Loans, and Lines of Credit<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of September&#160;30, 2021 and December&#160;31, 2020, the carrying value was not materially different from fair value, as the interest rates on the Company&#8217;s debt approximated rates currently available to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September 30, 2021) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,524&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a secured credit agreement (the &#8220;Credit Agreement,&#8221; and the credit facility thereunder, the &#8220;Credit Facility&#8221;) with Truist Bank (f.k.a. SunTrust Bank), in its capacity as administrative agent for the lenders, as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders. The Credit Agreement provided a five-year revolving credit facility to the Company of $100.0 million, which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also provided a term loan of $190.0 million. Amounts borrowed under the Credit Agreement bore interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#8220;LIBOR&#8221;), adjusted for any reserve requirement in effect, plus a spread of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread between 1.00% and 2.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the agent entered into a Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement and, together with the Company, granted the lenders a security interest in all of its assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the &#8220;Lenders&#8221;), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Wells Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent, in its entirety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement provides for a five-year revolving credit facility (&#8220;Revolver Loan&#8221;) to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts borrowed under the Amended Credit Agreement will bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on  LIBOR, adjusted for any reserve requirement in effect, plus a spread of from 1.25% to 2.5%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.5%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. As of September&#160;30, 2021, the interest rate on Amended Credit Facility was 1.65%.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual agent fee of $50,000 and an annual facility fee of 0.175% to 0.35% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to 1.25% to 2.5%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter.  The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. At September&#160;30, 2021 and December&#160;31, 2020, the unamortized deferred financing cost was $4.5&#160;million and $4.6&#160;million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of this purchase, APC assumed the existing loans held by MPP, AMG Properties, and ZLL. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MPP</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $6.4&#160;million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of September&#160;30, 2021, the balance outstanding was $6.1 million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1. <br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG Properties</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $0.7&#160;million with a variable interest rate of 0.30% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of September&#160;30, 2021, the balance outstanding was $0.7 million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZLL</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $0.7&#160;million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of September&#160;30, 2021, the balance outstanding was $0.6 million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;). Tag 8 is a VIE consolidated by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Construction Loan allows Tag 8 to borrow up to $10.7 million with a maturity date of December 1, 2022 (&#8220;Construction Loan Term&#8221;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#8220;Permanent Loan Term&#8221;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be 2.0% per annum in excess of the LIBOR rate. As of September&#160;30, 2021, the balance outstanding was $0.1&#160;million. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#8217;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated earnings before interest, taxes, depreciation, and amortization (&#8220;EBITDA&#8221;) minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the nine months ended September&#160;30, 2021 and 2020, was 2.15% and 3.79%, respectively. Interest expense in the consolidated statements of operations included amortization of deferred </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">debt issuance costs for the three and nine months ended September&#160;30, 2021 and 2020, of $0.2 million and $0.3 million, respectively, and $0.9 million and $1.0 million, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit &#8211; Related Party</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#8220;APC Business Loan Agreement&#8221;) was amended to decrease loan availability to $4.1 million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. One of the Company&#8217;s board members is the chairman and CEO of Preferred Bank. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO established an irrevocable standby letter of credit with Preferred Bank, which is affiliated with one of the Company&#8217;s board members, totaling $14.8&#160;million for the benefit of CMS. In August 2020, the irrevocable standby letter of credit was  released by CMS. As of September&#160;30, 2021, there were no outstanding letters of credit and the Company had $25.0&#160;million available under the Amended Credit Facility.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741860231576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Mezzanine and Stockholders' Equity</a></td>
<td class="text">Mezzanine and Stockholders&#8217; Equity<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature of the APC shares (see Note 2) is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC&#8217;s shares were not redeemable, and it was not probable that the shares would become redeemable, as of September&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, 141,638 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Treasury Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC owned 10,925,702 and 12,323,164 shares of ApolloMed&#8217;s common stock as of September&#160;30, 2021 and December&#160;31, 2020, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. In March 2021, the Company issued 34,158 shares of common stock to APC as a result of APC exercising their warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, APC paid dividends of $10.0&#160;million and $19.9&#160;million, respectively. During the nine months ended September&#160;30, 2021 and 2020, APC paid dividends of $29.9 million and $49.5 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, CDSC did not pay any dividends. During the nine months ended September&#160;30, 2021 and 2020, CDSC paid dividends of $1.5 million and $0.6 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741994486632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three and nine months ended September&#160;30, 2021 and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of operations (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to total share-based payments outstanding as of September&#160;30, 2021, was $7.4 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,638&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.71&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, options were exercised for 40,000 shares of the Company&#8217;s common stock, resulting in proceeds of $0.2&#160;million. During the nine months ended September&#160;30, 2020, options were exercised for 120,000 shares of the Company&#8217;s common stock, resulting in proceeds of approximately $0.3 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, the Company granted 24,437 stock options with a vesting period of two years to certain ApolloMed executives with an exercise price of $23.24, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock awards to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day&#8217;s closing market price of the Company&#8217;s common stock. During the nine months ended September&#160;30, 2021, the Company granted restricted stock awards totaling 159,267 shares with a weighted average grant date fair value of $28.24. The grant date fair value of the restricted stock was $4.5&#160;million and will be recognized on a straight-line basis over the awards&#8217; vesting period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc3MDQ4NTQ4YTBjNTQ2YmVhYTEwYTQyYzgwNTUzYTcxL3NlYzo3NzA0ODU0OGEwYzU0NmJlYWExMGE0MmM4MDU1M2E3MV85NC9mcmFnOjcxZWNkMTE2MTY1NzQzZTQ5Y2UzNTcxMDkzMzgwMWNjL3RleHRyZWdpb246NzFlY2QxMTYxNjU3NDNlNDljZTM1NzEwOTMzODAxY2NfMTY0OA_28ab602c-7a29-4dcd-a454-db6a953fd86b">one</span> to three years. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624,760)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants expired/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,803)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,428</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,135</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                  10.00 &#8211; 11.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During the nine months ended September&#160;30, 2021 and 2020, common stock warrants were exercised for 624,760 and 800,709 shares of the Company&#8217;s common stock, respectively, which resulted in proceeds of approximately $6.4&#160;million and $6.2 million, respectively. The exercise price ranged from $9.00 to $11.00 per share for the exercises during the nine months ended September&#160;30, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861333032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California Department of Managed Healthcare (&#8220;DMHC&#8221;) regulations, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the payor and provider contracts with the Company&#8217;s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS. The guarantee generally must be in an amount equal to 2% of the Company&#8217;s benchmark Medicare Part A and Part B expenditures. In August 2020, $14.8&#160;million of the irrevocable standby letters of credit were released by CMS and no amounts remained outstanding as of September&#160;30, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $0.3 million and $3.8&#160;million, respectively, for the benefit of certain health plans (see Note 9). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741963294984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party TransactionsDuring the three and nine months ended September&#160;30, 2021 and 2020, NMM earned approximately $4.5 million and $4.2 million, respectively, and $13.2 million and $12.6 million, respectively, in management fees from LMA, which is accounted for under the equity method based on the 25% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5).<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $0.7 million and $0.5 million, respectively, and $1.7 million and $1.5 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC (see Note 5).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $2.2 million and $1.2 million, respectively, and $5.4 million and $3.8 million, respectively, to DMG for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC (see Note 5).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $0.3&#160;million and $0.1 million, respectively, and $0.4 million and $0.2 million to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $24,000 and $23,000, respectively, and $0.1 million and $0.1 million, respectively, to Fresenius Medical Care (&#8220;Fresenius&#8221;) and its subsidiaries for services as a provider. During the three and nine months ended September&#160;30, 2021 and 2020, APAACO paid approximately $0.2 million and $0.2 million, respectively, and $0.5 million and $0.5 million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company&#8217;s board members is an officer of Fresenius.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, APC paid approximately $0.7 million and $0.1 million, respectively, and $1.1 million and $0.1 million, respectively, to Fulgent Genetics, Inc. for services as a provider. One of the Company&#8217;s board members is a board member of Fulgent Genetics, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, APC paid an aggregate of approximately $10.1 million and $7.1 million to shareholders, respectively, which included approximately $1.8 million and $1.7 million, respectively, to shareholders who are also officers of APC. During the nine months ended September&#160;30, 2021 and 2020, APC paid an aggregate of approximately $25.3 million and $23.4 million to shareholders, respectively, and $5.6 million and $6.5 million, respectively, to shareholders who are also officers of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, the Company paid approximately $0 and $39,000, respectively, and $0 and $0.3 million, respectively, to Critical Quality Management Corporation (&#8220;CQMC&#8221;) for an office lease. CQMC shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2021 and 2020, SCHC paid approximately $0.1 million and $0.1 million, respectively, and $0.3 million and $0.3 million, respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine ended September&#160;30, 2021 and 2020, APC paid approximately $0.4 million and $0.4 million, respectively, and $1.1 million and $1.1 million, respectively, to One MSO for an office lease, which is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 5).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;), Aurion Corporation (&#8220;Aurion&#8221;), and AHMC Healthcare Inc. (&#8220;AHMC&#8221;) for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,579&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,474&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,081&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and nine months ended September&#160;30, 2021 and 2020, the Company has recognized risk pool revenue under this agreement of $21.5 million and $10.5 million, and $47.1&#160;million and $31.5&#160;million, respectfully, of which $47.9 million and $45.3 million remained outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021 and 2020, NMM paid approximately $44,000 and $27,000, respectively, to an ApolloMed board member for consulting services. During the three months ended September&#160;30, 2021 and 2020, there were no payments to such ApolloMed board member for consulting services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s officers, including the Company&#8217;s Co-CEOs, Dr. Kenneth Sim and Dr. Thomas Lam, are reported in the accompanying consolidated statements of operations on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments, loans receivable, and line of credits from related parties, see Notes 5, 6, and 9, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861333032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for the nine months ended September&#160;30, 2021 and September&#160;30, 2020, was 31.5% and 28.8%, respectively. The tax rate for the nine months ended September&#160;30, 2021, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2016 through December&#160;31, 2020, and for the years ended December 31, 2017 through December&#160;31, 2020, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741872220648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, APC held 10,925,702 and 12,323,164 shares of ApolloMed&#8217;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,301,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,364,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,273,640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,551,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,608,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,149,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,339,372&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,249,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,301,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,364,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,273,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,551,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,608,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,149,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,339,372&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,249,967&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741859943992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities (VIEs)</a></td>
<td class="text">Variable Interest Entities (VIEs)<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Variable Interest Entities&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and their treatment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#8217;s other consolidated VIEs were not considered significant. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due from affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861326616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of one month to five years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of September&#160;30, 2021 and December&#160;31, 2020, assets recorded under finance leases were $0.3 million and $0.4 million, respectively, and accumulated depreciation associated with finance leases were $0.5 million and $0.4 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(709)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.93 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of September&#160;30, 2021, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September&#160;30, 2021)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,856&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company does not have additional operating and finance leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of one month to five years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of September&#160;30, 2021 and December&#160;31, 2020, assets recorded under finance leases were $0.3 million and $0.4 million, respectively, and accumulated depreciation associated with finance leases were $0.5 million and $0.4 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(709)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.93 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of September&#160;30, 2021, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September&#160;30, 2021)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,856&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company does not have additional operating and finance leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861427432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsDMGIn October 2021, the Company entered into an agreement to purchase within three years all of the remaining equity interests in DMG. The Company currently owns 40% of DMG and has committed to purchasing the remaining 60% within three years. In accordance with relevant accounting guidance, the Company has determined that DMG is a variable interest entity of the Company; therefore, DMG's financial statements will be consolidated with those of the Company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741864703656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying consolidated balance sheets at December&#160;31, 2020, have been derived from the Company&#8217;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of September&#160;30, 2021, and for the three and nine months ended September&#160;30, 2021 and 2020, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;15, 2021. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of September&#160;30, 2021 and December&#160;31, 2020, and the consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020, include the accounts of ApolloMed; its consolidated subsidiaries, NMM, AMM, and APAACO; its consolidated VIEs, AP-AMH, AP-AMH 2, and Sun Labs; AP-AMH 2&#8217;s consolidated subsidiary, APCMG; AMM&#8217;s consolidated VIE, SCHC; NMM&#8217;s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM&#8217;s consolidated VIE, APC; APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties and ZLL, APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div>If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">Business CombinationsThe Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div>The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of September&#160;30, 2021 and December&#160;31, 2020, certificates of deposit amounted to approximately $67.5 million and $67.6 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Equity securities held by the Company are comprised of common stock of a payor partner that completed its initial public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span>(&#8220;IPO&#8221;) in June 2021 and Clinigence Holdings, Inc. (&#8220;Clinigence&#8221;). The shares were acquired as a result of UCAP selling its<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock', window );">Receivables, Receivables &#8211; Related Parties, and Loan Receivable - Related Party</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables,  Receivables &#8211; Related Parties, and Loan Receivable - Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivable &#8211; related party consist of promissory notes from payees that are expected to be collected between two to four years and accrue interest per annum. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivables relate to each health plan&#8217;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div>Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risks</a></td>
<td class="text">Concentrations of Credit RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of operations present disaggregated revenue by service type.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements of Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Intangible Assets and Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div>Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Investments in Other Entities - Equity Method and Investments in Privately Held Entities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of operations under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The </span></div>investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock', window );">Medical Liabilities</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, and APCMG (&#8220;consolidated IPAs&#8221;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryCashAndPayablePolicyTextBlock', window );">Fiduciary Cash and Payable</a></td>
<td class="text">Fiduciary Cash and PayableThe consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of operations.</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. The fair value of the derivative instrument as of September&#160;30, 2021, was $1.0 million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants<br/></span></div>In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of operations.  The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. The fair value of the derivative instrument as of September&#160;30, 2021 was $1.0&#160;million and is presented within other assets in the accompanying consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospital&#8217;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, the Company must submit to CMS its selections for risk arrangement, the amount of the profit/loss cap, alternative payment mechanism, benefits enhancements, if any, and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 8), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company recognized $21.8&#160;million related to savings from the 2020 performance years. The settlement was finalized in October 2021 and recorded as revenue in risk pool settlements and incentives in the accompanying consolidated statements of operations for the three and nine months ended September&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance year 2021, the Company receives monthly AIPBP payments at a rate of approximately $8.0 million per month from CMS, and must comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $23.9 million and $72.0 million in total AIPBP payments for the three and nine months ended September&#160;30, 2021, respectively, of which $17.6 million and $48.9 million has been recognized as revenue for the three months and nine months ended September&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system, and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of operations in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div>Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards, such as options, is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 for a discussion of shares treated as treasury shares for accounting purposes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MinorityInterestPolicyPolicyTextBlock', window );">Noncontrolling Interests</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityPolicyTextBlock', window );">Mezzanine Equity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of September&#160;30, 2021 and December&#160;31, 2020, APC&#8217;s shares were not redeemable, nor was it probable the shares would become redeemable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BeneficialInterestPolicyTextBlock', window );">Beneficial Interest</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Interest<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI, APC received a beneficial interest in the equity method investment sold, pursuant to the terms of the stock purchase agreement. The estimated fair value of such interest in April 2020, was&#160;$15.7 million and is included in other assets in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#8217;s gross margin for the year ended December 31, 2020, was assessed and beneficial interest was concluded to not be collectible. The $15.7 million was written off and expensed in other income in the accompanying consolidated statements of operations for the nine months ended September&#160;30, 2021.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BeneficialInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BeneficialInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryCashAndPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiduciary Cash and Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryCashAndPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MinorityInterestPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minority Interest Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MinorityInterestPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Receivables and receivables from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 405<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491204&amp;loc=d3e4879-115612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 720<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49178521&amp;loc=d3e9162-115647<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861619800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue by Each Payor Type</a></td>
<td class="text">The following table presents disaggregated revenue generated by payor type for the three and nine months ended September&#160;30, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Contributions to Revenue and Receivables by Payor</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.643%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Carrying Amounts and Fair Values of Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of September&#160;30, 2021, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds*</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; certificates of deposit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,955&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2020, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861988872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Change in Carrying Value of Goodwill</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the nine months ended September&#160;30, 2021 was as follows (in thousands);</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741860229912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net September 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,147)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,544)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September 30, 2021) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861421880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rollforward of Equity Method Investment (in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Investment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allocation of Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contribution</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Entity Consolidated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sale</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA Line of Business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,654)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,182)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diagnostic Medical Group</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">531 W. College, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">One MSO, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tag-8 Medical Investment Group, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,680)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,768)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,182)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at September&#160;30, 2021 and December&#160;31, 2020, and summarized statements of operations for the nine months ended September&#160;30, 2021 and 2020, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,868)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,369)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College LLC&#8217;s balance sheets at September&#160;30, 2021 and December&#160;31, 2020, and statements of operations for the nine months ended September&#160;30, 2021 and 2020, are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Members&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and members&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,432&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operation</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(799)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741860309912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741872179000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Medical Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249,530)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,027)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861522792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans and Lines of Credit (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Credit Facility</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Commitments of Credit Facility</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September 30, 2021) </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,524&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741860013064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three and nine months ended September&#160;30, 2021 and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of operations (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Transactions Under Stock Option Plans</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,638&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.71&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text">During the nine months ended September&#160;30, 2021, the Company granted 24,437 stock options with a vesting period of two years to certain ApolloMed executives with an exercise price of $23.24, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624,760)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants expired/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,803)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,428</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,135</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                  10.00 &#8211; 11.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861321352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Fees Incurred and Revenue Earned from Related Party Transactions</a></td>
<td class="text">The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,579&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,474&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,081&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741860204024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share Computations</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,301,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,364,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,273,640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,551,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,608,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,149,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,339,372&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,249,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Shares Included in the Diluted Earnings Per Share Computations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,301,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,364,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,273,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,551,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,608,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,149,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,339,372&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,249,967&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741859982136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Assets and Liabilities, Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#8217;s other consolidated VIEs were not considered significant. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due from affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741959027480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Information Related to Lease Costs</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(709)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.93 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of September&#160;30, 2021, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September&#160;30, 2021)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,856&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Finance Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of September&#160;30, 2021, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the nine months ended September&#160;30, 2021)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,856&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741954629656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 01, 1999</div></th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>clinic </div>
<div>plan</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember', window );">Apollo-Sun Labs Management, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase', window );">Equity interest purchase obligation, period to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Equity interest purchase obligation, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember', window );">Access Primary Care Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,015,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock subscriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodProxyVotesPercentage', window );">Proxy votes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember', window );">AP-AMH Medical Corporation | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableTermOfReceivable', window );">Term of receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableStatedInterestRate', window );">Stated rate of note of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate', window );">Interest rate in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement', window );">Fixed term of amended and restated management and administrative services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MPP, AMG Properties, and ZLL Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of shares transferred in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Apollo Medical Holdings, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.77%<span></span>
</td>
<td class="nump">22.58%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Concourse Diagnostic Surgery Center, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AP-AMH Medical Corporation | Affiliated Entity | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Maverick Medical Group, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFederallyQualifiedHealthPlans', window );">Number federally qualified health plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Dr. Jay | Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AmgIncMember', window );">AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFamilyPracticeClinics', window );">Number of family practice clinics | clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AssetAcquisitionPercentageOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Percentage Of Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AssetAcquisitionPercentageOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Period to Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Modifications, Subsequent Default, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableStatedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Stated Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableStatedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableTermOfReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Term Of Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableTermOfReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The initial fixed term of amended and restated management and administrative services agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFamilyPracticeClinics">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Family Practice Clinics</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFamilyPracticeClinics</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFederallyQualifiedHealthPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Federally Qualified Health Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFederallyQualifiedHealthPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodProxyVotesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Proxy Votes, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodProxyVotesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_Dr.JayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_Dr.JayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741863651320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>unit</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Amount deposit accounts exceeded FDIC insured limit</a></td>
<td class="nump">$ 301,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301,700,000<span></span>
</td>
<td class="nump">$ 301,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">67,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,540,000<span></span>
</td>
<td class="nump">67,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,637,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000,000<span></span>
</td>
<td class="nump">57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Equity securities, FV-NI, unrealized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,000,000)<span></span>
</td>
<td class="nump">$ 21,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear', window );">Risk pool surplus or deficits, settlement period after risk pool performance year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of main reporting units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">243,353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,353,000<span></span>
</td>
<td class="nump">243,353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,053,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="nump">8,827,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,827,000<span></span>
</td>
<td class="nump">8,827,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,642,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">1,045,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,045,000<span></span>
</td>
<td class="nump">1,045,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenueMonthlyAmount', window );">Payments received, monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenue', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,900,000<span></span>
</td>
<td class="nump">72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenueRevenueRecognized', window );">Payments received, revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600,000<span></span>
</td>
<td class="nump">48,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">17,259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,259,000<span></span>
</td>
<td class="nump">17,259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,988,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">1,045,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,045,000<span></span>
</td>
<td class="nump">1,045,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">67,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,500,000<span></span>
</td>
<td class="nump">67,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC | Universal Care Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationCash', window );">Contingent consideration, cash held in escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares', window );">Contingent consideration, preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue', window );">Contingent consideration, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Universal Care Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Additional cash consideration entitled to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds', window );">Write off of additional proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Accrued contract liability recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities | Interest rate swap | Cash flow hedges: | Derivatives designated as hedging instruments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember', window );">PMPM Managed Care Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management Fee Income Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_ClinigenceHoldingsIncMember', window );">Clinigence Holdings, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireCommonStockAndWarrants', window );">Payments to acquire common stock and warrants</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_CMSMember', window );">CMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport', window );">Expected period of payment upon termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears', window );">Revenue from risk pool settlements from prior performance years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Disposed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOwnershipPercentageDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Write-off of Additional Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MarketableSecuritiesCurrentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Current, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MarketableSecuritiesCurrentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenueMonthlyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue, Monthly Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenueMonthlyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenueRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenueRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Common Stock And Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Risk Pool Settlements From Prior Performance Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_ClinigenceHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_ClinigenceHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_CMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_CMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741868487416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 227,117<span></span>
</td>
<td class="nump">$ 180,123<span></span>
</td>
<td class="nump">$ 578,815<span></span>
</td>
<td class="nump">$ 510,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">36,960<span></span>
</td>
<td class="nump">25,041<span></span>
</td>
<td class="nump">102,522<span></span>
</td>
<td class="nump">75,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">103,919<span></span>
</td>
<td class="nump">79,649<span></span>
</td>
<td class="nump">232,869<span></span>
</td>
<td class="nump">206,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">74,262<span></span>
</td>
<td class="nump">65,849<span></span>
</td>
<td class="nump">212,408<span></span>
</td>
<td class="nump">200,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember', window );">Other third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 11,976<span></span>
</td>
<td class="nump">$ 9,584<span></span>
</td>
<td class="nump">$ 31,016<span></span>
</td>
<td class="nump">$ 27,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741866836808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="nump">12.70%<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.10%<span></span>
</td>
<td class="nump">10.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">13.30%<span></span>
</td>
<td class="nump">16.20%<span></span>
</td>
<td class="nump">15.40%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">17.10%<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor F</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor G</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AccountsReceivableAndNetRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AccountsReceivableAndNetRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741866438296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 89,678<span></span>
</td>
<td class="nump">$ 115,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">67,540<span></span>
</td>
<td class="nump">67,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">61,018<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">219,281<span></span>
</td>
<td class="nump">183,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="nump">1,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">2,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">89,678<span></span>
</td>
<td class="nump">115,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">67,540<span></span>
</td>
<td class="nump">67,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">57,108<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">214,326<span></span>
</td>
<td class="nump">183,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">3,910<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">4,955<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="nump">1,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741871939848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember', window );">Access Primary Care Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember', window );">Apollo-Sun Labs Management, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741959027480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Summary of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, January 1, 2021</a></td>
<td class="nump">$ 239,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, September 30, 2021</a></td>
<td class="nump">$ 243,353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741868498344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (101,147)<span></span>
</td>
<td class="num">$ (89,544)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">82,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross</a></td>
<td class="nump">184,741<span></span>
</td>
<td class="nump">176,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">83,594<span></span>
</td>
<td class="nump">86,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived assets:</a></td>
<td class="nump">996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">148,845<span></span>
</td>
<td class="nump">143,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(82,117)<span></span>
</td>
<td class="num">(73,169)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 66,728<span></span>
</td>
<td class="nump">$ 70,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember', window );">Management contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 22,832<span></span>
</td>
<td class="nump">$ 22,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(13,128)<span></span>
</td>
<td class="num">(11,715)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 9,704<span></span>
</td>
<td class="nump">$ 11,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember', window );">Member relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 8,997<span></span>
</td>
<td class="nump">$ 6,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,129)<span></span>
</td>
<td class="num">(3,234)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 4,868<span></span>
</td>
<td class="nump">$ 3,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember', window );">Patient management platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 2,060<span></span>
</td>
<td class="nump">$ 2,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,579)<span></span>
</td>
<td class="num">(1,270)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="nump">$ 790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trade names/trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 1,011<span></span>
</td>
<td class="nump">$ 1,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 817<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741869227784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741869087864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2021 (excluding the nine months ended September 30, 2021)</a></td>
<td class="nump">$ 4,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">13,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">11,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">10,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">9,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">32,908<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 82,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741865513688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Equity Method Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 403<span></span>
</td>
<td class="num">(3,680)<span></span>
</td>
<td class="nump">$ 3,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">$ 45,046<span></span>
</td>
<td class="nump">45,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA Line of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">4,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">1,542<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">2,943<span></span>
</td>
<td class="nump">2,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">17,051<span></span>
</td>
<td class="nump">17,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">2,774<span></span>
</td>
<td class="nump">2,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember', window );">Tag-6 Medical Investment Group, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">4,756<span></span>
</td>
<td class="nump">4,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember', window );">Tag-8 Medical Investment Group, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember', window );">CAIPA MSO, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentAdditionalInvestment', window );">Initial Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">$ 11,769<span></span>
</td>
<td class="nump">$ 11,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentAdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Additional Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentAdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Consolidated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741852255592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>provider</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>provider</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>provider</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 403<span></span>
</td>
<td class="num">(3,680)<span></span>
</td>
<td class="nump">$ 3,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MediPortal LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares', window );">Membership interests purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Payments to purchase membership interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest', window );">Membership interests acquired (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants received (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption', window );">Term of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests', window );">Options to purchase additional membership interests (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet', window );">Number of warrants available to purchase, contingent upon the portal completion date (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember', window );">Network Medical Management, Inc. | AchievaMed, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears', window );">Percentage of voting common stock, within five years</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment', window );">Duration of investment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost', window );">Investment amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Related investment balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfEmployees', window );">Number of employees | provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC and APC-LSMA | Convertible Secured Promissory Note | Dr. Arteaga</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion', window );">Ownership upon conversion of finance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageSold', window );">Ownership percentage sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="num">$ (4,700)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC | Convertible Secured Promissory Note | Dr. Arteaga</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease', window );">Equity method investment, conversion of finance receivable, ownership percentage increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC | Ancillary Service Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRealEstate', window );">Purchase price of real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC | College Street Investment LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC | Network Medical Management, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC &#8211; related party | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember', window );">Tag-6 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember', window );">Tag-6 Medical Investment Group, LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember', window );">Tag-8 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember', window );">Tag-8 Medical Investment Group, LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember', window );">CAIPA MSO, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember', window );">CAIPA MSO, LLC | Apollo Medical Holdings, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOwnershipPercentageSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage, Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOwnershipPercentageSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of member capital in limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MediPortalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MediPortalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_AchievaMedInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_AchievaMedInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_CollegeStreetInvestmentLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_CollegeStreetInvestmentLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741868314504">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Summarized Balance Sheets and Statements of Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 204,768<span></span>
</td>
<td class="nump">$ 166,082<span></span>
</td>
<td class="nump">$ 204,768<span></span>
</td>
<td class="nump">$ 166,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property, and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">871,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">116,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">440,321<span></span>
</td>
<td class="nump">229,418<span></span>
</td>
<td class="nump">440,321<span></span>
</td>
<td class="nump">229,418<span></span>
</td>
<td class="nump">$ 404,582<span></span>
</td>
<td class="nump">$ 349,687<span></span>
</td>
<td class="nump">330,911<span></span>
</td>
<td class="nump">$ 207,848<span></span>
</td>
<td class="nump">$ 197,961<span></span>
</td>
<td class="nump">$ 192,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">871,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,117<span></span>
</td>
<td class="nump">180,123<span></span>
</td>
<td class="nump">578,815<span></span>
</td>
<td class="nump">510,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">173,957<span></span>
</td>
<td class="nump">142,767<span></span>
</td>
<td class="nump">482,884<span></span>
</td>
<td class="nump">455,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,160<span></span>
</td>
<td class="nump">37,356<span></span>
</td>
<td class="nump">95,931<span></span>
</td>
<td class="nump">54,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">500<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="num">(14,080)<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(120)<span></span>
</td>
<td class="nump">10,751<span></span>
</td>
<td class="nump">31,575<span></span>
</td>
<td class="nump">44,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,385)<span></span>
</td>
<td class="nump">$ 25,424<span></span>
</td>
<td class="nump">68,603<span></span>
</td>
<td class="nump">109,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,417<span></span>
</td>
<td class="nump">138,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,786<span></span>
</td>
<td class="nump">138,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,369)<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property, and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 34,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="nump">828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(295)<span></span>
</td>
<td class="num">(828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (297)<span></span>
</td>
<td class="num">$ (799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $601.8&#160;million and $576.1&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $92.8&#160;million and $88.6&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. The VIE balances do not include $994.8&#160;million of investment in affiliates and $15.8&#160;million of amounts due from affiliates as of September&#160;30, 2021 and $225.1&#160;million of investment in affiliates and $22.7&#160;million of amounts due to affiliates as of December&#160;31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741867881032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loan Receivable and Loan Receivable &#8211; Related Parties - Additional Information (Details) - Convertible Secured Promissory Note - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Oct. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Pacific6 Enterprises | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">AHMC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Note receivable, amount</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableInterestRateStatedPercentage', window );">Note receivable, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Interest Rate, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 80<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922355-210448<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1404<br> -Paragraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Pacific6EnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Pacific6EnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741865615944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 23,051<span></span>
</td>
<td class="nump">$ 9,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SpecialtyCapitationPayableCurrent', window );">Capitation payable</a></td>
<td class="nump">2,967<span></span>
</td>
<td class="nump">3,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SubcontractorIPAPayable', window );">Subcontractor IPA payable</a></td>
<td class="nump">2,686<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">2,298<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">17,259<span></span>
</td>
<td class="nump">12,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">8,547<span></span>
</td>
<td class="nump">6,970<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 57,505<span></span>
</td>
<td class="nump">$ 36,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SpecialtyCapitationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of specialty capitation payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SpecialtyCapitationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SubcontractorIPAPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subcontractor IPA Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SubcontractorIPAPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741867756024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities - Schedule of Medical Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Medical Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, beginning of period</a></td>
<td class="nump">$ 50,330<span></span>
</td>
<td class="nump">$ 58,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Acquired (see Note 3)</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current period</a></td>
<td class="nump">242,619<span></span>
</td>
<td class="nump">229,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior periods</a></td>
<td class="num">(498)<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">242,121<span></span>
</td>
<td class="nump">230,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current period</a></td>
<td class="num">(200,582)<span></span>
</td>
<td class="num">(178,796)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior periods</a></td>
<td class="num">(48,948)<span></span>
</td>
<td class="num">(53,231)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="num">(249,530)<span></span>
</td>
<td class="num">(232,027)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="num">(224)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, end of period</a></td>
<td class="nump">$ 42,872<span></span>
</td>
<td class="nump">$ 57,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsForMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsForMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741866184904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loans and Lines of Credit - Credit Facility (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 187,524<span></span>
</td>
<td class="nump">$ 245,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of debt</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(10,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized financing costs</a></td>
<td class="num">(4,504)<span></span>
</td>
<td class="num">(4,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="nump">182,813<span></span>
</td>
<td class="nump">230,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember', window );">Real Estate Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">7,447<span></span>
</td>
<td class="nump">7,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember', window );">Construction Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">178,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ameh_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741851651816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans and Lines of Credit - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 05, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 01, 2023</div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,504,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,605,000<span></span>
</td>
<td class="nump">$ 4,504,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">967,000<span></span>
</td>
<td class="nump">$ 2,466,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,343,000<span></span>
</td>
<td class="nump">$ 8,007,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Medical Property Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AMG Properties LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | ZLL Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember', window );">Medical Property Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Debt instrument, covenant, debt coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember', window );">Medical Property Partners LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember', window );">AMG Properties LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Debt instrument, covenant, debt coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember', window );">AMG Properties LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember', window );">ZLL Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Debt instrument, covenant, debt coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember', window );">ZLL Partners LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios', window );">Number of key financial ratios | financial_ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum', window );">Maximum consolidated leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Minimum consolidated interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Average effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
<td class="nump">3.79%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Minimum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Maximum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Annual agent fee</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">0.175%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember', window );">Construction Loan | Tag-8 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum', window );">Debt instrument, covenant, cash flow coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember', window );">Construction Loan | Tag-8 Medical Investment Group, LLC | London Interbank Offered Rate (LIBOR) | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Revolving credit facility term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Revolving credit facility term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Amended Credit Agreement | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | APC Business Loan Agreement | APC | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember', window );">Term Loan A | Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Amended Credit Agreement | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Amount available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APAACO | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc. | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AssetAcquisitionPercentageOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Percentage Of Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AssetAcquisitionPercentageOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Key Financial Ratios</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentNumberOfKeyFinancialRatios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_MedicalPropertyPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_MedicalPropertyPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_AMGPropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_AMGPropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_ZLLPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_ZLLPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_Tag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_Tag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ameh_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaacoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaacoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741869217272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loans and Lines of Credit - Schedule of Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021 (excluding the nine months ended September 30, 2021)</a></td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LongTermDebtMaturityAfterYearFour', window );">2025</a></td>
<td class="nump">186,747<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total</a></td>
<td class="nump">$ 187,524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741866243896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesMerger', window );">Holdback shares not issued to former shareholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,323,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Number of shares issues as a result of warrants exercised</a></td>
<td class="nump">34,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,323,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">$ 19.9<span></span>
</td>
<td class="nump">$ 29.9<span></span>
</td>
<td class="nump">$ 49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_CDSCMember', window );">CDSC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_CDSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_CDSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741868629064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,420<span></span>
</td>
<td class="nump">$ 648<span></span>
</td>
<td class="nump">$ 4,322<span></span>
</td>
<td class="nump">$ 2,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 818<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 2,528<span></span>
</td>
<td class="nump">$ 1,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741871922936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 14.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod', window );">Warrants exercised (in shares)</a></td>
<td class="nump">624,760<span></span>
</td>
<td class="nump">800,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from warrants exercised</a></td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Exercise price of warrants exercised (in dollars per share)</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Exercise price of warrants exercised (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember', window );">APC Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Purchase price adjustment from Merger</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period (in shares)</a></td>
<td class="nump">24,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 23.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares)</a></td>
<td class="nump">159,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 28.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Grant date fair value of restricted stock to be recognized straight-line</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued During Period Value Stock Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741858881672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">700,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="nump">24,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="num">(120,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(9,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">700,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">534,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 13.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">23.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">5.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share)</a></td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">14.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 9.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">3 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">2 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding</a></td>
<td class="nump">$ 53,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">$ 41,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741869193320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details) - Board members<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.19%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market value of common stock (in dollars per share)</a></td>
<td class="nump">$ 12.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741870518120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Warrant (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharesWarrantsRollForward', window );"><strong>Shares, Warrants [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,878,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="num">(624,760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightCancelledInPeriod', window );">Warrants expired/forfeited (in shares)</a></td>
<td class="num">(17,803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">1,235,563<span></span>
</td>
<td class="nump">1,878,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedAverageExercisePriceWarrantsRollForward', window );"><strong>Weighted Average Exercise Price, Warrants [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 10.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod', window );">Warrants granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod', window );">Warrants exercised (in dollars per share)</a></td>
<td class="nump">10.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod', window );">Warrants expired/forfeited (in dollars per share)</a></td>
<td class="nump">9.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="nump">$ 10.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract', window );"><strong>Weighted Average Remaining Contractual Term Years [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm', window );">Warrants outstanding</a></td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
<td class="text">1 year 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AggregateintrinsicvalueAbstract', window );"><strong>Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, beginning balance</a></td>
<td class="nump">$ 14,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue', window );">Warrants granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue', window );">Warrants exercised</a></td>
<td class="nump">20,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue', window );">Warrants expired/forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, ending balance</a></td>
<td class="nump">$ 99,500<span></span>
</td>
<td class="nump">$ 14,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AggregateintrinsicvalueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AggregateintrinsicvalueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, cancelled in period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights exercised in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights forfeited in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SharesWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SharesWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedAverageExercisePriceWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedAverageExercisePriceWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedaverageremainingcontractualtermyearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741866027480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="nump">$ 10.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember', window );">Warrant Exercise Price Range One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">635,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">635,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember', window );">Warrant Exercise Price Range Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">600,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">600,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">1,235,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">1,235,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741867957464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount', window );">General amount of guarantee (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">$ 187,524,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APAACO | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">14,800,000<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc. | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of financial guarantee on benchmark Medicare expenditure amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PercentageOfFinancialGuaranteeBenchmarkAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaacoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaacoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741872050216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized risk pool revenue</a></td>
<td class="nump">$ 10,579<span></span>
</td>
<td class="nump">$ 5,474<span></span>
</td>
<td class="nump">$ 36,112<span></span>
</td>
<td class="nump">$ 23,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | Board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentConsultingFees', window );">Consulting services paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | LMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">13,200<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | PMIOC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | DMG | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember', window );">APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">10,100<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
<td class="nump">23,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember', window );">Advance Diagnostic Surgery Center | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember', window );">Fresenius | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember', window );">Fresenius | APA ACO Inc | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember', window );">Fulgent Genetics, Inc. | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember', window );">APC Shareholders and Officers | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember', window );">Critical Quality Management Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember', window );">Numen LLC | SCHC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized risk pool revenue</a></td>
<td class="nump">21,500<span></span>
</td>
<td class="nump">$ 47,100<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">$ 31,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Amount outstanding under agreement</a></td>
<td class="nump">$ 47,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember', window );">LMA | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember', window );">PMIOC | APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember', window );">DMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember', window );">DMG | APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Consulting Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentMadeToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit/Duration (Amount paid to related party in relation to providing services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentMadeToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaAcoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaAcoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_SCHCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_SCHCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741868835304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Fees Incurred and Income Received (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Receipts, net</a></td>
<td class="nump">$ 10,579<span></span>
</td>
<td class="nump">$ 5,474<span></span>
</td>
<td class="nump">$ 36,112<span></span>
</td>
<td class="nump">$ 23,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet', window );">AHMC &#8211; Risk pool, capitation, claims payment</a></td>
<td class="nump">10,712<span></span>
</td>
<td class="nump">5,683<span></span>
</td>
<td class="nump">36,505<span></span>
</td>
<td class="nump">23,739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Receipts, net</a></td>
<td class="nump">21,500<span></span>
</td>
<td class="nump">47,100<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">31,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember', window );">HSMSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember', window );">Aurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">$ (100)<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="num">$ (252)<span></span>
</td>
<td class="num">$ (228)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance Services Revenue, Capitation, And Claims Payment, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741958748968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">31.50%<span></span>
</td>
<td class="nump">28.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861492536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Treasury shares not included in the calculation of earnings per share (in shares)</a></td>
<td class="nump">10,925,702<span></span>
</td>
<td class="nump">12,323,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741867309544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Earnings Per Share Computations (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">44,301,060<span></span>
</td>
<td class="nump">36,364,839<span></span>
</td>
<td class="nump">43,608,116<span></span>
</td>
<td class="nump">36,149,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">46,273,640<span></span>
</td>
<td class="nump">37,551,740<span></span>
</td>
<td class="nump">45,339,372<span></span>
</td>
<td class="nump">37,249,967<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741868203208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">44,301,060<span></span>
</td>
<td class="nump">36,364,839<span></span>
</td>
<td class="nump">43,608,116<span></span>
</td>
<td class="nump">36,149,692<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">46,273,640<span></span>
</td>
<td class="nump">37,551,740<span></span>
</td>
<td class="nump">45,339,372<span></span>
</td>
<td class="nump">37,249,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">583,639<span></span>
</td>
<td class="nump">187,843<span></span>
</td>
<td class="nump">498,296<span></span>
</td>
<td class="nump">178,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">305,725<span></span>
</td>
<td class="nump">38,252<span></span>
</td>
<td class="nump">261,025<span></span>
</td>
<td class="nump">31,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">1,083,216<span></span>
</td>
<td class="nump">960,806<span></span>
</td>
<td class="nump">971,935<span></span>
</td>
<td class="nump">890,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741974301544">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 204,768<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
<td class="nump">$ 166,082<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128,558<span></span>
</td>
<td class="nump">67,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,753<span></span>
</td>
<td class="nump">7,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,626<span></span>
</td>
<td class="nump">49,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,773<span></span>
</td>
<td class="nump">4,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,734<span></span>
</td>
<td class="nump">16,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">427,212<span></span>
</td>
<td class="nump">338,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,594<span></span>
</td>
<td class="nump">86,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243,353<span></span>
</td>
<td class="nump">239,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent', window );">Loans receivable &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,046<span></span>
</td>
<td class="nump">43,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,134<span></span>
</td>
<td class="nump">18,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,195<span></span>
</td>
<td class="nump">18,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">444,082<span></span>
</td>
<td class="nump">478,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">871,294<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57,505<span></span>
</td>
<td class="nump">36,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,827<span></span>
</td>
<td class="nump">9,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,872<span></span>
</td>
<td class="nump">50,330<span></span>
</td>
<td class="nump">$ 57,455<span></span>
</td>
<td class="nump">$ 58,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">207<span></span>
</td>
<td class="nump">10,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,658<span></span>
</td>
<td class="nump">3,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">116,759<span></span>
</td>
<td class="nump">114,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">182,813<span></span>
</td>
<td class="nump">230,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,592<span></span>
</td>
<td class="nump">10,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">221<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,856<span></span>
</td>
<td class="nump">15,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,232<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222,714<span></span>
</td>
<td class="nump">257,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">339,473<span></span>
</td>
<td class="nump">372,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">121,258<span></span>
</td>
<td class="nump">126,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">124,569<span></span>
</td>
<td class="nump">67,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,927<span></span>
</td>
<td class="nump">5,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,454<span></span>
</td>
<td class="nump">46,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,267<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">293<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,808<span></span>
</td>
<td class="nump">14,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesCurrent', window );">Loan receivable &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliateCurrent', window );">Amount due from affiliate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">346,340<span></span>
</td>
<td class="nump">261,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Land, property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,253<span></span>
</td>
<td class="nump">27,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,140<span></span>
</td>
<td class="nump">69,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">109,460<span></span>
</td>
<td class="nump">109,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent', window );">Loans receivable &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">104<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Investment in affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">994,785<span></span>
</td>
<td class="nump">225,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,046<span></span>
</td>
<td class="nump">43,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Investment in privately held entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">405<span></span>
</td>
<td class="nump">36,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,258<span></span>
</td>
<td class="nump">6,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">17,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,265,984<span></span>
</td>
<td class="nump">539,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,612,324<span></span>
</td>
<td class="nump">801,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,202<span></span>
</td>
<td class="nump">12,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,827<span></span>
</td>
<td class="nump">9,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,998<span></span>
</td>
<td class="nump">37,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrent', window );">Amount due to affiliate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">207<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,131<span></span>
</td>
<td class="nump">89,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,245<span></span>
</td>
<td class="nump">7,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,941<span></span>
</td>
<td class="nump">9,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">221<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,262<span></span>
</td>
<td class="nump">5,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,679<span></span>
</td>
<td class="nump">22,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 92,810<span></span>
</td>
<td class="nump">$ 111,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $601.8&#160;million and $576.1&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $92.8&#160;million and $88.6&#160;million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. The VIE balances do not include $994.8&#160;million of investment in affiliates and $15.8&#160;million of amounts due from affiliates as of September&#160;30, 2021 and $225.1&#160;million of investment in affiliates and $22.7&#160;million of amounts due to affiliates as of December&#160;31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=d3e56071-112765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741871852680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable', window );">Operating lease, termination period, if applicable</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable', window );">Finance lease, termination period, if applicable</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Assets recorded under finance leases</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated depreciation associated with finance leases</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741962817784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,379<span></span>
</td>
<td class="nump">$ 1,784<span></span>
</td>
<td class="nump">$ 3,893<span></span>
</td>
<td class="nump">$ 5,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease expense</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(235)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="num">(709)<span></span>
</td>
<td class="num">(567)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost, net</a></td>
<td class="nump">$ 1,174<span></span>
</td>
<td class="nump">$ 1,607<span></span>
</td>
<td class="nump">$ 3,273<span></span>
</td>
<td class="nump">$ 4,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741958182184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,414<span></span>
</td>
<td class="nump">$ 1,489<span></span>
</td>
<td class="nump">$ 3,903<span></span>
</td>
<td class="nump">$ 4,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted Average Remaining Lease Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">6 years 5 months 8 days<span></span>
</td>
<td class="text">6 years 11 months 4 days<span></span>
</td>
<td class="text">6 years 5 months 8 days<span></span>
</td>
<td class="text">6 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
<td class="text">3 years 11 months 1 day<span></span>
</td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
<td class="text">3 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageDiscountRateAbstract', window );"><strong>Weighted Average Discount Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CashPaidForLeaseLiabilitiesAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741866271560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Payments Under Non-cancelable Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (excluding the nine months ended September&#160;30, 2021)</a></td>
<td class="nump">$ 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">2,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">6,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">20,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">16,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">2,658<span></span>
</td>
<td class="nump">$ 3,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">13,856<span></span>
</td>
<td class="nump">15,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (excluding the nine months ended September&#160;30, 2021)</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741860206584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - DMG<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod', window );">Equity method investment, additional purchase commitment period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase', window );">Additional ownership percentage committed to purchase</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Additional Percentage Committed to Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Additional Purchase Commitment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139741861427432">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted Cash Equivalents, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsCurrent</td>
<td class="nump">$ 746,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted Cash Equivalents, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsCurrent</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted Cash Equivalents, Noncurrent</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted Cash Equivalents, Noncurrent</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIJL0B?FSE6.9954D<Q]_M4$'^SZKAH>?=]$_U\F;9)Z34HY5]F<ZU\O+031
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MC,9QS,[!T?"=IZ^TLT;T%&OD.7]MVQ\M2!YCX2Q< ,<$MG>_$P#'6620]G@
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M>1"U&7=!0+W0]-S6 2'!YI4+$&=&DXU1>B&*#-P8P"$<[18%&Y="8V+SM@V
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M!QE&:)(#'>LU:*-/H,VH[1^;&/+)>E46=WU[!10.4"N>\Q@RBAQ5!#5@HT^
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MPE'D2#BYP2#W8_!2\[DLQX;#)#KUV7VJ4GKXR!X'3H60>2T%&#EV&C< Y'X
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MN#IL^#)T6_D+%,MN&+I&/B*5!>>X +^O.LB;_\(#XI\D^?Y_ 5!+ P04
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M;<XD=C?ZSS%19)4"MO)=C&/5YDEHJ]=EF\,.FPA%&*X)GOFM+5A&6 "?L \
M<&5RN@%HS-!Z<(C>NX4"4R6;+EU?,55^,-NR:B* 2#'S[W9+=R:I9 =[SA"0
MQ3++C8?K.[-HJZS!DXNPOOVT6"?%BJ;>9#4)5Z71N[<SI4Z<^R:I%NMH<LK$
M,8ZN&>9RFQ7X%&S.)BE <N/28CI4("6! F !2?H;R"Y>\P$B,:OIX, S!0K3
M'' &8%5XS;OWD!">P?%';,+JZAJ9$BX]B99)5B$U.I[CB'23P+$&Q&^2CX:
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MQPUD4#V7BJ,X72)3): /5B;+W1C@+BEMI7VR#YXO@\4Q!9]TEK3W_F%HP=@
M$#("&0?8W^%-F1K ]W)_GS=L*Q6[G@,#0@SV%< #9KD@Q\'OL,G9<A<1(9$B
M#M#P_#1Q2;CBV<@J1EY"<'F3(GXM]>#6H*X,PB $##B>Q_%A;C@O-"<N(^-C
MV0LV6V0=X%]$D[%_WBU9D(U>M\LE.@]1R/%.PGQ,IX:DK7>TD3Q+4%J2-"4;
M AE&.R>?3U=A;+>HT[R,IL'461UP$B+WHBQ&J.F#!"'+6A!)B@)J+'0(0:96
MQB-^P,\6_9!,BIOD-Y#M<-6*:;O[R(9,=5 ?(K*"H0]?X@8>"WR\=+Z;!5L2
MK:JR15Z4+#XRQ7>(@M@6L0#8 !QX_WB/H[?!R$S^P.9K)7\@8J;-'4_4MZ\O
MHH3!W)8/IL*3 I"MUAU4P6IJ8)MY4LF5&+<R!3-$S EO)P-.(MX+/,^U4\?)
MW[$$MH.$T,-V+*Y!FZ((%,LD^.$>A"E\02G] I@H6-IN=Y'+ [EM$Q]RX'1I
MLALUY0C^^.*RG^&Y== 69ITI/F:+CR,D4\7+O1Q1G'N'FM(6!3XRB27AS%D@
MJ:A5,'"&PR+.2Z#6%7,;0&<RK\MJWHL/=?N "58K:/<\!D&"C[,RWH]/?1X
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M;-S.>EA\\NI@W#U'E%.;[LU#$(@QJX$".ZDZI'YO2YQ"1"S0XD)W"J9O^4R
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M)YVAAQ<"%"59\'@D@N&L" ?LQY+!P.:29]"J+'A(PB3"#@-#?S5S4B(A&PY
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MR8UYAC;.1?0W#83J=;A\<MKYQK@0%@!FT.0D/IZ>P:>3^/+T-%CV='(93R\
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M^'U9EHU^P0DP_8# >_V_4$L#!!0    ( %&!95.,<,(HA08  '(0   8
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MB@DU:" Y(@-I(4P0Q-*KG%QBAB,M.;1@4TP__W0XVW_VTHL"J369DEK4Y.*
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MMF#OV9$QLC"VD>"-=F1*)P+VM 28X8"!6GK.D_<6-D([H,6R.TUM$1^#$)3
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M3^],^)?#UG*]3I:I!&JE'$*ANL FUC@!8XB_%02 N_"8-APT(CT#('0;F=,
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M";3*E?@EA9-+RGUOE;C4*E[@"T?)K,@+1<UZO&CUOUN^A<6!(!::DJ/9]U3
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M.3; >F:193/@ -VS;?XO4$L#!!0    ( %&!95.($XMXVP(  $L&   9
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*U5VV[;, S]%<(;A@TPZEM\29<$
M2"_#]E @:'=Y&/:@V'0B5+8\25[:OQ\E.UXVK,4>]F)+%,_A(672BX-4]WJ/
M:."A$:U>>GMCNO,@T.4>&Z;/9(<MG=12-<S05NT"W2EDE0,U(HC#, L:QEMO
MM7"VC5HM9&\$;W&C0/=-P]3C!0IY6'J1=S3<\MW>6$.P6G1LAW=H/G4;1;M@
M8JEX@ZWFL@6%]=);1^<7,^OO'#YS/.B3-=A,ME+>V\V':NF%5A *+(UE8/3Z
M@9<HA"4B&=]'3F\*:8&GZR/[.Y<[Y;)E&B^E^,(KLU]ZA0<5UJP7YE8>WN.8
M3VKY2BFT>\)A\$W(N>RUD<T()@4-;X<W>QCK< (HPB< \0B(G>XAD%-YQ0Q;
M+90\@++>Q&87+E6')G&\M9=R9Q2=<L*9U;HL9=\:#1OVR+8"@;45D%'U6,'U
M ]V]1KT(#(6R@* <:2\&VO@)VCG<R-;L-5RW%5:_XP.2..F,CSHOXF<)[[ [
M@R3T(0[CZ!F^9,H[<7S)$WQCNOI7ODQH^+K>:J/H2_GV3(C9%&+F0LS^=VF?
MI;5=>JX[5N+2HS;4J'Z@]V^QX.,>X5(V'6L?7[THXBA_2_D?D=T)DHU(/")+
M26VH#9ED#89H:BFHGWF[@]>\)8OL-0'UFW.@FS+8;%&YZ[K"<MQ$/JS_C/42
MXL0/TX@6<S]-9W#).FZ8Z]>C3^S/LQP2/YU%<-=O28F[(:G@PV9]XI45&41^
MEL6P4;)&;<<&$U CR<_F.9TE>0%7/8*1-$X$L]ET3!E.#K$?SPM(0RK/0 ^"
MLRT7W)U&N1^G<XA(2E%,92VIDE2=06U!^G+(_'D>PD=I*/"_%?8EI+F?ABDM
MDLR/9@G\[<L+3AJ\0;5S8\S>"@48>GVR3I-R/0R(7^[#F+UA:L=;#0)K@H9G
M>>J!&D;7L#&R<^-B*PT-'[?<T[1'91WHO);2'#<VP/3_6/T$4$L#!!0    (
M %&!95,7 T/%+0,   $'   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM
M;*55;6_;-A#^*P=M&&Q B"1*BBS7-N!X'39@&8RFW3X,^T!+9YNK1*HD72?_
M?D=*5ATT#0;TB\27>YY[CG<\+LY*?S1'1 N/;2/-,CA:V\VCR%1';+FY41U*
MVMDKW7)+4WV(3*>1UQ[4-A&+X]NHY4(&JX5?V^K50IUL(R1N-9A3VW+]=(>-
M.B^#)+@LO!.'HW4+T6K1\0,^H/W0;37-HI&E%BU*(Y0$C?MEL$[F=YFS]P9_
M"CR;JS&X2'9*?723W^IE$#M!V&!E'0.GWV?<8-,X(I+Q:> ,1I<.>#V^L/_B
M8Z=8=MS@1C5_B=H>E\$L@!KW_-38=^K\*P[QY(ZO4HWQ7S@/MG$ U<E8U0Y@
M4M *V?_YXW ._P? !@#SNGM'7N7/W/+50JLS:&=-;&[@0_5H$B>D2\J#U;0K
M"&=7]UB+BC?PN^ [T0@KT"PB2\1N.ZH&DKN>A'V#I(1[)>W1P%M98_T<'Y&@
M416[J+ICKQ(^8'<#:1P"BUGR"E\Z1IEZOO0;?)?HGH#*&#[(CHL:-@T7K0$N
MQ^&Z_I=.G$K.PMM'*GN#(:Q=V3BDD/"%YN_USEA-)?7/*^JR45WFU67?EX-7
M2=SEG9N.5[@,Z'8:U)\Q>(D9WA\1-JKMN'SZZ8<92XHW!MK!KKFRJQ3=/&.Q
M!K4'2Z"]:N@*"WF "9V%/:J3H;,STSE0NBRV.]0^9\]G]U]3A[##@Y#241%W
MAUJH&GZ$/ [3-':#65BPG([^TTEH$C QB/"'L@CI%)(B!R^<O?%Q*$GY,H[H
M$D7%-9)\0ZL:&^Y"L JJ/L="5B=-I'/8N#^E>O#/,A;>)B4P5H9)F<&65O6P
M:6"2E3/R'19I N^5)2\O>',4"4N 4> E!;#E3ZT7YZKN^]1-J,N&^8Q-89(4
M=#SE[?0KA;.PS$CD)$]#EB;30:>O]0G+RC!/8]IE*0MC5DROJIW C&6.^I;P
M+V8,9?TL5Q3IK& N5T68Y3F\= VBJ[;4HC[XYNL*ZR1MWZ'&U;&_K_NV]L6\
M?QSNN::*,=#@GJ#Q39$'H/N&VT^LZGR3VRE++=,/C_1&H78&M+]75#[#Q#D8
M7[W5?U!+ P04    " !1@6533WL)8 $1  !R.@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6SM6WEOVTB6_RH%;WIA XPLTI:/[B2 [#@]:=@3PTFF
M,;O8/TID2:H)16J*I(_]]/M[KXJE(G4XG9E@N@<+!#%%5;UZ]UEZ]5":+]5<
MJ5H\+O*B>KTWK^OECX>'53I7"UD-RJ4J\,VT- M9XZ.9'59+HV3&FQ;Y83(<
MGAPNI"[VWKSB=[?FS:NRJ7-=J%LCJF:QD.;I0N7EP^N]>*]]<:=G\YI>'+YY
MM90S]5'5GY>W!I\./91,+U11Z;(01DU?[XWC'R^.:3TO^(M6#U7P+(B225E^
MH0_OL]=[0T)(Y2JM"8+$GWMUJ?*<  &-OSN8>_Y(VA@^M]#?,>V@92(K=5GF
MO^JLGK_>.]L3F9K*)J_ORH<_*4?/B."E95[Q_^+!KCW&XK2IZG+A-@.#A2[L
M7_GH^!!L.!MNV9"X#0GC;0]B+-_*6KYY9<H'86@UH-$#D\J[@9PN2"@?:X-O
M-?;5;RZ-RG0MWLE4Y[I^BL2%++Z(ZU(6E9!%)JZQOA+E5-B%KPYK'$I;#U-W
MP(4](-ERP+FX*8MZ7HFK(E-9=_\AD/48)RW&%\E.@!_5<B".AI%(ADF\ ]Z1
MY\ 1PSO: N^MFM3BK:[2O*P:H\1_CR=5;: M_[,#^+$'?LS C[\?>[_Y@&C3
M":*W07R:*W%9+I:R>/K/_SA+XM.?*F@U6#*1N2Q2)=(2%EC5#*/&XFF9PY)U
M,1/[NL";LJEP3G7PHX!D:K68*./%(]ZJU+V)^<U0?%)FP?B)L7@A^,CD)SS%
MIV=1G(S$G;HO\WOLX#7QV3 :#H?BQ/ZY4S(75U4M:^68>!H='Y_B_]'9$&04
MD%QCS9VWGY[Z$SZ5-?8R9?$9UB?'(CD>1:?#D;A65?6CN&R,444MEJ5A ""7
M5^\GP],#L1\/H[.S\P.W^',A%[3N?U4FIKH HX@A:4E\VC^.1L/C _I[,AQA
M1UG,7M9$-L,#J6=)=!8?X2D!HY(X9B&HJM;P,@10:B/N9=XH0J)LC,B[(!XD
MR8@^0[B9:"HZ_%K=JUPD0A?+!E@L#: 9G3_!=>8,MBZ!( 1MY"17\"'F"WP^
MEJ6J&H@QRW>#!$F'UJ08L2:DTI@G.MKB2E@592V("*-ECJ,S/9TJYNK4E(N
M,.AFQ3!T@<4@71CL @X%O]VHD'*Y-.6CXY%=GEJ9X21Y+W7.A(', ,2 >;O2
M60D+9RUN:C)V,&2A:P29E7YO/!O1C[]\4M)40A49P0K8LF8+XT79@&QFX;YZ
M3/.&MQ", D(3"^L4%3G%#6P_@'*,1O28B.2,'XY$$O,#%)?>#F$L)!R 1#2>
M@HU0K)/H%.9@=?V%5W1G\^.948IH%>^+X,QD&)]'(>G BH22D7!*(46EP&=\
M3"T8Z<'LTR9B5#+\J7]&Q._CGUH<V]W3UO$PW@WH-_;P+IS6/SDH!PB+]5Q\
M,@U<D?5Q^]/!EX$<B(]-@=?N[4$$I(6&-%.Y! B< T63&0Q%DU>G%  $L$8Z
MD>8D U.Q1DKWB5RGT%75@#U0BUS58 AK2,L#$(7U%>D4N>1@7R9ND5@H0QPC
ME"+QR^T-LB9 O)PC?W O_SP8#R)Q\_G=SW FY&_"UW?E$P3(9)+GEH7,9"3>
MZ2GQ8*Z-A<R'71*-?Y;DLMP6IL119=5_3?XPI'M-FB?AO>[52U)K^ GRO.S'
M^J+JF!2A]"(>#@=#)"1YCH,C\3#7Z1RL)SU7EH_$LH!C53/Q\/"V61+4%\EH
M!64+KC*ORA!A=H,Y>7?&XWP80K!F5XE):1"IR3<2&RSV?<!8$_@?24+%OZ(!
M&\F["/5W>@262I.N1K1DDX,HES7S8%\>\/>\F;3KJC&E]5 I7*%:EA4I9JMW
M*5!4U;*TOL1_#:(^#SX.1 :71;X&7@_"H270D3O5L")^!%,58MS[BP]WPUC<
M0J/%OC,@?MF:#9#._@;CH*B"<TEZ.%096($!?=I85L!F%#QU6D=BF3<D/YOB
M$S8353_08<E@./R!5>Z(GEC+@B!$&;8 QPS>P!\C4]85Y\O9-J>>(V 9PIS,
MLHP$\-N?'  *[6(N]K%I48D]*LGW0&5 _A%I3^$J!W8]+#*DB"R)Z4:-ZCC1
MB+T0M+[2F4:Y ].^N8F\-[0^J.=H?P;.LB"?55!0@.Z0M8PW^MMGUJX48-F8
MJL%*TF0V4R"!Z ,J2*N!#"BJ&#LQLS"5LCB6DUS/V+/T@^,NLP(^8$0Y4PS>
M\\ZS9<9'9*'O;6,,4> -$CJ)'((.)D;*JE)U%3D7 Y0C!HTR4^0:(5Q:&Z0=
MJ)E2ZQLMA:3G!)C<.72((X\V*]%H.*Q]#Y<8<6#].V 9*NHJ2P59*S2B]8;C
MVY?CFS]QGCD0'PKQ2X,P$)_8^+TKGH*NA8W[= K1RAG-SN@Z=COZW/[&(-L#
M]VRP[4=58ME7QE7.C*H&T:&-R%U,9AUE)2&1$"9\:#^\6K'X6.L0=,H/G"(8
M;CKXEH#;#]F; S =WP_"T2KXCJNJ3+731,X'2<^Z+/M;"24 !?!FR)YE,6/U
M+[)#<,US+.#/M7T7^/,B\WC1NE^A/Q%'SD^E05)9OGQ;DE16!*H'\=?2?!$7
M.(ZL_U>5YQ5D;F;E-N0W)Q;;:+IN,ZBZW.Q;6-]#;<<W"*:I,K4$S+[F1R)C
MBUBEJ#'7'92F3JS#LZ=T_$H+[;KU*<XD6,.\ N,90:]V=<$VLVKS#1NMORY)
M:N-OIX#U%K4AA3K^AA3JY3,YE+.0P' H4>IOW)!V;:?K <L0>5%E<@VY6<(P
M'ZZ"E1>#>H1M$CQ=4 6EL@*%<S^,$+;MAM ?1Z(/SM5K,H4S1Y[$,8EVZ^(>
M*L4%G%5;)SD6'#4$F22YU%01%8AL51 9H!D(^SFE8JCZ22\1+)&'44'\V4>X
M;4IB_1AE'19F2JE<)UH^%\^1?1%M/OO:F;]NU54G("CG'RN9Y43UGY"@<FLA
M'B2C'XB^9##ZE^2F0&38XA!_!QRVMVBB]48*@=P2X[E-$P].1C\,PMX?(F_+
M<.X4+>53H$(NLBMN2+T8V68<NQJ_Q/L+MVHXB$\M-X:#(SPX(E=]FK#U\KR6
MDXN929/ESHLT%7"*5NDE-"O7*0,F!/ZIC _9Q,9&S,$I5OT1T(H,86E#DV"[
M%7YG=675)(G TAA1DA4C"A;:-Z A;)>%B5=[BDMX*;7KQZ(UW>$JO:] =GZ!
MXL<>V99O_0C0231MZABD1ZTSW:89ST1RAU/5.=6U0O,GIT /I?BBGMI.KI66
M+A%1E.3$-4\;VT-ET5!'O,RU35)8.EUV+*@;19Z=(Y>D<8U>-(ONOJ[(B$CJ
MG0)MZIY2?E2@SCX=664A:_-1)9< GTF.Y(S?5%= L=689W!!:KB&B_<=:;D)
M*;8YAU'R31B];;/K=[Y7?LF]\F<:D48AL)!8LQ9 O]E._NAD,/+Y3]#L=NF>
M>;)U5U"LMKZ0"WVNV]9K-G^TS&Q4Y^G!#BR&@].OQ&*+9P[8U(=/7>L50A1U
M,NAT2MJ=N7F'$X7OR4O;@':O6X2XF9UK.;&^VDX.J("C.O<E9XQNL,&)?YL;
MD@+1RB88>VQE1D#\!I[[O+Q 7;)QP[; 14Q8'4^::I5/3]46'['B[+C^C;.-
MKZ"4(^F+XT#Y"!Y>G*R2^I4+S8'%^OCJ0[$) 2N65%9S=E-&D^N'N0((47K%
MXP2\&KNFR/CVDC+7=,XQ0HJ8VF-A(^7F]A:K;GY&G5LND5%SBDW8_M?U-2<6
MDC!M<J<O\.<M. M<(CHL7,_&)_8Y4S!7.3=5=A^!;VV/!!0<M632RUX'C,L5
M&:2V\,Y7Y%VHS+5%*+\CIUK;=#KC?&<JQLV,?-V(H!\-VW1IBWC!4PAR"7&X
M6,<'LT!/!L=>H.ZL>^2L'"Q[219E.2.P>N4@;2:&_)?TD//63#WZVLX&H4S2
M5.Y7:B]]K U=O/BE; SY%U=!WAJ]4.(.1PS:_L[[J0?]2'#(+?M4*NJS:"$I
M1:_TK" T)9=6M:Z;NH5@QT4 HJ?L+"")@9W3 S-$;C<0*WJ\LAD?+#%-31/&
M#68'X?1$(T6IJ55+_1?==>_)\+DLMATZETW-Z0HAYZ02KPI64IQ^8.,Q_F4;
MO^XX?NUG5)9:EUD ,U),Z8I2&!9$H>U48?+4CA+#\6]WZNJR*D^S>H20*W6P
M'B5C'R5[!D$F$*HI:6-OQ>_/'L*X]A7V</3O8 ]=H?S.32,0T)K"_3&L!"'"
M1X?DM-5+>ON'-X=_B_!@0_COVP9.5C9 BO/'4/SU&TLH2,;@:.Z(_B1GXJQO
M!6FX:Y-)](8</./P_>FU,]L>]<"=1M6\^,O[JUZ=^[1^K68=?4GW;"H'",C:
M/F;;J8XW&,^:H7J3M!:9;$><[Y*ML'_?43=0X;LMK&JDV/Q-T&EQ1%'38Z7@
M7H1>TZVVXM0;6$[<*F1)<Y "7[*N+%'JMF5(UR0ZK=D!V6I'@$"4>Q&JMA/!
MR [MN-PI2J'NV\M)[JXIG<L6*XM:<U%*UZU*KM@+-Z().AF^*TT@K%P  $E]
MU(Y[\3'T<L$8QO6(UT14;Y0]22-:P:GFY,)P/&RN%NW@DVNJMGIP.D##@MH6
M;L]HP]%*&VYQFBQ(Y3>HPN=E6;BC^?:PJRPW[(GL32SR:QVAK2N!I6="[,@4
MJ80NN";^118-M;BL7AP-Q#OJ1_?>HIZL8=0]W3[:U+IMYRW) *%CR4//HEEP
M!_PQ#68HW#[G+?^ UPR2Z@^TQ$O/R:W:R3K6(NG,W3<CO5I%:U[XDDK:=W 1
MNUQQQ^W =HC+9(/3\+X.*)./5&(BF!K5&5R&#0RO+E<7[S^]'?MQ',R_H;:S
M&S-E?D3$;AL&TQC7-<UHOJTGC1WL</ *P@*Q!J4Q-T:_2X2XXJD'M6"]>Z/(
MO_':KG0L57[/VE! LT3]3=BL,;_E5J*]<L-9$NE/,HA'[8V@T_,?^MV.]SU"
M6]_4D2\W0_S]2Q>!B=-N$-H3IW6#MAO#%%#?VEU3KH)Y5#V'$V/4?B-=MI.7
M=%LZJ&HVMW2B]OOS[H8X'.QVN=*_C\W20PIWYYI@MX@C3]QTN: V$.D$6]R'
M,%>*AU'0+5U?/.[F ]W;#=V+)=OWKFZ#4,?1==:@E9E*C:(QF T7-LWT%P5?
M'(=.Y1/UDOR&:6-X[LHW=EP[R4U<6Z_6F1;;L= N\H+IA75QT^WS&.<=,M]#
M75(:4',S7KNQQ-==0_)WF"964C2?EO<ECRKH'I7%6VX:^6;M&(&&G1.ZOK3I
MEH-%@PK1V\O5:#:XC@6Z_4%1>QO5CU^"*U\K#8'[AG-@)&B^2M>^@[S1XF5;
M^ER' 9?X_/S<7HNUPJ<8$<3_KO.9E#1:6C E55O+I'.I*6[8"R57'VAS5QD'
M*'*LO*Y7\FJ'.+?C\>4'NAB/,D97<\Z/A#9T5\&.^KJR#D9O&]0^*+/D= I]
M98IY8?F59$76=Y)@7L3'@S-O]*W;F:@"<8SSP,N;CSQ><'7GJK;\.OQ9G+GB
MABX6,+2=41ZQ\4'9E#&,\YNO+H>#CKG,^G=(_(QVZUPVZ*Q#M4();2>OVBV?
M\+ =%F\OY-@89IWUT2XQM/='YDKF.'*)3,A-ZW;,;2G[;FAR6>N4?\?@\]/V
MSB%;Q J?U8@(JF0O"BTI*<\J>SO!%@6JH@WNEH.[T(+8J%WJGO&M@J;@/("+
M;[U*,G1A2W27X\OLOO5WMB??@6*O5]E)*BM6FU/:PH<4'X++EW/*R(SZE\KO
M:+<9_;_\MLAOTX_3#H/? 2Z4F?&O'2FA1O5A?Q+HW_H?5([M[PA7R^VO,6^D
M08%#-PNFV(JZ?;1G+\.V'^IRR;\JG)0U.,V/D!$T@!;@^VE9UNT'.L#_S/3-
M_P%02P,$%     @ 48%E4]JFJL!$!0  4@T  !D   !X;"]W;W)K<VAE971S
M+W-H965T,38N>&ULK5=9;]PV$/XKQ#;H 0A:2;N^4MN CQ3-@P,C[O%0]($K
MC5:$*5(AJ:PWO[XS0TE>)UXC;?K@M43.?#/?7*1.-];=^P8@B(=6&W\V:T+H
M7L_GOFR@E3ZU'1C<J:UK9<!7MY[[SH&L6*G5\R++#N>M5&9V?LIKM^[\U/9!
M*P.W3OB^;:7;7H*VF[-9/AL7WJMU$VAA?G[:R37<0?B]NW7X-I]0*M6"\<H:
MX: ^FUWDKR^7),\"?RC8^)UG04Q6UM[3R]OJ;):10Z"A#(0@\=]'N *M"0C=
M^#!@SB:3I+C[/*+_PMR1RTIZN++Z3U6%YFQV/!,5U++7X;W=_ H#GP/"*ZWV
M_"LV479Q-!-E[X-M!V7TH%4F_I</0QQV%(ZS/0K%H%"PW]$0>WDM@SP_=78C
M'$DC&CTP5=9&YY2AI-P%A[L*]<+Y#7SZ) TN"FDJ<1=L>=]878'S/X@W'WH5
MMJ?S@'9(>EX.F)<1L]B#>2)NK F-%V],!=53_3GZ-SE9C$Y>%B\"WD&7BD66
MB"(K\A?P%A/I!>,M]N$]0U.\LP'$7Q<K'QR6RM\OF%E.9I9L9OF_QO:_8G[_
MW7&1'_T\TGD4O/ B-( =5$';<2O4($/O0-B:=RYNKX1OI ,O?O0 ,1+%3T)Y
M86P0WFK06ZS+T"C#"B6FUV&IHC[J)KP&T6Q<$I6%J/RAEUK56R&]Z "[R( )
MHRPQ:'!C!6!$J:7WJE90D:RQ9C"" 5@+90*@>P$?&!XEVHF?=2(@,^MPJ S0
M*4D- ?$CMPU"L$\4"1QM*PT)^Z""V,CH;N?LBC:0D@S,:U2VO:[0T]*V\!3
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MD@+_0#(!SA=:NW;#"KHO3Z?_!5!+ P04    " !1@653<(Z4O74(   W%
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M.B3Y&??C.;]\?#<<@]3+4)U$=Y(9J6L 1$>FT/L[C=SW6>5H4_DBI2'S>HM
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M/)J S^<*':AN:('FN]SE?P%02P,$%     @ 48%E4Q7;'7BV!0  < X  !D
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M+V7Z6>D.X9X.L\*C/BZ^\.$#J(,"]D+AHRT^DOE_;Q3P-W _7&.4/(1ELLP
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M+](%^^+;-QF!"&(PSODJ6; <#O/O1X?V9F3ME]T* SGD$<_RC&4%7\24!8@
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M.?>^Z!JV8I-_G86C&8. ;B4I/30@7<=UU=7J@00,O?A*/I"1\[-\H5/09_K
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M*0@!UEK',*9M1+\'\0<ZC[KO!O=D2*\F"$C AP$BD/M$C.:]@"9/(H'<[5W
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;,57;6_;-A#^*P=O'=I
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M-M-:(!.>1;%&T*J/".I%AQJ/L)=EV&#3#">;"F[/^LTK*V,_2%KDG9*VD6Y
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M0(X[U@A[H]IOV/<S<WR9$L;_0MOESM( LL985?5@JJ#BLONRI_X>#@#GT1N
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M=<1LM#<;.;/1:V'@=2H[M"-7SZVZI+^4ZZ.8]L).])878N;AC=1"?1?>?&$
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M4VC:@.M3I>SZ@P"Z*^O%/U!+ P04    " !1@653I+J].>L"   Z!@  &0
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M-Z,R G/LN,>)TVWH<AOMJ&>&X9X>*33>@/:WFLJGG_@ YV=O\2]02P,$%
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M]B@+>V6A518^IPS+**\+#G(.C>(=P;[\1O=\5ZSWHE/)'NL5R_CI"&M2<_7
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MLC2-O%G1^$?M NA]J90];ER"X8>R_ ]02P,$%     @ 48%E4\EV_D1K P
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M+1E@?6&,W]U0@/VG[^7_ 5!+ P04    " !1@653Z8##_.X$   Z$   &0
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;+U:;6_;.!+^*T3N!;M
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MPF-M/K\TA>;, #Y&=/A^/;& F1PZ1/[Q_Z?$ F=R;.!,=EZ&PH'SYZ0$'R/
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MMB&&HR'>T\2<DI*.9"MJ345O*PN"QRL 7BM,PSS/IA.AJ"/- "Z(?+<#6P[
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M6>XP2N:44?UR2)Z-JY9S95O&TP '0=#SGPX0C"J"42W!89)8>E-);6=!,9&
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MI%#-G&PV1J[=(%A(@V/%+4O\M8"R #Q?2FEV&^N@^UFE?P!02P,$%     @
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MZG/^])MN.R3J^N9Y6C;_!D]M;#@*YMNRRM=M8=."=9+M_H__;0?BH("I9[@
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MB,=R^8!&#,LCS2L,$INW]W>G];K9I)M%<P=UB8KJ1=5=!M51AP5&Q+ Z.JS
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M_C'/J\TW](^>;?_@XL7_ 5!+ P04    " !1@653,D$M02H*  #<,@  &0
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M'WS)6C"M><E+UH%??TD11,_!].]-R;^"=XPOFSEX"J[[-5M^8W/PJJB*>L;
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M83W5M I+EI1G* U7$C0N^L&P>3$^=_;>X O'G=F;@\MDKM2C6]RD_2!R :'
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M>VF:>_5) UP;J/DM8_*UHQ_-]B-I_A]02P,$%     @ 48%E4ZB%4;V9 P
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MA1\E(&!S,91UUA.5E!?'_HHO:;S*CZD]QFD:A_GEDE%1"S* ^/\\CM.7+]D
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MIV\SX.W%%Z/[G/!UHJ:S%%9*E7/15\7$BVFXV$B6FW'OD4DU/)KE1GU! -<
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MO3.SI/QX>@-EZSI\*]',BUO6YD4#91W,>24E'@TK,+R1^6]02P,$%     @
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M=-4L^A21$K:\E>Y![[] GT\P6&AIPY?L>VP<D:*U3M<]&1W40G5__M+7X8B
M.J<)K">P?PF7[Q#2GI"&1#MG(:T5=SS/C-X3X]&HY@>A-H&-V0CE3W'C#.X*
MY+G\EALEU,Z2-1BRJ;@!\I',RU+X(G-)[E1W4WS)SU;@N)#V'"'60VU&'7KP
M2K3HXRVZ>.R=>-?D7BM767*K2BA/\)?C_(2-"%!,?J@ .U1@P485-]!<D#3^
M0%C,DE.&QNDK*)">!'H\8B<=#B0->I-W].;KY8C*9%"9!)7T_X_UUU?$D#L'
MM?T]$F$Z1)B.^OR&/<.VYK6_"41I1X0J9(NG@@/B*B %ET4KN\NCMP0.IAHT
M%6CD#)&=P/FIN]19F 8+OA\]YTE\S:97,<OH\_$9G0"RE*7)Y60 =EG2HZ=2
M@]F%#F))H5OENE<SK Y-:A[>)OT+[SK</3<[H2R1L$5J?'&%X4W7-;J)TTUX
M>(_:X3,.PPH;+1@/P/VMUNXP\0&&UIV_ 5!+ P04    " !1@653RXCHG2 #
M   \"@  &0   'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6RU5EUOVC 4_2M6
M-DVMM)$/YP,Z0"H?T_90"15M?9CV8!)#K"9Q9AOH_OUL)V0AN)1UV@N)G7/.
M]3W8OG>XI^R1IQ@+\)1G!1]9J1#EC6WS.,4YXCU:XD)^65.6(R&';&/SDF&4
M:%*>V9[CA':.2&&-AWINP<9#NA49*?"" ;[-<\1^37!&]R/+M0X3]V23"C5A
MCX<EVN E%E_+!9,CNU%)2(X+3F@!&%Z/K%OW9AXIO 9\(WC/6^] 9;*B]%$-
MOB0CRU$+PAF.A5) \K'#4YQE2D@NXV>M:34A%;']?E#_I'.7N:P0QU.:/9!$
MI".K;X$$K]$V$_=T_QG7^01*+Z89U[]@7V&CT +QE@N:UV2Y@IP4U1,]U3ZT
M"%+'3/!J@M<E^,\08$V ET;P:X)_:82@)NC4[2IW;=P,"30>,KH'3*&EFGK1
M[FNV](L4:I\L!9-?B>2)\1RQ@A0;#A:8@66*& 8?@&%R2O-R*Y#Z<SFXFF&!
M2,:O)?8ML %7$#ZTA5R0DK7C.OBD"NX]$QR".UJ(E(-YD>#$P)^=YP_.\&UI
M1..&=W!CXIT57.*R!Z#S'GB.YQK6,[V<[IC2^;?H\U='/S(#-EL#:CUX^=;X
M?KOB@LG#_>.,OM_H^UK??TF_E/IZ"X%W;_J>ZWY41Y_$X(H4(*%9AE@+<VW:
M9E6@O@ZD;L;=V.E%T=#>M?\[$\@/CT&S4Y#;@_UCT/R%<$=N!(T;P6O=2$BV
M%3CY"S\"TP+]CA\FD!]T_#@%23]@QP]CN,#L1]CX$9[UXT%?\3)KM,-,5JSZ
MD@%T#6*:Y[+&R+LQ?@2R]G&!BD1Z9]@^%<GH414^:"W:]Z'C.J'3\>D4"$,8
M^GTXZ'AE4(2ATW?=SB:;FQ1=?Q ./+-G4>-9]-\\:V^R,ZY%ISF&7B3MZ+IV
M"H11$+A1%S@S* 80#F#D=5PS*7K^8!!V3Y[=*H<Y9AO=AW!IP;80U?77S#:M
MSJVN\)WYB7LS=0WS,]D:59W,'_FJK[I#;$-DA<SP6H92I\ "K.I5JH&@I2[&
M*RID:=>OJ6SO,%, ^7U-J3@,5("F81S_!E!+ P04    " !1@6532E*&*+0#
M  #'#0  &0   'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6S%5VV/XC80_BL6
ME:H[J=W$=EZW@+0+5+=23UHM:N]#U0_>Q$"Z24QMLUS_?<=.-D#PYE KU"_$
M-C//S#PS]MCCO9 O:L.Y1E^KLE:3T4;K[:WGJ6S#*Z9NQ);7\,]*R(IIF,JU
MI[:2L]PJ5:5'?#_R*E;4H^G8KCW*Z5CL=%G4_%$BM:LJ)O^^YZ783T9X]+;P
M5*PWVBQXT_&6K?F2ZU^WCQ)F7H>2%Q6O52%J)/EJ,KK#MPL<& 4K\5O!]^IH
MC$PHST*\F,E#/AGYQB->\DP;" :?5S[C96F0P(^_6M!19],H'H_?T'^VP4,P
MSTSQF2B_%+G>3$;)".5\Q7:E?A+[3[P-*#1XF2B5_47[5M8?H6RGM*A:9?"@
M*NKFR[ZV1!PI (Y;@;0*I*\0O*- 6P5ZJ86@50@NM1"V"C9TKXG=$C=GFDW'
M4NR1--* 9@:6?:L-?!6U*92EEO!O 7IZNF"R+NJU0H]<HN6&28Y^;+X*/=19
MN<MYCHH:S8MRIV'HD)^):KO3S.1=H0]SKEE1JH\ HRS,V-/@I['F9:U/]XU/
MY!V?*/HL:KU1:%&#=8?^?%@_'=#W@)^.)/)&TCT9!%SR[0VB_@^(^ 0[_)E=
MKNZ[POEOUA?_VOH)&;2K&&KQZ.45\_LO((,>-*_4'P,6@LY"8"T$[UCX8G<W
M%!M[Y1).J[:0D%BA3%05'"^P+;(7!.>>TJS.P1OT_7<)P?@G<V@4&?H %=LH
M?7257V,^M.;-2?HZ#0+J8S\"?EZ/\WHN2",:!0E-3P7G#D0:^0G&T:G@PH6(
M@S1*22=XPEG8<19>C;.\W=O?8"T\CS$B,=#19^U<D,9AB..^X-R!&%*:TICT
M6',ADB!-H]C-6M2Q%@VRMFPXV=JS:Z!RXPXOOM+>2#H+R:#'=_F?T!2@4VN%
MM$#["]/^C=0F9_R&"51ZK\IGYV(XB9. ]M)Z+A:D"4G[6\&!!F!!Z$YIVA&4
M#A+TQ)66168X:4)G>R;SH>1B_] K_2NE%Q_U8_P_)+@U>K*#_# F82_#+KF$
MA+W].'>(D0C[?;B%"P[3 +M3C,F!)#)\VC$I&3 TQ/BAG^%K-31\Z&AXN*5=
M*:OGW03["27]KC-S"*;0GORHGU>'7(Q3>I;7<[DD]8,D[276.[J85ERN[8M
M08R[6C<WCFZU>W7<V;MV;_T>W\ZP8WUN7BGV(GR ;YXXGYE<%W A+?D*3/DW
M,3@KFU=#,]%B:Z_%ST+#)=L.-_#2XM((P/\K(?3;Q!CHWF[3?P!02P,$%
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M=MRW1V%FFI#?P+0)B!RW(L=!JO=<,IG!*R2&>5\@<=)*G/Q+'@?$@L:S5I\
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M63)U:TU[K>FHUO>":(IO%!$NQ:FEF$TA="O.>L79N")7N 2;/3:J#ANE>4A
MW<'#965F%Q_!J<<+C :,1:-N[HB45X!6=:/TPT.9;@21RHF?R/Y;9=G$8^"
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " !1@653F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M %&!95,3[2U)204  )D5   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " !1@653C#VCT-<*   W+@  &
M            @(&,#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ 48%E4[TN5Z@@!@  5Q@  !@              ("!F1@  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( %&!95.#D^N7J0<  $XB
M   8              " @>\>  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " !1@6537)&5XD +  !>10  &               @('.)@
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 48%E4P8/[?UW
M"@  72\  !@              ("!1#(  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( %&!95/]3HN"7A<  )Y$   8              "
M@?$\  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !1@653
MM( ^S5TI  !\AP  &               @(&%5   >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ 48%E4XQPPBB%!@  <A   !@
M     ("!&'X  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M %&!95.<(>TSA@0  .,*   9              " @=.$  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ 48%E4YS2S@<Q$   'S@  !D
M             ("!D(D  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " !1@653\0BL[D$$  #""0  &0              @('XF0  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %&!95.($XMXVP(
M $L&   9              " @7">  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ 48%E4Q<#0\4M P   0<  !D              ("!
M@J$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !1@653
M3WL)8 $1  !R.@  &0              @('FI   >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( %&!95/:IJK 1 4  %(-   9
M      " @1ZV  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ 48%E4X,FRZO:!@  A1(  !D              ("!F;L  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !1@653<(Z4O74(   W%
M&0              @(&JP@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( %&!95-BL?B)S@<  *,;   9              " @5;+  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 48%E4Q7;'7BV
M!0  < X  !D              ("!6],  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " !1@653LITTR7D$  #.#0  &0
M@(%(V0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( %&!
M95,Z.)<1$@@  %<3   9              " @?C=  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ 48%E4[B"YL4>!@  <1P  !D
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M=#(W+GAM;%!+ 0(4 Q0    ( %&!95-C&^G.200  $8*   9
M  " @3<X 0!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M48%E4Z9:*;RQ!0  O@X  !D              ("!MSP! 'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " !1@653I+J].>L"   Z!@  &0
M            @(&?0@$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( %&!95/]'J,)/@,   ('   9              " @<%% 0!X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 48%E4R3HXT6# P
MQ@<  !D              ("!-DD! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " !1@653)KH<N"T&  !N$   &0              @('P
M3 $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( %&!95-8
ML$4V^ (  %P&   9              " @513 0!X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ 48%E4\EV_D1K P  T@H  !D
M     ("!@U8! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %&!95/ROM@6G ,  ',-   9              "
M@<QV 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 48%E
M4_57_9C> P  [!(  !D              ("!GWH! 'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " !1@653L8)XI00%  #(&0  &0
M        @(&T?@$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( %&!95/<(MQ5_@(  -@)   9              " @>^# 0!X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 48%E4U"\*;!7 @  =@4
M !D              ("!)(<! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " !1@653GL=#2( %  !U'   &0              @(&RB0$
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( %&!95/'.#34
MA@(  +@&   9              " @6F/ 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ 48%E4P*U 9*4 @  O08  !D
M ("!)I(! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " !1
M@653U@=S+ID'  #2+@  &0              @('QE $ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( %&!95,PKM,P? P  'Q1   9
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M970U,RYX;6Q02P$"% ,4    " !1@653Y0K*L%D#   6#   &0
M    @('^O0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M %&!95/+,M@V< L  /1-   9              " @8[! 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ 48%E4W_<#95\ @  /P8  !D
M             ("!-<T! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    " !1@653[[+OMH\#  "S#   &0              @('HSP$ >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( %&!95-4/C)'!P,
M *L*   9              " @:[3 0!X;"]W;W)K<VAE971S+W-H965T-3@N
M>&UL4$L! A0#%     @ 48%E4T4VI;H2!0  '1<  !D              ("!
M[-8! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !1@653
M7'-IS%@$   S$0  &0              @($UW $ >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;%!+ 0(4 Q0    ( %&!95./1PD*Y (  *8'   9
M      " @<3@ 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%
M  @ 48%E4Z1.A_PD!   %Q   !D              ("!W^,! 'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " !1@653]'CE6P($  !>$P
M&0              @($ZZ $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+
M 0(4 Q0    ( %&!95/W(TW!?P,   H.   9              " @7/L 0!X
M;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ 48%E4PM<Z;#I
M!@  B"D  !D              ("!*? ! 'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6Q02P$"% ,4    " !1@653\AX8*H$#  "?#   &0
M@(%)]P$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( %&!
M95,UE.,S* (  "\%   9              " @0'[ 0!X;"]W;W)K<VAE971S
M+W-H965T-C<N>&UL4$L! A0#%     @ 48%E4WN:ZB)B @  Q@4  !D
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M=#<R+GAM;%!+ 0(4 Q0    ( %&!95/(AV'#* ,  #8*   9
M  " @>D6 @!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @
M48%E4[7_:D:] P  ' \  !D              ("!2!H" 'AL+W=O<FMS:&5E
M=',O<VAE970W-"YX;6Q02P$"% ,4    " !1@653WVI',NT#  "'#P  &0
M            @($\'@( >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4
M Q0    ( %&!95,PJ&:%B0(  /X&   9              " @6 B @!X;"]W
M;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ 48%E4\EHR;$4 @
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M2P$"% ,4    " !1@653>NU.;58"  ".+0  &@              @ '2,0(
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !1@6535:BY
M9Q("  !S+   $P              @ %@- ( 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     50!5 $H7  "C-@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>500</ContextCount>
  <ElementCount>565</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>151</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Business Combinations and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwill</Role>
      <ShortName>Business Combinations and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2119105 - Disclosure - Investments in Other Entities ??? Equity Method</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod</Role>
      <ShortName>Investments in Other Entities ??? Equity Method</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - Loan Receivable and Loan Receivable ??? Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties</Role>
      <ShortName>Loan Receivable and Loan Receivable ??? Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Medical Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilities</Role>
      <ShortName>Medical Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Credit Facility, Bank Loans and Lines of Credit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit</Role>
      <ShortName>Credit Facility, Bank Loans and Lines of Credit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Mezzanine and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquity</Role>
      <ShortName>Mezzanine and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139111 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2147112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2149113 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2153114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2155115 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2160116 - Disclosure - Variable Interest Entities (VIEs)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</Role>
      <ShortName>Variable Interest Entities (VIEs)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2163117 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2169118 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Business Combinations and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables</Role>
      <ShortName>Business Combinations and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BusinessCombinationsandGoodwill</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/IntangibleAssetsNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Investments in Other Entities ??? Equity Method (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables</Role>
      <ShortName>Investments in Other Entities ??? Equity Method (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Medical Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesTables</Role>
      <ShortName>Medical Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MedicalLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Credit Facility, Bank Loans and Lines of Credit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables</Role>
      <ShortName>Credit Facility, Bank Loans and Lines of Credit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/StockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2350309 - Disclosure - Related-Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related-Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/RelatedPartyTransactions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2356310 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/EarningsPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2361311 - Disclosure - Variable Interest Entities (VIEs) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</Role>
      <ShortName>Variable Interest Entities (VIEs) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2364312 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/Leases</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails</Role>
      <ShortName>Business Combinations and Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails</Role>
      <ShortName>Business Combinations and Goodwill - Summary of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets, Net - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Investments in Other Entities ??? Equity Method - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Investments in Other Entities ??? Equity Method - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Investments in Other Entities ??? Equity Method - Summarized Balance Sheets and Statements of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Summarized Balance Sheets and Statements of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Loan Receivable and Loan Receivable ??? Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Loan Receivable and Loan Receivable ??? Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails</Role>
      <ShortName>Medical Liabilities - Schedule of Medical Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Credit Facility, Bank Loans and Lines of Credit - Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails</Role>
      <ShortName>Credit Facility, Bank Loans and Lines of Credit - Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Credit Facility, Bank Loans and Lines of Credit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails</Role>
      <ShortName>Credit Facility, Bank Loans and Lines of Credit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Credit Facility, Bank Loans and Lines of Credit - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails</Role>
      <ShortName>Credit Facility, Bank Loans and Lines of Credit - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Stock Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails</Role>
      <ShortName>Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Stock-Based Compensation - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails</Role>
      <ShortName>Stock-Based Compensation - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2451428 - Disclosure - Related-Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related-Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2452429 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails</Role>
      <ShortName>Related-Party Transactions - Fees Incurred and Income Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2457431 - Disclosure - Earnings Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails</Role>
      <ShortName>Earnings Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2458432 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2459433 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2462434 - Disclosure - Variable Interest Entities (VIEs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails</Role>
      <ShortName>Variable Interest Entities (VIEs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2465435 - Disclosure - Leases - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesAdditionalinformationDetails</Role>
      <ShortName>Leases - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2466436 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2467437 - Disclosure - Leases - Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2468438 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails</Role>
      <ShortName>Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2470439 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ameh-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - ameh-20210930.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - ameh-20210930.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ameh-20210930.htm">ameh-20210930.htm</File>
    <File>ameh-20210930.xsd</File>
    <File>ameh-20210930_cal.xml</File>
    <File>ameh-20210930_def.xml</File>
    <File>ameh-20210930_lab.xml</File>
    <File>ameh-20210930_pre.xml</File>
    <File>ex3112021093010-q.htm</File>
    <File>ex3122021093010-q.htm</File>
    <File>ex3132021093010-q.htm</File>
    <File>ex322021093010-q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ameh-20210930.htm": {
   "axisCustom": 1,
   "axisStandard": 38,
   "contextCount": 500,
   "dts": {
    "calculationLink": {
     "local": [
      "ameh-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ameh-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ameh-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ameh-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ameh-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ameh-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 814,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 6
   },
   "keyCustom": 107,
   "keyStandard": 458,
   "memberCustom": 87,
   "memberStandard": 44,
   "nsprefix": "ameh",
   "nsuri": "http://www.apollomed.net/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.apollomed.net/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Intangible Assets, Net",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119105 - Disclosure - Investments in Other Entities \u2014 Equity Method",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod",
     "shortName": "Investments in Other Entities \u2014 Equity Method",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - Loan Receivable and Loan Receivable \u2013 Related Parties",
     "role": "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties",
     "shortName": "Loan Receivable and Loan Receivable \u2013 Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Medical Liabilities",
     "role": "http://www.apollomed.net/role/MedicalLiabilities",
     "shortName": "Medical Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Credit Facility, Bank Loans and Lines of Credit",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit",
     "shortName": "Credit Facility, Bank Loans and Lines of Credit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Mezzanine and Stockholders' Equity",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquity",
     "shortName": "Mezzanine and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139111 - Disclosure - Stock Based Compensation",
     "role": "http://www.apollomed.net/role/StockBasedCompensation",
     "shortName": "Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147112 - Disclosure - Commitments and Contingencies",
     "role": "http://www.apollomed.net/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149113 - Disclosure - Related-Party Transactions",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NotesAndLoansReceivableNetNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153114 - Disclosure - Income Taxes",
     "role": "http://www.apollomed.net/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155115 - Disclosure - Earnings Per Share",
     "role": "http://www.apollomed.net/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160116 - Disclosure - Variable Interest Entities (VIEs)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEs",
     "shortName": "Variable Interest Entities (VIEs)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163117 - Disclosure - Leases",
     "role": "http://www.apollomed.net/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169118 - Disclosure - Subsequent Events",
     "role": "http://www.apollomed.net/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Business Combinations and Goodwill (Tables)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables",
     "shortName": "Business Combinations and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Intangible Assets, Net (Tables)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Investments in Other Entities \u2014 Equity Method (Tables)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables",
     "shortName": "Investments in Other Entities \u2014 Equity Method (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Medical Liabilities (Tables)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesTables",
     "shortName": "Medical Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Credit Facility, Bank Loans and Lines of Credit (Tables)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables",
     "shortName": "Credit Facility, Bank Loans and Lines of Credit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Stock Based Compensation (Tables)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationTables",
     "shortName": "Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350309 - Disclosure - Related-Party Transactions (Tables)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsTables",
     "shortName": "Related-Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356310 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.apollomed.net/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361311 - Disclosure - Variable Interest Entities (VIEs) (Tables)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables",
     "shortName": "Variable Interest Entities (VIEs) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364312 - Disclosure - Leases (Tables)",
     "role": "http://www.apollomed.net/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "ib05af751a8be4d57b25abcbf5cb700aa_I20210831",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
     "shortName": "Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i19c94975ba3e411ca4090953760b5a7f_D20210801-20210831",
      "decimals": null,
      "lang": "en-US",
      "name": "ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i620cf562ac9c414d9a3092d147a50325_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i51f1ae095a524c598ba9ab90870d3358_D20210701-20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i51f1ae095a524c598ba9ab90870d3358_D20210701-20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
     "shortName": "Business Combinations and Goodwill - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "if2f519bb3a21437e99c17cddc631e9cd_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i2044abfbff374e8e958e907e8efcac87_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails",
     "shortName": "Business Combinations and Goodwill - Summary of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Intangible Assets, Net - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails",
     "shortName": "Intangible Assets, Net - Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i2044abfbff374e8e958e907e8efcac87_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Investments in Other Entities \u2014 Equity Method - Equity Method Investments (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:EquityMethodInvestmentAdditionalInvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentSoldCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Investments in Other Entities \u2014 Equity Method - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i78f6b75f6efe4952a520c49f86b2ac80_I20180531",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i274e819937824ba3b8be663aca7657a1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "ide4f8e08db044e18a9dd68755ff37c94_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Investments in Other Entities \u2014 Equity Method - Summarized Balance Sheets and Statements of Income (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Summarized Balance Sheets and Statements of Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i3b3c4acf3b1e46489358ab28afc9e3a3_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i525bb8235fd64a5c8f0c02ec9cbb55e4_I20201030",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Loan Receivable and Loan Receivable \u2013 Related Parties - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
     "shortName": "Loan Receivable and Loan Receivable \u2013 Related Parties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i525bb8235fd64a5c8f0c02ec9cbb55e4_I20201030",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i2044abfbff374e8e958e907e8efcac87_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
     "shortName": "Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Credit Facility, Bank Loans and Lines of Credit - Credit Facility (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails",
     "shortName": "Credit Facility, Bank Loans and Lines of Credit - Credit Facility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Credit Facility, Bank Loans and Lines of Credit - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
     "shortName": "Credit Facility, Bank Loans and Lines of Credit - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i6f8776621075492eacb36b4093b785ae_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:AssetAcquisitionPercentageOfSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Credit Facility, Bank Loans and Lines of Credit - Schedule of Maturities (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails",
     "shortName": "Credit Facility, Bank Loans and Lines of Credit - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:StockIssuedDuringPeriodSharesMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:StockIssuedDuringPeriodSharesMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Stock Based Compensation - Share-Based Compensation Expense (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Stock Based Compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
     "shortName": "Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i1e3d3eae2e02493aab069801d3ca1602_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i2044abfbff374e8e958e907e8efcac87_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails",
     "shortName": "Stock-Based Compensation - Summary of Warrant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:NumberOfWarrantsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Stock-Based Compensation - Warrants (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails",
     "shortName": "Stock-Based Compensation - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i72d599d61813449280a927233fdb0405_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:PercentageOfFinancialGuaranteeBenchmarkAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:PercentageOfFinancialGuaranteeBenchmarkAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451428 - Disclosure - Related-Party Transactions - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related-Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ameh:PaymentConsultingFees",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i5973967987a64974bf0b313e96b45d1b_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:PaymentConsultingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452429 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails",
     "shortName": "Related-Party Transactions - Fees Incurred and Income Received (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i6956147d1b1d44068bcecf36bebb1819_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "ia1bd75ff5a784460bc879854f3dc5e14_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457431 - Disclosure - Earnings Per Share - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
     "shortName": "Earnings Per Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "ia1bd75ff5a784460bc879854f3dc5e14_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458432 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
     "shortName": "Earnings Per Share - Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.apollomed.net/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459433 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
     "shortName": "Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "ie1b43cafde674d70aa71314660d7da57_D20210701-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462434 - Disclosure - Variable Interest Entities (VIEs) (Details)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails",
     "shortName": "Variable Interest Entities (VIEs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "ic1e0dd2e99004d919fd565b247e9d0e1_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465435 - Disclosure - Leases - Additional information (Details)",
     "role": "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
     "shortName": "Leases - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466436 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467437 - Disclosure - Leases - Other Information Related to Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i9204aec484984ed29b67419657e5334e_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468438 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
     "shortName": "Leases - Future Minimum Payments Under Non-cancelable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i38ab054fe9a44fa7991c114c1a431acf_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i347edc610f5f44f797de7ecdf6022137_I20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470439 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i6af953349f5741e6903f07fe40567fb1_D20211001-20211031",
      "decimals": null,
      "lang": "en-US",
      "name": "ameh:EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Business Combinations and Goodwill",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwill",
     "shortName": "Business Combinations and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i98abf3b35b1e47579577f59184a244a3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i274e819937824ba3b8be663aca7657a1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - ameh-20210930.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - ameh-20210930.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210930.htm",
      "contextRef": "i274e819937824ba3b8be663aca7657a1_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 151,
   "tag": {
    "ameh_AHMCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AHMC [Member]",
        "terseLabel": "AHMC",
        "verboseLabel": "AHMC"
       }
      }
     },
     "localname": "AHMCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AMGPropertiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AMG Properties LLC",
        "label": "AMG Properties LLC [Member]",
        "terseLabel": "AMG Properties LLC"
       }
      }
     },
     "localname": "AMGPropertiesLLCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APAMHMedicalCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AP-AMH Medical Corporation [Member]",
        "label": "AP-AMH Medical Corporation [Member]",
        "terseLabel": "AP-AMH Medical Corporation"
       }
      }
     },
     "localname": "APAMHMedicalCorporationMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APCAndAPCLSMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "APC And APC-LSMA [Member]",
        "label": "APC And APC-LSMA [Member]",
        "terseLabel": "APC and APC-LSMA"
       }
      }
     },
     "localname": "APCAndAPCLSMAMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccessPrimaryCareMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Access Primary Care Medical Group",
        "label": "Access Primary Care Medical Group [Member]",
        "terseLabel": "Access Primary Care Medical Group"
       }
      }
     },
     "localname": "AccessPrimaryCareMedicalGroupMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountableHealthCareIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accountable Health Care IPA [Member]",
        "verboseLabel": "Accountable Health Care"
       }
      }
     },
     "localname": "AccountableHealthCareIPAMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsPayableAndAccruedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable And Accrued Expenses [Member]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsReceivableAndNetRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable And Net Revenue [Line Items]",
        "terseLabel": "Accounts Receivable And Net Revenue [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueLineItems",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AccountsReceivableAndNetRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable And Net Revenue [Table]",
        "terseLabel": "Accounts Receivable And Net Revenue [Table]"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueTable",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AchievaMedInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AchievaMed, Inc. [Member]",
        "label": "AchievaMed, Inc. [Member]",
        "terseLabel": "AchievaMed, Inc."
       }
      }
     },
     "localname": "AchievaMedInc.Member",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met",
        "label": "Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met",
        "terseLabel": "Additional cash consideration entitled to be received"
       }
      }
     },
     "localname": "AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_AdvanceDiagnosticSurgeryCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance Diagnostic Surgery Center [Member]",
        "terseLabel": "Advance Diagnostic Surgery Center"
       }
      }
     },
     "localname": "AdvanceDiagnosticSurgeryCenterMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AggregateintrinsicvalueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "localname": "AggregateintrinsicvalueAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AlliedPacificOfCaliforniaIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allied Pacific Of California IPA",
        "label": "Allied Pacific Of California IPA [Member]",
        "terseLabel": "APC",
        "verboseLabel": "APC"
       }
      }
     },
     "localname": "AlliedPacificOfCaliforniaIPAMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AlphaCareMedicalGroupInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alpha Care Medical Group, Inc. [Member]",
        "label": "Alpha Care Medical Group, Inc. [Member]",
        "terseLabel": "Alpha Care Medical Group, Inc."
       }
      }
     },
     "localname": "AlphaCareMedicalGroupInc.Member",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AmgIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AMG, Inc [Member]",
        "terseLabel": "AMG, Inc"
       }
      }
     },
     "localname": "AmgIncMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AncillaryServiceContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ancillary Service Contract [Member]",
        "terseLabel": "Ancillary Service Contract"
       }
      }
     },
     "localname": "AncillaryServiceContractMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApaAcoIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APA ACO Inc [Member]",
        "terseLabel": "APA ACO Inc"
       }
      }
     },
     "localname": "ApaAcoIncMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApaacoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APAACO [Member]",
        "terseLabel": "APAACO"
       }
      }
     },
     "localname": "ApaacoMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcBusinessLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Business Loan Agreement [Member]",
        "terseLabel": "APC Business Loan Agreement"
       }
      }
     },
     "localname": "ApcBusinessLoanAgreementMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcLsmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC LSMA [Member]",
        "terseLabel": "APC LSMA"
       }
      }
     },
     "localname": "ApcLsmaMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Shareholders [Member]",
        "terseLabel": "APC Shareholders"
       }
      }
     },
     "localname": "ApcShareholdersMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Stock Option [Member]",
        "terseLabel": "APC Stock Option"
       }
      }
     },
     "localname": "ApcStockOptionMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApolloMedicalHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Apollo Medical Holdings, Inc [Member]",
        "terseLabel": "Apollo Medical Holdings, Inc"
       }
      }
     },
     "localname": "ApolloMedicalHoldingsIncMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApolloSunLabsManagementLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apollo-Sun Labs Management, LLC",
        "label": "Apollo-Sun Labs Management, LLC [Member]",
        "terseLabel": "Apollo-Sun Labs Management, LLC"
       }
      }
     },
     "localname": "ApolloSunLabsManagementLLCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AssetAcquisitionPercentageOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Percentage Of Shares Acquired",
        "label": "Asset Acquisition, Percentage Of Shares Acquired",
        "terseLabel": "Asset acquisition, percentage of shares acquired"
       }
      }
     },
     "localname": "AssetAcquisitionPercentageOfSharesAcquired",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_AurionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_Aurion Member",
        "label": "Aurion [Member]",
        "verboseLabel": "Aurion"
       }
      }
     },
     "localname": "AurionMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_BeneficialInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Interest",
        "label": "Beneficial Interest [Policy Text Block]",
        "terseLabel": "Beneficial Interest"
       }
      }
     },
     "localname": "BeneficialInterestPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Equity Interest Purchase Obligation, Noncurrent",
        "label": "Business Combination, Equity Interest Purchase Obligation, Noncurrent",
        "terseLabel": "Equity interest purchase obligation, noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationEquityInterestPurchaseObligationNoncurrent",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Equity Interest Purchase Obligation, Period to Purchase",
        "label": "Business Combination, Equity Interest Purchase Obligation, Period to Purchase",
        "terseLabel": "Equity interest purchase obligation, period to purchase"
       }
      }
     },
     "localname": "BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_CAIPAMSOLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CAIPA MSO, LLC",
        "label": "CAIPA MSO, LLC [Member]",
        "terseLabel": "CAIPA MSO, LLC"
       }
      }
     },
     "localname": "CAIPAMSOLLCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CDSCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CDSC",
        "label": "CDSC [Member]",
        "terseLabel": "CDSC"
       }
      }
     },
     "localname": "CDSCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CMSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CMS [Member]",
        "label": "CMS [Member]",
        "terseLabel": "CMS"
       }
      }
     },
     "localname": "CMSMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CancellationOfRestrictedStockAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancellation of Restricted Stock Awards",
        "label": "Cancellation of Restricted Stock Awards",
        "terseLabel": "Cancellation of restricted stock awards"
       }
      }
     },
     "localname": "CancellationOfRestrictedStockAwards",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_CashPaidForLeaseLiabilitiesAbstractAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid For Lease Liabilities [Abstract]",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForLeaseLiabilitiesAbstractAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ClassOfWarrantOrRightCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, cancelled in period",
        "label": "Class Of Warrant Or Right Cancelled In Period",
        "negatedLabel": "Warrants expired/forfeited (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCancelledInPeriod",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercisable",
        "label": "Class Of Warrant Or Right Exercisable",
        "terseLabel": "Warrants Exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightIssuedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Issued in Period",
        "label": "Class Of Warrant Or Right Issued In Period",
        "verboseLabel": "Warrants Outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedInPeriod",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term",
        "verboseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights exercised in period.",
        "label": "Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights forfeited in period.",
        "label": "Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants expired/forfeited"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights granted in period.",
        "label": "Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants granted"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights outstanding.",
        "label": "Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "periodStartLabel": "Warrants outstanding, beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "periodEndLabel": "Warrants outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in dollars per share)",
        "terseLabel": "Weighted Average Exercise\u00a0Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights exercised during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period",
        "verboseLabel": "Warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights forfeited during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period",
        "verboseLabel": "Warrants expired/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights granted during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period",
        "verboseLabel": "Warrants granted (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClinigenceHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinigence Holdings, Inc.",
        "label": "Clinigence Holdings, Inc. [Member]",
        "terseLabel": "Clinigence Holdings, Inc."
       }
      }
     },
     "localname": "ClinigenceHoldingsIncMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CollegeStreetInvestmentLpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "College Street Investment LP [Member].",
        "label": "College Street Investment LP [Member]",
        "terseLabel": "College Street Investment LP"
       }
      }
     },
     "localname": "CollegeStreetInvestmentLpMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommercialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:CommercialMember",
        "label": "Commercial [Member]",
        "terseLabel": "Commercial"
       }
      }
     },
     "localname": "CommercialMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ConcourseDiagnosticSurgeryCenterLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concourse Diagnostic Surgery Center, LLC [Member]",
        "terseLabel": "Concourse Diagnostic Surgery Center, LLC"
       }
      }
     },
     "localname": "ConcourseDiagnosticSurgeryCenterLlcMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ConstructionLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Construction Loan",
        "label": "Construction Loan [Member]",
        "terseLabel": "Construction Loan"
       }
      }
     },
     "localname": "ConstructionLoanMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ContractTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Type [Axis]",
        "terseLabel": "Contract Type [Axis]"
       }
      }
     },
     "localname": "ContractTypeAxis",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Type [Domain]",
        "terseLabel": "Contract Type [Domain]"
       }
      }
     },
     "localname": "ContractTypeDomain",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CriticalQualityManagementCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_Critical Quality Management Corp Member",
        "label": "Critical Quality Management Corp [Member]",
        "terseLabel": "Critical Quality Management Corp"
       }
      }
     },
     "localname": "CriticalQualityManagementCorpMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum",
        "terseLabel": "Debt instrument, covenant, cash flow coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCashFlowCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Debt Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Debt Coverage Ratio, Minimum",
        "terseLabel": "Debt instrument, covenant, debt coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDebtCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Minimum consolidated interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "terseLabel": "Maximum consolidated leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentNumberOfKeyFinancialRatios": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Key Financial Ratios",
        "label": "Debt Instrument, Number Of Key Financial Ratios",
        "terseLabel": "Number of key financial ratios"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfKeyFinancialRatios",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_DeferredTaxLiabilitiesAdjustedToGoodwill": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Adjusted To Goodwill",
        "label": "Deferred Tax Liabilities, Adjusted To Goodwill",
        "terseLabel": "Deferred tax liability adjustment to goodwill"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAdjustedToGoodwill",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DeferredTaxLiabilitiesWarrantsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Warrants Exercised",
        "label": "Deferred Tax Liabilities, Warrants Exercised",
        "terseLabel": "Deferred tax liability adjustment related to warrant exercises"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DescriptionOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Business [Line Items]",
        "terseLabel": "Description Of Business [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfBusinessLineItems",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DescriptionOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Business [Table]",
        "terseLabel": "Description Of Business [Table]"
       }
      }
     },
     "localname": "DescriptionOfBusinessTable",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DiagnosticMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diagnostic Medical Group [Member]",
        "terseLabel": "Diagnostic Medical Group"
       }
      }
     },
     "localname": "DiagnosticMedicalGroupMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DmgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DMG [Member]",
        "terseLabel": "DMG"
       }
      }
     },
     "localname": "DmgMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.ArteagaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Arteaga [Member]",
        "label": "Dr. Arteaga [Member]",
        "verboseLabel": "Dr. Arteaga"
       }
      }
     },
     "localname": "Dr.ArteagaMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.JayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Jay [Member]",
        "label": "Dr. Jay [Member]",
        "terseLabel": "Dr. Jay"
       }
      }
     },
     "localname": "Dr.JayMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_EarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Earnings Per Share [Table]",
        "label": "Earnings Per Share [Line Items]",
        "terseLabel": "Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareLineItems",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EarningsPerShareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share [Table]",
        "label": "Earnings Per Share [Table]",
        "terseLabel": "Earnings Per Share [Table]"
       }
      }
     },
     "localname": "EarningsPerShareTable",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EquityMethodAndOtherEquityInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method And Other Equity Investments [Text Block]",
        "label": "Equity Method And Other Equity Investments [Text Block]",
        "verboseLabel": "Investments in Other Entities \u2014 Equity Method"
       }
      }
     },
     "localname": "EquityMethodAndOtherEquityInvestmentsTextBlock",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_EquityMethodInvestmentAdditionalInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Additional Investment",
        "label": "Equity Method Investment, Additional Investment",
        "terseLabel": "Initial Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentAdditionalInvestment",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentAdditionalPercentageCommittedToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Additional Percentage Committed to Purchase",
        "label": "Equity Method Investment, Additional Percentage Committed to Purchase",
        "terseLabel": "Additional ownership percentage committed to purchase"
       }
      }
     },
     "localname": "EquityMethodInvestmentAdditionalPercentageCommittedToPurchase",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Additional Purchase Commitment Period",
        "label": "Equity Method Investment, Additional Purchase Commitment Period",
        "terseLabel": "Equity method investment, additional purchase commitment period"
       }
      }
     },
     "localname": "EquityMethodInvestmentAdditionalPurchaseCommitmentPeriod",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase",
        "label": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase",
        "terseLabel": "Equity method investment, conversion of finance receivable, ownership percentage increase"
       }
      }
     },
     "localname": "EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion",
        "label": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion",
        "terseLabel": "Ownership upon conversion of finance receivable"
       }
      }
     },
     "localname": "EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentOwnershipPercentageDisposed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Disposed",
        "label": "Equity Method Investment, Ownership Percentage Disposed",
        "terseLabel": "Ownership interest disposed"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageDisposed",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentOwnershipPercentageSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage, Sold",
        "label": "Equity Method Investment, Ownership Percentage, Sold",
        "terseLabel": "Ownership percentage sold"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageSold",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Cash",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Cash",
        "terseLabel": "Contingent consideration, cash held in escrow"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationCash",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Fair Value",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Fair Value",
        "terseLabel": "Contingent consideration, fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationFairValue",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Preferred Shares",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Preferred Shares",
        "terseLabel": "Contingent consideration, preferred shares"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationPreferredShares",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Write-off of Additional Proceeds",
        "label": "Equity Method Investment, Write-off of Additional Proceeds",
        "terseLabel": "Write off of additional proceeds"
       }
      }
     },
     "localname": "EquityMethodInvestmentWriteOffOfAdditionalProceeds",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsConsolidated": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Consolidated",
        "label": "Equity Method Investments, Consolidated",
        "negatedTerseLabel": "Entity Consolidated"
       }
      }
     },
     "localname": "EquityMethodInvestmentsConsolidated",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Contribution",
        "label": "Equity Method Investments, Contribution",
        "terseLabel": "Contribution"
       }
      }
     },
     "localname": "EquityMethodInvestmentsContribution",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments [Roll Forward]",
        "label": "Equity Method Investments [Roll Forward]",
        "terseLabel": "Equity Method Investments [Roll Forward]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsRollForward",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option",
        "label": "Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option",
        "terseLabel": "Term of option"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Related investment balance"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "terseLabel": "Investment amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "terseLabel": "Duration of investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "terseLabel": "Membership interests acquired (in dollars per share)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "terseLabel": "Options to purchase additional membership interests (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met",
        "terseLabel": "Number of warrants available to purchase, contingent upon the portal completion date (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "terseLabel": "Percentage of voting common stock, within five years"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "terseLabel": "Membership interests purchased (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities without Readily Determinable Fair Value, Ownership Percentage",
        "label": "Equity Securities Without Readily Determinable Fair Value, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FiduciaryAccountsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Fiduciary Accounts Payable Current",
        "terseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "FiduciaryAccountsPayableCurrent",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiduciaryCashAndPayablePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiduciary Cash and Payable",
        "label": "Fiduciary Cash and Payable [Policy Text Block]",
        "terseLabel": "Fiduciary Cash and Payable"
       }
      }
     },
     "localname": "FiduciaryCashAndPayablePolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, To Be Paid, After Year Four",
        "label": "Finance Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FinanceReceivableInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Interest Rate, Stated Percentage",
        "label": "Finance Receivable, Interest Rate, Stated Percentage",
        "terseLabel": "Note receivable, interest rate"
       }
      }
     },
     "localname": "FinanceReceivableInterestRateStatedPercentage",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "label": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "terseLabel": "Interest rate in the event of default"
       }
      }
     },
     "localname": "FinanceReceivableModificationsSubsequentDefaultInterestRate",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableStatedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Stated Interest Rate",
        "label": "Finance Receivable, Stated Interest Rate",
        "terseLabel": "Stated rate of note of loan receivable"
       }
      }
     },
     "localname": "FinanceReceivableStatedInterestRate",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableTermOfReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Term Of Receivable",
        "label": "Finance Receivable, Term Of Receivable",
        "terseLabel": "Term of receivable"
       }
      }
     },
     "localname": "FinanceReceivableTermOfReceivable",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiveThreeOneW.CollegeLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Three One W. College LLC [Member]",
        "terseLabel": "531 W. College LLC",
        "verboseLabel": "531 W. College, LLC \u2013 related party"
       }
      }
     },
     "localname": "FiveThreeOneW.CollegeLLCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_FreseniusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fresenius",
        "label": "Fresenius [Member]",
        "terseLabel": "Fresenius"
       }
      }
     },
     "localname": "FreseniusMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_FulgentGeneticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fulgent Genetics, Inc.",
        "label": "Fulgent Genetics, Inc. [Member]",
        "terseLabel": "Fulgent Genetics, Inc."
       }
      }
     },
     "localname": "FulgentGeneticsIncMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HSMSOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_HSMSO Member",
        "label": "HSMSO [Member]",
        "verboseLabel": "HSMSO"
       }
      }
     },
     "localname": "HSMSOMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HealthCareCapitationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh_HealthCareCapitationRevenueMember",
        "label": "Health Care Capitation Revenue [Member]",
        "verboseLabel": "Capitation, net"
       }
      }
     },
     "localname": "HealthCareCapitationRevenueMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_IncreaseDecreaseInMedicalLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.",
        "label": "Increase (Decrease) In Medical Liabilities",
        "verboseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicalLiabilities",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents increase in operating lease assets.",
        "label": "Increase (Decrease) In Operating Lease Assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseAssets",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.",
        "label": "Increase (Decrease) In Prepaid Expenses And Other Current Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The initial fixed term of amended and restated management and administrative services agreement.",
        "label": "Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement",
        "terseLabel": "Fixed term of amended and restated management and administrative services agreement"
       }
      }
     },
     "localname": "InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "label": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "terseLabel": "AHMC \u2013 Risk pool, capitation, claims payment"
       }
      }
     },
     "localname": "InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of Investment in privately held entity that does not report net asset value per share .",
        "label": "Investment In Privately Held Entity That Does Not Report Net Asset Value",
        "verboseLabel": "Investments in privately held entities"
       }
      }
     },
     "localname": "InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LasalleMedicalAssociatesIpaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LaSalle Medical Associates IPA [Member]",
        "terseLabel": "LaSalle Medical Associates \u2013 IPA Line of Business",
        "verboseLabel": "LaSalle Medical Associates"
       }
      }
     },
     "localname": "LasalleMedicalAssociatesIpaMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]",
        "verboseLabel": "Right-of-use assets obtained in exchange for lease liabilities:"
       }
      }
     },
     "localname": "LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LeaseWeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Weighted Average Discount Rate [Abstract]",
        "verboseLabel": "Weighted Average Discount Rate"
       }
      }
     },
     "localname": "LeaseWeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LeaseWeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Weighted Average Remaining Lease Term [Abstract]",
        "verboseLabel": "Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "LeaseWeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Finance Lease, Termination Period, If Applicable",
        "label": "Lessee, Finance Lease, Termination Period, If Applicable",
        "terseLabel": "Finance lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period, If Applicable",
        "label": "Lessee, Operating Lease, Termination Period, If Applicable",
        "terseLabel": "Operating lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LMA [Member]",
        "terseLabel": "LMA"
       }
      }
     },
     "localname": "LmaMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LoanReceivableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Receivable",
        "label": "Loan Receivable [Text Block]",
        "verboseLabel": "Loan Receivable and Loan Receivable \u2013 Related Parties"
       }
      }
     },
     "localname": "LoanReceivableTextBlock",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_LongTermDebtMaturityAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, After Year Four",
        "label": "Long-Term Debt, Maturity, After Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturityAfterYearFour",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MPP, AMG Properties, and ZLL Asset Acquisition",
        "label": "MPP, AMG Properties, and ZLL Asset Acquisition [Member]",
        "terseLabel": "MPP, AMG Properties, and ZLL Asset Acquisition"
       }
      }
     },
     "localname": "MPPAMGPropertiesAndZLLAssetAcquisitionMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ManagementContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Contracts",
        "label": "Management Contracts [Member]",
        "verboseLabel": "Management contracts"
       }
      }
     },
     "localname": "ManagementContractsMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MarketableSecuritiesCurrentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Current, Maturity Period",
        "label": "Marketable Securities, Current, Maturity Period",
        "terseLabel": "Short-term marketable securities, maturity period"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMaturityPeriod",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_MaverickMedicalGroupIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maverick Medical Group, Inc [Member]",
        "terseLabel": "Maverick Medical Group, Inc"
       }
      }
     },
     "localname": "MaverickMedicalGroupIncMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MediPortalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MediPortal LLC [Member]",
        "terseLabel": "MediPortal LLC"
       }
      }
     },
     "localname": "MediPortalLLCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:MedicaidMember",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Care Costs [Abstract]",
        "label": "Medical Care Costs [Abstract]",
        "terseLabel": "Components of medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "MedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MedicalPropertyPartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Property Partners LLC",
        "label": "Medical Property Partners LLC [Member]",
        "terseLabel": "Medical Property Partners LLC"
       }
      }
     },
     "localname": "MedicalPropertyPartnersLLCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:MedicareMember",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MemberRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member Relationships",
        "label": "Member Relationships [Member]",
        "terseLabel": "Member relationships"
       }
      }
     },
     "localname": "MemberRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MezzanineEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEZZANINE EQUITY [Abstract]",
        "verboseLabel": "Mezzanine equity"
       }
      }
     },
     "localname": "MezzanineEquityAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MezzanineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine [Member]",
        "terseLabel": "Mezzanine"
       }
      }
     },
     "localname": "MezzanineMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MinorityInterestPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minority Interest Policy.",
        "label": "Minority Interest Policy [Policy Text Block]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterestPolicyPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "label": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NetworkMedicalManagementIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Network Medical Management, Inc. [Member]",
        "terseLabel": "Network Medical Management, Inc."
       }
      }
     },
     "localname": "NetworkMedicalManagementIncMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkMedicalManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Network Medical Management [Member]",
        "terseLabel": "NMM"
       }
      }
     },
     "localname": "NetworkMedicalManagementMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Network Relationships",
        "label": "Network Relationships [Member]",
        "terseLabel": "Network relationships"
       }
      }
     },
     "localname": "NetworkRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NoncontrollingInterestIncreaseFromCapitalCharge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest. Increase from Capital Charge",
        "label": "Noncontrolling Interest. Increase from Capital Charge",
        "terseLabel": "Noncontrolling interest capital charge"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromCapitalCharge",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Employees",
        "label": "Number Of Employees",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "NumberOfEmployees",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfFamilyPracticeClinics": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Family Practice Clinics",
        "label": "Number Of Family Practice Clinics",
        "terseLabel": "Number of family practice clinics"
       }
      }
     },
     "localname": "NumberOfFamilyPracticeClinics",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfFederallyQualifiedHealthPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Federally Qualified Health Plans",
        "label": "Number Of Federally Qualified Health Plans",
        "terseLabel": "Number federally qualified health plans"
       }
      }
     },
     "localname": "NumberOfFederallyQualifiedHealthPlans",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised",
        "label": "Number Of Warrants Exercised",
        "negatedLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumberOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Warrants Granted",
        "label": "Number Of Warrants Granted",
        "verboseLabel": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsGranted",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumenLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numen LLC [Member]",
        "terseLabel": "Numen LLC"
       }
      }
     },
     "localname": "NumenLLCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, Inc. [Member]",
        "label": "One MSO, Inc. [Member]",
        "terseLabel": "One MSO, Inc."
       }
      }
     },
     "localname": "OneMSOInc.Member",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, LLC",
        "label": "One MSO, LLC [Member]",
        "terseLabel": "One MSO, LLC \u2013 related party"
       }
      }
     },
     "localname": "OneMSOLLCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC",
        "label": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC [Member]",
        "terseLabel": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OtherThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:OtherThirdPartiesMember",
        "label": "Other Third Parties [Member]",
        "terseLabel": "Other third parties"
       }
      }
     },
     "localname": "OtherThirdPartiesMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Pacific6EnterprisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pacific6 Enterprises [Member]",
        "label": "Pacific6 Enterprises [Member]",
        "terseLabel": "Pacific6 Enterprises"
       }
      }
     },
     "localname": "Pacific6EnterprisesMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PacificMedicalImagingAndOncologyCenterIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pacific Medical Imaging and Oncology Center, Inc [Member]",
        "terseLabel": "Pacific Medical Imaging &amp; Oncology Center, Inc."
       }
      }
     },
     "localname": "PacificMedicalImagingAndOncologyCenterIncMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PatientManagementPlatformMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient Management Platform",
        "label": "Patient Management Platform [Member]",
        "terseLabel": "Patient management platform"
       }
      }
     },
     "localname": "PatientManagementPlatformMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentConsultingFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Consulting Fees",
        "label": "Payment Consulting Fees",
        "terseLabel": "Consulting services paid"
       }
      }
     },
     "localname": "PaymentConsultingFees",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentMadeToRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit/Duration (Amount paid to related party in relation to providing services",
        "label": "Payment Made To Related Party",
        "terseLabel": "Payments to related parties"
       }
      }
     },
     "localname": "PaymentMadeToRelatedParty",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Revenue",
        "label": "Payment Of Revenue",
        "terseLabel": "Payments received"
       }
      }
     },
     "localname": "PaymentOfRevenue",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenueMonthlyAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Revenue, Monthly Amount",
        "label": "Payment Of Revenue, Monthly Amount",
        "terseLabel": "Payments received, monthly"
       }
      }
     },
     "localname": "PaymentOfRevenueMonthlyAmount",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenueRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Revenue, Revenue Recognized",
        "label": "Payment Of Revenue, Revenue Recognized",
        "terseLabel": "Payments received, revenue"
       }
      }
     },
     "localname": "PaymentOfRevenueRevenueRecognized",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentsForMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Medical Care Costs [Abstract]",
        "label": "Payments For Medical Care Costs [Abstract]",
        "terseLabel": "Payments for medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "PaymentsForMedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_PaymentsToAcquireCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Common Stock And Warrants",
        "label": "Payments To Acquire Common Stock And Warrants",
        "terseLabel": "Payments to acquire common stock and warrants"
       }
      }
     },
     "localname": "PaymentsToAcquireCommonStockAndWarrants",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Payments to purchase membership interests"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PayorAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor A [Member]",
        "label": "Payor A [Member]",
        "terseLabel": "Payor A"
       }
      }
     },
     "localname": "PayorAMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor B [Member]",
        "label": "Payor B [Member]",
        "terseLabel": "Payor B"
       }
      }
     },
     "localname": "PayorBMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor C [Member]",
        "label": "Payor C [Member]",
        "terseLabel": "Payor C"
       }
      }
     },
     "localname": "PayorCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payor D [Member]",
        "terseLabel": "Payor D"
       }
      }
     },
     "localname": "PayorDMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorFMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor F [Member]",
        "label": "Payor F [Member]",
        "terseLabel": "Payor F"
       }
      }
     },
     "localname": "PayorFMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor G",
        "label": "Payor G [Member]",
        "terseLabel": "Payor G"
       }
      }
     },
     "localname": "PayorGMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PerMemberPerMonthManagedCareContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per-Member-Per-Month Managed Care Contract [Member]",
        "label": "Per-Member-Per-Month Managed Care Contract [Member]",
        "terseLabel": "PMPM Managed Care Contract"
       }
      }
     },
     "localname": "PerMemberPerMonthManagedCareContractMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PercentageOfFinancialGuaranteeBenchmarkAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of financial guarantee on benchmark Medicare expenditure amount.",
        "label": "Percentage Of Financial Guarantee Benchmark Amount",
        "terseLabel": "General amount of guarantee (as a percent)"
       }
      }
     },
     "localname": "PercentageOfFinancialGuaranteeBenchmarkAmount",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_PmiocMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PMIOC [Member]",
        "terseLabel": "PMIOC"
       }
      }
     },
     "localname": "PmiocMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PreferredBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Bank [Member]",
        "terseLabel": "Preferred Bank"
       }
      }
     },
     "localname": "PreferredBankMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Cash Received from Consolidation of Variable Interest Entity",
        "label": "Proceeds from Cash Received from Consolidation of Variable Interest Entity",
        "terseLabel": "Cash received from consolidation of VIE"
       }
      }
     },
     "localname": "ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ProceedsFromSaleOfNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Noncontrolling Interest",
        "label": "Proceeds from Sale of Noncontrolling Interest",
        "terseLabel": "Proceeds from sale of noncontrolling interest"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNoncontrollingInterest",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Receivables and receivables from related parties.",
        "label": "Receivables And Related parties Receivables Policy Text Block [Policy Text Block]",
        "verboseLabel": "Receivables, Receivables \u2013 Related Parties, and Loan Receivable - Related Party"
       }
      }
     },
     "localname": "ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]",
        "verboseLabel": "Reconciliation of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_RevenueFromRiskPoolSettlementsFromPriorPerformanceYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Risk Pool Settlements From Prior Performance Years",
        "label": "Revenue From Risk Pool Settlements From Prior Performance Years",
        "terseLabel": "Revenue from risk pool settlements from prior performance years"
       }
      }
     },
     "localname": "RevenueFromRiskPoolSettlementsFromPriorPerformanceYears",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "terseLabel": "Expected period of payment upon termination of agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "label": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "terseLabel": "Risk pool surplus or deficits, settlement period after risk pool performance year"
       }
      }
     },
     "localname": "RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_SCHCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SCHC [Member]",
        "label": "SCHC [Member]",
        "terseLabel": "SCHC"
       }
      }
     },
     "localname": "SCHCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate",
        "verboseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "label": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "terseLabel": "Exercise price of warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ShareholdersAndOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders And Officers [Member]",
        "terseLabel": "APC Shareholders and Officers"
       }
      }
     },
     "localname": "ShareholdersAndOfficersMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_SharesWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares, Warrants [Roll Forward]",
        "label": "Shares, Warrants [Roll Forward]",
        "terseLabel": "Shares, Warrants [Roll Forward]"
       }
      }
     },
     "localname": "SharesWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SpecialtyCapitationPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of specialty capitation payable current.",
        "label": "Specialty Capitation Payable Current",
        "verboseLabel": "Capitation payable"
       }
      }
     },
     "localname": "SpecialtyCapitationPayableCurrent",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockAwardsAndUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Awards And Units",
        "label": "Stock Awards And Units [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "StockAwardsAndUnitsMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_StockIssuedDuringPeriodProxyVotesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Proxy Votes, Percentage",
        "label": "Stock Issued During Period, Proxy Votes, Percentage",
        "terseLabel": "Proxy votes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodProxyVotesPercentage",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Cashless Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Cashless Warrants Exercised",
        "terseLabel": "Shares issued for cashless exercise of warrants (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCashlessWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to merger.",
        "label": "Stock Issued During Period, Shares, Merger",
        "terseLabel": "Holdback shares not issued to former shareholders (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesMerger",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "verboseLabel": "Number of shares issues as a result of warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Cashless Warrants Exercised",
        "label": "Stock Issued During Period, Value, Cashless Warrants Exercised",
        "terseLabel": "Shares issued for cashless exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCashlessWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of share issued exercise of option and warrants during the period",
        "label": "Stock issued during the period shares of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents value of stock issued during the period",
        "label": "Stock issued during the period value of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SubcontractorIPAPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subcontractor IPA Payable",
        "label": "Subcontractor IPA Payable",
        "verboseLabel": "Subcontractor IPA payable"
       }
      }
     },
     "localname": "SubcontractorIPAPayable",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_Tag6MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-6 Medical Investment Group, LLC",
        "label": "Tag-6 Medical Investment Group, LLC [Member]",
        "terseLabel": "Tag-6 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "Tag6MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-6 Medical Investment Group, LLC - Related Party",
        "label": "Tag-6 Medical Investment Group, LLC - Related Party [Member]",
        "terseLabel": "Tag-6 Medical Investment Group, LLC \u2013 related party"
       }
      }
     },
     "localname": "Tag6MedicalInvestmentGroupLLCRelatedPartyMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Tag8MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-8 Medical Investment Group, LLC",
        "label": "Tag-8 Medical Investment Group, LLC [Member]",
        "terseLabel": "Tag-8 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "Tag8MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-8 Medical Investment Group, LLC - Related Party",
        "label": "Tag-8 Medical Investment Group, LLC - Related Party [Member]",
        "terseLabel": "Tag-8 Medical Investment Group, LLC \u2013 related party"
       }
      }
     },
     "localname": "Tag8MedicalInvestmentGroupLLCRelatedPartyMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_TemporaryEquityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity [Policy Text Block]",
        "label": "Temporary Equity [Policy Text Block]",
        "terseLabel": "Mezzanine Equity"
       }
      }
     },
     "localname": "TemporaryEquityPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_TermLoanAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A [Member]",
        "label": "Term Loan A [Member]",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoanAMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UniversalCareAcquisitionPartnersLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universal Care Acquisition Partners, LLC [Member]",
        "terseLabel": "Universal Care Acquisition Partners, LLC"
       }
      }
     },
     "localname": "UniversalCareAcquisitionPartnersLlcMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UniversalCareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universal Care Inc [Member]",
        "terseLabel": "Universal Care Inc"
       }
      }
     },
     "localname": "UniversalCareIncMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UnrealizedGainLossFromInvestmentInEquitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized (Gain) Loss from Investment in Equity Securities",
        "label": "Unrealized (Gain) Loss from Investment in Equity Securities",
        "negatedLabel": "Unrealized (gain) loss from investment in equity securities"
       }
      }
     },
     "localname": "UnrealizedGainLossFromInvestmentInEquitySecurities",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_WarrantExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range One [Member]",
        "verboseLabel": "Warrant Exercise Price Range One"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeOneMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range Three [Member]",
        "verboseLabel": "Warrant Exercise Price Range Three"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeThreeMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range Two [Member]",
        "verboseLabel": "Warrant Exercise Price Range Two"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeTwoMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Issued During Period Value Stock Options Exercised",
        "label": "Warrant Issued During Period Value Stock Options Exercised",
        "terseLabel": "Proceeds from warrants exercised"
       }
      }
     },
     "localname": "WarrantIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_WeightedAverageExercisePriceWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "label": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price, Warrants [Roll Forward]"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_WeightedaverageremainingcontractualtermyearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Years [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term Years [Abstract]"
       }
      }
     },
     "localname": "WeightedaverageremainingcontractualtermyearsAbstract",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ZLLPartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZLL Partners LLC",
        "label": "ZLL Partners LLC [Member]",
        "terseLabel": "ZLL Partners LLC"
       }
      }
     },
     "localname": "ZLLPartnersLLCMember",
     "nsuri": "http://www.apollomed.net/20210930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r399",
      "r579",
      "r580",
      "r583",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r140",
      "r288",
      "r293",
      "r299",
      "r488",
      "r489",
      "r496",
      "r497",
      "r586",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r140",
      "r288",
      "r293",
      "r299",
      "r488",
      "r489",
      "r496",
      "r497",
      "r586",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r72",
      "r74",
      "r137",
      "r138",
      "r305",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board members"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r217",
      "r380",
      "r385",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r304",
      "r342",
      "r402",
      "r405",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r626",
      "r697",
      "r700",
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r304",
      "r342",
      "r402",
      "r405",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r626",
      "r697",
      "r700",
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r217",
      "r380",
      "r385",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r215",
      "r380",
      "r383",
      "r627",
      "r696",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r215",
      "r380",
      "r383",
      "r627",
      "r696",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r304",
      "r342",
      "r391",
      "r402",
      "r405",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r626",
      "r697",
      "r700",
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r304",
      "r342",
      "r391",
      "r402",
      "r405",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r626",
      "r697",
      "r700",
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r73",
      "r74",
      "r137",
      "r138",
      "r305",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r150",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r150",
      "r155",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r150",
      "r155",
      "r282",
      "r403",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r218",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Total accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r47",
      "r590"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "verboseLabel": "Receivables and Receivables-Related Parties"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r36",
      "r219",
      "r220"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r62",
      "r136",
      "r580",
      "r583"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Receivables, net \u2013 related parties",
        "verboseLabel": "Receivables, net \u2013 related party"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r27",
      "r648",
      "r674"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r53"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r37",
      "r441",
      "r590"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r438",
      "r439",
      "r440",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional Paid-in\u00a0Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r407",
      "r435",
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r89",
      "r118",
      "r324",
      "r553"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r118",
      "r258",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Treasury shares not included in the calculation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r118",
      "r274"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of beneficial interest"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r133",
      "r197",
      "r207",
      "r213",
      "r235",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r488",
      "r496",
      "r541",
      "r588",
      "r590",
      "r646",
      "r672"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r67",
      "r133",
      "r235",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r488",
      "r496",
      "r541",
      "r588",
      "r590"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r529"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r133",
      "r235",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r488",
      "r496",
      "r541",
      "r588"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent assets",
        "verboseLabel": "Noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r223",
      "r225",
      "r247",
      "r653"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities \u2013 certificates of deposit"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r409",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r514",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BridgeLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.",
        "label": "Bridge Loan [Member]",
        "terseLabel": "Bridge Loan"
       }
      }
     },
     "localname": "BridgeLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r401",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r401",
      "r404",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r473",
      "r474",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r473",
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Value of shares transferred in acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r472",
      "r475",
      "r478"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Business combination, contingent consideration, liability",
        "verboseLabel": "APCMG contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations and Goodwill"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r3",
      "r141",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r44",
      "r120"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r16",
      "r121",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r111",
      "r120",
      "r126"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "terseLabel": "Cash, cash equivalents, restricted cash total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r111",
      "r542"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosures of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Amount deposit accounts exceeded FDIC insured limit"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r130",
      "r133",
      "r158",
      "r159",
      "r160",
      "r162",
      "r164",
      "r173",
      "r174",
      "r175",
      "r235",
      "r288",
      "r293",
      "r294",
      "r295",
      "r299",
      "r300",
      "r340",
      "r341",
      "r345",
      "r349",
      "r541",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise\u00a0Price\u00a0Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of warrants received (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r366",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r58",
      "r281",
      "r657",
      "r680"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r283",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r142",
      "r143",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common\u00a0Stock\u00a0Outstanding"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r33",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r33",
      "r590"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,397,050 and 42,249,137 shares issued and outstanding, excluding 10,925,702 and 12,323,164 treasury shares, as of September\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r183",
      "r184",
      "r217",
      "r539",
      "r540",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r183",
      "r184",
      "r217",
      "r539",
      "r540",
      "r707",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r183",
      "r184",
      "r217",
      "r539",
      "r540",
      "r707",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r179",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r183",
      "r184",
      "r217",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r183",
      "r184",
      "r217",
      "r539",
      "r540",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Other Entities - Equity Method and Investments in Privately Held Entities"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r495",
      "r499",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entity"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r368",
      "r369",
      "r381"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Accrued contract liability recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of services, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r182",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r129",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r318",
      "r325",
      "r326",
      "r328",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Credit Facility, Bank Loans and Lines of Credit"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r132",
      "r140",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r332",
      "r333",
      "r334",
      "r335",
      "r554",
      "r647",
      "r650",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r28",
      "r329",
      "r650",
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Total debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r301",
      "r332",
      "r333",
      "r552",
      "r554",
      "r555"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt, principal sum"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r55",
      "r321",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Average effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r55",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate on loan receivable"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r56",
      "r132",
      "r140",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r332",
      "r333",
      "r334",
      "r335",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r56",
      "r132",
      "r140",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r327",
      "r332",
      "r333",
      "r334",
      "r335",
      "r357",
      "r360",
      "r361",
      "r362",
      "r551",
      "r552",
      "r554",
      "r555",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Revolving credit facility term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r314",
      "r330",
      "r332",
      "r333",
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: Unamortized financing costs",
        "terseLabel": "Unamortized financing costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).",
        "label": "Deferred Credits and Other Liabilities",
        "terseLabel": "Amount outstanding under agreement"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r447",
      "r448"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "verboseLabel": "Deferred tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r118",
      "r194"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r70",
      "r71",
      "r74",
      "r538"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r69",
      "r74",
      "r75",
      "r517",
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r74",
      "r515",
      "r518",
      "r520",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r512",
      "r515",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r70",
      "r71",
      "r74",
      "r538"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "auth_ref": [
      "r516"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Loss on Derivative",
        "terseLabel": "Loss on interest rate swaps"
       }
      }
     },
     "localname": "DerivativeLossOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r139",
      "r509",
      "r510",
      "r512",
      "r513",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives designated as hedging instruments:"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Disaggregated Revenue by Each Payor Type"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r363",
      "r666"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "verboseLabel": "Dividends paid"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r53"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividend payable",
        "verboseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r27",
      "r30",
      "r649",
      "r673"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Dividend declared included in dividend payable"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromAffiliateCurrent": {
     "auth_ref": [
      "r62",
      "r580",
      "r582",
      "r587"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).",
        "label": "Due from Affiliate, Current",
        "terseLabel": "Amount due from affiliate"
       }
      }
     },
     "localname": "DueFromAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromAffiliates": {
     "auth_ref": [
      "r580",
      "r582",
      "r683"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Due from Affiliates",
        "terseLabel": "Due from affiliates"
       }
      }
     },
     "localname": "DueFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToAffiliateCurrent": {
     "auth_ref": [
      "r25",
      "r136",
      "r580",
      "r709"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Affiliate, Current",
        "terseLabel": "Amount due to affiliate"
       }
      }
     },
     "localname": "DueToAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToAffiliateCurrentAndNoncurrent": {
     "auth_ref": [
      "r580",
      "r587",
      "r656",
      "r682",
      "r710"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Due to Affiliate",
        "terseLabel": "Due to affiliate"
       }
      }
     },
     "localname": "DueToAffiliateCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r47",
      "r136",
      "r291",
      "r293",
      "r294",
      "r298",
      "r299",
      "r300",
      "r580"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r88",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r156",
      "r158",
      "r162",
      "r163",
      "r164",
      "r169",
      "r170",
      "r527",
      "r528",
      "r661",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings per share \u2013 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r88",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r158",
      "r162",
      "r163",
      "r164",
      "r169",
      "r170",
      "r527",
      "r528",
      "r661",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings per share \u2013 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r165",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r165",
      "r167",
      "r168",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r79",
      "r80",
      "r81",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154",
      "r172",
      "r237",
      "r356",
      "r363",
      "r438",
      "r439",
      "r440",
      "r457",
      "r458",
      "r526",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r701",
      "r702",
      "r703",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Amount invested for interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r2",
      "r133",
      "r235",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r2",
      "r133",
      "r235",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [
      "r91",
      "r92",
      "r118"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "negatedLabel": "Gain on sale of equity method investment",
        "terseLabel": "Gain on sale of equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the entity's equity method investment which has been sold.",
        "label": "Equity Method Investment, Amount Sold",
        "negatedTerseLabel": "Sale",
        "terseLabel": "Sale"
       }
      }
     },
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r45",
      "r198",
      "r232"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Investments in other entities \u2013 equity method",
        "verboseLabel": "Investments in other entities \u2013 equity method"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "verboseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r536"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "verboseLabel": "Investment in privately held entities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Marketable securities \u2013 equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r231",
      "r688"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Equity securities, FV-NI, unrealized gain (loss)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r529",
      "r530",
      "r531",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r529",
      "r530",
      "r531",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "verboseLabel": "Schedule of Carrying Amounts and Fair Values of Financial Instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r316",
      "r332",
      "r333",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r530",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r316",
      "r392",
      "r393",
      "r398",
      "r400",
      "r530",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r316",
      "r332",
      "r333",
      "r392",
      "r393",
      "r398",
      "r400",
      "r530",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r316",
      "r332",
      "r333",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r530",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r316",
      "r332",
      "r333",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r535",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r559",
      "r566",
      "r575"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "verboseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r558",
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "netLabel": "Less: current portion",
        "terseLabel": "Finance lease liabilities",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Finance Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Finance lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (excluding the nine months ended September\u00a030, 2021)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r560",
      "r569"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance lease obligations",
        "verboseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Assets recorded under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r559",
      "r566"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "terseLabel": "Accumulated depreciation associated with finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r559",
      "r566",
      "r575"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "verboseLabel": "Amortization of lease expense"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r572",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r571",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r248",
      "r249",
      "r250",
      "r251",
      "r327",
      "r354",
      "r525",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": {
     "auth_ref": [
      "r481",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Axis]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Axis]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": {
     "auth_ref": [
      "r481",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Domain]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Domain]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2021 (excluding the nine months ended September 30, 2021)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r259",
      "r261",
      "r265",
      "r269",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r265",
      "r629"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Amortized intangible assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r259",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r265",
      "r628"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r252",
      "r253",
      "r590",
      "r644"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance, September 30, 2021",
        "periodStartLabel": "Balance, January 1, 2021",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r255",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill and Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareCostsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r716",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.",
        "label": "Health Care Costs, Policy [Policy Text Block]",
        "verboseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "HealthCareCostsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HealthCareOtherMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other.",
        "label": "Health Care, Other [Member]",
        "terseLabel": "Risk pool settlements and incentives"
       }
      }
     },
     "localname": "HealthCareOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.",
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Fee-for-service, net"
       }
      }
     },
     "localname": "HealthCarePatientServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r512",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r118",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of finite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r118",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r118",
      "r274",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r273",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Intangible Assets and Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r83",
      "r197",
      "r206",
      "r209",
      "r212",
      "r214",
      "r642",
      "r659",
      "r663",
      "r689"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "(Loss) income before (benefit from) provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r84",
      "r118",
      "r195",
      "r232",
      "r658",
      "r685"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss (income) from equity method investments",
        "netLabel": "Income (loss) from equity method investments",
        "terseLabel": "Income (loss) from equity method investments",
        "verboseLabel": "Allocation of Income (Loss)"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]",
        "verboseLabel": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r134",
      "r451",
      "r452",
      "r455",
      "r459",
      "r461",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r135",
      "r153",
      "r154",
      "r196",
      "r449",
      "r460",
      "r462",
      "r690"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "(Benefit from) provision for income taxes",
        "verboseLabel": "Provision for income tax"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r445",
      "r446",
      "r452",
      "r453",
      "r454",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r114",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r63",
      "r655",
      "r684"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Receivables, net \u2013 related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of business combinations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r117",
      "r569"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "verboseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r260",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite lived assets:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r260",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible Assets, Gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r257",
      "r263"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r82",
      "r193",
      "r550",
      "r553",
      "r662"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r109",
      "r113",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r96",
      "r192"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investments in affiliates"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r573",
      "r575"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost, net"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Information Related to Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term, finance"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Renewal Term",
        "terseLabel": "Finance lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (excluding the nine months ended September\u00a030, 2021)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term, operating"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Amount outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r51",
      "r133",
      "r208",
      "r235",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r489",
      "r496",
      "r497",
      "r541",
      "r588",
      "r589"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r41",
      "r133",
      "r235",
      "r541",
      "r590",
      "r652",
      "r678"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "terseLabel": "Total liabilities, mezzanine equity, and stockholders\u2019 equity",
        "totalLabel": "Total liabilities, mezzanine equity, and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Deficit",
        "verboseLabel": "Liabilities, mezzanine equity, and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r54",
      "r133",
      "r235",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r489",
      "r496",
      "r497",
      "r541",
      "r588",
      "r589",
      "r590"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r28",
      "r29",
      "r133",
      "r235",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r489",
      "r496",
      "r497",
      "r541",
      "r588",
      "r589"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent liabilities",
        "verboseLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r691",
      "r694"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Medical liabilities, end of period",
        "periodStartLabel": "Medical liabilities, beginning of period",
        "terseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "terseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions",
        "terseLabel": "Acquired (see Note 3)"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r693"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "negatedLabel": "Current period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r693"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "negatedLabel": "Prior periods"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r692"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total medical care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Medical Liabilities [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r28",
      "r650",
      "r670"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "totalLabel": "Total",
        "verboseLabel": "Amount outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r49",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Commitment Fee Amount",
        "terseLabel": "Annual agent fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Required annual facility fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Expiration Period",
        "terseLabel": "Term of facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r49",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum loan availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Amount available"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r49",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r28",
      "r315",
      "r331",
      "r332",
      "r333",
      "r650",
      "r675"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Long-term debt, net of current portion and deferred financing costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Less: Current portion of debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r140",
      "r286",
      "r320"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r140",
      "r286",
      "r320"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r140",
      "r286",
      "r320"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2021 (excluding the nine months ended September 30, 2021)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion and deferred financing costs",
        "verboseLabel": "Long-term debt, net of current portion and deferred financing costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r56",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManagementFeeExpense": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).",
        "label": "Management Fee Expense",
        "negatedLabel": "Management fees"
       }
      }
     },
     "localname": "ManagementFeeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagementServiceMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractually stipulated right to receive compensation for operating and managing business.",
        "label": "Management Service [Member]",
        "terseLabel": "Management fee income",
        "verboseLabel": "Management Fee Income Contract"
       }
      }
     },
     "localname": "ManagementServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r7",
      "r52"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "verboseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MembersCapital": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of member capital in limited liability company (LLC).",
        "label": "Members' Capital",
        "terseLabel": "Initial capital contributions"
       }
      }
     },
     "localname": "MembersCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r65",
      "r133",
      "r235",
      "r288",
      "r293",
      "r294",
      "r295",
      "r299",
      "r300",
      "r541",
      "r651",
      "r677"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Dividends"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r363",
      "r486",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Purchase of noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r176",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r111",
      "r116",
      "r119"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r76",
      "r77",
      "r81",
      "r87",
      "r119",
      "r133",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r161",
      "r197",
      "r206",
      "r209",
      "r212",
      "r214",
      "r235",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r528",
      "r541",
      "r660",
      "r686"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Apollo Medical Holdings, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r76",
      "r77",
      "r81",
      "r153",
      "r154",
      "r492",
      "r506"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "verboseLabel": "Net (loss) income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": {
     "auth_ref": [
      "r123",
      "r124",
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.",
        "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received",
        "terseLabel": "Preferred shares received from sale of equity investment"
       }
      }
     },
     "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r364",
      "r470",
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "terseLabel": "Investment in noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": {
     "auth_ref": [
      "r364",
      "r486",
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.",
        "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest",
        "terseLabel": "Sales of noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r363",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r34",
      "r219",
      "r220",
      "r654"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Loan receivable \u2013 related party",
        "verboseLabel": "Loan receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Loans receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableGross": {
     "auth_ref": [
      "r221",
      "r238",
      "r241",
      "r243",
      "r245",
      "r246",
      "r733",
      "r734",
      "r735"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of financing receivable.",
        "label": "Financing Receivable, before Allowance for Credit Loss",
        "terseLabel": "Note receivable, amount"
       }
      }
     },
     "localname": "NotesReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Notes Receivable [Member]",
        "terseLabel": "Convertible Secured Promissory Note"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r36",
      "r219",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Amount of loan"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r62",
      "r136",
      "r580"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Current",
        "terseLabel": "Loan receivable \u2013 related party"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r18",
      "r35",
      "r136",
      "r580"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Noncurrent",
        "terseLabel": "Loans receivable \u2013 related party"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of main reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r197",
      "r206",
      "r209",
      "r212",
      "r214"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r567",
      "r575"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: current portion",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r561",
      "r569"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r572",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r571",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r24",
      "r645",
      "r671"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r66",
      "r590"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r45",
      "r681"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "terseLabel": "Investment in affiliates"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income",
        "verboseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables",
        "verboseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForFees": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for fees classified as other.",
        "label": "Payments for Other Fees",
        "terseLabel": "Fees paid"
       }
      }
     },
     "localname": "PaymentsForFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r115",
      "r693"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "negatedTotalLabel": "Total paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r101",
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Payments for business acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchase of investment \u2013 equity method"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRealEstate": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.",
        "label": "Payments to Acquire Real Estate",
        "terseLabel": "Purchase price of real estate"
       }
      }
     },
     "localname": "PaymentsToAcquireRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Distribution to noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r32",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r32",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r32",
      "r590"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r42",
      "r43"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r99",
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.",
        "label": "Proceeds from Collection of Long-term Loans to Related Parties",
        "terseLabel": "Proceeds from repayment of loans receivable \u2013 related parties"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r104",
      "r132"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Borrowings on revolver"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherOperatingActivities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from operating activities classified as other.",
        "label": "Proceeds from Other Operating Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromOtherOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sale of equity method investment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of stock options and warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r76",
      "r77",
      "r81",
      "r110",
      "r133",
      "r145",
      "r153",
      "r154",
      "r197",
      "r206",
      "r209",
      "r212",
      "r214",
      "r235",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r485",
      "r491",
      "r493",
      "r506",
      "r507",
      "r528",
      "r541",
      "r663"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net (loss) income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r68",
      "r275",
      "r566"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Land, property, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r20",
      "r21",
      "r275",
      "r590",
      "r665",
      "r679"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Land, property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealEstateLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan to finance the purchase of real estate, including but not limited to, land or building.",
        "label": "Real Estate Loan [Member]",
        "terseLabel": "Real Estate Loan"
       }
      }
     },
     "localname": "RealEstateLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r399",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r399",
      "r579",
      "r580",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.",
        "label": "Related Party Transaction, Other Revenues from Transactions with Related Party",
        "totalLabel": "Receipts, net",
        "verboseLabel": "Recognized risk pool revenue"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r399",
      "r579",
      "r583",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r577",
      "r578",
      "r580",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r4",
      "r16",
      "r126"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r4",
      "r16",
      "r126",
      "r712",
      "r714"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Restricted cash - current"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r10",
      "r24",
      "r126",
      "r712",
      "r713",
      "r714"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash - noncurrent"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r10",
      "r24",
      "r126",
      "r713"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r38",
      "r363",
      "r441",
      "r590",
      "r676",
      "r704",
      "r705"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154",
      "r237",
      "r438",
      "r439",
      "r440",
      "r457",
      "r458",
      "r526",
      "r701",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r190",
      "r191",
      "r205",
      "r210",
      "r211",
      "r215",
      "r216",
      "r217",
      "r379",
      "r380",
      "r627"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r94",
      "r291",
      "r293",
      "r294",
      "r298",
      "r299",
      "r300",
      "r711"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolver Loan",
        "verboseLabel": "Revolver Loan"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r570",
      "r575"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]"
       }
      }
     },
     "localname": "RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r183",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "verboseLabel": "Net Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r407",
      "r434",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r2",
      "r133",
      "r234",
      "r235",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r259",
      "r264",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r259",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Change in Carrying Value of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r268",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Medical Liabilities"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Commitments of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r581",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "verboseLabel": "Schedule of Fees Incurred and Revenue Earned from Related Party Transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "verboseLabel": "Schedule of Contributions to Revenue and Receivables by Payor"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r409",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r413",
      "r421",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Transactions Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r60",
      "r130",
      "r173",
      "r174",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r349",
      "r354",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r366",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r488",
      "r489",
      "r496",
      "r497",
      "r498",
      "r500",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r498",
      "r500",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "verboseLabel": "Schedule of Assets and Liabilities, Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "verboseLabel": "Schedule of Shares Included in the Diluted Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "verboseLabel": "Schedule of Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Reportable Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Annual dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r415",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "verboseLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r406",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r409",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Market value of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Grant date fair value of restricted stock to be recognized straight-line"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r429",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Equity, ending balance (in shares)",
        "periodStartLabel": "Equity, beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r284",
      "r285",
      "r482",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r130",
      "r133",
      "r158",
      "r159",
      "r160",
      "r162",
      "r164",
      "r173",
      "r174",
      "r175",
      "r235",
      "r288",
      "r293",
      "r294",
      "r295",
      "r299",
      "r300",
      "r340",
      "r341",
      "r345",
      "r349",
      "r356",
      "r541",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r61",
      "r79",
      "r80",
      "r81",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154",
      "r172",
      "r237",
      "r356",
      "r363",
      "r438",
      "r439",
      "r440",
      "r457",
      "r458",
      "r526",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r701",
      "r702",
      "r703",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r172",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r32",
      "r33",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Sale of shares by noncontrolling interest (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r32",
      "r33",
      "r356",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares purchased by related party"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r32",
      "r33",
      "r356",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedTerseLabel": "Cancellation of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r356",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r33",
      "r356",
      "r363",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Shares issued for exercise of options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r61",
      "r356",
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Sale of shares by noncontrolling interest"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r32",
      "r33",
      "r356",
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock subscriptions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r32",
      "r33",
      "r356",
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedTerseLabel": "Cancellation of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r32",
      "r33",
      "r356",
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r32",
      "r33",
      "r363",
      "r408",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r356",
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Purchase price adjustment from Merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r33",
      "r39",
      "r40",
      "r133",
      "r222",
      "r235",
      "r541",
      "r590"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity, parent"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r80",
      "r133",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r235",
      "r237",
      "r363",
      "r438",
      "r439",
      "r440",
      "r457",
      "r458",
      "r483",
      "r484",
      "r505",
      "r526",
      "r541",
      "r543",
      "r544",
      "r548",
      "r702",
      "r703",
      "r737"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "terseLabel": "Stockholders\u2019 deficit",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r131",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r363",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Mezzanine and Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r568",
      "r575"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r549",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r549",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r549",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r549",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r591",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r692"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r692"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r59",
      "r133",
      "r235",
      "r541"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "terseLabel": "Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trade names/trademarks"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r327",
      "r354",
      "r525",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r33",
      "r356",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredParValueMethod": {
     "auth_ref": [
      "r356",
      "r363",
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.",
        "label": "Treasury Stock, Value, Acquired, Par Value Method",
        "negatedLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredParValueMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized (loss) gain on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r177",
      "r178",
      "r180",
      "r181",
      "r185",
      "r186",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Variable Interest Entities (VIEs)"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEs"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r488",
      "r489",
      "r496",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrant"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Adjustments to weighted average shares of common stock (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r157",
      "r164"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r156",
      "r164"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4616395-111683"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/subtopic&trid=2560295"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.12(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "720",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9162-115647"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r722": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r723": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r724": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r725": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r726": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r727": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r728": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r729": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r730": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r731": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r732": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r733": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1404"
  },
  "r734": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)"
  },
  "r735": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)"
  },
  "r736": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0001628280-21-022011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-022011-xbrl.zip
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MR@WHR'G3H%F2:,+_.O[2.@37O!QEW_@(N/ 16H*CZ')*B7V)IORO^F5*!G*
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MZR_J =QK@6O?!=>ZDIQW^2CI?3^"4O (6XU')OKH11PXR)]_]2^_0VCOS36
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MYGO\_+B[^=X=<,H?M6QJS2>0+"7H?TW2GQHCY[2^ \8Z;\=U!\Q5R/Q4/FD
M6T>Y-U^OSE[JQWKWTK77QK/%\B]2[U=_WQ^\*_/%Z6S^6R][70?QWDM\\?ZG
M_S/F%PPY1N^A%J,NO*@\05('TM2AV&+=[IA_^6WEN.N+BU^KOMFK%R<SGIT]
MD%/2MZ@S??:B2/U&OIRI2^Y_<^<$5ZM'[>G9@G^Z]6JF#O?-)<H"6=UZO(YT
M2ZGK2RY>\>]?_.8;O;EQ;S[/4(:)-8*MP-E'AFP<1E,:J<,O5KQULCO#W"N
M/LEOO =0#;:YOA@1"X-"4X1K].0R$W(,<8\ NCU)@ Q!BKD:IZDTD$EHF470
M5F>IHJM[Y.)V"=#F7)PJ#R3;JBW1 YJ>8#ALK5*)C7V-XP5HM3S[\LYBOEJ<
MS&I?&%T7P[HG>P^;?^-RAG0BW^IWUE!^=E$R>[@X>[R<G>+R]6V92],WT!\G
M@EBS&*N+*0H@M,3%!QLYE*Q^,&&D\?J\:2&V.2?H]19Z2<518_ J]"!BU7A5
M6PA>'>)EWIYVF+?_%>@>+Q?UG,\>+=7?O9RQ7,#62QU?_E/PY.SY'17+=_#%
M[&Q=Q'HB+V5^+IO'Z,."0MI%0>%]IVFZ+#0U8ZO@'6N02[:QH9I;\@;6@)HK
M0,T!T(\ U%P?4+,Q0)NKXIV/P2B@!25[1*@I^(*F8FT#5-;V!M!=E?S> S3&
M*([8@#I=J(1H;"+/ 2TXL-0N+=0>+/0O6>AU =V<A5)-!J+%$ -"4KG:W6\1
M] 6$;&R3CJ%7TN<MIH_.GLMR'T-G+BYR5K,,N0(U6Z1E*Z:%)$#@_*1#YS X
M#A(QH]$ 68)Q# !6LQ"IACF+E" Q%#/IB#F8/>X^4)IL?&*LOHH&2Q.+[RO:
M'%/S 3.X20?*P>QQ]_$QF!(P..1@*J1FR->(WG.%7(/-?B_BXP.<X\6VB,NG
M]S%"MHR:7") L F"L\5B*20<6RU1?-R+"+EK) >)D=Z[0C%9'PV!9I$(C5Q+
M#"XV=BGO18P<P"8'B)(1,M:2&K4"(6<$$;8AZ .E1*I[$24'L,G=Q\ED2C88
M'5K)T*OF7DQTJ0&ISTTP[5KLK_7.8SR;[7>XS"99%'"A)H*:'8::]5\3+=H4
M*NY%N!P(T$&BIFG)53"" 2(84ZF$7#W56(L/X/<ML]RUA>X^>(JF)>C9B*::
M (DR%:\!E$QE:OG2Y4X]> YGH;N/H=4RL0>2?FB8$9"<)BL<1,TT1,I[$4,O
MG[TUKY=/[VU)E@U:#9"9A0&,*VB+<Q@1F_$YPGZ49 >!<Y#X:8-UJ/Q(SF8H
M:"A7-)X<-F3'N!_Q<RCKW'WT#&AC#$C>N Q02DG5)%],BL#&Q+@7T7,HZ]Q]
M["S. *JC5=/,('5=( );8D@2O <9('9.(DB!%8':A%.RH(J2F'PE%LW:6W39
M#1"D)A$-:L(0'360(F *9$I0 ]D:7%0_,D3E:A)VJEQKKA:I,6= 3+DD2C7;
MG*U/C7&\NRS[R>'[<HPG]]:?YYTM(P_DEU]P/IO_65+RIV_QJ[W1]_[GO!]$
M7YR^6,SUUP]V=#Y<S/N]72Y.3F;SXZM]G1/9O)F-E<!='\<"KE9*QK#EZAEL
MJ\6,EP@?B9(^?KJ83^EP 90&ZL/4'$,"3XC><#"IU$A-'W-[ \VM6F=]?Q>>
M/,99_79^L>/K9"(P$>5(+AN%1T.W+[FYIC$)K.:6MM:P-S ]D3-4[UKOX5*]
M[/%J(OA JD[SB] H,E#,) Z+0F0SQU@J[ T^DXY#B@ #YH;4,P@ *L$%+DZ<
M)6\=?)C6^_'!=7.5R2>4$?P[]/F4_;.M"&KJU$S/-]6N4S;.:=C,XIC93H ^
MH_/&PZ-:6I2:<K60(@@X*HBEA*19LD$#OZKU31_5FV.QBJ'B&IQ L( AE>0A
M)A.<44MV(0Z [23NFZ60N2!Q53F33,P1#6O:WIS7Q_(4 N68,K?A :TQNF0K
MU*H90X)(UM<4])%*TK?Q[!^@.\OWA@>W;[JJV;H2Q( '*3Y4E;7<#_EP3>;R
M_/D(,;VY:O;]8^U^,_E- ^1:37;]8+L%EVV)E'+VMG%T)8^7"&/RUEN!ADH*
MCCUCS@Z,\<5ZQ"0UH%>E275OH!FBSK8YF#@ ,9D""A5DC@H;))>=J4C"Z/<&
MIIW6V39H1I&32..FO@U"(D34N%=M-29P"OOCX28=AS2Y"I0H-?8(Z($22W*>
MLR>/!=SN4!KJ#B2,(6*(3;T^%$^E957>U!# -%^O]#9<Z>TXOATG-U>;?:CH
MX?J*/FYHQX%C3%C1N=YL@7U.Q18RC#5DX]]TJ1TS?487CX9'-8IMS@87C /(
M%!"+R3D;P!PK)]X_5&^.Q>;&(<18LX\-7 LY6JH^^^R:]^+M -A.XKY%KRXM
MM1R*BF[G;2D>6S!2]&?)LH<VL=-*X^X!]2C6)G+.F IB>PMY&R0Z"20FD]L_
M0 >K-.X>7+1,O;MR*@& 0LU8(@</GH @P%7Z-4),;ZZ:?3^_B9MIH)E+\HXB
M,"A"@4W19,]HSB?&]NEJ8;Q$&).WW@HT)E@TP:N!M@PD,6ORF2A2#<3-9]D;
M: :J-&X(IE99?*L:)1OV@07(I465/K;8&#WAWL"TZTKCICR<$Y\"H*MDP5M;
MJA<KJFNB>"K6[@T^DXY#BDX+(!R-4:RDIUWL$$UIX(/#LCN4AKH#D,A+]@&#
MBC!/FG4Z3!*9$9IX[R9PD/CF:K/ASX2%YE)2GE3K&S3C<G+*G="#4*Y$4^CE
M,KIX-#RJN5B]QWV-3&^R14$# 7OG,R3!$J;@% X6^_L["1"=$U>C >O5X0>V
MAB S<8&VAQ:[TXK9 ,=R-82'TJ3$EJ"84#"!U^C=-!FPE,O^ 3I8Q6P 3]QL
M] S5:!:AV7@H%1EZERUH&G/?;"@9(:8W5Y5M9>2,S\$R<%\=LGT/0(:&62"V
M*B$:*N,EPIB\]5:@X8+@FT+3$D+J"7^,1FU46LU5:,3SF\;J=[<"4TV035@G
M]IKK%U_8-"JLMS+5$A/O#4R[KIAM:@P:<<7F62)&J%5SD,"0)=K$T02#>X//
MI.-02JI&4G2^$(++#3VG8C!(=A#)KP5)'YPZOAV4!T'2D=G<W$^!EL7D2@9
M;,92:\PIA#Y"63/)\1)AG()D@]!84LM$H.35DZJ_) &L7%R$3$A>]@:: 03)
M)BV(HY -WEC6@)<10^/>-U#U258S*GL#TRX%R0;Q":SRO;B<O3%0'9:<0!&R
MPLG9!G%O\)ET''())/=]?TD5"*&G3!*C1\840T*[.Y2&N@/-Y9*<*0VE@3"1
M9J(9)81 T9&$#_O+C?!TR\W59N^5&#^NS=[&SG8W(Q)S\:XW>Y?,"!&+FE#M
MW3#]!.@SNG@T/*K9]/ZT&5I8=\G#W"QF=%%A;"FGM'^HWAR+Q5A:=*TTX@P,
M@;QAO?.1<BU]B-P V$[BOC4&JKZ: (G!,V-1]=T[LJJ5.&YY_VQB=TN?@P"J
MH@=BI8K!%PB*IVJ>1)10T-<LN'^ #K/T.0BXP4AW9]G4S "^4H@U8DM8B_3&
MP!<]$<>(Z<U5L^^U7=S48>BLE@R970PQ065#IL12Q7' 5C#@>(DP)F^]%6BX
MALPF^%P; +@^'HJPAHK6VFB ]P::8=K_;@HF=9S-DB4G+4(T"1.Z3+[6:@L5
MWA\+VG'[WXVU>ZCHBDVE'[4!M#Z+Y))=8&^3-[;L#3Z3CD.!:A1)'+CY=3TX
MH'J[9J/F#_6J!]-8LJVMW($F!AS$J-\8^PQ60HRHG],TWTJTY5)OPY7>'N'I
MEINKS3Y4]-<]_FLV=OPWD4H"1,NN)&A.LG=0*Y/1, 2>S 3H,[IX-#RJE&RO
M'E.SB4!%1G:N.$'GDPH.2&W_4+U!%JM"/E12+$V '(TF7#Y#7Q?- :RE ;"=
MQGW+%IIW*<0L$/K87-*LJ.;6*D@HO'\VL=-*XP" %B1-:9OFMP1L,[D4V7,P
M12-7?%,ZWB- !ZLT[AY<V^L5581[BVN 2EP+BG=.^A%[]I?"?H28WEPU^WY^
MLZ'#T$5RM+Y$UT0 J>1:3!_W4K,&PESB>(DP)F^]%6@2-\P^QU"Q (;6VY)(
M<DBJ.Q6ULC?0#%1IW%0[@6IZ<;'5!!%$7"DY%#"QD@3#:<2N='29W9;PJ0X;
M,ZFJ!S)(L0:5JF!ZOX<<[-[@,^DXI,(#4[(IHFF0T:&)SNK_2Z/8SY7M#J7!
M[H"+GIP@ML@ )?:5OKY[H\]M)HI^@%G#!VWV5Q7] ".75<=5C*$)&:@M8:PN
MMTC)-8[X9DOLF.DSNG@T E0KIU :-BH5HH'>PY]+R.H7;#'1[!^J-\=BHY4:
MI0_.<*Z+2.R[CU$E2@27"J?]PW:G%;/= XI<P5:AOHP-N:42^\( %VP&0RA[
M:*R#5<QV#VY(S6N^@-DE%:CBL>56-8-@".J<)5T*U!%B>G-5V?LZ?5--%7PC
M:S/V:<@04\S, =%:S6"LES>ETQ$284S>>BO0&(FE$MMF^C$>R<585<3>)  P
MV<K>0#-0Q6Q#,%$K1?-ZRP0.FFN(0650R!6<$"'M#4R[KIAM"!^LT)J79KL<
M53,BBAKW6HG$XFIV>X//I..0\:XX#OI?:! JZDWD;"(UE2>6'>P.I:'N0+$I
M96>24R</H9^ <8*:,3>Q69*)_WW7EE+6>OOJA[$1]O>UV2WEI-3'R/K*_*C=
MP9-96Z@;P6\?W]JFONYWZIKZ^M>7?LJ>JN \%.K3G306Q%1L]96, V6XV(M)
MK+:,V>D\D1/][@K9\NSULR7.5\@]1J]NOW[WF0N(5\NS+V^U-CN9]2<NP/]4
M$=Y?\\[BO'NQ%_V='BJ/WB64\N:?#Z3.&$_N+)8O%DOL'V_+/0\VIADT[E@I
M 34H 22+W#SUS2A]-FQNZRUWG1[KW/K DRGPY-V<_H(IU\KI/R35Q_F<\_GL
M@E'S\_[!WW#D5'!UOI2O+E]#?[QZ@:MGKG[OK_#;%0()("'E1*X"EEJL9]OK
M0,EJRG@QP?) T6M1="MA\>/5XYT37*T>M74*_+YR?*HDD]6MQTMILEQ*O4Z6
M?##,ZY?&5=39PF*#)56S-6= <@9CH827#9X/IK014@TD,X=B5C$F<2$,@06:
M-QB2\[494ZVIYK+V,,J6F\/XQ$Z?I_H]Z_F)/&H7Z?0#.7N^J-_.7VJR_#;)
M?O=1D0]I]D)S[,6E\_KG0M]S?KSZ=LY;S;4WUP(T$P-:]4GDC<(IU&JLP1$D
M35#*17*B-!UA7[0#:SZ^/K&I+F4H?1./M[;&".1]\<D@%)#F.UGL>'W-AO"[
MT^MKY\N5W)WA\7RQ.IOQT_/EL2Q?WY$>D.Z?_!F4P_![+&['&$D)N%45/] ,
MHNVGSL1BT#"&9I*C$&Z]X/NK4]R$AWGT\UR6J^>S%^\N:>)+O;]=BZ^=QC?+
MQ?F+4<>9-PGIBQ.<_RH=77^G_LQ'9Z,M)$\.;6X^ -:6;1(N5D*&5@N,N/?[
M'W"'N2M9I!/YI^#)V?,[N)3IF'.F!GU_:P/'&@9*"3G98DMU+K*DRR;%>B.G
M!,GC.[?F5?_W_M,'&TO ;Y^O9G-9K6ZQQIC5>J5S8!;T#"1O:'4M!AO -*/9
M!QBT5)!K,9PPQ18\7>:VRH*C&TZ'/TE=[R[_]G_PD_/CL7'NPQ3Y7=;]28J<
M/[TJRB>S^8Q_.PQ=//?1@2A[+YD3> @!)'N5+I8Q2ZVUH&LC5L%_0//3XU&+
MBO?/D;50(I0 61-68B9/A4DS5T)KQ>%X5]:VKB*O:?Q;1WN#"V66%%107"FK
MRHL%^S%\S1PDBF^<TP1*IWL.^PB*H-F!Y9"S2052SMARHA@K1^PM3.H$.+)!
M"#^%CS>L>IYCD)0Q8E$@8^ <G$N!DPM0:KQJ?GBH@W[(TENKE9S]-D4?/-:W
M^>;Q<J$PG/4UQ7G]\?[]#_]@(A7/T,@8+^+99F!NQ6KD\2@VFI#M9<'JP(^/
MX<>CN3QX^NC^_3O/\#A>5K7>%F'7]2U]4EFCS^???7XB_/&M6L?]3 4Y -0(
M!=2 :X D,>2K@F<:'W^NG4;J<X^7LU-<ONXIY+MERFVG$VDS&)$)V%*PF$F@
MAD0N(#&UT',*@U=#"_-D,5HO.CT]G]]'6CW .1ZO]X)LVXCL.G_?R"RTP@5*
M"H1>$P'-M4&57 D^14,!+[O3]1:6E].Q#TA]I/:ZP.K:<['SAL:;I!A#Y6*-
M1( 0R!=D9]!63@C@QEM'&1^:&U^\N7SSWRZ<73[YT94S@69#*QS09P#CB\T6
M5465U-AH<+PT9#OB,?>]A/L$Y\?R=H/3@]E\=GI^NBGI]/5LCG.>==&S.EN>
M]\_UP3&VKJM5NJG9K1ZUN_)BL;IZO6TZB.M.C[";.Z'*%B,(9PD6'"$FRZ+T
M\4!]XC-,E"[XZD"7;="E[W;SH0$EE=>UY<*:HU%+K!(\A93''T_&@N5VJO8&
MLRFYY)1#/^!%7O-F9P4EN(PYC3>5'C$\F\M4G:V)&G,_9PS6 Y:\[GY;2C:$
M?'7Z#L9G/;]?Z?AN/GLIRQ6>],ST'9'6=RCWG38;V*ZUH8UE[WW2[6\(-+ A
MF_86"J'+4B(D*Z3(9JRF&1.$ EU&Z#+R"/T':_)W^AKQL<Q9MKI=\\/H><U*
M^ :C9W2&6X@.N3!8J 6]*:Y:2!B,=^$2RC1R*!_@?Q;+.^>KL\6IVM-[6S=/
M]9'NO;>/WG6;N6P.O7Z6/0C;6F.#")@CJ"V6TA1(RV8*K9?&@=X@K7A$D8'D
M^Q :@)I3L<FGQ"FAJ'SE-I%$9WCT!LD[8NXG*8IM?1M<\6I[EKL94I3&H?YJ
ME.L!O8V,J-P0>B;W04@<0?2?%ARU)JX(@'&8C*E3CWL7"S++/^N(-<FH9]GW
MQ1O H E*5,OBU-0*?2D^B3XY]:BW(^P&B7G)^ZQW,A=N%DA2":EW&HP2J6+#
M-/68MSN[VWW$\SFXF'P-N35(@$78N=2J5U/S6'XUF/Z W8CB'514RW/) T,-
MC,FQ6.D]_FMMSN]'O)O5?8QW9&(+I/:6H@4AH<:523,'$1\=X7[$NZUC-TB\
M\Q;[8:F:-5& /F[95UM[)_/<##?&_8AWN["[W<<[,:UQ*RF#*\!8U&?J+\3>
M8TVMR'[$NUW8W>[C7=(;6(MU_=0QU!1R2,ZPKUF2=:Y./MX].GLNRV?/9\MU
MWY69;'MJP""!+UD;Q0<T"B#X1 6"\RS@6X$<: J-R$<%XB 1,$<6#QB++:"H
MQ5+(0N.$J!::'4\] @Y@B;L/A=0*&A<Q-2(PWB$AV1C!$9$/H4P]% Y@B;N/
MB<$VBV)*P*!Q,91,JFFHF)Q,]?[-/KPQQ\2W/=WGK']QT3GNR6SUT^W7MV7.
MST]Q^6&'.SR1U1-Y*?-S>2A_MBWC4S[ L]<OY(.-(9=,^]7%F]A^\+M<?HRO
M%\LM']L:1@^$F$VJSGC-JC26:/3P+OKDG2G-"/$$],"!P",A\"!:J-GDH6&U
MD01:JZ5![VP#4DR4'.H$M-"!P",A\#"+WE$I*[YOQTX03<G94 M2R%GV>1(Z
M\$#@D1!X$ TL+DF%4#T9[O58*JXQQFC$2JQV"O78 X&O2>#;>^F!N656QUIK
M*U"R+R*Y)H,2P)9L\."!#P0>M0>&*LK4DIP8 9<\MIJ92M]<(,X7/%0A]H?
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M4XV$%$J!@(@06DHY-&<A@YF"?!MYS6IXB^0HIH*)@*JQDB98%4*JX(TW:'W
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M1Q<)(D63BQ/+KL2VWLP2QCA6?2JULU%TB+'A_;GMG[+;D;-M"5H4S!H&/*9
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M- DE,1T$AP_F@M'5&@*94" W)F<=:(;L CA)R4T@F$\4[F%.)Z0<R7K-3"M
MBKU'7 VB,=9&B%#V?S[M=2>_#R,AQQ($C&LU*PD".P,U:"@H67_SU:ORAS?'
M]\9<)MLQ7R99H9+L*:8",6<+E1B!Q!KTI54*Q'&\WF#2"=P?#CV?B(<(E0S9
M1+X43?Y=+:8&1O'@HE(*1WP^Z0#B6_NW*:,:NO/H0;IOSVKY!I/F;F3KB-7
MU.W_]V=I3X0Z#8* C[E7_B G32- *0.I8JI1&,9+G0.(;U=#A3DBE5R])GW1
M(6<()M9",3KGT\V1>3OVYL-+OUI*PMCW TM?G52)SSFBBO[@D:*90H.._8!^
M]R6?:*" U2 /DA7]0C5Q/PP52ZJ"$L9;4Y\FXENIKT,$,0I6=DE4NGET6$4S
M=-5QJ)E[O 0Q[VW\O7.K"[IMEW)>+$Y.%I=<^>="7V9^O-I!$XF\F?B><C-@
M(@:KB1D)9</BN8908F.2>B#)Z"##ON0BJLFJ[SV+(/>C.91S<NO@/(4!>E/
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MZSD/FME/,= >"#LZPFYPV2!0;4B5<F#PI10B$VJQFDOT#B]VO(2]0N?.4E7
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MV3W]P7$F7KO900>QN7\P>,WDT>#-]V88'+P&%^O_6RJO6_YW_\AVEO_M>G_
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MCAEH-2![B4U C0Y!G8X1%;P]OV[2+L$D_YO/-)]J4 !SP"SPA#-C42L9.^9
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M'#-:ZN2##*!,J:X)\6"@]Q/]\%1 [[:N_8L7X6=!1I4(/YH(G^,A)HDC-F&
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MRDINGU5NS[?-I5/,Y;[I,F;S%J-$.DB"< ('4%&K% FS*+?/O9\[NQM^5Z)
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M^14IOX(+X/:CZ'-_O=:O"DN^^/.0]Z]"?B-4J79![R6,Y]D+W#E*B=!(XPB
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M2E8%*/N16%>+FV9"5&PO-+:99!RS0]:<&;!(G0E(10Y)$WKNL8H&BX;M"]'
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MF.J;ZD/.Q&0BB?I 0"8D+E%-E&;4"\=BPKBR*E27Z:\9H&;C2T #C]W$I=)
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M2B@P(OMFH_3*JF!=607EY83P4PA)%<+WAO!4?357/C 3"6<A9B]L.4%I))'
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MT<?5PFHP^E3!Z)0\AA0,LJB("<$28%X36ZIBN14)J1,VB::4G5W3%*@&H\L
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M,Z@,XW+''PV/.Z-O-]A:/HVTKDJWVSXWJS_7-CQ)'EP0@4K0'H3W:)D40"U
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M!>0JI2JE*J4JI2JE!R:E-KHVOM:/[-O$LSHZKDD\EQP=U#$<0+"(R6 1IXP
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M_CQ7:^F8QI8%%&DIP^L)TC(0)"A16"<?N159K:FYV*/V^L9%]97<6#<S->^
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M70Q:OG4:1>N>_?H,Y[)'?#0,YVZ#6UZ5*7:89]@;F':5O*Q%7E92NZQGE,@
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MGZD\(*?#<2\SDN>E<4GO0USDL63L7_KA=%G&BY]8!S=Q-KGZ)Q<CW<LGO4&
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M_#KL9PP;PS(U\,\Z/^2@ HI_;(Z"@\I[\N._.KW<&Z0?;3ZZ<WK\>=P#0C9
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M=$J*WK1A<N>TF)G%N5=>PI,?SY_CS=Z;A=U<,+M7$,C!_69>GQU$;W:?@?4
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MV]WE-SEH<+P(&\I[R9WL:UPREB]B ^@PK \;@0?Z]3GRKAC'KZ:W]Q;>S.$
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M2CEAK.?4LN!+*R5?GXMS137PN91Y,!G74<U>*63J_//3X>^O9=**@M$(2J$
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MMV<CS:XI5O?QW="_(VB>-2S>8/+A!I_A$=X)ALC1NT^9_=NC\46?Y,\TV.[
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MQ+)(&H1MHI)H+R,I$Z6"Z\(4EH&P971'F/L31LCAZ'_GOCF/U_0O/=??YQR
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M*AY<D8RC6)X'/TIZ63/27EC<IK!H0RU*J"2UMR3%,A))C2+8&9JH6- @))B
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M?]:?P%]X J\5%G!1G@HI--4Q.!Y+S04VFV1]2N(WTP@'3SH:(3*7N)2.!"]
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M*KRQ6F#CLFWC[Z_=M^S;E26/-N=L73$#KIK$:A+<P\P2O\&5N3>B_;8C)<]
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M(SN;5:5E*,%P?9;O1MS?ZKMY]$?CX7\1!1AD$L( S^+ 9I'3_&$PAK$-CF'
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M7G'[YR=SB<D[$Z)>SCO$+#OL;A<2V)S\IDIQMG)-F[3?&=8*!A[G0)ONR_M
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M#-#-IW.7+(^_$\0-D9PEL5L2MU92JVNZW]X-%-7@QMPW;<)NW-A6K;[7K?W
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M=:+3AZ#8+H*\NQ;D_9BS["$YWOC,)R5#84K06(TV=&H)B6C;4#EK*O< 9)[
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M!&=")IJS7!EP>Q+)4BT2SC-9T&/.'UUCK\\Q.#0Z(4-C8=5%W/V ;2/XDTO
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M;N2U]$PKA"JTI;8HB2K3BK!4I$2E145DFA0%8](:T-U/*1-]P?@&N9);M?0
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M8K!1I%2%A7]53&N:&J7S1T]%VN?E;=TJ-SHF/[!0!?^.@CP8S9V=TD& A</
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M?HXGU+3Q*4CY_"M=\_@GHI^;,#BLR5PHOY28XQ>TL;LWZ=B#)]?^N"+.[S^
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MEZCA3\'F=NOI9^&DWR]A%;B+L<3G>T37PNVSQJ1%T:'ZV8_LT\W1 C0 - <
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M0O4(P@+Q2"(V_/JSNK<FA!C$*&"G$D?6L'?O[M77NM;J-1A*J&4NRICNI5I
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MO[;WMS;>D_%OX%XGW^@7V=YHL=99B[:VNX>M[?;W]I\[/[X=[!_ ^.C.6?<
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M: )B$K/<3UDCY[%"W$B?, LV609XIYN*WOG<ZU'P[K'3-YYBJZ[[_SWIY#:
MOPQBK)H#LE\O-69>?:3WK9QR5V6*+>^8^SWW:HR#05FYJA_8H :M94!KFL)Q
MVM[XSMI[N]8I+'T@2#$*5(W)B!PU$HE@+2;PC^(R)W+<UWG]"IV[UWM[O+>#
MLD)2EW@TD6/#M5,\P$8/@DJL6"A[&X_W-KXN%"=U?L: SF*_5^_Y5=CS9W-[
M7E/I(IAA*/ D$)=.(".-19CRZ&')"2=^U/6=_G>%]OV(E8SO-9;VD;/]GH.O
MG_LU7@.%RP<[O:.8(U=[:7*LXVT_]P(?P+LSC9Q]P9=&Y\CGX)3PVPW<UK?7
M*$]YC7MR.%=*CJY1L>I"4 4;7>)BKI,I[I' +^%X^/OD^+@;LR*WW<VCZH<P
M0-#['_L]6*I<SWIPDNM:;QX-3OJYS?"7W+GY1[\SC/UQ!-E.M+7;XE[9P&R6
M%4TB.AP)TLH$Q#T8 )9$A@P'-D"2\8K0-V\IITU)[IS%7>=9K2XTW#/_KZ'A
MF4+#3(TZG$0(5B$L<XTZ+SVRT7M$*6>,.<PT#@ -U#2)N:]>/"ODN'PVY.<C
M<)[^B/I<R-!ZX0Z.7QZ7_ S@@>'5/:-96< :R^X9R\Y5S/4LD) ,1AI+BKC6
M ID@&0*,8H(G+GVN5<,7U+>[<!Q0>S=79?._5'93X\$#X<&4VV"P>:A0 GFM
M=$ZNB<@(YY%1G!(!8" -SO5W%7N!;7^JW6U6G-94:>D7'7IW\>[<(;CF6</?
MX_I]EC_AV1QY9*N/28UKR^#:;-0=-=Z38 G2G '/,=0C)VQ"4E!EC M1.ENY
M<PA]\ [1S]71\UI1XG%)4HT2CXP29S/UOA6+41$4(P\(% !')G&#7"(Y7S82
M+K/3E^&FJ8/55F8G?[2GA^6<$S99?=!9'W2^NH/.1W;V/:@NJ][^F+\Y/<NH
M5=I2*FWV'-,H9BRL#I*).\034&!KO$1<.*NHL[)4RP#2TA3Z8A.^FSOYZB/,
M%=[TJTY@ZTU_'YM^RF-)M#%B#=:N(0)QI2*R @>D:=0\1<PTCSEP63>5N=@S
M]TDV?7TX61]./F^^,CF=J"WPI9#K7)5$)W-!:PM"GKA&W&@ +>=S.Q\CJ23"
M8!7>O.6Z"4JL/I)\F5O^^;"5>LO?>LO/)(@Z1CQG&&D1 I 5CY'%G*'(@]:8
M*QD4?_-6L"9=<.;X)%O^%1XWYGWQ( >,S_3T8'4IS-@;"G#V5V\PB!G(\HLZ
M2.).B#5[F!BYC"$H@8)S"?'H.;).4D0"L2HEZ1SG^3#1-,6"&AY+FU<WWCO/
MR.'RFO'@<?E-C0</A <S#$8FPDQTR!'%$!<2(Q>50<0)D;CPP8B4CPUI$].+
M/7E6#P]>PZ'A5/QK[\M3A(8O;W9]++ZRS2/?CW80-V+U_QJUEDECV5X?3HJ1
MK>\:9ASCF<=8"SR&>8,T40HQ' /GU)GD9$YDN9C$4GM:7L3VO@<F4F_O%=O>
MIY/M[:F.*E&)F# ^QW(;9#6Q",A*D(1IQS!Y\Y;(%7&D7E+!@C]5!8L;T:RG
M+F^Q_"!?%KE;HN9N/ JWJ+8[>OHK.X#<R&9=.09\OPV%+LS!:FO)56O!5M>B
M?#"=N#E+>:T545BL$1CF-+<)X4@+2I!GR5M8UX 3Z$1.FUI=C(9Z@.9!C^W"
MNX8;US!8P^ E,(@9-=0+^(\G+H+5C'N-I4N):^(IKTJ0US"XPC X-0VH2,Q1
M%1#+I<>Y(&#Y,\^0$$EXZXB0EI=FE%P\2C/*>_5<WJ99VGFC@],UE0/(CGM5
M5<7?2@I!Y]\X;2?S/^=[_(P>"T]_8AV0\9/AY3^YV+UCMO49DX_0^6QQ6R F
MS[?QF?WSYHWE-)TTEMN?&'7'=B\B!Y;]=V03//)OMOO#G@[>_.=\LZ#.$9I;
MB<LF\7PO(*JN[$-7M[F[N-CFJ=K<;40W7+G>=;PUZ8:Y_J.U_9U\VU@G.[1U
M]NW@<Z>U_4FT#^%O&]UNBVZRUM=O!UL;GT[G&XRU-M9_;FW_\[VU\<_!SEG[
ML/WGYL_V1L;^G1];7V%L!_[G-[AO>^-#QN73]L:G74Z( [7*D%*1(QZ,1,8[
MAYC6*GI,),=VOGT=&" T4>^())03%C6.P2H?,6-.TR3F>Y*]ZX-9/&S\87U1
ML<W&[_;H>^.O'DA/LW0U_RM7D\TV<O7-6_2VNWY(YQ\!["KF/*6",,^UM)91
M0H!<B&B(<(&M3B.U<L7?.D.XG;_!MIJ;ZPM3]TCM_8[@SVHHHY%TXN!U;[7W
MNU@JASUU* I%$/>IN$4Y$DZRH+ /2>D7T\XO ,HVG.WF4BKC/GZ#^VKC=[$!
MV7-J["?AE[?LP'=EKSR]A@5]@,9^3-^L ]_2@V5U8[^;MK%KO/:F?AO1CR:#
ME,E8V,]O_@CGR8J0UT<XS^ (YY*PX]@_+-RTL7Z7P\@7ZH-\F2Y&#I0_61><
M%IXS8XQS6 1#I!4X&D5N=M)R>8>-;')N'@V TF4WXCO;[Y_")*X?P@0/5\6;
M>%M:7'D3#_[HM@YW1.OPVW[K<)/ .']\V]Z!<78[V1/8/O@$]P_=;]N?#^:]
MB:VO7TZ_'7P__7;X_G3GX,N/]L;OW?;!_O[6UP\'6]N;%/Y^T*;_=-M_MF=[
MY?S8)=AZYY5&6DB/N. 666(28M2S8+QF(C<T7+V.&8]T9%*CT2H]VQ)HI+GA
M5%$?))/<4ZN!*>.0DF":)B[PO?1<K2'I_B!I&I"=HB :*X<,=]G$=P8Y27/C
M+F<T)I(9ZZO\=W+W.DZKEUBVTNCR.?[;Z\* "KE[985ZE@G-9$H(;$FD,G%*
MJ4V:<L:3IUP(KN.]1)W4Z'-?Z#-;<H=%)A-E%FEC*>(DUYI40$E!FW@K9,#:
MY^H;&C=!VE:H/T!==^>^0R8PF#"@; P-J9QN**HIMH*KH"QSHF80*[:'9WI\
M*.:((PPQ1RWB4G)D<B,@0JE@B@L=J'CS5J[:%GX-GJ'/T78;[P=#.XS5X>4K
MR]]: H"\(,G%J(GP.5K+N>"I,#A(YYBSAM4D8I4 Z%QCCA! 622 '9UP A*!
M#3)2241%#-HR(ZP  %)-SB]FE#Y[GTJ]@\<[.%&C- M*!AUY%!Z4D(W$<$^C
MB2KHFD*LV Z>4@@316!$.11#KK=I(T8Z6(U\8"FH:&"'I[R#A;XS@ZA=$$NV
MQBW"7FV^V@UQ)8-@7N'H+==&<P<FC%;"2F,Y"R#&V%_.(&J(>1B(.5>(Q@8K
MA12(L!S&G>T5C;U'(DG"9<B." (0<V>&4#L95G>'1N=U# HVI[:< "\T1%+L
MC8N$2>K5S1A"?6CZ&#MWAAQ8GCBA FGC%>(\)V XKE' 6CC/&$DIW-NAZ>HY
M&)Y-F=ZJ^EV.HKR+E^&U-LYYE-39&J#N"Z!FHSI@=;S.B;+**K!> M@Q%N0*
M$<(,=ES)I'D^Q #[94%]F#NEB#UQPZQ[]$V\UGU/,>?6)9<24SSJ: 3\AQ6\
M2MYZ?4-.4N_[1]OW,ZT#P+@3CG'8]U*C;$0@*SA%P0E")9@9 9=&>:*I\#VG
MACYL"ZR5"4I>Z6N\A@.DO^)@\%MCTC&JUR]PUDMWIGG/$-27J19V>S8WE^3?
M.]K+X=T9P$>K4./U$GA]KF&"I(8PJB/B(AC$7<C]G8"Q$6^Y59%1:T+N[W27
MNJ/U =$*[\I'X5KUEKWSEIV)3K6*"X9]#DQUB&/ND:%2(LQB##H8[H0"TPHW
MM3:KL6M?PZ%0Q0J^@-QG0G 60R-UCNR1S^FQ=^ZO_L(QZ G\/#,+E:M(9*/O
M8S\>=DX.UX]"^>I@<)*SGM_EM6O'&J^6PJMSO=.3H3I$@Q0F"?% #7*&4)02
MQ8E$ZB3Q;][RIL!W*11<GS&M\ 9_ H=.O<$?>(-/"0FC,6$:.#*.*+ A&$.6
M*8JH\3CFPHA2R+S!Y0*/SU,VB[R;2^>F)L8-KO%P>>:/,<BZ@WCA?V#BH&'.
M.E_D!KIA$O_K+(QYJSE8;>6X:N1WU@!O]XY\;8,OG]]1J;MQ"<RH&;=1&B0U
ME6"*>XITD!3A(*,3@A-"<W5\39N:L'N*P%BI4L#7L-\[/<NKA[L7BG6/[FRL
ML>[V6#<M]ZNL==12A6)@8,$;E@\)"$>:!R*%\D:70UV&FY1<[+'Z %CW6,5^
M;U2Z[NFK]D48 .R.['.TG7[C7]L]B?E LG?2;W3/\=+&#YN+^N6_PY5"XV20
M_9-_Q7]CMT$;G:/CD^&@<=R'J_5AJ(U2MQB^-NS!/CX\MOU2G \^_!Z'^6L^
M#M8:ZZ4@X*3.6;7<XV)GI3#HN.K7Z*-1Z:]F*2+H1X$7HU'G\1WUAHW\./V.
M[<(@0B>E6,Y:4[]W./.(S09\.5^CD^N<P20T^O K&,U1>7=A+4-[?-SO_1S-
M5O7U$4# G>R_MM,MCP@//'.)M:>IO]FRPY-^J;FYE69!;3L/\367X6R=O=\-
M@FIG>,JM%_+I993(*9-S;5D*Q(=@G'^V93BGE35M/U:U-D] %G()SL/#3M5V
M<%R%<Z&8@[HL'Y[FYN*Y=4V^UEB*[_6IS(T>:J;NWX.,XH9S^RH+E6JZ9N0#
MU/[D:YK)NO;G%=4NJV#"124N7_11:-'[O\2?OGM2<"<#T1%\JW$(/]TO< 3*
M]V)AU%\;MR2)MVP#O7(3=UL;\@;/_V),R(>((IL2K<_Q>-3O>BM]['>.?.?8
M=C_'0YM;+?2WTA^=;$7N@%9]&?;DX2;=VG[/MC;>G[5I^[!U!N/,[6,.6[1]
MM@GC^/R]O?''X;>O'PXOM(\Y #MTV_/6=HOM4*!M&WMTZ\\/ASMG\/3PS.T_
M/V&X7W?G\%MJS9X'!QZ34LPC8L"DY(D!<_-@32;A8Y 8<^_PF[=W;QQ3M[N^
M5TBGKRRT=;4Q:?.H#;??_A&[_\964:LU("T#2+.Y2MR8X!4+2$F#$<="(<MQ
M 'M2.&6])LGF&%A=EWI\=-!AKRQJ;M5!)S.?[1^]&FN6P9K9XHZ8*^>DB\!V
M!$-<"H<<HPYADZ@542KE#$@^N2_V4Q.<&V,-KPG.ZF'-?C^N3*?.9X$VYZK
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M?W8.3PY_[_7[);STW6@W3YBI?&6BL@7CWU4I6B\(150PBD"O:F1#[I5AC6'
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M=T\R3@^.P2@,>30N#G_DFUVZNV 3 +6?;_1K>+#!),Q=Y$YCA[W@!!!9>IP
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M<R=<Y_#HER(?T^.A*PSM9T^"KS@ZO)0;CT3/]I_9.6)U<G@/AX.E^.!R3MX
M1H'27IC('9>6:*6C 39+A/9&8+W02*B=O'<$X^^BG7L2>,N!1B&I/09$3@1T
M=DP(^^@E35I*2[,[GUY,M/Z?+,#++32C%GMG%"8V<5A PZ/.U-]J';4ELE[H
M^U_H]@;<Y\>N\$Y8H$%(.)W/;6"UK24!,1FY)]19*G-MVK4%Z_P4YX( )$L>
M%#GOHJ2:!R>X-=R!'9G EE$J@4EI:"U:#R%:[W]F0J=Q#L7!B'&7$-=2($>I
M1H$*;(#4P8X'#,'WA"%>$*QD4"[&'-P7G0013DH33HU26M0+_2 +?=I>WQ6:
M,ZR81$S%D - /7)24I3K__"@J0\F967Q"!AR33GEYL5ZQ_FZEQQ9E&K*2U*6
M:%54Q ,!99PZ;4RV)\'&M,JGQ,WBI#A^$[MQ<S3J+'/KPX] 77OA_5%XS=*W
M25N?=H-QF!H9$$W9>$SP2M/<V5&0'&T$;*7T<UR3"\3O<D_]RIX&;L_8G+ W
M1O2[U!@_MJ<S%L7HQ"S&95TC2E/L@P B1CGWCNJ(:0S!@!A+1?%BW_R]9'B.
M1?W=I$SS'S'.M93'KT[*6SF^AH$QY%.DR)%<^(A;B4SR%$F"F=;*4E"H;]X*
MW,0+XBXJ]]E$,B;^D)%P/#6CNE8$ .QRRB1(]&M&NQ9I[>T:8V0BA"/#)6"<
MHO#*@C# !K5)1.\]49E4$;6BK*I>[!LN-C!H:5RD+G<*(2+DQ2;():]0R,FK
MTE,O\ZD+7F.+UGK$EZ9-&6:+WU_OL<J.T#W;#]V1K_-D "O2G$8)V>/C;L>7
M"V<8N5<.-ZOCBN,L:S:X2^7*&@P!SMSIHOS'RSUJRXD]CA)KRFD(FG-*F:$:
M$R$Q3+K&4=W"\U2+_8W$?N>T_6G7"RT YQ(*-HL])AHY#6@'-@7 6Q(&WZ?S
MR7MA _<\6>UX]-)HJYF2W!M' @V\7NN'6NLS8.\FTXD$E,:&'* 03$1&X)1;
MLG,).L<)QA_-_U1\39D='>U5<)-Y4X$; ,+J'4"BV0XWLS%EX[N,H@]SU-K\
M^?9Y:(/AE32U>0[OP<  0Z$_PKQQ+/S\:=.Y&+HJ*FXF\FM\<',9OJ\UGF$H
MY)7A1Z-I')R;J%'KI>YII;DNA891MWG;W2VR,&_6,\T"M59),(F4 ^V;VZ_Q
MD#Q307FRV*R?/RTN04N 07-!2Z6&VGEG4[L U5;Z_^+I'^.!?<[C&KQ>.RAG
MC.[M!@; 3()"1EF"> P:^*\RB!NA$DX^"6[>O!W^Z%TT@K['T\9DF:LM/V@V
MHBWAHUU_4O7J*B@"BU]*A)5W"I"<W[F'N;)#/O L![H67I8S_?._.X\N>3_F
MSEP@KKDW5XY27#:]Y0Y2>*FDO>O]&V%*AG^-!END;!2B\(J5T_9[ L(6DPP^
M >MFVBHPNA-!VBB/J*#1J<@DTS%G32VPM3+PY&R7K*-&2-RU(#3!EE"5(G6I
M=,,8JRP Y"M%K'-T4<0FGDS?6R1KA;O?1M ,-F#IF81-XH0YRZUG(A)#+-:>
MA(5MV):5N+$_\UUO5O*JIWS-DM?Z ;0H14NEC@P1%3'B)"2@P%@@881PC"0I
M4Y&\!13X%I)W@0A<&8^Q*@6/-L9A]2,5"33L76\P'"SW-"L777)-%:1^]+FR
M6H#]-GK\-'E\GQ]_67>O50&#^F"81@P(!YO9PD:GQCM,@B-V<8$#));R\A8(
M&.3L)A_+(LW:2.L592V>B78<OMI .!@_::WO"B)<+LN'9#)@_N8T7>,\0[!"
MV@;C6:+BS5NYP"2:A$O.-!X=)2;T3ZL,H9E$L+%I6I+H2H;1Q>RBB;3E8GVC
M=(W[$CRI@<0P%G@NLYVH HF3R@4:"=CC3-)Q"&8M> \O>%]8>WV7RNS.YP&1
M1')S!4^0H]XAKAG0 6&DR70'KUU6:/AFTG?)8>M:8^,RN<I-/*>"F*-! MAY
M/EM\X:02LY&BFW3#M>70:/SV>$"EMV>W8UUU_%%U[\TI9AE^40DLAA_VAYVS
MDIHT#B?-+"Q_\^1H].E5Z#OS\ OVVB1SZ B4Q5R)P[I0Y76%*O6S+E1Y;>')
MN4*5*;(0F-4*^!XG3CJ'@P :[D",88+\I:OVM/QEX3:X+,(B;^WIILJ60$58
MX>$O<6!-\6)]>.NNV3?8R27X8ZF,@MO50[Z%.IN84E^FC[$!C#Y#WD> J\[)
MX?I1N*#Y7K6&.U@_ X.>>I5\D/E0(:>B<!J0A6V%J&51RV@<#>'-6[Z 6IW7
M<%F^EI$-BCFW+KF4F,H^&R/@/ZS@5?+6:U5D Q/*2"T;3R$;N/5C%U,.*^ <
MPH%R$!"ID<64H@2<%*<<HNQDE@UYM6PT9_S_W2M2@9_2QWZIH7VA#W-!],\1
M6/_[*KDZ9WD^=PM[ZVBB'!I3O5"Q06\'^^7$H-_)!T= E6 5LRIZ7_HQPUOK
MH_H6ZQ_?Y1P;OU].F.RR431)*R4E* 0EN*'1YG*"H-8-<TH+&Q<CPKQGK8QE
M?9I(-#U8W$I_[X-R'90/0;N]8H_:P7L*T.^II<2;B(C2%(R;8) 1^0B!Z>0,
M&-F8Z2OZ'RQ<1.JEC\9@;6WBG!@K))6$.+!C=;Y?O8CWO8A<2N6]1"Y(#'8I
MM\A89U P0FBG'0:*O.PB:L*!%'CEJ#"<VJ!SB30IA:*$@,X6]2+>\R*"L6.Y
M2QB!+02*EGN&3+0"$2\,M<8S17RI%WQ!T5[_QO^<JTK4^O@1<+KU9^-COW><
M^TC$46;EM[_^*I'B-BOKD^[(4= 93 "]@G<+%.EP5 !ID@2:4X\'C?W8+16*
MKK[%ZNO"U1CBDIY_F/3G3T$^G "Q8&/V 8\T7V.LY+C;F0S2X7[C?3[)R65Y
MJJ(YY;U\_%PU72NU;;(LKY_LY>-#D:_.\#@IXBJ+^'C<.'(<Q5+NOJP-3,'.
MA=VM"!64@TIT5G(>N [88BSY0]@Y?U@_'R+^^@R83W3KTR[W+@J5.#+ 01"W
M0'.,Y0F!>M-:2).DU/G<X+(./V/C=B14_XYRG.;399:-%P]!^60$D**8N)'"
MY9H<%*0AMP8WGI3#9(P59FC\XH*B'<".!3FI,[26%XTOI<XZA3T7?$)*68DX
M41C!$F!$9> X5TJ17F3/OEA4G7,:15 E3X5X'(LON+S^.2GK4@5>!0MHV?B:
M2_+]/03L&C8^]$[Z^=QH5##H8Q^ M)'796U<86XS32[],U\GQRY,XI:;\Z!W
M:'-N>Q:)+(^V5%L8=H8GP_$5BMLW7P3P/6MLP-:U1@MD<A]&-NZ5.\:Y*?!5
M21*G#>M]_V0VN*+(?1[3*3S-L>WD\K2Y ESG_$DMQ3?*/G.V6\I!]$Z&);0P
MCW!9G,4JR12%BXQ&[A0U-'#&+,E9V\9X?"^^QMFVGJ\86_?.VNN[+'FL-6P;
M5AH5&**0SOO)&L6)-9&'0#.VDBMJDV05/Q_5D^>V,8Z :900F,8O(5<@J8ZZ
MCD#B,J^TH_HCO@=[!PA-Z6K@<JAH+O8 4IE=?=4Y6!>6#95V!_FX:Q34.I'E
M^!,V[R#^>M<0(0ZVKB!>&ZX=SUW95;1@026M)$^@X6^"ZM>&".5WKPP/>G5!
MD >E.H,+5CJ6:"[$I0'.0<D[)0P2#J"=, IJEEP2(%]%!S56AR8O2?W/FUK/
MWPJ89>J9BY]_OA=@$HC$")-2,:4%=T8[:P@#7064M)0 J$V"!P&*L_<<3 (M
M"0T !RB7O@.U904 A=;(2R,2& C8:GR3B(Y[-@E\%(DHSH1ACO-D8!0!*(VA
MS!IJ1H5],,X!C^,7M4EP?Z*QF9.L".AOEI.:\G[,QUT<.:X)TICZ%+'1*I1$
M4O8B38+S,/O"K --'0TF*"P8S^X7"\Q,X21MX+#CU25%*&KKX#9[Z0N%O20(
MV-?84I0\L8A+SI'1GB!OE)!<2\!@OQAF9_I1G5?\+\90H%X*Q;4.H/TYY4R#
M(#I*=%)$62GI3;"^-A26%TQ_!OK?DZ Q4[E@!(N@_Z5"AB9<Z@:$&%WT.8SL
M"D-A]0GVDO;#M[_^6OUGNM'1 55CL@[/] (,!9\\,Y9Y%4DNPZNU)=9%%XSA
M+'%=&PH/!!3??^1ZCTX 6S ,:6$ *)@,R"BL$(;9!\ @47#Q!(:"C=8!C_'"
MJ!Q)2:QAP8)-8PT/S% W]C)1A2X]I*\-A=N+1HZ+<]1H::)$!!0VXA;(C59"
M(.%U$H$%B95]N6<'Y1C_15D'2C#LG?<1T\2%T99&2IW5B9@ N\W5UL&]=<?>
M@.OL[7+,O9#4(ALYR74PP>9.8"Q@%W5R&NB98'D#70PLG5H'6<6_&), 9B.F
M'#87' ;SU%F3>\918221B3)U$U2O38+EI?'3&=BJV&DB,X@'*L$N2(0@T*@)
M43!=-9::X""7,PF>4UWW)2.?W_6*7%5"G4.?G_7#7Y=VO [ZK#O2-MMVKZ'G
MK0H_.QV+3(RY#FBE =JD4]"%R1QW"UH;W2W7PVG\L_E^KOS&Z6Q&ZO,6OQM4
M]IR;H]S;L/=C,)HA6(6JZ< M&N,P)0%*.5!Y(KE7TFD>DL ITN!]X.-T6WZ/
M^4FU?06HNY-3:X4-3EL541(YI[N*/E<>28N]M8ERGP.7R54NPDL-]DDN0V64
MT\LW7"-3LNFNVSQ'4F'W3:KE%8*:Z7#Y9*;&UF@SYG)74UH\(0@3?EQQ7+AK
M"_@V&3/87F[N=P0?%B9R;/N3!-WS1/I<FXRUS/#/ 0\,M)1TBL.JS66SZD19
M<@F/>HWX;T714\[LLR6XMVHA"H1YV"GYZ\-</+D_2LVLJ/RT,-"D]TF^1+7M
MX +K']\UQUU7X:^SCHZ9WH*C?AT7EFBX<&OGU6A.KS/8SX8/W!Y(R[ Q[N99
M<KC&<<<C&<@M:8955N0UTL"FTO 1[F:/,E0O$(4OQ[VCT:T'>7RCM,T%OVDV
M#L?6T+E%NR@$U?.X/!TA9I'H')4TZ@_VZ"07-ZOD@JTU_LBM0>;>!20;@C*:
MDVVVJ(#WN*O/T@$L47E'E0<VI$34SE-#M/7&)D,L*R24C6O<,(#HRTAH[5&X
M,1CF A<_=A/..<\>B"<V8!!)[9'!6",I#0U66:D=+1VD%S@4CDNG5EC1TFSF
MIY_IQ%0ZU121>+PX/ YB8TCN:<8YD]XQHC!U7N3><RJ(VI:^/]'Y<@:B0X&S
M2!HQBE[DR&9BLBWM$7=46,J8]ZD$-%R,PSOGIUQK;.6EGT#O"'0'5^)>40%V
M1,4F-20G.J%YP4!_EW,)_P#Z=I65?H[K@N++$)D5* C(%.A 8NW/G%D2(B#*
MN5:ZLP4K)EC__O?-[8WU23=.T-TGN>;OJ!-9F'01*Q8]:+N3_JC89<@=ESON
MI.K]5?Q5,QZ#/#4#V'JYGN53.0]NM^5NYC/("Y;7J_8;G-MY>[B]MRL"X\EY
MC1S'"O%@!=(D<)0T!_5.?>0FU'Z#D2GWOG1!RQ5@)QP[J_Z'+J5F;F1G5DBX
M$M-ZTTX7$[2U(QR-DPF^T,RE4V!\6(B^&S;"26EE5VKNY (_A;WFP,HPVP5\
M0?V0ZGSS%BU@[E8\\4(OF/-0-=L%9J,\6M4)YC63RN]\:WTW3[DB@$K!YZQN
MR0.R-#'$K+,:B*:/.=21KI%%1</S>B^IAISC4@0=<0+SP5%- !N%AG^%2\&8
MD0][M,JX7N6[K[)H?]I51N+(F$68<(.X]@$99RB8#C8D0E*2S)>*K&91O?!S
ME3FFT#RB)F-7P#E&5JI>'(X]"J/CE,R-1EVLYPA8Y76HZ@G5Y;V6+.]EGG5Y
MKV=:KJLHR<ZH%M"HAMVX8>QPOQ]C <?;J,XERT&F(#Q))ABM#"=&:V(M3XH%
M!\R3"C/2F^H2O;FD43W>_.^KO?]J[>K6]OI/&-]N<#IYPS32# O$8X)7G%@4
M836HEQHL*UV:-5[=HWV9!;\C4:H7_ X+[G=AOF,^>T<Y,1]QKCAR5CCD#/$R
M4*XHJWH+7;K@Y_5I<^GUC]%&HKFPGBJ>-#61FD03H*61'FS[20KA8@I5K_^M
MUQ_(U"XEC+AH,0K)2<09D\ABL.>)U%2X&#719<-?)%*WWO!WY,SU@M]VP4];
M&SN[(2D1&6$H\& !X6'#:\,2\CCEFI4PX0%G!\Z"]H$W+&WWW+TVN31TH?FC
M4J/%ZT#^V_@\JF7ZT?:'I\_XJ2_)J/WXKO%[+GZ7';)7QKBL;%N@K:-Y.DH*
M'1W7SK_PB#-=@\J)ZL?^V&@K82N_Y!^-7.E7_';B7\].(CLJ4SOL9<@"^V0P
M/AZN@E&K>K=+QFQ8ZAD'&D:U3)Q3[>"&G@4OP;IPP4YJ\Y,K^P[=I@7KJ 7,
M[R7:I'.T]\X>PR?#T]<,H[BUO;,+?#@:*00R(2?2!)X0D%6&M%."TB!SKD(N
M$WI5)8CM7&IL(B7II)\#&!K=SF%G.*HV=GS2!XM^$CN0C7,'GQ4AK'HW7B73
M,\W)JB/.='G3Q-$I4IC45C_.L1[#TL"H,^HZ-HB^"C*8+:Z6#_?A*MG=:DM)
MS,9>/@BK3HKRZ. [R?[;*YW(VJW6:-P6MNKH:M,!AW'K)?BV=;V3F<K.#4+&
M6[D:1L[>_/ANXA'N.0"@D4\&GGMRH]%SS71(ACG-\Y&G9PH+@#VVZ@  E^__
MV_'Y(&QN7%4CE9)T V,AQIAR#CC:\?DL<2;(X[R_VO5RY[C#\B2#<9B[W[>=
M?+Y81OCN_5;^\7D$NJ)RW#.J&_OW2.;^FLI<!3(K^7#7*,GU]7=;#1!]"_(V
MV"^11XT.+-B_O:H)ZOD--M.4=(&"F4E[L"D!WA8Q*U_LW5"6FM491]X-RR@4
M;K#F6GNNO.$4.+<%LU]*+53*"4#Q?@(6:GUR$WT"XSC;W.68!*%L0A%KG2,#
M?2[1$!!82)$9:X/)E84(7]/7I%Z-G78N'L74*:%U[UI_E^8NHY2^:<;>S007
M,"[7\8^EP#%\HUSN^LB:?FS\R'\LXPIBG D5DR48\T"MXS@F183#AALO+LE8
MOV%_Q8E85C TELRM:=S/.$;UE0G@YFGK;&?7>#"YE=.(24$19S$AJX4$0A,)
MB4:I&-R;MT<+&BK.1DXM:,8\ZG0R;B6T;Y?S%L#*IP1#LUYP;CAV3'C8#HR#
M9#A&[BFV:@%4?1XW?*G!:@:LSD!>=H/#/JCL/E \9O+K@?S:@%2RF'A'%)8Y
M<D\L<"+,-5"8="6_M!/YI-''<V0+[\Y1A<OA=G U49B=G2OX?H9^.PIZ6/+4
MQ<<HJ)/:2.,Y86#%.&IIU#8':5(5:D+PB'L,QN9S<3?OL#"(L!P=2[)/'A.*
MA&;4^*1+*;TK'?.+J("/_1*5N!]M%\3LN OB7?6WNEP@2W.>D]R*>MB!-0'S
M9Q)VGF4UFVG%!IK*X+1)W$@$VR>'L(7\W$F?ICEW&(/8:6XU=TZDZ&7 7K"@
MHUQX\#.OY\-)_S(]OT#:WO\\[E0G]^- BE<F6UG7^UVMLX]"&R2L /R&O8^,
M8!0Y0075P24P!MZ\!1L$G4;;'PO8:!'?9M< S-V@D7+ ?I6W$0=Y\?/:@XI/
M)SF2-,=3C":[&-!-P)\2[5FRJCO34-+.495[/4K#L.'?L;>B*KA^[BHY5G0X
M:G->B.HX[+_*3<D6U'/4%-WC_1PHG&?M>2@,"KO4$TYS!5H>I7=!DV2M#(E1
M+(*_&56O-<;]: S1.OBTRUE*U$2.O,4.-(9/R#&=\D&/P@*05>$2%'71@GPN
M&L,)QX474490%\03JP0SE%'*!<52\%IC/(3&:&]LYEP=8PE3*#*7.Z:5ZA^:
M(4:(34H)'*E[,1IC<8Q>67>E,->":POPQZ6+UA)L.? 8+ 2SBNSFT_+K%<]Q
M%OBC/=2-"52 'JNB4? =RN\\N"9:[*PE>#(93Z$(*_/PXI^/,Z;%4W(5(AEM
M76*."4<B5T(9H502A@"AI9R/T@?G$>D\ZOP][/GO^[TN*.S!^_\] <QI]X8Q
M-^OK]@:P*[;A9K]WX3M/##U;[\;0\\]^ZVSSY[?M';A7Z'X[^"1:VY_WOWW]
MT&V?M3L[]#W>^;IY^FWC_<]YZ&E_?7_6.OBCVS[8(VWZSR' SL_VGW]T=PZ_
ML!;]<+ #U]DY^/"]M?U':AVLT]:G7<8HT5$$!.:!1MPHB0SGN2NVMH(39Q5V
M\RU3K16.PK]2!<4Q9X8+PUWF*-)+@M,;8%G>'N<#^?Y)?/.V%<_.;(EMS-ZJ
MV049>=T;U<+,X]IYV%@8#GK]4,X/G24/'-PIZ54$7+$F^T =)<D;P[15"X-6
MG\,IT&2.GR$['XS:1X=X>%R6-D5;%-:X-RUP[$'I[M7X91!C(V_@!OUU7(=J
MU#TP4Y]I;/FPWRNDNZ03%K551&ST5B/T8O7CG(L/CYY/&H\GZ8BC[V9IW;<Y
M33 >-7S7#@:5FLQ5?WI'HYMTJ[(_TQ/;JJ55XW B])GTP9/U^CGQNKKTVKG#
MU=&S%7=^'E.>B7A85=8J2=_5*4'^Z+C?<\5>F6C=\8][)[E55I7T?^X"5YTD
M7-'"=S7-O*7/1B_'FE4/,+INSUQU/G2II5E)R_P9P&VT[/)69TD)+2N2F^+&
M,)MR4S7O:\7^7LX!6I$<T,=6R6VP)G8)F/O1F82THQ1QYT A8V*0U@YT%HN.
MF)1/*DE3L@6F9A9V9_WW,2[LVW\K4"D@UBD3GR,XQG9G7C<@[3F@H_QBM%D:
M/_9[%2!=^&2$.\-<(S#;I$"C,@2.L)IBHAK5.A;L@?=.JT'DTGQPX\&).^P4
M( .\!=B>%AF9,72'?=@;.3ZF*I2R?@PXVVN5$DD I\7WT@.4\S'G)L(M.OU\
MP9R<:&=SI:>_@[L<]O(N!>DKH/?#]G,<S6"4')X!N@H_G+IVRJ,<ED>9!JNL
M-3[&ZBQN<.+WJS$<#YO5WRZ;S/+\1<?E+3PS]N;$8)_)03__..5")>.I9(@?
M@9D'"N5\!OFH9@U<%":GLLJJ"HM%\8V3.(]FJCC,+%/E;3B7CC4MTS*3F%4]
M1#]6"5OY<4<BEH7@W/0.9L\LFXV]?.^1BB^S-1[$]"Q\=KT[5;8^/&L))XK]
M='+DA[W^Z86S3OAF-^X5!\@H/JF2[2+E^9N#B7KLE.H#1[&"PS)?\].P$J"_
MI'XKVFH[![B=P/P4;%U)M7WM.5[O1R[4L)S:PBY*+JWQA#,N4JZJB56R )*)
M@0*[I#W7LC[2\>R6R7U7Y/SOT6A>J9IJ;6^*K?7=A$,08".BR'*I IXB,BPY
MY!(VF$I/<"S%MIJ&BJ;""U*:KLP'7KCDW$8<DF?.,\J)]$Y&SY5)5MH8*;^D
M>G6]Y'=?\E9N<*@<!6X88PY'<(A[6&TCN4>6&^N]%\9%#4M.FXRR)I$76V#.
MJ(R);IZ801>4R&W,EOETJ2H$,*O0L:H8<:!\B=G0&M"EN=)1E6U<'*F7J+?9
M'RW*95ZD/ L5FM69>4!C79I9TAC"1Q\7I[WW.5XJWV84ISPH868MVX?K3"LL
M3;5A>:[E-E2T"7MFO3%*<Z*X,X3!]O5,"B/$J,$<P6Q,_=GM=M;UU/_KB(^]
M_QG[OC.8:>#]^O;:%]'>V(1K[U$81PF'APU"%<XA0%&"41 ]1A;V&HK2!4)E
M4B0W\V:\2<0"F^ 20<[$NO)5S#;H+E$UU2*,*GH &QVSY1MY\I?E&]?8W'76
M/@R2XV>=M?]BW:X;8Z/L^='NC6G)GJH"P9*%!S)0S)0N*X;I<D$.P= @%+$^
M<9 *J;467!!OE)1,"Z'OMQ;!9*E6)I+A\36+9[E=D16@W#%%D2@/+,X%I&UP
MN4JN"$S[3.[*2>6UX:7+IJ(+&7# 3@A.N;/!AF@B8 !W-)#DR/VFHM?K#>O-
MVWN[/EJA.%7(4L(1U]$CG1)'SEALE3-!ALS:S8(D]'/K/5_99^-N-;_NCA^6
MN*!$2L(">>42.Z^5 0Q)+'@1R>)XE5J>[B!/>[2]ONLL=PSF' 'I-&#X&XL,
M%PDI23@73/.40)[H(GFZ=5&#I 0P"(VMC&!P&FZEEYSYK#!8 *OD?HL:U$L-
M2\U:GW9=4BI0&E#T/L!2XX"<]!XQ+4.T)B1+<AJN65M0CO*&Y0Q>/$]ZM_'W
M.\"X4)W?VM,2D37!O#O#:+G\'7$4K'K%!0?8S"F+3!-E5.!&$<F28[C&T7L/
MO3D#O4R<<RDIAQB.$O%<)413)1 #%:U-DKF59RX5<OG>6AI&G8G26VT]BY1[
M0HVC-,ID'! _1X6O8?3>5SHW=Q,8>[!S@'R9H(%Q@\:T+FF4F,.:JVSPD*M[
M4UV)H@O=,%?[5FX6;6GX#:(M;^;%6?RC1P^_)&N7AD ^;!CB-.!P*V6/;3P:
ME+4:5;UYERL"%D_H[SD/^..HN\.*!">*]F3?^)_?OK9!MM_3UO8.:9]].ONV
M_4GLT"]G;;AV:^/[60ONU?K:/KBP;\Y@C]!//^%W/]L'7UA[H]UM;W0/OFVW
MX#KO?VQMM\ZV-M9_[M!VWC>\M;=K24J628- -G._3$>19APC:T,"GLDM)WP^
MP@^0TUGB09!-X(HDXW4$$],"P#EE99@/3BQ>:51FO3&[,+<(1KS^UN>'RCV5
M"FPR^'_DE KXBC:@<G./4&#5^.%C8_U^#"==$,GWA\?=WFF,?U?5.::2.#LE
MZUT0Q?)J*WV.OK=W!%LO5%[\(L"O6%Q9^\>N] $$0$9$!,LM"&T"MHPELB)0
MR4$PE([SXO<L*' .$$GYN.Y'8:I5PM3)(8P7+E)%;Y8C!>3*-O(S,C,I^]N?
M",RX1$U5V691#8[J?*+DPMQ3E=2J2LV@YV>*@,P7[\GA-[#+2GC+)9$M<)5_
MX5NC>*?1>6")61W,'C5.JA9WCAI[\2CVQ[U+PV'G*$?NE(.+\=0,QL>(^<2O
M3$2^_LWJ(_]2?MH[@=4-@U]_6RZJ\>W_,UK*\7E)CJQ"(%1=>SR(OXU?_#=T
M!K 6I[]UCHIHE!_]]_S10#Y$R+T]<C[22&2+]%8?3\\7UG!UQC#LPW]A?.?1
MQVOEH_\,P\7/N%[#E%[Z,5XCEWYVU66!#Q!]^<=77?;JST [U8-]7H.5-[KL
M?XKD5M(+&R3OJ/_W#7LSV4/6?]_K]P#AT B<4_EGG)+T&VZ0PG['-YI<P]S\
M&O3X9[[*?R^>5LYMP6KW/3[7QI72R(#=JG#Z?<;I@D+3DF, TQ-(FI^-59W1
MPTX(W?A$,]K.BF^)"7TP6;W!-4;*I'"9XY*CT0F-/$7/;,XSC[B+E%X_#_4L
MEUG&#XH%KVLN:XE]?(E=&FR]C_%J%933EY](I5^P _$DG6IL\,S+V'4/>K.5
MQXWG,!'_YX$>?O:A2Z[(2CWU,O5+I&38)ZD"R:XLXASA-AE#N;2.D'A=: ^;
M=U6-?$\Q+'9-S9>?9\_3 [6_<_BSNW6PO]_::,'G_WS_EHM(''S^OI.OO_U/
M=VMC\W2';O[X=O#]M$4_=,:_@7N=?*-?9!Y;ZZQ%VE\_?V]_;7?:?W[NP+/\
M;'_]PEL''^!:OQ]N;6^>[1Q^2*T._OG7]OMAZV_\8S=R[T4, 46).>*!<N2P
M48BX1'*%,HDM??-6+@CCGVMT=Z\;(G^TY,982BG-8?"\8JLAK8:TF48J06!!
M+?54<BNTE3@1C;E.(2CK_'71:S6D/0JDG4T@31/E60@..4(5XDXG9)3+.;4"
M:VR-DB+E.*7+2O[6D%9#VLN&-"*BQI@[H&6)N^",,<[J("P5W#!W;> /6RH<
MI,:[A\ [,J5P4BH")!M)GP#OL,/(P/HB90R).4N61O;F+6DJ<S$QKT:\&O%>
M ^(%2CG\ZXBRDBO@;6"9!B=H8%['*,)U 7 UXCT]XK$)XGFG?&(N(4]8+LDI
M,' ]3U&@6CD7A<>B(!Y5EZ6RK!;BW?7 YCE U.>9*(LJJ.*'[8<+WL3)X]/E
M'G\A3C]KR#(N=^P-*A$9>++.6F:(]2'@(!QCI':EK0 JG<ZXTD+0Q.'$D(S,
M RJY@*Q(/.=NLY18D$Z)-V\UN;/=N7CW/RC7NNEY6[UK\R[EP5DF2*Z. 1(@
MC".<2>J3YJGV%JW$KIUZBSAP0"VP0C8YV+4)1V2H@:VK,8LD-\N6^,U;)N[,
M).I=N[J[UF6#0!EB4F!<,^(H\]@SHR@ NDFJ=HBL_I:>.D2,)TI)P?-N]J,*
M591(Y'-//D$D=P[, ]H4M%;%+WA3*QHYLX;#GE8<:VVUUD;D"F*8)\9T;?.O
M_J:>VOP:1YN"9RB1!#:_H 2YI"SR.A@)"RH$-L7FUZNTJ:^Q[,<1]C#8>#4.
MU-\\_\W7$':U73H(E9R4*S)L;NG*&B5P,!#LT#O)Z2#%G55[Q>\Z-2]&?QJ*
MN8V>:VXTCX$:)Q4G1@H5!6/\)K%<M?Y\2OW9_GO&.Y733%E( B465*[AB9%F
M5J&4F(H8S)S$2=:?G-ZSS_Q.N^EYG"'66%ICZ36=X4F,/*3HE2(\]X3UC@7G
M8^ V2:II[19<";B<N@7!0!0,6XM(2!1Q;0@RC 5DE<*>1N&)RW&Q_)Z#R&JP
MK,'RU8/E'?O2U,1S!9!TZHW5+$3B24)"4Y?+73'D<# E=H-HQK1S^,U;WF3T
MGG,,:BRML?358VE05DCJ$H\F<FRX=HH' -8@J,2*U8%OSP!+9P+?(N9*.HF$
M\1;E-N%(IR@1]5)+R[7TSI:3K07M )X?EA8?[W]*V9G9DG>SQ;D65U$2JU1$
MZ<O13 FD2THD=<<MK(877+['HY)PY_J/7-DEI5FZ1BY3'I(!X<*"IV@LY\GF
MP'%/"/?$<I;+M"_NJ+1D5<@;E1IK]XYRH:48UDMT8/& SWZ>RXVU>\.=.)P6
M(IM>J?K1UG _]K?W[=%6E;"\*E4H'[T\67M[$^^JR(W!22/F1 !#-O?NX6#2
M.A:(H5A3IH%^J;4%37M&-2A7LW9ON>+-&S9LS26OCZOY/4J5O<6R7K+J1^-:
MSQ4^.\/3[0QVK[F<WM;Z+G4R:FD2BI)*D-A<?!KP";&()0L 2<:Y9UM.;[[D
MW2RJGZLK5S5#S% XKI8WJ<1WL=S;8AWXYCD5>I-K6K#G4XY,L-M=M1[L$PW6
M$'4?A=Z6J(5SVU"#J_I2/7[5FZJ?=JF+.5=]^OHG?UV3]+7\)8:;-)1]TH&N
MPZ3:O;CRXQSW!&Q\!'H6:^FKI>\QQ_DY'MK.$4C'RH_T'7PC&VTGMKOR8]V.
M_<.5'^0O.]'V![_6B'/U1M[;Z\?<?'WEUW,3]D<'K"F_\B/]QW9/5G\^SU<?
M7[!-7GAT[JQ'Z;Q?=MCX8(].;/^T<LE6S:DO+\MY58[&=9GG-SK.>T9G5PO[
M5%/,N77)Y2A%'G4T O[#*N8&&]9K=3^-WR]I>Y%['^^5\ON_GU[HT5)\S2,9
MV)J*0/LD.^17I8GU74^X#G:VX?H;[?WV@>=;&Y\[6W]^Z+3.X/L'K=/6P?N?
M[8,6:6_LL8LG7/";[4\8QD';9WN\_><FWSG</&N?O3]MG6V>EG' V+<V0FK-
MAJFFR#A6U")A641<)()RWT'$B S*4^ME$F_>*BJ:>D&?^7LN[O \@P)N"16K
M!+#W7-3F!1WO?XS] D7W@I/T 8%P;(^.S+VQ+5],^1H>EX/':5BJ"9%;$RU2
M*?=PQB$BQSE!7$D9J'<T1/SF+6%K]&+WP)<-CLM<XU;%R%<6)Q:>7Q+G-8O,
M>>LDU\9:+%4(,E>]HC9Y.A?W4R'##&6",?G?PDG_%"SAA2CAKD<)MS1*3'PN
M,RZ-[#&@-4[<!">F09=,>9!^PA"3$7 BR( ,!=@PS%'X!Y8[DC=OV9H2E_:[
MJXE+35P>+B[Q=H1ER7#$>Z0S$Q=2\="\E C&QP*F:01CCD<-/@&!$=X!@1$"
M&6T),MXF'#G5BGH IB8(V',A,(]=O6_2WN^I/%Y[L'\NG#2]]OHC"]U7=\QD
M>6P_UI]Y80>;1U5KU]I*6P;DSC?5<)K1P)#T4B&N!04KC0CDF#1,4 "]7)^4
M\B9G:H6*E=05B![(.W-'&%C>33-8:J/7KIK[ X&IJP;K9*72"@F9#.*.!:1-
M)$AB&Z2)&H0@MZ%@:_3.?NP: QX9 TKX+OUOO4SU,MVO:7#'<_ G-PWB2'?<
MQ3A8, ?/1-Y^66WK(*<7; X&)S%LG/1A:BOM7\7VSB:CC E ;0$LI?QG:X$S
M+;AUGJ,0B$4<*X.,U0XIPJ0GVH=HZ)NW'#?Q C_'K\NZ.%;Q&.9E[O"70/['
MV[OF_P\  5/^;ZGEPDB"8C0!<6HI\/_$$4D,D, +S$A\\U:LW5N]M1H%5IM7
MULNT0F#]I"6'[NJGO8#@)4^^/J*Z"W!/CZAD9,;0E%#4"N<B&P9I2@U**G)-
M&5 X0G.1#7UO1U3U*=0M3$W8;REV7NLYU(J;FG<$N#^JM3WIQ_HTZC9XUGXW
M8XLZ12R.F"/&,4/<4X$,O(<P#I+":EOCW9NWIJFIO(,I6CLW5XC=/!=3=,$^
MKXW1^\. F2Y7/D498T")$HTXF)[(4J^0CY8'3+1G4>9X0&WJLZAGA@-/?LA1
M+].S6*:1@3"^UWAPO*H3M$)!^+-Q>7>Y03W(YSW(U] 5^9(DXDEEQ\:XJ&/=
M)_D*Z_9V]2OK+.%G16<[YXY7/>?<2P36#$4@0D!G@Q(HZ,@#$8$SI=^\51@W
MN;IS(MSJ4:4[;_B5P\&;I\PL>L1GBF67&^JW [0ZG?=YX-C4+">:)1L2"+?E
M$7$N'3+><:0C\X!BEBG%WKPE?.U%-XV_&Z=;V0U_?W6%Z[S<Y[WAIWFYR0$I
MD8F X,F$N- ,.99KG"AA==+24!ZR'VZZW^^4EUOSB%?"(^ZGH'^=7?LLX87-
M5$_2V@:LD,4B-_G$0"4$MH@1P6B*E+$,+X+=1^S"ZW!-SG4\65&/VK,<Y3,8
M8NV;G.9TE$X"]^Z;O+*_T'R&?NV\?#+GY?NI$-3.RZ65]-9L/ [U@7-A#*)$
MY_XFR8.]3QE2(I<XY-%PS[*2YDW)[LOL7VJ;K;AW\^Z0L7)0N[39LMP</%.X
M7'G_Z#]5J[*CD!L;>GBYW<MOU6[3!T'0J=M4$!>DI!X13CGBA!!D%*>(!\]P
M2IZ2G%UGUA1YA?"YS#66?:YG 23/SN]Z"8S,4*X;NF-)#20W 9*I.]91K0TF
M'M8<!\2Q"<A(S%%@08HHO0_6O'E+9TIT/*4[MB8^KX?X/)E#]PXX-@-8YQVZ
MI/;H+H=04X^N8500KQ,RFA'$$\'(N620Q]%:$3EGT;YYRTG3W)M']U'(SLOH
M[5S5T2C=.4$=Q\8A_&)_T(A'(8;+VS./.WS^B/TXK9B2=VICM;.Z7ET!D=NW
M7CYHL;L5 :F:@ _&S5_G^\;ZWB$(6Z.TC&TVX(LGW6$6Q<Y1X[C?\S&&\M-E
MNH!+8QAPGA"P9;F H>92>ZF# (H4N.+7Y4 OUP[\$F$J^N)J67IM;;Q;V^MB
M:_M+_N[IUC9<<WV7&R>,<0$I&1CB3DEDN2I5)EGT3DLEV9NW>(U>HA+&G;T;
MMP P?(\ EJL!2^H2CR8"^^;:*1X S8*@$BL6YJK4UP#V> !VMLEW*4\<)^P1
M9A$C3C!#%FN,?$J*1I\,C_[-6U"%#XA@]AC^]A-6<QB[ITOA6>04AAQYQ#[P
MX+UU)FI%#(/7CCAVC7#5>/9 H@7_Y[N6>"P4F-HF&H,X\%AD,-.Y1*:.+FH>
M8T$P=E&LQN!UDR[HJ]4 _MX=5',BZ/=C..G&K;38:STKAEDN*_,.1/:P>F\[
ML_%M&-'O7?CB*Y/*UL$Z:Z_O8A.2L5*@)!QH5FH2 B9DD?",T>2$"')T&-$Y
M@JV^GL$A>><9C0867?+HO"8L,(":I'6DD?$WC0A;_1A6:M@_B;>U&F8P=%R!
M?4EM2V(>EX4Q8<H-L]9A:30F@7D+]Z(K5@3B?)'B/_N]P>#5JN.MC9VS7<DX
MCB""B!$,ZI@S@311'#$=O=%:F9";NEQ25KQ2M%/JUAGN-VSCWS@H2O>XS''6
MMU=A% 5^22(AH%<%CY1H&Z5D4070L%@3<E,G^H]>/PSBT;T)3/GCG^I1*FEY
MII[PV\O']CK9M4)I)_]_]KZTJ8TD:_>O*!QW(F8B2";WQ?U>1]#&]M"W)=IN
MNCWPA<@5!$+BU6(,O_Z>K-(&2(! @(#J:&.CI2HK\YPGGW/R+(0CXG5 /"B-
M3+(184T3!M5GA -=ZY]U:OD4HW?5X5+K=VH^=OL6&-C&::?5ZM0!8H#>^T&_
M"8(RE)GVF/$#3VOZ>*N9.><,-U'NHH2A)8MY2!)D"[M$77"6&^Y,E>.R(I*U
M2_>3M"%:YE#D(L*NZ!,RU$?D?0H@8<$H0^;5,E^KG1TV_6%I+':C[QRT@3*%
M'$J6;+-;^Y$9\EK-]F"5^[%[ CMBJ UZHQWRUY;UQPBH3:>5;8EBT0K!RQ\X
MZ838 I$,Q4=3EMFS(H5V0FK>SSVY&3L=A[MY(3B7B.20O'&ZKK+;\;33:^;/
MO._&ELTJ\<M9,_0/1][\J2\.?:=X\A7K>IW6H#__*]=Z.Y>TM0FDH-U_SV1Q
M4O0<I)63*S,V]?-P'+-["@J#7#?:8V03C/Z];9W9\]Z[?U]FYD#+KTSJO/D8
MDOCA3%(U?OX/_^.Z_[ZZBL7/*TM9ZBGW5"I*./P-!B$55@9M)$M8,,.-Q5?)
M7- D4G@_2,JX)=FW@I632E'GN%!RYBB'CNEW<\9P*T'\\#^%)WPB/H4''E:X
M94][\?WH'[^$9N^T9<_?-]O%.A5?^N7R3.4YO>)Y+P2I?'LRW>NXG/)A$.OP
MSL.WUXNWKAP8E.]ILDZQF?LV7B=SW[OILD2N@[%SI\O>$GN[8(CM23.$5GQT
MW9K=2'V!6-H[/> 0.9[GD'/V(WX:\X=+CW;?ROB+=/-:_5J&HX"/6M[X;JEC
M6/4UO;<-^]AQ/)^!QQ2.OBEGRCB6Y\7'Y1R(QL7A4>-BZ^?>YN'Q[L77?$K=
MW-X\!N[X=Q/N]1/>$WM'QQ?73KTWC]GVESJK'WT^WO[R[:B1GY%N\6VX?^/[
M%CP7C.^H=;*]T[C2!5[#:AH+?%-E[Z!A!EG8+I&)"EOKP=HU1?O2:]U+1Y;-
M0Y#F@:D:SP\F/SJ9GK::_?,W61IUKBW:'B8N+-,IQI=FC]X$(G^/5_2;[4]L
M4?2R\Z^?"%BF"\<D)TE,)J&($P%@40)IAQ/R25DIA11%4R[@N&1%\B.?0X'^
ML12F]N+P\UNS=XQ2-\9:,[/HV.O7NJ!M;[*3T2O"T+RLGV%5MX:+6B'HP@@Z
MW=D(\R282QZ1:"GB5A*D;3 H:NT$HX9[K_/!+7EP)=GE%,=_@0#Z4@EHW7:/
M8[]TZ.93@>D(C]DH6A4@>2WQZDL]Y"E.FF=L":_B).9)H?M2(P"J%%&>!Q2M
MX8@K;9"3-")"#2;,1:]R6VI"U_7U1@#/7ASD]?//C79[8%LUN'\SQ':HG3=C
MZVWVT7Q2]GDMK"4U?\: +F*W\R2V_>9PO2M>NC"X3;L,,0["ZL"0\YF7.J.1
M]=(B$4$LI"4IYN"8817VBIJ^,6HZ:33R4)N^\HLN"U7AQ^%R(76RRA68+@RF
MTVY2HA/0=D*0X$$ F#*+M"$,28R] WD(R:2E@>FK<I2.4QJOQ17=%*;^U$F-
MQ17?-_MP.W^',_QOL=<'TRN?+14QY+5" WLO+P!_YVH,=2\GGHR>K8R0M<6S
MY6#(3DI@;W9[18!9/#EM=<YC#H,LPMEL3GVRW1RL5IP'U[*G(W9_Y(A(6/A0
MA'WUUFOYEL6M:@$P:2KD;907,V\ 31C#H<U?F\J9:76*P+B3TM,RCK^\+;_F
M7HE><V+.YT]8%B>XQV)!Z3J(Y&%C80QC'AVV!F,MJ#/21)("7I6@]$__.VCV
MS[?:\/"#HK79-DQ.=^?0MF>&J[]T+\4#LA6_XL;7?:#>5N2\=19S81X?)-)>
M111<% Q8A _4O/M A%FC<E:P>IDZ-HQ2/QL&YM9L&9D[7Z'N$XC\0 E<7D3R
M@B)V)5RY>',3IF3,C-ZP#/YUUMC8CXX'*35&BD:;RT1II+7'"-:5:L6)9"(W
M\M6SHI;O ]QGMK=0@J)FB1@M#.$)<R-CK@ .LD@2=Y(2P^84]5@P+_&^04VW
M2N/&P4$W'L#<7"[V,150_V93'$$ :?U@7P1G7"[MR),GB%OCD!:$(EATSB..
MD>1X8KX^KT7-,-.QX!]G\.^:NQ1!G]\!T>O:C ,HLYU,18 W=  1"A$MM^8A
M)9B5[#--PG)H'&K^1(?-$&+[_1M:K%V\O;%/M75@UWJD+#6YE%Q E@L..Y:T
M1K 4M'3O/G3:(^=!9H@W12HJX8A77&BG)8_&&4VLH,JY9#41.E7)4L^:ZOEU
M'\.N'T@@B!F.$<>!(1.<1IX[KIQA'!C NP_]PQP1,C-A:KVVDA;0@L;==]LM
M:,7E9WFR3.6\<QYV6@'LK'+':73Z<32F[>ZW/-+>FTY*/MBGR81 :418Y8,[
MD2-A)0\(^YA@9TG,)GHUR7A5I/&N]OC8;IUNA7@VE(,L@+"Q9:HU)%_C7*_W
M=]'!,C?GQ>38<+XNY?RW[YUC0]8EN5_JSLWO@457#?;E#):N*\.6F6IUAQ*T
M#S@QFILA^5Q)6X5OXL[9.F]SDD;.B;GHO"H#'7I/5GZ<HVST6A$$54E?)7U/
M.<YQQ>F5'^E42>R5'^O.M:S/%1SD/W>S[?NO"G%N5N21,W3EUW/LK5WYD1;N
MY)4?Y3^;;;!(.P.X1IBI)D\=P/H<AOS(87/)>K?]VF^V/;#=\]*=31[0+FS1
M]/^7'I,U\ZR<8LZM2RXEIGC4T0CX@Q7\*WGKM2H.C#"AC#SDB/QCR_9ZVVFX
MI$,7W*Q3G1=ZK%B&59W\=K)[\M<Y_/G9^+('8X(Q?F\TZSN?3W;I;T>[)[\=
M-W8^MQI?_N)7PZIV3_::>SN_P9]/>._D\V%C\_!PEV[]K'_?@^\UFKLG7TG]
M^U]X;^?P<EJ[8X[28!/2-#+$<3X*XD$CXD"+.%'&,/ON UG32J\1^N @_'N4
MS'C4QC5W;=E8X<!=PA;N!P;T4O3E954?N=MOJH,V^7 % XO!P,54=8N@,;,4
M46<YXIX[I)6UR!E8,>J8%5P #.!UMJP<RA<' 8]8"6AEE7]VO1OG-8O,>>LD
MU\9:+%4(TKG@J$V>7BEB7:K[+?5N9JC^Z*!M?C7$>3VG*N6_B_)/6D[EH!_!
M*$&*:8-XXA39 +]*J9DG1LJ@ RC_NF1+:3E5[;G+:+]TO[WVCNV7;MB)I]1Q
M3K35Z^BL]'2*..FL)$5P,DF-(DL)<1<X<HXK) .V\#^)0E%01+ZF']Y9Z:FV
MX3>3SS7V-PRCTJN$KB=O%C4GH:OL#CY!LB_E E76PB(X=2D72]FH'--(D601
M9SY;"U$B[TG$6H7<"VC%<K$>I9WM&]/A^8;_ Q69WDF-'^(9*%3^6B),15#N
MI/@3-X%DC.O@&6(A!R1+19'V'F0>"\R\C#$052G^2U7\X;I5R[3:R_3D/7H7
MPN-+2%M9B$L!8#954H0Y0SA!*>62(L1SI*55R)# N;$^".56$8#?3,6DL14X
M[D'Y)LLE_7,ENP;/M 9?36/-IT6EZ0*<2@N7I HHJI@0UR8BDWA.+Z2:4,*9
M-O[=!TGYFI+7'5?_6M1GM8JG0Z]3C9_%%%R2R3?6Z]=2_^"I]7MB]@4K(Q,T
M(..]1MPGAJS4$3FE';5.NZ)A$,'K]'IOU&<I8U:I^",;?=4RK1 2/XK1M_C)
MX AP>Y7UMU0<GEA_CEOI! ^(<BV!7;&$K$D2D1BBE2$%S-2[#Q2O2:)7"(C?
MWA%@_'G:[,;P[U16_WNCAX$K; 3.##7Z:-L^MEH58[P74EVJZZVXC21(AQA
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M^+^7'9C%E9JV[6/MK-D_K,$MLB,3UJ9HG]2:-?+\.WR[W>G7[%D>3G9^PBV
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M %NA6;J;LU>QEEJ=L]Y:'E$9JUSLA:_,E3'R%9V# =4;=+-?=B4?ZT:YONF
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M$0 AN0&LA&W7$$Z1AE6W)$0-S#>O/7DTSAT]24[E%O>)\1"8B3XY(7/4*<,
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M$K6G;P6:E(W:*>-Y')0):Q=#?I#BHI-/%.(Z:!5"E^\":W-1OEK&EH)4#D<
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MR-$%" W&L,M%$S5E7-#DN'",)NN2,M%R61&:%P=REP*>F'/6&.$1M5$A3IA
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M61?^*PC&S/O:-U!T[8MT@A$<+1[=8Y*61=LC?5'4UB(D$,!@$47]^IO5#1
M-Y$@"#2(NN>.3!+H[NK*RJ>>S,KEPY?#[V]AK!]./GQ^\_WH)3SG]$,+_O8=
M[G5V*4-(T"*"B4*0,XXC+FV*&/,>:6FU*H@NB*6/4'7OJ5K$VP@,=:@ DX%A
M*< P:_%2,&UU=,@0S!#'S"&KP0#&8/L&%Z(LP\:77JEOK2TMZI?NDQ.#<F+0
MNG"=>*J%E*PP2G%#J<&12Q&8Q=P#WPN/3_BVY^1Y10@_EQBD:<&HEA$Y+A3B
M/%6@Y\0C:8*G4E@"2Q^HG]%-:A[,^W*42:UUG0>P[+@EQ!O,F;&:>2&HQ;!
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MY[$#>G16WFDB@(M9&513/%[=+5BWP)U*Q-F]LCVLI)OLM4P"IF2[&<3!1RG
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MY@9Z2[GQJIN^$+U;B?GJOX_<YNW=R WB?T<P :^^IL#1VC1S^_SV GH/Z6N
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M-G,Q&-"%+CS=5\/]VNH/ 2B!THU2P^$&K)].F*R-M#W\U/H95E:[!2/[??H
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MZ3,.4D-%90;,M.@G9IW=2^K 9WPP<%R'1_#+<4(\$.! A&-A1\Z#<"<&/45
M0R-Y,;X;'QXKRI(</@[]4?[%^$!?N#!$,,$?#P5WHZ$-@LQ@]0^.#61!>>?C
M<>#_<D8P!W?"S(HJ/YZ(.,TXKQ#YJ2T18T6WNB6K_HS]T(G@^0^!<#D^_/'1
MZ4=#98GD'U265S5[A/? SHJCQ8_D! :W<Q&415X:C:D2]KG_#M/0^ACX==(#
MH/AYP@<P^P_<?>23\+?W12T!%9DBZB)Z*(52E+1:Z?I__Z]> */.F5-9U7%-
M +H1#\*+Q1Y #6Y]@5S-YH:&!;O5DKW,;.>VNO7?,F>/J[<JU>Q],*#5_%.%
MW<&HZ<]@?TS6A7,<!P ] =!O9G?'N0QP@W]$OVH/6'KD'+-3/@9A1EA+J9!0
MIL]ZDRDT?F?6,WJR?@"XZ>4HUL-&E\B6<.B,<5-YC(9 1M:]/B7<[KKC(8=7
M!F(?;/4C!^AWXX0_V=CW7=C$HL@56%"<U@I4A#^!0//I^L[JS%(2Z>WEGASS
M"8T7"%O O_NR5[CO2;<0%!)^X.-_@\@#HLO]&!-_9KG6S+0@FT>03CZ9(UGM
M5J4^9V:@I+$-#\41& C_)T4&>4LV+YB\5+FZ]3%,IL.&?HBRY8:X1<=NA!.C
M!9"%&H=8K14'@7=ZOG<"I ONA6>C#$G[&=8 +XSA:512P0-8"ZHYF!8P)1SE
M].H?YY]/S Z\$\1AY-ALX 1AQ'KBGDM\@5^%*0M"^?[5ICQPP:H <\EL@'<L
MX8>Y_%Y:/QP8F.-?'DQH=4/"M) _H/V?%PU8A9<P<OX\P.0:2^HZ:.VP[ND5
M02&8\_ _(+6V8!,8ADBQ#WK$0)% D[X(N;$H8W I#-4JC3D2BI2W?8^"8)*"
M:!S''KL BPUEPO$\%,)N? \4D#;RX]"QAXR2YA#KX6T%QBI-5A/!F\,1JADI
M7QB#O 83^@T8LT'$I+$'YK(<]5%@_1ED*7=AUK;KXR!*1  U8;'$R'Z<DV32
MP&QY^\#@>:;#NDYPH]7._-Q9RZ%A5G.@M>Y+YA@.S78V'AD.9DT;#L\P'"RS
MTIFCLBN:"U+'8 : T1P<2 J0YB8 +U$/5N8]G5=O#(WB0["_V+-+0 ]X:N*=
MW,1QW'>-+!PV[7W>#1WIQ/J# 8 ^>W1P1>#V9B(SYZ4T\R[B/,W;MOW8D\+S
MC7QDN0@R9W.X1W/I+/:$[\C?GI75[&TX4<0>%%%GA,@([[!=[HQ"V<L4**5V
M7SL.4-42QS\=%P=;,%_RY=76CP/G6$VF!)(@W)6XTRL:@O7J7$-0FUO*W,(7
MSR.&7*7<4)\R::U:AN92,P(QXHXGD^25+),ZO)TAKNW(EU?#-<W(1MZ,E$#X
M]L9>;1K3"_9G$4,WL'!W!6'7#*R=^F$D8]\R=&S CF6[,9ZWP.XT!D5U%&:B
MEHU\X(O$C=V@QE)!/Y.-3A U78K4@XS:BAYI*'VC&!W*,(!4*Q/).4$ZD*D-
M3YRLG.DD81C/MD%?BB"<6=)**7D1&9,-2YHJ1LZDDLZYK)<OSQ<R@JCV,.$^
M0-U:$K".JT4"4+>6G@?7J]:<*.UJ F!5+"T KP*(7X6'E)0N1!^L>2>, CK9
M8HFT[,:ZEPI^?I6\N,J$O<] OCRRS<V#J&TF]HT\GL*#M?IT+&$5J>_Y7HRF
MG=,'VR.(L(]E=D0[%0;+/S=E1"K+,8<<M([,M%1V!IG^:#1.&XP[HC\O)D?K
MXV=CV?Y9ZVR:3M/(2R>&I!HS(:DY4H3[0MZ%G[4HQ2]AQXDUB1]T1W*=I_"
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M BN#20#@!7Y\/Y2FK4</29<'+;P!['V 73!T\IF4M^QQLF<E6PG3$'H#,!H
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MPE7%JKV9'%<+YA-Y?G)?)J0$CXY"=D<C[GA I154\7AZV"5G(:OCW=J1NA(
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M#J71%TJPHI!8>&"6!#H9[=V/".T[EQI&N][2EL0;8L4X (N"[B -A=M/0>/
M#(G-FO]H4^*M0ZQ-PVQM,51T"+;$U=15L0,S%-J6CC>4G$5FPVA9!W30LCT4
MR.49'IA!<&0:M;JIFRF7ED%;M]@.P1:X*%SH.C!+X*AEU!N6;JQ;9@8UVMOI
M?+PS*8CESS\\W.3#.[S[.'WA85UI7EH]_1 RQ-8@0+GAS+*J1J>^X3GJZE0H
M>4ZCEN>]D>=JW:BV-XSFO[X\+V_ZL/$=P]7O<<\?]Z69M4+.HO42.8MO+&%T
MEVVFC-LJM6>=M) !9R;6[*_AW4*\^YM<?<7J!GY *14>7E)4MX;'Z7UH=6$:
MBR_XHY&/Z\8+TE1#6A::2BXI%D;"@N0^U56#5X P.[9J?H!7D=E?8T^H<H_7
M@8,E&_QUAC"24N_%.3Z*0.1KHO,P1Z1E!T#/N7_[A"JL6%"A67U6084WO+,D
M*\<4:H0X>U'F.==2(%4#*NWR@K=R5V+HSESW;%N53O,5;E#6*^U:4]^@W/P&
MY<YX[ ?M$M^(!]^%"3',=]1W\';Y.I39WG)[^T,XIKO!:A]GLMH'JLRA'=.U
MC/K:^6+Z#&B]*])@XD5!+/L;S8/E/3]E:.U^/J(DM%6Q&B67-1D1W_BL<>6C
MAAT2/[/=,AIKYR2M18FM'H*M>H2YZ1B'8 5<B##\P$Y5871L<YKT97RF)NV@
MOAQ9U=96TG8.P1:0@O;#4XU&L9AD6G#6]L/9T\L]MPV.ZD:C6M<9"-N,9^R,
M<;,\F>I9!V+Z:'0.#<H-'6;;,MKFAEG,:Q&B9 >DVSC#R$XEL(PIG5/(?JQX
M?N=$:2GS>=UUZ;PC*:$^$3R@XNDX5JY*G3[MT*<=;WK:T1UA+Z9Y)QQ[[>E0
M">&CK+/]BFT-S&/V8J[SON^U:Z^_W/ML8\/2 RNO7_N+2]75.C"7T&JO*W#E
MBQ>77:9J!Q;3LDQ=/^6U9:I^:#AE61JG7EFF&K*7[E $@KHH'!ALF>VFT2K!
M\7QI#JC>($:Z%P? &]KJAQD;W8@&90>.YY]Y;S,VJAL-8<%@LQ@$W;5&0V]S
M/2<C)HWX 7OY.O8*Y%77#=(^@F7N'#E_!5*]9_][I>["F,VD*5HN+%_LO0B3
MYJI%JVP92IF0L%5*XJ2= -D1#J$:)DXU=4TIF'1.5#9;,LA -7V5=AS@C0CD
MC.8/E_2(5:,=RV9\=T'LA!'[Q+V?!EU4BD+LW R_I3M)>'.H#T(.OPD((6#J
M..WDV,'%5P0AG3*$,7:+E,].BC.YSU:!O0_#,,88:8]>&N+Q!S)!#29[%ZI_
M&,D$;]-[4DF+P[]>7_K!/1#ZE)HKRA5\KW3AJ\L?7[YBWT3?*WR<]8V4G][X
M$]C3\6\\8CGE'N]S6=OZBS- V@R=(/GM=^J$#C_OAJ%O._0O0W5/=((IDOW;
M!R' _HFP$.SF>D]]ZKS^>Z!:2K$<?2[D9QF%< [)O/!W_P3Y,>A2V9T?@/SZ
M)Y_QLE5N@2#Y_^,'/]DG>)T]-. )UP66!_?^HKGC.TY1?-*OZ8T+EJ2F"&R%
M ?G(!_;)8I[1T*&^DR3N>6&732=MV*PX=E2<$GR#]4DALHBX21V5L*EI3W8"
MEV_)J9B1CJ9FDVH$"5@JOWA3+!#19$[+W-F]::UFM^4^3%R$'UBX'1LIRH;+
MG U CT_PP!!8A;<:*$EF"E..E&@6[CVDT*%N ";0)_M*Y]I4)[UC99=3E""0
M^PCP$7^J7A7&O9/T=?!Q/,9AWUF-7+=K"04YA,!BT],/%AZ1S;<7K^L1?L9Z
M0O:E7B3+@9#90R(5./$+0 C'0T[W0'"39JEY,E"[)O4 3#)T^@X/"+&FAU.'
MO-075=I34I9S-R#3WMS(.6+<(^@W+8F/<3-F'G7/Q%_)V8,.B  ^M_U@[ >H
M@>,8_@KQRN0/0M8YG<-S[7Z3]KYR3.P=K&:FEODUYMB96JY3X?$D)V6!&'&Z
MZLK VA5VM-I%S1VX:+A0KP)!?6W#@A3(R[=C=Z*ZW3[Z[*>8)/EHP!_<2'W@
MK^"T7[IV+"NEH[S3O47TONF3'@^=9?==-X6QS<B_,X?_-;-2:ZQV2K]>8H"Y
M8J_(_9YL^R7S']8->2QS,+=V#^5!@&Y'[(84>R\[/.U5XLJB&VL$Y@67=3MD
M&#G]OBNV1(;5;BN_0I6M70A^GN9W9U? U, =EAOZ"C*SY3)FNT!@S.-'Q]%C
MM4JK@;84;$?5G:1M"2$.:-E\GC;OX!%Z06<="M*%$:SVV<K["A?$=H&>7P/!
M(W(F24NMYVGIVQ"QA+IH-2J-QJPR;I[6OB4'&6Q'UG5=4BBR@DFA6.1$+KPD
MCAP7!DOB"IBT#HXP*2(YS:"+8V%38)G2V=/XX(IEGDH>/;C!@#/JQW<_$JR3
M-CQ2P;6IR+PA([!4+D&&?RY@1(J_R%\F!P$PH!\'Q5A!%E^@Z*N\.4"' NP<
M_LE,27(G9'^/>0#\<"?L1N"53 P\?/$#^$GUY.\R1-B7H1\8S/'@@Q%%B%\A
M$%'B8ZS/R5G!E_0BX6GA(N'^QY3/O5QX7H;F\X$N+-X68%RLGY!JZLXE!6?!
M<4W#N4E/0)!?%:</)O*\C,8M:D.%G>=JSRUX=4Y2E\ZB6E'9/JM-9<'1685]
M7O02KJK9R5EAP+L/SJ2-,<*^*E&APJ@V#X()W?BAFQ+)Q\F$" :3]@83%H?X
M4SQ]0\:<4!1<77)52BGCW1AZQ5_&N2NP"RF26_P<PJ>G*AZ(T=P'%I"'B)"]
M'BTL>4CH#$2RS(64/21L.:/X.&YZYXD]>@/TW>)2.FL<C.\@DLTK%\B5 R!2
M9J3. 1V>^/(P,4HK?[!^'*QPM4<2*0F>D#+!'_!/JGAI5<S&G^A#<' [?S)R
M%I +6I )A/@U%IXL'DJHD=_K<SL\J!4V9>;RI$:=M_4+$"'K+2@HH(7@ ;RJ
MDHC:G1SF1T,POFANFRQ/PJQ5.+N##VK9F6!^J4;R?:?X@)D_1"S0Y@7$[MG'
M(EM D/DU/1>7UTH6M>.VQY67O\5J*!F3NZ'-PR&=L04.GN*"7F"16)"_J8KU
M!NM>G^(AJ(T9(GB2C*Y7IN:@6I?7U_"KRZ_L6O8VI]-:%,3_O;BHP#"S=7/5
M:')L#HHT@I'!RJD7[ MCUN1()7[*$H&!T]-E/-\.9;G;WF3IY*:!HY2>QA^I
MIQ&\GJ>QH;*76+D7%S8[")^C"WKM*J/_CM^S]E1J'4EC2A]*"<GRZ>C,?2K_
MB]*_THR6&>IF62V8L,3Q0GZH7@ROZ_E!X#\FV2DFJ&\NU81^Y"!*_./\;.KL
M?I+W6%95T(4<TYF[F+EK31U3[D+F;FDB=;L"_@>-_63_)\7WYUMVNQ<&/<-,
M)Q"O[N4W@UU>?@6KYF^7[!)DS0;>?PW\>"RS>E.0AN^S;-C;TV^G24[LA'5!
ML]DW/Z0D.$P-3K):8;[)XY^ZW[HIK(.Y-I.</4/F7%87;2'=RTLEUC*3$?^-
M ]%.0X&0)#6/Y[(-:3/*2K?@SRC+BU*C^6  ^D=:1+T,J+D")8I3' @L5M2*
M:$@9=/C4DDE6V-D3O\B2/FE;@_FGGJ_? R&1KB%,<,1_HM,W 75\0*<0UA@#
MSG$Z*0'MQ= ]*#V2-Q[[7IHFB)_EPEH@)("[].:IW1B_Y>,QR#\ED,V0@0)]
M"1883RY]:F%'SC'-?H2'4HA+B/PP@MI_J=O$T'?[,O=4ANB2.>=F=3V<A Y(
MD<=N<T]D+P6X.G*<XY=?O;1FG"A& L/KQ8.004%PV3DZ'G&:NKE4'O ,)AJJ
M($;R(^5/\ ?!>D+ X*XC>4D',!FPXTJ*A8(J;-4V&[N4&6AV*K5FZ\63[:J5
M6OL5B@V9E8ZYZ826?=>H+7[IQI.%83N;)1QN8;)FQ6QO-NQ6)EMOU79ELE:E
MUM@ARIJ=U89]^6I>>_%3RRQ]LN?\*F7?,<!]*0/<9PM*<ZV3*;63Z<SS/9 S
M,DL.*1]X!4]L*GZZY03A[=-%A!&YV'1LB7^,T5KVO'CTLJ19I]C9+BO=)?_E
MC'+$6Q*QV.H\/\GV:J6?YV<ZJBW]-*_A,;^_,M:N7Z;EL+7JC,KAEEX*YBJ5
M%H.7TS+  ML9<Y==<Z=?>G&0V"4/B35 O(TM4W:9V"'!+?TT%^K4B]]MVT!;
M8) M74CH7GY[C7M6+T:\E<NC;8^$VZQEO;U5FYNTTWR]8M:2$*]R5? Y+=Y6
M$N?2<;9D7-T&$?ZD45&CXOJK;AJ-=KMDZJ,E6$NPEF MP8<BP93Q9'W4,JQE
M6,OPR\OP&U4/V1[M+R^_OFI1BU=KX+$]DM4VB 4\JW_'!IAZP.Q9VZ-_ =[L
MCM-^P()1,YK-#7N^:KW5[#EP]FQFI&D&'0B#WJBKV!;/#O]V^:HU&E^M#=GV
M2-;8_-"L+,&'?6;/ID=?AV$H'[!@/"L>HS57,T@S2#-(,^B H\I8SD"'IU[?
M6M;N=7FM91U6/@S!:!BUYINV<]=ZJ]FS-^S1867-H$,.*V,9+QV?6K>OB(XJ
MEY8Y.JJL!6,NP>I&M=G4>EM6]M2,3KVAV5-6]NB(LF;0*T:47Z(IW<J)^^HY
ME;FMZF+68-E]/\8JFPFS#C.S_^6I4V*ML6K&^M;\BU.H%+$#K:WE$4NMK?-]
MNX[1;'4.65NUEF@M64%+&HUU;Q5K+=%:<E!:\JQS!:TF6DVTFI1=319T>W?Z
M?_G-:;6J]7:CWN95NU%O]@3G9I77+;M=;31JO&7^RVPV?_O]&0TL7ZH1YH)Q
MME/7[S1PB-:L:]O840?8PZZ!:;9#G57ZV"_3P38QSVFI]/:2GC:P'0=BS(.T
M[<S<3ERXS+23M!/:KA_&@0A5MQ?LL84M9Z@QS8_*;85][7:OX8$_8@=_A=V^
M<IULDN9 _X[[]S2\(1M>CJG9K.S()!*:JNYYU$Q7-KVAMD:A[+KS(+Q8&$E3
M6WC6\6Q_)&A ZM2)8R5=KZG/I6P:)AO5K-:%#(?@MJK8CLSW?)A7!<0ABN&7
MLH]GF':WCK 5SGW2%.C><Q+"RF9-:O8@22Z2<H#=^P:!/\(>.>&*-)GJ;+0:
M'0&K0'0%]4TCOL (*'S$DAXU,H5YVD/NW>/\;2>PXQ&00;9N4HN#)0EG3'V$
ML(NW'[">B")80J'+Y@]L+82/]HD20&6>J<XXKSHX)NB"D@K9$FM*6F+@:[K$
MI2O$ME?CL4L\@H&!FLF[J,M[(&"*(!I.2,V,[@-@'KPTGIGL/"FHL!0&%JTE
MFPCV*^\+&$;V;)><E7),[=P'KNH,C5(!(. ,8&!8:LI(&B\&R@<1A[FF#5K'
M/I+*H?Y9JG\L+#II404?2H%"LB5B*=L\99_GZ$=#@OQ+.0HK<K_[IP!)'0%B
M 8Q(7OAA5)CF/ + -&3+2-G\BQ0UKS-/JQF,0"TL+<FKR*^P:U> 7#+NACY2
M3?:YE)WEET!R*.Q$Y2Y3,4J;E'T&](K#,&D,W?6X.PD=@I,OZ;1.$Z+0;VX4
M*>$G5W-Z8BL@P2X%\.C-3%/"OZ6-L ?P;OC)1/! M;].>A&K[M>J(?&<5H6K
M[M^=U]R_=;-0+%]6V\%FH24P0.8;5SA,7HD#W_,1^ @3=L^>NA4B1;&-4!"A
M C=9+P(T=P"K1;^ MP7Z& J$\)O<!HS@@[MS[CG:WWC0SW;=01S%9 /XXX*!
MDOYR<Q!J6:\)0J41W:O!X$2U6&"W0R$BU@T"L)YV57:[M,.E_:K4EJ2:5AGL
M4; A[X/Q"[\:G/34PD-:.,\M/#-T0)2S%I$ A:'O@5LZ 7O\)YJAH"#T-6=V
M' 2J&:822R'M?=^;,LA2:\60EJJT/.9^KYR#$$?-_(,@V\O]="\W8$I@$O>I
MB;'-J0.L? 8^0C_'P$&2+^#?,"E;Y%::-@F%-3G> UB"?O <!6H\2X'>6A'.
MO8&T_'9/YM.I2ULX<7[&@8/\)?%$H>\#BQT/'+MP2C)!W@!?8_(<,M/0?\"N
ML/!U].A+\UE">MX ?(YXM%<0CQ>.R+RY3-V=7;*:<DGD?__^H_O][ORN>W?^
MCS/6_?Z9P0<7R;\_G]^>7ES=_K@YNV7=3U<_[MAE]^9O9W?LYOSV;PL"2;NR
MT23=1!AV16,W3OAS9Q8T7^L^^4'@/X+2).XI^4\CZ1*IEGA9BV0 8A^C$W$H
MX541(T!B!$","EMMYWIGMJL5E?8"BW)1Z\EWBU+OO[?.Q"KL+@U'J2=QEFE;
MY9F%]%#MLP7@WH&X0VXCK4;\$<L]1#CH QOX$QI)6I!9H^VQW.*.N&P<30^C
MY7@6![[<3.T)@!9Y6V'J?MHP1Q&.?;G6]&L@'<7L^MA0&2;(QV.8*$&:QR[.
M/UW=&"I4A$8KC(6-"V$@$3R())9$Z\/^XH2.!AN[P"W.PC%L^]06VZQ8C3_A
MTJQ*XT\8Q8'WRW[7,N[$&:P]@$_ ,.AQ=,C3D-0\"KBPN0?@8C&"7-J>CWK'
M, H^1?28,X=J,@?S%>8@I2%]/4:9DA 0QJ4PHN6!8)"-37:#@XV\71>CB2 9
M,%I(!H4B^52(CR^7\#M^S]KP*_:/\[.BDZ':E:NY&U(1JA5S535(9.<4NXD'
ML8RL8(_P"F/G!5545$+R6-6/,[^GS\V/2)=4S#F^N2]^R0%RS%"S[G$/M/M+
M'* VC"AX]P0ANM>G<HFM2IVMMCJ0#A=C=S@%V=<\"73##/_WXL)@E]?7,OS6
MO?R*'NH8#U\ #8_46F]PA#,Y BXU5&L]KK S;!G/%R& E(,0A*+W;PIO^\JJ
M51%AP%QR(_%_BQ%:%>V4]$,[5>H?T-)0450G)!+V.< W^R<'0;N- K35_PJ8
MYF'/L@"'O2%5 :K^$?LJ*I[CXJ7OB0G])ED3GL'&(W(74=[G#7ST3UB;"  ,
MI/0>3VF:8NZ%(*0\RKWN'!>0$>_*4TO F"J\D-SIA):&:EV/X@-KK9%N8[=0
M!-21BD&CMU(,9)/*I?WLB\(+PZ  %+6Q5FE4J[F1$6I0%.6W.-)(]MB4 P$]
M:!N 16(LVK&IA;W+'R4^*#T$&04UH!D@R6>VM?"1C[.E2CE5P6!%B%#DO\<M
M@Y#7>4#/"A  #P@9@3\L"4, )TK'>B1F'$S17Z(O/R2LD_,;IRWM?!))%:26
M+T1C-^ VQFKE*UT\ZB#RH1KU8UL001Y@]Y G+I.$;38/ASB51Y+;=+%C/E'Q
M[C#TP8%#":1#I'EX.[L2E($XE*]607_FP$,V'5 429JH#7!:^9C3L\A-$DP*
M-IR,?1A0QIG-/R6:J:*]A<$E@_#C)XV)::/ F$560P6=IT"%/=*1$?DDP"3T
MIQ$0 J!$^H_\Q)3/FR)X-(17@NA2;VI1[$T]#:,@O>_,2B=!T#FNBHX(YR+"
M]<41X37<NK;YVZ[%D3=R,K?I4=8+'N7IU?>[FZN+6_(FKV^N3L\^HP.Y,][5
M@NZT#]R-T^/\S^EI/2)-%/BNC &#'6,#;@9SLA;*NMQ-PY8V#P*'X)$\+I'2
MQ\AY:V$,6_R#DQX,IMO0F&.J#>R)"46+Y]/Y&#P!O']R.G3$@)W]$G9,&^C5
M8.# [BWI+K_,CAK5ET:R4Z;[N(<FB/JP+_#\E9Y/PTS)5+)T#+E!)PP>IPRN
ML$^9'P,69YX BQ>S\4)@%NIDE-ZVVAREC9CZ2S<Q6&#,K/$3LW$DCNG'\%?_
M6/T[X]O9+[4Q=]'O?!1!CH1/>0MHPW@T*VF)YXY0E%]+3@#8@VH!TK"+0VDF
M@Q7T]]1AG#WW_3MNSF#:CYPH*@0&\E-&4^K(.:9<D0!H9DB:A"'^F9[#]PV5
M@:-R5U XE:5.SL&86H^"(S$6MC-P,CO^]NR4!41+?!Z7)_\Z<N"=W ;#.):^
MCDP%&(UB#^P=Y?PL%_3,5!2I@/AY <E^D,7G_41(.,49P)<*'/) T"9%TYG6
M@XD,L)"0@JF!N.<!O37E22X#:;%I4MK0YFGFP)$'[<F$ ]0*&3G.=$H*E;.D
M^6T)5KDPLPSTBO31\_-.:VJD>O*\)EMW)B9!LFYV-(L+4HL5-@R.Y3^E=N4U
MZYCUXR 15E"7H)^$WU64!Z$!<4 J/]G5N4P:F7&&FH<1+TK;F7. -?. L=[Z
M7D!\%^W3JUJ=]37/F@H]EG7"R KN06._$D:VVV2[>W/'SL\I8F2:']G5W;>S
M&W;^_<O5S67W[OSJ^^:*T-JM0U=T9\R".W-Q]K5[(?V8L\_GW[_..C(E6M6B
M\U@R6WS<\'F D:PX"$5BZO;BT$&SF*SZ.2%2@;F_> #ONP]ROZ C?-@#9-8+
M:%<D<"=QP:; 1,XL#9*L+H&_!7/Y$D-TRO2>CD*-^82.0.B1!P=WG2PNQLG
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M@3Z0+)B0J_HH7-"-4&ZS<H#\M91D:=+!N8<M)N!NX00WR0;-AQC(HX>QDH4
MB$>(\M%PM?""P29^S,(A*3+.>1"[\O G=))00S)T7V:]RTWQ&@9EYP8[CP2,
MU#62XS?,+&%?Y!/I<>W*R>U/9K4CX]W\ 0\&)V"H2Q[80^74-61H1N$=$3H+
MO<!<Z/B\.!DDXT)Z293+>VD2X%)_;<JNV!C9E(41R\M.8>3;/V46&6V2/>$Z
MXD'(FPVYI$@O\R"G7>2"9.0N"!7(@50L4*/"OOF/F)=@I**'[B81<N9.B;00
M9I5&;G 8.$V_ZPL0%1D*<T;IE-.]_YD$7F.[*#O2W=%):8%YRO0#VPD8Q.5-
MIZE+1P1?Q;LP\^49>:@TOD<AB;ZZ@O=OX"RA2JI=JUUL2W(=Z$[;+#BDV)#%
MI&[3 1*,H..$_&-6^M@K7L!)WKZ2Z5=AGX3-8^E*$(CD693'>,6,A'E2B)/#
MY14,H?D;F8%&=93[/?R =@*90TT,58E "7ZGL6>.3'(HCP"M2YM'OMS_Y#%V
M;B1#@:%*0,X/C$L'*L''Y"]$H-?]4-JYZG1#9#H8)-\[7NXM&&%^A@%7VSWW
MVBJXUS^^WYQ]/;^].[LY^\QNNQ=GM^SJ"SO[^X_SN__!O>S'S?G=^9D\3/QQ
M>X9?*E]\!RVV[[ZW2>K ,^1CE9OG^V#-%Y.:/Y]]Z?ZXN+ME/ZZOOH,4?3^_
MNLD)4YG7N$1P-I>"5>XO[H,4U"OL\OS[&>#(ES. CUSZ>ID7M(CE42[9;6,(
M /PX$.8W"A"P0@B[/*M:K/0Z26SY*5#S)9+$K&IV-:RT9T= (OL$J(XAXP\R
MAV'RL02RNT0CFP6-//OO;^>?SN]V$(HQ;)+%[<6OH=-S5!A-WBFA BD!^$?)
M[0"JJR#0#:$\9+R"25$:NHL9>$XXS$(V3T>D>)CX*#BZ@'FLY,,W2,"H:%&F
M^U0ER<9+*>-0?$C^^-AWPK'+)Q\<CY9/#WTL"BR*]G2%).20_#J3^DI52KZJ
MX:S>K+ZNT%=359_D=ZU*O=%<^&VU8F[TG5FI-Q>_<_F32^;:J'3,32>T>%C3
MK#1;M96&?:),]II=8R0/GP#];65>2GU;)6=RJ_/\[D]IY9(">VN4/]XC3GX6
MH1TXX]E+S>M22@G_E"E4DW@WOZ+A*N7AUN#&*G6K7_.5FZN_,N#*4!:0A,+"
M:W-MRZK/U 1\4[V1!-@P%7LP>#4"R7GW,9&5(K0?*,B-OX+I\+G&H3)0/FY]
M@FP(=A"H9Q2-/[Q___CX6(%I5N[]A_?=P!Z"CQ*^%_U['KSO\XB_-ZOM6KW>
M? _3-<UZW:K6S5:UT3$[G??10[W5J57-?]6M>J]6&48 <-D-8(J4NUS6IA+!
M/9[3R !]<F3&+#HM,YL&)G^ #=<=HSD'OY:)'M]\EY)4#';NV14#"!,]^L'/
M]/O+7+ZN_(4:H&O_$3O2BV*G8 %69+#X;\+S!!AWM\[(8)>5SY7"A3PYQ^RV
M4G(WCQT5S$@\U7*\HC4)MF07AO[%NLG9Y[]]L# QD>+7)#N%> __QK/8* Z5
MX3F.@S!6QR28[LF DD>]XZ/:,=J:W_T'22=Y5&BVC/06I4S>H-0(,$[OG3!2
MB?+IB45JK-Z>U(__ZSV?=F1>'=M?![XU0F<(;6EHUM"\!C1C;8>D*"F"U#3B
M)?A,20I,'G,@Z&P+G$N#NQIV->QFL%O3L*MA=Q/8_>Y7LEJ)B\#WRHY\PI[6
M&\&O1E^-OCN$OG4=EM @/!>$.U6K4:TC"#< -CJ=?XE?UDE=@O"M3%*-822>
M+R=3L'@5X'16PSX5 &<@DFFI[JF4N>4WIM79$R8%3^ 3^6Z-6GN(6K6*J>%*
MPU41KAK5JM7NM-X_U#KMCFD!6M5.3(E6-[)$6Y^=(A\'=,2,9L]Y"DMH]:R%
M4B""BU#J5%4DGL*H-MYW2"#JK]R+\8ZBBM@V-$SM)4SIB**&J1F8LAK@W[Y_
MJ.-WU3Q,3:%3YNC"/\H'8=UQX+C,:FD VV, T[$Y#6 SL;EFK5&O8FRN;6)L
M;F<1+#TW-VLR,J9!;"]!K*Y!3(-8$<3:U5K#[#00Q#K-CE7;41#[:^R)Q(=L
M:_3:2_1J:/32Z#7M0S:;U0[ZD%:M79?@94V%NCY-L +1NE!D/3/TGATV-K5?
MN,>@U-2@I$%I!;_0FI,J=RM4[3RT?#!9 F$'#2WDL2O8^?DY_O.% 4P[A!J]
M$O1J:?32Z+6"0[A;Z*6=P7U'KKK.>YBE3+7LR+5\@CGD"C?U!AN=3L=$;]"J
M+SU1_$RM0-(.(+>P%%AA%RNF$:?Q"OTU01-6$),Y7F\9D$]S=3O*>:QH%-M'
M%--I$1K%IE&L6>U8]48#4*S6K-8;>11+FNBJ<HYS _!3T+8TNW\+:1)U>3%7
M ]I^ II.D]" -NM1FNUF1\;#.G5*GZ\GB$8P 3"5!S$LF D ,Z+[-VAY/05C
M6!<V8-B/36!;9G@S=9H-AUBQ:2V(JR^&N&7%NZ<RP93CJ2%N+R%.)U%HB%L)
MXFI%B/LG#P*\F^B$88PV7)C<U#Q5M:JES9:_PSCO.F?6PB:Y<X3PN1Y<BE\B
ML)V0*L7QB+TS30#-S3&SIC%38^92S-2I&QHS5\+,^NY@9O59F+GP:J?&3(V9
MA)DZLT1CYM,G'*DG78"SZP3G$@ ]4K7HTI,.]45:BVZJ1H@,TS6PJY!S[WC4
ME$B!,&#:\J B -M314/P-RD6FX9ITO]))*4.-;9<C6P!1?UZXEXH_HAE(Z7G
M;@<O%1/01SDO -?OJ?CT[]NM>#^WVGIYR^"WIN1GQYHAZTKENE+Y3MA@.C].
MVV K^:W-HM_:#?$0-KDK-6UTO9GATM1.IG8REP)<6P.<!K@G$U V<S(_+7 R
M"U6 FV_B8C8:#0/^;R\=3)U7<P XW=$XK7%Z%4.TO8(A^NG-#=&V-D0UP"V_
MSU'5"*<1+D&XIM6VVE4+_JPUK>9[/A+#$RQB:UHU\Y?X]:MN5B7.Y5J,R:HD
M6+R;VK[?"CL.G CP;A8P5N'SW)BF!IH=!YJ:63'_K)%F/Y%&_*J9P&;+K&*K
MA.K)']-WOQ1*7 =@O3ACL#O.?@%*X%D2NQK +\#$N<Y9/NJ&*[BJ=+$5[9=;
M'O2X)\*3JU^N "_5)KL*@,K29LE>HH6ET6)/K\@C6E@:+;;]T[U"BYI&BSVV
M+6IKH<47Q^/P)_RET4*CQ2Q:6'_>+ECD.X=K4-@4%)YI082RF_&*H&&VV8_*
M;>6TDL*'66M4,8K;[?MCC,3.@YA.M:DAYBT@9MTM64+2EO#'K)J5\^^W?WX>
MT[=OMKPJD?[[T\T%._?"B..1QF??CO'T0^O)@>G)[>DWK2=/ZLD=_^5[_F@"
MNUPDO)#Z9]I#,>):<0Y5<4Z[%UIQ-E&<4^[:L2LMR O'^]G#+":M1@>J1I_/
MOF@UVD2-/HN!XSD%+=+*<V#*<]']]-;*HY2A%,&FZC+]N. ]X2[98+14+9*J
MZYLS#<F;0/)U($)@GC9M]CW*796J\G;ELDJ'NJ?^ P9P^;U@Y\@6;E/H]S./
M./OBN((=#?Q@Q*-(7C4XIQNNC!0'H\(VO(##)WWF>&DN+6#/\3/A^8#58Z>V
M&;V_+*/.%TH/Q\SS1R<:5O3&<4B:H55CJ6K$@>>$PYQZ:.TX(.V@ZY;UCR50
MD33%8!O6U]U0L- &+8A=(8_95?I B$?A@? ';,C!'.L)X3%_Y) 9EK_X=!Z)
MT7_\/[-9_=BLFD>]XR/K6-TQ4)%9^>7MR=\JK O4&D_P:^Y-TM&2US,_2%[.
M'AW7A7>R0:JDZFK4[=DIB\?@% 5X#36,*L\R\W15G;7UIMF>4IFI.C9._R^_
M.:U6M=YNU-N\:C?JS9[@W*SRNF6WJXU&C;?,?UG5]F^_E[T63UF@ZO;\Z_?N
MW8^;LX7W<W)5@VC,.?Y>7GS,]M;$YWKJSB2JL1/0=<DPS;])+R6!0V</N0>N
MH4K",3NUNJ$>Q$M,=#]S"&XA ,B$V3P.$2J&3@C?TV5)> W "%[OE-<D$=AZ
M8LC= 5[$Q($H7TG]@" O]N A&H_'T= /8'7]RBJDWT;!IDZGTF[4-JG75(,G
M.XT7KX%4J]1K[1<?M5&KU)JMEZRLM' ?;S[;U'EMS6K-U:SN]=7%Q16[//M\
M?MJ]8-^N+CZ??_]Z:[#S[Z?S'+_Y]JI9+X?!^@07>]S^>1_XH+LGBKX#^G\?
M-^+9-@ROSW@G_$/6 ;F!-[>M51JV[?[:/TT^',0ZWX?OV=T0Q@G9!1\5EOQ<
M^5Y!KUYU#+6QD<4QCAB8N$Z?)13=&09ES#'89>5S!?][7?E6(>OPU#\Y'3IB
M,.=&TW_PT?@C'=(X:%#1SX^6)# ?S^/]-/(VEB!OZ>5!@[@&\?U<)X+X)_ S
M^IBIZ6@4+Q^'\MQ9#MPO ]3+3.32LUP#M0;J_5PG O59X-@,E-];!Z9?QZW=
M#VS-"$K(2K Z<_UN&E9G?C '5DL1>B]OE+VS.,K^ON?W)_ _PVCD_O[_ 5!+
M P04    " !1@653YUA&.T,?  !P;P$ $0   &%M96@M,C R,3 Y,S N>'-D
M[3UK<^)(DM_G5^A\$;=[$4/;&.QN]T[/!L9VMV^Q80T]O3M?-LI2 ;4M)$8/
MM^E??UD/(8&DJI* INX@8AX&*K,>F965K\KZY:^O,]=ZP4%(?._#2?/-V8F%
M/=MWB#?Y</)Y=-=X=_+77W_ZZ9?_:#3^<?W4LVY\.YYA+[*Z 481=JQO))I:
M7QP<?K7&@3^SOOC!5_*"&HU?&5#7GR\",IE&UOG9>7/]U^!]L]EVWCH73J,U
M=EJ-]J7SW'@W;C\WSEMGX_:X^8POSRY^GKQOGJ/V^;B%&^]:8[O1MJ_L!FH^
MMQN7Y^_>OGUKMZXNSZX8TM?P?6A/\0Q9,#$O?/\:?CB91M'\_>GIMV_?WGQK
MO?&#R>GYV5GS]!\/O2%K>B+:NL3[NM+Z]3EPD_:M4_KS,PIQTAS-\'2E.9K[
MKNO/L//&P]$IG>_95>LL:4Z1$0EZXH41\NPE>B<*&M%BCL-B&/CYE/Y,^SEK
MG#4;Y\UL3TZT!,MV<W'*?SRQ4!0%Y#F.\)T?S&[P&,4N@,3>'S%RR9A@!QC!
MQ934*PTR/T<HF.#H$98AG",;ZRS%KS]9%B41F<W](+*\'.P8A<]LK&' P>C,
M6C S3M2>;Z.(<2IM'R:3RT&=8C<*Z:=&BN/-:^B<G.J/( X;$X3F-4:1A>0C
M$=]4'TV&9YM75U>GKY0)B\=1R%2L?8/^V6B>5^NVC#OU^X9/C01N&V-(-V"U
M,21P&XZA<,>5<80*DGT.-8=1O(,U%R$!H+._J-)AB.TW$__EU,&$L;*"_=>;
MTS\8PZ_VB3S/CQ@\_49\-Y\3;^SS+^ K2K#W"=6>\#B1:SD!7; UV/_>H\ .
M?%>QCT[G@3_'041PF!7N#,$TP.,/)U3$-Q+I]2\7/;^!D21-<AVLLA[]^11
ML-M+9Y+ 4NI_. F! "[F:V/RQ.<!KCIQ  GA[&"$_C\_?QNY5></(';L_O^8
MOH/'5:</(,0C-69/H4?PNT6<#R>)LHD\Y]:+2+2X!RD1S-BJGEBTZ>>G>XG>
MP88B19)TGG2?COO7,] 1X1^KD>J\F3\!F\7161E\OYRN8UG#'X?8Z7N_LK_7
MMX@ %DTD@&N\I0VW2I1",/%E0@4);;K]QV&_=W_3&=W>7'=ZG<?N[?#3[>UH
MJ$V8<@P2JC095<Z!%$-8.2S(DD5E"5P61W8DR6@X0 ',:HHC N/<G#ZKZ.3$
MHB)!GUC6GU=P__>!$F\X@O\^W#Z.AOV[_N#VJ3.ZAU]K$:X$E9QHK;.SMHQH
M*5*K?V>E:(_DNGNX_?WWSN/]XVWG$;[O=__VJ=^[N7T:WO[]\_WHGQN34(%>
M3M8V& #Z9%UV94%?5K:S/UF\NR.Y[[J=X:>[7O_+YILSQ20GXL79V:4^$2E6
MBZ$](&+=X- .R)QB\\?7<4@\'(;Z^F(AM(0HH"4WFUQ1)*'M^F$<8/HAQ6/Y
M8RO!=.ATZ#@.PX_<C-Y\@R-$W UI),4LHU_[#/[1I1_\DG:4U?VM/XN^#DEK
MN48A"?WQ(#,)L(R&\6R&@H4_'I*)1\:@RGE1Q[;]& PF;S+P76*#[:E-[8TZ
MD6_<5I/9$BN$9]U1DF<[9 :?Z)+^ENG42GNUDFZ/+*!%G1_*"EHL<7[6/L_+
M@FVP!-@VXJ^C@- CV @]NS^(-T17,LYHG5VT=L49O/LC7^@1:RLJQ,X&(-<T
M+MN[.7".:LFVN M(@R:3 $\05R^?\ OV8OR\N$7V=( 6?D"[^9'L5FU$<OY[
MVV;^N%WPW^HP*8P8J/6\L.A0+396BU'IR)75>*#K>SQ? X#"R!<K"^!/V,;D
MA9T?SPNVP#^2-6L,2\Z?[]K,];@+_EP9JQ7Y2_:DF#+CI>S*.?7(I!6Y 07!
M CYW9O2'$.#N$ E^0VZ, >4= 4PVH8=F& 4LC!;^4%ZM/3HYRUZUF5MU)RPK
MAFR),3,,=-06'S;%LARXE1GY8;*N<-%T_=DS+ K;Y[!@'WW?^49<_<"7"H_4
MI= \:Q:<L(GS*(N2$3-!>B13LA)5K3XM;%+#KMEL%2CE2I(=I-DF7^WM6&8;
M]"&5U$UJ?]6@\]&TTN> Y5&<?+%EZI?BEU.^!99/+<IGCNMTWQ\@V>]I M6$
M@+SKA"&.PD<<:9.T"%9^AK:;>2L@Q6)Q-#];@.BP25#QK"S'(#\?+UIYE::8
M'(=X)A:L*KU7XL0N]L?K/U85A[60RV7A)5C9FM0$^2<ZHP(PU^@H"34I\J_F
M3@D.Z(\D_[$DWXJF6Q6OG,AOVV=7VD0^:K0RZM[%$:Q?9^8'$?G.AG?[.L=>
M6-GM7P>WG,KO0#?2IC+OR\IV9HG>#I34+SB,F(>,>/UHB@.6PT]P>/M'3*+%
M XZFOE.!NEKHY+KN53/O/LP@MHAG,=16@MOZK_]\=]X\_XO%.[%X+T<JKBU[
M9=VX E*INGQ^UBJR7BI3]#!U:1TJ9/_.0%07SEOH3"JMS\&2S:6,U&&%QMKG
M+(ZC("\CW9:4M(V[DO,(=4QNAT>.2EU%!N'>/?(=.]?(I=?4AU.,66APF5\?
M4JO+!I;8#=_4&8&<G5KM9H&SI@X[I6.SQ. L/CH>R%R.CQN*=(0'R6H]'WEI
M^@ LS>H73]BEA5(&B%VXU6:?:EBE*B8(F'S<@Z++9#TPDJY_QQBC^1=+=&:)
MWHZT+:;"5HZ;[?4H%Q,7[69.2=V )XZG3Y9M1#9'.$ +047X)HBQ(XQO?790
M8Y)O_<MF/O"5X+0$4D9G@39Q#QS2)E>N<4534A>?W(I\V\K[!;0H=XAVHW+)
M4Q^ZLFE5B;V+ON6R^UV[69,U5KW[FNQT@ +\ 3NT $&/H&?BDDJ*6P&H7$1?
M-?/!&8'$RF YZ-6O*(%+$4A%;NNLE=>3"RAQB (VOZ*I5,O_5E6$UL,N%9*M
M9KNI1<Q5D5A([@,4@-T %B*Z0S9=A,4U\KY20X#Z)7HT:<H?\P;Z90\T\4E%
M98L6I%JG*0>T$M0_6Q0Y,UNXGX+AIZ3E#8\T7%_SBK*U&E:YP 61F[-.*M+S
M$(6Q)@E6FU65R1MU(A?-[79S8[+G((YBNIQ(6_%,;:,O.5]<M)LY3;@Z7QS]
M4%79(Z-LH2@.:JEP6^A*SAR7[>:F9_^ZKK<<P4$RQP/^_AUYL$(LV.3;7Z>^
MZ^! A*<JZ.Y2-'*%[FTSG\VT1"C"3"G*/XD0U9%(8G6W(M<WZ$*^8]^USVL0
M]RC!L_1G*W2- +KKSZA#CHU'F[8EX/)->=7,)ZTP1!;#9&51'3PI*EI/4B12
M8ZE]ULK["<O(<HA64?'2#J<HP+EO:Z;S;M"%5%2VF^US[2U'?Z(]-@I^.N3D
MWF+B;.6(K(%:3F^:]E5([R*B'@]$]2Y?5H"@/_=9U<:.'9&7&HZ/^CW(:=YJ
MG^<2LR0TSQ:*8)* ]VDEG1ZIOUPMOC)A)PSC&?_SLP<JY;6+[*]@\ &"RN;L
MQAW)>8%*@ J\(/K]V<KT;+&N+=9W0W1^Y(G\?OV"@@!YT9:EP!I6.;4OVN>Y
M>+W>SA?='.FZ7!^Q(EO:T.O8Y'2\;)_G0HH2.B;(#Y)ZL!8SPE..P=*GM;>(
M-\%>I6JO,AQ2$[;]MIG/J<]@8\Z'%7Q'RFRMLF9=_/*]]ZY]GH\9R2AZ5)NS
M1,_D#2]& 77,VTR+T*9J*0+Y1KQJYF\C"%0-ALO*(CL2I&JFDP*-U*-T<=;*
MIU.4$^<0?4IER[L505D+N51*7C3;YSD?H82B1Q&I0>L[C,-[SXZ# #MPRO";
M3OQ&!':V17.M3N2T/V^?5]G-#8OV:26=L@-4W.)*^CU(-N!K,$*OE2Z/IS#2
M\_"BU<Q?NQ&KSL /<Z&W=%%7#Y]\%[7;K8+Z&BF!CC(S2\-;%'B@<8<#'+"8
MA#:Q<H#R;7/1S-]X2%!8@(-'1 YXX2NJC27@<G7QLI5/UL@3X1#5Q/7EW(H\
MJX14+M3>MENY\&(!Y8ZB34+3]<_4V1?SR55V1M;!+:?PNW8KY_ JI'#!E]G>
MCJ2&%6'_H>JX&SO8(=X-<6/0HG?) 1MT*6>,JW8KYX I9 P^ BL9 JT3(09Q
MY)D"GOD-!82><_=>A&$B45)-X[?[6WTND"*1:D279\W\]:8$G97@2VM\_)FB
M/-*'+VU%94D#E51QNFRV\@EU2EH=HAXE6^FJ$E8'EU1T7M*;*C7(=H#"L(=1
ME:(6HKE<P,&>R05\..#!+6Q%>;4"))=,8!?DU$8.?HCBA\\\M8'(!F5\U*CD
MPN>BW<IY/ 1E5LPT<N!F&E\3JH[Z'B^6QKZIF>"KATU..=A4^6I;">52U#2]
MAWU]T$F[?&%80;J,PT&$+2*?_UR/BII(Y<1\VVZ5G$(T+8_5T<LZ2I*J6)&_
M%*,'2U1>?/H!T,[BV0 M6)X&2UI\]#V;EA-TZ0FS"8EK=2$G^+MV*Q=!71)<
MU-,6'5I)CR(5$_ILI)T>&: .=2J\E+!1)T<FV#D3#./G$/\1PP1N7^@"Z:=J
MK@/*#86K9O[6>(K"XC@.>-VW<P.F"E+IYGI[UF[E\A1R]#K86,0OIZ_A>S2?
M4[V>?L,_>Y[/Q\Z^@F^PRVKO,H*C&9[^ZS&>/>.@/[Y#,^(N!@%-\[!Q%WH@
M-I 9/8<1_>[#R1BY(3ZQ/(#Z<** \HC+Q-B'DRB( >CU.7#)^SD.B._0(7\X
M(5X8(2\ZL4*@8$0B]KKNQ\"/YQ].>&L2X=F)%;'6XALOPA-0S> 'BN3DM'12
M-P1-/!_PVJ(N$\/\@.F@LW/BH^-3DL.H9^3$@;ACJS4E)PH:]*_PO>//$/$T
M9O4P&'0>/@X"'[IE55P]Y_=>C[W<T;'_B$G(V$8^RVHX3)AU\2W)#DV1G["F
MUXNTB3A4.]]0X(C++U\PF4Q!M^Z\X !-\!.F_1)OPIYUAO6)D3O"P:PCEJML
MX7[X,+:^]OP;0 ^]:JQ[UT5AV$\NK/2#)SK^\"/]<.\-V# TYU0J1;;9Q8Z6
M*P'26;";85>^^;(M3-A:Q4]4P-+"8H?05U^\;HW3.L[];Q[\-B5S((]-#\8)
MOO?L@&JKI63>=C?;/EW2E9OSWC263I1 I</XA)$;3;NP]^]!MDH90 5E E/<
MQ>X$OOB(08>#PQR673ZG\O9&S&:=LQY\A[V=SH1RJC[>X#&*W2B)SCRAJ)R?
M-\)I O,6O)7+]V@RU$$<V%/8:_UGETS8[]0HIOF^7E2Z+!MBK; P_*=G_K;$
MAQ-;E)2L(-9G/G K"A8Z^@>_5=D?#\G$8V2&@YWO8SB'!KY+[*1.;*GN4 7%
M%G:-$[V?+B@[Q,_XOKX&(+28!^3@D9]-0"]E 0E$E6G]6/INJ-AU)I,  SO3
M@#$L;$CLWY ;XUWKD\IN]ZT_@GB$W4U<PF_ C[LHG-)_J4QX02YS!GC.$Z8(
M;> 3^IMJT3;#N>\5X=)PB&U1/>X+ 8THCIXP<L"(OL$@)6<@.&&$=X@$C)R9
M!W@$W>_#,,;)AY&?R-2L7X5+V_!^W"4@ F94:-HX?,#EHMN D>W&91#R]+BZ
MJO 0>&IY.91JK"%Q,&>1Y4)45'OU4)IZ&/;@?,=8*$#,1SWBK$&[X1;;_;@S
MG\.)MGX@KJQ-93S[-^]2$H)M&H"XB;"[^(1=AR7R+$93%-WX.'ST8=O,_2"B
MC_)2MXJ<23;$6I]/'/R\.S8I-.QO7T$C(:&4+]2 >Y83.=T_J]VSI\V<U&35
MMR#D6$RP&89S;!,P61==-"?<IRQ>_^@J[ (-2%/%78Y.G#;UK,0B6!,H"V8J
MIC<Y1^@U\WI!4H1$;#[LE$Y4&WX#$^#'2ZLNB\6ZE&#\/*HFLPK =Z5^ZHJN
M5*(D#C?8E1]C1$>-\37V["E8J5\[,VJ7EIMXU;#LT >DS^%,P5CS)-,P(ATB
MW8<JLT,??M\F1L>=3Q%U*F9C6/>>_4;AEU2!F>#*^S1\&/;E\UAI8L*8DSCI
M[6SN^@N,U1'53,M]1U$S97(Z:P5Y>L1CGJ6P--2A!;OW[3+H/'P2/-_U U"P
MD3J$J@ R@>UN\#/8$S#XF$=:7C (ZHAZ0^Y<_QO]S()I=!0B'4ERNE='M1O&
MG<<!_J%>%N%JD[HR?H!+16\8^]8N1FAR*39%.@^&O-=3A$6U0$W85I\]0D.6
ML.WIM>HT78*ZN&F\LN<J8F45$)@PWT>ZYY7D6V]EPL@[+!-M&'L]&/,#\A#W
MJ2OGHH8S87:U8P?K1EFH-&YVT=6^157R?&EJFH.*\HA!-L/A%F-I*$\/UIP8
MWCW-)43N'7D% QV.G/ZX PT<,&-XG(2Z)%(^AR\[#AQ+A$X] EDUQ,$+L7'8
MF028M9 X,K?=T?Y=O@]@R&*6K9&>X\)G)=X 6BBV3P4,!DR7G<'4")1F$*ZU
M,D$@TCP"FA &PIMN"Z$5)1E#=X$_X[Y'MPLR0N*7K8S'V*@VZ%3O2G6J;&1>
MJ9I50V,"-ZPZY$+AD5OSWR3GTB  L9,VOO.#,2919;??QKWLUE'&SFC]E(]P
MY#/M-,";F3&J1)'M]6/L1N21SOZ<Q7B]R<8QTTJ8S#A3!GX (E.I>Q<V-4&>
M]&9(/O), Q/&VX$]I'1BK;0Q8=2@1/-ZB3T_% 6-6')<P R."!3>YYAI4B._
M^)@&G7*$9]0=%RR2MPC+SOE=]&6L"-J1#-^]R-Y+[@*O9Y6<U$] =SBMJ44K
MS>0K!MBW?SO17&\P_S_-,<%S1!Q1.H#ZYMEE=&&3L-22<HK716?LSA!$XV[6
MFYBN*C]&&;=F7FS2"(/7PF7LRG1F$V7F_VH;$\Z0HD#M\LK04F&J$^Z58=GW
M+O^]UULZD%5*5G%;$VA'0TH#D"4@/-D:9W))DJ56$:X2BGU3#80#7W[Z!V@8
M4^X=<[JL7"._W2:G914,)E#XCCBQ34#^)$Y4S00R)9RIZ6-)3#_1#=C-1LD1
M4MI^WQ[SXE3F@DMZ-R2<^[)3L@8F$W+D[NB=?) G+RR!#WD30CW_5+VAJ@^]
M:M"94>OA.P^/C$'W_2=&P9T?!Q*VW@"GH<IS7D-<]5=45C"+P4W-)&1:7EX#
MY!8"/9U<'%;(K*R+;M_BXHF$7P>^[P[C8.[&83^XP6-BDR@<XBCBC?E,&%/#
MGZQ*!Y"'\G?I:FR(=?^^,!$CI&&$Y5R60P_IUP,8S/K(RW=+;7S&6AV)UD*;
M=5Z))+MLO=UV(JX.@?&$@IIU<\KFJ&/[:N-IO9D)&EJ-*[Q\RZ7)2=N\'IS'
MO?]-W!ET:?!ZT.T-'U2W_8N:FD#F[+VKQ$9:C/QK3(TG;>5%&X6IZKDTN+E!
M7-0D4C_@[]^1!QM/%7M9:V;"V >!N%ERC;RO"E.XJ*D)<R@*VM7<<G50F;KU
M1/RW/Q8Z#'-?N O5W1,YE+EJ36&J0#^.Z-+3R%/)9?Z*N0<Z" VU&XO= B'3
M\V@LCM&LDDMA#=94BY%> (<1L;<5>SY21&W+6IL@Z6YP: >$13CZXT39D^92
MRB#,R: LOM[8<?X=AQ%\ZW_T?><;C+;B_<@B!,8*L,U"O4MAU/7#7=6@6.O#
M4#&W4GI1G8Q>TMJ$W5Y\ JV4[MO.H::'TE!Z%T])9/_%09H4OYVUJH+8T!5C
MZ0.C*0E86BFAQ6%D6Z2TN0E[A+EOV64(FACQV2.18C82 !/FLYF$7KIWQMQ_
MO:.#(-_-GBN&@-'B!PI)O]K&!%JOA5JI'\NV833+5!^M0I=J<!/F2N\JT]@)
M<E7:]WH[(T9?>!3DKEUMYX311VOH^2+FLY*7_T3OLO55+C(=2!/X83 COB+V
ML-+$A#%WG!=*^[0$^S .)CA8=#&-#2A$C1:L";-D4OZCQDGPT;A1*R(=JVU,
M&'5Q:?&,AVPWM<OK=+#_F%9R&P?LAZ2N!4LA"Z-EWIR$\FK0O:?:!;Z-L1/R
M"WSAE%_>Q0[[['NA[Q)'5!0M?/U34O!V<\RF>B99?('[E<>?D]2;_G,$7$P3
MEFY?0<V&TR_)M4RCMDJ>V0;F?;-49VXS^V+JNPX.5-IP<6,3Y*38M,+/M-#.
M(U;#F3"[XN(U/9PM6H->:]2_*4:QU[HWZ>7ZY(11<*4$P 3:\;&P.\9TZT_)
M7#6?<@ 3Y@-"H!>J;A*N-3)AW(6*#D]*K%<:<1UVW]F*7=]U\00/HP#3:X&)
M)ZFG>"]*"68$\>CMQ3@(R\PC9<6B"@B,F.\&E_)7(@T[N?:_UH,95_[3AVC2
M^KQ)?H6\V*(:T 26N$4!-;O"@5@29>E""<"^M<X>"A%(':%\@>+LVP1%(.7F
MJAOJ:D C:+6)ZW^E9AXO0<2_VDVD0=+=_BWZ#J^]U&59 <N:2JKKG#(8<]AC
M/=/G"Q /A.RX/TX+(R9V><6D(3DJ4RWU2E0VGKQU W]\)E3M7Q9IX*5E:"G]
MY*L=!1TU^][I33;=\SY151!758+$+VFG?DDZV06]*J+RY-3#M>]3M#22,_KF
MUXP!92!-V$GY>W3BY,\DH%6XA%<$;*HP[-@V#D.@#'UQ;;VDN3)HK08U@;S=
M#GTS<MA7>ND*&IHP_MI%19>R%S38>,85L#3I2?H<QT[[-.*5@VPL@KXRU1\7
MUR[2"F;($9BZ^1_H043LKVO/&*C\H%(@$S9,L1,ZH<<6ZKG+4>WHP-9T;-_!
MP+!'8H7[-]?,!,+Q>M*"LS[Y+@T,JY_454&9,#,^.N+HA(G25B:,?+1:N(T]
MO[H8X=?HVO7MKZ4;1P6VPZE%22\:LUNO(:*N,B"!V+=KOOQJCXBL5ZXTL@9K
M[(V+JGD8YB9?B)>P1!9$^C9K)MFYW-FN VLL#3=,9 [\.2](Z8^7]7&2<YIX
MO_D12R::P8#8<E#LQ+LC+XJJ$7L>E0G5?#J@SE(EWZ9O<=-7A%TR]@./(&HM
M*1[*4D.:<,;=!&_^!REJ>Z^V,6'4P_@Y\1SY :RHR!XOM^G*VIMZ[;GSZ4%U
MYRO3P@225'[$F&;!;>])9([-5'*NWT?7OKAN\*'5H>^KN]!6O,BA5XI0!64"
M*]_,)@J!F#8P8;R":>A^B%VZ.>YD[P>6M#:6SXI% 0R?/I#%U+W< [H%50(_
MST%&+&$JRIU-.S-!E=%U:SZ7O,^T-/968AH;>U&K=F=&*DQ)O3VF V^M>I\*
MFZF^U7Q$G-:<R2:\<Y]QB=U]/^Z2P(YG=$/8]/Y?N1]Z!SV9NJCKN4;2>ADE
MC<TIE;'RO*'2RUG6VH2SE][ITXBOY9J9,/9'''WS@Z\5,J=E$";,*'MY@CXQ
M, ;C6WGI0@%DPKR$'R$I)#=#$UJZ"<;JV;[K3T2*K7(C549CPMP[]I3@%_1
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M:2 GK=FLNFI>&<V^S89<3',TQ=QOR*NM]L>)29?<A@8F5]K'&V+==Y9R^:W
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M>SJ.G3PAVVNIK$F>?T[JL)<7&ZB XH<Z)'\YA1F']A3/T*\__2]02P,$%
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M/%O+-=J83.AS@WP+F&%="C8EQZ%;W[9KP9-2:&UA^;7C2A;,%<\@Z$A+,SR
MC[X.S,B&X"A5.DUMNQ7.D&K-&_/@\.UOQX3QIW$F+^XZ+1/6/IM!@Q#:@K+D
M8 ?&!03Z06'":1_[A$TV !I2L7AK-C000<OY-5<-#F\4IK/"F53D[V3A:T/N
M:@*;A(#"*Y>XM;E3 N]=J+9AAOL^F=%,&.T:X9[BG#9B^N%V3!B"\Z$DX,9Q
M.LRB!:]2 N-D4<HQ)3I5P]R-:QN*^.^3(@T%TJZCUOFPG-EY1@VA,,$)(<EM
M(H<Y@$*ER6V2DA9(9)5:.5OZ7(E=1]*M3W#-3! LNU0"+8MY!8IE!8X'#LYI
M$XI1WL4^?OE=J(84KCN(%UMWZ=U5% VGGV\QE]L%%72)] :2>4_O>B CSR<&
M6.<AYN+(].^C(;=!-Z307E.R-!=-,])</3U(C1*3JU/BZ.G,1W"%3@(ZTKE5
MI:#I=$^YB_"/.U2DD?#WVN*V$T6^CJ_XMA'=V@I]5E(Y(\%*0]8^EQJ",F03
M1%>$SZ6H3G4B6P(<4LRN*3UZ"*CMX(G+2/3:/+F1-AXU,P%BL97+A?S"4NJ
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M>Y*E$Q@$L[I/"LRN2(<48AX<XW8699N0\YT0;P][<H<!=;0@R10%59R'B"6
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M>IF)-""X8QSM'KF3@/V>J'TK :_0^-9!S!F@GJ1*,%[,V@!E3482GSTG*2:
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M'^&2KJ_A; PE^0-EC5\/H!'Z,!V<EHY>?S4_[Z%?X+(L(]]U&;5GLB*!,D%
M>V7 499MK?;'VV+?/:\Z(L*M/-Z=:K$"#W]'6W[L!P55.D4M%*%,^]]@+J:>
M4TDZ;RQ!FYZ6\6R2!!8LB91F'HR!2.N47M\#;%\8U*7\*]08KB3XY--HD*Z3
M>YG3H?B7.DL" DH&.^+U21OT0).E,?G,\@YWIOO@[@N5ZNNJ2K'BI)GSM)!$
MST .1I8FS3)#&3*@B;41Q8 PH<@@\CH9Y\M(]HD6#Y9PC8F;BU7.IDP?C2:3
M'EKXABL>B/"EDEJ58@<\%DDY&&GPDAM9)Q%@!9C]L7D?*. *Q\B'T7!T$]6<
MC9<,3]S%P!20;+TH+:(2\K&4/Y5SCN-IQRH-V+L7VK/G0[?"KW &7/&T^/&S
M]K+O8?IUE*ZER?=\YIH#VC^.<H44AE3J+#A*!"7CK*:JDB7:"M[N6=*Q6F\5
M*'2MDPK.RVI8'\$/2EWM[RC%LH#CX>O^Y&PT\8,>2)1'TIHDY8NSI3)QW)AR
M$KH<E-4YU=EE-D6Z;W2JJJD*!];EU=?<#:,>]]P,OA3;H,TD,EK)'DTH&9Q7
M*C,I;)T;R"4@^\:+;>1<Y21:4'.VU,ON^%YK83*BX1X=)!FS(5[X1'04)DB>
M 5P=CW8=HOTC0@>2K^"M_#D<W]JDKI^ P><<1':$N0*/64%":0MF?-3@A-.L
M4N';/<#VC1]=ZJ%"/Y7CZ5<8KY5 SZ+'I4Q0)&N+[A=#\]W:P$I;J.B"H\'X
M.EUF[\:U;R3I4 L5^JRL!Q;+[/+@.6YJFA*94^F)JP414F6JC6;1USE=?AIF
M="/["MU6;OI9LVGWYPAR'L09#2>O((_&,/N[S_X'3-[\0'G@\_M#/[YHP@-K
M1OHP1GWB61%C0R324D,"6L\D0!#">9;I\F3Z*AYSIXMZ]M&8IZ+P"K;2)>3Y
MNS7+$YSVK.8A1 #B&')%XG<$3VM*J-2>T92,E:XB#V\!VA,.;2?H"D;0R7B$
M*)IXLW2>,Q;P^=J5EF8^$E>FB5&CL].X8UM11^57&)Z]EA\HSAJ6"TROMJUV
MT^1TR!3I1D FA^N.BH04/#KS"I>=N76I3KQD8ZC/GB9UE5/!Y+D!N =*,\:U
M(T*C:2=!6V*%+0UM9-9.J, K]?:_ 6._6+"14"LTCUO,8%YTNWWE)_W8R\9Y
MFW4@VJ1,)-K5:+\C[6QD(*0#YFV=GL,KX3Q[C6\OY J=YI9!O>X/SJ>0>LH&
MP2+D4K:DB.3"("&C*!VKK*,":-9U.M.O ;1WVG^(H&MTHULJ8/7))MR+(K&\
MQ//1$$6/I!@NVB%/.><,*D]N>>Q.0-LH>0MA/G8GH%*>A@9L.H_3X_$\%ZVI
M9PS,*ZLX$+!-LV-T5%$"E)B0.'XA=5"M&-&JP',5@B=2VKV1,D<="K7C6MXY
MGNLIA_,2Q#:@.J_J7@MG]T7=VVOJMMH[$O/..,"],R(R2U*V)2)A/0FL)"YF
M18,,7OMV\P2>HN[OJ.;>D>HWD6Z'*B]EL;T_P ^F7P_1]#CT9_UI$[J<5V/-
MBX)3I@Y*ZGKPO RU]XQ8)QF)T4>K:/1LN0SN=KUMNT?MMNJZ(WV,J@FS0AGD
M%<#FCFT.BJJ8&7J4Y0QS)=XL23 FD"Q9XE$9T[)5R\;6W4HXSYD%W<FY0IK=
M>S_T7QK39;[2Q5A7IFA*#DGH;2A124$<H*^I("1'#4]!U<FF6P-H'PC0A:PK
MY,-=\?($-Z=;Z-"A0?<&UZE$1G3&&^(T+]D7I8A-&*-9G<D0=^/:!T)T*/D*
M"7/S-5\M^?JV96A,96XX<M:492=!\ 0S1/D<O:8^9U/G>+@+U3YPHC.IK[T$
MWDTOEO=O_N,_#CZ\^_#FX /^_/CP__OC^.CUFX^?WOSO/]]]_K\W06[7G^6>
M)]7LV;+)(I?ZN-#2Y \2"):3] 9-/\V,YHE3BP2A:FT?EWN>V7EOEQ1#IA"!
M!.4LD<XYXEDV)*DLN; J9%NIB6?GO5W>#6.9R0.O8?;/=[,Q35]' WP_)K,\
M]H^H_+>C\7<_3CUPN-5:?-.2D"5MN70]"I83JU4PV@B-_ZF5W+ )T"<1\=Z$
M)RN2'JHIID:?TUO@< &SO@ GI?P6)=_JKC8$X0T%PD2B9?9#&3[-%$E.."]=
M8 ;J=!;J!O_N65>5)K?B\SO7<8WNS+<FT DAT*<0EMCHRW1CH<N=12*"BHB^
M)F=,U''LGL"DOYWR9RO)=^CF-4&H&RD$#R$RVJ.?X?1L-/;CBYF@>DF$G+,5
M)&GIB,P1C5$5 V$@+5="T!3<?39=+7#[R:TGH<H*GN;[_G T;G;8&<*%#$L6
M[4>TD4_/FN39(C/T>?'E44*AS+1 ORH#)]F@Z*)@7H<ZF08M >XGZVIJJ4*F
M<B. V23FU^?C\FK N#]*L_WX(^(>]^-TWBK]H @%99.A7Q(LK*99&1U(; J-
MK%,H'9,(@K8\9IE]J&B0/0CS?E-N1[JLD"^]!GDS*/X.X,T(0,I**,!1PA4+
M1 JE2> HL9RIE.4^T>LZ"=9;@/XI>=BY-BOD=V_\"OT^;K),?6*,X>LCM9%$
M<@G$,FD(<$A:99TD5'(3'H3WIZ1?ESJLD N^Z4LS QT@2WQ=(DG!Q%E/?.=B
M)M0#=38E%U*=<MH'P?TI>=>A!CM,4&^<HUN(/W^%ZR_+<7[S \:Q/X'C?'PV
M[YGW3S\>^U)HSKF7.AN*EJLLD[D2)=[(2!1CG(F42ZB^E4>[%8S]Y-2.U=-A
M_OL]R)NWX6[@@IO@%37$!($;<::96$^!)*YD$F"U-'%+7MV/XJ>D5<?*Z3*K
M?C7RZV_#H9]\'<!DLH"Z6$7J94HC!RX(Y1PQ)Z/*FU &?#')T,VA:%H^C%"M
MGO\S4:E[A70YM?TNS WWUT,&$;)U69-$6>G"E?"8EM$2IY'Y2GEC6-B&0W<_
M_N>C4(?JJ#$(_G,1ROGXHD$_H_M!1*&,$9NVP)JR\^Q!E5B*(4Z!)RY8&I#P
MEM(Z-OD=H/:30%UKH\9 ^!O8&E8OH)WX<?/]K!=@+W'T/B,B,X$*!*HM\5):
MP@PSCFD=A:XS\Z(MPI^(0UWI:06A:D7L&XB+\E=(AZ/3TA!CUMG<N. "2#QE
M+8?B8SIBLU9$,T8M+8'>O/LHP6JL^TVRRKI;0;=:H?EKN^RD/[O)2LR9'%DF
M5+#2 E='X@"=A*B]0<@L4%4G_ZLUQ)^27%MJ:@6G:D79KW;=!= 8/5@T[$@6
MF1&)/@-Q5GNBC:0F:\U4KM.WJRW"GY)1V^EI!:&V;Z2R,G5C(:IRY?[J?-(?
MHBN!>VOH#V=;*T>Z.Y<\00>TB$8XXD3.1$A)<5_ET?I*K7D> G>_J59?@RMX
MMUWT_'[(LQ+&P2'NP%^@A,Z\T4(0!(:&HS*!> .!)"]3$/CB,+N4+[$N VRS
M!^\G<:JK8 5?MFX*<U=2T.LR\:IDHY4==5TVVA\S$?840#).E]:^U)1$64J<
M491$%24XY0S0.KDW7:U@/TGYJ'I>D06[=>[^_2_8)S^ XXP^,@RGB\SO>3:W
M,<:"D>6NH#3A3"Z6,"\*5%'.54(K,]6I>ML&]7X3<V?Z7$'&[=/SNRDRR,8H
M;7'75\$E(D.9K)"#("E9EJ7",X#5";35*"3IHL@A:^1-AD0B*Q75"GU")RTE
M%BS7RI>80R7'_>XBART*\F:=A4R,7%M\2;3+LDQ,8"38,E8T&1^90'.Q4DCU
MR?3<VJ;,; MA/G;/K5M+F+UN); V&I8I"4T;&K A. >T=(_(1%HD/VZKN#8A
M$JC I!&UH@MWP'HB7;DV4O<ZYFPM]FJCLBXQS8O0VX#:I$77QIQ8"6NWK;HJ
MJ&_E\*LN9+\S8DCF(K<VD^@B'HXN1Q)T<@0D!*L9C;+2O*,=$F)-_Z['XL,F
M(J\RD/[T=#2SP>>-)%CB5&:=",L,+48I!;$N6F)#U$E;*[Q553AP"\KNO9,.
M5'1K#.\V\JU0H'Z04B-$/SCQ_?1N.(\9S<'IR%/6>!":K,K8K83\SMX1[K1U
M.FAJ<YUFS7?"V@<B="?W"KO 1YCB^B MV@O/4:&GR($*1;1,N,<QC515BJ+Z
M"E%9IL'5<2E6X]D'&G0@Z3J#FE<XWW-LF7,:$SI3'''AF<<-\9&KD@JKFX0C
M&:K-:%Z+:A^XT)G4.ZR[3M#O'<$7/W@SG.)R&Z-'&"TB^D,D)8%&#S=(3@!)
MG T@ @LR\+MJJR<0?_TR^O82/WJF>_RB47FC[!4/?,9.X;;BZ_#=+E!F*.94
M;8.CA==WOSJO/W6W3MW6XA]U*+L.S^E;>+P ;J5,A*OLB50NE2BF+6%=Z96Q
MT=Q9@_D4=+C&#ZNFPDU$UG77Y/?PUU\>S_M%^T:=(7H3)5&412*-,\1*J@BC
M6FENA7,M^Z,L??#N3L7MQ#OJ2#9K_:-N&QF^ADD<]YORH%%>I&9<&?3OAGDT
M/FV2-%X7\VXPN8FO70_#S1_21?O"+9>VU+DP&2.8=H;*,NP"%%JN6=,H=$AX
M9$K6V_QQ6[QUUQYV?/FPJ^L"Q8.)@@LB1"IC$X,B7KK2:%DYFM&N \=;O81W
M/V>KC>-=4:H?O.W_@/09QJ?'^>"T$?C!,)4R6S18TE7O8/SA03I%(I31J=/^
M-U@T'SWX,H;F+WHQ@J1:HA63B[U*?2(>F"<V!<&4L#:Y=O6&72/;W=;5-3=N
M[&:/JK *X:(/HVGI(Q"A_ZT8Q1]@VK.1&>>U)>CAH$18,8E52D0XSY5C)0.R
M3JNEVUB>/VDZDG/7!LO;_M /(UP!FG'YZON>S93YD#5A.J!-YHTF+G-$EQ4>
MV3R!-:K51G+OHYZ_DBN(M.LN@+?0-<YP6@0E/N(WO:PD%5E[DDH&B11&DA ]
M$.Y24EY&_&^[G,X6#]M7I6\IU@XC/:OQO1^E?N['V4CJ3^=A O]Y7J)=,]?V
M!F[&'5IXW!,67<DOC90$RFS)E7)<"L:Y:E<EO 6(?:5))37LNJ?>!_C>_&K2
M@RS09=>:0(R*2*TB<0* 4$B:H5?/--0Q&MKA>_X\JJB/'?? NP+)0K+:Z4"X
M+A%8(7%G3(C91S1[960!S:"=5T3]/)S90AL==JN[JW'"R7CTX^(?Q73&[R-N
MD.A7]?#4-,E+6QII>R*SI,1;D8EG^ -!LPDM+=,-'OK\N5!5S!5:R,VNXV9E
MZN^&W_ T+.[R\?<AC"=?^V?7@!HG03L%!+PSZ$=Q3KQQ):!H.-B0J*PTKJPU
MQ.?/GKI:J3"K?+EH907$5Q>SPH ><XC1EZE;'M#"BA")C281[PT+)8M>Z#I)
M,1N W!\*U=),UVW?/IP7^1SGMX ?Y@>#B_]][@=HM$.:S>XZ&?@A'IJ2Y>Q1
MNT$JM+,R^G6>JC+*42?.\. 45+0ZC%H][OFSH))H:\P\O[R^N"H.OZ+H<<;S
M\EI6QU6/'F?P?(QX9)IH8ZER\VA&Q5A&^EGIHF5<UDFJ>AC>YT^I'>JKR_YM
MR["OE8(?CH:3?GDURC>?Q_@R9!@C5M9+$+2A5A.TTTLZ4G#X=@ C*>3,J ;\
M01TW>Q.4^T>ISG7391NWFUNJ/^T/+D[&/D[[$0[Q;_MQTG,^Q\  F4U#:0>=
M?*G!13V#\-K'I$+:\)1:]9CGK_>.15FC!=N)OR@F]^3S:+Z#+58.DUD/YDR]
MBNBM$U1>N5!,$@UOM)E49$PB/LBV3@'D?<B>/SVJZ*!&6[4-]JV;9=&367#@
M8)C*%\VM%5<N2!\HR25^B#99(,XE0ZPRALJL@(HZC64Z7,3^4.^Q--ME-[9&
M1@?XMDS7F&I+72\=%Y%[S4F,.N&6:S-NN19A)V>! 3!-VR7RM'_F\R=,32%W
MV4:MP;F"U3?9>W(^CE_]!([#H/_%SY?2'Z7/H\5O>CPRD7CF!/^'0G*F3-N+
M LUZ&I0 YR'<FZ/7%9@]H<^NU=)E-[6'+J 4;9R/9]$GXZTP*#>GP1"IJ22!
M*TU,1AN02RVCM+48=07CY^72 U71>6^TE2*9U9 D3A5:=)S0TCM&XNI)R"@8
M#U[@%TY[[EM19/TS:C?<J*KUCD3WV"TX5A4MZ)0X1 <$_X>2X$&C2PBY#/=R
M6;-D9'S655.=ZN^.\JE-Y%BSY*8-CCTLG]I(_.MJ;QXBNYJZ9)I%IK(E3 ;$
M TJB9V,8R3IJ(? KI>")ZW"#\JE.5+B)R+K.1CX8#/JE-7TL.7''^;!<!HW&
MP[Y_=W*P*)<UEG-A$M&T#%/G$MU4QBF)7,>8,E5ZN;W1.A_PWF<]8I'51DH8
MU9-@AX4&,WAG\6ARZA?%\,%'RKT@-&O 509!O-6!*(TN0:0ZL)9YQC<^]EFJ
M[<%RZ?P5C'%T/FQZ]<WN8 _]&*[((R$S)9TF41E5&O='8H.D1!N0.1MC&&LW
M=>KNYSQ+'78GN:Z3_@].#DL%TLGAT:?W"SS4^!@"FFTY:$MD5H:X,ON#I:1Q
MB=3ZEO/#5GSXLU3?EC+J.F/_X/3+NV&< S$N&Y%L("R45O24.F*]$R0GY846
MU@K%VBGKVJ<^2RT]5"H=9L1/QM/>87G587SFQ].+#XBLL;\49.6:\]25J2:9
M26*%H<27_K5&H%&FY!W6YN4-"3[@VNT(?K=\,[(.P3ZXAIU(M\,-M.#Y"&?S
MH-1EO>8RQ#FQVX#<I.-B*RJTAK=;+[,;38YVI88.+:G-P$:930XTDNQ]N7XS
M:.Y):P@31D&92VKU74[JL^+*&F_V$:FRB?0?P=\%'5V621"I1<0M-/#20# 0
M&Z7E#*)!W_[9^;L5-;2A,[R)>#MWAA'%'^\A]:,?'([&9Z/9S?UEIT!FC4>3
MAD59_(442)")$4<C]TIHJWV[:\P['[-_.N],J%V_[*_'O_XO?S$'8J/RADE+
M*"Z'2(FVKS?9$R\LY:;TT!&ZE7:O?^K>*?/!(JO0.O$C#$I%]TE96Y-<4](!
M1\/)JXOKOVD.K<8YE.@L4E82UKW,N-ZFM1R/V1D57:R3*=4>XSYX"I4UTZ%#
MOPKI_-UH@ZAJB_;;F!ZG/WLM+=Y!EBU44*4W[RUD0EH+%/%H*RAN>:5X6X9(
M- _,&6JSYW4*TG9%BGMZM#\>)S:1?,>.XT'._4&_ )J%S.;'GP*CN8AXZ#G<
M:B6ND* I$PEC7+$<T$LRK8:CM?(25V/8?2_>;34SZE2L%=IN7;:B/1SXR>0X
M-X79#:$]: 0B<)W<&"*%=L1"M(1KE6Q$MR716N.MUT#:)YNA&[E7:+-R'<^B
MXV8+1%5-A-N8'GF$RW9*6Y[<T(W$:\SLN(TLT=(%R'$"-I7!Z4F3H((BPKL4
MK$N6Q4I#.W;$@;936VI38!-!5U#])QCW87)P@BIL:CBN#Q:Q-HL$OO0K+PD<
M,B:$!IH8G0S@[VCT=:S".T#MWC385F?+!T)' N_01BA6RZ?X%=)Y&5ZYNN/&
M[9\"7 ;/30X64@:2<QDMD+PAP7-+M*8!\$>>0:LX1"N3<1ND^V!9[%1;'7;J
M*KC7X9J_5VV0=7ZI>3>FW=]D[DZWHZJ*Z=A;O0<A.,F"LIH(96SIZ&_*T,[2
MVIAS&U6&:%IY,4^6,G=<:#Y%QFRBC\YO.YNN]/.[F3(+O,Q%NLKFX28ERG#3
MM<F5^#X%],2S(9:B4Q]B=H&UJ[*Z^SF[O23I4AVC.K+L^EKSL$P[.A]/X'7?
M?QF.)M-^_'0^_@+CBT,HMT-'@P5*Y1&+RI%HZ<NX#QI)B#P0YF62 D*4+>MY
M6S]R/Y1?1\(='PR7[;R:[2QR<"P;1IPL5<4QJY+1(0A#HJ)_EG67T<L;C]X7
MV_+A\NRP1^<-((O;W190.K<.ET#LWAS<0AVKE+J%+&N]MXMX.[5.9..(+"UA
MI1::6"T%\28B6:FGT;6*.#T=M=YALM71ZB8BK&-T?3H?'ODPN1I(<G1TN,B
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M]'0TG+7L&*9_^O'8%]M:10!69I&8<ES*3$W)M8-B5T%4>)P*:!>^;OG />1
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MHQE:Y,Y$W%@3(S&;Y-#0D3FT:VNY>^Q[R-KGP((5K']P)/OZ>M^BN"_#\9<
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M$-0*#3<,<R>DT4!EBIIH6:JAO4O$.>J(4T89FK+JF5 =$!8^A7'0Q?Z&#_^
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MT HA-/7,Z^@=;ONVD#.5:GO%-='!@P9F+)KJB684;[9NF'X=15@/Z/=)UR@
MKK>*V:?)W%_<_?VKR6S^^V3^?V'^ >+D?#SZS]U4U_4_>C?_#--/G_WX^GR8
MG1DG020FB:%2$.D,)X$")PJD"\H[2D,;H1]LRD=X*-1=&QO]@J,VKA:IU,<*
M#N]X27>*#I.S*GN1281<.*81K#4JDVQUMLR;',-C90,#]J"ML7YW=MQ8G2VB
M_O6(NS<]ZP$K/,JSM9+86%P]1@6N&$6)<197#,["T$9GX+90?YA?564VJ&#>
M65Z+B?R]*\A^,[Z>Y]^GD]GLC'LGO6"1@)>6R"0QDF19$)J2S"I3P)D=EX^V
M>3+?GP4?V"!:%'/O.J7NCW^AQW.SD!FZ*PQ/"(VG14C=8R1?^G(+HKB3%,-C
MP_B1&?>:6?RPZGV90,66:[56Z+NK^6SNQPEG]&\8G7\N_OQ7F/IS6)Y*[Z<8
M IR5VNP<-<=5JZ$\P0!26ED0*S-X:Q*WC3A!]S3!'XO@" RG8L^[P=.\?AY]
M2TGS(%:]?[:=@6)1&$OQ1!.<X F7B$TV$)L#S=3A+\61Y:*VG.&/%7(,IM.@
MF=R^YKFR372__,7/X8:TXBQGKW160+CW*(A0")]HD*3\D MM,J6-ZL^.100_
M%MFS,+X&'7RZ68:G!1&V%L2+\_,IG.-<WXSGT]%X-HK=A.\<X&?.9YE=]L1#
MPD-:&8>'-.<8DW'GD^7&^89QS(%F_7VNM>=@8A6[7US?:N\J]U6.@=LS6RM0
M2GD,]JPOI%[*$2]T>?0<=<#?.1U75LRF4H3JV+X;NSX&W59DB^ZFLT"U5=98
M<F%+HRDB94E!Q%*%%@PE/%L>>0 NE.QEBSL,_GT96VOMU*08W6IU/-CR%S.]
MF<;]H%YG)I3@D2C3W9+92+QQD6258N(BL;3:-&K@[K<=ON_+*(] QVOL=OA5
M:+67#=$!"S$'PD%AD*VS(#:@_^$#!9^RE(HUJGK^#I\U#7)0#Z+RXWS69%1,
M1E&)-E7(KR-H8FTN9'>!L>@+DTZ;%KXG]JQI*TMX]%G3-AIY-@]">LSIQ[.F
M'9XU;64L>WD9LH.FGXL5\V0S#Y822E4H9PZ0($3$@,T!Y)"]7"5Z^>ZL=ZMG
M34=GO-LH>*_/F@1EU/,DB$KHXTAPBH0L'<D0\*31G+5Z,7_JSYJVTGCO9TW;
MJ*M!>?$'F,TQMBJ$$@7:\JU5\([KD(G5DA%)A2*N(\73FAO+>4ZI36G%6C@_
M[*>"FBJWDOHTFA=7^,TX%4K4*W_=84)Q94 X2KSUI5$ ?A4@2V)]1_^4D[*N
MC]WTZB2U%L+W&1W4T4CEGI(/ /U[-/_\ 2XZ><P^C[Y\FKR^2T+6!VKUYH-;
M@MQ_2\(*:GW,2!KHI/5.\P1D%F0 +PTJ6EDB/3#T%+4G&IR-/# C $[+?!YI
M:GA8Z]E&%=7).+_$A\Z6Y3KGTH4O,CPF<>((*((C*8*U5F:3S$K:=1/]YII/
MWV\/PZ:ZF-049$6OM4S\E]$4(OYZV<1<H?,C$YIQ H7^L];7U)74,,]X=.AK
MU7,Y[H]]>@H?*-_*._^'XC%U&Q9C@5M*.:$AHD\D+$/7F:O2@"HKB9XN2[V*
M@7HI^6;8[]>7W$WR%9_&W(!86&$?&-5]PSL ]N_W[:B"524.D%^+U;R 8U14
MCAI-#+-R05*D<:L*WAK'K=) >U'O'(<:'_&_ZFIQ&[%5UMYO**G+J\METLIK
MDY-3Q&3T'27G%L\68XD13.%IPZ/-O5X6]-+?O:'W>^;N+/Q)#<E5=IQ^\W_=
M 6($>OL2CW1-R[O>C!AL%%WK*AI4RBZY>F'2O:&?H0IWEMQ!:8>6E;"SV=7E
M]9?_'".&EQ<^_H$^!O[#6742HBW&;$=)M.O$5PB*0&D'('A21LF4?7&H2Q$^
M]Q@[6T,W$!1M,?K!Z8J"!9P*1.($QO\2'0!2GD(3@^LA>1.8<XVH0@Y.5[1S
MZ?G-^XP[&BZ\VR4[_PFFE^R,RYRYUCCIR MG O/EX10*&2,FR:Q@+K?I,=QN
M3D=X!U/7NJN]3*AK'BT8A785[&,S^]>D)"(N1O-O'_P<SK12FBFO2W[(XA0Y
MSBX&3DRR3$M&?8KZN/:5_I/[/I?"$1G,(6J MIGBA]'LCU^G4%X>P11F\VZ"
MB7H57)(DA!C1]Y2<6(%Q *3 G99@LCRR5B-]I_9C/1S46%J1+EV7W!N'@L@T
MDT290"3E":ICBC#&,Z>":;O:YZJFV3[?IQ.#[6M[\1\3,]%C._^RB>[UOI^=
MD1HM0 O<[253@7@+B:3@E%3221T;NLHMI_9]FNW1&$M%8J-ACSK7S>[7R33#
M:'XUA6Y>G',3F08"QK!"V.2(M8D1HYRE*J:45DLV:[_<?1KD=V/.1Z7M%O1#
M]6X7E8I:4DTR+:TF,G7$TQP)MQ($3<JP5MPHW^$CMD$[\T%4?NA';)OKGVQ&
MH)$#2='A.2+P#Y^3($Q:E6@ &DPOI^.[+E/=QA*>+%/=1B,'KB_L _5'F>H.
M:AU0:+B+3@YN1DP(WA4 :$VD!@SVC<DDJIB=U^C6VG1:YK-UF>K^K*>_*BI;
MS6JQG0 .P5B2C':(1)K"3&E)#A%2T#E&V<NC.KEBQJU4]$@QXQ;RW7CSLH^K
M^R434/7[^=4/;G<)_^@45EL!,6J5-%I'(]%]\-;)"-1SG7(L2WW#3?OJ$,,"
MHU<7?C9[EQ<?^F[ZH=#SW3K@26FA0'GBM<3="#<G$K@4Z(4;YE5*!NVQ2;3S
M.*ZAX>#:3[]'NW+SR]GBMS-V1AU-:&N)>,M*&9.,)+B82#; DHB!L= F;;<3
MW/WG+BK:TFHPUUYAM;OGK45\35AU2SC+C)89]W:',B R2$ILE)8XXS7HF)SV
MZ:D=K^]@)V$.321;^Q'.6GS7-*@;6% _0!'H:'S^:C*>3WV<HV]0JB;.!(UX
MZDM/>,KE.8,#] "@5-+RE)B+TOE^3W?J83IQ.VJOIXI7EYNGL=@:NZ1%4$HQ
MH7 92!.(5 *7@16"* B:*=!.A7X4F4^-=.*FL:M,*UY1K@&W/.X>(_^__<MG
M.4>I=# $$O=$9J>)-0Y/2(XQAO><&M/OUF4(BE,UE(:Z:-"R9*U,KO.<TE#&
M*$=WB=I<=K%,/ --(D0G@2D$UZ9+]&9,^[JUV+<3N[W #WW%\/C]3O?3V8NK
M^>?)M+2:[,K [[RE+?P@LY??[JV)VP=#TJ)=Q"Q)YH6DM;RY]!P<45$S,,8)
MSO?9WF;09 YUW5'+S'I5.NQ/W7LK@.PUI8<36B3M^DSI $Q^@R9U&"*_@QM<
MO050U5J>R4*(@5+A%"/)TE+.&7+A^$I$>*/! :2PUX:31[@ GN "_![L?QLC
MJ9VG6:'=OL7V;GSS=C(E[7.TA&6&\!SUQ)D<2/#<9(X2<]+WBI:>'NM82LWV
MJ,\UC/ZUE%$[F[L1WJ<_)TNV 1LY8PFWHZQ5Z1G,B)>E@WKYTBE.7<]ZQJ?'
M^F$K-96QMWWE$ZI]:<PI<!IYSL11JDK#N=+E).*^3$W2,ABC!1MH+;>C_;"7
MN@JIS!EX>SPGM$VJ7"I<OY9(3?%XUDD1EUT.B@KHV?_K>5#^5 Y4=Q=E"WTN
MS:H'C%/E\-E*!1O87W:17T,.'Q&E%$HDW!N")C)K1DH1,G%@8C3) 07^?-38
MB\.GAA:W$5M3#A]'\:3(W!'C$8,4%H@+Z!=P;;A0.LI(>SU(?4X</EL)?R.'
MSS:2:\KAPT"%*)PD0OD2!@ GW@1!.&2GI1#1L7IU[$?"X;.S"G>6W)XX?- [
MO!S-N\I[/T[E6GV$LQ['$;J)*76?[R_>C/-D>MEYD -* W<=JD:Q8)5I/B@?
M-!CY,N4D&D?&75BGH%.BU' +!M39KH,.N9J^'?+%RI"W5V@L,BZIX(1YAKX=
M'B[$64M)UI11F1*@C]_O"KK':(,BN??HR^*G^W-XEW\=C3U^M+_X^Y4O[BK
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M_W.!.OIZP@ &"+OR,X!'T"4&D(U/)*I4* 9$1HLOW7B#]\9HC *@%R7X49K
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M#4+1IVTR'4)Q[K%67;4]:RSUAB&.?9AN)U(<@^J4T53/YL1+#*)JIZ\G"#!
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MFQ)L*>398 F=>HCV]L?U2X0%_ON__1]02P,$%     @ 48%E4Y7/!R9K@@$
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M(5*:2,2@0%RQE(\9I*'ZR0LBR4C*DX3[5FGD7$DVM36D54RG#S Y^2H[C[[
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MYHE2LRFT3$S?!WJS96)H0 ?F?2T^U/(#K< 5:%1XN0):5J"$=9CA_@*HW&;
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M6=:J4)7W;92PX-3+QLU@N1MM-(:VVT]<5+@"VU<>-@-SLSTP=V,/C,5B-]H
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M!+$?^E7]'Y9$3*+ R!'2W<W4"+SED594\)L6%C32VM2J.8VL"3&[P&N,W?_
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M=Y] (VV5)6I]M="",BQ@-R"/8< <VCDK"E@+!:L?M=S'<>V3S= "8(O4AL,
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M#!2.Z]R<ZFWDZC9GE#ZL:7/NA7[\\#E?BO*^,B%TX-AGL9Q%B@48]C ,PC"
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M_<'. )>:A0"+X\9;T2"/S&!!T?8FLT&H!:4U/PU&);A!X+RDNF$W&7IL>D[
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M4ESE7K-Q7\V2J='0KXO55G<@]H<>J+9QL&?NSZM]0]R<M7^)=8_M\/57L=R
MK?V;H18__VE]=)L"T%IST^0QF<^MP0^U!CL4;D";1A8PQ>FU%RQLXM2K63-N
M.M9K+]I1DM>K*S0P_,#FV_EVG]2ZZPQ0")L0H3%$>9%"+%(".39O1":80@QA
MA,K<,[QP2L[TP@>?&K)IM/3<_Y_$T7%_?RTVD>F\4PV\40OQ[9&M?H_07*$7
M@[ [[Y.2QMU9]QE[M'/N_? U&>N6>I8+\T)^NWQDU6)6%C9%'7%8:I9#7#3#
MC7,!,TY$D;-"T&1 COH+*5-S3[N<ZJV6X+=63\_:F-.(.KJ,U^(4>]?L#='
M//,S$$3(+'\IZ15RR<\8>SI[_-R'XW:-^Z3^7'_]0\V_JX_+Q?I;/=.(BS++
M*!1E0B'.$@EYJ@N8*IEPFC'-M--LA&L5F1J)F.]:&J=MW-$2N%'*&,!&9AV_
MMG(WX+\46X'[1< !A]>"^"H-YXZ4F60#NG.0#6U(=_9^UQ[*;CI:F6V9JC\L
MV:*^7<BND'#QL.MSU1;J2ZZTIII"4E(&L9(9+-,<08(5(D*E7&J_N;C#])@:
M/>X? &X,L4&@M9UCU1C3=+S;FG/0Q^VZQ@I^Z^=['AMM548\D0V](%<<R@Z"
M,]*QK)\NKW0P.PBP\T>SPVXWC&)/=HKX\:%:J/=K]5C/A,)$4Y)#;OZ F#='
M,3F'A4Q0RCCGB'BUG[D@;VJ4>:8=R@_PFU49-#I[DN(EQ-W(+R".D4GN.@B]
M:<P1F*!T=4GFJ+3D",!+^G&][%I/[G09=M=AJ2@+5F9(P!399G^((4ASR6!1
M$"ED0:6D3DF\?F*G1CK[;L&Y7@-7M[KJ70=?!RP4NB/Z6\.!O<*S<L$IDB/5
M*_J5_"87.,Z[24Y7#RB>:STM=;C)_;I\HVR X]:.K[4QCG?F6SG3-$U)03E,
M><(A3NQDEJS0D*><J920C#*G2?2><J=&6%^_F5=&,]C7H]#* ^9^.HH(7F0^
MZI0^$5'[N@1O-A&U1OLVKF;UCP.Q1]U:'*A'JE$+"[E?>9H_<+VE:!ZW&Z_L
MS-_&@Q*S 9</<TA/-+2P$[PJJ=KRDJ\KL^W6:K52LGW/;/SB^GU=/RMIF\*:
M'QIOB20*"6ZVQTP+^Q; A>W@DT(ND40T124NO7K?!]1M:F^*?VP*0^NVRF"]
M,\76A3!A[&F;POGYM2&7T\WY?:5%BOQ&.M7AYP8<& ;V++O9N-%;XT!K71.W
MW-@7SI.. 'I0=SND?J/ZY!& ?>FXQQ QC/L_KY9/:K7^89MYK\UMK;BGIAG<
M)LS:OH":\N9[_6NMFEEQS>OG5A@WY;D9 _16/:V4J%C7(_SVT3:6^=_6@2H5
M4CF6)2S* D.<XA2RG#"8854@33#."/9Y)<17>6IOB@^&06[ 4V?W34,H:F/U
M#5@HS\X](RRZVXMC6DL9^7WR>;M^C;GM,FXMWCO=ZCSRMKT'7&IH[ :-X>::
MQAO?LQWL&]_<9-_\<*^;\98JZ%MH!+5'?3F-MPPOWUDC2A[:C'TI?F_?CV^?
M5]7BH6W!T59QWNZ\Z7J6V_&B95%"KIC9I$@B89DC#0DN4L4+EB0X]^O([BAY
M:B\6F\B[MP/A/\ZU%P4_F1U)^ZF_^'9H=UT5QT![#*QCQ]J;B5[=;J#5>MNG
MJ57\!NRK'K)CNR=:@=NVNTH?N7>[)RC'#=Q];S",T=X_/K%JU7:*-SL \Y6J
MC,??#FLVE%NMU;SZKN1,*)(*)G+(,U380M$$LD0JJ)A":8H+7C*OQ 1'N5-C
MLYW:EM-THRAL-+4\UEDQ:(RZZT*X45@$>",3V"&R.YW!9B;[NSVPP[&7)U!!
MN<M5]JC,Y0G(2][RO7P8:WTQ_L*J$L;7NV/U-]M/N6L.RQ!E)*4)Q)P9FDJ8
MM,TN!)1%QF2:):J4J5\)WSE1/H_.6*.4-YH"853UHY_SB#)-%)(:YMB.\.!)
M DNL"!09(Y(E>5)@K]!*"#S'8/HX:+JQ=PB,(M/U'CQ6QZ:XO=,R'#E?PB$H
M&Y\5-BK]7C+Y)=]>_/R C(Q==L?[Q>=5]=WLJ><__J[FLDU2^_J-K=\NE<V7
M_:)L>^]/9@MN";YMR5HDB/"$ES!/J4UA90*6QG.$HM!9*C,L2I5X=#.^2IGI
MD?1^YI-MR+JQ"'PS)@'5#8[S2#JX;K$<4CU&6X#8#N9NQHGM8;P%WIJRR9&U
MQ@!K3=.#H[4'V.KXQB+OYL;7K8U'CLAH:S12VDC3(Z+=!^P/ICGUM/P :[MH
MTB[:PBS:JEVTA5FN9AO6-4=^4JLVN 1"=3\.@GEOQLEU$L9+0@F"Q$%>2I@[
M#HSQJI5AX#>?S<HTIZ--)*;K;$'25#%[SJA*99QAUE2Z*04UY4629FG!A%,O
M/0=94_.'6U7!&[!5%C3:>H9J>\!U#,Z&@2QV./8,6C%ZB%P&)&S$M4?>N#'6
MRX8?154=+O%CC7JU-C[XD_G>?&.UNGU8J:;95],I6:V>V&K]XY/YGG2=,8H"
MT4)S#4O$<XBE0I#9L;V%80ZLA11:.!5<>$F=&I/L:PFLFI[-1_P@[V>5:$!&
MYI<!&#H3RR!,^BC&W'"/7LS?7E*+G\112&80"!NZ&79QW*XFV]1S)$HA:%E
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M?TX<X530I! 04:8,2R04,IT2R'59)%J*+%5>L[XOR)N:4[)3=]/@Z<&H;1O
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M=%^/:MBX]A7ZC!O&OAZXHZAU@%M>4W:LFHZ=VP%%'YFYM?GS19M8C#.1R4)
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M-K#QHQO& MB8 '8V@,:(IA.(:B+$^^;<M"&/QI2@P8UKL P=Z!BDR]A!CVL
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M2'E>8)66-).)3[S\M)BI1<A;+>U#:@<H@]5&6?!LM?7LDWL:6#<__'JX(K_
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MA>J"  EBN) *&^)CVOP'8UAJ1"##7*%,)UB+S*/@^+)$GV=OG#KC3N<7;99
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MAJJA'()H?S6EUQU'K*L<8NEAA>6@.UR9(7BJL \AP04J"X@R\W[ 6F%8ID3
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MA?E1-.4%FS(XQX69=)Z00B<$ECC+(1)$V50X"B56QKJ6-$EPZEO_SX^$Z5V
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M"40YPI B5,*$8"YY0@N&B%>L1,]D4SMQ#F@%*T.L9[1$'[".41.1X!HZ>N(
M*4OGW2"9["YPQ(VEZ)MPW)@*!]9/8BM<WGD=M]B>DO_K2U,6':$B1\2(EH+9
MNHD9A[1,A%F1(M<XEZFD?%Q/UPF-TW->_:P>J\7"=G_CS/Q"J%=0@R^N*.4T
M2ZE2,*O-'T%S:&8NH*"XX 0CDB$Y>ZZ/L'<+^2^PIH>T#N^27.[[BE3]YQ37
M>1Q7XTTK-WT#9FNB'#@(&TXG8*5<6X1IF",7J?S7L#NN@1S; 7=Y(C^E0*IJ
MUA2/N)?2[*OU&_/CP^KK\H_%3&->4)$*B!*50B3-<<!1H6 N19II+H5VBP+H
MF6-J=D-#)FCIO .64H,CL+2ZR>H^0/NE;228!I:700@Y"SL'#,Z(J[42?WU<
M?O\W\W8CJ<P/M8"J15/?F*,(%P>F.O'@\FA@S7/%-SNW1)TPE?&$,)IPF%*4
M0,0S!4FJ,2RE3 BE69;X)<"=3C&U[6TIW',T!J6NG0'238NZ#9Z!M[4G,O[U
MN"\R'[<4]^DTXU;AOLCF20'NRT\&1A8OY_/WRY75$3XL/E:,UUD9YE_^OGAF
ME7PS9]63;1/?_B#_]TM3EL'>X"W6:A> 7*04)XF$N>9&*K"<0<IR#8501B'0
M/*?"J3Q39+JF)DJVG !M3K^&%]#P4(</M#_N^ $M0W?@7FRJ[_9-8P?NA@F.
M;HZT[FY"[!56<V#)]QH+Z1]A'1?VN('8D6@;-UX[+J G8=V1AP\HAF.[X7U:
MKC9L_O'CF[9+&TLSD>"40:$PMW62<\BPD>TL%V6:LSP55#@7OCDSP=2$](Y$
M8&CT*+AR#KQ^ 1D#DH$EW2$:L?O>]?#>6P[EW'OCE3[IH?J@S$G?<P&;\^>7
M=;6PYMWRB5>+VO?3W1PW9; ^F47_QM;J@<^KQ_KWS87QUV7WFUF""YY@P6&9
M9D91DX6&5.L2,B0X$P73F$CGS1R!H*EM_C:NI*N1"9Y;.L%RR\(=:.X%;(QG
M]VL/*1%C%1VDRLAK,[ 4ZK@!>^SL!0&UB]41#A[V%NO3=K$^O<YB>=37&GG1
M1JJ]-<[B^1T\$9'N/:ABS#/>P181E8.#,.:X88Z.#PNQ4F:8MZKY\\.BCK&Z
M%\*VANP:FLT*04I2Y!3FN3DC42X9) E)8*JSK$A(R5.4^ 4EN$T\O4B#]Y5\
M$15;_0"L)36L+Z$C\&Z.A/A@#GQN=02#GSJ2_V+M_B94M2.[ZV@8S_+WPRFJ
M8>\X]:AVNQ\<QV:YY]NAC8L:<[]2ZU\-4TUCQ:V;K50J*]*BA#JE.41)2B$7
MR-CA25GDPIPY,DW]Q%+O?-.31CL:P7Q'N6]KHEZ(4U[(+!60(TX@RC(&N688
MBIQCGHI,4.I50B,:P&-8/</#ZR;?HX$VDOO7T'D']L ;PHOKA$GD_DU],X[<
ML<F!^=,>32XOA0;/=[V>:D_L<K&I%H]J(<Q<;ZNUF"_7+ROU5?VY^=FP\8\9
M085$N5(0*YP9J8(D9(P9(<,H+EF>(IXX^4[#II^:F-FCOKDEV:??-];>:QW<
MQ,]PZ XLCWJ!!3O:P>^6>E"3'[/481!ND0/WO4@8.90_!)[3X/Z@40+\S&_F
M;+U^T%T5[H?59YN5VY>;NWOX_7*E564>VV9!%HE2*-4I%$9;A4A+&S"$S$^B
M%+I,*5,,N>FN\8F;GJ+;D0K4G\^VR<6_Z8[FVYLTQ5U7!Q_TJZW5T.+6\@4>
M]+9A 'A8@9JWJR4>]M^Z ULFP8>K&:I#KZ>'F_K5UG6LODG=DCW72[;=;+8)
M8M?=Q(:OKBS#:[#;HO)E97,V-M]4>T?TUTCNZD$0[W5<QYUQ/!?V($@=.+.'
MF2%N9="??^S_IHXWE2E)=*(26"J5V^(4 A*4:"AYFF*.TR(E3CUB_:>>FAER
M6.@R))S7 W8WRV,8, <^!KUPC%8?]#(DHU0*/3/])&J&7H;%M7IHSPB!PLE*
MQ ?]][6JJR$_\ VK%E;TO?M3?+,I2T8:/IASDEE+YJ-UK6^#WF:D*,N"D]RL
M3((AXKF$E*4,LHRRC% BM,K]/-XW4#,],V%+*)A;2CV=)[<LC*,\&P?LH06<
MY0(N-31\@)H1T'%B;_$Z7NH8X-V*U.SL0GLC2L3;08TK(F^@9UR9>3MP)T(T
MPI#17#.M5OEBOOU.K[Q_?%RI1R/-/RPVQB995Z)NK#F3)"\%XBF4-"<0(4%L
M'"\S^B O"[/.29JIF[TQ[O1,3[)>=L#<;)E[+%.P<V48Z%_1G[+'T,Y)<@>V
M3($M5TWKXC%7Z6:7R3"K-9*79 ?\][IG]#7GB#DQQW"*^&,:X ?QF.2U71_^
M>#AX.P(&#3CMFAC!7]3FVU+N6D*_69H?5VOS;3_H]]7"5D?YK(2JOMLPG(<_
M%DVWZ%WIHRY^9Y:SE."""YB560D1XPQRJG*8E@4K44(HS]P36>+2-C4721N<
M^U2S9W9NQ]\=$%L.[8;7#8]@M67R#BP[-NUV;_DT0S2,>HCGR*OO<*2^WIH.
M?,"VR]EP!C[L+>>..7O^MNR!SWO+N>5PK\(;^/#JR^EQ]K[>LHYU7S'Z\OH=
MU,,L0.^Q'7G*\0[Q8; Z.-('FB(DW90M6%.YR,8SV/"L=9=T2DHL2%%"R64"
M4<XP9+S,H,ILE"9-TS)WK [8/]'T#- =J?:L;6CU24*]"*G# 1@%IH'/LCU\
MMD1>3TOU <KC:(D"V$BGQ#G@8J7Q7H.A/YGWXMLCIO1>X^ PL??JTP-&E^Z*
MKBA$!;*9^ A;>T88>T9*!4LA:<%9CDODU]?:9_:I62SN(9"!)5/\UL;MFF0P
MQ(=VV$4$>YAHTT$#Y/THF%ZLZ;4 ^K!!;DM\<J]STOSS)_/DIU6U7-G&;^MT
M)@4ALC B4"*=082DME5*C%C$*:89+V6&\]FB=E YEAZ.1)G3MJ7-MMVG;[C=
M6Q/7^F(#DWQN72TW\3CF"DR^;E3[*\O;'6B6L&8O?J91)+@'R4FZE;97R5Z*
M!.BE/*=8PP<8\!_9FLWGRA:Z$6Q^OUXO164DV/K#,VN-*947DMDVP$S:,O^V
M<BC7G$-"4JJQ)ARE3F&';M--32O]R+Y8@D%+,=B1#/[G_R!9FOX'^/#I'GRL
M%O7]65<GP<.,O;X"YAV$=:I@2E)NSD-C,' E-,0,%46)L<BQ\'"E1%V#<5PJ
MEU<A*M .#I:HX U]5EW^=NTW&[D2F#,RO:Z$ZZ.,YU)PYNC M>#^5FC-]KKF
MBHWY_*[>L@U[T^3'SK(2:9W( C*!A1'4U/RD<@$3D4JIC!+-4>Y7N/W\1%,3
MT6UM\CUB@:46M.3Z%G"_@&Z_;(B)V=!7B8%P!51S[\?BAI+N%P8>N:Y[/WNG
MQ=VO/!]F?AL]\$E]-@*F/<,X3W*2L@(2BE*(,LT@SVW22"IPGA"4">Y5WOUH
M_*EM_IH\8.GSLX./87.S9V\ 8^!=O<,AXKE^A>VH]N'Q'*/:>1<8/+;7+CT6
MMG.;6]PO2KRLZE(7[[__6K4RP1B N\(7,TI5K@M.89K::X(DR2 K&((IDFG.
M;'(V<SK8?2>>VE[_A:W^H3;V-ANLM\1OS3#5Q%#L?N,G$)Q7PTU2#('QT(I!
M ^".YCOP_K_@KQ_BR1%?4*(*&.?)1Y4\OI <BR3O]T.=_ OUH-^LC%&S><]$
M[;3ZK)Y895L9_KQ<K99_F!_>,/-IV1RC)"\(S6SR5U(JB!3BD)2$09D@4>@$
M*TJ]6JC[33\UN77_9.O, ?:=57/_^HN>T+LZYH<"='#_>^-H:T@''>UW8$L]
MV)(/.OIC>MA#<(OL2/<B861_>0@\IV[QH%&BQ:>OWRP7Z^6\DO8J;Z941HT&
M)B!/2@:12#2DI>908)$7,L=(Y[R[E_QZ4^SYP;P!MXY?QW.V[%-Z<PCQ(=X.
M3MA8\+UN[/;Z;D@8;PZO#H;SE6.F76&-$0%]%J. L.;#<5X[5ODL5PX!R.??
M"U,XF_:F#WJ;@OM%/=9SS!126$MD@^8R#1'%VDAF)F!9I +3@@G,O.J\7IQI
M:FID0ZA5?I;;5/5U2ZN?2GD97#?M,0ID TO='5J[Q/XOU]#RU@>O(A%5];L\
MVZA:WE6FCQ6ZZR^$]@202ANM<*,^5M]M[O[&? &5L;#JE/[U+^Q_+U=U^N.O
MYD-YN[0:Y$RBG*02"9BA)(-("@DY)2DD!2-&4N<E+;B/^ B@86J"9<<"G%L>
MP(Z)IFB&.5)K/D"3YVTY ;\WO'C&X(:LF)M,&G@=!I96PRQ!0-N!8! C]R#P
MIV/DA@3!0)UV)P@?*M"9I\S(ZD)QD[;K_/KMB[+195_-NJH929B6JBPA(T94
MHL(H7M36($D9%26G2<Z$E]#TIF!J(M-\M\C3C><-NJ,G;T@HAW;FU;3?'9=>
MNMO57KJSG:.X:H-F+0^@9B*B1R\4O[A./6\JQO7KA8)TXMH+'BA,U+U5J^H[
MLQ$7'Y?K]<-B]_>9(+K0&<MACE .$6,,$JY+2&A1IAC9KJA>Y30O3S4UX67I
M \O%KD?BRH8-K/]@SYYV9 ^Z;L(K#F8#2ZD=448PM=#M_BV>)+H.1E21TS/=
MJ++E.MO'0L3AC8"[@/_\\LN7AS8:J&0HSY#01B(0:HQ$E-1U*V'!DS1!N90X
M<6S7=#RTSW<]3FQU39R'\WD?)P=??2#O ^_IFJJ0I/-][CU<[($HC.1*__//
M/QL*04-B))_Y&:9[?>/[SX_G S]#Y8&O^]SO Y61:LW:&EMUD8[/ZKM:O*BO
M-B9@U^DFIWF:I<*([())B!)L]!+)."R$R)G*>)DAS\*Y3O-.3S!]$=^4?)G7
MU_U[+"@)6@8 _P'>,?'-ME]<&L/ 4."IOS@MB*,J$QODH;6: WHMQAVJO]<T
M@T$:#7FA%%?=<9IY7,W'!XP3)<CKY0!]Z,O+TQ-;_7C07ZK'1:4KP1:;MF6F
ML=P^+>>532>OYYOE@G!%A8*YEAPBI%/(<F-5J20K4EP64E+EG"/H,?'4+*N6
M=%NJ:X]XL*,>=.2WN\Q']?!9$ ?%;""8!Q9;DT'80_D;".F1E,.(B/NICP&P
M]:J7/N.-IWX&<'F@GH:\'W :W+^LS%?6&CZ"*9R)'$-<XM3V@9/0J*7&4,[R
M(E<I+Y64'N;Q_MC34T,;ZCRDR %4#H(XE/V!)6U#5HB-? " AYP,!6)$*[D%
M):J9?([M7D%V\,)XDNH<G0>BZ.P#8:;RX0U!=S$P4V7!TB*74.5&YB"9)9 G
M"$&=J(P46J$L(7ZV\?F)IB>%=E=D@JV_ 3U?_K$&=H'V@L%".LE< -K-YKT=
MO(%EV,G%8D=C/(NV'X.H)NR%J4:U6?O9/392KSP=H(=TH63OV5,U__&I3J<6
MZHUYO!+KF5:ES+*<0T:Y;5#+*>0HU1"EA=0TRU69$F<[M'>JJ5F>NW!'79,+
MGEMZ@6@(]CB_^S%VT&BB(3>P>&A!LX6U&] Z4L&;R*!Y:$'1P!M)+=I]>;X@
M^JE)3KCTZDW](XRG2#EQ<J!9N;T1G "U2Q_]K=I\6[YL/BLFS41OE1%=3]7"
M&H_O6;6J^X&<J20^XU1KJC(!4U08O4R7U#;[$S O$YX*+D4I$L_&'+?2-#4!
M_7"FJ89WRL_-"^4@O,>'?V I?Y+7#EJ60,L3V&<*6*Z:3E3G>RN,OVC>J5QC
M+MZXV5Y[B_C'((L8DA46"VZ'Q+&;IQH[MRP6-F?2SZ(-'>:BZ$H]OED^<3.9
M_?QM_ELE:Y-GN:@[\VJU6BF9SE2:Y3*UG:MR2FSG*@1I5BK(5<9HPG*4)4Z=
MJT(FG]I)>$ HV.PH]?-<>.'OYL\8"M6!#[B.;+!'=Y,$NX/YJP/,WKZ/$+RB
M>D2\"!C53Q("S;'W)&B,T#AIOOFP6&]6]5G^AJU6/ZK%8U.X9)8PJA5F!92(
M)!"I7$'"$8>)D5TZ2WFA-/*+E+X\V=2$U=?EALV!-!3[AD;W .HFC6+!-+#T
M^;A</$)[X@)+\!WXVVK94_\X("KZ.@J1XZ)[)APY,OHZZZ>QT0[OA,F(ORV7
M\H]J/O^\G,_?+U=_L)6<B4110@V.@MA Z5(QR&2)8:&-Z:^QR)5;S=F>.:8F
M$3H2P>^62-!2Z9D'>PY+-ZEP(T(#"P-?<+S%00_[4:7 N7E&W?P]C![O^;Y'
MP[9ZVSZPOK6IVP4_Z+^OFX34&9>2DCR1,+41?DB@$E*2Y9#+K!0Z0V6:%3Y;
MOF>NJ6W])B/7]LJU8$KPLC"0;EOHAER_]@'M)@\BP3>P7.@:E[;7L#6A<*FA
M(;7);[\#3)LEM&%E+T\O\SK,VYQ:JTWUSUK7C2=!' "+*DGZYAM5HC@P?BQ9
M7%X)DS#-5MJZ9W9=J68BE271DL*D;AR:)!3R1.2PU(CF!".6<3;;6+7<3;Y<
MG,E+NFSG&]K48#6Y?E+D,IAN,B0*1 -+D*X*QLZSN]>F+IYTN I%5-EP>;91
M)<-5IH_EPO47_'M;O&TO$FJO1F5E_F?U; Z F6;$B *C83"F)$09LSG:)3.8
M%D)*0:1C4$??)%/3-#HZP8Y0T%#JWL[B(J#]0B$63 /+@P"$O#I87(,@J'O%
MQ4%'ZUQQC:W]KA57GPUI&*[^^4^VJ!:JN</9MEM5*"NQSA1D1)<0(2XA21B"
M)2$2":,.F'_R:1=^?AJ?[W>D9N$=H6W]>I_^UQ>@[-_>L> 9>'O_\NY__:_[
M7S_\^@Z\^__^_N'K?T=M1.N"07_#ZPOOCMCNNI_ZPV;75YX-"<,T)-K&V<NY
M>>+Q0UM(Y,-"K*RI\-[0^H8]5T:???.-K6R D*19*H2")>8Y1*1$D*HRATFF
MBT(1Q4GN$9CI-_G4SO9#\G=56$1#-! UU3ZAAYZ+X2 @!H1X8,%QA&Y'^E]!
M1WP3-=^2#]X,#;9/Y.=PH(\5"QH5?,_XT##T^B-&/<<<,88TC-O#J-+ ,0+.
MB_>5?!$56_UH4Q/7G]@/&Y_3==<KA,::%@*6>4$@TN8GFA<89@7B+,O*@G&G
M*V:7R:9V'FS)!:RE%SPW!'N(I6L .\C\B+ -[DWN$.M(!2VM?DT?G9#S$. 1
M$1Q)8+>M:6S:R,6O\ [(%]6ZYY?&4/EAJS N5X"K'\N%!)MO"BR6JR<CSW>I
M:.*'L"]6&LR7BT>U^FLD(>^(<*]0OS;&>$+<D9L#H>WZ3IA;_K-B\W=K\]6I
MCTO6I? JBEBNJ80H5PB:GS/(5*EA*136A&B%J5?UUW.33$TH6QI!0R2P5/HY
MY,_"Z.:+OQ6<@47O,2X#=)OL0R"J]_WL1*,ZWOM8/?:Y]SX;XHECW]6J$O]H
M&U7_;;5\>3:Z7_NQTD(E+%$%E$HEQF 7"#*D)13$"(%2HT0K]XR>WJFFMO,[
M8D'7-KTF]\Z:,#[.N5YT75QTL3 ;VE%W&:[8'>:=(.GWV_6.,*+WSH630Q^>
MTQNAS1V; LR56M\OY)?-4OSCVW)NWE\W#L-905F!2\HAU]+6>]$(DH(+J!37
MJ4Z*0N+2YTK^VH33O)F?[ZB^ T]'?OL[P(PNO-YCI>Y+B__#RZ_OO"))JBDN
M$@6+HLB-7B81I$@D$#.6H3++<X&\BE='79'1PK*GM")NVEU,G <6['NDUDB^
MZT<MH)6F&Q21FV=>F73D=IEN$)PVR'1\+T M/ H@7WY7"[;8=,Y!^_<5>[1-
MT*OE+]6B>GIYFA5I21!+!&0<8R.,"@%YGG-($ET*A*G"W$D8!<X_-=G4D@7$
M7C>\O5N>E@-0Y_" GQ;+#9C;Y*W--[;XBX>&&;!0#FKGL/ /++(L\6!'O<V!
M:^B_VUY%@(X%4/-P!UHNA@7>PX<X[ *,Y%8<8B'\;(5P&'L-B(!AQ[,JPGD^
M,#5N&";,_GAC+Z&8V-@T[C<O1F-[4JMM4YC.#:\R*;5 ")82*8A0@2$GO(!,
MI067F4Y%YA@@Y#/M] *&.JKWE5\_5=8);C=U-C:$ Y\/6^QL[0C0$7S0;NK:
M_9&WFNL#4515UVGB4=5='RB.55ZO=P/4WKJ%P)O6/4>8( 23'*H,EQ!IGD%F
M3@*8)J1 0B0DSZ2S0KL_\M14U:9QPAL/Y>< )P=],I3[@25!RWA(==L#!#P4
MNU D1E+9G!'QT\/.<=VK81V\,)[N=([. ZWH[ -A^LX7M?I>"=5^0HA*E.9I
M"G%IA#@B6D):)#E,TS(A4NFB3+2/*^]@]*D)G)8X/X7E$"\WS208A8$%3TO7
M ->F9SF.JE$<SC"JZG"6N6,=X?Q#@7OT&UNIG]E:R3?+IV>U6-?B]WZU,HNI
MZBJV/__8/=-6MKVWJ=</S_;)];L_U4I4:[7^L/BD5M52_J9L J62]XW]U/W^
MT\J0/!,JQ3Q))51:4X@4H9!FG$.CB6!4%B@I,^5GW8S+P/3LI)8+H%HR)?BI
M6@"YG,_9:FUK,(*UY=[1X_9*GX6CK)OL4@\M3"U3D%NNP#[K8)]WVR5L_\&6
M?U #8'L/UQ#<@2T(P'PG#0QWH ,"M$ALGP(U%A&E]ZNL8=SC85P6QCU_7F5Y
M3@ZXUZ$BI%U,&YSX60E5?;?QB?<+^:O:M%W*/E8+]6&CGM:SI$AQF@H*4R(D
M1&F)(4EP 5F9"JVE8BES3PQRG75J6O$VBGE'.#"4 T/ZKBN?I1[4Y'OU8G%=
M" =;?@AX!SXAHB'KV=+%$ZG^=B^N@XW8"L:3O\,V,;XO!T8UU:WFZ](E;]5:
MK*I:!#;-VY3BJ4S2'&+-$HAD4AB;VT@=4F98YYI053CU*W28:VJRIB'UKJO$
MLT>N7\,\%YC=U-=(X TL26[ S3\TYCHB<:-B>N8;-R#F.N,GL3 .K]Q6X'EO
M6".HC&I5K1_T)_-M=4[97:M@R34N,EE"FBL"45'FQHS/,RBR0B!<TM1H-7YF
MO#\1TS/%:VIMCM$^O75,6==;<GFUMV18;6B/I7.35<,NQ\ B;%LG>E]XV64X
MOT"_#](!.AS!02I'>Y#Q*O6C_6&Z5$4Z8*00P^]9U/&(C<'9NNRQI@:#@L(R
MY48L\E1#EA08JJ+ F<:X1(53R<B+,TQ-R;K_] ;41+;N)1^#[1R +L;9C; ,
M;8@=(1+[GK&/_7[KZMR+(UI2/70?6DU]#X8I.._8:F'.V/4GM:J]1KO#4+,B
M%860D*:VGQ,I">0%UE E@A6)DJ0L//68BW--3UWI2+5.X,9S[*=\7(;53<>(
M M7 V_D4HX'4A:M@1-4*+L\VZN%_E>GC,_[Z"P%'^9LY6QL5X3=F_<N;]<.J
MJ0#[LEEOC-)HJ\H_/J[4(]NH#XO-JEJL*U%7@YRE(LT9SS#4F>W2JT5JI$>6
MPU3ILA18LB03L^?:__QEPU8;AT,_E!:?+7-,T7"[IV,#+'<,W &N'JN%74;
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MZ/WG+UWY"E40S;6TZ59$0<2(MKU6N=F"G.>T4#K33I7=C\:=FHRRE/F$X.T
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M-*(#DT<M[LB192X0!248JXY'91P7* XIR.G=*ZV/?4>%;D8D(J-20 %P%@L
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M252M[8)KL1K!,JCQ&=@VZ(,AM'5PLJ^Q[8,^A4]8"+V/^]H(;5U#"%4,L[0
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M+G(L7/R=3O;B=$ PFOO38B/?)B5AW_6< ZAV)P-70S4P)^XENMM*&.XTH!>
MH,< IWL:=?_?J^SAQK__X6LCAC^6"^,ZN9*B7+^GO.UH&Q1*BE01$\PE%50
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M%&>QD^.@3:]3LW.V0AL7A/JL9V[D;OT('5T(K7"W8X[@: Y,)%MY;YH".[7
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MX4?@'\N%O%=W*RG*]7O*ZW0+'\WISZJ=SSCE,$DQ!HG9NT$5"T"52D&>F)R
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M@%FA-U>4)X"H# *)\P)E21+S!'97,H\.):^L>O>XHGD<S<?#J\Z5'>AVYD-
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MO=:G1CA^/H_[@-D9%MXP#,P\W<%2^)2,)S4.:C'L]S"JE7!2N4/+X/1#'M;
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MM&$<Q2HZ,X0'PQ?5MVECCIK=WFNTL1C:YFK.@PW2[W:'X>#(N)Y9A_^V\T+
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MOJZGMOW3D<H]8+K-?_>^K#B=_X^DJW<+\58;$#/$$U9PA(#*9 X@1A#@.!5
MXB1&7!5%*J!MS/2Y3J9FB76)&!M!(R-II$6-C*SVH=-G(>VW;4(!-;#%X861
M4Q#U)1"\XJC/-CI:*/4EM7:CJ2\^>X5'Z-?E7+]1-:3URW*]XZV^$RD8<W.C
MF@-)B@3  C' 4B( 2^)8FOU>S*R2+3GW/#5*^"3_]2^Z*!>R]O'<5>,_HD81
M#R]"JR&P/,0; M@QG&<.4(R,V#L1,-&OPP1'N\(5WOG/JO?Q??Y<0#GIZN?4
MP*L>@[5I:'J-K!GD*$%8,H!Y3DRZ.0&P@AD0I! 93BA1N7R%,R\;V:?&H=UF
M;N<L*Z+;S=RW^F*L^EH^FPR<C0JO?GYE]8V,>E@5>N3_#4^F-L[B%\\%IOO-
MO,IY4^AOY]_X<"G -_1:IT@NHSC2D9&52/^.YT,N6 ]T&.0DPI@)>]O(Q<UE
M9_5AT?CZSA*8D1CB%#"<Y@#&K !4[QOUMC'-6%[(),GSX7/TGI5O:H91)^@U
MX6E##:6%;?.Z S3T)K5.I7LAL&V3<O=$8%NT&=UM7-N'BW%MHXSM&%EU@XSQ
MF(ETQQ_KD=+F7AR)83+EGN_VWR Y[D7,PN3#O=R-9]&/SK2H$]+1!2^-S5"M
M5_5L:G,JS6@F)<\S G#.H''WS $A%(.TX#E.8I[$A=,AKU6O4UN#=S8-GR0U
MIU6UL&T2QT:):$<+QV(@5@-A=]0;'-Z!5] =9,^!.4YZ-R?@PE8-L>IYW-(A
M+F <U0]Q>MF/NWY9+I;/<D6-I]N'!5]^DVVIQDU1 )P13A*4 I*9BD49A( 5
M4@&!8)+%29(4W"I^V[K'J7%64SKVI[86Z9],<5,MM!LS78;9CI6"@C<P(^W*
M&C7"1C^]ZU <HORB-3I!:>=RKZ-2CC4(AW1C_Z(?U;2F6/6XO.7_?"E7LCF\
M^2377Y=BYU1FQB#.8YD3D#!> "AD 3 1&9"<)0K&!:24>*39L>W?:@J-GUQG
M<WJJE_=R&V3VQS_@-$G^$LGF]/9;K8T;.5D/C!U'!<5Y'*KJ1#:79JW0W4UY
M(_;N$7<XOG)%*BAM67<^*GNY0G)(8L[O>QSEOB_%B[;%5C_:Q)2Z3W/"?)3_
M6R7:3H(,(&Q\^BC- 6,P!WE6(*1B3(FP/YZUZW-JIM-&ZFB3D[45W.%(SA)N
MBR/4\" .O:D[BY_3'LX;4X>CR_#8CG0<Z?&-NATENB'3>SQHV=1X1WYNNNT=
MXSF^ZKF]E6O3_,-J^;T44KSY\=?*E(IH%@)MY][R=?F]OCG45B?$J,A30!,D
M (0* BQ5#@HN52'S+$T+-ELOUW1NN<^U[MJ)M3<"#+AQD^N(F[GPTTM5%^K]
M4_3<:F&2"Y:=!A'=J."X&[8?%<MM\2!8#[T_UC#7E/.P ^Y/?^T@WP@?W5Z&
MV7VK[(Q8V#VS???C;IZ=83G:1;NWX%F39L%74N\'W\KF?S\L[KO=^QU]+C5-
M;,Z62 :E8'D"5*J-4)BJ#%"N.) (,RQ(G&'J=(1GW_74#-*[K^:2J$YYNCV;
MHMLJ-/.2LG)>#\]-M- 35&^VV4M5+F15F:A?5BYJ<Z3Z+\?R-/:#9<=XPPS!
MP(S7"1W]U(EM3E.CC>11*_H@AX/NB(4M-F/?_;@E9IQA.2HLX]Z"'^.]E6R]
MO?_HO+(^T[7<38$X$[".FLG,]6JBV2XG #-->0*S+$YS1G-HY4ONUNW4F.[V
MNQZ#)QG)_[^Z:]EQ&\>B^_X*KJ9G80XHB1)%#-! 'I-&@.I44)W!++(P*#XJ
MGKCL0'8EJ?GZ(?7P6S8ID[(: 8(JET3>>V@=79*7YRHES2M';M*]06E]P,X1
M>3OJ\H]G8-HR!N_LHTXV2:O &+VOCNJ/K]Q@\LI5EET/RE-N<!QRE./=/18%
M:UV1>]4FF?QN_I=B&J>*J$1/*T6&%,2,*)@S/:V4$<*,15@EU*5H3$<W+D_+
MH)5B5N"QMK!GKF47K!:K?1Z@"CT#K+5H[M4VHZTQT@-"#FMW'I ::+&N!V)N
MBW47H#B[.M=U[W#+<1>LWUM_NW1M#PY\LZPHEIOOP-V2+1H%T+0@11Y1IL,P
MGD#,"PES(CBD).4(,4&$PT;(Z3[&%GWM6@F,F0X/= >*%HQW/3:!">\(ECZB
MLQWX./#=]3@-1'?V7R,WECL/P%F2Z[AU.(X[;_L>Q5VXM&=1TSE;K>Y5=0J[
M40 EA4(HYQRR%!4FM9= IG*CTBTCFC)91+%RJEYZU,7H^,U8:!;'ZCH1_<18
M3R!I-X.\#I_0'.<(C7N1T4[O_583/>YFV+*AG6X>U0?MOM)3IMKK9@E8ZBAI
MN5I-4QW2*)9$.HY17#_PU"PQI0F4*=8/?"J2&#D]\)<Z'-OCOYLOQ9I\J7:9
M_,K<LT.H[1C!)X"!^>%4KMG6V@FH[ V88]:!3-C<LL-.;YM3U@'!Q5RRKOOZ
ML<R=;NM>O2FEF*W?,6ZVG5[^8#]G3\]/KY=EN?Q1+Z#KOZQ?I@CS.*)"094@
M4R ]1S"GL81%@GDJ%-+_A OCN'0^-O9I[ 1S,X%HQ'LK!]RHQPE_.QH*A6I@
M2C)FFXBE-ARTED] B_3&>-!:[X^@^F#FE:R<#!B4N/I <TABO=IP([15N9[>
M_UC4JD)-(!]13@0I&)34B)@GD9X-901#%!<8"<6YP%9\=:+ML='1QCS':= I
MV,[3S)5@!&81!QRL2>*,Q^<X0-^V\_SKWPZ?_5/M#O)HGW&H?7+/7>(OTC"?
MO5_+I]54J53/8&0!,Q$1B"E+(!5Y 2-$X@BC--9SG6M#BTUO8WMX.UY]X'/U
MA\IDQU6-\V#WCR-Z07B;P,$./2^1PA$JP4.#;8\WCP6.G+=Y^1_?Y",;YX/^
MEC3O,)6S'-.40J1(!K&F$4A19%*J2:*0E%&FG/BDJZ.Q4<E1FH@QM>?2:">X
M=OSA [+ U-$3K2O3:(ZA")@XL]/9#5-ECET^GQQSXOHK95%>5?FUKQ;B;IM=
MVZA_B/O%@Q%O,SDX^H(/RT79_OJ:K6:K3^9(R/8\4AZE.4MS 042FEKB0L B
M,T+9"8WC2"H5Q[%=,DTX(UV>L6%2<?[D7Z1XGM=O:E:6+]6A@J?E\Z+)>MYJ
MAWA78O$W]G;,=]OQ#,R9'>HY$[!QIQK.78? Y\J;P%(OWL$.HPOCS\S;B,AX
MA[E3<<9_3_W>(97V2FU,4Z5A&DDA%>42BD@S/TZS M(X1S")"YH)DN8X<5H)
M/^YB;(%E+4##FU(@]6D5-SH^ :,=G5X'3N@%IPJ7VKH):.SSQV[=OGMEIQ/=
M#,HNW6X>LL.9*WNI*"QF:WDW^VZ.QZWUN,XT;U2M&]D9OI9"ARCE>O:_6MY/
MZ2?-U&9YI[\^4Y)*A&22P(P+#G&62)BG&84\PXIP'1NJPHH#KC5D;$SQ20^0
M9,9")RV _@-QGD6&A#=TZ%5Y 2LWP-:/FGTFH'4%[/HR 94W==4FX\] @^*D
MVC#(X PFY1!RD%Q5'ZY&]H(41/_VA]2'N!J% ]&(Z]OKN8=B\CYD/366=^:<
MXX,TBR0Z[*U^^R3+IVE$9"RCF$.N"-.Q*3$YH(A"2B1665*P**%.6RD6G8[M
M';2Q$,RKL[Y&@G\"5.V#XU:*#>:6.RJ>D0R]L5*9.VF68B2H;#3S_!;;Z@-@
MK/:XO^* D=]M%IN.A]UM<8#B:-/%Y=[!2W.]>GPL*]'"-\O5>IJAA&18""@P
M8R9S70?2'&.8()1G.(J8Q&2@NEM[AHV-U+9V E8MG Y6\FA_O"SB[1N-0F!"
M]%2<:.,>,/[=:! '*TK5>S#_6A6G+ =UR$)2)Y$/6"5JO[^_2@FHDRAYK.]T
MNOV>Q[YT$_?J]^52F&7Q/V7Y?<;EOW[R^;/0+_:W\ELI^:QZ7O3/<UE-/Q9[
MLY%ICA+]MI4*$C-%P%*D>F*0*5ADJ9XU1 GBW&GE^GJ3QO::-1Z9'<A5[8M^
MMF7K#A [_E3;7&S'$<>#9]>/I=VL8]@1"OP*;@>G<J<NT%P[9%96VE':]6D"
M-EY-JNM?V8R8^WDX;R#[/3]WO5G#GK?S!N/1^3Q_+??C[OK<[ZI1HYKR*#+G
M<E.89%D.,:::@F4>P8+D(F<,)[EPDL/;;WYLG/I^H=^<; YXHZVFOP[K<E8\
M5S)V;KQY@*,=!_9')S"?-8;]VJK.^6.DTRY[99>#+@9EBM/N'3[U'5?U338M
M9]^9D3';*8JS_;#-4GB9JI@K15,)"4XBB'F<0(:$R45E14XC@47.W9)/[3H>
MVU._-7&C:?DR <K,H+X;)US342WAMZ.$$* &)HL=/.^V>&YGI,VYW>T??6:P
MNJ'E.:/5LO.!,US=(#G.>'6\WYM$KTFA>)!<ZI[TI-4<ON$Q1QF#!28*XD(4
M,(]Y @N%48:S6$K)VEHW=HQUN5.KQVJ_P$U@MJHS><JMB5>KZQ[B;$=,GK"[
MK9INA>6#!98^)'0[X DMG7O8[:TE<SM@L)#*[;JS'^-4&BA?EG-]QZI>._NP
M7._4\HM0@D6&82YD 3$2":1IGD$J4U*D$15QXA0=G>]N;#'1KK6_MO6=C,$V
M>M-]X+8C'7\@!B:<J_!S)AL[6+P2S84N!R49._</"<;RKAZ[SF^EDF4IQ2?V
M<R<G_+"DLIBB+,5Q9F(9I?0$C'(%&<$93$D>YXC%12JM%E=<.AT;T;1F@S7[
MN9U^ 2;^^]QL(I=R;L(JHP'TH_8&R+8JM<.NI.V@6&P;!X Z^)2L05F;#.YV
M"S<<U8=WT=.UQ=1A%S< M@/MT'K!V&WCU1&LLYNJMFT-MV'JZ-W>9JCKO;U8
M?O<HZ)OE=[G0;=_)NIC @_FV->(Q4Y[0-!8$P4@5FN@C3" 31,*(Y2DM,"(H
MCQV(WK;?L7%]*Y&D!W^UG,]$1>OSQG!3:F&V!']?+-?@44?\)M%X_84M7!30
M'8;$BN9# !V<Z0_.BK=V3T!K.:A,WRA6A<'7B?)#X#P8ZWO#VY7[75&[0/_6
MS0WY!G#U\> EX'Q[7]&@)FY]MRS_O?C&9N+-G,V>S!9N\\,FG&WJA-=%- [7
M.*8TXB(FI( DSE.(B<H@97EFE QC(DE".$-N^D)^#!O;FV1KMN/RI[>1LENO
MN 7^@5\P&Y> 6I:@=@K4SE2)*\V/6\= X]FD*?L#3BS&^A0^\HNX9XTD3\8-
M+*?D%])CY27/[?<C\5><E\_FK!1?/DD];Y";\]^<<80QRR'+!($8"P2IH!P6
M)$D*EDE>H,)-2J6S+Y<'?1A%E-I&LSPC5^";2T7RR\#:D:@7L *S8F,C:-"J
MK QPSOXB%%[IJKNW0?GGHM.'A'+YAIX5LMGZN93WJJG9J&>Q4R$+)K,B@QG!
M#&*).,RSG,-89$J(/"4IQBX!VW$78PN]WLH5+V??JM3BI=K(L3M6M3Y&THX+
MKL,G, G4QAE4MN:!ST'DA+IQ\%M[^KB;86M,=[IY5$NZ^\H>:WL?&9^I&?]#
MBAEG\_=/[+%6\+G7E#)?/KZ\D:8LHB:8IJ 2S16)3=DN01""F.(",D0CPPH1
M)T664AY9+_ Y=CXV@FC,!XW]H'$ _(T]??LG:)T M1>F0"C_A\,2E.O(6*SS
M!<0[,.%T06WF8:> OEQ"S&T-JB=R9Q>B7-L<;C6JI[=[2U)]V^A[$$M[M5C7
MA/@P6WU]_?):+OB7)U9^??5SMIHBBK%"60J13"O5608+(Q!&*,59QJ*H$&[5
MN"YT.#:NVK,7&(/!QE[PV5CL6J?K$N)V88Y/' -ST#40]CB_9(>+Y]-)%SH=
M^.R1'03')XLL[^L1+OU'SAZ_&$&9>F6]W5[]6,ZX;/=<'Y;S^;ME^8.58EHH
M1929,#&>91 C*F$>Q1E,JW+TE'']SSI<<NQ\;!34F@_:*O2M Z#R8"=[X+/Q
M C1NN%0!=1T>BY@I(.B!^6J$>#OLE0;$?: -4^_XNX6L/0$\&[*ZMCE<R-K3
MV[V0M6\;_8IB5\F7G_2]5;1$1"HB#3<D*%$F<2:#-.8$QIE I(@DHZE5?'JR
M];&]"5K[@#'0*?H\#9X%C5\#2?BXTAX-YY+.)[V^5,QY_Z9!RSB?M/>P@//I
MBWJ>CFB$\.]5MXY@K5\]E7&>R#2G4/ <&Y5I!*D>79@)+.(\*F(66PECN7<]
MMB=XMWK 68'-5:,U[WJ&PGY0[.:98: .S P>478_:>$,F-]3%_;=#WL"PQF6
MH],8[BT,E:M5?_S17%EO(QJ9U&@:1RDE.98P09A S H"J2@22#G"HE B1GGB
M=AS5EVE6S^J@AU8;Z\"W*G$C=,I6QX#94>*@@S#ZE*WF3\:Y33I#I?]\RXRM
M\X#?.&.KP[B19VR=A_3ZC*T+[?<Z?K')0[A7;1;"W:9X9,'R(A)1!AG).<0F
M,J4Y22'%7'&<<!71U.'(Q;F^QA:%[F9HW&\S-'K4Z;0!VF*6Z0^^P$1Y%7*N
MZ?LVF%Q(V3_;Q)!I^C:^'*3F6]W2Q0N[@Z#O^OK;+^TG^K^"K>1OO_P?4$L#
M!!0    ( %&!95-L*CKJU?8  ,CO"@ 5    86UE:"TR,#(Q,#DS,%]P<F4N
M>&ULW'U9=ULYDN9[_XJ<G-=!)O:E3W7/4<K.3,_8EMIV5LWT"P^6@,TNBM20
ME-.J7S^!2VK?KL@+7;A.=Z5E229B^1"(" 0B_O(_OYW,?O@*R]5T,?^W']E/
M],<?8!X7:3K__&\__O'I5V)__)___B__\I?_1LC_^>7#VQ]>+>+9"<S7/QPN
MP:\A_?#G=/WEA[\E6/W]A[Q<G/SPM\7R[].OGI!_[_[1X>+T?#G]_&7] Z><
MW?[I\E\9D\DDE8C(21"I4R VRT"XH%EF%D!3]3\^_ROC7O(L@%B1(Y'11>)9
MD$1S:XR)PFGJN@^=3>=__]?RG^!7\ ,R-U]U?_VW'[^LUZ?_^O//?_[YYT_?
MPG+VTV+Y^6=.J?CYXK=_W/[ZMSN__Z?H?ILYYW[N?GKYJZOI?;^('\M^_C_O
MWGZ,7^#$D^E\M?;S6!983?]UU7WS[2+Z=2?S)^GZX<'?*'\C%[]&RK<(XT2P
MG[ZMTH___B\__+ 1QW(Q@P^0?RA__O'AS8TE_>EB-EN<0/II#NN?RV_\?*%B
M/T^OY^OI^OS-/"^6)QVYR$+WD>OS4_BW'U?3D],97'SORQ+RO_WH3^ +*;JF
M3M!"R']_]/-^OB+S= FK\FOE^V_Q&]N/+30-1S)\6\,\P48\%RO/%O'&+\V*
M<A;+BW\Y\P%FW7<G"::3PP7NEX.P6B]]7$^LHN D4R0ZAP .7I&0@B76IJ2T
M"TI+?E-"A945\M+I<@7QI\^+KS_C!_]<I%:^Z,37B>[.<AMY[4;WA9 ^X>].
MC#59<(O;*#E*I-24>!H%,<XI!HP+&^)>9%]?[2;5U_5\L(P_+)8)EFA[+I;S
MRWA'YS=QO_V-GT_]$C^(Q"_36;KXU\4(#:&K]6( R6W4@N3^^ -RG6&YA/1V
MHY4'F>LX6Z-%ANXWA]#X?YSY)7[B[/P#G"Z6ZXG,EEH6 HDI<2*%\L0+EPB+
MW(/F@6>?!U'^K85[X8"WCX-]Y-D()(YA.5V@L4RO\!2?Q PZ*%!$A0QXO.)!
MXA4R8#@UP+Q6T>UGQ.Y=MA<<1/MPV%V6C8#AT]+/5],B^"V@F;52%HG(Q#/:
M.(2VHV"*B\%X5D$IF88Y'6ZMW L2LGU(["71D5&Q\:!^G<[@_=E)@.5$QNR1
M>W0N*: P<K+$:=!$" XI.,M5V \-MU?LA0+5+@KVDF 3VO\ GZ=%"//U>W3H
M)X)93AV5!$6 /D]*>,"Q:(AARLG(<\K,#X" FZOV0H%N'05[2+())+R9Q\42
M35@G^(\H?SA<G,W7R_/#18()9SFAEY.(<AB22V7PL,M 20A4I6B8D&X(T_ H
M$;UP8EK'R7!R;@(VG_RW-PG%-\W33:)C:PF5PN ;S1VQ6J.0N/5X#EI&LE?>
MA61EBF( P#RP?"^HV-:A,H1LFP#)04JH@M7VC[?3.; )2V@>!0;5E*9$I!%H
M()VG)(.2T1I+N60# .2>I7N!P[4.CGUEVB@P. ;9/GEF@6CG'9K G(E5J22.
M8XHN4H-6L HP>+_T%?W^D/$\H;:$C$/\\FCY:?'G?*(9DP[]:!)B$8K)C#BA
M2WHNB&1%L,X,X8+<6;@?*AK.:@XAT)8PT3E-1\OCY>+K=!Z+S^1DLMH1%DLB
MAAETNAG+!%(*6J##+;@=#ABW5N^'CH9SG8.)MB6('"]6:S_[S^EIYU1#!!DD
M340+AUQ(QTLF7Q,K9586'2:;Z'  N;%V/W@TG/L<2*PC@Z-8O8,E^(YN'1B-
M465B##K-,KM G&624(?'HN!"):_V@L/UU?H!H.%,Y\ZB&UGEY>)]=OQE,;_(
MS65F@T14DA@HAM89;9GW,I 8J9;4*ZXC[*7VVROV4WW#Z<V]1#BR^C]"/%LB
M=!D/GZ;K&4P<9 :14_1Q$EHKFA3RKS6A.D/4#IQC^[F/MU?LI_Z&\YI[B7!D
M]7]:^E+:]/'\)"QF$T]#S"9R$KV02#B"UT<5B'34>>,90[NVE^YO+-=/\0TG
M*G<77A,^X.'9LLAI<R%7^$#AGZV*+QLT1Q8B$P;YR(9X!X)PG1R&QUH(N=^Q
M_]CJ_3#1?$9R -$V 9$W<_PT%,?T*[SR:[]E:P*61@QO!/&"HGNC02'4T<$-
MGCF,D;6+L)^+\-CJ_2#2?%YR -$V 9%RJ[L\Q'#X\V)Y/M%,8L#+@3")IY[T
M(1,+-I"$P0X%@WX1E0,@X\:B_:JHFD]'[B[()G#P\<3/9K^<K:9S#( G7/NH
MH\Q$&4 7B$N/HLB*,&Y-0J>8^D%P<&/1?CAH/@&YNR";P,'K$UA^QB/OM^7B
MS_67P\7)J9^?3YA/"LFFR '#D\\KAVQXC(H=^&@X"]D,D7N\=_%^N&@^];B_
M8)O Q\<O,)M=4"^-T0%X)BF7TXYE])DA,6(@RZ@4E8D.44=S?<U^:&@^T[BS
M&)L  1)^4JHZ%O'O'[^@W%9'9^OR)J2$4Y- &3!!/3%91.2&6>(\!E("O)8N
M>1WL?J7X3]/0#R0-9R,'%O/(H#DX@7DJ9:2_SOSGB>;@-$N60!:(]N(D.81Y
MJ2[G!ITDH_5^OL6-Y?I!H>'LY.[":Z0:^]?I*OK9_P6__!6_LYI(QV6*%ATA
MZTKI,* ,&,5S#SAHPY2*VNVE_P<6[H>$AA.50PBT*4QL'AILF(# H@3(Z!E+
M](8TY7@&*D%L$DG;Y"EZT0.BXMK2_7#1<!YS&*&VX5@@&TL_>S-/\.U_P_E$
M^("41T^RI,@ E:'<Q'!B)'@)06K&!O$E;B[;#Q'M9S'W$.;8%]F;=-J5I;MX
MC21SMH'91)AS>/YQ73)M0I D<DI.:J'T?JG+AU;NAXF&TY:#B'0P6/SEYSMR
M?(O?V/F1]^'1^X]';]^\.OCT^M4O!V\/WA^^_OC[Z]>?/MZDO-\+[X<_;)CG
MW3V)W?-M]]F*?/;^=-(5.Y7SX2C_.IW[>9SB(;'8O.:Z1)608 0MJ(*D"PB
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MC7L0#@R:P27;P#7*A8C.?UTL#V=^>E*L^_:+]%]GFV3LMN!ZHM#I],IQDJE
MTYYT+)>2C'#GC?82>.!U_:X^5([KQ%>R4]74U  $MQ;WS3PN3N"3_W9E<4V.
M- 1EB3:"$^F"08F%1$JM%U-." J/->;?ZUB\GZ1QRQ'J'8(#** )I^O5].LT
MP3S=MLJE7I]E+XAUY3DWDDV<*R-0658834LG69W$P@,$C5MG4 E'0PB_ 7MT
MO53UTNY>\.)MHC9[1IP*Y8X;=T2P#@BC(MG 01JHD\5\C*IQ:PPJH6DP-30
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M'2\72'5W]R&=YXP%I%>[\J#31^+*1&UJ='8:3Q8KZL#EBH;FNF[N@Y =1=N
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M IG[/^CG*\)ND[S]O#LPVHU(^+:&><+@?+^=?[3\[.?3?W1$WNA&B$@XOL;
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MOGPU79TN5GYVE-\NYI_?3K]"ZLI7[P100@J6.+4$:#?A+J$W&KM>&%2#\*!
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MX/0+IS[E/HITC5?A(I!K_O$+XNI=_=M5)=4X\R!X4 *!H<_DJV4/T3 )A7Q
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MR!25_[;$B2!968L(;-VKD5BH@1$#I*!<6T$!D>?-0?@H>>//,>H?@OWH:@0
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MIF#.)G)[/ ^E6]^VFY\ZQF?\X_1\B+A&H>>?MH0'RU(62H'7@8XPHUSM2\*
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MP6NK+<M%=QP>T__+Q[NQ]:+I_6ZYL;J&-D*/,/.!G/\W\\4?89$G4M64(^V
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ME1#@>28A<JZL]@8S:Y21V O]PUK!DT!U $6/ -[/B782!%)X3YZ&E=7Q8$Z
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M(/D8@A$QA48#0 \D>'S&<1\4/5YBV$YK(PCXNC+WZL<-1NFSUWT-I \JT[D
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M3V>?;TMERXP2Q; L,@AC+2A'F]K5S2VS9=%&+Y1L\R#^)%G#1F"]P:=_%8P
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M>8\0,]L=%:V2N6@DY;H Q%&=#$7(=[IHQXWWHM7DQ9=2H[>7GKO5Z.TC]#%
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ML:L6]N)S9SBY.D(B.\*RXB!<(*1'5R"BUX"6%Z<+9]:T1TH/E0K[R?89H.S
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M[.NGQ;U6/#RJB$%9 H=VH )R<F ,!7[H71*16XF#AGOM!KGGB9O&X(X$@^=
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MG\JJ+[.OGQ;WLHXV,R49\T ,JV_F(H>04@2M33')2U^&Z:+=X/4\<=,%T2/
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MX_>,!J_1F+\]@/PE@.;XN6ZKGWMCVIU*16FP1I&#$$T$KT4"DX(/UD=R]]M
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M0HI,HP_@4$2*MU0=Y>ZKM^.48$&+XML\^W^2I!X1N:OD'SJ%HXBABTSO!Z2
M?99JJK!NYMI]R4Y*K<A%-H&B=RDY.$X_:15,BCEGT>A>82,YT]Y7-472_NR?
MNB;QZ3*7DIV6F#-$6;UI%7VMP$I0^]I(\H.=B,-ZG^U7=#;ZQ=+(;MB(7.S
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M>=8RB!2%:5,E,Y# 'T%O;H/$'?3FUG*<,#>T6IZ?W#(2\_4FUE?@+F"0P0I
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MQLA@NCP-+QB5]9\'E9Q$(H&X(X06<2X")*$Z%.NE<I%$P#D453I\#V7&H$_
MTE)0BX!#@3R5 A00Q8AN*1<PS1%B'@T-*X$Y^5_$&IF$"H!-!0!RPQEG3TC-
MB$123<P,N)H/A;&P=["$XDMO-UA97,*?F1FS9NT+AF!C[R#87XG7JX.36G!\
M9G*0Y7(#B41%D8#'0W/D@MDC5','&X"!&$B.X24<L#J0PHRP!5:+@4>12_&9
M"1-*93)HAPRKE?3X2;4*.8/7AAP"7!@'_'E,=!_"$4V&G+2!O.XR"36".BT%
MS4/NK0B:S#_Y1X%J-/&XQ?X),MP2G#V\T):=!XI6!HI@(/3S,<BA!LJ#)RBR
M1G._@7M(C_8&N<WR:8 3<<D-3!5$T*7#;\.KB)DZI)G9O0FFS $'J.0C^22L
M,@T= (V-A7'D"+5XXOI!8;Z@U65JUEQ2A[T\"R_P4\QI&PL%4"S88I04S!V3
MF&Q@!!-4"W1 >*W@DD6"/64&\[=;K<8E>T>ERG PR )U8Z,45*H(,TDQ X!;
MSHB%#H 67E4LBR'X-N!8$4@:VG/V!%+>>VP/]@G;]<8ZMG<FMC6([TZ).R,=
M5L=8, 0P-2JAR/W4 /A1IB*JJ68SA 'F!1T(*>P4M<&F87&].3 ZG/FELE)U
M2>:Z%/.0.Y1F.@6<&Z=EPE!IY@QP@G?($Y H$N .)3S%=8150,Q[2,-Z$RFP
M_$L&=;A/H/:$W1U3F3E6PXCS* +)*<80*[-!.LZER XL[1\WJTF'86@(#&N\
M9AVHS&ZW8)<\0N>U.0KRZ-O;*C*827VW++F?";#'01 '>*$P9/L$PYQ;?837
MD8(;_EP(NI*-</P.1D4MH,(PTXB'I<2[H==8&0OO\4 5^C)X6I2?+I'#+4TB
M #9PW:/:N>&P*>/NK */,9)L;M>1MVI$S5RE($NZA<"92Q]N/G)JGQ(I[KG,
M#RX>U2\^>8J>"/Y]W^TU7\YNSYU^LMG"*2[H#-EU&;P+9D/X?8=P69/%<^LH
M2&.KM)EK!?<"NHQC82WG7\D= P5J!,N9 /M<)X< <:!J@ZD _J- GZU+_D<F
MP'RW!K,D=$<<1__?U/U0C="6(/E@L@0 $/?6N$L/!0>XY'E^OKF:<'J/B=M+
M0)>ZG7AUY[&S(ZKO F&^#_(G&QL8D#)H:/B< +<"-I>\T 10!\JTZ-6# >E@
MLA@P [/DG,D3S\;#O)>N#/9PU]4& 1!IH)<B0($[4@0PN2/U''5%GS]%,E9R
MS#&))G28_S*@<Q[E<2K5E$/I9*0\<](53 ,&_Q:%4=[E]_S57S$W7%SX:K/]
MO >P9OBC2QNP,73'UBU_Z#+F:]<X9@T'REH5MZJ+)G1@E,SL]B;;?O_>>B?$
M?X[TK(,4$%,: ,/<EV@$[5M43NC4%/ZYJRA+1.%DP+EUV_;Y'&C8ZY<@E)*F
MAK=F7\X@WZ>23ELB<0%QC<[ROO*)0[O&J!M @^:3XN;'%^<FGYZ63YIUM-J"
MJ9;-!LX=*CN'*I:ME[TNGS9K6TNKY6!KV==ZK1^77Y^>_NW=-FOE:F.W;BMN
M(OQDP'2;E"9O"O7" B&.G5JU]($$FVG\T:3[^?[QB].!\1+(<54FY?[__*Y=
M _?& Z#?9M%=27N:A_G=JGUR\-5! W*.^URZ;[+BYHY@K1(GX%Y0\!\EG>U^
MY0SJA%@*9N+I/9G9]Q6G47UL]7B'E/,#KURY"=D D"VI)D\/J$J7DD]MTW)X
MIN!V5*DS$CPBW0<>9B@2R(W?]3IE?JMA,\'<1=-OBZ5G=>3PUI]G@S)<<^7H
MD3"8+^>*2^8_IY*J^+N^[M;QQ5]02P,$%     @ 48%E4S[M@:M["   :BP
M !4   !E>#,Q,C(P,C$P.3,P,3 M<2YH=&WM6EE3(S<7??]^A6(J$ZCRUEY8
M#$.5,9X:5TV @">3/*7DEMK6A[K5D=0VSJ_/O5)[PV:9(F$\5'@P[M9VK^[1
MN4>R3GXXO^ST?[_JDI&-);GZ?/:IUR&%4J7RI=ZI5,[[Y^1C_^=/I%&N!J2O
M:6*$%2JALE+I7A1(861MVJI4)I-)>5(O*SVL]*\KV%6C(I4RO,PL*YR>X!OX
MY)2=_N_DAU*)G*LPBWEB2:@YM9R1S(AD2+XP;FY)J937ZJATJL5P9$FM6@O(
M%Z5OQ9CZ<BNLY*>S?DXJ_OFDX@8Y&2@V/3UA8DP$>U\009.'835D4?4P:!S0
MZ'"?U7CSL#:@;)\V#^@? 1A9@>J^C;%3R=\78I&41AS';S5JY8-F:H\G@ME1
M*ZA6?RRXJJ<GD4HLC*>AO?_JNUGKS/([6Z)2#).6<ZG@F\Z*0R65;NU4W=\Q
MEI0B&@LY;?W4%S$WY()/R+6*:?)3T4 82H9K$?F*1OS%P28PSSU.O,D'T(\4
M"9^Y$-30:-+][6/OK-<G]:!<6S5YL[$AS"[7Q^Z-2!@\M>K[Z;]O?F.C^>]V
M@OWJ\3;;O7G:.]WK?N]#K]/N]RXOR.4'<G7=N^CTKMJ?("#=SN=^[]<NO(8:
MW>L'O8NI'@(DK4K]L&O>OKYS!PUP[NKS]<WG]D6?]"^_.]MONAT7DGJUAF'I
M?^R2F_;U6?NB>U.Z_.U3]W?2[O2QI%:M/KQ>EKVKK7KW_\Q8$4V_T7KI%<D9
ML#93";D1<9&$7*,UQ(ZH?;?3/'QX*=UW*:6, 467)(_\2MK@Y,IJ*]4.OAE-
M!.697Z\_^NI,!4?E)DY#CXSHF!/-QX)/(-_9D3#DSXQJ@+Z<POM4:4L@3!^4
MCDE0+?U"5$3:J9)2D9\Y$R&5Y*.2V+,IDEX2EB%^1V\T?K6MB]\9-1 UB$\\
M);>)FDC.AKSHPY@'CRDP(5&@:6 $*A)"DRG)$JLS#AZ RG&"!Z)*20Q/6D!$
M(QK"*TU4+"RQRM=;JY#PD!M#]12KQ/26P[A+?1IXQ\ 8&%(ZM01C8(50:%!'
M4"V!YF )XYI,1B(<$9/AQZ+]A&N>=X(.Q,)(D%&HR";"CL!!D_+0&8C]IF":
M8N#F&)HQ,I@N3\,;1F7]^T$E)Y%((.X(H46<BP!)J [%>JE<)!%P#D5=#]]#
MF3'H$["T%-0BX% @3Z4 !40QHEO*!4QSA)A[0\-*8&[#4,0:F80*@$T% '+#
M&6=/2,V(1%)-S RXF@^%L9"W+*'XTML-5A:7\&=FQJQ9^X8AV-@Z"/97XO5N
MY[ 6'!R;'&2YW$ B45$DX''7[+E@]@C5W,$&8" &DF-X"0>L#J0P(VR!U6+@
M4>12?&;"A%*9#-HAPVHE/7Y2K4+.X+4ANP 7Q@%_'A/=NW!$DR$G;2"OZTQ"
MC:!.2T%SEWLK@B;S3_Y1H!!-/&ZQ?X(,MP1G#R^TY=D#12L#13 0^GD?Y% #
MY<$+%%FCN=W W:5[6X/<9ODHP(DXYP:F"B+HTN'3\"IBI@YI9I[?!%/F@ -4
M\I%\$E:9A@Z QL;".'*$6CQQ_: P7]#J,C5K+JG#7IZ%%_@IYK2-A0(H%FPQ
M2@KF#E9,-C""":H%.B"\5G#)(L&>,H/YVZU6XY*]HU)E.!AD@;JQ40HJ5829
MI)@!P"UGQ$('0 NO*I;%$'P;<*P() WM.7L!*6\]M@?;A.UZ8QW;SR:V-8@_
MGQ*?C718'6/!$,#4J(0B]U,#X$>9BJBFFLT0!I@7=""DL%/4!IN&Q?7FP.AP
MYI?*2M4EF>M2S%WN4)KI%'!NG)8)0Z69,\ )WB%/0*)(@#N4\!37$58!,>\A
M#>M-I,#R;QG4X3:!VA-V=TQEYE@-(\ZC""2G&$.LS ;I.)<BSV!I_[A933H,
M0T-@6.,UZT!E]F$+GI-'Z+PV1T$>/;VM(H.9U'?+DON9 'L<!'& -PI#MDTP
MS+G51W@=*;CASX6@*]D(QZ]@5-0"*@PSC7A82KP;>HV5L? >SU*A+X.G1?GI
M$ME]H$D$P :NNU<[-QPV9=R=5> Q1I+-[=KS5HVHF:L49$FW$#ASZ</-1T[M
M4R+%+9?YP<6]^L473]$+P;_MN[WFV]GMN=-/-ELXQ06=(;LN@W?!; B_KQ N
M:[)X;AT%:6R5-G.MX%Y EW$LK.7\D=PQ4*!&L)P)L,]UL@L0!ZHVF K@/PKT
MV;KD?V8"S'=K,$M"=\2Q]]^F[E4U0EN"Y(/)$@! W%OC+CT4'."2Y_GYYFK"
MZ2TF;B\!7>IVXM6=Q\Z.J+X*A/D^R)]L;&! RJ"AX7,"?!"PN>2%)H Z4*9%
MKQX,2 >3Q8 9F"7G3)YX-A[FO75EL(6[KC8(@$@#O10!"MR1(H#)':GGJ"OZ
M_"F2L9)CCDDTH</\EP&=\RB/4ZFF'$HG(^69DZY@&C#XCRB,\G-^2-\4]^V]
M 7#OO@;L\-SY<\N?GHSYV@V.6<.!LE;%K>JB"1T8)3.[WN2)2Q_^<Z1G/:<0
MX-( ".&V1".(3(O*"9V:PK]WUV1I7;NL?6+=+GONJ8:M>0D")FEJ>&OVY1C2
M<RKIM"42-^VNT7'>5SX]:-<8TSQ(QAP?#A>^.#?YZ*A\V*RCU19,M6PV<.Y0
MV3E4L6R];+]\U*P]6%HM!P^6/=9K_:"\?W3TCW?;K)6KC>=U6W$3X2<#IMND
M-'E?J!<6"'%DTJJE=R38S+KW)MW/]^LO00?&<^"R5563^__]NW8!5!D/@"V;
M17?G[&4>YG>0MLG!=SL-2!'N<_EFR(J?;PNM]Q+&TX&L$B<D'ZN:4Z@33BEX
MA*?M9.;*(_.#:N'!R7GL'MOKWXYR<[<)(4_>N?M&<>ZH4F<D>$2Z=SS,,->3
M2[\+W7K3=Z_\B3)HLS7C]^[E^OD"K;C\O,T2J.)OX;K[P*=_ U!+ P04
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M"A[X<R'H6K;"\3L8%;6 "L-,(QY6"N\6J[$R%I[CM2G8,GA;E-\ND>,=0R(
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MP$[$$KIRP:DHT=Z'\]YIST=NY:'>[4H#""T53?V$)03N&NYA^L]KKV[5_O+
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M     &%M96@M,C R,3 Y,S N:'1M4$L! A0#%     @ 48%E4^=81CM#'P
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M,#(Q,#DS,%]L86(N>&UL4$L! A0#%     @ 48%E4VPJ.NK5]@  R.\* !4
M             ( !]?(% &%M96@M,C R,3 Y,S!?<')E+GAM;%!+ 0(4 Q0
M   ( %&!95,[J#R.GP@  - L   5              "  ?WI!@!E>#,Q,3(P
M,C$P.3,P,3 M<2YH=&U02P$"% ,4    " !1@653/NV!JWL(  !J+   %0
M            @ '/\@8 97@S,3(R,#(Q,#DS,#$P+7$N:'1M4$L! A0#%
M  @ 48%E4V<I+)AC"   L2L  !4              ( !??L& &5X,S$S,C R
M,3 Y,S Q,"UQ+FAT;5!+ 0(4 Q0    ( %&!95.-UR^&4P4  -\I   4
M          "  1,$!P!E>#,R,C R,3 Y,S Q,"UQ+FAT;5!+!08     "@ *
+ )4"  "8"0<    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
